

# FIRST AID<sup>®</sup> FOR THE<sup>®</sup>

# USMLE<sup>®</sup> STEP 1

# 2017

**A STUDENT-TO-STUDENT GUIDE**

- 1,300+ frequently tested facts and mnemonics ●
- High-yield updates throughout with reorganized neurology chapter ●
- 100+ new and revised color illustrations and photos ●
- Student-proven exam tips and strategies ●
- Revised resource guide with web and mobile apps ●

**Mc  
Graw  
Hill**  
Education

TAO LE ■ VIKAS BHUSHAN  
MATTHEW SOCHAT ■ YASH CHAVDA

# FIRST AID FOR THE®

# USMLE STEP 1 2017

## **TAO LE, MD, MHS**

Associate Clinical Professor  
Chief, Section of Allergy and Immunology  
Department of Medicine  
University of Louisville School of Medicine

## **VIKAS BHUSHAN, MD**

Boracay

## **MATTHEW SOCHAT, MD**

Resident, Department of Internal Medicine  
Temple University Hospital

## **KIMBERLY KALLIANOS, MD**

Resident, Department of Radiology and Biomedical Imaging  
University of California, San Francisco School of Medicine

## **YASH CHAVDA, DO**

Resident, Department of Emergency Medicine  
St. Barnabas Hospital, Bronx

## **ANDREW ZUREICK**

University of Michigan Medical School  
Class of 2018

## **MEHBOOB KALANI, MD**

Resident, Department of Internal Medicine  
Allegheny Health Network Medical Education Consortium



New York / Chicago / San Francisco / Athens / London / Madrid / Mexico City  
Milan / New Delhi / Singapore / Sydney / Toronto

Copyright © 2017 by McGraw-Hill Education. All rights reserved. Except as permitted under the United States Copyright Act of 1976, no part of this publication may be reproduced or distributed in any form or by any means, or stored in a database or retrieval system, without the prior written permission of the publisher.

ISBN: 978-1-25-983762-3

MHID: 1-25-983762-9.

The material in this eBook also appears in the print version of this title: ISBN: 978-1-25-983763-0,  
MHID: 1-25-983763-7.

eBook conversion by codeMantra  
Version 1.0

All trademarks are trademarks of their respective owners. Rather than put a trademark symbol after every occurrence of a trademarked name, we use names in an editorial fashion only, and to the benefit of the trademark owner, with no intention of infringement of the trademark. Where such designations appear in this book, they have been printed with initial caps.

McGraw-Hill Education eBooks are available at special quantity discounts to use as premiums and sales promotions or for use in corporate training programs. To contact a representative, please visit the Contact Us page at [www.mhprofessional.com](http://www.mhprofessional.com).

### **Notice**

Medicine is an ever-changing science. As new research and clinical experience broaden our knowledge, changes in treatment and drug therapy are required. The authors and the publisher of this work have checked with sources believed to be reliable in their efforts to provide information that is complete and generally in accord with the standards accepted at the time of publication. However, in view of the possibility of human error or changes in medical sciences, neither the authors nor the publisher nor any other party who has been involved in the preparation or publication of this work warrants that the information contained herein is in every respect accurate or complete, and they disclaim all responsibility for any errors or omissions or for the results obtained from use of the information contained in this work. Readers are encouraged to confirm the information contained herein with other sources. For example and in particular, readers are advised to check the product information sheet included in the package of each drug they plan to administer to be certain that the information contained in this work is accurate and that changes have not been made in the recommended dose or in the contraindications for administration. This recommendation is of particular importance in connection with new or infrequently used drugs.

### **TERMS OF USE**

This is a copyrighted work and McGraw-Hill Education and its licensors reserve all rights in and to the work. Use of this work is subject to these terms. Except as permitted under the Copyright Act of 1976 and the right to store and retrieve one copy of the work, you may not decompile, disassemble, reverse engineer, reproduce, modify, create derivative works based upon, transmit, distribute, disseminate, sell, publish or sublicense the work or any part of it without McGraw-Hill Education's prior consent. You may use the work for your own noncommercial and personal use; any other use of the work is strictly prohibited. Your right to use the work may be terminated if you fail to comply with these terms.

THE WORK IS PROVIDED "AS IS." MCGRAW-HILL EDUCATION AND ITS LICENSORS MAKE NO GUARANTEES OR WARRANTIES AS TO THE ACCURACY, ADEQUACY OR COMPLETENESS OF OR RESULTS TO BE OBTAINED FROM USING THE WORK, INCLUDING ANY INFORMATION THAT CAN BE ACCESSED THROUGH THE WORK VIA HYPERLINK OR OTHERWISE, AND EXPRESSLY DISCLAIM ANY WARRANTY, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. McGraw-Hill Education and its licensors do not warrant or guarantee that the functions contained in the work will meet your requirements or that its operation will be uninterrupted or error free. Neither McGraw-Hill Education nor its licensors shall be liable to you or anyone else for any inaccuracy, error or omission, regardless of cause, in the work or for any damages resulting therefrom. McGraw-Hill Education has no responsibility for the content of any information accessed through the work. Under no circumstances shall McGraw-Hill Education and/or its licensors be liable for any indirect, incidental, special, punitive, consequential or similar damages that result from the use of or inability to use the work, even if any of them has been advised of the possibility of such damages. This limitation of liability shall apply to any claim or cause whatsoever whether such claim or cause arises in contract, tort or otherwise.

## **Dedication**

---

To the contributors to this and past editions, who took time to share their knowledge, insight, and humor for the benefit of students and physicians everywhere.

# Contents

Contributing Authors	vii	General Acknowledgments	xiii
Associate Authors	viii	How to Contribute	xvii
Faculty Advisors	ix	How to Use This Book	xix
Preface	xi	Selected USMLE Laboratory Values	xx
Special Acknowledgments	xii	First Aid Checklist for the USMLE Step 1	xxii

## ▶ SECTION I GUIDE TO EFFICIENT EXAM PREPARATION 1

Introduction	2	Test-Taking Strategies	20
USMLE Step 1—The Basics	2	Clinical Vignette Strategies	21
Defining Your Goal	12	If You Think You Failed	22
Excelling in the Preclinical Years	13	Testing Agencies	22
Timeline for Study	14	References	23
Study Materials	18		

## ▶ SECTION I SUPPLEMENT SPECIAL SITUATIONS 25

## ▶ SECTION II HIGH-YIELD GENERAL PRINCIPLES 27

How to Use the Database	28	Pathology	203
Biochemistry	31	Pharmacology	223
Immunology	91	Public Health Sciences	245
Microbiology	119		

**▶ SECTION III HIGH-YIELD ORGAN SYSTEMS 263**

Approaching the Organ Systems	264	Neurology and Special Senses	459
Cardiovascular	267	Psychiatry	523
Endocrine	311	Renal	547
Gastrointestinal	343	Reproductive	579
Hematology and Oncology	385	Respiratory	625
Musculoskeletal, Skin, and Connective Tissue	423	Rapid Review	651

**▶ SECTION IV TOP-RATED REVIEW RESOURCES 671**

How to Use the Database	672	Cell Biology and Histology	677
Question Banks	674	Microbiology and Immunology	677
Question Books	674	Pathology	677
Web and Mobile Apps	674	Pharmacology	678
Comprehensive	675	Physiology	679
Anatomy, Embryology, and Neuroscience	675	Abbreviations and Symbols	681
Behavioral Science	676	Image Acknowledgments	689
Biochemistry	676		
Index	711	About the Editors	777

---

# Contributing Authors

## **MARINA BOUSHRA, MD**

Resident, Department of Emergency Medicine  
East Carolina University/Vidant Medical Center

## **THEODORE CRISOSTOMO-WYNNE**

F. Edward Hébert School of Medicine  
Class of 2017

## **MATTHEW S. DELFINER**

New York Institute of Technology College of Osteopathic Medicine  
Class of 2017

## **ANGELA GAUTHIER**

Yale School of Medicine  
Class of 2018

## **BENJAMIN GOUGH, DO**

Resident, Department of General Surgery  
Christiana Care Health System

## **JAN ANDRE GRAUMAN, MD, MA**

Family Medicine Resident, Northern Remote Stream  
University of Manitoba

## **JESSICA F. JOHNSTON, MSc**

Yale School of Medicine  
MD/PhD Candidate

## **JAMES N. McCOY**

Texas A&M Health Science Center  
Class of 2017

## **M. SCOTT MOORE, DO**

Research Fellow  
Affiliated Dermatology

## **JUN YEN NG, MD**

Intern  
Central Queensland Hospital and Health Services

## **SATYAJIT REDDY, MD**

Resident, Department of Internal Medicine  
Temple University Hospital

## **VADIM ROSIN**

University of Michigan Medical School  
Class of 2017

## **SARAH SCHIMANSKY, MB BCh BAO**

Academic Foundation Doctor  
North Bristol NHS Trust

## **ZACHARY G. SCHWAM, MD**

Resident, Department of Otolaryngology  
Icahn School of Medicine at Mount Sinai

## **NINO SIKHARULIDZE, MD**

Department of Endocrinology  
Tbilisi State Medical University

## **VAISHNAVI VAIDYANATHAN**

University of Missouri-Kansas City School of Medicine  
Class of 2018

## **IMAGE AND ILLUSTRATION TEAM**

### **RYAN W. HADDEN**

University of Alabama School of Medicine  
Class of 2017

### **RENATA VELAPATIÑO**

San Martín de Porres University  
School of Medicine

---

# Associate Authors

## **JAMES E. BATES, MD**

Resident, Department of Radiation Oncology  
University of Florida School of Medicine

## **REED GILBOW, MD**

Resident, Department of Otolaryngology–Head and Neck Surgery  
University of Virginia School of Medicine

## **RYAN KELSCH**

Midwestern University Chicago College of Osteopathic Medicine  
Class of 2017

## **JESSE D. SENGILLO**

SUNY Downstate College of Medicine  
Class of 2018

## **WENHUI ZHOU**

Tufts University School of Medicine  
MD/PhD Candidate

## **IMAGE AND ILLUSTRATION TEAM**

### **NAKEYA KHOZEMA DEWASWALA**

Lokmanya Tilak Municipal Medical College  
Class of 2016



# Faculty Advisors

## **MARK A.W. ANDREWS, PhD**

Lake Erie College of Osteopathic Medicine at Seton Hill  
Greensburg, PA

## **MARIA ANTONELLI, MD**

Clinical Faculty, Division of Rheumatology  
Case Western Reserve University School of Medicine

## **HERMAN SINGH BAGGA, MD**

Urologist, Allegheny Health Network  
University of Pittsburgh Medical Center

## **ADITYA BARDIA, MBBS, MPH**

Attending Physician, Massachusetts General Hospital  
Harvard Medical School

## **PAULETTE BERND, PhD**

Professor, Department of Pathology and Cell Biology  
Columbia University College of Physicians and Surgeons

## **SHELDON CAMPBELL, MD, PhD**

Associate Professor of Laboratory Medicine  
Yale School of Medicine

## **BROOKS D. CASH, MD**

Professor of Medicine, Division of Gastroenterology  
University of South Alabama School of Medicine

## **SHIVANI VERMA CHMURA, MD**

Adjunct Clinical Faculty, Department of Psychiatry  
Stanford University School of Medicine

## **PETER V. CHIN-HONG, MD**

Professor, Department of Medicine  
University of California, San Francisco School of Medicine

## **CHRISTINA E. CIACCIO, MD, MSc**

Assistant Professor, Departments of Pediatrics and Medicine  
The University of Chicago Pritzker School of Medicine

## **LINDA S. COSTANZO, PhD**

Professor, Physiology & Biophysics  
Virginia Commonwealth University School of Medicine

## **ANTHONY L. DeFRANCO, PhD**

Professor, Department of Microbiology and Immunology  
University of California, San Francisco School of Medicine

## **CHARLES S. DELA CRUZ, MD, PhD**

Assistant Professor, Department of Pulmonary and Critical Care Medicine  
Yale School of Medicine

## **CONRAD FISCHER, MD**

Associate Professor, Medicine, Physiology, and Pharmacology  
Touro College of Medicine

## **JEFFREY J. GOLD, MD**

Associate Professor, Department of Neurology  
Assistant Professor, University of California, San Diego School of Medicine

## **RAYUDU GOPALAKRISHNA, PhD**

Associate Professor, Department of Cell and Neurobiology  
Keck School of Medicine of University of Southern California

## **RYAN C.W. HALL, MD**

Assistant Professor, Department of Psychiatry  
University of South Florida

## **LOUISE HAWLEY, PhD**

Immediate Past Professor and Chair, Department of Microbiology  
Ross University School of Medicine

## **MARGARET M. HAYES, MD**

Instructor of Medicine  
Harvard Medical School

## **JEFFREY W. HOFMANN, MD, PhD**

Resident, Department of Pathology  
University of California, San Francisco School of Medicine

## **BRIAN C. JENSEN, MD**

Assistant Professor of Medicine and Pharmacology  
University of North Carolina Health Care

## **CLARK KEBODEAUX, PharmD**

Clinical Assistant Professor, Pharmacy Practice and Science  
University of Kentucky College of Pharmacy

## **MICHAEL R. KING, MD**

Instructor, Department of Pediatric Anesthesiology  
Northwestern University Feinberg School of Medicine

## **KRISTINE KRAFTS, MD**

Assistant Professor, Department of Basic Sciences  
University of Minnesota School of Medicine

**GERALD LEE, MD**

Assistant Professor, Department of Pediatrics  
University of Louisville School of Medicine

**KACHIU C. LEE, MD, MPH**

Assistant Clinical Professor, Department of Dermatology  
Brown University, Providence, Rhode Island

**WARREN LEVINSON, MD, PhD**

Professor, Department of Microbiology and Immunology  
University of California, San Francisco School of Medicine

**PETER MARKS, MD, PhD**

Center for Biologics Evaluation and Research  
US Food and Drug Administration

**J. RYAN MARTIN, MD**

Assistant Professor of Obstetrics, Gynecology, and Reproductive Sciences  
Yale School of Medicine

**DOUGLAS A. MATA, MD, MPH**

Brigham and Women's Hospital  
Harvard Medical School

**VICKI PARK, PhD**

Associate Professor, Pediatrics and Medical Education  
University of Tennessee Health Science Center

**JEANNINE RAHIMIAN, MD, MBA**

Associate Professor, Obstetrics and Gynecology  
David Geffen School of Medicine at UCLA

**SOROUSH RAIS-BAHRAMI, MD**

Assistant Professor, Urology and Radiology  
The University of Alabama at Birmingham School of Medicine

**SASAN SAKIANI, MD**

Assistant Professor, Department of Medicine  
Case Western Reserve University School of Medicine

**ROBERT A. SASSO, MD**

Professor of Clinical Medicine  
Ross University School of Medicine

**JOSEPH L. SCHINDLER, MD**

Assistant Professor, Neurology and Neurosurgery  
Yale School of Medicine

**MELANIE SCHORR, MD**

Research Fellow, Department of Medicine  
Massachusetts General Hospital

**NATHAN W. SKELLEY, MD**

Assistant Professor, Department of Orthopaedic Surgery  
University of Missouri, The Missouri Orthopaedic Institute

**SHEENA STANARD, MD, MHS**

Hospitalist  
State University of New York Upstate Hospital

**HOWARD M. STEINMAN, PhD**

Assistant Dean, Biomedical Science Education  
Albert Einstein College of Medicine

**STEPHEN F. THUNG, MD**

Associate Professor, Department of Obstetrics and Gynecology  
The Ohio State University College of Medicine

**RICHARD P. USATINE, MD**

Professor, Dermatology and Cutaneous Surgery  
University of Texas Health Science Center San Antonio

**PRASHANT VAISHNAVA, MD**

Assistant Professor, Department of Medicine  
Mount Sinai Hospital and Icahn School of Medicine

**J. MATTHEW VELKEY, PhD**

Assistant Dean, Basic Science Education  
Duke University School of Medicine

**BRIAN WALCOTT, MD**

Clinical Instructor, Department of Neurological Surgery  
University of California, San Francisco

**TISHA WANG, MD**

Associate Clinical Professor, Department of Medicine  
David Geffen School of Medicine at UCLA

**SYLVIA WASSERTHEIL-SMOLLER, PhD**

Professor Emerita, Department of Epidemiology and Population Health  
Albert Einstein College of Medicine

**ADAM WEINSTEIN, MD**

Assistant Professor, Pediatric Nephrology and Medical Education  
Geisel School of Medicine at Dartmouth

# Preface

With the 27th edition of *First Aid for the USMLE Step 1*, we continue our commitment to providing students with the most useful and up-to-date preparation guide for the USMLE Step 1. This edition represents an outstanding revision in many ways, including:

- 30+ entirely new facts with continued expansion of quality improvement principles, safety science, and healthcare delivery to align more closely with the USMLE Content Outline.
- Hundreds of major fact updates culled from thousands of student and faculty contributions.
- Extensive text revisions, new mnemonics, clarifications, and corrections curated by a team of more than 25 medical student and resident physician authors who excelled on their Step 1 examinations and verified by a team of expert faculty advisors and nationally recognized USMLE instructors.
- Complete reorganization of the neurology chapter to better distinguish normal physiology from neuropathology and to emphasize the special senses.
- Improved Rapid Review section with page numbers to the text, to quickly find these high-yield concepts in context.
- Updated with more than 100+ new or revised full-color photos to help visualize various disorders, descriptive findings, and basic science concepts. In particular, imaging photos have been labeled and optimized to show both normal anatomy and pathologic findings.
- Updated with dozens of new and revised diagrams. We continue to expand our collaboration with USMLE-Rx (MedIQ Learning, LLC) to develop and enhance illustrations with improved information design to help students integrate pathophysiology, therapeutics, and diseases into memorable frameworks.
- A revised exam preparation guide with updated data from the USMLE and NRMP. The guide also features new evidence-based techniques for efficient and effective test preparation. The updated supplemental guide for IMGs, osteopathic and podiatry students, and students with a disability can be found at our blog, [www.firstaidteam.com](http://www.firstaidteam.com).
- An updated summary guide to student-recommended USMLE Step 1 review resources, including mobile apps for iOS and Android. The full resource guide with detailed descriptions can be found at our blog.
- Real-time Step 1 updates and corrections can also be found exclusively on our blog.

We invite students and faculty to share their thoughts and ideas to help us continually improve *First Aid for the USMLE Step 1* through our blog and collaborative editorial platform. (See How to Contribute, p. xvii.)

<i>Louisville</i>	Tao Le
<i>Boracay</i>	Vikas Bhushan
<i>Philadelphia</i>	Matthew Sochat
<i>New York City</i>	Yash Chavda
<i>Ann Arbor</i>	Andrew Zureick
<i>Pittsburgh</i>	Mehboob Kalani
<i>San Francisco</i>	Kimberly Kallianos

# Special Acknowledgments

This has been a collaborative project from the start. We gratefully acknowledge the thousands of thoughtful comments, corrections, and advice of the many medical students, international medical graduates, and faculty who have supported the authors in our continuing development of *First Aid for the USMLE Step 1*.

We provide special acknowledgment and thanks to the following individuals who made exemplary contributions to this edition through our voting, proofreading, and crowdsourcing platform: Anosh Ahmed, Kashif Badar, Humood Boqambar, Anup Chalise, Wendy Chen, Francis Deng, Anthony J. Febres, Okubit Gebreyonas, Richard Godby, Christina Govas, Eric Irons, Nikhar Kinger, Katherine Kramme, Jonathan Li, Micah Mathai, Nicolaus Mephis, Ryan Meyer, Joseph Mininni, Iraj Nasrabadi, Jimmy Tam Huy Pham, Keyhan Piranviseh, Anthony Purgianto, Casey Joseph Rosenthal, Sana Sheraz, Avinainder Singh, Paul Walden, Isabella Wu, and Xuebao Zhang. For illustration contributions, we also thank Wendy Abbott.

For support and encouragement throughout the process, we are grateful to Thao Pham, Jinky Flang, and Jonathan Kirsch, Esq. Thanks to Louise Petersen for organizing and supporting the project. Thanks to our publisher, McGraw-Hill, for the valuable assistance of its staff, including Christina Thomas, Jim Shanahan, Laura Libretti, Midge Haramis, and Jeffrey Herzich.

We are also very grateful to Dr. Fred Howell and Dr. Robert Cannon of Textensor Ltd for providing us extensive customization and support for their powerful Annotate.co collaborative editing platform ([www.annotate.co](http://www.annotate.co)), which allows us to efficiently manage thousands of contributions. Thanks to Dr. Richard Usatine for his outstanding dermatologic and clinical image contributions. Thanks also to Jean-Christophe Fournet ([www.humpath.com](http://www.humpath.com)), Dr. Ed Uthman, and Dr. Frank Gaillard ([www.radiopaedia.org](http://www.radiopaedia.org)) for generously allowing us to access some of their striking photographs. We especially thank Dr. Kristine Krafts for many insightful text and image contributions throughout the extensive revision.

For exceptional editorial leadership, enormous thanks to Christine Diedrich, Emma Underdown, and Catherine Johnson. Thank you to our USMLE-Rx/ScholarRx team of editors, Linda Davoli, Jacqueline Mahon, Janene Matragrano, Erika Nein, Isabel Nogueira, Rebecca Stigall, Ashley Vaughn, and Hannah Warnshuis. Many thanks to Tara Price for page design and all-around InDesign expertise. Special thanks to our indexer Dr. Anne Fifer. We are also grateful to our medical illustrator, Hans Neuhart, for his creative work on the new and updated illustrations. Lastly, tremendous thanks to Rainbow Graphics, especially David Hommel and Donna Campbell, for remarkable ongoing editorial and production support under time pressure.

<i>Louisville</i>	Tao Le
<i>Boracay</i>	Vikas Bhushan
<i>Philadelphia</i>	Matthew Sochat
<i>New York City</i>	Yash Chavda
<i>Ann Arbor</i>	Andrew Zureick
<i>Pittsburgh</i>	Mehboob Kalani
<i>San Francisco</i>	Kimberly Kallianos

---

# General Acknowledgments

Each year we are fortunate to receive the input of thousands of medical students and graduates who provide new material, clarifications, and potential corrections through our website and our collaborative editing platform. This has been a tremendous help in clarifying difficult concepts, correcting errata from the previous edition, and minimizing new errata during the revision of the current edition. This reflects our long-standing vision of a true, student-to-student publication. We have done our best to thank each person individually below, but we recognize that errors and omissions are likely. Therefore, we will post an updated list of acknowledgments at our website, [www.firstaidteam.com/bonus/](http://www.firstaidteam.com/bonus/). We will gladly make corrections if they are brought to our attention.

For submitting contributions and corrections, many thanks to Mohammed Abed, Asif Abidi, John David Adame, Poppy Addison, Onaola Adedeji, Comfort Agaba, Vivian Agumadu, Bilawal Ahmed, Zoey Akah, Hamed Akbari, Pegah Akbari, Marwan Alahiri, Fadi Al-Asadi, Lourdes Alberty, Christian Alch, Erica Alcibiade, Majed Alghamdi, Mohammed Alhaidar, Nasir Alhamdan, Albert Alhatem, Alaa Alibrahim, Mohammed Alsaggaf, Luai M. Alsakaf, Khaled Al-Sawalmeh, Vaidehi Ambai, Kevin An, Anna Anderson, Christopher Anderson, Mehdi Ansari, Nelson Arellano, Gabriel Arom, Immad Attique, Nicholas Austin, Mary Ayad, Cho New Aye, Marwan Azzam, Ram Baboo, Rahaf Baker, Brian Baksa, Vijay Balakrishnan, Vyshnavy Balendra, Melissa Banez, Gauri Barlingay, Ross Barman, Frances M. Marrero Barrera, Josh Barrick, Jason Batey, Priya Batta, Rosemary Noel Beavers, Sean Behan, Jorge Martinez Bencosme, Kene Ben-Okafor, Elodie Marie Betances, Maria Betances, Shea Bielby, Johnathon Bishop, Aaron Blackshaw, Edgar Blecker, Cary Blum, Peter Boateng, Nwamaka Bob-Ume, Victoria Bone, Stephanie Borinsky, Adam Bortner, Chantal Brand, Shannon Brougner, Sareena Brown, Rob Brumer, Ryan Brunetti, Takur Buck, Alejandro Bugarini, Nimerta Burmhi, James Butz, Jennifer Byrd, Stefan Campbell, Fiorella B. Castillo, Harold Cedeño, Kenan Celtik, Yusuf Chao, Kyriakos Chatzopoulos, Jessica Chen, Julia Chen, Stephanie Yi-Tsi Chen, Willie Chen, Charlie Cheng, Olivia Cheng, Shani Chibber, Tiffany Chomko, Manita Choudhary, Eric Christie, Melissa Chung, Casey Lane Clark, Beth Clymer, Sam Cochran, Lauren Coleman, Benjamin Comora, Jensyn Cone, Zachary R. Conley, Sarah Corral, Eliana Costantino, Ian Cox, Robert Cox, Crosby Culp, John Cummins, Helen Dainton, Christopher Dallo, Jonathan Dang, Laura Dankovich, Atman Dave, Eric Davied, Joshua Davis, Danielle Davis, Solomon Dawson, Ezra Dayan, Ryan DeAngelis, Kathryn Demitruk, Jessie Dhaliwal, Rahim Dhanani, Travis Dice, Abiot Didana, Cheri Dijamco, Ozan Dikilitas, Isaac M. Dodd, Kirsten Dowling, Mitch Dunklebarger, Khanh Duong, Marco Duverseau, Josh East, Jeremy Eckes, Elise Edoka, Rachel Einarsson, Hannah Eisen, Tyler Emerson, Jon Erdman, Cynthia Estrada, Matthew Fadus, Giselle Falconi, Tabbassum Fayyaz, Ravali Feeramachaneni, Kaveh Fekri, Albert Fernandez, Maria Vanessa Ferrer, Roberto Hurtado Fiel, Nicholas Field, Ryan Finn, Helen Francis, Daniel Franco, Cameron Frederick, Eli Fredman, Sheri Frickey, Gianfranco Frojo, Malak Fuad, James Fuqua, Anita Gade, Sudha Gade, Nicholas Gamboa, Avi Gandhi, Jared Gans, Russell Garcia, P. M. Gayed, Nicholas Geiger, Alejandro Gener, John George, Maikel Ragaai Fahmi Gerges, Imran Ghare, Gaby Ghobrial, Javid Ghomashi, Gino Giannone, Lizz Gilmore, Priscilla Alvarez Gonzalez, Luis Fernando Gonzalez-Ciccarelli, Ashwani Gore, Sophie Gott, Crystal D. Green, Brian Grice, John Grotberg, Li Guiqin,

Nita Gupta, Gail Gutman, Samuel Guyer, Natalia Guzmman-Seda, Fuad Habbal, Sean M. Hacking, Erik Haley, Oday Halhouli, Martin Halicek, Isaiah Hammonds, Nicola Hampel, Brian Handal, Roy Handelsman, Jamison Harvey, Hunaid Hasan, Makenzie Hatfield Kresch, Joel Hayden, Mona Hdeib, Kasey Helmlinger, Katy Helms, Michelle Herberts, Cinthia Marie Gonzalez Hernandez, Ariana Hess, Mitchell Heuermann, Richard Hickman, Tiffany Hinojosa, Joyce Ho, M. Ho, Patrick Holman, Jeffeory Howard, Paige Hoyer, Jonathan C. Hu, Ann Hua, Jack Hua, I-Chun Hung, Frank S. Hurd, Ibrahim Hyder, David Ianacone, Jouzif Ibrahim, Taylin Im, Saira Iqbal, Josh Isserman, Mimoza Isufi, Kelechi Izunobi, Pegah Jahangiri, Sakshi Jain, Maryam Mohammed Jallo, Mitra Jamshidian, Neetu Jamwal, Paige Jarmuz, Zahran Jdaitawi, Kyu-Jin Jeon, Benjamin Hans Jeuk, Jose F. Jimenez, Sally Jo, Alfredo Joffre, Andrew Johnson, Jordan E. Johnson, Kai Johnson, Katherine Joltikov, Gavin Jones, Saman Doroodgar Jorshery, Vaidehi Joshi, Shirley Ju, Michael Kagan, Hanna Kakish, Kirill Karlin, Michael Karp, Aaron R. Kaufman, LaDonna Kears, Sorena Keihani, Shamim Khan, Tamer Khashab, Mitra Khosravi, Amin Khosrowpour, Neharika Khurana, Beom Soo Kim, Christina Kim, Robert Kim, Yoo Jung Kim, Megan King, Vladimer Kitiashvili, David E. Klein, Mohammed Sammy Knefati, George Koch, Noah Kojima, Amol Koldhekar, Samantha Kops, Sai Krishna Korada, Zachary Koretz, Heather Kornmehl, David Kowal, Kathleen Kramer, Akash Kroeger, Elan Krojanker, Matthew Kurian, Anita Kurre, Rachel Kushner, Eustina Kwon, Michael Larson, George Lasker, Evangelia Lazaris, Aaron A. Lebron Burgos, Christina Dami Lee, James Lee, Jennifer Lee, Erica Lee, Rachel Leeman, Ryan Lena, Stacy Leung, Guanqun Li, Yedda Li, Ramon Li, Guohua Liang, Soobin Lim, Meng-Chen Vanessa Lin, Matthew Lippmann, Selina Liu, Alnardo Lora, Yancheng Luo, Ahmed Lutfi, Martin Ma, Ahmad Mahadeen, Nandita N. Mahajan, Gajendra Maharjan, Megan Maier, Nodari Maisuradze, Rohail Malik, Andrew Martella, Beatriz Martinez, Eden Marx, Christy Mathew, Aletha Anisha Mathias, Alex McDonald, Robert McKenna, Maggie Meier, Wendy Mejia, Theresa Meloche, Elizabeth Mertilus, Jersey Mettillie-Butts, Marielle Meurice, Sarah Michelson, Austin Mike-Mayer, Nardine Mikhail, Vincent Mirabile, Ahmed Mohamed, Hassan Reyad Mohsen, Nate Moore, Rose Mueller, Amer Muhyieddeen, Natia Murvelashvili, Anadarajan Nadarajan, Louai Naddaf, Shane Naidoo, Khushabu Nayak, Mai-Trang Nguyen, Michael Nguyen, Thomas Nienaber, Bharati Nimje, Cynthia Noguera, Albert Nwabueze, Devon O'Brien, Lola Ogunsuyi, Ololade Ogunsuyi, Olguta Olea, Wilson Omesiete, Michael Osinski, Vasily Ovechko, Jordan Owens, Devon Pace, Zonghao Pan, Khang Wen Pang, Olga Paniagua, Silvia Paola, Erika Parisi, Andrew Park, Madhumithaa Parthasarathy, Ishan Patel, Saikrishna Patibandla, Iqra Patoli, David Patterson, Lanieka Peck, Alexander Pennekamp, Luisa Peress, Max Petersen, Romela Petrosyan, Patryk Piekos, Sarah Pietruszka, Luis Pina, Yuval Pinto, Andrew Piropato, Phillip Plager, Netanya Pollock, Gautham Prabhakar, Will Preston, Grace Pryor, Audrey Pulitzer, Tyler Putnam, Connie Qiu, Brian Quaranto, Fatima Quddusi, Carlos Quinonez, Maria Qureshi, Samir Rahman, Saad Rahmat, Alia Raja, Vinaya Rajan, Arun Rajaratnam, Ferza Raks, Juhi Ramchandani, Judith Ramel, Josean Ramos, Cesar Augusto Hernandez Rangel, Dhakshitha Rao, Mohsin Raza, Sushma Reddy, Dave Reyes, Lenisse Miguelina Reyes, Robert Riggio, Ernest James Rin, Julia Ringel, Moshe Roberts, Clara Robertson, Sam Robinson, Agalic Rodriguez, Juliana D. Rodriguez, Jorge Roman, Luis Rosario, Alexander Rowan, Julietta Rubin, Daniel Rubinger, Martin Runnström, Nicholas Russo, David Rutenberg, Sean Saadat, Stuart Sacks, Rorita Sadhu, Atin Saha, Haneen Salah, Mohamad Saleh, Rafael E. Valle Salinas, Jacqueline Sanchez, Natalia Santiago-Morales, Steven Sapozhnikov, Ashley Sareen, Jason Sarte, Claire Sathe, Darya Savel, Osama Sbeitan, Ghil Schwarz, Caleb Seavey, Roopak Sekhon, Anna Sevilla, Anand Sewak, Akash Shah, Anna Shah, Muneeb Shah, Sherina Shahbazian, Abdulla Shaheen, Ojochide Shaibu, Mhd Tayseer Shamaa, Bryan Shapiro, Dolly Sharma, Demetrio Sharp, Jia Shi, Helen Shi, Ryan Sieli, Tyler Simpson, Vikal Singh, Chandandeep Singh, Ramzi Skaik, Omar Abu Slieh, Joey Sneij, Navjot Sobti, Tom Soker, Jun Song, Sushant Soni, Mihir Soparkar, Vlasios Sotirchos, Amelia St.Ange, Mac Staben, Clay Stafford, Allan Stolarski, Sonia A Sugumar, Mark Anthony Sy, Angela Taeschner, Dawood Tafti, Nitin Tandan, David Taylor, Abiolah Telesford, George Terre, Sam Thomas, Akhilesh Thota, Sandra Tomlinson-Hansen, Carlos E. Velez Torres, Derrick Tran, Vi Tran, Michael Troutman, Cindy L. Tsui, Harika R. Tula, Michael Turgeon, Esonoes Tururu, Marcia Uddoh, Daniel Udrea, Nkechi Ukeekwe, Sara Usman, Akash Vadhavana, Royson L. Vallliyil, Leah D. Vance, Blanca Vargas, Alexander

Vartanov, Jayalakshmi Venkateswaran, Bhanu Verma, Shawn Verma, Andrea Victorio, Anthony Viola III, Miriam Volosen, Habiba Wada, Benjamin Warren, Juliana Watson, Hannah Wellman, Stanley J. Welsh, Pang Khang Wen, Richard Whitlock, Jimbo Wilhite, Michael Winter, Jonathan Wolfson, John Worth, Eva Wu, Birdy Xu, Antonio Yaghy, Jehan Yahya, Xiaofeng Yan, Rebecca Ye, Raquel Yokoda, Alexander Yuen, William Yuen, Alan Zats, Billy Zhang, Park Zheng, and Andrew Zilavy.

---

# How to Contribute

This version of *First Aid for the USMLE Step 1* incorporates thousands of contributions and improvements suggested by student and faculty advisors. We invite you to participate in this process. Please send us your suggestions for:

- Study and test-taking strategies for the USMLE Step 1
- New facts, mnemonics, diagrams, and clinical images
- High-yield topics that may appear on future Step 1 exams
- Personal ratings and comments on review books, question banks, apps, videos, and courses

For each new entry incorporated into the next edition, you will receive up to a **\$20 Amazon.com gift card** as well as personal acknowledgment in the next edition. Significant contributions will be compensated at the discretion of the authors. Also, let us know about material in this edition that you feel is low yield and should be deleted.

All submissions including potential errata should ideally be supported with hyperlinks to a dynamically updated Web resource such as UpToDate, AccessMedicine, and ClinicalKey.

We welcome potential errata on grammar and style if the change improves readability. Please note that *First Aid* style is somewhat unique; for example, we have fully adopted the *AMA Manual of Style* recommendations on eponyms (“We recommend that the possessive form be omitted in eponymous terms”) and on abbreviations (no periods with eg, ie, etc).

The preferred way to submit new entries, clarifications, mnemonics, or potential corrections with a valid, authoritative reference is via our website: **[www.firstaidteam.com](http://www.firstaidteam.com)**.

This website will be continuously updated with validated errata, new high-yield content, and a new online platform to contribute suggestions, mnemonics, diagrams, clinical images, and potential errata.

Alternatively, you can email us at: **[firstaidteam@yahoo.com](mailto:firstaidteam@yahoo.com)**.

Contributions submitted by **May 15, 2017**, receive priority consideration for the 2018 edition of *First Aid for the USMLE Step 1*. We thank you for taking the time to share your experience and apologize in advance that we cannot individually respond to all contributors as we receive thousands of contributions each year.



## ▶ NOTE TO CONTRIBUTORS

All contributions become property of the authors and are subject to editing and reviewing. Please verify all data and spellings carefully. Contributions should be supported by at least two high-quality references.

Check our website first to avoid duplicate submissions. In the event that similar or duplicate entries are received, only the first complete entry received with valid, authoritative references will be credited. Please follow the style, punctuation, and format of this edition as much as possible.

## ▶ JOIN THE FIRST AID TEAM

The *First Aid* author team is pleased to offer part-time and full-time paid internships in medical education and publishing to motivated medical students and physicians. Internships range from a few months (eg, a summer) up to a full year. Participants will have an opportunity to author, edit, and earn academic credit on a wide variety of projects, including the popular *First Aid* series.

For 2017, we are actively seeking passionate medical students and graduates with a specific interest in improving our medical illustrations, expanding our database of medical photographs, and developing the software that supports our crowdsourcing platform. We welcome people with prior experience and talent in these areas. Relevant skills include clinical imaging, digital photography, digital asset management, information design, medical illustration, graphic design, and software development.

Please email us at [firstaidteam@yahoo.com](mailto:firstaidteam@yahoo.com) with a CV and summary of your interest or sample work.

# How to Use This Book

**CONGRATULATIONS:** You now possess the book that has guided nearly two million students to USMLE success for over 25 years. With appropriate care, the binding should last the useful life of the book. Keep in mind that putting excessive flattening pressure on any binding will accelerate its failure. If you purchased a book that you believe is defective, please **immediately** return it to the place of purchase. If you encounter ongoing issues, you can also contact Customer Service at our publisher, McGraw-Hill Education, at <https://www.mheducation.com/contact.html>.

**START EARLY:** Use this book as early as possible while learning the basic medical sciences. The first semester of your first year is not too early! Devise a study plan by reading Section I: Guide to Efficient Exam Preparation, and make an early decision on resources to use by checking Section IV: Top-Rated Review Resources. Note that *First Aid* is neither a textbook nor a comprehensive review book, and it is not a panacea for inadequate preparation.

**CONSIDER *FIRST AID* YOUR ANNOTATION HUB:** Annotate material from other resources, such as class notes or comprehensive textbooks, into your book. This will keep all the high-yield information you need in one place. Other tips on keeping yourself organized:

- For best results, use fine-tipped ballpoint pens (eg, BIC Pro+, Uni-Ball Jetstream Sports, Pilot Drawing Pen, Zebra F-301). If you like gel pens, try Pentel Slicci, and for markers that dry almost immediately, consider Staedtler Triplus Fineliner, Pilot Drawing Pen, and Sharpies.
- Consider using pens with different colors of ink to indicate different sources of information (eg, blue for USMLE-Rx Step 1 Qmax, green for UWorld Step 1 Qbank).
- Choose highlighters that are bright and dry quickly to minimize smudging and bleeding through the page (eg, Tombow Kei Coat, Sharpie Gel).
- Many students de-spine their book and get it 3-hole-punched. This will allow you to insert materials from other sources, such as course syllabi.

**INTEGRATE STUDY WITH CASES, FLASH CARDS, AND QUESTIONS:** To broaden your learning strategy, consider integrating your *First Aid* study with case-based reviews (eg, *First Aid Cases for the USMLE Step 1*), flash cards (eg, First Aid Flash Facts), and practice questions (eg, the USMLE-Rx Step 1 Qmax). Read the chapter in the book, then test your comprehension by using cases, flash cards, and questions that cover the same topics. Maintain access to more comprehensive resources (eg, *First Aid for the Basic Sciences: General Principles and Organ Systems* and First Aid Express videos) for deeper review as needed.

**PRIME YOUR MEMORY:** Return to your annotated Sections II and III several days before taking the USMLE Step 1. The book can serve as a useful way of retaining key associations and keeping high-yield facts fresh in your memory just prior to the exam. The Rapid Review section includes high-yield topics to help guide your studying.

**CONTRIBUTE TO *FIRST AID*:** Reviewing the book immediately after your exam can help us improve the next edition. Decide what was truly high and low yield and send us your comments. Feel free to send us scanned images from your annotated *First Aid* book as additional support. Of course, always remember that **all examinees are under agreement with the NBME to not disclose the specific details of copyrighted test material.**

# Selected USMLE Laboratory Values

\* = Included in the Biochemical Profile (SMA-12)

Blood, Plasma, Serum	Reference Range	SI Reference Intervals
* Alanine aminotransferase (ALT, GPT at 30°C)	8–20 U/L	8–20 U/L
Amylase, serum	25–125 U/L	25–125 U/L
* Aspartate aminotransferase (AST, GOT at 30°C)	8–20 U/L	8–20 U/L
Bilirubin, serum (adult)		
Total // Direct	0.1–1.0 mg/dL // 0.0–0.3 mg/dL	2–17 μmol/L // 0–5 μmol/L
* Calcium, serum (Total)	8.4–10.2 mg/dL	2.1–2.8 mmol/L
* Cholesterol, serum (Total)	< 200 mg/dL	< 5.2 mmol/L
* Creatinine, serum (Total)	0.6–1.2 mg/dL	53–106 μmol/L
Electrolytes, serum		
Sodium	136–145 mEq/L	136–145 mmol/L
Chloride	95–105 mEq/L	95–105 mmol/L
* Potassium	3.5–5.0 mEq/L	3.5–5.0 mmol/L
Bicarbonate	22–28 mEq/L	22–28 mmol/L
Magnesium	1.5 mEq/L	0.75–1.0 mmol/L
Gases, arterial blood (room air)		
P <sub>O<sub>2</sub></sub>	75–105 mm Hg	10.0–14.0 kPa
P <sub>CO<sub>2</sub></sub>	33–44 mm Hg	4.4–5.9 kPa
pH	7.35–7.45	[H <sup>+</sup> ] 36–44 nmol/L
* Glucose, serum	Fasting: 70–110 mg/dL 2-h postprandial: < 120 mg/dL	3.8–6.1 mmol/L < 6.6 mmol/L
Growth hormone – arginine stimulation	Fasting: < 5 ng/mL provocative stimuli: > 7 ng/mL	< 5 μg/L > 7 μg/L
Osmolality, serum	275–295 mOsm/kg	275–295 mOsm/kg
* Phosphatase (alkaline), serum (p-NPP at 30°C)	20–70 U/L	20–70 U/L
* Phosphorus (inorganic), serum	3.0–4.5 mg/dL	1.0–1.5 mmol/L
Prolactin, serum (hPRL)	< 20 ng/mL	< 20 μg/L
* Proteins, serum		
Total (recumbent)	6.0–7.8 g/dL	60–78 g/L
Albumin	3.5–5.5 g/dL	35–55 g/L
Globulins	2.3–3.5 g/dL	23–35 g/L
* Urea nitrogen, serum (BUN)	7–18 mg/dL	1.2–3.0 mmol/L
* Uric acid, serum	3.0–8.2 mg/dL	0.18–0.48 mmol/L

(continues)

Cerebrospinal Fluid	Reference Range	SI Reference Intervals
Glucose	40–70 mg/dL	2.2–3.9 mmol/L
<b>Hematologic</b>		
Erythrocyte count	Male: 4.3–5.9 million/mm <sup>3</sup> Female: 3.5–5.5 million/mm <sup>3</sup>	4.3–5.9 × 10 <sup>12</sup> /L 3.5–5.5 × 10 <sup>12</sup> /L
Erythrocyte sedimentation rate (Westergen)	Male: 0–15 mm/h Female: 0–20 mm/h	0–15 mm/h 0–20 mm/h
Hematocrit	Male: 41–53% Female: 36–46%	0.41–0.53 0.36–0.46
Hemoglobin, blood	Male: 13.5–17.5 g/dL Female: 12.0–16.0 g/dL	2.09–2.71 mmol/L 1.86–2.48 mmol/L
Hemoglobin, plasma	1–4 mg/dL	0.16–0.62 μmol/L
Leukocyte count and differential		
Leukocyte count	4500–11,000/mm <sup>3</sup>	4.5–11.0 × 10 <sup>9</sup> /L
Segmented neutrophils	54–62%	0.54–0.62
Band forms	3–5%	0.03–0.05
Eosinophils	1–3%	0.01–0.03
Basophils	0–0.75%	0–0.0075
Lymphocytes	25–33%	0.25–0.33
Monocytes	3–7%	0.03–0.07
Mean corpuscular hemoglobin	25.4–34.6 pg/cell	0.39–0.54 fmol/cell
Mean corpuscular volume	80–100 μm <sup>3</sup>	80–100 fL
Partial thromboplastin time (activated)	25–40 seconds	25–40 seconds
Platelet count	150,000–400,000/mm <sup>3</sup>	150–400 × 10 <sup>9</sup> /L
Prothrombin time	11–15 seconds	11–15 seconds
Reticulocyte count	0.5–1.5% of red cells	0.005–0.015
<b>Sweat</b>		
Chloride	0–35 mmol/L	0–35 mmol/L
<b>Urine</b>		
Proteins, total	< 150 mg/24 h	< 0.15 g/24 h

## First Aid Checklist for the USMLE Step 1

This is an example of how you might use the information in Section I to prepare for the USMLE Step 1. Refer to corresponding topics in Section I for more details.

### Years Prior

- Select top-rated review resources as study guides for first-year medical school courses.
- Ask for advice from those who have recently taken the USMLE Step 1.

### Months Prior

- Review computer test format and registration information.
- Register six months in advance. Carefully verify name and address printed on scheduling permit. Call Prometric or go online for test date ASAP.
- Define goals for the USMLE Step 1 (eg, comfortably pass, beat the mean, ace the test).
- Set up a realistic timeline for study. Cover less crammable subjects first. Review subject-by-subject emphasis and clinical vignette format.
- Simulate the USMLE Step 1 to pinpoint strengths and weaknesses in knowledge and test-taking skills.
- Evaluate and choose study methods and materials (eg, review books, question banks).

### Weeks Prior

- Simulate the USMLE Step 1 again. Assess how close you are to your goal.
- Pinpoint remaining weaknesses. Stay healthy (exercise, sleep).
- Verify information on admission ticket (eg, location, date).

### One Week Prior

- Remember comfort measures (loose clothing, earplugs, etc).
- Work out test site logistics such as location, transportation, parking, and lunch.
- Call Prometric and confirm your exam appointment.

### One Day Prior

- Relax.
- Lightly review short-term material if necessary. Skim high-yield facts.
- Get a good night's sleep.
- Make sure the name printed on your photo ID appears EXACTLY the same as the name printed on your scheduling permit.

### Day of Exam

- Relax. Eat breakfast. Minimize bathroom breaks during the exam by avoiding excessive morning caffeine.
- Analyze and make adjustments in test-taking technique. You are allowed to review notes/study material during breaks on exam day.

### After the Exam

- Celebrate, regardless.
- Send feedback to us on our website at [www.firstaidteam.com](http://www.firstaidteam.com).

# Guide to Efficient Exam Preparation

*“A mind of moderate capacity which closely pursues one study must infallibly arrive at great proficiency in that study.”*

—Mary Shelley, *Frankenstein*

*“Finally, from so little sleeping and so much reading, his brain dried up and he went completely out of his mind.”*

—Miguel de Cervantes Saavedra, *Don Quixote*

*“Sometimes the questions are complicated and the answers are simple.”*

—Dr. Seuss

*“He who knows all the answers has not been asked all the questions.”*

—Confucius

*“It’s what you learn after you know it all that counts.”*

—John Wooden

*“A goal without a plan is just a wish.”*

—Antoine de Saint-Exupéry

▶ Introduction	2
▶ USMLE Step 1—The Basics	2
▶ Defining Your Goal	12
▶ Excelling in the Preclinical Years	13
▶ Timeline for Study	14
▶ Study Materials	18
▶ Test-Taking Strategies	20
▶ Clinical Vignette Strategies	21
▶ If You Think You Failed	22
▶ Testing Agencies	22
▶ References	23

## ▶ INTRODUCTION

Relax.

This section is intended to make your exam preparation easier, not harder. Our goal is to reduce your level of anxiety and help you make the most of your efforts by helping you understand more about the United States Medical Licensing Examination, Step 1 (USMLE Step 1). As a medical student, you are no doubt familiar with taking standardized examinations and quickly absorbing large amounts of material. When you first confront the USMLE Step 1, however, you may find it all too easy to become sidetracked from your goal of studying with maximal effectiveness. Common mistakes that students make when studying for Step 1 include the following:

- Starting to study (including *First Aid*) too late
- Starting to study intensely too early and burning out
- Starting to prepare for boards before creating a knowledge foundation
- Using inefficient or inappropriate study methods
- Buying the wrong resources or buying too many resources
- Buying only one publisher's review series for all subjects
- Not using practice examinations to maximum benefit
- Not understanding how scoring is performed or what the score means
- Not using review books along with your classes
- Not analyzing and improving your test-taking strategies
- Getting bogged down by reviewing difficult topics excessively
- Studying material that is rarely tested on the USMLE Step 1
- Failing to master certain high-yield subjects owing to overconfidence
- Using *First Aid* as your sole study resource
- Trying to prepare for it all alone

▶ *The test at a glance:*

- 8-hour exam
- Total of 280 multiple choice items
- 7 test blocks (60 min/block)
- Up to 40 test items per block
- 45 minutes of break time, plus another 15 if you skip the tutorial

In this section, we offer advice to help you avoid these pitfalls and be more productive in your studies.

## ▶ USMLE STEP 1—THE BASICS

The USMLE Step 1 is the first of three examinations that you must pass in order to become a licensed physician in the United States. The USMLE is a joint endeavor of the National Board of Medical Examiners (NBME) and the Federation of State Medical Boards (FSMB). The USMLE serves as the single examination system for US medical students and international medical graduates (IMGs) seeking medical licensure in the United States.

The Step 1 exam includes test items drawn from the following content areas<sup>1</sup>:

### **DISCIPLINE**

Aging  
Anatomy  
Behavioral Sciences  
Biochemistry  
Biostatistics and Epidemiology  
Genetics  
Immunology  
Microbiology  
Molecular and Cell Biology  
Nutrition  
Pathology  
Pharmacology  
Physiology

### **ORGAN SYSTEM**

Behavioral Health & Nervous  
Systems/Special Senses  
Biostatistics & Epidemiology/  
Population Health/  
Social Sciences  
Blood & Lymphoreticular System  
Cardiovascular System  
Endocrine System  
Gastrointestinal System  
General Principles of Foundational  
Science  
Immune System  
Multisystem Processes & Disorders  
Musculoskeletal, Skin, &  
Subcutaneous Tissue  
Renal/Urinary System  
Reproductive System  
Respiratory System

### **How Is the Computer-Based Test (CBT) Structured?**

The CBT Step 1 exam consists of one “optional” tutorial/simulation block and seven “real” question blocks of up to 40 questions per block with no more than 280 questions in total, timed at 60 minutes per block. A short 11-question survey follows the last question block. The computer begins the survey with a prompt to proceed to the next block of questions.

Once an examinee finishes a particular question block on the CBT, he or she must click on a screen icon to continue to the next block. Examinees **cannot** go back and change their answers to questions from any previously completed block. However, changing answers is allowed **within** a block of questions as long as the block has not been ended and if time permits.

### **What Is the CBT Like?**

Given the unique environment of the CBT, it's important that you become familiar ahead of time with what your test-day conditions will be like. In fact, you can easily add up to 15 minutes to your break time! This is because the 15-minute tutorial offered on exam day may be skipped if you are already familiar with the exam procedures and the testing interface. The 15 minutes is then added to your allotted break time of 45 minutes for a total of 1 hour of potential break time. You can download the tutorial from the USMLE website and do it before test day. This tutorial interface is very similar to the one you will use in the exam; learn it now and you can skip taking it during the exam, giving you up to 15 extra minutes of break time. You can also gain experience

► *If you know the format, you can skip the tutorial and add up to 15 minutes to your break time!*



with the CBT format by taking the 120 practice questions (3 blocks with 40 questions each) available online or by signing up for a practice session at a test center.

For security reasons, examinees are not allowed to bring any personal electronic equipment into the testing area. This includes both digital and analog watches, iPods, tablets, calculators, cell phones, and electronic paging devices. Examinees are also prohibited from carrying in their books, notes, pens/pencils, and scratch paper. Food and beverages are also prohibited in the testing area. The testing centers are monitored by audio and video surveillance equipment. However, most testing centers allot each examinee a small locker outside the testing area in which he or she can store snacks, beverages, and personal items.

The typical question screen in the CBT consists of a question followed by a number of choices on which an examinee can click, together with several navigational buttons on the top of the screen. There is a countdown timer on the lower left corner of the screen as well. There is also a button that allows the examinee to mark a question for review. If a given question happens to be longer than the screen (which occurs very rarely), a scroll bar will appear on the right, allowing the examinee to see the rest of the question. Regardless of whether the examinee clicks on an answer choice or leaves it blank, he or she must click the “Next” button to advance to the next question.

The USMLE features a small number of media clips in the form of audio and/or video. There may even be a question with a multimedia heart sound simulation. In these questions, a digital image of a torso appears on the screen, and the examinee directs a digital stethoscope to various auscultation points to listen for heart and breath sounds. The USMLE orientation materials include several practice questions in these formats. During the exam tutorial, examinees are given an opportunity to ensure that both the audio headphones and the volume are functioning properly. If you are already familiar with the tutorial and planning on skipping it, first skip ahead to the section where you can test your headphones. After you are sure the headphones are working properly, proceed to the exam.

The examinee can call up a window displaying normal laboratory values. In order to do so, he or she must click the “Lab” icon on the top part of the screen. Afterward, the examinee will have the option to choose between “Blood,” “Cerebrospinal,” “Hematologic,” or “Sweat and Urine.” The normal-values screen may obscure the question if it is expanded. The examinee may have to scroll down to search for the needed lab values. You might want to memorize some common lab values so you spend less time on questions that require you to analyze these.

The CBT interface provides a running list of questions on the left part of the screen at all times. The software also permits examinees to highlight or cross out information by using their mouse. There is a “Notes” icon on the top part of the screen that allows students to write notes to themselves for review at a later time. Finally, the USMLE has recently added new functionality including text magnification and reverse color (white text on black background). Being

▶ **Keyboard shortcuts:**

- *A, B, etc—letter choices*
- *Enter or spacebar—move to next question*
- *Esc—exit pop-up Lab and Exhibit windows*
- *Alt-T—countdown timers for current session and overall test*

▶ **Heart sounds are tested via media questions.**

*Make sure you know how different heart diseases sound on auscultation.*

▶ **Be sure to test your headphones during the tutorial.**

▶ **Familiarize yourself with the commonly tested lab values.**

▶ **Illustrations on the test include:**

- *Gross specimen photos*
- *Histology slides*
- *Medical imaging (eg, x-ray, CT, MRI)*
- *Electron micrographs*
- *Line drawings*

familiar with these features can save time and may help you better view and organize the information you need to answer a question.

For those who feel they might benefit, the USMLE offers an opportunity to take a simulated test, or “CBT Practice Session” at a Prometric center. Students are eligible to register for this three-and-one-half-hour practice session after they have received their scheduling permit.

The same USMLE Step 1 sample test items (120 questions) available on the USMLE website, [www.usmle.org](http://www.usmle.org), are used at these sessions. **No new items will be presented.** The session is divided into a short tutorial and three 1-hour blocks of ~40 test items each at a cost of \$75, if your testing region is in the United States or Canada. Students receive a printed percent-correct score after completing the session. **No explanations of questions are provided.**

You may register for a practice session online at [www.usmle.org](http://www.usmle.org). A separate scheduling permit is issued for the practice session. Students should allow two weeks for receipt of this permit.

### How Do I Register to Take the Exam?

Prometric test centers offer Step 1 on a year-round basis, except for the first two weeks in January and major holidays. The exam is given every day except Sunday at most centers. Some schools administer the exam on their own campuses. Check with the test center you want to use before making your exam plans.

US students can apply to take Step 1 at the NBME website. This application allows you to select one of 12 overlapping three-month blocks in which to be tested (eg, April–May–June, June–July–August). Choose your three-month eligibility period wisely. If you need to reschedule outside your initial three-month period, you can request a one-time extension of eligibility for the next contiguous three-month period, and pay a rescheduling fee. The application also includes a photo ID form that must be certified by an official at your medical school to verify your enrollment. After the NBME processes your application, it will send you a scheduling permit.

The scheduling permit you receive from the NBME will contain your USMLE identification number, the eligibility period in which you may take the exam, and two additional numbers. The first of these is known as your “scheduling number.” You must have this number in order to make your exam appointment with Prometric. The second number is known as the “candidate identification number,” or CIN. Examinees must enter their CINs at the Prometric workstation in order to access their exams. However, you will not be allowed to bring your permit into the exam and will be asked to copy your CIN onto your scratch paper. Prometric has no access to the codes. **Do not lose your permit!** You will not be allowed to take the exam unless you present this permit along with an unexpired, government-issued photo ID that includes your signature (such as a driver’s license or passport). Make sure the name on your photo ID exactly matches the name that appears on your scheduling permit.

▶ *Ctrl-Alt-Delete are the keys of death during the exam. Don’t touch them at the same time!*

▶ *You can take a shortened CBT practice test at a Prometric center.*

▶ *The Prometric Web site will display a calendar with open test dates.*

▶ *The confirmation emails that Prometric and NBME send are not the same as the scheduling permit.*

▶ *Test scheduling is done on a “first-come, first-served” basis. It’s important to call and schedule an exam date as soon as you receive your scheduling permit.*

▶ *Register six months in advance for seating and scheduling preference.*

Once you receive your scheduling permit, you may access the Prometric website or call Prometric’s toll-free number to arrange a time to take the exam. You may contact Prometric two weeks before the test date if you want to confirm identification requirements. Although requests for taking the exam may be completed more than six months before the test date, examinees will not receive their scheduling permits earlier than six months before the eligibility period. The eligibility period is the three-month period you have chosen to take the exam. Most medical students choose the April–June or June–August period. Because exams are scheduled on a “first-come, first-served” basis, it is recommended that you contact Prometric as soon as you receive your permit. After you’ve scheduled your exam, it’s a good idea to confirm your exam appointment with Prometric at least one week before your test date. Prometric will provide appointment confirmation on a print-out and by email. Be sure to read the *2017 USMLE Bulletin of Information* for further details.

### **What If I Need to Reschedule the Exam?**

You can change your test date and/or center by contacting Prometric at 1-800-MED-EXAM (1-800-633-3926) or [www.prometric.com](http://www.prometric.com). Make sure to have your CIN when rescheduling. If you are rescheduling by phone, you must speak with a Prometric representative; leaving a voicemail message will not suffice. To avoid a rescheduling fee, you will need to request a change at least 31 calendar days before your appointment. Please note that your rescheduled test date must fall within your assigned three-month eligibility period.

### **When Should I Register for the Exam?**

You should plan to register as far in advance as possible ahead of your desired test date (eg, six months), but, depending on your particular test center, new dates and times may open closer to the date. Scheduling early will guarantee that you will get either your test center of choice or one within a 50-mile radius of your first choice. For most US medical students, the desired testing window is in June, since most medical school curricula for the second year end in May or June. Thus, US medical students should plan to register before January in anticipation of a June test date. The timing of the exam is more flexible for IMGs, as it is related only to when they finish exam preparation. Talk with upperclassmen who have already taken the test so you have real-life experience from students who went through a similar curriculum, then formulate your own strategy.

### **Where Can I Take the Exam?**

Your testing location is arranged with Prometric when you call for your test date (after you receive your scheduling permit). For a list of Prometric locations nearest you, visit [www.prometric.com](http://www.prometric.com).

### How Long Will I Have to Wait Before I Get My Scores?

The USMLE reports scores in three to four weeks, unless there are delays in score processing. Examinees will be notified via email when their scores are available. By following the online instructions, examinees will be able to view, download, and print their score report. Additional information about score timetables and accessibility is available on the official USMLE website.

### What About Time?

Time is of special interest on the CBT exam. Here's a breakdown of the exam schedule:

15 minutes	Tutorial (skip if familiar with test format and features)
7 hours	Seven 60-minute question blocks
45 minutes	Break time (includes time for lunch)

The computer will keep track of how much time has elapsed on the exam. However, the computer will show you only how much time you have remaining in a given block. Therefore, it is up to you to determine if you are pacing yourself properly (at a rate of approximately one question per 90 seconds).

The computer will not warn you if you are spending more than your allotted time for a break. You should therefore budget your time so that you can take a short break when you need one and have time to eat. You must be especially careful not to spend too much time in between blocks (you should keep track of how much time elapses from the time you finish a block of questions to the time you start the next block). After you finish one question block, you'll need to click to proceed to the next block of questions. If you do not click within 30 seconds, you will automatically be entered into a break period.

Break time for the day is 45 minutes, but you are not required to use all of it, nor are you required to use any of it. You can gain extra break time (but not extra time for the question blocks) by skipping the tutorial or by finishing a block ahead of the allotted time. Any time remaining on the clock when you finish a block gets added to your remaining break time. Once a new question block has been started, you may not take a break until you have reached the end of that block. If you do so, this will be recorded as an "unauthorized break" and will be reported on your final score report.

Finally, be aware that it may take a few minutes of your break time to "check out" of the secure resting room and then "check in" again to resume testing, so plan accordingly. The "check-in" process may include fingerprints, pocket checks, and metal detector scanning. Some students recommend pocketless clothing on exam day to streamline the process.

### If I Freak Out and Leave, What Happens to My Score?

Your scheduling permit shows a CIN that you will need to enter to start your exam. Entering the CIN is the same as breaking the seal on a test book,

► Gain extra break time by skipping the tutorial or finishing a block early.

► Be careful to watch the clock on your break time.

and you are considered to have started the exam when you do so. However, no score will be reported if you do not complete the exam. In fact, if you leave at any time from the start of the test to the last block, no score will be reported. The fact that you started but did not complete the exam, however, will appear on your USMLE score transcript. Even though a score is not posted for incomplete tests, examinees may still get an option to request that their scores be calculated and reported if they desire; unanswered questions will be scored as incorrect.

The exam ends when all question blocks have been completed or when their time has expired. As you leave the testing center, you will receive a printed test-completion notice to document your completion of the exam. To receive an official score, you must finish the entire exam.

### What Types of Questions Are Asked?

► Nearly three fourths of Step 1 questions begin with a description of a patient.

All questions on the exam are **one-best-answer multiple choice items**. Sequential item sets have been removed. Most questions consist of a clinical scenario or a direct question followed by a list of five or more options. You are required to select the single best answer among the options given. There are no “except,” “not,” or matching questions on the exam. A number of options may be partially correct, in which case you must select the option that best answers the question or completes the statement. Additionally, keep in mind that experimental questions may appear on the exam, which do not affect your score.


### How Is the Test Scored?

Each Step 1 examinee receives an electronic score report that includes the examinee’s pass/fail status, a three-digit test score, and a graphic depiction of the examinee’s performance by discipline and organ system or subject area. The actual organ system profiles reported may depend on the statistical characteristics of a given administration of the examination.

The USMLE score report is divided into two sections: performance by discipline and performance by organ system. Each of the questions (minus experimental questions) is tagged according to any or all relevant content areas. Your performance in each discipline and each organ system is represented by a line of X’s, where the width of the line is related to the confidence interval for your performance, which is often a direct consequence of the total number of questions for each discipline/system. If any lines have an asterisk (\*) at the far right, this means your performance was exemplary in that area—not necessarily representing a perfect score, but often close to it (see Figure 1).

The NBME provides a three-digit test score based on the total number of items answered correctly on the examination (see Figure 2). Your three-digit score will be qualified by the mean and standard deviation of US and Canadian

FIGURE 1. Sample USMLE Step 1 Performance Profile




medical school first-time examinees. The translation from the lines of X's and number of asterisks you receive on your report to the three-digit score is unclear, but higher three-digit scores are associated with more asterisks.

Since some questions may be experimental and are not counted, it is possible to get different scores for the same number of correct answers. In 2015, the mean score was 229 with a standard deviation of 20.

► The mean Step 1 score for US medical students continues to rise, from 200 in 1991 to 229 in 2015.

FIGURE 2. Scoring Scale for the USMLE Step 1.



A score of 192 or higher is required to pass Step 1. The NBME does not report the minimum number of correct responses needed to pass, but estimates that it is roughly 60–70%. The NBME may adjust the minimum passing score in the future, so please check the USMLE website or [www.firstaidteam.com](http://www.firstaidteam.com) for updates.

According to the USMLE, medical schools receive a listing of total scores and pass/fail results plus group summaries by discipline and organ system. Students can withhold their scores from their medical school if they wish. Official USMLE transcripts, which can be sent on request to residency programs, include only total scores, not performance profiles.

Consult the USMLE website or your medical school for the most current and accurate information regarding the examination.

### What Does My Score Mean?

The most important point with the Step 1 score is passing versus failing. Passing essentially means, “Hey, you’re on your way to becoming a fully licensed doc.” As Table 1 shows, the majority of students pass the exam, so remember, we told you to relax.

Beyond that, the main point of having a quantitative score is to give you a sense of how well you’ve done on the exam and to help schools and residencies rank their students and applicants, respectively.

### Official NBME/USMLE Resources

The NBME offers a Comprehensive Basic Science Examination (CBSE) for practice that is a shorter version of the Step 1. The CBSE contains four blocks

TABLE 1. Passing Rates for the 2014–2015 USMLE Step 1.<sup>2</sup>

	2014		2015	
	No. Tested	% Passing	No. Tested	% Passing
Allopathic 1st takers	19,582	96%	20,213	96%
Repeaters	812	68%	898	68%
Allopathic total	20,394	95%	21,111	94%
Osteopathic 1st takers	2,810	93%	3,185	93%
Repeaters	36	69%	37	65%
Osteopathic total	2,846	93%	3,222	93%
<b>Total US/Canadian</b>	<b>23,240</b>	<b>95%</b>	<b>24,333</b>	<b>94%</b>
IMG 1st takers	15,149	78%	15,030	78%
Repeaters	2,889	38%	2,719	38%
IMG total	18,038	72%	17,749	72%
<b>Total Step 1 examinees</b>	<b>41,278</b>	<b>85%</b>	<b>42,082</b>	<b>85%</b>

of 50 questions each and covers material that is typically learned during the basic science years. Scores range from 45 to 95 and correlate with a Step 1 equivalent (see Table 2). The standard error of measurement is approximately 3 points, meaning a score of 80 would estimate the student's proficiency is somewhere between 77 and 83. In other words, the actual Step 1 score could be predicted to be between 218 and 232. Of course, these values do not correlate exactly, and they do not reflect different test preparation methods. Many schools use this test to gauge whether a student is expected to pass Step 1. If this test is offered by your school, it is usually conducted at the end of regular didactic time before any dedicated Step 1 preparation. If you do not encounter the CBSE before your dedicated study time, you need not worry about taking it. Use the information to help set realistic goals and timetables for your success.

The NBME also offers six forms of Comprehensive Basic Science Self-Assessment (CBSSA). Students who prepared for the exam using this web-based tool reported that they found the format and content highly indicative of questions tested on the actual exam. In addition, the CBSSA is a fair predictor of USMLE performance (see Table 3). The test interface, however, does not match the actual USMLE test interface, so practicing with these forms alone is not advised.

The CBSSA exists in two formats: standard-paced and self-paced, both of which consist of four sections of 50 questions each (for a total of 200 multiple choice items). The standard-paced format allows the user up to 65 minutes to complete each section, reflecting time limits similar to the actual exam. By contrast, the self-paced format places a 4:20 time limit on answering all multiple choice questions. Every few years, a new form is released and an older one is retired, reflecting changes in exam content. Therefore, the newer exams tend to be more similar to the actual Step 1, and scores from these exams tend to provide a better estimation of exam day performance.

Keep in mind that this bank of questions is available only on the web. The NBME requires that users log on, register, and start the test within 30 days of registration. Once the assessment has begun, users are required to complete the sections within 20 days. Following completion of the questions, the CBSSA provides a performance profile indicating the user's relative strengths and weaknesses, much like the report profile for the USMLE Step 1 exam. The profile is scaled with an average score of 500 and a standard deviation of 100. Please note that the CBSSAs do not list the correct answers to the questions at the end of the session. However, forms can be purchased with an extended feedback option; these tests show you which questions you answered incorrectly, but do not show you the correct answer or explain why your choice was wrong. Feedback from the self-assessment takes the form of a performance profile and nothing more. The NBME charges \$50 for assessments without feedback and \$60 for assessments with expanded feedback. The fees are payable by credit card or money order. For more information regarding the CBSE and the CBSSA, visit the NBME's website at [www.nbme.org](http://www.nbme.org).

TABLE 2. CBSE to USMLE Score Prediction.

CBSE Score	Step 1 Equivalent
≥ 94	≥ 260
92	255
90	250
88	245
86	240
84	235
82	230
80	225
78	220
76	215
74	210
72	205
70	200
68	195
66	190
64	185
62	180
60	175
58	170
56	165
54	160
52	155
50	150
48	145
46	140
≤ 44	≤ 135

► Practice questions may be easier than the actual exam.



TABLE 3. CBSSA to USMLE Score Prediction.

CBSSA Score	Approximate USMLE Step 1 Score
150	153
200	164
250	175
300	185
350	196
400	207
450	217
500	228
550	239
600	249
650	260
700	271
750	281
800	292

The NBME scoring system is weighted for each assessment exam. While some exams seem more difficult than others, the score reported takes into account these inter-test differences when predicting Step 1 performance. Also, while many students report seeing Step 1 questions “word-for-word” out of the assessments, the NBME makes special note that no live USMLE questions are shown on any NBME assessment.

Lastly, the International Foundations of Medicine (IFOM) offers a Basic Science Examination (BSE) practice exam at participating Prometric test centers for \$200. Students may also take the self-assessment test online for \$35 through the NBME’s website. The IFOM BSE is intended to determine an examinee’s relative areas of strength and weakness in general areas of basic science—not to predict performance on the USMLE Step 1 exam—and the content covered by the two examinations is somewhat different. However, because there is substantial overlap in content coverage and many IFOM items were previously used on the USMLE Step 1, it is possible to roughly project IFOM performance onto the USMLE Step 1 score scale. More information is available at <http://www.nbme.org/ifom/>.


#### ► DEFINING YOUR GOAL

It is useful to define your own personal performance goal when approaching the USMLE Step 1. Your style and intensity of preparation can then be matched to your goal. Furthermore, your goal may depend on your school’s requirements, your specialty choice, your grades to date, and your personal assessment of the test’s importance. Do your best to define your goals early so that you can prepare accordingly.

► *Some competitive residency programs place more weight on Step 1 scores when choosing candidates to interview.*

► *Fourth-year medical students have the best feel for how Step 1 scores factor into the residency application process.*

The value of the USMLE Step 1 score in selecting residency applicants remains controversial, and some have called for less emphasis to be placed on the score when selecting or screening applicants.<sup>3</sup> For the time being, however, it continues to be an important part of the residency application, and it is not uncommon for some specialties to implement filters that screen out applicants who score below a certain cutoff. This is more likely to be seen in competitive specialties (eg orthopedic surgery, ophthalmology, dermatology, otolaryngology). Independent of your career goals, you can maximize your future options by doing your best to obtain the highest score possible (see Figure 3). At the same time, your Step 1 score is only one of a number of factors that are assessed when you apply for residency. In fact, many residency programs value other criteria such as letters of recommendation, third-year clerkship grades, honors, and research experience more than a high score on Step 1. Fourth-year medical students who have recently completed the residency application process can be a valuable resource in this regard.

FIGURE 3. Median USMLE Step 1 Score by Specialty for Matched US Seniors.<sup>a,b</sup>

## ▶ EXCELLING IN THE PRECLINICAL YEARS

Many students feel overwhelmed during the first few weeks of medical school and struggle to find a workable system. Strategies that worked during your undergraduate years may or may not work as you prepare for the USMLE Step 1. Below are three study methods to use during the preclinical years and their effectiveness for Step 1 preparation. Regardless of your choice, the foundation of knowledge you build during your basic science years is the most important resource for success on the USMLE Step 1.

### Read, Highlight, Reread

This is the traditional way of learning and involves reading through material in an attempt to directly memorize it. Common sources include lecture notes and textbooks. Students read through these sources multiple times and use methods such as highlighting to emphasize important points. Because this method is passive and does not use active techniques, such as information retrieval (eg, applying learned material while answering a practice question), it tends to be of minimal value for Step 1 preparation. Students do not learn how to actively recall learned information and apply it to difficult Step 1 questions. As a result, it has largely been abandoned in favor of more active techniques.<sup>4</sup>

### Flash Cards

There is no shortage of flash card applications, from make-your-own cards to purchasable premade decks. Self-made flash cards, if done correctly, offer the ability to objectively test necessary facts. Written in an open-ended format and coupled with spaced repetition, they train both recognition and recall. Spaced repetition and active recall have been consistently shown to improve long-term retention of knowledge. Studies have also linked spaced repetition learning

▶ Watch out for flash card overload!

with flash cards to higher exam scores.<sup>5,6,7</sup> Apps (eg, Anki, First Aid Flash Facts) exist for various smartphones and tablets, so the flash cards are always accessible. However, the ease of quickly creating digital cards and sharing can lead to flash card overload (it is unsustainable to make 50 flash cards per lecture!). Even at a modest pace, the thousands upon thousands of cards are too overwhelming for Step 1 preparation. Unless you have specified high-yield cards (and checked the content with high-yield resources), stick to premade cards by reputable sources that curate the vast amount of knowledge for you.

### Tables and Summaries

This is a more active (and time intensive) form of learning. It consists of integrating the pertinent information from resources on each subject into tables and summaries that cut across topics within the same category. A table is a graphical means of organizing information succinctly. A summary is actively explaining the synthesized content in a manner that is understandable to the learner. The key is to synthesize the sequentially presented material. While many review sources offer this material in various styles and formats, your own class notes may in fact be concise enough to use as an adjunct for Step 1 preparation, and they have the added benefit of being organized to your liking.

## ▶ TIMELINE FOR STUDY

### Before Starting

Your preparation for the USMLE Step 1 should begin when you enter medical school. Organize and commit to studying from the beginning so that when the time comes to prepare for the USMLE, you will be ready with a strong foundation.


### Make a Schedule

After you have defined your goals, map out a study schedule that is consistent with your objectives, your vacation time, the difficulty of your ongoing coursework, and your family and social commitments (see Figure 4). Determine whether you want to spread out your study time or concentrate it into 14-hour study days in the final weeks. Then factor in your own history in preparing for standardized examinations (eg, SAT, MCAT). Talk to students at your school who have recently taken Step 1. Ask them for their study schedules, especially those who have study habits and goals similar to yours.

Typically, US medical schools allot between four and eight weeks for dedicated Step 1 preparation. The time you dedicate to exam preparation will depend on your target score as well as your success in preparing yourself during the first two years of medical school. Some students reserve about a week at the

▶ *Customize your schedule. Tackle your weakest section first.*

FIGURE 4. Typical Timeline for the USMLE Step 1.



end of their study period for final review; others save just a few days. When you have scheduled your exam date, do your best to adhere to it. Studies show that a later testing date does not translate into a higher score, so avoid pushing back your test date without good reason.<sup>8</sup>

Make your schedule realistic, and set achievable goals. Many students make the mistake of studying at a level of detail that requires too much time for a comprehensive review—reading *Gray’s Anatomy* in a couple of days is not a realistic goal! Have one catch-up day per week of studying. No matter how well you stick to your schedule, unexpected events happen. But don’t let yourself procrastinate because you have catch-up days; stick to your schedule as closely as possible and revise it regularly on the basis of your actual progress. Be careful not to lose focus. Beware of feelings of inadequacy when comparing study schedules and progress with your peers. **Avoid others who stress you out.** Focus on a few top-rated resources that suit your learning style—not on some obscure books your friends may pass down to you. Accept the fact that you cannot learn it all.

You will need time for uninterrupted and focused study. Plan your personal affairs to minimize crisis situations near the date of the test. Allot an adequate number of breaks in your study schedule to avoid burnout. Maintain a healthy lifestyle with proper diet, exercise, and sleep.

Another important aspect of your preparation is your studying environment. **Study where you have always been comfortable studying.** Be sure to include everything you need close by (review books, notes, coffee, snacks, etc). If you’re the kind of person who cannot study alone, form a study group with other students taking the exam. The main point here is to create a comfortable environment with minimal distractions.

### Year(s) Prior

The knowledge you gained during your first two years of medical school and even during your undergraduate years should provide the groundwork on which to base your test preparation. Student scores on NBME subject tests (commonly known as “shelf exams”) have been shown to be highly correlated

► “Crammable” subjects should be covered later and less crammable subjects earlier.

► Avoid burnout. Maintain proper diet, exercise, and sleep habits.

► Buy review books early (first year) and use while studying for courses.

with subsequent Step 1 scores.<sup>9</sup> Moreover, undergraduate science GPAs as well as MCAT scores are strong predictors of performance on the Step 1 exam.<sup>10</sup>

We also recommend that you buy highly rated review books early in your first year of medical school and use them as you study throughout the two years. When Step 1 comes along, these books will be familiar and personalized to the way in which you learn. It is risky and intimidating to use unfamiliar review books in the final two or three weeks preceding the exam. Some students find it helpful to personalize and annotate *First Aid* throughout the curriculum.

### Months Prior

Review test dates and the application procedure. Testing for the USMLE Step 1 is done on a year-round basis. If you have disabilities or special circumstances, contact the NBME as early as possible to discuss test accommodations (see the Section I Supplement at [www.firstaidteam.com/bonus](http://www.firstaidteam.com/bonus)).

► Simulate the USMLE Step 1 under “real” conditions before beginning your studies.

Use this time to finalize your ideal schedule. Consider upcoming breaks and whether you want to relax or study. Work backward from your test date to make sure you finish at least one question bank. Also add time to redo missed or flagged questions (which may be half the bank). This is the time to build a structured plan with enough flexibility for the realities of life.

Begin doing blocks of questions from reputable question banks under “real” conditions. Don’t use tutor mode until you’re sure you can finish blocks in the allotted time. It is important to continue balancing success in your normal studies with the Step 1 test preparation process.

### Weeks Prior (Dedicated Preparation)

► In the final two weeks, focus on review, practice questions, and endurance. Stay confident!

Your dedicated prep time may be one week or two months. You should have a working plan as you go into this period. Finish your schoolwork strong, take a day off, and then get to work. Start by simulating a full-length USMLE Step 1 if you haven’t yet done so. Consider doing one NBME CBSSA and the free questions from the NBME website. Alternatively, you could choose 7 blocks of randomized questions from a commercial question bank. Make sure you get feedback on your strengths and weaknesses and adjust your studying accordingly. Many students study from review sources or comprehensive programs for part of the day, then do question blocks. Also, keep in mind that reviewing a question block can take upward of two hours. Feedback from CBSSA exams and question banks will help you focus on your weaknesses.

### One Week Prior

Make sure you have your CIN (found on your scheduling permit) as well as other items necessary for the day of the examination, including a current driver’s license or another form of photo ID with your signature (make sure the

name on your **ID exactly** matches that on your scheduling permit). Confirm the Prometric testing center location and test time. Work out how you will get to the testing center and what parking and traffic problems you might encounter. Drive separately from other students taking the test on the same day, and exchange cell phone numbers in case of emergencies. If possible, visit the testing site to get a better idea of the testing conditions you will face. Determine what you will do for lunch. Make sure you have everything you need to ensure that you will be comfortable and alert at the test site. It may be beneficial to adjust your schedule to start waking up at the same time that you will on your test day. And of course, make sure to maintain a healthy lifestyle and get enough sleep.

### One Day Prior

Try your best to relax and rest the night before the test. Double-check your admissions and test-taking materials as well as the comfort measures discussed earlier so that you will not have to deal with such details on the morning of the exam. At this point it will be more effective to review short-term memory material that you're already familiar with than to try to learn new material. The Rapid Review section at the end of this book is high yield for last-minute studying. Remember that regardless of how hard you have studied, you cannot know everything. There will be things on the exam that you have never even seen before, so do not panic. Do not underestimate your abilities.

Many students report difficulty sleeping the night prior to the exam. This is often exacerbated by going to bed much earlier than usual. Do whatever it takes to ensure a good night's sleep (eg, massage, exercise, warm milk, no back-lit screens at night). Do not change your daily routine prior to the exam. Exam day is not the day for a caffeine-withdrawal headache.

### Morning of the Exam

On the morning of the Step 1 exam, wake up at your regular time and eat a normal breakfast. If you think it will help you, have a close friend or family member check to make sure you get out of bed. Make sure you have your scheduling permit admission ticket, test-taking materials, and comfort measures as discussed earlier. Wear loose, comfortable clothing. Plan for a variable temperature in the testing center. Arrive at the test site 30 minutes before the time designated on the admission ticket; however, do not come too early, as doing so may intensify your anxiety. When you arrive at the test site, the proctor should give you a USMLE information sheet that will explain critical factors such as the proper use of break time. Seating may be assigned, but ask to be reseated if necessary; you need to be seated in an area that will allow you to remain comfortable and to concentrate. Get to know your testing station, especially if you have never been in a Prometric testing center before. Listen to your proctors regarding any changes in instructions or testing procedures that may apply to your test site.

#### ► One week before the test:

- Sleep according to the same schedule you'll use on test day
- Review the CBT tutorial one last time
- Call Prometric to confirm test date and time

► No notes, books, calculators, pagers, cell phones, recording devices, or watches of any kind are allowed in the testing area, but they are allowed in lockers.

► Arrive at the testing center 30 minutes before your scheduled exam time. If you arrive more than half an hour late, you will not be allowed to take the test.

Finally, remember that it is natural (and even beneficial) to be a little nervous. Focus on being mentally clear and alert. Avoid panic. When you are asked to begin the exam, take a deep breath, focus on the screen, and then begin. Keep an eye on the timer. Take advantage of breaks between blocks to stretch, maybe do some jumping jacks, and relax for a moment with deep breathing or stretching.

### After the Test

After you have completed the exam, be sure to have fun and relax regardless of how you may feel. Taking the test is an achievement in itself. Remember, you are much more likely to have passed than not. Enjoy the free time you have before your clerkships. Expect to experience some “reentry” phenomena as you try to regain a real life. Once you have recovered sufficiently from the test (or from partying), we invite you to send us your feedback, corrections, and suggestions for entries, facts, mnemonics, strategies, resource ratings, and the like (see p. xvii, How to Contribute). Sharing your experience will benefit fellow medical students and IMGs.

## ▶ STUDY MATERIALS

### Quality Considerations

Although an ever-increasing number of review books and software are now available on the market, the quality of such material is highly variable. Some common problems are as follows:

- Certain review books are too detailed to allow for review in a reasonable amount of time or cover subtopics that are not emphasized on the exam.
- Many sample question books were originally written years ago and have not been adequately updated to reflect recent trends.
- Some question banks test to a level of detail that you will not find on the exam.

▶ *If a given review book is not working for you, stop using it no matter how highly rated it may be or how much it costs.*

### Review Books

In selecting review books, be sure to weigh different opinions against each other, read the reviews and ratings in Section IV of this guide, examine the books closely in the bookstore, and choose carefully. You are investing not only money but also your limited study time. Do not worry about finding the “perfect” book, as many subjects simply do not have one, and different students prefer different formats. Supplement your chosen books with personal notes from other sources, including what you learn from question banks.

There are two types of review books: those that are stand-alone titles and those that are part of a series. Books in a series generally have the same style,

and you must decide if that style works for you. However, a given style is not optimal for every subject.

You should also find out which books are up to date. Some recent editions reflect major improvements, whereas others contain only cursory changes. Take into consideration how a book reflects the format of the USMLE Step 1.

### Apps

With the explosion of smartphones and tablets, apps are an increasingly popular way to review for the Step 1 exam. The majority of apps are compatible with both iOS and Android. Many popular Step 1 review resources (eg, UWorld, USMLE-Rx) have apps that are compatible with their software. Many popular web references (eg, UpToDate) also now offer app versions. All of these apps offer flexibility, allowing you to study while away from a computer (eg, while traveling).

### Practice Tests

Taking practice tests provides valuable information about potential strengths and weaknesses in your fund of knowledge and test-taking skills. Some students use practice examinations simply as a means of breaking up the monotony of studying and adding variety to their study schedule, whereas other students rely almost solely on practice. You should also subscribe to one or more high-quality question banks. In addition, students report that many current practice-exam books have questions that are, on average, shorter and less clinically oriented than those on the current USMLE Step 1.

Additionally, some students preparing for the Step 1 exam have started to incorporate case-based books intended primarily for clinical students on the wards or studying for the Step 2 CK exam. *First Aid Cases for the USMLE Step 1* aims to directly address this need.

After taking a practice test, spend time on each question and each answer choice whether you were right or wrong. There are important teaching points in each explanation. Knowing why a wrong answer choice is incorrect is just as important as knowing why the right answer is correct. Do not panic if your practice scores are low as many questions try to trick or distract you to highlight a certain point. Use the questions you missed or were unsure about to develop focused plans during your scheduled catch-up time.

### Textbooks and Course Syllabi

Limit your use of textbooks and course syllabi for Step 1 review. Many textbooks are too detailed for high-yield review and include material that is generally not tested on the USMLE Step 1 (eg, drug dosages, complex chemical structures). Syllabi, although familiar, are inconsistent across medical schools and frequently reflect the emphasis of individual faculty,

▶ *Charts and diagrams may be the best approach for physiology and biochemistry, whereas tables and outlines may be preferable for microbiology.*

▶ *Most practice exams are shorter and less clinical than the real thing.*

▶ *Use practice tests to identify concepts and areas of weakness, not just facts that you missed.*



which often does not correspond to that of the USMLE Step 1. Syllabi also tend to be less organized than top-rated books and generally contain fewer diagrams and study questions.

### ▶ TEST-TAKING STRATEGIES

▶ *Practice! Develop your test-taking skills and strategies well before the test date.*

Your test performance will be influenced by both your knowledge and your test-taking skills. You can strengthen your performance by considering each of these factors. Test-taking skills and strategies should be developed and perfected well in advance of the test date so that you can concentrate on the test itself. We suggest that you try the following strategies to see if they might work for you.

#### **Pacing**

You have seven hours to complete 280 questions. Note that each one-hour block contains up to 40 questions. This works out to approximately 90 seconds per question. We recommend following the “1 minute rule” to pace yourself. Spend no more than 1 minute on each question. If you are still unsure about the answer after this time, mark the question, make an educated guess, and move on. Following this rule, you should have approximately 20 minutes left after all questions are answered, which you can use to revisit all of your marked questions. Remember that some questions may be experimental and do not count for points (and reassure yourself that these experimental questions are the ones that are stumping you). In the past, pacing errors have been detrimental to the performance of even highly prepared examinees. The bottom line is to keep one eye on the clock at all times!

▶ *Time management is an important skill for exam success.*

#### **Dealing with Each Question**

There are several established techniques for efficiently approaching multiple choice questions; find what works for you. One technique begins with identifying each question as easy, workable, or impossible. Your goal should be to answer all easy questions, resolve all workable questions in a reasonable amount of time, and make quick and intelligent guesses on all impossible questions. Most students read the stem, think of the answer, and turn immediately to the choices. A second technique is to first skim the answer choices to get a context, then read the last sentence of the question (the lead-in), and then read through the passage quickly, extracting only information relevant to answering the question. This can be particularly helpful for questions with long clinical vignettes. Try a variety of techniques on practice exams and see what works best for you. If you get overwhelmed, remember that a 30-second time out to refocus may get you back on track.

## Guessing

There is **no penalty** for wrong answers. Thus, **no test block should be left with unanswered questions.** A hunch is probably better than a random guess. If you have to guess, we suggest selecting an answer you recognize over one with which you are totally unfamiliar.

## Changing Your Answer

The conventional wisdom is not to change answers that you have already marked unless there is a convincing and logical reason to do so—in other words, go with your “first hunch.” Many question banks tell you how many questions you changed from right to wrong, wrong to wrong, and wrong to right. Use this feedback to judge how good a second-guesser you are. If you have extra time, reread the question stem and make sure you didn’t misinterpret the question.

▶ *Go with your first hunch, unless you are certain that you are a good second-guesser.*

## ▶ CLINICAL VIGNETTE STRATEGIES

In recent years, the USMLE Step 1 has become increasingly clinically oriented. This change mirrors the trend in medical education toward introducing students to clinical problem solving during the basic science years. The increasing clinical emphasis on Step 1 may be challenging to those students who attend schools with a more traditional curriculum.

▶ *Be prepared to read fast and think on your feet!*

## What Is a Clinical Vignette?

A clinical vignette is a short (usually paragraph-long) description of a patient, including demographics, presenting symptoms, signs, and other information concerning the patient. Sometimes this paragraph is followed by a brief listing of important physical findings and/or laboratory results. The task of assimilating all this information and answering the associated question in the span of one minute can be intimidating. So be prepared to read quickly and think on your feet. Remember that the question is often indirectly asking something you already know.

▶ *Practice questions that include case histories or descriptive vignettes are critical for Step 1 preparation.*

## Strategy

Remember that Step 1 vignettes usually describe diseases or disorders in their most classic presentation. So look for cardinal signs (eg, malar rash for SLE or nuchal rigidity for meningitis) in the narrative history. Be aware that the question will contain classic signs and symptoms instead of buzzwords. Sometimes the data from labs and the physical exam will help you confirm or reject possible diagnoses, thereby helping you rule answer choices in or out. In some cases, they will be a dead giveaway for the diagnosis.

▶ *Step 1 vignettes usually describe diseases or disorders in their most classic presentation.*

Making a diagnosis from the history and data is often not the final answer. Not infrequently, the diagnosis is divulged at the end of the vignette, after you have just struggled through the narrative to come up with a diagnosis of your own. The question might then ask about a related aspect of the diagnosed disease. Consider skimming the answer choices and lead-in before diving into a long stem. However, be careful with skimming the answer choices; going too fast may warp your perception of what the vignette is asking.

#### ▶ IF YOU THINK YOU FAILED

After the test, many examinees feel that they have failed, and most are at the very least unsure of their pass/fail status. There are several sensible steps you can take to plan for the future in the event that you do not achieve a passing score. First, save and organize all your study materials, including review books, practice tests, and notes. Familiarize yourself with the reapplication procedures for Step 1, including application deadlines and upcoming test dates.

▶ *If you pass Step 1 (score of 192 or above), you are not allowed to retake the exam.*

Make sure you know both your school's and the NBME's policies regarding retakes. The NBME allows a maximum of six attempts to pass each Step examination.<sup>11</sup> You may take Step 1 no more than three times within a 12-month period. Your fourth and subsequent attempts must be at least 12 months after your first attempt at that exam and at least six months after your most recent attempt at that exam.

The performance profiles on the back of the USMLE Step 1 score report provide valuable feedback concerning your relative strengths and weaknesses. Study these profiles closely. Set up a study timeline to strengthen gaps in your knowledge as well as to maintain and improve what you already know. Do not neglect high-yield subjects. It is normal to feel somewhat anxious about retaking the test, but if anxiety becomes a problem, seek appropriate counseling.

#### ▶ TESTING AGENCIES

- **National Board of Medical Examiners (NBME) / USMLE Secretariat**  
Department of Licensing Examination Services  
3750 Market Street  
Philadelphia, PA 19104-3102  
(215) 590-9500 (operator) or  
(215) 590-9700 (automated information line)  
Fax: (215) 590-9457  
Email: [webmail@nbme.org](mailto:webmail@nbme.org)  
[www.nbme.org](http://www.nbme.org)

- **Educational Commission for Foreign Medical Graduates (ECFMG)**  
3624 Market Street  
Philadelphia, PA 19104-2685  
(215) 386-5900  
Fax: (215) 386-9196  
Email: [info@ecfm.org](mailto:info@ecfm.org)  
[www.ecfm.org](http://www.ecfm.org)

## ▶ REFERENCES

1. United States Medical Licensing Examination. Available at: <http://www.usmle.org/bulletin/exam-content>. Accessed September 1, 2016.
2. United States Medical Licensing Examination. 2015 Performance Data. Available at: [http://www.usmle.org/performance-data/default.aspx#2015\\_step-1](http://www.usmle.org/performance-data/default.aspx#2015_step-1). Accessed September 1, 2016.
3. Prober CG, Kolars JC, First LR, et al. A plea to reassess the role of United States Medical Licensing Examination Step 1 scores in residency selection. *Acad Med*. 2016; 91(1):12–15.
4. Dunlosky D, Rawson KA, Marsh EJ, et al. Improving students' learning with effective learning techniques: promising directions from cognitive and educational psychology. *Psychol Sci Public Interest*. 2013, 14(1):4–58.
5. Deng F, Gluckstein JA, Larsen DP. Student-directed retrieval practice is a predictor of medical licensing examination performance. *Perspect Med Educ*. 2015 Oct 23.
6. Larsen DP, Butler AC, Roediger HL 3rd. Repeated testing improves long-term retention relative to repeated study: a randomised controlled trial. *Med Educ*. 2009 Dec;43(12):1174–1181.
7. Augustin M. How to learn effectively in medical school: test yourself, learn actively, and repeat in intervals. *Yale J Biol Med*. 2014 Jun 6;87(2):207–212. eCollection 2014 Jun.
8. Pohl CA, Robeson MR, Hojat M, et al. Sooner or later? USMLE Step 1 performance and test administration date at the end of the second year. *Acad Med*. 2002, 77(10):S17–S19.
9. Holtman MC, Swanson DB, Ripkey DR, et al. Using basic science subject tests to identify students at risk for failing Step 1. *Acad Med*. 2001, 76(10):S48–S51.
10. Basco WT, Way DP, Gilbert GE, et al. Undergraduate institutional MCAT scores as predictors of USMLE Step 1 performance. *Acad Med*. 2002, 77(10):S13–S16.
11. United States Medical Licensing Examination. 2014 USMLE Bulletin of Information. <http://www.usmle.org/pdfs/bulletin/2014bulletin.pdf>. Accessed September 1, 2016.

▶ NOTES

Two columns of horizontal lines for taking notes.

# Special Situations

Please visit [www.firstaidteam.com/bonus/](http://www.firstaidteam.com/bonus/) to view this section.

- ▶ First Aid for the International Medical Graduate 2
- ▶ First Aid for the Osteopathic Medical Student 13
- ▶ First Aid for the Podiatric Medical Student 17
- ▶ First Aid for the Student Requiring Test Accommodations 19

▶ NOTES

Two columns of horizontal lines for taking notes.

# High-Yield General Principles

*“There comes a time when for every addition of knowledge you forget something that you knew before. It is of the highest importance, therefore, not to have useless facts elbowing out the useful ones.”*

—Sir Arthur Conan Doyle, *A Study in Scarlet*

*“Never regard study as a duty, but as the enviable opportunity to learn.”*

—Albert Einstein

*“Live as if you were to die tomorrow. Learn as if you were to live forever.”*

—Gandhi

▶ How to Use the Database	28
▶ Biochemistry	31
▶ Immunology	91
▶ Microbiology	119
▶ Pathology	203
▶ Pharmacology	223
▶ Public Health Sciences	245



## ▶ HOW TO USE THE DATABASE

The 2017 edition of *First Aid for the USMLE Step 1* contains a revised and expanded database of basic science material that students, student authors, and faculty authors have identified as high yield for board review. The information is presented in a partially organ-based format. Hence, Section II is devoted to the foundational principles of biochemistry, microbiology, immunology, basic pathology, basic pharmacology, and public health sciences. Section III focuses on organ systems, with subsections covering the embryology, anatomy and histology, physiology, clinical pathology, and clinical pharmacology relevant to each. Each subsection is then divided into smaller topic areas containing related facts. Individual facts are generally presented in a three-column format, with the **Title** of the fact in the first column, the **Description** of the fact in the second column, and the **Mnemonic** or **Special Note** in the third column. Some facts do not have a mnemonic and are presented in a two-column format. Others are presented in list or tabular form in order to emphasize key associations.




The database structure used in Sections II and III is useful for reviewing material already learned. These sections are **not** ideal for learning complex or highly conceptual material for the first time.

The database of high-yield facts is not comprehensive. Use it to complement your core study material and not as your primary study source. The facts and notes have been condensed and edited to emphasize the essential material, and as a result, each entry is “incomplete” and arguably “over-simplified.” Often, the more you research a topic, the more complex it becomes, with certain topics resisting simplification. Work with the material, add your own notes and mnemonics, and recognize that not all memory techniques work for all students.

We update the database of high-yield facts annually to keep current with new trends in boards emphasis, including clinical relevance. However, we must note that inevitably many other high-yield topics are not yet included in our database.

We actively encourage medical students and faculty to submit high-yield topics, well-written entries, diagrams, clinical images, and useful mnemonics so that we may enhance the database for future students. We also solicit recommendations of alternate tools for study that may be useful in preparing for the examination, such as charts, flash cards, apps, and online resources (see How to Contribute, p. xvii).

### Image Acknowledgments

All images and diagrams marked with  are © USMLE-Rx.com (MedIQ Learning, LLC) and reproduced here by special permission. All images marked with  are © Dr. Richard P. Usatine, author of *The Color Atlas of Family Medicine*, *The Color Atlas of Internal Medicine*, and *The Color Atlas of Pediatrics*, and are reproduced here by special permission ([www.usatinemedia.com](http://www.usatinemedia.com)). Images and diagrams marked with  are adapted or reproduced with permission of other sources as listed on page 689. Images and diagrams with no acknowledgment are part of this book.

### Disclaimer

The entries in this section reflect student opinions of what is high yield. Because of the diverse sources of material, no attempt has been made to trace or reference the origins of entries individually. We have regarded mnemonics as essentially in the public domain. Errata will gladly be corrected if brought to the attention of the authors, either through our online errata submission form at [www.firstaidteam.com](http://www.firstaidteam.com) or directly by email to [firstaidteam@yahoo.com](mailto:firstaidteam@yahoo.com).



## Biochemistry

*“Biochemistry is the study of carbon compounds that crawl.”*

—Mike Adams

*“We think we have found the basic mechanism by which life comes from life.”*

—Francis H. C. Crick


*“The biochemistry and biophysics are the notes required for life; they conspire, collectively, to generate the real unit of life, the organism.”*

—Ursula Goodenough


This high-yield material includes molecular biology, genetics, cell biology, and principles of metabolism (especially vitamins, cofactors, minerals, and single-enzyme-deficiency diseases). When studying metabolic pathways, emphasize important regulatory steps and enzyme deficiencies that result in disease, as well as reactions targeted by pharmacologic interventions. For example, understanding the defect in Lesch-Nyhan syndrome and its clinical consequences is higher yield than memorizing every intermediate in the purine salvage pathway. Do not spend time on hard-core organic chemistry, mechanisms, or physical chemistry. Detailed chemical structures are infrequently tested; however, many structures have been included here to help students learn reactions and the important enzymes involved. Familiarity with the biochemical techniques that have medical relevance—such as ELISA, immunoelectrophoresis, Southern blotting, and PCR—is useful. Review the related biochemistry when studying pharmacology or genetic diseases as a way to reinforce and integrate the material.

▶ Molecular	32
▶ Cellular	42
▶ Laboratory Techniques	48
▶ Genetics	52
▶ Nutrition	61
▶ Metabolism	68

## ► BIOCHEMISTRY—MOLECULAR

**Chromatin structure**

DNA exists in the condensed, chromatin form in order to fit into the nucleus. Negatively charged DNA loops twice around positively charged histone octamer to form nucleosome “beads on a string.” Histones are rich in the amino acids lysine and arginine. H1 binds to the nucleosome and to “linker DNA,” thereby stabilizing the chromatin fiber. In mitosis, DNA condenses to form chromosomes. DNA and histone synthesis occur during S phase.

**Heterochromatin**

Condensed, appears darker on EM (labeled H in **A**). Transcriptionally inactive, sterically inaccessible. ↑ methylation, ↓ acetylation.

**Hetero**Chromatin = **H**ighly **C**ondensed.  
Barr bodies (inactive X chromosomes) are heterochromatin.

**Euchromatin**

Less condensed, appears lighter on EM (labeled E in **A**). Transcriptionally active, sterically accessible.

*Eu* = true, “truly transcribed.”  
**E**uchromatin is **E**xpressed.

**DNA methylation**

Template strand cytosine and adenine are methylated in DNA replication, which allows mismatch repair enzymes to distinguish between old and new strands in prokaryotes. DNA methylation at CpG islands represses transcription.

CpG **M**ethylation **M**akes DNA **M**ute.

**Histone methylation**

Usually reversibly represses DNA transcription, but can activate it in some cases depending on methylation location.

Histone **M**ethylation **M**ostly **M**akes DNA **M**ute.

**Histone acetylation**

Relaxes DNA coiling, allowing for transcription.

Histone **A**cetylation makes DNA **A**ctive.

**Nucleotides**

Nucleo**S**ide = base + (deoxy)ribose (**S**ugar).

Nucleo**T**ide = base + (deoxy)ribose + phospho**T**e;  
linked by 3'-5' phosphodiester bond.

**PUR**ines (**A,G**)—2 rings.

**PY**rimidines (**C,U,T**)—1 ring.

Deamination of cytosine makes uracil.  
Deamination of adenine makes guanine.  
Uracil found in RNA; thymine in DNA.  
Methylation of uracil makes thymine.


5' end of incoming nucleotide bears the triphosphate (energy source for the bond).  
Triphosphate bond is target of 3' hydroxyl attack.

**PUR**e **A**s **G**old.

**CUT** the **PY** (pie).

**Thy**mine has a **methy**l.

G-C bond (3 H bonds) stronger than A-T bond (2 H bonds). ↑ G-C content → ↑ melting temperature of DNA. "**C-G** bonds are like **Crazy G**lue."




**GAG**—Amino acids necessary for purine synthesis:

- G**lycine
- A**spartate
- G**lutamine

**De novo pyrimidine and purine synthesis**

Various immunosuppressive, antineoplastic, and antibiotic drugs function by interfering with nucleotide synthesis:



**Disrupt pyrimidine synthesis:**

- **Leflunomide**: inhibits dihydroorotate dehydrogenase
- **Methotrexate (MTX)**, **trimethoprim (TMP)**, and **pyrimethamine**: inhibit dihydrofolate reductase (↓ deoxythymidine monophosphate [dTMP]) in humans, bacteria, and protozoa, respectively
- **5-fluorouracil (5-FU)**: forms 5-F-dUMP, which inhibits thymidylate synthase (↓ dTMP)


**Disrupt purine synthesis:**

- **6-mercaptopurine (6-MP)** and its prodrug **azathioprine**: inhibit de novo purine synthesis
- **Mycophenolate** and **ribavirin**: inhibit inosine monophosphate dehydrogenase

**Disrupts purine and pyrimidine synthesis:**

- **Hydroxyurea**: inhibits ribonucleotide reductase

## Purine salvage deficiencies



ADA, adenosine deaminase; APRT, adenine phosphoribosyltransferase; HGPRT, hypoxanthine guanine phosphoribosyltransferase; XO, xanthine oxidase.

ⓧ

### Adenosine deaminase deficiency

ADA is required for degradation of adenosine and deoxyadenosine. In ADA deficiency,  $\uparrow$  dATP  $\rightarrow$  toxicity in lymphocytes.

One of the major causes of autosomal recessive SCID.

### Lesch-Nyhan syndrome

Defective purine salvage due to absent **HGPRT**, which converts hypoxanthine to IMP and guanine to GMP. Results in excess uric acid production and de novo purine synthesis. X-linked recessive.

Findings: intellectual disability, self-mutilation, aggression, hyperuricemia (orange “sand” [sodium urate crystals] in diaper), gout, dystonia.

Treatment: allopurinol or febuxostat (2nd line).

### HGPRT:

**H**yperuricemia

**G**out

**P**issed off (aggression, self-mutilation)

**R**etardation (intellectual disability)

**DysT**onia

### Genetic code features

#### Unambiguous

Each codon specifies only 1 amino acid.

#### Degenerate/redundant

Most amino acids are coded by multiple codons.

**Wobble**—codons that differ in 3rd, “wobble” position may code for the same tRNA/amino acid. Specific base pairing is usually only required in the first 2 nucleotide positions of mRNA codon.

Exceptions: methionine and tryptophan encoded by only 1 codon (AUG and UGG, respectively).

#### Commaless, nonoverlapping

Read from a fixed starting point as a continuous sequence of bases.

Exceptions: some viruses.

#### Universal


Genetic code is conserved throughout evolution.

Exception in humans: mitochondria.

**DNA replication**

Eukaryotic DNA replication is more complex than the prokaryotic process but uses many enzymes analogous to those listed below. In both prokaryotes and eukaryotes, DNA replication is semiconservative, involves both continuous and discontinuous (Okazaki fragment) synthesis, and occurs in the 5' → 3' direction.

<b>Origin of replication A</b>	Particular consensus sequence of base pairs in genome where DNA replication begins. May be single (prokaryotes) or multiple (eukaryotes).	AT-rich sequences (such as TATA box regions) are found in promoters and origins of replication.
<b>Replication fork B</b>	Y-shaped region along DNA template where leading and lagging strands are synthesized.	
<b>Helicase C</b>	Unwinds DNA template at replication fork.	
<b>Single-stranded binding proteins D</b>	Prevent strands from reannealing.	
<b>DNA topoisomerases E</b>	Create a single- or double-stranded break in the helix to add or remove supercoils.	Irinotecan/topotecan inhibit eukaryotic topoisomerase I. Etoposide/teniposide inhibit eukaryotic topoisomerase II. Fluoroquinolones inhibit prokaryotic topoisomerase II (DNA gyrase) and topoisomerase IV.
<b>Primase F</b>	Makes an RNA primer on which DNA polymerase III can initiate replication.	
<b>DNA polymerase III G</b>	Prokaryotes only. Elongates leading strand by adding deoxynucleotides to the 3' end. Elongates lagging strand until it reaches primer of preceding fragment. 3' → 5' exonuclease activity “proofreads” each added nucleotide.	DNA polymerase III has 5' → 3' synthesis and proofreads with 3' → 5' exonuclease. Drugs blocking DNA replication often have a modified 3' OH, thereby preventing addition of the next nucleotide (“chain termination”).
<b>DNA polymerase I H</b>	Prokaryotic only. Degrades RNA primer; replaces it with DNA.	Same functions as DNA polymerase III, also excises RNA primer with 5' → 3' exonuclease.
<b>DNA ligase I</b>	Catalyzes the formation of a phosphodiester bond within a strand of double-stranded DNA.	Joins Okazaki fragments.
<b>Telomerase</b>	Eukaryotes only. An RNA-dependent DNA polymerase that adds DNA to 3' ends of chromosomes to avoid loss of genetic material with every duplication.	Often dysregulated in cancer cells, allowing unlimited replication.





**Mutations in DNA**

Severity of damage: silent << missense < nonsense < frameshift.

For point (silent, missense, and nonsense) mutations:



- **Transition**—purine to purine (eg, A to G) or pyrimidine to pyrimidine (eg, C to T).
- **Transversion**—purine to pyrimidine (eg, A to T) or pyrimidine to purine (eg, C to G).

<b>Silent</b>	Nucleotide substitution but codes for same (synonymous) amino acid; often base change in 3rd position of codon (tRNA wobble).	
<b>Missense</b>	Nucleotide substitution resulting in changed amino acid (called conservative if new amino acid is similar in chemical structure).	Sickle cell disease (substitution of glutamic acid with valine).
<b>Nonsense</b>	Nucleotide substitution resulting in early <b>stop</b> codon (UAG, UAA, UGA). Usually results in nonfunctional protein.	<b>Stop the nonsense!</b>
<b>Frameshift</b>	Deletion or insertion of a number of nucleotides not divisible by 3, resulting in misreading of all nucleotides downstream. Protein may be shorter or longer, and its function may be disrupted or altered.	Duchenne muscular dystrophy, Tay-Sachs disease.
<b>Splice site</b>	Mutation at a splice site → retained intron in the mRNA → protein with impaired or altered function.	Rare cause of cancers, dementia, epilepsy, some types of $\beta$ -thalassemia.

**Lac operon**

Classic example of a genetic response to an environmental change. Glucose is the preferred metabolic substrate in *E. coli*, but when glucose is absent and lactose is available, the *lac* operon is activated to switch to lactose metabolism. Mechanism of shift:


- Low glucose → ↑ adenylate cyclase activity → ↑ generation of cAMP from ATP → activation of catabolite activator protein (CAP) → ↑ transcription.
- High lactose → unbinds repressor protein from repressor/operator site → ↑ transcription.



**DNA repair**

Single strand		
<b>Nucleotide excision repair</b>	Specific endonucleases release the oligonucleotides containing damaged bases; DNA polymerase and ligase fill and reseal the gap, respectively. Repairs bulky helix-distorting lesions. Occurs in G <sub>1</sub> phase of cell cycle.	Defective in xeroderma pigmentosum, which prevents repair of pyrimidine dimers that are formed as a result of ultraviolet light exposure.
<b>Base excision repair</b>	Base-specific <b>G</b> lycosylase removes altered base and creates AP site (apurinic/aprimidinic). One or more nucleotides are removed by AP- <b>E</b> ndonuclease, which cleaves the 5' end. <b>L</b> yase cleaves the 3' end. DNA <b>P</b> olymerase- $\beta$ fills the gap and DNA <b>L</b> igase seals it. Occurs throughout cell cycle.	Important in repair of spontaneous/toxic deamination. “ <b>GEL P</b> lease”
<b>Mismatch repair</b>	Newly synthesized strand is recognized, mismatched nucleotides are removed, and the gap is filled and resealed. Occurs predominantly in G <sub>2</sub> phase of cell cycle.	Defective in Lynch syndrome (hereditary nonpolyposis colorectal cancer [HNPCC]).
Double strand		
<b>Nonhomologous end joining</b>	Brings together 2 ends of DNA fragments to repair double-stranded breaks. No requirement for homology. Some DNA may be lost.	Defective in ataxia telangiectasia, breast/ovarian cancers with <i>BRCA1</i> mutation, and Fanconi anemia.
Start and stop codons		
<b>mRNA start codons</b>	AUG (or rarely GUG).	<b>AUG</b> in <b>AUG</b> urates protein synthesis.
Eukaryotes	Codes for methionine, which may be removed before translation is completed.	
Prokaryotes	Codes for <i>N</i> -formylmethionine (fMet).	fMet stimulates neutrophil chemotaxis.
<b>mRNA stop codons</b>	UGA, UAA, UAG.	<b>UGA</b> = <b>U</b> Go <b>A</b> way. <b>UAA</b> = <b>U</b> Are <b>A</b> way. <b>UAG</b> = <b>U</b> Are <b>G</b> one.

### Functional organization of a eukaryotic gene




### Regulation of gene expression

<b>Promoter</b>	Site where RNA polymerase II and multiple other transcription factors bind to DNA upstream from gene locus (AT-rich upstream sequence with TATA and CAAT boxes).	Promoter mutation commonly results in dramatic ↓ in level of gene transcription.
<b>Enhancer</b>	Stretch of DNA that alters gene expression by binding transcription factors (eg, activator proteins).	Enhancers and silencers may be located close to, far from, or even within (in an intron) the gene whose expression it regulates.
<b>Silencer</b>	Site where negative regulators (repressors) bind.	

### RNA polymerases

<b>Eukaryotes</b>	<p>RNA polymerase I makes <b>r</b>rRNA (most numerous RNA, <b>r</b>ampant).</p> <p>RNA polymerase II makes <b>m</b>mRNA (largest RNA, <b>m</b>assive). mRNA is read 5' to 3'.</p> <p>RNA polymerase III makes 5S rRNA, <b>t</b>tRNA (smallest RNA, <b>t</b>iny).</p> <p>No proofreading function, but can initiate chains. RNA polymerase II opens DNA at promoter site.</p>	<p>I, II, and III are numbered in the same order that their products are used in protein synthesis: rRNA, mRNA, then tRNA.</p> <p>α-amanitin, found in <i>Amanita phalloides</i> (death cap mushrooms), inhibits RNA polymerase II. Causes severe hepatotoxicity if ingested.</p> <p>Actinomycin D inhibits RNA polymerase in both prokaryotes and eukaryotes.</p>
<b>Prokaryotes</b>	1 RNA polymerase (multisubunit complex) makes all 3 kinds of RNA.	Rifampin inhibits DNA-dependent RNA polymerase in prokaryotes.

### RNA processing (eukaryotes)



Initial transcript is called heterogeneous nuclear RNA (hnRNA). hnRNA is then modified and becomes mRNA.

The following processes occur in the nucleus:

- Capping of 5' end (addition of 7-methylguanosine cap)
- Polyadenylation of 3' end ( $\approx 200$  A's)
- Splicing out of introns

Capped, tailed, and spliced transcript is called mRNA.

mRNA is transported out of the nucleus into the cytosol, where it is translated.


mRNA quality control occurs at cytoplasmic processing bodies (P-bodies), which contain exonucleases, decapping enzymes, and microRNAs; mRNAs may be stored in P-bodies for future translation.

Poly-A polymerase does not require a template. AAUAAA = polyadenylation signal.

**Splicing of pre-mRNA**

- 1 Primary transcript combines with small nuclear ribonucleoproteins (snRNPs) and other proteins to form spliceosome.
- 2 Lariat-shaped (looped) intermediate is generated.
- 3 Lariat is released to precisely remove intron and join 2 exons.

Antibodies to spliceosomal snRNPs (anti-Smith antibodies) are highly specific for SLE. Anti-U1 RNP antibodies are highly associated with mixed connective tissue disease (MCTD).

**Introns vs exons**


Exons contain the actual genetic information coding for protein.

Introns are intervening noncoding segments of DNA.

Different exons are frequently combined by alternative splicing to produce a larger number of unique proteins.

Introns are **intervening** sequences and stay **in** the nucleus, whereas **exons exit** and are **expressed**.

Abnormal splicing variants are implicated in oncogenesis and many genetic disorders (eg,  $\beta$ -thalassemia).

**microRNAs**

MicroRNAs (miRNA) are small, conserved, noncoding RNA molecules that posttranscriptionally regulate gene expression by targeting the 3' untranslated region of specific mRNAs for degradation or translational repression. Abnormal expression of miRNAs contributes to certain malignancies (eg, by silencing an mRNA from a tumor suppressor gene).

## tRNA

## Structure

75–90 nucleotides, 2° structure, cloverleaf form, anticodon end is opposite 3' aminoacyl end. All tRNAs, both eukaryotic and prokaryotic, have CCA at 3' end along with a high percentage of chemically modified bases. The amino acid is covalently bound to the 3' end of the tRNA. **CCA Can Carry Amino acids.**

T-arm: contains the TΨC (ribothymidine, pseudouridine, cytidine) sequence necessary for tRNA-ribosome binding. **T-arm Tethers** tRNA molecule to ribosome.


D-arm: contains dihydrouridine residues necessary for tRNA recognition by the correct aminoacyl-tRNA synthetase. **D-arm Detects** the tRNA by aminoacyl-tRNA synthetase.

Acceptor stem: the 5'-CCA-3' is the amino acid acceptor site.


## Charging

Aminoacyl-tRNA synthetase (1 per amino acid; “matchmaker”; uses ATP) scrutinizes amino acid before and after it binds to tRNA. If incorrect, bond is hydrolyzed. The amino acid-tRNA bond has energy for formation of peptide bond. A mischarged tRNA reads usual codon but inserts wrong amino acid.

Aminoacyl-tRNA synthetase and binding of charged tRNA to the codon are responsible for accuracy of amino acid selection.



**Protein synthesis**

<b>Initiation</b>	Initiated by GTP hydrolysis; initiation factors (eukaryotic IFs) help assemble the 40S ribosomal subunit with the initiator tRNA and are released when the mRNA and the ribosomal 60S subunit assemble with the complex.	Eukaryotes: 40S + 60S → 80S ( <b>E</b> ven). Pr <b>O</b> karyotes: 30S + 50S → 70S ( <b>O</b> dd). Synthesis occurs from N-terminus to C-terminus.
<b>Elongation</b>	<ol style="list-style-type: none"> <li>1. Aminoacyl-tRNA binds to A site (except for initiator methionine)</li> <li>2. rRNA (“ribozyme”) catalyzes peptide bond formation, transfers growing polypeptide to amino acid in A site</li> <li>3. Ribosome advances 3 nucleotides toward 3' end of mRNA, moving peptidyl tRNA to P site (translocation)</li> </ol>	<b>A</b> TP—tRNA <b>A</b> ctivation (charging). <b>G</b> TTP—tRNA <b>G</b> ripping and <b>G</b> oing places (translocation).  Think of “going <b>APE</b> ”: <b>A</b> site = incoming <b>A</b> minoacyl-tRNA. <b>P</b> site = accommodates growing <b>P</b> eptide. <b>E</b> site = holds <b>E</b> mpy tRNA as it <b>E</b> xits.
<b>Termination</b>	Stop codon is recognized by release factor, and completed polypeptide is released from ribosome.	
 <p>The diagram illustrates a eukaryotic ribosome with its 60S and 40S subunits. The E (Exit), P (Peptide), and A (Aminoacyl) sites are clearly labeled. An mRNA strand is shown passing through the ribosome, with a growing polypeptide chain attached to a tRNA in the P site. The 5' and 3' ends of the mRNA are indicated. An arrow points to the right, indicating the direction of translocation.</p>		
<b>Posttranslational modifications</b>		
<b>Trimming</b>	Removal of N- or C-terminal propeptides from zymogen to generate mature protein (eg, trypsinogen to trypsin).	
<b>Covalent alterations</b>	Phosphorylation, glycosylation, hydroxylation, methylation, acetylation, and ubiquitination.	
<b>Chaperone protein</b>	Intracellular protein involved in facilitating and/or maintaining protein folding. For example, in yeast, heat shock proteins (eg, HSP60) are expressed at high temperatures to prevent protein denaturing/misfolding.	

## ► BIOCHEMISTRY—CELLULAR

**Cell cycle phases**

Checkpoints control transitions between phases of cell cycle. This process is regulated by cyclins, cyclin-dependent kinases (CDKs), and tumor suppressors. M phase (shortest phase of cell cycle) includes mitosis (prophase, prometaphase, metaphase, anaphase, telophase) and cytokinesis (cytoplasm splits in two).  $G_1$  and  $G_0$  are of variable duration.

## REGULATION OF CELL CYCLE

**Cyclin-dependent kinases**

Constitutive and inactive.

**Cyclins**


Regulatory proteins that control cell cycle events; phase specific; activate CDKs.

**Cyclin-CDK complexes**

Phosphorylate other proteins to coordinate cell cycle progression; must be activated and inactivated at appropriate times for cell cycle to progress.

**Tumor suppressors**

p53 induces p21, which inhibits CDKs  
 → hypophosphorylation (activation) of Rb  
 → inhibition of  $G_1$ -S progression. Mutations in tumor suppressor genes can result in unrestrained cell division (eg, Li-Fraumeni syndrome).



## CELL TYPES

**Permanent**

Remain in  $G_0$ , regenerate from stem cells.

Neurons, skeletal and cardiac muscle, RBCs.

**Stable (quiescent)**

Enter  $G_1$  from  $G_0$  when stimulated.

Hepatocytes, lymphocytes.

**Labile**

Never go to  $G_0$ , divide rapidly with a short  $G_1$ . Most affected by chemotherapy.

Bone marrow, gut epithelium, skin, hair follicles, germ cells.

**Rough endoplasmic reticulum**

Site of synthesis of secretory (exported) proteins and of N-linked oligosaccharide addition to many proteins.

Mucus-secreting goblet cells of the small intestine and antibody-secreting plasma cells are rich in RER.

Nissl bodies (RER in neurons)—synthesize peptide neurotransmitters for secretion.  
 Free ribosomes—unattached to any membrane; site of synthesis of cytosolic and organellar proteins.

**Smooth endoplasmic reticulum**

Site of steroid synthesis and detoxification of drugs and poisons. Lacks surface ribosomes.


Liver hepatocytes and steroid hormone-producing cells of the adrenal cortex and gonads are rich in SER.

## Cell trafficking

Golgi is the distribution center for proteins and lipids from the ER to the vesicles and plasma membrane. Modifies N-oligosaccharides on asparagine. Adds O-oligosaccharides on serine and threonine. Adds mannose-6-phosphate to proteins for trafficking to lysosomes.

Endosomes are sorting centers for material from outside the cell or from the Golgi, sending it to lysosomes for destruction or back to the membrane/Golgi for further use.

**I-cell disease** (inclusion cell disease/mucopolidosis type II)—inherited lysosomal storage disorder; defect in *N*-acetylglucosaminyl-1-phosphotransferase → failure of the Golgi to phosphorylate mannose residues (ie, ↓ mannose-6-phosphate) on glycoproteins → proteins are secreted extracellularly rather than delivered to lysosomes. Results in coarse facial features, clouded corneas, restricted joint movement, and high plasma levels of lysosomal enzymes. Often fatal in childhood.



### Signal recognition particle (SRP)

Abundant, cytosolic ribonucleoprotein that traffics proteins from the ribosome to the RER. Absent or dysfunctional SRP → proteins accumulate in the cytosol.

### Vesicular trafficking proteins

COPI: Golgi → Golgi (retrograde); *cis*-Golgi → ER.

COPII: ER → *cis*-Golgi (anterograde).

“**Two** (COPII) steps forward (anterograde); **one** (COPI) step back (retrograde).”

Clathrin: *trans*-Golgi → lysosomes; plasma membrane → endosomes (receptor-mediated endocytosis [eg, LDL receptor activity]).

## Peroxisome

Membrane-enclosed organelle involved in catabolism of very-long-chain fatty acids (through  $\beta$ -oxidation), branched-chain fatty acids, amino acids, and ethanol.

Peroxisomal disorders commonly lead to neurologic diseases due to deficits in synthesis of plasmalogens, important phospholipids in myelin. Peroxisomal diseases include Zellweger syndrome (hypotonia, seizures, hepatomegaly, early death) and Refsum disease (scaly skin, ataxia, cataracts/night blindness, shortening of 4th toe, epiphyseal dysplasia).

## Proteasome

Barrel-shaped protein complex that degrades damaged or ubiquitin-tagged proteins. Defects in the ubiquitin-proteasome system have been implicated in some cases of Parkinson disease.




**Cytoskeletal elements** A network of protein fibers within the cytoplasm that supports cell structure, cell and organelle movement, and cell division.

TYPE OF FILAMENT	PREDOMINANT FUNCTION	EXAMPLES
<b>Microfilaments</b>	Muscle contraction, cytokinesis	Actin, microvilli.
<b>Intermediate filaments</b>	Maintain cell structure	Vimentin, desmin, cytokeratin, lamins, glial fibrillary acid proteins (GFAP), neurofilaments.
<b>Microtubules</b>	Movement, cell division	Cilia, flagella, mitotic spindle, axonal trafficking, centrioles.

### Immunohistochemical stains for intermediate filaments

STAIN	CELL TYPE	IDENTIFIES
<b>Vimentin</b>	<b>M</b> esenchymal tissue (eg, fibroblasts, endothelial cells, macrophages)	<b>M</b> esenchymal tumors (eg, sarcoma), but also many other tumors (eg, endometrial carcinoma, renal cell carcinoma, meningioma)
<b>DesMin</b>	<b>M</b> uscle	Muscle tumors (eg, rhabdomyosarcoma)
<b>Cytokeratin</b>	Epithelial cells	Epithelial tumors (eg, squamous cell carcinoma)
<b>GFAP</b>	Neuro <b>G</b> lia (eg, astrocytes, Schwann cells, oligodendrocytes)	Astrocytoma, <b>G</b> lioblastoma
<b>Neurofilaments</b>	Neurons	Neuronal tumors (eg, neuroblastoma)

### Microtubule



Cylindrical outer structure composed of a helical array of polymerized heterodimers of  $\alpha$ - and  $\beta$ -tubulin. Each dimer has 2 GTP bound. Incorporated into flagella, cilia, mitotic spindles. Grows slowly, collapses quickly. Also involved in slow axoplasmic transport in neurons.

**Molecular motor proteins**—transport cellular cargo toward opposite ends of microtubule tracks.

- Dynein—retrograde to microtubule (+  $\rightarrow$  -).
- Kinesin—anterograde to microtubule (-  $\rightarrow$  +).

Drugs that act on microtubules (**M**icrotubules **G**et **C**onstructed **V**ery **P**oorly):


- **M**ebendazole (antihelminthic)
- **G**riseofulvin (antifungal)
- **C**olchicine (antigout)
- **V**incristine/**V**inblastine (anticancer)
- **P**aclitaxel (anticancer)

**N**egative end **N**ear **N**ucleus  
**P**ositive end **P**oints to **P**eriphery

**Cilia structure**


9 doublet + 2 singlet arrangement of microtubules (arrows in **A**).  
Basal body (base of cilium below cell membrane) consists of 9 microtubule triplets (arrow in **B**) with no central microtubules.  
Axonemal dynein—ATPase that links peripheral 9 doublets and causes bending of cilium by differential sliding of doublets.

**Kartagener syndrome (1° ciliary dyskinesia)**—immotile cilia due to a dynein arm defect. Results in ↓ male and female fertility due to immotile sperm and dysfunctional fallopian tube cilia, respectively; ↑ risk of ectopic pregnancy. Can cause bronchiectasis, recurrent sinusitis, chronic ear infections, conductive hearing loss, and situs inversus (eg, dextrocardia on CXR **C**).

**Sodium-potassium pump**

$\text{Na}^+$ - $\text{K}^+$  ATPase is located in the plasma membrane with ATP site on cytosolic side. For each ATP consumed,  $3\text{Na}^+$  go out of the cell (pump phosphorylated) and  $2\text{K}^+$  come into the cell (pump dephosphorylated). Plasma membrane is an asymmetric lipid bilayer containing cholesterol, phospholipids, sphingolipids, glycolipids, and proteins.

**Pumpkin = pump  $\text{K}^+$  in.**  
Ouabain inhibits by binding to  $\text{K}^+$  site. Cardiac glycosides (digoxin and digitoxin) directly inhibit the  $\text{Na}^+$ - $\text{K}^+$  ATPase, which leads to indirect inhibition of  $\text{Na}^+$ / $\text{Ca}^{2+}$  exchange → ↑  $[\text{Ca}^{2+}]_i$ ; → ↑ cardiac contractility.




**Collagen**

Most abundant protein in the human body.  
Extensively modified by posttranslational modification.  
Organizes and strengthens extracellular matrix.

**Be (So Totally) Cool, Read Books.**

<b>Type I</b>	Most common (90%)— <b>B</b> one (made by osteoblasts), <b>S</b> kin, <b>T</b> endon, dentin, fascia, cornea, late wound repair.	Type <b>I</b> : <b>bone</b> . ↓ production in osteogenesis imperfecta type I.
<b>Type II</b>	<b>C</b> artilage (including hyaline), vitreous body, nucleus pulposus.	Type <b>II</b> : <b>cartwo</b> lage.
<b>Type III</b>	<b>R</b> eticulin—skin, <b>blood vessels</b> , uterus, fetal tissue, granulation tissue.	Type <b>III</b> : deficient in the uncommon, <b>vascular</b> type of <b>Ehlers-Danlos syndrome (ThreE D)</b> .
<b>Type IV</b>	<b>B</b> asement membrane, basal lamina, lens.	Type <b>IV</b> : under the <b>floor</b> (basement membrane). Defective in Alport syndrome; targeted by autoantibodies in Goodpasture syndrome.

**Collagen synthesis and structure**

- Synthesis**—translation of collagen  $\alpha$  chains (preprocollagen)—usually Gly-X-Y (X and Y are proline or lysine). Glycine content best reflects collagen synthesis (collagen is  $\frac{1}{3}$  glycine).
- Hydroxylation**—hydroxylation of specific proline and lysine residues. Requires vitamin C; deficiency  $\rightarrow$  scurvy.
- Glycosylation**—glycosylation of pro- $\alpha$ -chain hydroxylysine residues and formation of procollagen via hydrogen and disulfide bonds (triple helix of 3 collagen  $\alpha$  chains). Problems forming triple helix  $\rightarrow$  osteogenesis imperfecta.
- Exocytosis**—exocytosis of procollagen into extracellular space.
- Proteolytic processing**—cleavage of disulfide-rich terminal regions of procollagen  $\rightarrow$  insoluble tropocollagen. Problems with cleavage  $\rightarrow$  Ehlers-Danlos syndrome.
- Cross-linking**—reinforcement of many staggered tropocollagen molecules by covalent lysine-hydroxylysine cross-linkage (by copper-containing lysyl oxidase) to make collagen fibrils. Problems with cross-linking  $\rightarrow$  Ehlers-Danlos syndrome, Menkes disease.

### Osteogenesis imperfecta


Genetic bone disorder (brittle bone disease) caused by a variety of gene defects (most commonly *COL1A1* and *COL1A2*). Most common form is autosomal dominant with ↓ production of otherwise normal type I collagen. Manifestations can include:

- Multiple fractures with minimal trauma **A B**; may occur during the birth process
- Blue sclerae **C** due to the translucent connective tissue over choroidal veins
- Some forms have tooth abnormalities, including opalescent teeth that wear easily due to lack of dentin (dentinogenesis imperfecta)
- Hearing loss (abnormal ossicles)

May be confused with child abuse.

Patients can't **BITE**:

**B**ones = multiple fractures  
**I** (eye) = blue sclerae  
**T**eeth = dental imperfections  
**E**ar = hearing loss



### Ehlers-Danlos syndrome




Faulty collagen synthesis causing hyperextensible skin, tendency to bleed (easy bruising), and hypermobile joints **A**. Multiple types. Inheritance and severity vary. Can be autosomal dominant or recessive. May be associated with joint dislocation, berry and aortic aneurysms, organ rupture.

Hypermobility type (joint instability): most common type.  
 Classical type (joint and skin symptoms): caused by a mutation in type V collagen (eg, *COL5A1*, *COL5A2*).  
 Vascular type (vascular and organ rupture): deficient type III collagen.

### Menkes disease

X-linked recessive connective tissue disease caused by impaired copper absorption and transport due to defective Menkes protein (*ATP7A*). Leads to ↓ activity of lysyl oxidase (copper is a necessary cofactor). Results in brittle, “kinky” hair, growth retardation, and hypotonia.

**Elastin**

Stretchy protein within skin, lungs, large arteries, elastic ligaments, vocal cords, ligamenta flava (connect vertebrae → relaxed and stretched conformations).

Rich in nonhydroxylated proline, glycine, and lysine residues.

Tropoelastin with fibrillin scaffolding.

Cross-linking takes place extracellularly and gives elastin its elastic properties.

Broken down by elastase, which is normally inhibited by  $\alpha_1$ -antitrypsin.

$\alpha_1$ -Antitrypsin deficiency results in excess elastase activity, which can cause emphysema.


Wrinkles of aging are due to ↓ collagen and elastin production.

☒ **Marfan syndrome**—autosomal dominant connective tissue disorder affecting skeleton, heart, and eyes. *FBNI* gene mutation on chromosome 15 results in defective fibrillin, a glycoprotein that forms a sheath around elastin. Findings: tall with long extremities; pectus carinatum (more specific) or pectus excavatum; hypermobile joints; long, tapering fingers and toes (arachnodactyly); cystic medial necrosis of aorta; aortic incompetence and dissecting aortic aneurysms; floppy mitral valve. Subluxation of lenses, typically upward and temporally.

## ► BIOCHEMISTRY—LABORATORY TECHNIQUES

**Polymerase chain reaction**


Molecular biology laboratory procedure used to amplify a desired fragment of DNA. Useful as a diagnostic tool (eg, neonatal HIV, herpes encephalitis).



## Blotting procedures

### Southern blot

1. DNA sample is enzymatically cleaved into smaller pieces, which are separated on a gel by electrophoresis, and then transferred to a filter.
2. Filter is exposed to radiolabeled DNA probe that recognizes and anneals to its complementary strand.
3. Resulting double-stranded, labeled piece of DNA is visualized when filter is exposed to film.



### Northern blot

Similar to Southern blot, except that an **RNA** sample is electrophoresed. Useful for studying mRNA levels, which are reflective of gene expression.

### Western blot

Sample protein is separated via gel electrophoresis and transferred to a membrane. Labeled antibody is used to bind to relevant **protein** (eg, confirmatory test for HIV after ⊕ ELISA).

### Southwestern blot

Identifies **DNA-binding proteins** (eg, transcription factors) using labeled oligonucleotide probes.

### SNOW DRoP:

Southern = DNA

Northern = RNA

Western = Protein

**Flow cytometry**


Laboratory technique to assess size, granularity, and protein expression (immunophenotype) of individual cells in a sample.

Cells are tagged with antibodies specific to surface or intracellular proteins. Antibodies are then tagged with a unique fluorescent dye. Sample is analyzed one cell at a time by focusing a laser on the cell and measuring light scatter and intensity of fluorescence.

Data are plotted either as histogram (one measure) or scatter plot (any two measures, as shown). In illustration:

- Cells in left lower quadrant ⊖ for both CD8 and CD3.
- Cells in right lower quadrant ⊕ for CD8 and ⊖ for CD3. Right lower quadrant is empty because all CD8-expressing cells also express CD3.
- Cells in left upper quadrant ⊕ for CD3 and ⊖ for CD8.
- Cells in right upper quadrant ⊕ for CD8 and CD3 (red + blue → purple).

Commonly used in workup of hematologic abnormalities (eg, paroxysmal nocturnal hemoglobinuria, fetal RBCs in mother's blood) and immunodeficiencies (eg, CD4 cell count in HIV).

**Microarrays**

Thousands of nucleic acid sequences are arranged in grids on glass or silicon. DNA or RNA probes are hybridized to the chip, and a scanner detects the relative amounts of complementary binding. Used to profile gene expression levels of thousands of genes simultaneously to study certain diseases and treatments. Able to detect single nucleotide polymorphisms (SNPs) and copy number variations (CNVs) for a variety of applications including genotyping, clinical genetic testing, forensic analysis, cancer mutations, and genetic linkage analysis.

**Enzyme-linked immunosorbent assay**

Immunologic test used to detect the presence of either a specific antigen (eg, HBsAg) or antibody (eg, anti-HBs) in a patient's blood sample. Detection involves the use of an antibody linked to an enzyme. Added substrate reacts with enzyme, producing a detectable signal. Can have high sensitivity and specificity, but is less specific than Western blot.

**Karyotyping**

A process in which metaphase chromosomes are stained, ordered, and numbered according to morphology, size, arm-length ratio, and banding pattern (arrows in **A** point to extensive abnormalities in a cancer cell).

Can be performed on a sample of blood, bone marrow, amniotic fluid, or placental tissue.


Used to diagnose chromosomal imbalances (eg, autosomal trisomies, sex chromosome disorders).

**Fluorescence in situ hybridization**

Fluorescent DNA or RNA probe binds to specific gene site of interest on chromosomes (arrows in **A** point to abnormalities in a cancer cell, whose karyotype is seen above; each fluorescent color represents a chromosome-specific probe).

Used for specific localization of genes and direct visualization of chromosomal anomalies at the molecular level.

- Microdeletion—no fluorescence on a chromosome compared to fluorescence at the same locus on the second copy of that chromosome
- Translocation—fluorescence signal that corresponds to one chromosome is found in a different chromosome
- Duplication—extra site of fluorescence on one chromosome relative to its homologous chromosome

**Cloning methods**

Cloning is the production of a recombinant DNA molecule that is self-perpetuating.

Steps:

1. Isolate eukaryotic mRNA (post-RNA processing) of interest.
2. Expose mRNA to reverse transcriptase to produce cDNA (lacks introns).
3. Insert cDNA fragments into bacterial plasmids containing antibiotic resistance genes.
4. Transform recombinant plasmid into bacteria.
5. Surviving bacteria on antibiotic medium produce cloned DNA (copies of cDNA).



**Gene expression modifications**

Transgenic strategies in mice involve:

- Random insertion of gene into mouse genome
- Targeted insertion or deletion of gene through homologous recombination with mouse gene

Knock-**out** = removing a gene, taking it **out**.  
Knock-**in** = **in**serting a gene.

**Cre-lox system**

Can inducibly manipulate genes at specific developmental points (eg, to study a gene whose deletion causes embryonic death).

**RNA interference**

dsRNA is synthesized that is complementary to the mRNA sequence of interest. When transfected into human cells, dsRNA separates and promotes degradation of target mRNA, “knocking down” gene expression.

## ► BIOCHEMISTRY—GENETICS

**Genetic terms**

TERM	DEFINITION	EXAMPLE
<b>Codominance</b>	Both alleles contribute to the phenotype of the heterozygote.	Blood groups A, B, AB; $\alpha_1$ -antitrypsin deficiency.
<b>Variable expressivity</b>	Patients with the same genotype have varying phenotypes.	2 patients with neurofibromatosis type 1 (NF1) may have varying disease severity.
<b>Incomplete penetrance</b>	Not all individuals with a mutant genotype show the mutant phenotype.	<i>BRCA1</i> gene mutations do not always result in breast or ovarian cancer.
<b>Pleiotropy</b>	One gene contributes to multiple phenotypic effects.	Untreated phenylketonuria (PKU) manifests with light skin, intellectual disability, and musty body odor.
<b>Anticipation</b>	Increased severity or earlier onset of disease in succeeding generations.	Trinucleotide repeat diseases (eg, Huntington disease).
<b>Loss of heterozygosity</b>	If a patient inherits or develops a mutation in a tumor suppressor gene, the complementary allele must be deleted/mutated before cancer develops. This is not true of oncogenes.	Retinoblastoma and the “two-hit hypothesis,” Lynch syndrome (HNPCC), Li-Fraumeni syndrome.
<b>Dominant negative mutation</b>	Exerts a dominant effect. A heterozygote produces a nonfunctional altered protein that also prevents the normal gene product from functioning.	Mutation of a transcription factor in its allosteric site. Nonfunctioning mutant can still bind DNA, preventing wild-type transcription factor from binding.
<b>Linkage disequilibrium</b>	Tendency for certain alleles at 2 linked loci to occur together more or less often than expected by chance. Measured in a population, not in a family, and often varies in different populations.	

**Genetic terms (continued)**

TERM	DEFINITION	EXAMPLE
<b>Mosaicism</b>	Presence of genetically distinct cell lines in the same individual. Somatic mosaicism—mutation arises from mitotic errors after fertilization and propagates through multiple tissues or organs. Gonadal mosaicism—mutation only in egg or sperm cells. If parents and relatives do not have the disease, suspect gonadal (or germline) mosaicism.	<b>McCune-Albright syndrome</b> —due to mutation affecting G-protein signaling. Presents with unilateral café-au-lait spots with ragged edges, polyostotic fibrous dysplasia, and at least one endocrinopathy (eg, precocious puberty). Lethal if mutation occurs before fertilization (affecting all cells), but survivable in patients with mosaicism.
<b>Locus heterogeneity</b>	Mutations at different loci can produce a similar phenotype.	Albinism.
<b>Allelic heterogeneity</b>	Different mutations in the same locus produce the same phenotype.	β-thalassemia.
<b>Heteroplasmy</b>	Presence of both normal and mutated mtDNA, resulting in variable expression in mitochondrially inherited disease.	
<b>Uniparental disomy</b>	Offspring receives 2 copies of a chromosome from 1 parent and no copies from the other parent. HeterodIsomy (heterozygous) indicates a meiosis I error. IsodIsomy (homozygous) indicates a meiosis II error or postzygotic chromosomal duplication of one of a pair of chromosomes, and loss of the other of the original pair.	Uniparental is euploid (correct number of chromosomes), not aneuploid. Most occurrences of uniparental disomy (UPD) → normal phenotype. Consider UPD in an individual manifesting a recessive disorder when only one parent is a carrier.

**Hardy-Weinberg population genetics**

	$pA$	$qa$
$pA$	AA $p \times p = p^2$	Aa $p \times q$
$qa$	Aa $p \times q$	aa $q \times q = q^2$

If a population is in Hardy-Weinberg equilibrium and if  $p$  and  $q$  are the frequencies of separate alleles, then:  $p^2 + 2pq + q^2 = 1$  and  $p + q = 1$ , which implies that:  
 $p^2$  = frequency of homozygosity for allele A  
 $q^2$  = frequency of homozygosity for allele a  
 $2pq$  = frequency of heterozygosity (carrier frequency, if an autosomal recessive disease).  
 The frequency of an X-linked recessive disease in males =  $q$  and in females =  $q^2$ .

Hardy-Weinberg law assumptions include:

- No mutation occurring at the locus
- Natural selection is not occurring
- Completely random mating
- No net migration

**Imprinting**

At some loci, only one allele is active; the other is inactive (imprinted/inactivated by methylation). With one allele inactivated, deletion of the active allele → disease.

Both Prader-Willi and Angelman syndromes are due to mutation or deletion of genes on chromosome 15.

**Prader-Willi syndrome**


Maternal imprinting: gene from mom is normally silent and **P**aternal gene is deleted/mutated. Results in hyperphagia, obesity, intellectual disability, hypogonadism, and hypotonia.

25% of cases due to maternal uniparental disomy (two maternally imprinted genes are received; no paternal gene received).

**AngelMan syndrome**


Paternal imprinting: gene from dad is normally silent and **M**aternal gene is deleted/mutated. Results in inappropriate laughter (“happy puppet”), seizures, ataxia, and severe intellectual disability.

5% of cases due to paternal uniparental disomy (two paternally imprinted genes are received; no maternal gene received).

**Modes of inheritance****Autosomal dominant**

Often due to defects in structural genes. Many generations, both males and females are affected.

Often pleiotropic (multiple apparently unrelated effects) and variably expressive (different between individuals). Family history crucial to diagnosis. With one affected (heterozygous) parent, on average,  $\frac{1}{2}$  of children affected.


**Autosomal recessive**

Often due to enzyme deficiencies. Usually seen in only 1 generation.

Commonly more severe than dominant disorders; patients often present in childhood.


↑ risk in consanguineous families.

With 2 carrier (heterozygous) parents, on average:  $\frac{1}{4}$  of children will be affected (homozygous),  $\frac{1}{2}$  of children will be carriers, and  $\frac{1}{4}$  of children will be neither affected nor carriers.

**X-linked recessive**


Sons of heterozygous mothers have a 50% chance of being affected. No male-to-male transmission. Skips generations.

Commonly more severe in males. Females usually must be homozygous to be affected.

**X-linked dominant**

Transmitted through both parents. Mothers transmit to 50% of daughters and sons; fathers transmit to all daughters but no sons.

**Hypophosphatemic rickets**—formerly known as vitamin D-resistant rickets. Inherited disorder resulting in ↑ phosphate wasting at proximal tubule. Results in rickets-like presentation. Other examples: fragile X syndrome, Alport syndrome.

**Mitochondrial inheritance**

Transmitted only through the mother. All offspring of affected females may show signs of disease.

Variable expression in a population or even within a family due to heteroplasmy.

**Mitochondrial myopathies**—rare disorders; often present with myopathy, lactic acidosis, and CNS disease, eg, MELAS syndrome (mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes). 2° to failure in oxidative phosphorylation. Muscle biopsy often shows “ragged red fibers” (due to accumulation of diseased mitochondria).

□ = unaffected male; ■ = affected male; ○ = unaffected female; ● = affected female.

**Autosomal dominant diseases**

Achondroplasia, autosomal dominant polycystic kidney disease, familial adenomatous polyposis, familial hypercholesterolemia, hereditary hemorrhagic telangiectasia, hereditary spherocytosis, Huntington disease, Li-Fraumeni syndrome, Marfan syndrome, multiple endocrine neoplasias, neurofibromatosis type 1 (von Recklinghausen disease), neurofibromatosis type 2, tuberous sclerosis, von Hippel-Lindau disease.

**Autosomal recessive diseases**

Albinism, autosomal recessive polycystic kidney disease (ARPKD), cystic fibrosis, glycogen storage diseases, hemochromatosis, Kartagener syndrome, mucopolysaccharidoses (except Hunter syndrome), phenylketonuria, sickle cell anemia, sphingolipidoses (except Fabry disease), thalassemias, Wilson disease.

**Cystic fibrosis**

## GENETICS

Autosomal recessive; defect in *CFTR* gene on chromosome 7; commonly a deletion of Phe508. Most common lethal genetic disease in Caucasian population.

## PATHOPHYSIOLOGY

*CFTR* encodes an ATP-gated  $\text{Cl}^-$  channel that secretes  $\text{Cl}^-$  in lungs and GI tract, and reabsorbs  $\text{Cl}^-$  in sweat glands. Most common mutation → misfolded protein → protein retained in RER and not transported to cell membrane, causing ↓  $\text{Cl}^-$  (and  $\text{H}_2\text{O}$ ) secretion; ↑ intracellular  $\text{Cl}^-$  results in compensatory ↑  $\text{Na}^+$  reabsorption via epithelial  $\text{Na}^+$  channels → ↑  $\text{H}_2\text{O}$  reabsorption → abnormally thick mucus secreted into lungs and GI tract. ↑  $\text{Na}^+$  reabsorption also causes more negative transepithelial potential difference.

## DIAGNOSIS

↑  $\text{Cl}^-$  concentration (> 60 mEq/L) in sweat is diagnostic. Can present with contraction alkalosis and hypokalemia (ECF effects analogous to a patient taking a loop diuretic) because of ECF  $\text{H}_2\text{O}/\text{Na}^+$  losses and concomitant renal  $\text{K}^+/\text{H}^+$  wasting. ↑ immunoreactive trypsinogen (newborn screening).

## COMPLICATIONS

Recurrent pulmonary infections (eg, *S aureus* [early infancy], *P aeruginosa* [adolescence]), chronic bronchitis and bronchiectasis → reticulonodular pattern on CXR, opacification of sinuses. Pancreatic insufficiency, malabsorption with steatorrhea, fat-soluble vitamin deficiencies (A, D, E, K), biliary cirrhosis, liver disease. Meconium ileus in newborns. Infertility in men (absence of vas deferens, spermatogenesis may be unaffected) and subfertility in women (amenorrhea, abnormally thick cervical mucus). Nasal polyps, clubbing of nails.

## TREATMENT

Multifactorial: chest physiotherapy, albuterol, aerosolized dornase alfa (DNAse), and hypertonic saline facilitate mucus clearance. Azithromycin used as anti-inflammatory agent. Ibuprofen slows disease progression. Pancreatic enzymes for insufficiency.

**X-linked recessive disorders**


Ornithine transcarbamylase deficiency, Fabry disease, Wiskott-Aldrich syndrome, Ocular albinism, G6PD deficiency, Hunter syndrome, Bruton agammaglobulinemia, Hemophilia A and B, Lesch-Nyhan syndrome, Duchenne (and Becker) muscular dystrophy.

**Lyonization**—female carriers variably affected depending on the pattern of inactivation of the X chromosome carrying the mutant vs normal gene.

**Oblivious Female Will Often Give Her Boys Her x-Linked Disorders**

## Muscular dystrophies

### Duchenne



X-linked disorder typically due to **frameshift** or nonsense mutations → truncated or absent dystrophin protein → progressive myofiber damage. Weakness begins in pelvic girdle muscles and progresses superiorly. Pseudohypertrophy of calf muscles due to fibrofatty replacement of muscle **A**. Waddling gait. Onset before 5 years of age. Dilated cardiomyopathy is common cause of death.

**D**uchenne = **d**eleted **d**ystrophin.

Dystrophin gene (*DMD*) is the largest protein-coding human gene → ↑ chance of spontaneous mutation. Dystrophin helps anchor muscle fibers, primarily in skeletal and cardiac muscle. It connects the intracellular cytoskeleton (actin) to the transmembrane proteins  $\alpha$ - and  $\beta$ -dystroglycan, which are connected to the extracellular matrix (ECM). Loss of dystrophin results in myonecrosis. ↑ CK and aldolase are seen; genetic testing confirms diagnosis.

### Becker

X-linked disorder typically due to **non-frameshift** deletions in dystrophin gene (partially functional instead of truncated). Less severe than Duchenne. Onset in adolescence or early adulthood.

Deletions can cause both Duchenne and Becker muscular dystrophies.  $\frac{2}{3}$  of cases have large deletions spanning one or more exons.


### Myotonic type 1

Autosomal dominant. **CTG** trinucleotide repeat expansion in the *DMPK* gene → abnormal expression of myotonin protein kinase → myotonia, muscle wasting, cataracts, testicular atrophy, frontal balding, arrhythmia.

**C**ataracts, **T**oupee (early balding in men), **G**onadal atrophy.

**Gower sign**—patient uses upper extremities to help stand up.

Classically seen in Duchenne muscular dystrophy, but also seen in other muscular dystrophies and inflammatory myopathies (eg, polymyositis).



**Fragile X syndrome**

X-linked dominant inheritance. Trinucleotide repeat in *FMRI* gene → hypermethylation → ↓ expression. Most common cause of inherited intellectual disability and autism and 2nd most common cause of genetically associated mental deficiency (after Down syndrome). Findings: post-pubertal macroorchidism (enlarged testes), long face with a large jaw, large everted ears, autism, mitral valve prolapse.

Trinucleotide repeat disorder (**CGG**)<sub>n</sub>.  
**C**hin (protruding), **G**iant **G**onads

**Trinucleotide repeat expansion diseases**

**Huntington** disease, **myotonic** dystrophy, **fragile X** syndrome, and **Friedreich** ataxia.  
 May show genetic anticipation (disease severity ↑ and age of onset ↓ in successive generations).  
 Huntington disease = (**CAG**)<sub>n</sub>  
 Myotonic dystrophy = (**CTG**)<sub>n</sub>  
 Fragile X syndrome = (**CGG**)<sub>n</sub>  
 Friedreich ataxia = (**GAA**)<sub>n</sub>

**Try** (trinucleotide) **hunting** for **my fragile** cage-free eggs (X).

**C**audate has ↓ **ACh** and **GABA**  
**C**ataracts, **T**oupee (early balding in men),  
**G**onadal atrophy  
**C**hin (protruding), **G**iant **G**onads  
 Ataxic **GAAit**

## Autosomal trisomies

**Down syndrome**  
(trisomy 21)

Findings: intellectual disability, flat facies, prominent epicanthal folds, single palmar crease, gap between 1st 2 toes, duodenal atresia, Hirschsprung disease, congenital heart disease (eg, atrioventricular septal defect), Brushfield spots. Associated with early-onset Alzheimer disease (chromosome 21 codes for amyloid precursor protein) and ↑ risk of ALL and AML.

95% of cases due to meiotic nondisjunction (↑ with advanced maternal age; from 1:1500 in women < 20 to 1:25 in women > 45 years old).

4% of cases due to unbalanced Robertsonian translocation, most typically between chromosomes 14 and 21. 1% of cases due to mosaicism (no association with maternal nondisjunction; postfertilization mitotic error).

Incidence 1:700.

**D**rinking age (21).

Most common viable chromosomal disorder and most common cause of genetic intellectual disability.

First-trimester ultrasound commonly shows ↑ nuchal translucency and hypoplastic nasal bone; ↓ serum PAPP-A, ↑ free β-hCG.

Second-trimester quad screen shows ↓ α-fetoprotein, ↑ β-hCG, ↓ estriol, ↑ inhibin A.

**Edwards syndrome**  
(trisomy 18)

Findings: **P**RINCE Edward—**P**rominent occiput, **R**ocker-bottom feet, **I**ntellectual disability, **N**ondisjunction, **C**lenched fists (with overlapping fingers), low-set **E**ars, micrognathia (small jaw), congenital heart disease. Death usually occurs by age 1.

Incidence 1:8000.

**E**lection age (18).

2nd most common autosomal trisomy resulting in live birth (most common is Down syndrome).

PAPP-A and free β-hCG are ↓ in first trimester.

Quad screen shows ↓ α-fetoprotein, ↓ β-hCG, ↓ estriol, ↓ or normal inhibin A.


**Patau syndrome**  
(trisomy 13)

Findings: severe intellectual disability, rocker-bottom feet, microphthalmia, microcephaly, cleft li**P**/Palate, holo**P**rosencephaly, **P**olydactyly, cutis **a**Plasia, congenital heart disease. Death usually occurs by age 1.

Incidence 1:15,000.

**P**uberty (13).

First-trimester pregnancy screen shows ↓ free β-hCG, ↓ PAPP-A.





**Genetic disorders by chromosome**

CHROMOSOME	SELECTED EXAMPLES
3	von Hippel-Lindau disease, renal cell carcinoma
4	ADPKD ( <i>PKD2</i> ), achondroplasia, Huntington disease
5	Cri-du-chat syndrome, familial adenomatous polyposis
6	Hemochromatosis ( <i>HFE</i> )
7	Williams syndrome, cystic fibrosis
9	Friedreich ataxia
11	Wilms tumor, $\beta$ -globin gene defects (eg, sickle cell disease, $\beta$ -thalassemia, MEN1)
13	Patau syndrome, Wilson disease, retinoblastoma ( <i>RBI</i> ), <i>BRCA2</i>
15	Prader-Willi syndrome, Angelman syndrome, Marfan syndrome
16	ADPKD ( <i>PKD1</i> ), $\alpha$ -globin gene defects (eg, $\alpha$ -thalassemia)
17	Neurofibromatosis type 1, <i>BRCA1</i> , <i>p53</i>
18	Edwards syndrome
21	Down syndrome
22	Neurofibromatosis type 2, DiGeorge syndrome (22q11)
X	Fragile X syndrome, X-linked agammaglobulinemia, Klinefelter syndrome (XXY)

**Robertsonian translocation**

Chromosomal translocation that commonly involves chromosome pairs 13, 14, 15, 21, and 22. One of the most common types of translocation. Occurs when the long arms of 2 acrocentric chromosomes (chromosomes with centromeres near their ends) fuse at the centromere and the 2 short arms are lost. Balanced translocations normally do not cause any abnormal phenotype. Unbalanced translocations can result in miscarriage, stillbirth, and chromosomal imbalance (eg, Down syndrome, Patau syndrome).

**Cri-du-chat syndrome**

Congenital microdeletion of short arm of chromosome 5 (46,XX or XY, 5p<sup>-</sup>). Findings: microcephaly, moderate to severe intellectual disability, high-pitched **crying**/**meowing**, epicanthal folds, cardiac abnormalities (VSD).

*Cri du chat* = **cry** of the **cat**.

**Williams syndrome**

Congenital microdeletion of long arm of chromosome 7 (deleted region includes elastin gene). Findings: distinctive “elfin” facies, intellectual disability, hypercalcemia ( $\uparrow$  sensitivity to vitamin D), well-developed verbal skills, extreme friendliness with strangers, cardiovascular problems.

**22q11 deletion syndromes**

Microdeletion at chromosome 22q11 → variable presentations including **C**left palate, **A**bnormal facies, **T**hymic aplasia → T-cell deficiency, **C**ardiac defects, and **H**ypocalcemia 2° to parathyroid aplasia.

**DiGeorge syndrome**—thymic, parathyroid, and cardiac defects.

**Velocardiofacial syndrome**—palate, facial, and cardiac defects.

**CATCH-22.**

Due to aberrant development of 3rd and 4th branchial pouches.

## ▶ BIOCHEMISTRY—NUTRITION

**Vitamins: fat soluble**

A, D, E, K. Absorption dependent on gut and pancreas. Toxicity more common than for water-soluble vitamins because fat-soluble vitamins accumulate in fat.

Malabsorption syndromes with steatorrhea, such as cystic fibrosis and celiac disease, or mineral oil intake can cause fat-soluble vitamin deficiencies.

**Vitamins: water soluble**

B<sub>1</sub> (thiamine: TPP)  
 B<sub>2</sub> (riboflavin: FAD, FMN)  
 B<sub>3</sub> (niacin: NAD<sup>+</sup>)  
 B<sub>5</sub> (pantothenic acid: CoA)  
 B<sub>6</sub> (pyridoxine: PLP)  
 B<sub>7</sub> (biotin)  
 B<sub>9</sub> (folate)  
 B<sub>12</sub> (cobalamin)  
 C (ascorbic acid)

All wash out easily from body except B<sub>12</sub> and B<sub>9</sub> (folate). B<sub>12</sub> stored in liver for ~ 3–4 years. B<sub>9</sub> stored in liver for ~ 3–4 months.

B-complex deficiencies often result in dermatitis, glossitis, and diarrhea.

Can be coenzymes (eg, ascorbic acid) or precursors to organic cofactors (eg, FAD, NAD<sup>+</sup>).

**Vitamin A (retinol)**

FUNCTION	Antioxidant; constituent of visual pigments ( <b>retinal</b> ); essential for normal differentiation of epithelial cells into specialized tissue (pancreatic cells, mucus-secreting cells); prevents squamous metaplasia. Used to treat measles and acute promyelocytic leukemia (APL).	<b>Retinol</b> is vitamin <b>A</b> , so think <b>retin-A</b> (used topically for wrinkles and <b>A</b> cne). Found in liver and leafy vegetables. Use oral isotretinoin to treat severe cystic acne. Use <i>all-trans</i> retinoic acid to treat acute promyelocytic leukemia.
DEFICIENCY	Night blindness (nyctalopia); dry, scaly skin (xerosis cutis); corneal degeneration (keratomalacia); Bitot spots on conjunctiva; immunosuppression.	
EXCESS	Acute toxicity—nausea, vomiting, vertigo, and blurred vision. Chronic toxicity—alopecia, dry skin (eg, scaliness), hepatic toxicity and enlargement, arthralgias, and pseudotumor cerebri. Teratogenic (cleft palate, cardiac abnormalities), therefore a $\ominus$ pregnancy test and two forms of contraception are required before isotretinoin (vitamin A derivative) is prescribed.	<b>Isotretinoin is teratogenic.</b>

**Vitamin B<sub>1</sub> (thiamine)**

FUNCTION	In thiamine pyrophosphate (TPP), a cofactor for several dehydrogenase enzyme reactions: <ul style="list-style-type: none"> <li>▪ Pyruvate dehydrogenase (links glycolysis to TCA cycle)</li> <li>▪ <math>\alpha</math>-ketoglutarate dehydrogenase (TCA cycle)</li> <li>▪ Transketolase (HMP shunt)</li> <li>▪ Branched-chain ketoacid dehydrogenase</li> </ul>	Think <b>ATP</b> : $\alpha$ -ketoglutarate dehydrogenase, <b>T</b> ransketolase, and <b>P</b> yruvate dehydrogenase. Spell beriberi as <b>Ber1Ber1</b> to remember vitamin <b>B<sub>1</sub></b> . <b>Wernicke-Korsakoff syndrome</b> —confusion, ophthalmoplegia, ataxia (classic triad) + confabulation, personality change, memory loss (permanent). Damage to medial dorsal nucleus of thalamus, mammillary bodies. <b>Dry beriberi</b> —polyneuritis, symmetrical muscle wasting. <b>Wet beriberi</b> —high-output cardiac failure (dilated cardiomyopathy), edema.
DEFICIENCY	Impaired glucose breakdown $\rightarrow$ ATP depletion worsened by glucose infusion; highly aerobic tissues (eg, brain, heart) are affected first. In alcoholic or malnourished patients, give thiamine before dextrose to $\downarrow$ risk of precipitating Wernicke encephalopathy. Diagnosis made by $\uparrow$ in RBC transketolase activity following vitamin B <sub>1</sub> administration.	

**Vitamin B<sub>2</sub> (riboflavin)**

FUNCTION	Component of flavins FAD and FMN, used as cofactors in redox reactions, eg, the succinate dehydrogenase reaction in the TCA cycle.	FAD and FMN are derived from ribo <b>F</b> lavin (B <sub>2</sub> ≈ 2 ATP).
DEFICIENCY	Cheilosis (inflammation of lips, scaling and fissures at the corners of the mouth), Corneal vascularization.	The 2 <b>C</b> 's of B <sub>2</sub> .

**Vitamin B<sub>3</sub> (niacin)**

FUNCTION	Constituent of NAD <sup>+</sup> , NADP <sup>+</sup> (used in redox reactions). Derived from tryptophan. Synthesis requires vitamins B <sub>2</sub> and B <sub>6</sub> . Used to treat dyslipidemia; lowers levels of VLDL and raises levels of HDL.	NAD derived from <b>N</b> iacin (B <sub>3</sub> ≈ 3 ATP).
DEFICIENCY	Glossitis. Severe deficiency leads to pellagra, which can be caused by Hartnup disease, malignant carcinoid syndrome (↑ tryptophan metabolism), and isoniazid (↓ vitamin B <sub>6</sub> ). Symptoms of pellagra: <b>D</b> iarrhea, <b>D</b> ementia (also hallucinations), <b>D</b> ermatitis (C3/C4 dermatome circumferential “broad collar” rash [Casal necklace], hyperpigmentation of sun-exposed limbs <b>A</b> ).	The 3 <b>D</b> 's of B <sub>3</sub> . <b>Hartnup disease</b> —autosomal recessive. Deficiency of neutral amino acid (eg, tryptophan) transporters in proximal renal tubular cells and on enterocytes → neutral aminoaciduria and ↓ absorption from the gut → ↓ tryptophan for conversion to niacin → pellagra-like symptoms. Treat with high-protein diet and nicotinic acid.
EXCESS	Facial flushing (induced by prostaglandin, not histamine; can avoid by taking aspirin with niacin), hyperglycemia, hyperuricemia.	

**Vitamin B<sub>5</sub> (pantothenic acid)**

FUNCTION	Essential component of coenzyme A (CoA, a cofactor for acyl transfers) and fatty acid synthase.	B <sub>5</sub> is “ <b>p</b> ento”thenic acid.
DEFICIENCY	Dermatitis, enteritis, alopecia, adrenal insufficiency.	

**Vitamin B<sub>6</sub> (pyridoxine)**

FUNCTION	Converted to pyridoxal phosphate (PLP), a cofactor used in transamination (eg, ALT and AST), decarboxylation reactions, glycogen phosphorylase. Synthesis of cystathionine, heme, niacin, histamine, and neurotransmitters including serotonin, epinephrine, norepinephrine (NE), dopamine, and GABA.	
DEFICIENCY	Convulsions, hyperirritability, peripheral neuropathy (deficiency inducible by isoniazid and oral contraceptives), sideroblastic anemias due to impaired hemoglobin synthesis and iron excess.	

**Vitamin B<sub>7</sub> (biotin)**


FUNCTION	<p>Cofactor for carboxylation enzymes (which add a 1-carbon group):</p> <ul style="list-style-type: none"> <li>▪ Pyruvate carboxylase: pyruvate (3C) → oxaloacetate (4C)</li> <li>▪ Acetyl-CoA carboxylase: acetyl-CoA (2C) → malonyl-CoA (3C)</li> <li>▪ Propionyl-CoA carboxylase: propionyl-CoA (3C) → methylmalonyl-CoA (4C)</li> </ul>	“ <b>A</b> vidin in egg whites <b>a</b> vidly binds biotin.”
DEFICIENCY	<p>Relatively rare. Dermatitis, alopecia, enteritis. Caused by antibiotic use or excessive ingestion of raw egg whites.</p>	

**Vitamin B<sub>9</sub> (folate)**

FUNCTION	<p>Converted to tetrahydrofolic acid (THF), a coenzyme for 1-carbon transfer/methylation reactions.</p> <p>Important for the synthesis of nitrogenous bases in DNA and RNA.</p>	<p>Found in leafy green vegetables. Absorbed in jejunum. <b>F</b>olate from <b>f</b>oliage.</p> <p>Small reserve pool stored primarily in the liver.</p>
DEFICIENCY	<p>Macrocytic, megaloblastic anemia; hypersegmented polymorphonuclear cells (PMNs); glossitis; no neurologic symptoms (as opposed to vitamin B<sub>12</sub> deficiency). Labs: ↑ homocysteine, normal methylmalonic acid levels. Most common vitamin deficiency in the United States. Seen in alcoholism and pregnancy.</p>	<p>Deficiency can be caused by several drugs (eg, phenytoin, sulfonamides, methotrexate).</p> <p>Supplemental maternal folic acid at least 1 month prior to conception and during early pregnancy to ↓ risk of neural tube defects.</p>

**Vitamin B<sub>12</sub> (cobalamin)**

FUNCTION	Cofactor for methionine synthase (transfers CH <sub>3</sub> groups as methylcobalamin) and methylmalonyl-CoA mutase. Important for DNA synthesis.	Found in animal products. Synthesized only by microorganisms. Very large reserve pool (several years) stored primarily in the liver. Deficiency caused by malabsorption (eg, sprue, enteritis, <i>Diphyllobothrium latum</i> ), lack of intrinsic factor (pernicious anemia, gastric bypass surgery), absence of terminal ileum (surgical resection, eg, for Crohn disease), or insufficient intake (eg, veganism). Anti-intrinsic factor antibodies diagnostic for pernicious anemia.
DEFICIENCY	Macrocytic, megaloblastic anemia; hypersegmented PMNs; paresthesias and subacute combined degeneration (degeneration of dorsal columns, lateral corticospinal tracts, and spinocerebellar tracts) due to abnormal myelin. Associated with ↑ serum homocysteine and methylmalonic acid levels, along with 2° folate deficiency. Prolonged deficiency → irreversible nerve damage.	



**Vitamin C (ascorbic acid)**

FUNCTION	Antioxidant; also facilitates iron absorption by reducing it to Fe <sup>2+</sup> state. Necessary for hydroxylation of proline and lysine in collagen synthesis. Necessary for dopamine β-hydroxylase, which converts dopamine to NE.	Found in fruits and vegetables. Pronounce “ <b>absorbic</b> ” acid. Ancillary treatment for methemoglobinemia by reducing Fe <sup>3+</sup> to Fe <sup>2+</sup> .
DEFICIENCY	<b>Scurvy</b> —swollen gums, bruising, petechiae, hemarthrosis, anemia, poor wound healing, perifollicular and subperiosteal hemorrhages, “corkscrew” hair. Weakened immune response.	Vitamin <b>C</b> deficiency causes <b>sCurvy</b> due to a <b>C</b> ollagen synthesis defect.
EXCESS	Nausea, vomiting, diarrhea, fatigue, calcium oxalate nephrolithiasis. Can ↑ risk of iron toxicity in predisposed individuals (eg, those with transfusions, hereditary hemochromatosis).	

**Vitamin D**

D<sub>2</sub> = ergocalciferol—ingested from plants.

D<sub>3</sub> = cholecalciferol—consumed in milk, formed in sun-exposed skin (stratum basale).

25-OH D<sub>3</sub> = storage form.

1,25-(OH)<sub>2</sub> D<sub>3</sub> (calcitriol) = active form.

**FUNCTION**

↑ intestinal absorption of calcium and phosphate, ↑ bone mineralization at low levels, ↑ bone resorption at higher levels.

**DEFICIENCY**

Rickets in children (deformity, such as genu varum “bow legs” **A**), osteomalacia in adults (bone pain and muscle weakness), hypocalcemic tetany. Breastfed infants should receive oral vitamin D. Deficiency is exacerbated by low sun exposure, pigmented skin, prematurity.

**EXCESS**

Hypercalcemia, hypercalciuria, loss of appetite, stupor. Seen in granulomatous disease (↑ activation of vitamin D by epithelioid macrophages).

**Vitamin E (tocopherol/tocotrienol)****FUNCTION**

Antioxidant (protects RBCs and membranes from free radical damage).

High-dose supplementation may alter metabolism of vitamin K → enhanced anticoagulant effects of warfarin.

**DEFICIENCY**

Hemolytic anemia, acanthocytosis, muscle weakness, posterior column and spinocerebellar tract demyelination.

Neurologic presentation may appear similar to vitamin B<sub>12</sub> deficiency, but without megaloblastic anemia, hypersegmented neutrophils, or ↑ serum methylmalonic acid levels.

**Vitamin K (phytomenadione, phylloquinone, phytonadione)****FUNCTION**

Activated by epoxide reductase to the reduced form, which is a cofactor for the  $\gamma$ -carboxylation of glutamic acid residues on various proteins required for blood clotting. Synthesized by intestinal flora.

**K** is for **K**oagulation. Necessary for the maturation of clotting factors II, VII, IX, X, and proteins C and S. Warfarin inhibits vitamin K–dependent synthesis of these factors and proteins.

**DEFICIENCY**

Neonatal hemorrhage with ↑ PT and ↑ aPTT but normal bleeding time (neonates have sterile intestines and are unable to synthesize vitamin K). Can also occur after prolonged use of broad-spectrum antibiotics.

Not in breast milk; neonates are given vitamin K injection at birth to prevent hemorrhagic disease of the newborn.

**Zinc****FUNCTION**

Mineral essential for the activity of 100+ enzymes. Important in the formation of zinc fingers (transcription factor motif).

**DEFICIENCY**

Delayed wound healing, hypogonadism, ↓ adult hair (axillary, facial, pubic), dysgeusia, anosmia, acrodermatitis enteropathica **A**. May predispose to alcoholic cirrhosis.

**Protein-energy malnutrition****Kwashiorkor**

Protein malnutrition resulting in skin lesions, edema due to ↓ plasma oncotic pressure, liver malfunction (fatty change due to ↓ apolipoprotein synthesis). Clinical picture is small child with swollen abdomen **A**.

Kwashiorkor results from protein-

deficient **MEALS**:

**M**alnutrition

**E**dema

**A**nemia

**L**iver (fatty)

**S**kin lesions (hyperkeratosis/  
hyperpigmentation)


**Marasmus**

Malnutrition not causing edema. Diet is deficient in calories but no nutrients are entirely absent.

**M**arasmus results in **M**uscle wasting **B**.



## Ethanol metabolism



**FOME**pizole—inhibits alcohol dehydrogenase and is an antidote **F**or **O**verdoses of **M**ethanol or **E**thylene glycol.

**Disulfiram**—inhibits acetaldehyde dehydrogenase (acetaldehyde accumulates, contributing to hangover symptoms), **dis**couraging drinking.

$\text{NAD}^+$  is the limiting reagent.


Alcohol dehydrogenase operates via zero-order kinetics.

Ethanol metabolism  $\uparrow$   $\text{NADH}/\text{NAD}^+$  ratio in liver, causing:

- Pyruvate  $\rightarrow$  lactate (lactic acidosis)
- Oxaloacetate  $\rightarrow$  malate (prevents gluconeogenesis  $\rightarrow$  fasting hypoglycemia)
- Dihydroxyacetone phosphate  $\rightarrow$  glycerol-3-phosphate (combines with fatty acids to make triglycerides  $\rightarrow$  hepatosteatosis)

End result is clinical picture seen in chronic alcoholism.

Additionally,  $\uparrow$   $\text{NADH}/\text{NAD}^+$  ratio disfavors TCA production of  $\text{NADH} \rightarrow \uparrow$  utilization of acetyl-CoA for ketogenesis ( $\rightarrow$  ketoacidosis) and lipogenesis ( $\rightarrow$  hepatosteatosis).



## ► BIOCHEMISTRY—METABOLISM

## Metabolism sites

## Mitochondria

Fatty acid oxidation ( $\beta$ -oxidation), acetyl-CoA production, TCA cycle, oxidative phosphorylation, ketogenesis.

## Cytoplasm

Glycolysis, HMP shunt, and synthesis of steroids (SER), proteins (ribosomes, RER), fatty acids, cholesterol, and nucleotides.

## Both

**H**eme synthesis, **U**rea cycle, **G**luconeogenesis. **HUGs** take **two** (ie, both).

**Enzyme terminology** An enzyme's name often describes its function. For example, glucokinase is an enzyme that catalyzes the phosphorylation of glucose using a molecule of ATP. The following are commonly used enzyme descriptors.


<b>Kinase</b>	Catalyzes transfer of a phosphate group from a high-energy molecule (usually ATP) to a substrate (eg, phosphofructokinase).
<b>Phosphorylase</b>	Adds inorganic phosphate onto substrate without using ATP (eg, glycogen phosphorylase).
<b>Phosphatase</b>	Removes phosphate group from substrate (eg, fructose-1,6-bisphosphatase).
<b>Dehydrogenase</b>	Catalyzes oxidation-reduction reactions (eg, pyruvate dehydrogenase).
<b>Hydroxylase</b>	Adds hydroxyl group (–OH) onto substrate (eg, tyrosine hydroxylase).
<b>Carboxylase</b>	Transfers CO <sub>2</sub> groups with the help of biotin (eg, pyruvate carboxylase).
<b>Mutase</b>	Relocates a functional group within a molecule (eg, vitamin B <sub>12</sub> -dependent methylmalonyl-CoA mutase).
<b>Synthase/synthetase</b>	Combines 2 molecules into 1 (condensation reaction) either using an energy source (synthase, eg, glycogen synthase) or not (synthetase, eg, PRPP synthetase).

### Rate-determining enzymes of metabolic processes

PROCESS	ENZYME	REGULATORS
<b>Glycolysis</b>	Phosphofructokinase-1 (PFK-1)	AMP ⊕, fructose-2,6-bisphosphate ⊕ ATP ⊖, citrate ⊖
<b>Gluconeogenesis</b>	Fructose-1,6-bisphosphatase	Citrate ⊕ AMP ⊖, fructose-2,6-bisphosphate ⊖
<b>TCA cycle</b>	Isocitrate dehydrogenase	ADP ⊕ ATP ⊖, NADH ⊖
<b>Glycogenesis</b>	Glycogen synthase	Glucose-6-phosphate ⊕, insulin ⊕, cortisol ⊕ Epinephrine ⊖, glucagon ⊖
<b>Glycogenolysis</b>	Glycogen phosphorylase	Epinephrine ⊕, glucagon ⊕, AMP ⊕ Glucose-6-phosphate ⊖, insulin ⊖, ATP ⊖
<b>HMP shunt</b>	Glucose-6-phosphate dehydrogenase (G6PD)	NADP <sup>+</sup> ⊕ NADPH ⊖
<b>De novo pyrimidine synthesis</b>	Carbamoyl phosphate synthetase II	ATP ⊕, PRPP ⊕ UTP ⊖
<b>De novo purine synthesis</b>	Glutamine-phosphoribosylpyrophosphate (PRPP) amidotransferase	AMP ⊖, inosine monophosphate (IMP) ⊖, GMP ⊖
<b>Urea cycle</b>	Carbamoyl phosphate synthetase I	N-acetylglutamate ⊕
<b>Fatty acid synthesis</b>	Acetyl-CoA carboxylase (ACC)	Insulin ⊕, citrate ⊕ Glucagon ⊖, palmitoyl-CoA ⊖
<b>Fatty acid oxidation</b>	Carnitine acyltransferase I	Malonyl-CoA ⊖
<b>Ketogenesis</b>	HMG-CoA synthase	
<b>Cholesterol synthesis</b>	HMG-CoA reductase	Insulin ⊕, thyroxine ⊕ Glucagon ⊖, cholesterol ⊖

## Summary of pathways

- 1 Galactokinase (*mild galactosemia*)
- 2 Galactose-1-phosphate uridylyltransferase (*severe galactosemia*)
- 3 Hexokinase/glucokinase
- 4 Glucose-6-phosphatase (*von Gierke disease*)
- 5 Glucose-6-phosphate dehydrogenase
- 6 Transketolase
- 7 Phosphofruktokinase-1
- 8 Fructose-1,6-bisphosphatase
- 9 Fructokinase (*essential fructosuria*)
- 10 Aldolase B (*fructose intolerance*)
- 11 Aldolase B (*liver*), A (*muscle*)
- 12 Triose phosphate isomerase
- 13 Pyruvate kinase
- 14 Pyruvate dehydrogenase
- 15 Pyruvate carboxylase
- 16 PEP carboxykinase
- 17 Citrate synthase
- 18 Isocitrate dehydrogenase
- 19  $\alpha$ -ketoglutarate dehydrogenase
- 20 Ornithine transcarbamyase
- 21 Propionyl-CoA carboxylase
- 22 HMG-CoA reductase



**ATP production**

Aerobic metabolism of glucose produces 32 net ATP via malate-aspartate shuttle (heart and liver), 30 net ATP via glycerol-3-phosphate shuttle (muscle).

Anaerobic glycolysis produces only 2 net ATP per glucose molecule.

ATP hydrolysis can be coupled to energetically unfavorable reactions.

Arsenic causes glycolysis to produce zero net ATP.

**Activated carriers**

CARRIER MOLECULE	CARRIED IN ACTIVATED FORM
ATP	Phosphoryl groups
NADH, NADPH, FADH <sub>2</sub>	Electrons
CoA, lipoamide	Acyl groups
Biotin	CO <sub>2</sub>
Tetrahydrofolates	1-carbon units
S-adenosylmethionine (SAM)	CH <sub>3</sub> groups
TPP	Aldehydes

**Universal electron acceptors**

Nicotinamides (NAD<sup>+</sup> from vitamin B<sub>3</sub>, NADP<sup>+</sup>) and flavin nucleotides (FAD<sup>+</sup> from vitamin B<sub>2</sub>).  
 NAD<sup>+</sup> is generally used in **catabolic** processes to carry reducing equivalents away as NADH.  
 NADPH is used in **anabolic** processes (steroid and fatty acid synthesis) as a supply of reducing equivalents.

NADPH is a product of the HMP shunt.  
 NADPH is used in:

- Anabolic processes
- Respiratory burst
- Cytochrome P-450 system
- Glutathione reductase

**Hexokinase vs glucokinase**

Phosphorylation of glucose to yield glucose-6-phosphate serves as the 1st committed step of glycolysis (also serves as the 1st step of glycogen synthesis in the liver). Reaction is catalyzed by either hexokinase or glucokinase, depending on the tissue. At low glucose concentrations, hexokinase sequesters glucose in the tissue. At high glucose concentrations, excess glucose is stored in the liver.

	Hexokinase	Glucokinase
Location	Most tissues, except liver and pancreatic β cells	Liver, β cells of pancreas
K <sub>m</sub>	Lower (↑ affinity)	Higher (↓ affinity)
V <sub>max</sub>	Lower (↓ capacity)	Higher (↑ capacity)
Induced by insulin	No	Yes
Feedback-inhibited by glucose-6-phosphate	Yes	No


### Glycolysis regulation, key enzymes

Net glycolysis (cytoplasm):




Equation not balanced chemically, and exact balanced equation depends on ionization state of reactants and products.

#### REQUIRE ATP



Glucose-6-P  $\ominus$  hexokinase.

Fructose-6-P  $\ominus$  glucokinase.





AMP  $\oplus$ , fructose-2,6-bisphosphate  $\oplus$ .

ATP  $\ominus$ , citrate  $\ominus$ .

<sup>a</sup>Glucokinase in liver and  $\beta$  cells of pancreas; hexokinase in all other tissues.


#### PRODUCE ATP



Fructose-1,6-bisphosphate  $\oplus$ .

ATP  $\ominus$ , alanine  $\ominus$ .

### Regulation by fructose-2,6-bisphosphate




**FBPase-2 (fructose bisphosphatase-2)** and **PFK-2 (phosphofructokinase-2)** are the same bifunctional enzyme whose function is reversed by phosphorylation by protein kinase A.

**Fasting state:**  $\uparrow$  glucagon  $\rightarrow$   $\uparrow$  cAMP  $\rightarrow$   $\uparrow$  protein kinase A  $\rightarrow$   $\uparrow$  FBPase-2,  $\downarrow$  PFK-2, less glycolysis, more gluconeogenesis.

**Fed state:**  $\uparrow$  insulin  $\rightarrow$   $\downarrow$  cAMP  $\rightarrow$   $\downarrow$  protein kinase A  $\rightarrow$   $\downarrow$  FBPase-2,  $\uparrow$  PFK-2, more glycolysis, less gluconeogenesis.

### Pyruvate dehydrogenase complex

Mitochondrial enzyme complex linking glycolysis and TCA cycle. Differentially regulated in fed/fasting states (active in fed state).



The complex contains 3 enzymes that require 5 cofactors:

1. Thiamine pyrophosphate ( $\text{B}_1$ )
2. Lipoic acid
3. CoA ( $\text{B}_5$ , pantothenic acid)
4. FAD ( $\text{B}_2$ , riboflavin)
5.  $\text{NAD}^+$  ( $\text{B}_3$ , niacin)

Activated by:

- $\uparrow$   $\text{NAD}^+/\text{NADH}$  ratio
- $\uparrow$  ADP
- $\uparrow$   $\text{Ca}^{2+}$

The complex is similar to the  $\alpha$ -ketoglutarate dehydrogenase complex (same cofactors, similar substrate and action), which converts  $\alpha$ -ketoglutarate  $\rightarrow$  succinyl-CoA (TCA cycle).

**The Lovely Co-enzymes For Nerds.**

Arsenic inhibits lipoic acid. Arsenic poisoning clinical findings: vomiting, rice-water stools, garlic breath, QT prolongation.


**Pyruvate dehydrogenase complex deficiency**

Causes a buildup of pyruvate that gets shunted to lactate (via LDH) and alanine (via ALT).  
X-linked.

FINDINGS	Neurologic defects, lactic acidosis, ↑ serum alanine starting in infancy.
TREATMENT	↑ intake of ketogenic nutrients (eg, high fat content or ↑ lysine and leucine).

Lysine and Leucine—the onLy pureLy ketogenic amino acids.


**Pyruvate metabolism**



Functions of different pyruvate metabolic pathways (and their associated cofactors):

- 1 Alanine aminotransferase ( $B_6$ ): alanine carries amino groups to the liver from muscle
- 2 Pyruvate carboxylase (biotin): oxaloacetate can replenish TCA cycle or be used in gluconeogenesis
- 3 Pyruvate dehydrogenase ( $B_1, B_2, B_3, B_5$ , lipoic acid): transition from glycolysis to the TCA cycle
- 4 Lactic acid dehydrogenase ( $B_3$ ): end of anaerobic glycolysis (major pathway in RBCs, WBCs, kidney medulla, lens, testes, and cornea)

**TCA cycle (Krebs cycle)** Pyruvate → acetyl-CoA produces 1 NADH, 1  $CO_2$ .




The TCA cycle produces 3 NADH, 1  $FADH_2$ , 2  $CO_2$ , 1 GTP per acetyl-CoA = 10 ATP/ acetyl-CoA (2x everything per glucose). TCA cycle reactions occur in the mitochondria.

$\alpha$ -ketoglutarate dehydrogenase complex requires the same cofactors as the pyruvate dehydrogenase complex ( $B_1, B_2, B_3, B_5$ , lipoic acid).

**Citrate Is Krebs' Starting Substrate For Making Oxaloacetate.**

### Electron transport chain and oxidative phosphorylation

NADH electrons from glycolysis enter mitochondria via the malate-aspartate or glycerol-3-phosphate shuttle.  $\text{FADH}_2$  electrons are transferred to complex II (at a lower energy level than NADH). The passage of electrons results in the formation of a proton gradient that, coupled to oxidative phosphorylation, drives the production of ATP.



#### ATP PRODUCED VIA ATP SYNTHASE

1 NADH  $\rightarrow$  2.5 ATP; 1  $\text{FADH}_2 \rightarrow$  1.5 ATP.

#### OXIDATIVE PHOSPHORYLATION POISONS

<b>Electron transport inhibitors</b>	Directly inhibit electron transport, causing a $\downarrow$ proton gradient and block of ATP synthesis.	<b>Rotenone</b> : complex <b>one</b> inhibitor. “An- <b>3</b> -mycin” (antimycin) A: complex <b>3</b> inhibitor. <b>CO/CN</b> : complex <b>4</b> inhibitors ( <b>4</b> letters).
<b>ATP synthase inhibitors</b>	Directly inhibit mitochondrial ATP synthase, causing an $\uparrow$ proton gradient. No ATP is produced because electron transport stops.	Oligomycin.
<b>Uncoupling agents</b>	$\uparrow$ permeability of membrane, causing a $\downarrow$ proton gradient and $\uparrow$ $\text{O}_2$ consumption. ATP synthesis stops, but electron transport continues. Produces heat.	2,4-Dinitrophenol (used illicitly for weight loss), aspirin (fevers often occur after aspirin overdose), thermogenin in brown fat.


### Gluconeogenesis, irreversible enzymes

<b>Pyruvate carboxylase</b>	In mitochondria. Pyruvate $\rightarrow$ oxaloacetate.	<b>Pathway Produces Fresh Glucose.</b> Requires biotin, ATP. Activated by acetyl-CoA.
<b>Phosphoenolpyruvate carboxykinase</b>	In cytosol. Oxaloacetate $\rightarrow$ phosphoenolpyruvate.	Requires GTP.
<b>Fructose-1,6-bisphosphatase</b>	In cytosol. Fructose-1,6-bisphosphate $\rightarrow$ fructose-6-phosphate.	Citrate $\oplus$ , AMP $\ominus$ , fructose 2,6-bisphosphate $\ominus$ .
<b>Glucose-6-phosphatase</b>	In ER. Glucose-6-phosphate $\rightarrow$ glucose.	

Occurs primarily in liver; serves to maintain euglycemia during fasting. Enzymes also found in kidney, intestinal epithelium. Deficiency of the key gluconeogenic enzymes causes hypoglycemia. (Muscle cannot participate in gluconeogenesis because it lacks glucose-6-phosphatase). Odd-chain fatty acids yield 1 propionyl-CoA during metabolism, which can enter the TCA cycle (as succinyl-CoA), undergo gluconeogenesis, and serve as a glucose source. Even-chain fatty acids cannot produce new glucose, since they yield only acetyl-CoA equivalents.

**HMP shunt (pentose phosphate pathway)**

Provides a source of NADPH from abundantly available glucose-6-P (NADPH is required for reductive reactions, eg, glutathione reduction inside RBCs, fatty acid and cholesterol biosynthesis). Additionally, this pathway yields ribose for nucleotide synthesis and glycolytic intermediates. 2 distinct phases (oxidative and nonoxidative), both of which occur in the cytoplasm. No ATP is used or produced.  
 Sites: lactating mammary glands, liver, adrenal cortex (sites of fatty acid or steroid synthesis), RBCs.




**Glucose-6-phosphate dehydrogenase deficiency**

NADPH is necessary to keep glutathione reduced, which in turn detoxifies free radicals and peroxides. ↓ NADPH in RBCs leads to hemolytic anemia due to poor RBC defense against oxidizing agents (eg, fava beans, sulfonamides, primaquine, antituberculosis drugs). Infection (most common cause) can also precipitate hemolysis; inflammatory response produces free radicals that diffuse into RBCs, causing oxidative damage.

X-linked recessive disorder; most common human enzyme deficiency; more prevalent among African Americans. ↑ malarial resistance.

**Heinz bodies**—denatured **Hemoglobin** precipitates within RBCs due to oxidative stress.

**Bite cells**—result from the phagocytic removal of **Heinz** bodies by splenic macrophages. Think, “**Bite** into some **Heinz** ketchup.”





### Disorders of fructose metabolism

#### Essential fructosuria

Involves a defect in **fructokinase**. Autosomal recessive. A benign, asymptomatic condition, since fructose is not trapped in cells.

Symptoms: fructose appears in blood and urine.


Disorders of fructose metabolism cause milder symptoms than analogous disorders of galactose metabolism.

#### Fructose intolerance

Hereditary deficiency of **aldolase B**. Autosomal recessive. Fructose-1-phosphate accumulates, causing a ↓ in available phosphate, which results in inhibition of glycogenolysis and gluconeogenesis. Symptoms present following consumption of fruit, juice, or honey. Urine dipstick will be ⊖ (tests for glucose only); reducing sugar can be detected in the urine (nonspecific test for inborn errors of carbohydrate metabolism).

Symptoms: hypoglycemia, jaundice, cirrhosis, vomiting.

Treatment: ↓ intake of both fructose and sucrose (glucose + fructose).



### Disorders of galactose metabolism

#### Galactokinase deficiency

Hereditary deficiency of **galactokinase**. Galactitol accumulates if galactose is present in diet.

Relatively mild condition. Autosomal recessive.

Symptoms: galactose appears in blood (galactosemia) and urine (galactosuria); infantile cataracts.


May present as failure to track objects or to develop a social smile.

#### Classic galactosemia

Absence of **galactose-1-phosphate uridylyltransferase**. Autosomal recessive. Damage is caused by accumulation of toxic substances (including galactitol, which accumulates in the lens of the eye).

Symptoms develop when infant begins feeding (lactose present in breast milk and routine formula) and include failure to thrive, jaundice, hepatomegaly, infantile cataracts, intellectual disability. Can predispose to *E coli* sepsis in neonates.

Treatment: exclude galactose and lactose (galactose + glucose) from diet.



Fructose is to **Aldolase B** as Galactose is to **UridylTransferase (FAB GUT)**.

The more serious defects lead to  $\text{PO}_4^{3-}$  depletion.


**Sorbitol**

An alternative method of trapping glucose in the cell is to convert it to its alcohol counterpart, called sorbitol, via aldose reductase. Some tissues then convert sorbitol to fructose using sorbitol dehydrogenase; tissues with an insufficient amount/activity of this enzyme are at risk for intracellular sorbitol accumulation, causing osmotic damage (eg, cataracts, retinopathy, and peripheral neuropathy seen with chronic hyperglycemia in diabetes). High blood levels of galactose also result in conversion to the osmotically active galactitol via aldose reductase.

Liver, ovaries, and seminal vesicles have both enzymes.



Lens has primarily aldose reductase. Retina, Kidneys, and Schwann cells have only aldose reductase (LuRKS).



**Lactase deficiency**

Insufficient lactase enzyme → dietary lactose intolerance. Lactase functions on the brush border to digest lactose (in human and cow milk) into glucose and galactose.  
 Primary: age-dependent decline after childhood (absence of lactase-persistent allele), common in people of Asian, African, or Native American descent.  
 Secondary: loss of brush border due to gastroenteritis (eg, rotavirus), autoimmune disease, etc.  
 Congenital lactase deficiency: rare, due to defective gene.  
 Stool demonstrates ↓ pH and breath shows ↑ hydrogen content with lactose hydrogen breath test.  
 Intestinal biopsy reveals normal mucosa in patients with hereditary lactose intolerance.

**FINDINGS**

Bloating, cramps, flatulence, osmotic diarrhea.

**TREATMENT**

Avoid dairy products or add lactase pills to diet; lactose-free milk.

**Amino acids**

Only L-amino acids are found in proteins.

**Essential**

Glucogenic: methionine (**Met**), histidine (**His**), valine (**Val**).  
 Glucogenic/ketogenic: isoleucine (Ile), phenylalanine (Phe), threonine (Thr), tryptophan (Trp).  
 Ketogenic: leucine (Leu), lysine (Lys).

**I met his valentine, she is so sweet (glucogenic).**  
 All essential amino acids need to be supplied in the diet.

**Acidic**

Aspartic acid (Asp) and glutamic acid (Glu).  
 Negatively charged at body pH.

**Basic**


Histidine (**His**), lysine (**Lys**), arginine (**Arg**).  
 Arg is most **basic**.  
 His has no charge at body pH.

**His lys (lies) are basic.**  
 Arg and His are required during periods of growth. Arg and Lys are ↑ in histones, which bind negatively charged DNA.


## Urea cycle

Amino acid catabolism results in the formation of common metabolites (eg, pyruvate, acetyl-CoA), which serve as metabolic fuels. Excess nitrogen generated by this process is converted to urea and excreted by the kidneys.


Ordinarily, Careless Crappers Are Also Frivolous About Urination.



## Transport of ammonia by alanine



## Hyperammonemia



Can be acquired (eg, liver disease) or hereditary (eg, urea cycle enzyme deficiencies). Results in excess  $\text{NH}_3$ , which depletes  $\alpha$ -ketoglutarate, leading to inhibition of TCA cycle.

Treatment: limit protein in diet.

May be given to  $\downarrow$  ammonia levels:

- Lactulose to acidify the GI tract and trap  $\text{NH}_4^+$  for excretion.
- Antibiotics (eg, rifaximin) to  $\downarrow$  colonic ammoniagenic bacteria.
- Benzoate, phenylacetate, or phenylbutyrate react with glycine or glutamine, forming products that are renally excreted.


Ammonia accumulation—tremor (asterixis), slurring of speech, somnolence, vomiting, cerebral edema, blurring of vision.

**Ornithine transcarbamylase deficiency**


Most common urea cycle disorder. X-linked recessive (vs other urea cycle enzyme deficiencies, which are autosomal recessive). Interferes with the body's ability to eliminate ammonia. Often evident in the first few days of life, but may present later. Excess carbamoyl phosphate is converted to orotic acid (part of the pyrimidine synthesis pathway).

Findings: ↑ orotic acid in blood and urine, ↓ BUN, symptoms of hyperammonemia. No megaloblastic anemia (vs orotic aciduria).

**Amino acid derivatives**



**Catecholamine synthesis/tyrosine catabolism**



**Phenylketonuria**

Due to ↓ phenylalanine hydroxylase or ↓ tetrahydrobiopterin (BH<sub>4</sub>) cofactor (malignant PKU). Tyrosine becomes essential. ↑ phenylalanine → excess phenyl ketones in urine.

Findings: intellectual disability, growth retardation, seizures, fair skin, eczema, musty body odor.

Treatment: ↓ phenylalanine and ↑ tyrosine in diet, tetrahydrobiopterin supplementation.

**Maternal PKU**—lack of proper dietary therapy during pregnancy. Findings in infant: microcephaly, intellectual disability, growth retardation, congenital heart defects.

Autosomal recessive. Incidence ≈ 1:10,000.

Screening occurs 2–3 days after birth (normal at birth because of maternal enzyme during fetal life).

Phenyl ketones—phenylacetate, phenyllactate, and phenylpyruvate.

Disorder of **aromatic** amino acid metabolism → musty body **odor**.

PKU patients must avoid the artificial sweetener aspartame, which contains phenylalanine.

**Maple syrup urine disease**

Blocked degradation of **branched** amino acids (**I**soleucine, **L**eucine, **V**aline) due to ↓ branched-chain α-ketoacid dehydrogenase (B<sub>1</sub>). Causes ↑ α-ketoacids in the blood, especially those of leucine.

Causes severe CNS defects, intellectual disability, and death.

Treatment: restriction of isoleucine, leucine, valine in diet, and thiamine supplementation.

Autosomal recessive.

Presentation: vomiting, poor feeding, urine smells like maple syrup/burnt sugar.

**I** Love **V**ermont **m**aple **s**yrup from maple trees (with **B**<sub>1</sub>**r**anches).

**Alkaptonuria**

Congenital deficiency of homogentisate oxidase in the degradative pathway of tyrosine to fumarate → pigment-forming homogentisic acid accumulates in tissue **A**. Autosomal recessive. Usually benign.

Findings: bluish-black connective tissue, ear cartilage, and sclerae (ochronosis); urine turns black on prolonged exposure to air. May have debilitating arthralgias (homogentisic acid toxic to cartilage).


**Homocystinuria**

Types (all autosomal recessive):


- Cystathionine synthase deficiency (treatment: ↓ methionine, ↑ cysteine, ↑ B<sub>6</sub>, B<sub>12</sub>, and folate in diet)
- ↓ affinity of cystathionine synthase for pyridoxal phosphate (treatment: ↑↑ B<sub>6</sub> and ↑ cysteine in diet)
- Methionine synthase (homocysteine methyltransferase) deficiency (treatment: ↑ methionine in diet)

All forms result in excess homocysteine.

**HOMOCY**stinuria: ↑↑ **H**omocysteine in urine, **O**steoporosis, **M**arfanoid habitus, **O**cular changes (downward and inward lens subluxation), **C**ardiovascular effects (thrombosis and atherosclerosis → stroke and MI), **kY**phosis, intellectual disability.



**Cystinuria**




Hereditary defect of renal PCT and intestinal amino acid transporter that prevents reabsorption of **C**ystine, **O**rnithine, **L**ysine, and **A**rginine (**COLA**).

Excess cystine in the urine can lead to recurrent precipitation of hexagonal cystine stones **A**. Treatment: urinary alkalization (eg, potassium citrate, acetazolamide) and chelating agents (eg, penicillamine) ↑ solubility of cystine stones; good hydration.

Autosomal recessive. Common (1:7000). Urinary cyanide-nitroprusside test is diagnostic.

Cystine is made of 2 cysteines connected by a disulfide bond.

**Glycogen regulation by insulin and glucagon/epinephrine**



**Glycogen**

Branches have  $\alpha$ -(1,6) bonds; linkages have  $\alpha$ -(1,4) bonds.

**Skeletal muscle**


Glycogen undergoes glycogenolysis  $\rightarrow$  glucose-1-phosphate  $\rightarrow$  glucose-6-phosphate, which is rapidly metabolized during exercise.

**Hepatocytes**

Glycogen is stored and undergoes glycogenolysis to maintain blood sugar at appropriate levels.

Glycogen phosphorylase **4** liberates glucose-1-phosphate residues off branched glycogen until 4 glucose units remain on a branch. Then 4- $\alpha$ -D-glucanotransferase (debranching enzyme **5**) moves 3 molecules of glucose-1-phosphate from the branch to the linkage. Then  $\alpha$ -1,6-glucosidase (debranching enzyme **6**) cleaves off the last residue, liberating glucose.

“Limit dextrin” refers to the one to four residues remaining on a branch after glycogen phosphorylase has already shortened it.



Note: A small amount of glycogen is degraded in lysosomes by **7**  $\alpha$ -1,4-glucosidase (acid maltase).

**Glycogen storage diseases**

12 types, all resulting in abnormal glycogen metabolism and an accumulation of glycogen within cells. Periodic acid–Schiff stain identifies glycogen and is useful in identifying these diseases.





Very Poor Carbohydrate Metabolism.  
Types I, II, III, and V are autosomal recessive.


DISEASE	FINDINGS	DEFICIENT ENZYME	COMMENTS
<b>Von Gierke disease (type I)</b>	Severe fasting hypoglycemia, ↑↑ Glycogen in liver, ↑ blood lactate, ↑ triglycerides, ↑ uric acid (Gout), and hepatomegaly.	Glucose-6-phosphatase	Treatment: frequent oral glucose/cornstarch; avoidance of fructose and galactose Impaired gluconeogenesis and glycogenolysis
<b>Pompe disease (type II)</b>	Cardiomegaly, hypertrophic cardiomyopathy, hypotonia, exercise intolerance, and systemic findings lead to early death.	Lysosomal acid $\alpha$ -1,4-glucosidase with $\alpha$ -1,6-glucosidase activity (acid maltase)	PomPe trashes the PumP (1,4) (heart, liver, and muscle)
<b>Cori disease (type III)</b>	Milder form of von Gierke (type I) with normal blood lactate levels. Accumulation of limit dextrin–like structures in cytosol.	Debranching enzyme ( $\alpha$ -1,6-glucosidase)	Gluconeogenesis is intact
<b>McArdle disease (type V)</b>	↑ glycogen in muscle, but muscle cannot break it down → painful Muscle cramps, Myoglobinuria (red urine) with strenuous exercise, and arrhythmia from electrolyte abnormalities. Second-wind phenomenon noted during exercise due to ↑ muscular blood flow.	Skeletal muscle glycogen phosphorylase (Myophosphorylase)	Blood glucose levels typically unaffected McArdle = Muscle



**Lysosomal storage diseases**

Each is caused by a deficiency in one of the many lysosomal enzymes. Results in an accumulation of abnormal metabolic products.

DISEASE	FINDINGS	DEFICIENT ENZYME	ACCUMULATED SUBSTRATE	INHERITANCE
<b>Sphingolipidoses</b>				
<b>Tay-Sachs disease</b> 	Progressive neurodegeneration, developmental delay, “cherry-red” spot on macula <b>A</b> , lysosomes with onion skin, no hepatosplenomegaly (vs Niemann-Pick).	<b>1</b> HeXosaminidase <b>A</b> (“T <b>Ay-SaX</b> ”)	GM <sub>2</sub> ganglioside	AR
<b>Fabry disease</b> 	Early: Triad of episodic peripheral neuropathy, angiokeratomas <b>B</b> , hypohidrosis. Late: progressive renal failure, cardiovascular disease.	<b>2</b> α-galactosidase A	Ceramide trihexoside	XR
<b>Metachromatic leukodystrophy</b>	Central and peripheral demyelination with ataxia, dementia.	<b>3</b> Arylsulfatase A	Cerebroside sulfate	AR
<b>Krabbe disease</b>	Peripheral neuropathy, destruction of oligodendrocytes, developmental delay, optic atrophy, globoid cells.	<b>4</b> Galactocerebrosidase	Galactocerebroside, psychosine	AR
<b>Gaucher disease</b> 	Most common. Hepatosplenomegaly, pancytopenia, osteoporosis, avascular necrosis of femur, bone crises, Gaucher cells <b>C</b> (lipid-laden macrophages resembling crumpled tissue paper).	<b>5</b> Glucocerebrosidase (β-glucosidase); treat with recombinant glucocerebrosidase	Glucocerebroside	AR
<b>Niemann-Pick disease</b> 	Progressive neurodegeneration, hepatosplenomegaly, foam cells (lipid-laden macrophages) <b>D</b> , “cherry-red” spot on macula <b>A</b> .	<b>6</b> Sphingomyelinase	Sphingomyelin	AR
<b>Mucopolysaccharidoses</b>				
<b>Hurler syndrome</b>	Developmental delay, gargoylism, airway obstruction, corneal clouding, hepatosplenomegaly.	α-L-iduronidase	Heparan sulfate, dermatan sulfate	AR
<b>Hunter syndrome</b>	Mild Hurler + aggressive behavior, no corneal clouding.	Iduronate sulfatase	Heparan sulfate, dermatan sulfate	XR




**No man picks (Niemann-Pick)** his nose with his **sphinger (sphingomyelinase)**.

Tay-Sa**X** lacks heXosaminidase.

**Hunters** see clearly (no corneal clouding) and aggressively aim for the **X (X-linked recessive)**.

↑ incidence of Tay-Sachs, Niemann-Pick, and some forms of Gaucher disease in Ashkenazi Jews.

## Fatty acid metabolism



Fatty acid synthesis requires transport of citrate from mitochondria to cytosol. Predominantly occurs in liver, lactating mammary glands, and adipose tissue.

Long-chain fatty acid (LCFA) degradation requires carnitine-dependent transport into the mitochondrial matrix.

“SYtrate” = SYnthesis.

CARNitine = CARnage of fatty acids.

**Systemic 1° carnitine deficiency**—inherited defect in transport of LCFAs into the mitochondria → toxic accumulation. Causes weakness, hypotonia, and hypoketotic hypoglycemia.

**Medium-chain acyl-CoA dehydrogenase deficiency**—↓ ability to break down fatty acids into acetyl-CoA → accumulation of fatty acyl carnitines in the blood with hypoketotic hypoglycemia. Causes vomiting, lethargy, seizures, coma, liver dysfunction. Can lead to sudden death in infants or children. Treat by avoiding fasting.

**Ketone bodies**


In the liver, fatty acids and amino acids are metabolized to acetoacetate and  $\beta$ -hydroxybutyrate (to be used in muscle and brain).

In prolonged starvation and diabetic ketoacidosis, oxaloacetate is depleted for gluconeogenesis. In alcoholism, excess NADH shunts oxaloacetate to malate. Both processes cause a buildup of acetyl-CoA, which shunts glucose and FFA toward the production of ketone bodies.


Ketone bodies: acetone, acetoacetate,  $\beta$ -hydroxybutyrate.

Breath smells like acetone (fruity odor).

Urine test for ketones can detect acetoacetate, but not  $\beta$ -hydroxybutyrate.




**Metabolic fuel use**



kcal (# letters = # kcal)  
 1g **carb** = 4 kcal  
 1g **alcohol** = 7 kcal  
 1g **fatty acid** = 9 kcal

<b>Fasting and starvation</b>	Priorities are to supply sufficient glucose to the brain and RBCs and to preserve protein.	
<b>Fed state (after a meal)</b>	Glycolysis and aerobic respiration.	Insulin stimulates storage of lipids, proteins, and glycogen.
<b>Fasting (between meals)</b>	Hepatic glycogenolysis (major); hepatic gluconeogenesis, adipose release of FFA (minor).	Glucagon and epinephrine stimulate use of fuel reserves.
<b>Starvation days 1–3</b>	Blood glucose levels maintained by: <ul style="list-style-type: none"> <li>▪ Hepatic glycogenolysis</li> <li>▪ Adipose release of FFA</li> <li>▪ Muscle and liver, which shift fuel use from glucose to FFA</li> <li>▪ Hepatic gluconeogenesis from peripheral tissue lactate and alanine, and from adipose tissue glycerol and propionyl-CoA (from odd-chain FFA—the only triacylglycerol components that contribute to gluconeogenesis)</li> </ul>	Glycogen reserves depleted after day 1. RBCs lack mitochondria and therefore cannot use ketones.
<b>Starvation after day 3</b>	Adipose stores (ketone bodies become the main source of energy for the brain). After these are depleted, vital protein degradation accelerates, leading to organ failure and death. Amount of excess stores determines survival time.	

### Lipid transport, key enzymes




Pancreatic lipase—degradation of dietary triglycerides (TGs) in small intestine.

Lipoprotein lipase (LPL)—degradation of TGs circulating in chylomicrons and VLDLs. Found on vascular endothelial surface.

Hepatic TG lipase (HL)—degradation of TGs remaining in IDL.

Hormone-sensitive lipase—degradation of TGs stored in adipocytes.



LCAT—catalyzes esterification of  $\frac{2}{3}$  of plasma cholesterol.

Cholesterol ester transfer protein (CETP)—mediates transfer of cholesterol esters to other lipoprotein particles.

**Major apolipoproteins**

Apolipoprotein	Function	Chylomicron					
		Chylomicron	remnant	VLDL	IDL	LDL	HDL
<b>E</b>	Mediates remnant uptake ( <b>E</b> verything <b>E</b> xcept LDL)	✓	✓	✓	✓		✓
<b>A-I</b>	Activates LCAT	✓					✓
<b>C-II</b>	Lipoprotein lipase <b>C</b> ofactor that <b>C</b> atalyzes <b>C</b> leavage	✓		✓			✓
<b>B-48</b>	Mediates chylomicron secretion into lymphatics	✓	✓				
<b>B-100</b>	Binds LDL receptor			✓	✓	✓	

**Lipoprotein functions**

Lipoproteins are composed of varying proportions of cholesterol, TGs, and phospholipids. LDL and HDL carry the most cholesterol.

LDL transports cholesterol from liver to tissues.

**LDL is Lousy.**

HDL transports cholesterol from periphery to liver.

**HDL is Healthy.**

<b>Cholesterol</b>	Needed to maintain cell membrane integrity and synthesize bile acid, steroids, and vitamin D.
<b>Chylomicron</b>	Delivers dietary TGs to peripheral tissues. Delivers cholesterol to liver in the form of chylomicron remnants, which are mostly depleted of their TGs. Secreted by intestinal epithelial cells.
<b>VLDL</b>	Delivers hepatic TGs to peripheral tissue. Secreted by liver.
<b>IDL</b>	Formed in the degradation of VLDL. Delivers TGs and cholesterol to liver.
<b>LDL</b>	Delivers hepatic cholesterol to peripheral tissues. Formed by hepatic lipase modification of IDL in the liver and peripheral tissue. Taken up by target cells via receptor-mediated endocytosis.
<b>HDL</b>	Mediates reverse cholesterol transport from periphery to liver. Acts as a repository for apolipoproteins C and E (which are needed for chylomicron and VLDL metabolism). Secreted from both liver and intestine. Alcohol ↑ synthesis.

**Abetalipoproteinemia**

Autosomal recessive. Chylomicrons, VLDL, LDL absent. Deficiency in ApoB48, ApoB100.

Affected infants present with severe fat malabsorption, steatorrhea, failure to thrive. Later manifestations include retinitis pigmentosa, spinocerebellar degeneration due to vitamin E deficiency, progressive ataxia, acanthocytosis.

Treatment: restriction of long-chain fatty acids, large doses of oral vitamin E.

**Familial dyslipidemias**

TYPE	INHERITANCE	PATHOGENESIS	↑ BLOOD LEVEL	CLINICAL
<b>I—Hyperchylomicronemia</b>	AR	Lipoprotein lipase or apolipoprotein C-II deficiency	Chylomicrons, TG, cholesterol	Pancreatitis, hepatosplenomegaly, and eruptive/pruritic xanthomas (no ↑ risk for atherosclerosis). Creamy layer in supernatant.
<b>II—Familial hypercholesterolemia</b>	AD	Absent or defective LDL receptors	IIa: LDL, cholesterol IIb: LDL, cholesterol, VLDL	Heterozygotes (1:500) have cholesterol ≈ 300mg/dL; homozygotes (very rare) have cholesterol ≈ 700+ mg/dL. Accelerated atherosclerosis (may have MI before age 20), tendon (Achilles) xanthomas, and corneal arcus.
<b>III—Dysbeta-lipoproteinemia</b>	AR	Defective ApoE	Chylomicrons, VLDL	Premature atherosclerosis, tuberoeruptive xanthomas, xanthoma striatum palmare.
<b>IV—Hypertriglyceridemia</b>	AD	Hepatic overproduction of VLDL	VLDL, TG	Hypertriglyceridemia (> 1000 mg/dL) can cause acute pancreatitis.

# Immunology

*“I hate to disappoint you, but my rubber lips are immune to your charms.”*  
—Batman & Robin

*“No State shall make or enforce any law which shall abridge the privileges or immunities of citizens of the United States . . .”*  
—The United States Constitution

Mastery of the basic principles and facts in the immunology section will be useful for the Step 1 exam. Cell surface markers are important to know because they are clinically useful (eg, in identifying specific types of immunodeficiency or cancer) and are functionally critical to the jobs immune cells carry out. By spending a little extra effort here, it is possible to turn a traditionally difficult subject into one that is high yield.

- ▶ Lymphoid Structures 92
- ▶ Lymphocytes 95
- ▶ Immune Responses 102
- ▶ Immunosuppressants 116



## ► IMMUNOLOGY—LYMPHOID STRUCTURES

**Immune system organs**

1° organs:

- Bone marrow—immune cell production, B cell maturation
- Thymus—T cell maturation

2° organs:

- Spleen, lymph nodes, tonsils, Peyer patches
- Allow immune cells to interact with antigen

**Lymph node**

A 2° lymphoid organ that has many afferents, 1 or more efferents. Encapsulated, with trabeculae. Functions are nonspecific filtration by macrophages, storage of B and T cells, and immune response activation.

**Follicle**


Site of B-cell localization and proliferation. In outer cortex. 1° follicles are dense and dormant. 2° follicles have pale central germinal centers and are active.

**Medulla**

Consists of medullary cords (closely packed lymphocytes and plasma cells) and medullary sinuses. Medullary sinuses communicate with efferent lymphatics and contain reticular cells and macrophages.

**Paracortex**

Houses T cells. Region of cortex between follicles and medulla. Contains high endothelial venules through which T and B cells enter from blood. Not well developed in patients with DiGeorge syndrome. Paracortex enlarges in an extreme cellular immune response (eg, viral infection).




**Lymph drainage**

LYMPH NODE CLUSTER	AREA OF BODY DRAINED
Cervical	Head and neck
Hilar	Lungs
Mediastinal	Trachea and esophagus
Axillary	Upper limb, breast, skin above umbilicus
Celiac	Liver, stomach, spleen, pancreas, upper duodenum
Superior mesenteric	Lower duodenum, jejunum, ileum, colon to splenic flexure
Inferior mesenteric	Colon from splenic flexure to upper rectum
Internal iliac	Lower rectum to anal canal (above pectinate line), bladder, vagina (middle third), cervix, prostate
Para-aortic	Testes, ovaries, kidneys, uterus
Superficial inguinal	Anal canal (below pectinate line), skin below umbilicus (except popliteal area), scrotum, vulva
Popliteal	Dorsolateral foot, posterior calf

Right lymphatic duct drains right side of body above diaphragm.

Thoracic duct drains everything else into junction of left subclavian and internal jugular veins.

## Spleen



Located in LUQ of abdomen, anterior to left kidney, protected by 9th-11th ribs. Sinusoids are long, vascular channels in red pulp (red arrows in **A**) with fenestrated “barrel hoop” basement membrane.


- T cells are found in the periarteriolar lymphatic sheath (PALS) within the white pulp (white arrows in **A**).
- B cells are found in follicles within the white pulp.
- The marginal zone, in between the red pulp and white pulp, contains macrophages and specialized B cells, and is where antigen-presenting cells (APCs) capture blood-borne antigens for recognition by lymphocytes. Macrophages found nearby in spleen remove encapsulated bacteria.

Splenic dysfunction (eg, postsplenectomy, sickle cell disease): ↓ IgM → ↓ complement activation → ↓ C3b opsonization → ↑ susceptibility to encapsulated organisms.


Postsplenectomy:

- Howell-Jolly bodies (nuclear remnants)
- Target cells
- Thrombocytosis (loss of sequestration and removal)
- Lymphocytosis (loss of sequestration)

Vaccinate patients undergoing splenectomy against encapsulated organisms (pneumococcal, Hib, meningococcal).



## Thymus



Located in the anterosuperior mediastinum. Site of T-cell differentiation and maturation. Encapsulated. **T**hymus is derived from the **T**hird pharyngeal pouch. Lymphocytes of mesenchymal origin. Cortex is dense with immature T cells; medulla is pale with mature T cells and Hassall corpuscles **A** containing epithelial reticular cells.

**T** cells = **T**hymus

**B** cells = **B**one marrow

Hypoplastic in DiGeorge syndrome and severe combined immunodeficiency (SCID).

**Thymoma**—benign neoplasm of thymus.

Associated with myasthenia gravis and superior vena cava syndrome.

## ▶ IMMUNOLOGY—LYMPHOCYTES

**Innate vs adaptive immunity**

	<b>Innate immunity</b>	<b>Adaptive immunity</b>
COMPONENTS	Neutrophils, macrophages, monocytes, dendritic cells, natural killer (NK) cells (lymphoid origin), complement	T cells, B cells, circulating antibodies
MECHANISM	Germline encoded	Variation through V(D)J recombination during lymphocyte development
RESISTANCE	Resistance persists through generations; does not change within an organism's lifetime	Microbial resistance not heritable
RESPONSE TO PATHOGENS	Nonspecific Occurs rapidly (minutes to hours) No memory response	Highly specific, refined over time Develops over long periods; memory response is faster and more robust
PHYSICAL BARRIERS	Epithelial tight junctions, mucus	—
SECRETED PROTEINS	Lysozyme, complement, C-reactive protein (CRP), defensins	Immunoglobulins
KEY FEATURES IN PATHOGEN RECOGNITION	Toll-like receptors (TLRs): pattern recognition receptors that recognize pathogen-associated molecular patterns (PAMPs). Examples of PAMPs include LPS (gram $\ominus$ bacteria), flagellin (bacteria), nucleic acids (viruses).	Memory cells: activated B and T cells; subsequent exposure to a previously encountered antigen → stronger, quicker immune response

**Major histocompatibility complex I and II**

MHC encoded by HLA genes. Present antigen fragments to T cells and bind T-cell receptors (TCRs).

	MHC I	MHC II
LOCI	HLA-A, HLA-B, HLA-C MHC I loci have 1 letter	HLA-DP, HLA-DQ, HLA-DR MHC II loci have 2 letters
BINDING	TCR and CD8	TCR and CD4
STRUCTURE	1 long chain, 1 short chain	2 equal-length chains
EXPRESSION	All nucleated cells, APCs, platelets Not on RBCs	APCs
FUNCTION	Present <b>endogenously</b> synthesized antigens (eg, viral or cytosolic proteins) to <b>CD8+ cytotoxic T cells</b>	Present <b>exogenously</b> synthesized antigens (eg, bacterial proteins) to <b>CD4+ helper T cells</b>
ANTIGEN LOADING	Antigen peptides loaded onto MHC I in RER after delivery via TAP (transporter associated with antigen processing)	Antigen loaded following release of invariant chain in an acidified endosome
ASSOCIATED PROTEINS	$\beta_2$ -microglobulin	Invariant chain
STRUCTURE		

**HLA subtypes associated with diseases**

<b>A3</b>	Hemochromatosis	
<b>B8</b>	Addison disease, myasthenia gravis, Graves disease	
<b>B27</b>	<b>P</b> soriatic arthritis, <b>A</b> nkylosing spondylitis, <b>I</b> BD-associated arthritis, <b>R</b> eactive arthritis	<b>PAIR</b> . Also known as seronegative arthropathies.
<b>DQ2/DQ8</b>	Celiac disease	I ate (8) too (2) much gluten at Dairy Queen.
<b>DR2</b>	<b>M</b> ultiple sclerosis, <b>h</b> ay fever, SLE, <b>G</b> ood <b>p</b> asture syndrome	<b>M</b> ultiple <b>h</b> ay pastures have <b>d</b> irt.
<b>DR3</b>	Diabetes mellitus type 1, <b>S</b> LE, Graves disease, Hashimoto thyroiditis, Addison disease	<b>2-3, S-L-E</b>
<b>DR4</b>	<b>R</b> heumatoid arthritis, diabetes mellitus type 1, Addison disease	There are <b>4</b> walls in a " <b>r</b> heum" (room).
<b>DR5</b>	Pernicious anemia → vitamin B <sub>12</sub> deficiency, Hashimoto thyroiditis	

**Natural killer cells**

Lymphocyte member of innate immune system.  
 Use perforin and granzymes to induce apoptosis of virally infected cells and tumor cells.  
 Activity enhanced by IL-2, IL-12, IFN- $\alpha$ , and IFN- $\beta$ .  
 Induced to kill when exposed to a nonspecific activation signal on target cell and/or to an absence of MHC I on target cell surface.  
 Also kills via antibody-dependent cell-mediated cytotoxicity (CD16 binds Fc region of bound Ig, activating the NK cell).

**Major functions of B and T cells**


**B cells**

Humoral immunity.  
 Recognize antigen—undergo somatic hypermutation to optimize antigen specificity.  
 Produce antibody—differentiate into plasma cells to secrete specific immunoglobulins.  
 Maintain immunologic memory—memory B cells persist and accelerate future response to antigen.

**T cells**

Cell-mediated immunity.  
 CD4+ T cells help B cells make antibodies and produce cytokines to recruit phagocytes and activate other leukocytes.  
 CD8+ T cells directly kill virus-infected cells.  
 Delayed cell-mediated hypersensitivity (type IV).  
 Acute and chronic cellular organ rejection.  
**Rule of 8:** MHC II  $\times$  CD4 = 8; MHC I  $\times$  CD8 = 8.

**Differentiation of T cells**



**Positive selection**

Thymic cortex. T cells expressing TCRs capable of binding self-MHC on cortical epithelial cells survive.

**Negative selection**

Thymic medulla. T cells expressing TCRs with high affinity for self antigens undergo apoptosis. Tissue-restricted self-antigens are expressed in the thymus due to the action of autoimmune regulator (AIRE); deficiency leads to autoimmune polyendocrine syndrome-1.

**Helper T cells****Th1 cell**

Secretes IFN- $\gamma$  and IL-2

Activates macrophages and cytotoxic T cells

Differentiation induced by IFN- $\gamma$  and IL-12

Inhibited by IL-4 and IL-10 (from Th2 cell)

Macrophage-lymphocyte interaction—dendritic cells, macrophages, and other APCs release IL-12, which stimulates T cells to differentiate into Th1 cells. Th1 cells release IFN- $\gamma$  to stimulate macrophages.

Helper T cells have CD4, which binds to MHC II on APCs.

**Th2 cell**

Secretes IL-4, IL-5, IL-6, IL-10, IL-13

Recruits eosinophils for parasite defense and promotes IgE production by B cells

Differentiation induced by IL-2 and IL-4

Inhibited by IFN- $\gamma$  (from Th1 cell)

**Cytotoxic T cells**

Kill virus-infected, neoplastic, and donor graft cells by inducing apoptosis.

Release cytotoxic granules containing preformed proteins (eg, perforin, granzyme B).

Cytotoxic T cells have CD8, which binds to MHC I on virus-infected cells.

**Regulatory T cells**

Help maintain specific immune tolerance by suppressing CD4 and CD8 T-cell effector functions.

Identified by expression of CD3, CD4, CD25, and FOXP3.

Activated regulatory T cells (Tregs) produce anti-inflammatory cytokines (eg, IL-10, TGF- $\beta$ ).


**IPEX (Immune dysregulation, Polyendocrinopathy, Enteropathy, X-linked) syndrome—**

genetic deficiency of FOXP3  $\rightarrow$  autoimmunity. Characterized by enteropathy, endocrinopathy, nail dystrophy, dermatitis, and/or other autoimmune dermatologic conditions. Associated with diabetes in male infants.

**T- and B-cell activation** APCs: B cells, dendritic cells, Langerhans cells, macrophages.  
Two signals are required for T-cell activation, B-cell activation, and class switching.


### T-cell activation

- ❶ Dendritic cell (specialized APC) samples antigen, processes antigen, and migrates to the draining lymph node.
- ❷ T-cell activation (signal 1): antigen is presented on MHC II and recognized by TCR on Th (CD4+) cell. Endogenous or cross-presented antigen is presented on MHC I to Tc (CD8+) cell.
- ❸ Proliferation and survival (signal 2): costimulatory signal via interaction of B7 protein on dendritic cell (CD80/86) and CD28 on naïve T cell.
- ❹ Th cell activates and produces cytokines. Tc cell activates and is able to recognize and kill virus-infected cell.



### B-cell activation and class switching


- ❶ Th-cell activation as above.
- ❷ B-cell receptor-mediated endocytosis; foreign antigen is presented on MHC II and recognized by TCR on Th cell.
- ❸ CD40 receptor on B cell binds CD40 ligand (CD40L) on Th cell.
- ❹ Th cell secretes cytokines that determine Ig class switching of B cell. B cell activates and undergoes class switching, affinity maturation, and antibody production.





### Antibody structure and function

Fab (containing the variable/hypervariable regions) consisting of light (L) and heavy (H) chains recognizes antigens. Fc region of IgM and IgG fixes complement. Heavy chain contributes to Fc and Fab regions. Light chain contributes only to Fab region.



#### Fab:

- **F**ragment, **a**ntigen **b**inding
- Determines idiotype: unique antigen-binding pocket; only 1 antigenic specificity expressed per B cell

#### Fc:


- **C**onstant
- **C**arboxy terminal
- **C**omplement binding
- **C**arbohydrate side chains
- Determines isotype (IgM, IgD, etc)

#### Generation of antibody diversity (antigen independent)

1. Random recombination of VJ (light-chain) or V(D)J (heavy-chain) genes
2. Random addition of nucleotides to DNA during recombination by terminal deoxynucleotidyl transferase (TdT)
3. Random combination of heavy chains with light chains

#### Generation of antibody specificity (antigen dependent)

4. Somatic hypermutation and affinity maturation (variable region)
5. Isotype switching (constant region)



## Immunoglobulin isotypes


All isotypes can exist as monomers. Mature, naive B cells prior to activation express IgM and IgD on their surfaces. They may differentiate in germinal centers of lymph nodes by isotype switching (gene rearrangement; mediated by cytokines and CD40L) into plasma cells that secrete IgA, IgE, or IgG.

### IgG




Main antibody in 2° (**delayed**) response to an antigen. Most abundant isotype in serum. Fixes complement, crosses the placenta (provides infants with passive immunity), opsonizes bacteria, neutralizes bacterial toxins and viruses.

### IgA



Prevents attachment of bacteria and viruses to mucous membranes; does not fix complement. Monomer (in circulation) or dimer (with J chain when secreted). Crosses epithelial cells by transcytosis. Produced in GI tract (eg, by Peyer patches) and protects against gut infections (eg, *Giardia*). Most produced antibody overall, but has lower serum concentrations. Released into secretions (tears, saliva, mucus) and breast milk. Picks up secretory component from epithelial cells, which protects the Fc portion from luminal proteases.

### IgM



Produced in the 1° (**immediate**) response to an antigen. Fixes complement but does not cross the placenta. Antigen receptor on the surface of B cells. Monomer on B cell, pentamer with J chain when secreted. Pentamer enables avid binding to antigen while humoral response evolves.

### IgD



Unclear function. Found on surface of many B cells and in serum.

### IgE



Binds mast cells and basophils; cross-links when exposed to allergen, mediating immediate (type I) hypersensitivity through release of inflammatory mediators such as histamine. Contributes to immunity to worms by activating eosinophils. Lowest concentration in serum.

## Antigen type and memory

### Thymus-independent antigens

Antigens lacking a peptide component (eg, lipopolysaccharides from gram  $\ominus$  bacteria); cannot be presented by MHC to T cells. Weakly immunogenic; vaccines often require boosters and adjuvants (eg, pneumococcal polysaccharide vaccine).

### Thymus-dependent antigens

Antigens containing a protein component (eg, diphtheria vaccine). Class switching and immunologic memory occur as a result of direct contact of B cells with Th cells.

## ► IMMUNOLOGY—IMMUNE RESPONSES

**Acute-phase reactants** Factors whose serum concentrations change significantly in response to inflammation; produced by the liver in both acute and chronic inflammatory states. Notably induced by IL-6.

## POSITIVE (UPREGULATED)

<b>C-reactive protein</b>	Opsonin; fixes complement and facilitates phagocytosis. Measured clinically as a nonspecific sign of ongoing inflammation.
<b>Ferritin</b>	Binds and sequesters iron to inhibit microbial iron scavenging.
<b>Fibrinogen</b>	Coagulation factor; promotes endothelial repair; correlates with ESR.
<b>Hepcidin</b>	↓ iron absorption (by degrading ferroportin) and ↓ iron release (from macrophages) → anemia of chronic disease.
<b>Serum amyloid A</b>	Prolonged elevation can lead to amyloidosis.


## NEGATIVE (DOWNREGULATED)

<b>Albumin</b>	Reduction conserves amino acids for positive reactants.
<b>Transferrin</b>	Internalized by macrophages to sequester iron.

**Complement**

System of hepatically synthesized plasma proteins that play a role in innate immunity and inflammation. Membrane attack complex (MAC) defends against gram  $\ominus$  bacteria.

<p>ACTIVATION</p>	<p><b>Classic</b> pathway—IgG or IgM mediated. Alternative pathway—microbe surface molecules. Lectin pathway—mannose or other sugars on microbe surface.</p>	<p><b>GM</b> makes <b>classic</b> cars.</p>
<p>FUNCTIONS</p>	<p>C3b—opsonization. C3a, C4a, C5a—<b>anaphylaxis</b>. C5a—neutrophil chemotaxis. C5b-9—cytolysis by MAC.</p> <p><b>Opsonins</b>—C3b and IgG are the two 1° opsonins in bacterial defense; enhance phagocytosis. C3b also helps clear immune complexes.</p>	<p><b>C3b binds bacteria</b>.</p> <p><i>Opsonin</i> (Greek) = to prepare for eating.</p>
<p><b>Inhibitors</b>—decay-accelerating factor (DAF, aka CD55) and C1 esterase inhibitor help prevent complement activation on self cells (eg, RBCs).</p>		



**Complement disorders**

Complement protein deficiencies

**C3 deficiency** Increases risk of severe, recurrent pyogenic sinus and respiratory tract infections; ↑ susceptibility to type III hypersensitivity reactions.

**C5–C9 deficiencies** Terminal complement deficiency increases susceptibility to recurrent *Neisseria* bacteremia.

Complement regulatory protein deficiencies

**C1 esterase inhibitor deficiency** Causes hereditary angioedema due to unregulated activation of kallikrein → ↑ bradykinin. Characterized by ↓ C4 levels. ACE inhibitors are contraindicated.

**CD55 deficiency** Also called decay-accelerating factor (DAF) deficiency. Causes complement-mediated lysis of RBCs and paroxysmal nocturnal hemoglobinuria.

## Important cytokines

### SECRETED BY MACROPHAGES

<b>Interleukin-1</b>	Causes fever, acute inflammation. Activates endothelium to express adhesion molecules. Induces chemokine secretion to recruit WBCs.	<p><b>“Hot T-bone stEAK”:</b></p> <p>IL-1: fever (<b>hot</b>).</p> <p>IL-2: stimulates <b>T</b> cells.</p> <p>IL-3: stimulates <b>bone</b> marrow.</p> <p>IL-4: stimulates Ig<b>E</b> production.</p> <p>IL-5: stimulates Ig<b>A</b> production.</p> <p>IL-6: stimulates a<b>K</b>ute-phase protein production.</p>
<b>Interleukin-6</b>	Causes fever and stimulates production of acute-phase proteins.	
<b>Interleukin-8</b>	Major chemotactic factor for neutrophils.	<b>“Clean up on aisle 8.”</b> Neutrophils are recruited by <b>IL-8</b> to <b>clear</b> infections.
<b>Interleukin-12</b>	Induces differentiation of T cells into Th1 cells. Activates NK cells.	
<b>Tumor necrosis factor-<math>\alpha</math></b>	Activates endothelium. Causes WBC recruitment, vascular leak.	Causes cachexia in malignancy. Maintains granulomas in TB. IL-1, IL-6, and TNF- $\alpha$ can mediate sepsis.

### SECRETED BY ALL T CELLS

<b>Interleukin-2</b>	Stimulates growth of helper, cytotoxic, and regulatory T cells, and NK cells.	
<b>Interleukin-3</b>	Supports growth and differentiation of bone marrow stem cells. Functions like GM-CSF.	

### FROM Th1 CELLS


<b>Interferon-<math>\gamma</math></b>	Secreted by NK cells and T cells in response to antigen or IL-12 from macrophages; stimulates macrophages to kill phagocytosed pathogens. Inhibits differentiation of Th2 cells.	Also activates NK cells to kill virus-infected cells. Increases MHC expression and antigen presentation by all cells.
---------------------------------------	--	---

### FROM Th2 CELLS

<b>Interleukin-4</b>	Induces differentiation of T cells into Th2 cells. Promotes growth of B cells. Enhances class switching to IgE and IgG.	
<b>Interleukin-5</b>	Promotes growth and differentiation of B cells. Enhances class switching to IgA. Stimulates growth and differentiation of eosinophils.	
<b>Interleukin-10</b>	Attenuates inflammatory response. Decreases expression of MHC class II and Th1 cytokines. Inhibits activated macrophages and dendritic cells. Also secreted by regulatory T cells.	TGF- $\beta$ and IL-10 both <b>attenuate</b> the immune response.

### Respiratory burst (oxidative burst)

Involves the activation of the phagocyte NADPH oxidase complex (eg, in neutrophils, monocytes), which utilizes  $O_2$  as a substrate. Plays an important role in the immune response → rapid release of reactive oxygen species (ROS). NADPH plays a role in both the creation and neutralization of ROS. Myeloperoxidase is a blue-green heme-containing pigment that gives sputum its color.



Phagocytes of patients with CGD can utilize  $H_2O_2$  generated by invading organisms and convert it to ROS. Patients are at ↑ risk for infection by catalase ⊕ species (eg, *S aureus*, *Aspergillus*) capable of neutralizing their own  $H_2O_2$ , leaving phagocytes without ROS for fighting infections.

Pyocyanin of *P aeruginosa* functions to generate ROS to kill competing microbes. Lactoferrin is a protein found in secretory fluids and neutrophils that inhibits microbial growth via iron chelation.

### Interferon- $\alpha$ and - $\beta$

A part of innate host defense against both RNA and DNA viruses. **Interferons** are glycoproteins synthesized by virus-infected cells that act locally on uninfected cells, “priming them” for viral defense by helping to degrade viral nucleic acid and protein.

**Interfere** with viruses.

<b>Cell surface proteins</b>	MHC I present on all nucleated cells (ie, not mature RBCs).	
<b>T cells</b>	TCR (binds antigen-MHC complex) CD3 (associated with TCR for signal transduction) CD28 (binds B7 on APC) CXCR4/CCR5 (co-receptors for HIV)	
Helper T cells	CD4, CD40L	
Cytotoxic T cells	CD8 CXCR4/CCR5	
Regulatory T cells	CD4, CD25	
<b>B cells</b>	Ig (binds antigen) CD19, CD20, CD21 (receptor for EBV), CD40 MHC II, B7	You can drink <b>B</b> eer at the <b>B</b> ar when you're <b>21</b> : <b>B</b> cells, Epstein- <b>B</b> arr virus, <b>CD21</b> .
<b>Macrophages</b>	CD14 (receptor for PAMPs, eg, LPS), CD40 CCR5 MHC II, B7 (CD80/86) Fc and C3b receptors (enhanced phagocytosis)	
<b>NK cells</b>	CD56 (suggestive marker for NK)	
<b>Hematopoietic stem cells</b>	CD34	

**Anergy** State during which a cell cannot become activated by exposure to its antigen. T and B cells become anergic when exposed to their antigen without costimulatory signal (signal 2). Another mechanism of self-tolerance.

**Effects of bacterial toxins** Superantigens (*S pyogenes* and *S aureus*)—cross-link the  $\beta$  region of the T-cell receptor to the MHC class II on APCs. Can activate any CD4+ T cell → massive release of cytokines.  
Endotoxins/lipopolysaccharide (gram  $\ominus$  bacteria)—directly stimulate macrophages by binding to endotoxin receptor TLR4/CD14; Th cells are not involved.

**Antigenic variation** Classic examples:

- Bacteria—*Salmonella* (2 flagellar variants), *Borrelia recurrentis* (relapsing fever), *N gonorrhoeae* (pilus protein)
- Viruses—influenza, HIV, HCV
- Parasites—trypanosomes

Some mechanisms for variation include DNA rearrangement and RNA segment reassortment (eg, influenza major shift) or protein mutations (eg, influenza minor drift).

**Passive vs active immunity**

	Passive	Active
MEANS OF ACQUISITION	Receiving preformed antibodies	Exposure to foreign antigens
ONSET	Rapid	Slow
DURATION	Short span of antibodies (half-life = 3 weeks)	Long-lasting protection (memory)
EXAMPLES	IgA in breast milk, maternal IgG crossing placenta, antitoxin, humanized monoclonal antibody	Natural infection, vaccines, toxoid
NOTES	After exposure to <b>T</b> etanus toxin, <b>B</b> otulinum toxin, <b>H</b> BV, <b>V</b> aricella, <b>R</b> abies virus, or diphtheria antitoxin, unvaccinated patients are given preformed antibodies (passive)—“ <b>T</b> o <b>B</b> e <b>H</b> ealed <b>V</b> ery <b>R</b> apidly”	Combined passive and active immunizations can be given for hepatitis B or rabies exposure

**Vaccination**


Induces an active immune response (humoral and/or cellular) to specific pathogens.

VACCINE TYPE	DESCRIPTION	PROS/CONS	EXAMPLES
<b>Live attenuated vaccine</b>	Microorganism loses its pathogenicity but retains capacity for transient growth within inoculated host. Induces <b>cellular and humoral responses</b> . MMR and varicella are live vaccines that can be given to patients with HIV who have a CD4 cell count > 200/mm <sup>3</sup> .	Pro: induces strong, often lifelong immunity. Con: may revert to virulent form. Often contraindicated in pregnancy and immunodeficiency.	BCG, influenza (intranasal), measles, mumps, polio (Sabin), rotavirus, rubella, varicella, yellow fever.
<b>Inactivated or killed vaccine</b>	Pathogen is inactivated by heat or chemicals. Maintaining epitope structure on surface antigens is important for immune response. Mainly induces a <b>humoral response</b> .	Pro: safer than live vaccines. Con: weaker immune response; booster shots usually required.	<b>R</b> abies, <b>I</b> nfluenza (injection), <b>P</b> olio (Salk), hepatitis <b>A</b> (“ <b>R.I.P. Always</b> ”).



**Hypersensitivity types** Four types: **A**naphylactic and **A**topic (type I), **C**ytotoxic (antibody mediated, type II), **I**mmune complex (type III), **D**elayed (cell mediated, type IV) (**ACID**).

### Type I



Anaphylactic and atopic—free antigen cross-links IgE on presensitized mast cells and basophils, triggering immediate release of vasoactive amines that act at postcapillary venules (ie, histamine). Reaction develops rapidly after antigen exposure because of preformed antibody. Delayed phase results from mast cells and basophils releasing cytokines that induce cellular inflammation.

**F**irst (type) and **F**ast (anaphylaxis).


Types I, II, and III are all antibody mediated.

Test: skin test or blood test (ELISA) for allergen-specific IgE.

Example:

- Anaphylaxis (eg, food, drug, or bee sting allergies)

### Type II



Antibodies bind to cell-surface antigens → cellular destruction, inflammation, and cellular dysfunction.

Cellular destruction: cell is opsonized (coated) by antibodies, leading to either:

- Phagocytosis and/or activation of complement system.
- NK cell killing (antibody-dependent cellular cytotoxicity).

Inflammation—binding of antibodies to cell surfaces → activation of complement system and Fc receptor-mediated inflammation.

Cellular dysfunction—antibodies bind to cell surface receptors → abnormal blockade or activation of downstream process.

**D**irect Coombs test—detects antibodies attached **directly** to the RBC surface.

Indirect Coombs test—detects presence of unbound antibodies in the serum

Examples:


- Autoimmune-hemolytic anemia
- Immune thrombocytopenic purpura
- Transfusion reactions
- Hemolytic disease of the newborn

Examples:

- Goodpasture syndrome
- Rheumatic fever
- Hyperacute transplant rejection

Examples:

- Myasthenia gravis
- Graves disease

**Hypersensitivity types (continued)****Type III**

Immune complex—antigen-antibody (IgG) complexes activate complement, which attracts neutrophils; neutrophils release lysosomal enzymes.

Can be associated with vasculitis and systemic manifestations.

**Serum sickness**—an immune complex disease in which antibodies to foreign proteins are produced (takes 5 days). Immune complexes form and are deposited in membranes, where they fix complement (leads to tissue damage). More common than Arthus reaction.

**Arthus reaction**—a local subacute antibody-mediated hypersensitivity reaction. Intradermal injection of antigen into a presensitized (has circulating IgG) individual leads to immune complex formation in the skin. Characterized by edema, necrosis, and activation of complement.


In type **III** reaction, imagine an immune complex as **3** things stuck together: antigen-antibody-complement.

Examples:

- SLE
- Polyarteritis nodosa
- Poststreptococcal glomerulonephritis

Most serum sickness is now caused by drugs (not serum) acting as haptens. Fever, urticaria, arthralgia, proteinuria, lymphadenopathy occur 5–10 days after antigen exposure.

Antigen-antibody complexes cause the Arthus reaction.

**Type IV**

Two mechanisms, each involving T cells:

1. Direct cell cytotoxicity: CD8+ cytotoxic T cells kill targeted cells.
2. Delayed-type hypersensitivity: sensitized CD4+ helper T cells encounter antigen and release cytokines → inflammation and macrophage activation.

Response does not involve antibodies (vs types I, II, and III).

Example:

- Type 1 diabetes mellitus

Examples:

- Contact dermatitis (eg, poison ivy, nickel allergy)
- Graft-versus-host disease

Tests: PPD, patch test.

**4T's**: **T** cells, **T**ransplant rejections, **T**B skin tests, **T**ouching (contact dermatitis).

**Fourth** (type) and **last** (delayed).

**Blood transfusion reactions**

TYPE	PATHOGENESIS	CLINICAL PRESENTATION	TIMING
<b>Allergic/anaphylactic reaction</b>	Type I hypersensitivity reaction against plasma proteins in transfused blood. IgA-deficient individuals must receive blood products without IgA.	Urticaria, pruritus, fever, wheezing, hypotension, respiratory arrest, shock.	Within minutes to 2–3 hours
<b>Febrile nonhemolytic transfusion reaction</b>	Type II hypersensitivity reaction. Host antibodies against donor HLA antigens and WBCs.	Fever, headaches, chills, flushing.	Within 1–6 hours
<b>Acute hemolytic transfusion reaction</b>	Type II hypersensitivity reaction. Intravascular hemolysis (ABO blood group incompatibility) or extravascular hemolysis (host antibody reaction against foreign antigen on donor RBCs).	Fever, hypotension, tachypnea, tachycardia, flank pain, hemoglobinuria (intravascular hemolysis), jaundice (extravascular).	Within 1 hour
<b>Transfusion-related acute lung injury</b>	Donor anti-leukocyte antibodies against recipient neutrophils and pulmonary endothelial cells.	Respiratory distress and noncardiogenic pulmonary edema.	Within 6 hours



## Autoantibodies

AUTOANTIBODY	ASSOCIATED DISORDER
Anti-ACh receptor	Myasthenia gravis
Anti-glomerular basement membrane	Goodpasture syndrome
Anti- $\beta_2$ glycoprotein	Antiphospholipid syndrome
Anticardiolipin, lupus anticoagulant	SLE, antiphospholipid syndrome
Anticentromere	Limited scleroderma (CREST syndrome)
Anti-desmoglein (anti-desmosome)	Pemphigus vulgaris
Anti-glutamic acid decarboxylase, islet cell cytoplasmic antibodies	Type 1 diabetes mellitus
Anti-hemidesmosome	Bullous pemphigoid
Antisynthetase (eg, anti-Jo-1), anti-SRP, anti-helicase (anti-Mi-2)	Polymyositis, dermatomyositis
Antimicrosomal, antithyroglobulin, anti-thyroid peroxidase	Hashimoto thyroiditis
Antimitochondrial	1° biliary cirrhosis
Antiparietal cell, anti-intrinsic factor	Pernicious anemia
Antiphospholipase A <sub>2</sub> receptor	1° membranous nephropathy
Anti-Scl-70 (anti-DNA topoisomerase I)	Scleroderma (diffuse)
Anti-smooth muscle	Autoimmune hepatitis type 1
Anti-SSA, anti-SSB (anti-Ro, anti-La)	Sjögren syndrome
Anti-TSH receptor	Graves disease
Anti-presynaptic voltage-gated calcium channel	Lambert-Eaton myasthenic syndrome
IgA anti-endomysial, IgA anti-tissue transglutaminase	Celiac disease
MPO-ANCA/p-ANCA	Microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome), ulcerative colitis
PR3-ANCA/c-ANCA	Granulomatosis with polyangiitis (Wegener)
Rheumatoid factor (IgM antibody against IgG Fc region), anti-CCP (more specific)	Rheumatoid arthritis
Antinuclear (ANA)	Nonspecific screening antibody, often associated with SLE
Anti-dsDNA, anti-Smith	SLE
Anti-histone	Drug-induced lupus
Anti-U1 RNP (ribonucleoprotein)	Mixed connective tissue disease

## Immunodeficiencies

DISEASE	DEFECT	PRESENTATION	FINDINGS
<b>B-cell disorders</b>			
<b>X-linked (Bruton) agammaglobulinemia</b>	Defect in <b>BTK</b> , a tyrosine kinase gene → no <b>B</b> -cell maturation. X-linked recessive (↑ in <b>B</b> oys).	Recurrent bacterial and enteroviral infections after 6 months (↓ maternal IgG).	Absent B cells in peripheral blood, ↓ Ig of all classes. Absent/scanty lymph nodes and tonsils. Live vaccines contraindicated.
<b>Selective IgA deficiency</b>	Unknown. Most common 1° immunodeficiency.	Majority <b>A</b> symptomatic. Can see <b>A</b> irway and GI infections, <b>A</b> utoimmune disease, <b>A</b> topy, <b>A</b> naphylaxis to IgA-containing products.	↓ IgA with normal IgG, IgM levels. ↑ susceptibility to giardiasis.
<b>Common variable immunodeficiency</b>	Defect in B-cell differentiation. Many causes.	Usually presents after age 2 and may be considerably delayed; ↑ risk of autoimmune disease, bronchiectasis, lymphoma, sinopulmonary infections.	↓ plasma cells, ↓ immunoglobulins.
<b>T-cell disorders</b>			
<b>Thymic aplasia (DiGeorge syndrome)</b>	22q11 deletion; failure to develop 3rd and 4th pharyngeal pouches → absent thymus and parathyroids.	Tetany (hypocalcemia), recurrent viral/fungal infections (T-cell deficiency), conotruncal abnormalities (eg, tetralogy of Fallot, truncus arteriosus).	↓ T cells, ↓ PTH, ↓ Ca <sup>2+</sup> . Absent thymic shadow on CXR.
<b>IL-12 receptor deficiency</b>	↓ Th1 response. Autosomal recessive.	Disseminated mycobacterial and fungal infections; may present after administration of BCG vaccine.	↓ IFN-γ.
<b>Autosomal dominant hyper-IgE syndrome (Job syndrome)</b>	Deficiency of Th17 cells due to <b>STAT3</b> mutation → impaired recruitment of neutrophils to sites of infection.	<b>FATED</b> : coarse <b>F</b> acies, cold (noninflamed) staphylococcal <b>A</b> bscesses, retained primary <b>T</b> eeth, ↑ <b>IgE</b> , <b>D</b> ermatologic problems (eczema). Bone fractures from minor trauma.	↑ IgE, ↓ IFN-γ. ↑ eosinophils.
<b>Chronic mucocutaneous candidiasis</b>	T-cell dysfunction. Many causes.	Noninvasive <i>Candida albicans</i> infections of skin and mucous membranes.	Absent in vitro T-cell proliferation in response to <i>Candida</i> antigens. Absent cutaneous reaction to <i>Candida</i> antigens.

**Immunodeficiencies (continued)**

DISEASE	DEFECT	PRESENTATION	FINDINGS
<b>B- and T-cell disorders</b>			
<b>Severe combined immunodeficiency</b>	Several types including defective IL-2R gamma chain (most common, X-linked), adenosine deaminase deficiency (autosomal recessive).	Failure to thrive, chronic diarrhea, thrush. Recurrent viral, bacterial, fungal, and protozoal infections. Treatment: avoid live vaccines, give antimicrobial prophylaxis and IVIG; bone marrow transplant curative (no concern for rejection).	↓ T-cell receptor excision circles (TRECs). Absence of thymic shadow (CXR), germinal centers (lymph node biopsy), and T cells (flow cytometry).
<b>Ataxia-telangiectasia</b> 	Defects in <i>ATM</i> gene → failure to repair DNA double strand breaks → cell cycle arrest.	Triad: cerebellar defects (Ataxia), spider Angiomas (telangiectasia <b>A</b> ), IgA deficiency.	↑ AFP. ↓ IgA, IgG, and IgE. Lymphopenia, cerebellar atrophy. ↑ risk of lymphoma and leukemia.
<b>Hyper-IgM syndrome</b>	Most commonly due to defective CD40L on Th cells → class switching defect; X-linked recessive.	Severe pyogenic infections early in life; opportunistic infection with <i>Pneumocystis</i> , <i>Cryptosporidium</i> , CMV.	Normal or ↑ IgM. ↓↓ IgG, IgA, IgE. Failure to make germinal centers.
<b>Wiskott-Aldrich syndrome</b>	Mutation in <i>WASP</i> gene; leukocytes and platelets unable to reorganize actin cytoskeleton → defective antigen presentation. X-linked recessive.	<b>WATER: Wiskott-Aldrich:</b> Thrombocytopenia, Eczema, Recurrent (pyogenic) infections. ↑ risk of autoimmune disease and malignancy.	↓ to normal IgG, IgM. ↑ IgE, IgA. Fewer and smaller platelets.
<b>Phagocyte dysfunction</b>			
<b>Leukocyte adhesion deficiency (type 1)</b>	Defect in LFA-1 integrin (CD18) protein on phagocytes; impaired migration and chemotaxis; autosomal recessive.	Recurrent skin and mucosal bacterial infections, absent pus, impaired wound healing, delayed (> 30 days) separation of umbilical cord.	↑ neutrophils. Absence of neutrophils at infection sites.
<b>Chédiak-Higashi syndrome</b> 	Defect in lysosomal trafficking regulator gene ( <i>LYST</i> ). Microtubule dysfunction in phagosome-lysosome fusion; autosomal recessive.	Recurrent pyogenic infections by staphylococci and streptococci, partial albinism, peripheral neuropathy, progressive neurodegeneration, infiltrative lymphohistiocytosis.	Giant granules ( <b>B</b> , arrows) in granulocytes and platelets. Pancytopenia. Mild coagulation defects.
<b>Chronic granulomatous disease</b>	Defect of NADPH oxidase → ↓ reactive oxygen species (eg, superoxide) and ↓ respiratory burst in neutrophils; X-linked recessive most common.	↑ susceptibility to catalase ⊕ organisms.	Abnormal dihydrorhodamine (flow cytometry) test (↓ green fluorescence). Nitroblue tetrazolium dye reduction test (obsolete) fails to turn blue.

**Infections in immunodeficiency**

PATHOGEN	↓ T CELLS	↓ B CELLS	↓ GRANULOCYTES	↓ COMPLEMENT
<b>Bacteria</b>	Sepsis	Encapsulated (Please <b>SHINE</b> my <b>SKiS</b> ): <i>Pseudomonas aeruginosa</i> , <i>Streptococcus pneumoniae</i> , <i>Haemophilus Influenzae</i> type B, <i>Neisseria meningitidis</i> , <i>Escherichia coli</i> , <i>Salmonella</i> , <i>Klebsiella pneumoniae</i> , Group B <i>Streptococcus</i>	<i>Staphylococcus</i> , <i>Burkholderia cepacia</i> , <i>Pseudomonas aeruginosa</i> , <i>Serratia</i> , <i>Nocardia</i>	Encapsulated species with early component deficiencies <i>Neisseria</i> with late complement (C5–C9) deficiencies
<b>Viruses</b>	CMV, EBV, JC virus, VZV, chronic infection with respiratory/GI viruses	Enteroviral encephalitis, poliovirus (live vaccine contraindicated)	N/A	N/A
<b>Fungi/parasites</b>	<i>Candida</i> (local), PCP, <i>Cryptococcus</i>	GI giardiasis (no IgA)	<i>Candida</i> (systemic), <i>Aspergillus</i> , <i>Mucor</i>	N/A

Note: **B**-cell deficiencies tend to produce recurrent **b**acterial infections, whereas T-cell deficiencies produce more fungal and viral infections.

**Grafts**

<b>Autograft</b>	From self.
<b>Syngeneic graft (isograft)</b>	From identical twin or clone.
<b>Allograft</b>	From nonidentical individual of same species.
<b>Xenograft</b>	From different species.

**Transplant rejection**

TYPE OF REJECTION	ONSET	PATHOGENESIS	FEATURES
<b>Hyperacute</b>	Within minutes	Pre-existing recipient antibodies react to donor antigen (type II hypersensitivity reaction), activate complement.	Widespread thrombosis of graft vessels → ischemia/necrosis. Graft must be removed.
<b>Acute</b>	Weeks to months	Cellular: CD8+ T cells activated against donor MHCs (type IV hypersensitivity reaction). Humoral: similar to hyperacute, except antibodies develop after transplant.	Vasculitis of graft vessels with dense interstitial lymphocytic infiltrate. Prevent/reverse with immunosuppressants.
<b>Chronic</b>	Months to years	CD4+ T cells respond to recipient APCs presenting donor peptides, including allogeneic MHC. Both cellular and humoral components (type II and IV hypersensitivity reactions).	Recipient T cells react and secrete cytokines → proliferation of vascular smooth muscle, parenchymal atrophy, interstitial fibrosis. Dominated by arteriosclerosis. Organ-specific examples: <ul style="list-style-type: none"> <li>▪ Bronchiolitis obliterans (lung)</li> <li>▪ Accelerated atherosclerosis (heart)</li> <li>▪ Chronic graft nephropathy (kidney)</li> <li>▪ Vanishing bile duct syndrome (liver)</li> </ul>
<b>Graft-versus-host disease</b>	Varies	Grafted immunocompetent T cells proliferate in the immunocompromised host and reject host cells with “foreign” proteins → severe organ dysfunction. Type IV hypersensitivity reaction.	Maculopapular rash, jaundice, diarrhea, hepatosplenomegaly. Usually in bone marrow and liver transplants (rich in lymphocytes). Potentially beneficial in bone marrow transplant for leukemia (graft-versus-tumor effect).




## ► IMMUNOLOGY—IMMUNOSUPPRESSANTS

**Immunosuppressants** Agents that block lymphocyte activation and proliferation. Reduce acute transplant rejection by suppressing cellular immunity (used as prophylaxis). Frequently combined to achieve greater efficacy with ↓ toxicity. Chronic suppression ↑ risk of infection and malignancy.

DRUG	MECHANISM	OTHER USE	TOXICITY	NOTES
<b>Cyclosporine</b>	Calcineurin inhibitor; binds <b>cyclophilin</b> . Blocks T-cell activation by <b>preventing IL-2 transcription</b> .	Psoriasis, rheumatoid arthritis.	<b>Nephrotoxicity</b> , hypertension, hyperlipidemia, neurotoxicity, gingival hyperplasia, hirsutism.	Both calcineurin inhibitors are highly nephrotoxic.
<b>Tacrolimus (FK506)</b>	Calcineurin inhibitor; binds <b>FK506</b> binding protein (FKBP). Blocks T-cell activation by <b>preventing IL-2 transcription</b> .		Similar to cyclosporine, ↑ risk of diabetes and neurotoxicity; no gingival hyperplasia or hirsutism.	
<b>Sirolimus (Rapamycin)</b>	<b>mTOR</b> inhibitor; binds FKBP. Blocks T-cell activation and B-cell differentiation by <b>preventing response to IL-2</b> .	Kidney transplant rejection prophylaxis specifically.	“Pan <b>Sir</b> topenia” (pancytopenia), insulin resistance, hyperlipidemia; <b>not nephrotoxic</b> .	Kidney “ <b>sir</b> -vives.” Synergistic with cyclosporine. Also used in drug-eluting stents.
<b>Basiliximab</b>	Monoclonal antibody; blocks IL-2R.		Edema, hypertension, tremor.	
<b>Azathioprine</b>	Antimetabolite precursor of 6-mercaptopurine. Inhibits lymphocyte proliferation by blocking nucleotide synthesis.	Rheumatoid arthritis, Crohn disease, glomerulonephritis, other autoimmune conditions.	Pancytopenia.	6-MP degraded by xanthine oxidase; toxicity ↑ by allopurinol. Pronounce “azathio- <b>purine</b> .”
<b>Mycophenolate mofetil</b>	Reversibly inhibits IMP dehydrogenase, preventing purine synthesis of B and T cells.	Lupus nephritis.	GI upset, pancytopenia, hypertension, hyperglycemia. Less nephrotoxic and neurotoxic.	Associated with invasive CMV infection.
<b>Corticosteroids</b>	Inhibit NF-κB. Suppress both B- and T-cell function by ↓ transcription of many cytokines. Induce T cell apoptosis.	Many autoimmune and inflammatory disorders, adrenal insufficiency, asthma, CLL, non-Hodgkin lymphoma.	Cushing syndrome, osteoporosis, hyperglycemia, diabetes, amenorrhea, adrenocortical atrophy, peptic ulcers, psychosis, cataracts, avascular necrosis (femoral head).	Demargination of WBCs causes artificial leukocytosis. Adrenal insufficiency may develop if drug is stopped abruptly after chronic use.

**Immunosuppression targets**



**Recombinant cytokines and clinical uses**

AGENT	CLINICAL USES
Aldesleukin (IL-2)	Renal cell carcinoma, metastatic melanoma
Epoetin alfa (erythropoietin)	Anemias (especially in renal failure)
Filgrastim (G-CSF)	Recovery of bone marrow and WBC counts by <b>granulocyte</b> stimulation
Sargramostim (GM-CSF)	Recovery of bone marrow and WBC counts by <b>granulocyte</b> and <b>monocyte</b> stimulation
IFN- $\alpha$	Chronic hepatitis B and C, Kaposi sarcoma, malignant melanoma, hairy cell leukemia, condyloma acuminata, renal cell carcinoma
IFN- $\beta$	Multiple sclerosis
IFN- $\gamma$	Chronic <b>granulomatous</b> disease
Romiplostim (thrombopoietin analog), eltrombopag (thrombopoietin receptor agonist)	Thrombocytopenia
Oprelvekin (IL-11)	Thrombocytopenia

## Therapeutic antibodies

AGENT	TARGET	CLINICAL USE	NOTES
<b>Cancer therapy</b>			
<b>Alemtuzumab</b>	CD52	CLL, MS	“ <b>Alymtuzumab</b> ”—chronic lymphocytic leukemia
<b>Bevacizumab</b>	VEGF	Colorectal cancer, renal cell carcinoma, non-small cell lung cancer	
<b>Cetuximab</b>	EGFR	Stage IV colorectal cancer, head and neck cancer	
<b>Rituximab</b>	CD20	B-cell non-Hodgkin lymphoma, CLL, rheumatoid arthritis, ITP	
<b>Trastuzumab</b>	HER2/neu	Breast cancer, gastric cancer	HER2—“ <b>tras2zumab</b> ”
<b>Autoimmune disease therapy</b>			
<b>Adalimumab, certolizumab, golimumab, infliximab</b>	Soluble TNF- $\alpha$	IBD, rheumatoid arthritis, ankylosing spondylitis, psoriasis	Etanercept is a decoy TNF- $\alpha$ receptor and not a monoclonal antibody
<b>Daclizumab</b>	CD25 (part of IL-2 receptor)	Relapsing multiple sclerosis	
<b>Eculizumab</b>	Complement protein C5	Paroxysmal nocturnal hemoglobinuria	
<b>Natalizumab</b>	$\alpha$ 4-integrin	Multiple sclerosis, Crohn disease	$\alpha$ 4-integrin: WBC adhesion Risk of PML in patients with JC virus
<b>Ustekinumab</b>	IL-12/IL-23	Psoriasis, psoriatic arthritis	
<b>Other applications</b>			
<b>Abciximab</b>	Platelet glycoproteins <b>IIb/IIIa</b>	Antiplatelet agent for prevention of ischemic complications in patients undergoing percutaneous coronary intervention	<b>IIb</b> times <b>IIIa</b> equals “ <b>absiximab</b> ”
<b>Denosumab</b>	RANKL	Osteoporosis; inhibits osteoclast maturation (mimics osteoprotegerin)	<b>Denosumab</b> affects <b>osteoclasts</b>
<b>Digoxin immune Fab</b>	Digoxin	Antidote for digoxin toxicity	
<b>Omalizumab</b>	IgE	Refractory allergic asthma; prevents IgE binding to Fc $\epsilon$ RI	
<b>Palivizumab</b>	RSV F protein	RSV prophylaxis for high-risk infants	Pali <b>VI</b> zumab— <b>VI</b> rus
<b>Ranibizumab, bevacizumab</b>	VEGF	Neovascular age-related macular degeneration, proliferative diabetic retinopathy and macular edema	

# Microbiology

*“Support bacteria. They’re the only culture some people have.”*

—Steven Wright

*“What lies behind us and what lies ahead of us are tiny matters compared to what lies within us.”*

—Henry S. Haskins

*“Infectious disease is merely a disagreeable instance of a widely prevalent tendency of all living creatures to save themselves the bother of building, by their own efforts, the things they require.”*

—Hans Zinsser

▶ Basic Bacteriology	120
▶ Clinical Bacteriology	130
▶ Mycology	147
▶ Parasitology	151
▶ Virology	158
▶ Systems	174
▶ Antimicrobials	183

Microbiology questions on the Step 1 exam often require two (or more) steps: Given a certain clinical presentation, you will first need to identify the most likely causative organism, and you will then need to provide an answer regarding some feature of that organism. For example, a description of a child with fever and a petechial rash will be followed by a question that reads, “From what site does the responsible organism usually enter the blood?”


This section therefore presents organisms in two major ways: in individual microbial “profiles” and in the context of the systems they infect and the clinical presentations they produce. You should become familiar with both formats. When reviewing the systems approach, remind yourself of the features of each microbe by returning to the individual profiles. Also be sure to memorize the laboratory characteristics that allow you to identify microbes.

## ► MICROBIOLOGY—BASIC BACTERIOLOGY

## Bacterial structures

STRUCTURE	CHEMICAL COMPOSITION	FUNCTION
<b>Appendages</b>		
<b>Flagellum</b>	Proteins.	Motility.
<b>Pilus/fimbria</b>	Glycoprotein.	Mediate adherence of bacteria to cell surface; sex pilus forms during conjugation.
<b>Specialized structures</b>		
<b>Spore</b>	Keratin-like coat; dipicolinic acid; peptidoglycan, DNA.	Gram $\oplus$ only. Survival: resist dehydration, heat, chemicals.
<b>Cell envelope</b>		
<b>Capsule</b>	Organized, discrete polysaccharide layer (except poly-D-glutamate on <i>B anthracis</i> ).	Protects against phagocytosis.
<b>Glycocalyx</b>	Loose network of polysaccharides.	Mediates adherence to surfaces, especially foreign surfaces (eg, indwelling catheters).
<b>Outer membrane</b>	Outer leaflet: contains endotoxin (LPS/LOS). Embedded proteins: porins and other outer membrane proteins (OMPs) Inner leaflet: phospholipids.	Gram $\ominus$ only. Endotoxin: lipid A induces TNF and IL-1; antigenic O polysaccharide component. Most OMPs are antigenic. Porins: transport across outer membrane.
<b>Periplasm</b>	Space between cytoplasmic membrane and outer membrane in gram $\ominus$ bacteria. (Peptidoglycan in middle.)	Accumulates components exiting gram $\ominus$ cells, including hydrolytic enzymes (eg, $\beta$ -lactamases).
<b>Cell wall</b>	Peptidoglycan is a sugar backbone with peptide side chains cross-linked by transpeptidase.	Net-like structure gives rigid support, protects against osmotic pressure damage.
<b>Cytoplasmic membrane</b>	Phospholipid bilayer sac with embedded proteins (eg, penicillin-binding proteins [PBPs]) and other enzymes. Lipoteichoic acids (gram $\oplus$ only) extend from membrane to exterior.	Site of oxidative and transport enzymes; PBPs involved in cell wall synthesis. Lipoteichoic acids induce TNF- $\alpha$ and IL-1.

## Cell walls




**Bacterial taxonomy**

MORPHOLOGY	Gram ⊕ examples	Gram ⊖ examples
Spherical (coccus)	<i>Staphylococcus</i> (clusters) <i>Streptococcus</i> (chains or pairs) <i>Enterococcus</i> (pairs or short chains)	<i>Moraxella catarrhalis</i> <i>Neisseria</i>
Rod (bacillus)	<i>Bacillus</i> <i>Clostridium</i> <i>Corynebacterium</i> <i>Gardnerella</i> (gram variable) <i>Lactobacillus</i> <i>Listeria</i> <i>Mycobacterium</i> (acid fast) <i>Propionibacterium</i>	Enterics: <ul style="list-style-type: none"> <li>▪ <i>Bacteroides</i></li> <li>▪ <i>Campylobacter</i></li> <li>▪ <i>E coli</i></li> <li>▪ <i>Enterobacter</i></li> <li>▪ <i>Fusobacterium</i></li> <li>▪ <i>Helicobacter</i></li> <li>▪ <i>Klebsiella</i></li> <li>▪ <i>Proteus</i></li> <li>▪ <i>Pseudomonas</i></li> <li>▪ <i>Salmonella</i></li> <li>▪ <i>Serratia</i></li> <li>▪ <i>Shigella</i></li> <li>▪ <i>Vibrio</i></li> <li>▪ <i>Yersinia</i></li> </ul> Respiratory: <ul style="list-style-type: none"> <li>▪ <i>Bordetella</i></li> <li>▪ <i>Burkholderia cepacia</i></li> <li>▪ <i>Haemophilus</i> (pleomorphic)</li> <li>▪ <i>Legionella</i> (silver stain)</li> </ul> Zoonotic: <ul style="list-style-type: none"> <li>▪ <i>Bartonella</i></li> <li>▪ <i>Brucella</i></li> <li>▪ <i>Francisella</i></li> <li>▪ <i>Pasteurella</i></li> </ul>
Branching filamentous	<i>Actinomyces</i> <i>Nocardia</i> (weakly acid fast)	
Pleomorphic (no cell wall)		<i>Anaplasma</i> , <i>Ehrlichia</i> <i>Chlamydiae</i> (Giemsa) <i>Rickettsiae</i> (Giemsa) <i>Mycoplasma</i> (contains sterols, which do not Gram stain)
Spiral		Spirochetes: <ul style="list-style-type: none"> <li>▪ <i>Borrelia</i> (Giemsa)</li> <li>▪ <i>Leptospira</i></li> <li>▪ <i>Treponema</i></li> </ul>

## Stains

<b>Gram stain</b>	First-line lab test in bacterial identification. Bacteria with thick peptidoglycan layer retain crystal violet dye (gram ⊕); bacteria with thin peptidoglycan layer turn red or pink (gram ⊖) with counterstain. These bugs do not Gram stain well ( <b>T</b> hese <b>L</b> ittle <b>M</b> icrobes <b>M</b> ay <b>U</b> nfortunately <b>L</b> ack <b>R</b> eal <b>C</b> olor <b>B</b> ut <b>A</b> re <b>E</b> verywhere).	
	<i>Treponema</i> , <i>Leptospira</i>	Too thin to be visualized.
	<i>Mycobacteria</i>	Cell wall has high lipid content.
	<i>Mycoplasma</i> , <i>Ureaplasma</i>	No cell wall.
	<i>Legionella</i> , <i>Rickettsia</i> , <i>Chlamydia</i> , <i>Bartonella</i> , <i>Anaplasma</i> , <i>Ehrlichia</i>	Primarily intracellular; also, <i>Chlamydia</i> lack classic peptidoglycan because of ↓ muramic acid.
<b>Giemsa stain</b>	<i>Chlamydia</i> , <i>Borrelia</i> , <i>Rickettsia</i> , Trypanosomes <b>A</b> , <i>Plasmodium</i>	Certain <b>B</b> ugs <b>R</b> eally <b>T</b> ry my <b>P</b> atience.
<b>Periodic acid–Schiff stain</b>	Stains <b>glycogen</b> , mucopolysaccharides; used to diagnose Whipple disease ( <i>Tropheryma whipplei</i> <b>B</b> )	<b>Pa</b> Ss the <b>sugar</b> .
<b>Ziehl-Neelsen stain (carbol fuchsin)</b>	Acid-fast bacteria (eg, <i>Mycobacteria</i> <b>C</b> , <i>Nocardia</i> ; stains mycolic acid in cell wall); protozoa (eg, <i>Cryptosporidium</i> oocysts)	Current standard of care is auramine-rhodamine stain for screening (inexpensive, more sensitive but less specific).
<b>India ink stain</b>	<i>Cryptococcus neoformans</i> <b>D</b> ; mucicarmine can also be used to stain thick polysaccharide capsule red	
<b>Silver stain</b>	Fungi (eg, <i>Coccidioides</i> <b>E</b> , <i>Pneumocystis jirovecii</i> ), <i>Legionella</i> , <i>Helicobacter pylori</i>	
<b>Fluorescent antibody stain</b>	Used to identify many bacteria and viruses.	Example is FTA-ABS for syphilis.



## Properties of growth media

The same type of media can possess both (or neither) of these properties.

<b>Selective media</b>	Favors the growth of particular organism while preventing growth of other organisms, eg, Thayer-Martin agar contains antibiotics that allow the selective growth of <i>Neisseria</i> by inhibiting the growth of other sensitive organisms.
<b>Indicator (differential) media</b>	Yields a color change in response to the metabolism of certain organisms, eg, MacConkey agar contains a pH indicator; a lactose fermenter like <i>E coli</i> will convert lactose to acidic metabolites → color change.

**Special culture requirements**

BUG	MEDIA USED FOR ISOLATION	MEDIA CONTENTS/OTHER
<i>H influenzae</i>	Chocolate agar	Factors V (NAD <sup>+</sup> ) and X (hematin)
<i>N gonorrhoeae</i> , <i>N meningitidis</i>	Thayer-Martin agar	Selectively favors growth of <i>Neisseria</i> by inhibiting growth of gram ⊕ organisms with Vancomycin, gram ⊖ organisms except <i>Neisseria</i> with Trimethoprim and Colistin, and fungi with Nystatin Very Typically Cultures <i>Neisseria</i>
<i>B pertussis</i>	Bordet-Gengou agar ( <b>Bordet</b> for <i>Bordetella</i> ) Regan-Lowe medium	Potato extract Charcoal, blood, and antibiotic
<i>C diphtheriae</i>	Tellurite agar, Löffler medium	
<i>M tuberculosis</i>	Löwenstein-Jensen agar	
<i>M pneumoniae</i>	Eaton agar	Requires cholesterol
Lactose-fermenting enterics	MacConkey agar	Fermentation produces acid, causing colonies to turn pink
<i>E coli</i>	Eosin–methylene blue (EMB) agar	Colonies with green metallic sheen
<i>Legionella</i>	Charcoal yeast extract agar buffered with cysteine and iron	
Fungi	Sabouraud agar	“ <b>Sab</b> ’s a <b>fun</b> guy!”

**Aerobes**

Use an O<sub>2</sub>-dependent system to generate ATP. Examples include *Nocardia*, *Pseudomonas aeruginosa*, and *Mycobacterium tuberculosis*. Reactivation of *M tuberculosis* (eg, after immunocompromise or TNF-α inhibitor use) has a predilection for the apices of the lung.

Nagging **Pests Must Breathe**.

**Anaerobes**

Examples include *Clostridium*, *Bacteroides*, *Fusobacterium*, and *Actinomyces*. They lack catalase and/or superoxide dismutase and are thus susceptible to oxidative damage. Generally foul smelling (short-chain fatty acids), are difficult to culture, and produce gas in tissue (CO<sub>2</sub> and H<sub>2</sub>).

Anaerobes **Can't Breathe Fresh Air**.

Anaerobes are normal flora in GI tract, typically pathogenic elsewhere. AminO<sub>2</sub>glycosides are ineffective against anaerobes because these antibiotics require O<sub>2</sub> to enter into bacterial cell.

**Facultative anaerobes**


Use fermentation and other nonoxygen-dependent pathways to generate ATP but are not killed by O<sub>2</sub>.

Streptococci, staphylococci, and enteric gram ⊕ bacteria.



**Intracellular bugs**

<b>Obligate intracellular</b>	<i>Rickettsia</i> , <b>CH</b> lamydia, <b>CO</b> xiella. Rely on host ATP.	Stay inside (cells) when it is Really <b>CH</b> illy and <b>CO</b> ld.
<b>Facultative intracellular</b>	<i>Salmonella</i> , <i>Neisseria</i> , <i>Brucella</i> , <i>Mycobacterium</i> , <i>Listeria</i> , <i>Francisella</i> , <i>Legionella</i> , <i>Yersinia pestis</i> .	Some <b>N</b> asty <b>B</b> ugs <b>M</b> ay <b>L</b> ive <b>F</b> acultative <b>LY</b> .

**Encapsulated bacteria**

Examples are *Pseudomonas aeruginosa*, *Streptococcus pneumoniae* **A**, *Haemophilus influenzae* type B, *Neisseria meningitidis*, *Escherichia coli*, *Salmonella*, *Klebsiella pneumoniae*, and group B **Strep**. Their capsules serve as an antiphagocytic virulence factor.

Capsular polysaccharide + protein conjugate serves as an antigen in vaccines.

Please **SHINE** my **SKiS**.

Are opsonized, and then cleared by spleen.

Asplenic have ↓ opsonizing ability and thus ↑ risk for severe infections. Give *S pneumoniae*, *H influenzae*, *N meningitidis* vaccines.

**Encapsulated bacteria vaccines**

Some vaccines containing polysaccharide capsule antigens are conjugated to a carrier protein, enhancing immunogenicity by promoting T-cell activation and subsequent class switching. A polysaccharide antigen alone cannot be presented to T cells.

Pneumococcal vaccine: PCV13 (pneumococcal conjugate vaccine), PPSV23 (pneumococcal polysaccharide vaccine with no conjugated protein)


*H influenzae* type B (conjugate vaccine)

Meningococcal vaccine (conjugate vaccine)

**Urease-positive organisms**

*Proteus*, *Cryptococcus*, *H pylori*, *Ureaplasma*, *Nocardia*, *Klebsiella*, *S epidermidis*, *S saprophyticus*. Urease hydrolyzes urea to release ammonia and CO<sub>2</sub> → ↑ pH. Predisposes to struvite (ammonium magnesium phosphate) stones, particularly *Proteus*.

Pee **CHUNKSS**.

**Catalase-positive organisms**

*Catalase* degrades H<sub>2</sub>O<sub>2</sub> into H<sub>2</sub>O and bubbles of O<sub>2</sub> **A** before it can be converted to microbicidal products by the enzyme myeloperoxidase. People with chronic granulomatous disease (NADPH oxidase deficiency) have recurrent infections with certain catalase ⊕ organisms.

Examples: *Nocardia*, *Pseudomonas*, *Listeria*, *Aspergillus*, *Candida*, *E coli*, *Staphylococci*, *Serratia*, *B cepacia*, *H pylori*.


**Cats** Need **PLACESS** to **Belch** their **Hairballs**.

<b>Pigment-producing bacteria</b>	<i>Actinomyces israelii</i> —yellow “sulfur” granules, which are composed of filaments of bacteria.	Israel has yellow sand.
	<i>S aureus</i> —yellow pigment.	<i>Aureus</i> (Latin) = gold.
	<i>P aeruginosa</i> —blue-green pigment (pyocyanin and pyoverdinin).	<i>Aerugula</i> is green.
	<i>Serratia marcescens</i> —red pigment.	<i>Serratia marcescens</i> —think red maraschino cherries.
<b>In vivo biofilm-producing bacteria</b>	<i>S epidermidis</i>	Catheter and prosthetic device infections
	Viridans streptococci ( <i>S mutans</i> , <i>S sanguinis</i> )	Dental plaques, infective endocarditis
	<i>P aeruginosa</i>	Respiratory tree colonization in patients with cystic fibrosis, ventilator-associated pneumonia. Contact lens-associated keratitis
	Nontypeable (unencapsulated) <i>H influenzae</i>	Otitis media
<b>Bacterial virulence factors</b>	These promote evasion of host immune response.	
<b>Protein A</b>	Binds Fc region of IgG. Prevents opsonization and phagocytosis. Expressed by <i>S aureus</i> .	
<b>IgA protease</b>	Enzyme that cleaves IgA, allowing bacteria to adhere to and colonize mucous membranes. Secreted by <i>S pneumoniae</i> , <i>H influenzae</i> type B, and <i>Neisseria</i> (SHiN).	
<b>M protein</b>	Helps prevent phagocytosis. Expressed by group A streptococci. Shares similar epitopes to human cellular proteins (molecular mimicry); possibly underlies the autoimmune response seen in acute rheumatic fever.	
<b>Type III secretion system</b>	Also known as “injectisome.” Needle-like protein appendage facilitating direct delivery of toxins from certain gram $\ominus$ bacteria (eg, <i>Pseudomonas</i> , <i>Salmonella</i> , <i>Shigella</i> , <i>E coli</i> ) to eukaryotic host cell.	

## Bacterial genetics

## Transformation


Competent bacteria are able to bind and import short pieces of environmental naked bacterial chromosomal DNA (from bacterial cell lysis). The transfer and expression of newly transferred genes is called transformation. A feature of many bacteria, especially *S pneumoniae*, *H influenzae* type B, and *Neisseria* (SHiN). Any DNA can be used. Adding deoxyribonuclease to environment will degrade naked DNA in medium → no transformation seen.




## Conjugation

 $F^+ \times F^-$ 

$F^+$  plasmid contains genes required for sex pilus and conjugation. Bacteria without this plasmid are termed  $F^-$ . Sex pilus on  $F^+$  bacterium contacts  $F^-$  bacterium. A single strand of plasmid DNA is transferred across the conjugal bridge (“mating bridge”). No transfer of chromosomal DNA.

 $Hfr \times F^-$ 


$F^+$  plasmid can become incorporated into bacterial chromosomal DNA, termed high-frequency recombination (Hfr) cell. Transfer of part of plasmid and a few flanking chromosomal genes. High-frequency recombination may integrate some of those bacterial genes. The recipient cell remains  $F^-$  but now may have new bacterial genes.



## Transduction


Generalized

A “packaging” event. Lytic phage infects bacterium, leading to cleavage of bacterial DNA. Parts of bacterial chromosomal DNA may become packaged in phage capsid. Phage infects another bacterium, transferring these genes.



Specialized


An “excision” event. Lysogenic phage infects bacterium; viral DNA incorporates into bacterial chromosome. When phage DNA is excised, flanking bacterial genes may be excised with it. DNA is packaged into phage capsid and can infect another bacterium. Genes for the following 5 bacterial toxins are encoded in a lysogenic phage (ABCD'S): Group A strep erythrogenic toxin, Botulinum toxin, Cholera toxin, Diphtheria toxin, Shiga toxin.




**Bacterial genetics (continued)**

**Transposition**

Segment of DNA (eg, transposon) that can “jump” (excision and reintegration) from one location to another, can transfer genes from plasmid to chromosome and vice versa. When excision occurs, may include some flanking chromosomal DNA, which can be incorporated into a plasmid and transferred to another bacterium (eg, *vanA* gene from vancomycin-resistant *Enterococcus* to *S aureus*).



**Spore-forming bacteria**



Some bacteria can form spores **A** at the end of the stationary phase when nutrients are limited. Spores are highly resistant to heat and chemicals. Have dipicolinic acid in their core. Have no metabolic activity. Must autoclave to potentially kill spores (as is done to surgical equipment) by steaming at 121°C for 15 minutes.

- |                                |                          |
|--------------------------------|--------------------------|
| <i>Bacillus anthracis</i>      | Anthrax                  |
| <i>Bacillus cereus</i>         | Food poisoning           |
| <i>Clostridium botulinum</i>   | Botulism                 |
| <i>Clostridium difficile</i>   | Pseudomembranous colitis |
| <i>Clostridium perfringens</i> | Gas gangrene             |
| <i>Clostridium tetani</i>      | Tetanus                  |

**Main features of exotoxins and endotoxins**

	Exotoxins	Endotoxin
SOURCE	Certain species of gram ⊕ and gram ⊖ bacteria	Outer cell membrane of most gram ⊖ bacteria
SECRETED FROM CELL	Yes	No
CHEMISTRY	Polypeptide	Lipid A component of LPS (structural part of bacteria; released when lysed)
LOCATION OF GENES	Plasmid or bacteriophage	Bacterial chromosome
ADVERSE EFFECTS	High (fatal dose on the order of 1 μg)	Low (fatal dose on the order of hundreds of micrograms)
CLINICAL EFFECTS	Various effects (see following pages)	Fever, shock (hypotension), DIC
MODE OF ACTION	Various modes (see following pages)	Induces TNF, IL-1, and IL-6
ANTIGENICITY	Induces high-titer antibodies called antitoxins	Poorly antigenic
VACCINES	Toxoids used as vaccines	No toxoids formed and no vaccine available
HEAT STABILITY	Destroyed rapidly at 60°C (except staphylococcal enterotoxin and <i>E coli</i> heat-stable toxin)	Stable at 100°C for 1 hr
TYPICAL DISEASES	Tetanus, botulism, diphtheria	Meningococemia; sepsis by gram ⊖ rods

## Bugs with exotoxins

BACTERIA	TOXIN	MECHANISM	MANIFESTATION
<b>Inhibit protein synthesis</b>			
<i>Corynebacterium diphtheriae</i>	Diphtheria toxin <sup>a</sup>	Inactivate elongation factor (EF-2)	Pharyngitis with pseudomembranes in throat and severe lymphadenopathy (bull neck)
<i>Pseudomonas aeruginosa</i>	Exotoxin A <sup>a</sup>		Host cell death
<i>Shigella</i> spp.	Shiga toxin (ST) <sup>a</sup>	Inactivate 60S ribosome by removing adenine from rRNA	GI mucosal damage → dysentery; ST also enhances cytokine release, causing hemolytic-uremic syndrome (HUS)
<b>Enterohemorrhagic <i>E coli</i> (EHEC)</b>	Shiga-like toxin (SLT) <sup>a</sup>		SLT enhances cytokine release, causing HUS (prototypically in EHEC serotype O157:H7). Unlike <i>Shigella</i> , EHEC does not invade host cells
<b>Increase fluid secretion</b>			
<b>Enterotoxigenic <i>E coli</i> (ETEC)</b>	Heat- <b>labile</b> toxin (LT) <sup>a</sup>	Overactivates adenylate cyclase (↑ cAMP) → ↑ Cl <sup>-</sup> secretion in gut and H <sub>2</sub> O efflux	Watery diarrhea: “ <b>labile</b> in the <b>A</b> ir ( <b>A</b> denylate cyclase), <b>stable</b> on the <b>G</b> round ( <b>G</b> uanylate cyclase)”
	Heat- <b>stable</b> toxin (ST)	Overactivates guanylate cyclase (↑ cGMP) → ↓ resorption of NaCl and H <sub>2</sub> O in gut	
<i>Bacillus anthracis</i>	Edema toxin <sup>a</sup>	Mimics the adenylate cyclase enzyme (↑ cAMP)	Likely responsible for characteristic edematous borders of black eschar in cutaneous anthrax
<i>Vibrio cholerae</i>	Cholera toxin <sup>a</sup>	Overactivates adenylate cyclase (↑ cAMP) by permanently activating G <sub>s</sub> → ↑ Cl <sup>-</sup> secretion in gut and H <sub>2</sub> O efflux	Voluminous “rice-water” diarrhea
<b>Inhibit phagocytic ability</b>			
<i>Bordetella pertussis</i>	Pertussis toxin <sup>a</sup>	Overactivates adenylate cyclase (↑ cAMP) by disabling G <sub>i</sub> , impairing phagocytosis to permit survival of microbe	<b>Whooping cough</b> —child coughs on expiration and “whoops” on inspiration (toxin may not actually be a cause of cough; can cause “100-day cough” in adults)
<b>Inhibit release of neurotransmitter</b>			
<i>Clostridium tetani</i>	Tetanospasmin <sup>a</sup>	Both are proteases that cleave SNARE (soluble NSF attachment protein receptor), a set of proteins required for neurotransmitter release via vesicular fusion	Spastic paralysis, risus sardonicus, and “lockjaw”; toxin prevents release of <b>inhibitory</b> (GABA and glycine) neurotransmitters from Renshaw cells in spinal cord
<i>Clostridium botulinum</i>	Botulinum toxin <sup>a</sup>		Flaccid paralysis, floppy baby; toxin prevents release of <b>stimulatory</b> (ACh) signals at neuromuscular junctions → flaccid paralysis

<sup>a</sup>An AB toxin (aka, two-component toxin [or three for anthrax]) with **B** enabling **b**inding and triggering uptake (endocytosis) of the **a**ctive **A** component. The A components are usually ADP ribosyltransferases; others have enzymatic activities as listed in chart.

**Bugs with exotoxins (continued)**


BACTERIA	TOXIN	MECHANISM	MANIFESTATION
<b>Lyse cell membranes</b>			
<i>Clostridium perfringens</i>	Alpha toxin	Phospholipase (lecithinase) that degrades tissue and cell membranes	Degradation of phospholipids → myonecrosis (“gas gangrene”) and hemolysis (“double zone” of hemolysis on blood agar)
<i>Streptococcus pyogenes</i>	Streptolysin O	Protein that degrades cell membrane	Lyses RBCs; contributes to β-hemolysis; host antibodies against toxin (ASO) used to diagnose rheumatic fever (do not confuse with immune complexes of poststreptococcal glomerulonephritis)
<b>Superantigens causing shock</b>			
<i>Staphylococcus aureus</i>	Toxic shock syndrome toxin (TSST-1)	Binds to MHC II and TCR outside of antigen binding site to cause overwhelming release of IL-1, IL-2, IFN-γ, and TNF-α → shock	Toxic shock syndrome: fever, rash, shock; other toxins cause scalded skin syndrome (exfoliative toxin) and food poisoning (heat-stable enterotoxin)
<i>Streptococcus pyogenes</i>	Exotoxin A		Toxic shock–like syndrome: fever, rash, shock; scarlet fever

**Endotoxin**

LPS found in outer membrane of gram ⊖ bacteria (both cocci and rods). Composed of O antigen + core polysaccharide + lipid A (the toxic component). Released upon cell lysis or by living cells by blebs detaching from outer surface membrane (vs exotoxin, which is actively secreted). Three main effects: macrophage activation (TLR4), complement activation, and tissue factor activation.


**ENDOTOXINS:**

- E**dema
- N**itric oxide
- DIC/Death**
- O**uter membrane
- TNF-α**
- O**-antigen + core polysaccharide + lipid A
- eX**tremely heat stable
- IL-1** and **IL-6**
- N**eutrophil chemotaxis
- S**hock



## ► MICROBIOLOGY—CLINICAL BACTERIOLOGY

## Gram-positive lab algorithm



Important **tests** are in **bold**. Important **pathogens** are in **bold italics**.  
 Note: Enterococcus is either α- or γ-hemolytic.



## Gram-positive cocci antibiotic tests

## Staphylococci

**NO**vobiocin—*Saprophyticus* is **R**esistant;  
*Epidermidis* is **S**ensitive.

On the office's "**staph**" retreat, there was  
**NO StRESs**.


## Streptococci

**O**ptochin—*Viridans* is **R**esistant; *Pneumoniae* is  
**S**ensitive.

**OVRPS** (overpass).


**B**acitracin—group **B** strep are **R**esistant; group  
**A** strep are **S**ensitive.

**B-BRAS**.

**$\alpha$ -hemolytic bacteria**


Gram  $\oplus$  cocci. Partial reduction of hemoglobin causes greenish or brownish color without clearing around growth on blood agar **A**. Include the following organisms:

- *Streptococcus pneumoniae* (catalase  $\ominus$  and optochin sensitive)
- Viridans streptococci (catalase  $\ominus$  and optochin resistant)

 **$\beta$ -hemolytic bacteria**

Gram  $\oplus$  cocci. Complete lysis of RBCs  $\rightarrow$  clear area surrounding colony on blood agar **A**. Include the following organisms:

- *Staphylococcus aureus* (catalase and coagulase  $\oplus$ )
- *Streptococcus pyogenes*—group A strep (catalase  $\ominus$  and bacitracin sensitive)
- *Streptococcus agalactiae*—group B strep (catalase  $\ominus$  and bacitracin resistant)

***Staphylococcus aureus***

Gram  $\oplus$ ,  $\beta$ -hemolytic, catalase  $\oplus$ , coagulase  $\oplus$  cocci in clusters **A**. Protein A (virulence factor) binds Fc-IgG, inhibiting complement activation and phagocytosis. Commonly colonizes the nares, axilla, and groin.

Causes:

- Inflammatory disease—skin infections, organ abscesses, pneumonia (often after influenza virus infection), endocarditis, septic arthritis, and osteomyelitis.
- Toxin-mediated disease—toxic shock syndrome (TSST-1), scalded skin syndrome (exfoliative toxin), rapid-onset food poisoning (enterotoxins).
- MRSA (methicillin-resistant *S aureus*) infection—important cause of serious nosocomial and community-acquired infections; resistant to methicillin and nafcillin because of altered penicillin-binding protein.

TSST-1 is a superantigen that binds to MHC II and T-cell receptor, resulting in polyclonal T-cell activation.

Staphylococcal toxic shock syndrome (TSS) presents as fever, vomiting, rash, desquamation, shock, end-organ failure. TSS results in  $\uparrow$  AST,  $\uparrow$  ALT,  $\uparrow$  bilirubin. Associated with prolonged use of vaginal tampons or nasal packing.

Compare with *Streptococcus pyogenes* TSS (a toxic shock-like syndrome associated with painful skin infection).

*S aureus* food poisoning due to ingestion of preformed toxin  $\rightarrow$  short incubation period (2–6 hr) followed by nonbloody diarrhea and emesis. Enterotoxin is heat stable  $\rightarrow$  not destroyed by cooking.

Bad staph (*aureus*) make coagulase and toxins. Forms fibrin clot around self  $\rightarrow$  abscess.

***Staphylococcus epidermidis***

Gram  $\oplus$ , catalase  $\oplus$ , coagulase  $\ominus$ , urease  $\oplus$  cocci in clusters. Novobiocin sensitive. Does not ferment mannitol (vs *S aureus*).


Normal flora of skin; contaminates blood cultures.

Infects prosthetic devices (eg, hip implant, heart valve) and IV catheters by producing adherent biofilms.



***Staphylococcus saprophyticus***

Gram  $\oplus$ , catalase  $\oplus$ , coagulase  $\ominus$ , urease  $\oplus$  cocci in clusters. Novobiocin resistant.  
Normal flora of female genital tract and perineum.  
Second most common cause of uncomplicated UTI in young women (most common is *E coli*).

***Streptococcus pneumoniae***

Gram  $\oplus$ , lancet-shaped diplococci **A**.  
Encapsulated. IgA protease. Optochin sensitive. Most common cause of:


- Meningitis
- Otitis media (in children)
- Bacterial pneumonia
- Sinusitis

Pneumococcus is associated with “rusty” sputum, sepsis in patients with sickle cell disease, and asplenic patients.  
No virulence without capsule.

**Viridans group streptococci**

Gram  $\oplus$ ,  $\alpha$ -hemolytic cocci. They are normal flora of the oropharynx that cause dental caries (*Streptococcus mutans* and *S mitis*) and subacute bacterial endocarditis at damaged **heart** valves (*S sanguinis*). Resistant to optochin, differentiating them from *S pneumoniae*, which is  $\alpha$ -hemolytic but is optochin sensitive.

*Sanguinis* = **blood**. Think, “there is lots of **blood** in the **heart**” (endocarditis). *S sanguinis* makes dextrans, which bind to fibrin-platelet aggregates on damaged heart valves.  
Viridans group strep live in the mouth because they are not afraid **of-the-chin** (**op-to-chin** resistant).

***Streptococcus pyogenes* (group A streptococci)**

Gram  $\oplus$  cocci in chains **A**. Group A strep cause:

- Pyogenic—pharyngitis, cellulitis, impetigo (“honey-crusted” lesions), erysipelas
- Toxicogenic—scarlet fever, toxic shock-like syndrome, necrotizing fasciitis
- Immunologic—rheumatic fever, glomerulonephritis

Bacitracin sensitive,  $\beta$ -hemolytic, pyrrolidonyl arylamidase (PYR)  $\oplus$ . Hyaluronic acid capsule inhibits phagocytosis. Antibodies to M protein enhance host defenses against *S pyogenes* but can give rise to rheumatic fever.

ASO titer or anti-DNase B antibodies indicate recent *S pyogenes* infection.

**JONES** (major criteria for acute rheumatic fever):

- J**oints—polyarthriti**s**
- ♥**—carditi**s**
- N**odules (subcutaneous)
- E**rythema marginat**u**m
- S**ydenham chorea

**Pharyngitis** can result in rheumatic “**ph**ever” and glomerulone**ph**ritis.

Impetigo usually precedes glomerulonephritis.  
**Scarlet fever**—blanching, sandpaper-like body rash, strawberry tongue, and circumoral pallor in the setting of group A streptococcal pharyngitis (erythrogenic toxin  $\oplus$ ).

***Streptococcus agalactiae* (group B streptococci)**

Gram  $\oplus$  cocci, bacitracin resistant,  $\beta$ -hemolytic, Group **B** for **B**abies!  
 colonizes vagina; causes pneumonia, meningitis, and sepsis, mainly in **babies**.  
 Produces CAMP factor, which enlarges the area of hemolysis formed by *S aureus*. (Note: CAMP stands for the authors of the test, not cyclic AMP.) Hippurate test  $\oplus$ . PYR  $\ominus$ .  
 Screen pregnant women at 35–37 weeks of gestation with rectal + vaginal swabs. Patients with  $\oplus$  culture receive intrapartum penicillin prophylaxis.

***Streptococcus bovis***

Gram  $\oplus$  cocci, colonizes the gut. *S gallolyticus* (*S bovis* biotype 1) can cause bacteremia and subacute endocarditis and is associated with colon cancer. **B**ovis in the **b**lood = **c**ancer in the **c**olon.

**Enterococci**

Gram  $\oplus$  cocci. Enterococci (*E faecalis* and *E faecium*) are normal colonic flora that are penicillin G resistant and cause UTI, biliary tract infections, and subacute endocarditis (following GI/GU procedures). Catalase  $\ominus$ , PYR  $\oplus$ , variable hemolysis. Enterococci, hardier than nonenterococcal group D, can grow in 6.5% NaCl and bile (lab test).  
*Entero* = intestine, *faecalis* = feces, *strepto* = twisted (chains), *coccus* = berry.  
 VRE (vancomycin-resistant enterococci) are an important cause of nosocomial infection.

***Bacillus anthracis***

Gram  $\oplus$ , spore-forming rod that produces anthrax toxin. The only bacterium with a polypeptide capsule (contains D-glutamate). Colonies show a halo of projections, sometimes referred to as “medusa head” appearance.

**Cutaneous anthrax**

Painless papule surrounded by vesicles  $\rightarrow$  ulcer with black eschar (**A**) (painless, necrotic)  $\rightarrow$  uncommonly progresses to bacteremia and death.

**Pulmonary anthrax**

Inhalation of spores  $\rightarrow$  flu-like symptoms that rapidly progress to fever, pulmonary hemorrhage, mediastinitis, and shock. Also known as woolsorter’s disease

**Bacillus cereus**

Gram ⊕ rod. Causes food poisoning.  
Spores survive cooking rice. Keeping rice warm results in germination of spores and enterotoxin formation.  
Emetic type usually seen with rice and pasta.  
Nausea and vomiting within 1–5 hr. Caused by cereulide, a preformed toxin.  
Diarrheal type causes watery, nonbloody diarrhea and GI pain within 8–18 hr.

Reheated rice syndrome.

**Clostridia (with exotoxins)**

Gram ⊕, spore-forming, obligate anaerobic rods.

**C tetani**

Produces tetanospasmin, an exotoxin causing tetanus. Tetanus toxin (and botulinum toxin) are proteases that cleave SNARE proteins for neurotransmitters. Blocks release of inhibitory neurotransmitters, GABA and glycine, from Renshaw cells in spinal cord.  
Causes spastic paralysis, trismus (lockjaw), risus sardonicus (raised eyebrows and open grin), opisthotonos (spasms of spinal extensors).  
Prevent with tetanus vaccine. Treat with antitoxin +/- vaccine booster, diazepam (for muscle spasms), and wound debridement.

Tetanus is tetanic paralysis.

**C botulinum**

Produces a heat-labile toxin that inhibits ACh release at the neuromuscular junction, causing botulism. In adults, disease is caused by ingestion of preformed toxin. In babies, ingestion of spores (eg, in honey) leads to disease (floppy baby syndrome). Treat with antitoxin.

Symptoms of botulism (the 4 D's): Diplopia, Dysarthria, Dysphagia, Dyspnea.


Botulinum is from bad bottles of food, juice, and honey (causes a descending flaccid paralysis). Local botox injections used to treat focal dystonia, achalasia, and muscle spasms. Also used for cosmetic reduction of facial wrinkles.

**C perfringens**

Produces α toxin (lecithinase, a phospholipase) that can cause myonecrosis (gas gangrene A) and hemolysis.

Perfringens perforates a gangrenous leg.


Spores can survive in undercooked food; when ingested, bacteria release heat-labile enterotoxin → food poisoning.

**C difficile**

Produces 2 toxins. Toxin A, an enterotoxin, binds to brush border of gut and alters fluid secretion. Toxin B, a cytotoxin, disrupts cytoskeleton via actin depolymerization. Both toxins lead to diarrhea → pseudomembranous colitis B. Often 2° to antibiotic use, especially clindamycin or ampicillin; associated with PPI use. Diagnosed by detecting one or both toxins in stool by antigen detection or PCR.

Difficile causes diarrhea. Treatment: metronidazole or oral vancomycin. For recurrent cases, consider repeating prior regimen, fidaxomicin, or fecal microbiota transplant.

**Corynebacterium diphtheriae**



Gram ⊕ rod; transmitted via respiratory droplets. Causes diphtheria via exotoxin encoded by β-prophage. Potent exotoxin inhibits protein synthesis via ADP-ribosylation of EF-2.

Symptoms include pseudomembranous pharyngitis (grayish-white membrane **A**) with lymphadenopathy, myocarditis, and arrhythmias.

Lab diagnosis based on gram ⊕ rods with metachromatic (blue and red) granules and ⊕ Elek test for toxin.

Toxoid vaccine prevents diphtheria.


*Coryne* = club shaped.

Black colonies on cystine-tellurite agar.

**ABCDEFGF:**

- A**DP-ribosylation
- β**-prophage
- C***orynebacterium*
- D***iphtheriae*
- E**longation **F**actor 2
- G**ranules

**Listeria monocytogenes**





Gram ⊕, facultative intracellular rod; acquired by ingestion of unpasteurized dairy products and cold deli meats, via transplacental transmission, or by vaginal transmission during birth. Grows well at refrigeration temperatures (4°–10°C; “cold enrichment”).

Forms “rocket tails” (red in **A**) via actin polymerization that allow intracellular movement and cell-to-cell spread across cell membranes, thereby avoiding antibody. Characteristic tumbling motility in broth.

Can cause amnionitis, septicemia, and spontaneous abortion in pregnant women; granulomatosis infantiseptica; neonatal meningitis; meningitis in immunocompromised patients; mild, self-limited gastroenteritis in healthy individuals.

Treatment: ampicillin.

**Nocardia vs Actinomyces**



Both are gram ⊕ and form long, branching filaments resembling fungi.

**Nocardia**

Aerobe  
 Acid fast (weak) **A**  
 Found in soil  
 Causes pulmonary infections in immunocompromised (can mimic TB but with ⊖ PPD); cutaneous infections after trauma in immunocompetent; can spread to CNS

Treat with sulfonamides (TMP-SMX)


**Actinomyces**

Anaerobe  
 Not acid fast **B**  
 Normal oral, reproductive, and GI flora  
 Causes oral/facial abscesses that drain through sinus tracts; often associated with dental caries/extraction; forms yellow “sulfur granules”; can also cause PID with IUDs

Treat with penicillin

Treatment is a **SNAP**: Sulfonamides—**N**ocardia; **A**ctinomyces—**P**enicillin

## Primary and secondary tuberculosis




PPD ⊕ if current infection or past exposure.


PPD ⊖ if no infection and in sarcoidosis or HIV infection (especially with low CD4+ cell count).

Interferon- $\gamma$  release assay (IGRA) has fewer false positives from BCG vaccination.

Caseating granulomas **A** with central necrosis (upper left) and Langhans giant cells (arrow) are characteristic of 2° tuberculosis.



## Mycobacteria



*Mycobacterium tuberculosis* (TB, often resistant to multiple drugs).

*M avium-intracellulare* (causes disseminated, non-TB disease in AIDS; often resistant to multiple drugs). Prophylaxis with azithromycin when CD4+ count < 50 cells/mm<sup>3</sup>.

*M scrofulaceum* (cervical lymphadenitis in children).

*M marinum* (hand infection in aquarium handlers).

All mycobacteria are acid-fast organisms (pink rods; arrows in **A**).

TB symptoms include fever, night sweats, weight loss, cough (nonproductive or productive), hemoptysis.

Cord factor creates a “serpentine cord” appearance in virulent *M tuberculosis* strains; activates macrophages (promoting granuloma formation) and induces release of TNF- $\alpha$ . Sulfatides (surface glycolipids) inhibit phagolysosomal fusion.

**Leprosy (Hansen disease)**




Caused by *Mycobacterium leprae*, an acid-fast bacillus that likes cool temperatures (infects skin and superficial nerves—“glove and stocking” loss of sensation **A**) and cannot be grown in vitro. Diagnosed via skin biopsy or tissue PCR. Reservoir in United States: armadillos.

Hansen disease has 2 forms (many cases fall temporarily between two extremes):

- **Lepromatous**—presents diffusely over the skin, with leonine (lion-like) facies **B**, and is communicable; characterized by low cell-mediated immunity with a humoral Th2 response. Lepromatous form can be lethal.
- **Tuberculoid**—limited to a few hypoesthetic, hairless skin plaques; characterized by high cell-mediated immunity with a largely Th1-type immune response.

Treatment: dapsone and rifampin for tuberculoid form; clofazimine is added for lepromatous form.

**Gram-negative lab algorithm**



Important **tests** are in **bold**. Important **pathogens** are in **bold italics**.



### Lactose-fermenting enteric bacteria


Fermentation of **lactose** → pink colonies on MacCon**key** agar. Examples include **Klebsiella**, **E coli**, **Enterobacter**, and **Serratia** (weak fermenter). *E coli* produces β-galactosidase, which breaks down lactose into glucose and galactose.

**Lactose** is **key**.

Test with MacCon**KEE'S** agar.

EMB agar—lactose fermenters grow as purple/black colonies. *E coli* grows colonies with a green sheen.

### Neisseria



Gram ⊖ diplococci. Metabolize glucose and produce IgA proteases. Contain lipooligosaccharides (LOS) with strong endotoxin activity. *N gonorrhoeae* is often intracellular (within neutrophils) **A**.

**MeninGococci** ferment **Maltose** and **G**lucose.  
**Gonococci** ferment **G**lucose.




#### Gonococci

No polysaccharide capsule  
No maltose metabolized  
No vaccine due to antigenic variation of pilus proteins  
Sexually or perinatally transmitted  
Causes gonorrhea, septic arthritis, neonatal conjunctivitis (2–5 days after birth), pelvic inflammatory disease (PID), and Fitz-Hugh–Curtis syndrome  
Condoms ↓ sexual transmission, erythromycin eye ointment prevents neonatal blindness  
Treatment: ceftriaxone + (azithromycin or doxycycline) for possible chlamydial coinfection

#### Meningococci

Polysaccharide capsule  
Maltose fermentation  
Vaccine (type B vaccine not widely available)  
Transmitted via respiratory and oral secretions  
Causes meningococemia with petechial hemorrhages and gangrene of toes **B**, meningitis, Waterhouse-Friderichsen syndrome (adrenal insufficiency, fever, DIC, shock)  
Rifampin, ciprofloxacin, or ceftriaxone prophylaxis in close contacts  
Treatment: ceftriaxone or penicillin G


### Haemophilus influenzae



Small gram ⊖ (coccobacillary) rod. Aerosol transmission. Nontypeable (unencapsulated) strains are the most common cause of mucosal infections (otitis media, conjunctivitis, bronchitis) as well as invasive infections since the vaccine for capsular type b was introduced. Produces IgA protease. Culture on chocolate agar, which contains factors V (NAD<sup>+</sup>) and X (hematin) for growth; can also be grown with *S aureus*, which provides factor V through the hemolysis of RBCs. **HaEMOPhilus** causes **E**piglottitis (endoscopic appearance in **A**, can be “cherry red” in children; “thumb sign” on x-ray **B**), **M**eningitis, **O**titis media, and **P**neumonia.

Vaccine contains type b capsular polysaccharide (polyribosylribitol phosphate) conjugated to diphtheria toxoid or other protein. Given between 2 and 18 months of age.

Does not cause the flu (influenza virus does).




Treatment: amoxicillin +/- clavulanate for mucosal infections; ceftriaxone for meningitis; rifampin prophylaxis for close contacts.

***Bordetella pertussis***

Gram  $\ominus$ , aerobic coccobacillus. Virulence factors include pertussis toxin (disables  $G_i$ ) and tracheal cytotoxin. Three clinical stages:

- Catarrhal—low-grade fevers, coryza.
- Paroxysmal—paroxysms of intense cough followed by inspiratory “whoop” (“whooping cough”), posttussive vomiting.
- Convalescent—gradual recovery of chronic cough.

Prevented by Tdap, DTaP vaccines. May be mistaken as viral infection due to lymphocytic infiltrate resulting from immune response.

***Legionella pneumophila***


Gram  $\ominus$  rod. Gram stains poorly—use **silver** stain. Grow on **charcoal** yeast extract medium with **iron** and **cysteine**. Detected by presence of antigen in urine. Labs may show hyponatremia. Aerosol transmission from environmental water source habitat (eg, air conditioning systems, hot water tanks). No person-to-person transmission.

Treatment: macrolide or quinolone.

**Legionnaires' disease**—severe pneumonia (often unilateral and lobar **A**), fever, GI and CNS symptoms. Common in smokers and in chronic lung disease.

**Pontiac fever**—mild flu-like syndrome.

Think of a French **legionnaire** (soldier) with his **silver** helmet, sitting around a campfire (**charcoal**) with his **iron** dagger—he is no **sis**sy (cysteine).

***Pseudomonas aeruginosa***

Aerobic, motile, gram  $\ominus$  rod. Non-lactose fermenting, oxidase  $\oplus$ . Produces pyocyanin (blue-green pigment **A**); has a grape-like odor. Produces endotoxin (fever, shock), exotoxin A (inactivates EF-2), phospholipase C (degrades cell membranes), and pyocyanin (generates reactive oxygen species).

**PSEUDOMONAS** is associated with:

- **P**neumonia, pyocyanin
- **S**epsis
- **E**cthyma gangrenosum
- **U**TI
- **D**iabetes, drug use
- **O**steomyelitis (eg, puncture wounds)
- **M**ucoid polysaccharide capsule
- **O**titis externa (swimmer's ear)
- **N**osocomial infections (catheters, equipment)
- **E**xotoxin **A**
- **S**kin infections (hot tub folliculitis)

Treatments include “**CAMPFIRE**” drugs:

- **C**arbapenems
- **A**minoglycosides
- **M**onobactams
- **P**olymyxins (eg, polymyxin B, colistin)
- **F**luoroquinolones (eg, ciprofloxacin, levofloxacin)
- **T**HIRd- and fourth-generation cephalosporins (eg, ceftazidime, cefepime)
- **E**xtended-spectrum penicillins (eg, piperacillin, ticarcillin)

**Aeruginosa**—**aerobic**.

Mucoid polysaccharide capsule may contribute to chronic pneumonia in cystic fibrosis patients due to biofilm formation.

Can cause wound infection in burn victims.

Corneal ulcers/keratitis in contact lens wearers/ minor eye trauma.

Frequently found in water → hot tub folliculitis.


**Ecthyma gangrenosum**—rapidly progressive, necrotic cutaneous lesion **B** caused by *Pseudomonas* bacteremia. Typically seen in immunocompromised patients.



**Escherichia coli**

Gram  $\ominus$  rod. *E coli* virulence factors: fimbriae—cystitis and pyelonephritis (P-pili); K capsule—pneumonia, neonatal meningitis; LPS endotoxin—septic shock.


STRAIN	TOXIN AND MECHANISM	PRESENTATION
<b>EIEC</b>	Microbe invades intestinal mucosa and causes necrosis and inflammation.	<b>I</b> nvasive; dysentery. Clinical manifestations similar to <i>Shigella</i> .
<b>ETEC</b>	Produces heat-labile and heat-stable enterotoxins. No inflammation or invasion.	<b>T</b> ravelers' diarrhea (watery).
<b>EPEC</b>	No toxin produced. Adheres to apical surface, flattens villi, prevents absorption.	Diarrhea, usually in children ( <b>P</b> ediatrics).
<b>EHEC</b>	O157:H7 is most common serotype in US. Often transmitted via undercooked meat, raw leafy vegetables. Shiga-like toxin causes <b>hemolytic-uremic syndrome</b> : triad of anemia, thrombocytopenia, and acute renal failure due to microthrombi forming on damaged endothelium → mechanical hemolysis (with schistocytes on peripheral blood smear), platelet consumption, and ↓ renal blood flow.	Dysentery (toxin alone causes necrosis and inflammation). Does not ferment sorbitol (vs other <i>E coli</i> ). <b>H</b> emorrhagic, <b>H</b> amburgers, <b>H</b> emolytic-uremic syndrome.

**Klebsiella**

Gram  $\ominus$  rod; intestinal flora that causes lobar pneumonia in alcoholics and diabetics when aspirated. Very mucoid colonies **A** caused by abundant polysaccharide capsules. Dark red “currant jelly” sputum (blood/mucus).  
Also cause of nosocomial UTIs.

**5 A's of Klebsiella:**

- A**spiration pneumonia
- A**bscess in lungs and liver
- A**lcoholics
- D**i-**A**-betics
- “Curr-**A**-nt jelly” sputum


**Campylobacter jejuni**

Gram  $\ominus$ , comma or S shaped (with polar flagella) **A**, oxidase  $\oplus$ , grows at **42°C** (“*Campylobacter* likes the **hot campfire**”). Major cause of bloody diarrhea, especially in children. Fecal-oral transmission through person-to-person contact or via ingestion of undercooked contaminated poultry or meat, unpasteurized milk. Contact with infected animals (dogs, cats, pigs) is also a risk factor. Common antecedent to Guillain-Barré syndrome and reactive arthritis.

**Salmonella vs Shigella** Both *Salmonella* and *Shigella* are gram  $\ominus$  rods, non-lactose fermenters, oxidase  $\ominus$ , and can invade the GI tract via M cells of Peyer patches.

	<i>Salmonella typhi</i>	<i>Salmonella</i> spp. (except <i>S typhi</i> )	<i>Shigella</i>
RESERVOIRS	Humans only	Humans and animals	Humans only
SPREAD	Can disseminate hematogenously	Can disseminate hematogenously	Cell to cell; no hematogenous spread
H <sub>2</sub> S PRODUCTION	Yes	Yes	No
FLAGELLA	Yes ( <b>salmon swim</b> )	Yes ( <b>salmon swim</b> )	No
VIRULENCE FACTORS	Endotoxin; Vi capsule	Endotoxin	Endotoxin; Shiga toxin (enterotoxin)
INFECTIOUS DOSE (ID <sub>50</sub> )	High—large inoculum required because organism inactivated by gastric acids	High	Low—very small inoculum required; resistant to gastric acids
EFFECT OF ANTIBIOTICS ON FECAL EXCRETION	Prolongs duration	Prolongs duration	Shortens duration
IMMUNE RESPONSE	Primarily monocytes	PMNs in disseminated disease	Primarily PMN infiltration
GI MANIFESTATIONS	Constipation, followed by diarrhea	Diarrhea (possibly bloody)	Bloody diarrhea (bacillary dysentery)
VACCINE	Oral vaccine contains live attenuated <i>S typhi</i> IM vaccine contains Vi capsular polysaccharide	No vaccine	No vaccine
UNIQUE PROPERTIES	<ul style="list-style-type: none"> <li>Causes typhoid fever (rose spots on abdomen, constipation, abdominal pain, fever); treat with ceftriaxone or fluoroquinolone</li> <li>Carrier state with gallbladder colonization</li> </ul>	<ul style="list-style-type: none"> <li>Poultry, eggs, pets, and turtles are common sources</li> <li>Antibiotics not indicated</li> <li>Gastroenteritis is usually caused by non-typhoidal <i>Salmonella</i></li> </ul>	<ul style="list-style-type: none"> <li><b>Four F's: Fingers, Flies, Food, Feces</b></li> <li>In order of decreasing severity (less toxin produced): <i>S dysenteriae</i>, <i>S flexneri</i>, <i>S boydii</i>, <i>S sonnei</i></li> <li>Invasion of M cells is key to pathogenicity: organisms that produce little toxin can cause disease</li> </ul>


### *Vibrio cholerae*



Gram  $\ominus$ , flagellated, comma shaped **A**, oxidase  $\oplus$ , grows in alkaline media. Endemic to developing countries. Produces profuse rice-water diarrhea via enterotoxin that permanently activates G<sub>s</sub>,  $\uparrow$  cAMP. Sensitive to stomach acid (acid labile); requires large inoculum (high ID<sub>50</sub>) unless host has  $\downarrow$  gastric acidity. Transmitted via ingestion of contaminated water or uncooked food (eg, raw shellfish). Prompt oral rehydration is necessary.


### *Yersinia enterocolitica*

Gram  $\ominus$  rod. Usually transmitted from pet feces (eg, puppies), contaminated milk, or pork. Causes acute diarrhea or pseudoappendicitis (right lower abdominal pain due to mesenteric adenitis and/or terminal ileitis).

**Helicobacter pylori**

Curved, flagellated (motile), gram  $\ominus$  rod **A** that is **triple**  $\oplus$ : catalase  $\oplus$ , oxidase  $\oplus$ , and urease  $\oplus$  (can use urea breath test or fecal antigen test for diagnosis). Urease produces ammonia, creating an alkaline environment, which helps *H pylori* survive in acidic mucosa. Colonizes mainly antrum of stomach; causes gastritis and peptic ulcers (especially duodenal). Risk factor for peptic ulcer disease, gastric adenocarcinoma, and MALT lymphoma.

Most common initial treatment is **triple** therapy: **A**moxicillin (metronidazole if penicillin allergy) + **C**larithromycin + **P**roton pump inhibitor; **A**ntibiotics **C**ure **P**ylori.

**Spirochetes**

Spiral-shaped bacteria **A** with axial filaments.

Includes *Borrelia* (big size), *Leptospira*, and *Treponema*. Only *Borrelia* can be visualized using aniline dyes (Wright or Giemsa stain) in light microscopy due to size. *Treponema* is visualized by dark-field microscopy or direct fluorescent antibody (DFA) microscopy.

**BLT.**

*Borrelia* is **B**ig.

**Leptospira interrogans**

Spirochete with hook-shaped ends found in water contaminated with animal urine.

**Leptospirosis**—flu-like symptoms, myalgias (classically of calves), jaundice, photophobia with conjunctival suffusion (erythema without exudate). Prevalent among surfers and in tropics (eg, Hawaii).

**Weil disease** (icterohemorrhagic leptospirosis)—severe form with jaundice and azotemia from liver and kidney dysfunction, fever, hemorrhage, and anemia.

**Lyme disease**

Caused by *Borrelia burgdorferi*, which is transmitted by the *Ixodes* deer tick **A** (also vector for *Anaplasma* spp. and protozoa *Babesia*). Natural reservoir is the mouse (and important to tick life cycle).

Common in northeastern United States. Stage 1—early localized: erythema migrans (typical “bull’s-eye” configuration **B** is pathognomonic but not always present), flu-like symptoms.

Stage 2—early disseminated: secondary lesions, carditis, AV block, facial nerve (Bell) palsy, migratory myalgias/transient arthritis.

Stage 3—late disseminated: encephalopathies, chronic arthritis.

A Key **L**yme pie to the **F**ACE:

**F**acial nerve palsy (typically bilateral)

**A**rthritis

**C**ardiac block

**E**rythema migrans

Treatment: doxycycline (1st line); amoxicillin and cefuroxime in pregnant women and children.



**Syphilis**

Caused by spirochete *Treponema pallidum*.

**Primary syphilis**

Localized disease presenting with **painless chancre** **A**. If available, use dark-field microscopy to visualize treponemes in fluid from chancre **B**. VDRL ⊕ in ~ 80%.

**Secondary syphilis**

Disseminated disease with constitutional symptoms, maculopapular rash **C** (including palms **D** and soles), condylomata lata **E** (smooth, moist, painless, wart-like white lesions on genitals), lymphadenopathy, patchy hair loss; also confirmable with dark-field microscopy. Serologic testing: VDRL/RPR (nonspecific), confirm diagnosis with specific test (eg, FTA-ABS). **Secondary syphilis = Systemic**. Latent syphilis (⊕ serology without symptoms) may follow.

**Tertiary syphilis**

Gummas **F** (chronic granulomas), aortitis (vasa vasorum destruction), neurosyphilis (tabes dorsalis, “general paresis”), Argyll Robertson pupil (constricts with accommodation but is not reactive to light; also called “prostitute’s pupil” since it accommodates but does not react). Signs: broad-based ataxia, ⊕ Romberg, Charcot joint, stroke without hypertension. For neurosyphilis: test spinal fluid with VDRL, FTA-ABS, and PCR.

**Congenital syphilis**

Presents with facial abnormalities such as rhagades (linear scars at angle of mouth, black arrow in **G**), snuffles (nasal discharge, red arrow in **G**), saddle nose, notched (Hutchinson) teeth **H**, mulberry molars, and short maxilla; saber shins; CN VIII deafness. To prevent, treat mother early in pregnancy, as placental transmission typically occurs after first trimester.

**VDRL false positives**

VDRL detects nonspecific antibody that reacts with beef cardiolipin. Quantitative, inexpensive, and widely available test for syphilis (sensitive but not specific).

False-positive results on **VDRL** with:  
**V**iral infection (eg, EBV, hepatitis)  
**D**rugs  
**R**heumatic fever  
**L**upus and leprosy


**Jarisch-Herxheimer reaction**

Flu-like syndrome (fever, chills, headache, myalgia) after antibiotics are started; due to killed bacteria (usually spirochetes) releasing toxins.

**Zoonotic bacteria** Zoonosis: infectious disease transmitted between animals and humans.

SPECIES	DISEASE	TRANSMISSION AND SOURCE
<i>Anaplasma</i> spp.	Anaplasmosis	<i>Ixodes</i> ticks (live on deer and mice)
<i>Bartonella</i> spp.	Cat scratch disease, bacillary angiomatosis	Cat scratch
<i>Borrelia burgdorferi</i>	Lyme disease	<i>Ixodes</i> ticks (live on deer and mice)
<i>Borrelia recurrentis</i>	<b>Relapsing</b> fever	Louse (recurrent due to variable surface antigens)
<i>Brucella</i> spp.	Brucellosis/ <b>undulant</b> fever	<b>Un</b> pasteurized dairy
<i>Campylobacter</i>	Bloody diarrhea	Feces from infected pets/animals; contaminated meats/foods/hands
<i>Chlamydophila psittaci</i>	Psittacosis	Parrots, other birds
<i>Coxiella burnetii</i>	Q fever	Aerosols of cattle/sheep amniotic fluid
<i>Ehrlichia chaffeensis</i>	Ehrlichiosis	<i>Amblyomma</i> (Lone Star tick)
<i>Francisella tularensis</i>	Tularemia	Ticks, rabbits, deer flies
<i>Leptospira</i> spp.	Leptospirosis	Animal urine in water; recreational water use
<i>Mycobacterium leprae</i>	Leprosy	Humans with lepromatous leprosy; armadillo (rare)
<i>Pasteurella multocida</i>	Cellulitis, osteomyelitis	Animal bite, cats, dogs
<i>Rickettsia prowazekii</i>	Epidemic typhus	Human to human via human body louse
<i>Rickettsia rickettsii</i>	Rocky Mountain spotted fever	<i>Dermacentor</i> (dog tick)
<i>Rickettsia typhi</i>	Endemic typhus	Fleas
<i>Salmonella</i> spp. (except <i>S typhi</i> )	Diarrhea (which may be bloody), vomiting, fever, abdominal cramps	Reptiles and poultry
<i>Yersinia pestis</i>	Plague	Fleas (rats and prairie dogs are reservoirs)

### ***Gardnerella vaginalis***



A pleomorphic, gram-variable rod involved in bacterial vaginosis. Presents as a gray vaginal discharge with a **fishy** smell; nonpainful (vs vaginitis). Associated with sexual activity, but not sexually transmitted. Bacterial vaginosis is also characterized by overgrowth of certain anaerobic bacteria in vagina. **Clue** cells (vaginal epithelial cells covered with *Gardnerella*) have stippled appearance along outer margin (arrow in **A**).

Treatment: metronidazole or clindamycin.

I don't have a **clue** why I smell **fish** in the **vagina garden**!

Amine whiff test—mixing discharge with 10% KOH enhances fishy odor.

**Rickettsial diseases and vector-borne illnesses**

Treatment: doxycycline (caution during pregnancy; alternative is chloramphenicol).

## RASH COMMON

**Rocky Mountain spotted fever**

*Rickettsia rickettsii*, vector is tick. Despite its name, disease occurs primarily in the South Atlantic states, especially North Carolina. Rash typically starts at wrists **A** and ankles and then spreads to trunk, palms, and soles.

Classic triad—headache, fever, rash (vasculitis). **Palms** and **soles** rash is seen in **C**oxsackievirus **A** infection (hand, foot, and mouth disease), **R**ocky Mountain spotted fever, and 2° **S**yphilis (you drive **CARS** using your **palms** and **soles**).

**Typhus**

Endemic (fleas)—*R typhi*.  
Epidemic (human body louse)—*R prowazekii*.  
Rash starts centrally and spreads out, sparing palms and soles.

*Rickettsii* on the w**R**ists, **T**yphus on the **T**runk.

## RASH RARE

**Ehrlichiosis**

*Ehrlichia*, vector is tick. **M**onocytes with morulae **B** (mul**berry**-like inclusions) in cytoplasm.

**MEGA berry**—  
**M**onocytes = **E**hrlichiosis  
**G**ranulocytes = **A**naplasmosis


**Anaplasmosis**

*Anaplasma*, vector is tick. **G**ranulocytes with morulae **C** in cytoplasm.

**Q fever**

*Coxiella burnetii*, no arthropod vector. Spores inhaled as aerosols from cattle/sheep amniotic fluid. Presents as pneumonia. Common cause of culture ⊖ endocarditis.

**Q** fever is **Q**ueer because it has no rash or vector and its causative organism can survive outside in its endospore form. Not in the *Rickettsia* genus, but closely related.



**Chlamydiae**

Chlamydiae cannot make their own ATP. They are obligate intracellular organisms that cause mucosal infections. 2 forms:

- **E**lementary body (small, dense) is “**E**nfectious” and **E**nters cell via **E**ndocytosis; transforms into reticulate body.
- **R**eticulate body **R**eplicates in cell by fission; **R**eorganizes into elementary bodies.

*Chlamydia trachomatis* causes reactive arthritis (Reiter syndrome), follicular conjunctivitis **A**, nongonococcal urethritis, and PID.

*Chlamydophila pneumoniae* and *Chlamydophila psittaci* cause atypical pneumonia; transmitted by aerosol.

Treatment: azithromycin (favored because one-time treatment) or doxycycline (+ ceftriaxone for possible concomitant gonorrhea).

*Chlamys* = cloak (intracellular).

*C psittaci*—has an avian reservoir (**p**arrots), causes atypical **p**neumonia.

Lab diagnosis: PCR, nucleic acid amplification test. Cytoplasmic inclusions (reticulate bodies) seen on Giemsa or fluorescent antibody-stained smear.

The chlamydial cell wall lacks classic peptidoglycan (due to reduced muramic acid), rendering  $\beta$ -lactam antibiotics ineffective.

**Chlamydia trachomatis serotypes****Types A, B, and C**

Chronic infection, cause blindness due to follicular conjunctivitis in Africa.

**ABC** = **A**frica, **B**lindness, **C**hronic infection.

**Types D–K**


Urethritis/PID, ectopic pregnancy, neonatal pneumonia (staccato cough) with eosinophilia, neonatal conjunctivitis (1–2 weeks after birth).

D–K = everything else.

Neonatal disease can be acquired during passage through infected birth canal.

**Types L1, L2, and L3**

**Lymphogranuloma venereum**—small, painless ulcers on genitals → swollen, painful inguinal lymph nodes that ulcerate (buboes). Treat with doxycycline.

**Mycoplasma pneumoniae**

Classic cause of atypical “walking” pneumonia (insidious onset, headache, nonproductive cough, patchy or diffuse interstitial infiltrate). X-ray looks worse than patient. High titer of **cold** agglutinins (IgM), which can agglutinate or lyse RBCs. Grown on Eaton agar.

Treatment: macrolides, doxycycline, or fluoroquinolone (penicillin ineffective since *Mycoplasma* have no cell wall).

No cell wall. Not seen on Gram stain.

Pleomorphic **A**.

Bacterial membrane contains sterols for stability.

Mycoplasma pneumoniae is more common in patients < 30 years old.

Frequent outbreaks in military recruits and prisons.

*Mycoplasma* gets **cold** without a **coat** (cell wall).

## ▶ MICROBIOLOGY—MYCOLOGY





**Systemic mycoses**

All of the following can cause pneumonia and can disseminate.

All are caused by dimorphic fungi: **cold** (20°C) = **mold**; **heat** (37°C) = **yeast**. Only exception is *Coccidioides*, which is a spherule (not yeast) in tissue.

Systemic mycoses can form granulomas (like TB); cannot be transmitted person-to-person (unlike TB).

Treatment: fluconazole or itraconazole for **local** infection; amphotericin B for **systemic** infection.

DISEASE	ENDEMIC LOCATION	PATHOLOGIC FEATURES	UNIQUE SIGNS/SYMPTOMS	NOTES
<b>Histoplasmosis</b> 	Mississippi and Ohio River Valleys	Macrophage filled with <i>Histoplasma</i> (smaller than RBC) <b>A</b>	Palatal/tongue ulcers, splenomegaly	<b>Histo hides</b> (within macrophages) Bird (eg, starlings) or bat droppings Diagnosis via urine/serum antigen
<b>Blastomycosis</b> 	Eastern and Central US	Broad-based budding of <i>Blastomyces</i> (same size as RBC) <b>B</b>	Inflammatory lung disease, can disseminate to skin/bone Verrucous skin lesions can simulate SCC Forms granulomatous nodules	<b>Blasto buds broadly</b>
<b>Coccidioidomycosis</b> 	Southwestern US, California	Spherule (much larger than RBC) filled with endospores of <i>Coccidioides</i> <b>C</b>	Disseminates to skin/bone Erythema nodosum (desert bumps) or multiforme Arthralgias (desert rheumatism) Can cause meningitis	
<b>Para-coccidioidomycosis</b> 	<b>Latin America</b>	Budding yeast of <i>Paracoccidioides</i> with “ <b>captain’s wheel</b> ” formation (much larger than RBC) <b>D</b>	Similar to Coccidioidomycosis, males > females	<b>Paracoccidio parasails</b> with the <b>captain’s wheel</b> all the way to <b>Latin America</b>



**Cutaneous mycoses**

<b>Tinea (dermatophytes)</b>	Tinea is the clinical name given to dermatophyte (cutaneous fungal) infections. Dermatophytes include <i>Microsporum</i> , <i>Trichophyton</i> , and <i>Epidermophyton</i> . Branching septate hyphae visible on KOH preparation with blue fungal stain <b>A</b> . Associated with pruritus.
<b>Tinea capitis</b>	Occurs on head, scalp. Associated with lymphadenopathy, alopecia, scaling <b>B</b> .
<b>Tinea corporis</b>	Occurs on torso. Characterized by erythematous scaling rings (“ringworm”) and central clearing <b>C</b> . Can be acquired from contact with an infected cat or dog.
<b>Tinea cruris</b>	Occurs in inguinal area <b>D</b> . Often does not show the central clearing seen in tinea corporis.
<b>Tinea pedis</b>	Three varieties: <ul style="list-style-type: none"> <li>▪ Interdigital <b>E</b>; most common</li> <li>▪ Moccasin distribution <b>F</b></li> <li>▪ Vesicular type</li> </ul>
<b>Tinea unguium</b>	Onychomycosis; occurs on nails.
<b>Tinea (pityriasis) versicolor</b>	Caused by <i>Malassezia</i> spp. ( <i>Pityrosporum</i> spp.), a yeast-like fungus (not a dermatophyte despite being called tinea). Degradation of lipids produces acids that damage melanocytes and cause hypopigmented <b>G</b> , hyperpigmented, and/or pink patches. Less pruritic than dermatophytes. Can occur any time of year, but more common in summer (hot, humid weather). “Spaghetti and meatballs” appearance on microscopy <b>H</b> . Treatment: selenium sulfide, topical and/or oral antifungal medications.



**Opportunistic fungal infections*****Candida albicans***

*alba* = white. Dimorphic; forms pseudohyphae and budding yeasts at 20°C **A**, germ tubes at 37°C **B**.

Systemic or superficial fungal infection. Causes oral **C** and esophageal thrush in immunocompromised (neonates, steroids, diabetes, AIDS), vulvovaginitis (diabetes, use of antibiotics), diaper rash, endocarditis (IV drug users), disseminated candidiasis (especially in neutropenic patients), chronic mucocutaneous candidiasis.

Treatment: oral fluconazole/topical azole for vaginal; nystatin, fluconazole, or caspofungin for oral/esophageal; fluconazole, caspofungin, or amphotericin B for systemic.

***Aspergillus fumigatus***

Septate hyphae that branch at 45° Acute Angle **D**. Produces conidia in radiating chains at end of conidiophore **E**.

Causes invasive aspergillosis in immunocompromised, patients with chronic granulomatous disease. Can cause aspergillomas in pre-existing lung cavities, especially after TB infection.

Some species of *Aspergillus* produce **A**flatoxins (associated with hepatocellular carcinoma).

**Allergic bronchopulmonary aspergillosis (ABPA)**: hypersensitivity response associated with asthma and cystic fibrosis; may cause bronchiectasis and eosinophilia.

***Cryptococcus neoformans***

5–10 μm with narrow budding. Heavily encapsulated yeast. Not dimorphic.

Found in soil, pigeon droppings. Acquired through inhalation with hematogenous dissemination to meninges. Culture on Sabouraud agar. Highlighted with India ink (clear halo **F**) and mucicarmine (red inner capsule **G**). Latex agglutination test detects polysaccharide capsular antigen and is more specific.

Causes cryptococcosis, cryptococcal meningitis, cryptococcal encephalitis (“soap bubble” lesions in brain), primarily in immunocompromised.

Treatment: amphotericin B + flucytosine followed by fluconazole for cryptococcal meningitis.


***Mucor and Rhizopus* spp.**

Irregular, broad, nonseptate hyphae branching at wide angles **H**.

Mucormycosis. Causes disease mostly in ketoacidotic diabetic and/or neutropenic patients (eg, leukemia). Fungi proliferate in blood vessel walls, penetrate cribriform plate, and enter brain.

Rhinocerebral, frontal lobe abscess; cavernous sinus thrombosis. Headache, facial pain, black necrotic eschar on face; may have cranial nerve involvement.


Treatment: surgical debridement, amphotericin B.



***Pneumocystis jirovecii***

Causes *Pneumocystis* pneumonia (PCP), a diffuse interstitial pneumonia **A**. Yeast-like fungus (originally classified as protozoan). Inhaled. Most infections are asymptomatic. Immunosuppression (eg, AIDS) predisposes to disease. Diffuse, bilateral ground-glass opacities on CXR/CT **B**. Diagnosed by lung biopsy or lavage. Disc-shaped yeast seen on methenamine silver stain of lung tissue **C**.

Treatment/prophylaxis: TMP-SMX, pentamidine, dapsone (prophylaxis only), atovaquone. Start prophylaxis when CD4+ count drops to  $< 200$  cells/mm<sup>3</sup> in HIV patients.

***Sporothrix schenckii***

Sporotrichosis. Dimorphic, **cigar**-shaped budding yeast that grows in branching hyphae with **rosettes** of conidia; lives on vegetation. When spores are traumatically introduced into the skin, typically by a thorn (“**rose gardener’s** disease”), causes local pustule or ulcer **A** with nodules along draining lymphatics (ascending lymphangitis). Disseminated disease possible in immunocompromised host.

Treatment: itraconazole or **pot**assium iodide.

Think of a **rose gardener** who smokes a **cigar** and **pot**.

## ▶ MICROBIOLOGY—PARASITOLOGY


## Protozoa—gastrointestinal infections

ORGANISM	DISEASE	TRANSMISSION	DIAGNOSIS	TREATMENT
<i>Giardia lamblia</i>	<b>Giardiasis</b> —bloating, flatulence, foul-smelling, fatty diarrhea (often seen in campers/hikers)—think <b>fat-rich Ghirardelli</b> chocolates for <b>fatty</b> stools of <b>Giardia</b>	Cysts in water	Multinucleated trophozoites <b>A</b> or cysts <b>B</b> in stool, antigen detection	Metronidazole
<i>Entamoeba histolytica</i>	<b>Amebiasis</b> —bloody diarrhea (dysentery), liver abscess (“anchovy paste” exudate), RUQ pain; histology shows flask-shaped ulcer	Cysts in water	Serology and/or trophozoites (with engulfed RBCs <b>C</b> in the cytoplasm) or cysts with up to 4 nuclei in stool <b>D</b> ; <b>Entamoeba Eats Erythrocytes</b> , antigen detection	Metronidazole; paromomycin or iodoquinol for asymptomatic cyst passers
<i>Cryptosporidium</i>	Severe diarrhea in AIDS Mild disease (watery diarrhea) in immunocompetent hosts	Oocysts in water	Oocysts on acid-fast stain <b>E</b> , antigen detection	Prevention (by filtering city water supplies); nitazoxanide in immunocompetent hosts




## Protozoa—CNS infections

ORGANISM	DISEASE	TRANSMISSION	DIAGNOSIS	TREATMENT
<i>Toxoplasma gondii</i>	Congenital toxoplasmosis = classic triad of chorioretinitis, hydrocephalus, and intracranial calcifications; reactivation in AIDS → brain abscesses usually seen as multiple ring-enhancing lesions on MRI <b>A</b>	Cysts in meat (most common); oocysts in cat feces; crosses placenta (pregnant women should avoid cats)	Serology, biopsy (tachyzoite) <b>B</b>	Sulfadiazine + pyrimethamine
<i>Naegleria fowleri</i>	Rapidly fatal meningoencephalitis	Swimming in <b>freshwater</b> lakes (think <b>Nalgene</b> bottle filled with <b>fresh water</b> containing <b>Naegleria</b> ); enters via cribriform plate	Amoebas in spinal fluid <b>C</b>	Amphotericin B has been effective for a few survivors
<i>Trypanosoma brucei</i>	<b>African sleeping sickness</b> —enlarged lymph nodes, recurring fever (due to antigenic variation), somnolence, coma Two subspecies: <i>Trypanosoma brucei rhodesiense</i> , <i>Trypanosoma brucei gambiense</i>	Tsetse fly, a painful bite	Trypomastigote in blood smear <b>D</b>	<b>Suramin</b> for blood-borne disease or <b>melarsoprol</b> for CNS penetration (“ <b>I sure am mellow</b> when I’m <b>sleeping</b> ”; remember <b>melatonin</b> helps with <b>sleep</b> )






## Protozoa—hematologic infections

ORGANISM	DISEASE	TRANSMISSION	DIAGNOSIS	TREATMENT
<b><i>Plasmodium</i></b> <i>P vivax/ovale</i> <i>P falciparum</i> <i>P malariae</i>	<b>Malaria</b> —fever, headache, anemia, splenomegaly <i>P vivax/ovale</i> —48-hr cycle (tertian; includes fever on first day and third day, thus fevers are actually 48 hr apart); dormant form (hypnozoite) in liver <i>P falciparum</i> —severe; irregular fever patterns; parasitized RBCs occlude capillaries in brain (cerebral malaria), kidneys, lungs <i>P malariae</i> —72-hr cycle (quartan)	<i>Anopheles</i> mosquito	Blood smear: trophozoite ring form within RBC <b>A</b> , schizont containing merozoites; red granules (Schüffner stippling) <b>B</b> throughout RBC cytoplasm seen with <i>P vivax/ovale</i>	Chloroquine (for sensitive species), which blocks <i>Plasmodium</i> heme polymerase; if resistant, use mefloquine or atovaquone/proguanil If life-threatening, use intravenous quinidine or artesunate (test for G6PD deficiency) For <i>P vivax/ovale</i> , add primaquine for hypnozoite (test for G6PD deficiency)
<b><i>Babesia</i></b>	<b>Babesiosis</b> —fever and hemolytic anemia; predominantly in northeastern United States; asplenia ↑ risk of severe disease	<i>Ixodes</i> tick (same as <i>Borrelia burgdorferi</i> of Lyme disease; may often coinfect humans)	Blood smear: ring form <b>C1</b> , “Maltese cross” <b>C2</b> ; PCR	Atovaquone + azithromycin



## Protozoa—others

ORGANISM	DISEASE	TRANSMISSION	DIAGNOSIS	TREATMENT
<b>Visceral infections</b>				
<b><i>Trypanosoma cruzi</i></b> 	<b>Chagas disease</b> —dilated cardiomyopathy with apical atrophy, megacolon, megaesophagus; predominantly in South America Unilateral periorbital swelling (Romaña sign) characteristic of acute stage	Reduviid bug (“kissing bug”) feces, deposited in a painless bite (much like a <b>kiss</b> )	Trypomastigote in blood smear <b>A</b>	<b>Benznidazole</b> or nifurtimox; <b>Cruzing</b> in my <b>Benz</b> , with a <b>fur</b> coat on
<b><i>Leishmania donovani</i></b> 	<b>Visceral leishmaniasis (kala-azar)</b> —spiking fevers, hepatosplenomegaly, pancytopenia <b>Cutaneous leishmaniasis</b> —skin ulcers	Sandfly	Macrophages containing amastigotes <b>B</b>	Amphotericin B, sodium stibogluconate
<b>Sexually transmitted infections</b>				
<b><i>Trichomonas vaginalis</i></b> 	<b>Vaginitis</b> —foul-smelling, greenish discharge; itching and burning; do not confuse with <i>Gardnerella vaginalis</i> , a gram-variable bacterium associated with bacterial vaginosis	Sexual (cannot exist outside human because it cannot form cysts)	Trophozoites (motile) <b>C</b> on wet mount; “strawberry cervix”	Metronidazole for patient and partner (prophylaxis)

## Nematode routes of infection

Ingested—*Enterobius*, *Ascaris*, *Toxocara*, *Trichinella*  
 Cutaneous—*Strongyloides*, *Ancylostoma*, *Necator*  
 Bites—*Loa loa*, *Onchocerca volvulus*, *Wuchereria bancrofti*

You’ll get sick if you **EATT** these!

These get into your feet from the **SAN**d.

Lay **LOW** to avoid getting bitten.

## Immune response to helminths

Eosinophils act by type I and type II hypersensitivity reactions in responding to helminths. Type I—neutralization of histamine and leukotrienes. Type II—eosinophils attach to surface of helminths via IgE and release cytotoxins (eg, major basic protein) contained in their granules.

**Nematodes (roundworms)**

ORGANISM	DISEASE	TRANSMISSION	TREATMENT
<b>Intestinal</b>			
<i>Enterobius vermicularis</i> (pinworm)	Causes anal pruritus (diagnosed by seeing egg <b>A</b> via the tape test)	Fecal-oral	Pyrantel pamoate or bendazoles (because worms are <b>bendy</b> )
<i>Ascaris lumbricoides</i> (giant roundworm)	May cause obstruction at ileocecal valve, biliary obstruction, intestinal perforation, migrates from nose/mouth	Fecal-oral; knobby-coated, oval eggs seen in feces under microscope <b>B</b>	Bendazoles
<i>Strongyloides stercoralis</i> (threadworm)	Causes vomiting, diarrhea, epigastric pain (may mimic peptic ulcer)	Larvae in soil penetrate skin; rhabditiform larvae seen in feces under microscope	Ivermectin or bendazoles
<i>Ancylostoma duodenale</i> , <i>Necator americanus</i> (hookworms)	Cause anemia by sucking blood from intestinal wall <b>Cutaneous larva migrans</b> —pruritic, serpiginous rash from walking barefoot on contaminated beach	Larvae penetrate skin	Bendazoles or pyrantel pamoate
<i>Trichinella spiralis</i>	Larvae enter bloodstream, encyst in striated muscle → muscle inflammation <b>Trichinosis</b> —fever, vomiting, nausea, periorbital edema, myalgia	Undercooked meat (especially pork); fecal-oral (less likely)	Bendazoles
<i>Trichuris trichiura</i> (whipworm)	Often asymptomatic; loose stools/anemia, rectal prolapse in children (heavy infection)	Fecal-oral	Bendazoles
<b>Tissue</b>			
<i>Toxocara canis</i>	<b>Visceral larva migrans</b> —nematodes migrate to blood through intestinal wall → inflammation and damage. Often affects heart (myocarditis), liver, eyes (visual impairment, blindness), and CNS (seizures, coma)	Fecal-oral	Bendazoles
<i>Onchocerca volvulus</i>	Skin changes, loss of elastic fibers, and river blindness ( <b>black</b> flies, <b>black</b> skin nodules, “ <b>black</b> sight”); allergic reaction to microfilaria possible	Female blackfly	Ivermectin ( <b>iver</b> mectin for <b>river</b> blindness)
<i>Loa loa</i>	Swelling in skin, worm in conjunctiva	Deer fly, horse fly, mango fly	Diethylcarbamazine
<i>Wuchereria bancrofti</i>	<b>Lymphatic filariasis (elephantiasis)</b> —worms invade lymph nodes → inflammation → lymphedema <b>C</b> ; symptom onset after 9 mo–1 yr	Female mosquito	Diethylcarbamazine







**Cestodes (tapeworms)**

ORGANISM	DISEASE	TRANSMISSION	TREATMENT
<i>Taenia solium</i> <b>A</b>	Intestinal tapeworm	Ingestion of larvae encysted in undercooked pork	Praziquantel
	Cysticercosis, neurocysticercosis <b>B</b>	Ingestion of eggs in food contaminated with human feces	Praziquantel; albendazole for neurocysticercosis
<i>Diphyllobothrium latum</i>	Vitamin B <sub>12</sub> deficiency (tapeworm competes for B <sub>12</sub> in intestine) → megaloblastic anemia	Ingestion of larvae in raw freshwater fish	Praziquantel
<i>Echinococcus granulosus</i> <b>C</b>	Hydatid cysts (“eggshell calcification” <b>D</b> ) in liver <b>E</b> ; cyst rupture can cause anaphylaxis	Ingestion of eggs in food contaminated with dog feces Sheep are an intermediate host	Albendazole

**Trematodes (flukes)**

ORGANISM	DISEASE	TRANSMISSION	TREATMENT
<i>Schistosoma</i>	Liver and spleen enlargement ( <i>S. mansoni</i> , egg with lateral spine <b>A</b> ), fibrosis, inflammation, portal hypertension	Snails are host; cercariae penetrate skin of humans	Praziquantel
	Chronic infection with <i>S. haematobium</i> (egg with terminal spine <b>B</b> ) can lead to squamous cell carcinoma of the bladder (painless hematuria) and pulmonary hypertension		
<i>Clonorchis sinensis</i>	Biliary tract inflammation → pigmented gallstones Associated with cholangiocarcinoma	Undercooked fish	Praziquantel




**Ectoparasites*****Sarcoptes scabiei***

Mite burrow into stratum corneum and cause **scabies**—pruritus (worse at night) and serpiginous burrows (lines) in webspace of hands and feet **A**.

Common in children, crowded populations (jails, nursing homes); transmission through skin-to-skin contact (most common) or via fomites.

Treatment: permethrin cream, washing/drying all clothing/bedding, treat close contacts.

***Pediculus humanus/Phthirus pubis***

Blood-sucking lice that cause intense pruritus with associated excoriations, commonly on scalp and neck (head lice) or waistband and axilla (body lice).


Can transmit *Rickettsia prowazekii* (epidemic typhus), *Borrelia recurrentis* (relapsing fever), *Bartonella quintana* (trench fever).

Treatment includes pyrethroids, malathion, or ivermectin lotion, and nit **B** combing. Children with head lice can be treated at home without interrupting school attendance.

**Parasite hints**

ASSOCIATIONS	ORGANISM
Biliary tract disease, cholangiocarcinoma	<i>Clonorchis sinensis</i>
Brain cysts, seizures	<i>Taenia solium</i> (neurocysticercosis)
Hematuria, squamous cell bladder cancer	<i>Schistosoma haematobium</i>
Liver (hydatid) cysts	<i>Echinococcus granulosus</i>
Microcytic anemia	<i>Ancylostoma</i> , <i>Necator</i>
Myalgias, periorbital edema	<i>Trichinella spiralis</i>
Perianal pruritus	<i>Enterobius</i>
Portal hypertension	<i>Schistosoma mansoni</i> , <i>Schistosoma japonicum</i>
Vitamin B <sub>12</sub> deficiency	<i>Diphyllobothrium latum</i>

## ► MICROBIOLOGY—VIROLOGY

**Viral structure—  
general features****Viral genetics****Recombination**

Exchange of genes between 2 chromosomes by crossing over within regions of significant base sequence homology.

**Reassortment**

When viruses with segmented genomes (eg, influenza virus) exchange genetic material. For example, the 2009 novel H1N1 influenza A pandemic emerged via complex viral reassortment of genes from human, swine, and avian viruses. Has potential to cause antigenic shift.

**Complementation**

When 1 of 2 viruses that infect the cell has a mutation that results in a nonfunctional protein, the nonmutated virus “complements” the mutated one by making a functional protein that serves both viruses. For example, hepatitis D virus requires the presence of replicating hepatitis B virus to supply HBsAg, the envelope protein for HDV.

**Phenotypic mixing**

Occurs with simultaneous infection of a cell with 2 viruses. Genome of virus A can be partially or completely coated (forming pseudovirion) with the surface proteins of virus B. Type B protein coat determines the tropism (infectivity) of the hybrid virus. However, the progeny from this infection have a type A coat that is encoded by its type A genetic material.

**Viral vaccines****Live attenuated  
vaccines**

MMR, Yellow fever, Rotavirus, Influenza (intranasal), Chickenpox (VZV), Smallpox, Sabin polio virus.

“**M**usic and **LYRIC**SS are best enjoyed **Live**.”  
MMR = measles, mumps, rubella; live attenuated vaccine that can be given to HIV ⊕ patients who do not show signs of immunodeficiency.

**Killed**

Rabies, Influenza (injected), Salk Polio, and HAV vaccines. Killed/inactivated vaccines induce only humoral immunity but are stable.

Sal**K** = **Killed**.  
**RIP** Always.

**Subunit**

HBV (antigen = HBsAg), HPV (types 6, 11, 16, and 18).


**DNA viral genomes**

All DNA viruses except the Parvoviridae are dsDNA.  
All are linear except papilloma-, polyoma-, and hepadnaviruses (circular).

All are dsDNA (like our cells), except “**part-of-a-virus**” (**parvovirus**) is ssDNA.  
*Parvus* = small.

<b>RNA viral genomes</b>	All RNA viruses except Reoviridae are ssRNA. ⊕ stranded RNA viruses: I went to a <b>retro</b> ( <b>retrovirus</b> ) <b>toga</b> ( <b>togavirus</b> ) party, where I drank <b>flavored</b> ( <b>flavivirus</b> ) <b>Corona</b> ( <b>coronavirus</b> ) and ate <b>hippie</b> ( <b>hepevirus</b> ) <b>California</b> ( <b>calicivirus</b> ) <b>pickles</b> ( <b>picornavirus</b> ).	All are ssRNA (like our mRNA), except “ <b>repeato-virus</b> ” ( <b>reovirus</b> ) is dsRNA.
<b>Naked viral genome infectivity</b>	Purified nucleic acids of most dsDNA (except poxviruses and HBV) and ⊕ strand ssRNA (≈ mRNA) viruses are infectious. Naked nucleic acids of ⊖ strand ssRNA and dsRNA viruses are not infectious. They require polymerases contained in the complete virion.	
<b>Viral replication</b>		
<b>DNA viruses</b>	All replicate in the nucleus (except poxvirus). “ <b>Pox</b> is out of the <b>box</b> (nucleus).”	
<b>RNA viruses</b>	All replicate in the cytoplasm (except influenza virus and retroviruses).	
<b>Viral envelopes</b>	<p><b>Naked</b> (nonenveloped) viruses include <b>Papillomavirus</b>, <b>Adenovirus</b>, <b>Parvovirus</b>, <b>Polyomavirus</b>, <b>Calicivirus</b>, <b>Picornavirus</b>, <b>Reovirus</b>, and <b>Hepevirus</b>.</p> <p>Generally, enveloped viruses acquire their envelopes from plasma membrane when they exit from cell. Exceptions include herpesviruses, which acquire envelopes from nuclear membrane.</p>	<p>Give <b>PAPP</b> smears and <b>CPR</b> to a <b>naked hippie</b> (<b>hepevirus</b>).</p> <p>DNA = <b>PAPP</b>; RNA = <b>CPR</b> and <b>hepevirus</b>.</p>
<b>DNA virus characteristics</b>	Some general rules—all DNA viruses:	
	<b>GENERAL RULE</b>	<b>COMMENTS</b>
	Are <b>HHAPPPPy</b> viruses	<b>H</b> epadna, <b>H</b> erpes, <b>A</b> deno, <b>P</b> ox, <b>P</b> arvo, <b>P</b> apilloma, <b>P</b> olyoma.
	Are double stranded	Except parvo (single stranded).
	Have linear genomes	Except papilloma and polyoma (circular, supercoiled) and hepadna (circular, incomplete).
	Are icosahedral	Except pox (complex).
	Replicate in the nucleus	Except pox (carries own DNA-dependent RNA polymerase).

**DNA viruses**


VIRAL FAMILY	ENVELOPE	DNA STRUCTURE	MEDICAL IMPORTANCE
<b>Herpesviruses</b>	Yes	DS and linear	See Herpesviruses entry
<b>Poxvirus</b>	Yes	DS and linear (largest DNA virus)	Smallpox eradicated world wide by use of the live-attenuated vaccine Cowpox (“milkmaid blisters”) <b>Molluscum contagiosum</b> —flesh-colored papule with central umbilication
<b>Hepadnavirus</b>	Yes	Partially DS and circular	HBV: <ul style="list-style-type: none"> <li>▪ Acute or chronic hepatitis</li> <li>▪ Not a retrovirus but has reverse transcriptase</li> </ul>
<b>Adenovirus</b>	No	DS and linear	Febrile pharyngitis <b>A</b> —sore throat Acute hemorrhagic cystitis Pneumonia Conjunctivitis—“pink eye”
			
<b>Papillomavirus</b>	No	DS and circular	HPV—warts (serotypes 1, 2, 6, 11), CIN, cervical cancer (most commonly 16, 18)
<b>Polyomavirus</b>	No	DS and circular	JC virus—progressive multifocal leukoencephalopathy (PML) in HIV BK virus—transplant patients, commonly targets kidney <b>JC: J</b> unky <b>C</b> erebrum; <b>BK: B</b> ad <b>K</b> idney
<b>Parvovirus</b>	No	SS and linear (smallest DNA virus)	B19 virus—aplastic crises in sickle cell disease, “slapped cheek” rash in children (erythema infectiosum, or fifth disease) RBC destruction in fetus leads to hydrops fetalis and death, in adults leads to pure RBC aplasia and rheumatoid arthritis–like symptoms


**Herpesviruses** Enveloped, DS, and linear viruses

VIRUS	ROUTE OF TRANSMISSION	CLINICAL SIGNIFICANCE	NOTES
<b>Herpes simplex virus-1</b>	Respiratory secretions, saliva	Gingivostomatitis, keratoconjunctivitis <b>A</b> , herpes labialis <b>B</b> , herpetic whitlow on finger, temporal lobe encephalitis, esophagitis, erythema multiforme.	Most common cause of sporadic encephalitis, can present as altered mental status, seizures, and/or aphasia.
<b>Herpes simplex virus-2</b>	Sexual contact, perinatal	Herpes genitalis <b>C</b> , neonatal herpes.	Latent in sacral ganglia. Viral meningitis more common with HSV-2 than with HSV-1.
<b>Varicella-Zoster virus (HHV-3)</b>	Respiratory secretions	Varicella-zoster (chickenpox <b>D</b> , shingles <b>E</b> ), encephalitis, pneumonia. Most common complication of shingles is post-herpetic neuralgia.	Latent in dorsal root or trigeminal ganglia; CN V <sub>1</sub> branch involvement can cause herpes zoster ophthalmicus.

**Herpesviruses (continued)**

VIRUS	ROUTE OF TRANSMISSION	CLINICAL SIGNIFICANCE	NOTES
<b>Epstein-Barr virus (HHV-4)</b>	Respiratory secretions, saliva; aka “kissing disease,” (common in teens, young adults)	<b>Mononucleosis</b> —fever, hepatosplenomegaly, pharyngitis, and lymphadenopathy (especially posterior cervical nodes <b>F</b> ). Avoid contact sports until resolution due to risk of splenic rupture. Associated with lymphomas (eg, endemic Burkitt lymphoma), nasopharyngeal carcinoma (especially Asian adults), lymphoproliferative disease in transplant patients.	Infects B cells through CD21. Atypical lymphocytes on peripheral blood smear <b>G</b> —not infected B cells but reactive cytotoxic T cells. ⊕ Monospot test—heterophile antibodies detected by agglutination of sheep or horse RBCs. Use of amoxicillin in mononucleosis can cause characteristic maculopapular rash.
<b>Cytomegalovirus (HHV-5)</b>	Congenital transfusion, sexual contact, saliva, urine, transplant	Mononucleosis (⊖ Monospot) in immunocompetent patients; infection in immunocompromised, especially pneumonia in transplant patients; esophagitis; AIDS <b>retinitis</b> (“ <b>sight</b> omegalovirus”): hemorrhage, cotton-wool exudates, vision loss. Congenital CMV	Infected cells have characteristic “owl eye” inclusions <b>H</b> . Latent in mononuclear cells.
<b>Human herpesviruses 6 and 7</b>	Saliva	Roseola infantum (exanthem subitum): high fevers for several days that can cause seizures, followed by diffuse macular rash <b>I</b> .	<b>Roseola</b> : fever first, <b>Rosie</b> (cheeks) later. HHV-7—less common cause of roseola.
<b>Human herpesvirus 8</b>	Sexual contact	Kaposi sarcoma (neoplasm of endothelial cells). Seen in HIV/AIDS and transplant patients. Dark/violaceous plaques or nodules <b>J</b> representing vascular proliferations.	Can also affect GI tract and lungs.



**HSV identification**

Viral culture for skin/genitalia.

CSF PCR for herpes encephalitis.

Tzanck test—a smear of an opened skin vesicle to detect multinucleated giant cells **A** commonly seen in HSV-1, HSV-2, and VZV infection. PCR of skin lesions is currently test of choice.

Intranuclear eosinophilic Cowdry A inclusions also seen with HSV-1, HSV-2, VZV.

**Tzanck** heavens I do not have herpes.

**Receptors used by viruses**

VIRUS	RECEPTORS
CMV	Integrins (heparan sulfate)
EBV	CD21
HIV	CD4, CXCR4, CCR5
Parvovirus B19	P antigen on RBCs
Rabies	Nicotinic AChR
Rhinovirus	ICAM-1

## RNA viruses

VIRAL FAMILY	ENVELOPE	RNA STRUCTURE	CAPSID SYMMETRY	MEDICAL IMPORTANCE
<b>Reoviruses</b>	No	DS linear 10–12 segments	Icosahedral (double)	Coltivirus <sup>a</sup> —Colorado tick fever Rotavirus—cause of fatal diarrhea in children
<b>Picornaviruses</b>	No	SS ⊕ linear	Icosahedral	<b>P</b> oliovirus—polio-Salk/Sabin vaccines—IPV/OPV <b>E</b> chovirus—aseptic meningitis <b>R</b> hinovirus—“common cold” <b>C</b> oxsackievirus—aseptic meningitis; herpangina (mouth blisters, fever); hand, foot, and mouth disease; myocarditis; pericarditis <b>H</b> AV—acute viral hepatitis <b>PERCH</b>
<b>Hepevirus</b>	No	SS ⊕ linear	Icosahedral	HEV
<b>Caliciviruses</b>	No	SS ⊕ linear	Icosahedral	Norovirus—viral gastroenteritis
<b>Flaviviruses</b>	Yes	SS ⊕ linear	Icosahedral	HCV Yellow fever <sup>a</sup> Dengue <sup>a</sup> St. Louis encephalitis <sup>a</sup> West Nile virus <sup>a</sup> (meningoencephalitis) Zika virus
<b>Togaviruses</b>	Yes	SS ⊕ linear	Icosahedral	Rubella Western and Eastern equine encephalitis <sup>a</sup> Chikungunya virus
<b>Retroviruses</b>	Yes	SS ⊕ linear 2 copies	Icosahedral (HTLV), complex and conical (HIV)	Have reverse transcriptase HTLV—T-cell leukemia HIV—AIDS
<b>Coronaviruses</b>	Yes	SS ⊕ linear	Helical	“Common cold,” SARS, MERS
<b>Orthomyxoviruses</b>	Yes	SS ⊖ linear 8 segments	Helical	Influenza virus
<b>Paramyxoviruses</b>	Yes	SS ⊖ linear Nonsegmented	Helical	<b>PaRaM</b> yxovirus: <b>P</b> arainfluenza—croup <b>R</b> SV—bronchiolitis in babies; <b>R</b> x—ribavirin <b>M</b> easles, <b>M</b> umps
<b>Rhabdoviruses</b>	Yes	SS ⊖ linear	Helical	Rabies
<b>Filoviruses</b>	Yes	SS ⊖ linear	Helical	Ebola/Marburg hemorrhagic fever—often fatal!
<b>Arenaviruses</b>	Yes	SS ⊕ and ⊖ circular 2 segments	Helical	LCMV—lymphocytic choriomeningitis virus Lassa fever encephalitis—spread by rodents
<b>Bunyaviruses</b>	Yes	SS ⊖ circular 3 segments	Helical	California encephalitis <sup>a</sup> Sandfly/Rift Valley fevers <sup>a</sup> Crimean-Congo hemorrhagic fever <sup>a</sup> Hantavirus—hemorrhagic fever, pneumonia
<b>Delta virus</b>	Yes	SS ⊖ circular	Uncertain	HDV is a “defective” virus that requires the presence of HBV to replicate

SS, single-stranded; DS, double-stranded; ⊕, positive sense; ⊖, negative sense; <sup>a</sup>= **arbo**virus, **ar**thropod **bo**rne (mosquitoes, ticks).



**Negative-stranded viruses**

Must transcribe  $\ominus$  strand to  $\oplus$ . Virion brings its own RNA-dependent RNA polymerase. They include **A**renaviruses, **B**unyaviruses, **P**aramyxoviruses, **O**rthomyxoviruses, **F**iloviruses, and **R**habdoviruses.

Always **B**ring **P**olymerase **O**r **F**ail **R**eplication.

**Segmented viruses**

All are RNA viruses. They include **B**unyaviruses, **O**rthomyxoviruses (influenza viruses), **A**renaviruses, and **R**eoviruses.

**BOAR.**

**Picornavirus**

Includes **P**oliovirus, **E**chovirus, **R**hinovirus, **C**oxsackievirus, and **H**AV. RNA is translated into 1 large polypeptide that is cleaved by proteases into functional viral proteins. Can cause aseptic (viral) meningitis (except rhinovirus and HAV). All are enteroviruses except rhinovirus.

Pico**RNA**virus = small **RNA** virus. **PERCH** on a “**peak**” (**pico**).

**Rhinovirus**


A picornavirus. Nonenveloped RNA virus. Cause of common cold; > 100 serologic types. Acid labile—destroyed by stomach acid; therefore, does not infect the GI tract (unlike the other picornaviruses).

**Rhino** has a runny **nose**.

**Yellow fever virus**

A flavivirus (also an arbovirus) transmitted by *Aedes* mosquitoes. Virus has a monkey or human reservoir. Symptoms: high fever, black vomitus, and jaundice. May see Councilman bodies (eosinophilic apoptotic globules) on liver biopsy.

*Flavi* = yellow, jaundice.

**Rotavirus**

Rotavirus **A**, the most important global cause of infantile gastroenteritis, is a segmented dsRNA virus (a reovirus). Major cause of acute diarrhea in the United States during winter, especially in day care centers, kindergartens. Villous destruction with atrophy leads to ↓ absorption of  $\text{Na}^+$  and loss of  $\text{K}^+$ .


**ROTA**virus = **R**ight **O**ut **T**he **A**nus.

CDC recommends routine vaccination of all infants.

**Influenza viruses**


Orthomyxoviruses. Enveloped,  $\ominus$  ssRNA viruses with 8-segment genome. Contain hemagglutinin (binds sialic acid and promotes viral entry) and neuraminidase (promotes progeny virion release) antigens. Patients at risk for fatal bacterial superinfection, most commonly *S aureus*, *S pneumoniae*, and *H influenzae*.

Reformulated vaccine (“the flu shot”) contains viral strains most likely to appear during the flu season, due to the virus’ rapid genetic change. Killed viral vaccine is most frequently used. Live attenuated vaccine contains temperature-sensitive mutant that replicates in the nose but not in the lung; administered intranasally.

**Genetic shift/  
antigenic shift**

Causes pandemics. Reassortment of viral genome segments, such as when segments of human flu A virus reassort with swine flu A virus.

**S**udden **s**hift is more deadly than **g**radual **d**rift.

**Genetic drift/  
antigenic drift**

Causes epidemics. Minor (antigenic drift) changes based on random mutation in hemagglutinin or neuraminidase genes.

**Rubella virus**


A togavirus. Causes rubella, once known as German (3-day) measles. Fever, postauricular and other lymphadenopathy, arthralgias, and fine, confluent rash that starts on face and spreads centrifugally to involve trunk and extremities **A**. Causes mild disease in children but serious congenital disease (a ToRCHeS infection). Congenital rubella findings include “blueberry muffin” appearance due to dermal extramedullary hematopoiesis.

**Paramyxoviruses**

Paramyxoviruses cause disease in children. They include those that cause parainfluenza (croup: seal-like barking cough), mumps, measles, RSV, and human metapneumovirus, which causes respiratory tract infection (bronchiolitis, pneumonia) in infants. All contain surface F (fusion) protein, which causes respiratory epithelial cells to fuse and form multinucleated cells. Palivizumab (monoclonal antibody against F protein) prevents pneumonia caused by RSV infection in premature infants.


**P**alivizumab for **P**aramyxovirus (RSV) **P**rophylaxis in **P**remies.

### Croup (acute laryngo-tracheobronchitis)



Caused by parainfluenza viruses (paramyxovirus). Virus membrane contains hemagglutinin (binds sialic acid and promotes viral entry) and neuraminidase (promotes progeny virion release) antigens. Results in a “seal-like” barking cough and inspiratory stridor. Narrowing of upper trachea and subglottis leads to characteristic steeple sign on x-ray **A**. Severe croup can result in pulsus paradoxus 2° to upper airway obstruction.

### Measles (rubeola) virus



A paramyxovirus that causes measles. Usual presentation involves prodromal fever with cough, coryza, and conjunctivitis, then eventually Koplik spots (bright red spots with blue-white center on buccal mucosa **A**), followed 1–2 days later by a maculopapular rash **B** that starts at the head/neck and spreads downward. Lymphadenitis with Warthin-Finkeldey giant cells (fused lymphocytes) in a background of paracortical hyperplasia. SSPE (subacute sclerosing panencephalitis, occurring years later), encephalitis (1:2000), and giant cell pneumonia (rarely, in immunosuppressed) are possible sequelae.

3 C's of measles:

- Cough
- Coryza
- Conjunctivitis

Vitamin A supplementation can reduce morbidity and mortality from measles, particularly in malnourished children.


### Mumps virus



A paramyxovirus that causes mumps, uncommon due to effectiveness of MMR vaccine.

Symptoms: **P**arotitis **A**, **O**rchitis (inflammation of testes), aseptic **M**eningitis, and **P**ancreatitis. Can cause sterility (especially after puberty).

Mumps makes your parotid glands and testes as big as **POM-Poms**.


**Rabies virus**

Bullet-shaped virus **A**. Negri bodies (cytoplasmic inclusions **B**) commonly found in Purkinje cells of cerebellum and in hippocampal neurons. Rabies has long incubation period (weeks to months) before symptom onset. Postexposure prophylaxis is wound cleaning plus immunization with killed vaccine and rabies immunoglobulin. Example of passive-active immunity.

Travels to the CNS by migrating in a retrograde fashion (via dynein motors) up nerve axons after binding to ACh receptors.

Progression of disease: fever, malaise  
→ agitation, photophobia, hydrophobia, hypersalivation → paralysis, coma → death.

Infection more commonly from bat, raccoon, and skunk bites than from dog bites in the United States; aerosol transmission (eg, bat caves) also possible.

**Ebola virus**

A filovirus **A** that targets endothelial cells, phagocytes, hepatocytes. Following an incubation period of up to 21 days, presents with abrupt onset of flu-like symptoms, diarrhea/vomiting, high fever, myalgia. Can progress to DIC, diffuse hemorrhage, shock. Diagnosed with RT-PCR within 48 hr of symptom onset. High mortality rate.

Transmission requires direct contact with bodily fluids, fomites (including dead bodies), infected bats or primates (apes/monkeys); high incidence of nosocomial infection.

Supportive care, no definitive treatment. Strict isolation of infected individuals and barrier practices for health care workers are key to preventing transmission.

**Zika virus**

A flavivirus most commonly transmitted by *Aedes* mosquito bites. Causes conjunctivitis, low-grade pyrexia, and itchy rash in 20% cases. Can lead to congenital microcephaly or miscarriages if transmitted in utero. Diagnose with RT-PCR or serology.

Sexual and vertical transmission possible. Outbreaks more common in tropical and subtropical climates. Supportive care, no definitive treatment.

**Hepatitis viruses**

Signs and symptoms of all hepatitis viruses: episodes of fever, jaundice, ↑ ALT and AST. Naked viruses (HAV and HEV) lack an envelope and are not destroyed by the gut: the **vowels** hit your **bowels**.

HBV DNA polymerase has DNA- and RNA-dependent activities. Upon entry into nucleus, the polymerase completes the partial dsDNA. Host RNA polymerase transcribes mRNA from viral DNA to make viral proteins. The DNA polymerase then reverse transcribes viral RNA to DNA, which is the genome of the progeny virus.

HCV lacks 3'-5' exonuclease activity → no proofreading ability → variation in antigenic structures of HCV envelope proteins. Host antibody production lags behind production of new mutant strains of HCV.


Virus	HAV	HBV	HCV	HDV	HEV
FAMILY	RNA picornavirus	DNA hepadnavirus	RNA flavivirus	RNA deltavirus	RNA hepevirus
TRANSMISSION	Fecal-oral (shellfish, travelers, day care)	Parenteral ( <b>B</b> lood), sexual ( <b>B</b> aby-making), perinatal ( <b>B</b> irthing)	Primarily blood (IVDU, post-transfusion)	Parenteral, sexual, perinatal	Fecal-oral, especially waterborne
INCUBATION	Short (weeks)	Long (months)	Long	Superinfection (HDV after HBV) = short Coinfection (HDV with HBV) = long	Short
CLINICAL COURSE	Asymptomatic (usually), <b>A</b> cute	Initially like serum sickness (fever, arthralgias, rash); may progress to carcinoma	May progress to <b>C</b> irrhosis or <b>C</b> arcinoma	Similar to HBV	Fulminant hepatitis in <b>E</b> xpectant (pregnant) women
PROGNOSIS	Good	Adults → mostly full resolution; neonates → worse prognosis	Majority develop stable, <b>C</b> hronic hepatitis <b>C</b>	Superinfection → worse prognosis	High mortality in pregnant women
HCC RISK	No	Yes	Yes	Yes	No
LIVER BIOPSY	Hepatocyte swelling, monocyte infiltration, Councilman bodies	Granular eosinophilic "ground glass" appearance; cytotoxic T cells mediate damage	Lymphoid aggregates with focal areas of macrovesicular steatosis	Similar to HBV	Patchy necrosis
NOTES	No carrier state (" <b>A</b> lone")	Carrier state common	Carrier state very common	<b>D</b> efective virus, <b>D</b> epends on HBV HBsAg	<b>E</b> nteric, <b>E</b> pidemic, no carrier state

**Extrahepatic manifestations of hepatitis B and C**

	<b>Hepatitis B</b>	<b>Hepatitis C</b>
HEMATOLOGIC	Aplastic anemia	Essential mixed cryoglobulinemia, ↑ risk B-cell NHL, ITP, autoimmune hemolytic anemia
RENAL	Membranous GN → membranoproliferative GN	Membranoproliferative GN → membranous GN
VASCULAR	Polyarteritis nodosa	Leukocytoclastic vasculitis
DERMATOLOGIC		Sporadic porphyria cutanea tarda, lichen planus
ENDOCRINE		↑ risk of diabetes mellitus, autoimmune hypothyroidism


### Hepatitis serologic markers

<b>Anti-HAV (IgM)</b>	IgM antibody to HAV; best test to detect acute hepatitis A.
<b>Anti-HAV (IgG)</b>	IgG antibody indicates prior HAV infection and/or prior vaccination; protects against reinfection.
<b>HBsAg</b>	Antigen found on surface of HBV; indicates hepatitis B infection.
<b>Anti-HBs</b>	Antibody to HBsAg; indicates immunity to hepatitis B due to vaccination or recovery from infection.
<b>HBcAg</b>	Antigen associated with core of HBV.
<b>Anti-HBc</b>	Antibody to HBcAg; IgM = acute/recent infection; IgG = prior exposure or chronic infection. IgM anti-HBc may be the sole ⊕ marker of infection during window period.
<b>HBeAg</b>	Secreted by infected hepatocyte into circulation. Not part of mature HBV virion. Indicates active viral replication and therefore high transmissibility and poorer prognosis.
<b>Anti-HBe</b>	Antibody to HBeAg; indicates low transmissibility.



	HBsAg	Anti-HBs	HBeAg	Anti-HBe	Anti-HBc
Acute HBV	✓		✓		IgM
Window				✓	IgM
Chronic HBV (high infectivity)	✓		✓		IgG
Chronic HBV (low infectivity)	✓			✓	IgG
Recovery		✓		✓	IgG
Immunized		✓			

## HIV



Diploid genome (2 molecules of RNA).

The 3 structural genes (protein coded for):

- *env* (gp120 and gp41):
  - Formed from cleavage of gp160 to form envelope glycoproteins.
  - gp120—attachment to host CD4+ T cell.
  - gp41—fusion and entry.
- *gag* (p24 and p17)—capsid and matrix proteins, respectively.
- *pol*—reverse transcriptase, aspartate protease, integrase.

Reverse transcriptase synthesizes dsDNA from genomic RNA; dsDNA integrates into host genome.

Virus binds CD4 as well as a coreceptor, either CCR5 on macrophages (early infection) or CXCR4 on T cells (late infection).



Homozygous CCR5 mutation = immunity.

Heterozygous CCR5 mutation = slower course.

## HIV diagnosis

Presumptive diagnosis made with ELISA (sensitive, high false ⊕ rate and low threshold, **rule out** test); ⊕ results confirmed with Western blot assay (specific, low false ⊕ rate and high threshold, **rule in** test).


Viral load tests determine the amount of viral RNA in the plasma. High viral load associated with poor prognosis. Also use viral load to monitor effect of drug therapy. HIV genotyping used to determine appropriate therapy.

AIDS diagnosis  $\leq 200$  CD4+ cells/mm<sup>3</sup> (normal: 500–1500 cells/mm<sup>3</sup>). HIV⊕ with AIDS-defining condition (eg, *Pneumocystis pneumonia*) or CD4+ percentage < 14%.

ELISA/Western blot tests look for antibodies to viral proteins; these tests often are falsely ⊖ in the first 1–2 months of HIV infection and falsely ⊕ initially in babies born to infected mothers (anti-gp120 crosses placenta). Use PCR in neonates to detect viral load.



## Time course of untreated HIV infection



Dashed lines on CD4+ count axis indicate moderate immunocompromise (< 400 CD4+ cells/mm<sup>3</sup>) and when AIDS-defining illnesses emerge (< 200 CD4+ cells/mm<sup>3</sup>).

Most patients who do not receive treatment eventually die of complications of HIV infection.

**F**our stages of untreated infection:

1. **F**lu-like (acute)
2. **F**eeling fine (latent)
3. **F**alling count
4. **F**inal crisis

During clinical latency phase, virus replicates in lymph nodes

**Common diseases of HIV-positive adults**

As CD4+ cell count ↓, risks of reactivation of past infections (eg, TB, HSV, shingles), dissemination of bacterial infections and fungal infections (eg, coccidioidomycosis), and non-Hodgkin lymphomas ↑.

PATHOGEN	PRESENTATION	FINDINGS
<b>CD4+ cell count &lt; 500/mm<sup>3</sup></b>		
<i>Candida albicans</i>	Oral thrush	Scrapable white plaque, pseudohyphae on microscopy
EBV	Oral hairy leukoplakia	Unscrapable white plaque on lateral tongue
<i>Bartonella henselae</i>	Bacillary angiomatosis	Biopsy with neutrophilic inflammation
HHV-8	Kaposi sarcoma	Biopsy with lymphocytic inflammation
HPV	Squamous cell carcinoma, commonly of anus (men who have sex with men) or cervix (women)	
<b>CD4+ cell count &lt; 200/mm<sup>3</sup></b>		
<i>Histoplasma capsulatum</i>	Fever, weight loss, fatigue, cough, dyspnea, nausea, vomiting, diarrhea	Oval yeast cells within macrophages
HIV	Dementia	
JC virus (reactivation)	Progressive multifocal leukoencephalopathy	Nonenhancing areas of demyelination on MRI
<i>Pneumocystis jirovecii</i>	<i>Pneumocystis</i> pneumonia	“Ground-glass” opacities on CXR
<b>CD4+ cell count &lt; 100/mm<sup>3</sup></b>		
<i>Aspergillus fumigatus</i>	Hemoptysis, pleuritic pain	Cavitation or infiltrates on chest imaging
<i>Candida albicans</i>	Esophagitis	White plaques on endoscopy; yeast and pseudohyphae on biopsy
CMV	Retinitis, esophagitis, colitis, pneumonitis, encephalitis	Linear ulcers on endoscopy, cotton-wool spots on funduscopy Biopsy reveals cells with intranuclear (owl eye) inclusion bodies
<i>Cryptococcus neoformans</i>	Meningitis	Encapsulated yeast on India ink stain or capsular antigen ⊕
<i>Cryptosporidium</i> spp.	Chronic, watery diarrhea	Acid-fast oocysts in stool
EBV	B-cell lymphoma (eg, non-Hodgkin lymphoma, CNS lymphoma)	CNS lymphoma—ring enhancing, may be solitary (vs <i>Toxoplasma</i> )
<i>Mycobacterium avium-intracellulare</i> , <i>Mycobacterium avium</i> complex	Nonspecific systemic symptoms (fever, night sweats, weight loss) or focal lymphadenitis	
<i>Toxoplasma gondii</i>	Brain abscesses	Multiple ring-enhancing lesions on MRI

**Prions**

Prion diseases are caused by the conversion of a normal (predominantly  $\alpha$ -helical) protein termed prion protein (PrP<sup>c</sup>) to a  $\beta$ -pleated form (PrP<sup>sc</sup>), which is transmissible via CNS-related tissue (iatrogenic CJD) or food contaminated by BSE-infected animal products (variant CJD). PrP<sup>sc</sup> resists protease degradation and facilitates the conversion of still more PrP<sup>c</sup> to PrP<sup>sc</sup>. Resistant to standard sterilizing procedures, including standard autoclaving. Accumulation of PrP<sup>sc</sup> results in spongiform encephalopathy and dementia, ataxia, and death.

**Creutzfeldt-Jakob disease**—rapidly progressive dementia, typically sporadic (some familial forms).

**Bovine spongiform encephalopathy (BSE)**—also known as “mad cow disease.”

**Kuru**—acquired prion disease noted in tribal populations practicing human cannibalism.

## ► MICROBIOLOGY—SYSTEMS

**Normal flora:  
dominant**

LOCATION	MICROORGANISM
Skin	<i>S epidermidis</i>
Nose	<i>S epidermidis</i> ; colonized by <i>S aureus</i>
Oropharynx	Viridans group streptococci
Dental plaque	<i>S mutans</i>
Colon	<i>B fragilis</i> > <i>E coli</i>
Vagina	<i>Lactobacillus</i> , colonized by <i>E coli</i> and group B strep

Neonates delivered by C-section have no flora but are rapidly colonized after birth.

**Bugs causing food-  
borne illness**

*S aureus* and *B cereus* food poisoning starts quickly and ends quickly.

MICROORGANISM	SOURCE OF INFECTION
<i>B cereus</i>	Reheated rice. “Food poisoning from reheated rice? <b>Be serious!</b> ” ( <i>B cereus</i> )
<i>C botulinum</i>	Improperly canned foods (toxins), raw honey (spores)
<i>C perfringens</i>	Reheated meat
<i>E coli</i> O157:H7	Undercooked meat
<i>L monocytogenes</i>	Deli meats, soft cheeses
<i>Salmonella</i>	Poultry, meat, and eggs
<i>S aureus</i>	Meats, mayonnaise, custard; preformed toxin
<i>V parahaemolyticus</i> and <i>V vulnificus</i> <sup>a</sup>	Contaminated seafood

<sup>a</sup>*V vulnificus* can also cause wound infections from contact with contaminated water or shellfish.

**Bugs causing diarrhea**

Bloody diarrhea	
<i>Campylobacter</i>	Comma- or S-shaped organisms; growth at 42°C
<i>E histolytica</i>	Protozoan; amebic dysentery; liver abscess
Enterohemorrhagic <i>E coli</i>	O157:H7; can cause HUS; makes Shiga-like toxin
Enteroinvasive <i>E coli</i>	Invades colonic mucosa
<i>Salmonella</i> (non-typhoidal)	Lactose ⊖; flagellar motility; has animal reservoir, especially poultry and eggs
<i>Shigella</i>	Lactose ⊖; very low ID <sub>50</sub> ; produces Shiga toxin (human reservoir only); bacillary dysentery
<i>Y enterocolitica</i>	Day care outbreaks, pseudoappendicitis
Watery diarrhea	
<i>C difficile</i>	Pseudomembranous colitis; associated with antibiotics and PPIs; occasionally bloody diarrhea
<i>C perfringens</i>	Also causes gas gangrene
Enterotoxigenic <i>E coli</i>	Travelers' diarrhea; produces heat-labile (LT) and heat-stable (ST) toxins
Protozoa	<i>Giardia</i> , <i>Cryptosporidium</i>
<i>V cholerae</i>	Comma-shaped organisms; rice-water diarrhea; often from infected seafood
Viruses	Rotavirus, norovirus, adenovirus

**Common causes of pneumonia**

NEONATES (< 4 WK)	CHILDREN (4 WK–18 YR)	ADULTS (18–40 YR)	ADULTS (40–65 YR)	ELDERLY
Group B streptococci	Viruses ( <b>RSV</b> )	<i>Mycoplasma</i>	<i>S pneumoniae</i>	<i>S pneumoniae</i>
<i>E coli</i>	<b>Mycoplasma</b>	<i>C pneumoniae</i>	<i>H influenzae</i>	Influenza virus
	<b>C trachomatis</b>	<i>S pneumoniae</i>	Anaerobes	Anaerobes
	(infants–3 yr)	Viruses (eg, influenza)	Viruses	<i>H influenzae</i>
	<b>C pneumoniae</b>		<i>Mycoplasma</i>	Gram ⊖ rods
	(school-aged children)			
	<b>S pneumoniae</b>			
	<b>Runts May Cough</b>			
	<b>Chunky Sputum</b>			

**Special groups**

Alcoholic	<i>Klebsiella</i> , anaerobes usually due to aspiration (eg, <i>Peptostreptococcus</i> , <i>Fusobacterium</i> , <i>Prevotella</i> , <i>Bacteroides</i> )
IV drug users	<i>S pneumoniae</i> , <i>S aureus</i>
Aspiration	Anaerobes
Atypical	<i>Mycoplasma</i> , <i>Legionella</i> , <i>Chlamydia</i>
Cystic fibrosis	<i>Pseudomonas</i> , <i>S aureus</i> , <i>S pneumoniae</i> , <i>Burkholderia cepacia</i>
Immunocompromised	<i>S aureus</i> , enteric gram ⊖ rods, fungi, viruses, <i>P jirovecii</i> (with HIV)
Nosocomial (hospital acquired)	<i>S aureus</i> , <i>Pseudomonas</i> , other enteric gram ⊖ rods
Postviral	<i>S pneumoniae</i> , <i>S aureus</i> , <i>H influenzae</i>

**Common causes of meningitis**

NEWBORN (0–6 MO)	CHILDREN (6 MO–6 YR)	6–60 YR	60 YR +
Group B streptococci	<i>S pneumoniae</i>	<i>S pneumoniae</i>	<i>S pneumoniae</i>
<i>E coli</i>	<i>N meningitidis</i>	<i>N meningitidis</i> (#1 in teens)	Gram ⊖ rods
<i>Listeria</i>	<i>H influenzae</i> type B	Enteroviruses	<i>Listeria</i>
	Enteroviruses	HSV	

Give ceftriaxone and vancomycin empirically (add ampicillin if *Listeria* is suspected).

Viral causes of meningitis: enteroviruses (especially coxsackievirus), HSV-2 (HSV-1 = encephalitis), HIV, West Nile virus (also causes encephalitis), VZV.

In HIV: *Cryptococcus* spp.

Note: Incidence of *H influenzae* meningitis has ↓ greatly due to conjugate *H influenzae* vaccinations. Today, cases are usually seen in unimmunized children.

**CSF findings in meningitis**


	OPENING PRESSURE	CELL TYPE	PROTEIN	GLUCOSE
<b>Bacterial</b>	↑	↑ PMNs	↑	↓
<b>Fungal/TB</b>	↑	↑ lymphocytes	↑	↓
<b>Viral</b>	Normal/↑	↑ lymphocytes	Normal/↑	Normal

**Infections causing brain abscess**

Most commonly viridans streptococci and *Staphylococcus aureus*. If dental infection or extraction precedes abscess, oral anaerobes commonly involved.

Multiple abscesses are usually from bacteremia; single lesions from contiguous sites: otitis media and mastoiditis → temporal lobe and cerebellum; sinusitis or dental infection → frontal lobe.

*Toxoplasma* reactivation in AIDS.

**Osteomyelitis**

RISK FACTOR	ASSOCIATED INFECTION
Assume if no other information is available	<i>S aureus</i> (most common overall)
Sexually active	<i>Neisseria gonorrhoeae</i> (rare), septic arthritis more common
Sickle cell disease	<i>Salmonella</i> and <i>S aureus</i>
Prosthetic joint replacement	<i>S aureus</i> and <i>S epidermidis</i>
Vertebral involvement	<i>S aureus</i> , <i>Mycobacterium tuberculosis</i> (Pott disease)
Cat and dog bites	<i>Pasteurella multocida</i>
IV drug abuse	<i>Pseudomonas</i> , <i>Candida</i> , <i>S aureus</i> are most common

Elevated C-reactive protein (CRP) and erythrocyte sedimentation rate common but nonspecific. MRI is best for detecting acute infection and detailing anatomic involvement **A**. Radiographs are insensitive early but can be useful in chronic osteomyelitis **B**.

## Urinary tract infections

Cystitis presents with dysuria, frequency, urgency, suprapubic pain, and WBCs (but not WBC casts) in urine. Primarily caused by ascension of microbes from urethra to bladder. Males—infants with congenital defects, vesicoureteral reflux. Elderly—enlarged prostate. Ascension to kidney results in pyelonephritis, which presents with fever, chills, flank pain, costovertebral angle tenderness, hematuria, and WBC casts.



Ten times more common in women (shorter urethras colonized by fecal flora). Other predisposing factors: obstruction, kidney surgery, catheterization, GU malformation, diabetes, pregnancy.

## UTI bugs

SPECIES	FEATURES	COMMENTS
<i>Escherichia coli</i>	Leading cause of UTI. Colonies show green metallic sheen on EMB agar.	Diagnostic markers: ⊕ Leukocyte esterase = evidence of WBC activity.
<i>Staphylococcus saprophyticus</i>	2nd leading cause of UTI in sexually active women.	⊕ Nitrite test = reduction of urinary nitrates by bacterial species (eg, <i>E coli</i> ).
<i>Klebsiella pneumoniae</i>	3rd leading cause of UTI. Large mucoid capsule and viscous colonies.	⊕ Urease test = urease-producing bugs (eg, <i>S saprophyticus</i> , <i>Proteus</i> , <i>Klebsiella</i> ).
<i>Serratia marcescens</i>	Some strains produce a red pigment; often nosocomial and drug resistant.	
<i>Enterococcus</i>	Often nosocomial and drug resistant.	
<i>Proteus mirabilis</i>	Motility causes “swarming” on agar; produces urease; associated with struvite stones.	
<i>Pseudomonas aeruginosa</i>	Blue-green pigment and fruity odor; usually nosocomial and drug resistant.	



## Common vaginal infections

	Bacterial vaginosis	<i>Trichomonas vaginitis</i>	<i>Candida vulvovaginitis</i>
SIGNS AND SYMPTOMS	No inflammation Thin, white discharge <b>A</b> with fishy odor	Inflammation (“strawberry cervix”) Frothy, yellow-green, foul-smelling discharge	Inflammation Thick, white, “cottage cheese” discharge <b>C</b>
LAB FINDINGS	Clue cells pH > 4.5	Motile trichomonads <b>B</b> pH > 4.5	Pseudohyphae pH normal (4.0–4.5)
TREATMENT	Metronidazole	Metronidazole Treat sexual partner(s)	-azoles



**ToRCHeS infections**

Microbes that may pass from mother to fetus. Transmission is transplacental in most cases, or via delivery (especially HSV-2). Nonspecific signs common to many **ToRCHeS** infections include hepatosplenomegaly, jaundice, thrombocytopenia, and growth retardation. Other important infectious agents include *Streptococcus agalactiae* (group B streptococci), *E coli*, and *Listeria monocytogenes*—all causes of meningitis in neonates. Parvovirus B19 causes hydrops fetalis.

AGENT	MODES OF MATERNAL TRANSMISSION	MATERNAL MANIFESTATIONS	NEONATAL MANIFESTATIONS
<b>Toxoplasma gondii</b> 	Cat feces or ingestion of undercooked meat	Usually asymptomatic; lymphadenopathy (rarely)	Classic triad: chorioretinitis, hydrocephalus, and intracranial calcifications, +/- "blueberry muffin" rash <b>A</b> .
<b>Rubella</b>	Respiratory droplets	Rash, lymphadenopathy, polyarthritis, polyarthralgia	Classic triad: abnormalities of <b>eye</b> (cataract) and <b>ear</b> (deafness) and congenital <b>heart</b> disease (PDA); ± "blueberry muffin" rash. " <b>I</b> (eye) ♥ <b>ruby</b> ( <b>rubella</b> ) <b>earrings</b> ."
<b>Cytomegalovirus</b> 	Sexual contact, organ transplants	Usually asymptomatic; mononucleosis-like illness	Hearing loss, seizures, petechial rash, "blueberry muffin" rash, periventricular calcifications <b>B</b>
<b>HIV</b>	Sexual contact, needlestick	Variable presentation depending on CD4+ cell count	Recurrent infections, chronic diarrhea
<b>Herpes simplex virus-2</b>	Skin or mucous membrane contact	Usually asymptomatic; herpetic (vesicular) lesions	Meningoencephalitis, herpetic (vesicular) lesions
<b>Syphilis</b>	Sexual contact	Chancre (1°) and disseminated rash (2°) are the two stages likely to result in fetal infection	Often results in stillbirth, hydrops fetalis; if child survives, presents with facial abnormalities (eg, notched teeth, saddle nose, short maxilla), saber shins, CN VIII deafness


**Red rashes of childhood**



AGENT	ASSOCIATED SYNDROME/DISEASE	CLINICAL PRESENTATION
Coxsackievirus type A	Hand-foot-mouth disease	Oval-shaped vesicles on palms and soles <b>A</b> ; vesicles and ulcers in oral mucosa
Human herpesvirus 6	Roseola (exanthem subitum)	Asymptomatic rose-colored macules appear on body after several days of high fever; can present with febrile seizures; usually affects infants
Measles virus	Measles (rubeola)	Confluent rash beginning at head and moving down; preceded by cough, coryza, conjunctivitis, and blue-white (Koplik) spots on buccal mucosa
Parvovirus B19	Erythema infectiosum (fifth disease)	“Slapped cheek” rash on face <b>B</b> (can cause hydrops fetalis in pregnant women)
Rubella virus	Rubella (German measles)	Pink macules and papules begin at head and move down, remain discrete → fine desquamating truncal rash; postauricular lymphadenopathy
<i>Streptococcus pyogenes</i>	Scarlet fever	Erythematous, sandpaper-like rash <b>C</b> with fever and sore throat
Varicella-Zoster virus	Chickenpox	Vesicular rash begins on trunk; spreads to face <b>D</b> and extremities with lesions of different stages





**Sexually transmitted infections**

DISEASE	CLINICAL FEATURES	ORGANISM
AIDS	Opportunistic infections, Kaposi sarcoma, lymphoma	HIV
Chancroid	Painful genital ulcer with exudate, inguinal adenopathy	<i>Haemophilus ducreyi</i> (it's so painful, you “do cry”)
Chlamydia	Urethritis, cervicitis, epididymitis, conjunctivitis, reactive arthritis, PID	<i>Chlamydia trachomatis</i> (D–K)
Condylomata acuminata	Genital warts, koilocytes	HPV-6 and -11
Genital herpes	Painful penile, vulvar, or cervical vesicles and ulcers; can cause systemic symptoms such as fever, headache, myalgia	HSV-2, less commonly HSV-1
Gonorrhea	Urethritis, cervicitis, PID, prostatitis, epididymitis, arthritis, creamy purulent discharge	<i>Neisseria gonorrhoeae</i>
Granuloma inguinale (Donovanosis)	Painless, beefy red ulcer that bleeds readily on contact <b>A</b> Not common in US	<i>Klebsiella (Calymmatobacterium) granulomatis</i> ; cytoplasmic Donovan bodies (bipolar staining) seen on microscopy
<b>A</b> 		
Hepatitis B	Jaundice	HBV
Lymphogranuloma venereum	Infection of lymphatics; painless genital ulcers, painful lymphadenopathy (ie, buboes)	<i>C trachomatis</i> (L1–L3)
Primary syphilis	Painless chancre	<i>Treponema pallidum</i>
Secondary syphilis	Fever, lymphadenopathy, skin rashes, condylomata lata	
Tertiary syphilis	Gummas, tabes dorsalis, general paresis, aortitis, Argyll Robertson pupil	
Trichomoniasis	Vaginitis, strawberry cervix, motile in wet prep	<i>Trichomonas vaginalis</i>

**Pelvic inflammatory disease**

Top bugs—*Chlamydia trachomatis* (subacute, often undiagnosed), *Neisseria gonorrhoeae* (acute). *C trachomatis*—most common bacterial STI in the United States. Cervical motion tenderness (chandelier sign), purulent cervical discharge **A**. PID may include salpingitis, endometritis, hydrosalpinx, and tubo-ovarian abscess.

Salpingitis is a risk factor for ectopic pregnancy, infertility, chronic pelvic pain, and adhesions. Can lead to **Fitz-Hugh–Curtis syndrome**—infection of the liver capsule and “violin string” adhesions of peritoneum to liver **B**.

**Nosocomial infections** *E coli* (UTI) and *S aureus* (wound infection) are the two most common causes.

RISK FACTOR	PATHOGEN	UNIQUE SIGNS/SYMPTOMS
Antibiotic use	<i>Clostridium difficile</i>	Watery diarrhea, leukocytosis
Aspiration (2° to altered mental status, old age)	Polymicrobial, gram $\ominus$ bacteria, often anaerobes	Right lower lobe infiltrate or right upper/middle lobe (patient recumbent); purulent malodorous sputum
Decubitus ulcers, surgical wounds, drains	<i>S aureus</i> (including MRSA), gram $\ominus$ anaerobes ( <i>Bacteroides</i> , <i>Prevotella</i> , <i>Fusobacterium</i> )	Erythema, tenderness, induration, drainage from surgical wound sites
Intravascular catheters	<i>S aureus</i> (including MRSA), <i>S epidermidis</i> (long term), <i>Enterobacter</i>	Erythema, induration, tenderness, drainage from access sites
Mechanical ventilation, endotracheal intubation	Late onset: <i>P aeruginosa</i> , <i>Klebsiella</i> , <i>Acinetobacter</i> , <i>S aureus</i>	New infiltrate on CXR, $\uparrow$ sputum production; sweet odor ( <i>Pseudomonas</i> )
Renal dialysis unit, needlestick	HBV, HCV	
Urinary catheterization	<i>E coli</i> , <i>Klebsiella</i> , <i>Proteus</i> spp.	Dysuria, leukocytosis, flank pain or costovertebral angle tenderness
Water aerosols	<i>Legionella</i>	Signs of pneumonia, GI symptoms (nausea, vomiting), neurologic abnormalities

**Bugs affecting unvaccinated children**


CLINICAL PRESENTATION	FINDINGS/LABS	PATHOGEN
<b>Dermatologic</b>		
<b>Rash</b>	Beginning at head and moving down with postauricular lymphadenopathy	Rubella virus
	Beginning at head and moving down; rash preceded by cough, coryza, conjunctivitis, and blue-white (Koplik) spots on buccal mucosa	Measles virus
<b>Neurologic</b>		
<b>Meningitis</b>	Microbe colonizes nasopharynx	<i>H influenzae</i> type B
	Can also lead to myalgia and paralysis	Poliovirus
<b>Respiratory</b>		
<b>Epiglottitis</b>	Fever with dysphagia, drooling, and difficulty breathing due to edematous “cherry red” epiglottitis; “thumbprint sign” on x-ray	<i>H influenzae</i> type B (also capable of causing epiglottitis in fully immunized children)
<b>Pharyngitis</b>	Grayish oropharyngeal exudate (“pseudomembranes” may obstruct airway); painful throat	<i>Corynebacterium diphtheriae</i> (elaborates toxin that causes necrosis in pharynx, cardiac, and CNS tissue)

**Bug hints (if all else fails)**

CHARACTERISTIC	ORGANISM
Asplenic patient (due to surgical splenectomy or autosplenectomy, eg, chronic sickle cell disease)	Encapsulated microbes, especially <b>SHiN</b> ( <i>S pneumoniae</i> >> <i>H influenzae</i> type B > <i>N meningitidis</i> )
Branching rods in oral infection, sulfur granules	<i>Actinomyces israelii</i>
Chronic granulomatous disease	Catalase ⊕ microbes, especially <i>S aureus</i>
“Currant jelly” sputum	<i>Klebsiella</i>
Dog or cat bite	<i>Pasteurella multocida</i>
Facial nerve palsy (typically bilateral)	<i>Borrelia burgdorferi</i> (Lyme disease)
Fungal infection in diabetic or immunocompromised patient	<i>Mucor</i> or <i>Rhizopus</i> spp.
Health care provider	HBV (from needlestick)
Neutropenic patients	<i>Candida albicans</i> (systemic), <i>Aspergillus</i>
Organ transplant recipient	CMV
PAS ⊕	<i>Tropheryma whipplei</i> (Whipple disease)
Pediatric infection	<i>Haemophilus influenzae</i> (including epiglottitis)
Pneumonia in cystic fibrosis, burn infection	<i>Pseudomonas aeruginosa</i>
Pus, empyema, abscess	<i>S aureus</i>
Rash on hands and feet	Coxsackie A virus, <i>Treponema pallidum</i> , <i>Rickettsia rickettsii</i>
Sepsis/meningitis in newborn	Group B strep
Surgical wound	<i>S aureus</i>
Traumatic open wound	<i>Clostridium perfringens</i>

► MICROBIOLOGY—ANTIMICROBIALS

Antimicrobial therapy



**Penicillin G, V**

Penicillin G (IV and IM form), penicillin V (oral). Prototype  $\beta$ -lactam antibiotics.

**MECHANISM**

D-Ala-D-Ala structural analog. Bind penicillin-binding proteins (transpeptidases). Block transpeptidase cross-linking of peptidoglycan in cell wall. Activate autolytic enzymes.

**CLINICAL USE**

Mostly used for gram  $\oplus$  organisms (*S pneumoniae*, *S pyogenes*, *Actinomyces*). Also used for gram  $\ominus$  cocci (mainly *N meningitidis*) and spirochetes (namely *T pallidum*). Bactericidal for gram  $\oplus$  cocci, gram  $\oplus$  rods, gram  $\ominus$  cocci, and spirochetes. Penicillinase sensitive.

**ADVERSE EFFECTS**

Hypersensitivity reactions, direct Coombs  $\oplus$  hemolytic anemia.

**RESISTANCE**

Penicillinase in bacteria (a type of  $\beta$ -lactamase) cleaves  $\beta$ -lactam ring.

**Penicillinase-sensitive penicillins**

Amoxicillin, ampicillin; aminopenicillins.

MECHANISM	Same as penicillin. Wider spectrum; penicillinase sensitive. Also combine with clavulanic acid to protect against destruction by $\beta$ -lactamase.	<b>AM</b> ino <b>Pen</b> icillins are <b>AMP</b> ed-up penicillin. Am <b>O</b> xicillin has greater <b>O</b> ral bioavailability than ampicillin.
CLINICAL USE	Extended-spectrum penicillin— <b>H</b> influenzae, <b>H</b> pylori, <b>E</b> coli, <b>L</b> isteria monocytogenes, <b>P</b> roteus mirabilis, <b>S</b> almonella, <b>S</b> higella, enterococci.	Coverage: ampicillin/amoxicillin <b>HHELPSS</b> kill enterococci.
ADVERSE EFFECTS	Hypersensitivity reactions; rash; pseudomembranous colitis.	
MECHANISM OF RESISTANCE	Penicillinase in bacteria (a type of $\beta$ -lactamase) cleaves $\beta$ -lactam ring.	

**Penicillinase-resistant penicillins**

Dicloxacillin, nafcillin, oxacillin.

MECHANISM	Same as penicillin. Narrow spectrum; penicillinase resistant because bulky R group blocks access of $\beta$ -lactamase to $\beta$ -lactam ring.	
CLINICAL USE	<i>S aureus</i> (except MRSA; resistant because of altered penicillin-binding protein target site).	“Use <b>naf</b> (nafcillin) for <b>staph</b> .”
ADVERSE EFFECTS	Hypersensitivity reactions, interstitial nephritis.	

**Antipseudomonal penicillins**

Piperacillin, ticarcillin.

MECHANISM	Same as penicillin. Extended spectrum.	
CLINICAL USE	<i>Pseudomonas</i> spp. and gram $\ominus$ rods; susceptible to penicillinase; use with $\beta$ -lactamase inhibitors.	
ADVERSE EFFECTS	Hypersensitivity reactions.	

 **$\beta$ -lactamase inhibitors**

Include **C**lavulanic acid, **A**vibactam, **S**ulbactam, **T**azobactam. Often added to penicillin antibiotics to protect the antibiotic from destruction by  $\beta$ -lactamase (penicillinase).

**CAST.**

**Cephalosporins (generations I–V)**

MECHANISM	β-lactam drugs that inhibit cell wall synthesis but are less susceptible to penicillinases. Bactericidal.	Organisms typically not covered by 1st–4th generation cephalosporins are <b>LAME</b> : <i>Listeria</i> , Atypicals ( <i>Chlamydia</i> , <i>Mycoplasma</i> ), MRSA, and Enterococci.
CLINICAL USE	<p>1st generation (cefazolin, cephalexin)—gram ⊕ cocci, <i>Proteus mirabilis</i>, <i>E coli</i>, <i>Klebsiella pneumoniae</i>. Cefazolin used prior to surgery to prevent <i>S aureus</i> wound infections.</p> <p>2nd generation (cefaclor, cefoxitin, cefuroxime)—gram ⊕ cocci, <i>H influenzae</i>, <i>Enterobacter aerogenes</i>, <i>Neisseria</i> spp., <i>Serratia marcescens</i>, <i>Proteus mirabilis</i>, <i>E coli</i>, <i>Klebsiella pneumoniae</i>.</p> <p>3rd generation (ceftriaxone, cefotaxime, cefpodoxime, ceftazidime)—serious gram ⊖ infections resistant to other β-lactams.</p> <p>4th generation (cefepime)—gram ⊖ organisms, with ↑ activity against <i>Pseudomonas</i> and gram ⊕ organisms.</p> <p>5th generation (ceftaroline)—broad gram ⊕ and gram ⊖ organism coverage; unlike 1st–4th generation cephalosporins, ceftaroline covers <i>Listeria</i>, MRSA, and <i>Enterococcus faecalis</i>—does not cover <i>Pseudomonas</i>.</p>	<p>1st generation—<b>PEcK</b>.</p> <p><b>Fake fox fur.</b></p> <p>2nd generation—<b>HENS PEcK</b>.</p> <p>Can cross blood-brain barrier.</p> <p>Ceftriaxone—meningitis, gonorrhea, disseminated Lyme disease.</p> <p>Ceftazidime—<i>Pseudomonas</i>.</p>
ADVERSE EFFECTS	Hypersensitivity reactions, autoimmune hemolytic anemia, disulfiram-like reaction, vitamin K deficiency. Low rate of cross-reactivity even in penicillin-allergic patients. ↑ nephrotoxicity of aminoglycosides.	
MECHANISM OF RESISTANCE	Structural change in penicillin-binding proteins (transpeptidases).	

**Carbapenems**

Imipenem, meropenem, ertapenem, doripenem.

MECHANISM	Imipenem is a broad-spectrum, $\beta$ -lactamase-resistant carbapenem. Always administered with cilastatin (inhibitor of renal dehydropeptidase I) to $\downarrow$ inactivation of drug in renal tubules.	With imipenem, “the kill is <b>lastin</b> ’ with <b>cilastatin</b> .” Newer carbapenems include ertapenem (limited <i>Pseudomonas</i> coverage) and doripenem.
CLINICAL USE	Gram $\oplus$ cocci, gram $\ominus$ rods, and anaerobes. Wide spectrum, but significant side effects limit use to life-threatening infections or after other drugs have failed. Meropenem has a $\downarrow$ risk of seizures and is stable to dehydropeptidase I.	
ADVERSE EFFECTS	GI distress, skin rash, and CNS toxicity (seizures) at high plasma levels.	


**Monobactams**

Aztreonam


MECHANISM	Less susceptible to $\beta$ -lactamases. Prevents peptidoglycan cross-linking by binding to penicillin-binding protein 3. Synergistic with aminoglycosides. No cross-allergenicity with penicillins.	
CLINICAL USE	Gram $\ominus$ rods only—no activity against gram $\oplus$ rods or anaerobes. For penicillin-allergic patients and those with renal insufficiency who cannot tolerate aminoglycosides.	
ADVERSE EFFECTS	Usually nontoxic; occasional GI upset.	

**Vancomycin**

MECHANISM	Inhibits cell wall peptidoglycan formation by binding D-ala D-ala portion of cell wall precursors. Bactericidal against most bacteria (bacteriostatic against <i>C difficile</i> ). Not susceptible to $\beta$ -lactamases.	
CLINICAL USE	Gram $\oplus$ bugs only—serious, multidrug-resistant organisms, including MRSA, <i>S epidermidis</i> , sensitive <i>Enterococcus</i> species, and <i>Clostridium difficile</i> (oral dose for pseudomembranous colitis).	
ADVERSE EFFECTS	Well tolerated in general—but <b>NOT</b> trouble free. <b>N</b> ephrotoxicity, <b>O</b> totoxicity, <b>T</b> hrombophlebitis, diffuse flushing— <b>red man syndrome</b> <b>A</b> (largely preventable by pretreatment with antihistamines and slow infusion rate).	
MECHANISM OF RESISTANCE	Occurs in bacteria (eg, <i>Enterococcus</i> ) via amino acid modification of <b>D-Ala-D-Ala</b> to D-Ala-D-Lac. “Pay back <b>2 D-Alas</b> (dollars) for <b>vandalizing</b> ( <b>van</b> comycin).”	



**Protein synthesis inhibitors**



Specifically target smaller bacterial ribosome (70S, made of 30S and 50S subunits), leaving human ribosome (80S) unaffected.

**30S inhibitors**

- A** = Aminoglycosides [bactericidal]
- T** = Tetracyclines [bacteriostatic]

**50S inhibitors**

- C** = Chloramphenicol, Clindamycin [bacteriostatic]
  - E** = Erythromycin (macrolides) [bacteriostatic]
  - L** = Linezolid [variable]
- “Buy **AT 30**, **CCEL** (sell) at **50**.”

**Aminoglycosides**

**G**entamicin, **N**eomycin, **A**mikacin, **T**obramycin, **S**treptomycin.

“**Mean**” (aminoglycoside) **GNATS** ca**NNOT** kill anaerobes.

<b>MECHANISM</b>	Bactericidal; irreversible inhibition of initiation complex through binding of the 30S subunit. Can cause misreading of mRNA. Also block translocation. Require O <sub>2</sub> for uptake; therefore ineffective against anaerobes.
<b>CLINICAL USE</b>	Severe gram ⊖ rod infections. Synergistic with β-lactam antibiotics. Neomycin for bowel surgery.
<b>ADVERSE EFFECTS</b>	<b>N</b> ephrotoxicity, <b>N</b> eurovascular blockade, <b>O</b> totoxicity (especially when used with loop diuretics). <b>T</b> eratogen.
<b>MECHANISM OF RESISTANCE</b>	Bacterial transferase enzymes inactivate the drug by acetylation, phosphorylation, or adenylation.



**Tetracyclines**

Tetracycline, doxycycline, minocycline.

MECHANISM	Bacteriostatic; bind to 30S and prevent attachment of aminoacyl-tRNA; limited CNS penetration. Doxycycline is fecally eliminated and can be used in patients with renal failure. Do not take tetracyclines with milk ( $\text{Ca}^{2+}$ ), antacids ( $\text{Ca}^{2+}$ or $\text{Mg}^{2+}$ ), or iron-containing preparations because divalent cations inhibit drugs' absorption in the gut.
CLINICAL USE	<i>Borrelia burgdorferi</i> , <i>M pneumoniae</i> . Drugs' ability to accumulate intracellularly makes them very effective against <i>Rickettsia</i> and <i>Chlamydia</i> . Also used to treat acne. Doxycycline effective against MRSA.
ADVERSE EFFECTS	GI distress, discoloration of teeth and inhibition of bone growth in children, photosensitivity. Contraindicated in pregnancy.
MECHANISM OF RESISTANCE	↓ uptake or ↑ efflux out of bacterial cells by plasmid-encoded transport pumps.

**Glycylcyclines**

Tigecycline.

MECHANISM	Tetracycline derivative. Binds to 30S, inhibiting protein synthesis. Generally bacteriostatic.
CLINICAL USE	Broad-spectrum anaerobic, gram $\ominus$ , and gram $\oplus$ coverage. Multidrug-resistant (MRSA, VRE) organisms or infections requiring deep tissue penetration.
ADVERSE EFFECTS	GI symptoms: nausea, vomiting.

**Chloramphenicol**

MECHANISM	Blocks peptidyltransferase at 50S ribosomal subunit. Bacteriostatic.
CLINICAL USE	Meningitis ( <i>Haemophilus influenzae</i> , <i>Neisseria meningitidis</i> , <i>Streptococcus pneumoniae</i> ) and Rocky Mountain spotted fever ( <i>Rickettsia rickettsii</i> ). Limited use owing to toxicities but often still used in developing countries because of low cost.
ADVERSE EFFECTS	Anemia (dose dependent), aplastic anemia (dose independent), gray baby syndrome (in premature infants because they lack liver UDP-glucuronyltransferase).
MECHANISM OF RESISTANCE	Plasmid-encoded acetyltransferase inactivates the drug.

**Clindamycin**


MECHANISM	Blocks peptide transfer (translocation) at 50S ribosomal subunit. Bacteriostatic.
CLINICAL USE	Anaerobic infections (eg, <i>Bacteroides</i> spp., <i>Clostridium perfringens</i> ) in aspiration pneumonia, lung abscesses, and oral infections. Also effective against invasive group A streptococcal infection. Treats anaerobic infections <b>above</b> the diaphragm vs metronidazole (anaerobic infections <b>below</b> diaphragm).
ADVERSE EFFECTS	Pseudomembranous colitis ( <i>C difficile</i> overgrowth), fever, diarrhea.

<b>Oxazolidinones</b>	Linezolid.
MECHANISM	Inhibit protein synthesis by binding to 50S subunit and preventing formation of the initiation complex.
CLINICAL USE	Gram ⊕ species including MRSA and VRE.
ADVERSE EFFECTS	Bone marrow suppression (especially thrombocytopenia), peripheral neuropathy, serotonin syndrome.
MECHANISM OF RESISTANCE	Point mutation of ribosomal RNA.
<b>Macrolides</b>	Azithromycin, clarithromycin, erythromycin.
MECHANISM	Inhibit protein synthesis by blocking translocation (“macro <b>slides</b> ”); bind to the 23S rRNA of the 50S ribosomal subunit. Bacteriostatic.
CLINICAL USE	Atypical pneumonias ( <i>Mycoplasma</i> , <i>Chlamydia</i> , <i>Legionella</i> ), STIs ( <i>Chlamydia</i> ), gram ⊕ cocci (streptococcal infections in patients allergic to penicillin), and <i>B pertussis</i> .
ADVERSE EFFECTS	<b>MACRO</b> : Gastrointestinal <b>M</b> otility issues, <b>A</b> rrhythmia caused by prolonged <b>QT</b> interval, acute <b>C</b> holestatic hepatitis, <b>R</b> ash, <b>eO</b> sinophilia. Increases serum concentration of theophylline, oral anticoagulants. Clarithromycin and erythromycin inhibit cytochrome P-450.
MECHANISM OF RESISTANCE	Methylation of 23S rRNA-binding site prevents binding of drug.

<b>Sulfonamides</b>	
	Sulfamethoxazole (SMX), sulfisoxazole, sulfadiazine.
MECHANISM	Inhibit dihydropteroate synthase, thus inhibiting folate synthesis. Bacteriostatic (bactericidal when combined with trimethoprim).
CLINICAL USE	Gram $\oplus$ , gram $\ominus$ , <i>Nocardia</i> . SMX for simple UTI.
ADVERSE EFFECTS	Hypersensitivity reactions, hemolysis if G6PD deficient, nephrotoxicity (tubulointerstitial nephritis), photosensitivity, Stevens-Johnson syndrome, kernicterus in infants, displace other drugs from albumin (eg, warfarin).
MECHANISM OF RESISTANCE	Altered enzyme (bacterial dihydropteroate synthase), $\downarrow$ uptake, or $\uparrow$ PABA synthesis.

<b>Dapsone</b>	
MECHANISM	Similar to sulfonamides, but structurally distinct agent.
CLINICAL USE	Leprosy (lepromatous and tuberculoid), <i>Pneumocystis jirovecii</i> prophylaxis.
ADVERSE EFFECTS	Hemolysis if G6PD deficient.

<b>Trimethoprim</b>	
MECHANISM	Inhibits bacterial dihydrofolate reductase. Bacteriostatic.
CLINICAL USE	Used in combination with sulfonamides (trimethoprim-sulfamethoxazole [TMP-SMX]), causing sequential block of folate synthesis. Combination used for UTIs, <i>Shigella</i> , <i>Salmonella</i> , <i>Pneumocystis jirovecii</i> pneumonia treatment and prophylaxis, toxoplasmosis prophylaxis.
ADVERSE EFFECTS	Megaloblastic anemia, leukopenia, granulocytopenia. (May alleviate with supplemental folic acid). <b>TMP</b> Treats <b>Marrow</b> <b>Poorly</b> .



<b>Fluoroquinolones</b>	
	Ciprofloxacin, norfloxacin, levofloxacin, ofloxacin, moxifloxacin, gemifloxacin, enoxacin.
MECHANISM	Inhibit prokaryotic enzymes topoisomerase II (DNA gyrase) and topoisomerase IV. Bactericidal. Must not be taken with antacids.
CLINICAL USE	Gram $\ominus$ rods of urinary and GI tracts (including <i>Pseudomonas</i> ), some gram $\oplus$ organisms, otitis externa.
ADVERSE EFFECTS	GI upset, superinfections, skin rashes, headache, dizziness. Less commonly, can cause leg cramps and myalgias. Contraindicated in pregnant women, nursing mothers, and children < 18 years old due to possible damage to cartilage. Some may prolong QT interval. May cause tendonitis or tendon rupture in people > 60 years old and in patients taking prednisone. Ciprofloxacin inhibits cytochrome P-450. <b>Fluoroquinolones hurt attachments to your bones.</b>
MECHANISM OF RESISTANCE	Chromosome-encoded mutation in DNA gyrase, plasmid-mediated resistance, efflux pumps.

**Daptomycin**

MECHANISM	Lipopeptide that disrupts cell membranes of gram $\oplus$ cocci by creating transmembrane channels.
CLINICAL USE	<i>S aureus</i> skin infections (especially MRSA), bacteremia, endocarditis, VRE. <b>Not used for pneumonia (avidly binds to and is inactivated by surfactant).</b>
ADVERSE EFFECTS	Myopathy, rhabdomyolysis.


**Metronidazole**

MECHANISM	Forms toxic free radical metabolites in the bacterial cell that damage DNA. Bactericidal, antiprotozoal.
CLINICAL USE	Treats <i>Giardia</i> , <i>Entamoeba</i> , <i>Trichomonas</i> , <i>Gardnerella vaginalis</i> , Anaerobes ( <i>Bacteroides</i> , <i>C difficile</i> ). Can be used in place of amoxicillin in <i>H pylori</i> “triple therapy” in case of penicillin allergy. <b>GET GAP on the Metro with metronidazole!</b> Treats anaerobic infection <b>below</b> the diaphragm vs clindamycin (anaerobic infections <b>above</b> diaphragm).
ADVERSE EFFECTS	Disulfiram-like reaction (severe flushing, tachycardia, hypotension) with alcohol; headache, metallic taste.

## Antimycobacterial drugs

BACTERIUM	PROPHYLAXIS	TREATMENT
<i>M tuberculosis</i>	Isoniazid	Rifampin, Isoniazid, Pyrazinamide, Ethambutol ( <b>RIPE</b> for treatment)
<i>M avium–intracellulare</i>	Azithromycin, rifabutin	More drug resistant than <i>M tuberculosis</i> . Azithromycin or clarithromycin + ethambutol. Can add rifabutin or ciprofloxacin.
<i>M leprae</i>	N/A	Long-term treatment with dapsone and rifampin for tuberculoid form. Add clofazimine for lepromatous form.

## MYCOBACTERIAL CELL



## Rifamycins

Rifampin, rifabutin.

MECHANISM	Inhibit DNA-dependent RNA polymerase.	<b>Rifampin's 4 R's:</b> RNA polymerase inhibitor Ramps up microsomal cytochrome P-450 Red/orange body fluids Rapid resistance if used alone
CLINICAL USE	<i>Mycobacterium tuberculosis</i> ; delay resistance to dapsone when used for leprosy. Used for meningococcal prophylaxis and chemoprophylaxis in contacts of children with <i>Haemophilus influenzae</i> type B.	<b>Rifampin ramps up cytochrome P-450, but rifabutin does not.</b>
ADVERSE EFFECTS	Minor hepatotoxicity and drug interactions (↑ cytochrome P-450); orange body fluids (nonhazardous side effect). Rifabutin favored over rifampin in patients with HIV infection due to less cytochrome P-450 stimulation.	
MECHANISM OF RESISTANCE	Mutations reduce drug binding to RNA polymerase. Monotherapy rapidly leads to resistance.	

**Isoniazid**

MECHANISM	↓ synthesis of mycolic acids. Bacterial catalase-peroxidase (encoded by KatG) needed to convert INH to active metabolite.	
CLINICAL USE	<i>Mycobacterium tuberculosis</i> . The only agent used as solo prophylaxis against TB. Also used as monotherapy for latent TB.	Different INH half-lives in fast vs slow acetylators.
ADVERSE EFFECTS	Hepatotoxicity, P-450 inhibition, drug-induced SLE, anion gap metabolic acidosis, vitamin B <sub>6</sub> deficiency (peripheral neuropathy, sideroblastic anemia). Administer with pyridoxine (B <sub>6</sub> ).	<b>INH Injures Neurons and Hepatocytes.</b>
MECHANISM OF RESISTANCE	Mutations leading to underexpression of KatG.	

**Pyrazinamide**

MECHANISM	Mechanism uncertain. Pyrazinamide is a prodrug that is converted to the active compound pyrazinoic acid. Works best at acidic pH (eg, in host phagolysosomes).	
CLINICAL USE	<i>Mycobacterium tuberculosis</i> .	
ADVERSE EFFECTS	Hyperuricemia, hepatotoxicity.	

**Ethambutol**

MECHANISM	↓ carbohydrate polymerization of mycobacterium cell wall by blocking arabinosyltransferase.	
CLINICAL USE	<i>Mycobacterium tuberculosis</i> .	
ADVERSE EFFECTS	<b>Optic</b> neuropathy (red-green color blindness). Pronounce “ <b>ey</b> thambutol.”	

**Streptomycin**

MECHANISM	Interferes with 30S component of ribosome.	
CLINICAL USE	<i>Mycobacterium tuberculosis</i> (2nd line).	
ADVERSE EFFECTS	Tinnitus, vertigo, ataxia, nephrotoxicity.	

### Antimicrobial prophylaxis

CLINICAL SCENARIO	MEDICATION
High risk for endocarditis and undergoing surgical or dental procedures	Amoxicillin
Exposure to gonorrhea	Ceftriaxone
History of recurrent UTIs	TMP-SMX
Exposure to meningococcal infection	Ceftriaxone, ciprofloxacin, or rifampin
Pregnant woman carrying group B strep	Intrapartum penicillin G or ampicillin
Prevention of gonococcal conjunctivitis in newborn	Erythromycin ointment on eyes
Prevention of postsurgical infection due to <i>S aureus</i>	Cefazolin
Prophylaxis of strep pharyngitis in child with prior rheumatic fever	Benzathine penicillin G or oral penicillin V
Exposure to syphilis	Benzathine penicillin G

### Prophylaxis in HIV patients

CELL COUNT	PROPHYLAXIS	INFECTION
CD4 < 200 cells/mm <sup>3</sup>	TMP-SMX	<i>Pneumocystis pneumonia</i>
CD4 < 100 cells/mm <sup>3</sup>	TMP-SMX	<i>Pneumocystis pneumonia</i> and toxoplasmosis
CD4 < 50 cells/mm <sup>3</sup>	Azithromycin or clarithromycin	<i>Mycobacterium avium</i> complex


### Treatment of highly resistant bacteria

MRSA: vancomycin, daptomycin, linezolid, tigecycline, ceftaroline, doxycycline.

VRE: linezolid and streptogramins (quinupristin, dalfopristin).

Multidrug-resistant *P aeruginosa*, multidrug-resistant *Acinetobacter baumannii*: polymyxins B and E (colistin).

### Antifungal therapy



**Amphotericin B**

MECHANISM	Binds ergosterol (unique to fungi); forms membrane pores that allow leakage of electrolytes.	Amphotericin “tears” holes in the fungal membrane by forming pores.
CLINICAL USE	Serious, systemic mycoses. <i>Cryptococcus</i> (amphotericin B with/without flucytosine for cryptococcal meningitis), <i>Blastomyces</i> , <i>Coccidioides</i> , <i>Histoplasma</i> , <i>Candida</i> , <i>Mucor</i> . Intrathecally for fungal meningitis. Supplement K <sup>+</sup> and Mg <sup>2+</sup> because of altered renal tubule permeability.	
ADVERSE EFFECTS	Fever/chills (“shake and bake”), hypotension, nephrotoxicity, arrhythmias, anemia, IV phlebitis (“ <b>amphoterrible</b> ”). Hydration ↓ nephrotoxicity. Liposomal amphotericin ↓ toxicity.	

**Nystatin**

MECHANISM	Same as amphotericin B. Topical use only as too toxic for systemic use.
CLINICAL USE	“Swish and swallow” for oral candidiasis (thrush); topical for diaper rash or vaginal candidiasis.

**Flucytosine**

MECHANISM	Inhibits DNA and RNA biosynthesis by conversion to 5-fluorouracil by cytosine deaminase.
CLINICAL USE	Systemic fungal infections (especially meningitis caused by <i>Cryptococcus</i> ) in combination with amphotericin B.
ADVERSE EFFECTS	Bone marrow suppression.

**Azoles**

	Clotrimazole, fluconazole, itraconazole, ketoconazole, miconazole, voriconazole, isavuconazole.
MECHANISM	Inhibit fungal sterol (ergosterol) synthesis by inhibiting the cytochrome P-450 enzyme that converts lanosterol to ergosterol.
CLINICAL USE	Local and less serious systemic mycoses. Fluconazole for chronic suppression of cryptococcal meningitis in AIDS patients and candidal infections of all types. Itraconazole for <i>Blastomyces</i> , <i>Coccidioides</i> , <i>Histoplasma</i> . Clotrimazole and miconazole for topical fungal infections. Voriconazole for <i>Aspergillus</i> and some <i>Candida</i> . Isavuconazole for serious <i>Aspergillus</i> and Mucorales infections.
ADVERSE EFFECTS	Testosterone synthesis inhibition (gynecomastia, especially with ketoconazole), liver dysfunction (inhibits cytochrome P-450).

**Terbinafine**

MECHANISM	Inhibits the fungal enzyme squalene epoxidase.
CLINICAL USE	Dermatophytoses (especially onychomycosis—fungal infection of finger or toe nails).
ADVERSE EFFECTS	GI upset, headaches, hepatotoxicity, taste disturbance.



**Echinocandins**

Anidulafungin, caspofungin, micafungin.

**MECHANISM**

Inhibit cell wall synthesis by inhibiting synthesis of  $\beta$ -glucan.

**CLINICAL USE**

Invasive aspergillosis, *Candida*.

**ADVERSE EFFECTS**

GI upset, flushing (by histamine release).

**Griseofulvin****MECHANISM**

Interferes with microtubule function; disrupts mitosis. Deposits in keratin-containing tissues (eg, nails).

**CLINICAL USE**

Oral treatment of superficial infections; inhibits growth of dermatophytes (tinea, ringworm).

**ADVERSE EFFECTS**

Teratogenic, carcinogenic, confusion, headaches, disulfiram-like reaction,  $\uparrow$  cytochrome P-450 and warfarin metabolism.

**Antiprotozoan therapy**

Pyrimethamine (toxoplasmosis), suramin and melarsoprol (*Trypanosoma brucei*), nifurtimox (*T cruzi*), sodium stibogluconate (leishmaniasis).

**Anti-mite/lice therapy**

Permethrin (neuronal membrane depolarization via  $\text{Na}^+$  channels), malathion (acetylcholinesterase inhibitor), lindane (blocks GABA channels  $\rightarrow$  neurotoxicity). Used to treat scabies (*Sarcoptes scabiei*) and lice (*Pediculus* and *Pthirus*).

Treat **PML** (**P**esty **M**ites and **L**ice) with **PML** (**P**ermethrin, **M**alathion, **L**indane), because they **NAG** you (**N**a, **A**ChE, **G**ABA blockade).

**Chloroquine****MECHANISM**

Blocks detoxification of heme into hemozoin. Heme accumulates and is toxic to plasmodia.

**CLINICAL USE**

Treatment of plasmodial species other than *P falciparum* (frequency of resistance in *P falciparum* is too high). Resistance due to membrane pump that  $\downarrow$  intracellular concentration of drug. Treat *P falciparum* with artemether/lumefantrine or atovaquone/proguanil. For life-threatening malaria, use quinidine in US (quinine elsewhere) or artesunate.


**ADVERSE EFFECTS**

Retinopathy; pruritus (especially in dark-skinned individuals).

**Anthelmintic therapy**

Mebendazole (microtubule inhibitor), pyrantel pamoate, ivermectin, diethylcarbamazine, praziquantel.

**Antiviral therapy**



**Oseltamivir, zanamivir**

<b>MECHANISM</b>	Inhibit influenza neuraminidase → ↓ release of progeny virus.
<b>CLINICAL USE</b>	Treatment and prevention of both influenza A and B. Beginning therapy within 48 hours of symptom onset may shorten duration of illness.

**Acyclovir, famciclovir, valacyclovir**

<b>MECHANISM</b>	Guanosine analogs. Monophosphorylated by HSV/VZV thymidine kinase and not phosphorylated in uninfected cells → few adverse effects. Triphosphate formed by cellular enzymes. Preferentially inhibit viral DNA polymerase by chain termination.
<b>CLINICAL USE</b>	HSV and VZV. Weak activity against EBV. No activity against CMV. Used for HSV-induced mucocutaneous and genital lesions as well as for encephalitis. Prophylaxis in immunocompromised patients. No effect on latent forms of HSV and VZV. Valacyclovir, a prodrug of acyclovir, has better oral bioavailability. For herpes zoster, use famciclovir.
<b>ADVERSE EFFECTS</b>	Obstructive crystalline nephropathy and acute renal failure if not adequately hydrated.
<b>MECHANISM OF RESISTANCE</b>	Mutated viral thymidine kinase.

**Ganciclovir**

MECHANISM	5'-monophosphate formed by a CMV viral kinase. Guanosine analog. Triphosphate formed by cellular kinases. Preferentially inhibits viral DNA polymerase.
CLINICAL USE	CMV, especially in immunocompromised patients. Valganciclovir, a prodrug of ganciclovir, has better oral bioavailability.
ADVERSE EFFECTS	Bone marrow suppression (leukopenia, neutropenia, thrombocytopenia), renal toxicity. More toxic to host enzymes than acyclovir.
MECHANISM OF RESISTANCE	Mutated viral kinase.

**Foscarnet**

MECHANISM	Viral DNA/RNA polymerase inhibitor and HIV reverse transcriptase inhibitor. Binds to pyrophosphate-binding site of enzyme. Does not require any kinase activation.	<b>Foscarnet</b> = pyro <b>fos</b> phate analog.
CLINICAL USE	CMV retinitis in immunocompromised patients when ganciclovir fails; acyclovir-resistant HSV.	
ADVERSE EFFECTS	Nephrotoxicity, electrolyte abnormalities (hypo- or hypercalcemia, hypo- or hyperphosphatemia, hypokalemia, hypomagnesemia) can lead to seizures.	
MECHANISM OF RESISTANCE	Mutated DNA polymerase.	

**Cidofovir**

MECHANISM	Preferentially inhibits viral DNA polymerase. Does not require phosphorylation by viral kinase.
CLINICAL USE	CMV retinitis in immunocompromised patients; acyclovir-resistant HSV. Long half-life.
ADVERSE EFFECTS	Nephrotoxicity (coadminister with probenecid and IV saline to ↓ toxicity).

**HIV therapy**

Highly active antiretroviral therapy (HAART): often initiated at the time of HIV diagnosis. Strongest indication for patients presenting with AIDS-defining illness, low CD4+ cell counts (< 500 cells/mm<sup>3</sup>), or high viral load. Regimen consists of 3 drugs to prevent resistance: 2 NRTIs and preferably an integrase inhibitor.

DRUG	MECHANISM	TOXICITY
<b>NRTIs</b>		
Abacavir (ABC) Didanosine (ddI) Emtricitabine (FTC) Lamivudine (3TC) Stavudine (d4T) Tenofovir (TDF) Zidovudine (ZDV, formerly AZT)	Competitively inhibit nucleotide binding to reverse transcriptase and terminate the DNA chain (lack a 3' OH group). <b>T</b> enofovir is a nucleo <b>T</b> ide; the others are nucleosides. All need to be phosphorylated to be active. ZDV can be used for general prophylaxis and during pregnancy to ↓ risk of fetal transmission. <b>Have you dined (vudine) with my nuclear (nucleosides) family?</b>	Bone marrow suppression (can be reversed with granulocyte colony-stimulating factor [G-CSF] and erythropoietin), peripheral neuropathy, lactic acidosis (nucleosides), anemia (ZDV), pancreatitis (didanosine). Abacavir contraindicated if patient has HLA-B*5701 mutation due to ↑ risk of hypersensitivity.
<b>NNRTIs</b>		
Delavirdine Efavirenz Nevirapine	Bind to reverse transcriptase at site different from NRTIs. Do not require phosphorylation to be active or compete with nucleotides.	Rash and hepatotoxicity are common to all NNRTIs. Vivid dreams and CNS symptoms are common with efavirenz. Delavirdine and efavirenz are contraindicated in pregnancy.
<b>Protease inhibitors</b>		
Atazanavir Darunavir Fosamprenavir Indinavir Lopinavir Ritonavir Saquinavir	Assembly of virions depends on HIV-1 protease ( <i>pol</i> gene), which cleaves the polypeptide products of HIV mRNA into their functional parts. Thus, protease inhibitors prevent maturation of new viruses. Ritonavir can “boost” other drug concentrations by inhibiting cytochrome P-450. <b>Navir (never) tease a protease.</b>	Hyperglycemia, GI intolerance (nausea, diarrhea), lipodystrophy (Cushing-like syndrome). Nephropathy, hematuria, thrombocytopenia (indinavir). Rifampin (potent CYP/UGT inducer) reduces protease inhibitor concentrations; use rifabutin instead.
<b>Integrase inhibitors</b>		
Raltegravir Elvitegravir Dolutegravir	Inhibits HIV genome integration into host cell chromosome by reversibly inhibiting HIV integrase.	↑ creatine kinase.
<b>Fusion inhibitors</b>		
Enfuvirtide	Binds gp41, inhibiting viral entry.	Skin reaction at injection sites. Enfuvirtide inhibits <b>fusion</b> .
Maraviroc	Binds CCR-5 on surface of T cells/monocytes, inhibiting interaction with gp120.	Maraviroc inhibits <b>docking</b> .

**Interferons**

MECHANISM	Glycoproteins normally synthesized by virus-infected cells, exhibiting a wide range of antiviral and antitumoral properties.
CLINICAL USE	IFN- $\alpha$ : chronic hepatitis B and C, Kaposi sarcoma, hairy cell leukemia, condyloma acuminatum, renal cell carcinoma, malignant melanoma. IFN- $\beta$ : multiple sclerosis. IFN- $\gamma$ : chronic granulomatous disease.
ADVERSE EFFECTS	Flu-like symptoms, depression, neutropenia, myopathy.

**Hepatitis C therapy**

DRUG	MECHANISM	CLINICAL USE
<b>Ribavirin</b>	Inhibits synthesis of guanine nucleotides by competitively inhibiting inosine monophosphate dehydrogenase.	Chronic HCV; also used in RSV (palivizumab preferred in children) Adverse effects: hemolytic anemia; severe teratogen.
<b>Sofosbuvir</b>	Inhibits HCV RNA-dependent RNA polymerase acting as a chain terminator.	Chronic HCV in combination with ribavirin, simeprevir, ledipasvir (NS5A inhibitor), +/- peginterferon alfa. Do not use as monotherapy. Adverse effects: fatigue, headache, nausea.
<b>Simeprevir</b>	HCV protease inhibitor; prevents viral replication.	Chronic HCV in combination with ledipasvir (NS5A inhibitor). Do not use as monotherapy. Adverse effects: photosensitivity reactions, rash.

**Disinfection and sterilization**

	Goals include the reduction of pathogenic organism counts to safe levels (disinfection) and the inactivation of self-propagating biological entities (sterilization).
<b>Autoclave</b>	Pressurized steam at $> 120^{\circ}\text{C}$ . May be sporicidal.
<b>Alcohols</b>	Denature proteins and disrupt cell membranes. Not sporicidal.
<b>Chlorhexidine</b>	Denatures proteins and disrupts cell membranes. Not sporicidal.
<b>Hydrogen peroxide</b>	Free radical oxidation. Sporicidal.
<b>Iodine and iodophors</b>	Halogenation of DNA, RNA, and proteins. May be sporicidal.

**Antimicrobials to  
avoid in pregnancy**

ANTIMICROBIAL	ADVERSE EFFECT
<b>S</b> ulfonamides	Kernicterus
<b>A</b> minoglycosides	Ototoxicity
<b>F</b> luoroquinolones	Cartilage damage
<b>C</b> larithromycin	Embryotoxic
<b>T</b> etracyclines	Discolored teeth, inhibition of bone growth
<b>R</b> ibavirin	Teratogenic
<b>G</b> riseofulvin	Teratogenic
<b>C</b> hloramphenicol	Gray baby syndrome

**SAFe Children Take Really Good Care.**



# Pathology

*“Digressions, objections, delight in mockery, carefree mistrust are signs of health; everything unconditional belongs in pathology.”*

—Friedrich Nietzsche

*“You cannot separate passion from pathology any more than you can separate a person’s spirit from his body.”*

—Richard Selzer

The fundamental principles of pathology are key to understanding diseases in all organ systems. Major topics such as inflammation and neoplasia appear frequently in questions across different organ systems, and such topics are definitely high yield. For example, the concepts of cell injury and inflammation are key to understanding the inflammatory response that follows myocardial infarction, a very common subject of board questions. Similarly, a familiarity with the early cellular changes that culminate in the development of neoplasias—for example, esophageal or colon cancer—is critical. Finally, make sure you recognize the major tumor-associated genes and are comfortable with key cancer concepts such as tumor staging and metastasis.

▶ Inflammation	204
▶ Neoplasia	214



## ▶ PATHOLOGY—INFLAMMATION

**Apoptosis**

ATP-dependent programmed cell death.

Intrinsic and extrinsic pathways; both pathways activate caspases (cytosolic proteases) → cellular breakdown including cell shrinkage, chromatin condensation, membrane blebbing, and formation of apoptotic bodies, which are then phagocytosed.

Characterized by deeply eosinophilic cytoplasm and basophilic nucleus, pyknosis (nuclear shrinkage), and karyorrhexis (fragmentation caused by endonuclease-mediated cleavage). Cell membrane typically remains intact without significant inflammation (unlike necrosis). DNA laddering (fragments in multiples of 180 bp) is a sensitive indicator of apoptosis.

**Intrinsic (mitochondrial) pathway**

Involved in tissue remodeling in embryogenesis. Occurs when a regulating factor is withdrawn from a proliferating cell population (eg, ↓ IL-2 after a completed immunologic reaction → apoptosis of proliferating effector cells). Also occurs after exposure to injurious stimuli (eg, radiation, toxins, hypoxia).

Regulated by Bcl-2 family of proteins. BAX and BAK are proapoptotic, while Bcl-2 and Bcl-x are antiapoptotic.

Bcl-2 keeps the mitochondrial outer membrane impermeable and therefore prevents cytochrome c release from the inner mitochondrial matrix. Bcl-2 overexpression (eg, follicular lymphoma t[14;18]) → ↓ caspase activation → tumorigenesis.


**Extrinsic (death receptor) pathway**

2 pathways:

- Ligand receptor interactions (FasL binding to Fas [CD95] or TNF- $\alpha$  binding to its receptor)
- Immune cell (cytotoxic T-cell release of perforin and granzyme B)

Fas-FasL interaction is necessary in thymic medullary negative selection. Mutations in Fas ↑ numbers of circulating self-reacting lymphocytes due to failure of clonal deletion.


Defective Fas-FasL interactions cause autoimmune lymphoproliferative syndrome.




**Necrosis**

Enzymatic degradation and protein denaturation of cell due to exogenous injury → intracellular components leak. Inflammatory process (unlike apoptosis).


TYPE	SEEN IN	DUE TO	HISTOLOGY
<b>Coagulative</b>	Ischemia/infarcts in most tissues (except brain)	Ischemia or infarction; proteins denature, then enzymatic degradation	Cell outlines preserved but nuclei disappear; ↑ cytoplasmic binding of eosin dyes <b>A</b>
<b>Liquefactive</b>	Bacterial abscesses, brain infarcts	Neutrophils release lysosomal enzymes that digest the tissue <b>B</b> ; enzymatic degradation first, then proteins denature	Early: cellular debris and macrophages Late: cystic spaces and cavitation (brain) Neutrophils and cell debris seen with bacterial infection
<b>Caseous</b>	TB, systemic fungi (eg, <i>Histoplasma capsulatum</i> ), <i>Nocardia</i>	Macrophages wall off the infecting microorganism → granular debris <b>C</b>	Fragmented cells and debris surrounded by lymphocytes and macrophages
<b>Fat</b>	Enzymatic: acute pancreatitis (saponification of peripancreatic fat) Nonenzymatic: traumatic (eg, injury to breast tissue)	Damaged cells release lipase to break down triglycerides, liberating fatty acids to bind calcium → saponification	Outlines of dead fat cells without peripheral nuclei; saponification of fat (combined with Ca <sup>2+</sup> ) appears dark blue on H&E stain <b>D</b>
<b>Fibrinoid</b>	Immune reactions in vessels (eg, polyarteritis nodosa), preeclampsia, malignant hypertension	Immune complexes combine with fibrin → vessel wall damage (type III hypersensitivity reaction)	Vessel walls are thick and pink <b>E</b>
<b>Gangrenous</b>	Distal extremity and GI tract, after chronic ischemia	Dry: ischemia <b>F</b> Wet: superinfection	Coagulative Liquefactive superimposed on coagulative



## Cell injury



## Ischemia




Inadequate blood supply to meet demand.

Regions most vulnerable to hypoxia/ischemia and subsequent infarction:

ORGAN	REGION
Brain	ACA/MCA/PCA boundary areas <sup>a,b</sup>
Heart	Subendocardium (LV)
Kidney	Straight segment of proximal tubule (medulla) Thick ascending limb (medulla)
Liver	Area around central vein (zone III)
Colon	Splenic flexure, <sup>a</sup> rectum <sup>a</sup>


<sup>a</sup>Watershed areas (border zones) receive blood supply from most distal branches of 2 arteries with limited collateral vascularity. These areas are susceptible to ischemia from hypoperfusion (eg, ACA/MCA [anterior] and MCA/PCA [posterior] watershed areas in blue **A**).

<sup>b</sup>Neurons most vulnerable to hypoxic-ischemic insults include Purkinje cells of the cerebellum and pyramidal cells of the hippocampus and neocortex (zones 3, 5, 6).

**Types of infarcts****Red infarct**

Red (hemorrhagic) infarcts **A** occur in venous occlusion and tissues with multiple blood supplies, such as liver, lung, intestine, testes; reperfusion (eg, after angioplasty). Reperfusion injury is due to damage by free radicals.

**Red** = reperfusion.

**Pale infarct**

Pale (anemic) infarcts **B** occur in solid organs with a single (end-arterial) blood supply, such as heart, kidney, and spleen.

**Inflammation**

Characterized by *rubor* (redness), *dolor* (pain), *calor* (heat), *tumor* (swelling), and *functio laesa* (loss of function).

**Vascular component**

↑ vascular permeability, vasodilation, endothelial injury.

**Cellular component**

Neutrophils extravasate from circulation to injured tissue to participate in inflammation through phagocytosis, degranulation, and inflammatory mediator release.



**Acute**

Neutrophil, eosinophil, antibody (pre-existing), mast cell, and basophil mediated. Acute inflammation is rapid onset (seconds to minutes) and of short duration (minutes to days). Outcomes include complete resolution, abscess formation, or progression to chronic inflammation.

**Chronic**

Mononuclear cell (monocytes/macrophages, lymphocytes, plasma cells) and fibroblast mediated. Characterized by persistent destruction and repair. Associated with blood vessel proliferation, fibrosis. Granuloma: nodular collections of epithelioid macrophages and giant cells. Outcomes include scarring, amyloidosis, and neoplastic transformation.

Types of calcification	Dystrophic calcification	Metastatic calcification
CA <sup>2+</sup> DEPOSITION	In abnormal tissues	In normal tissues
EXTENT	Tends to be localized (eg, calcific aortic stenosis) <b>A</b> shows dystrophic calcification (yellow star), and thick fibrotic wall (red arrows)	Widespread (ie, diffuse, metastatic) <b>B</b> shows metastatic calcifications of alveolar walls in acute pneumonitis (arrows)
ASSOCIATED CONDITIONS	TB (lung and pericardium) and other granulomatous infections; liquefactive necrosis of chronic abscesses; fat necrosis; infarcts; thrombi; schistosomiasis; congenital CMV, toxoplasmosis, rubella; psammoma bodies; CREST syndrome	Predominantly in interstitial tissues of kidney, lung, and gastric mucosa (these tissues lose acid quickly; ↑ pH favors Ca <sup>2+</sup> deposition) Nephrocalcinosis of collecting ducts may lead to nephrogenic diabetes insipidus and renal failure
ETIOLOGY	2° to injury or necrosis	2° to hypercalcemia (eg, 1° hyperparathyroidism, sarcoidosis, hypervitaminosis D) or high calcium-phosphate product levels (eg, chronic renal failure with 2° hyperparathyroidism, long-term dialysis, calciphylaxis, multiple myeloma)
SERUM CA <sup>2+</sup> LEVELS	Patients are usually normocalcemic	Patients are usually not normocalcemic




**Leukocyte extravasation**

Extravasation predominantly occurs at postcapillary venules.

WBCs exit from blood vessels at sites of tissue injury and inflammation in 4 steps:

STEP	VASCULATURE/STROMA	LEUKOCYTE
<b>1</b> Margination and rolling— defective in leukocyte adhesion deficiency type 2 (↓ Sialyl-Lewis <sup>X</sup> )	E-selectin (upregulated by TNF and IL-1)	Sialyl-Lewis <sup>X</sup>
	P-selectin (released from Weibel-Palade bodies)	Sialyl-Lewis <sup>X</sup>
	GlyCAM-1, CD34	L-selectin
<b>2</b> Tight binding (adhesion)— defective in leukocyte adhesion deficiency type 1 (↓ CD18 integrin subunit)	ICAM-1 (CD54)	CD11/18 integrins (LFA-1, Mac-1)
	VCAM-1 (CD106)	VLA-4 integrin
<b>3</b> Diapedesis—WBC travels between endothelial cells and exits blood vessel	PECAM-1 (CD31)	PECAM-1 (CD31)
<b>4</b> Migration—WBC travels through interstitium to site of injury or infection guided by chemotactic signals	Chemotactic products released in response to bacteria: C5a, IL-8, LTB <sub>4</sub> , kallikrein, platelet-activating factor	Various



**Free radical injury**

Free radicals damage cells via membrane lipid peroxidation, protein modification, and DNA breakage.

Initiated via radiation exposure (eg, cancer therapy), metabolism of drugs (phase I), redox reactions, nitric oxide (eg, inflammation), transition metals, WBC (eg, neutrophils, macrophages) oxidative burst.

Free radicals can be eliminated by scavenging enzymes (eg, catalase, superoxide dismutase, glutathione peroxidase), spontaneous decay, antioxidants (eg, vitamins A, C, E), and certain metal carrier proteins (eg, transferrin, ceruloplasmin).

Examples:

- Oxygen toxicity: retinopathy of prematurity (abnormal vascularization), bronchopulmonary dysplasia, reperfusion injury after thrombolytic therapy
- Drug/chemical toxicity: carbon tetrachloride and acetaminophen overdose (hepatotoxicity)
- Metal storage diseases: hemochromatosis (iron) and Wilson disease (copper)

**Scar formation**


70–80% of tensile strength regained at 3 months; minimal additional tensile strength will be regained afterward.

SCAR TYPE	<b>Hypertrophic A</b>	<b>Keloid B</b>
COLLAGEN SYNTHESIS	↑ (type III collagen)	↑↑↑ (disorganized types I and III collagen)
COLLAGEN ORGANIZATION	Parallel	Disorganized
EXTENT OF SCAR	Confined to borders of original wound	Extends beyond borders of original wound with “claw-like” projections typically on earlobes, face, upper extremities
RECURRENCE	Infrequent	Frequent
PREDISPOSITION	None	↑ incidence in ethnic groups with darker skin



**Wound healing**

Tissue mediators	MEDIATOR	ROLE
	PDGF <sup>F</sup>	Secreted by activated platelets and macrophages Induces vascular remodeling and smooth muscle cell migration Stimulates fibroblast growth for collagen synthesis
	FGF	Stimulates angiogenesis
	EGF	Stimulates cell growth via tyrosine kinases (eg, EGFR/ <i>ErbB1</i> )
	TGF- $\beta$	Angiogenesis, fibrosis
	Metalloproteinases	Tissue remodeling
	VEGF	Stimulates angiogenesis
PHASE OF WOUND HEALING	EFFECTOR CELLS	CHARACTERISTICS
<b>Inflammatory (up to 3 days after wound)</b>	Platelets, neutrophils, macrophages	Clot formation, $\uparrow$ vessel permeability and neutrophil migration into tissue; macrophages clear debris 2 days later
<b>Proliferative (day 3–weeks after wound)</b>	Fibroblasts, myofibroblasts, endothelial cells, keratinocytes, macrophages	Deposition of granulation tissue and type III collagen, angiogenesis, epithelial cell proliferation, dissolution of clot, and wound contraction (mediated by myofibroblasts) Delayed wound healing in vitamin C deficiency and copper deficiency
<b>Remodeling (1 week–6+ months after wound)</b>	Fibroblasts	Type III collagen replaced by type I collagen, $\uparrow$ tensile strength of tissue Delayed wound healing in zinc deficiency

**Granulomatous diseases**

Bacterial:

- *Mycobacteria* (tuberculosis, leprosy)
- *Bartonella henselae* (cat scratch disease)
- *Listeria monocytogenes* (granulomatosis infantiseptica)
- *Treponema pallidum* (3° syphilis)

Fungal: endemic mycoses (eg, histoplasmosis)

Parasitic: schistosomiasis

Chronic granulomatous disease

Autoinflammatory:

- Sarcoidosis
- Crohn disease
- Primary biliary cirrhosis
- Subacute (de Quervain/granulomatous) thyroiditis
- Granulomatosis with polyangiitis (Wegener)
- Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)
- Giant cell (temporal) arteritis
- Takayasu arteritis

Foreign material: berylliosis, talcosis, hypersensitivity pneumonitis

Granulomas are composed of epithelioid cells (macrophages with abundant pink cytoplasm) with surrounding multinucleated giant cells and lymphocytes. Th<sub>1</sub> cells secrete IFN- $\gamma$ , activating macrophages. TNF- $\alpha$  from macrophages induces and maintains granuloma formation. Anti-TNF drugs can, as a side effect, cause sequestering granulomas to break down, leading to disseminated disease. Always test for latent TB before starting anti-TNF therapy. Associated with hypercalcemia due to calcitriol (1,25-[OH]<sub>2</sub> vitamin D<sub>3</sub>) production. Caseating necrosis is more common with an infectious etiology (eg, TB). Diagnosis of sarcoidosis requires noncaseating granulomas **A** on biopsy.



**Exudate vs transudate****Exudate**

Cellular (cloudy)

↑ protein (&gt; 2.9 g/dL)

↑ LDH (vs serum)

Due to:

- Lymphatic obstruction (chylous)
- Inflammation/infection
- Malignancy

**Transudate**

Hypocellular (clear)

↓ protein (&lt; 2.5 g/dL)

↓ LDH (vs serum)

Due to:

- ↑ hydrostatic pressure (eg, HF, Na<sup>+</sup> retention)
- ↓ oncotic pressure (eg, cirrhosis, nephrotic syndrome)

**Light criteria**

Diagnostic analysis comparing serum and pleural fluid protein and LDH levels.

Pleural effusion is exudative if ≥ 1 of the following criteria is met:

- Pleural effusion protein/serum protein ratio > 0.5
- Pleural effusion LDH/serum LDH ratio > 0.6
- Pleural effusion LDH > ⅔ of the upper limit of normal for serum LDH

**Erythrocyte****sedimentation rate**

Products of inflammation (eg, fibrinogen) coat RBCs and cause aggregation. The denser RBC aggregates fall at a faster rate within a pipette tube. Often co-tested with CRP levels.

**↑ ESR**

Most anemias

Infections

Inflammation (eg, giant cell [temporal] arteritis, polymyalgia rheumatica)

Cancer (eg, metastases, multiple myeloma)

Renal disease (end-stage or nephrotic syndrome)

Pregnancy

**↓ ESR**

Sickle cell anemia (altered shape)

Polycythemia (↑ RBCs “dilute” aggregation factors)

HF


Microcytosis

Hypofibrinogenemia


**Amyloidosis**

Abnormal aggregation of proteins (or their fragments) into  $\beta$ -pleated linear sheets  $\rightarrow$  insoluble fibrils  $\rightarrow$  cellular damage and apoptosis. Amyloid deposits visualized by Congo red stain **A**, polarized light (apple green birefringence) **B**, and H&E stain (**C** shows deposits in glomerular mesangial areas [white arrows], tubular basement membranes [black arrows]).

COMMON TYPES	DESCRIPTION
<b>AL (primary)</b>	Due to deposition of proteins from Ig <b>L</b> ight chains. Can occur as a plasma cell disorder or associated with multiple myeloma. Often affects multiple organ systems, including renal (nephrotic syndrome), cardiac (restrictive cardiomyopathy, arrhythmia), hematologic (easy bruising, splenomegaly), GI (hepatomegaly), and neurologic (neuropathy).
<b>AA (secondary)</b>	Seen with chronic inflammatory conditions such as rheumatoid arthritis, IBD, spondyloarthropathy, familial Mediterranean fever, protracted infection. Fibrils composed of serum <b>A</b> myloid <b>A</b> . Often multisystem like AL amyloidosis.
<b>Dialysis-related</b>	Fibrils composed of $\beta_2$ -microglobulin in patients with ESRD and/or on long-term dialysis. May present as carpal tunnel syndrome.
<b>Heritable</b>	Heterogeneous group of disorders, including familial amyloid polyneuropathies due to transthyretin gene mutation.
<b>Age-related (senile) systemic</b>	Due to deposition of normal (wild-type) transthyretin (TTR) predominantly in cardiac ventricles. Slower progression of cardiac dysfunction relative to AL amyloidosis.
<b>Organ-specific</b>	Amyloid deposition localized to a single organ. Most important form is amyloidosis in Alzheimer disease due to deposition of $\beta$ -amyloid protein cleaved from amyloid precursor protein (APP). Islet amyloid polypeptide (IAPP) is commonly seen in diabetes mellitus type 2 and is caused by deposition of amylin in pancreatic islets. Isolated atrial amyloidosis due to atrial natriuretic peptide is common in normal aging and can predispose to increased risk of atrial fibrillation. Amyloid deposition to ventricular endomyocardium in restrictive cardiomyopathy. Calcitonin deposition in tumor cells in medullary carcinoma of the thyroid.



**Lipofuscin**




A yellow-brown “wear and tear” pigment **A** associated with normal aging. Formed by oxidation and polymerization of autophagocytosed organellar membranes. Autopsy of elderly person will reveal deposits in heart, colon, liver, kidney, eye, and other organs.

## ▶ PATHOLOGY—NEOPLASIA

**Cellular changes**

<b>Hyperplasia</b>	↑ in number of cells. May be a risk factor for future malignancy (eg, endometrial hyperplasia) but not considered premalignant.
<b>Hypertrophy</b>	↑ in size of cells.
<b>Atrophy</b>	↓ in tissue mass due to ↓ in size and/or number of cells. Causes include disuse, denervation, loss of blood supply, loss of hormonal stimulation, poor nutrition.
<b>Dysplasia</b>	Disordered, non-neoplastic cell growth. Term used only with epithelial cells. Mild dysplasia is usually reversible; severe dysplasia usually progresses to carcinoma in situ.
<b>Metaplasia</b>	Replacement of one cell type by another. Usually due to exposure to an irritant, such as gastric acid or cigarette smoke. Reversible if the irritant is removed but may undergo malignant transformation with persistent insult (eg, Barrett esophagus → esophageal adenocarcinoma).
<b>Neoplasia</b>	Uncontrolled, clonal proliferation of cells. Can be benign or malignant.
<b>Anaplasia</b>	Complete lack of differentiation of cells in a malignant neoplasm.
<b>Differentiation</b>	The degree to which a malignant tumor resembles its tissue of origin: <ul style="list-style-type: none"> <li>▪ Well-differentiated tumors (often less aggressive) closely resemble their tissue of origin.</li> <li>▪ Poorly differentiated tumors (often more aggressive) look almost nothing like their tissue of origin.</li> </ul>




**Neoplastic progression**

Hallmarks of cancer: evasion of apoptosis, growth signal self-sufficiency, anti-growth signal insensitivity, sustained angiogenesis, limitless replicative potential, tissue invasion, and metastasis.


**Normal cells**

Normal cells with basal → apical polarity. See cervical example **A**, which shows normal cells and spectrum of dysplasia, as discussed below.



**Dysplasia**

Abnormal proliferation of cells with loss of size, shape, and orientation (eg, koilocytic change, arrow in **A**). Compare vs hyperplasia (cells ↑ in number).




**Carcinoma in situ/preinvasive**

Neoplastic cells have not invaded the intact basement membrane.  
 ↑ nuclear:cytoplasmic ratio and clumped chromatin.  
 Neoplastic cells encompass entire thickness.



**Invasive carcinoma**

Cells have invaded basement membrane using collagenases and hydrolases (metalloproteinases).  
 Cell-cell contacts lost by inactivation of E-cadherin.





**Metastasis**

Spread to distant organ via lymphatics or blood.

“Seed and soil” theory of metastasis:

- Seed = tumor embolus.
- Soil = target organ is often the first-encountered capillary bed (eg, liver, lungs, bone, brain, etc).



Normal

Mild dysplasia

Moderate dysplasia

Severe dysplasia/  
carcinoma in situ

**Tumor grade vs stage**

<b>Grade</b>	Degree of cellular differentiation and mitotic activity on histology. Range from low grade (well differentiated) to high grade (poorly differentiated, undifferentiated or anaplastic).	Stage generally has more prognostic value than grade (eg, a high-stage yet low-grade tumor is usually worse than a low-stage yet high-grade tumor).
<b>Stage</b>	Degree of localization/spread based on site and size of 1° lesion, spread to regional lymph nodes, presence of metastases. Based on clinical (c) or pathology (p) findings. Example: cT3N1M0	TNM staging system ( <b>S</b> tage = <b>S</b> pread): <b>T</b> = Tumor size/invasiveness <b>N</b> = Node involvement <b>M</b> = Metastases Each TNM factor has independent prognostic value; N and M factors are often most important.

**Tumor nomenclature**

**Carcinoma** implies epithelial origin, whereas **sarcoma** denotes mesenchymal origin. Both terms imply malignancy.

**Benign** tumors are usually well differentiated, well demarcated, low mitotic activity, no metastasis, no necrosis.

**Malignant** tumors may show poor differentiation, erratic growth, local invasion, metastasis, and ↓ apoptosis. Upregulation of telomerase prevents chromosome shortening and cell death.

Terms for non-neoplastic malformations include hamartoma (disorganized overgrowth of tissues in their native location, eg, Peutz-Jeghers polyps) and choristoma (normal tissue in a foreign location, eg, gastric tissue located in distal ileum in Meckel diverticulum).

CELL TYPE	BENIGN	MALIGNANT
<b>Epithelium</b>	Adenoma, papilloma	Adenocarcinoma, papillary carcinoma
<b>Mesenchyme</b>		
Blood cells		Leukemia, lymphoma
Blood vessels	Hemangioma	Angiosarcoma
Smooth muscle	Leiomyoma	Leiomyosarcoma
Striated muscle	Rhabdomyoma	Rhabdomyosarcoma
Connective tissue	Fibroma	Fibrosarcoma
Bone	Osteoma	Osteosarcoma
Fat	Lipoma	Liposarcoma
Melanocyte	Nevus/mole	Melanoma

**Cancer epidemiology**

Skin cancer (basal > squamous >>> melanoma) is the most common cancer (not included below).

	MEN	WOMEN	CHILDREN (AGE 0–14)	NOTES
<b>Cancer incidence</b>	1. Prostate 2. Lung 3. Colon/rectum	1. Breast 2. Lung 3. Colon/rectum	1. Leukemia 2. Brain and CNS 3. Neuroblastoma	Lung cancer incidence has dropped in men, but has not changed significantly in women.
<b>Cancer mortality</b>	1. Lung 2. Prostate 3. Colon/rectum	1. Lung 2. Breast 3. Colon/rectum	1. Leukemia 2. Brain and CNS 3. Neuroblastoma	Cancer is the 2nd leading cause of death in the United States (heart disease is 1st).

**Paraneoplastic syndromes**

MANIFESTATION	DESCRIPTION/MECHANISM	MOST COMMONLY ASSOCIATED CANCER(S)
<b>Cutaneous</b>		
Acanthosis nigricans	Hyperpigmented velvety plaques in axilla and neck	Gastric adenocarcinoma and other visceral malignancies (but more commonly associated with obesity and insulin resistance)
Sign of Leser-Trélat	Sudden onset of multiple seborrheic keratoses	GI adenocarcinomas and other visceral malignancies
<b>Endocrine</b>		
Hypercalcemia	PTHrP  ↑ 1,25-(OH) <sub>2</sub> vitamin D <sub>3</sub> (calcitriol)	Squamous cell carcinomas of lung, head, and neck; renal, bladder, breast, and ovarian carcinomas Lymphoma
Cushing syndrome	↑ ACTH	Small cell lung cancer
Hyponatremia (SIADH)	↑ ADH	
<b>Hematologic</b>		
Polycythemia	↑ Erythropoietin	Renal cell carcinoma, hepatocellular carcinoma, hemangioblastoma, pheochromocytoma, leiomyoma
Pure red cell aplasia	Anemia with low reticulocytes	Thymoma
Good syndrome	Hypogammaglobulinemia	
Trousseau syndrome	Migratory superficial thrombophlebitis	
Nonbacterial thrombotic (marantic) endocarditis	Deposition of sterile platelet thrombi on heart valves	Adenocarcinomas, especially pancreatic
<b>Neuromuscular</b>		
Anti-NMDA receptor encephalitis	Psychiatric disturbance, memory deficits, seizures, dyskinesias, autonomic instability, language dysfunction	Ovarian teratoma
Opsoclonus-myoclonus ataxia syndrome	“Dancing eyes, dancing feet”	Neuroblastoma (children), small cell lung cancer (adults)
Paraneoplastic cerebellar degeneration	Antibodies against antigens in Purkinje cells	Small cell lung cancer (anti-Hu), gynecologic and breast cancers (anti-Yo), and Hodgkin lymphoma (anti-Tr)
Paraneoplastic encephalomyelitis	Antibodies against Hu antigens in neurons	Small cell lung cancer
Lambert-Eaton myasthenic syndrome	Antibodies against presynaptic (P/Q-type) Ca <sup>2+</sup> channels at NMJ	Small cell lung cancer
Myasthenia gravis	Antibodies against postsynaptic ACh receptors at NMJ	Thymoma

**Oncogenes**Gain of function → ↑ cancer risk. Need damage to only **one** allele of an **oncogene**.

GENE	GENE PRODUCT	ASSOCIATED NEOPLASM
<b>ALK</b>	Receptor tyrosine kinase	Lung adenocarcinoma
<b>BCR-ABL</b>	Tyrosine kinase	CML, ALL
<b>BCL-2</b>	Antiapoptotic molecule (inhibits apoptosis)	Follicular and diffuse large B cell lymphomas
<b>BRAF</b>	Serine/threonine kinase	Melanoma, non-Hodgkin lymphoma, papillary thyroid carcinoma
<b>c-KIT</b>	Cytokine receptor	Gastrointestinal stromal tumor (GIST)
<b>c-MYC</b>	Transcription factor	Burkitt lymphoma
<b>HER2/neu (c-erbB2)</b>	Receptor tyrosine kinase	Breast and gastric carcinomas
<b>JAK2</b>	Tyrosine kinase	Chronic myeloproliferative disorders
<b>KRAS</b>	GTPase	Colon cancer, lung cancer, pancreatic cancer
<b>MYCL1</b>	Transcription factor	<b>Lung tumor</b>
<b>MYCN</b>	Transcription factor	<b>Neuroblastoma</b>
<b>RET</b>	Receptor tyrosine kinase	MEN 2A and 2B, medullary thyroid cancer

**Tumor suppressor genes**Loss of function → ↑ cancer risk; both (**two**) alleles of a **tumor suppressor gene** must be lost for expression of disease.


GENE	GENE PRODUCT	ASSOCIATED CONDITION
<b>APC</b>	Negative regulator of $\beta$ -catenin/WNT pathway	Colorectal cancer (associated with FAP)
<b>BRCA1/BRCA2</b>	DNA repair protein	<b>Breast</b> , ovarian, and pancreatic cancer
<b>CDKN2A</b>	p16, blocks $G_1 \rightarrow S$ phase	Melanoma, pancreatic cancer
<b>DCC</b>	<b>DCC</b> — <b>D</b> eleted in <b>C</b> olon <b>C</b> ancer	Colon cancer
<b>DPC4/SMAD4</b>	<b>DPC</b> — <b>D</b> eleted in <b>P</b> ancreatic <b>C</b> ancer	Pancreatic cancer
<b>MEN1</b>	Menin	MEN 1
<b>NF1</b>	Neurofibromin (Ras GTPase activating protein)	<b>Neurofibromatosis type 1</b>
<b>NF2</b>	Merlin (schwannomin) protein	<b>Neurofibromatosis type 2</b>
<b>PTEN</b>	Tyrosine phosphatase of $PIP_3$ (eg, protein kinase B [AKT] activation)	Breast cancer, prostate cancer, endometrial cancer
<b>Rb</b>	Inhibits E2F; blocks $G_1 \rightarrow S$ phase	<b>Retinoblastoma</b> , osteosarcoma
<b>TP53</b>	p53, activates p21, blocks $G_1 \rightarrow S$ phase	Most human cancers, Li-Fraumeni syndrome (multiple malignancies at early age, aka, <b>SBLA</b> cancer syndrome: <b>S</b> arcoma, <b>B</b> reast, <b>L</b> eukemia, <b>A</b> drenal gland)
<b>TSC1</b>	Hamartin protein	<b>Tuberous sclerosis</b>
<b>TSC2</b>	Tuberin protein	<b>Tuberous sclerosis</b>
<b>VHL</b>	Inhibits hypoxia inducible factor 1 $\alpha$	<b>von Hippel-Lindau disease</b>
<b>WT1</b>	Transcription factor that regulates urogenital development	<b>Wilms tumor</b> (nephroblastoma)

Oncogenic microbes	Microbe	Associated cancer
	EBV	Burkitt lymphoma, Hodgkin lymphoma, nasopharyngeal carcinoma, 1° CNS lymphoma (in immunocompromised patients)
	HBV, HCV	Hepatocellular carcinoma
	HHV-8	Kaposi sarcoma
	HPV	Cervical and penile/anal carcinoma (types 16, 18), head and neck cancer
	<i>H pylori</i>	Gastric adenocarcinoma and MALT lymphoma
	HTLV-1	Adult T-cell leukemia/lymphoma
	Liver fluke ( <i>Clonorchis sinensis</i> )	Cholangiocarcinoma
	<i>Schistosoma haematobium</i>	Bladder cancer (squamous cell)

### Carcinogens

TOXIN	ORGAN	IMPACT
Aflatoxins ( <i>Aspergillus</i> )	Liver	Hepatocellular carcinoma
Alkylating agents	Blood	Leukemia/lymphoma
Aromatic amines (eg, benzidine, 2-naphthylamine)	Bladder	Transitional cell carcinoma
Arsenic	Liver Lung Skin	Angiosarcoma Lung cancer Squamous cell carcinoma
Asbestos	Lung	Bronchogenic carcinoma > mesothelioma
Carbon tetrachloride	Liver	Centrilobular necrosis, fatty change
Cigarette smoke	Bladder Cervix Esophagus Kidney Larynx Lung Pancreas	Transitional cell carcinoma Cervical carcinoma Squamous cell carcinoma/adenocarcinoma Renal cell carcinoma Squamous cell carcinoma Squamous cell and small cell carcinoma Pancreatic adenocarcinoma
Ethanol	Esophagus Liver	Squamous cell carcinoma Hepatocellular carcinoma
Ionizing radiation	Thyroid	Papillary thyroid carcinoma
Nitrosamines (smoked foods)	Stomach	Gastric cancer
Radon	Lung	Lung cancer (2nd leading cause after cigarette smoke)
Vinyl chloride	Liver	Angiosarcoma



**Psammoma bodies**

Laminated, concentric spherules with dystrophic calcification **A**, **PSaMM**oma bodies are seen in:

- **P**apillary carcinoma of thyroid
- **S**erous papillary cystadenocarcinoma of ovary
- **M**eningioma
- Malignant **M**esothelioma

**Serum tumor markers**

Tumor markers should not be used as the 1° tool for cancer diagnosis or screening. They may be used to monitor tumor recurrence and response to therapy, but definitive diagnosis is made via biopsy.

MARKER	ASSOCIATED CANCER	NOTES
<b>Alkaline phosphatase</b>	Metastases to bone or liver, Paget disease of bone, seminoma (placental ALP).	Must exclude hepatic origin by checking LFTs and GGT levels.
<b>α-fetoprotein</b>	Hepatocellular carcinoma, hepatoblastoma, yolk sac (endodermal sinus) tumor, mixed germ cell tumor.	Normally made by fetus. Transiently elevated in pregnancy. High levels associated with neural tube and abdominal wall defects, low levels associated with Down syndrome.
<b>β-hCG</b>	<b>H</b> ydantidiform moles and <b>C</b> horiocarcinomas ( <b>G</b> estational trophoblastic disease), testicular cancer, mixed germ cell tumor.	Produced by syncytiotrophoblasts of the placenta.
<b>CA 15-3/CA 27-29</b>	Breast cancer.	
<b>CA 19-9</b>	Pancreatic adenocarcinoma.	
<b>CA 125</b>	Ovarian cancer.	
<b>Calcitonin</b>	Medullary thyroid carcinoma (alone and in MEN2A, MEN2B).	
<b>CEA</b>	Major associations: colorectal and pancreatic cancers. Minor associations: gastric, breast, and medullary thyroid carcinomas.	<b>C</b> arcinoembryonic antigen. Very nonspecific.
<b>Chromogranin</b>	Neuroendocrine tumors.	
<b>PSA</b>	Prostate cancer.	<b>P</b> rostate-specific antigen. Can also be elevated in BPH and prostatitis. Questionable risk/benefit for screening. Surveillance marker for recurrent disease after prostatectomy.

**P-glycoprotein**

Also known as multidrug resistance protein 1 (MDR1). Classically seen in adrenocortical carcinoma but also expressed by other cancer cells (eg, colon, liver). Used to pump out toxins, including chemotherapeutic agents (one mechanism of ↓ responsiveness or resistance to chemotherapy over time).


**Cachexia**

Weight loss, muscle atrophy, and fatigue that occur in chronic disease (eg, cancer, AIDS, heart failure, COPD). Mediated by TNF, IFN- $\gamma$ , IL-1, and IL-6.

**Common metastases**

Most sarcomas spread hematogenously; most carcinomas spread via lymphatics. However, **Four Carcinomas Route Hematogenously: Follicular thyroid carcinoma, Choriocarcinoma, Renal cell carcinoma, and Hepatocellular carcinoma.**

SITE OF METASTASIS	1° TUMOR	NOTES
<b>Brain</b>	Lung > breast > melanoma, colon, kidney.	50% of brain tumors are from metastases <b>A B</b> . Commonly seen as multiple well-circumscribed tumors at gray/white matter junction.
<b>Liver</b>	Colon >> stomach > pancreas.	Liver <b>C D</b> and lung are the most common sites of metastasis after the regional lymph nodes.
<b>Bone</b>	Prostate, breast > lung, thyroid, kidney.	Bone metastasis <b>E F</b> >> 1° bone tumors (eg, multiple myeloma, lytic). Common mets to bone: breast (mixed), lung (lytic), thyroid (lytic), kidney (lytic), prostate (blastic). Predilection for axial skeleton <b>G</b> .





# Pharmacology

*“Take me, I am the drug; take me, I am hallucinogenic.”*

—Salvador Dali

*“I was under medication when I made the decision not to burn the tapes.”*

—Richard Nixon

*“I wondher why ye can always read a doctor’s bill an’ ye niver can read his purscription.”*

—Finley Peter Dunne

*“Once you get locked into a serious drug collection, the tendency is to push it as far as you can.”*

—Hunter S. Thompson

Preparation for questions on pharmacology is straightforward. Memorizing all the key drugs and their characteristics (eg, mechanisms, clinical use, and important side effects) is high yield. Focus on understanding the prototype drugs in each class. Avoid memorizing obscure derivatives. Learn the “classic” and distinguishing toxicities of the major drugs. Specific drug dosages or trade names are generally not testable. Reviewing associated biochemistry, physiology, and microbiology can be useful while studying pharmacology. There is a strong emphasis on ANS, CNS, antimicrobial, and cardiovascular agents as well as on NSAIDs. Much of the material is clinically relevant. We occasionally mention drugs that are no longer available in the US, but help illustrate high-yield pharmacologic or disease mechanisms. They are highlighted as being of historical significance and should not appear on the USMLE. However, recently approved drugs are fair game for the exam.

▶ Pharmacokinetics & Pharmacodynamics	224
▶ Autonomic Drugs	229
▶ Toxicities and Side Effects	239
▶ Miscellaneous	244

## ► PHARMACOLOGY—PHARMACOKINETICS &amp; PHARMACODYNAMICS

## Enzyme kinetics


## Michaelis-Menten kinetics

$K_m$  is inversely related to the affinity of the enzyme for its substrate.


$V_{max}$  is directly proportional to the enzyme concentration.

Most enzymatic reactions follow a hyperbolic curve (ie, Michaelis-Menten kinetics); however, enzymatic reactions that exhibit a sigmoid curve usually indicate cooperative kinetics (eg, hemoglobin).

[S] = concentration of substrate; V = velocity.



## Effects of enzyme inhibition




## Lineweaver-Burk plot


$\uparrow$  y-intercept,  $\downarrow$   $V_{max}$ .

The further to the right the x-intercept (ie, closer to zero), the greater the  $K_m$  and the lower the affinity.

Reversible competitive inhibitors cross each other competitively, whereas noncompetitive inhibitors do not.



## Effects of enzyme inhibition



	Competitive inhibitors, reversible	Competitive inhibitors, irreversible	Noncompetitive inhibitors
Resemble substrate	Yes	Yes	No
Overcome by $\uparrow$ [S]	Yes	No	No
Bind active site	Yes	Yes	No
Effect on $V_{max}$	Unchanged	$\downarrow$	$\downarrow$
Effect on $K_m$	$\uparrow$	Unchanged	Unchanged
Pharmacodynamics	$\downarrow$ potency	$\downarrow$ efficacy	$\downarrow$ efficacy

**Pharmacokinetics**

**Bioavailability (F)** Fraction of administered drug reaching systemic circulation unchanged. For an IV dose,  $F = 100\%$ . Orally:  $F$  typically  $< 100\%$  due to incomplete absorption and first-pass metabolism.

**Volume of distribution ( $V_d$ )** Theoretical volume occupied by the total amount of drug in the body relative to its plasma concentration. Apparent  $V_d$  of plasma protein-bound drugs can be altered by liver and kidney disease ( $\downarrow$  protein binding,  $\uparrow V_d$ ). Drugs may distribute in more than one compartment.

$$V_d = \frac{\text{amount of drug in the body}}{\text{plasma drug concentration}}$$

$V_d$	COMPARTMENT	DRUG TYPES
Low	Intravascular	Large/charged molecules; plasma protein bound
Medium	ECF	Small hydrophilic molecules
High	All tissues including fat	Small lipophilic molecules, especially if bound to tissue protein

**Clearance (CL)** The volume of plasma cleared of drug per unit time. Clearance may be impaired with defects in cardiac, hepatic, or renal function.

$$CL = \frac{\text{rate of elimination of drug}}{\text{plasma drug concentration}} = V_d \times K_e \text{ (elimination constant)}$$

**Half-life ( $t_{1/2}$ )** The time required to change the amount of drug in the body by  $\frac{1}{2}$  during elimination. In first-order kinetics, a drug infused at a constant rate takes 4–5 half-lives to reach steady state. It takes 3.3 half-lives to reach 90% of the steady-state level.

$$t_{1/2} = \frac{0.693 \times V_d}{CL} \text{ in first-order elimination}$$

# of half-lives	1	2	3	4
% remaining	50%	25%	12.5%	6.25%

**Dosage calculations**

$$\text{Loading dose} = \frac{C_p \times V_d}{F}$$

$$\text{Maintenance dose} = \frac{C_p \times CL \times \tau}{F}$$

$C_p$  = target plasma concentration at steady state  
 $\tau$  = dosage interval (time between doses), if not administered continuously

In renal or liver disease, maintenance dose  $\downarrow$  and loading dose is usually unchanged. Time to steady state depends primarily on  $t_{1/2}$  and is independent of dose and dosing frequency.

**Types of drug interactions**

TERM	DEFINITION	EXAMPLE
<b>Additive</b>	Effect of substance A and B together is equal to the sum of their individual effects	Aspirin and acetaminophen
<b>Permissive</b>	Presence of substance A is required for the full effects of substance B	Cortisol on catecholamine responsiveness
<b>Synergistic</b>	Effect of substance A and B together is greater than the sum of their individual effects	Clopidogrel with aspirin
<b>Tachyphylactic</b>	Acute decrease in response to a drug after initial/repeated administration	Nitrates, niacin, phenylephrine, LSD, MDMA

## Elimination of drugs

## Zero-order elimination

Rate of elimination is constant regardless of  $C_p$  (ie, constant **amount** of drug eliminated per unit time).  $C_p \downarrow$  linearly with time. Examples of drugs—**P**henytoin, **E**thanol, and **A**spirin (at high or toxic concentrations).



Capacity-limited elimination.

**PEA.** (A pea is round, shaped like the “0” in **zero-order**.)

## First-order elimination

Rate of elimination is directly proportional to the drug concentration (ie, constant **fraction** of drug eliminated per unit time).  $C_p \downarrow$  exponentially with time. Applies to most drugs.

Flow-dependent elimination.




## Urine pH and drug elimination

Ionized species are trapped in urine and cleared quickly. Neutral forms can be reabsorbed.


## Weak acids

Examples: phenobarbital, methotrexate, aspirin (salicylates). Trapped in basic environments. Treat overdose with bicarbonate to alkalinize urine.



## Weak bases

Example: amphetamines, TCAs. Trapped in acidic environments. Treat overdose with ammonium chloride to acidify urine.



## Drug metabolism

## Phase I

Reduction, oxidation, hydrolysis with cytochrome P-450 usually yield slightly polar, water-soluble metabolites (often still active).

Geriatric patients lose phase I first.

## Phase II


Conjugation (**M**ethylation, **G**lucuronidation, **A**cetylation, **S**ulfation) usually yields very polar, inactive metabolites (renally excreted).

Geriatric patients have **More GAS** (phase II). Patients who are slow acetylators have  $\uparrow$  side effects from certain drugs because of  $\downarrow$  rate of metabolism.

**Efficacy vs potency**


**Efficacy**

Maximal effect a drug can produce. Represented by the y-value ( $V_{max}$ ).  $\uparrow$  y-value =  $\uparrow V_{max}$  =  $\uparrow$  efficacy. Unrelated to potency (ie, efficacious drugs can have high or low potency). Partial agonists have less efficacy than full agonists.




**Potency**

Amount of drug needed for a given effect. Represented by the x-value ( $EC_{50}$ ). Left shifting =  $\downarrow EC_{50}$  =  $\uparrow$  potency =  $\downarrow$  drug needed. Unrelated to efficacy (ie, potent drugs can have high or low efficacy).





## Receptor binding



AGONIST WITH	EFFECT	EXAMPLE
<b>A</b> Competitive antagonist	Shifts curve right ( $\downarrow$ potency), no change in efficacy. Can be overcome by $\uparrow$ the concentration of agonist substrate.	Diazepam (agonist) + <b>flumazenil</b> (competitive antagonist) on GABA receptor.
<b>B</b> Noncompetitive antagonist	Shifts curve down ( $\downarrow$ efficacy). Cannot be overcome by $\uparrow$ agonist substrate concentration.	Norepinephrine (agonist) + <b>phenoxybenzamine</b> (noncompetitive antagonist) on $\alpha$ -receptors.
<b>C</b> Partial agonist (alone)	Acts at same site as full agonist, but with lower maximal effect ( $\downarrow$ efficacy). Potency is an independent variable.	Morphine (full agonist) vs <b>buprenorphine</b> (partial agonist) at opioid $\mu$ -receptors.

## Therapeutic index


Measurement of drug safety.

$$\frac{TD_{50}}{ED_{50}} = \frac{\text{median toxic dose}}{\text{median effective dose}}$$

Therapeutic window—dosage range that can safely and effectively treat disease.


**TITE:** Therapeutic Index =  $TD_{50} / ED_{50}$ .

Safer drugs have higher TI values. Drugs with lower TI values frequently require monitoring (eg, **Warfarin**, **Theophylline**, **Digoxin**, **Lithium**; **Warning! These Drugs are Lethal!**).  $LD_{50}$  (lethal median dose) often replaces  $TD_{50}$  in animal studies.



▶ PHARMACOLOGY—AUTONOMIC DRUGS

Central and peripheral nervous system



Adrenal medulla is directly innervated by preganglionic sympathetic fibers.  
Sweat glands are part of the sympathetic pathway but are innervated by cholinergic fibers.


**Acetylcholine receptors**

Nicotinic ACh receptors are ligand-gated  $\text{Na}^+/\text{K}^+$  channels. Two subtypes:  $\text{N}_\text{N}$  (found in autonomic ganglia, adrenal medulla) and  $\text{N}_\text{M}$  (found in neuromuscular junction of skeletal muscle). Muscarinic ACh receptors are G-protein-coupled receptors that usually act through 2nd messengers. 5 subtypes:  $\text{M}_{1-5}$  found in heart, smooth muscle, brain, exocrine glands, and on sweat glands (cholinergic sympathetic).

## G-protein-linked second messengers

RECEPTOR	G-PROTEIN CLASS	MAJOR FUNCTIONS
<b>Sympathetic</b>		
$\alpha_1$	q	↑ vascular smooth muscle contraction, ↑ pupillary dilator muscle contraction (mydriasis), ↑ intestinal and bladder sphincter muscle contraction
$\alpha_2$	i	↓ sympathetic (adrenergic) outflow, ↓ insulin release, ↓ lipolysis, ↑ platelet aggregation, ↓ aqueous humor production
$\beta_1$	s	↑ heart rate, ↑ contractility ( <b>one</b> heart), ↑ renin release, ↑ lipolysis
$\beta_2$	s	Vasodilation, bronchodilation ( <b>two</b> lungs), ↑ lipolysis, ↑ insulin release, ↓ uterine tone (tocolysis), ciliary muscle relaxation, ↑ aqueous humor production
$\beta_3$	s	↑ lipolysis, ↑ thermogenesis in skeletal muscle, ↑ bladder relaxation
<b>Parasympathetic</b>		
$M_1$	q	Mediates higher cognitive functions, stimulates enteric nervous system
$M_2$	i	↓ heart rate and contractility of atria
$M_3$	q	↑ exocrine gland secretions (eg, lacrimal, sweat, salivary, gastric acid), ↑ gut peristalsis, ↑ bladder contraction, bronchoconstriction, ↑ pupillary sphincter muscle contraction (miosis), ciliary muscle contraction (accommodation), ↑ insulin release
<b>Dopamine</b>		
$D_1$	s	Relaxes renal vascular smooth muscle, activates direct pathway of striatum
$D_2$	i	Modulates transmitter release, especially in brain, inhibits indirect pathway of striatum
<b>Histamine</b>		
$H_1$	q	↑ nasal and bronchial mucus production, ↑ vascular permeability, contraction of bronchioles, pruritus, pain
$H_2$	s	↑ gastric acid secretion
<b>Vasopressin</b>		
$V_1$	q	↑ vascular smooth muscle contraction
$V_2$	s	↑ $H_2O$ permeability and reabsorption in collecting <b>tu</b> bules of kidney


“After **q**isses (kisses), you get a **q**iq (kick) out of **s**iq (sick) **s**qs (super kinky sex).”



**Autonomic drugs**

Release of norepinephrine from a sympathetic nerve ending is modulated by NE itself, acting on presynaptic  $\alpha_2$ -autoreceptors  $\rightarrow$  negative feedback.

Amphetamines use the NE transporter (NET) to enter the presynaptic terminal, where they utilize the vesicular monoamine transporter (VMAT) to enter neurosecretory vesicles. This displaces NE from the vesicles. Once NE reaches a concentration threshold within the presynaptic terminal, the action of NET is reversed, and NE is expelled into the synaptic cleft, contributing to the characteristics and effects of  $\uparrow$  NE observed in patients taking amphetamines.



Circles with rotating arrows represent transporters.

## Cholinomimetic agents

DRUG	ACTION	APPLICATIONS
<b>Direct agonists</b>		
<b>Bethanechol</b>	Activates <b>b</b> owel and <b>b</b> ladder smooth muscle; resistant to AChE, no nicotinic activity. “ <b>Bethany, call (bethanechol) me to activate your bowels and bladder.</b> ”	Postoperative ileus, neurogenic ileus, urinary retention
<b>Carbachol</b>	<b>C</b> arbon copy of <b>a</b> cetyl <b>ch</b> oline (but resistant to AChE).	Constricts pupil and relieves intraocular pressure in open-angle glaucoma
<b>Methacholine</b>	Stimulates <b>m</b> uscarinic receptors in airway when inhaled.	Challenge test for diagnosis of asthma
<b>Pilocarpine</b>	Contracts ciliary muscle of eye (open-angle glaucoma), pupillary sphincter (closed-angle glaucoma); resistant to AChE, can cross blood-brain barrier (tertiary amine). “You cry, drool, and sweat on your <b>p</b> illow.”	Potent stimulator of sweat, tears, and saliva Open-angle and closed-angle glaucoma, xerostomia (Sjögren syndrome)
<b>Indirect agonists (anticholinesterases)</b>		
<b>Galantamine, donepezil, rivastigmine</b>	↑ ACh.	<b>A</b> lzheimer disease ( <b>A</b> lzheimer patients <b>g</b> allantly swim <b>d</b> own the <b>r</b> iver)
<b>Edrophonium</b>	↑ ACh.	Historically used to diagnose myasthenia gravis; replaced by anti-AChR Ab (anti-acetylcholine receptor antibody) test.
<b>Neostigmine</b>	↑ ACh. <b>Neo</b> CNS = <b>No</b> CNS penetration (quaternary amine).	Postoperative and neurogenic ileus and urinary retention, myasthenia gravis, reversal of neuromuscular junction blockade (postoperative).
<b>Physostigmine</b>	↑ ACh. <b>Phy</b> sostigmine “ <b>phy</b> xes” atropine overdose.	Antidote for anticholinergic toxicity; <b>ph</b> reely (freely) crosses blood-brain barrier → CNS (tertiary amine).
<b>Pyridostigmine</b>	↑ ACh; ↑ muscle strength. <b>Pyri</b> do <b>st</b> igmine gets <b>ri</b> d of <b>my</b> asthenia <b>g</b> ravis.	Myasthenia gravis (long acting); does not penetrate CNS (quaternary amine).

Note: With all cholinomimetic agents, watch for exacerbation of COPD, asthma, and peptic ulcers when giving to susceptible patients.

**Cholinesterase inhibitor poisoning**

Often due to organophosphates, such as parathion, that **irreversibly** inhibit AChE. Causes **D**iarrhea, **U**rination, **M**iosis, **B**ronchospasm, **B**radycardia, **E**xcitation of skeletal muscle and CNS, **L**acrimation, **S**weating, and **S**alivation. May lead to respiratory failure if untreated.

**DUMBELSS.**

Organophosphates are often components of insecticides; poisoning usually seen in farmers. Antidote—atropine (competitive inhibitor) + pralidoxime (regenerates AChE if given early).

**Muscarinic antagonists**

DRUGS	ORGAN SYSTEMS	APPLICATIONS
<b>Atropine, homatropine, tropicamide</b>	Eye	Produce mydriasis and cycloplegia.
<b>Benz</b> tropine, trihexyphenidyl	CNS	<b>P</b> arkinson disease (“ <b>p</b> ark my <b>Benz</b> ”). Acute dystonia.
<b>Glycopyrrolate</b>	GI, respiratory	Parenteral: preoperative use to reduce airway secretions. Oral: drooling, peptic ulcer.
<b>Hyoscyamine, dicyclomine</b>	GI	Antispasmodics for irritable bowel syndrome.
<b>Ipr</b> atropium, tiotropium	Respiratory	COPD, asthma (“ <b>I pray</b> I can breathe soon!”).
<b>Oxybutynin, solifenacin, tolterodine</b>	Genitourinary	Reduce bladder spasms and urge urinary incontinence (overactive bladder).
<b>Scopolamine</b>	CNS	Motion sickness.

**Atropine** Muscarinic antagonist. Used to treat bradycardia and for ophthalmic applications.


ORGAN SYSTEM	ACTION	NOTES
Eye	↑ pupil dilation, cycloplegia	Blocks <b>DUMBB</b> eLSS in cholinesterase inhibitor poisoning. Does not block excitation of skeletal muscle and CNS (mediated by nicotinic receptors).
Airway	↓ secretions	
Stomach	↓ acid secretion	
Gut	↓ motility	
Bladder	↓ urgency in cystitis	
ADVERSE EFFECTS	↑ body <b>temperature</b> (due to ↓ sweating); rapid pulse; dry mouth; <b>dry, flushed skin; cycloplegia</b> ; constipation; <b>disorientation</b> Can cause acute angle-closure glaucoma in elderly (due to mydriasis), urinary retention in men with prostatic hyperplasia, and hyperthermia in infants.	Side effects: <b>H</b> ot as a hare <b>D</b> ry as a bone <b>R</b> ed as a beet <b>B</b> lind as a bat <b>M</b> ad as a hatter Jimson weed ( <i>Datura</i> ) → gardener’s pupil (mydriasis due to plant alkaloids)

**Sympathomimetics**

DRUG	ACTION	APPLICATIONS
<b>Direct sympathomimetics</b>		
<b>Albuterol, salmeterol</b>	$\beta_2 > \beta_1$	Albuterol for acute asthma or COPD. Salmeterol for long-term asthma or COPD control.
<b>Dobutamine</b>	$\beta_1 > \beta_2, \alpha$	Heart failure (HF) (inotropic > chronotropic), cardiac stress testing.
<b>Dopamine</b>	$D_1 = D_2 > \beta > \alpha$	Unstable bradycardia, HF, shock; inotropic and chronotropic effects at lower doses due to $\beta$ effects; vasoconstriction at high doses due to $\alpha$ effects.
<b>Epinephrine</b>	$\beta > \alpha$	Anaphylaxis, asthma, open-angle glaucoma; $\alpha$ effects predominate at high doses. Significantly stronger effect at $\beta_2$ -receptor than norepinephrine.
<b>Fenoldopam</b>	$D_1$	Postoperative hypertension, hypertensive crisis. Vasodilator (coronary, peripheral, renal, and splanchnic). Promotes natriuresis. Can cause hypotension and tachycardia.
<b>Isoproterenol</b>	$\beta_1 = \beta_2$	Electrophysiologic evaluation of tachyarrhythmias. Can worsen ischemia.
<b>Midodrine</b>	$\alpha_1$	Autonomic insufficiency and postural hypotension. May exacerbate supine hypertension.
<b>Mirabegron</b>	$\beta_3$	Urinary urge incontinence or overactive bladder.
<b>Norepinephrine</b>	$\alpha_1 > \alpha_2 > \beta_1$	Hypotension, septic shock.
<b>Phenylephrine</b>	$\alpha_1 > \alpha_2$	Hypotension (vasoconstrictor), ocular procedures (mydriatic), rhinitis (decongestant).
<b>Indirect sympathomimetics</b>		
<b>Amphetamine</b>	Indirect general agonist, reuptake inhibitor, also releases stored catecholamines	Narcolepsy, obesity, ADHD.
<b>Cocaine</b>	Indirect general agonist, reuptake inhibitor	Causes vasoconstriction and local anesthesia. Never give $\beta$ -blockers if cocaine intoxication is suspected (can lead to unopposed $\alpha_1$ activation and extreme hypertension).
<b>Ephedrine</b>	Indirect general agonist, releases stored catecholamines	Nasal decongestion (pseudoephedrine), urinary incontinence, hypotension.

**Norepinephrine vs isoproterenol**

NE ↑ systolic and diastolic pressures as a result of  $\alpha_1$ -mediated vasoconstriction → ↑ mean arterial pressure → reflex bradycardia. However, isoproterenol (rarely used) has little  $\alpha$  effect but causes  $\beta_2$ -mediated vasodilation, resulting in ↓ mean arterial pressure and ↑ heart rate through  $\beta_1$  and reflex activity.



**Sympatholytics ( $\alpha_2$ -agonists)**


DRUG	APPLICATIONS	ADVERSE EFFECTS
<b>Clonidine, guanfacine</b>	Hypertensive urgency (limited situations), ADHD, Tourette syndrome	CNS depression, bradycardia, hypotension, respiratory depression, miosis, rebound hypertension with abrupt cessation
<b><math>\alpha</math>-methyldopa</b>	Hypertension in pregnancy	Direct Coombs ⊕ hemolysis, SLE-like syndrome



**α-blockers**

DRUG	APPLICATIONS	ADVERSE EFFECTS
<b>Nonselective</b>		
<b>Phenoxybenzamine</b>	Irreversible. Pheochromocytoma (used preoperatively) to prevent catecholamine (hypertensive) crisis	Orthostatic hypotension, reflex tachycardia
<b>Phentolamine</b>	Reversible. Give to patients on MAO inhibitors who eat tyramine-containing foods	
<b>α<sub>1</sub> selective (-osin ending)</b>		
<b>Prazosin, terazosin, doxazosin, tamsulosin</b>	Urinary symptoms of BPH; PTSD (prazosin); hypertension (except tamsulosin)	1st-dose orthostatic hypotension, dizziness, headache
<b>α<sub>2</sub> selective</b>		
<b>Mirtazapine</b>	Depression	Sedation, ↑ serum cholesterol, ↑ appetite

## Effects of α-blocker (eg, phentolamine) on BP responses to epinephrine and phenylephrine



Epinephrine response exhibits reversal of mean arterial pressure from a net increase (the α response) to a net decrease (the β<sub>2</sub> response).

Phenylephrine response is suppressed but not reversed because it is a “pure” α-agonist (lacks β-agonist properties).

**β-blockers**

Acebutolol, atenolol, betaxolol, bisoprolol, carvedilol, esmolol, labetalol, metoprolol, nadolol, nebivolol, pindolol, propranolol, timolol.

APPLICATION	ACTIONS	NOTES/EXAMPLES
Angina pectoris	↓ heart rate and contractility, resulting in ↓ O <sub>2</sub> consumption	
Myocardial infarction	↓ mortality	
Supraventricular tachycardia	↓ AV conduction velocity (class II antiarrhythmic)	Metoprolol, esmolol
Hypertension	↓ cardiac output, ↓ renin secretion (due to β <sub>1</sub> -receptor blockade on JGA cells)	
Heart failure	↓ mortality (bisoprolol, carvedilol, metoprolol)	
Glaucoma	↓ production of aqueous humor	Timolol
Variceal bleeding	↓ hepatic venous pressure gradient and portal hypertension	Nadolol, propranolol
ADVERSE EFFECTS	Erectile dysfunction, cardiovascular adverse effects (bradycardia, AV block, HF), CNS adverse effects (seizures, sedation, sleep alterations), dyslipidemia (metoprolol), and asthma/COPD exacerbations	Use with caution in cocaine users due to risk of unopposed α-adrenergic receptor agonist activity
SELECTIVITY	β <sub>1</sub> -selective antagonists (β <sub>1</sub> > β <sub>2</sub> )— <b>a</b> cebutolol (partial agonist), <b>a</b> tenolol, <b>b</b> etaxolol, <b>b</b> isoprolol, <b>e</b> smolol, <b>m</b> etoprolol	Selective antagonists mostly go from <b>A</b> to <b>M</b> (β <sub>1</sub> with <b>1</b> st half of alphabet)
	Nonselective antagonists (β <sub>1</sub> = β <sub>2</sub> )— <b>n</b> adolol, <b>p</b> indolol (partial agonist), <b>p</b> ropranolol, <b>t</b> imolol	Nonselective antagonists mostly go from <b>N</b> to <b>Z</b> (β <sub>2</sub> with <b>2</b> nd half of alphabet)
	Nonselective α- and β-antagonists—carvedilol, labetalol	Nonselective α- and β-antagonists have modified suffixes (instead of “-olol”)
	Nebivolol combines cardiac-selective β <sub>1</sub> -adrenergic blockade with stimulation of β <sub>3</sub> -receptors (activate nitric oxide synthase in the vasculature and ↓ SVR)	

**Ingested seafood toxins**

TOXIN	SOURCE	ACTION	SYMPTOMS	TREATMENT
<b>Tetrodotoxin</b>	Pufferfish.	Highly potent toxin; binds fast voltage-gated Na <sup>+</sup> channels in cardiac/nerve tissue, preventing depolarization.	Nausea, diarrhea, paresthesias, weakness, dizziness, loss of reflexes.	Supportive.
<b>Ciguatoxin</b>	Reef fish such as barracuda, snapper, and moray eel.	Opens Na <sup>+</sup> channels, causing depolarization.	Nausea, vomiting, diarrhea; perioral numbness; reversal of hot and cold sensations; bradycardia, heart block, hypotension.	Supportive.
<b>Histamine (scombroid poisoning)</b>	Spoiled dark-meat fish such as tuna, mahi-mahi, mackerel, and bonito.	Bacterial histidine decarboxylase converts histidine to histamine. Frequently misdiagnosed as fish allergy.	Mimics anaphylaxis: acute burning sensation of mouth, flushing of face, erythema, urticaria, itching. May progress to bronchospasm, angioedema, hypotension.	Antihistamines. Albuterol and epinephrine if needed.

**Beers criteria**

Widely used criteria developed to reduce potentially inappropriate prescribing and harmful polypharmacy in the geriatric population. Includes > 50 medications that should be avoided in elderly patients due to ↓ efficacy and/or ↑ risk of adverse events. Examples include:

- Anticholinergics, antihistamines, antidepressants, benzodiazepines, opioids (↑ risk of delirium, sedation, falls, constipation, urinary retention)
- α-blockers (↑ risk of hypotension)
- PPIs (↑ risk of *C difficile* infection)
- NSAIDs (↑ risk of GI bleeding, especially with concomitant anticoagulation)

▶ PHARMACOLOGY—TOXICITIES AND SIDE EFFECTS

**Specific toxicity treatments**

TOXIN	TREATMENT
Acetaminophen	N-acetylcysteine (replenishes glutathione)
AChE inhibitors, organophosphates	Atropine > pralidoxime
Antimuscarinic, anticholinergic agents	Physostigmine, control hyperthermia
Arsenic	Dimercaprol, succimer
Benzodiazepines	Flumazenil
β-blockers	Atropine, glucagon
Carbon monoxide	100% O <sub>2</sub> , hyperbaric O <sub>2</sub>
<b>Copper</b>	<b>Penicillamine</b> , trientine ( <b>Copper penny</b> )
Cyanide	Nitrite + thiosulfate, hydroxocobalamin
Digitalis (digoxin)	Anti-dig Fab fragments
Heparin	Protamine sulfate
<b>Iron</b>	De <b>fer</b> oxamine, de <b>fer</b> asirox, de <b>fer</b> iprone
Lead	EDTA, dimercaprol, succimer, penicillamine
<b>Mercury</b>	Di <b>mer</b> caprol, succi <b>mer</b>
Methanol, ethylene glycol (antifreeze)	Fomepizole > ethanol, dialysis
<b>Methemoglobin</b>	<b>Meth</b> ylene blue, vitamin C
<b>OpiOids</b>	Na <b>OxO</b> ne
Salicylates	NaHCO <sub>3</sub> (alkalinize urine), dialysis
TCAs	NaHCO <sub>3</sub>
Warfarin	Vitamin K (delayed effect), fresh frozen plasma (immediate)

**Drug reactions—cardiovascular**

DRUG REACTION	CAUSAL AGENTS
<b>Coronary vasospasm</b>	Amphetamines, cocaine, ergot alkaloids, sumatriptan
<b>Cutaneous flushing</b>	<b>V</b> ancomycin, <b>A</b> denosine, <b>N</b> iacin, <b>N</b> itrates, <b>Ca</b> <sup>2+</sup> channel blockers, <b>E</b> chinocandins ( <b>VANNCE</b> )
<b>Dilated cardiomyopathy</b>	Anthracyclines (eg, doxorubicin, daunorubicin); prevent with dexrazoxane
<b>Torsades de pointes</b>	Anti <b>A</b> rrhythmics (class IA, III), anti <b>B</b> iotics (eg, macrolides), anti“ <b>C</b> ”ychotics (eg, haloperidol), anti <b>D</b> epressants (eg, TCAs), anti <b>E</b> metics (eg, ondansetron) ( <b>ABCDE</b> )

**Drug reactions—endocrine/reproductive**

DRUG REACTION	CAUSAL AGENTS	NOTES
<b>Adrenocortical insufficiency</b>	HPA suppression 2° to glucocorticoid withdrawal	
<b>Diabetes insipidus</b>	Lithium, demeclocycline	
<b>Hot flashes</b>	Tamoxifen, clomiphene	
<b>Hyperglycemia</b>	Tacrolimus, Protease inhibitors, Niacin, HCTZ, Corticosteroids	Taking Pills Necessitates Having blood Checked
<b>Hypothyroidism</b>	Lithium, amiodarone, sulfonamides	
<b>SIADH</b>	Carbamazepine, Cyclophosphamide, SSRIs	Can't Concentrate Serum Sodium

**Drug reactions—gastrointestinal**

DRUG REACTION	CAUSAL AGENTS	NOTES
<b>Acute cholestatic hepatitis, jaundice</b>	Erythromycin	
<b>Diarrhea</b>	Acamprosate, acarbose, cholinesterase inhibitors, colchicine, erythromycin, ezetimibe, metformin, misoprostol, orlistat, pramlintide, quinidine, SSRIs	
<b>Focal to massive hepatic necrosis</b>	Halothane, <i>Amanita phalloides</i> (death cap mushroom), Valproic acid, Acetaminophen	Liver "HAVAc"
<b>Hepatitis</b>	Rifampin, isoniazid, pyrazinamide, statins, fibrates	
<b>Pancreatitis</b>	Didanosine, Corticosteroids, Alcohol, Valproic acid, Azathioprine, Diuretics (furosemide, HCTZ)	Drugs Causing A Violent Abdominal Distress
<b>Pill-induced esophagitis</b>	Bisphosphonates, ferrous sulfate, NSAIDs, potassium chloride, tetracyclines	Caustic effect minimized with upright posture and adequate water ingestion.
<b>Pseudomembranous colitis</b>	Ampicillin, cephalosporins, clindamycin, fluoroquinolones	Antibiotics predispose to superinfection by resistant <i>C difficile</i>

**Drug reactions—hematologic**

DRUG REACTION	CAUSAL AGENTS	NOTES
<b>Agranulocytosis</b>	Clozapine, Carbamazepine, Propylthiouracil, Methimazole, Colchicine, Ganciclovir	Can Cause Pretty Major Collapse of Granulocytes
<b>Aplastic anemia</b>	Carbamazepine, Methimazole, NSAIDs, Benzene, Chloramphenicol, Propylthiouracil	Can't Make New Blood Cells Properly
<b>Direct Coombs-positive hemolytic anemia</b>	Methyldopa, penicillin	
<b>Drug reaction with eosinophilia and systemic symptoms (DRESS)</b>	Allopurinol, anticonvulsants, antibiotics, sulfa drugs	Potentially fatal delayed hypersensitivity reaction. Latency period (2–8 weeks) followed by fever, morbilliform skin rash, and frequent multiorgan involvement. Treatment: withdrawal of offending drug, corticosteroids.
<b>Gray baby syndrome</b>	Chloramphenicol	
<b>Hemolysis in G6PD deficiency</b>	Isoniazid, Sulfonamides, Dapsone, Primaquine, Aspirin, Ibuprofen, Nitrofurantoin	Hemolysis <b>IS D PAIN</b>
<b>Megaloblastic anemia</b>	Hydroxyurea, Phenytoin, Methotrexate, Sulfa drugs	You're having a <b>mega blast</b> with <b>PMS</b>
<b>Thrombocytopenia</b>	Heparin	
<b>Thrombotic complications</b>	Combined oral contraceptives, hormone replacement therapy, SERMs (eg, tamoxifen, raloxifene, clomiphene)	Estrogen-mediated side effect

**Drug reactions—musculoskeletal/skin/connective tissue**

DRUG REACTION	CAUSAL AGENTS	NOTES
<b>Fat redistribution</b>	Protease inhibitors, Glucocorticoids	<b>Fat PiG</b>
<b>Gingival hyperplasia</b>	Phenytoin, Ca <sup>2+</sup> channel blockers, cyclosporine	
<b>Hyperuricemia (gout)</b>	Pyrazinamide, Thiazides, Furosemide, Niacin, Cyclosporine	<b>Painful Tophi</b> and <b>Feet Need Care</b>
<b>Myopathy</b>	Statins, fibrates, niacin, colchicine, daptomycin, hydroxychloroquine, interferon- $\alpha$ , penicillamine, glucocorticoids	
<b>Osteoporosis</b>	Corticosteroids, depot medroxyprogesterone acetate, GnRH agonists, aromatase inhibitors, anticonvulsants, heparin	
<b>Photosensitivity</b>	Sulfonamides, Amiodarone, Tetracyclines, 5-FU	<b>SAT For Photo</b>
<b>Rash (Stevens-Johnson syndrome)</b>	Anti-epileptic drugs (especially lamotrigine), allopurinol, sulfa drugs, penicillin	<b>Steven Johnson</b> has <b>epileptic allergy</b> to <b>sulfa drugs</b> and <b>penicillin</b>
<b>SLE-like syndrome</b>	Sulfa drugs, Hydralazine, Isoniazid, Procainamide, Phenytoin, Etanercept	Having lupus is " <b>SHIPP-E</b> "
<b>Teeth discoloration</b>	Tetracyclines	<b>Teeth</b> racyclines
<b>Tendonitis, tendon rupture, and cartilage damage</b>	Fluoroquinolones	

**Drug reactions—neurologic**

DRUG REACTION	CAUSAL AGENTS	NOTES
<b>Cinchonism</b>	Quinidine, quinine	Can present with tinnitus, hearing/vision loss, psychosis, and cognitive impairment
<b>Parkinson-like syndrome</b>	Antipsychotics, <b>R</b> eserpine, <b>M</b> etoclopramide	Cogwheel rigidity of <b>ARM</b>
<b>Seizures</b>	Isoniazid (vitamin B <sub>6</sub> deficiency), <b>B</b> upropion, <b>I</b> mipenem/cilastatin, <b>T</b> ramadol, <b>E</b> nflurane	With <b>seizures</b> , <b>I BITE</b> my tongue
<b>Tardive dyskinesia</b>	Antipsychotics, metoclopramide	

**Drug reactions—renal/genitourinary**

DRUG REACTION	CAUSAL AGENTS	NOTES
<b>Fanconi syndrome</b>	Cisplatin, ifosfamide, expired tetracyclines, tenofovir	
<b>Hemorrhagic cystitis</b>	Cyclophosphamide, ifosfamide	Prevent by coadministering with mesna
<b>Interstitial nephritis</b>	Penicillins, furosemide, NSAIDs, proton pump inhibitors, sulfa drugs	

**Drug reactions—respiratory**

DRUG REACTION	CAUSAL AGENTS	NOTES
<b>Dry cough</b>	ACE inhibitors	
<b>Pulmonary fibrosis</b>	<b>M</b> ethotrexate, <b>N</b> itrofurantoin, <b>C</b> armustine, <b>B</b> leomycin, <b>B</b> usulfan, <b>A</b> midarone	<b>My Nose Cannot Breathe Bad Air</b>

**Drug reactions—multiorgan**

DRUG REACTION	CAUSAL AGENTS	NOTES
<b>Antimuscarinic</b>	Atropine, TCAs, H <sub>1</sub> -blockers, antipsychotics	
<b>Disulfiram-like reaction</b>	1st-generation <b>S</b> ulfonyleureas, <b>P</b> rocarbazine, certain <b>C</b> ephalosporins, <b>G</b> riseofulvin, <b>M</b> etronidazole	<b>Sorry Pals, Can't Go Mingle.</b>
<b>Nephrotoxicity/ototoxicity</b>	Aminoglycosides, vancomycin, loop diuretics, cisplatin, amphotericin B	Cisplatin toxicity may respond to amifostine.

Cytochrome P-450 interactions (selected)	Inducers (+)	Substrates	Inhibitors (-)
	<p><b>C</b>hronic <b>a</b>lcohol use  <b>S</b>t. John's wort  <b>P</b>henytoin  <b>P</b>henobarbital  <b>N</b>evirapine  <b>R</b>ifampin  <b>G</b>riseofulvin  <b>C</b>arbamazepine</p>	<p><b>A</b>nti-epileptics  <b>T</b>heophylline  <b>W</b>arfarin  <b>O</b>CPs</p>	<p><b>S</b>odium valproate  <b>I</b>soniazid  <b>C</b>imetidine  <b>K</b>etoconazole  <b>F</b>luconazole  <b>A</b>cute alcohol abuse  <b>C</b>hloramphenicol  <b>E</b>rythromycin (macrolides)  <b>S</b>ulfonamides  <b>C</b>iprofloxacin  <b>O</b>meprazole  <b>M</b>etronidazole</p>
	<p><b>C</b>hronic alcoholics <b>S</b>teal  <b>P</b>hen-Phen and <b>N</b>ever  <b>R</b>efuse <b>G</b>reasy <b>C</b>arbs</p>	<p><b>A</b>lways <b>T</b>hink <b>W</b>hen  <b>O</b>utdoors</p>	<p><b>SICKFACES.COM</b></p>

**Sulfa drugs**

Sulfonamide antibiotics, **S**ulfasalazine, **P**robenecid, **F**urosemide, **A**cetazolamide, **C**elecoxib, **T**hiazides, **S**ulfonylureas. Patients with sulfa allergies may develop fever, urinary tract infection, Stevens-Johnson syndrome, hemolytic anemia, thrombocytopenia, agranulocytosis, acute interstitial nephritis, and urticaria (hives). Symptoms range from mild to life threatening.

**Scary Sulfa Pharm FACTS**



## ▶ PHARMACOLOGY—MISCELLANEOUS

## Drug names

ENDING	CATEGORY	EXAMPLE
<b>Antimicrobial</b>		
-azole	Ergosterol synthesis inhibitor	Ketoconazole
-bendazole	Antiparasitic/antihelminthic	Mebendazole
-cillin	Transpeptidase (penicillin-binding protein)	Ampicillin
-cycline	Protein synthesis inhibitor	Tetracycline
-ivir	Neuraminidase inhibitor	Oseltamivir
-navir	Protease inhibitor	Ritonavir
-ovir	DNA polymerase inhibitor	Acyclovir
-thromycin	Macrolide antibiotic	Azithromycin
<b>CNS</b>		
-ane	Inhalational general anesthetic	Halothane
-azine	Typical antipsychotic	Thioridazine
-barbital	Barbiturate	Phenobarbital
-caine	Local anesthetic	Lidocaine
-etine	SSRI	Fluoxetine
-ipramine, -triptyline	TCA	Imipramine, amitriptyline
-triptan	5-HT <sub>1B/1D</sub> agonist	Sumatriptan
-zepam, -zolam	Benzodiazepine	Diazepam, alprazolam
<b>Autonomic</b>		
-chol	Cholinergic agonist	Bethanechol, carbachol
-curium, -curonium	Nondepolarizing paralytic	Atracurium, vecuronium
-olol	β-blocker	Propranolol
-stigmine	AChE inhibitor	Neostigmine
-terol	β <sub>2</sub> -agonist	Albuterol
-zosin	α <sub>1</sub> -antagonist	Prazosin
<b>Cardiovascular</b>		
-afil	PDE-5 inhibitor	Sildenafil
-dipine	Dihydropyridine Ca <sup>2+</sup> channel blocker	Amlodipine
-pril	ACE inhibitor	Captopril
-sartan	Angiotensin-II receptor blocker	Losartan
-statin	HMG-CoA reductase inhibitor	Atorvastatin
-xaban	Direct factor <b>Xa</b> inhibitor	Apixaban, edoxaban, rivaroxaban
<b>Other</b>		
-dronate	Bisphosphonate	Alendronate
-glitazone	PPAR-γ activator	Rosiglitazone
-prazole	Proton pump inhibitor	Omeprazole
-prost	Prostaglandin analog	Latanoprost
-tidine	H <sub>2</sub> -antagonist	Cimetidine
-tinib	Tyrosine kinase inhibitor	Imatinib
-tropin	Pituitary hormone	Somatotropin
-ximab	Chimeric monoclonal Ab	Basiliximab
-zumab	Humanized monoclonal Ab	Daclizumab

# Public Health Sciences

*“It is a mathematical fact that fifty percent of all doctors graduate in the bottom half of their class.”*

—Author Unknown

*“There are two kinds of statistics: the kind you look up and the kind you make up.”*

—Rex Stout

*“On a long enough time line, the survival rate for everyone drops to zero.”*

—Chuck Palahniuk

*“There are three kinds of lies: lies, damned lies, and statistics.”*

—Mark Twain

A heterogenous mix of epidemiology, biostatistics, ethics, law, healthcare delivery, patient safety, quality improvement, and more falls under the heading of public health sciences. Biostatistics and epidemiology are the foundations of evidence-based medicine and are very high yield. Make sure you can apply biostatistical concepts such as sensitivity, specificity, and predictive values in a problem-solving format.

Medical ethics questions may seem less concrete than questions from other disciplines. For example, if a patient does or says something, what should you do or say in response? Many medical students do not diligently study these topics because the material is felt to be easy or a matter of common sense. In our opinion, this is a missed opportunity.

In addition, the key aspects of the doctor-patient relationship (eg, communication skills) are high yield. Last, the exam has also recently added an emphasis on patient safety and quality improvement topics, which are discussed in this chapter.

▶ Epidemiology & Biostatistics	246
▶ Ethics	253
▶ The Well Patient	258
▶ Healthcare Delivery	259
▶ Quality and Safety	261

## ▶ PUBLIC HEALTH SCIENCES—EPIDEMIOLOGY &amp; BIOSTATISTICS

**Observational studies**

STUDY TYPE	DESIGN	MEASURES/EXAMPLE
<b>Cross-sectional study</b>	Frequency of disease and frequency of risk-related factors are assessed in the present. Asks, “What is happening?”	Disease prevalence. Can show risk factor association with disease, but does not establish causality.
<b>Case-control study</b>	Compares a group of people with disease to a group without disease. Looks to see if odds of prior exposure or risk factor differs by disease state. Asks, “What happened?”	Odds ratio (OR). Patients with COPD had higher odds of a history of smoking than those without COPD.
<b>Cohort study</b>	Compares a group with a given exposure or risk factor to a group without such exposure. Looks to see if exposure or risk factor is associated with later development of disease. Can be prospective (asks, “Who will develop disease?”) or retrospective (asks, “Who developed the disease [exposed vs nonexposed]?”).	Relative risk (RR). “Smokers had a higher risk of developing COPD than nonsmokers.”
<b>Twin concordance study</b>	Compares the frequency with which both monozygotic twins vs both dizygotic twins develop the same disease.	Measures heritability and influence of environmental factors (“nature vs nurture”).
<b>Adoption study</b>	Compares siblings raised by biological vs adoptive parents.	Measures heritability and influence of environmental factors.

**Clinical trial**

Experimental study involving humans. Compares therapeutic benefits of 2 or more treatments, or of treatment and placebo. Study quality improves when study is randomized, controlled, and double-blinded (ie, neither patient nor doctor knows whether the patient is in the treatment or control group). Triple-blind refers to the additional blinding of the researchers analyzing the data. Four phases (“Does the drug **SWIM**?”).

DRUG TRIALS	TYPICAL STUDY SAMPLE	PURPOSE
<b>Phase I</b>	Small number of healthy volunteers.	“Is it <b>S</b> afe?” Assesses safety, toxicity, pharmacokinetics, and pharmacodynamics.
<b>Phase II</b>	Small number of patients with disease of interest.	“Does it <b>W</b> ork?” Assesses treatment efficacy, optimal dosing, and adverse effects.
<b>Phase III</b>	Large number of patients randomly assigned either to the treatment under investigation or to the best available treatment (or placebo).	“Is it as good or better?” Compares the new treatment to the current standard of care (any <b>I</b> mprovement?).
<b>Phase IV</b>	Postmarketing surveillance of patients after treatment is approved.	“Can it stay?” Detects rare or long-term adverse effects. Can result in treatment being withdrawn from <b>M</b> arket.

**Evaluation of diagnostic tests**

Uses 2 × 2 table comparing test results with the actual presence of disease. TP = true positive; FP = false positive; TN = true negative; FN = false negative.

Sensitivity and specificity are fixed properties of a test. PPV and NPV vary depending on disease prevalence in population being tested.

		Disease		
		⊕	⊖	
Test	⊕	TP	FP	PPV = TP/(TP + FP)
	⊖	FN	TN	NPV = TN/(TN + FN)
		Sensitivity = TP/(TP + FN)	Specificity = TN/(TN + FP)	Prevalence = TP + FN = (TP + FN + FP + TN)

**Sensitivity (true-positive rate)**

Proportion of all people with disease who test positive, or the probability that when the disease is present, the test is positive. Value approaching 100% is desirable for **ruling out** disease and indicates a **low false-negative rate**. High sensitivity test used for screening in diseases with low prevalence.

= TP / (TP + FN)  
= 1 – false-negative rate  
**SN-N-OUT** = highly **SeNsitive** test, when **Negative**, rules **OUT** disease  
If sensitivity is 100%, then FN is zero. So, all negatives must be TNs.

**Specificity (true-negative rate)**

Proportion of all people without disease who test negative, or the probability that when the disease is absent, the test is negative. Value approaching 100% is desirable for **ruling in** disease and indicates a **low false-positive rate**. High specificity test used for confirmation after a positive screening test.

= TN / (TN + FP)  
= 1 – false-positive rate  
**SP-P-IN** = highly **SPecific** test, when **Positive**, rules **IN** disease  
If specificity is 100%, then FP is zero. So, all positives must be TPs.

**Positive predictive value**


Proportion of positive test results that are true positive. Probability that a person who has a positive test result actually has the disease.

PPV = TP / (TP + FP)  
PPV varies directly with pretest probability (baseline risk, such as prevalence of disease):  
high pretest probability → high PPV

**Negative predictive value**

Proportion of negative test results that are true negative. Probability that a person with a negative test result actually does not have the disease.

NPV = TN / (TN + FN)  
NPV varies inversely with prevalence or pretest probability: high pretest probability → low NPV



**POSSIBLE CUTOFF VALUES**  
A = 100% sensitivity cutoff value  
B = practical compromise between specificity and sensitivity  
C = 100% specificity cutoff value

Lowering the cutoff point:	↑ Sensitivity ↑ NPV
B → A (↑ FP ↓ FN)	↓ Specificity ↓ PPV
Raising the cutoff point:	↑ Specificity ↑ PPV
B → C (↑ FN ↓ FP)	↓ Sensitivity ↓ NPV

For example, in diabetes screening, raising the blood glucose cutoff level at which a patient is diagnosed will ↓ sensitivity, ↑ specificity, ↑ PPV, and ↓ NPV. The opposite changes occur with decreasing the blood glucose cutoff level.

**Likelihood ratio**

LRs can be multiplied with pretest odds of disease to estimate posttest odds. LR<sup>+</sup> > 10 and/or LR<sup>-</sup> < 0.1 are easy-to-remember indicators of a very useful diagnostic test.

$$LR^+ = \frac{\text{sensitivity}}{1 - \text{specificity}} = \frac{\text{True positive rate}}{\text{False positive rate}}$$

$$LR^- = \frac{1 - \text{sensitivity}}{\text{specificity}} = \frac{\text{False negative rate}}{\text{True negative rate}}$$


**Quantifying risk**

Definitions and formulas are based on the classic  $2 \times 2$  or contingency table.

	Disease	
	⊕	⊖
⊕	a	b
⊖	c	d

<b>Odds ratio</b>	Typically used in case-control studies. OR depicts the odds of an event (eg, disease) occurring giving a certain exposure (a/b) vs the odds of an event occurring in the absence of that exposure (c/d).	$OR = \frac{a/b}{c/d} = \frac{ad}{bc}$
<b>Relative risk</b>	Typically used in cohort studies. Risk of developing disease in the exposed group divided by risk in the unexposed group (eg, if 21% of smokers develop lung cancer vs 1% of nonsmokers, $RR = 21/1 = 21$ ). For rare diseases (low prevalence), OR approximates RR. $RR = 1 \rightarrow$ no association between exposure and disease. $RR > 1 \rightarrow$ exposure associated with $\uparrow$ disease occurrence. $RR < 1 \rightarrow$ exposure associated with $\downarrow$ disease occurrence.	$RR = \frac{a/(a+b)}{c/(c+d)}$
<b>Attributable risk</b>	The difference in risk between exposed and unexposed groups, or the proportion of disease occurrences that are attributable to the exposure (eg, if risk of lung cancer in smokers is 21% and risk in nonsmokers is 1%, then 20% of the lung cancer risk in smokers is attributable to smoking).	$AR = \frac{a}{a+b} - \frac{c}{c+d}$
<b>Relative risk reduction</b>	The proportion of risk reduction attributable to the intervention as compared to a control (eg, if 2% of patients who receive a flu shot develop the flu, while 8% of unvaccinated patients develop the flu, then $RR = 2/8 = 0.25$ , and $RRR = 0.75$ ).	$RRR = 1 - RR$
<b>Absolute risk reduction</b>	The difference in risk (not the proportion) attributable to the intervention as compared to a control (eg, if 8% of people who receive a placebo vaccine develop the flu vs 2% of people who receive a flu vaccine, then $ARR = 8\% - 2\% = 6\% = .06$ ).	$ARR = \frac{c}{c+d} - \frac{a}{a+b}$
<b>Number needed to treat</b>	Number of patients who need to be treated for 1 patient to benefit. Lower number = better treatment.	$NNT = 1/ARR$
<b>Number needed to harm</b>	Number of patients who need to be exposed to a risk factor for 1 patient to be harmed. Higher number = safer exposure.	$NNH = 1/AR$

**Incidence vs prevalence**



$$\text{Incidence rate} = \frac{\# \text{ of new cases}}{\# \text{ of people at risk}} \quad (\text{during a specified time period})$$

$$\text{Prevalence} = \frac{\# \text{ of existing cases}}{\text{Total \# of people in a population}} \quad (\text{at a point in time})$$

$$\frac{\text{Prevalence}}{1 - \text{prevalence}} = \frac{\text{Incidence rate} \times \text{average duration of disease}}{1 - \text{prevalence}}$$

Prevalence  $\approx$  incidence for short duration disease (eg, common cold).

Prevalence  $>$  incidence for chronic diseases, due to large # of existing cases (eg, diabetes).

**Incidence** looks at new cases (**incidents**).

**Prevalence** looks at **all** current cases.

Prevalence  $\sim$  pretest probability.

$\uparrow$  prevalence  $\rightarrow \uparrow$  PPV and  $\downarrow$  NPV.

**Precision vs accuracy**

**Precision (reliability)**

The consistency and reproducibility of a test.  
The absence of random variation in a test.

Random error  $\downarrow$  precision in a test.


$\uparrow$  precision  $\rightarrow \downarrow$  standard deviation.

$\uparrow$  precision  $\rightarrow \uparrow$  statistical power ( $1 - \beta$ ).

**Accuracy (validity)**

The trueness of test measurements.  
The absence of systematic error or bias in a test.


Systematic error  $\downarrow$  accuracy in a test.






**Bias and study errors**

TYPE	DEFINITION	EXAMPLES	STRATEGY TO REDUCE BIAS
<b>Recruiting participants</b>			
<b>Selection bias</b>	Nonrandom sampling or treatment allocation of subjects such that study population is not representative of target population (eg, study participants included based on adherence or other criteria related to outcome). Most commonly a sampling bias.	Berkson bias—study population selected from hospital is less healthy than general population Healthy worker effect—study population is healthier than the general population Non-response bias—participating subjects differ from nonrespondents in meaningful ways	Randomization Ensure the choice of the right comparison/reference group
<b>Performing study</b>			
<b>Recall bias</b>	Awareness of disorder alters recall by subjects; common in retrospective studies.	Patients with disease recall exposure after learning of similar cases	Decrease time from exposure to follow-up
<b>Measurement bias</b>	Information is gathered in a systemically distorted manner.	Association between HPV and cervical cancer not observed when using non-standardized classifications Hawthorne effect—participants change their behavior in response to their awareness of being observed	Use objective, standardized, and previously tested methods of data collection that are planned ahead of time Use placebo group
<b>Procedure bias</b>	Subjects in different groups are not treated the same.	Patients in treatment group spend more time in highly specialized hospital units	Blinding and use of placebo reduce influence of participants and researchers on procedures and interpretation of outcomes as neither are aware of group allocation
<b>Observer-expectancy bias</b>	Researcher's belief in the efficacy of a treatment changes the outcome of that treatment (aka Pygmalion effect; self-fulfilling prophecy).	If observer expects treatment group to show signs of recovery, then he is more likely to document positive outcomes	
<b>Interpreting results</b>			
<b>Confounding bias</b>	When a factor is related to both the exposure and outcome, but not on the causal pathway → factor distorts or confuses effect of exposure on outcome.	Pulmonary disease is more common in coal workers than the general population; however, people who work in coal mines also smoke more frequently than the general population	Multiple/repeated studies Crossover studies (subjects act as their own controls) Matching (patients with similar characteristics in both treatment and control groups) Restriction Randomization
<b>Lead-time bias</b>	Early detection is confused with ↑ survival.	Early detection makes it seem as though survival has increased, but the natural history of the disease has not changed	Measure “back-end” survival (adjust survival according to the severity of disease at the time of diagnosis)

**Statistical distribution**

<b>Measures of central tendency</b>	Mean = (sum of values)/(total number of values).	Most affected by outliers (extreme values).
	Median = middle value of a list of data sorted from least to greatest.	If there is an even number of values, the median will be the average of the middle two values.
	Mode = most common value.	Least affected by outliers.
<b>Measures of dispersion</b>	Standard deviation = how much variability exists in a set of values, around the mean of these values.	$\sigma = \text{SD}$ ; $n = \text{sample size}$ .
	Standard error = an estimate of how much variability exists in a (theoretical) set of sample means around the true population mean.	Variance = $(\text{SD})^2$ . $\text{SE} = \sigma/\sqrt{n}$ . $\text{SE} \downarrow$ as $n \uparrow$ .
<b>Normal distribution</b>	Gaussian, also called bell-shaped.	
	Mean = median = mode.	

**Nonnormal distributions**

<b>Bimodal</b>	Suggests two different populations (eg, metabolic polymorphism such as fast vs slow acetylators; age at onset of Hodgkin lymphoma; suicide rate by age).	
<b>Positive skew</b>	Typically, mean > median > mode. Asymmetry with longer tail on right.	
<b>Negative skew</b>	Typically, mean < median < mode. Asymmetry with longer tail on left.	

**Statistical hypotheses**

<b>Null (<math>H_0</math>)</b>	Hypothesis of no difference or relationship (eg, there is no association between the disease and the risk factor in the population).	Reality		
		$H_1$	$H_0$	
<b>Alternative (<math>H_1</math>)</b>	Hypothesis of some difference or relationship (eg, there is some association between the disease and the risk factor in the population).	Study rejects $H_0$	Power ( $1 - \beta$ )	$\alpha$ Type I error
		Study does not reject $H_0$	$\beta$ Type II error	Correct



### Outcomes of statistical hypothesis testing

<b>Correct result</b>	<p>Stating that there is an effect or difference when one exists (null hypothesis rejected in favor of alternative hypothesis).</p> <p>Stating that there is not an effect or difference when none exists (null hypothesis not rejected).</p>	
<b>Incorrect result</b>		
<b>Type I error (<math>\alpha</math>)</b>	<p>Stating that there is an effect or difference when none exists (null hypothesis incorrectly rejected in favor of alternative hypothesis).</p> <p><math>\alpha</math> is the probability of making a type I error. <math>p</math> is judged against a preset <math>\alpha</math> level of significance (usually 0.05). If <math>p &lt; 0.05</math>, then there is less than a 5% chance that the data will show something that is not really there.</p>	<p>Also known as false-positive error.</p> <p><math>\alpha</math> = you <b>a</b>ccused an innocent man. You can never “prove” the alternate hypothesis, but you can reject the null hypothesis as being very unlikely.</p>
<b>Type II error (<math>\beta</math>)</b>	<p>Stating that there is not an effect or difference when one exists (null hypothesis is not rejected when it is in fact false).</p> <p><math>\beta</math> is the probability of making a type II error. <math>\beta</math> is related to statistical power (<math>1 - \beta</math>), which is the probability of rejecting the null hypothesis when it is false.</p> <p>↑ power and ↓ <math>\beta</math> by:</p> <ul style="list-style-type: none"> <li>▪ ↑ sample size</li> <li>▪ ↑ expected effect size</li> <li>▪ ↑ precision of measurement</li> </ul>	<p>Also known as false-negative error.</p> <p><math>\beta</math> = you <b>b</b>lindly let the guilty man go free. If you ↑ sample size, you ↑ power. There is <b>power in numbers</b>.</p>
<b>Confidence interval</b>	<p>Range of values within which the true mean of the population is expected to fall, with a specified probability.</p> <p>CI for population mean = <math>\bar{x} \pm Z(SE)</math></p> <p>The 95% CI (corresponding to <math>\alpha = .05</math>) is often used.</p> <p>For the 95% CI, <math>Z = 1.96</math>.</p> <p>For the 99% CI, <math>Z = 2.58</math>.</p>	<p>If the 95% CI for a mean difference between 2 variables includes 0, then there is no significant difference and <math>H_0</math> is not rejected.</p> <p>If the 95% CI for odds ratio or relative risk includes 1, <math>H_0</math> is not rejected.</p> <p>If the CIs between 2 groups do not overlap → statistically significant difference exists.</p> <p>If the CIs between 2 groups overlap → usually no significant difference exists.</p>

## Common statistical tests

<b>t-test</b>	Checks differences between <b>means</b> of <b>2</b> groups.	<b>Tea is meant for 2.</b> Example: comparing the mean blood pressure between men and women.
<b>ANOVA</b>	Checks differences between means of <b>3</b> or more groups.	<b>3</b> words: <b>AN</b> alysis <b>O</b> f <b>V</b> ariance. Example: comparing the mean blood pressure between members of 3 different ethnic groups.
<b>Chi-square (<math>\chi^2</math>)</b>	Checks differences between 2 or more percentages or proportions of <b>categorical</b> outcomes (not mean values).	Pronounce <b>Chi-tegorical</b> . Example: comparing the percentage of members of 3 different ethnic groups who have essential hypertension.


## Pearson correlation coefficient

$r$  is always between  $-1$  and  $+1$ . The closer the absolute value of  $r$  is to 1, the stronger the linear correlation between the 2 variables.

Positive  $r$  value  $\rightarrow$  positive correlation (as one variable  $\uparrow$ , the other variable  $\uparrow$ ).

Negative  $r$  value  $\rightarrow$  negative correlation (as one variable  $\uparrow$ , the other variable  $\downarrow$ ).

Coefficient of determination =  $r^2$  (amount of variance in one variable that can be explained by variance in another variable).



## ▶ BEHAVIORAL SCIENCE—ETHICS

## Core ethical principles

<b>Autonomy</b>	Obligation to respect patients as individuals (truth-telling, confidentiality), to create conditions necessary for autonomous choice (informed consent), and to honor their preference in accepting or not accepting medical care.
<b>Beneficence</b>	Physicians have a special ethical (fiduciary) duty to act in the patient's best interest. May conflict with autonomy (an informed patient has the right to decide) or what is best for society (eg, mandatory TB treatment). Traditionally, patient interest supersedes.
<b>Nonmaleficence</b>	"Do no harm." Must be balanced against beneficence; if the benefits outweigh the risks, a patient may make an informed decision to proceed (most surgeries and medications fall into this category).
<b>Justice</b>	To treat persons fairly and equitably. This does not always imply equally (eg, triage).

**Informed consent**

A process (not just a document/signature) that requires:

- Disclosure: discussion of pertinent information
- Understanding: ability to comprehend
- Capacity: ability to reason and make one's own decisions (distinct from competence, a legal determination)
- Voluntariness: freedom from coercion and manipulation

Patients must have an intelligent understanding of their diagnosis and the risks/benefits of proposed treatment and alternative options, including no treatment.

Patient must be informed that he or she can revoke written consent at any time, even orally.

Exceptions to informed consent:

- Patient lacks decision-making capacity or is legally incompetent
- Implied consent in an emergency
- Therapeutic privilege—withholding information when disclosure would severely harm the patient or undermine informed decision-making capacity
- Waiver—patient explicitly waives the right of informed consent

**Consent for minors**

A minor is generally any person < 18 years old. Parental consent laws in relation to healthcare vary by state. In general, parental consent should be obtained, but exceptions exist for emergency treatment (eg, blood transfusions) or if minor is legally emancipated (eg, married, self supporting, or in the military).

Situations in which parental consent is usually not required:

- **Sex** (contraception, STIs, pregnancy)
- **Drugs** (substance abuse)
- **Rock and roll** (emergency/trauma)

Physicians should always encourage healthy minor-guardian communication.

Physician should seek a minor's assent even if their consent is not required.

**Decision-making capacity**

Physician must determine whether the patient is psychologically and legally capable of making a particular healthcare decision. Note that decisions made with capacity cannot be revoked simply if the patient later loses capacity.

Capacity is determined by a physician for a specific healthcare-related decision (eg, to refuse medical care). Competency is determined by a judge and usually refers to more global categories of decision making (eg, legally unable to make any healthcare-related decision).

Components:

- Patient is ≥ 18 years old or otherwise legally emancipated
- Patient makes and communicates a choice
- Patient is informed (knows and understands)
- Decision remains stable over time
- Decision is consistent with patient's values and goals, not clouded by a mood disorder
- Decision is not a result of altered mental status (eg, delirium, psychosis, intoxication)

<b>Advance directives</b>	Instructions given by a patient in anticipation of the need for a medical decision. Details vary per state law.
<b>Oral advance directive</b>	Incapacitated patient's prior oral statements commonly used as guide. Problems arise from variance in interpretation. If patient was informed, directive was specific, patient made a choice, and decision was repeated over time to multiple people, then the oral directive is more valid.
<b>Written advance directive</b>	Specifies specific healthcare interventions that a patient anticipates he or she would accept or reject during treatment for a critical or life-threatening illness. A living will is an example.
<b>Medical power of attorney</b>	Patient designates an agent to make medical decisions in the event that he/she loses decision-making capacity. Patient may also specify decisions in clinical situations. Can be revoked by patient if decision-making capacity is intact. More flexible than a living will.
<b>Do not resuscitate order</b>	DNR order applies to cardiopulmonary resuscitation (CPR). Other resuscitative measures that follow (cardioversion, intubation) are also typically avoided.

**Surrogate decision-maker** If a patient loses decision-making capacity and has not prepared an advance directive, individuals (surrogates) who know the patient must determine what the patient would have done. Priority of surrogates: **spouse** → adult **Children** → **Parents** → **Siblings** → other relatives (the **spouse ChiPS in**).

**Confidentiality** Confidentiality respects patient privacy and autonomy. If patient is not present or is incapacitated, disclosing information to family and friends should be guided by professional judgment of patient's best interest. The patient may voluntarily waive the right to confidentiality (eg, insurance company request).

General principles for exceptions to confidentiality:

- Potential physical harm to others is serious and imminent
- Likelihood of harm to self is great
- No alternative means exist to warn or to protect those at risk
- Physicians can take steps to prevent harm

Examples of exceptions to patient confidentiality (many are state-specific) include the following ("The physician's good judgment **SAVED** the day"):

- **Suicidal/homicidal** patients
- **Abuse** (children, elderly, and/or prisoners)
- **Duty to protect**—State-specific laws that sometimes allow physician to inform or somehow protect potential **Victim** from harm.
- **Epileptic** patients and other impaired automobile drivers.
- **Reportable Diseases** (eg, STIs, hepatitis, food poisoning); physicians may have a duty to warn public officials, who will then notify people at risk. Dangerous communicable diseases, such as TB or Ebola, may require involuntary treatment.

**Ethical situations**

SITUATION	APPROPRIATE RESPONSE
Patient is not adherent.	Attempt to identify the reason for nonadherence and determine his/her willingness to change; do not coerce the patient into adhering and do not refer him/her to another physician.
Patient desires an unnecessary procedure.	Attempt to understand why the patient wants the procedure and address underlying concerns. Do not refuse to see the patient and do not refer him/her to another physician. Avoid performing unnecessary procedures.
Patient has difficulty taking medications.	Provide written instructions; attempt to simplify treatment regimens; use teach-back method (ask patient to repeat regimen back to physician) to ensure comprehension.
Family members ask for information about patient's prognosis.	Avoid discussing issues with relatives without the patient's permission.
A patient's family member asks you not to disclose the results of a test if the prognosis is poor because the patient will be "unable to handle it."	Attempt to identify why the family member believes such information would be detrimental to the patient's condition. Explain that as long as the patient has decision-making capacity and does not indicate otherwise, communication of information concerning his/her care will not be withheld. However, if you believe the patient might seriously harm himself or others if informed, then you may invoke therapeutic privilege and withhold the information.
A 17-year-old girl is pregnant and requests an abortion.	Many states require parental notification or consent for minors for an abortion. Unless there are specific medical risks associated with pregnancy, a physician should not sway the patient's decision for an elective abortion (regardless of maternal age or fetal condition).
A 15-year-old girl is pregnant and wants to keep the child. Her parents want you to tell her to give the child up for adoption.	The patient retains the right to make decisions regarding her child, even if her parents disagree. Provide information to the teenager about the practical issues of caring for a baby. Discuss the options, if requested. Encourage discussion between the teenager and her parents to reach the best decision.
A terminally ill patient requests physician assistance in ending his/her own life.	In the overwhelming majority of states, refuse involvement in any form of physician-assisted suicide. Physicians may, however, prescribe medically appropriate analgesics that coincidentally shorten the patient's life.
Patient is suicidal.	Assess the seriousness of the threat. If it is serious, suggest that the patient remain in the hospital voluntarily; patient can be hospitalized involuntarily if he/she refuses.
Patient states that he/she finds you attractive.	Ask direct, closed-ended questions and use a chaperone if necessary. Romantic relationships with patients are never appropriate.
A woman who had a mastectomy says she now feels "ugly."	Find out why the patient feels this way. Do not offer falsely reassuring statements (eg, "You still look good").
Patient is angry about the long time he/she spent in the waiting room.	Acknowledge the patient's anger, but do not take a patient's anger personally. Apologize for any inconvenience. Stay away from efforts to explain the delay.
Patient is upset with the way he/she was treated by another doctor.	Suggest that the patient speak directly to that physician regarding his/her concerns. If the problem is with a member of the office staff, tell the patient you will speak to that person.
An invasive test is performed on the wrong patient.	Regardless of the outcome, a physician is ethically obligated to inform a patient that a mistake has been made.

**Ethical situations (continued)**

SITUATION	APPROPRIATE RESPONSE
A patient requires a treatment not covered by his/her insurance.	Never limit or deny care because of the expense in time or money. Discuss all treatment options with patients, even if some are not covered by their insurance companies.
A 7-year-old boy loses a sister to cancer and now feels responsible.	At ages 5–7, children begin to understand that death is permanent, that all life functions end completely at death, and that everything that is alive eventually dies. Provide a direct, concrete description of his sister's death. Avoid clichés and euphemisms. Reassure that the boy is not responsible. Identify and normalize fears and feelings. Encourage play and healthy coping behaviors (eg, remembering her in his own way).
Patient is victim of intimate partner violence.	Ask if patient is safe and has an emergency plan. Do not necessarily pressure patient to leave his or her partner, or disclose the incident to the authorities (unless required by state law).
Patient wants to try alternative or holistic medicine.	Find out why and allow patient to do so as long as there are no contraindications, medication interactions, or adverse effects to the new treatment.
Physician colleague presents to work impaired.	If impaired or incompetent, colleague is a threat to patient safety. Report the situation to local supervisory personnel. Should the organization fail to take action, alert the state licensing board.
Patient is officially determined to suffer brain death. Patient's family insists on maintaining life support indefinitely because patient is still moving when touched.	Gently explain to family that there is no chance of recovery, and that brain death is equivalent to death. Movement is due to spinal arc reflex and is not voluntary. Bring case to appropriate ethics board regarding futility of care and withdrawal of life support.
A pharmaceutical company offers you a sponsorship in exchange for advertising its new drug.	Reject this offer. Generally, decline gifts and sponsorships to avoid any appearance of conflict of interest. The AMA Code of Ethics does make exceptions for gifts directly benefitting patients; gifts of minimal value; special funding for medical education of students, residents, fellows; grants whose recipients are chosen by independent institutional criteria; and funds that are distributed without attribution to sponsors.
An adult refuses care because it is against his/her religious beliefs.	Work with the patient by either explaining the treatment or pursuing alternative treatments. However, a physician should never force a competent adult to receive care if it is contrary to the patient's religious beliefs.
Mother and 15-year-old daughter are unresponsive following a car accident and are bleeding internally. Father says do not transfuse because they are Jehovah's Witnesses.	Transfuse daughter, but do not transfuse mother. Emergent care can be refused by the healthcare proxy for an adult, particularly when patient preferences are known or reasonably inferred, but not for a minor.

## ▶ PUBLIC HEALTH SCIENCES—THE WELL PATIENT

**Early developmental milestones**

Milestone dates are ranges that have been approximated and vary by source. Children not meeting milestones may need assessment for potential developmental delay.

AGE	MOTOR	SOCIAL	VERBAL/COGNITIVE
<b>Infant</b>	<b>Parents</b>	<b>Start</b>	<b>Observing,</b>
0–12 mo	<p><b>P</b>rimitive reflexes disappear—Moro (by 3 mo), rooting (by 4 mo), palmar (by 6 mo), Babinski (by 12 mo)</p> <p><b>P</b>osture—lifts head up prone (by 1 mo), rolls and sits (by 6 mo), crawls (by 8 mo), stands (by 10 mo), walks (by 12–18 mo)</p> <p><b>P</b>icks—passes toys hand to hand (by 6 mo), <b>P</b>incer grasp (by 10 mo)</p> <p><b>P</b>oints to objects (by 12 mo)</p>	<p><b>S</b>ocial smile (by 2 mo)</p> <p><b>S</b>tranger anxiety (by 6 mo)</p> <p><b>S</b>eparation anxiety (by 9 mo)</p>	<p><b>O</b>rients—first to voice (by 4 mo), then to name and gestures (by 9 mo)</p> <p><b>O</b>bject permanence (by 9 mo)</p> <p><b>O</b>ratory—says “mama” and “dada” (by 10 mo)</p>
<b>Toddler</b>	<b>Child</b>	<b>Rearing</b>	<b>Working,</b>
12–36 mo	<p><b>C</b>ruises, takes first steps (by 12 mo)</p> <p><b>C</b>limbs stairs (by 18 mo)</p> <p><b>C</b>ubes stacked—number = age (yr) × 3</p> <p><b>C</b>utlery—feeds self with fork and spoon (by 20 mo)</p> <p><b>K</b>icks ball (by 24 mo)</p>	<p><b>R</b>ecreation—parallel play (by 24–36 mo)</p> <p><b>R</b>approchement—moves away from and returns to mother (by 24 mo)</p> <p><b>R</b>ealization—core gender identity formed (by 36 mo)</p>	<p><b>W</b>ords—<b>200</b> words by age <b>2</b> (<b>2 zeros</b>), <b>2</b>-word sentences</p>
<b>Preschool</b>	<b>Don't</b>	<b>Forget, they're still</b>	<b>Learning!</b>
3–5 yr	<p><b>D</b>rive—tricycle (<b>3</b> wheels at <b>3</b> yr)</p> <p><b>D</b>rawings—copies line or circle, stick figure (by 4 yr)</p> <p><b>D</b>exterity—hops on one foot (by 4 yr), uses buttons or zippers, grooms self (by 5 yr)</p>	<p><b>F</b>reedom—comfortably spends part of day away from mother (by 3 yr)</p> <p><b>F</b>riends—cooperative play, has imaginary friends (by 4 yr)</p>	<p><b>L</b>anguage—<b>1000</b> words by age <b>3</b> (<b>3 zeros</b>), uses complete sentences and prepositions (by 4 yr)</p> <p><b>L</b>egends—can tell detailed stories (by 4 yr)</p>

**Car seats for children**

Children should ride in rear-facing car seats until they are 2 years old and in car seats with a harness until they are 4 years. Older children should use a booster seat until they are 8 years old or until the seat belt fits properly. Children < 12 years old should not ride in a seat with a front-facing airbag.

**Changes in the elderly**

Sexual changes:

- Men—slower erection/ejaculation, longer refractory period.
- Women—vaginal shortening, thinning, and dryness.

Sleep patterns: ↓ REM and slow-wave sleep; ↑ sleep onset latency; ↑ early awakenings.

↑ suicide rate.

↓ vision and hearing.

↓ immune response.

↓ renal, pulmonary, and GI function.

↓ muscle mass, ↑ fat.

Intelligence does not decrease.

**▶ PUBLIC HEALTH SCIENCES—HEALTHCARE DELIVERY****Disease prevention**

<b>Primary</b>	Prevent disease before it occurs (eg, HPV vaccination)	
<b>Secondary</b>	Screen early for and manage existing but asymptomatic disease (eg, Pap smear for cervical cancer)	
<b>Tertiary</b>	Treatment to reduce complications from disease that is ongoing or has long-term effects (eg, chemotherapy)	<b>Quaternary</b> —identifying patients at risk of unnecessary treatment, protecting from the harm of new interventions (eg, electronic sharing of patient records to avoid duplicating recent laboratory and imaging studies)

**Major medical insurance plans**

<b>Health Maintenance Organization</b>	Patients are restricted (except in emergencies) to a limited panel of providers who are in the network. Payment is denied for any service that does not meet established, evidence-based guidelines. Requires referral from primary care provider to see a specialist.
<b>Point of Service</b>	Patients are allowed to see providers outside of the network, but have higher out-of-pocket costs, including higher copays and deductibles, for out-of-network services. Requires referral from primary care provider to see a specialist.
<b>Preferred Provider Organization</b>	Patients are allowed to see physicians who are within or outside of the network. All services have higher copays and deductibles. Does not require referral from primary care provider to see a specialist.
<b>Exclusive Provider Organization</b>	Patients are limited (except in emergencies) to a network of doctors, specialists, and hospitals. Does not require referral from primary care provider to see a specialist.



### Healthcare payment models

<b>Capitation</b>	Physicians receive a set amount per patient assigned to them per period of time, regardless of how much the patient uses the healthcare system.
<b>Discounted fee-for-service</b>	Patient pays for each individual service at a predetermined, discounted rate.
<b>Global payment</b>	Patient pays for all expenses associated with a single incident of care with a single payment. Most commonly used during elective surgeries, as it covers the cost of surgery as well as the necessary pre- and postoperative visits.

### Medicare and Medicaid

Medicare and Medicaid—federal social healthcare programs that originated from amendments to the Social Security Act. Medicare is available to patients  $\geq 65$  years old,  $< 65$  with certain disabilities, and those with end-stage renal disease. Medicaid is joint federal and state health assistance for people with limited income and/or resources.

Medicar**E** is for **E**lderly.  
Medicai**D** is for **D**estitute.

The 4 parts of Medicare:

- Part **A**: Hospit**A**l insurance, home hospice care
- Part **B**: **B**asic medical **b**ills (eg, doctor's fees, diagnostic testing)
- Part **C**: (parts A + B = **C**ombo) delivered by approved private **c**ompanies
- Part **D**: Prescription **D**rugs

### Hospice care

Medical care focused on providing comfort and palliation instead of definitive cure. Available to patients on Medicare or Medicaid and in most private insurance plans whose life expectancy is  $< 6$  months.

During end-of-life care, priority is given to improving the patient's comfort and relieving pain, and care often includes opioid medications. Facilitating comfort is prioritized over potential side effects (eg, respiratory depression). This prioritization of positive effects over negative effects is known as the **principle of double effect**.

### Common causes of death (US) by age

	< 1 YR	1–14 YR	15–34 YR	35–44 YR	45–64 YR	65+ YR
<b>#1</b>	Congenital malformations	Unintentional injury	Unintentional injury	Unintentional injury	Cancer	Heart disease
<b>#2</b>	Preterm birth	Cancer	Suicide	Cancer	Heart disease	Cancer
<b>#3</b>	Maternal pregnancy complication	Congenital malformations	Homicide	Heart disease	Unintentional injury	Chronic respiratory disease

**Hospitalized conditions with frequent readmissions**

	MEDICARE	MEDICAID	PRIVATE INSURANCE	UNINSURED
#1	Congestive HF	Mood disorders	Maintenance of chemotherapy or radiotherapy	Mood disorders
#2	Septicemia	Schizophrenia/psychotic disorders	Mood disorders	Alcohol-related disorders
#3	Pneumonia	Diabetes mellitus with complications	Complications of surgical procedures or medical care	Diabetes mellitus with complications

Readmission for any reason within 30 days of original admission.


► PUBLIC HEALTH SCIENCES—QUALITY AND SAFETY

**Safety culture** Organizational environment in which everyone can freely bring up safety concerns without fear of censure. Facilitates error identification. Event reporting systems collect data on errors for internal and external monitoring.

**Human factors design** Forcing functions (those that prevent undesirable actions [eg, connecting feeding syringe to IV tubing]) are the most effective. Standardization improves process reliability (eg, clinical pathways, guidelines, checklists). Simplification reduces wasteful activities (eg, consolidating electronic medical records [EMRs]). Deficient designs hinder workflow and lead to staff workarounds that bypass safety features (eg, patient ID barcodes affixed to computers due to unreadable wristbands).

**PDSA cycle** Process improvement model to test changes in real clinical setting. Impact on patients:

- **P**lan—define problem and solution
- **D**o—test new process
- **S**tudy—measure and analyze data
- **A**ct—integrate new process into regular workflow




**Quality measurements** Plotted on run and control charts.

	MEASURE	EXAMPLE
<b>Outcome</b>	Impact on patients	Average HbA <sub>1c</sub> of patients with diabetes
<b>Process</b>	Performance of system as planned	Percentage of target patients whose HbA <sub>1c</sub> was measured in the past 6 months
<b>Balancing</b>	Impact on other systems/outcomes	Incidence of hypoglycemia among those patients

**Swiss cheese model**

Focuses on systems and conditions rather than an individual's error. The risk of a threat becoming a reality is mitigated by differing layers and types of defenses. Patient harm can occur despite multiple safeguards when “the holes in the cheese line up.”

**Types of medical errors**

May involve patient identification, diagnosis, monitoring, nosocomial infection, medications, procedures, devices, documentation, handoffs. Errors causing harmful outcomes must be disclosed to patients.

**Active error**

Occurs at level of frontline operator (eg, wrong IV pump dose programmed).

Immediate impact.

**Latent error**

Occurs in processes indirect from operator but impacts patient care (eg, different types of IV pumps used within same hospital).

Accident waiting to happen.

**Medical error analysis****Root cause analysis**

Uses records and participant interviews to identify all the underlying problems that led to an error. Categories of causes include process, people (providers or patients), environment, equipment, materials, management.

Retrospective approach applied after failure event to prevent recurrence.

Plotted on fishbone (Ishikawa, cause-and-effect) diagram. Fix causes with corrective action plan.

**Failure mode and effects analysis**

Uses inductive reasoning to identify all the ways a process might fail and prioritize these by their probability of occurrence and impact on patients.

Forward-looking approach applied before process implementation to prevent failure occurrence.

# High-Yield Organ Systems

*“Symptoms, then, are in reality nothing but the cry from suffering organs.”*  
—Jean-Martin Charcot

*“Man is an intelligence in servitude to his organs.”*  
—Aldous Huxley

*“Learn that you are a machine, your heart an engine, your lungs a fanning machine and a sieve, your brain with its two lobes an electric battery.”*  
—Andrew T. Still

▶ Approaching the Organ Systems	264
▶ Cardiovascular	267
▶ Endocrine	311
▶ Gastrointestinal	343
▶ Hematology and Oncology	385
▶ Musculoskeletal, Skin, and Connective Tissue	423
▶ Neurology and Special Senses	459
▶ Psychiatry	523
▶ Renal	547
▶ Reproductive	579
▶ Respiratory	625

### ▶ APPROACHING THE ORGAN SYSTEMS

In this section, we have divided the High-Yield Facts into the major **Organ Systems**. Within each Organ System are several subsections, including **Embryology**, **Anatomy**, **Physiology**, **Pathology**, and **Pharmacology**. As you progress through each Organ System, refer back to information in the previous subsections to organize these basic science subsections into a “vertically integrated” framework for learning. Below is some general advice for studying the organ systems by these subsections.

#### **Embryology**

Relevant embryology is included in each organ system subsection. Embryology tends to correspond well with the relevant anatomy, especially with regard to congenital malformations.

#### **Anatomy**

Several topics fall under this heading, including gross anatomy, histology, and neuroanatomy. Do not memorize all the small details; however, do not ignore anatomy altogether. Review what you have already learned and what you wish you had learned. Many questions require two or more steps. The first step is to identify a structure on anatomic cross section, electron micrograph, or photomicrograph. The second step may require an understanding of the clinical significance of the structure.

When studying, stress clinically important material. For example, be familiar with gross anatomy and radiologic anatomy related to specific diseases (eg, Pancoast tumor, Horner syndrome), traumatic injuries (eg, fractures, sensory and motor nerve deficits), procedures (eg, lumbar puncture), and common surgeries (eg, cholecystectomy). There are also many questions on the exam involving x-rays, CT scans, and neuro MRI scans. Many students suggest browsing through a general radiology atlas, pathology atlas, and histology atlas. Focus on learning basic anatomy at key levels in the body (eg, sagittal brain MRI; axial CT of the midthorax, abdomen, and pelvis). Basic neuroanatomy (especially pathways, blood supply, and functional anatomy), associated neuropathology, and neurophysiology have good yield. Please note that many of the photographic images in this book are for illustrative purposes and are not necessarily reflective of Step 1 emphasis.

#### **Physiology**

The portion of the examination dealing with physiology is broad and concept oriented and thus does not lend itself as well to fact-based review. Diagrams are often the best study aids, especially given the increasing number of questions requiring the interpretation of diagrams. Learn to apply basic physiologic relationships in a variety of ways (eg, the Fick equation, clearance equations). You are seldom asked to perform complex

calculations. Hormones are the focus of many questions, so learn their sites of production and action as well as their regulatory mechanisms.

A large portion of the physiology tested on the USMLE Step 1 is clinically relevant and involves understanding physiologic changes associated with pathologic processes (eg, changes in pulmonary function with COPD). Thus, it is worthwhile to review the physiologic changes that are found with common pathologies of the major organ systems (eg, heart, lungs, kidneys, GI tract) and endocrine glands.

### **Pathology**

Questions dealing with this discipline are difficult to prepare for because of the sheer volume of material involved. Review the basic principles and hallmark characteristics of the key diseases. Given the clinical orientation of Step 1, it is no longer sufficient to know only the “buzzword” associations of certain diseases (eg, café-au-lait macules and neurofibromatosis); you must also know the clinical descriptions of these findings.

Given the clinical slant of the USMLE Step 1, it is also important to review the classic presenting signs and symptoms of diseases as well as their associated laboratory findings. Delve into the signs, symptoms, and pathophysiology of major diseases that have a high prevalence in the United States (eg, alcoholism, diabetes, hypertension, heart failure, ischemic heart disease, infectious disease). Be prepared to think one step beyond the simple diagnosis to treatment or complications.

The examination includes a number of color photomicrographs and photographs of gross specimens that are presented in the setting of a brief clinical history. However, read the question and the choices carefully before looking at the illustration, because the history will help you identify the pathologic process. Flip through an illustrated pathology textbook, color atlases, and appropriate Web sites in order to look at the pictures in the days before the exam. Pay attention to potential clues such as age, sex, ethnicity, occupation, recent activities and exposures, and specialized lab tests.

### **Pharmacology**

Preparation for questions on pharmacology is straightforward. Memorizing all the key drugs and their characteristics (eg, mechanisms, clinical use, and important side effects) is high yield. Focus on understanding the prototype drugs in each class. Avoid memorizing obscure derivatives. Learn the “classic” and distinguishing toxicities of the major drugs. Do not bother with drug dosages or trade names. Reviewing associated biochemistry, physiology, and microbiology can be useful while studying pharmacology. There is a strong emphasis on ANS, CNS, antimicrobial, and cardiovascular agents as well as NSAIDs. Much of the material is clinically relevant. Newer drugs on the market are also fair game.



# Cardiovascular

*“As for me, except for an occasional heart attack, I feel as young as I ever did.”*

—Robert Benchley

*“Hearts will never be practical until they are made unbreakable.”*

—The Wizard of Oz

*“As the arteries grow hard, the heart grows soft.”*

—H. L. Mencken

*“Nobody has ever measured, not even poets, how much the heart can hold.”*

—Zelda Fitzgerald

*“Only from the heart can you touch the sky.”*

—Rumi

*“It is not the size of the man but the size of his heart that matters.”*

—Evander Holyfield

▶ Embryology	268
▶ Anatomy	271
▶ Physiology	272
▶ Pathology	288
▶ Pharmacology	304



## ▶ CARDIOVASCULAR—EMBRYOLOGY

## Heart embryology

EMBRYONIC STRUCTURE	GIVES RISE TO
Truncus arteriosus	Ascending aorta and pulmonary trunk
Bulbus cordis	Smooth parts (outflow tract) of left and right ventricles
Endocardial cushion	Atrial septum, membranous interventricular septum; AV and semilunar valves
Primitive atrium	Trabeculated part of left and right atria
Primitive ventricle	Trabeculated part of left and right ventricles
Primitive pulmonary vein	Smooth part of left atrium
Left horn of sinus venosus	Coronary sinus
Right horn of sinus venosus	Smooth part of right atrium (sinus venarum)
Right common cardinal vein and right anterior cardinal vein	Superior vena cava (SVC)

## Heart morphogenesis

First functional organ in vertebrate embryos; beats spontaneously by week 4 of development.

## Cardiac looping

Primary heart tube loops to establish left-right polarity; begins in week 4 of gestation.

Defect in left-right dynein (involved in L/R asymmetry) can lead to dextrocardia, as seen in Kartagener syndrome (primary ciliary dyskinesia).


## Septation of the chambers

## Atria

- Septum primum grows toward endocardial cushions, narrowing foramen primum.
- Foramen secundum forms in septum primum (foramen primum disappears).
- Septum secundum develops as foramen secundum maintains right-to-left shunt.
- Septum secundum expands and covers most of the foramen secundum. The residual foramen is the foramen ovale.
- Remaining portion of septum primum forms valve of foramen ovale.

- (Not shown) Septum secundum and septum primum fuse to form the atrial septum.
- (Not shown) Foramen ovale usually closes soon after birth because of ↑ LA pressure.

**Patent foramen ovale**—caused by failure of septum primum and septum secundum to fuse after birth; most are left untreated. Can lead to paradoxical emboli (venous thromboemboli that enter systemic arterial circulation), similar to those resulting from an ASD.




**Heart morphogenesis (continued)**

**Ventricles**

- ❶ Muscular interventricular septum forms. Opening is called interventricular foramen.
- ❷ Aorticopulmonary septum rotates and fuses with muscular ventricular septum to form membranous interventricular septum, closing interventricular foramen.
- ❸ Growth of endocardial cushions separates atria from ventricles and contributes to both atrial septation and membranous portion of the interventricular septum.

**Ventricular septal defect**—most common congenital cardiac anomaly, usually occurs in membranous septum.



**Outflow tract formation**

Neural crest and endocardial cell migrations  
 → truncal and bulbar ridges that spiral and fuse to form aorticopulmonary septum  
 → ascending aorta and pulmonary trunk.

Conotruncal abnormalities associated with failure of neural crest cells to migrate:


- Transposition of great vessels.
- Tetralogy of Fallot.
- Persistent truncus arteriosus.

**Valve development**

Aortic/pulmonary: derived from endocardial cushions of outflow tract.  
 Mitral/tricuspid: derived from fused endocardial cushions of the AV canal.

Valvular anomalies may be stenotic, regurgitant, atretic (eg, tricuspid atresia), or displaced (eg, Ebstein anomaly).

## Fetal circulation



Blood in umbilical vein has a  $PO_2$  of  $\approx 30$  mm Hg and is  $\approx 80\%$  saturated with  $O_2$ . Umbilical arteries have low  $O_2$  saturation.

3 important shunts:

- 1 Blood entering fetus through the umbilical vein is conducted via the **ductus venosus** into the IVC, bypassing hepatic circulation.
- 2 Most of the highly **Oxygenated** blood reaching the heart via the IVC is directed through the **foramen ovale** and pumped into the aorta to supply the head and body.
- 3 **Deoxygenated** blood from the SVC passes through the RA  $\rightarrow$  RV  $\rightarrow$  main pulmonary artery  $\rightarrow$  **Ductus arteriosus**  $\rightarrow$  **D**escending aorta; shunt is due to high fetal pulmonary artery resistance (due partly to low  $O_2$  tension).

At birth, infant takes a breath;  $\downarrow$  resistance in pulmonary vasculature  $\rightarrow$   $\uparrow$  left atrial pressure vs right atrial pressure; foramen ovale closes (now called fossa ovalis);  $\uparrow$  in  $O_2$  (from respiration) and  $\downarrow$  in prostaglandins (from placental separation)  $\rightarrow$  closure of ductus arteriosus.

Indomethacin helps close PDA  $\rightarrow$  ligamentum arteriosum (remnant of ductus arteriosus).


Prostaglandins **E<sub>1</sub>** and **E<sub>2</sub>** **kEEp** PDA open.

## Fetal-postnatal derivatives

Allantois $\rightarrow$ urachus	Median umbilical ligament	Urachus is part of allantoic duct between bladder and umbilicus.
Ductus arteriosus	Ligamentum arteriosum	
Ductus venosus	Ligamentum venosum	
Foramen ovale	Fossa ovalis	
Notochord	Nucleus pulposus	
Umbilical arteries	Median umbilical ligaments	
Umbilical vein	Ligamentum teres hepatis (round ligament)	Contained in falciform ligament.

▶ CARDIOVASCULAR—ANATOMY

**Anatomy of the heart**



SA and AV nodes are supplied by branches of the RCA. Infarct may cause nodal dysfunction (bradycardia or heart block).


Right-dominant circulation (85%) = PDA arises from RCA.

Left-dominant circulation (8%) = PDA arises from LCX.

Codominant circulation (7%) = PDA arises from both LCX and RCA.

Coronary artery occlusion most commonly occurs in the LAD.

Coronary blood flow peaks in early diastole.



The most posterior part of the heart is the left atrium **A**; enlargement can cause dysphagia (due to compression of the esophagus) or hoarseness (due to compression of the left recurrent laryngeal nerve, a branch of the vagus).

Pericardium consists of 3 layers (from outer to inner):

- Fibrous pericardium
- Parietal layer of serous pericardium
- Visceral layer of serous pericardium

Pericardial cavity lies between parietal and visceral layers.

Pericardium innervated by phrenic nerve. Pericarditis can cause referred pain to the shoulder.

## ▶ CARDIOVASCULAR—PHYSIOLOGY

**Cardiac output**

CO = stroke volume (SV) × heart rate (HR)

Fick principle:

$$\text{CO} = \frac{\text{rate of O}_2 \text{ consumption}}{\text{arterial O}_2 \text{ content} - \text{venous O}_2 \text{ content}}$$

Mean arterial pressure (MAP) = CO × total peripheral resistance (TPR)

MAP =  $\frac{2}{3}$  diastolic pressure +  $\frac{1}{3}$  systolic pressure

Pulse pressure = systolic pressure – diastolic pressure

Pulse pressure is proportional to SV, inversely proportional to arterial compliance.

SV = end-diastolic volume (EDV) – end-systolic volume (ESV)

During the early stages of exercise, CO is maintained by ↑ HR and ↑ SV. During the late stages of exercise, CO is maintained by ↑ HR only (SV plateaus).


Diastole is preferentially shortened with ↑ HR; less filling time → ↓ CO (eg, ventricular tachycardia).

↑ pulse pressure in hyperthyroidism, aortic regurgitation, aortic stiffening (isolated systolic hypertension in elderly), obstructive sleep apnea (↑ sympathetic tone), exercise (transient).

↓ pulse pressure in aortic stenosis, cardiogenic shock, cardiac tamponade, advanced heart failure (HF).

**Cardiac output variables**

<b>Stroke volume</b>	<p>Stroke Volume affected by <b>C</b>ontractility, <b>A</b>fterload, and <b>P</b>reload.                  ↑ SV with:</p> <ul style="list-style-type: none"> <li>▪ ↑ Contractility (eg, anxiety, exercise)</li> <li>▪ ↑ Preload (eg, early pregnancy)</li> <li>▪ ↓ Afterload</li> </ul>	<p><b>SV CAP.</b>                  A failing heart has ↓ SV (systolic and/or diastolic dysfunction)</p>
<b>Contractility</b>	<p>Contractility (and SV) ↑ with:</p> <ul style="list-style-type: none"> <li>▪ Catecholamine stimulation via β<sub>1</sub> receptor:                         <ul style="list-style-type: none"> <li>▪ Ca<sup>2+</sup> channels phosphorylated → ↑ Ca<sup>2+</sup> entry → ↑ Ca<sup>2+</sup>-induced Ca<sup>2+</sup> release and ↑ Ca<sup>2+</sup> storage in sarcoplasmic reticulum</li> <li>▪ Phospholamban phosphorylation → active Ca<sup>2+</sup> ATPase → ↑ Ca<sup>2+</sup> storage in sarcoplasmic reticulum</li> </ul> </li> <li>▪ ↑ intracellular Ca<sup>2+</sup></li> <li>▪ ↓ extracellular Na<sup>+</sup> (↓ activity of Na<sup>+</sup>/Ca<sup>2+</sup> exchanger)</li> <li>▪ Digitalis (blocks Na<sup>+</sup>/K<sup>+</sup> pump → ↑ intracellular Na<sup>+</sup> → ↓ Na<sup>+</sup>/Ca<sup>2+</sup> exchanger activity → ↑ intracellular Ca<sup>2+</sup>)</li> </ul>	<p>Contractility (and SV) ↓ with:</p> <ul style="list-style-type: none"> <li>▪ β<sub>1</sub>-blockade (↓ cAMP)</li> <li>▪ HF with systolic dysfunction</li> <li>▪ Acidosis</li> <li>▪ Hypoxia/hypercapnia (↓ PO<sub>2</sub>/↑ PCO<sub>2</sub>)</li> <li>▪ Non-dihydropyridine Ca<sup>2+</sup> channel blockers</li> </ul>
<b>Myocardial oxygen demand</b>	<p>Myo<b>CARD</b>ial O<sub>2</sub> demand is ↑ by:</p> <ul style="list-style-type: none"> <li>▪ ↑ <b>C</b>ontractility</li> <li>▪ ↑ <b>A</b>fterload (proportional to arterial pressure)</li> <li>▪ ↑ heart <b>R</b>ate</li> <li>▪ ↑ <b>D</b>iameter of ventricle (↑ wall tension)</li> </ul>	<p>Wall tension follows Laplace's law:                  Wall tension = pressure × radius                  Wall stress = <math>\frac{\text{pressure} \times \text{radius}}{2 \times \text{wall thickness}}</math></p>
<b>Preload</b>	<p>Preload approximated by ventricular EDV; depends on venous tone and circulating blood volume.</p>	<p><b>V</b>enous vasodilators (eg, nitroglycerin) ↓ <b>prE</b>load.</p>
<b>Afterload</b>	<p>Afterload approximated by MAP.                  ↑ afterload → ↑ pressure → ↑ wall tension per Laplace's law.                   LV compensates for ↑ afterload by thickening (hypertrophy) in order to ↓ wall tension.</p>	<p><b>A</b>rterial vasodilators (eg, hydr<b>AL</b>azine) ↓ <b>A</b>fterload.                  ACE inhibitors and ARBs ↓ both preload and afterload.                  Chronic hypertension (↑ MAP) → LV hypertrophy.</p>
<b>Ejection fraction</b>	<p><math display="block">EF = \frac{SV}{EDV} = \frac{EDV - ESV}{EDV}</math>                 Left ventricular EF is an index of ventricular contractility.</p>	<p>EF ↓ in systolic HF.                  EF normal in HF with preserved ejection fraction (HFpEF).</p>

**Starling curve**

Force of contraction is proportional to end-diastolic length of cardiac muscle fiber (preload).

↑ contractility with catecholamines, positive inotropes (eg, digoxin).

↓ contractility with loss of myocardium (eg, MI), β-blockers (acutely), non-dihydropyridine Ca<sup>2+</sup> channel blockers, dilated cardiomyopathy.

**Resistance, pressure, flow**

$$\Delta P = Q \times R$$

Similar to Ohm's law:  $\Delta V = IR$

Volumetric flow rate ( $Q$ ) = flow velocity ( $v$ ) × cross-sectional area ( $A$ )

Resistance

$$= \frac{\text{driving pressure } (\Delta P)}{\text{flow } (Q)} = \frac{8\eta \text{ (viscosity)} \times \text{length}}{\pi r^4}$$

Total resistance of vessels in series:

$$R_T = R_1 + R_2 + R_3 \dots$$

Total resistance of vessels in parallel:

$$\frac{1}{R_T} = \frac{1}{R_1} + \frac{1}{R_2} + \frac{1}{R_3} \dots$$

Capillaries have highest total cross-sectional area and lowest flow velocity.

Pressure gradient drives flow from high pressure to low pressure.


Arterioles account for most of TPR. Veins provide most of blood storage capacity.

Viscosity depends mostly on hematocrit.

Viscosity ↑ in hyperproteinemic states (eg, multiple myeloma), polycythemia.

Viscosity ↓ in anemia.

**Cardiac and vascular function curves**




Intersection of curves = operating point of heart (ie, venous return and CO are equal).

GRAPH	EFFECT	EXAMPLES
<b>A</b> Inotropy	Changes in contractility → altered CO for a given RA pressure (preload).	<b>1</b> Catecholamines, digoxin ⊕ <b>2</b> Uncompensated HF, narcotic overdose, sympathetic inhibition ⊖
<b>B</b> Venous return	Changes in circulating volume or venous tone → altered RA pressure for a given CO. Mean systemic pressure (x-intercept) changes with volume/venous tone.	<b>3</b> Fluid infusion, sympathetic activity ⊕ <b>4</b> Acute hemorrhage, spinal anesthesia ⊖
<b>C</b> Total peripheral resistance	At a given mean systemic pressure (x-intercept) and RA pressure, changes in TPR → altered CO.	<b>5</b> Vasopressors ⊕ <b>6</b> Exercise, AV shunt ⊖

Changes often occur in tandem, and may be reinforcing (eg, exercise ↑ inotropy and ↓ TPR to maximize CO) or compensatory (eg, HF ↓ inotropy → fluid retention to ↑ preload to maintain CO).



## Pressure-volume loops and cardiac cycle



The black loop represents normal cardiac physiology.

Phases—left ventricle:

- 1 Isovolumetric contraction—period between mitral valve closing and aortic valve opening; period of highest  $O_2$  consumption
- 2 Systolic ejection—period between aortic valve opening and closing
- 3 Isovolumetric relaxation—period between aortic valve closing and mitral valve opening
- 4 Rapid filling—period just after mitral valve opening
- 5 Reduced filling—period just before mitral valve closing

Heart sounds:

S1—mitral and tricuspid valve closure. Loudest at mitral area.

S2—aortic and pulmonary valve closure. Loudest at left upper sternal border.

S3—in early diastole during rapid ventricular filling phase. Associated with ↑ filling pressures (eg, mitral regurgitation, HF) and more common in dilated ventricles (but can be normal in children and young adults).

S4—in late diastole (“atrial kick”). Best heard at apex with patient in left lateral decubitus position. High atrial pressure. Associated with ventricular noncompliance (eg, hypertrophy). Left atrium must push against stiff LV wall. Consider abnormal, regardless of patient age.

Jugular venous pulse (JVP):


**a** wave—atrial contraction. Absent in atrial fibrillation (AF).

**c** wave—RV contraction (closed tricuspid valve bulging into atrium).

**x** descent—downward displacement of closed tricuspid valve during rapid ventricular ejection phase. Reduced or absent in tricuspid regurgitation and right HF because pressure gradients are reduced.

**v** wave—↑ right atrial pressure due to filling (“villing”) against closed tricuspid valve.


**y** descent—RA emptying into RV. Prominent in constrictive pericarditis, absent in cardiac tamponade.



**Splitting**


**Normal splitting**

Inspiration → drop in intrathoracic pressure  
 → ↑ venous return → ↑ RV filling → ↑ RV stroke volume → ↑ RV ejection time  
 → delayed closure of pulmonic valve.  
 ↓ pulmonary impedance (↑ capacity of the pulmonary circulation) also occurs during inspiration, which contributes to delayed closure of pulmonic valve.




**Wide splitting**

Seen in conditions that delay RV emptying (eg, pulmonic stenosis, right bundle branch block). Causes delayed pulmonic sound (especially on inspiration). An exaggeration of normal splitting.




**Fixed splitting**

Heard in ASD. ASD → left-to-right shunt  
 → ↑ RA and RV volumes → ↑ flow through pulmonic valve such that, regardless of breath, pulmonic closure is greatly delayed.



**Paradoxical splitting**

Heard in conditions that delay aortic valve closure (eg, aortic stenosis, left bundle branch block). Normal order of valve closure is reversed so that P2 sound occurs before delayed A2 sound. Therefore on inspiration, P2 closes later and moves closer to A2, thereby “paradoxically” eliminating the split (usually heard in expiration).



E = Expiration  
 I = Inspiration

## Auscultation of the heart


Where to listen: **APT M****Aortic area:****Systolic murmur**

Aortic stenosis  
Flow murmur  
(eg, physiologic murmur)  
Aortic valve sclerosis

**Left sternal border:**

**Diastolic murmur**  
Aortic regurgitation  
Pulmonic regurgitation  
**Systolic murmur**  
Hypertrophic  
cardiomyopathy

 Aortic  
 Pulmonic  
 Tricuspid  
 Mitral

**Pulmonic area:**

**Systolic ejection murmur**  
Pulmonic stenosis  
Flow murmur

**Tricuspid area:**

**Holosystolic murmur**  
Tricuspid regurgitation  
Ventricular septal defect  
**Diastolic murmur**  
Tricuspid stenosis  
Atrial septal defect (↑ flow  
across tricuspid valve)

**Mitral area (apex):**

**Holosystolic murmur**  
Mitral regurgitation  
**Systolic murmur**  
Mitral valve prolapse  
**Diastolic murmur**  
Mitral stenosis

Rx

## BEDSIDE MANEUVER

## EFFECT

Inspiration (↑ venous return to right atrium)

↑ intensity of right heart sounds

Hand grip (↑ afterload)

↑ intensity of MR, AR, and VSD murmurs  
↓ hypertrophic cardiomyopathy and AS murmurs  
MVP: later onset of click/murmur

Valsalva (phase II), standing up (↓ preload)

↓ intensity of most murmurs (including AS)  
↑ intensity of hypertrophic cardiomyopathy murmur  
MVP: earlier onset of click/murmur

Rapid squatting (↑ venous return, ↑ preload, ↑ afterload)

↓ intensity of hypertrophic cardiomyopathy murmur  
↑ intensity of AS, MR, and VSD murmurs  
MVP: later onset of click/murmur


Systolic heart sounds include the murmurs of aortic/pulmonic stenosis, mitral/tricuspid regurgitation, VSD, MVP, hypertrophic cardiomyopathy.

Diastolic heart sounds include the murmurs of aortic/pulmonic regurgitation, mitral/tricuspid stenosis.

**Heart murmurs**


**Systolic**

**Aortic stenosis**




Crescendo-decrescendo systolic ejection murmur (ejection click may be present). LV >> aortic pressure during systole. Loudest at heart base; radiates to carotids. “Pulsus parvus et tardus”—pulses are weak with a delayed peak. Can lead to **Syncope**, **Angina**, and **Dyspnea** on exertion (**SAD**). Most commonly due to age-related calcification in older patients (> 60 years old) or in younger patients with early-onset calcification of bicuspid aortic valve.

**Mitral/tricuspid regurgitation**




Holosystolic, high-pitched “blowing murmur.” Mitral—loudest at apex and radiates toward axilla. MR is often due to ischemic heart disease (post-MI), MVP, LV dilatation. Tricuspid—loudest at tricuspid area. TR commonly caused by RV dilatation. Rheumatic fever and infective endocarditis can cause either MR or TR.

**Mitral valve prolapse**



Late systolic crescendo murmur with midsystolic click (MC; due to sudden tensing of chordae tendineae). Most frequent valvular lesion. Best heard over apex. Loudest just before S2. Usually benign. Can predispose to infective endocarditis. Can be caused by myxomatous degeneration (1° or 2° to connective tissue disease such as Marfan or Ehlers-Danlos syndrome), rheumatic fever, chordae rupture.


**Ventricular septal defect**



Holosystolic, harsh-sounding murmur. Loudest at tricuspid area.


**Diastolic**

**Aortic regurgitation**



High-pitched “blowing” early diastolic decrescendo murmur. Long diastolic murmur, hyperdynamic pulse, and head bobbing when severe and chronic. Wide pulse pressure. Often due to aortic root dilation, bicuspid aortic valve, endocarditis, rheumatic fever. Progresses to left HF.


**Mitral stenosis**



Follows opening snap (OS; due to abrupt halt in leaflet motion in diastole, after rapid opening due to fusion at leaflet tips). Delayed rumbling mid-to-late diastolic murmur (↓ interval between S2 and OS correlates with ↑ severity). LA >> LV pressure during diastole. Often a late (and highly specific) sequela of rheumatic fever. Chronic MS can result in LA dilatation.

**Continuous**

**Patent ductus arteriosus**



Continuous machine-like murmur. Loudest at S2. Often due to congenital rubella or prematurity. Best heard at left infraclavicular area.

### Myocardial action potential

Also occurs in bundle of His and Purkinje fibers.

**Phase 0** = rapid upstroke and depolarization—voltage-gated  $\text{Na}^+$  channels open.

**Phase 1** = initial repolarization—inactivation of voltage-gated  $\text{Na}^+$  channels. Voltage-gated  $\text{K}^+$  channels begin to open.


**Phase 2** = plateau— $\text{Ca}^{2+}$  influx through voltage-gated  $\text{Ca}^{2+}$  channels balances  $\text{K}^+$  efflux.  $\text{Ca}^{2+}$  influx triggers  $\text{Ca}^{2+}$  release from sarcoplasmic reticulum and myocyte contraction.

**Phase 3** = rapid repolarization—massive  $\text{K}^+$  efflux due to opening of voltage-gated slow  $\text{K}^+$  channels and closure of voltage-gated  $\text{Ca}^{2+}$  channels.

**Phase 4** = resting potential—high  $\text{K}^+$  permeability through  $\text{K}^+$  channels.

In contrast to skeletal muscle:

- Cardiac muscle action potential has a plateau, which is due to  $\text{Ca}^{2+}$  influx and  $\text{K}^+$  efflux.
- Cardiac muscle contraction requires  $\text{Ca}^{2+}$  influx from ECF to induce  $\text{Ca}^{2+}$  release from sarcoplasmic reticulum ( $\text{Ca}^{2+}$ -induced  $\text{Ca}^{2+}$  release).
- Cardiac myocytes are electrically coupled to each other by gap junctions.



### Pacemaker action potential


Occurs in the SA and AV nodes. Key differences from the ventricular action potential include:

**Phase 0** = upstroke—opening of voltage-gated  $\text{Ca}^{2+}$  channels. Fast voltage-gated  $\text{Na}^+$  channels are permanently inactivated because of the less negative resting potential of these cells. Results in a slow conduction velocity that is used by the AV node to prolong transmission from the atria to ventricles.

Phases 1 and 2 are absent.

**Phase 3** = inactivation of the  $\text{Ca}^{2+}$  channels and  $\uparrow$  activation of  $\text{K}^+$  channels  $\rightarrow \uparrow \text{K}^+$  efflux.

**Phase 4** = slow spontaneous diastolic depolarization due to  $I_f$  (“funny current”).  $I_f$  channels responsible for a slow, mixed  $\text{Na}^+/\text{K}^+$  inward current; different from  $I_{\text{Na}}$  in phase 0 of ventricular action potential. Accounts for automaticity of SA and AV nodes. The slope of phase 4 in the SA node determines HR. ACh/adenosine  $\downarrow$  the rate of diastolic depolarization and  $\downarrow$  HR, while catecholamines  $\uparrow$  depolarization and  $\uparrow$  HR. Sympathetic stimulation  $\uparrow$  the chance that  $I_f$  channels are open and thus  $\uparrow$  HR.



**Electrocardiogram**

Conduction pathway—SA node → atria  
→ AV node → bundle of His → right and  
left bundle branches → Purkinje fibers  
→ ventricles; left bundle branch divides into  
left anterior and posterior fascicles.

SA node “pacemaker” inherent dominance with  
slow phase of upstroke.

AV node—located in posteroinferior part of  
interatrial septum. Blood supply usually  
from RCA. 100-msec delay allows time for  
ventricular filling.

Pacemaker rates—SA > AV > bundle of His/  
Purkinje/ventricles.

Speed of conduction—Purkinje > atria  
> ventricles > AV node.

P wave—atrial depolarization. Atrial  
repolarization is masked by QRS complex.

PR interval—time from start of atrial  
depolarization to start of ventricular  
depolarization (normally < 200 msec).

QRS complex—ventricular depolarization  
(normally < 120 msec).



QT interval—ventricular depolarization,  
mechanical contraction of the ventricles,  
ventricular repolarization.


T wave—ventricular repolarization. T-wave  
inversion may indicate ischemia or recent MI.

J point—junction between end of QRS complex  
and start of ST segment.

ST segment—isoelectric, ventricles depolarized.

U wave—prominent in hypokalemia,  
bradycardia.



**Torsades de pointes**

Polymorphic ventricular tachycardia, characterized by shifting sinusoidal waveforms on ECG; can progress to ventricular fibrillation (VF). Long QT interval predisposes to torsades de pointes. Caused by drugs, ↓ K<sup>+</sup>, ↓ Mg<sup>2+</sup>, congenital abnormalities. Treatment includes magnesium sulfate.

Drug-induced long QT (**ABCDE**):

- Anti**A**rrhythmics (class IA, III)
- Anti**B**iotics (eg, macrolides)
- Anti“**C**”ychotics (eg, haloperidol)
- Anti**D**epressants (eg, TCAs)
- Anti**E**metics (eg, ondansetron)

Torsades de pointes = twisting of the points

**Congenital long QT syndrome**

Inherited disorder of myocardial repolarization, typically due to ion channel defects; ↑ risk of sudden cardiac death (SCD) due to torsades de pointes. Includes:


- **Romano-Ward syndrome**—autosomal dominant, pure cardiac phenotype (no deafness).
- **Jervell and Lange-Nielsen syndrome**—autosomal recessive, sensorineural deafness.

**Brugada syndrome**

Autosomal dominant disorder most common in Asian males. ECG pattern of pseudo-right bundle branch block and ST elevations in V<sub>1</sub>-V<sub>3</sub>. ↑ risk of ventricular tachyarrhythmias and SCD. Prevent SCD with implantable cardioverter-defibrillator (ICD).








**Wolff-Parkinson-White syndrome**

Most common type of ventricular pre-excitation syndrome. Abnormal fast accessory conduction pathway from atria to ventricle (bundle of Kent) bypasses the rate-slowing AV node → ventricles begin to partially depolarize earlier → characteristic delta wave with widened QRS complex and shortened PR interval on ECG. May result in reentry circuit → supraventricular tachycardia.





## ECG tracings


RHYTHM	DESCRIPTION	EXAMPLE
<b>Atrial fibrillation</b>	Chaotic and erratic baseline with no discrete P waves in between irregularly spaced QRS complexes. Irregularly irregular heartbeat. Most common risk factors include hypertension and coronary artery disease (CAD). Can lead to thromboembolic events, particularly stroke. Treatment includes anticoagulation, rate control, rhythm control, and/or cardioversion.	
<b>Atrial flutter</b>	A rapid succession of identical, back-to-back atrial depolarization waves. The identical appearance accounts for the “sawtooth” appearance of the flutter waves. Treat like atrial fibrillation. Definitive treatment is catheter ablation.	
<b>Ventricular fibrillation</b>	A completely erratic rhythm with no identifiable waves. Fatal arrhythmia without immediate CPR and defibrillation.	
<b>AV block</b>		
<b>First degree</b>	The PR interval is prolonged (> 200 msec). Benign and asymptomatic. No treatment required.	
<b>Second degree</b>		
<b>Mobitz type I (Wenckebach)</b>	Progressive lengthening of PR interval until a beat is “dropped” (a P wave not followed by a QRS complex). Usually asymptomatic. Variable RR interval with a pattern (regularly irregular).	
<b>Mobitz type II</b>	Dropped beats that are not preceded by a change in the length of the PR interval (as in type I). May progress to 3rd-degree block. Often treated with pacemaker.	
<b>Third degree (complete)</b>	The atria and ventricles beat independently of each other. P waves and QRS complexes not rhythmically associated. Atrial rate > ventricular rate. Usually treated with pacemaker. Can be caused by Lyme disease.	

**Atrial natriuretic peptide**

Released from **atrial myocytes** in response to  $\uparrow$  blood volume and atrial pressure. Acts via cGMP. Causes vasodilation and  $\downarrow$   $\text{Na}^+$  reabsorption at the renal collecting tubule. Dilates afferent renal arterioles and constricts efferent arterioles, promoting diuresis and contributing to “aldosterone escape” mechanism.

**B-type (brain) natriuretic peptide**

Released from **ventricular myocytes** in response to  $\uparrow$  tension. Similar physiologic action to ANP, with longer half-life. BNP blood test used for diagnosing HF (very good negative predictive value). Available in recombinant form (nesiritide) for treatment of HF.

**Baroreceptors and chemoreceptors****Receptors:**

- Aortic arch transmits via vagus nerve to solitary nucleus of medulla (responds to  $\downarrow$  and  $\uparrow$  in BP).
- Carotid sinus (dilated region at carotid bifurcation) transmits via glossopharyngeal nerve to solitary nucleus of medulla (responds to  $\downarrow$  and  $\uparrow$  in BP).

**Baroreceptors:**


- Hypotension— $\downarrow$  arterial pressure  $\rightarrow$   $\downarrow$  stretch  $\rightarrow$   $\downarrow$  afferent baroreceptor firing  $\rightarrow$   $\uparrow$  efferent sympathetic firing and  $\downarrow$  efferent parasympathetic stimulation  $\rightarrow$  vasoconstriction,  $\uparrow$  HR,  $\uparrow$  contractility,  $\uparrow$  BP. Important in the response to severe hemorrhage.
- Carotid massage— $\uparrow$  pressure on carotid sinus  $\rightarrow$   $\uparrow$  stretch  $\rightarrow$   $\uparrow$  afferent baroreceptor firing  $\rightarrow$   $\uparrow$  AV node refractory period  $\rightarrow$   $\downarrow$  HR.
- Component of Cushing reflex (triad of hypertension, bradycardia, and respiratory depression)— $\uparrow$  intracranial pressure constricts arterioles  $\rightarrow$  cerebral ischemia  $\rightarrow$   $\uparrow$   $\text{pCO}_2$  and  $\downarrow$  pH  $\rightarrow$  central reflex sympathetic  $\uparrow$  in perfusion pressure (hypertension)  $\rightarrow$   $\uparrow$  stretch  $\rightarrow$  peripheral reflex baroreceptor-induced bradycardia.

**Chemoreceptors:**

- Peripheral—carotid and aortic bodies are stimulated by  $\downarrow$   $\text{PO}_2$  ( $< 60$  mm Hg),  $\uparrow$   $\text{PCO}_2$ , and  $\downarrow$  pH of blood.
- Central—are stimulated by changes in pH and  $\text{PCO}_2$  of brain interstitial fluid, which in turn are influenced by arterial  $\text{CO}_2$ . Do not directly respond to  $\text{PO}_2$ .

**Normal cardiac pressures**


Pulmonary capillary wedge pressure (PCWP; in mm Hg) is a good approximation of left atrial pressure. In mitral stenosis, PCWP > LV end diastolic pressure. PCWP is measured with pulmonary artery catheter (Swan-Ganz catheter).

**Autoregulation**

How blood flow to an organ remains constant over a wide range of perfusion pressures.

ORGAN	FACTORS DETERMINING AUTOREGULATION	
Heart	Local metabolites (vasodilatory): adenosine, NO, CO <sub>2</sub> , ↓ O <sub>2</sub>	Note: the pulmonary vasculature is unique in that hypoxia causes vasoconstriction so that only well-ventilated areas are perfused. In other organs, hypoxia causes vasodilation.  CO <sub>2</sub> , H <sup>+</sup> , Adenosine, Lactate, K <sup>+</sup> (CHALK)
Brain	Local metabolites (vasodilatory): CO <sub>2</sub> (pH)	
Kidneys	Myogenic and tubuloglomerular feedback	
Lungs	Hypoxia causes vasoconstriction	
Skeletal muscle	Local metabolites during exercise: lactate, adenosine, K <sup>+</sup> , H <sup>+</sup> , CO <sub>2</sub> At rest: sympathetic tone	
Skin	Sympathetic stimulation most important mechanism for temperature control	

### Capillary fluid exchange



Starling forces determine fluid movement through capillary membranes:

- $P_c$  = capillary pressure—pushes fluid out of capillary
- $P_i$  = interstitial fluid pressure—pushes fluid into capillary
- $\pi_c$  = plasma colloid osmotic (oncotic) pressure—pulls fluid into capillary
- $\pi_i$  = interstitial fluid colloid osmotic pressure—pulls fluid out of capillary

$$J_v = \text{net fluid flow} = K_f [(P_c - P_i) - \zeta(\pi_c - \pi_i)]$$

$K_f$  = capillary permeability to fluid

$\zeta$  = reflection coefficient (measure of capillary permeability to protein)

Edema—excess fluid outflow into interstitium commonly caused by:

- $\uparrow$  capillary pressure ( $\uparrow P_c$ ; eg, HF)
- $\downarrow$  plasma proteins ( $\downarrow \pi_c$ ; eg, nephrotic syndrome, liver failure, protein malnutrition)
- $\uparrow$  capillary permeability ( $\uparrow K_f$ ; eg, toxins, infections, burns)
- $\uparrow$  interstitial fluid colloid osmotic pressure ( $\uparrow \pi_i$ ; eg, lymphatic blockage)

## ▶ CARDIOVASCULAR—PATHOLOGY

## Congenital heart diseases

## RIGHT-TO-LEFT SHUNTS

Early cyanosis—“blue babies.” Often diagnosed prenatally or become evident immediately after birth. Usually require urgent surgical treatment and/or maintenance of a PDA.

The **5 Ts**:

1. **T**runcus arteriosus (1 vessel)
2. **T**ransposition (2 switched vessels)
3. **T**ricuspid atresia (3 = **Tri**)
4. **T**etralogy of Fallot (4 = **Tetra**)
5. **TAPVR** (5 letters in the name)

**Persistent truncus arteriosus**


Truncus arteriosus fails to divide into pulmonary trunk and aorta due to lack of aorticopulmonary septum formation; most patients have accompanying VSD.

**D-transposition of great vessels**

Aorta leaves RV (anterior) and pulmonary trunk leaves LV (posterior) → separation of systemic and pulmonary circulations. Not compatible with life unless a shunt is present to allow mixing of blood (eg, VSD, PDA, or patent foramen ovale).

Due to failure of the aorticopulmonary septum to spiral.

Without surgical intervention, most infants die within the first few months of life.

**Tricuspid atresia**

Absence of tricuspid valve and hypoplastic RV; requires both ASD and VSD for viability.

**Tetralogy of Fallot**

Caused by anterosuperior displacement of the infundibular septum. Most common cause of early childhood cyanosis.



- 1 **P**ulmonary infundibular stenosis (most important determinant for prognosis)
- 2 **R**ight ventricular hypertrophy (RVH)—boot-shaped heart on CXR **A**
- 3 **O**verriding aorta
- 4 **V**SD

Pulmonary stenosis forces right-to-left flow across VSD → RVH, “tet spells” (often caused by crying, fever, and exercise due to exacerbation of RV outflow obstruction).

**PROVe.**

Squatting: ↑ SVR, ↓ right-to-left shunt, improves cyanosis.

Treatment: early surgical correction.

**Total anomalous pulmonary venous return**

Pulmonary veins drain into right heart circulation (SVC, coronary sinus, etc); associated with ASD and sometimes PDA to allow for right-to-left shunting to maintain CO.

**Ebstein anomaly**

Characterized by displacement of tricuspid valve leaflets downward into RV, artificially “atrializing” the ventricle. Associated with tricuspid regurgitation and right HF. Can be caused by lithium exposure in utero.

**Congenital heart diseases (continued)**

**LEFT-TO-RIGHT SHUNTS**

Acyanotic at presentation; cyanosis may occur years later.  
Frequency: VSD > ASD > PDA.


Right-to-Left shunts: ea**RL**y cyanosis.  
Left-to-Right shunts: “**LateR**” cyanosis.

**Ventricular septal defect**

Most common congenital cardiac defect. Asymptomatic at birth, may manifest weeks later or remain asymptomatic throughout life. Most self resolve; larger lesions may lead to LV overload and HF.

O<sub>2</sub> saturation ↑ in RV and pulmonary artery.


**Atrial septal defect**



Defect in interatrial septum **B**; loud S1; wide, fixed split S2. Ostium secundum defects most common and usually occur as isolated findings; ostium primum defects rarer yet usually occur with other cardiac anomalies. Symptoms range from none to HF. Distinct from patent foramen ovale in that septa are missing tissue rather than unfused.

O<sub>2</sub> saturation ↑ in RA, RV, and pulmonary artery. May lead to paradoxical emboli (systemic venous emboli use ASD to bypass lungs and become systemic arterial emboli).

**Patent ductus arteriosus**




In fetal period, shunt is right to left (normal). In neonatal period, ↓ pulmonary vascular resistance → shunt becomes left to right → progressive RVH and/or LVH and HF. Associated with a continuous, “machine-like” murmur. Patency is maintained by PGE synthesis and low O<sub>2</sub> tension. Uncorrected PDA **C** can eventually result in late cyanosis in the lower extremities (differential cyanosis).

“**Endomethacin**” (indomethacin) **ends** patency of PDA; PGE keeps ductus **G**oing (may be necessary to sustain life in conditions such as transposition of the great vessels). PDA is normal in utero and normally closes only after birth.

**Eisenmenger syndrome**




Uncorrected left-to-right shunt (VSD, ASD, PDA) → ↑ pulmonary blood flow → pathologic remodeling of vasculature → pulmonary arterial hypertension. RVH occurs to compensate → shunt becomes right to left. Causes late cyanosis, clubbing **D**, and polycythemia. Age of onset varies.



**OTHER ANOMALIES**

**Coarctation of the aorta**

Aortic narrowing near insertion of ductus arteriosus (“juxtaductal”). Associated with bicuspid aortic valve, other heart defects, and Turner syndrome. Hypertension in upper extremities and weak, delayed pulse in lower extremities (brachial-femoral delay). With age, intercostal arteries enlarge due to collateral circulation; arteries erode ribs → notched appearance on CXR. Complications include HF, ↑ risk of cerebral hemorrhage (berry aneurysms), aortic rupture, and possible endocarditis.



**Congenital cardiac defect associations**


DISORDER	DEFECT
Alcohol exposure in utero (fetal alcohol syndrome)	VSD, PDA, ASD, tetralogy of Fallot
Congenital rubella	PDA, pulmonary artery stenosis, septal defects
Down syndrome	AV septal defect (endocardial cushion defect), VSD, ASD
Infant of diabetic mother	Transposition of great vessels
Marfan syndrome	MVP, thoracic aortic aneurysm and dissection, aortic regurgitation
Prenatal lithium exposure	Ebstein anomaly
Turner syndrome	Bicuspid aortic valve, coarctation of aorta
Williams syndrome	Supravalvular aortic stenosis
22q11 syndromes	Truncus arteriosus, tetralogy of Fallot

**Hypertension**

Defined as persistent systolic BP  $\geq 140$  mm Hg and/or diastolic BP  $\geq 90$  mm Hg

**RISK FACTORS**

$\uparrow$  age, obesity, diabetes, physical inactivity, excess salt intake, excess alcohol intake, family history; African American > Caucasian > Asian.

**FEATURES**

90% of hypertension is 1° (essential) and related to  $\uparrow$  CO or  $\uparrow$  TPR. Remaining 10% mostly 2° to renal/renovascular disease (eg, fibromuscular dysplasia [which has characteristic “string of beads” appearance of renal artery **A**], atherosclerosis) and 1° hyperaldosteronism.

**Hypertensive urgency**—severe ( $\geq 180/\geq 120$  mm Hg) hypertension without acute end-organ damage.

**Hypertensive emergency**—severe hypertension with evidence of acute end-organ damage (eg, encephalopathy, stroke, retinal hemorrhages and exudates, papilledema, MI, HF, aortic dissection, kidney injury, microangiopathic hemolytic anemia, eclampsia).

**PREDISPOSES TO**

CAD, LVH, HF, atrial fibrillation; aortic dissection, aortic aneurysm; stroke; chronic kidney disease (hypertensive nephropathy); retinopathy.

**Hyperlipidemia signs**


<b>Xanthomas</b>	Plaques or nodules composed of lipid-laden histiocytes in skin <b>A</b> , especially the eyelids (xanthelasma <b>B</b> ).
<b>Tendinous xanthoma</b>	Lipid deposit in tendon <b>C</b> , especially Achilles.
<b>Corneal arcus</b>	Lipid deposit in cornea. Common in elderly (arcus senilis <b>D</b> ), but appears earlier in life in hypercholesterolemia.

**Arteriosclerosis**

Hardening of arteries, with arterial wall thickening and loss of elasticity.

<b>Arteriosclerosis</b>	Common. Affects small arteries and arterioles. Two types: hyaline (thickening of vessel walls in essential hypertension or diabetes mellitus <b>A</b> ) and hyperplastic (“onion skinning” in severe hypertension <b>B</b> with proliferation of smooth muscle cells).
-------------------------	--

<b>Mönckeberg sclerosis (medial calcific sclerosis)</b>	Uncommon. Affects medium-sized arteries. Calcification of internal elastic lamina and media of arteries → vascular stiffening without obstruction. “Pipestem” appearance on x-ray <b>C</b> . Does not obstruct blood flow; intima not involved.
---	---






**Atherosclerosis**

Very common. Disease of elastic arteries and large- and medium-sized muscular arteries; a form of arteriosclerosis caused by buildup of cholesterol plaques.

**LOCATION**

Abdominal aorta > coronary artery > popliteal artery > carotid artery **A**.

**RISK FACTORS**


Modifiable: smoking, hypertension, hyperlipidemia (↑ LDL), diabetes.  
Nonmodifiable: age, sex (↑ in men and postmenopausal women), family history.

**SYMPTOMS**

Angina, claudication, but can be asymptomatic.

**PROGRESSION**

Inflammation important in pathogenesis: endothelial cell dysfunction → macrophage and LDL accumulation → foam cell formation → fatty streaks → smooth muscle cell migration (involves PDGF and FGF), proliferation, and extracellular matrix deposition → fibrous plaque → complex atheromas **B**.

**COMPLICATIONS**


Aneurysms, ischemia, infarcts, peripheral vascular disease, thrombus, emboli.

**Aortic aneurysm**

Localized pathologic dilatation of the aorta. May cause abdominal and/or back pain, which is a sign of leaking, dissection, or imminent rupture.

**Abdominal aortic aneurysm**

Associated with atherosclerosis. Risk factors include history of tobacco use, ↑ age, male sex, family history. May present as palpable pulsatile abdominal mass (arrows in **A** point to outer dilated calcified aortic wall, with partial crescent-shaped nonopacification of aorta due to flap/clot).


**Thoracic aortic aneurysm**

Associated with cystic medial degeneration. Risk factors include hypertension, bicuspid aortic valve, connective tissue disease (eg, Marfan syndrome). Also historically associated with 3° syphilis (obliterative endarteritis of the vasa vasorum). Aortic root dilatation may lead to aortic valve regurgitation.

**Traumatic aortic rupture**

Due to trauma and/or deceleration injury, most commonly at aortic isthmus (proximal descending aorta just distal to origin of left subclavian artery).

**Aortic dissection**



Longitudinal intimal tear forming a false lumen (arrows in **A** show flap extending into ascending aorta, Stanford type A dissection). Associated with hypertension, bicuspid aortic valve, inherited connective tissue disorders (eg, Marfan syndrome). Can present with tearing, sudden-onset chest pain, radiating to the back +/- markedly unequal BP in arms. CXR shows mediastinal widening. Can result in organ ischemia, aortic rupture, death. Two types:

- Stanford type **A** (proximal): involves **A**scending aorta. May extend to aortic arch or descending aorta. May result in acute aortic regurgitation or cardiac tamponade. Treatment: surgery.
- Stanford type **B** (distal): only involves descending aorta (**B**elow ligamentum arteriosum). Treat medically with  $\beta$ -blockers, then vasodilators.

**Ischemic heart disease manifestations**

**Angina**

Chest pain due to ischemic myocardium 2° to coronary artery narrowing or spasm; no myocyte necrosis.

- **Stable**—usually 2° to atherosclerosis; exertional chest pain in classic distribution (usually with ST depression on ECG), resolving with rest or nitroglycerin.
- **Variant (Prinzmetal)**—occurs at rest 2° to coronary artery spasm; transient ST elevation on ECG. Smoking is a risk factor, but hypertension and hypercholesterolemia are not. Triggers may include cocaine, alcohol, and triptans. Treat with  $Ca^{2+}$  channel blockers, nitrates, and smoking cessation (if applicable).
- **Unstable**—thrombosis with incomplete coronary artery occlusion; +/- ST depression and/or T-wave inversion on ECG but no cardiac biomarker elevation (unlike NSTEMI); ↑ in frequency or intensity of chest pain or any chest pain at rest.

**Coronary steal syndrome**

Distal to coronary stenosis, vessels are maximally dilated at baseline. Administration of vasodilators (eg, dipyridamole, regadenoson) dilates normal vessels and shunts blood toward well-perfused areas, thereby diverting flow away from vessels that are stenosed and leading to ischemia in myocardium perfused by these vessels. Principle behind pharmacologic stress tests with coronary vasodilators.

**Sudden cardiac death**

Death from cardiac causes within 1 hour of onset of symptoms, most commonly due to a lethal arrhythmia (eg, VF). Associated with CAD (up to 70% of cases), cardiomyopathy (hypertrophic, dilated), and hereditary ion channelopathies (eg, long QT syndrome, Brugada syndrome). Prevent with implantable cardioverter-defibrillator (ICD).

**Chronic ischemic heart disease**

Progressive onset of HF over many years due to chronic ischemic myocardial damage.

**Myocardial infarction**



Most often acute thrombosis due to rupture of coronary artery atherosclerotic plaque. ↑ cardiac biomarkers (CK-MB, troponins) are diagnostic.

**ST-segment elevation MI (STEMI)**

Transmural infarcts  
Full thickness of myocardial wall involved  
ST elevation on ECG, Q waves

**Non-ST-segment elevation MI (NSTEMI)**









Subendocardial infarcts  
Subendocardium (inner 1/3) especially vulnerable to ischemia  
ST depression on ECG



### Evolution of myocardial infarction

Commonly occluded coronary arteries: LAD > RCA > circumflex.

Symptoms: diaphoresis, nausea, vomiting, severe retrosternal pain, pain in left arm and/or jaw, shortness of breath, fatigue.

TIME	GROSS	LIGHT MICROSCOPE	COMPLICATIONS
0–24 hr	None  <p>Occluded artery Infarct Dark mottling; pale with tetrazolium stain</p>	Early coagulative necrosis, release of necrotic cell contents into blood; edema, hemorrhage, wavy fibers. Neutrophils appear. Reperfusion injury, associated with generation of free radicals, leads to hypercontraction of myofibrils through ↑ free calcium influx. 	Ventricular arrhythmia, HF, cardiogenic shock.
1–3 days	 <p>Hyperemia</p>	Extensive coagulative necrosis. Tissue surrounding infarct shows acute inflammation with neutrophils. 	Postinfarction fibrinous pericarditis.
3–14 days	 <p>Hyperemic border; central yellow-brown softening—maximally yellow and soft by 10 days</p>	Macrophages, then granulation tissue at margins. 	Free wall rupture → tamponade; papillary muscle rupture → mitral regurgitation; interventricular septal rupture due to macrophage-mediated structural degradation. LV pseudoaneurysm (risk of rupture).
2 weeks to several months	 <p>Recanalized artery Gray-white</p>	Contracted scar complete. 	Dressler syndrome, HF, arrhythmias, true ventricular aneurysm (risk of mural thrombus).


**Diagnosis of myocardial infarction**

In the first 6 hours, ECG is the gold standard. Cardiac troponin I rises after 4 hours (peaks at 24 hr) and is ↑ for 7–10 days; more specific than other protein markers.

CK-MB rises after 6–12 hours (peaks at 16–24 hr) and is predominantly found in myocardium but can also be released from skeletal muscle. Useful in diagnosing reinfarction following acute MI because levels return to normal after 48 hours.

Large MIs lead to greater elevations in troponin I and CK-MB. Exact curves vary with testing procedure.

ECG changes can include ST elevation (STEMI, transmural infarct), ST depression (NSTEMI, subendocardial infarct), hyperacute (peaked) T waves, T-wave inversion, new left bundle branch block, and pathologic Q waves or poor R wave progression (evolving or old transmural infarct).




**ECG localization of STEMI**

INFARCT LOCATION	LEADS WITH ST ELEVATIONS OR Q WAVES
Anteroseptal (LAD)	V <sub>1</sub> –V <sub>2</sub>
Anteroapical (distal LAD)	V <sub>3</sub> –V <sub>4</sub>
Anterolateral (LAD or LCX)	V <sub>5</sub> –V <sub>6</sub>
Lateral (LCX)	I, aVL
Inferior (RCA)	II, III, aVF
Posterior (PDA)	V <sub>7</sub> –V <sub>9</sub> , ST depression in V <sub>1</sub> –V <sub>3</sub> with tall R waves

**Myocardial infarction complications**

<b>Cardiac arrhythmia</b>	Occurs within the first few days after MI. Important cause of death before reaching the hospital and within the first 24 hours post-MI.
<b>Postinfarction fibrinous pericarditis</b>	Occurs 1–3 days after MI. Friction rub.
<b>Papillary muscle rupture</b>	Occurs 2–7 days after MI. Posteromedial papillary muscle rupture <b>A</b> ↑ risk due to single blood supply from posterior descending artery. Can result in severe mitral regurgitation.
<b>Interventricular septal rupture</b>	Occurs 3–5 days after MI. Macrophage-mediated degradation → VSD.
<b>Ventricular pseudoaneurysm formation</b>	Occurs 3–14 days after MI. Contained free wall rupture <b>B</b> ; ↓ CO, risk of arrhythmia, embolus from mural thrombus.
<b>Ventricular free wall rupture</b>	Occurs 5–14 days after MI. Free wall rupture <b>C</b> → cardiac tamponade. LV hypertrophy and previous MI protect against free wall rupture.
<b>True ventricular aneurysm</b>	Occurs 2 weeks to several months after MI. Outward bulge with contraction (“dyskinesia”), associated with fibrosis.
<b>Dressler syndrome</b>	Occurs several weeks after MI. Autoimmune phenomenon resulting in fibrinous pericarditis.
<b>LV failure and pulmonary edema</b>	Can occur 2° to LV infarction, VSD, free wall rupture, papillary muscle rupture with mitral regurgitation.


**Acute coronary syndrome treatments**

**Unstable angina/NSTEMI**—Anticoagulation (eg, heparin), antiplatelet therapy (eg, aspirin) + ADP receptor inhibitors (eg, clopidogrel),  $\beta$ -blockers, ACE inhibitors, statins. Symptom control with nitroglycerin and morphine.

**STEMI**—In addition to above, reperfusion therapy most important (percutaneous coronary intervention preferred over fibrinolysis).

## Cardiomyopathies

### Dilated cardiomyopathy



Most common cardiomyopathy (90% of cases). Often idiopathic or familial. Other etiologies include chronic **A**lcohol abuse, wet **B**eriberi, **C**oxsackie B viral myocarditis, chronic **C**ocaine use, **C**hagas disease, **D**oxorubicin toxicity, hemochromatosis, sarcoidosis, peripartum cardiomyopathy.

Findings: HF, S3, systolic regurgitant murmur, dilated heart on echocardiogram, balloon appearance of heart on CXR.

Treatment: Na<sup>+</sup> restriction, ACE inhibitors, β-blockers, diuretics, digoxin, ICD, heart transplant.

Systolic dysfunction ensues.

Eccentric hypertrophy **A** (sarcomeres added in series).

**ABCCCD**.

**Takotsubo cardiomyopathy**: “broken heart syndrome”—ventricular apical ballooning likely due to increased sympathetic stimulation (stressful situations).

### Hypertrophic cardiomyopathy



60–70% of cases are familial, autosomal dominant (most commonly due to mutations in genes encoding sarcomeric proteins, such as myosin binding protein C and β-myosin heavy chain). Can be associated with Friedreich ataxia. Causes syncope during exercise and may lead to sudden death in young athletes due to ventricular arrhythmia.

Findings: S4, systolic murmur. May see mitral regurgitation due to impaired mitral valve closure.

Treatment: cessation of high-intensity athletics, use of β-blocker or non-dihydropyridine Ca<sup>2+</sup> channel blockers (eg, verapamil). ICD if patient is high risk.

Diastolic dysfunction ensues.

Marked ventricular concentric hypertrophy (sarcomeres added in parallel) **B**, often septal predominance. Myofibrillar disarray and fibrosis.

Hypertrophic obstructive cardiomyopathy (subset)—asymmetric septal hypertrophy and systolic anterior motion of mitral valve → outflow obstruction → dyspnea, possible syncope.

### Restrictive/infiltrative cardiomyopathy

**P**ostradiation fibrosis, **L**offler syndrome, **E**ndocardial fibroelastosis (thick fibroelastic tissue in endocardium of young children), **A**myloidosis, **S**arcoidosis, **H**emochromatosis (although dilated cardiomyopathy is more common) (**P**uppy **LEASH**).

Diastolic dysfunction ensues. Can have low-voltage ECG despite thick myocardium (especially amyloid).

**Loffler syndrome**—endomyocardial fibrosis with a prominent eosinophilic infiltrate.

**Heart failure**

Clinical syndrome of cardiac pump dysfunction → congestion and low perfusion. Symptoms include dyspnea, orthopnea, fatigue; signs include S3 heart sound, rales, jugular venous distention (JVD), pitting edema **A**.

Systolic dysfunction—reduced EF, ↑ EDV; ↓ contractility often 2° to ischemia/MI or dilated cardiomyopathy.

Diastolic dysfunction—preserved EF, normal EDV; ↓ compliance often 2° to myocardial hypertrophy.

Right HF most often results from left HF. Cor pulmonale refers to isolated right HF due to pulmonary cause.

ACE inhibitors or angiotensin II receptor blockers, β-blockers (except in acute decompensated HF), and spironolactone ↓ mortality. Thiazide or loop diuretics are used mainly for symptomatic relief.

Hydralazine with nitrate therapy improves both symptoms and mortality in select patients.

**Left heart failure****Orthopnea**

Shortness of breath when supine: ↑ venous return from redistribution of blood (immediate gravity effect) exacerbates pulmonary vascular congestion.

**Paroxysmal nocturnal dyspnea**

Breathless awakening from sleep: ↑ venous return from redistribution of blood, reabsorption of peripheral edema, etc.

**Pulmonary edema**

↑ pulmonary venous pressure → pulmonary venous distention and transudation of fluid. Presence of hemosiderin-laden macrophages (“HF” cells) in lungs.

**Right heart failure****Hepatomegaly (nutmeg liver)**


↑ central venous pressure → ↑ resistance to portal flow. Rarely, leads to “cardiac cirrhosis.”

**Jugular venous distention**

↑ venous pressure.

**Peripheral edema**

↑ venous pressure → fluid transudation.



**Shock**

Inadequate organ perfusion and delivery of nutrients necessary for normal tissue and cellular function. Initially may be reversible but life threatening if not treated promptly.

	CAUSED BY	SKIN	PCWP (PRELOAD)	CO	SVR (AFTERLOAD)	TREATMENT
<b>Hypovolemic</b>	Hemorrhage, dehydration, burns	Cold, clammy	↓↓	↓	↑	IV fluids
<b>Cardiogenic</b>	Acute MI, HF, valvular dysfunction, arrhythmia					Inotropes, diuresis
<b>Obstructive</b>	Cardiac tamponade, pulmonary embolism, tension pneumothorax	Cold, clammy	↑ or ↓	↓↓	↑	Relieve obstruction
<b>Distributive</b>	Sepsis, anaphylaxis CNS injury	Warm Dry	↓ ↓	↑ ↓	↓↓ ↓↓	IV fluids, pressors

**Bacterial endocarditis**

Fever (most common symptom), new murmur, Roth spots (round white spots on retina surrounded by hemorrhage **A**), Osler nodes (tender raised lesions on finger or toe pads **B** due to immune complex deposition), Janeway lesions (small, painless, erythematous lesions on palm or sole) **C**, glomerulonephritis, septic arterial or pulmonary emboli, splinter hemorrhages **D** on nail bed. Multiple blood cultures necessary for diagnosis.

- **Acute**—*S aureus* (high virulence). Large vegetations on previously normal valves **E**. Rapid onset.
- **Subacute**—viridans streptococci (low virulence). Smaller vegetations on congenitally abnormal or diseased valves. Sequela of dental procedures. Gradual onset.

*S bovis* (*gallolyticus*) is present in colon cancer, *S epidermidis* on prosthetic valves.

Endocarditis may also be nonbacterial (marantic/thrombotic) 2° to malignancy, hypercoagulable state, or lupus.

Mitral valve is most frequently involved.

**Tricuspid valve endocarditis** is associated with IV **drug** abuse (don't “**tri**” **drugs**). Associated with *S aureus*, *Pseudomonas*, and *Candida*.


Culture ⊖; most likely *Coxiella burnetii*, *Bartonella* spp., HACEK (*Haemophilus*, *Aggregatibacter* (formerly *Actinobacillus*), *Cardiobacterium*, *Eikenella*, *Kingella*)

♥ Bacteria **FROM JANE** ♥:

- F**ever
- R**oth spots
- O**sler nodes
- M**urmur
- J**aneway lesions
- A**nemia
- N**ail-bed hemorrhage
- E**mboli





**Rheumatic fever**


A consequence of pharyngeal infection with group A  $\beta$ -hemolytic streptococci. Late sequelae include rheumatic heart disease, which affects heart valves—mitral > aortic >> tricuspid (high-pressure valves affected most). Early lesion is mitral valve regurgitation; late lesion is mitral stenosis. Associated with Aschoff bodies (granuloma with giant cells [blue arrows in **A**]), Anitschkow cells (enlarged macrophages with ovoid, wavy, rod-like nucleus [red arrow in **A**]),  $\uparrow$  anti-streptolysin O (ASO) titers.

Immune mediated (type II hypersensitivity); not a direct effect of bacteria. Antibodies to M protein cross-react with self antigens (molecular mimicry).

Treatment/prophylaxis: penicillin.


**JONES** (major criteria):

- J**oint (migratory polyarthritits)
- ♥** (carditis)
- N**odules in skin (subcutaneous)
- E**rythema marginatum
- S**ydenham chorea

**Acute pericarditis**

Inflammation of the pericardium [**A**, red arrows]. Commonly presents with sharp pain, aggravated by inspiration, and relieved by sitting up and leaning forward. Often complicated by pericardial effusion [between yellow arrows in **A**]. Presents with friction rub. ECG changes include widespread ST-segment elevation and/or PR depression.

Causes include idiopathic (most common; presumed viral), confirmed infection (eg, Coxsackievirus), neoplasia, autoimmune (eg, SLE, rheumatoid arthritis), uremia, cardiovascular (acute STEMI or Dressler syndrome), radiation therapy.

**Cardiac tamponade**

Compression of the heart by fluid (eg, blood, effusions [arrows in **A**] in pericardial space)  $\rightarrow$   $\downarrow$  CO. Equilibration of diastolic pressures in all 4 chambers.

Findings: Beck triad (hypotension, distended neck veins, distant heart sounds),  $\uparrow$  HR, pulsus paradoxus. ECG shows low-voltage QRS and electrical alternans (due to “swinging” movement of heart in large effusion).

**Pulsus paradoxus**— $\downarrow$  in amplitude of systolic BP by > 10 mm Hg during inspiration. Seen in cardiac tamponade, asthma, obstructive sleep apnea, pericarditis, croup.


**Syphilitic heart disease**

3° syphilis disrupts the vasa vasorum of the aorta with consequent atrophy of vessel wall and dilatation of aorta and valve ring. May see calcification of aortic root, ascending aortic arch, and thoracic aorta. Leads to “tree bark” appearance of aorta.

Can result in aneurysm of ascending aorta or aortic arch, aortic insufficiency.

**Cardiac tumors**

Most common heart tumor is a metastasis (eg, melanoma).

**Myxomas**

Most common 1° cardiac tumor (red arrows) in adults **A**. 90% occur in the atria (mostly left atrium). Myxomas are usually described as a “ball valve” obstruction in the left atrium (associated with multiple syncopal episodes). May auscultate early diastolic “tumor plop” sound. Histology: gelatinous material, myxoma cells immersed in glycosaminoglycans.

**Rhabdomyomas**

Most frequent 1° cardiac tumor in children (associated with tuberous sclerosis). Histology: hamartomatous growths.

**Kussmaul sign**

↑ in JVP on inspiration instead of a normal ↓.


Inspiration → negative intrathoracic pressure not transmitted to heart → impaired filling of right ventricle → blood backs up into venae cavae → JVD. May be seen with constrictive pericarditis, restrictive cardiomyopathies, right atrial or ventricular tumors.

## Vasculitides

	EPIDEMIOLOGY/PRESENTATION	PATHOLOGY/LABS
<b>Large-vessel vasculitis</b>		
<b>Giant cell (temporal) arteritis</b>	Usually elderly females. Unilateral headache (temporal artery), jaw claudication. May lead to irreversible blindness due to ophthalmic artery occlusion. Associated with polymyalgia rheumatica.	Most commonly affects branches of carotid artery. Focal granulomatous inflammation <b>A</b> . ↑ ESR. Treat with high-dose corticosteroids prior to temporal artery biopsy to prevent blindness.
<b>Takayasu arteritis</b>	Usually Asian females < 40 years old. “Pulseless disease” (weak upper extremity pulses), fever, night sweats, arthritis, myalgias, skin nodules, ocular disturbances.	Granulomatous thickening and narrowing of aortic arch and proximal great vessels <b>B</b> . ↑ ESR. Treat with corticosteroids.
<b>Medium-vessel vasculitis</b>		
<b>Polyarteritis nodosa</b>	Usually middle-aged men. Hepatitis B seropositivity in 30% of patients. Fever, weight loss, malaise, headache. GI: abdominal pain, melena. Hypertension, neurologic dysfunction, cutaneous eruptions, renal damage.	Typically involves renal and visceral vessels, not pulmonary arteries. Transmural inflammation of the arterial wall with fibrinoid necrosis. Different stages of inflammation may coexist in different vessels. Innumerable renal microaneurysms <b>C</b> and spasms on arteriogram. Treat with corticosteroids, cyclophosphamide.
<b>Kawasaki disease (mucocutaneous lymph node syndrome)</b>	Asian children < 4 years old. <b>C</b> onjunctival injection, <b>R</b> ash (polymorphous → desquamating), <b>A</b> denopathy (cervical), <b>S</b> trawberry tongue (oral mucositis) <b>D</b> , <b>H</b> and-foot changes (edema, erythema), <b>f</b> ever.	<b>CRASH</b> and <b>burn</b> . May develop coronary artery aneurysms <b>E</b> ; thrombosis or rupture can cause death. Treat with IV immunoglobulin and aspirin.
<b>Buerger disease (thromboangiitis obliterans)</b>	Heavy smokers, males < 40 years old. Intermittent claudication may lead to gangrene <b>F</b> , autoamputation of digits, superficial nodular phlebitis. Raynaud phenomenon is often present.	Segmental thrombosing vasculitis. Treat with smoking cessation.
<b>Small-vessel vasculitis</b>		
<b>Granulomatosis with polyangiitis (Wegener)</b>	Upper respiratory tract: perforation of nasal septum, chronic sinusitis, otitis media, mastoiditis. Lower respiratory tract: hemoptysis, cough, dyspnea. Renal: hematuria, red cell casts.	Triad: <ul style="list-style-type: none"> <li>▪ Focal necrotizing vasculitis</li> <li>▪ Necrotizing granulomas in the lung and upper airway</li> <li>▪ Necrotizing glomerulonephritis</li> </ul> PR3-ANCA/c-ANCA <b>G</b> (anti-proteinase 3). CXR: large nodular densities. Treat with cyclophosphamide, corticosteroids.
<b>Microscopic polyangiitis</b>	Necrotizing vasculitis commonly involving lung, kidneys, and skin with pauci-immune glomerulonephritis and palpable purpura. Presentation similar to granulomatosis with polyangiitis but without nasopharyngeal involvement.	No granulomas. MPO-ANCA/p-ANCA <b>H</b> (anti-myeloperoxidase). Treat with cyclophosphamide, corticosteroids.

**Vasculitides (continued)**

	EPIDEMIOLOGY/PRESENTATION	PATHOLOGY/LABS
<b>Small-vessel vasculitis (continued)</b>		
<b>Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)</b>	Asthma, sinusitis, skin nodules or purpura, peripheral neuropathy (eg, wrist/foot drop). Can also involve heart, GI, kidneys (pauci-immune glomerulonephritis).	Granulomatous, necrotizing vasculitis with eosinophilia <b>I</b> . MPO-ANCA/p-ANCA, ↑ IgE level.
<b>Henoch-Schönlein purpura</b>	Most common childhood systemic vasculitis. Often follows URI. Classic triad: <ul style="list-style-type: none"> <li>▪ Skin: palpable purpura on buttocks/legs <b>J</b></li> <li>▪ Arthralgias</li> <li>▪ GI: abdominal pain</li> </ul>	Vasculitis 2° to IgA immune complex deposition. Associated with IgA nephropathy (Berger disease).



**Hereditary hemorrhagic telangiectasia**

Inherited disorder of blood vessels. Findings: blanching skin lesions (telangiectasias), recurrent epistaxis, skin discolorations, arteriovenous malformations (AVMs), GI bleeding, hematuria. Also known as Osler-Weber-Rendu syndrome.

## ▶ CARDIOVASCULAR—PHARMACOLOGY

**Hypertension treatment**

<b>Primary (essential) hypertension</b>	Thiazide diuretics, ACE inhibitors, angiotensin II receptor blockers (ARBs), dihydropyridine Ca <sup>2+</sup> channel blockers.	
<b>Hypertension with heart failure</b>	Diuretics, ACE inhibitors/ARBs, β-blockers (compensated HF), aldosterone antagonists.	β-blockers must be used cautiously in decompensated HF and are contraindicated in cardiogenic shock.
<b>Hypertension with diabetes mellitus</b>	ACE inhibitors/ARBs, Ca <sup>2+</sup> channel blockers, thiazide diuretics, β-blockers.	ACE inhibitors/ARBs are protective against diabetic nephropathy.
<b>Hypertension in pregnancy</b>	Hydralazine, labetalol, methyldopa, nifedipine.	

**Calcium channel blockers**

	Amlodipine, clevidipine, nifedipine, nimodipine (dihydropyridines, act on vascular smooth muscle); diltiazem, verapamil (non-dihydropyridines, act on heart).	
<b>MECHANISM</b>	Block voltage-dependent L-type calcium channels of cardiac and smooth muscle → ↓ muscle contractility. Vascular smooth muscle—amlodipine = nifedipine > diltiazem > verapamil. Heart—verapamil > diltiazem > amlodipine = nifedipine (verapamil = ventricle).	
<b>CLINICAL USE</b>	Dihydropyridines (except nimodipine): hypertension, angina (including Prinzmetal), Raynaud phenomenon. Nimodipine: subarachnoid hemorrhage (prevents cerebral vasospasm). Nifedipine, clevidipine: hypertensive urgency or emergency. Non-dihydropyridines: hypertension, angina, atrial fibrillation/flutter.	
<b>ADVERSE EFFECTS</b>	Non-dihydropyridine: cardiac depression, AV block, hyperprolactinemia, constipation. Dihydropyridine: peripheral edema, flushing, dizziness, gingival hyperplasia.	

**Hydralazine**

<b>MECHANISM</b>	↑ cGMP → smooth muscle relaxation. Vasodilates arterioles > veins; afterload reduction.
<b>CLINICAL USE</b>	Severe hypertension (particularly acute), HF (with organic nitrate). Safe to use during pregnancy. Frequently coadministered with a β-blocker to prevent reflex tachycardia.
<b>ADVERSE EFFECTS</b>	Compensatory tachycardia (contraindicated in angina/CAD), fluid retention, headache, angina. Lupus-like syndrome.

**Hypertensive emergency**

	Treat with clevidipine, fenoldopam, labetalol, nifedipine, or nitroprusside.
<b>Nitroprusside</b>	Short acting; ↑ cGMP via direct release of NO. Can cause cyanide toxicity (releases cyanide).
<b>Fenoldopam</b>	Dopamine D <sub>1</sub> receptor agonist—coronary, peripheral, renal, and splanchnic vasodilation. ↓ BP, ↑ natriuresis. Also used postoperatively as an antihypertensive. Can cause hypotension and tachycardia.

<b>Nitrates</b>	Nitroglycerin, isosorbide dinitrate, isosorbide mononitrate.
MECHANISM	Vasodilate by ↑ NO in vascular smooth muscle → ↑ in cGMP and smooth muscle relaxation. Dilate veins >> arteries. ↓ preload.
CLINICAL USE	Angina, acute coronary syndrome, pulmonary edema.
ADVERSE EFFECTS	Reflex tachycardia (treat with β-blockers), hypotension, flushing, headache, “Monday disease” in industrial exposure: development of tolerance for the vasodilating action during the work week and loss of tolerance over the weekend → tachycardia, dizziness, headache upon reexposure. Contraindicated in right ventricular infarction.

**Antianginal therapy** Goal is reduction of myocardial O<sub>2</sub> consumption (MVO<sub>2</sub>) by ↓ 1 or more of the determinants of MVO<sub>2</sub>: end-diastolic volume, BP, HR, contractility.

COMPONENT	NITRATES	β-BLOCKERS	NITRATES + β-BLOCKERS
End-diastolic volume	↓	No effect or ↑	No effect or ↓
Blood pressure	↓	↓	↓
Contractility	No effect	↓	Little/no effect
Heart rate	↑ (reflex response)	↓	No effect or ↓
Ejection time	↓	↑	Little/no effect
MVO <sub>2</sub>	↓	↓	↓↓

Verapamil is similar to β-blockers in effect.

Pindolol and acebutolol are partial β-agonists that should be used with caution in angina.

**Ranolazine**


MECHANISM	Inhibits the late phase of sodium current thereby reducing diastolic wall tension and oxygen consumption. Does not affect heart rate or contractility.
CLINICAL USE	Angina refractory to other medical therapies.
ADVERSE EFFECTS	Constipation, dizziness, headache, nausea, QT prolongation.

**Milrinone**

MECHANISM	Selective PDE-3 inhibitor. In cardiomyocytes: ↑ cAMP accumulation → ↑ Ca <sup>2+</sup> influx → ↑ inotropy and chronotropy. In vascular smooth muscle: ↑ cAMP accumulation → inhibition of MLCK activity → general vasodilation.
CLINICAL USE	Short-term use in acute decompensated HF.
ADVERSE EFFECTS	Arrhythmias, hypotension.

## Lipid-lowering agents

DRUG	LDL	HDL	TRIGLYCERIDES	MECHANISMS OF ACTION	ADVERSE EFFECTS/PROBLEMS
<b>HMG-CoA reductase inhibitors</b> (eg, lovastatin, pravastatin)	↓↓↓	↑	↓	Inhibit conversion of HMG-CoA to mevalonate, a cholesterol precursor; ↓ mortality in CAD patients	Hepatotoxicity (↑ LFTs), myopathy (esp. when used with fibrates or niacin)
<b>Bile acid resins</b> Cholestyramine, colestipol, colesvelam	↓↓	Slightly ↑	Slightly ↑	Prevent intestinal reabsorption of bile acids; liver must use cholesterol to make more	GI upset, ↓ absorption of other drugs and fat-soluble vitamins
<b>Ezetimibe</b>	↓↓	↑/—	↓/—	Prevent cholesterol absorption at small intestine brush border	Rare ↑ LFTs, diarrhea
<b>Fibrates</b> Gemfibrozil, bezafibrate, fenofibrate	↓	↑	↓↓↓	Upregulate LPL → ↑ TG clearance Activates PPAR-α to induce HDL synthesis	Myopathy (↑ risk with statins), cholesterol gallstones
<b>Niacin (vitamin B<sub>3</sub>)</b>	↓↓	↑↑	↓	Inhibits lipolysis (hormone-sensitive lipase) in adipose tissue; reduces hepatic VLDL synthesis	Red, flushed face, which is ↓ by NSAIDs or long-term use Hyperglycemia Hyperuricemia
<b>PCSK9 inhibitors</b> Alirocumab, evolocumab	↓↓↓	↑	↓	Inactivation of LDL-receptor degradation, increasing amount of LDL removed from bloodstream	Myalgias, delirium, dementia, other neurocognitive effects




**Cardiac glycosides**

Digoxin.

**MECHANISM**

Direct inhibition of  $\text{Na}^+/\text{K}^+$  ATPase  
 → indirect inhibition of  $\text{Na}^+/\text{Ca}^{2+}$  exchanger.  
 $\uparrow [\text{Ca}^{2+}]_i$  → positive inotropy. Stimulates vagus nerve →  $\downarrow$  HR.

**CLINICAL USE**

HF ( $\uparrow$  contractility); atrial fibrillation ( $\downarrow$  conduction at AV node and depression of SA node).

**ADVERSE EFFECTS**

Cholinergic—nausea, vomiting, diarrhea, blurry yellow vision (think van Gogh), arrhythmias, AV block.

Can lead to hyperkalemia, which indicates poor prognosis.

Factors predisposing to toxicity: renal failure ( $\downarrow$  excretion), hypokalemia (permissive for digoxin binding at  $\text{K}^+$ -binding site on  $\text{Na}^+/\text{K}^+$  ATPase), drugs that displace digoxin from tissue-binding sites, and  $\downarrow$  clearance (eg, verapamil, amiodarone, quinidine).

**ANTIDOTE**


Slowly normalize  $\text{K}^+$ , cardiac pacer, anti-digoxin Fab fragments,  $\text{Mg}^{2+}$ .




**Antiarrhythmics—  
sodium channel  
blockers (class I)**

Slow or block (↓) conduction (especially in depolarized cells). ↓ slope of phase 0 depolarization. Are state dependent (selectively depress tissue that is frequently depolarized [eg, tachycardia]).


<b>Class IA</b>	<b>Quinidine, Procainamide, Disopyramide.</b> “The <b>Q</b> ueen <b>P</b> roclaims <b>D</b> iso’s <b>p</b> ramid.”
<b>MECHANISM</b>	↑ AP duration, ↑ effective refractory period (ERP) in ventricular action potential, ↑ QT interval, some potassium channel blocking effects.
<b>CLINICAL USE</b>	Both atrial and ventricular arrhythmias, especially re-entrant and ectopic SVT and VT.
<b>ADVERSE EFFECTS</b>	Cinchonism (headache, tinnitus with quinidine), reversible SLE-like syndrome (procainamide), HF (disopyramide), thrombocytopenia, torsades de pointes due to ↑ QT interval.



<b>Class IB</b>	<b>Lidocaine, Mexiletine.</b> “I’d <b>B</b> uy <b>L</b> iddy’s <b>M</b> exican <b>T</b> acos.”
<b>MECHANISM</b>	↓ AP duration. Preferentially affect ischemic or depolarized Purkinje and ventricular tissue. Phenytoin can also fall into the IB category.
<b>CLINICAL USE</b>	Acute ventricular arrhythmias (especially post-MI), digitalis-induced arrhythmias. <b>IB</b> is <b>B</b> est post-MI.
<b>ADVERSE EFFECTS</b>	CNS stimulation/depression, cardiovascular depression.




<b>Class IC</b>	<b>Flecainide, Propafenone.</b> “Can I have <b>F</b> ries, <b>P</b> lease.”
<b>MECHANISM</b>	Significantly prolongs ERP in AV node and accessory bypass tracts. No effect on ERP in Purkinje and ventricular tissue. Minimal effect on AP duration.
<b>CLINICAL USE</b>	SVTs, including atrial fibrillation. Only as a last resort in refractory VT.
<b>ADVERSE EFFECTS</b>	Proarrhythmic, especially post-MI (contraindicated). <b>IC</b> is <b>C</b> ontraindicated in structural and ischemic heart disease.



**Antiarrhythmics—  
β-blockers (class II)**

Metoprolol, propranolol, esmolol, atenolol, timolol, carvedilol.

MECHANISM	Decrease SA and AV nodal activity by ↓ cAMP, ↓ Ca <sup>2+</sup> currents. Suppress abnormal pacemakers by ↓ slope of phase 4. AV node particularly sensitive—↑ PR interval. Esmolol very short acting.
CLINICAL USE	SVT, ventricular rate control for atrial fibrillation and atrial flutter.
ADVERSE EFFECTS	Impotence, exacerbation of COPD and asthma, cardiovascular effects (bradycardia, AV block, HF), CNS effects (sedation, sleep alterations). May mask the signs of hypoglycemia. Metoprolol can cause dyslipidemia. Propranolol can exacerbate vasospasm in Prinzmetal angina. β-blockers (except the nonselective α- and β-antagonists carvedilol and labetalol) cause unopposed α <sub>1</sub> -agonism if given alone for pheochromocytoma or cocaine toxicity. Treat β-blocker overdose with saline, atropine, glucagon.




**Antiarrhythmics—  
potassium channel  
blockers (class III)**

Amiodarone, Ibutilide, Dofetilide, Sotalol.

**AIDS.**


MECHANISM	↑ AP duration, ↑ ERP, ↑ QT interval.	
CLINICAL USE	Atrial fibrillation, atrial flutter; ventricular tachycardia (amiodarone, sotalol).	
ADVERSE EFFECTS	Sotalol—torsades de pointes, excessive β blockade. Ibutilide—torsades de pointes. Amiodarone—pulmonary fibrosis, hepatotoxicity, hypothyroidism/hyperthyroidism (amiodarone is 40% iodine by weight), acts as hapten (corneal deposits, blue/gray skin deposits resulting in photodermatitis), neurologic effects, constipation, cardiovascular effects (bradycardia, heart block, HF).	Remember to check PFTs, LFTs, and TFTs when using amiodarone. Amiodarone is lipophilic and has class I, II, III, and IV effects.



**Antiarrhythmics—  
calcium channel  
blockers (class IV)**

Verapamil, diltiazem.

MECHANISM	↓ conduction velocity, ↑ ERP, ↑ PR interval.
CLINICAL USE	Prevention of nodal arrhythmias (eg, SVT), rate control in atrial fibrillation.
ADVERSE EFFECTS	Constipation, flushing, edema, cardiovascular effects (HF, AV block, sinus node depression).

**Other antiarrhythmics**

**Adenosine** ↑  $K^+$  out of cells → hyperpolarizing the cell and ↓  $I_{Ca}$ , decreasing AV node conduction. Drug of choice in diagnosing/terminating certain forms of SVT. Very short acting (~ 15 sec). Effects blunted by theophylline and caffeine (both are adenosine receptor antagonists). Adverse effects include flushing, hypotension, chest pain, sense of impending doom, bronchospasm.

**Mg<sup>2+</sup>** Effective in torsades de pointes and digoxin toxicity.

**Ivabradine**

MECHANISM	Selective inhibition of funny sodium channels ( $I_f$ ), prolonging slow depolarization phase (phase 4). ↓ SA node firing; negative chronotropic effect without inotropy. Reduces cardiac $O_2$ requirement.
CLINICAL USE	Chronic stable angina in patients who cannot take $\beta$ -blockers. Chronic HF with reduced ejection fraction.
ADVERSE EFFECTS	Luminous phenomena/visual brightness, hypertension, bradycardia.

# Endocrine


*“If you skew the endocrine system, you lose the pathways to self.”*  
—Hilary Mantel

*“We have learned that there is an endocrinology of elation and despair, a chemistry of mystical insight, and, in relation to the autonomic nervous system, a meteorology and even . . . an astro-physics of changing moods.”*  
—Aldous (Leonard) Huxley

*“Chocolate causes certain endocrine glands to secrete hormones that affect your feelings and behavior by making you happy.”*  
—Elaine Sherman, *Book of Divine Indulgences*

▶ Embryology	312
▶ Anatomy	312
▶ Physiology	314
▶ Pathology	323
▶ Pharmacology	340


## ▶ ENDOCRINE—EMBRYOLOGY

**Thyroid development**

Thyroid diverticulum arises from floor of primitive pharynx and descends into neck. Connected to tongue by thyroglossal duct, which normally disappears but may persist as cysts or the pyramidal lobe of thyroid. Foramen cecum is normal remnant of thyroglossal duct. Most common ectopic thyroid tissue site is the tongue (lingual thyroid). Removal may result in hypothyroidism if it is the only thyroid tissue present.

Thyroglossal duct cyst **A** presents as an anterior midline neck mass that moves with swallowing or protrusion of the tongue (vs persistent cervical sinus leading to branchial cleft cyst in lateral neck).

Thyroid tissue and parafollicular cells (aka, **C** cells, produce **C**alcitonin) of the thyroid are derived from endoderm.



## ▶ ENDOCRINE—ANATOMY

**Adrenal cortex and medulla**

Adrenal cortex (derived from mesoderm) and medulla (derived from neural crest).

ANATOMY	HISTOLOGY	1° REGULATION BY	HORMONE CLASS	1° HORMONE PRODUCED
Adrenal gland Capsule Superior surface of kidney	Zona <b>G</b> lomerulosa	Angiotensin II	Mineralocorticoids	Aldosterone
	Zona <b>F</b> asciculata	ACTH, CRH	Glucocorticoids	Cortisol
	Zona <b>R</b> eticularis	ACTH, CRH	Androgens	DHEA
MEDULLA	Chromaffin cells	Preganglionic sympathetic fibers	Catecholamines	Epi, NE

**GFR** corresponds with **S**alt (mineralocorticoids), **S**ugar (glucocorticoids), and **S**ex (androgens).

“The deeper you go, **the sweeter it gets.**”

**Pituitary gland****Anterior pituitary  
(adenohypophysis)**

Secretes FSH, LH, ACTH, TSH, prolactin, GH. Melanotropin (MSH) secreted from intermediate lobe of pituitary. Derived from oral ectoderm (Rathke pouch).

- $\alpha$  subunit—hormone subunit common to TSH, LH, FSH, and hCG.
- $\beta$  subunit—determines hormone specificity.

ACTH and MSH are derivatives of proopiomelanocortin (POMC).

**FLAT PiG:** FSH, LH, ACTH, TSH, PRL, GH.  
**B-FLAT:** Basophils—FSH, LH, ACTH, TSH.  
Acidophils: GH, PRL.

**Posterior pituitary  
(neurohypophysis)**


Stores and releases vasopressin (antidiuretic hormone, or ADH) and oxytocin, both made in the hypothalamus (supraoptic and paraventricular nuclei) and transported to posterior pituitary via neurophysins (carrier proteins). Derived from neuroectoderm.

**Endocrine pancreas  
cell types**

Islets of Langerhans are collections of  $\alpha$ ,  $\beta$ , and  $\delta$  endocrine cells. Islets arise from pancreatic buds.

- $\alpha$  = glucagon (peripheral)
- $\beta$  = insulin (central)
- $\delta$  = somatostatin (interspersed)

**Insulin ( $\beta$  cells) inside.**




## ▶ ENDOCRINE—PHYSIOLOGY

**Insulin**

## SYNTHESIS

Preproinsulin (synthesized in RER) → cleavage of “presignal” → proinsulin (stored in secretory granules) → cleavage of proinsulin → exocytosis of insulin and C-peptide equally. Insulin and C-peptide are ↑ in insulinoma and sulfonylurea use, whereas exogenous insulin lacks C-peptide.



## SOURCE

Released from pancreatic  $\beta$  cells.

## FUNCTION

Binds **insulin** receptors (tyrosine kinase activity **1**), **inducing** glucose uptake (carrier-mediated transport) **into** insulin-dependent tissue **2** and gene transcription.

Anabolic effects of insulin:

- ↑ glucose transport in skeletal muscle and adipose tissue
- ↑ glycogen synthesis and storage
- ↑ triglyceride synthesis
- ↑  $\text{Na}^+$  retention (kidneys)
- ↑ protein synthesis (muscles)
- ↑ cellular uptake of  $\text{K}^+$  and amino acids
- ↓ glucagon release
- ↓ lipolysis in adipose tissue

Unlike glucose, insulin does not cross placenta.

Insulin-dependent glucose transporters:

- GLUT4: adipose tissue, striated muscle (exercise can also increase GLUT4 expression)

Insulin-independent transporters:

- GLUT1: RBCs, brain, cornea, placenta
- GLUT2 (bidirectional):  $\beta$  islet cells, liver, kidney, small intestine
- GLUT3: brain, placenta
- GLUT5 (fructose): spermatocytes, GI tract



Brain utilizes glucose for metabolism normally and ketone bodies during starvation. RBCs utilize glucose because they lack mitochondria for aerobic metabolism.

**BRICK L** (insulin-independent glucose uptake): **Brain, RBCs, Intestine, Cornea, Kidney, Liver.**

## REGULATION

Glucose is the major regulator of insulin release. ↑ insulin response with oral vs IV glucose because of incretins such as glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which are released after meals and ↑  $\beta$  cell sensitivity to glucose. Release ↓ by  $\alpha_2$ , ↑ by  $\beta_2$  (**2** = regulates **insulin**)

Glucose enters  $\beta$  cells **3** → ↑ ATP generated from glucose metabolism **4** closes  $\text{K}^+$  channels (target of sulfonylureas) **5** and depolarizes  $\beta$  cell membrane **6**. Voltage-gated  $\text{Ca}^{2+}$  channels open →  $\text{Ca}^{2+}$  influx **7** and stimulation of insulin exocytosis **8**.



**Glucagon**

SOURCE	Made by $\alpha$ cells of pancreas.
FUNCTION	Glycogenolysis, gluconeogenesis, lipolysis, ketone production.
REGULATION	Secreted in response to hypoglycemia. Inhibited by insulin, hyperglycemia, and somatostatin.


**Hypothalamic-pituitary hormones**

HORMONE	FUNCTION	CLINICAL NOTES
<b>CRH</b>	↑ ACTH, MSH, $\beta$ -endorphin	↓ in chronic exogenous steroid use.
<b>Dopamine</b>	↓ prolactin, TSH	Dopamine antagonists (eg, antipsychotics) can cause galactorrhea due to hyperprolactinemia.
<b>GHRH</b>	↑ GH	Analog (tesamorelin) used to treat HIV-associated lipodystrophy.
<b>GnRH</b>	↑ FSH, LH	Suppressed by hyperprolactinemia. Tonic GnRH suppresses HPG axis. Pulsatile GnRH leads to puberty, fertility.
<b>Prolactin</b>	↓ GnRH	Pituitary prolactinoma → amenorrhea, osteoporosis, hypogonadism, galactorrhea.
<b>Somatostatin</b>	↓ GH, TSH	Analogues used to treat acromegaly.
<b>TRH</b>	↑ TSH, prolactin	↑ TRH (eg, in 1°/2° hypothyroidism) may increase prolactin secretion → galactorrhea.



**Prolactin**

<b>SOURCE</b>	Secreted mainly by anterior pituitary.	Structurally homologous to growth hormone.
<b>FUNCTION</b>	Stimulates milk production in breast; inhibits ovulation in females and spermatogenesis in males by inhibiting GnRH synthesis and release.	Excessive amounts of prolactin associated with ↓ libido.
<b>REGULATION</b>	Prolactin secretion from anterior pituitary is tonically inhibited by dopamine from tuberoinfundibular pathway of hypothalamus. Prolactin in turn inhibits its own secretion by ↑ dopamine synthesis and secretion from hypothalamus. TRH ↑ prolactin secretion (eg, in 1° or 2° hypothyroidism).	Dopamine agonists (eg, bromocriptine) inhibit prolactin secretion and can be used in treatment of prolactinoma. Dopamine antagonists (eg, most antipsychotics) and estrogens (eg, OCPs, pregnancy) stimulate prolactin secretion.



**Growth hormone (somatotropin)**

SOURCE	Secreted by anterior pituitary.	
FUNCTION	Stimulates linear growth and muscle mass through IGF-1 (somatomedin C) secretion by liver. ↑ insulin resistance (diabetogenic).	Somatostatin keeps your growth static. Somatomedin mediates your growth.
REGULATION	Released in pulses in response to growth hormone-releasing hormone (GHRH). Secretion ↑ during exercise, deep sleep, puberty, hypoglycemia. Secretion inhibited by glucose and somatostatin release via negative feedback by somatomedin.	Excess secretion of GH (eg, pituitary adenoma) may cause acromegaly (adults) or gigantism (children). Treat with somatostatin analogs (eg, octreotide) or surgery.


**Appetite regulation**

<b>Ghrelin</b>	Stimulates hunger (orexigenic effect) and GH release (via GH secretagog receptor). Produced by stomach. Sleep deprivation or Prader-Willi syndrome → ↑ ghrelin production.	<b>Ghrelin</b> makes you hungry.
<b>Leptin</b>	Satiety hormone. Produced by adipose tissue. Mutation of leptin gene → congenital obesity. Sleep deprivation or starvation → ↓ leptin production.	<b>Leptin</b> keeps you thin.
<b>Endocannabinoids</b>	Act at cannabinoid receptors in hypothalamus and nucleus accumbens, two key brain areas for the homeostatic and hedonic control of food intake → ↑ appetite.	Exogenous cannabinoids cause “the munchies.”

**Antidiuretic hormone**

SOURCE	Synthesized in hypothalamus (supraoptic nuclei), stored and secreted by posterior pituitary.	
FUNCTION	Regulates serum osmolarity (V <sub>2</sub> -receptors) and blood pressure (V <sub>1</sub> -receptors). Primary function is serum osmolarity regulation (ADH ↓ serum osmolarity, ↑ urine osmolarity) via regulation of aquaporin channel insertion in principal cells of renal collecting duct.	ADH level is ↓ in central diabetes insipidus (DI), normal or ↑ in nephrogenic DI. Nephrogenic DI can be caused by mutation in V <sub>2</sub> -receptor. Desmopressin acetate (ADH analog) is a treatment for central DI and nocturnal enuresis.
REGULATION	Osmoreceptors in hypothalamus (1°); hypovolemia.	

## Adrenal steroids and congenital adrenal hyperplasias

<sup>a</sup>Rate-limiting step.

ENZYME DEFICIENCY	MINERALOCORTICIDS	CORTISOL	SEX HORMONES	BP	[K <sup>+</sup> ]	LABS	PRESENTATION
<b>A</b> 17α-hydroxylase <sup>a</sup>	↑	↓	↓	↑	↓	↓ androstenedione	XY: ambiguous genitalia, undescended testes XX: lacks 2° sexual development
<b>B</b> 21-hydroxylase <sup>a</sup>	↓	↓	↑	↓	↑	↑ renin activity ↑ 17-hydroxyprogesterone	Most common Presents in infancy (salt wasting) or childhood (precocious puberty) XX: virilization
<b>C</b> 11β-hydroxylase <sup>a</sup>	↓ aldosterone ↑ 11-deoxycorticosterone (results in ↑ BP)	↓	↑	↑	↓	↓ renin activity	XX: virilization

<sup>a</sup>All congenital adrenal enzyme deficiencies are characterized by an enlargement of both adrenal glands due to ↑ ACTH stimulation (in response to ↓ cortisol) and by skin hyperpigmentation.

**Cortisol**

SOURCE	Adrenal zona fasciculata.	Bound to corticosteroid-binding globulin.
FUNCTION	<p>↑ <b>A</b>ppetite</p> <p>↑ <b>B</b>lood pressure:</p> <ul style="list-style-type: none"> <li>▪ Upregulates <math>\alpha_1</math>-receptors on arterioles → ↑ sensitivity to norepinephrine and epinephrine (permissive action)</li> <li>▪ At high concentrations, can bind to mineralocorticoid (aldosterone) receptors</li> </ul> <p>↑ <b>I</b>nsulin resistance (diabetogenic)</p> <p>↑ <b>G</b>luconeogenesis, lipolysis, and proteolysis (↓ glucose utilization)</p> <p>↓ <b>F</b>ibroblast activity (poor wound healing, ↓ collagen synthesis, ↑ striae)</p> <p>↓ <b>I</b>nflammatory and <b>I</b>mmune responses:</p> <ul style="list-style-type: none"> <li>▪ Inhibits production of leukotrienes and prostaglandins</li> <li>▪ Inhibits WBC adhesion → neutrophilia</li> <li>▪ Blocks histamine release from mast cells</li> <li>▪ Eosinopenia, lymphopenia</li> <li>▪ Blocks IL-2 production</li> </ul> <p>↓ <b>B</b>one formation (↓ osteoblast activity)</p>	<p>Cortisol is a <b>A BIG FIB</b>.</p> <p>Exogenous corticosteroids can cause reactivation of TB and candidiasis (blocks IL-2 production).</p>
REGULATION	CRH (hypothalamus) stimulates ACTH release (pituitary) → cortisol production in adrenal zona fasciculata. Excess cortisol ↓ CRH, ACTH, and cortisol secretion.	Chronic stress induces prolonged secretion.

**Calcium homeostasis**

Plasma $\text{Ca}^{2+}$ exists in three forms:	<ul style="list-style-type: none"> <li>▪ Ionized/free (~ 45%, active form)</li> <li>▪ Bound to albumin (~ 40%)</li> <li>▪ Bound to anions (~ 15%)</li> </ul>	<p>↑ in pH → ↑ affinity of albumin (↑ negative charge) to bind <math>\text{Ca}^{2+}</math> → hypocalcemia (cramps, pain, paresthesias, carpopedal spasm).</p> <p>Ionized/free <math>\text{Ca}^{2+}</math> is 1° regulator of PTH; changes in pH alter PTH secretion, whereas changes in albumin do not.</p>
--	--	---

**Vitamin D**

SOURCE	$\text{D}_3$ from exposure of skin to sun, ingestion of fish and plants. $\text{D}_2$ from ingestion of plants, fungi, yeasts. Both converted to 25-OH in liver and to 1,25-(OH) $_2$ vitamin D (active form) in kidney.	<p>Deficiency → rickets in kids, osteomalacia in adults. Caused by malabsorption, ↓ sunlight, poor diet, chronic kidney failure.</p> <p>24,25-(OH)<math>_2</math> <math>\text{D}_3</math> is an inactive form of vitamin D.</p>
FUNCTION	↑ absorption of dietary $\text{Ca}^{2+}$ and $\text{PO}_4^{3-}$ . Enhances bone mineralization.	PTH leads to ↑ $\text{Ca}^{2+}$ reabsorption and ↓ $\text{PO}_4^{3-}$ reabsorption in the kidney, whereas 1,25-(OH) $_2$ $\text{D}_3$ leads to ↑ absorption of both $\text{Ca}^{2+}$ and $\text{PO}_4^{3-}$ in the gut.
REGULATION	<p>↑ PTH, ↓ <math>\text{Ca}^{2+}</math>, ↓ <math>\text{PO}_4^{3-}</math> → ↑ 1,25-(OH)<math>_2</math> production.</p> <p>1,25-(OH)<math>_2</math> feedback inhibits its own production.</p>	

## Parathyroid hormone

### SOURCE

Chief cells of parathyroid.

### FUNCTION

↑ bone resorption of  $\text{Ca}^{2+}$  and  $\text{PO}_4^{3-}$ .  
 ↑ kidney reabsorption of  $\text{Ca}^{2+}$  in distal convoluted tubule.  
 ↓ reabsorption of  $\text{PO}_4^{3-}$  in proximal convoluted tubule.  
 ↑  $1,25\text{-(OH)}_2\text{D}_3$  (calcitriol) production by stimulating kidney  $1\alpha$ -hydroxylase in proximal convoluted tubule.


PTH ↑ serum  $\text{Ca}^{2+}$ , ↓ serum  $\text{PO}_4^{3-}$ , ↑ urine  $\text{PO}_4^{3-}$ , ↑ urine cAMP.  
 ↑ RANK-L (receptor activator of NF- $\kappa$ B ligand) secreted by osteoblasts and osteocytes. Binds RANK (receptor) on osteoclasts and their precursors to stimulate osteoclasts and ↑  $\text{Ca}^{2+}$  → bone resorption. Intermittent PTH release can also stimulate bone formation.

**PTH = Phosphate-Trashing Hormone.**

PTH-related peptide (PTHrP) functions like PTH and is commonly increased in malignancies (eg, squamous cell carcinoma of the lung, renal cell carcinoma).

### REGULATION

↓ serum  $\text{Ca}^{2+}$  → ↑ PTH secretion.  
 ↑ serum  $\text{PO}_4^{3-}$  → ↑ PTH secretion.  
 ↓ serum  $\text{Mg}^{2+}$  → ↑ PTH secretion.  
 ↓↓ serum  $\text{Mg}^{2+}$  → ↓ PTH secretion.  
 Common causes of ↓  $\text{Mg}^{2+}$  include diarrhea, aminoglycosides, diuretics, alcohol abuse.




**Calcitonin**

SOURCE	Parafollicular cells (C cells) of thyroid.	Calcitonin opposes actions of PTH. Not important in normal Ca <sup>2+</sup> homeostasis. Calcitonin <b>tones</b> down serum Ca <sup>2+</sup> levels and keeps it in <b>bones</b> .
FUNCTION	↓ bone resorption of Ca <sup>2+</sup> .	
REGULATION	↑ serum Ca <sup>2+</sup> → calcitonin secretion.	

**Thyroid hormones (T<sub>3</sub>/T<sub>4</sub>)**

Iodine-containing hormones that control the body's metabolic rate.

SOURCE	Follicles of thyroid. Most T <sub>3</sub> formed in target tissues.	T <sub>3</sub> functions— <b>4 B's</b> : <b>B</b> rain maturation <b>B</b> one growth <b>β</b> -adrenergic effects <b>B</b> asal metabolic rate ↑
FUNCTION	Bone growth (synergism with GH) CNS maturation ↑ β <sub>1</sub> receptors in heart = ↑ CO, HR, SV, contractility ↑ basal metabolic rate via ↑ Na <sup>+</sup> /K <sup>+</sup> -ATPase activity → ↑ O <sub>2</sub> consumption, RR, body temperature ↑ glycogenolysis, gluconeogenesis, lipolysis	Thyroxine-binding globulin (TBG) binds most T <sub>3</sub> /T <sub>4</sub> in blood; only free hormone is active. ↓ TBG in hepatic failure, steroids; ↑ TBG in pregnancy or OCP use (estrogen ↑ TBG). T <sub>4</sub> is major thyroid product; converted to T <sub>3</sub> in peripheral tissue by 5'-deiodinase. T <sub>3</sub> binds nuclear receptor with greater affinity than T <sub>4</sub> . Thyroid peroxidase is the enzyme responsible for oxidation and organification of iodide as well as coupling of monoiodotyrosine (MIT) and di-iodotyrosine (DIT). DIT + DIT = T <sub>4</sub> . DIT + MIT = T <sub>3</sub> . Propylthiouracil (PTU) inhibits both thyroid peroxidase and 5'-deiodinase. Methimazole inhibits thyroid peroxidase only. Glucocorticoids inhibit peripheral conversion of T <sub>4</sub> to T <sub>3</sub> .
REGULATION	TRH (hypothalamus) stimulates TSH (pituitary), which stimulates follicular cells. May also be stimulated by thyroid-stimulating immunoglobulin (TSI) in Graves disease. Negative feedback primarily by free T <sub>3</sub> /T <sub>4</sub> to anterior pituitary (↓ sensitivity to TRH) and hypothalamus (↓ TRH secretion). Wolff-Chaikoff effect—excess iodine temporarily inhibits thyroid peroxidase → ↓ iodine organification → ↓ T <sub>3</sub> /T <sub>4</sub> production.	



### Signaling pathways of endocrine hormones

<b>cAMP</b>	<b>FSH, LH, ACTH, TSH, CRH, hCG, ADH</b> (V <sub>2</sub> -receptor), <b>MSH, PTH</b> , calcitonin, GHRH, glucagon, histamine (H <sub>2</sub> -receptor)	<b>FLAT ChAMP</b>
<b>cGMP</b>	<b>BNP, ANP, EDRF (NO)</b>	<b>BAD GraMPa</b> Think vasodilators
<b>IP<sub>3</sub></b>	<b>GnRH, Oxytocin, ADH (V<sub>1</sub>-receptor), TRH,</b> <b>Histamine (H<sub>1</sub>-receptor), Angiotensin II,</b> <b>Gastrin</b>	<b>GOAT HAG</b>
<b>Intracellular receptor</b>	<b>Progesterone, Estrogen, Testosterone, Cortisol,</b> <b>Aldosterone, T<sub>3</sub>/T<sub>4</sub>, Vitamin D</b>	<b>PET CAT on TV</b>
<b>Receptor tyrosine kinase</b>	Insulin, <b>IGF-1, FGF, PDGF, EGF</b>	MAP kinase pathway Think <b>G</b> rowth <b>F</b> actors
<b>Nonreceptor tyrosine kinase</b>	<b>Prolactin, Immunomodulators</b> (eg, cytokines IL-2, IL-6, IFN), <b>GH, G-CSF, Erythropoietin,</b> <b>Thrombopoietin</b>	JAK/STAT pathway Think acidophils and cytokines <b>PIGGLET</b>


### Signaling pathway of steroid hormones

Steroid hormones are lipophilic and therefore must circulate bound to specific binding globulins, which ↑ their solubility.

In men, ↑ sex hormone-binding globulin (SHBG) lowers free testosterone  
→ gynecomastia.

In women, ↓ SHBG raises free testosterone  
→ hirsutism.



OCPs, pregnancy → ↑ SHBG.



▶ ENDOCRINE—PATHOLOGY

**Cushing syndrome**

ETIOLOGY	<p>↑ cortisol due to a variety of causes:</p> <ul style="list-style-type: none"> <li>▪ Exogenous corticosteroids—result in ↓ ACTH, bilateral adrenal atrophy. Most common cause.</li> <li>▪ Primary adrenal adenoma, hyperplasia, or carcinoma—result in ↓ ACTH, atrophy of uninvolved adrenal gland. Can also present with pseudohyperaldosteronism.</li> <li>▪ ACTH-secreting pituitary adenoma (Cushing disease); paraneoplastic ACTH secretion (eg, small cell lung cancer, bronchial carcinoids)—result in ↑ ACTH, bilateral adrenal hyperplasia. Cushing disease is responsible for the majority of endogenous cases of Cushing syndrome.</li> </ul>
FINDINGS	<p>Hypertension, weight gain, moon facies <b>A</b>, abdominal striae <b>B</b> and truncal obesity, buffalo hump, skin changes (eg, thinning, striae), osteoporosis, hyperglycemia (insulin resistance), amenorrhea, immunosuppression.</p>
DIAGNOSIS	<p>Screening tests include: ↑ free cortisol on 24-hr urinalysis, ↑ midnight salivary cortisol, and no suppression with overnight low-dose dexamethasone test. Measure serum ACTH. If ↓, suspect adrenal tumor or exogenous glucocorticoids. If ↑, distinguish between Cushing disease and ectopic ACTH secretion (eg, from small cell lung cancer) with a high-dose dexamethasone suppression test and CRH stimulation test. Ectopic secretion will not decrease with dexamethasone because the source is resistant to negative feedback; ectopic secretion will not increase with CRH because pituitary ACTH is suppressed.</p>





**Adrenal insufficiency**

Inability of adrenal glands to generate enough glucocorticoids +/- mineralocorticoids for the body's needs. Symptoms include weakness, fatigue, orthostatic hypotension, muscle aches, weight loss, GI disturbances, sugar and/or salt cravings. Treatment: glucocorticoid/mineralocorticoid replacement.

Diagnosis involves measurement of serum electrolytes, morning/random serum cortisol and ACTH (low cortisol, high ACTH in 1° adrenal insufficiency; low cortisol, low ACTH in 2°/3° adrenal insufficiency due to pituitary/hypothalamic disease), and response to ACTH stimulation test.

Alternatively, can use metyrapone stimulation test: metyrapone blocks last step of cortisol synthesis (11-deoxycortisol → cortisol). Normal response is ↓ cortisol and compensatory ↑ ACTH and 11-deoxycortisol. In 1° adrenal insufficiency, ACTH is ↑ but 11-deoxycortisol remains ↓ after test. In 2°/3° adrenal insufficiency, both ACTH and 11-deoxycortisol remain ↓ after test.

**Primary adrenal insufficiency**

Deficiency of aldosterone and cortisol production due to loss of gland function → hypotension (hyponatremic volume contraction), hyperkalemia, metabolic acidosis, skin and mucosal hyperpigmentation **A** (due to ↑ MSH, a byproduct of ACTH production from proopiomelanocortin [POMC]).

- **Acute**—sudden onset (eg, due to massive hemorrhage). May present with shock in acute adrenal crisis.
- **Chronic**—aka **Addison disease**. Due to adrenal atrophy or destruction by disease (autoimmune destruction most common in the Western world; TB most common in the developing world).

**Primary P**igments the skin/mucosa.

Associated with autoimmune polyglandular syndromes.

**Waterhouse-Friderichsen syndrome**—acute 1° adrenal insufficiency due to adrenal hemorrhage associated with septicemia (usually *Neisseria meningitidis*), DIC, endotoxic shock.

**Secondary adrenal insufficiency**

Seen with ↓ pituitary ACTH production. No skin/mucosal hyperpigmentation, no hyperkalemia (aldosterone synthesis preserved due to intact renin-angiotensin-aldosterone axis).

**Secondary S**pares the skin/mucosa.

**Tertiary adrenal insufficiency**

Seen in patients with chronic exogenous steroid use, precipitated by abrupt withdrawal. Aldosterone synthesis unaffected.

**Tertiary** from **T**reatment.

**Hyperaldosteronism**

Increased secretion of aldosterone from adrenal gland. Clinical features include hypertension, ↓ or normal K<sup>+</sup>, metabolic alkalosis. No edema due to aldosterone escape mechanism.

**Primary hyperaldosteronism**

Seen with adrenal adenoma (Conn syndrome) or bilateral adrenal hyperplasia. ↑ aldosterone, ↓ renin.



**Secondary hyperaldosteronism**

Seen in patients with renovascular hypertension, juxtaglomerular cell tumors (renin-producing), and edema (eg, cirrhosis, heart failure, nephrotic syndrome).

## Neuroendocrine tumors

Group of neoplasms originating from Kulchitsky and enterochromaffin-like cells. Occur in various organs (eg, thyroid: medullary carcinoma; lungs: small cell carcinoma; pancreas: islet cell tumor; adrenals: pheochromocytoma). Cells contain amine precursor uptake decarboxylase (APUD) and secrete different hormones (eg, 5-HIAA, neuron-specific enolase [NSE], chromogranin A).

### Neuroblastoma




Most common tumor of the adrenal medulla **A** in **children**, usually < 4 years old. Originates from neural crest cells. Occurs anywhere along the sympathetic chain.

Most common presentation is abdominal distension and a firm, irregular mass that can cross the midline (vs Wilms tumor, which is smooth and unilateral). Less likely to develop hypertension than with pheochromocytoma. Can also present with opsoclonus-myoclonus syndrome (“dancing eyes-dancing feet”).

↑ HVA and VMA (catecholamine metabolites) in urine. Homer-Wright rosettes **B** characteristic of neuroblastoma and medulloblastoma. Bombesin and NSE ⊕. Associated with overexpression of *N-myc* oncogene. Classified as an APUD tumor.

## Pheochromocytoma

### ETIOLOGY



Most common tumor of the adrenal medulla in **adults** **A**. Derived from chromaffin cells (arise from neural crest).  
May be associated with germline mutations (eg, *NF-1*, *VHL*, *RET* [MEN 2A, 2B]).

### Rule of 10's:

**10%** malignant

**10%** bilateral

**10%** extra-adrenal (eg, bladder wall, organ of Zuckerkandl)

**10%** calcify

**10%** kids

### SYMPTOMS

Most tumors secrete epinephrine, norepinephrine, and dopamine, which can cause episodic hypertension. Symptoms occur in “spells”—relapse and remit.

Episodic hyperadrenergic symptoms (**5 P's**):

**P**ressure (↑ BP)

**P**ain (headache)

**P**erspiration

**P**alpitations (tachycardia)

**P**allor

### FINDINGS

↑ catecholamines and metanephrines in urine and plasma.

### TREATMENT

Irreversible  $\alpha$ -antagonists (eg, phenoxybenzamine) followed by  $\beta$ -blockers prior to tumor resection.  $\alpha$ -blockade must be achieved before giving  $\beta$ -blockers to avoid a hypertensive crisis.

**Phenoxybenzamine** (16 letters) is given for **pheochromocytoma** (also 16 letters).

**Hypothyroidism vs hyperthyroidism**

	<b>Hypothyroidism</b>	<b>Hyperthyroidism</b>
SIGNS/SYMPTOMS	Cold intolerance ( $\downarrow$ heat production)	Heat intolerance ( $\uparrow$ heat production)
	Weight gain, $\downarrow$ appetite	Weight loss, $\uparrow$ appetite
	Hypoactivity, lethargy, fatigue, weakness, depressed mood	Hyperactivity, anxiety, insomnia, hand tremor
	Constipation	Diarrhea/hyperdefecation
	$\downarrow$ reflexes (delayed/slow relaxing)	$\uparrow$ reflexes (brisk)
	Hypothyroid myopathy (proximal muscle weakness, $\uparrow$ CK)	Thyrotoxic myopathy (proximal muscle weakness, normal CK)
	Myxedema (facial/periorbital)	Pretibial myxedema (Graves disease), periorbital edema
	Dry, cool skin; coarse, brittle hair Bradycardia, dyspnea on exertion	Warm, moist skin; fine hair Chest pain, palpitations, and arrhythmias (eg, atrial fibrillation) due to $\uparrow$ number and sensitivity of $\beta$ -adrenergic receptors
LAB FINDINGS	$\uparrow$ TSH (if $1^\circ$ )	$\downarrow$ TSH (if $1^\circ$ )
	$\downarrow$ free $T_3$ and $T_4$	$\uparrow$ free or total $T_3$ and $T_4$
	Hypercholesterolemia (due to $\downarrow$ LDL receptor expression)	Hypocholesterolemia (due to $\uparrow$ LDL receptor expression)

**Causes of goiter**

	<b>Smooth/diffuse</b>	<b>Nodular</b>
	Graves disease Hashimoto thyroiditis Iodine deficiency TSH-secreting pituitary adenoma	Toxic multinodular goiter Thyroid adenoma Thyroid cancer Thyroid cyst

## Hypothyroidism

<b>Hashimoto thyroiditis</b>	<p>Most common cause of hypothyroidism in iodine-sufficient regions; an autoimmune disorder with antithyroid peroxidase (antimicrosomal) and antithyroglobulin antibodies. Associated with ↑ risk of non-Hodgkin lymphoma (typically of B-cell origin).</p> <p>May be hyperthyroid early in course due to thyrotoxicosis during follicular rupture.</p> <p>Histologic findings: Hürthle cells, lymphoid aggregates with germinal centers <b>A</b>.</p> <p>Findings: moderately enlarged, <b>nontender</b> thyroid.</p>
<b>Congenital hypothyroidism (cretinism)</b>	<p>Severe fetal hypothyroidism due to maternal hypothyroidism, thyroid agenesis, thyroid dysgenesis (most common cause in US), iodine deficiency, dyshormonogenetic goiter.</p> <p>Findings: <b>P</b>ot-bellied, <b>P</b>ale, <b>P</b>uffy-faced child with <b>P</b>rotruding umbilicus, <b>P</b>rotuberant tongue, and <b>P</b>oor brain development: the <b>6 P's</b> <b>B C</b>.</p>
<b>Subacute granulomatous thyroiditis (de Quervain)</b>	<p>Self-limited disease often following a flu-like illness (eg, viral infection).</p> <p>May be hyperthyroid early in course, followed by hypothyroidism.</p> <p>Histology: granulomatous inflammation.</p> <p>Findings: ↑ ESR, jaw pain, very <b>tender</b> thyroid. (de <b>Q</b>uervain is associated with <b>p</b>ain.)</p>
<b>Riedel thyroiditis</b>	<p>Thyroid replaced by fibrous tissue with inflammatory infiltrate <b>D</b>. Fibrosis may extend to local structures (eg, trachea, esophagus), mimicking anaplastic carcinoma. 1/3 are hypothyroid.</p> <p>Considered a manifestation of IgG<sub>4</sub>-related systemic disease (eg, autoimmune pancreatitis, retroperitoneal fibrosis, noninfectious aortitis).</p> <p>Findings: fixed, hard (rock-like), <b>painless</b> goiter.</p>
<b>Other causes</b>	<p>Iodine deficiency <b>E</b>, goitrogens (eg, amiodarone, lithium), Wolff-Chaikoff effect (thyroid gland downregulation in response to ↑ iodide).</p>



**Hyperthyroidism****Graves disease**

Most common cause of hyperthyroidism. Thyroid-stimulating immunoglobulin (IgG; type II hypersensitivity) stimulates TSH receptors on thyroid (hyperthyroidism, diffuse goiter) and dermal fibroblasts (pretibial myxedema). Infiltration of retroorbital space by activated T-cells → ↑ cytokines (eg, TNF- $\alpha$ , IFN- $\gamma$ ) → ↑ fibroblast secretion of hydrophilic GAGs → ↑ osmotic muscle swelling, muscle inflammation, and adipocyte count → exophthalmos **A**. Often presents during stress (eg, pregnancy). Associated with HLA-DR3 and HLA-B8. Tall, crowded follicular epithelial cells; scalloped colloid **B**.

**Toxic multinodular goiter**


Focal patches of hyperfunctioning follicular cells distended with colloid **C** working independently of TSH (due to TSH receptor mutations in 60% of cases). ↑ release of T<sub>3</sub> and T<sub>4</sub>. Hot nodules are rarely malignant.


**Thyroid storm**

Uncommon but serious complication that occurs when hyperthyroidism is incompletely treated/untreated and then significantly worsens in the setting of acute stress such as infection, trauma, surgery. Presents with agitation, delirium, fever, diarrhea, coma, and tachyarrhythmia (cause of death). May see ↑ LFTs. Treat with the **4 P's**:  $\beta$ -blockers (eg, **P**ropranolol), **P**ropylthiouracil, corticosteroids (eg, **P**rednisolone), **P**otassium iodide (Lugol iodine).

**Jod-Basedow phenomenon**

Thyrotoxicosis if a patient with iodine deficiency and partially autonomous thyroid tissue (eg, autonomous nodule) is made iodine replete. Opposite of Wolff-Chaikoff effect.




**Thyroid adenoma**

Benign solitary growth of the thyroid. Most are nonfunctional (“cold”), can rarely cause hyperthyroidism via autonomous thyroid hormone production (“hot” or “toxic”). Most common histology is follicular **A**; absence of capsular or vascular invasion (unlike follicular carcinoma).

**Thyroid cancer**


Typically diagnosed with fine needle aspiration; treated with thyroidectomy. Complications of surgery include hoarseness (due to recurrent laryngeal nerve damage), hypocalcemia (due to removal of parathyroid glands), and transection of recurrent and superior laryngeal nerves (during ligation of inferior thyroid artery and superior laryngeal artery, respectively).

**Papillary carcinoma**

Most common, excellent prognosis. Empty-appearing nuclei with central clearing (“**Orphan Annie**” eyes) **A**, psam**Moma** bodies, nuclear grooves (**Papi** and **Moma** adopted **Orphan Annie**). ↑ risk with *RET* and *BRAF* mutations, childhood irradiation.

**Follicular carcinoma**

Good prognosis. Invades thyroid capsule and vasculature (unlike follicular adenoma), uniform follicles; hematogenous spread is common. Associated with *RAS* mutation.

**Medullary carcinoma**

From parafollicular “C cells”; produces calcitonin, sheets of cells in an amyloid stroma (stains with Congo red **B**). Associated with MEN 2A and 2B (*RET* mutations).


**Undifferentiated/  
anaplastic carcinoma**

Older patients; invades local structures, very poor prognosis.

**Lymphoma**

Associated with Hashimoto thyroiditis.

## Diagnosis of parathyroid disease



### Hypoparathyroidism

Due to accidental surgical excision of parathyroid glands, autoimmune destruction, or DiGeorge syndrome. Findings: tetany, hypocalcemia, hyperphosphatemia.


**Chvostek sign**—tapping of facial nerve (tap the **C**heek) → contraction of facial muscles.

**Trousseau sign**—occlusion of brachial artery with BP cuff (cuff the **T**riceps) → carpal spasm.

**Pseudohypoparathyroidism type 1A** (Albright hereditary osteodystrophy)—unresponsiveness of kidney to PTH → hypocalcemia despite ↑ PTH levels. Characterized by shortened 4th/5th digits, short stature. Autosomal dominant. Due to defective  $G_s$  protein  $\alpha$ -subunit causing end-organ resistance to PTH. Defect must be inherited from mother due to imprinting.

**Pseudopseudohypoparathyroidism**—physical exam features of Albright hereditary osteodystrophy but without end-organ PTH resistance (PTH level normal). Occurs when defective  $G_s$  protein  $\alpha$ -subunit is inherited from father.



**Hyperparathyroidism****Primary hyperparathyroidism**

Usually due to parathyroid adenoma or hyperplasia. **Hypercalcemia**, hypercalciuria (renal **stones**), polyuria (**thrones**), hypophosphatemia, ↑ PTH, ↑ ALP, ↑ cAMP in urine. Most often asymptomatic. May present with weakness and constipation (“**groans**”), abdominal/flank pain (kidney stones, acute pancreatitis), depression (“**psychiatric overtones**”).

**Osteitis fibrosa cystica**—cystic **bone** spaces filled with brown fibrous tissue **A** (“brown tumor” consisting of osteoclasts and deposited hemosiderin from hemorrhages; causes bone pain). Due to ↑ PTH, classically associated with 1° (but also seen with 2°) hyperparathyroidism.

“**Stones, thrones, bones, groans, and psychiatric overtones.**”

**Secondary hyperparathyroidism**

2° hyperplasia due to ↓ Ca<sup>2+</sup> absorption and/or ↑ PO<sub>4</sub><sup>3-</sup>, most often in chronic renal disease (causes hypovitaminosis D and hyperphosphatemia → ↓ Ca<sup>2+</sup>).

**Hypocalcemia**, hyperphosphatemia in chronic renal failure (vs hypophosphatemia with most other causes), ↑ ALP, ↑ PTH.


**Renal osteodystrophy**—renal disease → 2° and 3° hyperparathyroidism → bone lesions.

**Tertiary hyperparathyroidism**

Refractory (autonomous) hyperparathyroidism resulting from chronic renal disease. ↑↑ PTH, ↑ Ca<sup>2+</sup>.

**Familial hypocalciuric hypercalcemia**

Defective G-coupled Ca<sup>2+</sup>-sensing receptors in multiple tissues (eg, parathyroids, kidneys). Higher than normal Ca<sup>2+</sup> levels required to suppress PTH. Excessive renal Ca<sup>2+</sup> reuptake → mild hypercalcemia and hypocalciuria with normal to ↑ PTH levels.

**Pituitary adenoma**

Benign tumor, most commonly prolactinoma (arises from lactotrophs). Adenoma **A** may be functional (hormone producing) or nonfunctional (silent). Nonfunctional tumors present with mass effect (bitemporal hemianopia, hypopituitarism, headache). Functional tumor presentation is based on the hormone produced.

Prolactinoma in women classically presents as galactorrhea, amenorrhea, and ↓ bone density due to suppression of estrogen. Prolactinoma in men classically presents as low libido and infertility. Treatment: dopamine agonists (eg, bromocriptine, cabergoline), transsphenoidal resection.

**Nelson syndrome**

Enlargement of existing ACTH-secreting pituitary adenoma after bilateral adrenalectomy for refractory Cushing disease (due to removal of cortisol feedback mechanism). Presents with hyperpigmentation, headaches and bitemporal hemianopia. Treatment: pituitary irradiation or surgical resection.

**Acromegaly**

Excess GH in adults. Typically caused by pituitary adenoma.

**FINDINGS**

Large tongue with deep furrows, deep voice, large hands and feet, coarsening of facial features with aging **A**, frontal bossing, diaphoresis (excessive sweating), impaired glucose tolerance (insulin resistance). ↑ risk of colorectal polyps and cancer.

↑ GH in children → gigantism (↑ linear bone growth). HF most common cause of death.

**DIAGNOSIS**

↑ serum IGF-1; failure to suppress serum GH following oral glucose tolerance test; pituitary mass seen on brain MRI.

**TREATMENT**

Pituitary adenoma resection. If not cured, treat with octreotide (somatostatin analog) or pegvisomant (growth hormone receptor antagonist), dopamine agonists (eg, cabergoline).

**Laron syndrome (dwarfism)**

Defective growth hormone receptors → ↓ linear growth. ↑ GH, ↓ IGF-1. Clinical features include short height, small head circumference, characteristic facies with saddle nose and prominent forehead, delayed skeletal maturation, small genitalia.

**Diabetes insipidus**

Characterized by intense thirst and polyuria with inability to concentrate urine due to lack of ADH (central) or failure of response to circulating ADH (nephrogenic).

	Central DI	Nephrogenic DI
ETIOLOGY	Pituitary tumor, autoimmune, trauma, surgery, ischemic encephalopathy, idiopathic	Hereditary (ADH receptor mutation), 2° to hypercalcemia, hypokalemia, lithium, demeclocycline (ADH antagonist)
FINDINGS	↓ ADH Urine specific gravity < 1.006 Serum osmolality > 290 mOsm/kg Hyperosmotic volume contraction	Normal or ↑ ADH levels Urine specific gravity < 1.006 Serum osmolality > 290 mOsm/kg Hyperosmotic volume contraction
WATER DEPRIVATION TEST <sup>a</sup>	> 50% ↑ in urine osmolality only after administration of ADH analog	Minimal change in urine osmolality, even after administration of ADH analog
TREATMENT	Desmopressin acetate Hydration	HCTZ, indomethacin, amiloride Hydration, dietary salt restriction, avoidance of offending agent

<sup>a</sup>No water intake for 2–3 hr followed by hourly measurements of urine volume and osmolality and plasma Na<sup>+</sup> concentration and osmolality. ADH analog (desmopressin acetate) is administered if serum osmolality > 295–300 mOsm/kg, plasma Na<sup>+</sup> ≥ 145, or urine osmolality does not rise despite a rising plasma osmolality.

**Syndrome of inappropriate antidiuretic hormone secretion**

Characterized by:

- Excessive free water retention
- Euvolemic hyponatremia with continued urinary Na<sup>+</sup> excretion
- Urine osmolality > serum osmolality

Body responds to water retention with ↓ aldosterone and ↑ ANP and BNP → ↑ urinary Na<sup>+</sup> secretion → normalization of extracellular fluid volume → euvolemic hyponatremia. Very low serum Na<sup>+</sup> levels can lead to cerebral edema, seizures. Correct slowly to prevent osmotic demyelination syndrome (formerly known as central pontine myelinolysis).

SIADH causes include:

- Ectopic ADH (eg, small cell lung cancer)
- CNS disorders/head trauma
- Pulmonary disease
- Drugs (eg, cyclophosphamide)

Treatment: fluid restriction, salt tablets, IV hypertonic saline, diuretics, conivaptan, tolvaptan, demeclocycline.

Increased urine osmolality during water deprivation test indicates psychogenic polydipsia.

**Hypopituitarism**

Undersecretion of pituitary hormones due to:

- Nonsecreting pituitary adenoma, craniopharyngioma
- **Sheehan syndrome**—ischemic infarct of pituitary following postpartum bleeding; pregnancy-induced pituitary growth → ↑ susceptibility to hypoperfusion. Usually presents with failure to lactate, absent menstruation, cold intolerance
- **Empty sella syndrome**—atrophy or compression of pituitary (which lies in the sella turcica), often idiopathic, common in obese women
- **Pituitary apoplexy**—sudden hemorrhage of pituitary gland, often in the presence of an existing pituitary adenoma. Usually presents with sudden onset severe headache, visual impairment (eg, bitemporal hemianopia, diplopia due to CN III palsy), and features of hypopituitarism.
- Brain injury
- Radiation

Treatment: hormone replacement therapy (corticosteroids, thyroxine, sex steroids, human growth hormone).

---

## Diabetes mellitus

### ACUTE MANIFESTATIONS

Polydipsia, polyuria, polyphagia, weight loss, DKA (type 1), hyperosmolar coma (type 2). Rarely, can be caused by unopposed secretion of GH and epinephrine. Also seen in patients on glucocorticoid therapy (steroid diabetes).

### CHRONIC COMPLICATIONS

Nonenzymatic glycation:

- Small vessel disease (diffuse thickening of basement membrane) → retinopathy (hemorrhage, exudates, microaneurysms, vessel proliferation), glaucoma, neuropathy, nephropathy (nodular glomerulosclerosis, aka Kimmelstiel-Wilson nodules → progressive proteinuria [initially microalbuminuria; ACE inhibitors are renoprotective] and arteriolosclerosis → hypertension; both lead to chronic renal failure).
- Large vessel atherosclerosis, CAD, peripheral vascular occlusive disease, gangrene → limb loss, cerebrovascular disease. MI most common cause of death.

Osmotic damage (sorbitol accumulation in organs with aldose reductase and ↓ or absent sorbitol dehydrogenase):

- Neuropathy (motor, sensory [glove and stocking distribution], and autonomic degeneration)
- Cataracts

### DIAGNOSIS

#### TEST

HbA<sub>1c</sub>

Fasting plasma glucose

2-hour oral glucose tolerance test

#### DIAGNOSTIC CUTOFF

≥ 6.5%

≥ 126 mg/dL

≥ 200 mg/dL


#### NOTES

Reflects average blood glucose over prior 3 months

Fasting for > 8 hours

2 hours after consumption of 75 g of glucose in water

### Insulin deficiency or severe insulin insensitivity



**Type 1 vs type 2 diabetes mellitus**

Variable	Type 1	Type 2
1° DEFECT	Autoimmune destruction of $\beta$ cells (eg, due to glutamic acid decarboxylase antibodies)	$\uparrow$ resistance to insulin, progressive pancreatic $\beta$ -cell failure
INSULIN NECESSARY IN TREATMENT	Always	Sometimes
AGE (EXCEPTIONS COMMONLY OCCUR)	< 30 yr	> 40 yr
ASSOCIATION WITH OBESITY	No	Yes
GENETIC PREDISPOSITION	Relatively weak (50% concordance in identical twins), polygenic	Relatively strong (90% concordance in identical twins), polygenic
ASSOCIATION WITH HLA SYSTEM	Yes (HLA-DR3 and -DR4)	No
GLUCOSE INTOLERANCE	Severe	Mild to moderate
INSULIN SENSITIVITY	High	Low
KETOACIDOSIS	Common	Rare
$\beta$ -CELL NUMBERS IN THE ISLETS	$\downarrow$	Variable (with amyloid deposits)
SERUM INSULIN LEVEL	$\downarrow$	Variable
CLASSIC SYMPTOMS OF POLYURIA, POLYDIPSIA, POLYPHAGIA, WEIGHT LOSS	Common	Sometimes
HISTOLOGY	Islet leukocytic infiltrate	Islet amyloid polypeptide (IAPP) deposits

<b>Diabetic ketoacidosis</b>	One of the most feared complications of diabetes. Usually due to insulin noncompliance or $\uparrow$ insulin requirements from $\uparrow$ stress (eg, infection). Excess fat breakdown and $\uparrow$ ketogenesis from $\uparrow$ free fatty acids, which are then made into ketone bodies ( $\beta$ -hydroxybutyrate > acetoacetate). Usually occurs in type 1 diabetes, as endogenous insulin in type 2 diabetes usually prevents lipolysis.
SIGNS/SYMPTOMS	<b>DKA</b> is <b>D</b> eadly: <b>D</b> elirium/psychosis, <b>K</b> ussmaul respirations (rapid/deep breathing), <b>A</b> bdominal pain/nausea/vomiting, <b>D</b> ehydration. Fruity breath odor (due to exhaled acetone).
LABS	Hyperglycemia, $\uparrow$ $H^+$ , $\downarrow$ $HCO_3^-$ ( $\uparrow$ anion gap metabolic acidosis), $\uparrow$ blood ketone levels, leukocytosis. Hyperkalemia, but depleted intracellular $K^+$ due to transcellular shift from $\downarrow$ insulin and acidosis (therefore total body $K^+$ is depleted).
COMPLICATIONS	Life-threatening mucormycosis (usually caused by <i>Rhizopus</i> infection), cerebral edema, cardiac arrhythmias, heart failure.
TREATMENT	IV fluids, IV insulin, and $K^+$ (to replete intracellular stores); glucose if necessary to prevent hypoglycemia.

**Hyperosmolar  
hyperglycemic state**

State of profound hyperglycemia-induced dehydration and ↑ serum osmolality, classically seen in elderly type 2 diabetics with limited ability to drink. Hyperglycemia → excessive osmotic diuresis → dehydration → eventual onset of HHNS. Symptoms: thirst, polyuria, lethargy, focal neurological deficits (eg, seizures), can progress to coma and death if left untreated. Labs: hyperglycemia (often > 600 mg/dL), ↑ serum osmolality (> 320 mOsm/kg), no acidosis (pH > 7.3, ketone production inhibited by presence of insulin). Treatment: aggressive IV fluids, insulin therapy.

**Glucagonoma**


Tumor of pancreatic  $\alpha$  cells → overproduction of glucagon. Presents with **d**ermatitis (necrolytic migratory erythema), **d**iabetes (hyperglycemia), **DVT**, **d**eclining weight, **d**epression. Treatment: octreotide, surgery.

**Insulinoma**

Tumor of pancreatic  $\beta$  cells → overproduction of insulin → hypoglycemia. May see Whipple triad: low blood glucose, symptoms of hypoglycemia (eg, lethargy, syncope, diplopia), and resolution of symptoms after normalization of glucose levels. Symptomatic patients have ↓ blood glucose and ↑ C-peptide levels (vs exogenous insulin use). ~ 10% of cases associated with MEN 1 syndrome. Treatment: surgical resection.

**Somatostatinoma**

Tumor of pancreatic  $\delta$  cells → overproduction of somatostatin → ↓ secretion of secretin, cholecystokinin, glucagon, insulin, gastrin, gastric inhibitory peptide (GIP). May present with diabetes/glucose intolerance, steatorrhea, gallstones, achlorhydria. Treatment: surgical resection; somatostatin analogs (eg, octreotide) for symptom control.

**Carcinoid syndrome**

Rare syndrome caused by carcinoid tumors (neuroendocrine cells **A**; note prominent rosettes [arrow]), especially metastatic small bowel tumors, which secrete high levels of serotonin (5-HT). Not seen if tumor is limited to GI tract (5-HT undergoes first-pass metabolism in liver). Results in recurrent diarrhea, cutaneous flushing, asthmatic wheezing, right-sided valvular heart disease (tricuspid regurgitation, pulmonic stenosis). ↑ 5-hydroxyindoleacetic acid (5-HIAA) in urine, niacin deficiency (pellagra). Treatment: surgical resection, somatostatin analog (eg, octreotide).

**Rule of 1/3s:**

- 1/3** metastasize
- 1/3** present with 2nd malignancy
- 1/3** are multiple

Most common malignancy in the small intestine.

**Zollinger-Ellison  
syndrome**

Gastrin-secreting tumor (gastrinoma) of pancreas or duodenum. Acid hypersecretion causes recurrent ulcers in duodenum and jejunum. Presents with abdominal pain (peptic ulcer disease, distal ulcers), diarrhea (malabsorption). Positive secretin stimulation test: gastrin levels remain elevated after administration of secretin, which normally inhibits gastrin release. May be associated with MEN 1.

**Multiple endocrine neoplasias**

All **MEN** syndromes have autosomal **dominant** inheritance. “All **MEN** are **dominant**” (or so they think).

SUBTYPE	CHARACTERISTICS	COMMENTS
<b>MEN 1</b>	<p><b>P</b>ituitary tumors (prolactin or GH)</p> <p><b>P</b>ancreatic endocrine tumors—Zollinger-Ellison syndrome, insulinomas, VIPomas, glucagonomas (rare)</p> <p><b>P</b>arathyroid adenomas</p> <p>Associated with mutation of <i>MEN1</i> (menin, a tumor suppressor, chromosome 11)</p>	
<b>MEN 2A</b>	<p><b>P</b>arathyroid hyperplasia</p> <p>Medullary thyroid carcinoma—neoplasm of parafollicular or C cells; secretes calcitonin; prophylactic thyroidectomy required</p> <p><b>P</b>heochromocytoma (secretes catecholamines)</p> <p>Associated with mutation in <i>RET</i> (codes for receptor tyrosine kinase) in cells of neural crest origin</p>	
<b>MEN 2B</b>	<p>Medullary thyroid carcinoma</p> <p><b>P</b>heochromocytoma</p> <p>Mucosal neuromas (oral/intestinal ganglioneuromatosis)</p> <p>Associated with marfanoid habitus; mutation in <i>RET</i> gene</p>	

**MEN 1 = 3 P's:** Pituitary, Parathyroid, and Pancreas  
**MEN 2A = 2 P's:** Parathyroids and Pheochromocytoma  
**MEN 2B = 1 P:** Pheochromocytoma



## ▶ ENDOCRINE—PHARMACOLOGY

**Diabetes mellitus management**

Treatment strategies:

- Type 1 DM—dietary modifications, insulin replacement
- Type 2 DM—dietary modifications and exercise for weight loss; oral agents, non-insulin injectables, insulin replacement
- Gestational DM (GDM)—dietary modifications, exercise, insulin replacement if lifestyle modification fails

DRUG CLASSES	CLINICAL USE	ACTION	RISKS/CONCERNS
<b>Insulin preparations</b>			
<b>Insulin, rapid acting</b> Lispro, aspart, glulisine	Type 1 DM, type 2 DM, GDM (postprandial glucose control).	Binds insulin receptor (tyrosine kinase activity). Liver: ↑ glucose stored as glycogen. Muscle: ↑ glycogen, protein synthesis; ↑ K <sup>+</sup> uptake. Fat: ↑ TG storage.	Hypoglycemia, lipodystrophy, rare hypersensitivity reactions.
<b>Insulin, short acting</b> Regular	Type 1 DM, type 2 DM, GDM, DKA (IV), hyperkalemia (+ glucose), stress hyperglycemia.		
<b>Insulin, intermediate acting</b> NPH	Type 1 DM, type 2 DM, GDM.		
<b>Insulin, long acting</b> Detemir, glargine	Type 1 DM, type 2 DM, GDM (basal glucose control).		
<b>Oral drugs</b>			
<b>Biguanides</b> Metformin	Oral. First-line therapy in type 2 DM, causes modest weight loss. Can be used in patients without islet function.	Inhibit hepatic gluconeogenesis and the action of glucagon. ↓ gluconeogenesis, ↑ glycolysis, ↑ peripheral glucose uptake (↑ insulin sensitivity).	GI upset; most serious adverse effect is lactic acidosis (thus contraindicated in renal insufficiency).
<b>Sulfonylureas</b> First generation: chlorpropamide, tolbutamide Second generation: glimepiride, glipizide, glyburide	Stimulate release of endogenous insulin in type 2 DM. Require some islet function, so useless in type 1 DM.	Close K <sup>+</sup> channel in β cell membrane → cell depolarizes → insulin release via ↑ Ca <sup>2+</sup> influx.	Risk of hypoglycemia ↑ in renal failure, weight gain. First generation: disulfiram-like effects. Second generation: hypoglycemia.
<b>Glitazones/ thiazolidinediones</b> Pioglitazone, rosiglitazone	Used as monotherapy in type 2 DM or combined with above agents. Safe to use in renal impairment.	↑ insulin sensitivity in peripheral tissue. Binds to PPAR-γ nuclear transcription regulator. <sup>a</sup>	Weight gain, edema, HF, ↑ risk of fractures.

**Diabetes mellitus management (continued)**

DRUG CLASSES	CLINICAL USE	ACTION	RISKS/CONCERNS
<b>Oral hypoglycemic drugs (continued)</b>			
<b>Meglitinides</b> Nateglinide, repaglinide	Used as monotherapy in type 2 DM or combined with metformin.	Stimulate postprandial insulin release by binding to K <sup>+</sup> channels on β cell membranes (site differs from sulfonylureas).	Hypoglycemia (↑ risk with renal failure), weight gain.
<b>GLP-1 analogs</b> Exenatide, liraglutide (sc injection)	Type 2 DM.	↑ glucose-dependent insulin release, ↓ glucagon release, ↓ gastric emptying, ↑ satiety.	Nausea, vomiting, pancreatitis; modest weight loss.
<b>DPP-4 inhibitors</b> Linagliptin, saxagliptin, sitagliptin	Type 2 DM.	Inhibit DPP-4 enzyme that deactivates GLP-1, thereby ↑ glucose-dependent insulin release, ↓ glucagon release, ↓ gastric emptying, ↑ satiety.	Mild urinary or respiratory infections; weight neutral.
<b>Amylin analogs</b> Pramlintide (sc injection)	Type 1 DM, type 2 DM.	↓ gastric emptying, ↓ glucagon.	Hypoglycemia (in setting of mistimed prandial insulin), nausea.
<b>Sodium-glucose co-transporter 2 (SGLT2) inhibitors</b> Canagliflozin, dapagliflozin, empagliflozin	Type 2 DM.	Block reabsorption of glucose in PCT.	Glucosuria, UTIs, vaginal yeast infections, hyperkalemia, dehydration (orthostatic hypotension), weight loss.
<b>α-glucosidase inhibitors</b> Acarbose, miglitol	Type 2 DM.	Inhibit intestinal brush-border α-glucosidases. Delayed carbohydrate hydrolysis and glucose absorption → ↓ postprandial hyperglycemia.	GI disturbances.

<sup>a</sup>Genes activated by PPAR-γ regulate fatty acid storage and glucose metabolism. Activation of PPAR-γ ↑ insulin sensitivity and levels of adiponectin.

**Thioamides**

Propylthiouracil, methimazole.

MECHANISM	Block thyroid peroxidase, inhibiting the oxidation of iodide and the organification and coupling of iodine → inhibition of thyroid hormone synthesis. Propylthiouracil also blocks 5'-deiodinase → ↓ peripheral conversion of T <sub>4</sub> to T <sub>3</sub> .
CLINICAL USE	Hyperthyroidism. <b>PTU</b> blocks <b>P</b> eripheral conversion. PTU used in first trimester of pregnancy (due to methimazole teratogenicity); methimazole used in second and third trimesters of pregnancy (due to risk of PTU-induced hepatotoxicity).
ADVERSE EFFECTS	Skin rash, agranulocytosis (rare), aplastic anemia, hepatotoxicity. Methimazole is a possible teratogen (can cause aplasia cutis).

**Levothyroxine, triiodothyronine**

MECHANISM	Thyroid hormone replacement.
CLINICAL USE	Hypothyroidism, myxedema. Used off-label as weight loss supplements.
ADVERSE EFFECTS	Tachycardia, heat intolerance, tremors, arrhythmias.

**Hypothalamic/pituitary drugs**

DRUG	CLINICAL USE
ADH antagonists (conivaptan, tolvaptan)	SIADH, block action of ADH at V <sub>2</sub> -receptor.
Desmopressin acetate	Central (not nephrogenic) DI, von Willebrand disease, sleep enuresis.
GH	GH deficiency, Turner syndrome.
Oxytocin	Stimulates labor, uterine contractions, milk let-down; controls uterine hemorrhage.
Somatostatin (octreotide)	Acromegaly, carcinoid syndrome, gastrinoma, glucagonoma, esophageal varices.

**Demeclocycline**

MECHANISM	ADH antagonist (member of tetracycline family).
CLINICAL USE	SIADH.
ADVERSE EFFECTS	Nephrogenic DI, photosensitivity, abnormalities of bone and teeth.

**Fludrocortisone**

MECHANISM	Synthetic analog of aldosterone with little glucocorticoid effects.
CLINICAL USE	Mineralocorticoid replacement in 1° adrenal insufficiency.
ADVERSE EFFECTS	Similar to glucocorticoids; also edema, exacerbation of heart failure, hyperpigmentation.

**Cinacalcet**

MECHANISM	Sensitizes Ca <sup>2+</sup> -sensing receptor (CaSR) in parathyroid gland to circulating Ca <sup>2+</sup> → ↓ PTH.
CLINICAL USE	1° or 2° hyperparathyroidism.
ADVERSE EFFECTS	Hypocalcemia.

# Gastrointestinal

*“A good set of bowels is worth more to a man than any quantity of brains.”*

—Josh Billings

*“Man should strive to have his intestines relaxed all the days of his life.”*

—Moses Maimonides

*“Is life worth living? It all depends on the liver.”*

—William James

▶ Embryology	344
▶ Anatomy	345
▶ Physiology	356
▶ Pathology	359
▶ Pharmacology	381

## ▶ GASTROINTESTINAL—EMBRYOLOGY

**Normal gastrointestinal embryology**

Foregut—esophagus to upper duodenum.

Midgut—lower duodenum to proximal  $\frac{2}{3}$  of transverse colon.

Hindgut—distal  $\frac{1}{3}$  of transverse colon to anal canal above pectinate line.

Midgut development:

- 6th week—physiologic midgut herniates through umbilical ring
- 10th week—returns to abdominal cavity + rotates around superior mesenteric artery (SMA), total  $270^\circ$  counterclockwise

**Ventral wall defects and hernias**

Developmental defects due to failure of:

- Rostral fold closure—sternal defects (ectopia cordis)
- Lateral fold closure—omphalocele, gastroschisis
- Caudal fold closure—bladder exstrophy

**Gastroschisis**—extrusion of abdominal contents through abdominal folds (typically right of umbilicus); not covered by peritoneum or amnion.

**Omphalocele**—persistent herniation of abdominal contents into umbilical cord, **sealed** by peritoneum **A**.

**Congenital umbilical hernia**—incomplete closure of umbilical ring. Many close spontaneously.



**Tracheoesophageal anomalies**

Esophageal atresia (EA) with distal tracheoesophageal fistula (TEF) is the most common (85%).

Polyhydramnios in utero. Neonates drool, choke, and vomit with first feeding. TEF allows air to enter stomach (visible on CXR). Cyanosis is  $2^\circ$  to laryngospasm (to avoid reflux-related aspiration).

Clinical test: failure to pass nasogastric tube into stomach.

In **H**-type, the fistula resembles the letter **H**. In pure EA the CXR shows gasless abdomen.

**Intestinal atresia**

Presents with bilious vomiting and abdominal distension within first 1–2 days of life.


**Duodenal atresia**—failure to recanalize. Associated with “double bubble” (dilated stomach, proximal duodenum) on x-ray **A**). Associated with Down syndrome.

**Jejunal and ileal atresia**—disruption of mesenteric vessels → ischemic necrosis → segmental resorption (bowel discontinuity or “apple peel”).

**Hypertrophic pyloric stenosis**

Most common cause of gastric outlet obstruction in infants (1:600). Palpable olive-shaped mass in epigastric region, visible peristaltic waves, and nonbilious projectile vomiting at ~ 2–6 weeks old. More common in firstborn males; associated with exposure to macrolides. Results in hypokalemic hypochloremic metabolic alkalosis (2° to vomiting of gastric acid and subsequent volume contraction). Treatment is surgical incision (pyloromyotomy).

**Pancreas and spleen embryology**




Pancreas—derived from foregut. Ventral pancreatic buds contribute to uncinete process and main pancreatic duct. The dorsal pancreatic bud alone becomes the body, tail, isthmus, and accessory pancreatic duct. Both the ventral and dorsal buds contribute to pancreatic head.

**Annular pancreas**—ventral pancreatic bud abnormally encircles 2nd part of duodenum; forms a ring of pancreatic tissue that may cause duodenal narrowing **A** and vomiting.

**Pancreas divisum**—ventral and dorsal parts fail to fuse at 8 weeks. Common anomaly; mostly asymptomatic, but may cause chronic abdominal pain and/or pancreatitis.

Spleen—arises in mesentery of stomach (hence is mesodermal) but has foregut supply (celiac trunk → splenic artery).




► GASTROINTESTINAL—ANATOMY

**Retroperitoneal structures**


Retroperitoneal structures include GI structures that lack a mesentery and non-GI structures. Injuries to retroperitoneal structures can cause blood or gas accumulation in retroperitoneal space.

**SAD PUCKER:**

- Suprarenal (adrenal) glands [not shown]
- Aorta and IVC
- Duodenum (2nd through 4th parts)
- Pancreas (except tail)
- Ureters [not shown]
- Colon (descending and ascending)
- Kidneys
- Esophagus (thoracic portion) [not shown]
- Rectum (partially) [not shown]



### Important gastrointestinal ligaments



LIGAMENT	CONNECTS	STRUCTURES CONTAINED	NOTES
<b>Falciform</b>	Liver to anterior abdominal wall	Ligamentum teres hepatis (derivative of fetal umbilical vein)	Derivative of ventral mesentery
<b>Hepatoduodenal</b>	Liver to duodenum	Portal triad: proper hepatic artery, portal vein, common bile duct	Pringle maneuver—ligament may be compressed between thumb and index finger placed in omental foramen to control bleeding Borders the omental foramen, which connects the greater and lesser sacs Part of lesser omentum
<b>Gastrohepatic</b>	Liver to lesser curvature of stomach	Gastric arteries	Separates greater and lesser sacs on the right May be cut during surgery to access lesser sac Part of lesser omentum
<b>Gastrocolic</b> (not shown)	Greater curvature and transverse colon	Gastroepiploic arteries	Part of greater omentum
<b>Gastrosplenic</b>	Greater curvature and spleen	Short gastrics, left gastroepiploic vessels	Separates greater and lesser sacs on the left Part of greater omentum
<b>Splenorenal</b>	Spleen to posterior abdominal wall	Splenic artery and vein, tail of pancreas	

## Digestive tract anatomy


Layers of gut wall (inside to outside—**MSMS**):

- **M**ucosa—epithelium, lamina propria, muscularis mucosa
- **S**ubmucosa—includes **S**ubmucosal nerve plexus (Meissner), **S**ecretes fluid
- **M**uscularis externa—includes **M**yenteric nerve plexus (Auerbach), **M**otility
- **S**erosa (when intraperitoneal), adventitia (when retroperitoneal)

Ulcers can extend into submucosa, inner or outer muscular layer. Erosions are in the mucosa only.

Frequencies of basal electric rhythm (slow waves):

- Stomach—3 waves/min
- Duodenum—12 waves/min
- Ileum—8–9 waves/min




## Digestive tract histology

<b>Esophagus</b>	Nonkeratinized stratified squamous epithelium.
<b>Stomach</b>	Gastric glands.
<b>Duodenum</b>	Villi and microvilli ↑ absorptive surface. Brunner glands ( $\text{HCO}_3^-$ -secreting cells of submucosa) and crypts of Lieberkühn (contain stem cells that replace enterocytes/goblet cells and Paneth cells that secrete defensins, lysozyme, and TNF).
<b>Jejunum</b>	Plicae circulares (also present in distal duodenum) and crypts of Lieberkühn.
<b>Ileum</b>	Peyer patches (lymphoid aggregates in lamina propria, submucosa), plicae circulares (proximal ileum), and crypts of Lieberkühn. Largest number of goblet cells in the small intestine.
<b>Colon</b>	Crypts of Lieberkühn but no villi; abundant goblet cells.



## Abdominal aorta and branches



Arteries supplying GI structures branch **anteriorly**. Arteries supplying non-GI structures branch **laterally** and **posteriorly**.

**Superior mesenteric artery syndrome**—

Characterized by intermittent intestinal obstruction symptoms (primarily postprandial pain) when transverse (third) portion of duodenum is compressed between SMA and aorta. Typically occurs in conditions associated with diminished mesenteric fat (eg, low body weight/malnutrition).

**Gastrointestinal blood supply and innervation**

EMBRYONIC GUT REGION	ARTERY	PARASYMPATHETIC INNERVATION	VERTEBRAL LEVEL	STRUCTURES SUPPLIED
<b>Foregut</b>	Celiac	Vagus	T12/L1	Pharynx (vagus nerve only) and lower esophagus (celiac artery only) to proximal duodenum; liver, gallbladder, pancreas, spleen (mesoderm)
<b>Midgut</b>	SMA	Vagus	L1	Distal duodenum to proximal $\frac{2}{3}$ of transverse colon
<b>Hindgut</b>	IMA	Pelvic	L3	Distal $\frac{1}{3}$ of transverse colon to upper portion of rectum

**Celiac trunk**


Branches of celiac trunk: common hepatic, splenic, and left gastric. These constitute the main blood supply of the stomach.

Strong anastomoses exist between:


- Left and right gastroepiploics
- Left and right gastrics

Posterior duodenal ulcers penetrate gastroduodenal artery causing hemorrhage.

Anterior duodenal ulcers perforate into the anterior abdominal cavity, potentially leading to pneumoperitoneum.



### Portosystemic anastomoses




SITE OF ANASTOMOSIS	CLINICAL SIGN	PORTAL ↔ SYSTEMIC
① <b>Esophagus</b>	Esophageal varices	Left gastric ↔ azygos
② <b>Umbilicus</b>	<b>Caput</b> medusae	Paraumbilical ↔ small epigastric veins of the anterior abdominal wall.
③ <b>Rectum</b>	Anorectal varices	Superior rectal ↔ middle and inferior rectal

Varices of **gut**, **butt**, and **caput** (medusae) are commonly seen with portal hypertension.

- ④ Treatment with a **transjugular intrahepatic portosystemic shunt (TIPS)** between the portal vein and hepatic vein relieves portal hypertension by shunting blood to the systemic circulation, bypassing the liver. Can precipitate hepatic encephalopathy.

### Pectinate (dentate) line

Formed where endoderm (hindgut) meets ectoderm.



**Above pectinate line**—internal hemorrhoids, adenocarcinoma.

Arterial supply from superior rectal artery (branch of IMA).

Venous drainage: superior rectal vein → inferior mesenteric vein → splenic vein → portal vein.

Internal hemorrhoids receive visceral innervation and are therefore **not painful**.

Lymphatic drainage to internal iliac lymph nodes.

**Below pectinate line**—external hemorrhoids, anal fissures, squamous cell carcinoma.


Arterial supply from inferior rectal artery (branch of internal pudendal artery).

Venous drainage: inferior rectal vein → internal pudendal vein → internal iliac vein → common iliac vein → IVC.

External hemorrhoids receive somatic innervation (inferior rectal branch of pudendal nerve) and are therefore **painful** if thrombosed. Lymphatic drainage to superficial inguinal nodes.

**Anal fissure**—tear in the anal mucosa below the Pectinate line. **P**ain while **P**ooping; blood on toilet **P**aper. Located **P**osteriorly because this area is **P**oorly **P**erfused. Associated with low-fiber diets and constipation.

### Liver tissue architecture



Apical surface of hepatocytes faces bile canaliculi. Basolateral surface faces sinusoids. Kupffer cells, which are specialized macrophages, form the lining of these sinusoids (black arrows in **A**); 2 yellow arrows show hepatic venule).

Hepatic stellate (Ito) cells in space of Disse store vitamin A (when quiescent) and produce extracellular matrix (when activated).

Zone I—periportal zone:


- Affected 1st by viral hepatitis
- Ingested toxins (eg, cocaine)

Zone II—intermediate zone:


- Yellow fever

Zone III—pericentral vein (centrilobular) zone:


- Affected 1st by ischemia
- Contains cytochrome P-450 system
- Most sensitive to metabolic toxins
- Site of alcoholic hepatitis



**Biliary structures**



Gallstones (filling defects in gallbladder and cystic duct, red arrows in **A**) that reach the confluence of the common bile and pancreatic ducts at the ampulla of Vater can block both the common bile and pancreatic ducts (double duct sign), causing both cholangitis and pancreatitis, respectively. Tumors that arise in head of pancreas (usually ductal adenocarcinoma) can cause obstruction of common bile duct → enlarged gallbladder with painless jaundice (Courvoisier sign).



**Femoral region**

ORGANIZATION

**Lateral to medial: Nerve-Artery-Vein-Lymphatics.**

You go from **lateral to medial** to find your **NAVeL**.


**Femoral triangle**

Contains femoral nerve, artery, vein.


**Venous** near the **penis**.

**Femoral sheath**

Fascial tube 3–4 cm below inguinal ligament. Contains femoral vein, artery, and canal (deep inguinal lymph nodes) but not femoral nerve.




## Inguinal canal



## Hernias

A protrusion of peritoneum through an opening, usually at a site of weakness. Contents may be at risk for incarceration (not reducible back into abdomen/pelvis) and strangulation (ischemia and necrosis). Complicated hernias can present with tenderness, erythema, fever.

### Diaphragmatic hernia



Abdominal structures enter the thorax **A**; may occur due to congenital defect of pleuroperitoneal membrane, or as a result of trauma. Commonly occurs on left side due to relative protection of right hemidiaphragm by liver.

Most commonly a **hiatal hernia**, in which stomach herniates upward through the esophageal hiatus of the diaphragm.

**Sliding hiatal hernia** is most common.

Gastroesophageal junction is displaced upward; “hourglass stomach.”

**Paraesophageal hernia**—gastroesophageal junction is usually normal. Fundus protrudes into the thorax.

### Indirect inguinal hernia



Goes through the **internal** (deep) inguinal ring, external (superficial) inguinal ring, and **into** the scrotum. Enters internal inguinal ring lateral to inferior epigastric vessels. Occurs in **infants** owing to failure of processus vaginalis to close (can form hydrocele). Much more common in males **B**.

An indirect inguinal hernia follows the path of descent of the testes. Covered by all 3 layers of spermatic fascia.

### Direct inguinal hernia

Protrudes through the inguinal (Hesselbach) triangle. Bulges directly through parietal peritoneum medial to the inferior epigastric vessels but lateral to the rectus abdominis. Goes through the external (superficial) inguinal ring only. Covered by external spermatic fascia. Usually in older men, due to an acquired weakness in the transversalis fascia.

**MDs don't LIe:**


**M**edial to inferior epigastric vessels = **D**irect hernia.

**L**ateral to inferior epigastric vessels = **I**ndirect hernia.

### Femoral hernia

Protrudes below inguinal ligament through femoral canal below and lateral to pubic tubercle. More common in **females**, but overall inguinal hernias are the most common.

More likely to present with incarceration or strangulation than inguinal hernias.



Inguinal (Hesselbach) triangle:

- Inferior epigastric vessels
- Lateral border of rectus abdominis
- Inguinal ligament



## ► GASTROINTESTINAL—PHYSIOLOGY


## Gastrointestinal regulatory substances

REGULATORY SUBSTANCE	SOURCE	ACTION	REGULATION	NOTES
<b>Gastrin</b>	G cells (antrum of stomach, duodenum)	<ul style="list-style-type: none"> <li>↑ gastric H<sup>+</sup> secretion</li> <li>↑ growth of gastric mucosa</li> <li>↑ gastric motility</li> </ul>	<ul style="list-style-type: none"> <li>↑ by stomach distention/alkalinization, amino acids, peptides, vagal stimulation via gastrin-releasing peptide (GRP)</li> <li>↓ by pH &lt; 1.5</li> </ul>	<ul style="list-style-type: none"> <li>↑ by chronic PPI use.</li> <li>↑ in chronic atrophic gastritis (eg, <i>H pylori</i>).</li> <li>↑↑ in Zollinger-Ellison syndrome (gastrinoma).</li> </ul>
<b>Somatostatin</b>	D cells (pancreatic islets, GI mucosa)	<ul style="list-style-type: none"> <li>↓ gastric acid and pepsinogen secretion</li> <li>↓ pancreatic and small intestine fluid secretion</li> <li>↓ gallbladder contraction</li> <li>↓ insulin and glucagon release</li> </ul>	<ul style="list-style-type: none"> <li>↑ by acid</li> <li>↓ by vagal stimulation</li> </ul>	Inhibits secretion of various hormones (encourages <b>somato-stasis</b> ). Octreotide is an analog used to treat acromegaly, carcinoid syndrome, and variceal bleeding.
<b>Cholecystokinin</b>	I cells (duodenum, jejunum)	<ul style="list-style-type: none"> <li>↑ pancreatic secretion</li> <li>↑ gallbladder contraction</li> <li>↓ gastric emptying</li> <li>↑ sphincter of Oddi relaxation</li> </ul>	<ul style="list-style-type: none"> <li>↑ by fatty acids, amino acids</li> </ul>	Acts on neural muscarinic pathways to cause pancreatic secretion.
<b>Secretin</b>	S cells (duodenum)	<ul style="list-style-type: none"> <li>↑ pancreatic HCO<sub>3</sub><sup>-</sup> secretion</li> <li>↓ gastric acid secretion</li> <li>↑ bile secretion</li> </ul>	<ul style="list-style-type: none"> <li>↑ by acid, fatty acids in lumen of duodenum</li> </ul>	↑ HCO <sub>3</sub> <sup>-</sup> neutralizes gastric acid in duodenum, allowing pancreatic enzymes to function.
<b>Glucose-dependent insulinotropic peptide</b>	K cells (duodenum, jejunum)	<p>Exocrine:</p> <ul style="list-style-type: none"> <li>↓ gastric H<sup>+</sup> secretion</li> </ul> <p>Endocrine:</p> <ul style="list-style-type: none"> <li>↑ insulin release</li> </ul>	<ul style="list-style-type: none"> <li>↑ by fatty acids, amino acids, oral glucose</li> </ul>	Also known as gastric inhibitory peptide (GIP). Oral glucose load leads to ↑ insulin compared to IV equivalent due to GIP secretion.
<b>Motilin</b>	Small intestine	Produces migrating motor complexes (MMCs)	<ul style="list-style-type: none"> <li>↑ in fasting state</li> </ul>	Motilin receptor agonists (eg, erythromycin) are used to stimulate intestinal peristalsis.
<b>Vasoactive intestinal polypeptide</b>	Parasympathetic ganglia in sphincters, gallbladder, small intestine	<ul style="list-style-type: none"> <li>↑ intestinal water and electrolyte secretion</li> <li>↑ relaxation of intestinal smooth muscle and sphincters</li> </ul>	<ul style="list-style-type: none"> <li>↑ by distention and vagal stimulation</li> <li>↓ by adrenergic input</li> </ul>	<b>VIPoma</b> —non-α, non-β islet cell pancreatic tumor that secretes VIP. <b>Watery Diarrhea, Hypokalemia, and Achlorhydria (WDHA syndrome)</b> .
<b>Nitric oxide</b>		<ul style="list-style-type: none"> <li>↑ smooth muscle relaxation, including lower esophageal sphincter (LES)</li> </ul>		Loss of NO secretion is implicated in ↑ LES tone of achalasia.
<b>Ghrelin</b>	Stomach	<ul style="list-style-type: none"> <li>↑ appetite</li> </ul>	<ul style="list-style-type: none"> <li>↑ in fasting state</li> <li>↓ by food</li> </ul>	<ul style="list-style-type: none"> <li>↑ in Prader-Willi syndrome.</li> <li>↓ after gastric bypass surgery.</li> </ul>

**Gastrointestinal secretory products**

PRODUCT	SOURCE	ACTION	REGULATION	NOTES
<b>Intrinsic factor</b>	Parietal cells (stomach)	Vitamin B <sub>12</sub> -binding protein (required for B <sub>12</sub> uptake in terminal ileum)		Autoimmune destruction of parietal cells → chronic gastritis and pernicious anemia.
<b>Gastric acid</b>	Parietal cells (stomach)	↓ stomach pH	↑ by histamine, ACh, gastrin ↓ by somatostatin, GIP, prostaglandin, secretin	
<b>Pepsin</b>	Chief cells (stomach)	Protein digestion	↑ by vagal stimulation, local acid	Pepsinogen (inactive) is converted to pepsin (active) in the presence of H <sup>+</sup> .
<b>Bicarbonate</b>	Mucosal cells (stomach, duodenum, salivary glands, pancreas) and Brunner glands (duodenum)	Neutralizes acid	↑ by pancreatic and biliary secretion with secretin	Trapped in mucus that covers the gastric epithelium.

**Locations of gastrointestinal secretory cells**



Gastrin ↑ acid secretion primarily through its effects on enterochromaffin-like (ECL) cells (leading to histamine release) rather than through its direct effect on parietal cells.

**Pancreatic secretions** Isotonic fluid; low flow → high  $\text{Cl}^-$ , high flow → high  $\text{HCO}_3^-$ .

ENZYME	ROLE	NOTES
<b><math>\alpha</math>-amylase</b>	Starch digestion	Secreted in active form
<b>Lipases</b>	Fat digestion	
<b>Proteases</b>	Protein digestion	Includes trypsin, chymotrypsin, elastase, carboxypeptidases Secreted as proenzymes also known as zymogens
<b>Trypsinogen</b>	Converted to active enzyme trypsin → activation of other proenzymes and cleaving of additional trypsinogen molecules into active trypsin (positive feedback loop)	Converted to trypsin by enterokinase/ enteropeptidase, a brush-border enzyme on duodenal and jejunal mucosa

**Carbohydrate absorption** Only monosaccharides (glucose, galactose, fructose) are absorbed by enterocytes. Glucose and galactose are taken up by SGLT1 ( $\text{Na}^+$  dependent). Fructose is taken up by facilitated diffusion by GLUT5. All are transported to blood by GLUT2.  
D-xylose absorption test: distinguishes GI mucosal damage from other causes of malabsorption.

### Vitamin/mineral absorption

<b>Iron</b>	Absorbed as $\text{Fe}^{2+}$ in duodenum.	<b>Iron Fist, Bro</b> Clinically relevant in patients with small bowel disease or after resection.
<b>Folate</b>	Absorbed in small bowel.	
<b>B<sub>12</sub></b>	Absorbed in terminal ileum along with bile salts, requires intrinsic factor.	

### Peyer patches



Unencapsulated lymphoid tissue **A** found in lamina propria and submucosa of ileum. Contain specialized M cells that sample and present antigens to immune cells. B cells stimulated in germinal centers of Peyer patches differentiate into IgA-secreting plasma cells, which ultimately reside in lamina propria. IgA receives protective secretory component and is then transported across the epithelium to the gut to deal with intraluminal antigen.

Think of **IgA**, the **Intra-gut Antibody**. And always say “secretory IgA.”

**Bile** Composed of bile salts (bile acids conjugated to glycine or taurine, making them water soluble), phospholipids, cholesterol, bilirubin, water, and ions. Cholesterol 7 $\alpha$ -hydroxylase catalyzes rate-limiting step of bile acid synthesis.

Functions:

- Digestion and absorption of lipids and fat-soluble vitamins
- Cholesterol excretion (body's 1<sup>o</sup> means of eliminating cholesterol)
- Antimicrobial activity (via membrane disruption)



**Bilirubin**

Heme is metabolized by heme oxygenase to biliverdin, which is subsequently reduced to bilirubin.

Unconjugated bilirubin is removed from blood by liver, conjugated with glucuronate, and excreted in bile.


Direct bilirubin—conjugated with glucuronic acid; water soluble.

Indirect bilirubin—unconjugated; water **ins**oluble.

**► GASTROINTESTINAL—PATHOLOGY****Salivary gland tumors**

Most commonly benign and in parotid gland. Tumors in smaller glands more likely malignant. Typically present as painless mass/swelling. Facial pain or paralysis suggests malignant involvement of CN VII.

- **Pleomorphic adenoma** (benign mixed tumor)—most common salivary gland tumor **A**. Composed of chondromyxoid stroma and epithelium and recurs if incompletely excised or ruptured intraoperatively.
- **Mucoepidermoid carcinoma**—most common malignant tumor, has mucinous and squamous components.
- **Warthin tumor** (papillary cystadenoma lymphomatosum)—benign cystic tumor with germinal centers. Typically found in smokers. Bilateral in 10%; malignant in 10%.


**Achalasia**

Failure of LES to relax due to loss of myenteric (Auerbach) plexus → loss of postganglionic inhibitory neurons (that contain NO and VIP). High LES resting pressure and uncoordinated or absent peristalsis → progressive dysphagia to solids and liquids (vs obstruction—solids only). Barium swallow shows dilated esophagus with an area of distal stenosis. Associated with ↑ risk of esophageal cancer.



*Achalasia* = absence of relaxation.  
 “Bird’s beak” on barium swallow **A**.  
 2° achalasia may arise from Chagas disease (*T cruzi* infection) or extraesophageal malignancies (mass effect or paraneoplastic).

**Esophageal pathologies**


<b>Boerhaave syndrome</b>	Transmural, usually distal esophageal rupture with pneumomediastinum (arrows in <b>A</b> ) due to violent retching. Subcutaneous emphysema may be due to dissecting air (crepitus may be felt in the neck region or chest wall). Surgical emergency.
<b>Eosinophilic esophagitis</b>	Infiltration of eosinophils in the esophagus often in atopic patients. Food allergens → dysphagia, food impaction. Esophageal rings and linear furrows often seen on endoscopy. Unresponsive to GERD therapy.
<b>Esophageal strictures</b>	Associated with caustic ingestion and acid reflux.
<b>Esophageal varices</b>	Dilated submucosal veins (red arrows) <b>B C</b> in lower 1/3 of esophagus (white arrow) 2° to portal hypertension. Common in cirrhotics, may be source of life-threatening hematemesis.
<b>Esophagitis</b>	Associated with reflux, infection in immunocompromised ( <i>Candida</i> : white pseudomembrane; HSV-1: punched-out ulcers; CMV: linear ulcers), caustic ingestion, or pill esophagitis (eg, bisphosphonates, tetracycline, NSAIDs, iron, and potassium chloride).
<b>Gastroesophageal reflux disease</b>	Commonly presents as heartburn, regurgitation, dysphagia. May also present as chronic cough, hoarseness (laryngopharyngeal reflux). Associated with asthma. Transient decreases in LES tone.
<b>Mallory-Weiss syndrome</b>	Partial-thickness mucosal lacerations at gastroesophageal junction due to severe vomiting. Often presents with hematemesis and may be misdiagnosed as ruptured esophageal varices. Usually found in alcoholics and bulimics.
<b>Plummer-Vinson syndrome</b>	Triad of <b>D</b> ysphagia, <b>I</b> ron deficiency anemia, and <b>E</b> sophageal webs. May be associated with glossitis. Increased risk of esophageal squamous cell carcinoma (“ <b>Plumbers’ DIE</b> ”).
<b>Sclerodermal esophageal dysmotility</b>	Esophageal smooth muscle atrophy → ↓ LES pressure and dysmotility → acid reflux and dysphagia → stricture, Barrett esophagus, and aspiration. Part of CREST syndrome.



**Barrett esophagus**



Specialized intestinal metaplasia **A**—replacement of nonkeratinized stratified squamous epithelium with intestinal epithelium (nonciliated columnar with goblet cells [stained blue in **B**]) in distal esophagus. Due to chronic gastroesophageal reflux (GERD). Associated with ↑ risk of esophageal adenocarcinoma.



**Esophageal cancer**

Typically presents with progressive dysphagia (first solids, then liquids) and weight loss; poor prognosis.

CANCER	PART OF ESOPHAGUS AFFECTED	RISK FACTORS	PREVALENCE
<b>Squamous cell carcinoma</b>	Upper 2/3	Alcohol, hot liquids, caustic strictures, smoking, achalasia	More common worldwide
<b>Adenocarcinoma</b>	Lower 1/3	Chronic GERD, Barrett esophagus, obesity, smoking, achalasia	More common in America

## Gastritis

### Acute gastritis

Erosions can be caused by:

- NSAIDs—↓ PGE<sub>2</sub> → ↓ gastric mucosa protection
- Burns (Curling ulcer)—hypovolemia → mucosal ischemia
- Brain injury (Cushing ulcer)—↑ vagal stimulation → ↑ ACh → ↑ H<sup>+</sup> production

Especially common among alcoholics and patients taking daily NSAIDs (eg, patients with rheumatoid arthritis).

**Burned** by the **Curling** iron.

Always **Cushion** the **brain**.

### Chronic gastritis

Mucosal inflammation, often leading to atrophy (hypochlorhydria → hypergastrinemia) and intestinal G-cell metaplasia (↑ risk of gastric cancers).

#### *H pylori*

Most common. ↑ risk of peptic ulcer disease, MALT lymphoma.

Affects antrum first and spreads to body of stomach.


#### Autoimmune

Autoantibodies to parietal cells and intrinsic factor. ↑ risk of pernicious anemia.

Affects body/fundus of stomach.

## Ménétrier disease

Hyperplasia of gastric mucosa → hypertrophied rugae (look like brain gyri **A**), excess mucus production with resultant protein loss and parietal cell atrophy with ↓ acid production. Precancerous.



## Gastric cancer


Most commonly gastric adenocarcinoma; lymphoma, GI stromal tumor, carcinoid (rare). Early aggressive local spread with node/liver metastases. Often presents late, with weight loss, early satiety, and in some cases acanthosis nigricans or Leser-Trélat sign.

- **Intestinal**—associated with *H pylori*, dietary nitrosamines (smoked foods), tobacco smoking, achlorhydria, chronic gastritis. Commonly on lesser curvature; looks like ulcer with raised margins.
- **Diffuse**—not associated with *H pylori*; signet ring cells (mucin-filled cells with peripheral nuclei) **A**; stomach wall grossly thickened and leathery (linitis plastica).

**Virchow node**—involvement of left supraclavicular node by metastasis from stomach.

**Krukenberg tumor**—bilateral metastases to ovaries. Abundant mucin-secreting, signet ring cells.

**Sister Mary Joseph nodule**—subcutaneous periumbilical metastasis.



**Peptic ulcer disease**

	<b>Gastric ulcer</b>	<b>Duodenal ulcer</b>
PAIN	Can be <b>G</b> reater with meals—weight loss	<b>D</b> ecreases with meals—weight gain
<i>H PYLORI</i> INFECTION	~ 70%	~ 90%
MECHANISM	↓ mucosal protection against gastric acid	↓ mucosal protection or ↑ gastric acid secretion
OTHER CAUSES	NSAIDs	Zollinger-Ellison syndrome
RISK OF CARCINOMA	↑	Generally benign
OTHER	Biopsy margins to rule out malignancy	Hypertrophy of Brunner glands

**Ulcer complications****Hemorrhage**


Gastric, duodenal (posterior > anterior). Most common complication.  
 Ruptured gastric ulcer on the lesser curvature of stomach → bleeding from left gastric artery.  
 An ulcer on the posterior wall of duodenum → bleeding from gastroduodenal artery.

**Obstruction**


Pyloric channel, duodenal

**Perforation**

Duodenal (anterior > posterior).  
 May see free air under diaphragm **A** with referred pain to the shoulder via irritation of phrenic nerve.





**Malabsorption syndromes****Celiac disease**

Can cause diarrhea, steatorrhea, weight loss, weakness, vitamin and mineral deficiencies. Screen for fecal fat (eg, Sudan stain).

Gluten-sensitive enteropathy, celiac sprue. Autoimmune-mediated intolerance of gliadin (gluten protein found in wheat) → malabsorption and steatorrhea. Associated with HLA-DQ2, HLA-DQ8, northern European descent, dermatitis herpetiformis, ↓ bone density. Findings: IgA anti-tissue transglutaminase (IgA tTG), anti-endomysial, anti-deamidated gliadin peptide antibodies; villous atrophy (arrow in **A** shows blunting), crypt hyperplasia (double arrows in **A**), and intraepithelial lymphocytosis. Moderately ↑ risk of malignancy (eg, T-cell lymphoma).

↓ mucosal absorption primarily affects distal duodenum and/or proximal jejunum.  
D-xylose test: passively absorbed in proximal small intestine; blood and urine levels ↓ with mucosa defects or bacterial overgrowth, normal in pancreatic insufficiency.  
Treatment: gluten-free diet.

**Lactose intolerance**

Lactase deficiency. Normal-appearing villi, except when 2° to injury at tips of villi (eg, viral enteritis). Osmotic diarrhea with ↓ stool pH (colonic bacteria ferment lactose).

Lactose hydrogen breath test: ⊕ for lactose malabsorption if postlactose breath hydrogen value rises > 20 ppm compared with baseline.

**Pancreatic insufficiency**


Due to chronic pancreatitis, cystic fibrosis, obstructing cancer. Causes malabsorption of fat and fat-soluble vitamins (A, D, E, K) as well as vitamin B<sub>12</sub>.

↓ duodenal pH (bicarbonate) and fecal elastase.

**Tropical sprue**

Similar findings as celiac sprue (affects small bowel), but responds to antibiotics. Cause is unknown, but seen in residents of or recent visitors to tropics.

↓ mucosal absorption affecting duodenum and jejunum but can involve ileum with time. Associated with megaloblastic anemia due to folate deficiency and, later, B<sub>12</sub> deficiency.


**Whipple disease**

Infection with *Tropheryma whipplei* (intracellular gram ⊕); PAS ⊕ foamy macrophages in intestinal lamina propria **B**, mesenteric nodes. **C**ardiac symptoms, **A**rthralgias, and **N**eurologic symptoms are common. Diarrhea/steatorrhea occur later in disease course. Most common in older men.

**Foamy Whipped cream in a CAN.**

## Inflammatory bowel disease

	Crohn disease	Ulcerative colitis
LOCATION	Any portion of the GI tract, usually the terminal ileum and colon. <b>Skip</b> lesions, <b>rectal sparing</b> .	Colitis = colon inflammation. Continuous colonic lesions, always with rectal involvement.
GROSS MORPHOLOGY	Transmural inflammation → fistulas. <b>Cobblestone</b> mucosa, creeping <b>fat</b> , bowel wall thickening (“string sign” on barium swallow x-ray <b>A</b> ), linear ulcers, fissures.	Mucosal and submucosal inflammation only. Friable mucosa with superficial and/or deep ulcerations (compare normal <b>B</b> with diseased <b>C</b> ). Loss of haustra → “lead pipe” appearance on imaging.
MICROSCOPIC MORPHOLOGY	Noncaseating <b>granulomas</b> and lymphoid aggregates. Th1 mediated.	Crypt abscesses and ulcers, bleeding, no granulomas. Th2 mediated.
COMPLICATIONS	Malabsorption/malnutrition, colorectal cancer (↑ risk with pancolitis). Fistulas (eg, enterovesical fistulae, which can cause recurrent UTI and pneumaturia), phlegmon/abscess, strictures (causing obstruction), perianal disease.	Fulminant colitis, toxic megacolon, perforation.
INTESTINAL MANIFESTATION	Diarrhea that may or may not be bloody.	Bloody diarrhea.
EXTRINTESTINAL MANIFESTATIONS	Rash (pyoderma gangrenosum, erythema nodosum), eye inflammation (episcleritis, uveitis), oral ulcerations (aphthous stomatitis), arthritis (peripheral, spondylitis). Kidney stones (usually calcium oxalate), gallstones. May be ⊕ for anti- <i>Saccharomyces cerevisiae</i> antibodies (ASCA).	1° sclerosing cholangitis. Associated with p-ANCA.
TREATMENT	Corticosteroids, azathioprine, antibiotics (eg, ciprofloxacin, metronidazole), infliximab, adalimumab.	5-aminosalicylic preparations (eg, mesalamine), 6-mercaptopurine, infliximab, colectomy.
	For <b>Crohn</b> , think of a <b>fat granny</b> and an old <b>crone skipping</b> down a <b>cobblestone</b> road away from the <b>wreck</b> (rectal sparing).	Ulcerative colitis causes <b>ULCCERS</b> : <b>U</b> lcers <b>L</b> arge intestine <b>C</b> ontinuous, <b>C</b> olorectal carcinoma, <b>C</b> rypt abscesses <b>E</b> xtends proximally <b>R</b> ed diarrhea <b>S</b> clerosing cholangitis




### Irritable bowel syndrome

Recurrent abdominal pain associated with  $\geq 2$  of the following:

- Related to defecation
- Change in stool frequency
- Change in form (consistency) of stool

No structural abnormalities. Most common in middle-aged women. Chronic symptoms may be diarrhea-predominant, constipation-predominant, or mixed. Pathophysiology is multifaceted.

### Appendicitis



Acute inflammation of the appendix (yellow arrows in **A**), can be due to obstruction by fecalith (red arrow in **A**) (in adults) or lymphoid hyperplasia (in children).


Initial diffuse periumbilical pain migrates to McBurney point ( $\frac{1}{3}$  the distance from right anterior superior iliac spine to umbilicus). Nausea, fever; may perforate  $\rightarrow$  peritonitis; may elicit psoas, obturator, and Rovsing signs, guarding and rebound tenderness on exam.

Differential: diverticulitis (elderly), ectopic pregnancy (use  $\beta$ -hCG to rule out).

Treatment: appendectomy.

### Diverticula of the GI tract

#### Diverticulum



Blind pouch **A** protruding from the alimentary tract that communicates with the lumen of the gut. Most diverticula (esophagus, stomach, duodenum, colon) are acquired and are termed “false diverticula.”

“True” diverticulum—all 3 gut wall layers outpouch (eg, Meckel).

“False” diverticulum or pseudodiverticulum—only mucosa and submucosa outpouch. Occur especially where vasa recta perforate muscularis externa.


#### Diverticulosis

Many false diverticula of the colon, commonly sigmoid. Common (in  $\sim 50\%$  of people  $> 60$  years). Caused by  $\uparrow$  intraluminal pressure and focal weakness in colonic wall. Associated with low-fiber diets.

Often asymptomatic or associated with vague discomfort.


Complications include diverticular bleeding (painless hematochezia), diverticulitis.

#### Diverticulitis



Inflammation of diverticula **B** classically causing LLQ pain, fever, leukocytosis. Treat with antibiotics.

Complications: abscess, fistula (colovesical fistula  $\rightarrow$  pneumaturia), obstruction (inflammatory stenosis), perforation ( $\rightarrow$  peritonitis).


**Zenker diverticulum**

Pharyngoesophageal **false** diverticulum **A**.

Esophageal dysmotility causes herniation of mucosal tissue at Killian triangle between the thyropharyngeal and cricopharyngeal parts of the inferior pharyngeal constrictor. Presenting symptoms: dysphagia, obstruction, gurgling, aspiration, foul breath, neck mass. Most common in elderly males.

**Elder MIKE** has **bad breath**.

**Elderly**  
**Males**  
**Inferior pharyngeal constrictor**  
**Killian triangle**  
**Esophageal dysmotility**  
**Halitosis**


**Meckel diverticulum**

**True** diverticulum. Persistence of the vitelline duct. May contain ectopic acid-secreting gastric mucosa and/or pancreatic tissue. Most common congenital anomaly of GI tract. Can cause hematochezia/melena (less commonly), RLQ pain, intussusception, volvulus, or obstruction near terminal ileum. Contrast with omphalomesenteric cyst = cystic dilation of vitelline duct.

Diagnosis: pertechnetate study for uptake by ectopic gastric mucosa.

The rule of **2's**:

**2** times as likely in males.  
**2** inches long.  
**2** feet from the ileocecal valve.  
**2%** of population.  
 Commonly presents in first **2** years of life.  
 May have **2** types of epithelia (gastric/pancreatic).


**Hirschsprung disease**

Congenital megacolon characterized by lack of ganglion cells/enteric nervous plexuses (Auerbach and Meissner plexuses) in distal segment of colon. Due to failure of neural crest cell migration. Associated with mutations in *RET*.


Presents with bilious emesis, abdominal distention, and failure to pass meconium within 48 hours → chronic constipation. Normal portion of the colon proximal to the aganglionic segment is dilated, resulting in a “transition zone.”

Risk ↑ with Down syndrome.



Explosive expulsion of feces (squirt sign)  
 → empty rectum on digital exam.  
 Diagnosed by absence of ganglionic cells on rectal suction biopsy.  
 Treatment: resection.

**Malrotation**

Anomaly of midgut rotation during fetal development → improper positioning of bowel, formation of fibrous bands (Ladd bands). Can lead to volvulus, duodenal obstruction.


**Volvulus**

Twisting of portion of bowel around its mesentery; can lead to obstruction and infarction. Can occur throughout the GI tract. Midgut volvulus more common in infants and children. Sigmoid volvulus (coffee bean sign on x-ray **A**) more common in elderly.

**Intussusception**


Telescoping **A** of proximal bowel segment into distal segment, commonly at ileocecal junction. Compromised blood supply → intermittent abdominal pain often with “currant jelly” stools. Unusual in adults (associated with intraluminal mass or tumor that acts as lead point that is pulled into the lumen). Most common pathologic lead point is Meckel diverticulum.

Majority of cases occur in children and are idiopathic. May be associated with recent viral infection, such as adenovirus → Peyer patch hypertrophy → lead point. Also associated with rotavirus vaccine.



**Other intestinal disorders**


<b>Acute mesenteric ischemia</b>	Critical blockage of intestinal blood flow (often embolic occlusion of SMA) → small bowel necrosis <b>A</b> → abdominal pain out of proportion to physical findings. May see red “currant jelly” stools.
<b>Chronic mesenteric ischemia</b>	“Intestinal angina”: atherosclerosis of celiac artery, SMA, or IMA → intestinal hypoperfusion → postprandial epigastric pain → food aversion and weight loss.
<b>Colonic ischemia</b>	Reduction in intestinal blood flow causes ischemia. Crampy abdominal pain followed by hematochezia. Commonly occurs at watershed areas (splenic flexure, distal colon). Typically affects elderly. Thumbprint sign on imaging due to mucosal edema/hemorrhage.
<b>Angiodysplasia</b>	Tortuous dilation of vessels <b>B</b> → hematochezia. Most often found in the right-sided colon. More common in older patients. Confirmed by angiography.
<b>Adhesion</b>	Fibrous band of scar tissue; commonly forms after surgery; most common cause of small bowel obstruction <b>C</b> . Can have well-demarcated necrotic zones.
<b>Ileus</b>	Intestinal hypomotility without obstruction → constipation and ↓ flatus; distended/tympanic abdomen with ↓ bowel sounds. Associated with abdominal surgeries, opiates, hypokalemia, sepsis. Treatment: bowel rest, electrolyte correction, cholinergic drugs (stimulate intestinal motility).
<b>Meconium ileus</b>	In cystic fibrosis, meconium plug obstructs intestine, preventing stool passage at birth.
<b>Necrotizing enterocolitis</b>	Seen in premature, formula-fed infants with immature immune system. Necrosis of intestinal mucosa (primarily colonic) with possible perforation, which can lead to pneumatosis intestinalis <b>D</b> , free air in abdomen, portal venous gas.



**Colonic polyps**

Growths of tissue within the colon **A**. May be neoplastic or non-neoplastic. Grossly characterized as flat, sessile, or pedunculated (on a stalk) on the basis of protrusion into colonic lumen. Generally classified by histologic type.

HISTOLOGIC TYPE	CHARACTERISTICS
<b>Generally non-neoplastic</b>	
<b>Hamartomatous polyps</b>	Solitary lesions do not have significant risk of transformation. Growths of normal colonic tissue with distorted architecture. Associated with Peutz-Jeghers syndrome and juvenile polyposis.
<b>Mucosal polyps</b>	Small, usually < 5 mm. Look similar to normal mucosa. Clinically insignificant.
<b>Inflammatory pseudopolyps</b>	Result of mucosal erosion in inflammatory bowel disease.
<b>Submucosal polyps</b>	May include lesions such as lipomas, leiomyomas, fibromas, and others.
<b>Hyperplastic polyps</b>	Generally smaller and predominantly located in the rectosigmoid region. May occasionally evolve into serrated polyps and more advanced lesions.
<b>Malignant potential</b>	
<b>Adenomatous polyps</b>	Neoplastic, via chromosomal instability pathway with mutations in APC and KRAS. Tubular <b>B</b> histology has less malignant potential than villous <b>C</b> (“ <b>VILLOUS</b> histology is <b>VILLainOUS</b> ”); tubulovillous has intermediate malignant potential. Usually asymptomatic; may present with occult bleeding.
<b>Serrated polyps</b>	Premalignant, via CpG hypermethylation phenotype pathway with microsatellite instability and mutations in BRAF. “Saw-tooth” pattern of crypts on biopsy. Up to 20% of cases of sporadic CRC.

**Polyposis syndromes**


<b>Familial adenomatous polyposis</b>	Autosomal dominant mutation of APC tumor suppressor gene on chromosome 5q. 2-hit hypothesis. Thousands of polyps arise starting after puberty; pancolonic; always involves rectum. Prophylactic colectomy or else 100% progress to CRC.
<b>Gardner syndrome</b>	FAP + osseous and soft tissue tumors, congenital hypertrophy of retinal pigment epithelium, impacted/supernumerary teeth.
<b>Turcot syndrome</b>	FAP/Lynch syndrome + malignant CNS tumor (eg, medulloblastoma, glioma). <b>Turcot</b> = <b>Turban</b> .
<b>Peutz-Jeghers syndrome</b>	Autosomal dominant syndrome featuring numerous hamartomas throughout GI tract, along with hyperpigmented mouth, lips, hands, genitalia. Associated with ↑ risk of breast and GI cancers (eg, colorectal, stomach, small bowel, pancreatic).
<b>Juvenile polyposis syndrome</b>	Autosomal dominant syndrome in children (typically < 5 years old) featuring numerous hamartomatous polyps in the colon, stomach, small bowel. Associated with ↑ risk of CRC.

**Lynch syndrome**

Previously known as hereditary nonpolyposis colorectal cancer (HNPCC). Autosomal dominant mutation of DNA mismatch repair genes with subsequent microsatellite instability. ~ 80% progress to CRC. Proximal colon is always involved. Associated with endometrial, ovarian, and skin cancers.

**Colorectal cancer**

EPIDEMIOLOGY	Most patients are > 50 years old. ~ 25% have a family history.	
RISK FACTORS	Adenomatous and serrated polyps, familial cancer syndromes, IBD, tobacco use, diet of processed meat with low fiber.	
PRESENTATION	Rectosigmoid > ascending > descending. Ascending—exophytic mass, iron deficiency anemia, weight loss. Descending—infiltrating mass, partial obstruction, colicky pain, hematochezia. Rarely, presents with <i>S bovis</i> ( <i>gallolyticus</i> ) bacteremia.	Right side bleeds; left side obstructs.
DIAGNOSIS	Iron deficiency anemia in males (especially > 50 years old) and postmenopausal females raises suspicion. Screen low-risk patients starting at age 50 with colonoscopy <b>A</b> ; alternatives include flexible sigmoidoscopy, fecal occult blood testing (FOBT), fecal immunochemical testing (FIT), and CT colonography. Patients with a first-degree relative who has colon cancer should be screened via colonoscopy at age 40, or starting 10 years prior to their relative's presentation. Patients with IBD have a distinct screening protocol. “Apple core” lesion seen on barium enema x-ray <b>B</b> . CEA tumor marker: good for monitoring recurrence, should not be used for screening.	






### Molecular pathogenesis of colorectal cancer


Chromosomal instability pathway: mutations in *APC* cause FAP and most sporadic CRC (via adenoma-carcinoma sequence; **(fring)** order of events is **AK-53**).

Microsatellite instability pathway: mutations or methylation of mismatch repair genes (eg, *MLH1*) cause Lynch syndrome and some sporadic CRC (via serrated polyp pathway).

Overexpression of COX-2 has been linked to colorectal cancer, NSAIDs may be chemopreventive.




### Cirrhosis and portal hypertension



**Cirrhosis**—diffuse bridging fibrosis (via stellate cells) and regenerative nodules (red arrows in **A**; white arrows shows splenomegaly) disrupt normal architecture of liver; ↑ risk for hepatocellular carcinoma (HCC). Etiologies include alcohol (60–70% of cases in the US), nonalcoholic steatohepatitis, chronic viral hepatitis, autoimmune hepatitis, biliary disease, genetic/metabolic disorders.

**Portal hypertension**—↑ pressure in portal venous system. Etiologies include cirrhosis (most common cause in Western countries), vascular obstruction (eg, portal vein thrombosis, Budd-Chiari syndrome), schistosomiasis.



**Spontaneous bacterial peritonitis** Also known as 1° bacterial peritonitis. Common and potentially fatal bacterial infection in patients with cirrhosis and ascites. Often asymptomatic, but can cause fevers, chills, abdominal pain, ileus, or worsening encephalopathy. Commonly caused by aerobic gram  $\ominus$  organisms, especially *E coli*. Diagnosis: Paracentesis with ascitic fluid absolute neutrophil count (ANC) > 250 cells/mm<sup>3</sup>.

### Serum markers of liver pathology

#### ENZYMES RELEASED IN LIVER DAMAGE

<b>Aspartate aminotransferase and alanine aminotransferase</b>	<p>↑ in most liver disease: ALT &gt; AST</p> <p>↑ in alcoholic liver disease: AST &gt; ALT</p> <p>AST &gt; ALT in nonalcoholic liver disease suggests progression to advanced fibrosis or cirrhosis</p>
<b>Alkaline phosphatase</b>	↑ in cholestasis (eg, biliary obstruction), infiltrative disorders, bone disease
<b>γ-glutamyl transpeptidase</b>	↑ in various liver and biliary diseases (just as ALP can), but not in bone disease; associated with alcohol use

#### FUNCTIONAL LIVER MARKERS

<b>Bilirubin</b>	↑ in various liver diseases (eg, biliary obstruction, alcoholic or viral hepatitis, cirrhosis), hemolysis
<b>Albumin</b>	↓ in advanced liver disease (marker of liver's biosynthetic function)
<b>Prothrombin time</b>	↑ in advanced liver disease (↓ production of clotting factors, thereby measuring the liver's biosynthetic function)
<b>Platelets</b>	↓ in advanced liver disease (↓ thrombopoietin, liver sequestration) and portal hypertension (splenomegaly/splenic sequestration)

**Reye syndrome** Rare, often fatal childhood hepatic encephalopathy. Findings: mitochondrial abnormalities, fatty liver (microvesicular fatty change), hypoglycemia, vomiting, hepatomegaly, coma. Associated with viral infection (especially VZV and influenza B) that has been treated with aspirin. Mechanism: aspirin metabolites ↓ β-oxidation by reversible inhibition of mitochondrial enzymes. Avoid aspirin in children, except in those with Kawasaki disease.

**Alcoholic liver disease****Hepatic steatosis**

Macrovesicular fatty change **A** that may be reversible with alcohol cessation.



**Alcoholic hepatitis**

Requires sustained, long-term consumption. Swollen and necrotic hepatocytes with neutrophilic infiltration. Mallory bodies **B** (intracytoplasmic eosinophilic inclusions of damaged keratin filaments).

Make a to**AST** with alcohol:  
**AST** > ALT (ratio usually > 2:1).

**Alcoholic cirrhosis**

Final and usually irreversible form. Regenerative nodules surrounded by fibrous bands in response to chronic liver injury → portal hypertension and end-stage liver disease. Sclerosis around central vein (arrows in **C**) may be seen in early disease.

**Nonalcoholic fatty liver disease**

Metabolic syndrome (insulin resistance); obesity → fatty infiltration of hepatocytes **A** → cellular “ballooning” and eventual necrosis. May cause cirrhosis and HCC. Independent of alcohol use.

**ALT** > **AST** (Lipids)

**Hepatic encephalopathy**

Cirrhosis → portosystemic shunts → ↓  $\text{NH}_3$  metabolism → neuropsychiatric dysfunction. Reversible neuropsychiatric dysfunction ranging from disorientation/asterixis (mild) to difficult arousal or coma (severe). Triggers:

- ↑  $\text{NH}_3$  production and absorption (due to dietary protein, GI bleed, constipation, infection).
- ↓  $\text{NH}_3$  removal (due to renal failure, diuretics, bypassed hepatic blood flow post-TIPS).


Treatment: lactulose (↑  $\text{NH}_4^+$  generation) and rifaximin or neomycin (↓  $\text{NH}_3$  producing gut bacteria).

**Hepatocellular carcinoma/hepatoma**


Most common 1° malignant tumor of liver in adults **A**. Associated with HBV (+/- cirrhosis) and all other causes of cirrhosis (including HCV, alcoholic and nonalcoholic fatty liver disease, autoimmune disease, hemochromatosis,  $\alpha_1$ -antitrypsin deficiency) and specific carcinogens (eg, aflatoxin from *Aspergillus*). May lead to Budd-Chiari syndrome.

Findings: jaundice, tender hepatomegaly, ascites, polycythemia, anorexia. Spreads hematogenously.

Diagnosis:  $\uparrow$   $\alpha$ -fetoprotein; ultrasound or contrast CT/MRI **B**, biopsy.

**Other liver tumors****Cavernous hemangioma**

Common, benign liver tumor **A**; typically occurs at age 30–50 years. Biopsy contraindicated because of risk of hemorrhage.

**Hepatic adenoma**

Rare, benign liver tumor, often related to oral contraceptive or anabolic steroid use; may regress spontaneously or rupture (abdominal pain and shock).

**Angiosarcoma**

Malignant tumor of endothelial origin; associated with exposure to arsenic, vinyl chloride.

**Metastases**

GI malignancies, breast and lung cancer. Most common overall; metastases are rarely solitary.


**Budd-Chiari syndrome**


Thrombosis or compression of hepatic veins with centrilobular congestion and necrosis  $\rightarrow$  congestive liver disease (hepatomegaly, ascites, varices, abdominal pain, liver failure). Absence of JVD. Associated with hypercoagulable states, polycythemia vera, postpartum state, HCC. May cause nutmeg liver (mottled appearance).

 **$\alpha_1$ -antitrypsin deficiency**

Misfolded gene product protein aggregates in hepatocellular ER  $\rightarrow$  cirrhosis with PAS  $\oplus$  globules **A** in liver. Codominant trait. Often presents in young patients with liver damage and dyspnea without a history of smoking.

In lungs,  $\downarrow$   $\alpha_1$ -antitrypsin  $\rightarrow$  uninhibited elastase in alveoli  $\rightarrow$   $\downarrow$  elastic tissue  $\rightarrow$  panacinar emphysema.



**Jaundice**

Abnormal yellowing of the skin and/or sclera **A** due to bilirubin deposition. Hyperbilirubinemia 2° to ↑ production or ↓ disposition (impaired hepatic uptake, conjugation, excretion).

**HOT Liver**—common causes of increased levels of bilirubin:  
**H**emolysis  
**O**bstruction  
**T**umor  
**L**iver disease

---

**Unconjugated (indirect) hyperbilirubinemia**

Hemolytic, physiologic (newborns), Crigler-Najjar, Gilbert syndrome.

---

**Conjugated (direct) hyperbilirubinemia**

Biliary tract obstruction: gallstones, cholangiocarcinoma, pancreatic or liver cancer, liver fluke.

Biliary tract disease:

- 1° sclerosing cholangitis
- 1° biliary cholangitis

Excretion defect: Dubin-Johnson syndrome, Rotor syndrome.

---

**Mixed (direct and indirect) hyperbilirubinemia**

Hepatitis, cirrhosis.

---

**Physiologic neonatal jaundice**

At birth, immature UDP-glucuronosyltransferase → unconjugated hyperbilirubinemia → jaundice/kernicterus (deposition of unconjugated, lipid-soluble bilirubin in the brain, particularly basal ganglia).

Occurs after first 24 hours of life and usually resolves without treatment in 1–2 weeks.

Treatment: phototherapy (non-UV) isomerizes unconjugated bilirubin to water-soluble form.

---

**Hereditary hyperbilirubinemias**

All autosomal recessive.

**1 Gilbert syndrome**

Mildly ↓ UDP-glucuronosyltransferase conjugation and impaired bilirubin uptake. Asymptomatic or mild jaundice usually with stress, illness, or fasting. ↑ unconjugated bilirubin without overt hemolysis. Bilirubin ↑ with fasting and stress.

Relatively common, benign condition.

**2 Crigler-Najjar syndrome, type I**


Absent UDP-glucuronosyltransferase. Presents early in life; patients die within a few years. Findings: jaundice, kernicterus (bilirubin deposition in brain), ↑ unconjugated bilirubin. Treatment: plasmapheresis and phototherapy.

Type II is less severe and responds to phenobarbital, which ↑ liver enzyme synthesis.


**3 Dubin-Johnson syndrome**

Conjugated hyperbilirubinemia due to defective liver excretion. Grossly black liver. Benign.

**4 Rotor syndrome** is similar, but milder in presentation without black liver. Due to impaired hepatic uptake and excretion.



### Wilson disease (hepatolenticular degeneration)




Autosomal recessive mutations in hepatocyte copper-transporting ATPase (*ATP7B* gene; chromosome 13) → ↓ copper excretion into bile and incorporation into apoceruloplasmin → ↓ serum ceruloplasmin. Copper accumulates, especially in liver, brain, cornea, kidneys; ↑ urine copper.

Presents before age 40 with liver disease (eg, hepatitis, acute liver failure, cirrhosis), neurologic disease (eg, dysarthria, dystonia, tremor, parkinsonism), psychiatric disease, Kayser-Fleischer rings (deposits in Descemet membrane of cornea) **A**, hemolytic anemia, renal disease (eg, Fanconi syndrome).

Treatment: chelation with penicillamine or trientine, oral zinc.

### Hemochromatosis



Recessive mutations in *HFE* gene (C282Y > H63D, chromosome 6, associated with HLA-A3) → abnormal iron sensing and ↑ intestinal absorption (↑ ferritin, ↑ iron, ↓ TIBC → ↑ transferrin saturation). Iron overload can also be 2° to chronic transfusion therapy (eg, β-thalassemia major). Iron accumulates, especially in liver, pancreas, skin, heart, pituitary, joints. Hemosiderin (iron) can be identified on liver MRI or biopsy with Prussian blue stain **A**.

Presents after age 40 when total body iron > 20 g; iron loss through menstruation slows progression in women. Classic triad of cirrhosis, diabetes mellitus, skin pigmentation (“bronze diabetes”). Also causes restrictive cardiomyopathy (classic) or dilated cardiomyopathy (reversible), hypogonadism, arthropathy (calcium pyrophosphate deposition; especially metacarpophalangeal joints). HCC is common cause of death.



Treatment: repeated phlebotomy, chelation with deferasirox, deferoxamine, oral deferiprone.

### Biliary tract disease

May present with pruritus, jaundice, dark urine, light-colored stool, hepatosplenomegaly. Typically with cholestatic pattern of LFTs (↑ conjugated bilirubin, ↑ cholesterol, ↑ ALP).

	PATHOLOGY	EPIDEMIOLOGY	ADDITIONAL FEATURES
<b>Primary sclerosing cholangitis</b>	Unknown cause of concentric “onion skin” bile duct fibrosis → alternating strictures and dilation with “beading” of intra- and extrahepatic bile ducts on ERCP, magnetic resonance cholangiopancreatography (MRCP).	Classically in middle-aged men with IBD.	Associated with ulcerative colitis. p-ANCA ⊕. ↑ IgM. Can lead to 2° biliary cholangitis. ↑ risk of cholangiocarcinoma and gallbladder cancer.
<b>Primary biliary cholangitis</b>	Autoimmune reaction → lymphocytic infiltrate + granulomas → destruction of intralobular bile ducts.	Classically in middle-aged women.	Anti-mitochondrial antibody ⊕, ↑ IgM. Associated with other autoimmune conditions (eg, Sjögren syndrome, Hashimoto thyroiditis, CREST, rheumatoid arthritis, celiac disease).
<b>Secondary biliary cholangitis</b>	Extrahepatic biliary obstruction → ↑ pressure in intrahepatic ducts → injury/ fibrosis and bile stasis.	Patients with known obstructive lesions (gallstones, biliary strictures, pancreatic carcinoma).	May be complicated by ascending cholangitis.

## Gallstones (cholelithiasis)



↑ cholesterol and/or bilirubin, ↓ bile salts, and gallbladder stasis all cause stones.

2 types of stones:

- Cholesterol stones (radiolucent with 10–20% opaque due to calcifications)—80% of stones. Associated with obesity, Crohn disease, advanced age, estrogen therapy, multiparity, rapid weight loss, Native American origin.
- Pigment stones **A** (black = radiopaque,  $\text{Ca}^{2+}$  bilirubinate, hemolysis; brown = radiolucent, infection). Associated with Crohn disease, chronic hemolysis, alcoholic cirrhosis, advanced age, biliary infections, total parenteral nutrition (TPN).

Most common complication is cholecystitis; can also cause acute pancreatitis, ascending cholangitis.

Risk factors (**4 F**'s):

- F**emale
- F**at
- F**ertile (pregnant)
- F**orty

Diagnose with ultrasound **B**. Treat with elective cholecystectomy if symptomatic.

Can cause fistula between gallbladder and GI tract → air in biliary tree (pneumobilia) → passage of gallstones into intestinal tract → obstruction of ileocecal valve (gallstone ileus).

### RELATED PATHOLOGIES


#### Biliary colic

Associated with nausea/vomiting and dull RUQ pain. Neurohormonal activation (eg, by CCK after a fatty meal) triggers contraction of gallbladder, forcing stone into cystic duct. Labs are normal, ultrasound shows cholelithiasis.

#### Choledocholithiasis

Presence of gallstone(s) in common bile duct, often leading to elevated ALP, GGT, direct bilirubin, and/or AST/ALT.

#### Cholecystitis



Acute or chronic inflammation of gallbladder usually from cholelithiasis (stone at neck of gallbladder [red arrow in **C**] with gallbladder wall thickening [yellow arrows]).


Calculous cholecystitis: most common type; due to gallstone impaction in the cystic duct resulting in inflammation; can produce 2° infection.

Acalculous cholecystitis: due to gallbladder stasis, hypoperfusion, or infection (CMV); seen in critically ill patients.

Murphy sign: inspiratory arrest on RUQ palpation due to pain. ↑ ALP if bile duct becomes involved (eg, ascending cholangitis).

Diagnose with ultrasound or cholescintigraphy (HIDA scan). Failure to visualize gallbladder on HIDA scan suggests obstruction.

#### Porcelain gallbladder



Calcified gallbladder due to chronic cholecystitis; usually found incidentally on imaging **D**.

Treatment: prophylactic cholecystectomy due to high rates of gallbladder cancer (mostly adenocarcinoma).

#### Ascending cholangitis

Infection of biliary tree usually due to obstruction that leads to stasis/bacterial overgrowth.



Charcot triad of cholangitis:

- Jaundice
- Fever
- RUQ pain

Reynolds pentad adds:

- Altered mental status
- Shock (hypotension)




**Acute pancreatitis**

Autodigestion of pancreas by pancreatic enzymes (**A** shows pancreas [yellow arrows] surrounded by edema [red arrows]).

Causes: **I**diopathic, **G**allstones, **E**thanol, **T**rauma, **S**teroids, **M**umps, **A**utoimmune disease, **S**corpion sting, **H**ypercalcemia/**H**ypertriglyceridemia (> 1000 mg/dL), **E**RCP, **D**rugs (eg, sulfa drugs, NRTIs, protease inhibitors). **I GET SMASHED**.

Diagnosis by 2 of 3 criteria: acute epigastric pain often radiating to the back, ↑ serum amylase or lipase (more specific) to 3× upper limit of normal, or characteristic imaging findings.



Complications: pseudocyst **B** (lined by granulation tissue, not epithelium), necrosis, hemorrhage, infection, organ failure (ARDS, shock, renal failure), hypocalcemia (precipitation of Ca<sup>2+</sup> soaps).

**Chronic pancreatitis**

Chronic inflammation, atrophy, calcification of the pancreas **A**. Major causes are alcohol abuse and idiopathic. Complications include pancreatic insufficiency and pseudocysts.

Pancreatic insufficiency may manifest with steatorrhea, fat-soluble vitamin deficiency, diabetes mellitus.

Amylase and lipase may or may not be elevated (almost always elevated in acute pancreatitis).

**Pancreatic adenocarcinoma**

Very aggressive tumor arising from pancreatic ducts (disorganized glandular structure with cellular infiltration **A**); often metastatic at presentation, with average survival ~ 1 year after diagnosis.

Tumors more common in pancreatic head **B** (→ obstructive jaundice). Associated with CA 19-9 tumor marker (also CEA, less specific).

Risk factors:

- Tobacco use
- Chronic pancreatitis (especially > 20 years)
- Diabetes
- Age > 50 years
- Jewish and African-American males


Often presents with:

- Abdominal pain radiating to back
- Weight loss (due to malabsorption and anorexia)
- Migratory thrombophlebitis—redness and tenderness on palpation of extremities (**Trousseau syndrome**)
- Obstructive jaundice with palpable, nontender gallbladder (Courvoisier sign)

Treatment: Whipple procedure, chemotherapy, radiation therapy.

► GASTROINTESTINAL—PHARMACOLOGY

Acid suppression therapy



**H<sub>2</sub> blockers**

Cimetidine, ranitidine, famotidine, nizatidine. Take H<sub>2</sub> blockers before you dine. Think “table for 2” to remember H<sub>2</sub>.

MECHANISM

Reversible block of histamine H<sub>2</sub>-receptors → ↓ H<sup>+</sup> secretion by parietal cells.

CLINICAL USE

Peptic ulcer, gastritis, mild esophageal reflux.

ADVERSE EFFECTS

Cimetidine is a potent inhibitor of cytochrome P-450 (multiple drug interactions); it also has antiandrogenic effects (prolactin release, gynecomastia, impotence, ↓ libido in males); can cross blood-brain barrier (confusion, dizziness, headaches) and placenta. Both cimetidine and ranitidine ↓ renal excretion of creatinine. Other H<sub>2</sub> blockers are relatively free of these effects.

**Proton pump inhibitors**

Omeprazole, lansoprazole, esomeprazole, pantoprazole, dexlansoprazole.

MECHANISM

Irreversibly inhibit H<sup>+</sup>/K<sup>+</sup> ATPase in stomach parietal cells.

CLINICAL USE

Peptic ulcer, gastritis, esophageal reflux, Zollinger-Ellison syndrome, component of therapy for *H. pylori*, stress ulcer prophylaxis.

ADVERSE EFFECTS

↑ risk of *C. difficile* infection, pneumonia. ↓ serum Mg<sup>2+</sup> with long-term use.

**Antacid use** Can affect absorption, bioavailability, or urinary excretion of other drugs by altering gastric and urinary pH or by delaying gastric emptying.  
All can cause hypokalemia.  
Overuse can also cause the following problems.

<b>Aluminum hydroxide</b>	Constipation and hypophosphatemia; proximal muscle weakness, osteodystrophy, seizures	<b>Aluminum</b> amount of feces.
<b>Calcium carbonate</b>	Hypercalcemia (milk-alkali syndrome), rebound acid ↑	Can chelate and ↓ effectiveness of other drugs (eg, tetracycline).
<b>Magnesium hydroxide</b>	Diarrhea, hyporeflexia, hypotension, cardiac arrest	<b>Mg<sup>2+</sup> = Must go to</b> the bathroom.

### Bismuth, sucralfate

MECHANISM	Bind to ulcer base, providing physical protection and allowing HCO <sub>3</sub> <sup>-</sup> secretion to reestablish pH gradient in the mucous layer. Require acidic environment; usually not given with PPIs/H <sub>2</sub> blockers.
CLINICAL USE	↑ ulcer healing, travelers' diarrhea.

### Misoprostol

MECHANISM	A PGE <sub>1</sub> analog. ↑ production and secretion of gastric mucous barrier, ↓ acid production.
CLINICAL USE	Prevention of NSAID-induced peptic ulcers (NSAIDs block PGE <sub>1</sub> production). Also used off-label for induction of labor (ripens cervix).
ADVERSE EFFECTS	Diarrhea. Contraindicated in women of childbearing potential (abortifacient).

### Octreotide

MECHANISM	Long-acting somatostatin analog; inhibits secretion of various splanchnic vasodilatory hormones.
CLINICAL USE	Acute variceal bleeds, acromegaly, VIPoma, carcinoid tumors.
ADVERSE EFFECTS	Nausea, cramps, steatorrhea. ↑ risk of cholelithiasis due to CCK inhibition.

### Sulfasalazine

MECHANISM	A combination of sulfapyridine (antibacterial) and 5-aminosalicylic acid (anti-inflammatory). Activated by colonic bacteria.
CLINICAL USE	Ulcerative colitis, Crohn disease (colitis component).
ADVERSE EFFECTS	Malaise, nausea, sulfonamide toxicity, reversible oligospermia.

### Loperamide

MECHANISM	Agonist at μ-opioid receptors; slows gut motility. Poor CNS penetration (low addictive potential).
CLINICAL USE	Diarrhea.
ADVERSE EFFECTS	Constipation, nausea.

**Ondansetron**

MECHANISM	5-HT <sub>3</sub> antagonist; ↓ vagal stimulation. Powerful central-acting antiemetic.
CLINICAL USE	Control vomiting postoperatively and in patients undergoing cancer chemotherapy.
ADVERSE EFFECTS	Headache, constipation, QT interval prolongation, serotonin syndrome.

**Metoclopramide**

MECHANISM	D <sub>2</sub> receptor antagonist. ↑ resting tone, contractility, LES tone, motility, promotes gastric emptying. Does not influence colon transport time.
CLINICAL USE	Diabetic and postsurgery gastroparesis, antiemetic, persistent GERD..
ADVERSE EFFECTS	↑ parkinsonian effects, tardive dyskinesia. Restlessness, drowsiness, fatigue, depression, diarrhea. Drug interaction with digoxin and diabetic agents. Contraindicated in patients with small bowel obstruction or Parkinson disease (due to D <sub>2</sub> -receptor blockade).

**Orlistat**

MECHANISM	Inhibits gastric and pancreatic lipase → ↓ breakdown and absorption of dietary fats.
CLINICAL USE	Weight loss.
ADVERSE EFFECTS	Steatorrhea, ↓ absorption of fat-soluble vitamins.

**Laxatives**

Indicated for constipation or patients on opiates requiring a bowel regimen

<b>Bulk-forming laxatives</b>	Psyllium, methylcellulose
MECHANISM	Soluble fibers; draw water into gut lumen, forming a viscous liquid that promotes peristalsis
ADVERSE EFFECTS	Bloating
<b>Osmotic laxatives</b>	Magnesium hydroxide, magnesium citrate, polyethylene glycol, lactulose
MECHANISM	Provide osmotic load to draw water into GI lumen Lactulose also treats hepatic encephalopathy because gut flora degrade it into metabolites (lactic acid, acetic acid) that promote nitrogen excretion as NH <sub>4</sub> <sup>+</sup>
ADVERSE EFFECTS	Diarrhea, dehydration; may be abused by bulimics
<b>Stimulants</b>	Senna
MECHANISM	Enteric nerve stimulation → colonic contraction
ADVERSE EFFECTS	Diarrhea, melanosis coli
<b>Emollients</b>	Docusate
MECHANISM	Osmotic draw into lumen → ↑ water absorption by stool
ADVERSE EFFECTS	Diarrhea

**Aprepitant**

MECHANISM	Substance P antagonist. Blocks NK <sub>1</sub> receptors in brain.
CLINICAL USE	Antiemetic for chemotherapy-induced nausea and vomiting.

▶ NOTES

Lined writing area with horizontal lines.

# Hematology and Oncology

*“Of all that is written, I love only what a person has written with his own blood.”*

—Friedrich Nietzsche

*“I used to get stressed out, but my cancer has put everything into perspective.”*

—Delta Goodrem

*“The best blood will at some time get into a fool or a mosquito.”*

—Austin O’Malley


*“Carcinoma works cunningly from the inside out. Detection and treatment often work more slowly and gropingly, from the outside in.”*

—Christopher Hitchens

Study tip: When reviewing oncologic drugs, focus on mechanisms and side effects rather than details of clinical uses, which may be lower yield.

▶ Anatomy	386
▶ Physiology	389
▶ Pathology	394
▶ Pharmacology	413

## ▶ HEMATOLOGY AND ONCOLOGY—ANATOMY

**Erythrocyte**

Carries  $O_2$  to tissues and  $CO_2$  to lungs. Anucleate and lacks organelles; biconcave **A**, with large surface area-to-volume ratio for rapid gas exchange. Life span of 120 days. Source of energy is glucose (90% used in glycolysis, 10% used in HMP shunt). Membrane contains  $Cl^-/HCO_3^-$  antiporter, which allows RBCs to export  $HCO_3^-$  and transport  $CO_2$  from the periphery to the lungs for elimination.

*Eryth* = red; *cyte* = cell.


Erythrocytosis = polycythemia = ↑ hematocrit.

Anisocytosis = varying sizes.

Poikilocytosis = varying shapes.

Reticulocyte = immature RBC; reflects erythroid proliferation.

Bluish color on Wright-Giemsa stain of reticulocytes represents residual ribosomal RNA.

**Thrombocyte (platelet)**

Involved in 1° hemostasis. Small cytoplasmic fragment **A** derived from megakaryocytes. Life span of 8–10 days. When activated by endothelial injury, aggregates with other platelets and interacts with fibrinogen to form platelet plug. Contains dense granules (ADP,  $Ca^{2+}$ ) and  $\alpha$  granules (vWF, fibrinogen, fibronectin). Approximately  $\frac{1}{3}$  of platelet pool is stored in the spleen.

Thrombocytopenia or ↓ platelet function results in petechiae.

vWF receptor: GpIb.

Fibrinogen receptor: GpIIb/IIIa.

**Leukocyte**

Divided into granulocytes (neutrophil, eosinophil, basophil, mast cell) and mononuclear cells (monocytes, lymphocytes). WBC differential count from highest to lowest (normal ranges per USMLE):

**N**eutrophils (~ 60%)

**L**ymphocytes (~ 30%)


**M**onocytes (~ 6%)

**E**osinophils (~ 3%)

**B**asophils (~ 1%)

*Leuk* = white; *cyte* = cell.


**N**eutrophils **L**ike **M**aking **E**verything **B**etter.

**Neutrophil**

Acute inflammatory response cell. Increased in bacterial infections. Phagocytic. Multilobed nucleus **A**. Specific granules contain leukocyte alkaline phosphatase (LAP), collagenase, lysozyme, and lactoferrin. Azurophilic granules (lysosomes) contain proteinases, acid phosphatase, myeloperoxidase, and  $\beta$ -glucuronidase.


Hypersegmented neutrophils (nucleus has 6+ lobes) are seen in vitamin  $B_{12}$ / folate deficiency. ↑ band cells (immature neutrophils) reflect states of ↑ myeloid proliferation (bacterial infections, CML).

Important neutrophil chemotactic agents: C5a, IL-8,  $LTB_4$ , kallikrein, platelet-activating factor.

**Monocyte**


Differentiates into macrophage in tissues. Large, kidney-shaped nucleus **A**. Extensive “frosted glass” cytoplasm.

*Mono* = one (nucleus); *cyte* = cell. Found in blood.

**Macrophage**

Phagocytoses bacteria, cellular debris, and senescent RBCs. Long life in tissues. Macrophages differentiate from circulating blood monocytes **A**. Activated by  $\gamma$ -interferon. Can function as antigen-presenting cell via MHC II.

*Macro* = large; *phage* = eater. Found in tissue. Name differs in each tissue type (eg, Kupffer cells in the liver, histiocytes in connective tissue). Important component of granuloma formation (eg, TB, sarcoidosis). Lipid A from bacterial LPS binds CD14 on macrophages to initiate septic shock.


**Eosinophil**

Defends against helminthic infections (major basic protein). Bilobate nucleus. Packed with large eosinophilic granules of uniform size **A**. Highly phagocytic for antigen-antibody complexes.

Produces histaminase, major basic protein (MBP, a helminthotoxin), eosinophil peroxidase, eosinophil cationic protein, and eosinophil-derived neurotoxin.


*Eosin* = pink dye; *philic* = loving. Causes of eosinophilia = **NAACP**:

- N**eoplasia
- A**sthma
- A**llergic processes
- C**hronic adrenal insufficiency
- P**arasites (invasive)

**Basophil**

Mediates allergic reaction. Densely basophilic granules **A** contain heparin (anticoagulant) and histamine (vasodilator). Leukotrienes synthesized and released on demand.


**Basophilic**—staining readily with **basic** stains. Basophilia is uncommon, but can be a sign of myeloproliferative disease, particularly CML.

**Mast cell**


Mediates allergic reaction in local tissues. Mast cells contain basophilic granules **A** and originate from the same precursor as basophils but are not the same cell type. Can bind the Fc portion of IgE to membrane. IgE cross-links upon antigen binding → degranulation → release of histamine, heparin, tryptase, and eosinophil chemotactic factors.

Involved in type I hypersensitivity reactions. Cromolyn sodium prevents mast cell degranulation (used for asthma prophylaxis).




**Dendritic cell**

Highly phagocytic antigen-presenting cell (APC) **A**. Functions as link between innate and adaptive immune systems. Expresses MHC class II and Fc receptors on surface. Called Langerhans cell in the skin.


**Lymphocyte**

Refers to B cells, T cells, and NK cells. B cells and T cells mediate adaptive immunity. NK cells are part of the innate immune response. Round, densely staining nucleus with small amount of pale cytoplasm **A**.

**B cell**

Part of humoral immune response. Originates from stem cells in bone marrow and matures in marrow. Migrates to peripheral lymphoid tissue (follicles of lymph nodes, white pulp of spleen, unencapsulated lymphoid tissue). When antigen is encountered, B cells differentiate into plasma cells (which produce antibodies) and memory cells. Can function as an APC via MHC II.

**B** = Bone marrow.


**T cell**

Mediates cellular immune response. Originates from stem cells in the bone marrow, but matures in the thymus. T cells differentiate into cytotoxic T cells (express CD8, recognize MHC I), helper T cells (express CD4, recognize MHC II), and regulatory T cells. CD28 (costimulatory signal) necessary for T-cell activation. The majority of circulating lymphocytes are T cells (80%).

**T** is for Thymus.

CD4+ helper T cells are the primary target of HIV.

**Rule of 8:** MHC II  $\times$  CD4 = 8;  
MHC I  $\times$  CD8 = 8.

**Plasma cell**

Produces large amounts of antibody specific to a particular antigen. “Clock-face” chromatin distribution and eccentric nucleus, abundant RER, and well-developed Golgi apparatus (arrows in **A**). Found in bone marrow and normally do not circulate in peripheral blood.

Multiple myeloma is a plasma cell cancer.

## ▶ HEMATOLOGY AND ONCOLOGY—PHYSIOLOGY

**Fetal erythropoiesis**

Fetal erythropoiesis occurs in:

- **Yolk sac** (3–8 weeks)
- **Liver** (6 weeks–birth)
- **Spleen** (10–28 weeks)
- **Bone marrow** (18 weeks to adult)

**Young Liver Synthesizes Blood.**

**Hemoglobin development**

Embryonic globins:  $\zeta$  and  $\epsilon$ .


Fetal hemoglobin (HbF) =  $\alpha_2\gamma_2$ .

Adult hemoglobin (HbA<sub>1</sub>) =  $\alpha_2\beta_2$ .
















HbF has higher affinity for O<sub>2</sub> due to less avid binding of 2,3-BPG, allowing HbF to extract O<sub>2</sub> from maternal hemoglobin (HbA<sub>1</sub> and HbA<sub>2</sub>) across the placenta. HbA<sub>2</sub> ( $\alpha_2\delta_2$ ) is a form of adult hemoglobin present in small amounts.

From fetal to adult hemoglobin:

**Alpha Always; Gamma Goes, Becomes Beta.**



## Blood groups

	ABO classification				Rh classification	
	A	B	AB	O	Rh <sup>+</sup>	Rh <sup>-</sup>
RBC type						
Group antigens on RBC surface	A 	B 	A & B 	NONE	Rh (D) 	NONE
Antibodies in plasma	Anti-B  IgM	Anti-A  IgM	NONE	Anti-A  Anti-B  IgM	NONE	Anti-D  IgG
Clinical relevance	Receive B or AB → hemolytic reaction	Receive A or AB → hemolytic reaction	Universal recipient of RBCs; universal donor of plasma	Receive any non-O → hemolytic reaction Universal donor of RBCs; universal recipient of plasma	Universal recipient of RBCs	Treat mother with anti-D Ig (RhoGAM) during and after each pregnancy to prevent anti-D IgG formation

Rx

**Rh hemolytic disease of the newborn**

IgM does not cross placenta; IgG does cross placenta.


Rh<sup>-</sup> mothers exposed to fetal Rh<sup>+</sup> blood (often during delivery) may make anti-D IgG. In subsequent pregnancies, anti-D IgG crosses the placenta → hemolytic disease of the newborn (erythroblastosis fetalis) in the next fetus that is Rh<sup>+</sup>. Administration of anti-D IgG (RhoGAM) to Rh<sup>-</sup> pregnant women during third trimester and early postpartum period prevents maternal anti-D IgG production.

Rh<sup>-</sup> mothers have anti-D IgG only if previously exposed to Rh<sup>+</sup> blood.

**ABO hemolytic disease of the newborn**

Usually occurs in a type O mother with a type A or B fetus. Can occur in a first pregnancy as maternal anti-A and/or anti-B IgG antibodies may be formed prior to pregnancy. Does not worsen with future pregnancies. Presents as mild jaundice in the neonate within 24 hours of birth; treatment is phototherapy or exchange transfusion.


**Hemoglobin electrophoresis**



On a gel, hemoglobin migrates from the negatively charged cathode to the positively charged anode. HbA migrates the farthest, followed by HbF, HbS, and HbC. This is because the missense mutations in HbS and HbC replace glutamic acid  $\ominus$  with valine (neutral) and lysine  $\oplus$ , respectively, impacting the net protein charge.


**A Fat Santa Claus**

**Coagulation and kinin pathways**




## Coagulation cascade components

### Procoagulation



### Anticoagulation



Warfarin inhibits the enzyme vitamin K epoxide reductase.

Neonates lack enteric bacteria, which produce vitamin K.

**Vitamin K deficiency:** ↓ synthesis of factors II, VII, IX, X, protein C, protein S.

**vWF** carries/protects **VIII** (volksWagen

**F**actories make **gr8** (great) cars.


Antithrombin inhibits activated forms of factors II, VII, IX, X, XI, XII.

Heparin enhances the activity of antithrombin. Principal targets of antithrombin: thrombin and factor Xa.

Factor V Leiden mutation produces a factor V resistant to inhibition by activated protein C.

tPA is used clinically as a thrombolytic.

**Platelet plug formation (primary hemostasis)**



**Thrombogenesis**


Formation of insoluble fibrin mesh.

Aspirin irreversibly inhibits cyclooxygenase, thereby inhibiting TXA<sub>2</sub> synthesis.

Clopidogrel, prasugrel, and ticlopidine inhibit ADP-induced expression of GpIIb/IIIa via P2Y<sub>12</sub> receptor.








Abciximab, eptifibatide, and tirofiban inhibit GpIIb/IIIa directly.

Ristocetin activates vWF to bind GpIb. Failure of aggregation with ristocetin assay occurs in von Willebrand disease and Bernard-Soulier syndrome.








## ▶ HEMATOLOGY AND ONCOLOGY—PATHOLOGY


## Pathologic RBC forms

TYPE	EXAMPLE	ASSOCIATED PATHOLOGY	NOTES
<b>Acanthocyte</b> ("spur cell") <b>A</b>		Liver disease, abetalipoproteinemia (states of cholesterol dysregulation).	<i>Acantho</i> = spiny.
<b>Basophilic stippling</b> <b>B</b>		Lead poisoning, sideroblastic anemias, myelodysplastic syndromes.	Seen primarily in peripheral smear, vs ringed sideroblasts seen in bone marrow. Aggregation of residual ribosomes.
<b>Dacryocyte</b> ("teardrop cell") <b>C</b>		Bone marrow infiltration (eg, myelofibrosis).	RBC "sheds a <b>tear</b> " because it's mechanically squeezed out of its home in the bone marrow.
<b>Degmacyte</b> ("bite cell") <b>D</b>		G6PD deficiency.	
<b>Echinocyte</b> ("burr cell") <b>E</b>		End-stage renal disease, liver disease, pyruvate kinase deficiency.	Different from acanthocyte; its projections are more uniform and smaller.
<b>Elliptocyte</b> <b>F</b>		Hereditary elliptocytosis, usually asymptomatic; caused by mutation in genes encoding RBC membrane proteins (eg, spectrin).	
<b>Macro-ovalocyte</b> <b>G</b>		Megaloblastic anemia (also hypersegmented PMNs).	

## Pathologic RBC forms (continued)


TYPE	EXAMPLE	ASSOCIATED PATHOLOGY	NOTES
<b>Ringed sideroblast</b> <b>H</b>		Sideroblastic anemia. Excess iron in mitochondria.	Seen in bone marrow, vs basophilic stippling in peripheral smear.
<b>Schistocyte</b> <b>I</b>		Microangiopathic hemolytic anemias, including DIC, TTP/HUS, HELLP syndrome, mechanical hemolysis (eg, heart valve prosthesis).	Fragmented RBCs. Examples include helmet cell.
<b>Sickle cell</b> <b>J</b>		Sickle cell anemia.	Sickling occurs with dehydration, deoxygenation, and at high altitude.
<b>Spherocyte</b> <b>K</b>		Hereditary spherocytosis, drug- and infection-induced hemolytic anemia.	
<b>Target cell</b> <b>L</b>		HbC disease, Asplenia, Liver disease, Thalassemia.	“ <b>HALT</b> ,” said the hunter to his <b>target</b> .

## Other RBC abnormalities

TYPE	EXAMPLE	ASSOCIATED PATHOLOGY	NOTES
<b>Heinz bodies</b> <b>A</b>		Seen in G6PD deficiency.	Oxidation of Hb -SH groups to -S-S- → Hb precipitation (Heinz bodies), with subsequent phagocytic damage to RBC membrane → bite cells.
<b>Howell-Jolly bodies</b> <b>B</b>		Seen in patients with functional hyposplenia or asplenia.	Basophilic nuclear remnants found in RBCs. Howell-Jolly bodies are normally removed from RBCs by splenic macrophages.



## Anemias



On a peripheral blood smear, a lymphocyte nucleus is approximately the same size as a normocytic RBC. If RBC is larger than lymphocyte nucleus, consider macrocytosis; if RBC is smaller, consider microcytosis.

<sup>a</sup>Copper deficiency can cause a microcytic sideroblastic anemia.

<sup>b</sup>Corrected reticulocyte count (% reticulocytes × [patient hematocrit/normal hematocrit]) is used to determine if bone marrow response is adequate (> 2%).

## Microcytic (MCV &lt; 80 fL), hypochromic anemia

## Iron deficiency

↓ iron due to chronic bleeding (eg, GI loss, menorrhagia), malnutrition, absorption disorders, GI surgery (eg, gastrectomy), or ↑ demand (eg, pregnancy) → ↓ final step in heme synthesis.

Labs: ↓ iron, ↑ TIBC, ↓ ferritin, ↑ free erythrocyte protoporphyrin. Microcytosis and hypochromasia (central pallor) **A**.

Symptoms: fatigue, conjunctival pallor **B**, pica (consumption of nonfood substances), spoon nails (koilonychia).

May manifest as glossitis, cheilosis, **Plummer-Vinson syndrome** (triad of iron deficiency anemia, esophageal webs, and dysphagia).

## α-thalassemia

Defect: α-globin gene deletions → ↓ α-globin synthesis. *cis* deletion (both deletions occur on same chromosome) prevalent in Asian populations; *trans* deletion (deletions occur on separate chromosomes) prevalent in African populations.

4 allele deletion: no α-globin. Excess γ-globin forms γ<sub>4</sub> (Hb Barts). Incompatible with life (causes hydrops fetalis).

3 allele deletion: inheritance of chromosome with *cis* deletion + a chromosome with 1 allele deleted → HbH disease. Very little α-globin. Excess β-globin forms β<sub>4</sub> (HbH).

2 allele deletion: less clinically severe anemia.

1 allele deletion: no anemia (clinically silent).

**Microcytic (MCV < 80 fL), hypochromic anemia (continued)****β-thalassemia**

Point mutations in splice sites and promoter sequences → ↓ β-globin synthesis. Prevalent in Mediterranean populations.

**β-thalassemia minor** (heterozygote): β chain is underproduced. Usually asymptomatic. Diagnosis confirmed by ↑ HbA<sub>2</sub> (> 3.5%) on electrophoresis.

**β-thalassemia major** (homozygote): β chain is absent → severe microcytic, hypochromic anemia with target cells and increased anisopoikilocytosis **C** requiring blood transfusion (2° hemochromatosis). Marrow expansion (“crew cut” on skull x-ray) → skeletal deformities. “Chipmunk” facies. Extramedullary hematopoiesis → hepatosplenomegaly. ↑ risk of parvovirus B19–induced aplastic crisis. ↑ HbF (α<sub>2</sub>γ<sub>2</sub>). HbF is protective in the infant and disease becomes symptomatic only after 6 months, when fetal hemoglobin declines.

**HbS/β-thalassemia heterozygote**: mild to moderate sickle cell disease depending on amount of β-globin production.

**Lead poisoning**

Lead inhibits ferrochelatase and ALA dehydratase → ↓ heme synthesis and ↑ RBC protoporphyrin. Also inhibits rRNA degradation → RBCs retain aggregates of rRNA (basophilic stippling).

Symptoms of **LEAD** poisoning:

- **L**ead **L**ines on gingivae (Burton lines) and on metaphyses of long bones **D** on x-ray.
- **E**ncephalopathy and **E**rythrocyte basophilic stippling.
- **A**bdominal colic and sideroblastic **A**nemia.
- **D**rops—wrist and foot drop. **D**imercaprol and **E**DTA are 1st line of treatment.

**Succimer** used for chelation for kids (It “sucks” to be a kid who eats lead).

Exposure risk ↑ in old houses with chipped paint.

**Sideroblastic anemia**


Causes: genetic (eg, X-linked defect in ALA synthase gene), acquired (myelodysplastic syndromes), and reversible (alcohol is most common; also lead, vitamin B<sub>6</sub> deficiency, copper deficiency, isoniazid).

Lab findings: ↑ iron, normal/↓ TIBC, ↑ ferritin. Ringed sideroblasts (with iron-laden, Prussian blue–stained mitochondria) seen in bone marrow **E**. Peripheral blood smear: basophilic stippling of RBCs.

Treatment: pyridoxine (B<sub>6</sub>, cofactor for ALA synthase).



**Macrocytic (MCV > 100 fL) anemia**

	DESCRIPTION	FINDINGS
<b>Megaloblastic anemia</b> 	Impaired DNA synthesis → maturation of nucleus of precursor cells in bone marrow delayed relative to maturation of cytoplasm.	RBC macrocytosis, hypersegmented neutrophils <b>A</b> , glossitis.
<b>Folate deficiency</b>	Causes: malnutrition (eg, alcoholics), malabsorption, drugs (eg, methotrexate, trimethoprim, phenytoin), ↑ requirement (eg, hemolytic anemia, pregnancy).	↑ homocysteine, normal methylmalonic acid. <b>No neurologic symptoms</b> (vs B <sub>12</sub> deficiency).
<b>Vitamin B<sub>12</sub> (cobalamin) deficiency</b>	Causes: insufficient intake (eg, veganism), malabsorption (eg, Crohn disease), pernicious anemia, <i>Diphyllobothrium latum</i> (fish tapeworm), gastrectomy.	↑ homocysteine, ↑ methylmalonic acid. <b>Neurologic symptoms:</b> reversible dementia, subacute combined degeneration (due to involvement of B <sub>12</sub> in fatty acid pathways and myelin synthesis): spinocerebellar tract, lateral corticospinal tract, dorsal column dysfunction. Historically diagnosed with the Schilling test, a 4-stage test that determines if the cause is dietary insufficiency vs malabsorption. Anemia 2° to insufficient intake may take several years to develop due to liver's ability to store B <sub>12</sub> (as opposed to folate deficiency).
<b>Orotic aciduria</b>	Inability to convert orotic acid to UMP (de novo pyrimidine synthesis pathway) because of defect in UMP synthase. Autosomal recessive. Presents in children as failure to thrive, developmental delay, and megaloblastic anemia refractory to folate and B <sub>12</sub> . No hyperammonemia (vs ornithine transcarbamylase deficiency—↑ orotic acid with hyperammonemia).	Orotic acid in urine. Treatment: uridine monophosphate to bypass mutated enzyme.
<b>Nonmegaloblastic anemia</b>	Macrocytic anemia in which DNA synthesis is unimpaired. Causes: alcoholism, liver disease.	RBC macrocytosis without hypersegmented neutrophils.
<b>Diamond-Blackfan anemia</b>	Rapid-onset anemia within 1st year of life due to intrinsic defect in erythroid progenitor cells.	↑ % HbF (but ↓ total Hb). Short stature, craniofacial abnormalities, and upper extremity malformations (triphalangeal thumbs) in up to 50% of cases.

**Normocytic, normochromic anemia**

Normocytic, normochromic anemias are classified as nonhemolytic or hemolytic. The hemolytic anemias are further classified according to the cause of the hemolysis (intrinsic vs extrinsic to the RBC) and by the location of the hemolysis (intravascular vs extravascular). Hemolysis can lead to increases in LDH, reticulocytes, unconjugated bilirubin, urobilinogen in urine.

**Intravascular hemolysis**


Findings: ↓ haptoglobin, ↑ schistocytes on blood smear. Characteristic hemoglobinuria, hemosiderinuria, and urobilinogen in urine. May also see ↑ unconjugated bilirubin. Notable causes are mechanical hemolysis (eg, prosthetic valve), paroxysmal nocturnal hemoglobinuria, microangiopathic hemolytic anemias.

**Extravascular hemolysis**

Findings: macrophages in spleen clear RBCs. Spherocytes in peripheral smear (most commonly hereditary spherocytosis and autoimmune hemolytic anemia), no hemoglobinuria/hemosiderinuria. Can present with urobilinogen in urine.


**Nonhemolytic, normocytic anemia**

	DESCRIPTION	FINDINGS
<b>Anemia of chronic disease</b>	Inflammation → ↑ hepcidin (released by liver, binds ferroportin on intestinal mucosal cells and macrophages, thus inhibiting iron transport) → ↓ release of iron from macrophages and ↓ iron absorption from gut. Associated with conditions such as rheumatoid arthritis, SLE, neoplastic disorders, and chronic kidney disease.	↓ iron, ↓ TIBC, ↑ ferritin. Normocytic, but can become microcytic. Treatment: address underlying cause of inflammation, judicious use of blood transfusion, consider erythropoiesis-stimulating agents (ESAs) such as EPO (chronic kidney disease only).
<b>Aplastic anemia</b>	Caused by failure or destruction of myeloid stem cells due to: <ul style="list-style-type: none"> <li>▪ Radiation and drugs (benzene, chloramphenicol, alkylating agents, antimetabolites)</li> <li>▪ Viral agents (parvovirus B19, EBV, HIV, hepatitis viruses)</li> <li>▪ Fanconi anemia (DNA repair defect causing bone marrow failure; macrocytosis may be seen on CBC); also short stature, ↑ incidence of tumors/leukemia, café-au-lait spots, thumb/radial defects</li> <li>▪ Idiopathic (immune mediated, 1° stem cell defect); may follow acute hepatitis</li> </ul>	↓ reticulocyte count, ↑ EPO. Pancytopenia characterized by severe anemia, leukopenia, and thrombocytopenia. Normal cell morphology, but hypocellular bone marrow with fatty infiltration <b>A</b> (dry bone marrow tap). Symptoms: fatigue, malaise, pallor, purpura, mucosal bleeding, petechiae, infection. Treatment: withdrawal of offending agent, immunosuppressive regimens (eg, antithymocyte globulin, cyclosporine), bone marrow allograft, RBC/platelet transfusion, bone marrow stimulation (eg, GM-CSF).




## Intrinsic hemolytic anemia

	DESCRIPTION	FINDINGS
<b>Hereditary spherocytosis</b>	Extravascular hemolysis due to defect in proteins interacting with RBC membrane skeleton and plasma membrane (eg, ankyrin, band 3, protein 4.2, spectrin). Mostly autosomal dominant inheritance. Results in small, round RBCs with less surface area and no central pallor (↑ MCHC) → premature removal by spleen.	Splenomegaly, aplastic crisis (parvovirus B19 infection). Labs: osmotic fragility test ⊕. Normal to ↓ MCV with abundance of cells. Treatment: splenectomy.
<b>G6PD deficiency</b>	Most common enzymatic disorder of RBCs. Causes extravascular and intravascular hemolysis. X-linked recessive. Defect in G6PD → ↓ glutathione → ↑ RBC susceptibility to oxidant stress. Hemolytic anemia following oxidant stress (eg, sulfa drugs, antimalarials, infections, <b>fava beans</b> ).	Back pain, hemoglobinuria a few days after oxidant <b>stress</b> . Labs: blood smear shows RBCs with <b>Heinz</b> bodies and <b>bite</b> cells. “ <b>Stress</b> makes me eat <b>bites</b> of <b>fava beans</b> with <b>Heinz</b> ketchup.”
<b>Pyruvate kinase deficiency</b>	Autosomal recessive pyruvate kinase defect → ↓ ATP → rigid RBCs → extravascular hemolysis. Increases levels of 2,3-BPG → ↓ hemoglobin affinity for O <sub>2</sub> .	Hemolytic anemia in a newborn.
<b>Paroxysmal nocturnal hemoglobinuria</b>	↑ complement-mediated intravascular RBC lysis (impaired synthesis of GPI anchor for decay-accelerating factor that protects RBC membrane from complement). Acquired mutation in a hematopoietic stem cell. ↑ incidence of acute leukemias. Patients may report red or pink urine (from hemoglobinuria).	Associated with aplastic anemia. Triad: Coombs ⊖ hemolytic anemia, pancytopenia, and venous thrombosis. Labs: CD55/59 ⊖ RBCs on flow cytometry. Treatment: eculizumab (terminal complement inhibitor).
<b>Sickle cell anemia</b>	HbS point mutation causes a single amino acid replacement in β chain (substitution of glutamic acid with valine). Causes extravascular and intravascular hemolysis. Pathogenesis: low O <sub>2</sub> , high altitude, or acidosis precipitates sickling (deoxygenated HbS polymerizes) → anemia, vaso-occlusive disease. Newborns are initially asymptomatic because of ↑ HbF and ↓ HbS. Heterozygotes (sickle cell trait) also have resistance to malaria. 8% of African Americans carry an HbS allele. Sickle cells are crescent-shaped RBCs <b>A</b> . “Crew cut” on skull x-ray due to marrow expansion from ↑ erythropoiesis (also seen in thalassemias).	Complications in sickle cell disease: <ul style="list-style-type: none"> <li>▪ Aplastic crisis (due to parvovirus B19).</li> <li>▪ Autosplenectomy (Howell-Jolly bodies) → ↑ risk of infection by encapsulated organisms (eg, <i>S pneumoniae</i>).</li> <li>▪ Splenic infarct/sequestration crisis.</li> <li>▪ <i>Salmonella</i> osteomyelitis.</li> <li>▪ Painful crises (vaso-occlusive): dactylitis <b>B</b> (painful swelling of hands/feet), priapism, acute chest syndrome, avascular necrosis, stroke.</li> <li>▪ Renal papillary necrosis (↓ Po<sub>2</sub> in papilla) and microhematuria (medullary infarcts).</li> </ul> Diagnosis: hemoglobin electrophoresis. Treatment: hydroxyurea (↑ HbF), hydration.
<b>HbC disease</b>	Glutamic acid-to-lyCine (lysine) mutation in β-globin. Causes extravascular hemolysis.	Patients with HbSC (1 of each mutant gene) have milder disease than HbSS patients. Blood smear in homozygotes: hemoglobin <b>C</b> crystals inside RBCs, target cells.



**Extrinsic hemolytic anemia**

**Autoimmune hemolytic anemia**



DESCRIPTION

**Warm (IgG)**—chronic anemia seen in SLE and CLL and with certain drugs (eg,  $\alpha$ -methyl dopa) (“**w**arm weather is **G**reat”).  
**Cold (IgM and complement)**—acute anemia triggered by cold; seen in CLL, *Mycoplasma pneumoniae* infections, and infectious **M**ononucleosis (“**c**old weather is **M**MMiserable”). RBC agglutinates **A** may cause painful, blue fingers and toes with cold exposure.  
 Many warm and cold AIHAs are idiopathic in etiology.

FINDINGS

Autoimmune hemolytic anemias are usually Coombs  $\oplus$ .  
 Direct Coombs test—anti-Ig antibody (Coombs reagent) added to patient’s RBCs. RBCs agglutinate if RBCs are coated with Ig.  
 Indirect Coombs test—normal RBCs added to patient’s serum. If serum has anti-RBC surface Ig, RBCs agglutinate when Coombs reagent added.

	Patient component	Reagent(s)	$\oplus$ Result (agglutination)	$\ominus$ Result (no agglutination)
Direct Coombs	 RBCs +/- anti-RBC Ab	 Anti-human globulin (Coombs reagent)	 $\oplus$ Result Anti-RBC Ab present	 $\ominus$ Result Anti-RBC Ab absent
			 Patient serum +/- anti-donor RBC Ab	 Donor blood Anti-human globulin (Coombs reagent)

**Microangiopathic anemia**

Pathogenesis: RBCs are damaged when passing through obstructed or narrowed vessel lumina. Seen in DIC, TTP/HUS, SLE, HELLP syndrome, and malignant hypertension.

**Schistocytes** (eg, “helmet cells”) are seen on peripheral blood smear due to mechanical destruction (*schisto* = to split) of RBCs.

**Macroangiopathic anemia**

Prosthetic heart valves and aortic stenosis may also cause hemolytic anemia 2° to mechanical destruction of RBCs.

Schistocytes on peripheral blood smear.

**Infections**

$\uparrow$  destruction of RBCs (eg, malaria, *Babesia*).

**Lab values in anemia**

	Iron deficiency	Chronic disease	Hemo-chromatosis	Pregnancy/OCP use
Serum iron	↓	↓	↑	—
Transferrin or TIBC	↑	↓ <sup>a</sup>	↓	↑
Ferritin	↓	↑	↑	—
% transferrin saturation (serum iron/TIBC)	↓↓	—	↑↑	↓

↑↓ = 1° disturbance.

**Transferrin**—**transports** iron in blood.

TIBC—indirectly measures transferrin.

Ferritin—1° iron storage protein of body.

<sup>a</sup>Evolutionary reasoning—pathogens use circulating iron to thrive. The body has adapted a system in which iron is stored within the cells of the body and prevents pathogens from acquiring circulating iron.

**Leukopenias**

CELL TYPE	CELL COUNT	CAUSES
<b>Neutropenia</b>	Absolute neutrophil count < 1500 cells/mm <sup>3</sup> . Severe infections typical when < 500 cells/mm <sup>3</sup> .	Sepsis/postinfection, drugs (including chemotherapy), aplastic anemia, SLE, radiation
<b>Lymphopenia</b>	Absolute lymphocyte count < 1500 cells/mm <sup>3</sup> (< 3000 cells/mm <sup>3</sup> in children)	HIV, DiGeorge syndrome, SCID, SLE, corticosteroids, <sup>a</sup> radiation, sepsis, postoperative
<b>Eosinopenia</b>	Absolute eosinophil count < 30 cells/mm <sup>3</sup>	Cushing syndrome, corticosteroids <sup>a</sup>

<sup>a</sup>Corticosteroids cause neutrophilia, despite causing eosinopenia and lymphopenia. Corticosteroids ↓ activation of neutrophil adhesion molecules, impairing migration out of the vasculature to sites of inflammation. In contrast, corticosteroids sequester eosinophils in lymph nodes and cause apoptosis of lymphocytes.



**Left shift**


↑ neutrophil precursors, such as band cells and metamyelocytes, in peripheral blood. Usually seen with neutrophilia in the acute response to infection or inflammation. Called **leukoerythroblastic reaction** when left shift is seen with immature RBCs. Occurs with severe anemia (physiologic response) or marrow response (eg, fibrosis, tumor taking up space in marrow).

A **left shift** is a shift to a more **immature** cell in the maturation process.

**Heme synthesis, porphyrias, and lead poisoning**

The porphyrias are hereditary or acquired conditions of defective heme synthesis that lead to the accumulation of heme precursors. Lead inhibits specific enzymes needed in heme synthesis, leading to a similar condition.

CONDITION	AFFECTED ENZYME	ACCUMULATED SUBSTRATE	PRESENTING SYMPTOMS
<p><b>Lead poisoning</b></p> 	Ferrochelatase and ALA dehydratase	Protoporphyrin, ALA (blood)	<p>Microcytic anemia (basophilic stippling in peripheral smear <b>A</b>, ringed sideroblasts in bone marrow), GI and kidney disease.</p> <p>Children—exposure to lead paint → mental deterioration.</p> <p>Adults—environmental exposure (eg, batteries, ammunition) → headache, memory loss, demyelination.</p>
<p><b>Acute intermittent porphyria</b></p>	Porphobilinogen deaminase, previously known as uroporphyrinogen I synthase (autosomal dominant mutation)	Porphobilinogen, ALA	<p>Symptoms (<b>5 P's</b>):</p> <ul style="list-style-type: none"> <li>▪ Painful abdomen</li> <li>▪ Port wine–colored urine</li> <li>▪ Polyneuropathy</li> <li>▪ Psychological disturbances</li> <li>▪ Precipitated by drugs (eg, cytochrome P-450 inducers), alcohol, starvation</li> </ul> <p>Treatment: glucose and heme, which inhibit ALA synthase.</p>
<p><b>Porphyria cutanea tarda</b></p> 	Uroporphyrinogen decarboxylase (autosomal dominant mutation)	Uroporphyrin (tea-colored urine)	<p>Blistering cutaneous photosensitivity and hyperpigmentation <b>B</b>.</p> <p>Most common porphyria. Exacerbated with alcohol consumption.</p>



↓ heme → ↑ ALA synthase activity  
 ↑ heme → ↓ ALA synthase activity



**Iron poisoning**

High mortality rate with accidental ingestion by children (adult iron tablets may look like candy).

**MECHANISM**

Cell death due to peroxidation of membrane lipids.

**SYMPTOMS/SIGNS**

Nausea, vomiting, gastric bleeding, lethargy, scarring leading to GI obstruction.

**TREATMENT**


Chelation (eg, IV deferoxamine, oral deferasirox) and dialysis.

**Coagulation disorders**

PT—tests function of common and extrinsic pathway (factors I, II, V, VII, and X). Defect → ↑ PT. INR (international normalized ratio)—calculated from PT. 1 = normal, > 1 = prolonged. Most common test used to follow patients on warfarin.

PTT—tests function of common and intrinsic pathway (all factors except VII and XIII). Defect → ↑ PTT.

Coagulation disorders can be due to clotting factor deficiencies or acquired inhibitors. Diagnosed with a mixing study, in which normal plasma is added to patient's plasma. Clotting factor deficiencies should correct (the PT or PTT returns to within the appropriate normal range), whereas factor inhibitors will not correct.

DISORDER	PT	PTT	MECHANISM AND COMMENTS
<b>Hemophilia A, B, or C</b> 	—	↑	Intrinsic pathway coagulation defect. <ul style="list-style-type: none"> <li>▪ A: deficiency of factor VIII → ↑ PTT; X-linked recessive.</li> <li>▪ B: deficiency of factor IX → ↑ PTT; X-linked recessive.</li> <li>▪ C: deficiency of factor XI → ↑ PTT; autosomal recessive.</li> </ul> Macrohemorrhage in hemophilia—hemarthroses (bleeding into joints, such as knee <b>A</b> ), easy bruising, bleeding after trauma or surgery (eg, dental procedures). Treatment: desmopressin + factor VIII concentrate (A); factor IX concentrate (B); factor XI concentrate (C).
<b>Vitamin K deficiency</b>	↑	↑	General coagulation defect. Bleeding time normal. ↓ activity of factors II, VII, IX, X, protein C, protein S.

**Platelet disorders**

Defects in platelet plug formation → ↑ bleeding time (BT).

Platelet abnormalities → microhemorrhage: mucous membrane bleeding, epistaxis, petechiae, purpura, ↑ bleeding time, possibly decreased platelet count (PC).

DISORDER	PC	BT	MECHANISM AND COMMENTS
<b>Bernard-Soulier syndrome</b>	–/↓	↑	Defect in platelet plug formation. Large platelets. ↓ GpIb → defect in platelet-to-vWF adhesion.
<b>Glanzmann thrombasthenia</b>	–	↑	Defect in platelet integrin $\alpha_{IIb}\beta_3$ (GpIIb/IIIa) → defect in platelet-to-platelet aggregation, and therefore platelet plug formation. Labs: blood smear shows no platelet clumping.
<b>Hemolytic-uremic syndrome</b>	↓	↑	Characterized by thrombocytopenia, microangiopathic hemolytic anemia, and acute renal failure. Typical HUS is seen in children, accompanied by diarrhea and commonly caused by enterohemorrhagic <i>E coli</i> (EHEC) (eg, O157:H7). HUS in adults does not present with diarrhea; EHEC infection not required. Same spectrum as TTP, with a similar clinical presentation and same initial treatment of plasmapheresis.
<b>Immune thrombocytopenia</b>	↓	↑	Anti-GpIIb/IIIa antibodies → splenic macrophage consumption of platelet-antibody complex. May be 1° (idiopathic) or 2° to autoimmune disorder, viral illness, malignancy, or drug reaction. Labs: ↑ megakaryocytes on bone marrow biopsy. Treatment: steroids, IVIG, splenectomy (for refractory ITP).
<b>Thrombotic thrombocytopenic purpura</b>	↓	↑	Inhibition or deficiency of ADAMTS 13 (vWF metalloprotease) → ↓ degradation of vWF multimers. Pathogenesis: ↑ large vWF multimers → ↑ platelet adhesion → ↑ platelet aggregation and thrombosis. Labs: schistocytes, ↑ LDH, normal coagulation parameters. Symptoms: pentad of neurologic and renal symptoms, fever, thrombocytopenia, and microangiopathic hemolytic anemia. Treatment: plasmapheresis, steroids.

**Mixed platelet and coagulation disorders**

DISORDER	PC	BT	PT	PTT	MECHANISM AND COMMENTS
<b>von Willebrand disease</b>	—	↑	—	—/↑	<p>Intrinsic pathway coagulation defect: ↓ vWF → ↑ PTT (vWF acts to carry/protect factor VIII).</p> <p>Defect in platelet plug formation: ↓ vWF → defect in platelet-to-vWF adhesion.</p> <p>Autosomal dominant. Mild but most common inherited bleeding disorder. No platelet aggregation with ristocetin cofactor assay.</p> <p>Treatment: desmopressin, which releases vWF stored in endothelium.</p>
<b>Disseminated intravascular coagulation</b>	↓	↑	↑	↑	<p>Widespread activation of clotting → deficiency in clotting factors → bleeding state.</p> <p>Causes: <b>S</b>epsis (gram ⊖), <b>T</b>rauma, <b>O</b>bstetric complications, acute <b>P</b>ancreatitis, <b>M</b>alignancy, <b>N</b>ephrotic syndrome, <b>T</b>ransfusion (<b>STOP Making New Thrombi</b>).</p> <p>Labs: schistocytes, ↑ fibrin degradation products (D-dimers), ↓ fibrinogen, ↓ factors V and VIII.</p>

**Hereditary thrombosis syndromes leading to hypercoagulability**

DISEASE	DESCRIPTION
<b>Antithrombin deficiency</b>	<p>Inherited deficiency of antithrombin: has no direct effect on the PT, PTT, or thrombin time but diminishes the increase in PTT following heparin administration.</p> <p>Can also be acquired: renal failure/nephrotic syndrome → antithrombin loss in urine → ↓ inhibition of factors IIa and Xa.</p>
<b>Factor V Leiden</b>	<p>Production of mutant factor V (G → A DNA point mutation → Arg506Gln mutation near the cleavage site) that is resistant to degradation by activated protein C. Most common cause of inherited hypercoagulability in Caucasians. Complications include DVT, cerebral vein thromboses, recurrent pregnancy loss.</p>
<b>Protein C or S deficiency</b>	<p>↓ ability to inactivate factors Va and VIIIa. ↑ risk of thrombotic skin necrosis with hemorrhage after administration of warfarin. If this occurs, think protein C deficiency. Together, protein <b>C</b> Cancels, and protein <b>S</b> Stops, coagulation.</p>
<b>Prothrombin gene mutation</b>	<p>Mutation in 3' untranslated region → ↑ production of prothrombin → ↑ plasma levels and venous clots.</p>

**Blood transfusion therapy**

COMPONENT	DOSAGE EFFECT	CLINICAL USE
<b>Packed RBCs</b>	↑ Hb and O <sub>2</sub> carrying capacity	Acute blood loss, severe anemia
<b>Platelets</b>	↑ platelet count (↑ ~ 5000/mm <sup>3</sup> /unit)	Stop significant bleeding (thrombocytopenia, qualitative platelet defects)
<b>Fresh frozen plasma/ prothrombin complex concentrate</b>	↑ coagulation factor levels	DIC, cirrhosis, immediate anticoagulation reversal
<b>Cryoprecipitate</b>	Contains fibrinogen, factor VIII, factor XIII, vWF, and fibronectin	Coagulation factor deficiencies involving fibrinogen and factor VIII


Blood transfusion risks include infection transmission (low), transfusion reactions, iron overload (may lead to 2° hemochromatosis), hypocalcemia (citrate is a Ca<sup>2+</sup> chelator), and hyperkalemia (RBCs may lyse in old blood units).

**Leukemia vs lymphoma**

<b>Leukemia</b>	Lymphoid or myeloid neoplasm with widespread involvement of bone marrow. Tumor cells are usually found in peripheral blood.
<b>Lymphoma</b>	Discrete tumor mass arising from lymph nodes. Presentations often blur definitions.

**Hodgkin vs non-Hodgkin lymphoma**

Hodgkin	Non-Hodgkin
Both may present with constitutional (“B”) signs/symptoms: low-grade fever, night sweats, weight loss (patients are <b>B</b> othered by <b>B</b> symptoms).	
Localized, single group of nodes; contiguous spread (stage is strongest predictor of prognosis). Overall prognosis better than that of non-Hodgkin lymphoma.	Multiple lymph nodes involved; extranodal involvement common; noncontiguous spread.
Characterized by Reed-Sternberg cells.	Majority involve B cells; a few are of T-cell lineage.
Bimodal distribution—young adulthood and > 55 years; more common in men except for nodular sclerosing type.	Can occur in children and adults.
Associated with EBV.	May be associated with HIV and autoimmune diseases.



**Hodgkin lymphoma**

Contains Reed-Sternberg cells: distinctive tumor giant cells; binucleate or bilobed with the 2 halves as mirror images (“owl eyes” **A**). 2 owl eyes × 15 = 30. RS cells are CD15+ and CD30+ B-cell origin. Necessary but not sufficient for a diagnosis of Hodgkin lymphoma.


SUBTYPE	NOTES
Nodular sclerosing	Most common
Lymphocyte rich	Best prognosis
Mixed cellularity	Eosinophilia, seen in immunocompromised patients
Lymphocyte depleted	Seen in immunocompromised patients

## Non-Hodgkin lymphoma

TYPE	OCCURS IN	GENETICS	COMMENTS
<b>Neoplasms of mature B cells</b>			
<b>Burkitt lymphoma</b>	Adolescents or young adults	t(8;14)—translocation of <i>c-myc</i> (8) and heavy-chain Ig (14)	“Starry sky” appearance, sheets of lymphocytes with interspersed “tingible body” macrophages (arrows in <b>A</b> ). Associated with EBV. Jaw lesion <b>B</b> in endemic form in Africa; pelvis or abdomen in sporadic form.
<b>Diffuse large B-cell lymphoma</b>	Usually older adults, but 20% in children	Alterations in Bcl-2, Bcl-6	Most common type of non-Hodgkin lymphoma in adults.
<b>Follicular lymphoma</b>	Adults	t(14;18)—translocation of heavy-chain Ig (14) and <i>BCL-2</i> (18)	Indolent course; Bcl-2 inhibits apoptosis. Presents with painless “waxing and waning” lymphadenopathy. Follicular architecture: small cleaved cells (grade 1), large cells (grade 3), or mixture (grade 2).
<b>Mantle cell lymphoma</b>	Adult males	t(11;14)—translocation of cyclin D1 (11) and heavy-chain Ig (14), CD 5+	Very aggressive, patients typically present with late-stage disease.
<b>Marginal zone lymphoma</b>	Adults	t(11,18)	Associated with chronic inflammation (eg, Sjögren syndrome, chronic gastritis [MALT lymphoma]).
<b>Primary central nervous system lymphoma</b>	Adults	Most commonly associated with HIV/AIDS; pathogenesis involves EBV infection	Considered an AIDS-defining illness. Variable presentation: confusion, memory loss, seizures. Mass lesion(s) on MRI <b>C</b> , needs to be distinguished from toxoplasmosis via CSF analysis or other lab tests.
<b>Neoplasms of mature T cells</b>			
<b>Adult T-cell lymphoma</b>	Adults	Caused by HTLV (associated with IV drug abuse)	Adults present with cutaneous lesions; common in Japan, West Africa, and the Caribbean. Lytic bone lesions, hypercalcemia.
<b>Mycosis fungoides/Sézary syndrome</b>	Adults		Mycosis fungoides: skin patches <b>D</b> /plaques (cutaneous T-cell lymphoma), characterized by atypical CD4+ cells with “cerebriform” nuclei and intraepidermal neoplastic cell aggregates (Pautrier microabscess). May progress to Sézary syndrome (T-cell leukemia).



### Multiple myeloma



Monoclonal plasma cell (“fried egg” appearance) cancer that arises in the marrow and produces large amounts of IgG (55%) or IgA (25%). Bone marrow > 10% monoclonal plasma cells. Most common 1° tumor arising within bone in people > 40–50 years old.

Associated with:

- ↑ susceptibility to infection
- Primary amyloidosis (AL)
- Punched-out lytic bone lesions on x-ray **A**
- M spike on serum protein electrophoresis
- Ig light chains in urine (Bence Jones protein)
- Rouleaux formation **B** (RBCs stacked like poker chips in blood smear)

Numerous plasma cells **C** with “clock-face” chromatin and intracytoplasmic inclusions containing immunoglobulin.

**Monoclonal gammopathy of undetermined significance (MGUS)**—monoclonal expansion of plasma cells (bone marrow < 10% monoclonal plasma cells), asymptomatic, may lead to multiple myeloma. No “CRAB” findings. Patients with MGUS develop multiple myeloma at a rate of 1–2% per year.

Think **CRAB**:

Hyper**C**alcemia  
Renal involvement  
**A**nemia


**B**one lytic lesions/**B**ack pain

Multiple Myeloma: **M**onoclonal **M** protein spike

Distinguish from **Waldenström**

**macroglobulinemia** → M spike = IgM

→ hyperviscosity syndrome (eg, blurred vision, Raynaud phenomenon); no “**CRAB**” findings.



### Myelodysplastic syndromes


Stem-cell disorders involving ineffective hematopoiesis → defects in cell maturation of nonlymphoid lineages. Caused by de novo mutations or environmental exposure (eg, radiation, benzene, chemotherapy). Risk of transformation to AML.

**Pseudo-Pelger-Huet anomaly**—neutrophils with bilobed nuclei. Typically seen after chemotherapy.

**Leukemias**

Unregulated growth and differentiation of WBCs in bone marrow → marrow failure → anemia (↓ RBCs), infections (↓ mature WBCs), and hemorrhage (↓ platelets). Usually presents with ↑ circulating WBCs (malignant leukocytes in blood); rare cases present with normal/↓ WBCs. Leukemic cell infiltration of liver, spleen, lymph nodes, and skin (leukemia cutis) possible.

TYPE	NOTES
<b>Lymphoid neoplasms</b>	
<b>Acute lymphoblastic leukemia/lymphoma</b>	<p>Most frequently occurs in children; less common in adults (worse prognosis). T-cell ALL can present as mediastinal mass (presenting as SVC-like syndrome). Associated with Down syndrome. Peripheral blood and bone marrow have ↑↑↑ lymphoblasts <b>A</b>. TdT+ (marker of pre-T and pre-B cells), CD10+ (marker of pre-B cells). Most responsive to therapy. May spread to CNS and testes. t(12;21) → better prognosis.</p>
<b>Chronic lymphocytic leukemia/small lymphocytic lymphoma</b>	<p>Age: &gt; 60 years. Most common adult leukemia. CD20+, CD23+, CD5+ B-cell neoplasm. Often asymptomatic, progresses slowly; smudge cells <b>B</b> in peripheral blood smear; autoimmune hemolytic anemia. <b>CLL = Crushed Little Lymphocytes</b> (smudge cells). <b>Richter transformation</b>—CLL/SLL transformation into an aggressive lymphoma, most commonly diffuse large B-cell lymphoma (DLBCL).</p>
<b>Hairy cell leukemia</b>	<p>Age: Adult males. Mature B-cell tumor. Cells have filamentous, hair-like projections (fuzzy appearing on LM <b>C</b>). Peripheral lymphadenopathy is uncommon. Causes marrow fibrosis → dry tap on aspiration. Patients usually present with massive splenomegaly and pancytopenia. Stains TRAP (tartrate-resistant acid phosphatase) ⊕. TRAP stain largely replaced with flow cytometry. Treatment: cladribine, pentostatin.</p>
<b>Myeloid neoplasms</b>	
<b>Acute myelogenous leukemia</b>	<p>Median onset 65 years. Auer rods <b>D</b>; myeloperoxidase ⊕ cytoplasmic inclusions seen mostly in APL (formerly M3 AML); ↑↑↑ circulating myeloblasts on peripheral smear; adults. Risk factors: prior exposure to alkylating chemotherapy, radiation, myeloproliferative disorders, Down syndrome. APL: t(15;17), responds to all-<i>trans</i> retinoic acid (vitamin A), inducing differentiation of promyelocytes; DIC is a common presentation.</p>
<b>Chronic myelogenous leukemia</b>	<p>Occurs across the age spectrum with peak incidence 45–85 years, median age at diagnosis 64 years. Defined by the Philadelphia chromosome (t[9;22], <i>BCR-ABL</i>) and myeloid stem cell proliferation. Presents with dysregulated production of mature and maturing granulocytes (eg, neutrophils, metamyelocytes, myelocytes, basophils <b>E</b>) and splenomegaly. May accelerate and transform to AML or ALL (“blast crisis”). Very low LAP as a result of low activity in malignant neutrophils (vs benign neutrophilia [leukemoid reaction], in which LAP is ↑). Responds to <i>bcr-abl</i> tyrosine kinase inhibitors (eg, imatinib).</p>



**Chronic myeloproliferative disorders**

The myeloproliferative disorders (polycythemia vera, essential thrombocythemia, myelofibrosis, and CML) are malignant hematopoietic neoplasms with varying impacts on WBCs and myeloid cell lines. Associated with V617F JAK2 mutation.

**Polycythemia vera**

Primary polycythemia. Disorder of ↑ RBCs. May present as intense itching after hot shower. Rare but classic symptom is erythromelalgia (severe, burning pain and red-blue coloration) due to episodic blood clots in vessels of the extremities **A**.  
 ↓ EPO (vs 2° polycythemia, which presents with endogenous or artificially ↑ EPO).  
 Treatment: phlebotomy, hydroxyurea, ruxolitinib (JAK1/2 inhibitor).


**Essential thrombocythemia**

Characterized by massive proliferation of megakaryocytes and platelets. Symptoms include bleeding and thrombosis. Blood smear shows markedly increased number of platelets, which may be large or otherwise abnormally formed **B**. Erythromelalgia may occur.

**Myelofibrosis**

Obliteration of bone marrow with fibrosis **C** due to ↑ fibroblast activity. Often associated with massive splenomegaly and “teardrop” RBCs **D**. “Bone marrow is **crying** because it’s fibrosed and is a dry tap.”

	RBCs	WBCs	PLATELETS	PHILADELPHIA CHROMOSOME	JAK2 MUTATIONS
Polycythemia vera	↑	↑	↑	⊖	⊕
Essential thrombocythemia	–	–	↑	⊖	⊕ (30–50%)
Myelofibrosis	↓	Variable	Variable	⊖	⊕ (30–50%)
CML	↓	↑	↑	⊕	⊖



**Polycythemia**

	PLASMA VOLUME	RBC MASS	O <sub>2</sub> SATURATION	EPO LEVELS	ASSOCIATIONS
Relative	↓	–	–	–	Dehydration, burns.
Appropriate absolute	–	↑	↓	↑	Lung disease, congenital heart disease, high altitude.
Inappropriate absolute	–	↑	–	↑	Malignancy (eg, renal cell carcinoma, hepatocellular carcinoma), hydronephrosis. Due to ectopic EPO secretion.
Polycythemia vera	↑	↑↑	–	↓	EPO ↓ in PCV due to negative feedback suppressing renal EPO production.



### Chromosomal translocations

TRANSLOCATION	ASSOCIATED DISORDER
t(8;14)	Burkitt lymphoma ( <i>c-myc</i> activation)
t(9;22) ( <b>Philadelphia chromosome</b> )	<b>CML</b> ( <i>BCR-ABL</i> hybrid), ALL (less common, poor prognostic factor)
t(11;14)	Mantle cell lymphoma (cyclin D1 activation)
t(14;18)	Follicular lymphoma ( <i>BCL-2</i> activation)
t(15;17)	APL (M3 type of AML)


#### Philadelphia CreaML cheese.

The Ig heavy chain genes on chromosome 14 are constitutively expressed. When other genes (eg, *c-myc* and *BCL-2*) are translocated next to this heavy chain gene region, they are overexpressed.

Responds to all-*trans* retinoic acid.

### Langerhans cell histiocytosis

Collective group of proliferative disorders of dendritic (Langerhans) cells. Presents in a child as lytic bone lesions **A** and skin rash or as recurrent otitis media with a mass involving the mastoid bone. Cells are functionally immature and do not effectively stimulate primary T cells via antigen presentation. Cells express S-100 (mesodermal origin) and CD1a. Birbeck granules (“tennis rackets” or rod shaped on EM) are characteristic **B**.



## ▶ HEMATOLOGY AND ONCOLOGY—PHARMACOLOGY

**Heparin**

MECHANISM	Lowers the activity of thrombin and factor Xa. Short half-life.
CLINICAL USE	Immediate anticoagulation for pulmonary embolism (PE), acute coronary syndrome, MI, deep venous thrombosis (DVT). Used during pregnancy (does not cross placenta). Follow PTT.
ADVERSE EFFECTS	Bleeding, thrombocytopenia (HIT), osteoporosis, drug-drug interactions. For rapid reversal (antidote), use protamine sulfate (positively charged molecule that binds negatively charged heparin).
NOTES	Low-molecular-weight heparins (eg, enoxaparin, dalteparin) act predominantly on factor Xa. Fondaparinux acts only on factor Xa. Have better bioavailability and 2–4× longer half life than unfractionated heparin; can have better bioavailability, and 2–4 times longer half life; can be administered subcutaneously and without laboratory monitoring. Not easily reversible.  <b>Heparin-induced thrombocytopenia (HIT)</b> —development of IgG antibodies against heparin-bound platelet factor 4 (PF4). Antibody-heparin-PF4 complex activates platelets → thrombosis and thrombocytopenia.

**Direct thrombin inhibitors**

	Bivalirudin (related to hirudin, the anticoagulant used by leeches), argatroban, dabigatran (only oral agent in class).
MECHANISM	Directly inhibits activity of free and clot-associated thrombin.
CLINICAL USE	Venous thromboembolism, atrial fibrillation. Can be used in HIT. Does not require lab monitoring.
ADVERSE EFFECTS	Bleeding; can reverse dabigatran with idarucizumab. Consider PCC and/or antifibrinolytics (eg, tranexamic acid) if no reversal agent available.

**Warfarin****MECHANISM**

Interferes with  $\gamma$ -carboxylation of vitamin K–dependent clotting factors II, VII, IX, and X, and proteins C and S. Metabolism affected by polymorphisms in the gene for vitamin K epoxide reductase complex (*VKORC1*). In laboratory assay, has effect on **EX**trinsic pathway and  $\uparrow$  **PT**. Long half-life.

The **EX-Pr**esident**T** went to **war**(farin).

**CLINICAL USE**

Chronic anticoagulation (eg, venous thromboembolism prophylaxis, and prevention of stroke in atrial fibrillation). Not used in pregnant women (because warfarin, unlike heparin, crosses placenta). Follow PT/INR.

**ADVERSE EFFECTS**

Bleeding, teratogenic, skin/tissue necrosis **A**, drug-drug interactions. Proteins C and S have shorter half-lives than clotting factors II, VII, IX, and X, resulting in early transient hypercoagulability with warfarin use. Skin/tissue necrosis within first few days of large doses believed to be due to small vessel microthrombosis.

For reversal of warfarin, give vitamin K.

For rapid reversal, give fresh frozen plasma (FFP) or PCC.

Heparin “bridging”: heparin frequently used when starting warfarin. Heparin’s activation of antithrombin enables anticoagulation during initial, transient hypercoagulable state caused by warfarin. Initial heparin therapy reduces risk of recurrent venous thromboembolism and skin/tissue necrosis.

**Heparin vs warfarin**

	<b>Heparin</b>	<b>Warfarin</b>
<b>ROUTE OF ADMINISTRATION</b>	Parenteral (IV, SC)	Oral
<b>SITE OF ACTION</b>	Blood	Liver
<b>ONSET OF ACTION</b>	Rapid (seconds)	Slow, limited by half-lives of normal clotting factors
<b>MECHANISM OF ACTION</b>	Activates antithrombin, which $\downarrow$ the action of IIa (thrombin) and factor Xa	Impairs synthesis of vitamin K–dependent clotting factors II, VII, IX, and X, and anti-clotting proteins C and S
<b>DURATION OF ACTION</b>	Hours	Days
<b>AGENTS FOR REVERSAL</b>	Protamine sulfate	Vitamin K, FFP, PCC
<b>MONITORING</b>	PTT (intrinsic pathway)	PT/INR (extrinsic pathway)
<b>CROSSES PLACENTA</b>	No	Yes (teratogenic)

**Direct factor Xa inhibitors**

ApiXaban, rivaroXaban.

MECHANISM	Bind to and directly inhibit factor Xa.
CLINICAL USE	Treatment and prophylaxis for DVT and PE; stroke prophylaxis in patients with atrial fibrillation. Oral agents do not usually require coagulation monitoring.
ADVERSE EFFECTS	Bleeding. Not easily reversible.

**Thrombolytics**

Alteplase (tPA), reteplase (rPA), streptokinase, tenecteplase (TNK-tPA).

MECHANISM	Directly or indirectly aid conversion of plasminogen to plasmin, which cleaves thrombin and fibrin clots. ↑ PT, ↑ PTT, no change in platelet count.
CLINICAL USE	Early MI, early ischemic stroke, direct thrombolysis of severe PE.
ADVERSE EFFECTS	Bleeding. Contraindicated in patients with active bleeding, history of intracranial bleeding, recent surgery, known bleeding diatheses, or severe hypertension. Nonspecific reversal with antifibrinolytics (eg, aminocaproic acid, tranexamic acid), platelet transfusions, and factor corrections (eg, cryoprecipitate, FFP, PCC).

**ADP receptor inhibitors**

Clopidogrel, prasugrel, ticagrelor (reversible), ticlopidine.

MECHANISM	Inhibit platelet aggregation by irreversibly blocking ADP (P2Y <sub>12</sub> ) receptor. Prevent expression of glycoproteins IIb/IIIa on platelet surface.
CLINICAL USE	Acute coronary syndrome; coronary stenting. ↓ incidence or recurrence of thrombotic stroke.
ADVERSE EFFECTS	Neutropenia (ticlopidine). TTP may be seen.

**Cilostazol, dipyridamole**


MECHANISM	Phosphodiesterase inhibitors; ↑ cAMP in platelets, resulting in inhibition of platelet aggregation; vasodilators.
CLINICAL USE	Intermittent claudication, coronary vasodilation, prevention of stroke or TIAs (combined with aspirin).
ADVERSE EFFECTS	Nausea, headache, facial flushing, hypotension, abdominal pain.

**Glycoprotein IIb/IIIa inhibitors**


Abciximab, eptifibatide, tirofiban.

MECHANISM	Bind to the glycoprotein receptor IIb/IIIa on activated platelets, preventing aggregation. Abciximab is made from monoclonal antibody Fab fragments.
CLINICAL USE	Unstable angina, percutaneous coronary intervention.
ADVERSE EFFECTS	Bleeding, thrombocytopenia.

**Cancer drugs—cell cycle**



**Cancer drugs—targets**



**Antimetabolites**

DRUG	MECHANISM <sup>a</sup>	CLINICAL USE	ADVERSE EFFECTS
<b>Azathioprine, 6-mercaptopurine</b>	Purine (thiol) analogs → ↓ de novo purine synthesis. Activated by HGPRT. Azathioprine is metabolized into 6-MP.	Preventing organ rejection, rheumatoid arthritis, IBD, SLE; used to wean patients off steroids in chronic disease and to treat steroid-refractory chronic disease.	Myelosuppression, GI, liver. Azathioprine and 6-MP are metabolized by xanthine oxidase; thus both have ↑ toxicity with allopurinol or febuxostat.
<b>Cladribine</b>	Purine analog → multiple mechanisms (eg, inhibition of DNA polymerase, DNA strand breaks).	Hairy cell leukemia.	Myelosuppression, nephrotoxicity, and neurotoxicity.
<b>Cytarabine (arabinofuranosyl cytidine)</b>	Pyrimidine analog → inhibition of DNA polymerase.	Leukemias (AML), lymphomas.	Myelosuppression with megaloblastic anemia. <b>CYT</b> arabine causes pan <b>CYT</b> openia.
<b>5-fluorouracil</b>	Pyrimidine analog bioactivated to 5-FdUMP, which covalently complexes with thymidylate synthase and folic acid. Capecitabine is a prodrug with similar activity. This complex inhibits thymidylate synthase → ↓ dTMP → ↓ DNA synthesis.	Colon cancer, pancreatic cancer, basal cell carcinoma (topical). Effects enhanced with the addition of leucovorin.	Myelosuppression, palmar-plantar erythrodysesthesia (hand-foot syndrome).
<b>Methotrexate</b>	Folic acid analog that competitively inhibits dihydrofolate reductase → ↓ dTMP → ↓ DNA synthesis.	Cancers: leukemias (ALL), lymphomas, choriocarcinoma, sarcomas. Non-neoplastic: ectopic pregnancy, medical abortion (with misoprostol), rheumatoid arthritis, psoriasis, IBD, vasculitis.	Myelosuppression, which is reversible with leucovorin “rescue.” Hepatotoxicity. Mucositis (eg, mouth ulcers). Pulmonary fibrosis.

<sup>a</sup>All are S-phase specific.

**Antitumor antibiotics**

DRUG	MECHANISM	CLINICAL USE	ADVERSE EFFECTS
<b>Bleomycin</b>	Induces free radical formation → breaks in DNA strands.	Testicular cancer, Hodgkin lymphoma.	Pulmonary fibrosis, skin hyperpigmentation. Minimal myelosuppression.
<b>Dactinomycin (actinomycin D)</b>	Intercalates in DNA.	Wilms tumor, Ewing sarcoma, rhabdomyosarcoma. Used for childhood tumors.	Myelosuppression.
<b>Doxorubicin, daunorubicin</b>	Generate free radicals. Intercalate in DNA → breaks in DNA → ↓ replication.	Solid tumors, leukemias, lymphomas.	Cardiotoxicity (dilated cardiomyopathy), myelosuppression, alopecia. Dexrazoxane (iron chelating agent), used to prevent cardiotoxicity.

**Alkylating agents**

DRUG	MECHANISM	CLINICAL USE	ADVERSE EFFECTS
<b>Busulfan</b>	Cross-links DNA.	CML. Also used to ablate patient's bone marrow before bone marrow transplantation.	Severe myelosuppression (in almost all cases), pulmonary fibrosis, hyperpigmentation.
<b>Cyclophosphamide, ifosfamide</b>	Cross-link DNA at guanine N-7. Require bioactivation by liver. A nitrogen mustard.	Solid tumors, leukemia, lymphomas.	Myelosuppression; hemorrhagic cystitis, prevented with mesna (thiol group of mesna binds toxic metabolites) or N-acetylcysteine.
<b>Nitrosoureas</b>	Require bioactivation. Cross blood-brain barrier → CNS. Cross-link DNA.	Brain tumors (including glioblastoma multiforme).	CNS toxicity (convulsions, dizziness, ataxia).

**Microtubule inhibitors**

DRUG	MECHANISM	CLINICAL USE	ADVERSE EFFECTS
<b>Paclitaxel, other taxols</b>	Hyperstabilize polymerized microtubules in M phase so that mitotic spindle cannot break down (anaphase cannot occur).	Ovarian and breast carcinomas.	Myelosuppression, neuropathy, hypersensitivity.
<b>Vincristine, vinblastine</b>	Vinca alkaloids that bind $\beta$ -tubulin and inhibit its polymerization into microtubules → prevent mitotic spindle formation (M-phase arrest).	Solid tumors, leukemias, Hodgkin (vinblastine) and non-Hodgkin (vincristine) lymphomas.	Vincristine: neurotoxicity (areflexia, peripheral neuritis), constipation (including paralytic ileus).

**Cisplatin, carboplatin**

MECHANISM	Cross-link DNA.
CLINICAL USE	Testicular, bladder, ovary, and lung carcinomas.
ADVERSE EFFECTS	Nephrotoxicity, peripheral neuropathy, ototoxicity. Prevent nephrotoxicity with amifostine (free radical scavenger) and chloride (saline) diuresis.

**Etoposide, teniposide**

MECHANISM	Etoposide inhibits topoisomerase II → ↑ DNA degradation.
CLINICAL USE	Solid tumors (particularly testicular and small cell lung cancer), leukemias, lymphomas.
ADVERSE EFFECTS	Myelosuppression, alopecia.

**Irinotecan, topotecan**

MECHANISM	Inhibit topoisomerase I and prevent DNA unwinding and replication.
CLINICAL USE	Colon cancer (irinotecan); ovarian and small cell lung cancers (topotecan).
ADVERSE EFFECTS	Severe myelosuppression, diarrhea.

**Hydroxyurea**

MECHANISM	Inhibits ribonucleotide reductase → ↓ DNA Synthesis (S-phase specific).
CLINICAL USE	Myeloproliferative disorders (eg, CML, polycythemia vera), sickle cell (↑ HbF), melanoma.
ADVERSE EFFECTS	Severe myelosuppression.



**Bevacizumab**

MECHANISM	Monoclonal antibody against VEGF. Inhibits angiogenesis ( <b>BeV</b> acizumab inhibits <b>B</b> lood <b>V</b> essel formation).
CLINICAL USE	Solid tumors (colorectal cancer, renal cell carcinoma).
ADVERSE EFFECTS	Hemorrhage, blood clots, and impaired wound healing.

**Erlotinib**

MECHANISM	EGFR tyrosine kinase inhibitor.
CLINICAL USE	Non-small cell lung carcinoma.
ADVERSE EFFECTS	Rash.

**Cetuximab**

MECHANISM	Monoclonal antibody against EGFR.
CLINICAL USE	Stage IV colorectal cancer (wild-type <i>KRAS</i> ), head and neck cancer.
ADVERSE EFFECTS	Rash, elevated LFTs, diarrhea.

**Imatinib**

MECHANISM	Tyrosine kinase inhibitor of <i>BCR-ABL</i> (Philadelphia chromosome fusion gene in CML) and <i>c-kit</i> (common in GI stromal tumors).
CLINICAL USE	CML, GI stromal tumors (GIST).
ADVERSE EFFECTS	Fluid retention.

**Rituximab**

MECHANISM	Monoclonal antibody against CD20, which is found on most B-cell neoplasms.
CLINICAL USE	Non-Hodgkin lymphoma, CLL, ITP, rheumatoid arthritis.
ADVERSE EFFECTS	↑ risk of progressive multifocal leukoencephalopathy.

**Bortezomib, carfilzomib**

MECHANISM	Proteasome inhibitors, induce arrest at G2-M phase and apoptosis.
CLINICAL USE	Multiple myeloma, mantle cell lymphoma.
ADVERSE EFFECTS	Peripheral neuropathy, herpes zoster reactivation.

**Tamoxifen, raloxifene**

MECHANISM	Selective estrogen receptor modulators (SERMs)—receptor antagonists in breast and agonists in bone. Block the binding of estrogen to ER ⊕ cells.
CLINICAL USE	Breast cancer treatment (tamoxifen only) and prevention. Raloxifene also useful to prevent osteoporosis.
ADVERSE EFFECTS	Tamoxifen—partial agonist in endometrium, which ↑ the risk of endometrial cancer; “hot flashes.” <b>Raloxifene</b> —no ↑ in endometrial carcinoma (so you can <b>relax!</b> ), because it is an estrogen receptor antagonist in endometrial tissue. Both ↑ risk of thromboembolic events (eg, DVT, PE).

**Trastuzumab (Herceptin)**

MECHANISM	Monoclonal antibody against HER-2 ( <i>c-erbB2</i> ), a tyrosine kinase receptor. Helps kill cancer cells that overexpress HER-2, through inhibition of HER2-initiated cellular signaling and antibody-dependent cytotoxicity.
CLINICAL USE	HER-2 ⊕ breast cancer and gastric cancer (tras2zumab).
ADVERSE EFFECTS	Cardiotoxicity. “ <b>Heart</b> ceptin” damages the <b>heart</b> .

**Vemurafenib**


MECHANISM	Small molecule inhibitor of <i>BRAF</i> oncogene ⊕ melanoma. <b>VEmuRAF-enib</b> is for <b>V600E-mutated <i>BRAF</i> inhibition</b> .
CLINICAL USE	Metastatic melanoma.

**Tumor lysis syndrome**

Oncologic emergency triggered by massive tumor cell lysis, most often in lymphomas/leukemias. Release of  $K^+$  → hyperkalemia, release of  $PO_4^{3-}$  → hyperphosphatemia, hypocalcemia due to  $Ca^{2+}$  sequestration by  $PO_4^{3-}$ . ↑ nucleic acid breakdown → hyperuricemia → acute kidney injury. Treatments include aggressive hydration, allopurinol, rasburicase.

**Rasburicase**

MECHANISM	Recombinant uricase that catalyzes metabolism of uric acid to allantoin.
CLINICAL USE	Prevention and treatment of tumor lysis syndrome.

**Common  
chemotoxicities**

Cisplatin/**C**arboplatin → ototoxicity (and nephrotoxicity)

Vincristine → peripheral neuropathy

**B**leomycin, **B**usulfan → pulmonary fibrosis

**D**oxorubicin → cardiotoxicity

**T**rastuzumab (Herceptin) → cardiotoxicity

**C**isplatin/**C**arboplatin → nephrotoxicity (and ototoxicity)

**CY**clophosphamide → hemorrhagic cystitis

# Musculoskeletal, Skin, and Connective Tissue

*“Rigid, the skeleton of habit alone upholds the human frame.”*

—Virginia Woolf

*“Beauty may be skin deep, but ugly goes clear to the bone.”*

—Redd Foxx

*“The function of muscle is to pull and not to push, except in the case of the genitals and the tongue.”*

—Leonardo da Vinci

*“To thrive in life you need three bones. A wishbone. A backbone. And a funny bone.”*


—Reba McEntire







▶ Anatomy and Physiology	424
▶ Pathology	435
▶ Dermatology	446
▶ Pharmacology	455

## ▶ MUSCULOSKELETAL, SKIN, AND CONNECTIVE TISSUE—ANATOMY AND PHYSIOLOGY

**Knee exam**


ACL: extends from lateral femoral condyle to anterior tibia.  
 PCL: extends from medial femoral condyle to posterior tibia.  
 Perform knee exam with patient supine.



TEST	PROCEDURE	
<b>Anterior drawer sign</b>	Bending knee at 90° angle, ↑ anterior gliding of tibia due to ACL injury. Lachman test is similar, but at 30° angle.	 ACL tear Anterior drawer sign
<b>Posterior drawer sign</b>	Bending knee at 90° angle, ↑ posterior gliding of tibia due to PCL injury.	 PCL tear Posterior drawer sign
<b>Abnormal passive abduction</b>	Knee either extended or at ~ 30° angle, lateral (valgus) force → medial space widening of tibia → MCL injury.	 Abduction (valgus) force MCL tear
<b>Abnormal passive adduction</b>	Knee either extended or at ~ 30° angle, medial (varus) force → lateral space widening of tibia → LCL injury.	 Adduction (varus) force LCL tear
<b>McMurray test</b>	During flexion and extension of knee with rotation of tibia/foot: <ul style="list-style-type: none"> <li>▪ Pain, “popping” on external rotation → medial meniscal tear</li> <li>▪ Pain, “popping” on internal rotation → lateral meniscal tear</li> </ul>	 External rotation Medial tear   Internal rotation Lateral tear


**Common pediatric fractures**

- Greenstick fracture** Incomplete fracture extending partway through width of bone **A** following bending stress; bone is bent like a **green twig**.
- Torus fracture** Axial force applied to immature bone → simple buckle fracture of cortex **B**. Can be very subtle.




**Common knee conditions**

<b>“Unhappy triad”</b>	Common injury in contact sports due to lateral force applied to a planted leg. Classically, consists of damage to the ACL <b>A</b> , MCL, and medial meniscus (attached to MCL); however, lateral meniscus injury is more common. Presents with acute knee pain and signs of joint injury/instability.
<b>Prepatellar bursitis</b>	Inflammation of the prepatellar bursa in front of the kneecap <b>B</b> . Can be caused by repeated trauma or pressure from excessive kneeling (also called “housemaid’s knee”).
<b>Baker cyst</b>	Popliteal fluid collection (arrow in <b>C</b> ) in gastrocnemius-semimembranosus bursa commonly communicating with synovial space and related to chronic joint disease.



**Rotator cuff muscles**




Shoulder muscles that form the rotator cuff:

- **S**upraspinatus (suprascapular nerve)—abducts arm initially (before the action of the deltoid); most common rotator cuff injury (trauma or degeneration and impingement → tendinopathy or tear [arrow in **A**]), assessed by “empty/full can” test.
- **I**nfraspinatus (suprascapular nerve)—laterally rotates arm; pitching injury.
- **t**eres minor (axillary nerve)—adducts and laterally rotates arm.
- **S**ubscapularis (upper and lower subscapular nerves)—medially rotates and adducts arm.

Innervated primarily by C5-C6.

**SIItS** (small t is for teres minor).



**Arm abduction**

DEGREE	MUSCLE	NERVE
0°–15°	Supraspinatus	Suprascapular
15°–100°	Deltoid	Axillary
> 90°	Trapezius	Accessory
> 100°	Serratus anterior	Long thoracic

### Overuse injuries of the elbow


#### Medial epicondylitis (golfer's elbow)

Repetitive flexion (forehand shots) or idiopathic → pain near medial epicondyle.

#### Lateral epicondylitis (tennis elbow)

Repetitive extension (backhand shots) or idiopathic → pain near lateral epicondyle.


### Wrist bones



Scaphoid, Lunate, Triquetrum, Pisiform, Hamate, Capitate, Trapezoid, Trapezium **A**. (So Long To Pinky, Here Comes The Thumb).

Scaphoid (palpable in anatomic snuff box **B**) is the most commonly fractured carpal bone, typically due to a fall on an outstretched hand. Complications of proximal scaphoid fractures include avascular necrosis and nonunion due to retrograde blood supply.

Dislocation of lunate may cause acute carpal tunnel syndrome.



#### Carpal tunnel syndrome

Entrapment of median nerve in carpal tunnel; nerve compression → paresthesia, pain, and numbness in distribution of median nerve (thenar eminence atrophies but sensation spared, because palmar cutaneous branch enters the hand external to carpal tunnel). Associated with pregnancy (due to edema), rheumatoid arthritis, hypothyroidism, diabetes, acromegaly, dialysis-related amyloidosis; may be associated with repetitive use. Suggested by ⊕ Tinel sign (percussion of wrist causes tingling) and Phalen maneuver (90° flexion of wrist causes tingling).


#### Guyon canal syndrome

Compression of ulnar nerve at wrist or hand. Classically seen in cyclists due to pressure from handlebars.

**Upper extremity nerves**

NERVE	CAUSES OF INJURY	PRESENTATION
<b>Axillary (C5-C6)</b>	Fractured surgical neck of humerus; anterior dislocation of humerus	Flattened deltoid Loss of arm abduction at shoulder (> 15°) Loss of sensation over deltoid muscle and lateral arm
<b>Musculocutaneous (C5-C7)</b>	Upper trunk compression	Loss of forearm flexion and supination Loss of sensation over lateral forearm
<b>Radial (C5-T1)</b>	Midshaft fracture of humerus; compression of axilla, eg, due to crutches or sleeping with arm over chair (“Saturday night palsy”)	Wrist drop: loss of elbow, wrist, and finger extension ↓ grip strength (wrist extension necessary for maximal action of flexors) Loss of sensation over posterior arm/forearm and dorsal hand
<b>Median (C5-T1)</b>	Supracondylar fracture of humerus (proximal lesion); carpal tunnel syndrome and wrist laceration (distal lesion)	“Ape hand” and “Pope’s blessing” Loss of wrist flexion, flexion of lateral fingers, thumb opposition, lumbricals of 2nd and 3rd digits Loss of sensation over thenar eminence and dorsal and palmar aspects of lateral 3½ fingers with proximal lesion
<b>Ulnar (C8-T1)</b>	Fracture of medial epicondyle of humerus “funny bone” (proximal lesion); fractured hook of hamate (distal lesion) from fall on outstretched hand	“Ulnar claw” on digit extension Radial deviation of wrist upon flexion (proximal lesion) Loss of wrist flexion, flexion of medial fingers, abduction and adduction of fingers (interossei), actions of medial 2 lumbrical muscles Loss of sensation over medial 1½ fingers including hypothenar eminence
<b>Recurrent branch of median nerve (C5-T1)</b>	Superficial laceration of palm	“Ape hand” Loss of thenar muscle group: opposition, abduction, and flexion of thumb No loss of sensation


Humerus fractures, proximally to distally, follow the **ARM** (Axillary → Radial → Median)





**Brachial plexus lesions**

- 1 Erb palsy (“waiter’s tip”)
- 2 Klumpke palsy (claw hand)
- 3 Wrist drop
- 4 Winged scapula
- 5 Deltoid paralysis
- 6 “Saturday night palsy” (wrist drop)
- 7 Difficulty flexing elbow, variable sensory loss
- 8 Decreased thumb function, “Pope’s blessing”
- 9 Intrinsic muscles of hand, claw hand







Randy  
Travis  
Drinks  
Cold  
Beer

CONDITION	INJURY	CAUSES	MUSCLE DEFICIT	FUNCTIONAL DEFICIT	PRESENTATION
<b>Erb palsy (“waiter’s tip”)</b>	Traction or tear of <b>upper</b> (“Erb-er”) trunk: C5-C6 roots	Infants—lateral traction on neck during delivery Adults—trauma	Deltoid, supraspinatus Infraspinatus Biceps brachii	Abduction (arm hangs by side) Lateral rotation (arm medially rotated) Flexion, supination (arm extended and pronated)	
<b>Klumpke palsy</b>	Traction or tear of <b>lower</b> trunk: C8-T1 root	Infants—upward force on arm during delivery Adults—trauma (eg, grabbing a tree branch to break a fall)	Intrinsic hand muscles: lumbricals, interossei, thenar, hypothenar	Total claw hand: lumbricals normally flex MCP joints and extend DIP and PIP joints	
<b>Thoracic outlet syndrome</b>	Compression of <b>lower</b> trunk and subclavian vessels	Cervical rib (arrows in <b>A</b> ), Pancoast tumor	Same as Klumpke palsy	Atrophy of intrinsic hand muscles; ischemia, pain, and edema due to vascular compression	
<b>Winged scapula</b>	Lesion of long thoracic nerve	Axillary node dissection after mastectomy, stab wounds	Serratus anterior	Inability to anchor scapula to thoracic cage → cannot abduct arm above horizontal position	

**Distortions of the hand** At rest, a balance exists between the extrinsic flexors and extensors of the hand, as well as the intrinsic muscles of the hand—particularly the lumbrical muscles (flexion of MCP, extension of DIP and PIP joints).


“Clawing”—seen best with **distal** lesions of median or ulnar nerves. Remaining extrinsic flexors of the digits exaggerate the loss of the lumbricals → fingers extend at MCP, flex at DIP and PIP joints.

Deficits less pronounced in **proximal** lesions; deficits present during voluntary flexion of the digits.

PRESENTATION				
CONTEXT	Extending fingers/at rest	Making a fist	Extending fingers/at rest	Making a fist
LOCATION OF LESION	Distal ulnar nerve	Proximal median nerve	Distal median nerve	Proximal ulnar nerve
SIGN	“Ulnar claw”	“Pope’s blessing”	“Median claw”	“OK gesture”

Note: Atrophy of the thenar eminence (unopposable thumb → “ape hand”) can be seen in median nerve lesions, while atrophy of the hypothenar eminence can be seen in ulnar nerve lesions.

**Hand muscles**



Thenar (median)—**O**pponens pollicis, **A**bductor pollicis brevis, **F**lexor pollicis brevis, superficial head (deep head by ulnar nerve).

Hypothenar (ulnar)—**O**pponens digiti minimi, **A**bductor digiti minimi, **F**lexor digiti minimi brevis.

- ☒ Dorsal interossei—abduct the fingers.
- Palmar interossei—adduct the fingers.
- Lumbricals—flex at the MCP joint, extend PIP and DIP joints.

Both groups perform the same functions: **O**ppose, **A**bduct, and **F**lex (**OAF**).

**DAB** = **D**orsals **AB**duct.  
**PAD** = **P**almars **AD**duct.

## Lower extremity nerves

NERVE	INNERVATION	CAUSE OF INJURY	PRESENTATION/COMMENTS
<b>Iliohypogastric (T12-L1)</b>	Sensory—suprapubic region Motor—transversus abdominis and internal oblique	Abdominal surgery	Burning or tingling pain in surgical incision site radiating to inguinal and suprapubic region
<b>Genitofemoral nerve (L1-L2)</b>	Sensory—scrotum/labia majora, medial thigh Motor—cremaster	Laparoscopic surgery	↓ anterior thigh sensation beneath inguinal ligament; absent cremasteric reflex
<b>Lateral femoral cutaneous (L2-L3)</b>	Sensory—anterior and lateral thigh	Tight clothing, obesity, pregnancy	↓ thigh sensation (anterior and lateral)
<b>Obturator (L2-L4)</b>	Sensory—medial thigh Motor—obturator externus, adductor longus, adductor brevis, gracilis, pectineus, adductor magnus	Pelvic surgery	↓ thigh sensation (medial) and adduction
<b>Femoral (L2-L4)</b>	Sensory—anterior thigh, medial leg Motor—quadriceps, iliopsoas, pectineus, sartorius	Pelvic fracture	↓ thigh flexion and leg extension
<b>Sciatic (L4-S3)</b>	Sensory—posterior thigh Motor—semitendinosus, semimembranosus, biceps femoris, adductor magnus	Herniated disc	Splits into common peroneal and tibial nerves
<b>Common peroneal (L4-S2)</b>	Sensory—dorsum of foot Motor—biceps femoris, tibialis anterior, extensor muscles of foot	Trauma or compression of lateral aspect of leg, fibular neck fracture	<b>PED = Peroneal Everts and Dorsiflexes</b> ; if injured, foot drop <b>PED</b> Loss of sensation on dorsum of foot <b>Foot drop</b> —inverted and plantarflexed at rest, loss of eversion and dorsiflexion; “steppage gait”
<b>Tibial (L4-S3)</b>	Sensory—sole of foot Motor—triceps surae, plantaris, popliteus, flexor muscles of foot	Knee trauma, Baker cyst (proximal lesion); tarsal tunnel syndrome (distal lesion)	<b>TIP = Tibial Inverts and Plantarflexes</b> ; if injured, can't stand on <b>TIP</b> toes Inability to curl toes and loss of sensation on sole; in proximal lesions, foot everted at rest with loss of inversion and plantarflexion

**Lower extremity nerves (continued)**

NERVE	INNERVATION	CAUSE OF INJURY	PRESENTATION/COMMENTS
<p><b>Superior gluteal (L4-S1)</b></p>	<p>Motor—gluteus medius, gluteus minimus, tensor fascia latae</p>	<p>Iatrogenic injury during intramuscular injection to upper medial gluteal region</p>	<p>Trendelenburg sign/gait—pelvis tilts because weight-bearing leg cannot maintain alignment of pelvis through hip abduction</p> <p>Lesion is contralateral to the side of the hip that drops, ipsilateral to extremity on which the patient stands</p> <p>Choose superolateral quadrant (ideally the anterolateral region) as intramuscular injection site to avoid nerve injury</p>
<p><b>Inferior gluteal (L5-S2)</b></p>	<p>Motor—gluteus maximus</p>	<p>Posterior hip dislocation</p>	<p>Difficulty climbing stairs, rising from seated position; loss of hip extension</p>
<p><b>Pudendal (S2-S4)</b></p>	<p>Sensory—perineum Motor—external urethral and anal sphincters</p>	<p>Stretch injury during childbirth</p>	<p>↓ sensation in perineum and genital area; can cause fecal or urinary incontinence</p> <p>Can be blocked with local anesthetic during childbirth using ischial spine as a landmark for injection</p>

**Actions of hip muscles**

ACTION	MUSCLES
<b>Abductors</b>	Gluteus medius, gluteus minimus
<b>Adductors</b>	Adductor magnus, adductor longus, adductor brevis
<b>Extensors</b>	Gluteus maximus, semitendinosus, semimembranosus
<b>Flexors</b>	Iliopsoas, rectus femoris, tensor fascia lata, pectineus
<b>Internal rotation</b>	Gluteus medius, gluteus minimus, tensor fascia latae
<b>External rotation</b>	Iliopsoas, gluteus maximus, piriformis, obturator

**Signs of lumbosacral radiculopathy**

Paresthesia and weakness related to specific lumbosacral spinal nerves. Usually, the intervertebral disc herniates into the central canal, affecting the inferior nerves (eg, herniation of L3/4 disc affects L4 spinal nerve, but not L3).

Intervertebral discs generally herniate posterolaterally, due to the thin posterior longitudinal ligament and thicker anterior longitudinal ligament along the midline of the vertebral bodies.


DISC LEVEL	FINDINGS
L3–L4	Weakness of knee extension, ↓ patellar reflex
L4–L5	Weakness of dorsiflexion, difficulty in heel-walking
L5–S1	Weakness of plantar flexion, difficulty in toe-walking, ↓ Achilles reflex

**Neurovascular pairing**

Nerves and arteries are frequently named together by the bones/regions with which they are associated. The following are exceptions to this naming convention.

LOCATION	NERVE	ARTERY
<b>Axilla/lateral thorax</b>	Long thoracic	Lateral thoracic
<b>Surgical neck of humerus</b>	Axillary	Posterior circumflex
<b>Midshaft of humerus</b>	Radial	Deep brachial
<b>Distal humerus/ cubital fossa</b>	Median	Brachial
<b>Popliteal fossa</b>	Tibial	Popliteal
<b>Posterior to medial malleolus</b>	Tibial	Posterior tibial

**Muscle conduction to contraction**





T-tubules are extensions of plasma membrane juxtaposed with terminal cisternae of the sarcoplasmic reticulum, allowing for coordinated contraction of muscles.

In skeletal muscle, 1 T-tubule + 2 terminal cisternae = triad.

In cardiac muscle, 1 T-tubule + 1 terminal cisterna = dyad.

1. Action potential depolarization opens presynaptic voltage-gated Ca<sup>2+</sup> channels, inducing neurotransmitter release.
2. Postsynaptic ligand binding leads to muscle cell depolarization in the motor end plate.
3. Depolarization travels along muscle cell and down the T-tubule.
4. Depolarization of the voltage-sensitive dihydropyridine receptor, mechanically coupled to the ryanodine receptor on the sarcoplasmic reticulum, induces a conformational change in both receptors, causing Ca<sup>2+</sup> release from sarcoplasmic reticulum.
5. Released Ca<sup>2+</sup> binds to troponin C, causing a conformational change that moves tropomyosin out of the myosin-binding groove on actin filaments.
6. Myosin releases bound ADP and P<sub>i</sub> → displacement of myosin on the actin filament (power stroke). Contraction results in shortening of **H** and **I** bands and between **Z** lines (**HIZ** shrinkage), but the **A** band remains the same length (**A** band is **A**lways the same length) **A**.
7. Binding of a new ATP molecule causes detachment of myosin head from actin filament. Hydrolysis of bound ATP → ADP, myosin head adopts high-energy position (“cocked”) for the next contraction cycle.



**Types of muscle fibers**

**Type 1 muscle**


Slow twitch; red fibers resulting from ↑ mitochondria and myoglobin concentration (↑ oxidative phosphorylation) → sustained contraction. Proportion ↑ after endurance training.

Think “1 slow red ox.”

**Type 2 muscle**

Fast twitch; white fibers resulting from ↓ mitochondria and myoglobin concentration (↑ anaerobic glycolysis). Proportion ↑ after weight/resistance training, sprinting.

## Smooth muscle contraction



## Bone formation

### Endochondral ossification

Bones of axial skeleton, appendicular skeleton, and base of skull. Cartilaginous model of bone is first made by chondrocytes. Osteoclasts and osteoblasts later replace with woven bone and then remodel to lamellar bone. In adults, woven bone occurs after fractures and in Paget disease. Defective in achondroplasia.

### Membranous ossification

Bones of calvarium, facial bones, and clavicle. Woven bone formed directly without cartilage. Later remodeled to lamellar bone.

## Cell biology of bone

### Osteoblast

**B**uilds **b**one by secreting collagen and catalyzing mineralization in alkaline environment via ALP. Differentiates from mesenchymal stem cells in periosteum. Osteoblastic activity measured by bone ALP, osteocalcin, propeptides of type I procollagen.

### Osteoclast

Dissolves bone by secreting  $\text{H}^+$  and collagenases. Differentiates from a fusion of monocyte/macrophage lineage precursors.

### Parathyroid hormone

At low, intermittent levels, exerts anabolic effects (building bone) on osteoblasts and osteoclasts (indirect). Chronically  $\uparrow$  PTH levels ( $1^\circ$  hyperparathyroidism) cause catabolic effects (osteitis fibrosa cystica).



### Estrogen

Inhibits apoptosis in bone-forming osteoblasts and induces apoptosis in bone-resorbing osteoclasts. Causes closure of epiphyseal plate during puberty. Estrogen deficiency (surgical or postmenopausal)  $\rightarrow$   $\uparrow$  cycles of remodeling and bone resorption  $\rightarrow$   $\uparrow$  risk of osteoporosis.

## ▶ MUSCULOSKELETAL, SKIN, AND CONNECTIVE TISSUE—PATHOLOGY

**Achondroplasia**

Failure of longitudinal bone growth (endochondral ossification) → short limbs. Membranous ossification is affected → large head relative to limbs. Constitutive activation of fibroblast growth factor receptor (FGFR3) actually inhibits chondrocyte proliferation. > 85% of mutations occur sporadically; autosomal dominant with full penetrance (homozygosity is lethal). Most common cause of dwarfism.

**Osteoporosis**

Trabecular (spongy) and cortical bone lose mass and interconnections despite normal bone mineralization and lab values (serum  $\text{Ca}^{2+}$  and  $\text{PO}_4^{3-}$ ).



Most commonly due to ↑ bone resorption related to ↓ estrogen levels and old age. Can be secondary to drugs (eg, steroids, alcohol, anticonvulsants, anticoagulants, thyroid replacement therapy) or other medical conditions (eg, hyperparathyroidism, hyperthyroidism, multiple myeloma, malabsorption syndromes).

Diagnosed by a bone mineral density scan (dual-energy x-ray absorptiometry [DEXA]) with a T-score of  $\leq -2.5$  or by a fragility fracture of hip or vertebra. Screening recommended in women > 65 years old.

Prophylaxis: regular weight-bearing exercise and adequate  $\text{Ca}^{2+}$  and vitamin D intake throughout adulthood.

Treatment: bisphosphonates, teriparatide, SERMs, rarely calcitonin; denosumab (monoclonal antibody against RANKL).

Can lead to **vertebral compression fractures** (A), small arrows; large arrows show normal-for-age vertebral body height for comparison—acute back pain, loss of height, kyphosis. Also can present with fractures of femoral neck, distal radius (Colles fracture).

**Osteopetrosis**

Failure of normal bone resorption due to defective osteoclasts → thickened, dense bones that are prone to fracture. Defective osteoclasts cause overgrowth and sclerosis of cortical bone. Bone fills marrow space → pancytopenia, extramedullary hematopoiesis. Mutations (eg, carbonic anhydrase II) impair ability of osteoclast to generate acidic environment necessary for bone resorption. X-rays show diffuse symmetric skeletal sclerosis (bone-in-bone, “stone bone” A). Can result in cranial nerve impingement and palsies as a result of narrowed foramina. Bone marrow transplant is potentially curative as osteoclasts are derived from monocytes.





**Osteomalacia/rickets**

Defective mineralization of osteoid (osteomalacia) or cartilaginous growth plates (rickets, only in children). Most commonly due to vitamin D deficiency.

X-rays show osteopenia and “Looser zones” (pseudofractures) in osteomalacia, epiphyseal widening and metaphyseal cupping/fraying in rickets. Children with rickets have pathologic bow legs (genu varum **A**), bead-like costochondral junctions (rachitic rosary **B**), craniotabes (soft skull).

↓ vitamin D → ↓ serum  $\text{Ca}^{2+}$  → ↑ PTH secretion → ↓ serum  $\text{PO}_4^{3-}$ .

Hyperactivity of osteoblasts → ↑ ALP.

**Paget disease of bone (osteitis deformans)**


Common, localized disorder of bone remodeling caused by ↑ osteoclastic activity followed by ↑ osteoblastic activity that forms poor-quality bone. Serum  $\text{Ca}^{2+}$ , phosphorus, and PTH levels are normal. ↑ ALP. Mosaic pattern of woven and lamellar bone (osteocytes within lacunae in chaotic juxtapositions); long bone chalk-stick fractures. ↑ blood flow from ↑ arteriovenous shunts may cause high-output heart failure. ↑ risk of osteogenic sarcoma.

Hat size can be increased due to skull thickening **A**; hearing loss is common due to auditory foramen narrowing.


Stages of Paget disease:

- Lytic—osteoclasts
- Mixed—osteoclasts + osteoblasts
- Sclerotic—osteoblasts
- Quiescent—minimal osteoclast/osteoblast activity

Treatment: bisphosphonates.

**Osteonecrosis (avascular necrosis)**

Infarction of bone and marrow, usually very painful. Most common site is femoral head **A** (due to insufficiency of medial circumflex femoral artery). Causes include **C**orticosteroids, **A**lcoholism, **S**ickle cell disease, **T**rauma, “the **B**ends” (caisson/decompression disease), **L**Egg-Calvé-Perthes disease (idiopathic), **G**aucher disease, **S**lipped capital femoral epiphysis—**CAST** Bent **L**EGS.





**Lab values in bone disorders**

DISORDER	SERUM Ca <sup>2+</sup>	PO <sub>4</sub> <sup>3-</sup>	ALP	PTH	COMMENTS
<b>Osteoporosis</b>	—	—	—	—	↓ bone mass
<b>Osteopetrosis</b>	—/↓	—	—	—	Dense, brittle bones. Ca <sup>2+</sup> ↓ in severe, malignant disease
<b>Paget disease of bone</b>	—	—	↑	—	Abnormal “mosaic” bone architecture
<b>Osteitis fibrosa cystica</b>					“Brown tumors” due to fibrous replacement of bone, subperiosteal thinning
Primary hyperparathyroidism	↑	↓	↑	↑	Idiopathic or parathyroid hyperplasia, adenoma, carcinoma
Secondary hyperparathyroidism	↓	↑	↑	↑	Often as compensation for CKD (↓ PO <sub>4</sub> <sup>3-</sup> excretion and production of activated vitamin D)
<b>Osteomalacia/rickets</b>	↓	↓	↑	↑	Soft bones; vitamin D deficiency also causes 2° hyperparathyroidism
<b>Hypervitaminosis D</b>	↑	↑	—	↓	Caused by oversupplementation or granulomatous disease (eg, sarcoidosis)

## Primary bone tumors


TUMOR TYPE	EPIDEMIOLOGY/LOCATION	CHARACTERISTICS
<b>Benign tumors</b>		
<b>Osteochondroma</b>	Most common benign bone tumor. Males < 25 years old.	Bony exostosis with cartilaginous (chondroid) cap <b>A</b> . Rarely transforms to chondrosarcoma.
<b>Giant cell tumor</b>	20–40 years old. Epiphysis of long bones (often in knee region). Arises most commonly at distal femur and proximal tibia. “Osteoclastoma.”	Locally aggressive benign tumor. “Soap bubble” appearance on x-ray <b>B</b> . Multinucleated giant cells that express RANKL.
<b>Malignant tumors</b>		
<b>Osteosarcoma (osteogenic sarcoma)</b>	One of the most common malignant bone tumors. Bimodal distribution: 10–20 years old (1°), > 65 (2°). Predisposing factors: Paget disease of bone, bone infarcts, radiation, familial retinoblastoma, Li-Fraumeni syndrome (germline <i>p53</i> mutation). Metaphysis of long bones, often around knee <b>C</b> .	Codman triangle (from elevation of periosteum) or sunburst pattern on x-ray. Aggressive. Treat with surgical en bloc resection (with limb salvage) and chemotherapy.
<b>Ewing sarcoma</b>	Boys < 15 years old. Commonly appears in diaphysis of long bones, pelvis, scapula, ribs.	Anaplastic small blue cell malignant tumor <b>D</b> . Extremely aggressive with early metastases, but responsive to chemotherapy. “Onion skin” periosteal reaction in bone. Associated with t(11;22) translocation causing fusion protein EWS-FLI 1. <b>11 + 22 = 33</b> (Patrick <b>Ewing’s</b> jersey number).



**Osteoarthritis and rheumatoid arthritis**

	<b>Osteoarthritis</b>	<b>Rheumatoid arthritis</b>
<b>PATHOGENESIS</b>	Mechanical—wear and tear destroys articular cartilage (degenerative joint disorder) → inflammation with inadequate repair. Chondrocytes mediate degradation and inadequate repair.	Autoimmune—inflammation induces formation of pannus (proliferative granulation tissue <b>A</b> ), which erodes articular cartilage and bone.
<b>PREDISPOSING FACTORS</b>	Age, female, obesity, joint trauma.	Female, HLA-DR4, smoking, silica exposure. ⊕ rheumatoid factor (IgM antibody that targets IgG Fc region; in 80%), anti-cyclic citrullinated peptide antibody (more specific).
<b>PRESENTATION</b>	Pain in weight-bearing joints after use (eg, at the end of the day), improving with rest. Asymmetric joint involvement. Knee cartilage loss begins medially (“bowlegged”). No systemic symptoms.	Pain, swelling, and morning stiffness lasting > 1 hour, improving with use. Symmetric joint involvement. Systemic symptoms (fever, fatigue, weight loss). Extraarticular manifestations common.*
<b>JOINT FINDINGS</b>	Osteophytes (bone spurs), joint space narrowing, subchondral sclerosis and cysts. Synovial fluid non-inflammatory (WBC < 2000/mm <sup>3</sup> ). Involves DIP (Heberden nodes <b>B</b> ) and PIP (Bouchard nodes <b>C</b> ), and 1st CMC; not MCP.	Erosions, juxta-articular osteopenia, soft tissue swelling, subchondral cysts, joint space narrowing. Deformities: cervical subluxation, ulnar finger deviation, swan neck <b>D</b> , boutonniere <b>E</b> . Involves MCP, PIP, wrist; not DIP or 1st CMC. Synovial fluid inflammatory.
<b>TREATMENT</b>	Acetaminophen, NSAIDs, intra-articular glucocorticoids.	NSAIDs, glucocorticoids, disease-modifying agents (methotrexate, sulfasalazine, hydroxychloroquine, leflunomide), biologic agents (eg, TNF-α inhibitors).

\*Extraarticular manifestations include rheumatoid nodules (fibrinoid necrosis with palisading histiocytes) in subcutaneous tissue and lung (+ pneumoconiosis → Caplan syndrome), interstitial lung disease, pleuritis, pericarditis, anemia of chronic disease, neutropenia + splenomegaly (Felty syndrome), AA amyloidosis, Sjögren syndrome, scleritis, carpal tunnel syndrome.



**Gout****FINDINGS**

Acute inflammatory monoarthritis caused by precipitation of monosodium urate crystals in joints **A**. More common in males. Associated with hyperuricemia, which can be caused by:

- Underexcretion of uric acid (90% of patients)—largely idiopathic, potentiated by renal failure; can be exacerbated by certain medications (eg, thiazide diuretics).
- Overproduction of uric acid (10% of patients)—Lesch-Nyhan syndrome, PRPP excess, ↑ cell turnover (eg, tumor lysis syndrome), von Gierke disease.



Crystals are needle shaped and ⊖ birefringent under polarized light (yellow under parallel light, blue under perpendicular light **B**).

**SYMPTOMS**

Asymmetric joint distribution. Joint is swollen, red, and painful. Classic manifestation is painful MTP joint of big toe (podagra). Tophus formation **C** (often on external ear, olecranon bursa, or Achilles tendon). Acute attack tends to occur after a large meal with foods rich in purines (eg, red meat, seafood), trauma, surgery, dehydration, diuresis, or alcohol consumption (alcohol metabolites compete for same excretion sites in kidney as uric acid → ↓ uric acid secretion and subsequent buildup in blood).

**TREATMENT**

Acute: NSAIDs (eg, indomethacin), glucocorticoids, colchicine.  
Chronic (preventive): xanthine oxidase inhibitors (eg, allopurinol, febuxostat).

**Calcium pyrophosphate deposition disease**


Deposition of calcium pyrophosphate crystals within the joint space (arrows in **A**). Occurs in patients > 50 years old; both sexes affected equally. Usually idiopathic, sometimes associated with hemochromatosis, hyperparathyroidism, joint trauma. Pain and swelling with acute inflammation (pseudogout) and/or chronic degeneration (pseudo-osteoarthritis). Knee most commonly affected joint.


Chondrocalcinosis (cartilage calcification) on x-ray.

Crystals are rhomboid and weakly ⊕ birefringent under polarized light (blue when parallel to light) **B**.

Acute treatment: NSAIDs, colchicine, glucocorticoids.

Prophylaxis: colchicine.



**Sjögren syndrome**

Autoimmune disorder characterized by destruction of exocrine glands (especially lacrimal and salivary) by lymphocytic infiltrates **A**. Predominantly affects females 40–60 years old.

Findings:

- Inflammatory joint pain
- Keratoconjunctivitis sicca (↓ tear production and subsequent corneal damage)
- Xerostomia (↓ saliva production **B**)
- Presence of antinuclear antibodies, rheumatoid factor (can be in the absence of rheumatoid arthritis), antiribonucleoprotein antibodies: SS-A (anti-Ro) and/or SS-B (anti-La)
- Bilateral parotid enlargement

A common 1° disorder or a 2° syndrome associated with other autoimmune disorders (eg, rheumatoid arthritis, SLE, systemic sclerosis).

Complications: dental caries; mucosa-associated lymphoid tissue (MALT) lymphoma (may present as parotid enlargement).

Labial salivary gland biopsy can confirm diagnosis.

**Septic arthritis**

*S aureus*, *Streptococcus*, and *Neisseria gonorrhoeae* are common causes. Affected joint is swollen **A**, red, and painful. Synovial fluid purulent (WBC > 50,000/mm<sup>3</sup>).

**Gonococcal arthritis**—STI that presents as either purulent arthritis (eg, knee) or triad of polyarthralgia, tenosynovitis (eg, hand), dermatitis (eg, pustules).

**Seronegative spondyloarthritis**

Arthritis without rheumatoid factor (no anti-IgG antibody). Strong association with HLA-B27 (MHC class I serotype). Subtypes (**PAIR**) share variable occurrence of inflammatory back pain (associated with morning stiffness, improves with exercise), peripheral arthritis, enthesitis (inflamed insertion sites of tendons, eg, Achilles), dactylitis (“sausage fingers”), uveitis.

**Psoriatic arthritis**

Associated with skin psoriasis and nail lesions. Asymmetric and patchy involvement **A**. Dactylitis and “pencil-in-cup” deformity of DIP on x-ray **B**.

Seen in fewer than 1/3 of patients with psoriasis.

**Ankylosing spondylitis**

Symmetric involvement of spine and sacroiliac joints → ankylosis (joint fusion), uveitis, aortic regurgitation.

Bamboo spine (vertebral fusion) **C**. Can cause restrictive lung disease due to limited chest wall expansion (costovertebral and costosternal ankylosis).

More common in males.

**Inflammatory bowel disease**

Crohn disease and ulcerative colitis are often associated with spondyloarthritis.

**Reactive arthritis**


Formerly known as Reiter syndrome.

Classic triad:

- Conjunctivitis
- Urethritis
- Arthritis

“Can’t see, can’t pee, can’t bend my knee.”

*Shigella*, *Yersinia*, *Chlamydia*, *Campylobacter*, *Salmonella* (ShY ChiCS).



## Systemic lupus erythematosus

### SYMPTOMS



Classic presentation: rash, joint pain, and fever, most commonly in a female of reproductive age and African-American descent.

**Libman-Sacks Endocarditis**—nonbacterial, verrucous thrombi usually on mitral or aortic valve and can be present on either surface of the valve (but usually on undersurface) (**LSE** in **SLE**).

Lupus nephritis (glomerular deposition of anti-DNA immune complexes) can be nephritic or nephrotic (hematuria or proteinuria). Most common and severe type is diffuse proliferative.

Common causes of death in SLE:

- Cardiovascular disease
- Infections
- Renal disease

### RASH OR PAIN:

Rash (malar **A** or discoid **B**)

Arthritis (nonerosive)

Serositis

Hematologic disorders (eg, cytopenias)

Oral/nasopharyngeal ulcers

Renal disease

Photosensitivity

Antinuclear antibodies

Immunologic disorder (anti-dsDNA, anti-Sm, antiphospholipid)

Neurologic disorders (eg, seizures, psychosis)

### FINDINGS

Antinuclear antibodies (ANA)

Sensitive, not specific

Anti-dsDNA antibodies

Specific, poor prognosis (renal disease)

Anti-Smith antibodies

Specific, not prognostic (directed against snRNPs)

Antihistone antibodies

Sensitive for drug-induced lupus (eg, hydralazine, procainamide)

↓ C3, C4, and CH<sub>50</sub> due to immune complex formation.

### TREATMENT

NSAIDs, steroids, immunosuppressants, hydroxychloroquine.

## Antiphospholipid syndrome

1° or 2° autoimmune disorder (most commonly in SLE).

Diagnose based on clinical criteria including history of thrombosis (arterial or venous) or spontaneous abortion along with laboratory findings of lupus anticoagulant, anticardiolipin, anti-β<sub>2</sub> glycoprotein antibodies.

Treat with systemic anticoagulation.

Anticardiolipin antibodies can cause false-positive VDRL/RPR, and lupus anticoagulant can cause prolonged PTT, which is not corrected by the addition of normal platelet-free plasma.

## Mixed connective tissue disease

Features of SLE, systemic sclerosis, and/or polymyositis. Associated with anti-U1 RNP antibodies (speckled ANA).




**Sarcoidosis**

Characterized by immune-mediated, widespread noncaseating granulomas **A**, elevated serum ACE levels, and elevated CD4+/CD8+ ratio in bronchoalveolar lavage fluid. More common in African-American females. Often asymptomatic except for enlarged lymph nodes. Findings on CXR of bilateral adenopathy and coarse reticular opacities **B**; CT of the chest better demonstrates the extensive hilar and mediastinal adenopathy **C**.

Associated with restrictive lung disease (interstitial fibrosis), erythema nodosum, lupus pernio (skin lesions on face resembling lupus), Bell palsy, epithelioid granulomas containing microscopic Schaumann and asteroid bodies, uveitis, hypercalcemia (due to ↑ 1 $\alpha$ -hydroxylase-mediated vitamin D activation in macrophages).

Treatment: steroids (if symptomatic).

**Polymyalgia rheumatica**

## SYMPTOMS

Pain and stiffness in shoulders and hips, often with fever, malaise, weight loss. Does not cause muscular weakness. More common in women > 50 years old; associated with giant cell (temporal) arteritis.

## FINDINGS

↑ ESR, ↑ CRP, normal CK.

## TREATMENT

Rapid response to low-dose corticosteroids.

**Fibromyalgia**

Most commonly seen in women 20–50 years old. Chronic, widespread musculoskeletal pain associated with “tender points,” stiffness, paresthesias, poor sleep, fatigue, cognitive disturbance (“fibro fog”). Treatment: regular exercise, antidepressants (TCAs, SNRIs), anticonvulsants.

**Polymyositis/  
dermatomyositis**

↑ CK, ⊕ ANA, ⊕ anti-Jo-1, ⊕ anti-SRP, ⊕ anti-Mi-2 antibodies. Treatment: steroids followed by long-term immunosuppressant therapy (eg, methotrexate).

**Polymyositis**

Progressive symmetric proximal muscle weakness, characterized by endomysial inflammation with CD8+ T cells. Most often involves shoulders.

**Dermatomyositis**

Similar to polymyositis, but also involves malar rash (similar to SLE), Gottron papules **A**, heliotrope (erythematous periorbital) rash **B**, “shawl and face” rash **C**, “mechanic’s hands.” ↑ risk of occult malignancy. Perimysial inflammation and atrophy with CD4+ T cells.

**Neuromuscular junction diseases**

	<b>Myasthenia gravis</b>	<b>Lambert-Eaton myasthenic syndrome</b>
FREQUENCY	Most common NMJ disorder	Uncommon
PATHOPHYSIOLOGY	Autoantibodies to postsynaptic ACh receptor	Autoantibodies to presynaptic Ca <sup>2+</sup> channel → ↓ ACh release
CLINICAL	Ptosis, diplopia, weakness Worsens with muscle use Improvement after edrophonium (tensilon) test	Proximal muscle weakness, autonomic symptoms (dry mouth, impotence) Improves with muscle use
ASSOCIATED WITH	Thymoma, thymic hyperplasia	Small cell lung cancer
AChE INHIBITOR ADMINISTRATION	Reverses symptoms (edrophonium to diagnose, pyridostigmine to treat)	Minimal effect

**Raynaud phenomenon**

↓ blood flow to skin due to arteriolar (small vessel) vasospasm in response to cold or stress: color change from white (ischemia) to blue (hypoxia) to red (reperfusion). Most often in the fingers **A** and toes. Called **Raynaud disease** when 1° (idiopathic), **Raynaud syndrome** when 2° to a disease process such as mixed connective tissue disease, SLE, or CREST syndrome (limited form of systemic sclerosis). Digital ulceration (critical ischemia) seen in 2° Raynaud syndrome. Treat with Ca<sup>2+</sup> channel blockers.

**Scleroderma (systemic sclerosis)**

Triad of autoimmunity, noninflammatory vasculopathy, and collagen deposition with fibrosis.

Commonly sclerosis of skin, manifesting as puffy, taut skin **A** without wrinkles, fingertip pitting **B**. Also sclerosis of renal, pulmonary (most common cause of death), cardiovascular, GI systems. 75% female. 2 major types:

- **Diffuse scleroderma**—widespread skin involvement, rapid progression, early visceral involvement. Associated with anti-Scl-70 antibody (anti-DNA topoisomerase I antibody).
- **Limited scleroderma**—limited skin involvement confined to fingers and face. Also with **CREST** syndrome: **C**alcinosis **C**, anti-**C**entromere antibody, **R**aynaud phenomenon, **E**sophageal dysmotility, **S**clerodactyly, and **T**elangiectasia. More benign clinical course.



## ► MUSCULOSKELETAL, SKIN, AND CONNECTIVE TISSUE—DERMATOLOGY


**Skin layers**

Skin has 3 layers: epidermis, dermis, subcutaneous fat (hypodermis, subcutis).


Epidermis layers from surface to base **A**:

- Stratum **C**orneum (keratin)
- Stratum **L**ucidum
- Stratum **G**ranulosum
- Stratum **S**pinosum (desmosomes)
- Stratum **B**asale (stem cell site)

Californians **L**ike **G**irls in **S**tring **B**ikinis.



**Epithelial cell junctions**



**Dermatologic macroscopic terms (morphology)**

LESION	CHARACTERISTICS	EXAMPLES
<b>Macule</b>	Flat lesion with well-circumscribed change in skin color < 1 cm	Freckle, labial macule <b>A</b>
<b>Patch</b>	Macule > 1 cm	Large birthmark (congenital nevus) <b>B</b>
<b>Papule</b>	Elevated solid skin lesion < 1 cm	Mole (nevus) <b>C</b> , acne
<b>Plaque</b>	Papule > 1 cm	Psoriasis <b>D</b>
<b>Vesicle</b>	Small fluid-containing blister < 1 cm	Chickenpox (varicella), shingles (zoster) <b>E</b>
<b>Bulla</b>	Large fluid-containing blister > 1 cm	Bullous pemphigoid <b>F</b>
<b>Pustule</b>	Vesicle containing pus	Pustular psoriasis <b>G</b>
<b>Wheal</b>	Transient smooth papule or plaque	Hives (urticaria) <b>H</b>
<b>Scale</b>	Flaking off of stratum corneum	Eczema, psoriasis, SCC <b>I</b>
<b>Crust</b>	Dry exudate	Impetigo <b>J</b>



**Dermatologic microscopic terms**

LESION	CHARACTERISTICS	EXAMPLES
<b>Hyperkeratosis</b>	↑ thickness of stratum corneum	Psoriasis, calluses
<b>Parakeratosis</b>	Hyperkeratosis with retention of nuclei in stratum corneum	Psoriasis
<b>Hypergranulosis</b>	↑ thickness of stratum granulosum	Lichen planus
<b>Spongiosis</b>	Epidermal accumulation of edematous fluid in intercellular spaces	Eczematous dermatitis
<b>Acantholysis</b>	Separation of epidermal cells	Pemphigus vulgaris
<b>Acanthosis</b>	Epidermal hyperplasia (↑ spinosum)	Acanthosis nigricans

**Pigmented skin disorders**

<b>Albinism</b>	Normal melanocyte number with ↓ melanin production <b>A</b> due to ↓ tyrosinase activity or defective tyrosine transport. ↑ risk of skin cancer.
<b>Melasma (chloasma)</b>	Hyperpigmentation associated with pregnancy (“mask of pregnancy” <b>B</b> ) or OCP use.
<b>Vitiligo</b>	Irregular areas of complete depigmentation <b>C</b> . Caused by autoimmune destruction of melanocytes.




## Common skin disorders

<b>Acne</b>	Multifactorial etiology—↑ sebum/androgen production, abnormal keratinocyte desquamation, <i>Propionibacterium acnes</i> colonization of the pilosebaceous unit (comedones), and inflammation (papules/pustules <b>A</b> , nodules, cysts). Treatment includes retinoids, benzoyl peroxide, and antibiotics.
<b>Atopic dermatitis (eczema)</b>	Pruritic eruption, commonly on skin flexures. Often associated with other atopic diseases (asthma, allergic rhinitis, food allergies); ↑ serum IgE. Usually appears on face in infancy <b>B</b> and then in antecubital fossa <b>C</b> in children and adults.
<b>Allergic contact dermatitis</b>	Type IV hypersensitivity reaction that follows exposure to allergen. Lesions occur at site of contact (eg, nickel <b>D</b> , poison ivy, neomycin <b>E</b> ).
<b>Melanocytic nevus</b>	Common mole. Benign, but melanoma can arise in congenital or atypical moles. Intradermal nevi are papular <b>F</b> . Junctional nevi are flat macules <b>G</b> .
<b>Pseudofolliculitis barbae</b>	Foreign body inflammatory facial skin disorder characterized by firm, hyperpigmented papules and pustules that are painful and pruritic. Located on cheeks, jawline, and neck. Commonly occurs as a result of shaving (“razor bumps”), primarily affects African-American males.
<b>Psoriasis</b>	Papules and plaques with silvery scaling <b>H</b> , especially on knees and elbows. Acanthosis with parakeratotic scaling (nuclei still in stratum corneum), Munro microabscesses. ↑ stratum spinosum, ↓ stratum granulosum. Auspitz sign (arrow in <b>I</b> )—pinpoint bleeding spots from exposure of dermal papillae when scales are scraped off. Can be associated with nail pitting and psoriatic arthritis.
<b>Rosacea</b>	Inflammatory facial skin disorder characterized by erythematous papules and pustules <b>J</b> , but no comedones. May be associated with facial flushing in response to external stimuli (eg, alcohol, heat). Phymatous rosacea can cause rhinophyma (bulbous deformation of nose).
<b>Seborrheic keratosis</b>	Flat, greasy, pigmented squamous epithelial proliferation with keratin-filled cysts (horn cysts) <b>K</b> . Looks “stuck on.” Lesions occur on head, trunk, and extremities. Common benign neoplasm of older persons. Leser-Trélat sign <b>L</b> —sudden appearance of multiple seborrheic keratoses, indicating an underlying malignancy (eg, GI, lymphoid).
<b>Verrucae</b>	Warts; caused by HPV. Soft, tan-colored, cauliflower-like papules <b>M</b> . Epidermal hyperplasia, hyperkeratosis, koilocytosis. Condyloma acuminatum on genitals <b>N</b> .
<b>Urticaria</b>	Hives. Pruritic wheals that form after mast cell degranulation <b>O</b> . Characterized by superficial dermal edema and lymphatic channel dilation.



### Vascular tumors of skin

<b>Angiosarcoma</b>	Rare blood vessel malignancy typically occurring in the head, neck, and breast areas. Usually in elderly, on sun-exposed areas. Associated with radiation therapy and chronic postmastectomy lymphedema. Hepatic angiosarcoma associated with vinyl chloride and arsenic exposures. Very aggressive and difficult to resect due to delay in diagnosis.
<b>Bacillary angiomatosis</b>	Benign capillary skin papules <b>A</b> found in AIDS patients. Caused by <i>Bartonella henselae</i> infections. Frequently mistaken for Kaposi sarcoma, but has neutrophilic infiltrate.
<b>Cherry hemangioma</b>	Benign capillary hemangioma of the elderly <b>B</b> . Does not regress. Frequency ↑ with age.
<b>Cystic hygroma</b>	Cavernous lymphangioma of the neck <b>C</b> . Associated with Turner syndrome.
<b>Glomus tumor</b>	Benign, painful, red-blue tumor, commonly under fingernails <b>D</b> . Arises from modified smooth muscle cells of the thermoregulatory glomus body.
<b>Kaposi sarcoma</b>	Endothelial malignancy most commonly of the skin, but also mouth, GI tract, and respiratory tract. Associated with HHV-8 and HIV. Rarely mistaken for bacillary angiomatosis, but has lymphocytic infiltrate.
<b>Pyogenic granuloma</b>	Polypoid lobulated capillary hemangioma <b>E</b> that can ulcerate and bleed. Associated with trauma and pregnancy.
<b>Strawberry hemangioma</b>	Benign capillary hemangioma of infancy <b>F</b> . Appears in first few weeks of life (1/200 births); grows rapidly and regresses spontaneously by 5–8 years old.



**Skin infections****Bacterial infections****Impetigo**

Very superficial skin infection. Usually from *S aureus* or *S pyogenes*. Highly contagious. Honey-colored crusting **A**.

Bullous impetigo **B** has bullae and is usually caused by *S aureus*.

**Erysipelas**

Infection involving upper dermis and superficial lymphatics, usually from *S pyogenes*. Presents with well-defined demarcation between infected and normal skin **C**.

**Cellulitis**

Acute, painful, spreading infection of deeper dermis and subcutaneous tissues. Usually from *S pyogenes* or *S aureus*. Often starts with a break in skin from trauma or another infection **D**.

**Abscess**

Collection of pus from a walled-off infection within deeper layers of skin **E**. Offending organism is almost always *S aureus*.

**Necrotizing fasciitis**

Deeper tissue injury, usually from anaerobic bacteria or *S pyogenes*. Pain may be out of proportion to exam findings. Results in crepitus from methane and CO<sub>2</sub> production. “Flesh-eating bacteria.” Causes bullae and a purple color to the skin **F**.

**Staphylococcal scalded skin syndrome**

Exotoxin destroys keratinocyte attachments in stratum granulosum only (vs toxic epidermal necrolysis, which destroys epidermal-dermal junction). Characterized by fever and generalized erythematous rash with sloughing of the upper layers of the epidermis **G** that heals completely. ⊕ Nikolsky sign. Seen in newborns and children, adults with renal insufficiency.

**Viral infections****Herpes**

Herpes virus infections (HSV1 and HSV2) of skin can occur anywhere from mucosal surfaces to normal skin. These include herpes labialis, herpes genitalis, herpetic whitlow **H** (finger).

**Molluscum contagiosum**

Umbilicated papules **I** caused by a poxvirus. While frequently seen in children, it may be sexually transmitted in adults.

**Varicella zoster virus**

Causes varicella (chickenpox) and zoster (shingles). Varicella presents with multiple crops of lesions in various stages from vesicles to crusts. Zoster is a reactivation of the virus in dermatomal distribution (unless it is disseminated).

**Hairy leukoplakia**


Irregular, white, painless plaques on lateral tongue that cannot be scraped off **J**. EBV mediated. Occurs in HIV-positive patients, organ transplant recipients. Contrast with thrush (scrapable) and leukoplakia (precancerous).





**Blistering skin disorders**

<b>Pemphigus vulgaris</b>	Potentially fatal autoimmune skin disorder with IgG antibody against desmoglein (component of desmosomes, which connect keratinocytes in the stratum spinosum). Flaccid intraepidermal bullae <b>A</b> caused by acantholysis (separation of keratinocytes, resembling a “row of tombstones”); oral mucosa is also involved. Type II hypersensitivity reaction. Immunofluorescence reveals antibodies around epidermal cells in a reticular (net-like) pattern <b>B</b> . Nikolsky sign ⊕ (separation of epidermis upon manual stroking of skin).
<b>Bullous pemphigoid</b>	Less severe than pemphigus vulgaris. Involves IgG antibody against hemidesmosomes (epidermal basement membrane; antibodies are “bullo” the epidermis). Tense blisters <b>C</b> containing eosinophils affect skin but spare oral mucosa. Immunofluorescence reveals linear pattern at epidermal-dermal junction <b>D</b> . Nikolsky sign ⊖.
<b>Dermatitis herpetiformis</b>	Pruritic papules, vesicles, and bullae (often found on elbows) <b>E</b> . Deposits of IgA at tips of dermal papillae. Associated with celiac disease. Treatment: dapsone, gluten-free diet.
<b>Erythema multiforme</b>	Associated with infections (eg, <i>Mycoplasma pneumoniae</i> , HSV), drugs (eg, sulfa drugs, β-lactams, phenytoin), cancers, autoimmune disease. Presents with multiple types of lesions—macules, papules, vesicles, target lesions (look like targets with multiple rings and dusky center showing epithelial disruption) <b>F</b> .
<b>Stevens-Johnson syndrome</b>	Characterized by fever, bullae formation and necrosis, sloughing of skin at dermal-epidermal junction, high mortality rate. Typically 2 mucous membranes are involved <b>G H</b> , and targetoid skin lesions may appear, as seen in erythema multiforme. Usually associated with adverse drug reaction. A more severe form of Stevens-Johnson syndrome (SJS) with > 30% of the body surface area involved is <b>toxic epidermal necrolysis I J (TEN)</b> . 10–30% involvement denotes SJS-TEN.



**Miscellaneous skin disorders**

<b>Acanthosis nigricans</b>	Epidermal hyperplasia causing symmetric, hyperpigmented thickening of skin, especially in axilla or on neck <b>A B</b> . Associated with insulin resistance (eg, diabetes, obesity, Cushing syndrome), visceral malignancy (eg, gastric adenocarcinoma).
<b>Actinic keratosis</b>	Premalignant lesions caused by sun exposure. Small, rough, erythematous or brownish papules or plaques <b>C D</b> . Risk of squamous cell carcinoma is proportional to degree of epithelial dysplasia.
<b>Erythema nodosum</b>	Painful, raised inflammatory lesions of subcutaneous fat (panniculitis), usually on anterior shins. Often idiopathic, but can be associated with sarcoidosis, coccidioidomycosis, histoplasmosis, TB, streptococcal infections <b>E</b> , leprosy <b>F</b> , inflammatory bowel disease.
<b>Lichen Planus</b>	<b>P</b> ruritic, <b>P</b> urple, <b>P</b> olygonal <b>P</b> lanar <b>P</b> apules and <b>P</b> laques are the <b>6 P</b> 's of lichen <b>P</b> lanus <b>G H</b> . Mucosal involvement manifests as Wickham striae (reticular white lines) and hypergranulosis. Sawtooth infiltrate of lymphocytes at dermal-epidermal junction. Associated with hepatitis C.
<b>Pityriasis rosea</b>	“Herald patch” <b>I</b> followed days later by other scaly erythematous plaques, often in a “Christmas tree” distribution on trunk <b>J</b> . Multiple plaques with collarette scale. Self-resolving in 6–8 weeks.
<b>Sunburn</b>	Acute cutaneous inflammatory reaction due to excessive UV irradiation. Causes DNA mutations, inducing apoptosis of keratinocytes. <b>UVB</b> is dominant in sun <b>B</b> urn, <b>UVA</b> in t <b>A</b> nning and photo <b>A</b> ging. Exposure to <b>UVA</b> and <b>UVB</b> ↑ risk of skin cancer (basal cell carcinoma, squamous cell carcinoma, melanoma). Can also lead to impetigo.



## Skin cancer

### Basal cell carcinoma

Most common skin cancer. Found in sun-exposed areas of body (eg, face). Locally invasive, but rarely metastasizes. Waxy, pink, pearly nodules, commonly with telangiectasias, rolled borders, central crusting or ulceration **A**. BCCs also appear as nonhealing ulcers with infiltrating growth **B** or as a scaling plaque (superficial BCC) **C**. Basal cell tumors have “palisading” nuclei **D**.



### Squamous cell carcinoma

Second most common skin cancer. Associated with excessive exposure to sunlight, immunosuppression, chronically draining sinuses, and occasionally arsenic exposure. Commonly appears on face **E**, lower lip **F**, ears, hands. Locally invasive, may spread to lymph nodes, and will rarely metastasize. Ulcerative red lesions with frequent scale. Histopathology: keratin “pearls” **G**.

**Actinic keratosis**, a scaly plaque, is a precursor to squamous cell carcinoma.

**Keratoacanthoma** is a variant that grows rapidly (4–6 weeks) and may regress spontaneously over months **H**.




### Melanoma

Common tumor with significant risk of metastasis. S-100 tumor marker. Associated with sunlight exposure and dysplastic nevi; fair-skinned persons are at ↑ risk. Depth of tumor (Breslow thickness) correlates with risk of metastasis. Look for the **ABCDEs**: **A**symmetry, **B**order irregularity, **C**olor variation, **D**iameter > 6 mm, and **E**volution over time. At least 4 different types of melanoma, including superficial spreading **I**, nodular **J**, lentigo maligna **K**, and acral lentiginous **L**. Often driven by activating mutation in BRAF kinase. Primary treatment is excision with appropriately wide margins. Metastatic or unresectable melanoma in patients with BRAF V600E mutation may benefit from vemurafenib, a BRAF kinase inhibitor.



▶ MUSCULOSKELETAL, SKIN, AND CONNECTIVE TISSUE—PHARMACOLOGY

Arachidonic acid pathway



LTB<sub>4</sub> is a **neutrophil** chemotactic agent.

PGI<sub>2</sub> inhibits platelet aggregation and promotes vasodilation.

**Neutrophils** arrive “B4” others.

**Platelet-Gathering Inhibitor.**

Acetaminophen

MECHANISM	Reversibly inhibits cyclooxygenase, mostly in CNS. Inactivated peripherally.
CLINICAL USE	Antipyretic, analgesic, but not anti-inflammatory. Used instead of aspirin to avoid Reye syndrome in children with viral infection.
ADVERSE EFFECTS	Overdose produces hepatic necrosis; acetaminophen metabolite (NAPQI) depletes glutathione and forms toxic tissue byproducts in liver. N-acetylcysteine is antidote—regenerates glutathione.

**Aspirin**

MECHANISM	NSAID that irreversibly inhibits cyclooxygenase (both COX-1 and COX-2) by covalent acetylation → ↓ synthesis of TXA <sub>2</sub> and prostaglandins. ↑ bleeding time. No effect on PT, PTT. Effect lasts until new platelets are produced.
CLINICAL USE	Low dose (< 300 mg/day): ↓ platelet aggregation. Intermediate dose (300–2400 mg/day): antipyretic and analgesic. High dose (2400–4000 mg/day): anti-inflammatory.
ADVERSE EFFECTS	Gastric ulceration, tinnitus (CN VIII). Chronic use can lead to acute renal failure, interstitial nephritis, GI bleeding. Risk of Reye syndrome in children treated with aspirin for viral infection. Toxic doses cause respiratory alkalosis early, but transitions to mixed metabolic acidosis-respiratory alkalosis.

**Celecoxib**

MECHANISM	Reversibly and <b>selectively</b> inhibits the cyclooxygenase (COX) isoform 2 (“ <b>Selecoxib</b> ”), which is found in inflammatory cells and vascular endothelium and mediates inflammation and pain; spares COX-1, which helps maintain gastric mucosa. Thus, does not have the corrosive effects of other NSAIDs on the GI lining. Spares platelet function as TXA <sub>2</sub> production is dependent on COX-1.
CLINICAL USE	Rheumatoid arthritis, osteoarthritis.
ADVERSE EFFECTS	↑ risk of thrombosis. Sulfa allergy.

**Nonsteroidal anti-inflammatory drugs**

Ibuprofen, naproxen, indomethacin, ketorolac, diclofenac, meloxicam, piroxicam.

MECHANISM	Reversibly inhibit cyclooxygenase (both COX-1 and COX-2). Block prostaglandin synthesis.
CLINICAL USE	Antipyretic, analgesic, anti-inflammatory. Indomethacin is used to close a PDA.
ADVERSE EFFECTS	Interstitial nephritis, gastric ulcer (prostaglandins protect gastric mucosa), renal ischemia (prostaglandins vasodilate afferent arteriole), aplastic anemia.

**Leflunomide**

MECHANISM	Reversibly inhibits dihydroorotate dehydrogenase, preventing pyrimidine synthesis. Suppresses T-cell proliferation.
CLINICAL USE	Rheumatoid arthritis, psoriatic arthritis.
ADVERSE EFFECTS	Diarrhea, hypertension, hepatotoxicity, teratogenicity.

**Bisphosphonates**

Alendronate, ibandronate, risedronate, zoledronate.


MECHANISM	Pyrophosphate analogs; bind hydroxyapatite in bone, inhibiting osteoclast activity.
CLINICAL USE	Osteoporosis, hypercalcemia, Paget disease of bone, metastatic bone disease, osteogenesis imperfecta.
ADVERSE EFFECTS	Esophagitis (if taken orally, patients are advised to take with water and remain upright for 30 minutes), osteonecrosis of jaw, atypical stress fractures.

**Teriparatide**

MECHANISM	Recombinant PTH analog given subcutaneously daily. ↑ osteoblastic activity.
CLINICAL USE	Osteoporosis. Causes ↑ bone growth compared to antiresorptive therapies (eg, bisphosphonates).
ADVERSE EFFECTS	↑ risk of osteosarcoma (avoid use in patients with Paget disease of the bone or unexplained elevation of alkaline phosphatase). Avoid in patients who have had prior cancers or radiation therapy. Transient hypercalcemia.

**Gout drugs**

Chronic gout drugs (preventive)	
<b>Allopurinol</b>	Competitive inhibitor of xanthine oxidase. ↓ conversion of hypoxanthine and xanthine to urate. Also used in lymphoma and leukemia to prevent tumor lysis–associated urate nephropathy. ↑ concentrations of azathioprine and 6-MP (both normally metabolized by xanthine oxidase).
<b>Febuxostat</b>	Inhibits xanthine oxidase.
<b>Pegloticase</b>	Recombinant uricase that catalyzes metabolism of uric acid to allantoin (a more water-soluble product).
<b>Probenecid</b>	Inhibits reabsorption of uric acid in proximal convoluted tubule (also inhibits secretion of penicillin). Can precipitate uric acid calculi.
Acute gout drugs	
<b>NSAIDs</b>	Any full-dose NSAID (eg, naproxen, indomethacin). Avoid salicylates (may decrease uric acid excretion, particularly at low doses).
<b>Glucocorticoids</b>	Oral, intra-articular, or parenteral.
<b>Colchicine</b>	Binds and stabilizes tubulin to inhibit microtubule polymerization, impairing neutrophil chemotaxis and degranulation. Acute and prophylactic value. GI side effects.



**TNF-α inhibitors**

All TNF-α inhibitors predispose to infection, including reactivation of latent TB, since TNF is important in granuloma formation and stabilization.

DRUG	MECHANISM	CLINICAL USE
<b>Etanercept</b>	Fusion protein (receptor for TNF-α + IgG <sub>1</sub> Fc), produced by recombinant DNA. <b>Etanercept</b> <b>intercepts</b> TNF.	Rheumatoid arthritis, psoriasis, ankylosing spondylitis
<b>Infliximab, adalimumab, certolizumab, golimumab</b>	Anti-TNF-α monoclonal antibody.	Inflammatory bowel disease, rheumatoid arthritis, ankylosing spondylitis, psoriasis

▶ NOTES

Lined writing area for notes, consisting of two columns of horizontal lines.

# Neurology and Special Senses

*“Estimated amount of glucose used by an adult human brain each day, expressed in M&Ms: 250.”*

—Harper’s Index

*“Anything’s possible if you’ve got enough nerve.”*

—J.K. Rowling, *Harry Potter and the Order of the Phoenix*

*“I like nonsense; it wakes up the brain cells.”*

—Dr. Seuss

*“I believe in an open mind, but not so open that your brains fall out.”*

—Arthur Hays Sulzberger


*“The chief function of the body is to carry the brain around.”*

—Thomas Edison

▶ Embryology	460
▶ Anatomy and Physiology	463
▶ Neuropathology	481
▶ Otology	503
▶ Ophthalmology	504
▶ Pharmacology	514



## ▶ NEUROLOGY—EMBRYOLOGY


**Neural development**

Day 18  
↓  
Day 21

Notochord induces overlying ectoderm to differentiate into neuroectoderm and form neural plate. Neural plate gives rise to neural tube and neural crest cells.

Notochord becomes nucleus pulposus of intervertebral disc in adults.

Alar plate (dorsal): sensory  
Basal plate (ventral): motor } Same orientation as spinal cord.


**Regional specification of developing brain****Central and peripheral nervous systems origins**

Neuroepithelia in neural tube—CNS neurons, ependymal cells (inner lining of ventricles, make CSF), oligodendrocytes, astrocytes.

Neural crest—PNS neurons, Schwann cells.

Mesoderm—Microglia (like Macrophages).


<b>Neural tube defects</b>	Neuropores fail to fuse (4th week) → persistent connection between amniotic cavity and spinal canal. Associated with maternal diabetes as well as low folic acid intake before conception and during pregnancy. ↑ $\alpha$ -fetoprotein (AFP) in amniotic fluid and maternal serum (except spina bifida occulta = normal AFP). ↑ acetylcholinesterase (AChE) in amniotic fluid is a helpful confirmatory test (fetal AChE in CSF flows through defect into amniotic fluid).
<b>Anencephaly</b>	Failure of rostral neuropore to close → no forebrain, open calvarium. Clinical findings: polyhydramnios (no swallowing center in brain).
<b>Spina bifida occulta</b>	Failure of caudal neuropore to close, but no herniation. Usually seen at lower vertebral levels. Dura is intact. Associated with tuft of hair or skin dimple at level of bony defect.
<b>Meningocele</b>	Meninges (but no neural tissue) herniate through bony defect. Associated with spina bifida cystica.
<b>Meningomyelocele</b>	Meninges and neural tissue (eg, cauda equina) herniate through bony defect.



### Holoprosencephaly

Failure of left and right hemispheres to separate; usually occurs during weeks 5–6. May be related to mutations in sonic hedgehog signaling pathway. Moderate form has cleft lip/palate, most severe form results in cyclopia. Seen in trisomy 13 and fetal alcohol syndrome.

MRI **A** reveals monoventricle and fusion of basal ganglia (star in **A**).




### Posterior fossa malformations


**Chiari I malformation** Ectopia of cerebellar **tonsils** (1 structure) > 3–5 mm **A**. Congenital, usually asymptomatic in childhood, manifests in adulthood with headaches and cerebellar symptoms. Associated with spinal cavitations (eg, syringomyelia).

**Chiari II malformation** Herniation of low-lying cerebellar **vermis** and **tonsils** (2 structures) through foramen magnum with aqueductal stenosis → hydrocephalus. Usually associated with lumbosacral meningocele (may present as paralysis/sensory loss at and below the level of the lesion).

**Dandy-Walker syndrome** Agenesis of cerebellar vermis with cystic enlargement of 4th ventricle (arrow in **B**), fills the enlarged posterior fossa. Associated with noncommunicating hydrocephalus, spina bifida.




### Syringomyelia



Cystic cavity (syrinx) within central canal of spinal cord (yellow arrow in **A**). Fibers crossing in anterior white commissure (spinothalamic tract) are typically damaged first. Results in a “cape-like,” bilateral loss of pain and temperature sensation in upper extremities (fine touch sensation is preserved). Associated with Chiari malformations (red arrow shows low-lying cerebellar tonsils in **A**), trauma, and tumors.

*Syrinx* = tube, as in syringe.  
Most common at C8–T1.

**Tongue development**

1st and 2nd branchial arches form anterior  $\frac{2}{3}$  (thus sensation via CN V<sub>3</sub>, taste via CN VII).  
3rd and 4th branchial arches form posterior  $\frac{1}{3}$  (thus sensation and taste mainly via CN IX, extreme posterior via CN X).

Motor innervation is via CN XII to hyoglossus (retracts and depresses tongue), genioglossus (protrudes tongue), and styloglossus (draws sides of tongue upward to create a trough for swallowing).

Motor innervation is via CN X to palatoglossus (elevates posterior tongue during swallowing).


Taste—CN VII, IX, X (solitary nucleus).

Pain—CN V<sub>3</sub>, IX, X.

Motor—CN X, XII.


**▶ NEUROLOGY—ANATOMY AND PHYSIOLOGY****Neurons**

Signal-transmitting cells of the nervous system. Permanent cells—do not divide in adulthood. Signal-relaying cells with dendrites (receive input), cell bodies, and axons (send output). Cell bodies and dendrites can be seen on Nissl staining (stains RER). RER is not present in the axon. Injury to axon → **Wallerian degeneration**—degeneration of axon distal to site of injury and axonal retraction proximally; allows for potential regeneration of axon (if in PNS). Macrophages remove debris and myelin.

**Astrocytes**


Physical support, repair, extracellular K<sup>+</sup> buffer, removal of excess neurotransmitter, component of blood-brain barrier, glycogen fuel reserve buffer. Reactive gliosis in response to neural injury.

Derived from neuroectoderm. Astrocyte marker: GFAP.

**Microglia**


Phagocytic scavenger cells of CNS (mesodermal, mononuclear origin). Activated in response to tissue damage. Not readily discernible by Nissl stain.

HIV-infected microglia fuse to form multinucleated giant cells in CNS.


**Myelin**

↑ conduction velocity of signals transmitted down axons → saltatory conduction of action potential at the nodes of Ranvier, where there are high concentrations of  $\text{Na}^+$  channels. Synthesis of myelin by oligodendrocytes in CNS and Schwann cells in PNS.

Wraps and insulates axons (arrow in **A**): ↑ space constant and ↑ conduction velocity.

**Schwann cells**

Each Schwann cell myelinates only 1 PNS axon. Also promote axonal regeneration. Derived from neural crest. May be injured in Guillain-Barré syndrome.

**Oligodendrocytes**


Myelinates axons of neurons in CNS. Each oligodendrocyte can myelinate many axons (~ 30). Predominant type of glial cell in white matter.

Derived from neuroectoderm. “Fried egg” appearance histologically. Injured in multiple sclerosis, progressive multifocal leukoencephalopathy (PML), leukodystrophies.

**Sensory receptors**

RECEPTOR TYPE	SENSORY NEURON FIBER TYPE	LOCATION	SENSES
Free nerve endings	C—slow, unmyelinated fibers A $\delta$ —fast, myelinated fibers	All skin, epidermis, some viscera	Pain, temperature
Meissner corpuscles	Large, myelinated fibers; adapt quickly	Glabrous (hairless) skin	Dynamic, fine/light touch, position sense
Pacinian corpuscles	Large, myelinated fibers; adapt quickly	Deep skin layers, ligaments, joints	Vibration, pressure
Merkel discs	Large, myelinated fibers; adapt slowly	Finger tips, superficial skin	Pressure, deep static touch (eg, shapes, edges), position sense
Ruffini corpuscles	Dendritic endings with capsule; adapt slowly	Finger tips, joints	Pressure, slippage of objects along surface of skin, joint angle change

**Peripheral nerve**




Endoneurium—invests single nerve fiber layers (inflammatory infiltrate in Guillain-Barré syndrome).

**Perineurium** (blood-nerve **P**ermeability barrier)—surrounds a fascicle of nerve fibers. Must be rejoined in microsurgery for limb reattachment.

**Epineurium**—dense connective tissue that surrounds entire nerve (fascicles and blood vessels).

*Endo* = inner.  
*Peri* = around.  
*Epi* = outer.

**Chromatolysis**



Reaction of neuronal cell body to axonal injury. Changes reflect ↑ protein synthesis in effort to repair the damaged axon. Characterized by:

- Round cellular swelling **A**
- Displacement of the nucleus to the periphery
- Dispersion of Nissl substance throughout cytoplasm

Concurrent with Wallerian degeneration.

**Neurotransmitter changes with disease**

	LOCATION OF SYNTHESIS	ANXIETY	DEPRESSION	SCHIZOPHRENIA	ALZHEIMER DISEASE	HUNTINGTON DISEASE	PARKINSON DISEASE
Acetylcholine	Basal nucleus of Meynert				↓	↓	↑
Dopamine	Ventral tegmentum, SNc		↓	↑		↑	↓
GABA	Nucleus accumbens	↓				↓	
Norepinephrine	Locus ceruleus	↑	↓				
Serotonin	Raphe nucleus	↓	↓				↓


**Meninges**

Three membranes that surround and protect the brain and spinal cord.

- Dura mater—thick outer layer closest to skull. Derived from mesoderm.
- Arachnoid mater—middle layer, contains web-like connections. Derived from neural crest.
- Pia mater—thin, fibrous inner layer that firmly adheres to brain and spinal cord. Derived from neural crest.

CSF flows in the subarachnoid space, located between arachnoid and pia mater.

Epidural space—a potential space between the dura mater and skull containing fat and blood vessels.

**Blood-brain barrier**

Prevents circulating blood substances (eg, bacteria, drugs) from reaching the CSF/CNS. Formed by 3 structures:

- Tight junctions between nonfenestrated capillary endothelial cells
- Basement membrane
- Astrocyte foot processes

Glucose and amino acids cross slowly by carrier-mediated transport mechanisms.

Nonpolar/lipid-soluble substances cross rapidly via diffusion.

A few specialized brain regions with fenestrated capillaries and no blood-brain barrier allow molecules in blood to affect brain function (eg, area postrema—vomiting after chemo; OVLT [organum vasculosum lamina terminalis]—osmotic sensing) or neurosecretory products to enter circulation (eg, neurohypophysis—ADH release).

Infarction and/or neoplasm destroys endothelial cell tight junctions → vasogenic edema.

Other notable barriers include:

- Blood-testis barrier
- Maternal-fetal blood barrier of placenta

**Hypothalamus**

Maintains homeostasis by regulating **T**hirst and water balance, controlling **A**drenohypophysis (anterior pituitary) and **N**eurohypophysis (posterior pituitary) release of hormones produced in the hypothalamus, and regulating **H**unger, **A**utonomic nervous system, **T**emperature, and **S**exual urges (**TAN HATS**).

Inputs (areas not protected by blood-brain barrier): OVLT (senses change in osmolarity), area postrema (found in medulla, responds to emetics).

<b>Lateral area</b>	Hunger. Destruction → anorexia, failure to thrive (infants). Stimulated by ghrelin, inhibited by leptin.	If you zap your <b>lateral</b> area, you shrink <b>laterally</b> .
<b>Ventromedial area</b>	Satiety. Destruction (eg, craniopharyngioma) → hyperphagia. Stimulated by leptin.	If you zap your <b>ventromedial</b> area, you grow <b>ventrally</b> and <b>medially</b> .
<b>Anterior hypothalamus</b>	Cooling, parasympathetic.	<b>Anterior</b> nucleus = cool off ( <b>cooling</b> , pArasympathetic). <b>A/C</b> = <b>anterior cooling</b> .
<b>Posterior hypothalamus</b>	Heating, sympathetic.	Posterior nucleus = get fired up (heating, sympathetic). If you zap your <b>posterior</b> hypothalamus, you become a <b>poikilotherm</b> (cold-blooded, like a snake).
<b>Suprachiasmatic nucleus</b>	Circadian rhythm.	You need <b>sleep</b> to be <b>charismatic</b> (chiasmatic).
<b>Supraoptic and paraventricular nuclei</b>	Synthesize ADH and oxytocin	ADH and oxytocin are carried by neurophysins down axons to posterior pituitary, where these hormones are stored and released.

**Sleep physiology**

Sleep cycle is regulated by the circadian rhythm, which is driven by suprachiasmatic nucleus (SCN) of hypothalamus. Circadian rhythm controls nocturnal release of ACTH, prolactin, melatonin, norepinephrine: SCN → norepinephrine release → pineal gland → melatonin. SCN is regulated by environment (eg, light).

Two stages: rapid-eye movement (REM) and non-REM.

Alcohol, benzodiazepines, and barbiturates are associated with ↓ REM sleep and delta wave sleep; norepinephrine also ↓ REM sleep.

Oral desmopressin (ADH analog) is useful in treatment of bedwetting (sleep enuresis); preferred over imipramine because of the latter's adverse effects, although motivational therapy (eg, star chart) should still be first-line for bedwetting in children.

Benzodiazepines are useful for night terrors and sleepwalking by ↓ N3 and REM sleep.

SLEEP STAGE (% OF TOTAL SLEEP TIME IN YOUNG ADULTS)	DESCRIPTION	EEG WAVEFORM
<b>Awake (eyes open)</b>	Alert, active mental concentration	<b>B</b> eta (highest frequency, lowest amplitude)
<b>Awake (eyes closed)</b>		<b>A</b> lpha
<b>Non-REM sleep</b>		
Stage N1 (5%)	Light sleep	<b>T</b> heta
Stage N2 (45%)	Deeper sleep; when bruxism (teeth grinding) occurs	<b>S</b> leep spindles and <b>K</b> complexes
Stage N3 (25%)	Deepest non-REM sleep (slow-wave sleep); when sleepwalking, night terrors, and bedwetting occur	<b>D</b> elta (lowest frequency, highest amplitude)
<b>REM sleep (25%)</b>	Loss of motor tone, ↑ brain O <sub>2</sub> use, ↑ and variable pulse and blood pressure ↑ ACh; when dreaming, nightmares, and penile/clitoral tumescence occur; may serve memory processing function. Depression increases total REM sleep but decreases REM latency Extraocular movements due to activity of PPRF (paramedian pontine reticular formation/conjugate gaze center) Occurs every 90 minutes, and duration ↑ through the night	<b>B</b> eta At night, <b>BATS Drink Blood</b>




**Thalamus**

Major relay for all ascending sensory information except olfaction.

NUCLEUS	INPUT	SENSES	DESTINATION	MNEMONIC
<b>Ventral Postero-Lateral nucleus</b>	Spinothalamic and dorsal columns/ medial lemniscus	<b>V</b> ibration, <b>P</b> ain, <b>P</b> ressure, <b>P</b> roprioception, <b>L</b> ight touch, temperature	1° somatosensory cortex	
<b>Ventral postero-Medial nucleus</b>	Trigeminal and gustatory pathway	<b>F</b> ace sensation, taste	1° somatosensory cortex	<b>M</b> akeup goes on the <b>f</b> ace
<b>Lateral geniculate nucleus</b>	CN II	Vision	Calcarine sulcus	<b>L</b> ateral = <b>L</b> ight
<b>Medial geniculate nucleus</b>	Superior olive and inferior colliculus of tectum	Hearing	Auditory cortex of temporal lobe	<b>M</b> edial = <b>M</b> usic
<b>Ventral lateral nucleus</b>	Basal ganglia, cerebellum	Motor	Motor cortex	

**Limbic system**

Collection of neural structures involved in emotion, long-term memory, olfaction, behavior modulation, ANS function.

The famous **5 F's**.Papez circuit consists of hippocampus (red arrows in **A**), mammillary bodies, anterior thalamic nuclei, cingulate gyrus (yellow arrows in **A**), entorhinal cortex. Responsible for **F**eeding, **F**leeing, **F**ighting, **F**eeling, and **S**ex.**Dopaminergic pathways**

Commonly altered by drugs (eg, antipsychotics) and movement disorders (eg, Parkinson disease).

PATHWAY	SYMPTOMS OF ALTERED ACTIVITY	NOTES
<b>Mesocortical</b>	↓ activity → “negative” symptoms (eg, anergia, apathy, lack of spontaneity).	Antipsychotic drugs have limited effect.
<b>Mesolimbic</b>	↑ activity → “positive” symptoms (eg, delusions, hallucinations).	1° therapeutic target of antipsychotic drugs → ↓ positive symptoms (eg, in schizophrenia).
<b>Nigrostriatal</b>	↓ activity → extrapyramidal symptoms (eg, dystonia, akathisia, parkinsonism, tardive dyskinesia).	Major dopaminergic pathway in brain. Significantly affected by movement disorders and antipsychotic drugs.
<b>Tuberoinfundibular</b>	↓ activity → ↑ prolactin → ↓ libido, sexual dysfunction, galactorrhea, gynecomastia (in men).	

**Cerebellum**

Modulates movement; aids in coordination and balance.

Input:

- Contralateral cortex via middle cerebellar peduncle.
- Ipsilateral proprioceptive information via inferior cerebellar peduncle from spinal cord.

Output:

- The only output of cerebellar cortex = Purkinje cells (always **in**hibitory) → deep nuclei of cerebellum → contralateral cortex via superior cerebellar peduncle.
- Deep nuclei (lateral → medial)—**D**entate, **E**mboliform, **G**lobose, **F**astigial (“**D**on’t **E**at **G**reasy **F**oods”).

**L**ateral lesions—affect voluntary movement of extremities (**L**imbs); when injured, propensity to fall toward injured (ipsilateral) side.

**M**edial lesions—involvement of **M**idline structures (vermal cortex, fastigial nuclei) and/or flocculonodular lobe → truncal ataxia (wide-based cerebellar gait), nystagmus, head tilting. Generally result in bilateral motor deficits affecting axial and proximal limb musculature.

**Basal ganglia**

Important in voluntary movements and making postural adjustments.


Receives cortical input, provides negative feedback to cortex to modulate movement.

Striatum = putamen (motor) + caudate (cognitive).

Lentiform = putamen + globus pallidus.

**D<sub>1</sub>-Receptor = DIRECT** pathway.

**Indirect = Inhibitory.**




Excitatory pathway—cortical inputs stimulate the striatum, stimulating the release of GABA, which inhibits GABA release from the GPi, disinhibiting the thalamus via the GPi (↑ motion).


Inhibitory pathway—cortical inputs stimulate the striatum, releasing GABA that disinhibits STN via GPe inhibition, and STN stimulates GPi to inhibit the thalamus (↓ motion).

Dopamine binds to D<sub>1</sub>, stimulating the excitatory pathway, and to D<sub>2</sub>, inhibiting the inhibitory pathway → ↑ motion.

**Cerebral cortex regions**



**Homunculus**



Topographic representation of motor (shown) and sensory areas in the cerebral cortex. Distorted appearance is due to certain body regions being more richly innervated and thus having ↑ cortical representation.

**Cerebral perfusion**

Brain perfusion relies on tight autoregulation.

Cerebral perfusion is primarily driven by  $\text{PCO}_2$  ( $\text{PO}_2$  also modulates perfusion in severe hypoxia).



Cerebral perfusion relies on a pressure gradient between mean arterial pressure (MAP) and ICP.  $\downarrow$  blood pressure or  $\uparrow$  ICP  $\rightarrow$   $\downarrow$  cerebral perfusion pressure (CPP).

Therapeutic hyperventilation  $\rightarrow$   $\downarrow$   $\text{PCO}_2$


$\rightarrow$  vasoconstriction  $\rightarrow$   $\downarrow$  cerebral blood flow

$\rightarrow$   $\downarrow$  intracranial pressure (ICP). May be used to treat acute cerebral edema (eg, 2° to stroke) unresponsive to other interventions.

CPP = MAP – ICP. If CPP = 0, there is no cerebral perfusion  $\rightarrow$  brain death.

**Cerebral arteries—cortical distribution**


- Anterior cerebral artery (supplies anteromedial surface)
- Middle cerebral artery (supplies lateral surface)
- Posterior cerebral artery (supplies posterior and inferior surfaces)

**Watershed zones**

Between anterior cerebral/middle cerebral, posterior cerebral/middle cerebral arteries. Damage by severe hypotension  $\rightarrow$  upper leg/upper arm weakness, defects in higher-order visual processing.

**Circle of Willis**



System of anastomoses between anterior and posterior blood supplies to brain.



**Dural venous sinuses**

Large venous channels **A** that run through the dura. Drain blood from cerebral veins (arrow) and receive CSF from arachnoid granulations. Empty into internal jugular vein.

**Venous sinus thrombosis**—presents with signs/symptoms of ↑ ICP (eg, headache, seizures, focal neurologic deficits). May lead to venous hemorrhage. Associated with hypercoagulable states (eg, pregnancy, OCP use, factor V Leiden).



**Ventricular system**



Lateral ventricles → 3rd ventricle via right and left interventricular foramina of Monro.

3rd ventricle → 4th ventricle via cerebral aqueduct of Sylvius.

4th ventricle → subarachnoid space via:

- Foramina of **L**uschka = **L**ateral.
- Foramen of **M**agendie = **M**edial.

CSF is made by ependymal cells of choroid plexus; it is reabsorbed by arachnoid granulations and then drains into dural venous sinuses.

**Brain stem—ventral view**

4 CN are above pons (I, II, III, IV).

4 CN are in pons (V, VI, VII, VIII).

4 CN are in medulla (IX, X, XI, XII).

4 CN nuclei are medial (III, IV, VI, XII). “Factors of 12, except 1 and 2.”


**Brain stem—dorsal view (cerebellum removed)**

Pineal gland—melatonin secretion, circadian rhythms.

Superior colliculi—conjugate vertical gaze center.

Inferior colliculi—auditory.

Your eyes are **above** your ears, and the superior colliculus (visual) is **above** the inferior colliculus (auditory).

**Cranial nerve nuclei**

Located in tegmentum portion of brain stem (between dorsal and ventral portions):

- Midbrain—nuclei of CN III, IV
- Pons—nuclei of CN V, VI, VII, VIII
- Medulla—nuclei of CN IX, X, XII
- Spinal cord—nucleus of CN XI


**L**ateral nuclei = sensory (a**L**ar plate).

—Sulcus limitans—

**M**edial nuclei = **M**otor (basal plate).



## Cranial nerve and vessel pathways



## Cranial nerves

NERVE	CN	FUNCTION	TYPE	MNEMONIC
<b>Olfactory</b>	I	Smell (only CN without thalamic relay to cortex)	Sensory	Some
<b>Optic</b>	II	Sight	Sensory	Say
<b>Oculomotor</b>	III	Eye movement (SR, IR, MR, IO), pupillary constriction (sphincter pupillae: Edinger-Westphal nucleus, muscarinic receptors), accommodation, eyelid opening (levator palpebrae)	Motor	Marry
<b>Trochlear</b>	IV	Eye movement (SO)	Motor	Money
<b>Trigeminal</b>	V	Mastication, facial sensation (ophthalmic, maxillary, mandibular divisions), somatosensation from anterior $\frac{2}{3}$ of tongue	Both	But
<b>Abducens</b>	VI	Eye movement (LR)	Motor	My
<b>Facial</b>	VII	Facial movement, taste from anterior $\frac{2}{3}$ of tongue, lacrimation, salivation (submandibular and sublingual glands), eyelid closing (orbicularis oculi), auditory volume modulation (stapedius)	Both	Brother
<b>Vestibulocochlear</b>	VIII	Hearing, balance	Sensory	Says
<b>Glossopharyngeal</b>	IX	Taste and sensation from posterior $\frac{1}{3}$ of tongue, swallowing, salivation (parotid gland), monitoring carotid body and sinus chemo- and baroreceptors, and elevation of pharynx/larynx (stylopharyngeus)	Both	Big
<b>Vagus</b>	X	Taste from supraglottic region, swallowing, soft palate elevation, midline uvula, talking, cough reflex, parasympathetics to thoracoabdominal viscera, monitoring aortic arch chemo- and baroreceptors	Both	Brains
<b>Accessory</b>	XI	Head turning, shoulder shrugging (SCM, trapezius)	Motor	Matter
<b>Hypoglossal</b>	XII	Tongue movement	Motor	Most

**Vagal nuclei**

NUCLEUS	FUNCTION	CRANIAL NERVES
<b>Nucleus Solitarius</b>	Visceral <b>S</b> ensory information (eg, taste, baroreceptors, gut distention)	VII, IX, X
<b>Nucleus aMbiguus</b>	<b>M</b> otor innervation of pharynx, larynx, upper esophagus (eg, swallowing, palate elevation)	IX, X, XI (cranial portion)
<b>Dorsal motor nucleus</b>	Sends autonomic (parasympathetic) fibers to heart, lungs, upper GI	X

**Cranial nerve reflexes**

REFLEX	AFFERENT	EFFERENT
<b>Corneal</b>	V <sub>1</sub> ophthalmic (nasociliary branch)	VII (temporal branch: orbicularis oculi)
<b>Lacrimation</b>	V <sub>1</sub> (loss of reflex does not preclude emotional tears)	VII
<b>Jaw jerk</b>	V <sub>3</sub> (sensory—muscle spindle from masseter)	V <sub>3</sub> (motor—masseter)
<b>Pupillary</b>	II	III
<b>Gag</b>	IX	X

**Mastication muscles**

3 muscles close jaw: **M**asseter, **tM**poralis, **M**edial pterygoid. 1 opens: **L**ateral pterygoid. All are innervated by trigeminal nerve (V<sub>3</sub>).

**M**'s **M**unch.

**L**ateral **L**owers (when speaking of pterygoids with respect to jaw motion).

“It takes more muscle to keep your mouth shut.”

### Spinal nerves

There are 31 pairs of spinal nerves in total: 8 cervical, 12 thoracic, 5 lumbar, 5 sacral, 1 coccygeal. Nerves C1–C7 exit above the corresponding vertebra. C8 spinal nerve exits below C7 and above T1. All other nerves exit below (eg, C3 exits above the 3rd cervical vertebra; L2 exits below the 2nd lumbar vertebra).

**Vertebral disc herniation**—nucleus pulposus (soft central disc) herniates through annulus fibrosus (outer ring); usually occurs posterolaterally at L4–L5 or L5–S1. Nerve usually affected is below the level of herniation (eg, L3–L4 disc spares L3 nerve and involves L4 nerve). Compression of S1 nerve root → absent ankle reflex.


### Spinal cord—lower extent

In adults, spinal cord ends at lower border of L1–L2 vertebrae. Subarachnoid space (which contains the CSF) extends to lower border of S2 vertebra. Lumbar puncture is usually performed between L3–L4 or L4–L5 (level of cauda equina).

Goal of lumbar puncture is to obtain sample of CSF without damaging spinal cord. To **keep** the cord **alive**, keep the spinal needle between **L3** and **L5**.


### Spinal cord and associated tracts

**L**egs (**L**umbosacral) are **L**ateral in **L**ateral corticospinal, spinothalamic tracts **A**. Dorsal columns are organized as you are, with hands at sides. “Arms outside, legs inside.”



**Spinal tract anatomy and functions** Ascending tracts synapse and then cross.

TRACT	FUNCTION	1ST-ORDER NEURON	SYNAPSE 1	2ND-ORDER NEURON	SYNAPSE 2 + PROJECTIONS
<b>Ascending tracts</b>					
<b>Dorsal column</b>	Pressure, vibration, fine touch, proprioception	Sensory nerve ending → bypass pseudounipolar cell body in dorsal root ganglion → enter spinal cord → ascend ipsilaterally in dorsal columns	Nucleus gracilis, nucleus cuneatus (ipsilateral medulla)	Decussates in medulla → ascends contralaterally in medial lemniscus	VPL (thalamus) → sensory cortex
<b>Spinothalamic tract</b>	Lateral: pain, temperature Anterior: crude touch, pressure	Sensory nerve ending (Aδ and C fibers) → bypass pseudounipolar cell body in dorsal root ganglion → enter spinal cord	Ipsilateral gray matter (spinal cord)	Decussates at anterior white commissure → ascends contralaterally	
<b>Descending tract</b>					
<b>Lateral corticospinal tract</b>	Voluntary movement of contralateral limbs	UMN: cell body in 1° motor cortex → descends ipsilaterally (through internal capsule), most fibers decussate at caudal medulla (pyramidal decussation) → descends contralaterally	Cell body of anterior horn (spinal cord)	LMN: leaves spinal cord	NMJ → muscle fibers

**Clinical reflexes**

Reflexes count up in order (main nerve root bolded):

**Achilles reflex** = S1, S2 (“buckle my shoe”)

**Patellar reflex** = L3, L4 (“kick the door”)

**Biceps and brachioradialis reflexes** = C5, C6 (“pick up sticks”)

**Triceps reflex** = C7, C8 (“lay them straight”)

Additional reflexes:

**Cremasteric reflex** = L1, L2 (“testicles move”)

**Anal wink reflex** = S3, S4 (“winks galore”)

**Primitive reflexes**

CNS reflexes that are present in a healthy infant, but are absent in a neurologically intact adult. Normally disappear within 1st year of life. These “primitive” reflexes are inhibited by a mature/developing frontal lobe. They may reemerge in adults following frontal lobe lesions → loss of inhibition of these reflexes.

**Moro reflex**

“Hang on for life” reflex—abduct/extend arms when startled, and then draw together

**Rooting reflex**

Movement of head toward one side if cheek or mouth is stroked (nipple seeking)

**Sucking reflex**

Sucking response when roof of mouth is touched

**Palmar reflex**

Curling of fingers if palm is stroked


**Plantar reflex**

Dorsiflexion of large toe and fanning of other toes with plantar stimulation

Babinski sign—presence of this reflex in an adult, which may signify a UMN lesion

**Galant reflex**

Stroking along one side of the spine while newborn is in ventral suspension (face down) causes lateral flexion of lower body toward stimulated side

**Landmark dermatomes**

C2—posterior half of the skull.

C3—high turtleneck shirt.

C4—low-collar shirt.

C6—includes thumbs.

T4—at the nipple.

T7—at the xiphoid process.

T10—at the umbilicus (important for early appendicitis pain referral).

L1—at the inguinal ligament.

L4—includes the kneecaps.

S2, S3, S4—erection and sensation of penile and anal zones.

Diaphragm and gallbladder pain referred to the right shoulder via phrenic nerve (C3–C5).

Thumbs up sign on left hand looks like a **six** for C6.

**T4** at the **teat pore**.

**T10** at the belly **butten**.

**L1** is **IL** (Inguinal Ligament).

Down on **ALL 4's (L4)**.

“**S2, 3, 4** keep the penis off the **floor**.”

## ▶ NEUROLOGY—NEUROPATHOLOGY

**Common brain lesions**


AREA OF LESION	CONSEQUENCE	EXAMPLES
Frontal lobe	Disinhibition and deficits in concentration, orientation, judgment; may have reemergence of primitive reflexes.	
Frontal eye fields	Eyes look toward lesion.	
Paramedian pontine reticular formation	Eyes look away from side of lesion.	
Medial longitudinal fasciculus	Internuclear ophthalmoplegia (impaired adduction of ipsilateral eye; nystagmus of contralateral eye with abduction).	Multiple sclerosis.
Dominant parietal cortex	Agraphia, acalculia, finger agnosia, left-right disorientation.	Gerstmann syndrome.
Nondominant parietal cortex	Agnosia of the contralateral side of the world.	Hemispatial neglect syndrome.
Hippocampus (bilateral)	Anterograde amnesia—inability to make new memories.	
Basal ganglia	May result in tremor at rest, chorea, athetosis.	Parkinson disease, Huntington disease.
Subthalamic nucleus	Contralateral hemiballismus.	
Mammillary bodies (bilateral)	<b>Wernicke-Korsakoff syndrome</b> —Confusion, Ataxia, Nystagmus, Ophthalmoplegia, memory loss (anterograde and retrograde amnesia), confabulation, personality changes.	Wernicke problems come in a <b>CAN O'</b> beer.
Amygdala (bilateral)	<b>Klüver-Bucy syndrome</b> —disinhibited behavior (eg, hyperphagia, hypersexuality, hyperorality).	HSV-1 encephalitis.
Superior colliculus	<b>Parinaud syndrome</b> —paralysis of conjugate vertical gaze (rostral interstitial nucleus also involved).	Stroke, hydrocephalus, pinealoma.
Reticular activating system (midbrain)	Reduced levels of arousal and wakefulness (eg, coma).	
Cerebellar hemisphere	Intention tremor, limb ataxia, loss of balance; damage to cerebellum → ipsilateral deficits; fall toward side of lesion.	Cerebellar hemispheres are <b>laterally</b> located— affect <b>lateral</b> limbs.
Cerebellar vermis	Truncal ataxia, dysarthria.	Vermis is <b>centrally</b> located—affects <b>central</b> body. Degeneration associated with chronic alcohol use.

**Ischemic brain disease/stroke**

Irreversible damage begins after 5 minutes of hypoxia. Most vulnerable: hippocampus, neocortex, cerebellum, watershed areas. Irreversible neuronal injury. **Hippocampus** is most **vulnerable** to ischemic hypoxia (“**vulnerable hippos**”).

Stroke imaging: noncontrast CT to exclude hemorrhage (before tPA can be given). CT detects ischemic changes in 6–24 hr. Diffusion-weighted MRI can detect ischemia within 3–30 min.

TIME SINCE ISCHEMIC EVENT	12–24 HOURS	24–72 HOURS	3–5 DAYS	1–2 WEEKS	> 2 WEEKS
<b>Histologic features</b>	Red neurons (eosinophilic cytoplasm with pyknotic nuclei)	Necrosis + neutrophils	Macrophages (microglia)	Reactive gliosis + vascular proliferation	Glial scar

**Ischemic stroke**

Acute blockage of vessels → disruption of blood flow and subsequent ischemia → liquefactive necrosis.

3 types:

- Thrombotic—due to a clot forming directly at site of infarction (commonly the MCA **A**), usually over an atherosclerotic plaque.
- Embolic—embolus from another part of the body obstructs vessel. Can affect multiple vascular territories. Examples: atrial fibrillation; DVT with patent foramen ovale.
- Hypoxic—due to hypoperfusion or hypoxemia. Common during cardiovascular surgeries, tends to affect watershed areas.


Treatment: tPA (if within 3–4.5 hr of onset and no hemorrhage/risk of hemorrhage). Reduce risk with medical therapy (eg, aspirin, clopidogrel); optimum control of blood pressure, blood sugars, lipids; and treat conditions that ↑ risk (eg, atrial fibrillation).

**Transient ischemic attack**

Brief, reversible episode of focal neurologic dysfunction without acute infarction (⊖ MRI), with the majority resolving in < 15 minutes; deficits due to focal ischemia.


**Intracranial hemorrhage****Epidural hematoma**

Rupture of middle meningeal artery (branch of maxillary artery), often 2° to skull fracture **A** involving the pterion (thinnest area of the lateral skull). Lucid interval. Rapid expansion under systemic arterial pressure → transtentorial herniation, CN III palsy. CT shows biconvex (lentiform), hyperdense blood collection **B** not crossing suture lines.


**Subdural hematoma**

Rupture of bridging veins. Can be acute (traumatic, high-energy impact → hyperdense on CT) or chronic (associated with mild trauma, cerebral atrophy, elderly, alcoholism → hypodense on CT). Also seen in shaken babies. Predisposing factors: brain atrophy, trauma.

Crescent-shaped hemorrhage (red arrows in **C** and **D**) that crosses suture lines. Can cause midline shift (yellow arrow in **C**), findings of “acute on chronic” hemorrhage (blue arrows in **D**).

**Subarachnoid hemorrhage**

Bleeding **E F** due to trauma, or rupture of an aneurysm (such as a saccular aneurysm **E**) or arteriovenous malformation. Rapid time course. Patients complain of “worst headache of my life.” Bloody or yellow (xanthochromic) spinal tap. 4–10 days after hemorrhage, vasospasm (narrowing of blood vessels) can occur due to blood breakdown or rebleed → ischemic infarct; nimodipine used to prevent/reduce vasospasm. ↑ risk of developing communicating and/or obstructive hydrocephalus.

**Intraparenchymal hemorrhage**

Most commonly caused by systemic hypertension. Also seen with amyloid angiopathy (recurrent lobar hemorrhagic stroke in elderly), vasculitis, neoplasm. May be 2° to reperfusion injury in ischemic stroke. Typically occurs in basal ganglia **G** and internal capsule (Charcot-Bouchard microaneurysm of lenticulostriate vessels), but can also occur in cerebral hemispheres, brainstem, and cerebellum **H**.






## Effects of strokes

ARTERY	AREA OF LESION	SYMPTOMS	NOTES
<b>Anterior circulation</b>			
<b>Middle cerebral artery</b>	Motor and sensory cortices <b>A</b> —upper limb and face. Temporal lobe (Wernicke area); frontal lobe (Broca area).	Contralateral paralysis and sensory loss—face and upper limb. Aphasia if in dominant (usually left) hemisphere. Hemineglect if lesion affects nondominant (usually right) side.	Wernicke aphasia is associated with right superior quadrant visual field defect due to temporal lobe involvement.
<b>Anterior cerebral artery</b>	Motor and sensory cortices—lower limb.	Contralateral paralysis and sensory loss—lower limb.	
<b>Lenticulo-striate artery</b>	Striatum, internal capsule.	Contralateral paralysis and/or sensory loss—face and body. Absence of cortical signs (eg, neglect, aphasia, visual field loss).	Common location of lacunar infarcts <b>B</b> , due to hyaline arteriosclerosis 2° to unmanaged hypertension.
<b>Posterior circulation</b>			
<b>Anterior spinal artery</b>	Lateral corticospinal tract. Medial lemniscus. Caudal medulla—hypoglossal nerve.	Contralateral paralysis—upper and lower limbs. ↓ contralateral proprioception. Ipsilateral hypoglossal dysfunction (tongue deviates ipsilaterally).	<b>Medial medullary syndrome</b> —caused by infarct of paramedian branches of ASA and/or vertebral arteries.
<b>Posterior inferior cerebellar artery</b>	Lateral medulla: Nucleus ambiguus (CN IX, X, XI) Vestibular nuclei Lateral spinothalamic tract, spinal trigeminal nucleus  Sympathetic fibers Inferior cerebellar peduncle	<b>Dysphagia, hoarseness, ↓ gag reflex</b> Vomiting, vertigo, nystagmus ↓ pain and temperature sensation from contralateral body, ipsilateral face Ipsilateral Horner syndrome Ataxia, dysmetria	<b>Lateral medullary (Wallenberg) syndrome.</b> Nucleus ambiguus effects are specific to PICA lesions <b>C</b> . “Don’t <b>pick a (PICA) horse</b> (hoarseness) that <b>can’t eat</b> (dysphagia).” Also supplies inferior cerebellar peduncle (part of cerebellum).
<b>Anterior inferior cerebellar artery</b>	Lateral pons Facial nucleus  Vestibular nuclei Spinothalamic tract, spinal trigeminal nucleus  Sympathetic fibers Middle and inferior cerebellar peduncles	<b>Paralysis of face</b> , ↓ lacrimation, ↓ salivation, ↓ taste from anterior ⅓ of tongue Vomiting, vertigo, nystagmus ↓ pain and temperature sensation from contralateral body, ipsilateral face Ipsilateral Horner syndrome Ataxia, dysmetria	<b>Lateral pontine syndrome.</b> Facial nucleus effects are specific to AICA lesions. “ <b>Facial droop</b> means AICA’s <b>pooped</b> .” Also supplies middle and inferior cerebellar peduncles (part of cerebellum).

**Effects of strokes (continued)**

ARTERY	AREA OF LESION	SYMPTOMS	NOTES
<b>Basilar artery</b>	Pons, medulla, lower midbrain  Corticospinal and corticobulbar tracts  Ocular cranial nerve nuclei, paramedian pontine reticular formation	RAS spared, therefore preserved consciousness  Quadriplegia; loss of voluntary facial, mouth, and tongue movements  Loss of horizontal, but not vertical, eye movements	“Locked-in syndrome.”
<b>Posterior cerebral artery</b>	Occipital lobe <b>D</b> .	Contralateral hemianopia with macular sparing.	

**Central post-stroke pain syndrome**

Neuropathic pain due to thalamic lesions. Initial paresthesias followed in weeks to months by allodynia (ordinarily painless stimuli cause pain) and dysesthesia. Occurs in 10% of stroke patients.

**Aphasia**

Aphasia—higher-order language deficit (inability to understand/speak/read/write).

Dysarthria—motor inability to speak (movement deficit).

TYPE	SPEECH FLUENCY	COMPREHENSION	COMMENTS
<b>Repetition impaired</b>			
<b>Broca (expressive)</b>	Nonfluent	Intact	<b>Broca = Broken Boca</b> ( <i>boca</i> = mouth in Spanish). Broca area in inferior frontal gyrus of frontal lobe. Patient appears frustrated, insight intact.
<b>Wernicke (receptive)</b>	Fluent	Impaired	<b>Wernicke is Wordy</b> but makes no sense. Patients do not have insight. Wernicke area in superior temporal gyrus of temporal lobe.
<b>Conduction</b>	Fluent	Intact	Can be caused by damage to ar <b>C</b> uate fasciculus.
<b>Global</b>	Nonfluent	Impaired	Arcuate fasciculus; Broca and Wernicke areas affected ( <b>all</b> areas).
<b>Repetition intact</b>			
<b>Transcortical motor</b>	Nonfluent	Intact	Affects frontal lobe around Broca area, but Broca area is spared.
<b>Transcortical sensory</b>	Fluent	Impaired	Affects temporal lobe around Wernicke area, but Wernicke area is spared.
<b>Transcortical, mixed</b>	Nonfluent	Impaired	Broca and Wernicke areas and arcuate fasciculus remain intact; surrounding watershed areas affected.

**Aneurysms**

Abnormal dilation of an artery due to weakening of vessel wall.

**Saccular (berry) aneurysm**

Occurs at bifurcations in the circle of Willis. Most common site is junction of ACom and ACA. Associated with ADPKD, Ehlers-Danlos syndrome. Other risk factors: advanced age, hypertension, smoking, race (↑ risk in African-Americans).

Usually clinically silent until rupture (most common complication) → subarachnoid hemorrhage (“worst headache of my life” or “thunderclap headache”) → focal neurologic deficits. Can also cause symptoms via direct compression on surrounding structures by growing aneurysm.

- ACom—compression → bitemporal hemianopia (compression of optic chiasm); visual acuity deficits; rupture → ischemia in ACA distribution → contralateral lower extremity hemiparesis, sensory deficits.
- MCA—rupture → ischemia in MCA distribution → contralateral upper extremity and facial hemiparesis, sensory deficits.
- PCom—compression → ipsilateral CN III palsy → mydriasis (“blown pupil”); may also see ptosis, “down and out” eye.

**Charcot-Bouchard microaneurysm**

Common, associated with chronic hypertension; affects small vessels (eg, lenticulostriate arteries in basal ganglia, thalamus). Not visible on angiography.

**Seizures**

Characterized by synchronized, high-frequency neuronal firing. Variety of forms.

**Partial (focal) seizures**

Affect single area of the brain. Most commonly originate in medial temporal lobe. Often preceded by seizure aura; can secondarily generalize. Types:

- **Simple partial** (consciousness intact)—motor, sensory, autonomic, psychic
- **Complex partial** (impaired consciousness)

**Generalized seizures**

Diffuse. Types:

- **Absence** (petit mal)—3 Hz spike-and-wave discharges, no postictal confusion, blank stare
- **Myoclonic**—quick, repetitive jerks
- **Tonic-clonic** (grand mal)—alternating stiffening and movement
- **Tonic**—stiffening
- **Atonic**—“drop” seizures (falls to floor); commonly mistaken for fainting

**Epilepsy**—a disorder of recurrent seizures (febrile seizures are not epilepsy).

**Status epilepticus**—continuous (> 5–30 min) or recurring seizures that may result in brain injury.

Causes of seizures by age:

- Children—genetic, infection (febrile), trauma, congenital, metabolic
- Adults—tumor, trauma, stroke, infection
- Elderly—stroke, tumor, trauma, metabolic, infection

**Headaches**

Pain due to irritation of structures such as the dura, cranial nerves, or extracranial structures. More common in females, except cluster headaches.

CLASSIFICATION	LOCALIZATION	DURATION	DESCRIPTION	TREATMENT
<b>Cluster<sup>a</sup></b>	Unilateral	15 min–3 hr; repetitive	Repetitive brief headaches. Excruciating periorbital pain with lacrimation and rhinorrhea. May present with Horner syndrome.	Acute: sumatriptan, 100% O <sub>2</sub> Prophylaxis: verapamil
<b>Tension</b>	Bilateral	> 30 min (typically 4–6 hr); constant	Steady pain. No photophobia or phonophobia. No aura.	Analgesics, NSAIDs, acetaminophen; amitriptyline for chronic pain
<b>Migraine</b>	Unilateral	4–72 hr	Pulsating pain with nausea, photophobia, or phonophobia. May have “aura.” Due to irritation of CN V, meninges, or blood vessels (release of substance P, calcitonin gene-related peptide, vasoactive peptides).	Acute: NSAIDs, triptans, dihydroergotamine Prophylaxis: lifestyle changes (eg, sleep, exercise, diet), β-blockers, calcium channel blockers, amitriptyline, topiramate, valproate. <b>POUND</b> —Pulsatile, <b>O</b> ne-day duration, <b>U</b> nilateral, <b>N</b> ausea, <b>D</b> isabling

Other causes of headache include subarachnoid hemorrhage (“worst headache of my life”), meningitis, hydrocephalus, neoplasia, giant cell (temporal) arteritis.

<sup>a</sup> Compare with **trigeminal neuralgia**, which produces repetitive, unilateral, shooting pain in the distribution of CN V that lasts (typically) for < 1 minute (note: first-line therapy is carbamazepine).

**Movement disorders**

DISORDER	PRESENTATION	CHARACTERISTIC LESION	NOTES
<b>Akathisia</b>	Restlessness and intense urge to move		Can be seen with neuroleptic use or in Parkinson disease.
<b>Asterixis</b>	Extension of wrists causes “flapping” motion		Associated with hepatic encephalopathy, Wilson disease, and other metabolic derangements.
<b>Athetosis</b>	Slow, snake-like, writhing movements; especially seen in the fingers	Basal ganglia	
<b>Chorea</b>	Sudden, jerky, purposeless movements	Basal ganglia	<i>Chorea</i> = dancing. Sydenham chorea seen in acute rheumatic fever.
<b>Dystonia</b>	Sustained, involuntary muscle contractions		Writer’s cramp, blepharospasm, torticollis.
<b>Essential tremor</b>	High-frequency tremor with sustained posture (eg, outstretched arms), worsened with movement or when anxious		Often familial. Patients often self-medicate with alcohol, which ↓ tremor amplitude. Treatment: nonselective β-blockers (eg, propranolol), primidone.
<b>Hemiballismus</b>	Sudden, wild flailing of 1 arm +/- ipsilateral leg	Contralateral subthalamic nucleus (eg, lacunar stroke)	Pronounce “ <b>Half</b> -of-body <b>ballistic</b> .” Contralateral lesion.
<b>Intention tremor</b>	Slow, zigzag motion when pointing/extending toward a target	Cerebellar dysfunction	
<b>Myoclonus</b>	Sudden, brief, uncontrolled muscle contraction		Jerks; hiccups; common in metabolic abnormalities such as renal and liver failure.
<b>Resting tremor</b>	Uncontrolled movement of distal appendages (most noticeable in hands); tremor alleviated by intentional movement	Substantia nigra ( <b>P</b> arkinson disease)	Occurs at rest; “pill-rolling tremor” of Parkinson disease. When you <b>park</b> your car, it is at <b>rest</b> .


**Neurodegenerative disorders**

↓ in cognitive ability, memory, or function with intact consciousness.

DISEASE	DESCRIPTION	HISTOLOGIC/GROSS FINDINGS
<b>Parkinson disease</b>	<p>Parkinson <b>TRAPS</b> your body:</p> <ul style="list-style-type: none"> <li><b>T</b>remor (pill-rolling tremor at rest)</li> <li><b>R</b>igidity (cogwheel)</li> <li><b>A</b>kinesia (or bradykinesia)</li> <li><b>P</b>ostural instability</li> <li><b>S</b>huffling gait</li> </ul> <p>MPTP, a contaminant in illegal drugs, is metabolized to MPP<sup>+</sup>, which can cause parkinsonian symptoms.</p>	<p>Loss of dopaminergic neurons (ie, depigmentation) of substantia nigra pars compacta.</p> <p>Lewy bodies: composed of α-synuclein (intracellular eosinophilic inclusions <b>A</b>).</p>
<b>Huntington disease</b>	<p>Autosomal dominant trinucleotide (CAG)<sub>n</sub> repeat disorder on chromosome 4. Symptoms manifest between ages 20 and 50: chorea, athetosis, aggression, depression, dementia (sometimes initially mistaken for substance abuse).</p> <p>Anticipation results from expansion of <b>CAG</b> repeats. Caudate loses <b>ACh</b> and <b>GABA</b>.</p>	<p>Atrophy of caudate and putamen with ex vacuo ventriculomegaly.</p> <p>↑ dopamine, ↓ GABA, ↓ ACh in brain. Neuronal death via NMDA-R binding and glutamate excitotoxicity.</p>
<b>Alzheimer disease</b>	<p>Most common cause of dementia in elderly. Down syndrome patients have ↑ risk of developing Alzheimer disease, as APP is located on chromosome 21.</p> <p>Associated with the following altered proteins:</p> <ul style="list-style-type: none"> <li>▪ ApoE2: ↓ risk of sporadic form</li> <li>▪ ApoE4: ↑ risk of sporadic form</li> <li>▪ APP, presenilin-1, presenilin-2: familial forms (10%) with earlier onset</li> </ul> <p>↓ ACh</p>	<p>Widespread cortical atrophy (normal cortex <b>B</b>; cortex in Alzheimer disease <b>C</b>), especially hippocampus (arrows in <b>B</b> and <b>C</b>). Narrowing of gyri and widening of sulci.</p> <p>Senile plaques <b>D</b> in gray matter: extracellular β-amyloid core; may cause amyloid angiopathy → intracranial hemorrhage; Aβ (amyloid-β) synthesized by cleaving amyloid precursor protein (APP).</p> <p>Neurofibrillary tangles <b>E</b>: intracellular, hyperphosphorylated tau protein = insoluble cytoskeletal elements; number of tangles correlates with degree with dementia.</p>
<b>Frontotemporal dementia (Pick disease)</b>	<p>Early changes in personality and behavior (behavioral variant), or aphasia (primary progressive aphasia).</p> <p>May have associated movement disorders (eg, parkinsonism, ALS-like UMN/LMN degeneration).</p>	<p>Frontotemporal lobe degeneration <b>F</b>.</p> <p>Inclusions of hyperphosphorylated tau (round Pick bodies <b>G</b>) or ubiquitinated TDP-43.</p>
<b>Lewy body dementia</b>	<p>Dementia and visual hallucinations (“ha<b>Lewy</b>cinations”) → parkinsonian features</p>	<p>Intracellular Lewy bodies <b>A</b> primarily in cortex.</p>

**Neurodegenerative disorders (continued)**

DISEASE	DESCRIPTION	HISTOLOGIC/GROSS FINDINGS
<b>Vascular dementia</b>	Result of multiple arterial infarcts and/or chronic ischemia. Step-wise decline in cognitive ability with late-onset memory impairment. 2nd most common cause of dementia in elderly.	MRI or CT shows multiple cortical and/or subcortical infarcts.
<b>Creutzfeldt-Jakob disease</b>	Rapidly progressive (weeks to months) dementia with myoclonus (“startle myoclonus”). Commonly see periodic sharp waves on EEG and ↑ 14-3-3 protein in CSF.	Spongiform cortex. Prions (PrP <sup>c</sup> → PrP <sup>sc</sup> sheet [β-pleated sheet resistant to proteases]) <b>H</b> .

**Idiopathic intracranial hypertension (pseudotumor cerebri)**

↑ ICP with no apparent cause on imaging (eg, hydrocephalus, obstruction of CSF outflow). Risk factors include female gender, obesity, vitamin A excess, tetracycline, danazol.  
Findings: headache, diplopia (usually from CN VI palsy), no change in mental status. Papilledema seen on funduscopy. Lumbar puncture reveals ↑ opening pressure and provides headache relief.  
Treatment: weight loss, acetazolamide, topiramate, invasive procedures for refractory cases (eg, repeat lumbar puncture, CSF shunt placement, optic nerve sheath fenestration surgery).



**Hydrocephalus**

↑ CSF volume → ventricular dilation +/- ↑ ICP.

**Communicating****Communicating hydrocephalus**

↓ CSF absorption by arachnoid granulations (eg, arachnoid scarring post-meningitis) → ↑ ICP, papilledema, herniation.

**Normal pressure hydrocephalus**



Affects the elderly; idiopathic; CSF pressure elevated only episodically; does not result in increased subarachnoid space volume. Expansion of ventricles **A** distorts the fibers of the corona radiata → triad of **urinary incontinence, ataxia, and cognitive dysfunction** (sometimes reversible). “**Wet, wobbly, and wacky.**” Characteristic magnetic gait (feet appear stuck to floor).

**Noncommunicating (obstructive)****Noncommunicating hydrocephalus**

Caused by structural blockage of CSF circulation within ventricular system (eg, stenosis of aqueduct of Sylvius; colloid cyst blocking foramen of Monro; tumor **B**).

**Hydrocephalus mimics****Ex vacuo ventriculomegaly**

Appearance of ↑ CSF on imaging **C**, but is actually due to decreased brain tissue and neuronal atrophy (eg, Alzheimer disease, advanced HIV, Pick disease, Huntington disease). ICP is normal; triad is not seen.

**Osmotic demyelination syndrome (central pontine myelinolysis)**

Acute paralysis, dysarthria, dysphagia, diplopia, loss of consciousness. Can cause “locked-in syndrome.” Massive axonal demyelination in pontine white matter **A** 2° to osmotic changes. Commonly iatrogenic, caused by overly rapid correction of hyponatremia. In contrast, correcting hypernatremia too quickly results in cerebral edema/herniation.

Correcting serum Na<sup>+</sup> too fast:


- “From low to high, your pons will die” (osmotic demyelination syndrome)
- “From high to low, your brain will blow” (cerebral edema/herniation)

**Multiple sclerosis**

Autoimmune inflammation and demyelination of CNS (brain and spinal cord). Patients can present with optic neuritis (sudden loss of vision resulting in Marcus Gunn pupils), INO, hemiparesis, hemisensory symptoms, bladder/bowel dysfunction. Symptoms may exacerbate with increased body temperature (eg, hot bath, exercise). Relapsing and remitting is most common clinical course. Most often affects women in their 20s and 30s; more common in Caucasians living farther from equator. Neck flexion may precipitate sensation of electric shock running down spine (Lhermitte phenomenon).

Charcot triad of MS is a **SIN**:

- **S**canning speech
- **I**ntention tremor (also **I**ncontinence and **I**nternuclear ophthalmoplegia)
- **N**ystagmus

**FINDINGS**

↑ IgG level and myelin basic protein in CSF. Oligoclonal bands are diagnostic. MRI is gold standard. Periventricular plaques **A** (areas of oligodendrocyte loss and reactive gliosis) with preservation of axons. Multiple white matter lesions disseminated in space and time.

**TREATMENT**

Slow progression with disease-modifying therapies (eg,  $\beta$ -interferon, glatiramer, natalizumab). Treat acute flares with IV steroids. Symptomatic treatment for neurogenic bladder (catheterization, muscarinic antagonists), spasticity (baclofen, GABA<sub>B</sub> receptor agonists), pain (TCAs, anticonvulsants).

**Acute inflammatory demyelinating polyradiculopathy**

Most common subtype of **Guillain-Barré syndrome**. Autoimmune condition that destroys Schwann cells → inflammation and demyelination of peripheral nerves and motor fibers. Results in symmetric ascending muscle weakness/paralysis and depressed tendon reflexes beginning in lower extremities. Facial paralysis in 50% of cases. May see autonomic dysregulation (eg, cardiac irregularities, hypertension, hypotension) or sensory abnormalities. Almost all patients survive; the majority recover completely after weeks to months.


↑ CSF protein with normal cell count (albuminocytologic dissociation). ↑ protein may cause papilledema.

Associated with infections (eg, *Campylobacter jejuni*, viral) → autoimmune attack of peripheral myelin due to molecular mimicry, inoculations, and stress, but no definitive link to pathogens.

Respiratory support is critical until recovery. Additional treatment: plasmapheresis, IV immunoglobulins. No role for steroids.

### Other demyelinating and dysmyelinating diseases


<b>Acute disseminated (postinfectious) encephalomyelitis</b>	Multifocal inflammation and demyelination after infection or vaccination. Presents with rapidly progressive multifocal neurologic symptoms, altered mental status.
<b>Charcot-Marie-Tooth disease</b>	Also known as hereditary motor and sensory neuropathy (HMSN). Group of progressive hereditary nerve disorders related to the defective production of proteins involved in the structure and function of peripheral nerves or the myelin sheath. Typically autosomal dominant inheritance pattern and associated with foot deformities (eg, pes cavus, hammer toe), lower extremity weakness (eg, foot drop) and sensory deficits.
<b>Krabbe disease</b>	Autosomal recessive lysosomal storage disease due to deficiency of galactocerebrosidase. Buildup of galactocerebroside and psychosine destroys myelin sheath. Findings: peripheral neuropathy, developmental delay, optic atrophy, globoid cells.
<b>Metachromatic leukodystrophy</b>	Autosomal recessive lysosomal storage disease, most commonly due to arylsulfatase A deficiency. Buildup of sulfatides → impaired production and destruction of myelin sheath. Findings: central and peripheral demyelination with ataxia, dementia.
<b>Progressive multifocal leukoencephalopathy</b>	Demyelination of CNS <b>A</b> due to destruction of oligodendrocytes. Seen in 2–4% of AIDS patients (reactivation of latent JC virus infection). Rapidly progressive, usually fatal. ↑ risk associated with natalizumab, rituximab.



<b>Adrenoleukodystrophy</b>	X-linked genetic disorder typically affecting males. Disrupts metabolism of very-long-chain fatty acids → excessive buildup in nervous system, adrenal gland, testes. Progressive disease that can lead to long-term coma/death and adrenal gland crisis.
-----------------------------	---

## Neurocutaneous disorders













<b>Sturge-Weber syndrome (encephalotrigeminal angiomatosis)</b>	Congenital, noninherited (sporadic), developmental anomaly of neural crest derivatives due to somatic mosaicism for an activating mutation in one copy of the <i>GNAQ</i> gene. Affects small (capillary-sized) blood vessels → port-wine stain of the face <b>A</b> (nevus flammeus, a non-neoplastic “birthmark” in CN V <sub>1</sub> /V <sub>2</sub> distribution); ipsilateral leptomeningeal angioma <b>B</b> → seizures/epilepsy; intellectual disability; and episcleral hemangioma → ↑ IOP → early-onset glaucoma. <b>STURGE-Weber</b> : Sporadic, port-wine <b>Stain</b> ; <b>T</b> ram track calcifications (opposing gyri); <b>U</b> nilateral; <b>R</b> etardation (intellectual disability); <b>G</b> laucoma, <b>GNAQ</b> gene; <b>E</b> pilepsy.
<b>Tuberous sclerosis</b>	<i>TSC1/TSC2</i> mutation on chromosome 16. Autosomal dominant, variable expression. <b>HAMARTOMAS</b> : Hamartomas in CNS and skin; Angiofibromas <b>C</b> ; Mitral regurgitation; Ash-leaf spots <b>D</b> ; cardiac Rhabdomyoma; (Tuberous sclerosis); autosomal dOminant; Mental retardation (intellectual disability); renal Angiomyolipoma <b>E</b> ; Seizures, Shagreen patches. ↑ incidence of subependymal giant cell astrocytomas and ungual fibromas.
<b>Neurofibromatosis type I (von Recklinghausen disease)</b>	Mutation in <i>NF1</i> tumor suppressor gene on chromosome 17 (17 letters in “von Recklinghausen”), which normally codes for neurofibromin, a negative regulator of RAS. Autosomal dominant, 100% penetrance. Café-au-lait spots <b>F</b> , cutaneous neurofibromas <b>G</b> , optic gliomas, pheochromocytomas, Lisch nodules (pigmented iris hamartomas <b>H</b> ).
<b>Neurofibromatosis type II</b>	Mutation in <i>NF2</i> tumor suppressor gene on chromosome 22. Autosomal dominant. Findings: bilateral acoustic schwannomas, juvenile cataracts, meningiomas, and ependymomas. <b>NF2</b> affects 2 ears, 2 eyes, and 2 parts of the brain.
<b>von Hippel-Lindau disease</b>	Deletion of <i>VHL</i> gene on chromosome 3p ( <i>VHL</i> = 3 letters). Autosomal dominant. Characterized by development of numerous tumors, both benign and malignant. <b>HARP</b> : Hemangioblastomas (high vascularity with hyperchromatic nuclei <b>I</b> ) in retina, brain stem, cerebellum, spine <b>J</b> ; Angiomas (eg, cavernous hemangiomas in skin, mucosa, organs); bilateral Renal cell carcinomas; Pheochromocytomas.



## Adult primary brain tumors


TUMOR	DESCRIPTION	HISTOLOGY
<b>Glioblastoma multiforme (grade IV astrocytoma)</b>	Common, highly malignant 1° brain tumor with ~ 1-year median survival. Found in cerebral hemispheres <b>A</b> . Can cross corpus callosum (“butterfly glioma”).	Astrocyte origin, GFAP ⊕. “Pseudopalisading” pleomorphic tumor cells <b>B</b> border central areas of necrosis and hemorrhage.
<b>Oligodendroglioma</b>	Relatively rare, slow growing. Most often in frontal lobes <b>C</b> . “Chicken-wire” capillary pattern.	Oligodendrocyte origin. “Fried egg” cells—round nuclei with clear cytoplasm <b>D</b> . Often calcified.
<b>Meningioma</b>	Common, typically benign 1° brain tumor. Most often occurs near surfaces of brain and in parasagittal region. Extra-axial (external to brain parenchyma) and may have a dural attachment (“tail” <b>E</b> ). Often asymptomatic; may present with seizures or focal neurologic signs. Resection and/or radiosurgery.	Arachnoid cell origin. Spindle cells concentrically arranged in a whorled pattern; psammoma bodies <b>F</b> (laminated calcifications).
<b>Hemangioblastoma</b>	Most often cerebellar <b>G</b> . Associated with von Hippel-Lindau syndrome when found with retinal angiomas. Can produce erythropoietin → 2° polycythemia.	Blood vessel origin. Closely arranged, thin-walled capillaries with minimal intervening parenchyma <b>H</b> .
<b>Pituitary adenoma</b>	Adenoma may be nonfunctioning or hyperfunctioning. Most commonly from lactotrophs (prolactinoma) <b>I</b> → hyperprolactinemia; less commonly adenoma of somatotrophs (GH) → acromegaly/gigantism; corticotrophs (ACTH) → Cushing’s disease. Rarely, adenoma of thyrotrophs (TSH) and gonadotroph (FSH, LH). Bitemporal hemianopia due to pressure on optic chiasm ( <b>J</b> shows normal visual field above, patient’s perspective below). Sequelae include hyper- or hypopituitarism, which may be caused by pituitary apoplexy.	Hyperplasia of only one type of endocrine cells found in pituitary (ie, lactotroph, gonadotroph, somatotroph, corticotroph).
<b>Schwannoma</b>	Classically at the cerebellopontine angle <b>K</b> , but can be along any peripheral nerve. Often localized to CN VIII in internal acoustic meatus → vestibular schwannoma. Bilateral vestibular schwannomas found in NF-2. Resection or stereotactic radiosurgery.	Schwann cell origin <b>L</b> , S-100 ⊕.

**Adult primary brain tumors (continued)**


TUMOR	DESCRIPTION	HISTOLOGY	
			
			
			

## Childhood primary brain tumors

TUMOR	DESCRIPTION	HISTOLOGY
<b>Pilocytic (low-grade) astrocytoma</b>	Usually well circumscribed. In children, most often found in posterior fossa <b>A</b> (eg, cerebellum). May be supratentorial. Benign; good prognosis.	Glial cell origin, GFAP ⊕. Rosenthal fibers—eosinophilic, corkscrew fibers <b>B</b> . Cystic + solid (gross).
<b>Medulloblastoma</b>	Most common malignant brain tumor in childhood. Commonly involves cerebellum <b>C</b> . Can compress 4th ventricle, causing noncommunicating hydrocephalus. Can send “drop metastases” to spinal cord.	Form of primitive neuroectodermal tumor (PNET). Homer-Wright rosettes, small blue cells <b>D</b> .
<b>Ependymoma</b>	Most commonly found in 4th ventricle <b>E</b> . Can cause hydrocephalus. Poor prognosis.	Ependymal cell origin. Characteristic perivascular rosettes <b>F</b> . Rod-shaped blepharoplasts (basal ciliary bodies) found near the nucleus.
<b>Craniopharyngioma</b>	Most common childhood supratentorial tumor. May be confused with pituitary adenoma (both cause bitemporal hemianopia).	Derived from remnants of Rathke pouch. Calcification is common <b>G H</b> . Cholesterol crystals found in “motor oil”—like fluid within tumor.
<b>Pinealoma</b>	Tumor of pineal gland. Can cause Parinaud syndrome (compression of tectum → vertical gaze palsy); obstructive hydrocephalus (compression of cerebral aqueduct); precocious puberty in males (β-hCG production).	Similar to germ cell tumors (eg, testicular seminoma).



**Herniation syndromes**



- 1** Cingulate (subfalcine) herniation under falx cerebri      Can compress anterior cerebral artery.

---

- 2** Transtentorial (central/downward) herniation      Caudal displacement of brain stem → rupture of paramedian basilar artery branches → Duret hemorrhages. Usually fatal.

---

- 3** Uncal herniation      Uncus = medial temporal lobe. Compresses ipsilateral CN III (blown pupil, “down-and-out” gaze), ipsilateral PCA (contralateral homonymous hemianopia with macular sparing), contralateral crus cerebri at the Kernohan notch (ipsilateral paresis; a “false localization” sign).

---







- 4** Cerebellar tonsillar herniation into the foramen magnum      Coma and death result when these herniations compress the brain stem.

**Motor neuron signs**

SIGN	UMN LESION	LMN LESION	COMMENTS
Weakness	+	+	<b>Lower</b> motor neuron = everything <b>lowered</b> (less muscle mass, ↓ muscle tone, ↓ reflexes, downgoing toes).
Atrophy	–	+	
Fasciculations	–	+	<b>Upper</b> motor neuron = everything <b>up</b> (tone, DTRs, toes).
Reflexes	↑	↓	
Tone	↑	↓	Fasciculations = muscle twitching. Positive Babinski is normal in infants.
Babinski	+	–	
Spastic paresis	+	–	
Flaccid paralysis	–	+	
Clasp knife spasticity	+	–	



## Spinal cord lesions


AREA AFFECTED	DISEASE	CHARACTERISTICS
	Poliomyelitis and Werdnig-Hoffmann disease	<p>Congenital degeneration of anterior horns of spinal cord. LMN lesions only. “Floppy baby” with marked hypotonia and tongue fasciculations. Infantile type has median age of death of 7 months. Autosomal recessive inheritance.</p> <p>Poliomyelitis → asymmetric weakness. Werdnig-Hoffmann disease → symmetric weakness.</p>
	Amyotrophic lateral sclerosis	<p>Combined UMN and LMN deficits with no sensory or bowel/bladder deficits (due to loss of cortical and spinal cord motor neurons, respectively). Can be caused by defect in superoxide dismutase 1. Commonly presents with asymmetric limb weakness (hands/feet), fasciculations, eventual atrophy. Fatal. Commonly known as Lou Gehrig disease. Treatment: riluzole.</p>
	Complete occlusion of anterior spinal artery	<p>Sparses dorsal columns and Lissauer tract; mid-thoracic ASA territory is watershed area, as artery of Adamkiewicz supplies ASA below ~ T8. Presents with UMN deficit below the lesion (corticospinal tract), LMN deficit at the level of the lesion (anterior horn), and loss of pain and temperature sensation below the lesion (spinothalamic tract).</p>
	Tabes dorsalis	<p>Caused by 3<sup>o</sup> syphilis. Results from degeneration (demyelination) of dorsal columns and roots → progressive sensory ataxia (impaired proprioception → poor coordination). Associated with Charcot joints, shooting pain, Argyll Robertson pupils. Exam will demonstrate absence of DTRs and ⊕ Romberg sign.</p>
	Syringomyelia	<p>Syrinx expands and damages anterior white commissure of spinothalamic tract (2nd-order neurons) → bilateral loss of pain and temperature sensation in cape-like distribution; seen with Chiari I malformation; can expand and affect other tracts.</p>
	Vitamin B <sub>12</sub> deficiency	<p>Subacute combined degeneration (SCD)—demyelination of Spinocerebellar tracts, lateral Corticospinal tracts, and Dorsal columns. Ataxic gait, paresthesia, impaired position/vibration sense.</p>
	Cauda equina syndrome	<p>Unilateral symptoms including radicular pain, absent knee and ankle reflex, loss of bladder and anal sphincter control. Can cause saddle anesthesia. Treatment: emergent surgery and steroids. Due to compression of spinal roots from L2 and below, often caused by intravertebral disk herniation or tumors.</p>

**Poliomyelitis**

Caused by poliovirus (fecal-oral transmission). Replicates in oropharynx and small intestine before spreading via bloodstream to CNS. Infection causes destruction of cells in anterior horn of spinal cord (LMN death).

Signs of LMN lesion: asymmetric weakness, hypotonia, flaccid paralysis, fasciculations, hyporeflexia, muscle atrophy. Respiratory muscle involvement leads to respiratory failure. Signs of infection: malaise, headache, fever, nausea, etc.


CSF shows ↑ WBCs (lymphocytic pleocytosis) and slight ↑ of protein (with no change in CSF glucose). Virus recovered from stool or throat.

**Brown-Séquard syndrome**

Hemisection of spinal cord. Findings:

- 1 Ipsilateral loss of all sensation **at** level of lesion
- 2 Ipsilateral LMN signs (eg, flaccid paralysis) **at** level of lesion
- 3 Ipsilateral UMN signs **below** level of lesion (due to corticospinal tract damage)
- 4 Ipsilateral loss of proprioception, vibration, light (2-point discrimination) touch, and tactile sense **below** level of lesion (due to dorsal column damage).
- 5 Contralateral pain, temperature, and crude (non-discriminative) touch **below** level of lesion (due to spinothalamic tract damage)

If lesion occurs above T1, patient may present with ipsilateral Horner syndrome due to damage of oculosympathetic pathway.

**Friedreich ataxia**

Autosomal recessive trinucleotide repeat disorder ( $GAA$ )<sub>n</sub> on chromosome 9 in gene that encodes frataxin (iron binding protein). Leads to impairment in mitochondrial functioning. Degeneration of multiple spinal cord tracts → muscle weakness and loss of DTRs, vibratory sense, proprioception. **Staggering** gait, frequent **falling**, nystagmus, dysarthria, pes cavus, hammer toes, **diabetes mellitus**, **hypertrophic cardiomyopathy** (cause of death). Presents in childhood with kyphoscoliosis **A**.

Friedreich is **F**ratastic (**frataxin**): he's your favorite **frat** brother, always **staggering** and **falling** but has a **sweet, big heart**. Ataxic **GAA**it.

### Common cranial nerve lesions

<b>CN V motor lesion</b>	Jaw deviates <b>toward</b> side of lesion due to unopposed force from the opposite pterygoid muscle.
<b>CN X lesion</b>	Uvula deviates <b>away</b> from side of lesion. Weak side collapses and uvula points away.
<b>CN XI lesion</b>	Weakness turning head to contralateral side of lesion (SCM). Shoulder droop on side of lesion (trapezius). The left SCM contracts to help turn the head to the right.
<b>CN XII lesion</b>	LMN lesion. Tongue deviates <b>toward</b> side of lesion (“lick your wounds”) due to weakened tongue muscles on affected side.

### Facial nerve lesions


#### Upper motor neuron lesion

Destruction of motor cortex or connection between motor cortex and facial nucleus in pons → contralateral paralysis of lower muscles of facial expression. Forehead is spared due to its bilateral UMN innervation.

#### Lower motor neuron lesion

Destruction of facial nucleus or CN VII anywhere along its course → ipsilateral paralysis of upper and lower muscles of facial expression **A**, hyperacusis, loss of taste sensation to anterior tongue.

When idiopathic (most common), facial nerve palsy is called **Bell palsy**. May also be caused by Lyme disease, herpes simplex, herpes zoster (Ramsay Hunt syndrome), sarcoidosis, tumors (eg, parotid gland), diabetes mellitus. Treatment is corticosteroids, acyclovir. Most patients gradually recover function.



## ▶ NEUROLOGY—OTOLOGY

**Auditory physiology**

<b>Outer ear</b>	Visible portion of ear (pinna), includes auditory canal and eardrum. Transfers sound waves via vibration of eardrum.
<b>Middle ear</b>	Air-filled space with three bones called the ossicles (malleus, incus, stapes). Ossicles conduct and amplify sound from eardrum to inner ear.
<b>Inner ear</b>	Snail-shaped, fluid-filled cochlea. Contains basilar membrane that vibrates 2° to sound waves. Vibration transduced via specialized hair cells → auditory nerve signaling → brain stem. Each frequency leads to vibration at specific location on basilar membrane (tonotopy): <ul style="list-style-type: none"> <li>▪ Low frequency heard at apex near helicotrema (wide and flexible).</li> <li>▪ High frequency heard best at base of cochlea (thin and rigid).</li> </ul>

**Diagnosing hearing loss**


	RINNE TEST	WEBER TEST
<b>Conductive</b>	Abnormal (bone > air)	Localizes to affected ear
<b>Sensorineural</b>	Normal (air > bone)	Localizes to unaffected ear

**Types of hearing loss**

<b>Noise-induced</b>	Damage to stereociliated cells in organ of Corti. Loss of high-frequency hearing first. Sudden extremely loud noises can produce hearing loss due to tympanic membrane rupture.
<b>Presbycusis</b>	<b>Aging</b> -related sensorineural hearing loss (often of higher frequencies) due to destruction of hair cells at the cochlear base (preserved low-frequency hearing at apex).

**Cholesteatoma**

Overgrowth of desquamated keratin debris within the middle ear space (**A**, arrows); may erode ossicles, mastoid air cells → conductive hearing loss.



**Vertigo**

Sensation of spinning while actually stationary. Subtype of “dizziness,” but distinct from “lightheadedness.”


<b>Peripheral vertigo</b>	More common. Inner ear etiology (eg, semicircular canal debris, vestibular nerve infection, Ménière disease, benign paroxysmal positional vertigo). Positional testing → delayed horizontal nystagmus.
<b>Central vertigo</b>	Brain stem or cerebellar lesion (eg, stroke affecting vestibular nuclei or posterior fossa tumor). Findings: directional or purely vertical nystagmus, skew deviation, diplopia, dysmetria. Positional testing → immediate nystagmus in any direction; may change directions. Focal neurologic findings.

## ▶ NEUROLOGY—OPHTHALMOLOGY

## Normal eye



## Conjunctivitis



Inflammation of the conjunctiva → red eye **A**.

Allergic—itchy eyes, bilateral.

Bacterial—pus; treat with antibiotics.

Viral—most common, often adenovirus; sparse mucous discharge, swollen preauricular node; self-resolving.

## Refractive errors

Common cause of impaired vision, correctable with glasses.

## Hyperopia

Also known as “farsightedness.” Eye too short for refractive power of cornea and lens → light focused behind retina. Correct with convex (converging) lenses.

## Myopia

Also known as “nearsightedness.” Eye too long for refractive power of cornea and lens → light focused in front of retina. Correct with concave (diverging) lens.

## Astigmatism


Abnormal curvature of cornea → different refractive power at different axes. Correct with cylindrical lens.

## Presbyopia

**Aging**-related impaired accommodation (focusing on near objects), primarily due to ↓ lens elasticity, changes in lens curvature, ↓ strength of the ciliary muscle. Patients often need “reading glasses” (magnifiers).

**Cataract**

Painless, often bilateral, opacification of lens **A**, often resulting in ↓ vision. Acquired risk factors: ↑ age, smoking, excessive alcohol use, excessive sunlight, prolonged corticosteroid use, diabetes mellitus, trauma, infection; congenital risk factors: classic galactosemia, galactokinase deficiency, trisomies (13, 18, 21), TORCHeS infections (eg, rubella), Marfan syndrome, Alport syndrome, myotonic dystrophy, neurofibromatosis 2.

**Aqueous humor pathway**

**Glaucoma**

Optic disc atrophy with characteristic cupping (thinning of outer rim of optic nerve head **B** versus normal **A**), usually with elevated intraocular pressure (IOP) and progressive peripheral visual field loss if untreated. Treatment is through pharmacologic or surgical lowering of the IOP.

**Open-angle glaucoma**

Associated with ↑ age, African-American race, family history. Painless, more common in US. Primary—cause unclear.

Secondary—blocked trabecular meshwork from WBCs (eg, uveitis), RBCs (eg, vitreous hemorrhage), retinal elements (eg, retinal detachment).



**Closed- or narrow-angle glaucoma**

Primary—enlargement or forward movement of lens against central iris (pupil margin) → obstruction of normal aqueous flow through pupil → fluid builds up behind iris, pushing peripheral iris against cornea **C** and impeding flow through trabecular meshwork.


Secondary—hypoxia from retinal disease (eg, diabetes mellitus, vein occlusion) induces vasoproliferation in iris that contracts angle.

**Chronic closure**—often asymptomatic with damage to optic nerve and peripheral vision.

**Acute closure**—true ophthalmic emergency. ↑ IOP pushes iris forward → angle closes abruptly. Very painful, red eye **D**, sudden vision loss, halos around lights, frontal headache, fixed and mid-dilated pupil. Do not give epinephrine because of its mydriatic effect.


**Uveitis**

Inflammation of uvea; specific name based on location within affected eye. Anterior uveitis: iritis; posterior uveitis: choroiditis and/or retinitis. May have hypopyon (accumulation of pus in anterior chamber **A**) or conjunctival redness. Associated with systemic inflammatory disorders (eg, sarcoidosis, rheumatoid arthritis, juvenile idiopathic arthritis, HLA-B27–associated conditions).

**Age-related macular degeneration**


Degeneration of macula (central area of retina). Causes distortion (metamorphopsia) and eventual loss of central vision (scotomas).

- **Dry** (nonexudative, > 80%)—**D**eposition of yellowish extracellular material in between Bruch membrane and retinal pigment epithelium (“**D**rusen”) **A** with gradual ↓ in vision. Prevent progression with multivitamin and antioxidant supplements.
- **Wet** (exudative, 10–15%)—rapid loss of vision due to bleeding 2° to choroidal neovascularization. Treat with anti-VEGF (vascular endothelial growth factor) injections (eg, ranibizumab).

**Diabetic retinopathy**


Retinal damage due to chronic hyperglycemia. Two types:

- Nonproliferative—damaged capillaries leak blood → lipids and fluid seep into retina → hemorrhages (arrows in **A**) and macular edema. Treatment: blood sugar control.
- Proliferative—chronic hypoxia results in new blood vessel formation with resultant traction on retina. Treatment: peripheral retinal photocoagulation, surgery, anti-VEGF.

**Retinal vein occlusion**


Blockage of central or branch retinal vein due to compression from nearby arterial atherosclerosis.

Retinal hemorrhage and venous engorgement (arrows in **A**), edema in affected area.

**Retinal detachment**


Separation of neurosensory layer of retina (photoreceptor layer with rods and cones) from outermost pigmented epithelium (normally shields excess light, supports retina) → degeneration of photoreceptors → vision loss. May be 2° to retinal breaks, diabetic traction, inflammatory effusions. Visualized on fundoscopy as crinkling of retinal tissue **A** and changes in vessel direction.

Breaks more common in patients with high myopia and/or history of head trauma. Often preceded by posterior vitreous detachment (“flashes” and “floaters”) and eventual monocular loss of vision like a “curtain drawn down.” Surgical emergency.


**Central retinal artery occlusion**

Acute, painless monocular vision loss. Retina cloudy with attenuated vessels and “cherry-red” spot at fovea (center of macula) **A**. Evaluate for embolic source (eg, carotid artery atherosclerosis, cardiac vegetations, patent foramen ovale).




**Retinitis pigmentosa**

Inherited retinal degeneration. Painless, progressive vision loss beginning with night blindness (rods affected first). Bone spicule-shaped deposits around macula **A**.

**Retinitis**

Retinal edema and necrosis (arrows in **A**) leading to scar. Often viral (CMV, HSV, VZV), but can be bacterial or parasitic. May be associated with immunosuppression.

**Papilledema**

Optic disc swelling (usually bilateral) due to  $\uparrow$  ICP (eg,  $2^\circ$  to mass effect). Enlarged blind spot and elevated optic disc with blurred margins **A**.

**Pupillary control**

**Miosis**


Constriction, parasympathetic:

- 1st neuron: Edinger-Westphal nucleus to ciliary ganglion via CN III
- 2nd neuron: short ciliary nerves to sphincter pupillae muscles

**Pupillary light reflex**

Light in either retina sends a signal via CN II to pretectal nuclei (dashed lines in image) in midbrain that activates bilateral Edinger-Westphal nuclei; pupils contract bilaterally (consensual reflex).

Result: illumination of 1 eye results in bilateral pupillary constriction.



**Mydriasis**

Dilation, sympathetic:

- 1st neuron: hypothalamus to ciliospinal center of Budge (C8–T2)
- 2nd neuron: exit at T1 to superior cervical ganglion (travels along cervical sympathetic chain near lung apex, subclavian vessels)
- 3rd neuron: plexus along internal carotid, through cavernous sinus; enters orbit as long ciliary nerve to pupillary dilator muscles. Sympathetic fibers also innervate smooth muscle of eyelids (minor retractors) and sweat glands of forehead and face.

**Marcus Gunn pupil**

Afferent pupillary defect—due to optic nerve damage or severe retinal injury. ↓ bilateral pupillary constriction when light is shone in affected eye relative to unaffected eye. Tested with “swinging flashlight test.”

**Horner syndrome**


Sympathetic denervation of face →:

- **P**tosis (slight drooping of eyelid: superior tarsal muscle)
- **A**nhidrosis (absence of sweating) and flushing of affected side of face
- **M**iosis (pupil constriction)


Associated with lesion of spinal cord above T1 (eg, Brown-Séquard syndrome, late-stage syringomyelia) or of the stellate ganglion alongside the spinal cord (eg, Pancoast tumor). Any interruption results in Horner syndrome.

**PAM** is **horny** (Horner).


**P**tosis, **a**nhidrosis, and **m**iosis.



## Ocular motility



CN **VI** innervates the **Lateral Rectus**.  
 CN **IV** innervates the **Superior Oblique**.  
 CN **III** innervates the **Rest**.  
 The “chemical formula” **LR<sub>6</sub>SO<sub>4</sub>R<sub>3</sub>**.  
 The superior oblique abducts, intorts, and depresses while adducted.




To test each muscle, ask patient to move his/her eye in the path diagrammed to the right, from neutral position toward the muscle being tested.

**O**bliques go **O**pposite (left SO and IO tested with patient looking right).  
**IOU**: **IO** tested looking **U**p.

**CN III, IV, VI palsies**

**CN III damage**



CN III has both motor (central) and parasympathetic (peripheral) components. Motor output to extraocular muscles—affected primarily by vascular disease (eg, diabetes mellitus: glucose → sorbitol) due to ↓ diffusion of oxygen and nutrients to the interior fibers from compromised vasculature that resides on outside of nerve. Signs: ptosis, “down and out” gaze.

Parasympathetic output—fibers on the periphery are first affected by compression (eg, PCom aneurysm, uncal herniation). Signs: diminished or absent pupillary light reflex, “blown pupil” often with “down-and-out” gaze **A**.



**CN IV damage**

Eye moves upward, particularly with contralateral gaze **B** (problems going down stairs, may present with compensatory head tilt in the opposite direction).



**CN VI damage**


Medially directed eye that cannot abduct **C**.



**Visual field defects**

1. Right anopia
2. Bitemporal hemianopia (pituitary lesion, chiasm)
3. Left homonymous hemianopia
4. Left upper quadrantanopia (right temporal lesion, MCA)
5. Left lower quadrantanopia (right parietal lesion, MCA)
6. Left hemianopia with macular sparing (PCA infarct)
7. Central scotoma (eg, macular degeneration)

Meyer **L**oop—**L**ower retina; **L**oops around inferior horn of **L**ateral ventricle.  
 Dorsal optic radiation—superior retina; takes shortest path via internal capsule.




Note: When an image hits 1° visual cortex, it is upside down and left-right reversed.

**Cavernous sinus**

Collection of venous sinuses on either side of pituitary. Blood from eye and superficial cortex → cavernous sinus → internal jugular vein.

CNs III, IV, V<sub>1</sub>, VI, and occasionally V<sub>2</sub> plus postganglionic sympathetic pupillary fibers en route to orbit all pass through cavernous sinus. Cavernous portion of internal carotid artery is also here.


**Cavernous sinus syndrome**—presents with variable ophthalmoplegia, ↓ corneal sensation, Horner syndrome and occasional decreased maxillary sensation. 2° to pituitary tumor mass effect, carotid-cavernous fistula, or cavernous sinus thrombosis related to infection. CN VI is most susceptible to injury.



### Internuclear ophthalmoplegia

Medial longitudinal fasciculus (MLF): pair of tracts that allows for crosstalk between CN VI and CN III nuclei. Coordinates both eyes to move in same horizontal direction. Highly myelinated (must communicate quickly so eyes move at same time). Lesions may be unilateral or bilateral (latter classically seen in multiple sclerosis).


Lesion in MLF = internuclear ophthalmoplegia (INO), a conjugate horizontal gaze palsy. Lack of communication such that when CN VI nucleus activates ipsilateral lateral rectus, contralateral CN III nucleus does not stimulate medial rectus to contract. Abducting eye gets nystagmus (CN VI overfires to stimulate CN III). Convergence normal.



### MLF in MS.

When looking left, the left nucleus of CN VI fires, which contracts the left lateral rectus and stimulates the contralateral (right) nucleus of CN III via the right MLF to contract the right medial rectus.

Directional term (eg, right INO, left INO) refers to which eye is paralyzed.



## ▶ NEUROLOGY—PHARMACOLOGY

## Epilepsy drugs

	PARTIAL (FOCAL)	GENERALIZED			MECHANISM	SIDE EFFECTS	NOTES
		TONIC-CLONIC	ABSENCE	STATUS EPILEPTICUS			
<b>Ethosuximide</b>			*	✓	Blocks thalamic T-type $\text{Ca}^{2+}$ channels	<b>EFCHIJ</b> —Ethosuximide causes <b>F</b> atigue, <b>G</b> I distress, <b>H</b> eadache, <b>I</b> tching (and urticaria), and Stevens-Johnson syndrome	Sucks to have <b>S</b> ilent (absence) <b>S</b> eizures
<b>Benzodiazepines</b> (eg, diazepam, lorazepam, midazolam)			**	✓	↑ $\text{GABA}_A$ action	Sedation, tolerance, dependence, respiratory depression	Also for eclampsia seizures (1st line is $\text{MgSO}_4$ )
<b>Phenobarbital</b>	✓	✓			↑ $\text{GABA}_A$ action	Sedation, tolerance, dependence, induction of cytochrome P-450, cardiorespiratory depression	1st line in neonates
<b>Phenytoin, fosphenytoin</b>	✓	*	✓	***	Blocks $\text{Na}^+$ channels; zero-order kinetics	Neurologic: nystagmus, diplopia, ataxia, sedation, peripheral neuropathy. Dermatologic: hirsutism, Stevens-Johnson syndrome, gingival hyperplasia, DRESS syndrome. Musculoskeletal: osteopenia, SLE-like syndrome. Hematologic: megaloblastic anemia. Reproductive: teratogenesis (fetal hydantoin syndrome). Other: cytochrome P-450 induction	
<b>Carbamazepine</b>	* ✓	✓			Blocks $\text{Na}^+$ channels	Diplopia, ataxia, blood dyscrasias (agranulocytosis, aplastic anemia), liver toxicity, teratogenesis, induction of cytochrome P-450, SIADH, Stevens-Johnson syndrome	1st line for trigeminal neuralgia
<b>Valproic acid</b>	✓	* ✓	✓		↑ $\text{Na}^+$ channel inactivation, ↑ $\text{GABA}$ concentration by inhibiting $\text{GABA}$ transaminase	GI distress, rare but fatal hepatotoxicity (measure LFTs), pancreatitis, neural tube defects, tremor, weight gain, contraindicated in pregnancy	Also used for myoclonic seizures, bipolar disorder, migraine prophylaxis
<b>Vigabatrin</b>	✓				↑ $\text{GABA}$ by irreversibly inhibiting $\text{GABA}$ transaminase	Permanent visual loss (black box warning)	
<b>Gabapentin</b>	✓				Primarily inhibits high-voltage-activated $\text{Ca}^{2+}$ channels; designed as $\text{GABA}$ analog	Sedation, ataxia	Also used for peripheral neuropathy, postherpetic neuralgia
<b>Topiramate</b>	✓	✓			Blocks $\text{Na}^+$ channels, ↑ $\text{GABA}$ action	Sedation, mental dulling, kidney stones, weight loss, glaucoma	Also used for migraine prevention
<b>Lamotrigine</b>	✓	✓	✓		Blocks voltage-gated $\text{Na}^+$ channels, inhibits the release of glutamate	Stevens-Johnson syndrome (must be titrated slowly)	
<b>Levetiracetam</b>	✓	✓			Unknown; may modulate $\text{GABA}$ and glutamate release	Fatigue, drowsiness, headache, neuropsychiatric symptoms (eg, personality changes)	
<b>Tiagabine</b>	✓				↑ $\text{GABA}$ by inhibiting reuptake		

\* = 1st line; \*\* = 1st line for acute; \*\*\* = 1st line for prophylaxis.

<b>Barbiturates</b>	Phenobarbital, pentobarbital, thiopental, secobarbital.	
MECHANISM	Facilitate GABA <sub>A</sub> action by ↑ <b>duration</b> of Cl <sup>-</sup> channel opening, thus ↓ neuron firing (barbiturates ↑ <b>duration</b> ). Contraindicated in porphyria.	
CLINICAL USE	Sedative for anxiety, seizures, insomnia, induction of anesthesia (thiopental).	
ADVERSE EFFECTS	Respiratory and cardiovascular depression (can be fatal); CNS depression (can be exacerbated by alcohol use); dependence; drug interactions (induces cytochrome P-450). Overdose treatment is supportive (assist respiration and maintain BP).	
<b>Benzodiazepines</b>	Diazepam, lorazepam, triazolam, temazepam, oxazepam, midazolam, chlordiazepoxide, alprazolam.	
MECHANISM	Facilitate GABA <sub>A</sub> action by ↑ <b>frequency</b> of Cl <sup>-</sup> channel opening. ↓ REM sleep. Most have long half-lives and active metabolites (exceptions [ATOM]: Alprazolam, Triazolam, Oxazepam, and Midazolam are short acting → higher addictive potential).	“Frenzodiazepines” ↑ <b>frequency</b> . Benzos, barbs, and alcohol all bind the GABA <sub>A</sub> receptor, which is a ligand-gated Cl <sup>-</sup> channel. Oxazepam, Temazepam, and Lorazepam are metabolized <b>Outside The Liver</b>
CLINICAL USE	Anxiety, spasticity, status epilepticus (lorazepam and diazepam), eclampsia, detoxification (especially alcohol withdrawal–DTs), night terrors, sleepwalking, general anesthetic (amnesia, muscle relaxation), hypnotic (insomnia).	
ADVERSE EFFECTS	Dependence, additive CNS depression effects with alcohol. Less risk of respiratory depression and coma than with barbiturates. Treat overdose with flumazenil (competitive antagonist at GABA benzodiazepine receptor). Can precipitate seizures by causing acute benzodiazepine withdrawal.	
<b>Nonbenzodiazepine hypnotics</b>	<b>Z</b> olpidem, <b>Z</b> aleplon, <b>esZ</b> opiclone. “All <b>ZZZ</b> s put you to sleep.”	
MECHANISM	Act via the BZ1 subtype of the GABA receptor. Effects reversed by flumazenil. Sleep cycle less affected as compared with benzodiazepine hypnotics.	
CLINICAL USE	Insomnia.	
ADVERSE EFFECTS	Ataxia, headaches, confusion. Short duration because of rapid metabolism by liver enzymes. Unlike older sedative-hypnotics, cause only modest day-after psychomotor depression and few amnestic effects. ↓ dependence risk than benzodiazepines.	



**Suvorexant**

MECHANISM	Orexin (hypocretin) receptor antagonist.
CLINICAL USE	Insomnia.
ADVERSE EFFECTS	CNS depression, headache, dizziness, abnormal dreams, upper respiratory tract infection. Contraindicated in patients with narcolepsy. Not recommended in patients with liver disease. No or low physical dependence. Contraindicated with strong CYP3A4 inhibitors.

**Ramelteon**

MECHANISM	Melatonin receptor agonist, binds MT1 and MT2 in suprachiasmatic nucleus.
CLINICAL USE	Insomnia.
ADVERSE EFFECTS	Dizziness, nausea, fatigue, headache. No dependence (not a controlled substance).


**Triptans****Sumatriptan**

MECHANISM	5-HT <sub>1B/1D</sub> agonists. Inhibit trigeminal nerve activation; prevent vasoactive peptide release; induce vasoconstriction.	A <b>SUMo</b> wrestler <b>TRIPs</b> <b>AND</b> falls on your <b>head</b> .
CLINICAL USE	Acute migraine, cluster <b>head</b> ache attacks.	
ADVERSE EFFECTS	Coronary vasospasm (contraindicated in patients with CAD or Prinzmetal angina), mild paresthesia, serotonin syndrome (in combination with other 5-HT agonists).	

**Parkinson disease drugs**

Parkinsonism is due to loss of dopaminergic neurons and excess cholinergic activity.  
**B**romocriptine, **A**mantadine, **L**evodopa (with carbidopa), **S**elegiline (and COMT inhibitors),  
**A**ntimuscarinics (**BALSA**).

STRATEGY	AGENTS
Dopamine agonists	Ergot— <b>B</b> romocriptine Non-ergot (preferred)—pramipexole, ropinirole
↑ dopamine availability	<b>A</b> mantadine (↑ dopamine release and ↓ dopamine reuptake); toxicity = ataxia, livedo reticularis.
↑ L-DOPA availability	Agents prevent peripheral (pre-BBB) L-DOPA degradation → ↑ L-DOPA entering CNS → ↑ central L-DOPA available for conversion to dopamine. <ul style="list-style-type: none"> <li>▪ <b>L</b>evodopa (L-DOPA)/carbidopa—carbidopa blocks peripheral conversion of L-DOPA to dopamine by inhibiting DOPA decarboxylase. Also reduces side effects of peripheral L-DOPA conversion into dopamine (eg, nausea, vomiting).</li> <li>▪ Entacapone, tolcapone—prevent peripheral L-DOPA degradation to 3-O-methyldopa (3-OMD) by inhibiting COMT.</li> </ul>
Prevent dopamine breakdown	Agents act centrally (post-BBB) to inhibit breakdown of dopamine. <ul style="list-style-type: none"> <li>▪ <b>S</b>elegiline—blocks conversion of dopamine into DOPAC by selectively inhibiting MAO-B.</li> <li>▪ Tolcapone—blocks conversion of dopamine to 3-methoxytyramine (3-MT) by inhibiting central COMT.</li> </ul>
Curb excess cholinergic activity	<b>B</b> enzotropine, trihexyphenidyl ( <b>A</b> ntimuscarinic; improves tremor and rigidity but has little effect on bradykinesia in <b>P</b> arkinson disease). <b>P</b> ark your Mercedes- <b>B</b> enz.



**Levodopa/carbidopa**

MECHANISM	↑ level of dopamine in brain. Unlike dopamine, L-DOPA can cross blood-brain barrier and is converted by dopa decarboxylase in the CNS to dopamine. Carbidopa, a peripheral DOPA decarboxylase inhibitor, is given with L-DOPA to ↑ the bioavailability of L-DOPA in the brain and to limit peripheral side effects.
CLINICAL USE	Parkinson disease.
ADVERSE EFFECTS	Arrhythmias from ↑ peripheral formation of catecholamines. Long-term use can lead to dyskinesia following administration (“on-off” phenomenon), akinesia between doses.

**Selegiline, rasagiline**

MECHANISM	Selectively inhibit MAO-B (metabolize dopamine) → ↑ dopamine availability.
CLINICAL USE	Adjunctive agent to L-DOPA in treatment of Parkinson disease.
ADVERSE EFFECTS	May enhance adverse effects of L-DOPA.

**Huntington disease drugs**

Tetrabenazine and reserpine—inhibit vesicular monoamine transporter (VMAT) → ↓ dopamine vesicle packaging and release.  
Haloperidol—D<sub>2</sub> receptor antagonist.

**Riluzole**

Treatment for ALS that modestly ↑ survival by ↓ glutamate excitotoxicity via an unclear mechanism.

For **Lou** Gehrig disease, give **rilouzole**.

**Alzheimer disease drugs****Memantine**

MECHANISM	NMDA receptor antagonist; helps prevent excitotoxicity (mediated by Ca <sup>2+</sup> ).
ADVERSE EFFECTS	Dizziness, confusion, hallucinations.

**Donepezil, galantamine, rivastigmine, tacrine**

MECHANISM	AChE inhibitors.
ADVERSE EFFECTS	Nausea, dizziness, insomnia.

**Anesthetics—general principles**

CNS drugs must be lipid soluble (cross the blood-brain barrier) or be actively transported.  
Drugs with ↓ solubility in blood = rapid induction and recovery times.

Drugs with ↑ solubility in lipids = ↑ potency =  $\frac{1}{\text{MAC}}$

**MAC** = **M**inimal **A**lveolar **C**oncentration (of inhaled anesthetic) required to prevent 50% of subjects from moving in response to noxious stimulus (eg, skin incision).

Examples: nitrous oxide (N<sub>2</sub>O) has ↓ blood and lipid solubility, and thus fast induction and low potency. Halothane, in contrast, has ↑ lipid and blood solubility, and thus high potency and slow induction.

<b>Inhaled anesthetics</b>	Desflur <b>ane</b> , haloth <b>ane</b> , enflur <b>ane</b> , isoflur <b>ane</b> , sevoflur <b>ane</b> , methoxyflur <b>ane</b> , N <sub>2</sub> O.
MECHANISM	Mechanism unknown.
EFFECTS	Myocardial depression, respiratory depression, nausea/emesis, ↑ cerebral blood flow (↓ cerebral metabolic demand).
ADVERSE EFFECTS	<b>Hepatotoxicity</b> (halothane), <b>nephrotoxicity</b> (methoxyflurane), proconvulsant (enflurane, epileptogenic), expansion of trapped gas in a body cavity (N <sub>2</sub> O). <b>Malignant hyperthermia</b> —rare, life-threatening condition in which inhaled anesthetics or succinylcholine induce fever and severe muscle contractions. Susceptibility is often inherited as autosomal dominant with variable penetrance. Mutations in voltage-sensitive ryanodine receptor cause ↑ Ca <sup>2+</sup> release from sarcoplasmic reticulum. Treatment: dantrolene (a ryanodine receptor antagonist).
<b>Intravenous anesthetics</b>	<b>The Mighty King Proposes to Oprah.</b>
<b>Barbiturates</b> (Thiopental)	High potency, high lipid solubility, rapid entry into brain. Used for induction of anesthesia and short surgical procedures. Effect terminated by rapid redistribution into tissue and fat. ↓ cerebral blood flow.
<b>Benzodiazepines</b> (Midazolam)	Used for endoscopy; used adjunctively with gaseous anesthetics and narcotics. May cause severe postoperative respiratory depression, ↓ BP (treat overdose with flumazenil), anterograde amnesia.
<b>Arylcyclohexylamines</b> (Ketamine)	PCP analogs that act as dissociative anesthetics. Block NMDA receptors. Cardiovascular stimulants. Cause disorientation, hallucination, unpleasant dreams. ↑ cerebral blood flow.
<b>Propofol</b>	Used for sedation in ICU, rapid anesthesia induction, short procedures. Less postoperative nausea than thiopental. Potentiates GABA <sub>A</sub> .
<b>Opioids</b>	Morphine, fentanyl used with other CNS depressants during general anesthesia.
<b>Local anesthetics</b>	Esters—procaine, cocaine, tetracaine, benzocaine. Amides— <b>I</b> doca <b>I</b> ne, mep <b>I</b> vaca <b>I</b> ne, bup <b>I</b> vaca <b>I</b> ne (am <b>I</b> des have <b>2 I</b> 's in name).
MECHANISM	Block Na <sup>+</sup> channels by binding to specific receptors on inner portion of channel. Most effective in rapidly firing neurons. 3° amine local anesthetics penetrate membrane in uncharged form, then bind to ion channels as charged form. Can be given with vasoconstrictors (usually epinephrine) to enhance local action—↓ bleeding, ↑ anesthesia by ↓ systemic concentration. In infected (acidic) tissue, alkaline anesthetics are charged and cannot penetrate membrane effectively → need more anesthetic. Order of nerve blockade: small-diameter fibers > large diameter. Myelinated fibers > unmyelinated fibers. Overall, size factor predominates over myelination such that small myelinated fibers > small unmyelinated fibers > large myelinated fibers > large unmyelinated fibers. Order of loss: (1) pain, (2) temperature, (3) touch, (4) pressure.
CLINICAL USE	Minor surgical procedures, spinal anesthesia. If allergic to esters, give amides.
ADVERSE EFFECTS	CNS excitation, severe cardiovascular toxicity (bupivacaine), hypertension, hypotension, arrhythmias (cocaine), methemoglobinemia (benzocaine).

**Neuromuscular blocking drugs**

Muscle paralysis in surgery or mechanical ventilation. Selective for Nm nicotinic receptors at neuromuscular junction but not autonomic Nn receptors.

**Depolarizing**

Succinylcholine—strong ACh receptor agonist; produces sustained depolarization and prevents muscle contraction.

Reversal of blockade:

- Phase I (prolonged depolarization)—no antidote. Block potentiated by cholinesterase inhibitors.
- Phase II (repolarized but blocked; ACh receptors are available, but desensitized)—may be reversed with cholinesterase inhibitors.

Complications include hypercalcemia, hyperkalemia, malignant hyperthermia.

**Nondepolarizing**

Tubocurarine, atracurium, mivacurium, pancuronium, vecuronium, rocuronium—competitive antagonists—compete with ACh for receptors.

Reversal of blockade—neostigmine (must be given with atropine to prevent muscarinic effects such as bradycardia), edrophonium, and other cholinesterase inhibitors.

**Dantrolene****MECHANISM**

Prevents release of  $\text{Ca}^{2+}$  from the sarcoplasmic reticulum of skeletal muscle by binding to the ryanodine receptor.

**CLINICAL USE**

Malignant hyperthermia and neuroleptic malignant syndrome (a toxicity of antipsychotic drugs).

**Baclofen****MECHANISM**

Activates  $\text{GABA}_B$  receptors at spinal cord level, inducing skeletal muscle relaxation.

**CLINICAL USE**

Muscle spasms (eg, acute low back pain), multiple sclerosis.

**Cyclobenzaprine****MECHANISM**

Centrally acting skeletal muscle relaxant. Structurally related to TCAs, similar anticholinergic side effects.

**CLINICAL USE**

Muscle spasms.

**Opioid analgesics**

Morphine, oxycodone, fentanyl, codeine, loperamide, methadone, meperidine, dextromethorphan, diphenoxylate, pentazocine.

**MECHANISM**

Act as agonists at opioid receptors ( $\mu$  =  $\beta$ -endorphin,  $\delta$  = enkephalin,  $\kappa$  = dynorphin) to modulate synaptic transmission—open  $\text{K}^+$  channels, close  $\text{Ca}^{2+}$  channels  $\rightarrow$   $\downarrow$  synaptic transmission. Inhibit release of ACh, norepinephrine, 5-HT, glutamate, substance P.

**CLINICAL USE**

Pain, cough suppression (dextromethorphan), diarrhea (loperamide, diphenoxylate), acute pulmonary edema, maintenance programs for heroin addicts (methadone, buprenorphine + naloxone).

**ADVERSE EFFECTS**

Nausea, vomiting, pruritus, addiction, respiratory depression, constipation, miosis (except meperidine  $\rightarrow$  mydriasis), additive CNS depression with other drugs. Tolerance does not develop to miosis and constipation. Toxicity treated with naloxone (opioid receptor antagonist) and relapse prevention with naltrexone once detoxified.

**Pentazocine**

MECHANISM	$\kappa$ -opioid receptor agonist and $\mu$ -opioid receptor weak antagonist or partial agonist.
CLINICAL USE	Analgesia for moderate to severe pain.
ADVERSE EFFECTS	Can cause opioid withdrawal symptoms if patient is also taking full opioid antagonist (competition for opioid receptors).

**Butorphanol**

MECHANISM	$\kappa$ -opioid receptor agonist and $\mu$ -opioid receptor partial agonist; produces analgesia.
CLINICAL USE	Severe pain (eg, migraine, labor). Causes less respiratory depression than full opioid agonists.
ADVERSE EFFECTS	Can cause opioid withdrawal symptoms if patient is also taking full opioid agonist (competition for opioid receptors). Overdose not easily reversed with naloxone.

**Tramadol**

MECHANISM	Very weak opioid agonist; also inhibits 5-HT and norepinephrine reuptake (works on multiple neurotransmitters—“ <b>tram it all</b> ” in with <b>tramadol</b> ).
CLINICAL USE	Chronic pain.
ADVERSE EFFECTS	Similar to opioids. Decreases seizure threshold. Serotonin syndrome.

**Glaucoma drugs**

↓ IOP via ↓ amount of aqueous humor (inhibit synthesis/secretion or ↑ drainage).

DRUG	MECHANISM	ADVERSE EFFECTS
<b><math>\alpha</math>-agonists</b>		
<b>Epinephrine (<math>\alpha_1</math>), brimonidine (<math>\alpha_2</math>)</b>	↓ aqueous humor synthesis via vasoconstriction (epinephrine) ↓ aqueous humor synthesis (brimonidine)	Mydriasis ( $\alpha_1$ ); do not use in closed-angle glaucoma Blurry vision, ocular hyperemia, foreign body sensation, ocular allergic reactions, ocular pruritus
<b><math>\beta</math>-blockers</b>		
<b>Timolol, betaxolol, carteolol</b>	↓ aqueous humor synthesis	No pupillary or vision changes
<b>Diuretics</b>		
<b>Acetazolamide</b>	↓ aqueous humor synthesis via inhibition of carbonic anhydrase	No pupillary or vision changes
<b>Cholinomimetics (<math>M_3</math>)</b>		
<b>Direct (pilocarpine, carbachol) Indirect (physostigmine, echothiophate)</b>	↑ outflow of aqueous humor via contraction of ciliary muscle and opening of trabecular meshwork Use pilocarpine in emergencies—very effective at opening meshwork into canal of Schlemm	Miosis (contraction of pupillary sphincter muscles) and cyclospasm (contraction of ciliary muscle)
<b>Prostaglandin</b>		
<b>Bimatoprost, latanoprost (PGF<sub>2<math>\alpha</math></sub>)</b>	↑ outflow of aqueous humor via ↓ resistance of flow through uveoscleral pathway	Darkens color of iris (browning), eyelash growth

▶ NOTES

Two columns of horizontal lines for taking notes.

# Psychiatry

*“Words of comfort, skillfully administered, are the oldest therapy known to man.”*

—Louis Nizer

*“All men should strive to learn before they die what they are running from, and to, and why.”*

—James Thurber

*“Man wishes to be happy even when he so lives as to make happiness impossible.”*

—St. Augustine

*“It is far more important to know what sort of person has a disease, than to know what sort of disease a person has.”*

—Hippocrates

▶ Psychology 524

▶ Pathology 526

▶ Pharmacology 542



## ► PSYCHIATRY—PSYCHOLOGY

<b>Classical conditioning</b>	Learning in which a natural response (salivation) is elicited by a conditioned, or learned, stimulus (bell) that previously was presented in conjunction with an unconditioned stimulus (food).	Usually deals with <b>involuntary</b> responses. Pavlov's classical experiments with dogs—ringing the bell provoked salivation.									
<b>Operant conditioning</b>	Learning in which a particular action is elicited because it produces a punishment or reward. Usually deals with <b>voluntary</b> responses.										
<b>Reinforcement</b>	Target behavior (response) is followed by desired reward (positive reinforcement) or removal of aversive stimulus (negative reinforcement).										
<b>Extinction</b>	Discontinuation of reinforcement (positive or negative) eventually eliminates behavior. Can occur in operant or classical conditioning.										
<b>Punishment</b>	Repeated application of aversive stimulus (positive punishment) or removal of desired reward (negative punishment) to extinguish unwanted behavior (Skinner's operant conditioning quadrant).	<table border="1"> <thead> <tr> <th></th> <th>Increase behavior</th> <th>Decrease behavior</th> </tr> </thead> <tbody> <tr> <th>Add a stimulus</th> <td>Positive reinforcement</td> <td>Positive punishment</td> </tr> <tr> <th>Remove a stimulus</th> <td>Negative reinforcement</td> <td>Negative punishment</td> </tr> </tbody> </table>		Increase behavior	Decrease behavior	Add a stimulus	Positive reinforcement	Positive punishment	Remove a stimulus	Negative reinforcement	Negative punishment
	Increase behavior	Decrease behavior									
Add a stimulus	Positive reinforcement	Positive punishment									
Remove a stimulus	Negative reinforcement	Negative punishment									

**Transference and countertransference**

<b>Transference</b>	Patient projects feelings about formative or other important persons onto physician (eg, psychiatrist is seen as parent).
<b>Countertransference</b>	Doctor projects feelings about formative or other important persons onto patient (eg, patient reminds physician of younger sibling).

**Ego defenses**

Mental processes (unconscious or conscious) used to resolve conflict and prevent undesirable feelings (eg, anxiety, depression).

IMMATURE DEFENSES	DESCRIPTION	EXAMPLE
<b>Acting out</b>	Expressing unacceptable feelings and thoughts through actions.	Tantrums.
<b>Denial</b>	Avoiding the awareness of some painful reality.	A patient with cancer plans a full-time work schedule despite being warned of significant fatigue during chemotherapy.
<b>Displacement</b>	Redirection of emotions or impulses to a neutral person or object (vs projection).	A teacher is yelled at by the principal. Instead of confronting the principal directly, the teacher goes home and criticizes her husband's dinner selection.
<b>Dissociation</b>	Temporary, drastic change in personality, memory, consciousness, or motor behavior to avoid emotional stress. Patient has incomplete or no memory of traumatic event.	A victim of sexual abuse suddenly appears numb and detached when she is exposed to her abuser.

**Ego defenses (continued)**

IMMATURE DEFENSES	DESCRIPTION	EXAMPLE
<b>Fixation</b>	Partially remaining at a more childish level of development (vs regression).	A surgeon throws a tantrum in the operating room because the last case ran very late.
<b>Idealization</b>	Expressing extremely positive thoughts of self and others while ignoring negative thoughts.	A patient boasts about his physician and his accomplishments while ignoring any flaws.
<b>Identification</b>	Largely unconscious assumption of the characteristics, qualities, or traits of another person or group.	A resident starts putting his stethoscope in his pocket like his favorite attending, instead of wearing it around his neck like before.
<b>Intellectualization</b>	Using facts and logic to emotionally distance oneself from a stressful situation.	In a therapy session, patient diagnosed with cancer focuses only on rates of survival.
<b>Isolation (of affect)</b>	Separating feelings from ideas and events.	Describing murder in graphic detail with no emotional response.
<b>Passive aggression</b>	Demonstrating hostile feelings in a nonconfrontational manner; showing indirect opposition.	Disgruntled employee is repeatedly late to work, but won't admit it is a way to get back at the manager.
<b>Projection</b>	Attributing an unacceptable internal impulse to an external source (vs displacement).	A man who wants to cheat on his wife accuses his wife of being unfaithful.
<b>Rationalization</b>	Proclaiming logical reasons for actions actually performed for other reasons, usually to avoid self-blame.	After getting fired, claiming that the job was not important anyway.
<b>Reaction formation</b>	Replacing a warded-off idea or feeling by an (unconsciously derived) emphasis on its opposite (vs sublimation).	A patient with libidinous thoughts enters a monastery.
<b>Regression</b>	<b>Involuntarily</b> turning back the maturational clock and going back to earlier modes of dealing with the world (vs fixation).	Seen in children under stress such as illness, punishment, or birth of a new sibling (eg, bedwetting in a previously toilet-trained child when hospitalized).
<b>Repression</b>	Involuntarily withholding an idea or feeling from conscious awareness (vs suppression).	A 20-year-old does not remember going to counseling during his parents' divorce 10 years earlier.
<b>Splitting</b>	Believing that people are either all good or all bad at different times due to intolerance of ambiguity. Commonly seen in borderline personality disorder.	A patient says that all the nurses are cold and insensitive but that the doctors are warm and friendly.
<b>MATURE DEFENSES</b>		
<b>Sublimation</b>	Replacing an unacceptable wish with a course of action that is similar to the wish but does not conflict with one's value system (vs reaction formation).	Teenager's aggression toward his father is redirected to perform well in sports.
<b>Altruism</b>	Alleviating negative feelings via unsolicited generosity.	Mafia boss makes large donation to charity.
<b>Suppression</b>	<b>Intentionally</b> withholding an idea or feeling from conscious awareness (vs repression); temporary.	Choosing to not worry about the big game until it is time to play.
<b>Humor</b>	Appreciating the amusing nature of an anxiety-provoking or adverse situation.	Nervous medical student jokes about the boards.
<b>Mature</b> adults wear a <b>SASH</b> .		

## ► PSYCHIATRY—PATHOLOGY

**Infant deprivation effects**

Long-term deprivation of affection results in:

- Failure to thrive
- Poor language/socialization skills
- Lack of basic trust
- Reactive attachment disorder (infant withdrawn/unresponsive to comfort)

Deprivation for > 6 months can lead to irreversible changes.

Severe deprivation can result in infant death.

**Child abuse**

	<b>Physical abuse</b>	<b>Sexual abuse</b>
<b>EVIDENCE</b>	Fractures (eg, ribs, long bone spiral, multiple in different stages of healing), bruises (eg, trunk, ear, neck; in pattern of implement), burns (eg, cigarette, buttocks/thighs), subdural hematomas, retinal hemorrhages. During exam, children often avoid eye contact.	Genital, anal, or oral trauma; STIs; UTIs.
<b>ABUSER</b>	Usually biological mother.	Known to victim, usually male.
<b>EPIDEMIOLOGY</b>	40% of deaths related to child abuse or neglect occur in children < 1 year old.	Peak incidence 9–12 years old.

**Child neglect**

Failure to provide a child with adequate food, shelter, supervision, education, and/or affection. Most common form of child maltreatment. Evidence: poor hygiene, malnutrition, withdrawal, impaired social/emotional development, failure to thrive. As with child abuse, suspected child neglect must be reported to local child protective services.

**Vulnerable child syndrome**

Parents perceive the child as especially susceptible to illness or injury. Usually follows a serious illness or life-threatening event. Can result in missed school or overuse of medical services.

**Childhood and early-onset disorders**

<b>Attention-deficit hyperactivity disorder</b>	Onset before age 12. Limited attention span and poor impulse control. Characterized by hyperactivity, impulsivity, and/or inattention in multiple settings (school, home, places of worship, etc). Normal intelligence, but commonly coexists with difficulties in school. Continues into adulthood in as many as 50% of individuals. Treatment: stimulants (eg, methylphenidate) +/- cognitive behavioral therapy (CBT); alternatives include atomoxetine, guanfacine, clonidine.
<b>Autism spectrum disorder</b>	Characterized by poor social interactions, social communication deficits, repetitive/ritualized behaviors, restricted interests. Must present in early childhood. May be accompanied by intellectual disability; rarely accompanied by unusual abilities (savants). More common in boys. Associated with ↑ head/brain size.
<b>Rett syndrome</b>	X-linked dominant disorder seen almost exclusively in girls (affected males die in utero or shortly after birth). Majority of cases are caused by de novo mutation of <i>MECP2</i> . Symptoms usually become apparent around ages 1–4, including regression characterized by loss of development, loss of verbal abilities, intellectual disability, ataxia, stereotyped hand-wringing. No longer a solitary diagnosis within DSM-5.
<b>Conduct disorder</b>	Repetitive and pervasive behavior violating the basic rights of others or societal norms (eg, aggression to people and animals, destruction of property, theft). After age 18, often reclassified as antisocial personality disorder. Treatment for both: psychotherapy such as CBT.
<b>Oppositional defiant disorder</b>	Enduring pattern of hostile, defiant behavior toward authority figures in the absence of serious violations of social norms. Treatment: psychotherapy such as CBT.
<b>Separation anxiety disorder</b>	Overwhelming fear of separation from home or attachment figure. Can be normal behavior up to age 3–4. May lead to factitious physical complaints to avoid school. Treatment: CBT, play therapy, family therapy.
<b>Tourette syndrome</b>	Onset before age 18. Characterized by sudden, rapid, recurrent, nonrhythmic, stereotyped motor and vocal tics that persist for > 1 year. Coprolalia (involuntary obscene speech) found in only 10–20% of patients. Associated with OCD and ADHD. Treatment: psychoeducation, behavioral therapy. For intractable and distressing tics, high-potency antipsychotics (eg, haloperidol, fluphenazine, pimozide), tetrabenazine, $\alpha_2$ -agonists (eg, guanfacine, clonidine), or atypical antipsychotics may be used.
<b>Disruptive mood dysregulation disorder</b>	Onset before age 10. Severe and recurrent temper outbursts out of proportion to situation. Child is constantly angry and irritable between outbursts. Treatment: psychostimulants, antipsychotics, CBT.

**Orientation**

Patient's ability to know who he or she is, where he or she is, and the date and time. Order of loss: time → place → person.

Common causes of loss of orientation: alcohol, drugs, fluid/electrolyte imbalance, head trauma, hypoglycemia, infection, nutritional deficiencies.

**Amnesias**

<b>Retrograde amnesia</b>	Inability to remember things that occurred <b>before</b> a CNS insult.
<b>Anterograde amnesia</b>	Inability to remember things that occurred <b>after</b> a CNS insult (↓ acquisition of new memory).
<b>Korsakoff syndrome</b>	Amnesia (anterograde > retrograde) caused by vitamin B <sub>1</sub> deficiency and associated destruction of mammillary bodies. Seen in alcoholics as a late neuropsychiatric manifestation of Wernicke encephalopathy. Confabulations are characteristic.
<b>Dissociative amnesia</b>	Inability to recall important personal information, usually subsequent to severe trauma or stress. May be accompanied by <b>dissociative fugue</b> (abrupt travel or wandering during a period of dissociative amnesia, associated with traumatic circumstances).

**Dissociative disorders**

<b>Dissociative identity disorder</b>	Formerly known as multiple personality disorder. Presence of 2 or more distinct identities or personality states. More common in women. Associated with history of sexual abuse, PTSD, depression, substance abuse, borderline personality, somatoform conditions.
<b>Depersonalization/derealization disorder</b>	Persistent feelings of detachment or estrangement from one's own body, thoughts, perceptions, and actions (depersonalization) or one's environment (derealization).

**Delirium**

“Waxing and waning” level of consciousness with acute onset; rapid ↓ in attention span and level of arousal. Characterized by disorganized thinking, hallucinations (often visual), illusions, misperceptions, disturbance in sleep-wake cycle, cognitive dysfunction.

Usually 2° to other illness (eg, CNS disease, infection, trauma, substance abuse/withdrawal, metabolic/electrolyte disturbances, hemorrhage, urinary/fecal retention).

Most common presentation of altered mental status in inpatient setting, especially in the intensive care unit and with prolonged hospital stays. Commonly, diffuse slowing EEG.

Treatment is aimed at identifying and addressing underlying condition.

Antipsychotics may be used acutely as needed.

**Delirium** = changes in **sensorium**.  
May be caused by medications (eg, anticholinergics), especially in the elderly.  
**Reversible**.

<b>Dementia</b>	<p>↓ in intellectual function without affecting level of consciousness. Characterized by memory deficits, apraxia, aphasia, agnosia, loss of abstract thought, behavioral/personality changes, impaired judgment. A patient with dementia can develop delirium (eg, patient with Alzheimer disease who develops pneumonia is at ↑ risk for delirium).</p> <p>Irreversible causes: Alzheimer disease, Lewy body dementia, Huntington disease, Pick disease, cerebral infarct, Wilson disease, Creutzfeldt-Jakob disease, chronic substance abuse (due to neurotoxicity of drugs), HIV.</p> <p>Reversible causes: hypothyroidism, depression, vitamin deficiency (B<sub>1</sub>, B<sub>3</sub>, B<sub>12</sub>), normal pressure hydrocephalus, neurosyphilis.</p> <p>↑ incidence with age. EEG usually normal.</p>	<p>“<b>Dementia</b>” is characterized by <b>memory</b> loss. Usually <b>irreversible</b>.</p> <p>In elderly patients, depression and hypothyroidism may present like dementia (pseudodementia). Screen for depression, exclude neurosyphilis with RPR if high clinical suspicion, and measure TSH, B<sub>12</sub> levels.</p>
<b>Psychosis</b>	Distorted perception of reality characterized by delusions, hallucinations, and/or disorganized thought/speech. Can occur in patients with medical illness, psychiatric illness, or both.	
<b>Delusions</b>	Unique, false, fixed, idiosyncratic beliefs that persist despite the facts and are not typical of a patient’s culture or religion (eg, thinking aliens are communicating with you). Types include erotomanic, grandiose, jealous, persecutory, somatic, mixed, and unspecified.	
<b>Disorganized thought</b>	Speech may be incoherent (“word salad”), tangential, or derailed (“loose associations”).	
<b>Hallucinations</b>	<p>Perceptions in the absence of external stimuli (eg, seeing a light that is not actually present). Contrast with illusions, misperceptions of real external stimuli. Types include:</p> <ul style="list-style-type: none"> <li>▪ Visual—more commonly a feature of medical illness (eg, drug intoxication) than psychiatric illness.</li> <li>▪ Auditory—more commonly a feature of psychiatric illness (eg, schizophrenia) than medical illness.</li> <li>▪ Olfactory—often occur as an aura of temporal lobe epilepsy (eg, burning rubber) and in brain tumors.</li> <li>▪ Gustatory—rare, but seen in epilepsy.</li> <li>▪ Tactile—common in alcohol withdrawal and stimulant use (eg, cocaine, amphetamines), delusional parasitosis, “cocaine crawlies.”</li> <li>▪ Hypnagogic—occurs while <b>going</b> to sleep. Sometimes seen in narcolepsy.</li> <li>▪ Hypnopompic—occurs while waking from sleep (“<b>pomp</b>ous upon awakening”). Sometimes seen in narcolepsy.</li> </ul>	

**Schizophrenia**

Chronic mental disorder with periods of psychosis, disturbed behavior and thought, and decline in functioning **lasting > 6 months**. Associated with ↑ dopaminergic activity, ↓ dendritic branching.

Diagnosis requires at least 2 of the following, and at least 1 of these should include 1–3 (first 4 are “positive symptoms”):

1. Delusions
2. Hallucinations—often auditory
3. Disorganized speech
4. Disorganized or catatonic behavior
5. Negative symptoms (affective flattening, avolition, anhedonia, asociality, alogia)

**Brief psychotic disorder**—lasting < 1 month, usually stress related.

**Schizophreniform disorder**—lasting 1–6 months.

**Schizoaffective disorder**—Meets criteria for schizophrenia in addition to major mood disorder (major depressive or bipolar). To differentiate from a major mood disorder with psychotic features, patient must have > 2 weeks of hallucinations or delusions without major mood episode.

Frequent cannabis use is associated with psychosis/schizophrenia in teens.

Lifetime prevalence—1.5% (males = females, African Americans = Caucasians). Presents earlier in men (late teens to early 20s vs late 20s to early 30s in women). Patients are at ↑ risk for suicide.

Ventriculomegaly on brain imaging.

Treatment: atypical antipsychotics (eg, risperidone) are first line.

Negative symptoms often persist after treatment, despite resolution of positive symptoms.

**Delusional disorder**

Fixed, persistent, false belief system **lasting > 1 month**. Functioning otherwise not impaired (eg, a woman who genuinely believes she is married to a celebrity when, in fact, she is not). Can be shared by individuals in close relationships (folie à deux).

**Mood disorder**

Characterized by an abnormal range of moods or internal emotional states and loss of control over them. Severity of moods causes distress and impairment in social and occupational functioning. Includes major depressive disorder, bipolar disorder, dysthymic disorder, and cyclothymic disorder. Episodic superimposed psychotic features (delusions or hallucinations) may be present.

**Manic episode**

Distinct period of abnormally and persistently elevated, expansive, or irritable mood and abnormally and persistently ↑ activity or energy **lasting at least 1 week**. Often disturbing to patient.

Diagnosis requires hospitalization or at least 3 of the following (manics **DIG FAST**):

- **D**istractibility
- **I**rresponsibility—seeks pleasure without regard to consequences (hedonistic)
- **G**randiosity—inflated self-esteem
- **F**light of ideas—racing thoughts
- **↑** in goal-directed **A**ctivity/psychomotor **A**gitation
- **↓** need for **S**leep
- **T**alkativeness or pressured speech

<b>Hypomanic episode</b>	Like a manic episode except mood disturbance is not severe enough to cause marked impairment in social and/or occupational functioning or to necessitate hospitalization. No psychotic features. <b>Lasts at least 4 consecutive days.</b>	
<b>Bipolar disorder (manic depression)</b>	Bipolar I defined by presence of at least 1 manic episode +/- a hypomanic or depressive episode. Bipolar II defined by presence of a hypomanic and a depressive episode. Patient's mood and functioning usually return to normal between episodes. Use of antidepressants can precipitate mania. High suicide risk. Treatment: mood stabilizers (eg, lithium, valproic acid, carbamazepine, lamotrigine), atypical antipsychotics. <b>Cyclothymic disorder</b> —milder form of bipolar disorder <b>lasting at least 2 years</b> , fluctuating between mild depressive and hypomanic symptoms.	
<b>Major depressive disorder</b>	Episodes characterized by at least 5 of the 9 diagnostic symptoms <b>lasting ≥ 2 weeks</b> (symptoms must include patient-reported depressed mood or anhedonia). Treatment: CBT and SSRIs are first line. SNRIs, mirtazapine, bupropion can also be considered. Antidepressants are indicated if bipolar disorder is ruled out. Electroconvulsive therapy (ECT) in select patients.	Diagnostic symptoms: <b>SIG E CAPS:</b> <ul style="list-style-type: none"> <li>▪ Depressed mood</li> <li>▪ <b>S</b>leep disturbance</li> <li>▪ Loss of <b>I</b>nterest (anhedonia)</li> <li>▪ <b>G</b>uilt or feelings of worthlessness</li> <li>▪ <b>E</b>nergy loss and fatigue</li> <li>▪ <b>C</b>oncentration problems</li> <li>▪ <b>A</b>ppetite/weight changes</li> <li>▪ <b>P</b>sychemotor retardation or agitation</li> <li>▪ <b>S</b>uicidal ideations</li> </ul> Patients with depression typically have the following changes in their sleep stages: <ul style="list-style-type: none"> <li>▪ ↓ slow-wave sleep</li> <li>▪ ↓ REM latency</li> <li>▪ ↑ REM early in sleep cycle</li> <li>▪ ↑ total REM sleep</li> <li>▪ Repeated nighttime awakenings</li> <li>▪ Early-morning awakening (terminal insomnia)</li> </ul>
<b>Depression with atypical features</b>	Characterized by mood reactivity (being able to experience improved mood in response to positive events, albeit briefly), “reversed” vegetative symptoms (hypersomnia, hyperphagia), leaden paralysis (heavy feeling in arms and legs), long-standing interpersonal rejection sensitivity. Most common subtype of depression. Treatment: CBT and SSRIs are first line. MAO inhibitors are effective but not first line because of their risk profile.	



**Postpartum mood disturbances**

Onset within 4 weeks of delivery.

**Maternal (postpartum) “blues”**

50–85% incidence rate. Characterized by depressed affect, tearfulness, and fatigue starting 2–3 days after delivery. Usually resolves within 10 days. Treatment: supportive. Follow up to assess for possible postpartum depression.

**Postpartum depression**

10–15% incidence rate. Characterized by depressed affect, anxiety, and poor concentration for  $\geq 2$  weeks. Treatment: CBT and SSRIs are first line.

**Postpartum psychosis**

0.1–0.2% incidence rate. Characterized by mood-congruent delusions, hallucinations, and thoughts of harming the baby or self. Risk factors include history of bipolar or psychotic disorder, first pregnancy, family history, recent discontinuation of psychotropic medication. Treatment: hospitalization and initiation of atypical antipsychotic; if insufficient, ECT may be used.

**Grief**

The five stages of grief per the Kübler-Ross model are denial, anger, bargaining, depression, and acceptance, not necessarily in that order. Other normal grief symptoms include shock, guilt, sadness, anxiety, yearning, and somatic symptoms. Simple hallucinations of the deceased person are common (eg, hearing the deceased speaking). Duration varies widely; usually **< 6 months**. Pathologic grief is persistent and causes functional impairment. Can meet criteria for major depressive episode.

**Electroconvulsive therapy**

Used mainly for treatment-refractory depression, depression with psychotic symptoms, and acutely suicidality. Produces grand mal seizure in an anesthetized patient. Adverse effects include disorientation, temporary headache, partial anterograde/retrograde amnesia usually resolving in 6 months. Safe in pregnancy.

**Risk factors for suicide completion**

**S**ex (male)  
**A**ge (young adult or elderly)  
**D**epression  
**P**revious attempt (highest risk factor)  
**E**thanol or drug use  
**R**ational thinking loss (psychosis)  
**S**ickness (medical illness)  
**O**rganized plan  
**N**o spouse or other social support  
**S**tated future intent

**SAD PERSONS** are more likely to complete suicide.

Most common method in US is firearms; access to guns  $\uparrow$  risk of suicide completion.

Women try more often; men complete more often.

**Anxiety disorder**

Inappropriate experience of fear/worry and its physical manifestations (anxiety) incongruent with the magnitude of the perceived stressor. Symptoms interfere with daily functioning and are not attributable to another mental disorder, medical condition, or substance abuse. Includes panic disorder, phobias, generalized anxiety disorder, and selective mutism. Treatment: CBT, SSRIs, SNRIs.

**Panic disorder**

Defined by recurrent panic attacks (periods of intense fear and discomfort peaking in 10 minutes with at least 4 of the following): **P**alpitations, **P**aresthesias, **d**e**P**ersonalization or derealization, **A**bdominal distress or **N**ausea, **I**ntense fear of dying, **I**ntense fear of losing control or “going crazy,” **L**ight-headedness, **C**hest pain, **C**hills, **C**hoking, **S**weating, **S**haking, **S**hortness of breath. Strong genetic component. ↑ risk of suicide. Treatment: CBT, SSRIs, and venlafaxine are first line. Benzodiazepines occasionally used in acute setting.

**PANICS.**

Diagnosis requires attack followed by 1 month (or more) of 1 (or more) of the following:

- Persistent concern of additional attacks
- Worrying about consequences of attack
- Behavioral change related to attacks

Symptoms are the systemic manifestations of fear.

**Specific phobia**

Severe, persistent ( $\geq 6$  months) fear or anxiety due to presence or anticipation of a specific object or situation. Person often recognizes fear is excessive. Can be treated with systematic desensitization.

**Social anxiety disorder**—exaggerated fear of embarrassment in social situations (eg, public speaking, using public restrooms). Treatment: CBT, SSRIs, venlafaxine. For only occasional anxiety-inducing situations, benzodiazepine or  $\beta$ -blocker.

**Agoraphobia**—irrational fear/anxiety while facing or anticipating  $\geq 2$  specific situations (eg, open/closed spaces, lines, crowds, public transport). If severe, patients may refuse to leave their homes. Associated with panic disorder. Treatment: CBT, SSRIs.

**Generalized anxiety disorder**

Anxiety **lasting**  $> 6$  months unrelated to a specific person, situation, or event. Associated with restlessness, irritability, sleep disturbance, fatigue, muscle tension, difficulty concentrating. Treatment: CBT, SSRIs, SNRIs are first line. Buspirone, TCAs, benzodiazepines are second line.

**Adjustment disorder**—emotional symptoms (anxiety, depression) that occur within 3 months of an identifiable psychosocial stressor (eg, divorce, illness) **lasting**  $< 6$  months once the stressor has ended. If stressor lasts  $> 6$  months and causes continual impairment, it is GAD. Treatment: CBT, SSRIs.

**Obsessive-compulsive disorder**

Recurring intrusive thoughts, feelings, or sensations (obsessions) that cause severe distress; relieved in part by the performance of repetitive actions (compulsions). Ego-dystonic: behavior inconsistent with one's own beliefs and attitudes (vs obsessive-compulsive personality disorder). Associated with Tourette syndrome. Treatment: CBT, SSRIs, and clomipramine are first line.


**Body dysmorphic disorder**—preoccupation with minor or imagined defect in appearance → significant emotional distress or impaired functioning; patients often repeatedly seek cosmetic treatment. Treatment: CBT.

### Post-traumatic stress disorder

Exposure to prior trauma (eg, witnessing death, experiencing serious injury or rape) → persistent **H**yperarousal, **A**voidance of associated stimuli, intrusive **R**eexperiencing of the event (nightmares, flashbacks), changes in cognition or mood (fear, horror, **D**istress) (having PTSD is **HARD**).  
Disturbance **lasts > 1 month** with significant distress or impaired social-occupational functioning.  
Treatment: CBT, SSRIs, and venlafaxine are first line. Prazosin can reduce nightmares.

**Acute stress disorder**—lasts between **3 days and 1 month**. Treatment: CBT; pharmacotherapy is usually not indicated.

### Diagnostic criteria by symptom duration



### Personality

#### Personality trait

An enduring, repetitive pattern of perceiving, relating to, and thinking about the environment and oneself.

#### Personality disorder

Inflexible, maladaptive, and rigidly pervasive pattern of behavior causing subjective distress and/or impaired functioning; person is usually not aware of problem. Usually presents by early adulthood.

Three clusters, A, B, and C; remember as **W**eird, **W**ild, and **W**orried based on symptoms.

<b>Cluster A personality disorders</b>	Odd or eccentric; inability to develop meaningful social relationships. No psychosis; genetic association with schizophrenia.	<b>“Weird.”</b> Cluster <b>A</b> : <b>A</b> ccusatory, <b>A</b> loof, <b>A</b> wkward.
<b>Paranoid</b>	Pervasive distrust ( <b>A</b> ccusatory) and suspiciousness of others and a profoundly cynical view of the world.	
<b>Schizoid</b>	<b>V</b> oluntary social withdrawal ( <b>A</b> loof), limited emotional expression, content with social isolation (vs avoidant).	
<b>Schizotypal</b>	Eccentric appearance, odd beliefs or magical thinking, interpersonal <b>A</b> wkwardness.	Schizotypal = magical <b>t</b> hinking.
<b>Cluster B personality disorders</b>	Dramatic, emotional, or erratic; genetic association with mood disorders and substance abuse.	<b>“Wild.”</b> Cluster <b>B</b> : <b>B</b> ad, <b>B</b> orderline, flam <b>B</b> oyant, must be the <b>B</b> est
<b>Antisocial</b>	Disregard for and violation of rights of others with lack of remorse, criminality, impulsivity; males > females; must be ≥ 18 years old and have history of conduct disorder before age 15. Conduct disorder if < 18 years old.	<b>A</b> ntisocial = <b>s</b> ociopath. <b>B</b> ad.
<b>Borderline</b>	Unstable mood and interpersonal relationships, impulsivity, self-mutilation, suicidality, sense of emptiness; females > males; splitting is a major defense mechanism.	Treatment: dialectical behavior therapy. <b>B</b> orderline.
<b>Histrionic</b>	Excessive emotionality and excitability, attention seeking, sexually provocative, overly concerned with appearance.	Flam <b>B</b> oyant.
<b>Narcissistic</b>	Grandiosity, sense of entitlement; lacks empathy and requires excessive admiration; often demands the “best” and reacts to criticism with rage.	Must be the <b>B</b> est.
<b>Cluster C personality disorders</b>	Anxious or fearful; genetic association with anxiety disorders.	<b>“Worried.”</b> Cluster <b>C</b> : <b>C</b> owardly, obsessive- <b>C</b> ompulsive, <b>C</b> lingy.
<b>Avoidant</b>	Hypersensitive to rejection, socially inhibited, timid, feelings of inadequacy, desires relationships with others (vs schizoid).	<b>C</b> owardly.
<b>Obsessive-Compulsive</b>	Preoccupation with order, perfectionism, and control; ego-syntonic: behavior consistent with one’s own beliefs and attitudes (vs OCD).	
<b>Dependent</b>	Submissive and <b>C</b> lingy, excessive need to be taken care of, low self-confidence.	Patients often get stuck in abusive relationships.

<b>Malingering</b>	Patient <b>consciously</b> fakes, profoundly exaggerates, or claims to have a disorder in order to attain a specific 2° ( <b>external</b> ) <b>gain</b> (eg, avoiding work, obtaining compensation). Poor compliance with treatment or follow-up of diagnostic tests. Complaints cease after gain (vs factitious disorder).
<b>Factitious disorders</b>	Patient <b>consciously</b> creates physical and/or psychological symptoms in order to assume “sick role” and to get medical attention and sympathy (1° [ <b>internal</b> ] <b>gain</b> ).
<b>Factitious disorder imposed on self</b>	Also known as Munchausen syndrome. <b>Chronic</b> factitious disorder with predominantly physical signs and symptoms. Characterized by a history of multiple hospital admissions and willingness to undergo invasive procedures. More common in women and healthcare workers.
<b>Factitious disorder imposed on another</b>	Also known as Munchausen syndrome by proxy. Illness in a child or elderly patient is caused or fabricated by the caregiver. Motivation is to assume a sick role by proxy. Form of child/elder abuse.
<b>Somatic symptom and related disorders</b>	Category of disorders characterized by physical symptoms causing significant distress and impairment. Both illness production and motivation are <b>unconscious</b> drives. Symptoms not intentionally produced or feigned. More common in women.
<b>Somatic symptom disorder</b>	Variety of bodily complaints (eg, pain, fatigue) lasting for months to years. Associated with excessive, persistent thoughts and anxiety about symptoms. May co-occur with medical illness. Treatment: regular office visits with the same physician in combination with psychotherapy.
<b>Conversion disorder (functional neurologic symptom disorder)</b>	Loss of sensory or motor function (eg, paralysis, blindness, mutism), often following an acute stressor; patient is aware of but sometimes indifferent toward symptoms (“la belle indifférence”); more common in females, adolescents, and young adults.
<b>Illness anxiety disorder (hypochondriasis)</b>	Excessive preoccupation with acquiring or having a serious illness, often despite medical evaluation and reassurance; minimal somatic symptoms.

---

<b>Eating disorders</b>	Most common in young females.
<b>Anorexia nervosa</b>	Excessive dieting, exercise, or binge eating/purging with BMI < 18.5 kg/m <sup>2</sup> ; intense fear of gaining weight; and distortion or overvaluation of body image. Associated with ↓ bone density, severe weight loss, metatarsal stress fractures, amenorrhea (due to loss of pulsatile GnRH secretion), lanugo, anemia, electrolyte disturbances. Commonly coexists with depression. Psychotherapy and nutritional rehabilitation are first line; pharmacotherapy includes SSRIs. Refeeding syndrome (↑ insulin → hypophosphatemia → cardiac complications) can occur in significantly malnourished patients.
<b>Bulimia nervosa</b>	Binge eating with recurrent inappropriate compensatory behaviors (eg, self-induced vomiting, using laxatives or diuretics, fasting, excessive exercise) occurring weekly for at least 3 months and overvaluation of body image. Body weight often maintained within normal range. Associated with parotitis, enamel erosion, electrolyte disturbances (eg, hypokalemia, hypochloremia), metabolic alkalosis, dorsal hand calluses from induced vomiting (Russell sign). Treatment: psychotherapy, nutritional rehabilitation, antidepressants.
<b>Binge eating disorder</b>	Regular episodes of excessive, uncontrollable eating without inappropriate compensatory behaviors. ↑ risk of diabetes. Treatment: psychotherapy such as CBT is first-line; SSRIs, lisdexamfetamine.

---

<b>Gender dysphoria</b>	Persistent cross-gender identification that leads to persistent distress with sex assigned at birth. <b>Transsexualism</b> —desire to live as the opposite <b>sex</b> , often through surgery or hormone treatment. <b>Transvestism</b> —paraphilia, not gender dysphoria. Wearing clothes (eg, <b>vest</b> ) of the opposite sex (cross-dressing).
-------------------------	---

---

<b>Sexual dysfunction</b>	Includes sexual desire disorders (hypoactive sexual desire or sexual aversion), sexual arousal disorders (erectile dysfunction), orgasmic disorders (anorgasmia, premature ejaculation), sexual pain disorders (dyspareunia, vaginismus). Differential diagnosis includes: <ul style="list-style-type: none"><li>▪ Drug side effects (eg, antihypertensives, antipsychotics, SSRIs, ethanol)</li><li>▪ Medical disorders (eg, depression, diabetes, STIs)</li><li>▪ Psychological (eg, performance anxiety)</li></ul>
---------------------------	--

---

**Sleep terror disorder** Inconsolable periods of terror with screaming in the middle of the night; occurs during slow-wave/deep (stage N3) sleep. Most common in children. Occurs during non-REM sleep (no memory of the arousal episode) as opposed to nightmares that occur during REM sleep (memory of a scary dream). Cause unknown, but triggers include emotional stress, fever, or lack of sleep. Usually self limited.

---

**Narcolepsy**

Disordered regulation of sleep-wake cycles; 1° characteristic is excessive daytime sleepiness (awaken feeling rested).

Caused by ↓ hypocretin (orexin) production in lateral hypothalamus.

Also associated with:

- Hypnagogic (just before sleep) or hypnopompic (just before awakening) hallucinations.
- Nocturnal and narcoleptic sleep episodes that start with REM sleep (sleep paralysis).
- Cataplexy (loss of all muscle tone following strong emotional stimulus, such as laughter) in some patients.

Strong genetic component. Treatment: daytime stimulants (eg, amphetamines, modafinil) and nighttime sodium oxybate (GHB).

Hypnagogic—going to sleep

Hypnopompic—“pompous upon awakening”

---


**Substance use disorder**

Maladaptive pattern of substance use defined as 2 or more of the following signs in 1 year related specifically to substance use:

- Tolerance—need more to achieve same effect
  - Withdrawal—manifesting as characteristic signs and symptoms
  - Substance taken in larger amounts, or over longer time, than desired
  - Persistent desire or unsuccessful attempts to cut down
  - Significant energy spent obtaining, using, or recovering from substance
  - Important social, occupational, or recreational activities reduced
  - Continued use despite knowing substance causes physical and/or psychological problems
  - Craving
  - Recurrent use in physically dangerous situations
  - Failure to fulfill major obligations at work, school, or home
  - Social or interpersonal conflicts
-

**Stages of change in overcoming substance addiction**

1. **Precontemplation**—not yet acknowledging that there is a problem
2. **Contemplation**—acknowledging that there is a problem, but not yet ready or willing to make a change
3. **Preparation/determination**—getting ready to change behaviors
4. **Action/willpower**—changing behaviors
5. **Maintenance**—maintaining the behavioral changes
6. **Relapse**—returning to old behaviors and abandoning new changes. Does not always happen.





**Psychoactive drug intoxication and withdrawal**

DRUG	INTOXICATION	WITHDRAWAL
<b>Depressants</b>		
	Nonspecific: mood elevation, ↓ anxiety, sedation, behavioral disinhibition, respiratory depression.	Nonspecific: anxiety, tremor, seizures, insomnia.
<b>Alcohol</b>	Emotional lability, slurred speech, ataxia, coma, blackouts. Serum $\gamma$ -glutamyltransferase (GGT)—sensitive indicator of alcohol use. AST value is twice ALT value.	Time from last drink: 3–36 hr: minor symptoms similar to other depressants 6–48 hr: withdrawal seizures 12–48 hr: alcoholic hallucinosis (usually visual) 48–96 hr: delirium tremens (DTs) in 5% of cases Treatment: benzodiazepines.
<b>Opioids</b>	Euphoria, respiratory and CNS depression, ↓ gag reflex, pupillary constriction (pinpoint pupils), seizures (overdose). Most common cause of drug overdose death. Treatment: naloxone.	Sweating, dilated pupils, piloerection (“cold turkey”), fever, rhinorrhea, yawning, nausea, stomach cramps, diarrhea (“flu-like” symptoms). Treatment: long-term support, methadone, buprenorphine.
<b>Barbiturates</b>	Low safety margin, marked respiratory depression. Treatment: symptom management (eg, assist respiration, ↑ BP).	Delirium, life-threatening cardiovascular collapse.
<b>Benzodiazepines</b>	Greater safety margin. Ataxia, minor respiratory depression. Treatment: flumazenil (benzodiazepine receptor antagonist, but rarely used as it can precipitate seizures).	Sleep disturbance, depression, rebound anxiety, seizure.
<b>Stimulants</b>		
	Nonspecific: mood elevation, psychomotor agitation, insomnia, cardiac arrhythmias, tachycardia, anxiety.	Nonspecific: post-use “crash,” including depression, lethargy, ↑ appetite, sleep disturbance, vivid nightmares.
<b>Amphetamines</b>	Euphoria, grandiosity, pupillary dilation, prolonged wakefulness and attention, hypertension, tachycardia, anorexia, paranoia, fever. Severe: cardiac arrest, seizures. Treatment: benzodiazepines for agitation and seizures.	
<b>Cocaine</b>	Impaired judgment, pupillary dilation, hallucinations (including tactile), paranoid ideations, angina, sudden cardiac death. Treatment: $\alpha$ -blockers, benzodiazepines. $\beta$ -blockers not recommended.	
<b>Caffeine</b>	Restlessness, ↑ diuresis, muscle twitching.	Headache, difficulty concentrating, flu-like symptoms.
<b>Nicotine</b>	Restlessness.	Irritability, anxiety, restlessness, difficulty concentrating. Treatment: nicotine patch, gum, or lozenges; bupropion/varenicline.

**Psychoactive drug intoxication and withdrawal (continued)**

DRUG	INTOXICATION	WITHDRAWAL
<b>Hallucinogens</b>		
<b>Phencyclidine</b>	Violence, impulsivity, psychomotor agitation, nystagmus, tachycardia, hypertension, analgesia, psychosis, delirium, seizures. Trauma is most common complication. Treatment: benzodiazepines, rapid-acting antipsychotic.	
<b>Lysergic acid diethylamide (LSD)</b>	Perceptual distortion (visual, auditory), depersonalization, anxiety, paranoia, psychosis, possible flashbacks.	
<b>Marijuana (cannabinoid)</b>	Euphoria, anxiety, paranoid delusions, perception of slowed time, impaired judgment, social withdrawal, ↑ appetite, dry mouth, conjunctival injection, hallucinations. Pharmaceutical form is <b>dronabinol</b> : used as antiemetic (chemotherapy) and appetite stimulant (in AIDS).	Irritability, anxiety, depression, insomnia, restlessness, ↓ appetite.
<b>MDMA (ecstasy)</b>	Hallucinogenic stimulant: euphoria, disinhibition, hyperactivity, distorted sensory and time perception, teeth clenching. Life-threatening effects include hypertension, tachycardia, hyperthermia, hyponatremia, serotonin syndrome.	Depression, fatigue, change in appetite, difficulty concentrating, anxiety.
<b>Heroin detoxification medications</b>		
<b>Methadone</b>	Users at ↑ risk for hepatitis, HIV, abscesses, bacteremia, right-heart endocarditis.	
<b>Methadone</b>	Long-acting oral opiate used for heroin detoxification or long-term maintenance therapy.	
<b>Buprenorphine + naloxone</b>	Sublingually, buprenorphine (partial agonist) is absorbed and used for maintenance therapy. Naloxone (antagonist, not orally bioavailable) is added to lower IV abuse potential.	
<b>Naltrexone</b>	Long-acting opioid antagonist used for relapse prevention once detoxified.	
<b>Alcoholism</b>		
	Physiologic tolerance and dependence on alcohol with symptoms of withdrawal when intake is interrupted. Complications: alcoholic cirrhosis, hepatitis, pancreatitis, peripheral neuropathy, testicular atrophy. Treatment: disulfiram (to condition the patient to abstain from alcohol use), acamprosate, naltrexone, supportive care. Support groups such as Alcoholics Anonymous are helpful in sustaining abstinence and supporting patient and family.	
<b>Wernicke-Korsakoff syndrome</b>	Caused by vitamin B <sub>1</sub> deficiency. Triad of confusion, ophthalmoplegia, ataxia ( <b>Wernicke encephalopathy</b> ). May progress to irreversible memory loss, confabulation, personality change ( <b>Korsakoff syndrome</b> ). Symptoms may be precipitated by giving dextrose before administering vitamin B <sub>1</sub> to a patient with thiamine deficiency. Associated with periventricular hemorrhage/necrosis of mammillary bodies. Treatment: IV vitamin B <sub>1</sub> .	

**Delirium tremens**

Life-threatening alcohol withdrawal syndrome that peaks 2–4 days after last drink. Characterized by autonomic hyperactivity (eg, tachycardia, tremors, anxiety, seizures), electrolyte disturbances, respiratory alkalosis. Classically occurs in hospital setting (eg, 2–4 days postsurgery) in alcoholics not able to drink as inpatients. Treatment: benzodiazepines (eg, chlordiazepoxide, lorazepam, diazepam).

## ▶ PSYCHIATRY—PHARMACOLOGY

**Preferred medications for selected psychiatric conditions**

PSYCHIATRIC CONDITION	PREFERRED DRUGS
ADHD	Stimulants (methylphenidate, amphetamines)
Alcohol withdrawal	Benzodiazepines (eg, chlordiazepoxide, lorazepam, diazepam)
Bipolar disorder	Lithium, valproic acid, carbamazepine, lamotrigine, atypical antipsychotics
Bulimia nervosa	SSRIs
Depression	SSRIs
Generalized anxiety disorder	SSRIs, SNRIs
Obsessive-compulsive disorder	SSRIs, venlafaxine, clomipramine
Panic disorder	SSRIs, venlafaxine, benzodiazepines
PTSD	SSRIs, venlafaxine
Schizophrenia	Atypical antipsychotics
Social anxiety disorder	SSRIs, venlafaxine Performance only: $\beta$ -blockers, benzodiazepines
Tourette syndrome	Antipsychotics (eg, fluphenazine, pimozide), tetrabenazine

**Central nervous system stimulants**

Methylphenidate, dextroamphetamine, methamphetamine.

## MECHANISM

↑ catecholamines in the synaptic cleft, especially norepinephrine and dopamine.

## CLINICAL USE

ADHD, narcolepsy, appetite control.

## ADVERSE EFFECTS

Nervousness, agitation, anxiety, insomnia, anorexia, tachycardia, hypertension.

<b>Typical antipsychotics</b>	Haloperidol, pimozide, trifluoperazine, fluphenazine, thioridazine, chlorpromazine.	
MECHANISM	Block dopamine D <sub>2</sub> receptor (↑ cAMP).	
CLINICAL USE	Schizophrenia (1° positive symptoms), psychosis, bipolar disorder, delirium, Tourette syndrome, Huntington disease, OCD.	
POTENCY	<p><b>High</b> potency: <b>Tri</b>fluoperazine, <b>Flu</b>phenazine, <b>Hal</b>operidol (<b>Try to Fly High</b>)—neurologic side effects (eg, extrapyramidal symptoms [EPS]).</p> <p><b>Low</b> potency: <b>Chl</b>orpromazine, <b>Thi</b>oridazine (<b>Cheating Thieves are low</b>)—anticholinergic, antihistamine, α<sub>1</sub>-blockade effects.</p>	
ADVERSE EFFECTS	<p>Lipid soluble → stored in body fat → slow to be removed from body.</p> <p>Endocrine: dopamine receptor antagonism → hyperprolactinemia → galactorrhea, oligomenorrhea, gynecomastia.</p> <p>Metabolic: dyslipidemia, weight gain, hyperglycemia.</p> <p>Antimuscarinic: dry mouth, constipation.</p> <p>Antihistamine: sedation.</p> <p>α<sub>1</sub>-blockade: orthostatic hypotension.</p> <p>Cardiac: QT prolongation.</p> <p>Ophthalmologic: <b>Chl</b>orpromazine—<b>C</b>orneal deposits; <b>Thi</b>oridazine—<b>rE</b>tinal deposits.</p> <p><b>EPS—ADAPT:</b></p> <ul style="list-style-type: none"> <li>▪ Hours to days: <b>A</b>cute <b>D</b>ystonia (muscle spasm, stiffness, oculogyric crisis).</li> <li>▪ Days to months: <b>A</b>kathisia (restlessness), <b>P</b>arkinsonism (bradykinesia).</li> <li>▪ Months to years: <b>T</b>ardive dyskinesia (orofacial chorea).</li> </ul> <p>Treatment: benztropine (acute dystonia, tardive dyskinesia), benzodiazepines, β-blockers (akathisia).</p> <p><b>Neuroleptic malignant syndrome (NMS)</b>—<b>M</b>alignant <b>F</b>EVER: <b>M</b>yoglobinuria, <b>F</b>ever, <b>E</b>ncephalopathy, unstable <b>V</b>itals, ↑ <b>E</b>nzymes, muscle <b>R</b>igidity. Treatment: dantrolene, D<sub>2</sub> agonist (eg, bromocriptine).</p>	
<b>Atypical antipsychotics</b>	Aripiprazole, asenapine, clozapine, olanzapine, quetiapine, iloperidone, paliperidone, risperidone, lurasidone, ziprasidone.	
MECHANISM	Not completely understood. Most are D <sub>2</sub> antagonists; aripiprazole is D <sub>2</sub> partial agonist. Varied effects on 5-HT <sub>2</sub> , dopamine, and α- and H <sub>1</sub> -receptors.	
CLINICAL USE	Schizophrenia—both positive and negative symptoms. Also used for bipolar disorder, OCD, anxiety disorder, depression, mania, Tourette syndrome.	Use clozapine for treatment-resistant schizophrenia or schizoaffective disorder and for suicidality in schizophrenia.
ADVERSE EFFECTS	<p>All—prolonged QT interval, fewer EPS and anticholinergic side effects than typical antipsychotics.</p> <p>“-pines”—metabolic syndrome (weight gain, diabetes, hyperlipidemia). <b>Olanzapine</b> → <b>O</b>besity</p> <p>Clozapine—agranulocytosis (monitor WBCs frequently) and seizures (dose related). Must watch bone marrow <b>clozely</b> with <b>clozapine</b>.</p> <p>Risperidone—hyperprolactinemia (amenorrhea, galactorrhea, gynecomastia).</p>	

**Lithium**

MECHANISM	Not established; possibly related to inhibition of phosphoinositol cascade.
CLINICAL USE	Mood stabilizer for bipolar disorder; blocks relapse and acute manic events.
ADVERSE EFFECTS	Tremor, hypothyroidism, polyuria (causes nephrogenic diabetes insipidus), teratogenesis. Causes Ebstein anomaly in newborn if taken by pregnant mother. Narrow therapeutic window requires close monitoring of serum levels. Almost exclusively excreted by kidneys; most is reabsorbed at PCT with Na <sup>+</sup> . Thiazides (and other nephrotoxic agents) are implicated in lithium toxicity.


**LiTHIUM:**

Low **T**hyroid (hypothyroidism)  
**H**earth (Ebstein anomaly)  
**I**nsipidus (nephrogenic diabetes insipidus)  
**U**nwanted **M**ovements (tremor)

**Bupirone**

MECHANISM	Stimulates 5-HT <sub>1A</sub> receptors.
CLINICAL USE	Generalized anxiety disorder. Does not cause sedation, addiction, or tolerance. Takes 1–2 weeks to take effect. Does not interact with alcohol (vs barbiturates, benzodiazepines).

I'm always anxious if the **bus** will be **on** time, so I take **bupirone**.

**Antidepressants**

**Selective serotonin reuptake inhibitors**

Fluoxetine, fluvoxamine, paroxetine, sertraline, escitalopram, citalopram.

MECHANISM	Inhibit 5-HT reuptake.	It normally takes 4–8 weeks for antidepressants to have an effect.
CLINICAL USE	Depression, generalized anxiety disorder, panic disorder, OCD, bulimia, social anxiety disorder, PTSD, premature ejaculation, premenstrual dysphoric disorder.	
ADVERSE EFFECTS	Fewer than TCAs. GI distress, SIADH, sexual dysfunction (anorgasmia, ↓ libido).	

**Serotonin-norepinephrine reuptake inhibitors**

Venlafaxine, desvenlafaxine, duloxetine, levomilnacipran, milnacipran.

MECHANISM	Inhibit 5-HT and norepinephrine reuptake.
CLINICAL USE	Depression, general anxiety disorder, diabetic neuropathy. Venlafaxine is also indicated for social anxiety disorder, panic disorder, PTSD, OCD. Duloxetine is also indicated for fibromyalgia.
ADVERSE EFFECTS	↑ BP most common; also stimulant effects, sedation, nausea.

**Serotonin syndrome**

Can occur with any drug that ↑ 5-HT (eg, MAOIs, SSRIs, SNRIs, TCAs, tramadol, ondansetron, triptans, linezolid, MDMA, dextromethorphan). Characterized by **3 A's**: neuromuscular hyper**A**ctivity (clonus, hyperreflexia, hypertonia, tremor, seizure), **A**utonomic stimulation (hyperthermia, diaphoresis, diarrhea), and **A**gitation. Treatment: cyproheptadine (5-HT<sub>2</sub> receptor antagonist).

**Tricyclic antidepressants**

Amitriptyline, nortriptyline, imipramine, desipramine, clomipramine, doxepin, amoxapine.

MECHANISM	Inhibit NE and 5-HT reuptake.
CLINICAL USE	Major depression, OCD (clomipramine), peripheral neuropathy, chronic pain, migraine prophylaxis. Nocturnal enuresis (imipramine, although adverse effects may limit use).
ADVERSE EFFECTS	Sedation, α <sub>1</sub> -blocking effects including postural hypotension, and atropine-like (anticholinergic) side effects (tachycardia, urinary retention, dry mouth). 3° TCAs (amitriptyline) have more anticholinergic effects than 2° TCAs (nortriptyline). Can prolong QT interval. <b>Tri-C's</b> : <b>C</b> onvulsions, <b>C</b> oma, <b>C</b> ardiotoxicity (arrhythmia due to Na <sup>+</sup> channel inhibition); also respiratory depression, hyperpyrexia. Confusion and hallucinations in elderly due to anticholinergic side effects (nortriptyline better tolerated in the elderly). Treatment: NaHCO <sub>3</sub> to prevent arrhythmia.

**Monoamine oxidase inhibitors**

Tranylcypromine, Phenelzine, Isocarboxazid, Selegiline (selective MAO-B inhibitor).  
(MAO Takes Pride In Shanghai).

**MECHANISM**

Nonselective MAO inhibition ↑ levels of amine neurotransmitters (norepinephrine, 5-HT, dopamine).

**CLINICAL USE**

Atypical depression, anxiety. Parkinson disease (selegiline).

**ADVERSE EFFECTS**

CNS stimulation; hypertensive crisis, most notably with ingestion of tyramine, which is found in many foods such as aged cheese and wine. Tyramine displaces other neurotransmitters (eg, NE) into the synaptic cleft → ↑ sympathetic stimulation. Contraindicated with SSRIs, TCAs, St. John's wort, meperidine, dextromethorphan (to prevent serotonin syndrome).  
Wait 2 weeks after stopping MAO inhibitors before starting serotonergic drugs or stopping dietary restrictions.

**Atypical antidepressants****Bupropion**

Inhibits reuptake of NE and dopamine. Also used for smoking cessation. Toxicity: stimulant effects (tachycardia, insomnia), headache, seizures in anorexic/bulimic patients. May help alleviate sexual dysfunction.

**Mirtazapine**

$\alpha_2$ -antagonist (↑ release of NE and 5-HT), potent 5-HT<sub>2</sub> and 5-HT<sub>3</sub> receptor antagonist and H<sub>1</sub> antagonist. Toxicity: sedation (which may be desirable in depressed patients with insomnia), ↑ appetite, weight gain (which may be desirable in elderly or anorexic patients), dry mouth.

**Trazodone**

Primarily blocks 5-HT<sub>2</sub>,  $\alpha_1$ -adrenergic, and H<sub>1</sub> receptors; also weakly inhibits 5-HT reuptake. Used primarily for insomnia, as high doses are needed for antidepressant effects. Toxicity: sedation, nausea, priapism, postural hypotension. Called traZZZobone due to sedative and male-specific side effects.

**Varenicline**

Nicotinic ACh receptor partial agonist. Used for smoking cessation. Toxicity: sleep disturbance, may depress mood.

**Vilazodone**

Inhibits 5-HT reuptake; 5-HT<sub>1A</sub> receptor partial agonist. Used for major depressive disorder and generalized anxiety disorder (off-label). Toxicity: headache, diarrhea, nausea, ↑ weight, anticholinergic effects. May cause serotonin syndrome if taken with other serotonergic agents.

**Vortioxetine**

Inhibits 5-HT reuptake; 5-HT<sub>1A</sub> receptor agonist and 5-HT<sub>3</sub> receptor antagonist. Used for major depressive disorder. Toxicity: nausea, sexual dysfunction, sleep disturbances (abnormal dreams), anticholinergic effects. May cause serotonin syndrome if taken with other serotonergic agents.

# Renal

*“But I know all about love already. I know precious little still about kidneys.”*

—Aldous Huxley, *Antic Hay*

*“This too shall pass. Just like a kidney stone.”*

—Hunter Madsen

*“I drink too much. The last time I gave a urine sample it had an olive in it.”*

—Rodney Dangerfield

▶ Embryology	548
▶ Anatomy	550
▶ Physiology	551
▶ Pathology	562
▶ Pharmacology	574



## ▶ RENAL—EMBRYOLOGY

**Kidney embryology**



Pronephros—week 4; then degenerates.

Mesonephros—functions as interim kidney for 1st trimester; later contributes to male genital system.

Metanephros—permanent; first appears in 5th week of gestation; nephrogenesis continues through weeks 32–36 of gestation.

- Ureteric bud—derived from caudal end of mesonephric duct; gives rise to ureter, pelvises, calyces, collecting ducts; fully canalized by 10th week
- Metanephric mesenchyme (ie, metanephric blastema)—ureteric bud interacts with this tissue; interaction induces differentiation and formation of glomerulus through to distal convoluted tubule (DCT)
- Aberrant interaction between these 2 tissues may result in several congenital malformations of the kidney

Ureteropelvic junction—last to canalize → most common site of obstruction (can be detected on prenatal ultrasound as hydronephrosis).

**Potter sequence (syndrome)**


Oligohydramnios → compression of developing fetus → limb deformities, facial anomalies (eg, low-set ears and retrognathia **A**, flattened nose), compression of chest and lack of amniotic fluid aspiration into fetal lungs → pulmonary hypoplasia (cause of death).

Causes include ARPKD, obstructive uropathy (eg, posterior urethral valves), bilateral renal agenesis, chronic placental insufficiency.


Babies who can't "Pee" in utero develop **P**otter sequence.

**POTTER** sequence associated with:

- P**ulmonary hypoplasia
- O**ligohydramnios (trigger)
- T**wisted face
- T**wisted skin
- E**xtremity defects
- R**enal failure (in utero)

**Horseshoe kidney**

Inferior poles of both kidneys fuse abnormally **A**. As they ascend from pelvis during fetal development, horseshoe kidneys get trapped under inferior mesenteric artery and remain low in the abdomen. Kidneys function normally. Associated with hydronephrosis (eg, ureteropelvic junction obstruction), renal stones, infection, chromosomal aneuploidy syndromes (eg, Turner syndrome; trisomies 13, 18, 21), and rarely renal cancer.

**Congenital solitary functioning kidney**

Condition of being born with only one functioning kidney. Majority asymptomatic with compensatory hypertrophy of contralateral kidney, but anomalies in contralateral kidney are common. Often diagnosed prenatally via ultrasound.

**Unilateral renal agenesis**

Ureteric bud fails to develop and induce differentiation of metanephric mesenchyme → complete absence of kidney and ureter.

**Multicystic dysplastic kidney**

Ureteric bud fails to induce differentiation of metanephric mesenchyme → nonfunctional kidney consisting of cysts and connective tissue. Predominantly nonhereditary and usually unilateral; bilateral leads to Potter sequence.

**Duplex collecting system**


Bifurcation of ureteric bud before it enters the metanephric blastema creates a Y-shaped bifid ureter. Duplex collecting system can alternatively occur through two ureteric buds reaching and interacting with metanephric blastema. Strongly associated with vesicoureteral reflux and/or ureteral obstruction, ↑ risk for UTIs.

**Posterior urethral valves**


Membrane remnant in the posterior urethra in males; its persistence can lead to urethral obstruction. Can be diagnosed prenatally by hydronephrosis and dilated or thick-walled bladder on ultrasound. Most common cause of bladder outlet obstruction in male infants.

## ► RENAL—ANATOMY

## Kidney anatomy and glomerular structure



Cross-section of kidney



\*Components of glomerular filtration barrier.


Cross-section of glomerulus **A**

Left kidney is taken during donor transplantation because it has a longer renal vein.


**A**fferent = **A**rriving.

**E**fferent = **E**xiting.

Renal blood flow: renal artery → segmental artery → interlobular artery → arcuate artery → interlobular artery → afferent arteriole → glomerulus → efferent arteriole → vasa recta/peritubular capillaries → venous outflow.




## Course of ureters



Ureters **A** pass **under** uterine artery or **under** vas deferens (retroperitoneal).


Gynecologic procedures (eg, ligation of uterine or ovarian vessels) may damage ureter → ureteral obstruction or leak.

“Water (ureters) **under** the bridge (uterine artery or vas deferens).”



## ► RENAL—PHYSIOLOGY

## Fluid compartments



**HIKIN**: **H**igh **K**<sup>+</sup> **I**ntracellularly.

60–40–20 rule (% of body weight for average person):


- 60% total body water
- 40% ICF
- 20% ECF

Plasma volume can be measured by radiolabeling albumin.

Extracellular volume can be measured by inulin or mannitol.

Osmolality = 285–295 mOsm/kg H<sub>2</sub>O.

### Glomerular filtration barrier



Responsible for filtration of plasma according to size and charge selectivity.

Composed of:

- Fenestrated capillary endothelium
- Basement membrane with type IV collagen chains and heparan sulfate
- Epithelial layer consisting of podocyte foot processes **A**

Charge barrier—all 3 layers contain  $\ominus$  charged glycoproteins preventing  $\oplus$  charged molecule entry (eg, albumin).

Size barrier—fenestrated capillary epithelium (prevent entry of > 100 nm molecules/blood cells); podocyte foot processes interpose with basement membrane; slit diaphragm (prevent entry of molecules > 50–60 nm).

**Renal clearance**

$C_x = U_x V / P_x$  = volume of plasma from which the substance is completely cleared per unit time.

If  $C_x < \text{GFR}$ : net tubular reabsorption of X.

If  $C_x > \text{GFR}$ : net tubular secretion of X.

If  $C_x = \text{GFR}$ : no net secretion or reabsorption.

$C_x$  = clearance of X (mL/min).

$U_x$  = urine concentration of X (eg, mg/mL).

$P_x$  = plasma concentration of X (eg, mg/mL).

$V$  = urine flow rate (mL/min).

**Glomerular filtration rate**

Inulin clearance can be used to calculate GFR because it is freely filtered and is neither reabsorbed nor secreted.


$$\text{GFR} = U_{\text{inulin}} \times V / P_{\text{inulin}} = C_{\text{inulin}} \\ = K_f [(P_{\text{GC}} - P_{\text{BS}}) - (\pi_{\text{GC}} - \pi_{\text{BS}})]$$

(GC = glomerular capillary; BS = Bowman space.)  
 $\pi_{\text{BS}}$  normally equals zero;  $K_f$  = filtration constant.

Normal GFR  $\approx$  100 mL/min.

Creatinine clearance is an approximate measure of GFR. Slightly overestimates GFR because creatinine is moderately secreted by renal tubules.

Incremental reductions in GFR define the stages of chronic kidney disease.

**Effective renal plasma flow**

Effective renal plasma flow (eRPF) can be estimated using *para*-aminohippuric acid (PAH) clearance. Between filtration and secretion, there is nearly 100% excretion of all PAH that enters the kidney.

$$\text{eRPF} = U_{\text{PAH}} \times V / P_{\text{PAH}} = C_{\text{PAH}}$$

$$\text{Renal blood flow (RBF)} = \text{RPF} / (1 - \text{Hct}).$$

Plasma = 1 - hematocrit.

eRPF underestimates true renal plasma flow (RPF) slightly.

**Filtration**

Filtration fraction (FF) = GFR/RPF.

Normal FF = 20%.


Filtered load (mg/min) = GFR (mL/min) × plasma concentration (mg/mL).

GFR can be estimated with creatinine clearance.

RPF is best estimated with PAH clearance.

Prostaglandins Dilate Afferent arteriole (PDA)

ACE inhibitors Constrict Efferent arteriole (ACE)



**Changes in glomerular dynamics**

Effect	GFR	RPF	FF (GFR/RPF)
Afferent arteriole constriction	↓	↓	—
Efferent arteriole constriction	↑	↓	↑
↑ plasma protein concentration	↓	—	↓
↓ plasma protein concentration	↑	—	↑
Constriction of ureter	↓	—	↓
Dehydration	↓	↓↓	↑

### Calculation of reabsorption and secretion rate

Filtered load =  $GFR \times P_x$ .

Excretion rate =  $V \times U_x$ .

Reabsorption rate = filtered – excreted.

Secretion rate = excreted – filtered.

$$Fe_{Na} = \frac{Na^+ \text{ excreted}}{Na^+ \text{ filtered}} = \frac{V \times U_{Na}}{GFR \left( U_{Cr} \times \frac{V}{P_{Cr}} \right) \times P_{Na}} = \frac{P_{Cr} \times U_{Na}}{U_{Cr} \times P_{Na}}$$

### Glucose clearance

Glucose at a normal plasma level (range 60–120 mg/dL) is completely reabsorbed in proximal convoluted tubule (PCT) by  $Na^+$ /glucose cotransport.


In adults, at plasma glucose of  $\sim 200$  mg/dL, glucosuria begins (threshold). At rate of  $\sim 375$  mg/min, all transporters are fully saturated ( $T_m$ ).

Normal pregnancy may decrease ability of PCT to reabsorb glucose and amino acids  $\rightarrow$  glucosuria and aminoaciduria.


Sodium-glucose cotransporter 2 (SGLT2) inhibitors (eg, -flozin drugs) permit glucosuria at plasma concentrations  $< 200$  mg/dL.

Glucosuria is an important clinical clue to diabetes mellitus.

Splay is the region of substance clearance between threshold and  $T_m$ ; due to the heterogeneity of nephrons.




**Nephron physiology**




**Early PCT**—contains brush border. Reabsorbs all glucose and amino acids and most  $\text{HCO}_3^-$ ,  $\text{Na}^+$ ,  $\text{Cl}^-$ ,  $\text{PO}_4^{3-}$ ,  $\text{K}^+$ ,  $\text{H}_2\text{O}$ , and uric acid. Isotonic absorption. Generates and secretes  $\text{NH}_3$ , which enables the kidney to secrete more  $\text{H}^+$ .  
 PTH—inhibits  $\text{Na}^+/\text{PO}_4^{3-}$  cotransport →  $\text{PO}_4^{3-}$  excretion.  
 AT II—stimulates  $\text{Na}^+/\text{H}^+$  exchange → ↑  $\text{Na}^+$ ,  $\text{H}_2\text{O}$ , and  $\text{HCO}_3^-$  reabsorption (permitting contraction alkalosis).  
 65–80%  $\text{Na}^+$  reabsorbed.


**Thin descending loop of Henle**—passively reabsorbs  $\text{H}_2\text{O}$  via medullary hypertonicity (impermeable to  $\text{Na}^+$ ). Concentrating segment. Makes urine hypertonic.



**Thick ascending loop of Henle**—reabsorbs  $\text{Na}^+$ ,  $\text{K}^+$ , and  $\text{Cl}^-$ . Indirectly induces paracellular reabsorption of  $\text{Mg}^{2+}$  and  $\text{Ca}^{2+}$  through ⊕ lumen potential generated by  $\text{K}^+$  backleak. Impermeable to  $\text{H}_2\text{O}$ . Makes urine less concentrated as it ascends.  
 10–20%  $\text{Na}^+$  reabsorbed.



**Early DCT**—reabsorbs  $\text{Na}^+$ ,  $\text{Cl}^-$ . Makes urine fully dilute (hypotonic).  
 PTH—↑  $\text{Ca}^{2+}/\text{Na}^+$  exchange →  $\text{Ca}^{2+}$  reabsorption.  
 5–10%  $\text{Na}^+$  reabsorbed.



**Collecting tubule**—reabsorbs  $\text{Na}^+$  in exchange for secreting  $\text{K}^+$  and  $\text{H}^+$  (regulated by aldosterone).  
 Aldosterone—acts on mineralocorticoid receptor → mRNA → protein synthesis. In principal cells: ↑ apical  $\text{K}^+$  conductance, ↑  $\text{Na}^+/\text{K}^+$  pump, ↑ epithelial  $\text{Na}^+$  channel (ENaC) activity → lumen negativity →  $\text{K}^+$  secretion. In  $\alpha$ -intercalated cells: lumen negativity → ↑  $\text{H}^+$  ATPase activity → ↑  $\text{H}^+$  secretion → ↑  $\text{HCO}_3^-/\text{Cl}^-$  exchanger activity.  
 ADH—acts at  $\text{V}_2$  receptor → insertion of aquaporin  $\text{H}_2\text{O}$  channels on apical side.  
 3–5%  $\text{Na}^+$  reabsorbed.




<b>Renal tubular defects</b>	Fanconi syndrome is <b>first</b> (PCT), the rest are in <b>alphabetic</b> order.
<b>Fanconi syndrome</b>	Generalized reabsorptive defect in PCT. Associated with ↑ excretion of nearly all amino acids, glucose, $\text{HCO}_3^-$ , and $\text{PO}_4^{3-}$ . May result in metabolic acidosis (proximal renal tubular acidosis). Causes include hereditary defects (eg, Wilson disease, tyrosinemia, glycogen storage disease, cystinosis), ischemia, multiple myeloma, nephrotoxins/drugs (eg, ifosfamide, cisplatin, tenofovir, expired tetracyclines), lead poisoning.
<b>Bartter syndrome</b>	Reabsorptive defect in thick ascending loop of Henle. Affects $\text{Na}^+/\text{K}^+/2\text{Cl}^-$ cotransporter. Results in hypokalemia and metabolic alkalosis with hypercalciuria. Presents similarly to chronic loop diuretic use. Autosomal recessive.
<b>Gitelman syndrome</b>	Reabsorptive defect of $\text{NaCl}$ in DCT. Leads to hypokalemia, hypomagnesemia, metabolic alkalosis, hypocalciuria. Similar to using life-long thiazide diuretics. Autosomal recessive. Less severe than Bartter syndrome.
<b>Liddle syndrome</b>	Gain of function mutation → ↑ $\text{Na}^+$ reabsorption in collecting tubules (↑ activity of $\text{Na}^+$ channel). Results in hypertension, hypokalemia, metabolic alkalosis, ↓ aldosterone. Presents like hyperaldosteronism, but aldosterone is nearly undetectable. Autosomal dominant. Treatment: amiloride.
<b>Syndrome of Apparent Mineralocorticoid Excess</b>	Hereditary deficiency of $11\beta$ -hydroxysteroid dehydrogenase, which normally converts cortisol (can activate mineralocorticoid receptors) to cortisone (inactive on mineralocorticoid receptors) in cells containing mineralocorticoid receptors. Excess cortisol in these cells from enzyme deficiency → ↑ mineralocorticoid receptor activity → hypertension, hypokalemia, metabolic alkalosis. Low serum aldosterone levels. Can acquire disorder from glycyrrhethinic acid (present in licorice), which blocks activity of $11\beta$ -hydroxysteroid dehydrogenase. Treatment: corticosteroids (exogenous corticosteroids ↓ endogenous cortisol production → ↓ mineralocorticoid receptor activation). Cortisol tries to be the <b>SAME</b> as aldosterone.

**Relative concentrations along proximal convoluted tubules**

[TF/P] > 1  
when solute is reabsorbed less quickly than water or when solute is secreted


[TF/P] = 1  
when solute and water are reabsorbed at the same rate

[TF/P] < 1  
when solute is reabsorbed more quickly than water



Tubular inulin ↑ in concentration (but not amount) along the PCT as a result of water reabsorption. Cl<sup>-</sup> reabsorption occurs at a slower rate than Na<sup>+</sup> in early PCT and then matches the rate of Na<sup>+</sup> reabsorption more distally. Thus, its relative concentration ↑ before it plateaus.

### Renin-angiotensin-aldosterone system



<b>Renin</b>	Secreted by JG cells in response to ↓ renal arterial pressure, ↑ renal sympathetic discharge (β <sub>1</sub> effect), and ↓ Na <sup>+</sup> delivery to macula densa cells.
<b>AT II</b>	Helps maintain blood volume and blood pressure. Affects baroreceptor function; limits reflex bradycardia, which would normally accompany its pressor effects.
<b>ANP, BNP</b>	Released from atria (ANP) and ventricles (BNP) in response to ↑ volume; may act as a “check” on renin-angiotensin-aldosterone system; relaxes vascular smooth muscle via cGMP → ↑ GFR, ↓ renin. Dilates afferent arteriole, constricts efferent arteriole, promotes natriuresis.
<b>ADH</b>	Primarily regulates osmolarity; also responds to low blood volume states.
<b>Aldosterone</b>	Primarily regulates ECF volume and Na <sup>+</sup> content; responds to low blood volume states. Responds to hyperkalemia by ↑ K <sup>+</sup> excretion.

### Juxtaglomerular apparatus

Consists of mesangial cells, JG cells (modified smooth muscle of afferent arteriole) and the macula densa (NaCl sensor, part of DCT). JG cells secrete renin in response to ↓ renal blood pressure and ↑ sympathetic tone (β<sub>1</sub>). Macula densa cells sense ↓ NaCl delivery to DCT → ↑ renin release → efferent arteriole vasoconstriction → ↑ GFR.

JGA maintains GFR via renin-angiotensin-aldosterone system.

β-blockers can decrease BP by inhibiting β<sub>1</sub>-receptors of the JGA → ↓ renin release.

**Kidney endocrine functions**

<b>Erythropoietin</b>	Released by interstitial cells in peritubular capillary bed in response to hypoxia.	Stimulates RBC proliferation in bone marrow. Erythropoietin often supplemented in chronic kidney disease.
<b>Calciferol (vitamin D)</b>	PCT cells convert 25-OH vitamin D <sub>3</sub> to 1,25-(OH) <sub>2</sub> vitamin D <sub>3</sub> (calcitriol, active form).	$25\text{-OH D}_3 \xrightarrow{1\alpha\text{-hydroxylase}} 1,25\text{-(OH)}_2\text{ D}_3$ <p style="text-align: center;"> </p>
<b>Prostaglandins</b>	Paracrine secretion vasodilates the afferent arterioles to ↑ RBF.	NSAIDs block renal-protective prostaglandin synthesis → constriction of afferent arteriole and ↓ GFR; this may result in acute renal failure in low renal blood flow states.
<b>Dopamine</b>	Secreted by PCT cells, promotes natriuresis. At low doses, dilates interlobular arteries, afferent arterioles, efferent arterioles → ↑ RBF, little or no change in GFR. At higher doses, acts as vasoconstrictor.	

**Hormones acting on kidney**

**Atrial natriuretic peptide**


Secreted in response to ↑ atrial pressure. Causes ↑ GFR and ↑ Na<sup>+</sup> filtration with no compensatory Na<sup>+</sup> reabsorption in distal nephron. Net effect: Na<sup>+</sup> loss and volume loss.

**Angiotensin II**

Synthesized in response to ↓ BP. Causes efferent arteriole constriction → ↑ GFR and ↑ FF but with compensatory Na<sup>+</sup> reabsorption in proximal and distal nephron. Net effect: preservation of renal function (↑ FF) in low-volume state with simultaneous Na<sup>+</sup> reabsorption (both proximal and distal) to maintain circulating volume.

**Parathyroid hormone**

Secreted in response to ↓ plasma [Ca<sup>2+</sup>], ↑ plasma [PO<sub>4</sub><sup>3-</sup>], or ↓ plasma 1,25-(OH)<sub>2</sub> D<sub>3</sub>. Causes ↑ [Ca<sup>2+</sup>] reabsorption (DCT), ↓ [PO<sub>4</sub><sup>3-</sup>] reabsorption (PCT), and ↑ 1,25-(OH)<sub>2</sub> D<sub>3</sub> production (↑ Ca<sup>2+</sup> and PO<sub>4</sub><sup>3-</sup> absorption from gut via vitamin D).



**Aldosterone**

Secreted in response to ↓ blood volume (via AT II) and ↑ plasma [K<sup>+</sup>]; causes ↑ Na<sup>+</sup> reabsorption, ↑ K<sup>+</sup> secretion, ↑ H<sup>+</sup> secretion.

**ADH (vasopressin)**

Secreted in response to ↑ plasma osmolarity and ↓ blood volume. Binds to receptors on principal cells, causing ↑ number of aquaporins and ↑ H<sub>2</sub>O reabsorption.

**Potassium shifts**SHIFTS K<sup>+</sup> INTO CELL (CAUSING HYPOKALEMIA)SHIFTS K<sup>+</sup> OUT OF CELL (CAUSING HYPERKALEMIA)

Hypo-osmolarity	<b>D</b> igitalis (blocks Na <sup>+</sup> /K <sup>+</sup> ATPase)
Alkalosis	<b>H</b> yper <b>O</b> smolarity
β-adrenergic agonist (↑ Na <sup>+</sup> /K <sup>+</sup> ATPase)	<b>L</b> ysis of cells (eg, crush injury, rhabdomyolysis, tumor lysis syndrome)
Insulin (↑ Na <sup>+</sup> /K <sup>+</sup> ATPase)	<b>A</b> cidosis
<b>I</b> nulin shifts K <sup>+</sup> <b>i</b> nto cells	<b>β</b> -blocker
	High blood <b>S</b> ugar (insulin deficiency)
	<b>S</b> uccinylcholine (↑ risk in burns/muscle trauma)
	Hyperkalemia? <b>DO LAβSS</b>

**Electrolyte disturbances**

ELECTROLYTE	LOW SERUM CONCENTRATION	HIGH SERUM CONCENTRATION
Na <sup>+</sup>	Nausea and malaise, stupor, coma, seizures	Irritability, stupor, coma
K <sup>+</sup>	U waves and flattened T waves on ECG, arrhythmias, muscle cramps, spasm, weakness	Wide <b>Q</b> RS and peaked T waves on ECG, arrhythmias, muscle weakness
Ca <sup>2+</sup>	Tetany, seizures, <b>Q</b> T prolongation, twitching (Chvostek sign), spasm (Trousseau sign)	<b>S</b> tones (renal), <b>b</b> ones (pain), <b>g</b> roans (abdominal pain), <b>t</b> hrones (↑ urinary frequency), <b>p</b> sychiatric <b>o</b> vertones (anxiety, altered mental status)
Mg <sup>2+</sup>	Tetany, torsades de pointes, hypokalemia, hypocalcemia (when [Mg <sup>2+</sup> ] < 1.2 mg/dL)	↓ <b>D</b> T <b>R</b> s, lethargy, bradycardia, hypotension, cardiac arrest, hypocalcemia
PO <sub>4</sub> <sup>3-</sup>	Bone loss, osteomalacia (adults), rickets (children)	Renal stones, metastatic calcifications, hypocalcemia

**Features of renal disorders**

CONDITION	BLOOD PRESSURE	PLASMA RENIN	ALDOSTERONE	SERUM Mg <sup>2+</sup>	URINE Ca <sup>2+</sup>
<b>Bartter syndrome</b>	—	↑	↑		↑
<b>Gitelman syndrome</b>	—	↑	↑	↓	↓
<b>Liddle syndrome</b>	↑	↓	↓		
<b>SIADH</b>	—/↑	↓	↓		
<b>Primary hyperaldosteronism (Conn syndrome)</b>	↑	↓	↑		
<b>Renin-secreting tumor</b>	↑	↑	↑		

↑ ↓ = 1° disturbance.

**Acid-base physiology**

	pH	P <sub>CO<sub>2</sub></sub>	[HCO <sub>3</sub> <sup>-</sup> ]	COMPENSATORY RESPONSE
Metabolic acidosis	↓	↓	↓	Hyperventilation (immediate)
Metabolic alkalosis	↑	↑	↑	Hypoventilation (immediate)
Respiratory acidosis	↓	↑	↑	↑ renal [HCO <sub>3</sub> <sup>-</sup> ] reabsorption (delayed)
Respiratory alkalosis	↑	↓	↓	↓ renal [HCO <sub>3</sub> <sup>-</sup> ] reabsorption (delayed)


Key: ↑ ↓ = 1° disturbance; ↓ ↑ = compensatory response.

Henderson-Hasselbalch equation:  $pH = 6.1 + \log \frac{[HCO_3^-]}{0.03 P_{CO_2}}$

Predicted respiratory compensation for a simple metabolic acidosis can be calculated using the Winters formula. If measured P<sub>CO<sub>2</sub></sub> > predicted P<sub>CO<sub>2</sub></sub> → concomitant respiratory acidosis; if measured P<sub>CO<sub>2</sub></sub> < predicted P<sub>CO<sub>2</sub></sub> → concomitant respiratory alkalosis:

$$P_{CO_2} = 1.5 [HCO_3^-] + 8 \pm 2$$


**Acidosis and alkalosis**



RTA TYPE	NOTES
<b>Renal tubular acidosis</b>	A disorder of the renal tubules that leads to normal anion gap (hyperchloremic) metabolic acidosis.
<b>Distal renal tubular acidosis (type 1)</b>	Urine pH > 5.5. Defect in ability of $\alpha$ intercalated cells to secrete $H^+$ → no new $HCO_3^-$ is generated → metabolic acidosis. Associated with <b>hypokalemia</b> , ↑ risk for calcium phosphate kidney stones (due to ↑ urine pH and ↑ bone turnover). Causes: amphotericin B toxicity, analgesic nephropathy, congenital anomalies (obstruction) of urinary tract.
<b>Proximal renal tubular acidosis (type 2)</b>	Urine pH < 5.5. Defect in PCT $HCO_3^-$ reabsorption → ↑ excretion of $HCO_3^-$ in urine and subsequent metabolic acidosis. Urine is acidified by $\alpha$ -intercalated cells in collecting tubule. Associated with <b>hypokalemia</b> , ↑ risk for hypophosphatemic rickets. Causes: Fanconi syndrome and carbonic anhydrase inhibitors.
<b>Hyperkalemic renal tubular acidosis (type 4)</b>	Urine pH < 5.5. Hypoaldosteronism → <b>hyperkalemia</b> → ↓ $NH_3$ synthesis in PCT → ↓ $NH_4^+$ excretion. Causes: ↓ aldosterone production (eg, diabetic hyporeninism, ACE inhibitors, ARBs, NSAIDs, heparin, cyclosporine, adrenal insufficiency) or aldosterone resistance (eg, $K^+$ -sparing diuretics, nephropathy due to obstruction, TMP/SMX).

## ► RENAL—PATHOLOGY


<b>Casts in urine</b>	Presence of casts indicates that hematuria/pyuria is of glomerular or renal tubular origin. Bladder cancer, kidney stones → hematuria, no casts. Acute cystitis → pyuria, no casts.
<b>RBC casts A</b>	Glomerulonephritis, malignant hypertension.
<b>WBC casts B</b>	Tubulointerstitial inflammation, acute pyelonephritis, transplant rejection.
<b>Fatty casts (“oval fat bodies”)</b>	Nephrotic syndrome. Associated with “Maltese cross” sign.
<b>Granular (“muddy brown”) casts C</b>	Acute tubular necrosis.
<b>Waxy casts D</b>	End-stage renal disease/chronic renal failure.
<b>Hyaline casts E</b>	Nonspecific, can be a normal finding, often seen in concentrated urine samples.



**Nomenclature of glomerular disorders**

TYPE	CHARACTERISTICS	EXAMPLE
<b>Focal</b>	< 50% of glomeruli are involved	Focal segmental glomerulosclerosis
<b>Diffuse</b>	> 50% of glomeruli are involved	Diffuse proliferative glomerulonephritis
<b>Proliferative</b>	Hypercellular glomeruli	Membranoproliferative glomerulonephritis
<b>Membranous</b>	Thickening of glomerular basement membrane (GBM)	Membranous nephropathy
<b>Primary glomerular disease</b>	1° disease of the kidney specifically impacting the glomeruli	Minimal change disease
<b>Secondary glomerular disease</b>	Systemic disease or disease of another organ system that also impacts the glomeruli	SLE, diabetic nephropathy

**Glomerular diseases**





**Nephritic syndrome**

Nephritic syndrome = Inflammatory process. When glomeruli are involved, leads to hematuria and RBC casts in urine. Associated with azotemia, oliguria, hypertension (due to salt retention), proteinuria.

**Acute poststreptococcal glomerulonephritis**

LM—glomeruli enlarged and hypercellular **A**.  
 IF—(“starry sky”) granular appearance (“lumpy-bumpy”) **B** due to IgG, IgM, and C3 deposition along GBM and mesangium.  
 EM—subepithelial immune complex (IC) humps.

Most frequently seen in children. Occurs ~ 2–4 weeks after group A streptococcal infection of pharynx or skin. Resolves spontaneously. Type III hypersensitivity reaction.  
 Presents with peripheral and periorbital edema, cola-colored urine, hypertension.  
 Positive strep titers/serologies, ↓ complement levels (C3) due to consumption.

**Rapidly progressive (crescentic) glomerulonephritis**

LM and IF—crescent moon shape **C**. Crescents consist of fibrin and plasma proteins (eg, C3b) with glomerular parietal cells, monocytes, macrophages.

Several disease processes may result in this pattern, in particular:

- **Goodpasture syndrome**—type II hypersensitivity reaction; antibodies to GBM and alveolar basement membrane → linear IF
- Granulomatosis with polyangiitis (Wegener)
- **Microscopic Polyangiitis**

Poor prognosis. Rapidly deteriorating renal function (days to weeks).

Hematuria/hemoptysis.  
 Treatment: emergent plasmapheresis.

PR3-ANCA/c-ANCA. Pauci-immune (no Ig/C3 deposition).  
**MPO-ANCA/p-ANCA**. Pauci-immune (no Ig/C3 deposition).

**Diffuse proliferative glomerulonephritis**

Often due to SLE or membranoproliferative glomerulonephritis.  
 LM—“**wire looping**” of capillaries.  
 EM—subendothelial and sometimes intramembranous IgG-based ICs often with C3 deposition.  
 IF—granular.

A common cause of death in SLE (think “**wire lupus**”). DPGN and MPGN often present as nephrotic syndrome and nephritic syndrome concurrently.


**IgA nephropathy (Berger disease)**

LM—mesangial proliferation.  
 EM—mesangial IC deposits.  
 IF—IgA-based IC deposits in mesangium.  
 Renal pathology of Henoch-Schönlein purpura.

Episodic gross hematuria that occurs concurrently with respiratory or GI tract infections (IgA is secreted by mucosal linings).  
 Not to be confused with Buerger disease (thromboangiitis obliterans).

**Nephritic syndrome (continued)**

<b>Alport syndrome</b>	Mutation in type IV collagen → thinning and splitting of glomerular basement membrane. Most commonly X-linked dominant.	Eye problems (eg, retinopathy, lens dislocation), glomerulonephritis, sensorineural deafness; “can’t see, can’t pee, can’t hear a bee.” “Basket-weave” appearance on EM.
<b>Membrano-proliferative glomerulonephritis</b>	Type I—subendothelial immune complex (IC) deposits with granular IF; “tram-track” appearance on PAS stain <b>D</b> and H&E stain <b>E</b> due to GBM splitting caused by mesangial ingrowth. Type II—also called dense deposit disease.	MPGN is a nephritic syndrome that often copresents with nephrotic syndrome. Type I may be 2° to hepatitis B or C infection. May also be idiopathic. Type II is associated with C3 nephritic factor (IgG antibody that stabilizes C3 convertase → persistent complement activation → ↓ C3 levels).



LM = light microscopy; EM = electron microscopy; IF = immunofluorescence.

**Nephrotic syndrome**

Nephrotic syndrome—massive proteinuria (> 3.5 g/day) with hypoalbuminemia, resulting edema, hyperlipidemia. Frothy urine with fatty casts. Due to podocyte damage disrupting glomerular filtration charge barrier. May be 1° (eg, direct sclerosis of podocytes) or 2° (systemic process [eg, diabetes] secondarily damages podocytes). Associated with hypercoagulable state (eg, thromboembolism) due to antithrombin (AT) III loss in urine and ↑ risk of infection (due to loss of immunoglobulins in urine and soft tissue compromise by edema).

Severe nephritic syndrome may present with nephrotic syndrome features (nephritic-nephrotic syndrome) if damage to GBM is severe enough to damage charge barrier.

**Minimal change disease (lipoid nephrosis)**

LM—normal glomeruli (lipid may be seen in PCT cells).

IF ⊖.

EM—effacement of foot processes **A**.

Most common cause of nephrotic syndrome in children. Often 1° (idiopathic) and may be triggered by recent infection, immunization, immune stimulus. Rarely, may be 2° to lymphoma (eg, cytokine-mediated damage). 1° disease has excellent response to corticosteroids.

**Focal segmental glomerulosclerosis**

LM—segmental sclerosis and hyalinosis **B**.

IF—often ⊖, but may be ⊕ for nonspecific focal deposits of IgM, C3, C1.

EM—effacement of foot process similar to minimal change disease.

Most common cause of nephrotic syndrome in African Americans and Hispanics. Can be 1° (idiopathic) or 2° to other conditions (eg, HIV infection, sickle cell disease, heroin abuse, massive obesity, interferon treatment, chronic kidney disease due to congenital malformations). 1° disease has inconsistent response to steroids. May progress to chronic renal disease.

**Membranous nephropathy (membranous glomerulonephritis)**

LM—diffuse capillary and GBM thickening **C**.

IF—granular as a result of immune complex deposition. Nephrotic presentation of SLE.

EM—“spike and dome” appearance with subepithelial deposits.

Most common cause of 1° nephrotic syndrome in Caucasian adults. Can be 1° (eg, antibodies to phospholipase A<sub>2</sub> receptor) or 2° to drugs (eg, NSAIDs, penicillamine, gold), infections (eg, HBV, HCV, syphilis), SLE, or solid tumors. 1° disease has poor response to steroids. May progress to chronic renal disease.

**Amyloidosis**

LM—Congo red stain shows apple-green birefringence under polarized light due to amyloid deposition in the mesangium.

Kidney is the most commonly involved organ (systemic amyloidosis). Associated with chronic conditions that predispose to amyloid deposition (eg, AL amyloid, AA amyloid).


**Diabetic glomerulonephropathy**

LM—mesangial expansion, GBM thickening, eosinophilic nodular glomerulosclerosis (Kimmelstiel-Wilson lesions, arrows in **D**).

Nonenzymatic glycosylation of GBM → ↑ permeability, thickening.

Nonenzymatic glycosylation of efferent arterioles (hyaline arteriosclerosis) → ↑ GFR → mesangial expansion.




Most common cause of end-stage renal disease in the United States.




**Kidney stones**

Can lead to severe complications such as hydronephrosis, pyelonephritis. Presents with unilateral flank tenderness, colicky pain radiating to groin, hematuria. Treat and prevent by encouraging fluid intake. Most common kidney stone presentation: calcium oxalate stone in patient with hypercalciuria and normocalcemia.

CONTENT	PRECIPITATES WITH	X-RAY FINDINGS	CT FINDINGS	URINE CRYSTAL	NOTES
<b>Calcium</b>	Calcium oxalate: hypocitraturia	Radiopaque	Radiopaque	Shaped like envelope <b>A</b> or dumbbell	Calcium stones most common (80%); calcium oxalate more common than calcium phosphate stones. Hypocitraturia often associated with ↓ urine pH. Can result from ethylene glycol (antifreeze) ingestion, vitamin C abuse, hypocitraturia, malabsorption (eg, Crohn disease). Treatment: thiazides, citrate, low-sodium diet.
	Calcium phosphate: ↑ pH	Radiopaque	Radiopaque	Wedge-shaped prism	Treatment: low-sodium diet, thiazides.
<b>Ammonium magnesium phosphate</b>	↑ pH	Radiopaque	Radiopaque	Coffin lid <b>B</b>	Also known as struvite; account for 15% of stones. Caused by infection with urease ⊕ bugs (eg, <i>Proteus mirabilis</i> , <i>Staphylococcus saprophyticus</i> , <i>Klebsiella</i> ) that hydrolyze urea to ammonia → urine alkalinization. Commonly form staghorn calculi <b>C</b> . Treatment: eradication of underlying infection, surgical removal of stone.
<b>Uric acid</b>	↓ pH	Radiolucent	Minimally visible	Rhomboid <b>D</b> or rosettes	About 5% of all stones. Risk factors: ↓ urine volume, arid climates, acidic pH. Strong association with hyperuricemia (eg, gout). Often seen in diseases with ↑ cell turnover (eg, leukemia). Treatment: alkalinization of urine, allopurinol.
<b>Cystine</b>	↓ pH	Radiolucent	Sometimes visible	Hexagonal <b>E</b>	Hereditary (autosomal recessive) condition in which Cystine-reabsorbing PCT transporter loses function, causing cystinuria. Transporter defect also results in poor reabsorption of Ornithine, Lysine, Arginine (COLA). Cystine is poorly soluble, thus stones form in urine. Usually begins in childhood. Can form staghorn calculi. Sodium cyanide nitroprusside test ⊕. “SIXtine” stones have SIX sides. Treatment: low sodium diet, alkalinization of urine, chelating agents if refractory.



**Hydronephrosis**

Distention/dilation of renal pelvis and calyces **A**. Usually caused by urinary tract obstruction (eg, renal stones, severe BPH, cervical cancer, injury to ureter); other causes include retroperitoneal fibrosis, vesicoureteral reflux. Dilation occurs proximal to site of pathology. Serum creatinine becomes elevated if obstruction is bilateral or if patient has only one kidney. Leads to compression and possible atrophy of renal cortex and medulla.

**Renal cell carcinoma**


Originates from PCT cells → polygonal clear cells **A** filled with accumulated lipids and carbohydrates. Often golden-yellow **B** due to ↑ lipid content. Most common in men 50–70 years old. ↑ incidence with smoking and obesity. Manifests clinically with hematuria, palpable mass, 2° polycythemia, flank pain, fever, weight loss. Invades renal vein (may develop varicocele if left sided) then IVC and spreads hematogenously; metastasizes to lung and bone.

Treatment: surgery/ablation for localized disease.

Immunotherapy (eg, aldesleukin) or targeted therapy for metastatic disease, rarely curative. Resistant to chemotherapy and radiation therapy.

Most common 1° renal malignancy **C**.


Associated with gene deletion on chromosome 3 (sporadic or inherited as von Hippel-Lindau syndrome). **RCC = 3** letters = chromosome 3. Associated with paraneoplastic syndromes (eg, ectopic EPO, ACTH, PTHrP, renin).

**Renal oncocytoma**


Benign epithelial cell tumor arising from collecting ducts (arrows in **A** point to well-circumscribed mass with central scar).

Large eosinophilic cells with abundant mitochondria without perinuclear clearing **B** (vs chromophobe renal cell carcinoma). Presents with painless hematuria, flank pain, abdominal mass.

Often resected to exclude malignancy (eg, renal cell carcinoma).



### Nephroblastoma (Wilms tumor)




Most common renal malignancy of early childhood (ages 2–4). Contains embryonic glomerular structures. Presents with large, palpable, unilateral flank mass **A** and/or hematuria.

“Loss of function” mutations of tumor suppressor genes *WT1* or *WT2* on chromosome 11.

May be a part of several syndromes:


- **WAGR** complex: **W**ilms tumor, **A**niridia (absence of iris), **G**enitourinary malformations, mental **R**etardation/intellectual disability (*WT1* deletion)
- Denys-Drash: Wilms tumor, early-onset nephrotic syndrome, male pseudohermaphroditism (*WT1* mutation)
- Beckwith-Wiedemann: Wilms tumor, macroglossia, organomegaly, hemihyperplasia (*WT2* mutation)

### Transitional cell carcinoma



Most common tumor of urinary tract system (can occur in renal calyces, renal pelvis, ureters, and bladder) **A B**. Can be suggested by painless hematuria (no casts).

Associated with problems in your **Pee SAC**: **P**henacetin, **S**moking, **A**niline dyes, and **C**yclophosphamide.



### Squamous cell carcinoma of the bladder

Chronic irritation of urinary bladder → squamous metaplasia → dysplasia and squamous cell carcinoma.

Risk factors include *Schistosoma haematobium* infection (Middle East), chronic cystitis, smoking, chronic nephrolithiasis. Presents with painless hematuria.

### Urinary incontinence

#### Stress incontinence

Outlet incompetence (urethral hypermobility or intrinsic sphincteric deficiency) → leak with ↑ intra-abdominal pressure (eg, sneezing, lifting). ↑ risk with obesity, vaginal delivery, prostate surgery. ⊕ bladder stress test (directly observed leakage from urethra upon coughing or Valsalva maneuver). Treatment: pelvic floor muscle strengthening (Kegel) exercises, weight loss, pessaries.

#### Urgency incontinence

Overactive bladder (detrusor instability) → leak with urge to void immediately. Treatment: Kegel exercises, bladder training (timed voiding, distraction or relaxation techniques), antimuscarinics (eg, oxybutynin).

#### Mixed incontinence

Features of both stress and urgency incontinence.

#### Overflow incontinence

Incomplete emptying (detrusor underactivity or outlet obstruction) → leak with overfilling. ↑ post-void residual (urinary retention) on catheterization or ultrasound. Treatment: catheterization, relieve obstruction (eg, α-blockers for BPH).

### Urinary tract infection (acute bacterial cystitis)

Inflammation of urinary bladder. Presents as suprapubic pain, dysuria, urinary frequency, urgency.

Systemic signs (eg, high fever, chills) are usually absent.

Risk factors include female gender (short urethra), sexual intercourse (“honeymoon cystitis”), indwelling catheter, diabetes mellitus, impaired bladder emptying.

Causes:

- *E coli* (most common).
- *Staphylococcus saprophyticus*—seen in sexually active young women (*E coli* is still more common in this group).
- *Klebsiella*.
- *Proteus mirabilis*—urine has ammonia scent.

Lab findings: ⊕ leukocyte esterase. ⊕ nitrites (indicate gram ⊖ organisms). Sterile pyuria and ⊖ urine cultures suggest urethritis by *Neisseria gonorrhoeae* or *Chlamydia trachomatis*.

### Pyelonephritis

#### Acute pyelonephritis

Neutrophils infiltrate renal interstitium **A**. Affects cortex with relative sparing of glomeruli/vessels.

Presents with fevers, flank pain (costovertebral angle tenderness), nausea/vomiting, chills.

Causes include ascending UTI (*E coli* is most common), hematogenous spread to kidney. Presents with WBCs in urine +/- WBC casts. CT would show striated parenchymal enhancement **B**.

Risk factors include indwelling urinary catheter, urinary tract obstruction, vesicoureteral reflux, diabetes mellitus, pregnancy.

Complications include chronic pyelonephritis, renal papillary necrosis, perinephric abscess, urosepsis.


Treatment: antibiotics.

#### Chronic pyelonephritis

The result of recurrent episodes of acute pyelonephritis. Typically requires predisposition to infection such as vesicoureteral reflux or chronically obstructing kidney stones.

Coarse, asymmetric corticomedullary scarring, blunted calyx. Tubules can contain eosinophilic casts resembling thyroid tissue **C** (thyroidization of kidney).

**Xanthogranulomatous pyelonephritis**—rare; grossly orange nodules that can mimic tumor nodules; characterized by widespread kidney damage due to granulomatous tissue containing foamy macrophages.



#### Diffuse cortical necrosis

Acute generalized cortical infarction of both kidneys. Likely due to a combination of vasospasm and DIC.

Associated with obstetric catastrophes (eg, abruptio placentae), septic shock.

**Renal osteodystrophy** Hypocalcemia, hyperphosphatemia, and failure of vitamin D hydroxylation associated with chronic renal disease → 2° hyperparathyroidism. Hyperphosphatemia also independently ↓ serum Ca<sup>2+</sup> by causing tissue calcifications, whereas ↓ 1,25-(OH)<sub>2</sub>D<sub>3</sub> → ↓ intestinal Ca<sup>2+</sup> absorption. Causes subperiosteal thinning of bones.

**Acute kidney injury (acute renal failure)** Acute kidney injury is defined as an abrupt decline in renal function as measured by ↑ creatinine and ↑ BUN or by oliguria/anuria.

**Prerenal azotemia** Due to ↓ RBF (eg, hypotension) → ↓ GFR. Na<sup>+</sup>/H<sub>2</sub>O and BUN retained by kidney in an attempt to conserve volume → ↑ BUN/creatinine ratio (BUN is reabsorbed, creatinine is not) and ↓ FE<sub>Na</sub>.

**Intrinsic renal failure** Generally due to acute tubular necrosis or ischemia/toxins; less commonly due to acute glomerulonephritis (eg, RPGN, hemolytic uremic syndrome) or acute interstitial nephritis. In ATN, patchy necrosis → debris obstructing tubule and fluid backflow across necrotic tubule → ↓ GFR. Urine has epithelial/granular casts. BUN reabsorption is impaired → ↓ BUN/creatinine ratio and ↑ FE<sub>Na</sub>.

**Postrenal azotemia** Due to outflow obstruction (stones, BPH, neoplasia, congenital anomalies). Develops only with bilateral obstruction.

	Prerenal	Intrinsic renal	Postrenal
Urine osmolality (mOsm/kg)	> 500	< 350	< 350
Urine Na <sup>+</sup> (mEq/L)	< 20	> 40	> 40
FE <sub>Na</sub>	< 1%	> 2%	< 1% (mild) > 2% (severe)
Serum BUN/Cr	> 20	< 15	Varies

**Consequences of renal failure** Inability to make urine and excrete nitrogenous wastes. 2 forms of renal failure: acute (eg, ATN) and chronic (eg, hypertension, diabetes mellitus, congenital anomalies).  
 Consequences (**MAD HUNGER**):

- **M**etabolic **A**cidosis
- **D**yslipidemia (especially ↑ triglycerides)
- **H**yperkalemia
- **U**remia—clinical syndrome marked by ↑ BUN:
  - Nausea and anorexia
  - Pericarditis
  - Asterixis
  - Encephalopathy
  - Platelet dysfunction
- **N**a<sup>+</sup>/H<sub>2</sub>O retention (HF, pulmonary edema, hypertension)
- **G**rowth retardation and developmental delay
- **E**rythropoietin failure (anemia)
- **R**enal osteodystrophy



### Acute interstitial nephritis (tubulointerstitial nephritis)



Acute interstitial renal inflammation. Pyuria (classically eosinophils) and azotemia occurring after administration of drugs that act as haptens, inducing hypersensitivity (eg, diuretics, penicillin derivatives, proton pump inhibitors, sulfonamides, rifampin, NSAIDs). Less commonly may be 2° to other processes such as systemic infections (eg, mycoplasma) or autoimmune diseases (eg, Sjögren syndrome, SLE, sarcoidosis).

Associated with fever, rash, hematuria, and costovertebral angle tenderness, but can be asymptomatic.

Remember these **P**'s:

- **P**ee (diuretics)
- **P**ain-free (NSAIDs)
- **P**enicillins and cephalosporins
- **P**roton pump inhibitors
- Rifam**P**in

### Acute tubular necrosis



Most common cause of acute kidney injury in hospitalized patients. Spontaneously resolves in many cases. Can be fatal, especially during initial oliguric phase. ↑ FENa.

Key finding: granular (“muddy brown”) casts **A**.


3 stages:

1. Inciting event
2. Maintenance phase—oliguric; lasts 1–3 weeks; risk of hyperkalemia, metabolic acidosis, uremia
3. Recovery phase—polyuric; BUN and serum creatinine fall; risk of hypokalemia

Can be caused by ischemic or nephrotoxic injury:

- Ischemic—2° to ↓ renal blood flow (eg, hypotension, shock, sepsis, hemorrhage, HF). Results in death of tubular cells that may slough into tubular lumen **B** (PCT and thick ascending limb are highly susceptible to injury).
- Nephrotoxic—2° to injury resulting from toxic substances (eg, aminoglycosides, radiocontrast agents, lead, cisplatin, ethylene glycol), crush injury (myoglobinuria), hemoglobinuria. PCT is particularly susceptible to injury.

### Renal papillary necrosis



Sloughing of necrotic renal papillae **A** → gross hematuria and proteinuria. May be triggered by recent infection or immune stimulus. Associated with sickle cell disease or trait, acute pyelonephritis, NSAIDs, diabetes mellitus.

**SAAD** papa with papillary necrosis:

- S**ickle cell disease or trait
- A**cute pyelonephritis
- A**nalgesics (NSAIDs)
- D**iabetes mellitus

**Renal cyst disorders****Autosomal dominant polycystic kidney disease**

Numerous cysts in cortex and medulla **A** causing bilateral enlarged kidneys ultimately destroy kidney parenchyma. Presents with flank pain, hematuria, hypertension, urinary infection, progressive renal failure in ~ 50% of individuals.

Mutation in *PKD1* (85% of cases, chromosome 16) or *PKD2* (15% of cases, chromosome 4). Death from complications of chronic kidney disease or hypertension (caused by ↑ renin production). Associated with berry aneurysms, mitral valve prolapse, benign hepatic cysts, diverticulosis. Treatment: ACE inhibitors or ARBs.

**Autosomal recessive polycystic kidney disease**

Cystic dilation of collecting ducts **B**. Often presents in infancy. Associated with congenital hepatic fibrosis. Significant oliguric renal failure in utero can lead to Potter sequence. Concerns beyond neonatal period include systemic hypertension, progressive renal insufficiency, and portal hypertension from congenital hepatic fibrosis.

**Medullary cystic disease**

Inherited disease causing tubulointerstitial fibrosis and progressive renal insufficiency with inability to concentrate urine. Medullary cysts usually not visualized; shrunken kidneys on ultrasound. Poor prognosis.

**Simple vs complex renal cysts**


Simple cysts are filled with ultrafiltrate (anechoic on ultrasound **C**). Very common and account for majority of all renal masses. Found incidentally and typically asymptomatic.

Complex cysts, including those that are septated, enhanced, or have solid components on imaging require follow-up or removal due to risk of renal cell carcinoma.



## ▶ RENAL—PHARMACOLOGY


## Diuretics site of action



**Mannitol**


MECHANISM	Osmotic diuretic. ↑ tubular fluid osmolarity → ↑ urine flow, ↓ intracranial/intraocular pressure.
CLINICAL USE	Drug overdose, elevated intracranial/intraocular pressure.
ADVERSE EFFECTS	Pulmonary edema, dehydration. Contraindicated in anuria, HF.

**Acetazolamide**

MECHANISM	Carbonic anhydrase inhibitor. Causes self-limited $\text{NaHCO}_3$ diuresis and ↓ total body $\text{HCO}_3^-$ stores.	
CLINICAL USE	Glaucoma, urinary alkalization, metabolic alkalosis, altitude sickness, pseudotumor cerebri.	
ADVERSE EFFECTS	Proximal renal tubular acidosis, paresthesias, $\text{NH}_3$ toxicity, sulfa allergy, hypokalemia.	“ <b>ACID</b> ”azolamide causes <b>ACID</b> osis.


**Loop diuretics**

**Furosemide, bumetanide, torsemide**

MECHANISM	Sulfonamide loop diuretics. Inhibit cotransport system ( $\text{Na}^+/\text{K}^+/2\text{Cl}^-$ ) of thick ascending limb of loop of Henle. Abolish hypertonicity of medulla, preventing concentration of urine. Stimulate PGE release (vasodilatory effect on afferent arteriole); inhibited by NSAIDs. ↑ $\text{Ca}^{2+}$ excretion. <b>L</b> oops <b>L</b> ose $\text{Ca}^{2+}$ .	
CLINICAL USE	Edematous states (HF, cirrhosis, nephrotic syndrome, pulmonary edema), hypertension, hypercalcemia.	
ADVERSE EFFECTS	<b>O</b> totoxicity, <b>H</b> ypokalemia, <b>H</b> ypomagnesemia, <b>D</b> ehydration, <b>A</b> llergy (sulfa), metabolic <b>A</b> lkalosis, <b>N</b> ephritis (interstitial), <b>G</b> out.	

OHH DAANG!

**Ethacrynic acid**

MECHANISM	Nonsulfonamide inhibitor of cotransport system ( $\text{Na}^+/\text{K}^+/2\text{Cl}^-$ ) of thick ascending limb of loop of Henle.	
CLINICAL USE	Diuresis in patients allergic to sulfa drugs.	
ADVERSE EFFECTS	Similar to furosemide, but more ototoxic.	

**Loop** earrings hurt your **ears**.

**Thiazide diuretics**

Hydrochlorothiazide, chlorthalidone, metolazone.

**MECHANISM**


Inhibit NaCl reabsorption in early DCT  
→ ↓ diluting capacity of nephron. ↓ Ca<sup>2+</sup> excretion.

**CLINICAL USE**

Hypertension, HF, idiopathic hypercalciuria, nephrogenic diabetes insipidus, osteoporosis.

**ADVERSE EFFECTS**

Hypokalemic metabolic alkalosis, hyponatremia, hyperGlycemia, hyperLipidemia, hyperUricemia, hyperCalcemia. Sulfa allergy.

**Potassium-sparing diuretics**

Spironolactone and eplerenone; Triamterene, and Amiloride.

The K<sup>+</sup> STAs.

**MECHANISM**


Spironolactone and eplerenone are competitive aldosterone receptor antagonists in cortical collecting tubule. Triamterene and amiloride act at the same part of the tubule by blocking Na<sup>+</sup> channels in the cortical collecting tubule.

**CLINICAL USE**

Hyperaldosteronism, K<sup>+</sup> depletion, HF, hepatic ascites (spironolactone), nephrogenic DI (amiloride), antiandrogen.

**ADVERSE EFFECTS**

Hyperkalemia (can lead to arrhythmias), endocrine effects with spironolactone (eg, gynecomastia, antiandrogen effects).

**Diuretics: electrolyte changes****Urine NaCl**

↑ with all diuretics (strength varies based on potency of diuretic effect). Serum NaCl may decrease as a result.

**Urine K<sup>+</sup>**

↑ especially with loop and thiazide diuretics. Serum K<sup>+</sup> may decrease as a result.

**Blood pH**

↓ (**acidemia**): carbonic anhydrase inhibitors: ↓ HCO<sub>3</sub><sup>-</sup> reabsorption. K<sup>+</sup> sparing: aldosterone blockade prevents K<sup>+</sup> secretion and H<sup>+</sup> secretion. Additionally, hyperkalemia leads to K<sup>+</sup> entering all cells (via H<sup>+</sup>/K<sup>+</sup> exchanger) in exchange for H<sup>+</sup> exiting cells.

↑ (**alkalemia**): loop diuretics and thiazides cause alkalemia through several mechanisms:

- Volume contraction → ↑ AT II → ↑ Na<sup>+</sup>/H<sup>+</sup> exchange in PCT → ↑ HCO<sub>3</sub><sup>-</sup> reabsorption (“contraction alkalosis”)
- K<sup>+</sup> loss leads to K<sup>+</sup> exiting all cells (via H<sup>+</sup>/K<sup>+</sup> exchanger) in exchange for H<sup>+</sup> entering cells
- In low K<sup>+</sup> state, H<sup>+</sup> (rather than K<sup>+</sup>) is exchanged for Na<sup>+</sup> in cortical collecting tubule → alkalemia and “paradoxical aciduria”

**Urine Ca<sup>2+</sup>**

↑ with loop diuretics: ↓ paracellular Ca<sup>2+</sup> reabsorption → hypocalcemia.

↓ with thiazides: enhanced Ca<sup>2+</sup> reabsorption.

**Angiotensin-converting enzyme inhibitors**

Captopril, enalapril, lisinopril, ramipril.

MECHANISM	Inhibit ACE → ↓ AT II → ↓ GFR by preventing constriction of efferent arterioles. ↑ renin due to loss of negative feedback. Inhibition of ACE also prevents inactivation of bradykinin, a potent vasodilator.	
CLINICAL USE	Hypertension, HF (↓ mortality), proteinuria, diabetic nephropathy. Prevent unfavorable heart remodeling as a result of chronic hypertension.	In chronic kidney disease (eg, diabetic nephropathy), ↓ intraglomerular pressure, slowing GBM thickening.
ADVERSE EFFECTS	Cough, Angioedema (due to ↑ bradykinin; contraindicated in CI esterase inhibitor deficiency), Teratogen (fetal renal malformations), ↑ Creatinine (↓ GFR), Hyperkalemia, and Hypotension. Used with caution in bilateral renal artery stenosis because ACE inhibitors will further ↓ GFR → renal failure.	Captopril's <b>CATCHH</b> .

**Angiotensin II receptor blockers**

Losartan, candesartan, valsartan.

MECHANISM	Selectively block binding of angiotensin II to AT <sub>1</sub> receptor. Effects similar to ACE inhibitors, but ARBs do not increase bradykinin.	
CLINICAL USE	Hypertension, HF, proteinuria, or chronic kidney disease (eg, diabetic nephropathy) with intolerance to ACE inhibitors (eg, cough, angioedema).	
ADVERSE EFFECTS	Hyperkalemia, ↓ GFR, hypotension; teratogen.	

**Aliskiren**

MECHANISM	Direct renin inhibitor, blocks conversion of angiotensinogen to angiotensin I.
CLINICAL USE	Hypertension.
ADVERSE EFFECTS	Hyperkalemia, ↓ GFR, hypotension, angioedema. Relatively contraindicated in patients already taking ACE inhibitors or ARBs.



# Reproductive

*“Artificial insemination is when the farmer does it to the cow instead of the bull.”*

—Student essay

*“Whoever called it necking was a poor judge of anatomy.”*

—Groucho Marx

*“See, the problem is that God gives men a brain and a penis, and only enough blood to run one at a time.”*

—Robin Williams

*“I think you can say that life is a system in which proteins and nucleic acids interact in ways that allow the structure to grow and reproduce. It’s that growth and reproduction, the ability to make more of yourself, that’s important.”*

—Andrew H. Knoll

▶ Embryology	580
▶ Anatomy	591
▶ Physiology	595
▶ Pathology	603
▶ Pharmacology	620




## ► REPRODUCTIVE—EMBRYOLOGY

## Important genes of embryogenesis

<b>Sonic hedgehog gene</b>	Produced at base of limbs in zone of polarizing activity. Involved in patterning along anteroposterior axis and CNS development; mutation can cause holoprosencephaly.
<b>Wnt-7 gene</b>	Produced at apical ectodermal ridge (thickened ectoderm at distal end of each developing limb). Necessary for proper organization along dorsal-ventral axis.
<b>FGF gene</b>	Produced at apical ectodermal ridge. Stimulates mitosis of underlying mesoderm, providing for lengthening of limbs.
<b>Homeobox (Hox) genes</b>	Involved in segmental organization of embryo in a craniocaudal direction. Code for transcription factors. Hox mutations → appendages in wrong locations.

## Early fetal development

## Early embryonic development



<b>Within week 1</b>	hCG secretion begins around the time of implantation of blastocyst.	Blastocyst “sticks” at day 6.
<b>Within week 2</b>	Bilaminar disc (epiblast, hypoblast).	2 weeks = 2 layers.
<b>Within week 3</b>	Gastrulation forms trilaminar embryonic disc. Cells from epiblast invaginate → primitive streak → endoderm, mesoderm, ectoderm. Notochord arises from midline mesoderm; overlying ectoderm becomes neural plate.	3 weeks = 3 layers.
<b>Weeks 3–8 (embryonic period)</b>	Neural tube formed by neuroectoderm and closes by week 4. Organogenesis.	Extremely susceptible to teratogens.
<b>Week 4</b>	Heart begins to beat. Upper and lower limb buds begin to form.	4 weeks = 4 limbs and 4 heart chambers.
<b>Week 6</b>	Fetal cardiac activity visible by transvaginal ultrasound.	
<b>Week 8</b>	Fetal movements start.	Gait at week 8.
<b>Week 10</b>	Genitalia have male/female characteristics.	Tenitalia

**Embryologic derivatives**

<b>Ectoderm</b>		<b>External/outer layer</b>
<b>Surface ectoderm</b>	Epidermis; adenohypophysis (from Rathke pouch); lens of eye; epithelial linings of oral cavity, sensory organs of ear, and olfactory epithelium; anal canal below the pectinate line; parotid, sweat, mammary glands.	<b>Craniopharyngioma</b> —benign Rathke pouch tumor with cholesterol crystals, calcifications.
<b>Neural tube</b>	Brain (neurohypophysis, CNS neurons, oligodendrocytes, astrocytes, ependymal cells, pineal gland), retina, spinal cord.	Neuroectoderm—think CNS.
<b>Neural crest</b>	PNS (dorsal root ganglia, cranial nerves, autonomic ganglia, Schwann cells), melanocytes, chromaffin cells of adrenal medulla, parafollicular (C) cells of thyroid, pia and arachnoid, bones of the skull, odontoblasts, aorticopulmonary septum, endocardial cushions, myenteric (Auerbach) plexus.	Neural crest—think PNS and non-neural structures nearby.
<b>Mesoderm</b>		<b>Middle/“meat” layer.</b>
	Muscle, bone, connective tissue, serous linings of body cavities (eg, peritoneum), spleen (derived from foregut mesentery), cardiovascular structures, lymphatics, blood, wall of gut tube, upper vagina, kidneys, adrenal cortex, dermis, testes, ovaries. Notochord induces ectoderm to form neuroectoderm (neural plate). Its only postnatal derivative is the nucleus pulposus of the intervertebral disc.	Mesodermal defects = <b>VACTERL</b> : <b>V</b> ertebral defects <b>A</b> nal atresia <b>C</b> ardiac defects <b>T</b> racheo- <b>E</b> sophageal fistula <b>R</b> enal defects <b>L</b> imb defects (bone and muscle)
<b>Endoderm</b>		<b>“Enternal” layer.</b>
	Gut tube epithelium (including anal canal above the pectinate line), most of urethra and lower vagina (derived from urogenital sinus), luminal epithelial derivatives (eg, lungs, liver, gallbladder, pancreas, eustachian tube, thymus, parathyroid, thyroid follicular cells).	

**Types of errors in morphogenesis**

<b>Agensis</b>	Absent organ due to absent primordial tissue.
<b>Aplasia</b>	Absent organ despite presence of primordial tissue.
<b>Hypoplasia</b>	Incomplete organ development; primordial tissue present.
<b>Disruption</b>	2° breakdown of previously normal tissue or structure (eg, amniotic band syndrome).
<b>Deformation</b>	Extrinsic disruption; occurs after embryonic period.
<b>Malformation</b>	Intrinsic disruption; occurs during embryonic period (weeks 3–8).
<b>Sequence</b>	Abnormalities result from a single 1° embryologic event (eg, oligohydramnios → Potter sequence).

**Teratogens** Most susceptible in 3rd–8th weeks (embryonic period—organogenesis) of pregnancy. Before week 3, “all-or-none” effects. After week 8, growth and function affected.

TERATOGEN	EFFECTS ON FETUS	NOTES
<b>Medications</b>		
<b>ACE inhibitors</b>	Renal damage	
<b>Alkylating agents</b>	Absence of digits, multiple anomalies	
<b>Aminoglycosides</b>	Ototoxicity	<b>A mean guy</b> hit the baby in the <b>ear</b> .
<b>Antiepileptic drugs</b>	Neural tube defects, cardiac defects, cleft palate, skeletal abnormalities (eg, phalanx/nail hypoplasia, facial dysmorphism)	High-dose folate supplementation recommended. Most commonly valproate, carbamazepine, phenytoin, phenobarbital.
<b>Diethylstilbestrol</b>	Vaginal clear cell adenocarcinoma, congenital Müllerian anomalies	
<b>Folate antagonists</b>	Neural tube defects	Includes trimethoprim, methotrexate, antiepileptic drugs.
<b>Isotretinoin</b>	Multiple severe birth defects	Contraception mandatory. Iso <b>TERAT</b> inoin.
<b>Lithium</b>	Ebstein anomaly (apical displacement of tricuspid valve)	
<b>Methimazole</b>	Aplasia cutis congenita	
<b>Tetracyclines</b>	Discolored teeth, inhibited bone growth	“ <b>Teeth</b> racyclines.”
<b>Thalidomide</b>	Limb defects (phocomelia, micromelia—“flipper” limbs)	<b>Limb</b> defects with “tha- <b>limb</b> -domide.”
<b>Warfarin</b>	Bone deformities, fetal hemorrhage, abortion, ophthalmologic abnormalities	Do not wage <b>warfare</b> on the baby; keep it <b>heppy</b> with <b>heparin</b> (does not cross placenta).
<b>Substance abuse</b>		
<b>Alcohol</b>	Common cause of birth defects and intellectual disability; fetal alcohol syndrome	
<b>Cocaine</b>	Low birth weight, preterm birth, IUGR, placental abruption	Cocaine → vasoconstriction.
<b>Smoking (nicotine, CO)</b>	Low birth weight (leading cause in developed countries), preterm labor, placental problems, IUGR, SIDS	Nicotine → vasoconstriction. CO → impaired O <sub>2</sub> delivery.
<b>Other</b>		
<b>Iodine (lack or excess)</b>	Congenital goiter or hypothyroidism (cretinism)	
<b>Maternal diabetes</b>	Caudal regression syndrome (anal atresia to sirenomelia), congenital heart defects, neural tube defects, macrosomia, neonatal hypoglycemia	
<b>Methylmercury</b>	Neurotoxicity	Highest in swordfish, shark, tilefish, king mackerel.
<b>Vitamin A excess</b>	Extremely high risk for spontaneous abortions and birth defects (cleft palate, cardiac)	
<b>X-rays</b>	Microcephaly, intellectual disability	Minimized by lead shielding.


**Fetal alcohol syndrome**



Leading cause of intellectual disability in the US. Newborns of alcohol-consuming mothers have ↑ incidence of congenital abnormalities, including pre- and postnatal developmental retardation, microcephaly, facial abnormalities **A** (eg, smooth philtrum, thin vermilion border [upper lip], small palpebral fissures), limb dislocation, heart defects. Heart-lung fistulas and holoprosencephaly in most severe form. Mechanism is failure of cell migration.

**Twinning**

Dizygotic (“fraternal”) twins arise from 2 eggs that are separately fertilized by 2 different sperm (always 2 zygotes) and will have 2 separate amniotic sacs and 2 separate placentas (chorions). Monozygotic (“identical”) twins arise from 1 fertilized egg (1 egg + 1 sperm) that splits in early pregnancy. The timing of cleavage determines chorionicity (number of chorions) and amnionicity (number of amnions).



**Placenta**

1° site of nutrient and gas exchange between mother and fetus.

**Fetal component****Cytotrophoblast**

Inner layer of chorionic villi.

Cytotrophoblast makes **C**ells.


**Syncytiotrophoblast**

Outer layer of chorionic villi; synthesizes and secretes hormones, eg, hCG (structurally similar to LH; stimulates corpus luteum to secrete progesterone during first trimester).

**S**yncytiotrophoblast **s**ynthesizes hormones.  
Lacks MHC-I expression → ↓ chance of attack by maternal immune system.

**Maternal component****Decidua basalis**

Derived from endometrium. Maternal blood in lacunae.





**Umbilical cord**

Umbilical arteries (2)—return deoxygenated blood from fetal internal iliac arteries to placenta **A**.

Umbilical vein (1)—supplies oxygenated blood from placenta to fetus; drains into IVC via liver or via ductus venosus.

Single umbilical artery (2-vessel cord) is associated with congenital and chromosomal anomalies.

Umbilical arteries and vein are derived from allantois.



**Urachus**

In the 3rd week the yolk sac forms the allantois, which extends into urogenital sinus. Allantois becomes the urachus, a duct between fetal bladder and umbilicus.

**Patent urachus**


Total failure of urachus to obliterate → urine discharge from umbilicus.

**Urachal cyst**

Partial failure of urachus to obliterate; fluid-filled cavity lined with uroepithelium, between umbilicus and bladder. Can lead to infection, adenocarcinoma.

**Vesicourachal diverticulum**

Slight failure of urachus to obliterate → outpouching of bladder.



**Vitelline duct**


7th week—obliteration of vitelline duct (omphalomesenteric duct), which connects yolk sac to midgut lumen.

**Vitelline fistula**

Vitelline duct fails to close → meconium discharge from umbilicus.


**Meckel diverticulum**

Partial closure of vitelline duct, with patent portion attached to ileum (true diverticulum). May have heterotopic gastric and/or pancreatic tissue → melena, hematochezia, abdominal pain.



**Aortic arch derivatives** Develop into arterial system.

<b>1st</b>	Part of <b>max</b> illary artery (branch of external carotid).	<b>1st</b> arch is <b>max</b> imal.
<b>2nd</b>	<b>S</b> tapedial artery and hyoid artery.	<b>Second</b> = <b>S</b> tapedial.
<b>3rd</b>	<b>C</b> ommon <b>C</b> arotid artery and proximal part of internal <b>C</b> arotid artery.	<b>C</b> is <b>3rd</b> letter of alphabet.
<b>4th</b>	On left, aortic arch; on right, proximal part of right subclavian artery.	<b>4th</b> arch ( <b>4</b> limbs) = systemic.
<b>6th</b>	Proximal part of pulmonary arteries and (on left only) ductus arteriosus.	<b>6th</b> arch = pulmonary and the pulmonary-to-systemic shunt (ductus arteriosus).




**Branchial (pharyngeal) apparatus** Composed of branchial clefts, arches, pouches. Branchial **c**lefts—derived from **e**ctoderm. Also called branchial grooves. Branchial **a**rches—derived from mesoderm (muscles, arteries) and neural crest (bones, cartilage). Branchial **p**ouches—derived from endoderm.

**CAP** covers outside to inside:

**C**lefts = ectoderm

**A**rches = mesoderm + neural crest

**P**ouches = endoderm



**Branchial cleft derivatives**

1st cleft develops into external auditory meatus.

2nd through 4th clefts form temporary cervical sinuses, which are obliterated by proliferation of 2nd arch mesenchyme.

Persistent cervical sinus → branchial cleft cyst within lateral neck, anterior to sternocleidomastoid muscle. Immobile during swallowing.

**Branchial arch derivatives**

ARCH	CARTILAGE	MUSCLES	NERVES <sup>a</sup>	ABNORMALITIES/COMMENTS
<b>1st arch</b>	<p>Maxillary process → Maxilla, zygomatic bone</p> <p>Mandibular process → Meckel cartilage → Mandible, Malleus and incus, sphenomandibular ligament</p>	<p>Muscles of Mastication (temporalis, Masseter, lateral and Medial pterygoids), Mylohyoid, anterior belly of digastric, tensor tympani, anterior ⅔ of tongue</p>	CN V <sub>2</sub> and V <sub>3</sub> <b>chew</b>	<p>Pierre Robin sequence—micrognathia, glossoptosis, cleft palate, airway obstruction</p> <p>Trachea Collins syndrome—neural crest dysfunction → mandibular hypoplasia, facial abnormalities</p>
<b>2nd arch</b>	<p>Reichert cartilage: Stapes, Styloid process, lesser horn of hyoid, Stylohyoid ligament</p>	<p>Muscles of facial expression, Stapedius, Stylohyoid, platysma, posterior belly of digastric</p>	CN VII (facial expression) <b>smile</b>	
<b>3rd arch</b>	<p>Greater horn of hyoid</p>	<p>Stylopharyngeus (think of stylopharyngeus innervated by glossopharyngeal nerve)</p>	CN IX (stylopharyngeus) <b>swallow stylishly</b>	
<b>4th–6th arches</b>	<p>Arytenoids, Cricoid, Corniculate, Cuneiform, Thyroid (used to sing and ACCCT)</p>	<p>4th arch: most pharyngeal constrictors; cricothyroid, levator veli palatini</p> <p>6th arch: all intrinsic muscles of larynx except cricothyroid</p>	<p>4th arch: CN X (superior laryngeal branch) <b>simply swallow</b></p> <p>6th arch: CN X (recurrent laryngeal branch) <b>speak</b></p>	<p>Arches 3 and 4 form posterior ⅓ of tongue; arch 5 makes no major developmental contributions</p>

<sup>a</sup>These are the only CNs with both motor and sensory components (except V<sub>2</sub>, which is sensory only).

When at the restaurant of the golden arches, children tend to first **chew** (1), then **smile** (2), then **swallow stylishly** (3) or **simply swallow** (4), and then **speak** (6).



**Branchial pouch derivatives**

POUCH	DERIVATIVES	NOTES	MNEMONIC
<b>1st pouch</b>	Middle ear cavity, eustachian tube, mastoid air cells.	1st pouch contributes to endoderm-lined structures of ear.	<b>Ear, tonsils, bottom-to-top:</b> 1 ( <b>ear</b> ), 2 ( <b>tonsils</b> ), 3 dorsal ( <b>bottom</b> for inferior parathyroids), 3 ventral ( <b>to</b> = <b>thymus</b> ), 4 ( <b>top</b> = superior parathyroids).
<b>2nd pouch</b>	Epithelial lining of palatine tonsil.		
<b>3rd pouch</b>	Dorsal wings → <b>inferior</b> parathyroids. Ventral wings → thymus.	<b>3rd</b> pouch contributes to <b>3</b> structures (thymus, left and right inferior parathyroids). 3rd-pouch structures end up <b>below</b> 4th-pouch structures.	
<b>4th pouch</b>	Dorsal wings → <b>superior</b> parathyroids. Ventral wings → ultimobranchial body → parafollicular (C) cells of thyroid.		
<b>DiGeorge syndrome</b>	Chromosome 22q11 deletion. Aberrant development of 3rd and 4th pouches → T-cell deficiency (thymic aplasia) and hypocalcemia (failure of parathyroid development). Associated with cardiac defects (conotruncal anomalies).		


**Cleft lip and cleft palate**

Cleft lip

**Cleft lip**—failure of fusion of the maxillary and medial nasal processes (formation of 1° palate).

**Cleft palate**—failure of fusion of the two lateral palatine shelves or failure of fusion of lateral palatine shelves with the nasal septum and/or median palatine shelf (formation of 2° palate).


Cleft lip and cleft palate have distinct, multifactorial etiologies, but often occur together.




Cleft palate (partial) [X]

**Genital embryology**

<b>Female</b>	Default development. Mesonephric duct degenerates and paramesonephric duct develops.
<b>Male</b>	SRY gene on Y chromosome—produces testis-determining factor → testes development. Sertoli cells secrete Müllerian inhibitory factor (MIF) that suppresses development of paramesonephric ducts. Leydig cells secrete androgens that stimulate development of mesonephric ducts.
<b>Paramesonephric (Müllerian) duct</b>	Develops into female internal structures—fallopian tubes, uterus, upper portion of vagina (lower portion from urogenital sinus). Male remnant is appendix testis. <b>Müllerian agenesis (Mayer-Rokitansky-Küster-Hausler syndrome)</b> —may present as 1° amenorrhea (due to a lack of uterine development) in females with fully developed 2° sexual characteristics (functional ovaries).
<b>Mesonephric (Wolffian) duct</b>	Develops into male internal structures (except prostate)— <b>S</b> eminal vesicles, <b>E</b> pididymis, <b>E</b> jaculatory duct, <b>D</b> uctus deferens ( <b>SEED</b> ). In females, remnant of mesonephric duct → Gartner duct.



**Sexual determination**



- 1 No Sertoli cells or lack of Müllerian inhibitory factor → develop both male and female internal genitalia and male external genitalia
- 2 5α-reductase deficiency— inability to convert testosterone into DHT → male internal genitalia, ambiguous external genitalia until puberty (when ↑ testosterone levels cause masculinization)

In the testes:

- L**eydig **L**eads to male (internal and external) sexual differentiation.
- S**ertoli **S**huts down female (internal) sexual differentiation.

**Uterine (Müllerian duct) anomalies**

**Septate uterus**


Common anomaly vs normal uterus **A**. Incomplete resorption of septum **B**. ↓ fertility and early miscarriage/pregnancy loss. Treat with septoplasty.

**Bicornuate uterus**


Incomplete fusion of Müllerian ducts **C**. ↑ risk of complicated pregnancy, early pregnancy loss, malpresentation, prematurity.

**Uterus didelphys**

Complete failure of fusion → double uterus, cervix, vagina **D**. Pregnancy possible.




**Male/female genital homologs**



**Congenital penile abnormalities**


**Hypospadias**



Abnormal opening of penile urethra on ventral surface of penis due to failure of urethral folds to fuse.

Hypospadias is more common than epispadias. Associated with inguinal hernia and cryptorchidism.  
**Hypo** is **below**.

**Epispadias**



Abnormal opening of penile urethra on dorsal surface of penis due to faulty positioning of genital tubercle.

**Ex**strophy of the bladder is associated with **E**pispadias. When you have **E**pispadias, you hit your **E**ye when you p**EE**.

**Descent of testes and ovaries**

	MALE REMNANT	FEMALE REMNANT
<b>Gubernaculum (band of fibrous tissue)</b>	Anchors testes within scrotum.	Ovarian ligament + round ligament of uterus.
<b>Processus vaginalis (evagination of peritoneum)</b>	Forms tunica vaginalis.	Obliterated.

▶ REPRODUCTIVE—ANATOMY

**Gonadal drainage**

**Venous drainage**


Left ovary/testis → left gonadal vein → left renal vein → IVC.  
Right ovary/testis → right gonadal vein → IVC.

“Left gonadal vein takes the **L**ongest way.” Because the left spermatic vein enters the left renal vein at a 90° angle, flow is less laminar on left than on right → left venous pressure > right venous pressure → varicocele more common on the left.

**Lymphatic drainage**


Ovaries/testes → para-aortic lymph nodes.  
Body of uterus/cervix/superior bladder → external iliac nodes.  
Prostate/cervix/corpus cavernosum/proximal vagina → internal iliac nodes.  
Distal vagina/vulva/scrotum/distal anus → superficial inguinal nodes.  
Glans penis → deep inguinal nodes.

## Female reproductive anatomy




LIGAMENT	CONNECTS	STRUCTURES CONTAINED	NOTES
<b>Infundibulopelvic ligament (suspensory ligament of the ovary)</b>	Ovaries to lateral pelvic wall	Ovarian vessels	Ligate vessels during oophorectomy to avoid bleeding. Ureter courses retroperitoneally, close to gonadal vessels → at risk of injury during ligation of ovarian vessels.
<b>Cardinal ligament (not labeled)</b>	Cervix to side wall of pelvis	Uterine vessels	Ureter at risk of injury during ligation of uterine vessels in hysterectomy.
<b>Round ligament of the uterus</b>	Uterine fundus to labia majora		Derivative of gubernaculum. Travels through <b>round</b> inguinal canal; above the artery of Sampson.
<b>Broad ligament</b>	Uterus, fallopian tubes, and ovaries to pelvic side wall	Ovaries, fallopian tubes, round ligaments of uterus	Fold of peritoneum that comprises the mesosalpinx, mesometrium, and mesovarium.
<b>Ovarian ligament</b>	Medial pole of ovary to lateral uterus	—	Derivative of gubernaculum. Ovarian <b>L</b> igament <b>L</b> atches to <b>L</b> ateral uterus.

## Female reproductive epithelial histology



TISSUE	HISTOLOGY/NOTES
Vagina	Stratified squamous epithelium, nonkeratinized
Ectocervix	Stratified squamous epithelium, nonkeratinized
Transformation zone	Squamocolumnar junction <b>A</b> (most common area for cervical cancer)
Endocervix	Simple columnar epithelium
Uterus	Simple columnar epithelium with long tubular glands in proliferative phase; coiled glands in secretory phase
Fallopian tube	Simple columnar epithelium, ciliated
Ovary, outer surface	Simple cuboidal epithelium (germinal epithelium covering surface of ovary)

## Male reproductive anatomy



Pathway of sperm during ejaculation—

### SEVEN UP:

**S**eminiferous tubules  
**E**pididymis  
**V**as deferens  
**E**jaculatory ducts  
**(N**othing)  
**U**rethra  
**P**enis

## Urethral injury

Suspect if blood seen at urethral meatus. Urethral catheterization relatively contraindicated. Posterior urethra—membranous urethra prone to injury from pelvic fracture. Injury can cause urine to leak into retroperitoneal space. Anterior urethra—bulbar urethra at risk of damage due to perineal straddle injury. Can cause urine to leak beneath deep fascia of Buck. If fascia is torn, urine escapes into superficial perineal space.

## Autonomic innervation of the male sexual response

Erection—**P**arasympathetic nervous system (pelvic nerve):

- NO → ↑ cGMP → smooth muscle relaxation → vasodilation → proerectile.
- Norepinephrine → ↑  $[Ca^{2+}]_{in}$  → smooth muscle contraction → vasoconstriction → antierectile.

Emission—**S**ympathetic nervous system (hypogastric nerve).



Ejaculation—visceral and **S**omatic nerves (pudendal nerve).

**P**oint, **S**queeze, and **S**hoot.

PDE-5 inhibitors (eg, sildenafil) ↓ cGMP breakdown.

## Seminiferous tubules


CELL	FUNCTION	LOCATION/NOTES
<b>Spermatogonia</b> (germ cells)	Maintain germ cell pool and produce 1° spermatocytes.	Line seminiferous tubules <b>A</b>
<b>Sertoli cells</b> (non-germ cells)	Secrete inhibin B → inhibit FSH. Secrete androgen-binding protein → maintain local levels of testosterone. Produce MIF. Tight junctions between adjacent Sertoli cells form blood-testis barrier → isolate gametes from autoimmune attack. Support and nourish developing spermatozoa. Regulate spermatogenesis. Temperature sensitive; ↓ sperm production and ↓ inhibin B with ↑ temperature.	Line seminiferous tubules Convert testosterone and androstenedione to estrogens via aromatase <b>S</b> ertoli cells <b>S</b> upport <b>S</b> perm <b>S</b> ynthesis Homolog of female granulosa cells
<b>Leydig cells</b> (endocrine cells)	Secrete testosterone in the presence of LH; testosterone production unaffected by temperature.	Interstitial Homolog of female theca interna cells



► REPRODUCTIVE—PHYSIOLOGY

**Estrogen**

SOURCE	Ovary (17β-estradiol), placenta (estriol), adipose tissue (estrone via aromatization).	Potency: estradiol > estrone > estriol
FUNCTION	Development of genitalia and breast, female fat distribution. Growth of follicle, endometrial proliferation, ↑ myometrial excitability. Upregulation of estrogen, LH, and progesterone receptors; feedback inhibition of FSH and LH, then LH surge; stimulation of prolactin secretion. ↑ transport proteins, SHBG; ↑ HDL; ↓ LDL.	Pregnancy: ▪ 50-fold ↑ in estradiol and estrone ▪ 1000-fold ↑ in estriol (indicator of fetal well-being) Estrogen receptors expressed in cytoplasm; translocate to nucleus when bound by estrogen



**Progesterone**

SOURCE	Corpus luteum, placenta, adrenal cortex, testes.	Fall in progesterone after delivery disinhibits prolactin → lactation. ↑ progesterone is indicative of ovulation.
FUNCTION	Stimulation of endometrial glandular secretions and spiral artery development. Maintenance of pregnancy. ↓ myometrial excitability. Production of thick cervical mucus, which inhibits sperm entry into uterus. ↑ body temperature. Inhibition of gonadotropins (LH, FSH). Uterine smooth muscle relaxation (preventing contractions). ↓ estrogen receptor expression. Prevents endometrial hyperplasia.	<b>Progesterone is pro-gestation.</b> <b>Prolactin is pro-lactation.</b>




**Oogenesis**

1° oocytes begin meiosis I during fetal life and complete meiosis I just prior to ovulation.

Meiosis I is arrested in prOphase I for years until Ovulation (1° oocytes).

Meiosis II is arrested in **met**aphase II until fertilization (2° oocytes). “An egg **met** a sperm.”

If fertilization does not occur within 1 day, the 2° oocyte degenerates.

**Ovulation**


↑ estrogen, ↑ GnRH receptors on anterior pituitary. Estrogen surge then stimulates LH release → ovulation (rupture of follicle).

↑ temperature (progesterone induced).

**Mittelschmerz**—transient mid-cycle ovulatory pain (“**M**iddle hurts”); classically associated with peritoneal irritation (eg, follicular swelling/rupture, fallopian tube contraction). Can mimic appendicitis.

**Menstrual cycle**

Follicular phase can vary in length. Luteal phase is 14 days. Ovulation day + 14 days = menstruation.  
 Follicular growth is fastest during 2nd week of the follicular phase.  
 Estrogen stimulates endometrial proliferation.  
 Progesterone maintains endometrium to support implantation.  
 ↓ progesterone → ↓ fertility.



## Pregnancy

Fertilization most commonly occurs in upper end of fallopian tube (the ampulla). Occurs within 1 day of ovulation.

Implantation within the wall of the uterus occurs 6 days after fertilization.


Syncytiotrophoblasts secrete hCG, which is detectable in blood 1 week after conception and on home test in urine 2 weeks after conception.

Gestational age—calculated from date of last menstrual period.

Embryonic age—calculated from date of conception (gestational age minus 2 weeks).

Physiologic adaptations in pregnancy:

- ↑ cardiac output (↑ preload, ↓ afterload, ↑ HR → ↑ placental and uterus perfusion)
- Anemia (↑↑ plasma, ↑ RBCs)
- Hypercoagulability (to ↓ blood loss at delivery)
- Hyperventilation (eliminate fetal CO<sub>2</sub>)



Placental hormone secretion generally increases over the course of pregnancy, but hCG peaks at 8–10 weeks.

## Human chorionic gonadotropin

### SOURCE

Syncytiotrophoblast of placenta.

### FUNCTION

Maintains corpus luteum (and thus progesterone) for first 8–10 weeks of pregnancy by acting like LH (otherwise no luteal cell stimulation → abortion). After 8–10 weeks, placenta synthesizes its own estriol and progesterone and corpus luteum degenerates.

Used to detect pregnancy because it appears early in urine (see above).

Has identical  $\alpha$  subunit as LH, FSH, TSH (states of ↑ hCG can cause hyperthyroidism).  $\beta$  subunit is unique (pregnancy tests detect  $\beta$  subunit). hCG is ↑ in multiple gestations, hydatidiform moles, choriocarcinomas, and Down syndrome; hCG is ↓ in ectopic/failing pregnancy, Edward syndrome, and Patau syndrome.

## Human placental lactogen (chorionic somatomammotropin)







### SOURCE

Syncytiotrophoblast of placenta.

### FUNCTION

Stimulates insulin production, ↑ insulin resistance due to shunting carbohydrate metabolism toward supplying glucose/amino acids to fetus. ↑ lipolysis (due to insulin resistance).

**Apgar score**

	Score 2	Score 1	Score 0
<b>A</b> ppearance	 Pink	 Extremities blue	 Pale or blue
<b>P</b> ulse	> 100 bpm	< 100 bpm	No pulse
<b>G</b> rimace	Cries and pulls away	Grimaces or weak cry	No response to stimulation
<b>A</b> ctivity	 Active movement	 Arms, legs flexed	 No movement
<b>R</b> espiration	Strong cry	Slow, irregular	No breathing

Assessment of newborn vital signs following labor via a 10-point scale evaluated at 1 minute and 5 minutes. **A**pgar score is based on **A**ppearance, **P**ulse, **G**rimace, **A**ctivity, and **R**espiration. Apgar scores < 7 require further evaluation. If Apgar score remains low at later time points, there is ↑ risk the child will develop long-term neurologic damage.

**Low birth weight**

Defined as < 2500 g. Caused by prematurity or intrauterine growth restriction (IUGR). Associated with ↑ risk of sudden infant death syndrome (SIDS) and with ↑ overall mortality. Other problems include impaired thermoregulation and immune function, hypoglycemia, polycythemia, and impaired neurocognitive/emotional development. Complications include infections, respiratory distress syndrome, necrotizing enterocolitis, intraventricular hemorrhage, and persistent fetal circulation.

**Lactation**

After labor, the ↓ in progesterone and estrogen disinhibits lactation. Suckling is required to maintain milk production, since ↑ nerve stimulation → ↑ oxytocin and prolactin.  
 Prolactin—induces and maintains lactation and ↓ reproductive function.  
 Oxytocin—assists in milk letdown; also promotes uterine contractions.  
 Breast milk is the ideal nutrition for infants < 6 months old. Contains maternal immunoglobulins (conferring passive immunity; mostly IgA), macrophages, lymphocytes. Breast milk reduces infant infections and is associated with ↓ risk for child to develop asthma, allergies, diabetes mellitus, and obesity. Exclusively breastfed infants require vitamin D supplementation.  
 Breastfeeding ↓ maternal risk of breast and ovarian cancer and facilitates mother-child bonding.

**Menopause**

Diagnosed by amenorrhea for 12 months.  
 ↓ estrogen production due to age-linked decline in number of ovarian follicles. Average age at onset is 51 years (earlier in smokers).  
 Usually preceded by 4–5 years of abnormal menstrual cycles. Source of estrogen (estrone) after menopause becomes peripheral conversion of androgens, ↑ androgens → hirsutism.  
 ↑↑ FSH is specific for menopause (loss of negative feedback on FSH due to ↓ estrogen).

Hormonal changes: ↓ estrogen, ↑↑ FSH, ↑ LH (no surge), ↑ GnRH.  
 Causes **HAVOCS**: **H**ot flashes, **A**trophy of the **V**agina, **O**steoporosis, **C**oronary artery disease, **S**leep disturbances.  
 Menopause before age 40 suggests 1° ovarian insufficiency (premature ovarian failure).

**Androgens**

Testosterone, dihydrotestosterone (DHT), androstenedione.

**SOURCE**

DHT and testosterone (testis), **AnD**rostenedione (**AD**renal)

Potency: DHT > testosterone > androstenedione.

**FUNCTION**

Testosterone:

- Differentiation of epididymis, vas deferens, seminal vesicles (internal genitalia, except prostate).
- Growth spurt: penis, seminal vesicles, sperm, muscle, RBCs.
- Deepening of voice.
- Closing of epiphyseal plates (via estrogen converted from testosterone).
- Libido.

DHT:

- Early—differentiation of penis, scrotum, prostate.
- Late—prostate growth, balding, sebaceous gland activity.

Testosterone is converted to DHT by

5 $\alpha$ -reductase, which is inhibited by finasteride.  
 In the male, androgens are converted to estrogen by cytochrome P-450 aromatase (primarily in adipose tissue and testis).

Aromatase is the key enzyme in conversion of androgens to estrogen.


Exogenous testosterone → inhibition of hypothalamic–pituitary–gonadal axis → ↓ intratesticular testosterone → ↓ testicular size → azoospermia.

**Spermatogenesis**

Spermatogenesis begins at puberty with spermatogonia. Full development takes 2 months. Occurs in seminiferous tubules. Produces spermatids that undergo spermiogenesis (loss of cytoplasmic contents, gain of acrosomal cap) to form mature spermatozoon.


“Gonium” is going to be a sperm; “Zoon” is “Zooming” to egg.

N = ploidy  
C = # of chromatids



### Tanner stages of sexual development

Tanner stage is assigned independently to genitalia, pubic hair, and breast (eg, a person can have Tanner stage 2 genitalia, Tanner stage 3 pubic hair).



## ▶ REPRODUCTIVE—PATHOLOGY

**Sex chromosome disorders**

Aneuploidy most commonly due to meiotic nondisjunction.

**Klinefelter syndrome [male] (47,XXY)**

Testicular atrophy, eunuchoid body shape, tall, long extremities, gynecomastia, female hair distribution **A**. May present with developmental delay. Presence of inactivated X chromosome (Barr body). Common cause of hypogonadism seen in infertility work-up.

Dysgenesis of seminiferous tubules

→ ↓ inhibin B → ↑ FSH.

Abnormal Leydig cell function → ↓ testosterone → ↑ LH → ↑ estrogen.

**Turner syndrome [female] (45,XO)**

Short stature (if untreated; preventable with growth hormone therapy), ovarian dysgenesis (streak ovary), shield chest **B**, bicuspid aortic valve, coarctation (femoral < brachial pulse), lymphatic defects (result in webbed neck or cystic hygroma; lymphedema in feet, hands), horseshoe kidney **B**.

Most common cause of 1° amenorrhea. No Barr body.

Menopause before menarche.

↓ estrogen leads to ↑ LH, FSH.

Sometimes due to mitotic error → mosaicism (eg, 45,XO/46,XX).

Pregnancy is possible in some cases (IVF, exogenous estradiol-17β and progesterone).

**Double Y males (XYY)**

Phenotypically normal (usually undiagnosed), very tall. Normal fertility. May be associated with severe acne, learning disability, autism spectrum disorders.



**Ovotesticular disorder of sex development**

46,XX > 46,XY.

Both ovarian and testicular tissue present (ovotestis); ambiguous genitalia. Previously called true hermaphroditism.




Diagnosing disorders of sex hormones	Testosterone	LH	Diagnosis
	↑	↑	Defective androgen receptor
	↑	↓	Testosterone-secreting tumor, exogenous steroids
	↓	↑	Hypergonadotrophic hypogonadism (1°)
	↓	↓	Hypogonadotrophic hypogonadism (2°)
<b>Other disorders of sex development</b>	Disagreement between the phenotypic sex (external genitalia, influenced by hormonal levels) and the gonadal sex (testes vs ovaries, corresponds with Y chromosome). Includes the terms pseudohermaphrodite, hermaphrodite, and intersex.		
<b>46,XX DSD</b>	Ovaries present, but external genitalia are virilized or ambiguous. Due to excessive and inappropriate exposure to androgenic steroids during early gestation (eg, congenital adrenal hyperplasia or exogenous administration of androgens during pregnancy).		
<b>46,XY DSD</b>	Testes present, but external genitalia are female or ambiguous. Most common form is androgen insensitivity syndrome (testicular feminization).		
<b>Placental aromatase deficiency</b>	Inability to synthesize estrogens from androgens. Masculinization of female (46,XX DSD) infants (ambiguous genitalia), ↑ serum testosterone and androstenedione. Can present with maternal virilization during pregnancy (fetal androgens cross the placenta).		
<b>Androgen insensitivity syndrome</b>	Defect in androgen receptor resulting in normal-appearing female (46,XY DSD); female external genitalia with scant axillary and pubic (sexual) hair, rudimentary vagina; uterus and fallopian tubes absent. Patients develop normal functioning testes (often found in labia majora; surgically removed to prevent malignancy). ↑ testosterone, estrogen, LH (vs sex chromosome disorders).		
<b>5<math>\alpha</math>-reductase deficiency</b>	Autosomal recessive; sex limited to genetic males (46,XY DSD). Inability to convert testosterone to DHT. Ambiguous genitalia until puberty, when ↑ testosterone causes masculinization/↑ growth of external genitalia. Testosterone/estrogen levels are normal; LH is normal or ↑. Internal genitalia are normal.		
<b>Kallmann syndrome</b>	Failure to complete puberty; a form of hypogonadotropic hypogonadism. Defective migration of GnRH-releasing neurons and subsequent failure of GnRH-releasing olfactory bulbs to develop → ↓ synthesis of GnRH in the hypothalamus; anosmia; ↓ GnRH, FSH, LH, testosterone. Infertility (low sperm count in males; amenorrhea in females).		


**Hydatidiform mole**

Cystic swelling of chorionic villi and proliferation of chorionic epithelium (only trophoblast). Presents with vaginal bleeding, uterine enlargement more than expected, pelvic pressure/pain. Associated with hCG-mediated sequelae: early preeclampsia (before 20 weeks), theca-lutein cysts, hyperemesis gravidarum, hyperthyroidism. Treatment: dilation and curettage and methotrexate. Monitor  $\beta$ -hCG.

	Complete mole	Partial mole
KARYOTYPE	46,XX; 46,XY	69,XXX; 69,XXY; 69,XYY
COMPONENTS	Most commonly enucleated egg + single sperm (subsequently duplicates paternal DNA)	2 sperm + 1 egg
FETAL PARTS	No	Yes ( <b>partial = fetal parts</b> )
UTERINE SIZE	↑	—
hCG	↑↑↑↑	↑
IMAGING	“Honeycombed” uterus or “clusters of grapes” <b>A</b> , “snowstorm” on ultrasound <b>B</b>	Fetal parts
RISK OF MALIGNANCY (GESTATIONAL TROPHOBLASTIC NEOPLASIA)	15–20%	< 5%
RISK OF CHORIOCARCINOMA	2%	Rare

**Choriocarcinoma**

Rare; can develop during or after pregnancy in mother or baby. Malignancy of trophoblastic tissue **A** (cytotrophoblasts, syncytiotrophoblasts); **no** chorionic villi present. ↑ frequency of bilateral/multiple theca-lutein cysts. Presents with abnormal ↑  $\beta$ -hCG, shortness of breath, hemoptysis. Hematogenous spread to lungs → “cannonball” metastases **B**.




## Pregnancy complications


**Placental abruption**  
(abruptio placentae)

Premature separation (partial or complete) of placenta from uterine wall before delivery of infant. Risk factors: trauma (eg, motor vehicle accident), smoking, hypertension, preeclampsia, cocaine abuse.

Presentation: **abrupt**, painful bleeding (concealed or apparent) in third trimester; possible DIC, maternal shock, fetal distress. Life threatening for mother and fetus.



Complete abruption with concealed hemorrhage



Partial abruption (blue arrow) with apparent hemorrhage (red arrow)

**Placenta accreta/increta/percreta**



Defective decidual layer → abnormal attachment and separation after delivery. Risk factors: prior C-section, inflammation, placenta previa. Three types distinguishable by the depth of penetration:

**Placenta accreta**—placenta **attaches** to myometrium without penetrating it; most common type.


**Placenta increta**—placenta penetrates **into** myometrium.

**Placenta percreta**—placenta penetrates (“**perforates**”) through myometrium and into uterine serosa (invades entire uterine wall); can result in placental attachment to rectum or bladder.


Presentation: often detected on ultrasound prior to delivery. No separation of placenta after delivery → postpartum bleeding (can cause Sheehan syndrome).

**Placenta previa**

Attachment of placenta to lower uterine segment over (or < 2 cm from) internal cervical os. Risk factors: multiparity, prior C-section. Associated with painless third-trimester bleeding.




Partial placenta previa




Complete placenta previa

**Pregnancy complications (continued)****Vasa previa**

Fetal vessels run over, or in close proximity to, cervical os. May result in vessel rupture, exsanguination, fetal death. Presents with triad of membrane rupture, painless vaginal bleeding, fetal bradycardia (< 110 beats/min). Emergency C-section usually indicated. Frequently associated with velamentous umbilical cord insertion (cord inserts in chorioamniotic membrane rather than placenta → fetal vessels travel to placenta unprotected by Wharton jelly).

**Postpartum hemorrhage**

Due to 4 **T**'s: **T**one (uterine atony; most common), **T**rauma (lacerations, incisions, uterine rupture), **T**hrombin (coagulopathy), **T**issue (retained products of conception).

**Ectopic pregnancy**

Most often in ampulla of fallopian tube (A shows 10-mm embryo in oviduct at 7 weeks of gestation). Suspect with history of amenorrhea, lower-than-expected rise in hCG based on dates, and sudden lower abdominal pain; confirm with ultrasound. Often clinically mistaken for appendicitis.

Pain +/- bleeding.

Risk factors:

- Prior ectopic pregnancy
- History of infertility
- Salpingitis (PID)
- Ruptured appendix
- Prior tubal surgery

**Amniotic fluid abnormalities****Polyhydramnios**

Too much amniotic fluid; associated with fetal malformations (eg, esophageal/duodenal atresia, anencephaly; both result in inability to swallow amniotic fluid), maternal diabetes, fetal anemia, multiple gestations.

**Oligohydramnios**


Too little amniotic fluid; associated with placental insufficiency, bilateral renal agenesis, posterior urethral valves (in males) and resultant inability to excrete urine. Any profound oligohydramnios can cause Potter sequence.

**Hypertension in pregnancy**

<b>Gestational hypertension (pregnancy-induced hypertension)</b>	BP > 140/90 mm Hg after 20th week of gestation. No pre-existing hypertension. No proteinuria or end-organ damage.	Treatment: antihypertensives ( <b>H</b> ydralazine, <b>α</b> - <b>M</b> ethyl dopa, <b>L</b> abetalol, <b>N</b> ifedipine), deliver at 37–39 weeks. <b>H</b> ypertensive <b>M</b> oms <b>L</b> ove <b>N</b> ifedipine.
<b>Preeclampsia</b>	New-onset hypertension with either proteinuria or end-organ dysfunction after 20th week of gestation (< 20 weeks suggests molar pregnancy). Caused by abnormal placental spiral arteries → endothelial dysfunction, vasoconstriction, ischemia. Incidence ↑ in patients with pre-existing hypertension, diabetes, chronic renal disease, autoimmune disorders (eg, thrombophilias such as anticoagulant and anticardiolipin antibodies). Complications: placental abruption, coagulopathy, renal failure, uteroplacental insufficiency; may lead to eclampsia (+ seizures) and/or HELLP syndrome.	Treatment: antihypertensives, IV magnesium sulfate (to prevent seizure); definitive is delivery of fetus.
<b>Eclampsia</b>	Preeclampsia + maternal seizures. Maternal death due to stroke, intracranial hemorrhage, or ARDS.	Treatment: IV magnesium sulfate, antihypertensives, immediate delivery.
<b>HELLP syndrome</b>	<b>H</b> emolysis, <b>E</b> levated <b>L</b> iver enzymes, <b>L</b> ow <b>P</b> latelets. A manifestation of severe preeclampsia. Blood smear shows schistocytes. Can lead to hepatic subcapsular hematomas → rupture → severe hypotension.	Treatment: immediate delivery.
<b>Gynecologic tumor epidemiology</b>	Incidence (US)—endometrial > ovarian > cervical; cervical cancer is more common worldwide due to lack of screening or HPV vaccination. Worst prognosis—ovarian > endometrial > cervical.	

**Vaginal tumors**

<b>Squamous cell carcinoma</b>	Usually 2° to cervical SCC; 1° vaginal carcinoma rare.
<b>Clear cell adenocarcinoma</b>	Affects women who had exposure to DES in utero.
<b>Sarcoma botryoides</b>	Embryonal rhabdomyosarcoma variant. Affects girls < 4 years old; spindle-shaped cells; desmin ⊕. Presents with clear, grape-like, polypoid mass emerging from vagina.

**Cervical pathology****Dysplasia and carcinoma in situ**

Disordered epithelial growth; begins at basal layer of squamocolumnar junction (transformation zone) and extends outward. Classified as CIN 1, CIN 2, or CIN 3 (severe, irreversible dysplasia or carcinoma in situ), depending on extent of dysplasia. Associated with HPV-16 and HPV-18, which produce both the E6 gene product (inhibits *p53* suppressor gene) and E7 gene product (inhibits *RB* suppressor gene); koilocytes **A** are pathognomonic of HPV infection. May progress slowly to invasive carcinoma if left untreated. Typically asymptomatic (detected with Pap smear) or presents as abnormal vaginal bleeding (often postcoital).  
Risk factors: multiple sexual partners (#1), smoking, starting sexual intercourse at young age, HIV infection.

**Invasive carcinoma**


Often squamous cell carcinoma. Pap smear can detect cervical dysplasia before it progresses to invasive carcinoma. Diagnose via colposcopy and biopsy. Lateral invasion can block ureters → renal failure.

**Premature ovarian failure**

Premature atresia of ovarian follicles in women of reproductive age. Patients present with signs of menopause after puberty but before age 40. ↓ estrogen, ↑ LH, ↑ FSH.

**Most common causes of anovulation**

Pregnancy, polycystic ovarian syndrome, obesity, HPO axis abnormalities, premature ovarian failure, hyperprolactinemia, thyroid disorders, eating disorders, competitive athletics, Cushing syndrome, adrenal insufficiency.

**Polycystic ovarian syndrome (Stein-Leventhal syndrome)**

Hyperinsulinemia and/or insulin resistance hypothesized to alter hypothalamic hormonal feedback response → ↑ LH:FSH, ↑ androgens (eg, testosterone) from theca interna cells, ↓ rate of follicular maturation → unruptured follicles (cysts) + anovulation. Common cause of subfertility in women. Enlarged, bilateral cystic ovaries **A**; presents with amenorrhea/oligomenorrhea, hirsutism, acne, ↓ fertility. Associated with obesity. ↑ risk of endometrial cancer 2° to unopposed estrogen from repeated anovulatory cycles.  
Treatment: cycle control via weight reduction (↓ peripheral estrone formation), OCPs (prevent endometrial hyperplasia due to unopposed estrogen); clomiphene, metformin to induce ovulation; spironolactone, ketoconazole (antiandrogens) to treat hirsutism.

**Ovarian cysts**

<b>Follicular cyst</b>	Distention of unruptured graafian follicle. May be associated with hyperestrogenism, endometrial hyperplasia. Most common ovarian mass in young women.
<b>Theca-lutein cyst</b>	Often bilateral/multiple. Due to gonadotropin stimulation. Associated with choriocarcinoma and hydatidiform moles.

**Ovarian neoplasms**

Most common adnexal mass in women > 55 years old. Can be benign or malignant. Arise from surface epithelium, germ cells, or sex cord stromal tissue. Majority of malignant tumors are epithelial (serous cystadenocarcinoma most common). Risk ↑ with advanced age, infertility, endometriosis, PCOS, genetic predisposition (*BRCA-1* or *BRCA-2* mutation, Lynch syndrome, strong family history). Risk ↓ with previous pregnancy, history of breastfeeding, OCPs, tubal ligation. Presents with adnexal mass, abdominal distension, bowel obstruction, pleural effusion. Monitor response to therapy/relapse by measuring CA 125 levels (not good for screening).


**Benign ovarian neoplasms**

<b>Serous cystadenoma</b>	Most common ovarian neoplasm. Lined with fallopian tube–like epithelium. Often bilateral.
<b>Mucinous cystadenoma</b>	Multiloculated, large. Lined by mucus-secreting epithelium <b>A</b> .
<b>Endometrioma</b>	Endometriosis (ectopic endometrium-like tissue) within ovary with cyst formation. Presents with pelvic pain, dysmenorrhea, dyspareunia; symptoms may vary with menstrual cycle. “Chocolate cyst”—endometrioma filled with dark, reddish-brown blood. Complex mass on ultrasound.
<b>Mature cystic teratoma (dermoid cyst)</b>	Germ cell tumor, most common ovarian tumor in females 10–30 years old. Cystic mass containing elements from all 3 germ layers (eg, teeth, hair, sebum) <b>B</b> . Can present with pain 2° to ovarian enlargement or torsion. A monodermal form with thyroid tissue ( <i>struma ovarii</i> ) uncommonly presents with hyperthyroidism <b>C</b> .
<b>Brenner tumor</b>	Looks like bladder. Solid tumor that is pale yellow-tan and appears encapsulated. “Coffee bean” nuclei on H&E stain.
<b>Fibromas</b>	Bundles of spindle-shaped fibroblasts. <b>Meigs syndrome</b> —triad of ovarian fibroma, ascites, hydrothorax. “Pulling” sensation in groin.
<b>Thecoma</b>	Like granulosa cell tumors, may produce estrogen. Usually presents as abnormal uterine bleeding in a postmenopausal woman.



**Ovarian neoplasms (continued)**

Malignant ovarian neoplasms	
<b>Granulosa cell tumor</b>	Most common malignant stromal tumor. Predominantly women in their 50s. Often produces estrogen and/or progesterone and presents with postmenopausal bleeding, sexual precocity (in pre-adolescents), breast tenderness. Histology shows Call-Exner bodies <b>D</b> (granulosa cells arranged haphazardly around collections of eosinophilic fluid, resembling primordial follicles).
<b>Serous cystadenocarcinoma</b>	Most common malignant ovarian neoplasm, frequently bilateral. Psammoma bodies.
<b>Mucinous cystadenocarcinoma</b>	Pseudomyxoma peritonei—intraperitoneal accumulation of mucinous material from ovarian or appendiceal tumor.
<b>Immature teratoma</b>	Aggressive, contains fetal tissue, neuroectoderm. Commonly diagnosed before age 20. Typically represented by immature/embryonic-like neural tissue.
<b>Dysgerminoma</b>	Most common in adolescents. Equivalent to male seminoma but rarer. 1% of all ovarian tumors; 30% of germ cell tumors. Sheets of uniform “fried egg” cells <b>E</b> . hCG, LDH = tumor markers.
<b>Yolk sac (endodermal sinus) tumor</b>	Aggressive, in ovaries or testes and sacrococcygeal area in young children. Most common tumor in male infants. Yellow, friable (hemorrhagic), solid mass. 50% have Schiller-Duval bodies (resemble glomeruli) <b>F</b> . AFP = tumor marker.
<b>Krukenberg tumor</b>	GI malignancy that metastasizes to ovaries → mucin-secreting signet cell adenocarcinoma.





**Endometrial conditions** **PALM-COEIN:** Polyp, Adenomyosis, Leiomyoma, Malignancy and hyperplasia, Coagulopathy, Ovulatory dysfunction, Endometrial, Iatrogenic, and Not otherwise classified.


<b>Polyp</b>	Well-circumscribed collection of endometrial tissue within uterine wall. May contain smooth muscle cells. Can extend into endometrial cavity in the form of a polyp. May be asymptomatic or present with painless abnormal uterine bleeding.
<b>Adenomyosis</b>	Extension of endometrial tissue (glandular) into uterine myometrium. Caused by hyperplasia of basal layer of endometrium. Presents with dysmenorrhea, menorrhagia, uniformly enlarged, soft, globular uterus. Treatment: GnRH agonists, hysterectomy or excision of an organized adenomyoma.
<b>Asherman syndrome</b>	Adhesions and/or fibrosis of the endometrium. Often associated with dilation and curettage of intrauterine cavity.
<b>Leiomyoma (fibroid)</b>	Most common tumor in females. Often presents with multiple discrete tumors <b>A</b> . ↑ incidence in African Americans. Benign smooth muscle tumor; malignant transformation to leiomyosarcoma is rare. Estrogen sensitive—tumor size ↑ with pregnancy and ↓ with menopause. Peak occurrence at 20–40 years old. May be asymptomatic, cause abnormal uterine bleeding, or result in miscarriage. Severe bleeding may lead to iron deficiency anemia. Whorled pattern of smooth muscle bundles with well-demarcated borders <b>B</b> .
<b>Endometrial hyperplasia</b>	Abnormal endometrial gland proliferation <b>C</b> usually caused by excess estrogen stimulation. ↑ risk for endometrial carcinoma; nuclear atypia is greater risk factor than complex (vs simple) architecture. Presents as postmenopausal vaginal bleeding. Risk factors include anovulatory cycles, hormone replacement therapy, polycystic ovarian syndrome, granulosa cell tumor.
<b>Endometrial carcinoma</b>	Most common gynecologic malignancy <b>D</b> . Peak occurrence at 55–65 years old. Presents with vaginal bleeding. Typically preceded by endometrial hyperplasia. Risk factors include prolonged use of estrogen without progestins, obesity, diabetes, hypertension, nulliparity, late menopause, early menarche, Lynch syndrome.
<b>Endometritis</b>	Inflammation of endometrium <b>E</b> associated with retained products of conception following delivery, miscarriage, abortion, or with foreign body (eg, IUD). Retained material in uterus promotes infection by bacterial flora from vagina or intestinal tract. Treatment: gentamicin + clindamycin +/- ampicillin.

**Endometrial conditions (continued)****Endometriosis**


Non-neoplastic endometrium-like glands/stroma outside endometrial cavity. Can be found anywhere; most common sites are ovary (frequently bilateral), pelvis, peritoneum. In ovary, appears as endometrioma (blood-filled “chocolate cysts” [oval structures above and below asterisks in **F**]). May be due to retrograde flow, metaplastic transformation of multipotent cells, transportation of endometrial tissue via lymphatic system.

Characterized by cyclic pelvic pain, bleeding, dysmenorrhea, dyspareunia, dyschezia (pain with defecation), infertility; normal-sized uterus.

Treatment: NSAIDs, OCPs, progestins, GnRH agonists, danazol, laparoscopic removal.




## Breast pathology



**Benign breast disease**

<b>Fibrocystic changes</b>	<p>Most common in premenopausal women &gt; 35 years old. Present with premenstrual breast pain or lumps; often bilateral and multifocal. Nonproliferative lesions include simple cysts (fluid-filled duct dilation, blue dome), papillary apocrine change/metaplasia, stromal fibrosis. Risk of cancer is usually not increased.</p> <p>Subtypes include:</p> <ul style="list-style-type: none"> <li>▪ <b>Sclerosing adenosis</b>—acini and stromal fibrosis, associated with calcifications. Slight (1.5–2 ×) ↑ risk for cancer.</li> <li>▪ <b>Epithelial hyperplasia</b>—cells in terminal ductal or lobular epithelium. ↑ risk of carcinoma with atypical cells.</li> </ul>
<b>Inflammatory processes</b>	<p><b>Fat necrosis</b>—benign, usually painless, lump due to injury to breast tissue. Calcified oil cyst on mammography; necrotic fat and giant cells on biopsy. Up to 50% of patients may not report trauma.</p> <p><b>Lactational mastitis</b>—occurs during breastfeeding, ↑ risk of bacterial infection through cracks in nipple. <i>S aureus</i> is most common pathogen. Treat with antibiotics and continue breastfeeding.</p>
<b>Benign tumors</b>	<p><b>Fibroadenoma</b>—most common in women &lt; 35 years old. Small, well-defined, mobile mass <b>A</b>. ↑ size and tenderness with ↑ estrogen (eg, pregnancy, prior to menstruation). Risk of cancer is usually not increased.</p> <p><b>Intraductal papilloma</b>—small papillary tumor within lactiferous ducts, typically beneath areola. Most common cause of nipple discharge (serous or bloody). Slight (1.5–2 ×) ↑ risk for cancer.</p> <p><b>Phyllodes tumor</b>—large mass <b>B</b> of connective tissue and cysts with “leaf-like” lobulations <b>C</b>. Most common in 5th decade. Some may become malignant.</p>
<b>Gynecomastia</b>	<p>Breast enlargement in males due to ↑ estrogen compared with androgen activity. Physiologic (not pathologic) in newborn, pubertal, and elderly males, but may persist after puberty. Other causes include cirrhosis, hypogonadism (eg, Klinefelter syndrome), testicular tumors, and drugs (Spironolactone, <b>H</b>ormones, <b>C</b>imetidine, <b>K</b>etoconazole: “<b>S</b>ome <b>H</b>ormones <b>C</b>reate <b>K</b>nockers”).</p>




**Malignant breast tumors**

Commonly postmenopausal. Usually arise from terminal duct lobular unit. Amplification/overexpression of estrogen/progesterone receptors or *c-erbB2* (HER-2, an EGF receptor) is common; triple negative (ER  $\ominus$ , PR  $\ominus$ , and Her2/Neu  $\ominus$ ) more aggressive; type affects therapy and prognosis. Axillary lymph node involvement indicating metastasis is the most important prognostic factor in early-stage disease. Most often located in upper-outer quadrant of breast.

Risk factors:  $\uparrow$  estrogen exposure,  $\uparrow$  total number of menstrual cycles, older age at 1st live birth, obesity ( $\uparrow$  estrogen exposure as adipose tissue converts androstenedione to estrone), *BRCA1* or *BRCA2* gene mutations, African American ethnicity ( $\uparrow$  risk for triple  $\ominus$  breast cancer).

TYPE	CHARACTERISTICS	NOTES
<b>Noninvasive</b>		
<b>Ductal carcinoma in situ</b>	Fills ductal lumen (black arrow in <b>A</b> indicates neoplastic cells in duct; blue arrow shows engorged blood vessel). Arises from ductal atypia. Often seen early as microcalcifications on mammography.	Early malignancy without basement membrane penetration.
<b>Comedocarcinoma</b>	Ductal, central necrosis (arrow in <b>B</b> ). Subtype of DCIS.	
<b>Paget disease</b>	Results from underlying DCIS or invasive breast cancer. Eczematous patches on nipple <b>C</b> . Paget cells = intraepithelial adenocarcinoma cells.	
<b>Invasive</b>		
<b>Invasive ductal carcinoma</b>	Firm, fibrous, “rock-hard” mass with sharp margins and small, glandular, duct-like cells <b>D</b> . Tumor can deform suspensory ligaments $\rightarrow$ dimpling of skin. Classic morphology: “stellate” infiltration.	Most common (~ 75% of all breast cancers).
<b>Invasive lobular carcinoma</b>	Orderly row of cells (“single file” <b>E</b> ), due to $\downarrow$ E-cadherin expression.	Often bilateral with multiple lesions in the same location. <b>L</b> ines of cells = <b>L</b> obular.
<b>Medullary carcinoma</b>	Fleshy, cellular, lymphocytic infiltrate.	Good prognosis.
<b>Inflammatory breast cancer</b>	Dermal lymphatic invasion by breast carcinoma. Peau d’orange (breast skin resembles orange peel <b>F</b> ); neoplastic cells block lymphatic drainage.	Poor prognosis (50% survival at 5 years). Often mistaken for mastitis or Paget disease.

**Malignant breast tumors (continued)****Penile pathology****Peyronie disease**

Abnormal curvature of penis due to fibrous plaque within tunica albuginea. Associated with erectile dysfunction. Can cause pain, anxiety. Consider surgical repair once curvature stabilizes. Distinct from penile fracture (rupture of corpora cavernosa due to forced bending).

**Ischemic priapism**

Painful sustained erection lasting > 4 hours. Associated with sickle cell disease (sickled RBCs block venous drainage of corpus cavernosum vascular channels), medications (eg, sildenafil, trazodone). Treat immediately with corporal aspiration, intracavernosal phenylephrine, or surgical decompression to prevent ischemia.

**Squamous cell carcinoma**

More common in Asia, Africa, South America. Precursor in situ lesions: Bowen disease (in penile shaft, presents as leukoplakia), erythroplasia of Queyrat (cancer of glans, presents as erythroplakia), Bowenoid papulosis (carcinoma in situ of unclear malignant potential, presenting as reddish papules). Associated with uncircumcised males and HPV.


**Cryptorchidism**

Undescended testis (one or both); impaired spermatogenesis (since sperm develop best at temperatures < 37°C); can have normal testosterone levels (Leydig cells are mostly unaffected by temperature); associated with ↑ risk of germ cell tumors. Prematurity ↑ risk of cryptorchidism. ↓ inhibin B, ↑ FSH, ↑ LH; testosterone ↓ in bilateral cryptorchidism, normal in unilateral.

**Testicular torsion**

Rotation of testicle around spermatic cord and vascular pedicle. Commonly presents in males 12–18 years old. Characterized by acute, severe pain, high-riding testis, and absent cremasteric reflex.

Treatment: surgical correction (orchiopexy) within 6 hours, manual detorsion if surgical option unavailable in timeframe. If testis is not viable, orchiectomy. Orchiopexy, when performed, should be bilateral because the contralateral testis is at risk for subsequent torsion.

**Varicocele**

Dilated veins in pampiniform plexus due to ↑ venous pressure; most common cause of scrotal enlargement in adult males; most often on left side because of ↑ resistance to flow from left gonadal vein drainage into left renal vein; can cause infertility because of ↑ temperature; diagnosed by standing clinical exam/Valsalva maneuver (distension on inspection and “bag of worms” on palpation; augmented by Valsalva) or ultrasound with Doppler **A**; does not transilluminate.

Treatment: consider surgical ligation or embolization if associated with pain or infertility.

**Extragonadal germ cell tumors**

Arise in midline locations. In adults, most commonly in retroperitoneum, mediastinum, pineal, and suprasellar regions. In infants and young children, sacrococcygeal teratomas are most common.

**Scrotal masses**

Benign scrotal lesions present as testicular masses that can be transilluminated (vs solid testicular tumors).

**Congenital hydrocele**

Common cause of scrotal swelling **A** in infants, due to incomplete obliteration of processus vaginalis. Most spontaneously resolve by 1 year old. Transilluminating swelling.

**Acquired hydrocele**

Scrotal fluid collection usually 2° to infection, trauma, tumor. If bloody → hemocele.

**Spermatocele**

Cyst due to dilated epididymal duct or rete testis.

Paratesticular fluctuant nodule.

**Testicular germ cell tumors**

~ 95% of all testicular tumors. Most often occur in young men. Risk factors: cryptorchidism, Klinefelter syndrome. Can present as a mixed germ cell tumor. Testicular mass that does not transilluminate.

**Seminoma**

Malignant; painless, homogenous testicular enlargement; most common testicular tumor. Does not occur in infancy. Large cells in lobules with watery cytoplasm and “fried egg” appearance. ↑ placental ALP. Highly radiosensitive. Late metastasis, excellent prognosis. Similar to dysgerminoma in females.

**Yolk sac (endodermal sinus) tumor**

Yellow, mucinous. Aggressive malignancy of testes, analogous to ovarian yolk sac tumor. Schiller-Duval bodies resemble primitive glomeruli. ↑ AFP is highly characteristic. Most common testicular tumor in boys < 3 years old.

**Choriocarcinoma**

Malignant, ↑ hCG. Disordered syncytiotrophoblastic and cytotrophoblastic elements. Hematogenous metastases to lungs and brain. May produce gynecomastia, symptoms of hyperthyroidism (hCG is structurally similar to LH, FSH, TSH).

**Teratoma**

Unlike in females, mature teratoma in adult males may be malignant. Benign in children.

**Embryonal carcinoma**


Malignant, hemorrhagic mass with necrosis; painful; worse prognosis than seminoma. Often glandular/papillary morphology. “Pure” embryonal carcinoma is rare; most commonly mixed with other tumor types. May be associated with ↑ hCG and normal AFP levels when pure (↑ AFP when mixed).

<b>Testicular non-germ cell tumors</b>	5% of all testicular tumors. Mostly benign.
<b>Leydig cell</b>	Golden brown color; contains Reinke crystals (eosinophilic cytoplasmic inclusions). Produces androgens or estrogens → gynecomastia in men, precocious puberty in boys.
<b>Sertoli cell</b>	Androblastoma from sex cord stroma.
<b>Testicular lymphoma</b>	Most common testicular cancer in older men. Not a 1° cancer; arises from metastatic lymphoma to testes. Aggressive.

### Benign prostatic hyperplasia

Common in men > 50 years old. Characterized by smooth, elastic, firm nodular enlargement (hyperplasia not hypertrophy) of periurethral (lateral and middle) lobes, which compress the urethra into a vertical slit. Not premalignant. Often presents with ↑ frequency of urination, nocturia, difficulty starting and stopping urine stream, dysuria. May lead to distention and hypertrophy of bladder, hydronephrosis, UTIs. ↑ free prostate-specific antigen (PSA).

Treatment:  $\alpha_1$ -antagonists (terazosin, tamsulosin), which cause relaxation of smooth muscle;  $5\alpha$ -reductase inhibitors (eg, finasteride); PDE-5 inhibitors (eg, tadalafil); surgical resection (eg, TURP, ablation).



### Prostatitis

Characterized by dysuria, frequency, urgency, low back pain. Warm, tender, enlarged prostate. Acute bacterial—in older men most common bacterium is *E coli*; in young males consider *C trachomatis*, *N gonorrhoeae*.

Chronic prostatitis—either bacterial or nonbacterial (eg, 2° to previous infection, nerve problems, chemical irritation).


### Prostatic adenocarcinoma

Common in men > 50 years old. Arises most often from posterior lobe (peripheral zone) of prostate gland and is most frequently diagnosed by ↑ PSA and subsequent needle core biopsies. Prostatic acid phosphatase (PAP) and PSA are useful tumor markers (↑ total PSA, with ↓ fraction of free PSA). Osteoblastic metastases in bone may develop in late stages, as indicated by lower back pain and ↑ serum ALP and PSA.



## ▶ REPRODUCTIVE—PHARMACOLOGY

## Control of reproductive hormones



**Leuprolide**

MECHANISM	GnRH analog with agonist properties when used in pulsatile fashion; antagonist properties when used in continuous fashion (downregulates GnRH receptor in pituitary → ↓ FSH/LH).	<b>Leuprolide</b> can be used in <b>lieu</b> of GnRH.
CLINICAL USE	Uterine fibroids, endometriosis, precocious puberty, prostate cancer, infertility.	

**Estrogens**

	Ethinyl estradiol, DES, mestranol.	
MECHANISM	Bind estrogen receptors.	
CLINICAL USE	Hypogonadism or ovarian failure, menstrual abnormalities, hormone replacement therapy in postmenopausal women; use in men with androgen-dependent prostate cancer.	
ADVERSE EFFECTS	↑ risk of endometrial cancer (when given without progesterone), bleeding in postmenopausal women, clear cell adenocarcinoma of vagina in females exposed to DES in utero, ↑ risk of thrombi. Contraindications—ER ⊕ breast cancer, history of DVTs.	

**Selective estrogen receptor modulators**

<b>Clomiphene</b>	Antagonist at estrogen receptors in hypothalamus. Prevents normal feedback inhibition and ↑ release of LH and FSH from pituitary, which stimulates ovulation. Used to treat infertility due to anovulation (eg, PCOS). May cause hot flashes, ovarian enlargement, multiple simultaneous pregnancies, visual disturbances.	
<b>Tamoxifen</b>	Antagonist at breast; agonist at bone, uterus; ↑ risk of thromboembolic events and endometrial cancer. Used to treat and prevent recurrence of ER/PR ⊕ breast cancer.	
<b>Raloxifene</b>	Antagonist at breast, uterus; agonist at bone; ↑ risk of thromboembolic events but no increased risk of endometrial cancer (vs tamoxifen); used primarily to treat osteoporosis.	

**Aromatase inhibitors**

	Anastrozole, letrozole, exemestane.	
MECHANISM	Inhibit peripheral conversion of androgens to estrogen.	
CLINICAL USE	ER ⊕ breast cancer in postmenopausal women.	

**Hormone replacement therapy**

Used for relief or prevention of menopausal symptoms (eg, hot flashes, vaginal atrophy), osteoporosis (↑ estrogen, ↓ osteoclast activity). Unopposed estrogen replacement therapy ↑ risk of endometrial cancer, progesterone/progestin is added. Possible increased cardiovascular risk.

**Progestins**

Levonorgestrel, medroxyprogesterone, etonogestrel, norethindrone, megestrol, and many others when combined with estrogen.

**MECHANISM**

Bind progesterone receptors, ↓ growth and ↑ vascularization of endometrium, thicken cervical mucus.

**CLINICAL USE**

Contraception (forms include pill, intrauterine device, implant, depot injection), endometrial cancer, abnormal uterine bleeding. Progestin challenge: presence of withdrawal bleeding excludes anatomic defects (eg, Asherman syndrome) and chronic anovulation without estrogen.

**Antiprogestins**

Mifepristone, ulipristal.

**MECHANISM**

Competitive inhibitors of progestins at progesterone receptors.

**CLINICAL USE**

Termination of pregnancy (mifepristone with misoprostol); emergency contraception (ulipristal).

**Combined contraception**

Progestins and ethinyl estradiol; forms include pill, patch, vaginal ring.

Estrogen and progestins inhibit LH/FSH and thus prevent estrogen surge. No estrogen surge → no LH surge → no ovulation.

Progestins cause thickening of cervical mucus, thereby limiting access of sperm to uterus.

Progestins also inhibit endometrial proliferation → endometrium is less suitable to the implantation of an embryo.

Contraindications: smokers > 35 years old (↑ risk of cardiovascular events), patients with ↑ risk of cardiovascular disease (including history of venous thromboembolism, coronary artery disease, stroke), migraine (especially with aura), breast cancer.

**Copper intrauterine device****MECHANISM**

Produces local inflammatory reaction toxic to sperm and ova, preventing fertilization and implantation; hormone free.

**CLINICAL USE**

Long-acting reversible contraception. Most effective emergency contraception.

**ADVERSE EFFECTS**

Heavier or longer menses, dysmenorrhea. Risk of PID with insertion (contraindicated in active pelvic infection).

**Terbutaline, ritodrine**

β<sub>2</sub>-agonists that relax the uterus; used to ↓ contraction frequency in women during labor.

**Danazol****MECHANISM**

Synthetic androgen that acts as partial agonist at androgen receptors.

**CLINICAL USE**

Endometriosis, hereditary angioedema.

**ADVERSE EFFECTS**

Weight gain, edema, acne, hirsutism, masculinization, ↓ HDL levels, hepatotoxicity, pseudotumor cerebri.

**Testosterone, methyltestosterone**

MECHANISM	Agonists at androgen receptors.
CLINICAL USE	Treat hypogonadism and promote development of 2° sex characteristics; stimulate anabolism to promote recovery after burn or injury.
ADVERSE EFFECTS	Masculinization in females; ↓ intratesticular testosterone in males by inhibiting release of LH (via negative feedback) → gonadal atrophy. Premature closure of epiphyseal plates. ↑ LDL, ↓ HDL.

**Antiandrogens**

<b>Finasteride</b>	5 $\alpha$ -reductase inhibitor (↓ conversion of testosterone to DHT). Used for BPH and male-pattern baldness.	Testosterone $\xrightarrow{5\alpha\text{-reductase}}$ DHT (more potent).
<b>Flutamide</b>	Nonsteroidal competitive inhibitor at androgen receptors. Used for prostate carcinoma.	
<b>Ketoconazole</b>	Inhibits steroid synthesis (inhibits 17,20 desmolase/17 $\alpha$ -hydroxylase).	Used in PCOS to reduce androgenic symptoms.
<b>Spirolactone</b>	Inhibits steroid binding, 17,20 desmolase/17 $\alpha$ -hydroxylase.	Both can cause gynecomastia and amenorrhea.

**Tamsulosin**

$\alpha_1$ -antagonist used to treat BPH by inhibiting smooth muscle contraction. Selective for  $\alpha_{1A/D}$  receptors (found on prostate) vs vascular  $\alpha_{1B}$  receptors.

**Phosphodiesterase type 5 inhibitors**

Sildenafil, vardenafil, tadalafil.

MECHANISM	Inhibit PDE-5 → ↑ cGMP → prolonged smooth muscle relaxation in response to NO → ↑ blood flow in corpus cavernosum of penis, ↓ pulmonary vascular resistance.	Sildenafil, vardenafil, and tadalafil fill the penis.
CLINICAL USE	Erectile dysfunction, pulmonary hypertension, BPH (tadalafil only).	
ADVERSE EFFECTS	Headache, flushing, dyspepsia, cyanopia (blue-tinted vision). Risk of life-threatening hypotension in patients taking nitrates.	“Hot and sweaty,” but then Headache, Heartburn, Hypotension.

**Minoxidil**

MECHANISM	Direct arteriolar vasodilator.
CLINICAL USE	Androgenetic alopecia (pattern baldness), severe refractory hypertension.

► NOTES

Lined area for taking notes, consisting of two columns of horizontal lines.

# Respiratory

*“There’s so much pollution in the air now that if it weren’t for our lungs, there’d be no place to put it all.”*

—Robert Orben

*“Freedom is the oxygen of the soul.”*

—Moshe Dayan

*“Whenever I feel blue, I start breathing again.”*

—L. Frank Baum

*“Life is not the amount of breaths you take; it’s the moments that take your breath away.”*


—Will Smith, *Hitch*

▶ Embryology	626
▶ Anatomy	628
▶ Physiology	630
▶ Pathology	636
▶ Pharmacology	648

## ► RESPIRATORY—EMBRYOLOGY

**Lung development** Occurs in five stages. Initial development includes development of lung bud from distal end of respiratory diverticulum during week 4.

STAGE	IMPORTANT TERMS	NOTES
<b>Embryonic</b> (weeks 4–7)	Lung bud → trachea → bronchial buds → mainstem bronchi → secondary (lobar) bronchi → tertiary (segmental) bronchi.	Errors at this stage can lead to tracheoesophageal fistula.
<b>Pseudoglandular</b> (weeks 5–17)	Endodermal tubules → terminal bronchioles. Surrounded by modest capillary network.	Respiration impossible, incompatible with life.
<b>Canalicular</b> (weeks 16–25)	Terminal bronchioles → respiratory bronchioles → alveolar ducts. Surrounded by prominent capillary network.	Airways increase in diameter. Respiration capable at 25 weeks.
<b>Saccular</b> (week 26–birth)	Alveolar ducts → terminal sacs. Terminal sacs separated by 1° septae. Pneumocytes develop.	
<b>Alveolar</b> (week 36–8 years)	Terminal sacs → adult alveoli (due to 2° septation). In utero, “breathing” occurs via aspiration and expulsion of amniotic fluid → ↑ vascular resistance through gestation. At birth, fluid gets replaced with air → ↓ in pulmonary vascular resistance.	At birth: 20–70 million alveoli. By 8 years: 300–400 million alveoli.

**Congenital lung malformations**

**Pulmonary hypoplasia** Poorly developed bronchial tree with abnormal histology. Associated with congenital diaphragmatic hernia (usually left-sided), bilateral renal agenesis (Potter sequence).

**Bronchogenic cysts** Caused by abnormal budding of the foregut and dilation of terminal or large bronchi. Discrete, round, sharply defined, fluid-filled densities on CXR (air-filled if infected). Generally asymptomatic but can drain poorly, causing airway compression and/or recurrent respiratory infections.

**Club cells**



Nonciliated; low-columnar/cuboidal with secretory granules. Located in small airways. Secrete component of surfactant; degrade toxins; act as reserve cells.

**Alveolar cell types****Type I pneumocytes**

97% of alveolar surfaces. Line the alveoli. Squamous; thin for optimal gas diffusion.

**Type II pneumocytes**

Secrete surfactant from lamellar bodies (arrow in **A**) → ↓ alveolar surface tension, prevents alveolar collapse, ↓ lung recoil, and ↑ compliance. Cuboidal and clustered **B**. Also serve as precursors to type I cells and other type II cells. Proliferate during lung damage.




$$\text{Collapsing pressure } (P) = \frac{2 \text{ (surface tension)}}{\text{radius}}$$

Alveoli have ↑ tendency to collapse on expiration as radius ↓ (law of Laplace).

Pulmonary surfactant is a complex mix of lecithins, the most important of which is dipalmitoylphosphatidylcholine (DPPC). Surfactant synthesis begins around week 26 of gestation, but mature levels are not achieved until around week 35.

**Alveolar macrophages**

Phagocytose foreign materials, release cytokines and alveolar proteases.

**Neonatal respiratory distress syndrome**


Surfactant deficiency → ↑ surface tension → alveolar collapse (“ground-glass” appearance of lung fields) **A**.

Risk factors: prematurity, maternal diabetes (due to ↑ fetal insulin), C-section delivery (↓ release of fetal glucocorticoids; less stressful than vaginal delivery).

Complications: PDA, necrotizing enterocolitis. Treatment: maternal steroids before birth; exogenous surfactant for infant.

Therapeutic supplemental O<sub>2</sub> can result in **R**etinopathy of prematurity, **I**ntraventricular hemorrhage, **B**ronchopulmonary dysplasia (**RIB**).

Screening tests for fetal lung maturity: lecithin-sphingomyelin (L/S) ratio in amniotic fluid (≥ 2 is healthy; < 1.5 predictive of NRDS), foam stability index test, surfactant-albumin ratio. Persistently low O<sub>2</sub> tension → risk of PDA.





## ► RESPIRATORY—ANATOMY

**Respiratory tree****Conducting zone**

Large airways consist of nose, pharynx, larynx, trachea, and bronchi. Small airways consist of bronchioles that further divide into terminal bronchioles (large numbers in parallel → least airway resistance).

Warms, humidifies, and filters air but does not participate in gas exchange → “anatomic dead space.”

Cartilage and goblet cells extend to end of bronchi.


Pseudostratified ciliated columnar cells primarily make up epithelium of bronchus and extend to beginning of terminal bronchioles, then transition to cuboidal cells. Clear mucus and debris from lungs (mucociliary escalator).

Airway smooth muscle cells extend to end of terminal bronchioles (sparse beyond this point).


**Respiratory zone**

Lung parenchyma; consists of respiratory bronchioles, alveolar ducts, and alveoli. Participates in gas exchange.

Mostly cuboidal cells in respiratory bronchioles, then simple squamous cells up to alveoli. Cilia terminate in respiratory bronchioles. Alveolar macrophages clear debris and participate in immune response.



**Lung relations**





Right lung has 3 lobes; **L**eft has **L**ess **L**obes (2) and **L**ingula (homolog of right middle lobe). Instead of a middle lobe, left lung has a space occupied by the heart.


Relation of the pulmonary artery to the bronchus at each lung hilum is described by **RALS**—**R**ight **A**nterior; **L**eft **S**uperior. Carina is posterior to ascending aorta and anteromedial to descending aorta **A**.

Right lung is a more common site for inhaled foreign bodies because right main stem bronchus is wider, more vertical, and shorter than the left. If you aspirate a peanut:

- While upright—enters basal segments of right lower lobe. Preferentially on right, but bilateral basal segments can be involved.
- While supine—enters posterior segment of right upper lobe. Preferentially on right side.



**Diaphragm structures**



Structures perforating diaphragm:

- At T8: IVC, right phrenic nerve
- At T10: esophagus, vagus (CN 10; 2 trunks)
- At T12: aorta (red), thoracic duct (white), azygos vein (blue) (“At **T-1-2** it’s the **red, white, and blue**”)

Diaphragm is innervated by C3, 4, and 5 (phrenic nerve). Pain from diaphragm irritation (eg, air, blood, or pus in peritoneal cavity) can be referred to shoulder (C5) and trapezius ridge (C3, 4).

Number of letters = T level:

- T8**: vena cava
- T10**: “oesophagus”
- T12**: aortic hiatus

**I** (IVC) **ate** (8) **ten** (10) **eggs** (esophagus) **at** (aorta) **twelve** (12).

**C3, 4, 5** keeps the diaphragm **alive**.

Other bifurcations:


- The common carotid **bifourcates** at C**4**.
- The trachea **bifourcates** at T**4**.
- The abdominal aorta **bifourcates** at L**4**.

## ► RESPIRATORY—PHYSIOLOGY

**Lung volumes**

Note: a **capacity** is a sum of  $\geq 2$  physiologic volumes.

<b>Inspiratory reserve volume</b>	Air that can still be breathed in after normal inspiration
<b>Tidal volume</b>	Air that moves into lung with each quiet inspiration, typically 500 mL
<b>Expiratory reserve volume</b>	Air that can still be breathed out after normal expiration
<b>Residual volume</b>	Air in lung after maximal expiration; RV and any lung capacity that includes RV cannot be measured by spirometry
<b>Inspiratory capacity</b>	IRV + TV Air that can be breathed in after normal exhalation
<b>Functional residual capacity</b>	RV + ERV Volume of gas in lungs after normal expiration
<b>Vital capacity</b>	TV + IRV + ERV Maximum volume of gas that can be expired after a maximal inspiration
<b>Total lung capacity</b>	IRV + TV + ERV + RV Volume of gas present in lungs after a maximal inspiration

**Lung volumes (LITER)****Determination of physiologic dead space**

$$V_D = V_T \times \frac{P_{aCO_2} - P_{E}CO_2}{P_{aCO_2}}$$

$V_D$  = physiologic dead space = anatomic dead space of conducting airways plus alveolar dead space; apex of healthy lung is largest contributor of alveolar dead space. Volume of inspired air that does not take part in gas exchange.

$V_T$  = tidal volume.

$P_{aCO_2}$  = arterial  $PCO_2$ .

$P_{E}CO_2$  = expired air  $PCO_2$ .

**T**<sub>a</sub>co, **P**<sub>a</sub>co, **P**<sub>E</sub>co, **P**<sub>a</sub>co (refers to order of variables in equation)

Physiologic dead space—approximately equivalent to anatomic dead space in normal lungs. May be greater than anatomic dead space in lung diseases with  $\dot{V}/\dot{Q}$  defects.

Pathologic dead space—when part of the respiratory zone becomes unable to perform gas exchange. Ventilated but not perfused.

**Ventilation**

$$V_A = V_E - V_D$$

**Minute ventilation ( $V_E$ )**

Total volume of gas entering lungs per minute

$$V_E = V_T \times RR$$

**Alveolar ventilation ( $V_A$ )**

Volume of gas per unit time that reaches alveoli

$$V_A = (V_T - V_D) \times RR$$

Normal values:

Respiratory rate (RR) = 12–20 breaths/min

$V_T$  = 500 mL/breath

$V_D$  = 150 mL/breath

**Lung and chest wall**


Elastic recoil—tendency for lungs to collapse inward and chest wall to spring outward. At FRC, inward pull of lung is balanced by outward pull of chest wall, and system pressure is atmospheric.

Elastic properties of both chest wall and lungs determine their combined volume.


At FRC, airway and alveolar pressures are 0, and intrapleural pressure is negative (prevents atelectasis). PVR is at minimum.

Compliance—change in lung volume for a change in pressure; expressed as  $\Delta V/\Delta P$  and is inversely proportional to wall stiffness. High compliance = lung easier to fill (emphysema, normal aging), lower compliance = lung harder to fill (pulmonary fibrosis, pneumonia, NRDS, pulmonary edema). Surfactant increases compliance.

Hysteresis—lung inflation curve follows a different curve than the lung deflation curve due to need to overcome surface tension forces in inflation.



**Compliant** lungs **comply** (cooperate) and fill easily with air.

**Hemoglobin**

Hemoglobin (Hb) is composed of 4 polypeptide subunits (2  $\alpha$  and 2  $\beta$ ) and exists in 2 forms:

- Deoxygenated form has low affinity for  $O_2$ , thus promoting release/unloading of  $O_2$ .
- Oxygenated form has high affinity for  $O_2$  (300 $\times$ ). Hb exhibits positive cooperativity and negative allostery.

$\uparrow Cl^-$ ,  $H^+$ ,  $CO_2$ , 2,3-BPG, and temperature favor taut form over relaxed form (shifts dissociation curve right  $\rightarrow \uparrow O_2$  unloading).

Fetal Hb (2 $\alpha$  and 2 $\gamma$  subunits) has a higher affinity for  $O_2$  than adult Hb, driving diffusion of oxygen across the placenta from mother to fetus.  $\uparrow O_2$  affinity results from  $\downarrow$  affinity of HbF for 2,3-BPG.

Hemoglobin acts as buffer for  $H^+$  ions.

## Hemoglobin modifications

### Methemoglobin

Oxidized form of Hb (ferric,  $\text{Fe}^{3+}$ ) that does not bind  $\text{O}_2$  as readily, but has  $\uparrow$  affinity for cyanide.

Iron in Hb is normally in a reduced state (ferrous,  $\text{Fe}^{2+}$ ).

Methemoglobinemia may present with cyanosis and chocolate-colored blood.

Induced methemoglobinemia (using nitrites, followed by thiosulfate) may be used to treat cyanide poisoning.

Methemoglobinemia can be treated with **methylene blue** and vitamin C.

Nitrites (eg, from dietary intake or polluted/high altitude water sources) and benzocaine cause poisoning by oxidizing  $\text{Fe}^{2+}$  to  $\text{Fe}^{3+}$ .

$\text{Fe}^{2+}$  binds  $\text{O}_2$ .


### Carboxyhemoglobin

Form of Hb bound to CO in place of  $\text{O}_2$ .

Causes  $\downarrow$  oxygen-binding capacity with left shift in oxygen-hemoglobin dissociation curve.  $\downarrow$   $\text{O}_2$  unloading in tissues.

CO binds competitively to Hb and with 200 $\times$  greater affinity than  $\text{O}_2$ .

CO poisoning can present with headaches, dizziness, and cherry red skin. May be caused by fires, car exhaust, or gas heaters. Treat with 100%  $\text{O}_2$  and hyperbaric  $\text{O}_2$ .



## Oxygen-hemoglobin dissociation curve

Sigmoidal shape due to positive cooperativity (ie, tetrameric Hb molecule can bind 4  $\text{O}_2$  molecules and has higher affinity for each subsequent  $\text{O}_2$  molecule bound). Myoglobin is monomeric and thus does not show positive cooperativity; curve lacks sigmoidal appearance.

When curve shifts to the right,  $\downarrow$  affinity of Hb for  $\text{O}_2$  (facilitates unloading of  $\text{O}_2$  to tissue).

An  $\uparrow$  in all factors (including  $\text{H}^+$ ) causes a shift of the curve to the right.

A  $\downarrow$  in all factors (including  $\text{H}^+$ ) causes a left shift  $\rightarrow$   $\downarrow$   $\text{O}_2$  unloading  $\rightarrow$  renal hypoxia  $\rightarrow$   $\uparrow$  EPO synthesis  $\rightarrow$  compensatory erythrocytosis. **Lower = Left.**

Fetal Hb has higher affinity for  $\text{O}_2$  than adult Hb (due to low affinity for 2,3-BPG), so its dissociation curve is shifted left.

**Right shift—ACE BATs right handed:**

**A**cid


**C** $\text{O}_2$

**E**xercise

**2,3-BPG**

**A**ltitude

**T**emperature



**Oxygen content of blood**

$$O_2 \text{ content} = (1.34 \times Hb \times SaO_2) + (0.003 \times PaO_2)$$

Hb = hemoglobin level

SaO<sub>2</sub> = arterial O<sub>2</sub> saturation

PaO<sub>2</sub> = partial pressure of O<sub>2</sub> in arterial blood

Normally 1 g Hb can bind 1.34 mL O<sub>2</sub>; normal Hb amount in blood is 15 g/dL.

O<sub>2</sub> binding capacity ≈ 20.1 mL O<sub>2</sub>/dL blood.

With ↓ Hb there is ↓ O<sub>2</sub> content of arterial blood, but no change in O<sub>2</sub> saturation and PaO<sub>2</sub>.

O<sub>2</sub> delivery to tissues = cardiac output × O<sub>2</sub> content of blood.

	Hb concentration	% O <sub>2</sub> sat of Hb	Dissolved O <sub>2</sub> (PaO <sub>2</sub> )	Total O <sub>2</sub> content
CO poisoning	Normal	↓ (CO competes with O <sub>2</sub> )	Normal	↓
Anemia	↓	Normal	Normal	↓
Polycythemia	↑	Normal	Normal	↑

**Pulmonary circulation**

Normally a low-resistance, high-compliance system. PO<sub>2</sub> and PCO<sub>2</sub> exert opposite effects on pulmonary and systemic circulation. A ↓ in PAO<sub>2</sub> causes a hypoxic vasoconstriction that shifts blood away from poorly ventilated regions of lung to well-ventilated regions of lung.

Perfusion limited—O<sub>2</sub> (normal health), CO<sub>2</sub>, N<sub>2</sub>O. Gas equilibrates early along the length of the capillary. Diffusion can be ↑ only if blood flow ↑.

Diffusion limited—O<sub>2</sub> (emphysema, fibrosis), CO. Gas does not equilibrate by the time blood reaches the end of the capillary.

A consequence of pulmonary hypertension is cor pulmonale and subsequent right ventricular failure (jugular venous distention, edema, hepatomegaly).


$$\text{Diffusion: } \dot{V}_{\text{gas}} = A \times D_k \times \frac{P_1 - P_2}{T} \text{ where}$$

A = area, T = alveolar wall thickness,

D<sub>k</sub> = diffusion coefficient of gas, P<sub>1</sub> - P<sub>2</sub> = difference in partial pressures.

- A ↓ in emphysema.
- T ↑ in pulmonary fibrosis.

D<sub>LCO</sub> is the extent to which CO, a surrogate for O<sub>2</sub>, passes from air sacs of lungs into blood.



P<sub>a</sub> = partial pressure of gas in pulmonary capillary blood  
 P<sub>A</sub> = partial pressure of gas in alveolar air

**Pulmonary vascular resistance**

$$PVR = \frac{P_{\text{pulm artery}} - P_{L \text{ atrium}}}{\text{cardiac output}}$$

Remember:  $\Delta P = Q \times R$ , so  $R = \Delta P / Q$

$$R = 8\eta l / \pi r^4$$

R = resistance

$P_{\text{pulm artery}}$  = pressure in pulmonary artery

$P_{L \text{ atrium}} \approx$  pulmonary capillary wedge pressure

$\eta$  = viscosity of blood;  $l$  = vessel length;

$r$  = vessel radius

**Alveolar gas equation**

$$P_{A\text{O}_2} = P_{I\text{O}_2} - \frac{P_{a\text{CO}_2}}{R}$$

$$\approx 150 \text{ mm Hg}^a - \frac{P_{a\text{CO}_2}}{0.8}$$

<sup>a</sup>At sea level breathing room air

$P_{A\text{O}_2}$  = alveolar  $P_{\text{O}_2}$  (mm Hg)

$P_{I\text{O}_2}$  =  $P_{\text{O}_2}$  in inspired air (mm Hg)

$P_{a\text{CO}_2}$  = arterial  $P_{\text{CO}_2}$  (mm Hg)

R = respiratory quotient =  $\text{CO}_2$  produced/ $\text{O}_2$  consumed

A-a gradient =  $P_{A\text{O}_2} - P_{a\text{O}_2}$ . Normal range = 10–15 mm Hg

↑ A-a gradient may occur in hypoxemia; causes include shunting,  $\dot{V}/\dot{Q}$  mismatch, fibrosis (impairs diffusion)

**Oxygen deprivation****Hypoxia (↓  $\text{O}_2$  delivery to tissue)**

↓ cardiac output  
Hypoxemia  
Anemia  
CO poisoning

**Hypoxemia (↓  $P_{a\text{O}_2}$ )**

Normal A-a gradient

- High altitude
- Hypoventilation (eg, opioid use)

↑ A-a gradient

- $\dot{V}/\dot{Q}$  mismatch
- Diffusion limitation (eg, fibrosis)
- Right-to-left shunt

**Ischemia (loss of blood flow)**

Impeded arterial flow  
↓ venous drainage

**Ventilation/perfusion mismatch**

Ideally, ventilation is matched to perfusion (ie,  $\dot{V}/\dot{Q} = 1$ ) for adequate gas exchange.

Lung zones:

- $\dot{V}/\dot{Q}$  at apex of lung = 3 (wasted ventilation)
- $\dot{V}/\dot{Q}$  at base of lung = 0.6 (wasted perfusion)


Both ventilation and perfusion are greater at the base of the lung than at the apex of the lung.

With exercise (↑ cardiac output), there is vasodilation of apical capillaries →  $\dot{V}/\dot{Q}$  ratio approaches 1.

Certain organisms that thrive in high  $\text{O}_2$  (eg, TB) flourish in the apex.

$\dot{V}/\dot{Q} = 0$  = “airway” obstruction (shunt). In shunt, 100%  $\text{O}_2$  does not improve  $P_{a\text{O}_2}$  (eg, foreign body aspiration).

$\dot{V}/\dot{Q} = \infty$  = blood flow obstruction (physiologic dead space). Assuming < 100% dead space, 100%  $\text{O}_2$  improves  $P_{a\text{O}_2}$  (eg, pulmonary embolus).




### Carbon dioxide transport

CO<sub>2</sub> is transported from tissues to lungs in 3 forms:

- ❶ HCO<sub>3</sub><sup>-</sup> (70%).
- ❷ Carbaminohemoglobin or HbCO<sub>2</sub> (21–25%). CO<sub>2</sub> bound to Hb at N-terminus of globin (not heme). CO<sub>2</sub> binding favors taut form (O<sub>2</sub> unloaded).
- ❸ Dissolved CO<sub>2</sub> (5–9%).

In lungs, oxygenation of Hb promotes dissociation of H<sup>+</sup> from Hb. This shifts equilibrium toward CO<sub>2</sub> formation; therefore, CO<sub>2</sub> is released from RBCs (Haldane effect). In peripheral tissue, ↑ H<sup>+</sup> from tissue metabolism shifts curve to right, unloading O<sub>2</sub> (Bohr effect). Majority of blood CO<sub>2</sub> is carried as HCO<sub>3</sub><sup>-</sup> in the plasma.



### Response to high altitude

↓ atmospheric oxygen (PO<sub>2</sub>) → ↓ PaO<sub>2</sub> → ↑ ventilation → ↓ PaCO<sub>2</sub> → respiratory alkalosis → altitude sickness.

Chronic ↑ in ventilation.

↑ erythropoietin → ↑ hematocrit and Hb (chronic hypoxia).

↑ 2,3-BPG (binds to Hb so that Hb releases more O<sub>2</sub>).

Cellular changes (↑ mitochondria).

↑ renal excretion of HCO<sub>3</sub><sup>-</sup> to compensate for respiratory alkalosis (can augment with acetazolamide).

Chronic hypoxic pulmonary vasoconstriction results in pulmonary hypertension and RVH.

### Response to exercise

↑ CO<sub>2</sub> production.

↑ O<sub>2</sub> consumption.

↑ ventilation rate to meet O<sub>2</sub> demand.

$\dot{V}/\dot{Q}$  ratio from apex to base becomes more uniform.


↑ pulmonary blood flow due to ↑ cardiac output.

↓ pH during strenuous exercise (2° to lactic acidosis).

No change in PaO<sub>2</sub> and PaCO<sub>2</sub>, but ↑ in venous CO<sub>2</sub> content and ↓ in venous O<sub>2</sub> content.



## ► RESPIRATORY—PATHOLOGY

**Rhinosinusitis**

Obstruction of sinus drainage into nasal cavity → inflammation and pain over affected area (typically maxillary sinuses, filled with fluid on the right in **A**, which drain into the middle meatus, in adults).

Most common acute cause is viral URI; may cause superimposed bacterial infection, most commonly *S pneumoniae*, *H influenzae*, *M catarrhalis*.

**Epistaxis**

Nose bleed. Most commonly occurs in anterior segment of nostril (Kiesselbach plexus). Life-threatening hemorrhages occur in posterior segment (sphenopalatine artery, a branch of maxillary artery). Common causes include foreign body, trauma, allergic rhinitis, and nasal angiofibromas.

**Head and neck cancer**

Mostly squamous cell carcinoma. Risk factors include tobacco, alcohol, HPV-16 (oropharyngeal), EBV (nasopharyngeal). Field cancerization: carcinogen damages wide mucosal area → multiple tumors that develop independently after exposure.

**Deep venous thrombosis**

Blood clot within a deep vein → swelling, redness **A**, warmth, pain. Predisposed by Virchow triad (**SHE**):

- **S**tasis (eg, post-op, long drive/flight)
- **H**ypercoagulability (eg, defect in coagulation cascade proteins, such as factor V Leiden)
- **E**ndothelial damage (exposed collagen triggers clotting cascade)

D-dimer lab test used clinically to rule out DVT (high sensitivity, low specificity).

Most pulmonary emboli arise from proximal deep veins of lower extremity.

Use unfractionated heparin or low-molecular-weight heparins (eg, enoxaparin) for prophylaxis and acute management.

Use oral anticoagulants (eg, warfarin, rivaroxaban) for treatment (long-term prevention).

Imaging test of choice is compression ultrasound with Doppler.

**Pulmonary emboli**

$\dot{V}/\dot{Q}$  mismatch, hypoxemia, respiratory alkalosis. Sudden-onset dyspnea, pleuritic chest pain, tachypnea, tachycardia. Large emboli or saddle embolus **A** may cause sudden death.

Lines of Zahn are interdigitating areas of pink (platelets, fibrin) and red (RBCs) found only in thrombi formed before death; help distinguish pre- and postmortem thrombi **B**.

Types: **F**at, **A**ir, **T**hrombus, **B**acteria, **A**mniotic fluid, **T**umor.


Fat emboli—associated with long bone fractures and liposuction; classic triad of hypoxemia, neurologic abnormalities, petechial rash.

Amniotic fluid emboli—can lead to DIC, especially postpartum.


Air emboli—nitrogen bubbles precipitate in ascending divers (caisson disease, decompression sickness); treat with hyperbaric  $O_2$ ; or, can be iatrogenic 2° to invasive procedures (eg, central line placement).

CT pulmonary angiography is imaging test of choice for PE (look for filling defects) **C**.

An embolus moves like a **FAT BAT**.

**Flow volume loops**

Obstructive lung volumes > normal ( $\uparrow$  TLC,  $\uparrow$  FRC,  $\uparrow$  RV); restrictive lung volumes < normal. In obstructive,  $FEV_1$  is more dramatically reduced compared with FVC  $\rightarrow$  decreased  $FEV_1/FVC$  ratio. In restrictive, FVC is more reduced or close to same compared with  $FEV_1$   $\rightarrow$  increased or normal  $FEV_1/FVC$  ratio.





**Obstructive lung diseases**

Obstruction of air flow → air trapping in lungs. Airways close prematurely at high lung volumes → ↑ RV and ↑ FRC, ↑ TLC. PFTs: ↓↓ FEV<sub>1</sub>, ↓ FVC → ↓ FEV<sub>1</sub>/FVC ratio (hallmark), V/Q mismatch. Chronic, hypoxic pulmonary vasoconstriction can lead to cor pulmonale. Chronic obstructive pulmonary disease (COPD) includes chronic bronchitis and emphysema.

TYPE	PRESENTATION	PATHOLOGY	OTHER
<b>Chronic bronchitis</b> ("blue bloater")	Findings: wheezing, crackles, cyanosis (hypoxemia due to shunting), dyspnea, CO <sub>2</sub> retention, 2° polycythemia.	Hypertrophy and hyperplasia of mucus-secreting glands in bronchi → Reid index (thickness of mucosal gland layer to thickness of wall between epithelium and cartilage) > 50%.	Diagnostic criteria: productive cough for > 3 months in a year for > 2 consecutive years.
<b>Emphysema</b> ("pink puffer")	Centriacinar—associated with <b>smoking</b> <b>A B</b> . Frequently in <b>upper lobes</b> ( <b>smoke</b> rises <b>up</b> ). Panacinar—associated with α <sub>1</sub> -antitrypsin deficiency. Frequently in lower lobes.	Enlargement of air spaces ↓ recoil, ↑ compliance, ↓ D <sub>LCO</sub> from destruction of alveolar walls (arrow in <b>C</b> ). ↑ elastase activity → ↑ loss of elastic fibers → ↑ lung compliance.	CXR: ↑ AP diameter, flattened diaphragm, ↑ lung field lucency. Barrel-shaped chest <b>D</b> . Exhalation through pursed lips to increase airway pressure and prevent airway collapse.
<b>Asthma</b>	Findings: cough, wheezing, tachypnea, dyspnea, hypoxemia, ↓ inspiratory/expiratory ratio, pulsus paradoxus, mucus plugging <b>E</b> . Triggers: viral URIs, allergens, stress. Diagnosis supported by spirometry and methacholine challenge.	Bronchial hyperresponsiveness → reversible bronchoconstriction. Smooth muscle hypertrophy and hyperplasia, Curschmann spirals <b>F</b> (shed epithelium forms whorled mucous plugs), and Charcot-Leyden crystals <b>G</b> (eosinophilic, hexagonal, double-pointed, needle-like crystals formed from breakdown of eosinophils in sputum).	Aspirin-induced asthma: COX inhibition → leukotriene overproduction → airway constriction. Associated with nasal polyps.

**Obstructive lung diseases (continued)**

TYPE	PRESENTATION	PATHOLOGY	OTHER
<b>Bronchiectasis</b>	Findings: purulent sputum, recurrent infections, hemoptysis, digital clubbing.	Chronic necrotizing infection of bronchi → permanently dilated airways.	Associated with bronchial obstruction, poor ciliary motility (eg, smoking, Kartagener syndrome), cystic fibrosis <b>H</b> , allergic bronchopulmonary aspergillosis.

**Restrictive lung diseases**

Restricted lung expansion causes ↓ lung volumes (↓ FVC and TLC). PFTs: FEV<sub>1</sub>/FVC ratio ≥ 80%. Patient presents with short, shallow breaths.

Types:


- Poor breathing mechanics (extrapulmonary, peripheral hypoventilation, normal A-a gradient):
  - Poor muscular effort—polio, myasthenia gravis, Guillain-Barré syndrome
  - Poor structural apparatus—scoliosis, morbid obesity
- Interstitial lung diseases (pulmonary ↓ diffusing capacity, ↑ A-a gradient):
  - Pneumoconioses (eg, coal workers' pneumoconiosis, silicosis, asbestosis)
  - Sarcoidosis: bilateral hilar lymphadenopathy, noncaseating granuloma; ↑ ACE and Ca<sup>2+</sup>
  - Idiopathic pulmonary fibrosis **A** (repeated cycles of lung injury and wound healing with ↑ collagen deposition, “honeycomb” lung appearance and digital clubbing)
  - Granulomatosis with polyangiitis (Wegener)
  - Pulmonary Langerhans cell histiocytosis (eosinophilic granuloma)
  - Hypersensitivity pneumonitis
  - Drug toxicity (bleomycin, busulfan, amiodarone, methotrexate)

**Hypersensitivity pneumonitis**—mixed type III/IV hypersensitivity reaction to environmental antigen. Causes dyspnea, cough, chest tightness, headache. Often seen in farmers and those exposed to birds. Reversible in early stages if stimulus is avoided.


**Inhalation injury and sequelae**

Pulmonary complication associated with smoke and fire. Caused by heat, particulates ( $< 1 \mu\text{m}$  diameter), or irritants (eg,  $\text{NH}_3$ ) → chemical tracheobronchitis, edema, pneumonia, ARDS. Many patients present 2° to burns, CO inhalation, cyanide poisoning, or arsenic poisoning.

Bronchoscopy shows severe edema, congestion of bronchus, and soot deposition (**A**, 18 hours after inhalation injury; **B**, resolution at 11 days after injury).




<b>Pneumoconioses</b>	Coal workers' pneumoconiosis, silicosis, and asbestosis → ↑ risk of cor pulmonale, cancer, and Caplan syndrome (rheumatoid arthritis and pneumoconioses with intrapulmonary nodules).	<b>Asbestos</b> is from the <b>roof</b> (was common in insulation), but affects the <b>base</b> (lower lobes). <b>Silica and coal</b> are from the <b>base</b> (earth), but affect the <b>roof</b> (upper lobes).
<b>Asbestosis</b>	Associated with shipbuilding, roofing, plumbing. "Ivory white," calcified, supradiaphragmatic <b>A</b> and pleural <b>B</b> plaques are pathognomonic of asbestosis. Risk of bronchogenic carcinoma > risk of mesothelioma.	Affects lower lobes. Asbestos (ferruginous) bodies are golden-brown fusiform rods resembling dumbbells <b>C</b> , found in alveolar sputum sample, visualized using Prussian blue stain, often obtained by bronchoalveolar lavage. ↑ risk of pleural effusions.
<b>Berylliosis</b>	Associated with exposure to beryllium in aerospace and manufacturing industries. Granulomatous (noncaseating) on histology and therefore occasionally responsive to steroids.	Affects upper lobes.
<b>Coal workers' pneumoconiosis</b>	Prolonged coal dust exposure → macrophages laden with carbon → inflammation and fibrosis. Also known as black lung disease.	Affects upper lobes. <b>Anthracosis</b> —asymptomatic condition found in many urban dwellers exposed to sooty air.
<b>Silicosis</b>	Associated with foundries, sandblasting, mines. Macrophages respond to silica and release fibrogenic factors, leading to fibrosis. It is thought that silica may disrupt phagolysosomes and impair macrophages, increasing susceptibility to TB.	Affects upper lobes. "Eggshell" calcification of hilar lymph nodes on CXR.




<b>Mesothelioma</b>	Malignancy of the pleura associated with asbestosis. May result in hemorrhagic pleural effusion (exudative), pleural thickening.	Psammoma bodies seen on histology. Cytokeratin and calretinin ⊕ in almost all mesotheliomas, ⊖ in most carcinomas. Smoking not a risk factor.
---------------------	--	---

### Acute respiratory distress syndrome



Diagnosis of exclusion characterized by respiratory failure within 1 week of alveolar insult, bilateral lung opacities,  $\downarrow$   $\text{PaO}_2/\text{FiO}_2 < 300$  (hypoxemia due to  $\uparrow$  intrapulmonary shunting and diffusion abnormalities), no evidence of HF/fluid overload. Many causes and associations, including sepsis, pancreatitis, pneumonia, aspiration, trauma, shock. Endothelial damage  $\rightarrow$   $\uparrow$  alveolar capillary permeability  $\rightarrow$  protein-rich leakage into alveoli  $\rightarrow$  diffuse alveolar damage and noncardiogenic pulmonary edema (normal PCWP) **A**. Results in formation of intra-alveolar hyaline membranes **B**. Initial damage due to release of neutrophilic substances toxic to alveolar wall and pulmonary capillary endothelial cells, activation of coagulation cascade, and oxygen-derived free radicals. Management: mechanical ventilation with low tidal volumes, address underlying cause.



### Sleep apnea

Repeated cessation of breathing  $> 10$  seconds during sleep  $\rightarrow$  disrupted sleep  $\rightarrow$  daytime somnolence. Diagnosis confirmed by sleep study. Normal  $\text{PaO}_2$  during the day. Nocturnal hypoxia  $\rightarrow$  systemic/pulmonary hypertension, arrhythmias (atrial fibrillation/flutter), sudden death. Hypoxia  $\rightarrow$   $\uparrow$  EPO release  $\rightarrow$   $\uparrow$  erythropoiesis.

### Obstructive sleep apnea

Respiratory effort against airway obstruction. Associated with obesity, loud snoring. Caused by excess parapharyngeal tissue in adults, adenotonsillar hypertrophy in children. Treatment: weight loss, CPAP, surgery.

### Central sleep apnea

No respiratory effort due to **CNS** injury/toxicity, HF, opioids. May be associated with Cheyne-Stokes respiration. Treat with positive airway pressure.

### Obesity hypoventilation syndrome

Obesity ( $\text{BMI} \geq 30 \text{ kg/m}^2$ )  $\rightarrow$  hypoventilation  $\uparrow$   $\text{PaCO}_2$  during waking hours (retention);  $\downarrow$   $\text{PaO}_2$  and  $\uparrow$   $\text{PaCO}_2$  during sleep. Also known as Pickwickian syndrome.

**Pulmonary hypertension**

Normal mean pulmonary artery pressure = 10–14 mm Hg; pulmonary hypertension  $\geq$  25 mm Hg at rest. Results in arteriosclerosis, medial hypertrophy, intimal fibrosis of pulmonary arteries, plexiform lesions. Course: severe respiratory distress  $\rightarrow$  cyanosis and RVH  $\rightarrow$  death from decompensated cor pulmonale.

ETIOLOGIES	
<b>Pulmonary arterial hypertension</b>	Idiopathic PAH. Heritable PAH—often due to an inactivating mutation in <i>BMPR2</i> gene (normally inhibits vascular smooth muscle proliferation); poor prognosis. Other causes include drugs (eg, amphetamines, cocaine), connective tissue disease, HIV infection, portal hypertension, congenital heart disease, schistosomiasis.
<b>Left heart disease</b>	Causes include systolic/diastolic dysfunction and valvular disease (eg, mitral lung).
<b>Lung diseases or hypoxia</b>	Destruction of lung parenchyma (eg, COPD), lung inflammation/fibrosis (eg, interstitial lung diseases), hypoxemic vasoconstriction (eg, obstructive sleep apnea, living in high altitude).
<b>Chronic thromboembolic</b>	Recurrent microthrombi $\rightarrow$ $\downarrow$ cross-sectional area of pulmonary vascular bed.
<b>Multifactorial</b>	Causes include hematologic, systemic, and metabolic disorders.

**Lung—physical findings**

ABNORMALITY	BREATH SOUNDS	PERCUSSION	FREMITUS	TRACHEAL DEVIATION
<b>Pleural effusion</b>	$\downarrow$	Dull	$\downarrow$	— or away from side of lesion (if large)
<b>Atelectasis (bronchial obstruction)</b>	$\downarrow$	Dull	$\downarrow$	Toward side of lesion
<b>Simple pneumothorax</b>	$\downarrow$	Hyperresonant	$\downarrow$	—
<b>Tension pneumothorax</b>	$\downarrow$	Hyperresonant	$\downarrow$	Away from side of lesion
<b>Consolidation (lobar pneumonia, pulmonary edema)</b>	Bronchial breath sounds; late inspiratory crackles, egophony, bronchophony, whispered pectoriloquy	Dull	$\uparrow$	—



**Pleural effusions**

Excess accumulation of fluid **A** between pleural layers → restricted lung expansion during inspiration. Can be treated with thoracentesis to remove/reduce fluid **B**.

**Transudate**


↓ protein content. Due to ↑ hydrostatic pressure (eg, HF) or ↓ oncotic pressure (eg, nephrotic syndrome, cirrhosis).

**Exudate**

↑ protein content, cloudy. Due to malignancy, pneumonia, collagen vascular disease, trauma (occurs in states of ↑ vascular permeability). Must be drained due to risk of infection.

**Lymphatic**

Also known as chylothorax. Due to thoracic duct injury from trauma or malignancy. Milky-appearing fluid; ↑ triglycerides.

**Pneumothorax**

Accumulation of air in pleural space **A**. Dyspnea, uneven chest expansion. Chest pain, ↓ tactile fremitus, hyperresonance, and diminished breath sounds, all on the affected side.

**Primary spontaneous pneumothorax**

Due to rupture of apical subpleural bleb or cysts. Occurs most frequently in tall, thin, young males.

**Secondary spontaneous pneumothorax**


Due to diseased lung (eg, bullae in emphysema, infections), mechanical ventilation with use of high pressures → barotrauma.

**Traumatic pneumothorax**

Caused by blunt (eg, rib fracture) or penetrating (eg, gunshot) trauma.


**Tension pneumothorax**

Can be any of the above. Air enters pleural space but cannot exit. Increasing trapped air → tension pneumothorax. Trachea deviates away from affected lung **B**. Needs immediate needle decompression and chest tube placement.




**Pneumonia**

TYPE	TYPICAL ORGANISMS	CHARACTERISTICS
<b>Lobar</b>	<i>S pneumoniae</i> most frequently, also <i>Legionella</i> , <i>Klebsiella</i>	Intra-alveolar exudate → consolidation <b>A</b> ; may involve entire lobe <b>B</b> or lung.
<b>Bronchopneumonia</b>	<i>S pneumoniae</i> , <i>S aureus</i> , <i>H influenzae</i> , <i>Klebsiella</i>	Acute inflammatory infiltrates <b>C</b> from bronchioles into adjacent alveoli; patchy distribution involving ≥ 1 lobe <b>D</b> .
<b>Interstitial (atypical) pneumonia</b>	<i>Mycoplasma</i> , <i>Chlamydothila pneumoniae</i> , <i>Chlamydia psittaci</i> , <i>Legionella</i> , viruses (RSV, CMV, influenza, adenovirus)	Diffuse patchy inflammation localized to interstitial areas at alveolar walls; diffuse distribution involving ≥ 1 lobe <b>E</b> . Generally follows a more indolent course (“walking” pneumonia).
<b>Cryptogenic organizing pneumonia</b>		Formerly known as bronchiolitis obliterans organizing pneumonia (BOOP). Noninfectious pneumonia characterized by inflammation of bronchioles and surrounding structure. Etiology unknown. Secondary organizing pneumonia caused by chronic inflammatory diseases (eg, rheumatoid arthritis) or medication side effects (eg, amiodarone). ⊖ sputum and blood cultures, no response to antibiotics.

**Natural history of lobar pneumonia**


	<b>Congestion</b>	<b>Red hepatization</b>	<b>Gray hepatization</b>	<b>Resolution</b>
DAYS	1–2	3–4	5–7	8+
FINDINGS	Red-purple, partial consolidation of parenchyma Exudate with mostly bacteria	Red-brown, consolidated Exudate with fibrin, bacteria, RBCs, and WBCs	Uniformly gray Exudate full of WBCs and fibrin	Enzymes digest components of exudate

**Lung abscess**

Localized collection of pus within parenchyma **A**. Caused by aspiration of oropharyngeal contents (especially in patients predisposed to loss of consciousness [eg, alcoholics, epileptics]) or bronchial obstruction (eg, cancer).

Treatment: clindamycin.


Air-fluid levels **B** often seen on CXR. Fluid levels common in cavities; presence suggests cavitation. Due to anaerobes (eg, *Bacteroides*, *Fusobacterium*, *Peptostreptococcus*) or *S aureus*. Lung abscess 2° to aspiration is most often found in right lung. Location depends on patient's position during aspiration.

**Pancoast tumor (superior sulcus tumor)**

Carcinoma that occurs in the apex of lung **A** may cause Pancoast syndrome by invading cervical sympathetic chain.

Compression of locoregional structures may cause array of findings:

- Recurrent laryngeal nerve → hoarseness
- Stellate ganglion → Horner syndrome (ipsilateral ptosis, miosis, anhidrosis)
- Superior vena cava → SVC syndrome
- Brachiocephalic vein → brachiocephalic syndrome (unilateral symptoms)
- Brachial plexus → sensorimotor deficits

**Superior vena cava syndrome**

An obstruction of the SVC that impairs blood drainage from the head (“facial plethora”; note blanching after fingertip pressure in **A**), neck (jugular venous distention), and upper extremities (edema). Commonly caused by malignancy (eg, mediastinal mass, Pancoast tumor) and thrombosis from indwelling catheters **B**. Medical emergency. Can raise intracranial pressure (if obstruction is severe) → headaches, dizziness, ↑ risk of aneurysm/rupture of intracranial arteries.



**Lung cancer**

Leading cause of cancer death.

Presentation: cough, hemoptysis, bronchial obstruction, wheezing, pneumonic “coin” lesion on CXR or noncalcified nodule on CT.

Sites of metastases from lung cancer: adrenals, brain, bone (pathologic fracture), liver (jaundice, hepatomegaly).

In the lung, metastases (usually multiple lesions) are more common than 1° neoplasms. Most often from breast, colon, prostate, and bladder cancer.

**SPHERE** of complications:

**S**uperior vena cava syndrome

**P**ancoast tumor

**H**orner syndrome

**E**ndocrine (paraneoplastic)


**R**ecurrent laryngeal nerve compression (hoarseness)

**E**ffusions (pleural or pericardial)

Risk factors include smoking, secondhand smoke, radon, asbestos, family history.

**S**quamous and **S**mall cell carcinomas are **S**entral (central) and often caused by **S**moking.

TYPE	LOCATION	CHARACTERISTICS	HISTOLOGY
<b>Small cell</b>			
<b>Small cell (oat cell) carcinoma</b>	Central	Undifferentiated → very aggressive. May produce <b>ACTH</b> (Cushing syndrome), <b>SIADH</b> , or <b>Antibodies</b> against presynaptic $Ca^{2+}$ channels (Lambert-Eaton myasthenic syndrome) or neurons (paraneoplastic myelitis, encephalitis, subacute cerebellar degeneration). <b>Amplification</b> of <i>myc</i> oncogenes common. Managed with chemotherapy +/- radiation.	Neoplasm of neuroendocrine Kulchitsky cells → small dark blue cells <b>A</b> . Chromogranin <b>A</b> ⊕, neuron-specific enolase ⊕.
<b>Non-small cell</b>			
<b>Adenocarcinoma</b>	Peripheral	Most common lung cancer in nonsmokers and overall (except for metastases). Activating mutations include <b>KRAS</b> , <b>EGFR</b> , and <b>ALK</b> . Associated with hypertrophic osteoarthropathy (clubbing). Bronchioloalveolar subtype (adenocarcinoma in situ): CXR often shows hazy infiltrates similar to pneumonia; better prognosis. Bronchial carcinoid and bronchioloalveolar cell carcinoma have lesser association with smoking.	Glandular pattern on histology, often stains mucin ⊕ <b>B</b> . Bronchioloalveolar subtype: grows along alveolar septa → apparent “thickening” of alveolar walls. Tall, columnar cells containing mucus.
<b>Squamous cell carcinoma</b>	<b>C</b> entral	Hilar mass <b>C</b> arising from bronchus; <b>C</b> avitation; <b>C</b> igarettes; hyper <b>C</b> alcemia (produces PTHrP).	Keratin pearls <b>D</b> and intercellular bridges.
<b>Large cell carcinoma</b>	Peripheral	Highly anaplastic undifferentiated tumor; poor prognosis. Less responsive to chemotherapy; removed surgically. Strong association with smoking.	Pleomorphic giant cells <b>E</b> .
<b>Bronchial carcinoid tumor</b>	—	Excellent prognosis; metastasis rare. Symptoms due to mass effect or carcinoid syndrome (flushing, diarrhea, wheezing).	Nests of neuroendocrine cells; chromogranin A ⊕.



## ▶ RESPIRATORY—PHARMACOLOGY

**Antihistamines** Reversible inhibitors of H<sub>1</sub> histamine receptors.

**First generation** Diphenhydramine, dimenhydrinate, chlorpheniramine. Names contain “-en/-ine” or “-en/-ate.”

CLINICAL USES Allergy, motion sickness, sleep aid.

ADVERSE EFFECTS Sedation, antimuscarinic, anti- $\alpha$ -adrenergic.

**Second generation** Loratadine, fexofenadine, desloratadine, cetirizine. Names usually end in “-adine.”

CLINICAL USES Allergy.

ADVERSE EFFECTS Far less sedating than 1st generation because of ↓ entry into CNS.

**Guaifenesin** Expectorant—thins respiratory secretions; does not suppress cough reflex.

**N-acetylcysteine** Mucolytic—liquifies mucus in chronic bronchopulmonary diseases (eg, COPD, CF) by disrupting disulfide bonds. Also used as an antidote for acetaminophen overdose.

**Dextromethorphan** Antitussive (antagonizes NMDA glutamate receptors). Synthetic codeine analog. Has mild opioid effect when used in excess. Naloxone can be given for overdose. Mild abuse potential. May cause serotonin syndrome if combined with other serotonergic agents.

### Pseudoephedrine, phenylephrine

MECHANISM  $\alpha$ -adrenergic agonists, used as nasal decongestants.

CLINICAL USE Reduce hyperemia, edema, nasal congestion; open obstructed eustachian tubes. Pseudoephedrine also illicitly used to make methamphetamine.

ADVERSE EFFECTS Hypertension. Rebound congestion if used more than 4–6 days. Can also cause CNS stimulation/anxiety (pseudoephedrine).

### Pulmonary hypertension drugs

DRUG	MECHANISM	CLINICAL NOTES
<b>BosENtan</b>	Competitively antagonizes <b>EN</b> dothelin-1 receptors → ↓ pulmonary vascular resistance.	Hepatotoxic (monitor LFTs).
<b>Sildenafil</b>	Inhibits PDE-5 → ↑ cGMP → prolonged vasodilatory effect of nitric oxide.	Also used to treat erectile dysfunction.
<b>Epoprostenol, iloprost</b>	PGI <sub>2</sub> (prostacyclin) with direct vasodilatory effects on pulmonary and systemic arterial vascular beds. Inhibits platelet aggregation.	Side effects: flushing, jaw pain.

**Asthma drugs**

Bronchoconstriction is mediated by (1) inflammatory processes and (2) parasympathetic tone; therapy is directed at these 2 pathways.

**β<sub>2</sub>-agonists**

**Albuterol**—relaxes bronchial smooth muscle (short acting β<sub>2</sub>-agonist). Used during acute exacerbation.

**Salmeterol, formoterol**—long-acting agents for prophylaxis. Adverse effects are tremor and arrhythmia.

**Inhaled corticosteroids**

**Fluticasone, budesonide**—inhibit the synthesis of virtually all cytokines. Inactivate NF-κB, the transcription factor that induces production of TNF-α and other inflammatory agents. 1st-line therapy for chronic asthma. May cause oral thrush.

**Muscarinic antagonists**

**Tiotropium, ipratropium**—competitively block muscarinic receptors, preventing bronchoconstriction. Also used for COPD. Tiotropium is long acting.

**Antileukotrienes**

**Montelukast, zafirlukast**—block leukotriene receptors (CysLT1). Especially good for aspirin-induced and exercise-induced asthma.



**Zileuton**—5-lipoxygenase pathway inhibitor. Blocks conversion of arachidonic acid to leukotrienes. Hepatotoxic.

**Anti-IgE monoclonal therapy**

**Omalizumab**—binds mostly unbound serum IgE and blocks binding to FcεRI. Used in allergic asthma with ↑ IgE levels resistant to inhaled steroids and long-acting β<sub>2</sub>-agonists.

**Methylxanthines**

**Theophylline**—likely causes bronchodilation by inhibiting phosphodiesterase → ↑ cAMP levels due to ↓ cAMP hydrolysis. Usage is limited because of narrow therapeutic index (cardiotoxicity, neurotoxicity); metabolized by cytochrome P-450. Blocks actions of adenosine.



**Methacholine**

Nonselective muscarinic receptor (M<sub>3</sub>) agonist. Used in bronchial challenge test to help diagnose asthma.

▶ NOTES

Two columns of horizontal lines for taking notes.

# Rapid Review

*“Study without thought is vain: thought without study is dangerous.”*  
—Confucius

*“It is better, of course, to know useless things than to know nothing.”*  
—Lucius Annaeus Seneca

*“For every complex problem there is an answer that is clear, simple, and wrong.”*  
—H. L. Mencken

The following tables represent a collection of high-yield associations of diseases with their clinical findings, treatments, and pathophysiology. They serve as a quick review before the exam to tune your senses to commonly tested cases.

▶ Classic Presentations	652
▶ Classic Labs/ Findings	657
▶ Classic/Relevant Treatments	661
▶ Key Associations	664
▶ Equation Review	669



## ► CLASSIC PRESENTATIONS

CLINICAL PRESENTATION	DIAGNOSIS/DISEASE	PAGE
Abdominal pain, ascites, hepatomegaly	Budd-Chiari syndrome (posthepatic venous thrombosis)	375
Abdominal pain, diarrhea, leukocytosis, recent antibiotic use	<i>Clostridium difficile</i> infection	134
Achilles tendon xanthoma	Familial hypercholesterolemia (↓ LDL receptor signaling)	90
Adrenal hemorrhage, hypotension, DIC	Waterhouse-Friderichsen syndrome (meningococcemia)	138
Anaphylaxis following blood transfusion	IgA deficiency	112
Anterior “drawer sign” ⊕	Anterior cruciate ligament injury	424
Arachnodactyly, lens dislocation (upward), aortic dissection, hyperflexible joints	Marfan syndrome (fibrillin defect)	56
Athlete with polycythemia	2° to erythropoietin injection	411
Back pain, fever, night sweats	Pott disease (vertebral TB)	136
Bilateral acoustic schwannomas	Neurofibromatosis type 2	56
Bilateral hilar adenopathy, uveitis	Sarcoidosis (noncaseating granulomas)	444
Black eschar on face of patient with diabetic ketoacidosis	<i>Mucor</i> or <i>Rhizopus</i> fungal infection	149
Blue sclera	Osteogenesis imperfecta (type I collagen defect)	47
Bluish line on gingiva	Burton line (lead poisoning)	397
Bone pain, bone enlargement, arthritis	Paget disease of bone (↑ osteoblastic and osteoclastic activity)	436
Bounding pulses, wide pulse pressure, diastolic heart murmur, head bobbing	Aortic regurgitation	279
“Butterfly” facial rash and Raynaud phenomenon in a young female	Systemic lupus erythematosus	443
Café-au-lait spots, Lisch nodules (iris hamartoma), cutaneous neurofibromas, pheochromocytomas, optic gliomas	Neurofibromatosis type I	505
Café-au-lait spots (unilateral), polyostotic fibrous dysplasia, precocious puberty, multiple endocrine abnormalities	McCune-Albright syndrome (mosaic G-protein signaling mutation)	53
Calf pseudohypertrophy	Muscular dystrophy (most commonly Duchenne, due to X-linked recessive frameshift mutation of dystrophin gene)	57
Cervical lymphadenopathy, desquamating rash, coronary aneurysms, red conjunctivae and tongue, hand-foot changes	Kawasaki disease (treat with IVIG and aspirin)	302
“Cherry-red spots” on macula	Tay-Sachs (ganglioside accumulation) or Niemann-Pick (sphingomyelin accumulation), central retinal artery occlusion	84
Chest pain on exertion	Angina (stable: with moderate exertion; unstable: with minimal exertion or at rest)	293
Chest pain, pericardial effusion/friction rub, persistent fever following MI	Dressler syndrome (autoimmune-mediated post-MI fibrinous pericarditis, 2 weeks to several months after acute episode)	296

CLINICAL PRESENTATION	DIAGNOSIS/DISEASE	PAGE
Chest pain with ST depressions on EKG	Unstable angina (⊖ troponins) or NSTEMI (⊕ troponins)	293
Child uses arms to stand up from squat	Duchenne muscular dystrophy (Gowers sign)	57
Child with fever later develops red rash on face that spreads to body	Erythema infectiosum/fifth disease (“slapped cheeks” appearance, caused by parvovirus B19)	179
Chorea, dementia, caudate degeneration	Huntington disease (autosomal dominant CAG repeat expansion)	491
Chorioretinitis, hydrocephalus, intracranial calcifications	Congenital toxoplasmosis	152
Chronic exercise intolerance with myalgia, fatigue, painful cramps, myoglobinuria	McArdle disease (skeletal muscle glycogen phosphorylase deficiency)	83
Cold intolerance	Hypothyroidism	327
Conjugate horizontal gaze palsy, horizontal diplopia	Internuclear ophthalmoplegia (damage to MLF; may be unilateral or bilateral)	513
Continuous “machine-like” heart murmur	PDA (close with indomethacin; keep open with PGE analogs)	289
Cutaneous/dermal edema due to connective tissue deposition	Myxedema (caused by hypothyroidism, Graves disease [pretibial])	327
Cutaneous flushing, diarrhea, bronchospasm	Carcinoid syndrome (right-sided cardiac valvular lesions, ↑ 5-HIAA)	362
Dark purple skin/mouth nodules in a patient with AIDS	Kaposi sarcoma, associated with HHV-8	388
Deep, labored breathing/hyperventilation	Diabetic ketoacidosis (Kussmaul respirations)	337
Dermatitis, dementia, diarrhea	Pellagra (niacin [vitamin B <sub>3</sub> ] deficiency)	63
Dilated cardiomyopathy, edema, alcoholism or malnutrition	Wet beriberi (thiamine [vitamin B <sub>1</sub> ] deficiency)	62
Dog or cat bite resulting in infection	<i>Pasteurella multocida</i> (cellulitis at inoculation site)	144
Dry eyes, dry mouth, arthritis	Sjögren syndrome (autoimmune destruction of exocrine glands)	439
Dysphagia (esophageal webs), glossitis, iron deficiency anemia	Plummer-Vinson syndrome (may progress to esophageal squamous cell carcinoma)	396
Elastic skin, hypermobility of joints, ↑ bleeding tendency	Ehlers-Danlos syndrome (type V collagen defect, type III collagen defect seen in vascular subtype of ED)	47
Enlarged, hard left supraclavicular node	Virchow node (abdominal metastasis)	362
Episodic vertigo, tinnitus, hearing loss	Meniere disease	503
Erythroderma, lymphadenopathy, hepatosplenomegaly, atypical T cells	Mycosis fungoides (cutaneous T-cell lymphoma) or Sézary syndrome (mycosis fungoides + malignant T cells in blood)	408
Facial muscle spasm upon tapping	Chvostek sign (hypocalcemia)	331
Fat, female, forty, and fertile	Cholelithiasis (gallstones)	353
Fever, chills, headache, myalgia following antibiotic treatment for syphilis	Jarisch-Herxheimer reaction (rapid lysis of spirochetes results in endotoxin-like release)	143
Fever, cough, conjunctivitis, coryza, diffuse rash	Measles	163
Fever, night sweats, weight loss	B symptoms of lymphoma	407

CLINICAL PRESENTATION	DIAGNOSIS/DISEASE	PAGE
Fibrous plaques in soft tissue of penis with abnormal curvature	Peyronie disease (connective tissue disorder)	617
Golden brown rings around peripheral cornea	Wilson disease (Kayser-Fleischer rings due to copper accumulation)	378
Gout, intellectual disability, self-mutilating behavior in a boy	Lesch-Nyhan syndrome (HGPRT deficiency, X-linked recessive)	439
Hamartomatous GI polyps, hyperpigmentation of mouth/feet/hands/genitalia	Peutz-Jeghers syndrome (inherited, benign polyposis can cause bowel obstruction; ↑ cancer risk, mainly GI)	370
Hepatosplenomegaly, pancytopenia, osteoporosis, aseptic necrosis of femoral head, bone crises	Gaucher disease (glucocerebrosidase deficiency)	84
Hereditary nephritis, sensorineural hearing loss, cataracts	Alport syndrome (mutation in collagen IV)	46
Hyperphagia, hypersexuality, hyperorality, hyperdocility	Klüver-Bucy syndrome (bilateral amygdala lesion)	481
Hyperreflexia, hypertonia, Babinski sign present	UMN damage	499
Hyporeflexia, hypotonia, atrophy, fasciculations	LMN damage	499
Hypoxemia, polycythemia, hypercapnia	Chronic bronchitis (hyperplasia of mucous cells, “blue bloater”)	638
Indurated, ulcerated genital lesion	Nonpainful: chancre (1° syphilis, <i>Treponema pallidum</i> )	143
	Painful, with exudate: chancroid ( <i>Haemophilus ducreyi</i> )	180
Infant with cleft lip/palate, microcephaly or holoprosencephaly, polydactyly, cutis aplasia	Patau syndrome (trisomy 13)	59
Infant with hypoglycemia, hepatomegaly	Cori disease (debranching enzyme deficiency) or Von Gierke disease (glucose-6-phosphatase deficiency, more severe)	83
Infant with microcephaly, rocker-bottom feet, clenched hands, and structural heart defect	Edwards syndrome (trisomy 18)	59
Jaundice, palpable distended non-tender gallbladder	Courvoisier sign (distal malignant obstruction of biliary tree)	380
Large rash with bull’s-eye appearance	Erythema chronicum migrans from <i>Ixodes</i> tick bite (Lyme disease: <i>Borrelia</i> )	142
Lucid interval after traumatic brain injury	Epidural hematoma (middle meningeal artery rupture)	483
Male child, recurrent infections, no mature B cells	Bruton disease (X-linked agammaglobulinemia)	56
Mucosal bleeding and prolonged bleeding time	Glanzmann thrombasthenia (defect in platelet aggregation due to lack of GpIIb/IIIa)	405
Muffled heart sounds, distended neck veins, hypotension	Beck triad of cardiac tamponade	300
Multiple colon polyps, osteomas/soft tissue tumors, impacted/supernumerary teeth	Gardner syndrome (subtype of FAP)	370
Myopathy (infantile hypertrophic cardiomyopathy), exercise intolerance	Pompe disease (lysosomal $\alpha$ -1,4-glucosidase deficiency)	46
Neonate with arm paralysis following difficult birth	Erb-Duchenne palsy (superior trunk [C5–C6] brachial plexus injury: “waiter’s tip”)	428

CLINICAL PRESENTATION	DIAGNOSIS/DISEASE	PAGE
No lactation postpartum, absent menstruation, cold intolerance	Sheehan syndrome (pituitary infarction)	606
Nystagmus, intention tremor, scanning speech, bilateral internuclear ophthalmoplegia	Multiple sclerosis	493
Painful blue fingers/toes, hemolytic anemia	Cold agglutinin disease (autoimmune hemolytic anemia caused by <i>Mycoplasma pneumoniae</i> , infectious mononucleosis, CLL)	401
Painful fingers/toes changing color from white to blue to red with cold or stress	Raynaud phenomenon (vasospasm in extremities)	445
Painful, raised red lesions on pads of fingers/toes	Osler nodes (infective endocarditis, immune complex deposition)	299
Painless erythematous lesions on palms and soles	Janeway lesions (infective endocarditis, septic emboli/microabscesses)	299
Painless jaundice	Cancer of the pancreatic head obstructing bile duct	380
Palpable purpura on buttocks/legs, joint pain, abdominal pain (child), hematuria	Henoch-Schönlein purpura (IgA vasculitis affecting skin and kidneys)	303
Pancreatic, pituitary, parathyroid tumors	MEN 1 (autosomal dominant)	339
Periorbital and/or peripheral edema, proteinuria (> 3.5g/day), hypoalbuminemia, hypercholesterolemia	Nephrotic syndrome	563
Pink complexion, dyspnea, hyperventilation	Emphysema (“pink puffer,” centriacinar [smoking] or panacinar [ $\alpha_1$ -antitrypsin deficiency])	638
Polyuria, renal tubular acidosis type II, growth failure, electrolyte imbalances, hypophosphatemic rickets	Fanconi syndrome (multiple combined dysfunction of the proximal convoluted tubule)	399
Pruritic, purple, polygonal planar papules and plaques (6 P’s)	Lichen planus	453
Ptosis, miosis, anhidrosis	Horner syndrome (sympathetic chain lesion)	509
Pupil accommodates but doesn’t react	Neurosyphilis (Argyll Robertson pupil)	143
Rapidly progressive limb weakness that ascends following GI/upper respiratory infection	Guillain-Barré syndrome (acute inflammatory demyelinating polyradiculopathy subtype)	493
Rash on palms and soles	Coxsackie A, 2° syphilis, Rocky Mountain spotted fever	179
Recurrent cold (noninflamed) abscesses, unusual eczema, high serum IgE	Hyper-IgE syndrome (Job syndrome: neutrophil chemotaxis abnormality)	112
Red “currant jelly” sputum in alcoholic or diabetic patients	<i>Klebsiella pneumoniae</i> pneumonia	177
Red “currant jelly” stools	Acute mesenteric ischemia (adults), intussusception (children)	368 369
Red, itchy, swollen rash of nipple/areola	Paget disease of the breast (sign of underlying neoplasm)	616
Red urine in the morning, fragile RBCs	Paroxysmal nocturnal hemoglobinuria	400
Renal cell carcinoma (bilateral), hemangioblastomas, angiomas, pheochromocytoma	von Hippel-Lindau disease (dominant tumor suppressor gene mutation)	568
Resting tremor, rigidity, akinesia, postural instability, shuffling gait	Parkinson disease (loss of dopaminergic neurons in substantia nigra pars compacta)	490
Retinal hemorrhages with pale centers	Roth spots (bacterial endocarditis)	299

CLINICAL PRESENTATION	DIAGNOSIS/DISEASE	PAGE
Severe jaundice in neonate	Crigler-Najjar syndrome (congenital unconjugated hyperbilirubinemia)	377
Severe RLQ pain with palpation of LLQ	Rovsing sign (acute appendicitis)	366
Severe RLQ pain with deep tenderness	McBurney sign (acute appendicitis)	366
Short stature, café au lait spots, thumb/radial defects, ↑ incidence of tumors/leukemia, aplastic anemia	Fanconi anemia (genetic loss of DNA crosslink repair; often progresses to AML)	399
Single palmar crease	Down syndrome	59
Situs inversus, chronic sinusitis, bronchiectasis, infertility	Kartagener syndrome (dynein arm defect affecting cilia)	45
Skin hyperpigmentation, hypotension, fatigue	1° adrenocortical insufficiency (eg, Addison disease) causes ↑ ACTH and ↑ α-MSH production)	324
Slow, progressive muscle weakness in boys	Becker muscular dystrophy (X-linked missense mutation in dystrophin; less severe than Duchenne)	57 57
Small, irregular red spots on buccal/lingual mucosa with blue-white centers	Koplik spots (measles [rubeola] virus)	166
Smooth, moist, painless, wart-like white lesions on genitals	Condylomata lata (2° syphilis)	143
Splinter hemorrhages in fingernails	Bacterial endocarditis	299
“Strawberry tongue”	Scarlet fever Kawasaki disease	132 302
Streak ovaries, congenital heart disease, horseshoe kidney, cystic hygroma at birth, short stature, webbed neck, lymphedema	Turner syndrome (45,XO)	603
Sudden swollen/painful big toe joint, tophi	Gout/podagra (hyperuricemia)	440
Swollen gums, mucosal bleeding, poor wound healing, petechiae	Scurvy (vitamin C deficiency: can't hydroxylate proline/lysine for collagen synthesis)	65
Swollen, hard, painful finger joints	Osteoarthritis (osteophytes on PIP [Bouchard nodes], DIP [Heberden nodes])	439
Systolic ejection murmur (crescendo-decrescendo)	Aortic stenosis	279
Telangiectasias, recurrent epistaxis, skin discoloration, arteriovenous malformations, GI bleeding, hematuria	Osler-Weber-Rendu syndrome (hereditary hemorrhagic telangiectasia)	56
Thyroid and parathyroid tumors, pheochromocytoma	MEN 2A (autosomal dominant <i>RET</i> mutation)	326
Thyroid tumors, pheochromocytoma, ganglioneuromatosis	MEN 2B (autosomal dominant <i>RET</i> mutation)	339
Toe extension/fanning upon plantar scrape	Babinski sign (UMN lesion)	480
Unilateral facial drooping involving forehead	LMN facial nerve (CN VII) palsy; UMN lesions spare the forehead	502
Urethritis, conjunctivitis, arthritis in a male	Reactive arthritis associated with HLA-B27	146
Vascular birthmark (port-wine stain) of the face	Nevus flammeus (benign, but associated with Sturge-Weber syndrome)	505
Vomiting blood following gastroesophageal lacerations	Mallory-Weiss syndrome (alcoholic and bulimic patients)	360
Weight loss, diarrhea, arthritis, fever, adenopathy	Whipple disease ( <i>Tropheryma whippeli</i> )	122
“Worst headache of my life”	Subarachnoid hemorrhage	483

## ▶ CLASSIC LABS/FINDINGS

LAB/DIAGNOSTIC FINDING	DIAGNOSIS/DISEASE	PAGE
↑ AFP in amniotic fluid/maternal serum	Dating error, anencephaly, spina bifida (open neural tube defects)	461
Anticentromere antibodies	Scleroderma (CREST)	446
Anti-desmoglein (anti-desmosome) antibodies	Pemphigus vulgaris (blistering)	452
Anti-glomerular basement membrane antibodies	Goodpasture syndrome (glomerulonephritis and hemoptysis)	564
Antihistone antibodies	Drug-induced SLE (eg, hydralazine, isoniazid, phenytoin, procainamide)	443
Anti-IgG antibodies	Rheumatoid arthritis (systemic inflammation, joint pannus, boutonnière deformity)	439
Antimitochondrial antibodies (AMAs)	1° biliary cirrhosis (female, cholestasis, portal hypertension)	378
Antineutrophil cytoplasmic antibodies (ANCA)	Microscopic polyangiitis and eosinophilic granulomatosis with polyangiitis (MPO-ANCA/p-ANCA); granulomatosis with polyangiitis (Wegener; PR3-ANCA/c-ANCA); primary sclerosing cholangitis (MPO-ANCA/p-ANCA)	302 378
Antinuclear antibodies (ANAs: anti-Smith and anti-dsDNA)	SLE (type III hypersensitivity)	443
Antiplatelet antibodies	Idiopathic thrombocytopenic purpura	405
Anti-topoisomerase antibodies	Diffuse systemic scleroderma	446
Anti-transglutaminase/anti-gliadin/anti-endomysial antibodies	Celiac disease (diarrhea, weight loss)	364
“Apple core” lesion on barium enema x-ray	Colorectal cancer (usually left-sided)	371
Atypical lymphocytes	EBV	161
Azurophilic peroxidase ⊕ granular inclusions in granulocytes and myeloblasts	Auer rods (AML, especially the promyelocytic [M3] type)	410
Bacitracin response	Sensitive: <i>S pyogenes</i> (group A); resistant: <i>S agalactiae</i> (group B)	132 133
“Bamboo spine” on x-ray	Ankylosing spondylitis (chronic inflammatory arthritis: HLA-B27)	442
Basophilic nuclear remnants in RBCs	Howell-Jolly bodies (due to splenectomy or nonfunctional spleen)	395
Basophilic stippling of RBCs	Lead poisoning or sideroblastic anemia	394
Bloody or yellow tap on lumbar puncture	Subarachnoid hemorrhage	483
“Boot-shaped” heart on x-ray	Tetralogy of Fallot (due to RVH)	288
Branching gram ⊕ rods with sulfur granules	<i>Actinomyces israelii</i>	125
Bronchogenic apical lung tumor on imaging	Pancoast tumor (can compress cervical sympathetic chain and cause Horner syndrome)	264 646
“Brown” tumor of bone	Hyperparathyroidism or osteitis fibrosa cystica (deposited hemosiderin from hemorrhage gives brown color)	434

LAB/DIAGNOSTIC FINDING	DIAGNOSIS/DISEASE	PAGE
Cardiomegaly with apical atrophy	Chagas disease ( <i>Trypanosoma cruzi</i> )	154
Cellular crescents in Bowman capsule	Rapidly progressive crescentic glomerulonephritis	564
“Chocolate cyst” of ovary	Endometriosis (frequently involves both ovaries)	610
Circular grouping of dark tumor cells surrounding pale neurofibrils	Homer-Wright rosettes (neuroblastoma, medulloblastoma)	498
Colonies of mucoid <i>Pseudomonas</i> in lungs	Cystic fibrosis (autosomal recessive mutation in <i>CFTR</i> gene → fat-soluble vitamin deficiency and mucous plugs)	56
↓ AFP in amniotic fluid/maternal serum	Down syndrome or other chromosomal abnormalities	598
Degeneration of dorsal column fibers	Tabes dorsalis (3° syphilis), subacute combined degeneration (dorsal columns, lateral corticospinal, spinocerebellar tracts affected)	143
“Delta wave” on EKG, short PR interval, supraventricular tachycardia	Wolff-Parkinson-White syndrome (Bundle of Kent bypasses AV node)	283
Depigmentation of neurons in substantia nigra	Parkinson disease (basal ganglia disorder: rigidity, resting tremor, bradykinesia)	490
Desquamated epithelium casts in sputum	Curschmann spirals (bronchial asthma; can result in whorled mucous plugs)	638
Disarrayed granulosa cells arranged around collections of eosinophilic fluid	Call-Exner bodies (granulosa cell tumor of the ovary)	611
Dysplastic squamous cervical cells with “raisinoid” nuclei and hyperchromasia	Koilocytes (HPV: predisposes to cervical cancer)	609
Electrical alternans (alternating amplitude on EKG)	Pericardial tamponade	300
Enlarged cells with intranuclear inclusion bodies	“Owl eye” appearance of CMV	161
Enlarged thyroid cells with ground-glass nuclei with central clearing	“Orphan Annie” eyes nuclei (papillary carcinoma of the thyroid)	330
Eosinophilic cytoplasmic inclusion in liver cell	Mallory body (alcoholic liver disease)	374
Eosinophilic cytoplasmic inclusion in neuron	Lewy body (Parkinson disease and Lewy body dementia)	490
Eosinophilic globule in liver	Councilman body (viral hepatitis, yellow fever), represents hepatocyte undergoing apoptosis	168
Eosinophilic inclusion bodies in cytoplasm of hippocampal and cerebellar neurons	Negri bodies of rabies	167
Extracellular amyloid deposition in gray matter of brain	Senile plaques (Alzheimer disease)	490
Giant B cells with bilobed nuclei with prominent inclusions (“owl’s eye”)	Reed-Sternberg cells (Hodgkin lymphoma)	407
Glomerulus-like structure surrounding vessel in germ cells	Schiller-Duval bodies (yolk sac tumor)	618
“Hair on end” (“Crew-cut”) appearance on x-ray	β-thalassemia, sickle cell disease (marrow expansion)	397
hCG elevated	Choriocarcinoma, hydatidiform mole (occurs with and without embryo, and multiple pregnancy)	598
Heart nodules (granulomatous)	Aschoff bodies (rheumatic fever)	129
Heterophile antibodies	Infectious mononucleosis (EBV)	161
Hexagonal, double-pointed, needle-like crystals in bronchial secretions	Bronchial asthma (Charcot-Leyden crystals: eosinophilic granules)	638

LAB/DIAGNOSTIC FINDING	DIAGNOSIS/DISEASE	PAGE
High level of D-dimers	DVT, PE, DIC	392
Hilar lymphadenopathy, peripheral granulomatous lesion in middle or lower lung lobes (can calcify)	Ghon complex (1° TB: <i>Mycobacterium bacilli</i> )	136
“Honeycomb lung” on x-ray or CT	Interstitial pulmonary fibrosis	639
Hypercoagulability (leading to migrating DVTs and vasculitis)	Trousseau syndrome (adenocarcinoma of pancreas or lung)	380
Hypersegmented neutrophils	Megaloblastic anemia (B <sub>12</sub> deficiency: neurologic symptoms; folate deficiency: no neurologic symptoms)	398
Hypertension, hypokalemia, metabolic alkalosis	1° hyperaldosteronism (Conn syndrome)	323
Hypochromic, microcytic anemia	Iron deficiency anemia, lead poisoning, thalassemia (fetal hemoglobin sometimes present)	396
Intranuclear eosinophilic droplet-like bodies	Cowdry type A bodies (HSV or VZV)	162
Iron-containing nodules in alveolar septum	Ferruginous bodies (asbestosis: ↑ chance of lung cancer)	641
Keratin pearls on a skin biopsy	Squamous cell carcinoma	454
Large granules in phagocytes, immunodeficiency	Chédiak-Higashi disease (congenital failure of phagolysosome formation)	113
“Lead pipe” appearance of colon on abdominal imaging	Ulcerative colitis (loss of haustra)	365
Linear appearance of IgG deposition on glomerular and alveolar basement membranes	Goodpasture syndrome	564
Low serum ceruloplasmin	Wilson disease (hepatolenticular degeneration)	378
“Lumpy bumpy” appearance of glomeruli on immunofluorescence	Poststreptococcal glomerulonephritis (due to deposition of IgG, IgM, and C3)	564
Lytic (“punched-out”) bone lesions on x-ray	Multiple myeloma	409
Mammary gland (“blue domed”) cyst	Fibrocystic change of the breast	615
Monoclonal antibody spike	<ul style="list-style-type: none"> <li>▪ Multiple myeloma (usually IgG or IgA)</li> <li>▪ Monoclonal gammopathy of undetermined significance (MGUS consequence of aging)</li> <li>▪ Waldenström (M protein = IgM) macroglobulinemia</li> <li>▪ Primary amyloidosis</li> </ul>	409
Mucin-filled cell with peripheral nucleus	“Signet ring” (gastric carcinoma)	362
Narrowing of bowel lumen on barium x-ray	“String sign” (Crohn disease)	365
Necrotizing vasculitis (lungs) and necrotizing glomerulonephritis	Granulomatosis with polyangiitis (Wegener; PR3-ANCA/c-ANCA) and Goodpasture syndrome (anti-basement membrane antibodies)	564
Needle-shaped, ⊖ birefringent crystals	Gout (monosodium urate crystals)	440
Nodular hyaline deposits in glomeruli	Kimmelstiel-Wilson nodules (diabetic nephropathy)	566
Novobiocin response	Sensitive: <i>S epidermidis</i> ; resistant: <i>S saprophyticus</i>	131
“Nutmeg” appearance of liver	Chronic passive congestion of liver due to right heart failure or Budd-Chiari syndrome	375
“Onion skin” periosteal reaction	Ewing sarcoma (malignant small blue cell tumor)	438
Optochin sensitivity	Sensitive: <i>S pneumoniae</i> ; resistant: viridans streptococci ( <i>S mutans</i> , <i>S sanguis</i> )	130
Podocyte fusion or “effacement” on electron microscopy	Minimal change disease (child with nephrotic syndrome)	566



LAB/DIAGNOSTIC FINDING	DIAGNOSIS/DISEASE	PAGE
Protein aggregates in neurons from hyperphosphorylation of tau protein	Neurofibrillary tangles (Alzheimer disease) and Pick bodies (Pick disease)	490
Psammoma bodies	Meningiomas, papillary thyroid carcinoma, mesothelioma, papillary serous carcinoma of the endometrium and ovary	220
Pseudopalisading tumor cells on brain biopsy	Glioblastoma multiforme	496
Raised periosteum (creating a “Codman triangle”)	Aggressive bone lesion (eg, osteosarcoma, Ewing sarcoma, osteomyelitis)	438
RBC casts in urine	Glomerulonephritis	562
Rectangular, crystal-like, cytoplasmic inclusions in Leydig cells	Reinke crystals (Leydig cell tumor)	619
Recurrent infections, eczema, thrombocytopenia	Wiskott-Aldrich syndrome	113
Renal epithelial casts in urine	Intrinsic renal failure (eg, ischemia or toxic injury)	571
Rhomboid crystals, ⊕ birefringent	Pseudogout (calcium pyrophosphate dihydrate crystals)	439
Rib notching (inferior surface, on x-ray)	Coarctation of the aorta	289
Ring-enhancing brain lesion on CT/MRI in AIDS	<i>Toxoplasma gondii</i> , CNS lymphoma	152
Sheets of medium-sized lymphoid cells with scattered pale, tingible body–laden macrophages (“starry sky” histology)	Burkitt lymphoma (t[8:14] c-myc activation, associated with EBV; “starry sky” made up of malignant cells)	408
Silver-staining spherical aggregation of tau proteins in neurons	Pick bodies (Pick disease: progressive dementia, changes in personality)	490
“Soap bubble” in femur or tibia on x-ray	Giant cell tumor of bone (generally benign)	438
“Spikes” on basement membrane, “dome-like” subepithelial deposits	Membranous nephropathy (nephrotic syndrome)	566
Stacks of RBCs	Rouleaux formation (high ESR, multiple myeloma)	409
“Steeple” sign on frontal CXR	Croup (parainfluenza virus)	166
Bacteria-covered vaginal epithelial cells	“Clue cells” ( <i>Gardnerella vaginalis</i> )	144
<i>Streptococcus bovis</i> bacteremia	Colon cancer	133
“Tennis racket”-shaped cytoplasmic organelles (EM) in Langerhans cells	Birbeck granules (Langerhans cell histiocytosis)	411
Thousands of polyps on colonoscopy	Familial adenomatous polyposis (autosomal dominant, mutation of APC gene)	370
Thrombi made of white/red layers	Lines of Zahn (arterial thrombus, layers of platelets/RBCs)	637
“Thumb sign” on lateral neck x-ray	Epiglottitis ( <i>Haemophilus influenzae</i> )	138
Thyroid-like appearance of kidney	Chronic pyelonephritis (usually due to recurrent infections)	570
“Tram-track” appearance of capillary loops of glomerular basement membranes on light microscopy	Membranoproliferative glomerulonephritis	564
Triglyceride accumulation in liver cell vacuoles	Fatty liver disease (alcoholic or metabolic syndrome)	374
↑ uric acid levels	Gout, Lesch-Nyhan syndrome, tumor lysis syndrome, loop and thiazide diuretics	439 440

LAB/DIAGNOSTIC FINDING	DIAGNOSIS/DISEASE	PAGE
“Waxy” casts with very low urine flow	Chronic end-stage renal disease	562
WBC casts in urine	Acute pyelonephritis	562
WBCs that look “smudged”	CLL (almost always B cell)	410
“Wire loop” glomerular capillary appearance on light microscopy	Diffuse proliferative glomerulonephritis (usually seen with lupus)	564
Yellowish CSF	Xanthochromia (eg, due to subarachnoid hemorrhage)	483

## ▶ CLASSIC/RELEVANT TREATMENTS

CONDITION	COMMON TREATMENT(S)	PAGE
Absence seizures	Ethosuximide	514
Acute gout attack	NSAIDs, colchicine, glucocorticoids	457
Acute promyelocytic leukemia (M3)	All- <i>trans</i> retinoic acid	410
ADHD	Methylphenidate, amphetamines, CBT, atomoxetine, guanfacine, clonidine	527 542
Alcoholism	Disulfiram, acamprosate, naltrexone, supportive care	541
Alcohol withdrawal	Long-acting benzodiazepines	528
Anorexia	Nutrition, psychotherapy, mirtazapine	537
Arrhythmia in damaged cardiac tissue	Class IB antiarrhythmic (lidocaine, mexiletine)	308
Benign prostatic hyperplasia	$\alpha_1$ -antagonists, $5\alpha$ -reductase inhibitors, PDE-5 inhibitors	619
Bipolar disorder	Mood stabilizers (eg, lithium, valproic acid, carbamazepine), atypical antipsychotics	531
Breast cancer in postmenopausal woman	Aromatase inhibitor (anastrozole)	621
Buerger disease	Smoking cessation	302
Bulimia nervosa	SSRIs	537
<i>Candida albicans</i>	Topical azoles (vaginitis); nystatin, fluconazole, caspofungin (oral/esophageal); fluconazole, caspofungin, amphotericin B (systemic)	149
Carcinoid syndrome	Octreotide	382
<i>Chlamydia trachomatis</i>	Doxycycline (+ ceftriaxone for gonorrhea coinfection), erythromycin eye drops (conjunctivitis prophylaxis in infants)	146
Chronic gout	Xanthine oxidase inhibitors (eg, allopurinol, febuxostat); pegloticase; probenecid	440
Chronic hepatitis B or C	IFN- $\alpha$ (HBV and HCV); ribavirin, simeprevir, sofosbuvir (HCV)	200
Chronic myelogenous leukemia	Imatinib	410
<i>Clostridium botulinum</i>	Antitoxin	134
<i>Clostridium difficile</i>	Oral metronidazole; if refractory, oral vancomycin	134

CONDITION	COMMON TREATMENT(S)	PAGE
<i>Clostridium tetani</i>	Antitoxin	134
CMV	Ganciclovir, foscarnet, cidofovir	198
Crohn disease	Corticosteroids, infliximab, azathioprine	365
<i>Cryptococcus neoformans</i>	Fluconazole (in AIDS patients)	195
Cyclophosphamide-induced hemorrhagic cystitis	Mesna	418
Depression	SSRIs (first-line)	531
Diabetes insipidus	Desmopressin (central); hydrochlorothiazide, indomethacin, amiloride (nephrogenic)	334
Diabetes mellitus type 1	Dietary intervention (low carbohydrate) + insulin replacement	340
Diabetes mellitus type 2	Dietary intervention, oral hypoglycemics, and insulin (if refractory)	340
Diabetic ketoacidosis	Fluids, insulin, K <sup>+</sup>	340
Drug of choice for anticoagulation during pregnancy	Heparin	413
Enterococci	Vancomycin, aminopenicillins/cephalosporins	184
Erectile dysfunction	Sildenafil, tadalafil, vardenafil	623
ER ⊕ breast cancer	Tamoxifen	621
Ethylene glycol/methanol intoxication	Fomepizole (alcohol dehydrogenase inhibitor)	239
<i>Haemophilus influenzae</i> (B)	Rifampin (prophylaxis)	138
Generalized anxiety disorder	SSRIs, SNRIs (first line); buspirone (second line)	533
Granulomatosis with polyangiitis (Wegener)	Cyclophosphamide, corticosteroids	302
Heparin reversal	Protamine sulfate	413
HER2/neu ⊕ breast cancer	Trastuzumab	421
Hyperaldosteronism	Spirolactone	576
Hypercholesterolemia	Statin (first-line)	306
Hypertriglyceridemia	Fibrate	306
Immediate anticoagulation	Heparin	413
Infertility	Leuprolide, GnRH (pulsatile), clomiphene	619 621
Influenza	Oseltamivir, zanamivir	197
Kawasaki disease	IVIG, high-dose aspirin	302
<i>Legionella pneumophila</i>	Macrolides (eg, azithromycin)	139
Long-term anticoagulation	Warfarin, dabigatran, rivaroxaban and apixaban	414
Malaria	Chloroquine, mefloquine, atovaquone/proguanil (for blood schizont), primaquine (for liver hypnozoite)	153
Malignant hyperthermia	Dantrolene	513
Medical abortion	Mifepristone	622
Migraine	Abortive therapies (eg, sumatriptan, NSAIDs); prophylaxis (eg, propranolol, topiramate, CCBs, amitriptyline)	504

CONDITION	COMMON TREATMENT(S)	PAGE
Multiple sclerosis	Disease-modifying therapies (eg, $\beta$ -interferon, natalizumab); for acute flares, use IV steroids	493
<i>Mycobacterium tuberculosis</i>	RIPE (rifampin, isoniazid, pyrazinamide, ethambutol)	192
<i>Neisseria gonorrhoeae</i>	Ceftriaxone (add doxycycline to cover likely concurrent <i>C trachomatis</i> )	138
<i>Neisseria meningitidis</i>	Penicillin/ceftriaxone, rifampin (prophylaxis)	138
Neural tube defect prevention	Prenatal folic acid	582
Osteomalacia/rickets	Vitamin D supplementation	66
Osteoporosis	Calcium/vitamin D supplementation (prophylaxis); bisphosphonates, PTH analogs, SERMs, calcitonin, denosumab (treatment)	66
Patent ductus arteriosus	Close with indomethacin; keep open with PGE analogs	289
Pheochromocytoma	$\alpha$ -antagonists (eg, phenoxybenzamine)	326
<i>Pneumocystis jirovecii</i>	TMP-SMX (prophylaxis and treatment in immunosuppressed patients)	194
Prolactinoma	Cabergoline/bromocriptine (dopamine agonists)	332
Prostate adenocarcinoma/uterine fibroids	Leuprolide, GnRH (continuous)	621
Prostate adenocarcinoma	Flutamide	623
<i>Pseudomonas aeruginosa</i>	Antipseudomonal penicillins, aminoglycosides, carbapenems	139
Pulmonary arterial hypertension (idiopathic)	Sildenafil, bosentan, epoprostenol	648
<i>Rickettsia rickettsii</i>	Doxycycline, chloramphenicol	145
Schizophrenia (negative symptoms)	Atypical antipsychotics	543
Schizophrenia (positive symptoms)	Typical and atypical antipsychotics	543
SIADH	Fluid restriction, IV hypertonic saline, conivaptan/tolvaptan, demeclocycline	334
Sickle cell disease	Hydroxyurea ( $\uparrow$ fetal hemoglobin)	400
<i>Sporothrix schenckii</i>	Itraconazole, oral potassium iodide	150
Stable angina	Sublingual nitroglycerin	305
<i>Staphylococcus aureus</i>	MSSA: nafcillin, oxacillin, dicloxacillin (antistaphylococcal penicillins); MRSA: vancomycin, daptomycin, linezolid, ceftaroline	184
<i>Streptococcus bovis</i>	Penicillin prophylaxis; evaluation for colon cancer if linked to endocarditis	133
<i>Streptococcus pneumoniae</i>	Penicillin/cephalosporin (systemic infection, pneumonia), vancomycin (meningitis)	132
<i>Streptococcus pyogenes</i>	Penicillin prophylaxis	194
Temporal arteritis	High-dose steroids	302
Tonic-clonic seizures	Levetiracetam, phenytoin, valproate, carbamazepine	510
<i>Toxoplasma gondii</i>	Sulfadiazine + pyrimethamine	152

CONDITION	COMMON TREATMENT(S)	PAGE
<i>Treponema pallidum</i>	Penicillin	182
<i>Trichomonas vaginalis</i>	Metronidazole (patient and partner)	177
Trigeminal neuralgia (tic douloureux)	Carbamazepine	514
Ulcerative colitis	5-ASA preparations (eg, mesalamine), 6-mercaptopurine, infliximab, colectomy	365
UTI prophylaxis	TMP-SMX	190
Warfarin reversal	Fresh frozen plasma (acute), vitamin K (non-acute)	414

### ► KEY ASSOCIATIONS

DISEASE/FINDING	MOST COMMON/IMPORTANT ASSOCIATIONS	PAGE
Actinic (solar) keratosis	Precursor to squamous cell carcinoma	454
Acute gastric ulcer associated with CNS injury	Cushing ulcer (↑ intracranial pressure stimulates vagal gastric H <sup>+</sup> secretion)	362
Acute gastric ulcer associated with severe burns	Curling ulcer (greatly reduced plasma volume results in sloughing of gastric mucosa)	362
Age ranges for patient with ALL/CLL/AML/CML	ALL: child, CLL: adult > 60, AML: adult ~ 65, CML: adult 45–85	410
Alternating areas of transmural inflammation and normal colon	Skip lesions (Crohn disease)	365
Aortic aneurysm, abdominal	Atherosclerosis	292
Aortic aneurysm, ascending or arch	3° syphilis (syphilitic aortitis), vasa vasorum destruction	292
Aortic aneurysm, thoracic	Marfan syndrome (idiopathic cystic medial degeneration)	292
Aortic dissection	Hypertension	293
Atrophy of the mammillary bodies	Wernicke encephalopathy (thiamine deficiency causing ataxia, ophthalmoplegia, and confusion)	481
Autosplenectomy (fibrosis and shrinkage)	Sickle cell disease (hemoglobin S)	400
Bacteria associated with gastritis, peptic ulcer disease, and gastric malignancies (eg, adenocarcinoma, MALToma)	<i>H pylori</i>	142
Bacterial meningitis (adults and elderly)	<i>S pneumoniae</i>	176
Bacterial meningitis (newborns and kids)	Group B streptococcus/ <i>E coli</i> / <i>Listeria monocytogenes</i> (newborns), <i>S pneumoniae</i> / <i>N meningitidis</i> (kids/teens)	176
Bilateral ovarian metastases from gastric carcinoma	Krukenberg tumor (mucin-secreting signet ring cells)	362
Bleeding disorder with GpIb deficiency	Bernard-Soulier syndrome (defect in platelet adhesion to von Willebrand factor)	405
Brain tumor (adults)	Supratentorial: metastasis, astrocytoma (including glioblastoma multiforme), meningioma, schwannoma	496
Brain tumor (kids)	Infratentorial: medulloblastoma (cerebellum) or supratentorial: craniopharyngioma	498
Breast cancer	Invasive ductal carcinoma	616

DISEASE/FINDING	MOST COMMON/IMPORTANT ASSOCIATIONS	PAGE
Breast mass	Fibrocystic change, carcinoma (in postmenopausal women)	613
Breast tumor (benign, young woman)	Fibroadenoma	615
Cardiac 1° tumor (kids)	Rhabdomyoma, often seen in tuberous sclerosis	301
Cardiac manifestation of lupus	Marantic/thrombotic endocarditis (nonbacterial)	299
Cardiac tumor (adults)	Metastasis, myxoma (90% in left atrium; “ball valve”)	301
Cerebellar tonsillar herniation	Chiari I malformation	462
Chronic arrhythmia	Atrial fibrillation (associated with high risk of emboli)	284
Chronic atrophic gastritis (autoimmune)	Predisposition to gastric carcinoma (can also cause pernicious anemia)	362
Clear cell adenocarcinoma of the vagina	DES exposure in utero	609
Congenital adrenal hyperplasia, hypotension	21-hydroxylase deficiency	318
Congenital cardiac anomaly	VSD	290
Congenital conjugated hyperbilirubinemia (black liver)	Dubin-Johnson syndrome (inability of hepatocytes to secrete conjugated bilirubin into bile)	377
Constrictive pericarditis	TB (developing world); idiopathic, viral illness (developed world)	300
Cretinism	Iodine deficit/congenital hypothyroidism	328
Cushing syndrome	<ul style="list-style-type: none"> <li>▪ Iatrogenic (from corticosteroid therapy)</li> <li>▪ Adrenocortical adenoma (secretes excess cortisol)</li> <li>▪ ACTH-secreting pituitary adenoma (Cushing disease)</li> <li>▪ Paraneoplastic (due to ACTH secretion by tumors)</li> </ul>	323
Cyanosis (early; less common)	Tetralogy of Fallot, transposition of great vessels, truncus arteriosus	288
Death in CML	Blast crisis	410
Death in SLE	Lupus nephropathy	443
Dementia	Alzheimer disease, multiple infarcts (vascular dementia)	490
Demyelinating disease in young women	Multiple sclerosis	493
DIC	Severe sepsis, obstetric complications, cancer, burns, trauma, major surgery, acute pancreatitis, APL	406
Diverticulum in pharynx	Zenker diverticulum (diagnosed by barium swallow)	367
Ejection click	Aortic stenosis	279
Esophageal cancer	Squamous cell carcinoma (worldwide); adenocarcinoma (US)	361
Food poisoning (exotoxin mediated)	<i>S aureus</i> , <i>B cereus</i>	174
Gastric cancer	Adenocarcinoma	362
Glomerulonephritis (adults)	Berger disease (IgA nephropathy)	564
Gynecologic malignancy	Endometrial carcinoma (most common in US); cervical carcinoma (most common worldwide)	608
Heart murmur, congenital	Mitral valve prolapse	279
Heart valve in bacterial endocarditis	Mitral > aortic (rheumatic fever), tricuspid (IV drug abuse)	299

DISEASE/FINDING	MOST COMMON/IMPORTANT ASSOCIATIONS	PAGE
Helminth infection (US)	<i>Ascaris lumbricoides</i>	155
Hematoma—epidural	Rupture of middle meningeal artery (trauma; lentiform shaped)	479
Hematoma—subdural	Rupture of bridging veins (crescent shaped)	479
Hemochromatosis	Multiple blood transfusions or hereditary <i>HFE</i> mutation (can result in heart failure, “bronze diabetes,” and ↑ risk of hepatocellular carcinoma)	378
Hepatocellular carcinoma	Cirrhotic liver (associated with hepatitis B and C and with alcoholism)	372
Hereditary bleeding disorder	von Willebrand disease	406
Hereditary harmless jaundice	Gilbert syndrome (benign congenital unconjugated hyperbilirubinemia)	377
HLA-B27	Psoriatic arthritis, ankylosing spondylitis, IBD-associated arthritis, reactive arthritis (formerly Reiter syndrome)	442
HLA-DR3	Diabetes mellitus type 1, SLE, Graves disease, Hashimoto thyroiditis (also associated with HLA-DR5), Addison disease	337
HLA-DR4	Diabetes mellitus type 1, rheumatoid arthritis, Addison disease	337
Holosystolic murmur	VSD, tricuspid regurgitation, mitral regurgitation	279
Hypercoagulability, endothelial damage, blood stasis	Virchow triad (↑ risk of thrombosis)	636
Hypertension, 2°	Renal artery stenosis, chronic kidney disease (eg, polycystic kidney disease, diabetic nephropathy), hyperaldosteronism	290
Hypoparathyroidism	Accidental excision during thyroidectomy	330
Hypopituitarism	Pituitary adenoma (usually benign tumor)	335
Infection 2° to blood transfusion	Hepatitis C	168
Infections in chronic granulomatous disease	<i>S aureus</i> , <i>E coli</i> , <i>Aspergillus</i> (catalase ⊕)	113
Intellectual disability	Down syndrome, fragile X syndrome	59
Kidney stones	<ul style="list-style-type: none"> <li>▪ Calcium = radiopaque</li> <li>▪ Struvite (ammonium) = radiopaque (formed by urease ⊕ organisms such as <i>Klebsiella</i>, <i>Proteus</i> species, and <i>S saprophyticus</i>)</li> <li>▪ Uric acid = radiolucent</li> <li>▪ Cystine = radiolucent</li> </ul>	567
Late cyanotic shunt (uncorrected left to right becomes right to left)	Eisenmenger syndrome (caused by ASD, VSD, PDA; results in pulmonary hypertension/polycythemia)	289
Liver disease	Alcoholic cirrhosis	374
Lysosomal storage disease	Gaucher disease	84
Malignancy associated with noninfectious fever	Hodgkin lymphoma	407
Malignancy (kids)	Leukemia, brain tumors	410 498
Metastases to bone	Prostate, breast > lung, thyroid, kidney	221

DISEASE/FINDING	MOST COMMON/IMPORTANT ASSOCIATIONS	PAGE
Metastases to brain	Lung > breast > prostate > melanoma > GI	221
Metastases to liver	Colon >> stomach > pancreas	221
Microcytic anemia	Iron deficiency	396
Mitochondrial inheritance	Disease occurs in both males and females, inherited through females only	55
Mitral valve stenosis	Rheumatic heart disease	279
Mixed (UMN and LMN) motor neuron disease	Amyotrophic lateral sclerosis	500
Myocarditis	Coxsackie B	145
Nephrotic syndrome (adults)	Membranous nephropathy	566
Nephrotic syndrome (kids)	Minimal change disease	566
Neuron migration failure	Kallmann syndrome (hypogonadotropic hypogonadism and anosmia)	604
Nosocomial pneumonia	<i>S aureus</i> , <i>Pseudomonas</i> , other enteric gram $\ominus$ rods	181
Obstruction of male urinary tract	BPH	568
Opening snap	Mitral stenosis	279
Opportunistic infection in AIDS	<i>Pneumocystis jirovecii</i> pneumonia	150
Osteomyelitis	<i>S aureus</i> (most common overall)	131
Osteomyelitis in sickle cell disease	<i>Salmonella</i>	176
Osteomyelitis with IV drug use	<i>Pseudomonas</i> , <i>Candida</i> , <i>S aureus</i>	176
Ovarian tumor (benign, bilateral)	Serous cystadenoma	610
Ovarian tumor (malignant)	Serous cystadenocarcinoma	611
Pancreatitis (acute)	Gallstones, alcohol	380
Pancreatitis (chronic)	Alcohol (adults), cystic fibrosis (kids)	380
Pelvic inflammatory disease	<i>C trachomatis</i> , <i>N gonorrhoeae</i>	138
Philadelphia chromosome t(9;22) ( <i>BCR-ABL</i> )	CML (may sometimes be associated with ALL/AML)	410
Pituitary tumor	Prolactinoma, somatotrophic adenoma	496
1° amenorrhea	Turner syndrome (45,XO or 45,XO/46,XX mosaic)	603
1° bone tumor (adults)	Multiple myeloma	409
1° hyperaldosteronism	Adrenal hyperplasia or adenoma	560
1° hyperparathyroidism	Adenomas, hyperplasia, carcinoma	332
1° liver cancer	Hepatocellular carcinoma (chronic hepatitis, cirrhosis, hemochromatosis, $\alpha_1$ -antitrypsin deficiency, Wilson disease)	372
Pulmonary hypertension	Idiopathic, heritable, left heart disease (eg, HF), lung disease (eg, COPD), hypoxemic vasoconstriction (eg, OSA), thromboembolic (eg, PE)	633
Recurrent inflammation/thrombosis of small/medium vessels in extremities	Buerger disease (strongly associated with tobacco)	302
Refractory peptic ulcers and high gastrin levels	Zollinger-Ellison syndrome (gastrinoma of duodenum or pancreas), associated with MEN1	338



DISEASE/FINDING	MOST COMMON/IMPORTANT ASSOCIATIONS	PAGE
Renal tumor	Renal cell carcinoma: associated with von Hippel-Lindau and cigarette smoking; paraneoplastic syndromes (EPO, renin, PTHrP, ACTH)	568
Right heart failure due to a pulmonary cause	Cor pulmonale	633
S3 heart sound	↑ ventricular filling pressure (eg, mitral regurgitation, HF), common in dilated ventricles	276
S4 heart sound	Stiff/hypertrophic ventricle (aortic stenosis, restrictive cardiomyopathy)	276
2° hyperparathyroidism	Hypocalcemia of chronic kidney disease	319 559
Sexually transmitted disease	<i>C trachomatis</i> (usually coinfects with <i>N gonorrhoeae</i> )	146
SIADH	Small cell carcinoma of the lung	647
Site of diverticula	Sigmoid colon	366
Sites of atherosclerosis	Abdominal aorta > coronary artery > popliteal artery > carotid artery	292
t(14;18)	Follicular lymphomas ( <i>BCL-2</i> activation, anti-apoptotic oncogene)	408
t(8;14)	Burkitt lymphoma ( <i>c-myc</i> fusion, transcription factor oncogene)	408
t(9;22)	Philadelphia chromosome, CML ( <i>BCR-ABL</i> activation, tyrosine kinase oncogene)	418
Temporal arteritis	Risk of ipsilateral blindness due to occlusion of ophthalmic artery; polymyalgia rheumatica	211
Testicular tumor	Seminoma (malignant, radiosensitive), ↑ placental ALP	618
Thyroid cancer	Papillary carcinoma (childhood irradiation)	330
Tumor in women	Leiomyoma (estrogen dependent, not precancerous)	612
Tumor of infancy	Strawberry hemangioma (grows rapidly and regresses spontaneously by childhood)	450
Tumor of the adrenal medulla (adults)	Pheochromocytoma (usually benign)	326
Tumor of the adrenal medulla (kids)	Neuroblastoma (malignant)	325
Type of Hodgkin lymphoma	Nodular sclerosing (vs mixed cellularity, lymphocytic predominance, lymphocytic depletion)	407
Type of non-Hodgkin lymphoma	Diffuse large B-cell lymphoma	408
UTI	<i>E coli</i> , <i>Staphylococcus saprophyticus</i> (young women)	140
Vertebral compression fracture	Osteoporosis (type I: postmenopausal woman; type II: elderly man or woman)	435
Viral encephalitis affecting temporal lobe	HSV-1	481
Vitamin deficiency (USA)	Folate (pregnant women are at high risk; body stores only 3- to 4-month supply; prevents neural tube defects)	64

▶ EQUATION REVIEW

TOPIC	EQUATION	PAGE
Sensitivity	$\text{Sensitivity} = \text{TP} / (\text{TP} + \text{FN})$	247
Specificity	$\text{Specificity} = \text{TN} / (\text{TN} + \text{FP})$	247
Positive predictive value	$\text{PPV} = \text{TP} / (\text{TP} + \text{FP})$	247
Negative predictive value	$\text{NPV} = \text{TN} / (\text{FN} + \text{TN})$	247
Odds ratio (for case-control studies)	$\text{OR} = \frac{a/c}{b/d} = \frac{ad}{bc}$	248
Relative risk	$\text{RR} = \frac{a/(a+b)}{c/(c+d)}$	248
Attributable risk	$\text{AR} = \frac{a}{a+b} - \frac{c}{c+d}$	248
Relative risk reduction	$\text{RRR} = 1 - \text{RR}$	248
Absolute risk reduction	$\text{ARR} = \frac{c}{c+d} - \frac{a}{a+b}$	248
Number needed to treat	$\text{NNT} = 1/\text{ARR}$	248
Number needed to harm	$\text{NNH} = 1/\text{AR}$	248
Hardy-Weinberg equilibrium	$p^2 + 2pq + q^2 = 1$ $p + q = 1$	53
Volume of distribution	$V_d = \frac{\text{amount of drug in the body}}{\text{plasma drug concentration}}$	225
Half-life	$t_{1/2} = \frac{0.693 \times V_d}{\text{CL}}$	225
Drug clearance	$\text{CL} = \frac{\text{rate of elimination of drug}}{\text{plasma drug concentration}} = V_d \times K_e$ (elimination constant)	225
Loading dose	$\text{LD} = \frac{C_p \times V_d}{F}$	225
Maintenance dose	$D = \frac{C_p \times \text{CL} \times \tau}{F}$	225
Cardiac output	$\text{CO} = \frac{\text{rate of O}_2 \text{ consumption}}{\text{arterial O}_2 \text{ content} - \text{venous O}_2 \text{ content}}$  $\text{CO} = \text{stroke volume} \times \text{heart rate}$	272  272
Mean arterial pressure	$\text{MAP} = \text{cardiac output} \times \text{total peripheral resistance}$  $\text{MAP} = \frac{2}{3} \text{diastolic} + \frac{1}{3} \text{systolic}$	272  272
Stroke volume	$\text{SV} = \text{EDV} - \text{ESV}$	273
Ejection fraction	$\text{EF} = \frac{\text{SV}}{\text{EDV}} = \frac{\text{EDV} - \text{ESV}}{\text{EDV}}$	273

TOPIC	EQUATION	PAGE
Resistance	$\text{Resistance} = \frac{\text{driving pressure } (\Delta P)}{\text{flow } (Q)} = \frac{8\eta \text{ (viscosity)} \times \text{length}}{\pi r^4}$	274
Capillary fluid exchange	$J_v = \text{net fluid flow} = K_f[(P_c - P_i) - \zeta(\pi_c - \pi_i)]$	287
Renal clearance	$C_x = U_x V/P_x$	552
Glomerular filtration rate	$\text{GFR} = U_{\text{inulin}} \times V/P_{\text{inulin}} = C_{\text{inulin}}$ $\text{GFR} = K_f [(P_{\text{GC}} - P_{\text{BS}}) - (\pi_{\text{GC}} - \pi_{\text{BS}})]$	552
Effective renal plasma flow	$\text{eRPF} = U_{\text{PAH}} \times \frac{V}{P_{\text{PAH}}} = C_{\text{PAH}}$	552
Renal blood flow	$\text{RBF} = \frac{\text{RPF}}{1 - \text{Hct}}$	552
Filtration fraction	$\text{FF} = \frac{\text{GFR}}{\text{RPF}}$	553
Henderson-Hasselbalch equation (for extracellular pH)	$\text{pH} = 6.1 + \log \frac{[\text{HCO}_3^-]}{0.03 P_{\text{CO}_2}}$	561
Winters formula	$P_{\text{CO}_2} = 1.5 [\text{HCO}_3^-] + 8 \pm 2$	561
Physiologic dead space	$V_D = V_T \times \frac{P_{\text{aCO}_2} - P_{\text{ECO}_2}}{P_{\text{aCO}_2}}$	630
Pulmonary vascular resistance	$\text{PVR} = \frac{P_{\text{pulm artery}} - P_{\text{L atrium}}}{\text{cardiac output}}$	634
Alveolar gas equation	$P_{\text{AO}_2} = P_{\text{IO}_2} - \frac{P_{\text{aCO}_2}}{R}$	634

# Top-Rated Review Resources

*“Some books are to be tasted, others to be swallowed, and some few to be chewed and digested.”*

—Sir Francis Bacon

*“Always read something that will make you look good if you die in the middle of it.”*

—P.J. O'Rourke

*“So many books, so little time.”*

—Frank Zappa

*“If one cannot enjoy reading a book over and over again, there is no use in reading it at all.”*

—Oscar Wilde

▶ How to Use the Database	672
▶ Question Banks	674
▶ Question Books	674
▶ Web and Mobile Apps	674
▶ Comprehensive	675
▶ Anatomy, Embryology, and Neuroscience	675
▶ Behavioral Science	676
▶ Biochemistry	676
▶ Cell Biology and Histology	677
▶ Microbiology and Immunology	677
▶ Pathology	677
▶ Pharmacology	678
▶ Physiology	679

## ▶ HOW TO USE THE DATABASE

This section is a database of top-rated basic science review books, sample examination books, software, websites, and apps that have been marketed to medical students studying for the USMLE Step 1. For each recommended resource, we list (where applicable) the **Title**, the **First Author** (or editor), the **Current Publisher**, the **Copyright Year**, the **Number of Pages**, the **Approximate List Price**, the **Format** of the resource, and the **Number of Test Questions**. Finally, each recommended resource receives a **Rating**. Within each section, resources are arranged first by Rating and then alphabetically by the first author within each Rating group.

For a complete list of resources, including summaries that describe their overall style and utility, go to [www.firstaidteam.com/bonus](http://www.firstaidteam.com/bonus).

A letter rating scale with six different grades reflects the detailed student evaluations for **Rated Resources**. Each rated resource receives a rating as follows:

A+	Excellent for boards review.
A A–	Very good for boards review; choose among the group.
B+ B	Good, but use only after exhausting better resources.
B–	Fair, but there are many better resources in the discipline; or low-yield subject material.

The Rating is meant to reflect the overall usefulness of the resource in helping medical students prepare for the USMLE Step 1. This is based on a number of factors, including:

- The cost
- The readability of the text
- The appropriateness and accuracy of the material
- The quality and number of sample questions
- The quality of written answers to sample questions
- The quality and appropriateness of the illustrations (eg, graphs, diagrams, photographs)
- The length of the text (longer is not necessarily better)
- The quality and number of other resources available in the same discipline
- The importance of the discipline for the USMLE Step 1

Please note that ratings do not reflect the quality of the resources for purposes other than reviewing for the USMLE Step 1. Many books with lower ratings are well written and informative but are not ideal for boards

preparation. We have not listed or commented on general textbooks available in the basic sciences.

Evaluations are based on the cumulative results of formal and informal surveys of thousands of medical students at many medical schools across the country. The ratings represent a consensus opinion, but there may have been a broad range of opinion or limited student feedback on any particular resource.

Please note that the data listed are subject to change in that:

- Publishers' prices change frequently.
- Bookstores often charge an additional markup.
- New editions come out frequently, and the quality of updating varies.
- The same book may be reissued through another publisher.

We actively encourage medical students and faculty to submit their opinions and ratings of these basic science review materials so that we may update our database. (See p. xvii, How to Contribute.) In addition, we ask that publishers and authors submit for evaluation review copies of basic science review books, including new editions and books not included in our database. We also solicit reviews of new books or suggestions for alternate modes of study that may be useful in preparing for the examination, such as flash cards, computer software, commercial review courses, apps, and Web sites.

#### **Disclaimer/Conflict of Interest Statement**

No material in this book, including the ratings, reflects the opinion or influence of the publisher. All errors and omissions will gladly be corrected if brought to the attention of the authors through our blog at [www.firstaidteam.com](http://www.firstaidteam.com). Please note that USMLE-Rx and the entire *First Aid for the USMLE* series are publications by the senior authors of this book; the following ratings are based solely on recommendations from the student authors of this book as well as data from the student survey and feedback forms.

## ▶ TOP-RATED REVIEW RESOURCES

## Question Banks

		AUTHOR	PUBLISHER	TYPE	PRICE
<b>A<sup>+</sup></b>	<i>UWorld Qbank</i>	UWorld	www.uworld.com	Test/2400 q	\$129–\$599
<b>A</b>	<i>USMLE-Rx Qmax</i>	MedIQ Learning	www.usmle-rx.com	Test/2300 q	\$99–\$299
<b>A<sup>-</sup></b>	<i>Kaplan Qbank</i>	Kaplan	www.kaptest.com	Test/2200 q	\$99–\$199
<b>B<sup>+</sup></b>	<i>USMLE Consult</i>	Elsevier	www.usmleconsult.com	Test/2500 q	\$75–\$185

## Question Books

		AUTHOR	PUBLISHER	TYPE	PRICE
<b>A<sup>-</sup></b>	<i>First Aid Q&amp;A for the USMLE Step 1</i>	Le	McGraw-Hill, 2012, 784 pages	Test/1000 q	\$46.00
<b>B<sup>+</sup></b>	<i>Kaplan USMLE Step 1 Qbook</i>	Kaplan	Kaplan, 2015, 456 pages	Test/850 q	\$49.99
<b>B<sup>+</sup></b>	<i>PreTest Clinical Vignettes for the USMLE Step 1</i>	McGraw-Hill	McGraw-Hill, 2010, 318 pages	Test/322 q	\$41.00

## Web and Mobile Apps

		AUTHOR	PUBLISHER	TYPE	PRICE
<b>A</b>	<i>Anki</i>		www.ankisrs.net	Flash cards	Free/\$24.99
<b>A</b>	<i>First Aid Step 1 Express</i>		www.usmle-rx.com	Review/Test	\$99–\$349
<b>A</b>	<i>SketchyMedical</i>		www.SketchyMedical.com	Review	\$169–\$249
<b>B<sup>+</sup></b>	<i>Cram Fighter</i>		www.cramfighter.com	Study plan	\$29–\$99
<b>B<sup>+</sup></b>	<i>Firecracker</i>	Firecracker Inc.	www.firecracker.me	Review/ Test/1500 q	\$300–\$660
<b>B<sup>+</sup></b>	<i>First Aid Step 1 Flash Facts</i>		https://www.usmle-rx.com	Flash cards	\$49–\$149
<b>B<sup>+</sup></b>	<i>Memorang</i>	Memorang Inc.	www.memorangapp.com	Flash cards	Free/\$99
<b>B<sup>+</sup></b>	<i>WebPath: The Internet Pathology Laboratory</i>		library.med.utah.edu/WebPath/	Review/ Test/1300 q	Free
<b>B</b>	<i>Blue Histology</i>		www.lab.anhb.uwa.edu.au/mb140	Review/Test	Free
<b>B</b>	<i>Dr. Najeeb Lectures</i>		www.drnajeeblectures.com	Review	\$49–\$69
<b>B</b>	<i>Medical School Pathology</i>		www.medicalschoolpathology.com	Review	Free
<b>B</b>	<i>Osmosis</i>		www.osmosis.org	Test	\$31–\$599
<b>B</b>	<i>Radiopaedia.org</i>		www.radiopaedia.org	Cases/Test	Free
<b>B</b>	<i>The Pathology Guy</i>	Friedlander	www.pathguy.com	Review	Free
<b>B</b>	<i>Picmonic</i>		www.picmonic.com	Review	\$24–\$399
<b>B</b>	<i>The Whole Brain Atlas</i>	Johnson	www.med.harvard.edu/aanlib/	Review	Free
<b>B<sup>-</sup></b>	<i>Digital Anatomist Project: Interactive Atlases</i>	University of Washington	www9.biostr.washington.edu/da.html	Review	Free

## Comprehensive

		AUTHOR	PUBLISHER	TYPE	PRICE
<b>A</b>	<i>First Aid for the Basic Sciences: General Principles</i>	Le	McGraw-Hill, 2011, 576 pages	Review	\$72.00
<b>A</b>	<i>First Aid for the Basic Sciences: Organ Systems</i>	Le	McGraw-Hill, 2011, 880 pages	Review	\$93.00
<b>A</b>	<i>medEssentials for the USMLE Step 1</i>	Manley	Kaplan, 2012, 588 pages	Review	\$54.99
<b>A<sup>-</sup></b>	<i>Crush Step 1: The Ultimate USMLE Step 1 Review</i>	O'Connell	Saunders, 2013, 680 pages	Review	\$41.95
<b>A<sup>-</sup></b>	<i>USMLE Step 1 Secrets in Color</i>	Brown	Elsevier, 2016, 800 pages	Review	\$42.99
<b>A<sup>-</sup></b>	<i>First Aid Cases for the USMLE Step 1</i>	Le	McGraw-Hill, 2012, 448 pages	Cases	\$50.00
<b>B<sup>+</sup></b>	<i>Step-Up to USMLE Step 1 2015</i>	Jenkins	Lippincott Williams & Wilkins, 2014, 528 pages	Review	\$54.99
<b>B<sup>+</sup></b>	<i>Cracking the USMLE Step 1</i>	Princeton Review	Princeton Review, 2013, 832 pages	Review	\$44.99
<b>B<sup>+</sup></b>	<i>USMLE Images for the Boards: A Comprehensive Image-Based Review</i>	Tully	Elsevier, 2012, 296 pages	Review	\$42.95
<b>B</b>	<i>Déjà Review: USMLE Step 1</i>	Naheedy	McGraw-Hill, 2010, 416 pages	Review	\$25.00
<b>B<sup>-</sup></b>	<i>USMLE Step 1 Made Ridiculously Simple</i>	Carl	MedMaster, 2015, 416 pages	Review/Test 100 q	\$29.95

## Anatomy, Embryology, and Neuroscience

		AUTHOR	PUBLISHER	TYPE	PRICE
<b>A<sup>-</sup></b>	<i>High-Yield Embryology</i>	Dudek	Lippincott Williams & Wilkins, 2013, 176 pages	Review	\$39.99
<b>A<sup>-</sup></b>	<i>High-Yield Neuroanatomy</i>	Fix	Lippincott Williams & Wilkins, 2015, 208 pages	Review/ Test/50 q	\$36.99
<b>A<sup>-</sup></b>	<i>Anatomy—An Essential Textbook</i>	Gilroy	Thieme, 2013, 504 pages	Text/ Test/400 q	\$44.99
<b>A<sup>-</sup></b>	<i>Atlas of Anatomy</i>	Gilroy	Thieme, 2016, 760 pages	Text	\$82.99
<b>B<sup>+</sup></b>	<i>High-Yield Gross Anatomy</i>	Dudek	Lippincott Williams & Wilkins, 2014, 320 pages	Review	\$39.99
<b>B<sup>+</sup></b>	<i>Clinical Anatomy Made Ridiculously Simple</i>	Goldberg	MedMaster, 2012, 175 pages	Review	\$29.95
<b>B<sup>+</sup></b>	<i>PreTest Neuroscience</i>	Siegel	McGraw-Hill, 2013, 412 pages	Test/500 q	\$39.00
<b>B<sup>+</sup></b>	<i>Crash Course: Anatomy</i>	Sternhouse	Elsevier, 2015, 288 pages	Review	\$44.99
<b>B<sup>+</sup></b>	<i>Déjà Review: Neuroscience</i>	Tremblay	McGraw-Hill, 2010, 266 pages	Review	\$25.00
<b>B</b>	<i>BRS Embryology</i>	Dudek	Lippincott Williams & Wilkins, 2014, 336 pages	Review/ Test/220 q	\$51.99
<b>B</b>	<i>Anatomy Flash Cards: Anatomy on the Go</i>	Gilroy	Thieme, 2013, 565 flash cards	Flash cards	\$59.99
<b>B</b>	<i>Clinical Neuroanatomy Made Ridiculously Simple</i>	Goldberg	MedMaster, 2014, 90 pages + CD-ROM	Review/Test/ Few q	\$25.95



**Anatomy, Embryology, and Neuroscience (continued)**

		AUTHOR	PUBLISHER	TYPE	PRICE
<b>B</b>	<i>Rapid Review: Gross and Developmental Anatomy</i>	Moore	Elsevier, 2010, 304 pages	Review/ Test/450 q	\$42.95
<b>B</b>	<i>Case Files: Anatomy</i>	Toy	McGraw-Hill, 2014, 416 pages	Cases	\$35.00
<b>B</b>	<i>Case Files: Neuroscience</i>	Toy	McGraw-Hill, 2014, 432 pages	Cases	\$35.00
<b>B<sup>-</sup></b>	<i>Gray's Anatomy for Students Flash Cards</i>	Drake	Elsevier, 2014, 350 flash cards	Flash cards	\$39.99
<b>B<sup>-</sup></b>	<i>Netter's Anatomy Flash Cards</i>	Hansen	Saunders, 2014, 674 flash cards	Flash cards	\$39.95

**Behavioral Science**

		AUTHOR	PUBLISHER	TYPE	PRICE
<b>A</b>	<i>High-Yield Behavioral Science</i>	Fadem	Lippincott Williams & Wilkins, 2012, 144 pages	Review	\$37.99
<b>A<sup>-</sup></b>	<i>BRS Behavioral Science</i>	Fadem	Lippincott Williams & Wilkins, 2016, 384 pages	Review/ Test/700 q	\$49.99
<b>A<sup>-</sup></b>	<i>High-Yield Biostatistics, Epidemiology, and Public Health</i>	Glaser	Lippincott Williams & Wilkins, 2013, 168 pages	Review	\$42.99
<b>A<sup>-</sup></b>	<i>Clinical Biostatistics and Epidemiology Made Ridiculously Simple</i>	Weaver	MedMaster, 2011, 104 pages	Review	\$22.95
<b>B<sup>+</sup></b>	<i>USMLE Medical Ethics</i>	Fischer	Kaplan, 2012, 216 pages	Cases	Variable
<b>B<sup>+</sup></b>	<i>Jekel's Epidemiology, Biostatistics, Preventive Medicine, and Public Health</i>	Katz	Saunders, 2013, 420 pages	Review/ Test/477 q	\$59.95

**Biochemistry**

		AUTHOR	PUBLISHER	TYPE	PRICE
<b>A<sup>-</sup></b>	<i>Lange Flash Cards Biochemistry and Genetics</i>	Baron	McGraw-Hill, 2013, 184 flash cards	Flash cards	\$40.00
<b>A<sup>-</sup></b>	<i>Rapid Review: Biochemistry</i>	Pelley	Elsevier, 2010, 208 pages	Review/ Test/350 q	\$42.95
<b>B<sup>+</sup></b>	<i>Lippincott's Illustrated Reviews: Biochemistry</i>	Ferrier	Lippincott Williams & Wilkins, 2013, 560 pages	Review/ Test/500 q	\$75.99
<b>B<sup>+</sup></b>	<i>Déjà Review: Biochemistry</i>	Manzoul	McGraw-Hill, 2010, 206 pages	Review	\$25.00
<b>B<sup>+</sup></b>	<i>Medical Biochemistry—An Illustrated Review</i>	Panini	Thieme, 2013, 441 pages	Review/ Test/400 q	\$39.99
<b>B<sup>+</sup></b>	<i>PreTest Biochemistry and Genetics</i>	Wilson	McGraw-Hill, 2013, 592 pages	Test/500 q	\$38.00
<b>B</b>	<i>Clinical Biochemistry Made Ridiculously Simple</i>	Goldberg	MedMaster, 2010, 95 pages + foldout	Review	\$24.95
<b>B</b>	<i>BRS Biochemistry, Molecular Biology, and Genetics</i>	Lieberman	Lippincott Williams & Wilkins, 2013, 432 pages	Review/Test	\$51.99
<b>B<sup>-</sup></b>	<i>Case Files: Biochemistry</i>	Toy	McGraw-Hill, 2014, 480 pages	Cases	\$35.00

**Cell Biology and Histology**

		AUTHOR	PUBLISHER	TYPE	PRICE
<b>A<sup>-</sup></b>	<i>High-Yield Cell and Molecular Biology</i>	Dudek	Lippincott Williams & Wilkins, 2010, 151 pages	Review	\$37.99
<b>B</b>	<i>Elsevier's Integrated Review: Genetics</i>	Adkison	Elsevier, 2011, 272 pages	Review	\$42.95
<b>B</b>	<i>BRS Cell Biology and Histology</i>	Gartner	Lippincott Williams & Wilkins, 2014, 432 pages	Review/Test/320 q	\$49.99
<b>B</b>	<i>Crash Course: Cell Biology and Genetics</i>	Stubbs	Elsevier, 2015, 216 pages	Review	\$46.99
<b>B<sup>-</sup></b>	<i>Wheater's Functional Histology</i>	Young	Elsevier, 2013, 464 pages	Text	\$82.95

**Microbiology and Immunology**

		AUTHOR	PUBLISHER	TYPE	PRICE
<b>A</b>	<i>Déjà Review: Microbiology &amp; Immunology</i>	Chen	McGraw-Hill, 2010, 432 pages	Review	\$25.00
<b>A</b>	<i>Clinical Microbiology Made Ridiculously Simple</i>	Gladwin	MedMaster, 2015, 400 pages	Review	\$36.95
<b>A</b>	<i>Lange Microbiology &amp; Infectious Diseases Flash Cards</i>	Somers	McGraw-Hill, 2010, 189 flash cards	Flash cards	\$46.00
<b>A<sup>-</sup></b>	<i>Basic Immunology</i>	Abbas	Elsevier, 2015, 352 pages	Review	\$69.99
<b>A<sup>-</sup></b>	<i>Microcards: Microbiology Flash Cards</i>	Harpavat	Lippincott Williams & Wilkins, 2015, 312 flash cards	Flash cards	\$49.99
<b>A<sup>-</sup></b>	<i>Medical Microbiology and Immunology Flash Cards</i>	Rosenthal	Elsevier, 2016, 384 flash cards	Flash cards	\$39.99
<b>B<sup>+</sup></b>	<i>Elsevier's Integrated Immunology and Microbiology</i>	Actor	Elsevier, 2011, Kindle edition	Review	\$38.99
<b>B<sup>+</sup></b>	<i>Lippincott's Illustrated Reviews: Immunology</i>	Doan	Lippincott Williams & Wilkins, 2012, 384 pages	Review/Test/Few q	\$67.99
<b>B<sup>+</sup></b>	<i>Lippincott's Illustrated Reviews: Microbiology</i>	Harvey	Lippincott Williams & Wilkins, 2012, 448 pages	Review/Test/Few q	\$67.99
<b>B<sup>+</sup></b>	<i>Review of Medical Microbiology and Immunology</i>	Levinson	McGraw-Hill, 2016, 832 pages	Review/Test/654 q	\$64.00
<b>B</b>	<i>Case Studies in Immunology: Clinical Companion</i>	Geha	Garland Science, 2016, 358 pages	Cases	\$59.00
<b>B</b>	<i>Pretest: Microbiology</i>	Kettering	McGraw-Hill, 2013, 480 pages	Test/500 q	\$38.00
<b>B</b>	<i>Rapid Review: Microbiology and Immunology</i>	Rosenthal	Elsevier, 2010, 240 pages	Review/Test/400 q	\$42.95
<b>B</b>	<i>Case Files: Microbiology</i>	Toy	McGraw-Hill, 2014, 416 pages	Cases	\$36.00

**Pathology**

		AUTHOR	PUBLISHER	TYPE	PRICE
<b>A<sup>+</sup></b>	<i>Pathoma: Fundamentals of Pathology</i>	Sattar	Pathoma, 2016, 218 pages	Review/Lecture	\$82.95
<b>A</b>	<i>Rapid Review: Pathology</i>	Goljan	Elsevier, 2013, 784 pages	Review/Test/400 q	\$55.95

**Pathology (continued)**

		AUTHOR	PUBLISHER	TYPE	PRICE
<b>A<sup>-</sup></b>	<i>Lange Pathology Flash Cards</i>	Baron	McGraw-Hill, 2013, 300 flash cards	Flash cards	\$41.00
<b>A<sup>-</sup></b>	<i>Déjà Review: Pathology</i>	Davis	McGraw-Hill, 2010, 474 pages	Review	\$25.00
<b>A<sup>-</sup></b>	<i>Lippincott's Illustrated Q&amp;A Review of Rubin's Pathology</i>	Fenderson	Lippincott Williams & Wilkins, 2010, 336 pages	Test/1000 q	\$59.99
<b>A<sup>-</sup></b>	<i>Robbins and Cotran Review of Pathology</i>	Klatt	Elsevier, 2014, 504 pages	Test/1100 q	\$54.99
<b>A<sup>-</sup></b>	<i>BRS Pathology</i>	Schneider	Lippincott Williams & Wilkins, 2013, 480 pages	Review/ Test/450 q	\$51.99
<b>A<sup>-</sup></b>	<i>Crash Course: Pathology</i>	Xiu	Elsevier, 2015, 356 pages	Review	\$44.99
<b>B</b>	<i>PreTest Pathology</i>	Brown	McGraw-Hill, 2010, 612 pages	Test/500 q	\$39.00
<b>B</b>	<i>High-Yield Histopathology</i>	Dudek	Lippincott Williams & Wilkins, 2016, 350 pages	Review	\$35.99
<b>B</b>	<i>Pathophysiology of Disease: Introduction to Clinical Medicine</i>	McPhee	McGraw-Hill, 2014, 784 pages	Text	\$80.00
<b>B</b>	<i>Haematology at a Glance</i>	Mehta	Blackwell Science, 2014, 136 pages	Review	\$48.95
<b>B</b>	<i>Pocket Companion to Robbins and Cotran Pathologic Basis of Disease</i>	Mitchell	Elsevier, 2016, 896 pages	Review	\$39.99

**Pharmacology**

		AUTHOR	PUBLISHER	TYPE	PRICE
<b>A<sup>-</sup></b>	<i>Lange Pharmacology Flash Cards</i>	Baron	McGraw-Hill, 2013, 230 flash cards	Flash cards	\$41.00
<b>A<sup>-</sup></b>	<i>Master the Boards USMLE Step 1 Pharmacology Flashcards</i>	Fischer	Kaplan, 2015, 408 flash cards	Flash cards	\$54.99
<b>A<sup>-</sup></b>	<i>Déjà Review: Pharmacology</i>	Gleason	McGraw-Hill, 2010, 240 pages	Review	\$25.00
<b>A<sup>-</sup></b>	<i>Lippincott's Illustrated Reviews: Pharmacology</i>	Harvey	Lippincott Williams & Wilkins, 2014, 680 pages	Review/ Test/380 q	\$71.99
<b>A<sup>-</sup></b>	<i>Pharm Cards: Review Cards for Medical Students</i>	Johannsen	Lippincott Williams & Wilkins, 2010, 240 flash cards	Flash cards	\$49.99
<b>B<sup>+</sup></b>	<i>Crash Course: Pharmacology</i>	Battista	Elsevier, 2015, 236 pages	Review	\$44.99
<b>B<sup>+</sup></b>	<i>Pharmacology Flash Cards</i>	Brenner	Elsevier, 2012, 200 flash cards	Flash cards	\$39.95
<b>B<sup>+</sup></b>	<i>Elsevier's Integrated Pharmacology</i>	Kester	Elsevier, 2011, 264 pages	Review	\$42.95
<b>B<sup>+</sup></b>	<i>Rapid Review: Pharmacology</i>	Pazdernik	Elsevier, 2010, 360 pages	Review/ Test/450 q	\$42.95
<b>B<sup>+</sup></b>	<i>BRS Pharmacology</i>	Rosenfeld	Lippincott Williams & Wilkins, 2013, 384 pages	Review/ Test/200 q	\$51.99
<b>B</b>	<i>PreTest Pharmacology</i>	Shlafer	McGraw-Hill, 2013, 624 pages	Test/500 q	\$38.00
<b>B</b>	<i>Case Files: Pharmacology</i>	Toy	McGraw-Hill, 2013, 464 pages	Cases	\$35.00
<b>B</b>	<i>Katzung &amp; Trevor's Pharmacology: Examination and Board Review</i>	Trevor	McGraw-Hill, 2015, 592 pages	Review/ Test/1000 q	\$54.00

**Physiology**

		AUTHOR	PUBLISHER	TYPE	PRICE
<b>A<sup>+</sup></b>	<i>BRS Physiology</i>	Costanzo	Lippincott Williams & Wilkins, 2014, 328 pages	Review/ Test/350 q	\$53.99
<b>A</b>	<i>Acid-Base, Fluids, and Electrolytes Made Ridiculously Simple</i>	Preston	MedMaster, 2011, 156 pages	Review	\$22.95
<b>A<sup>-</sup></b>	<i>Physiology</i>	Costanzo	Saunders, 2013, 520 pages	Text	\$62.95
<b>A<sup>-</sup></b>	<i>Color Atlas of Physiology</i>	Silbernagl	Thieme, 2015, 472 pages	Review	\$49.99
<b>B<sup>+</sup></b>	<i>BRS Physiology Cases and Problems</i>	Costanzo	Lippincott Williams & Wilkins, 2012, 368 pages	Cases	\$51.99
<b>B<sup>+</sup></b>	<i>Déjà Review: Physiology</i>	Gould	McGraw-Hill, 2010, 298 pages	Review	\$25.00
<b>B<sup>+</sup></b>	<i>PreTest Physiology</i>	Metting	McGraw-Hill, 2013, 528 pages	Test/500 q	\$38.00
<b>B</b>	<i>Rapid Review: Physiology</i>	Brown	Elsevier, 2011, 288 pages	Test/350 q	\$42.95
<b>B</b>	<i>Vander's Renal Physiology</i>	Eaton	McGraw-Hill, 2013, 224 pages	Text	\$47.00
<b>B</b>	<i>Endocrine Physiology</i>	Molina	McGraw-Hill, 2013, 320 pages	Review	\$50.00
<b>B</b>	<i>Netter's Physiology Flash Cards</i>	Mulrone	Saunders, 2015, 200+ flash cards	Flash cards	\$39.99
<b>B</b>	<i>Pulmonary Pathophysiology: The Essentials</i>	West	Lippincott Williams & Wilkins, 2012, 208 pages	Review/ Test/50 q	\$52.99



## SECTION IV

# Abbreviations and Symbols

ABBREVIATION	MEANING
⊕	positive
⊖	negative
1°	primary
2°	secondary
3°	tertiary
1st MC*	1st metacarpal
A-a	alveolar-arterial [gradient]
AA	Alcoholics Anonymous, amyloid A
AAMC	Association of American Medical Colleges
Aao*	ascending aorta
Ab	antibody
ABP	androgen-binding protein
AC	adenyl cyclase
ACA	anterior cerebral artery
Acetyl-CoA	acetyl coenzyme A
ACD	anemia of chronic disease
ACE	angiotensin-converting enzyme
ACh	acetylcholine
AChE	acetylcholinesterase
ACL	anterior cruciate ligament
ACom	anterior communicating [artery]
ACTH	adrenocorticotrophic hormone
AD*	Alzheimer dementia
ADA	adenosine deaminase, Americans with Disabilities Act
ADH	antidiuretic hormone
ADHD	attention-deficit hyperactivity disorder
ADP	adenosine diphosphate
ADPKD	autosomal-dominant polycystic kidney disease
AFP	α-fetoprotein
Ag	antigen, silver
AICA	anterior inferior cerebellar artery
AIDS	acquired immunodeficiency syndrome
AIHA	autoimmune hemolytic anemia
AKT	protein kinase B
AL	amyloid light [chain]
ALA	aminolevulinatase
ALL	acute lymphoblastic (lymphocytic) leukemia
ALP	alkaline phosphatase
α <sub>1</sub> , α <sub>2</sub>	sympathetic receptors
ALS	amyotrophic lateral sclerosis
ALT	alanine transaminase
AMA	American Medical Association, antimitochondrial antibody
AML	acute myelogenous (myeloid) leukemia

ABBREVIATION	MEANING
AMP	adenosine monophosphate
ANA	antinuclear antibody
ANCA	antineutrophil cytoplasmic antibody
ANOVA	analysis of variance
ANP	atrial natriuretic peptide
ANS	autonomic nervous system
Ant*	anterior
anti-CCP	anti-cyclic citrullinated peptide
Ao*	aorta
AOA	American Osteopathic Association
AP	action potential, A & P [ribosomal binding sites]
APAF-1	apoptotic protease activating factor 1
APC	antigen-presenting cell, activated protein C
Apo	apolipoprotein
APP	amyloid precursor protein
APRT	adenine phosphoribosyltransferase
APSAC	anistreplase
aPTT	activated partial thromboplastin time
APUD	amine precursor uptake decarboxylase
AR	attributable risk, autosomal recessive, aortic regurgitation
ara-C	arabinofuranosyl cytidine (cytarabine)
ARB	angiotensin receptor blocker
ARDS	acute respiratory distress syndrome
Arg	arginine
ARMD	age-related macular degeneration
ARPKD	autosomal-recessive polycystic kidney disease
AS	aortic stenosis
ASA	anterior spinal artery
ASD	atrial septal defect
ASO	anti-streptolysin O
AST	aspartate transaminase
AT	angiotensin, antithrombin
ATCase	aspartate transcarbamoylase
ATN	acute tubular necrosis
ATP	adenosine triphosphate
ATPase	adenosine triphosphatase
ATTR	transthyretin-mediated amyloidosis
AV	atrioventricular
AZT	azidothymidine
β <sub>1</sub> , β <sub>2</sub>	sympathetic receptors
BAL	British anti-Lewisite [dimercaprol]
BCG	bacille Calmette-Guérin
BH <sub>4</sub>	tetrahydrobiopterin
BIMS	Biometric Identity Management System

\*Image abbreviation only

ABBREVIATION	MEANING
BM	basement membrane
BMI	body-mass index
BMR	basal metabolic rate
BOOP	bronchiolitis obliterans organizing pneumonia
BP	bisphosphate, blood pressure
BPG	bisphosphoglycerate
BPH	benign prostatic hyperplasia
BT	bleeding time
BUN	blood urea nitrogen
Ca*	capillary
Ca <sup>2+</sup>	calcium ion
CAD	coronary artery disease
CAF	common application form
CALLA	common acute lymphoblastic leukemia antigen
cAMP	cyclic adenosine monophosphate
CBG	corticosteroid-binding globulin
Cbl	cobalamin
Cbm*	cerebellum
CBSE	Comprehensive Basic Science Examination
CBSSA	Comprehensive Basic Science Self-Assessment
CBT	computer-based test, cognitive behavioral therapy
CC*	corpus callosum
CCA*	common carotid artery
CCK	cholecystokinin
CCS	computer-based case simulation
CD	cluster of differentiation
CDK	cyclin-dependent kinase
cDNA	complementary deoxyribonucleic acid
CEA	carcinoembryonic antigen
CETP	cholesterol-ester transfer protein
CF	cystic fibrosis
CFTR	cystic fibrosis transmembrane conductance regulator
CFX	circumflex [artery]
CGD	chronic granulomatous disease
cGMP	cyclic guanosine monophosphate
CGN	<i>cis</i> -Golgi network
C <sub>H</sub> <sup>1</sup> -C <sub>H</sub> <sup>3</sup>	constant regions, heavy chain [antibody]
ChAT	choline acetyltransferase
CHD*	common hepatic duct
χ <sup>2</sup>	chi-squared
CI	confidence interval
CIN	candidate identification number, carcinoma in situ, cervical intraepithelial neoplasia
CIS	Communication and Interpersonal Skills
CK	clinical knowledge, creatine kinase
CK-MB	creatine kinase, MB fraction
C <sub>L</sub>	constant region, light chain [antibody]
CL	clearance
Cl <sup>-</sup>	chloride ion
CLL	chronic lymphocytic leukemia
CMC	carpometacarpal (joint)
CML	chronic myelogenous (myeloid) leukemia
CMV	cytomegalovirus
CN	cranial nerve

ABBREVIATION	MEANING
CN <sup>-</sup>	cyanide ion
CNS	central nervous system
CNV	copy number variation
CO	carbon monoxide, cardiac output
CO <sub>2</sub>	carbon dioxide
CoA	coenzyme A
COL1A1	collagen, type I, alpha 1
COL1A2	collagen, type I, alpha 2
COMT	catechol-O-methyltransferase
COOH	carboxyl group
COP	coat protein
COPD	chronic obstructive pulmonary disease
CoQ	coenzyme Q
COX	cyclooxygenase
C <sub>p</sub>	plasma concentration
CPAP	continuous positive airway pressure
CPK	creatine phosphokinase
CPR	cardiopulmonary resuscitation
Cr	creatinine
CRC	colorectal cancer
CREST	calcinosis, Raynaud phenomenon, esophageal dysfunction, sclerosis, and telangiectasias [syndrome]
CRH	corticotropin-releasing hormone
CRP	C-reactive protein
CS	clinical skills
C-section	cesarean section
CSF	cerebrospinal fluid
CT	computed tomography
CTP	cytidine triphosphate
CVA	cerebrovascular accident
CVID	common variable immunodeficiency
CXR	chest x-ray
Cys	cysteine
DAF	decay-accelerating factor
DAG	diacylglycerol
dATP	deoxyadenosine triphosphate
DCIS	ductal carcinoma in situ
DCT	distal convoluted tubule
ddC	dideoxycytidine [zalcitabine]
ddI	didanosine
DES	diethylstilbestrol
DHAP	dihydroxyacetone phosphate
DHB	dihydrobiopterin
DHEA	dehydroepiandrosterone
DHF	dihydrofolic acid
DHS	Department of Homeland Security
DHT	dihydrotestosterone
DI	diabetes insipidus
DIC	disseminated intravascular coagulation
DIP	distal interphalangeal [joint]
DKA	diabetic ketoacidosis
Dlco	diffusing capacity for carbon monoxide
DM	diabetes mellitus
DNA	deoxyribonucleic acid
DNR	do not resuscitate

\*Image abbreviation only

ABBREVIATION	MEANING
dNTP	deoxynucleotide triphosphate
DO	doctor of osteopathy
DPGN	diffuse proliferative glomerulonephritis
DPM	doctor of podiatric medicine
DPP-4	dipeptidyl peptidase-4
DPPC	dipalmitoylphosphatidylcholine
DS	double stranded
dsDNA	double-stranded deoxyribonucleic acid
dsRNA	double-stranded ribonucleic acid
d4T	didehydrodeoxythymidine [stavudine]
dTMP	deoxythymidine monophosphate
DTR	deep tendon reflex
DTs	delirium tremens
dUDP	deoxyuridine diphosphate
dUMP	deoxyuridine monophosphate
DVT	deep venous thrombosis
E*	esophagitis, esophagus
EBV	Epstein-Barr virus
EC	ejection click
ECA*	external carotid artery
ECF	extracellular fluid
ECFMG	Educational Commission for Foreign Medical Graduates
ECCG	electrocardiogram
ECL	enterochromaffin-like [cell]
ECM	extracellular matrix
ECT	electroconvulsive therapy
ED <sub>50</sub>	median effective dose
EDRF	endothelium-derived relaxing factor
EDTA	ethylenediamine tetra-acetic acid
EDV	end-diastolic volume
EEG	electroencephalogram
EF	ejection fraction
EGF	epidermal growth factor
EHEC	enterohemorrhagic <i>E coli</i>
ELISA	enzyme-linked immunosorbent assay
EM	electron micrograph/microscopy
EMB	eosin–methylene blue
Epi	epinephrine
EPO	erythropoietin
EPS	extrapyramidal system
ER	endoplasmic reticulum, estrogen receptor
ERAS	Electronic Residency Application Service
ERCP	endoscopic retrograde cholangiopancreatography
ERP	effective refractory period
eRPF	effective renal plasma flow
ERT	estrogen replacement therapy
ERV	expiratory reserve volume
ESR	erythrocyte sedimentation rate
ESRD	end-stage renal disease
ESV	end-systolic volume
ETEC	enterotoxigenic <i>E coli</i>
EtOH	ethyl alcohol
EV	esophageal vein
F	bioavailability

ABBREVIATION	MEANING
FA	fatty acid
Fab	fragment, antigen-binding
FAD	flavin adenine dinucleotide
FAD <sup>+</sup>	oxidized flavin adenine dinucleotide
FADH <sub>2</sub>	reduced flavin adenine dinucleotide
FAP	familial adenomatous polyposis
F1,6BP	fructose-1,6-bisphosphate
F2,6BP	fructose-2,6-bisphosphate
FBPase	fructose biphosphatase
Fc	fragment, crystallizable
FcR	Fc receptor
5f-dUMP	5-fluorodeoxyuridine monophosphate
Fe <sup>2+</sup>	ferrous ion
Fe <sup>3+</sup>	ferric ion
Fem*	femur
FENa	excreted fraction of filtered sodium
FEV <sub>1</sub>	forced expiratory volume in 1 second
FF	filtration fraction
FFA	free fatty acid
FGF	fibroblast growth factor
FGFR	fibroblast growth factor receptor
FISH	fluorescence in situ hybridization
FKBP	FK506 binding protein
FLAIR	fluid-attenuated inversion recovery
f-met	formylmethionine
FMG	foreign medical graduate
FMN	flavin mononucleotide
FN	false negative
FNHTR	febrile nonhemolytic transfusion reaction
FP	false positive
F1P	fructose-1-phosphate
F6P	fructose-6-phosphate
FRC	functional residual capacity
FSH	follicle-stimulating hormone
FSMB	Federation of State Medical Boards
FTA-ABS	fluorescent treponemal antibody—absorbed
FTD*	frontotemporal dementia
5-FU	5-fluorouracil
FVC	forced vital capacity
GABA	γ-aminobutyric acid
GAG	glycosaminoglycan
Gal	galactose
GBM	glomerular basement membrane
GC	glomerular capillary
G-CSF	granulocyte colony-stimulating factor
GERD	gastroesophageal reflux disease
GFAP	glial fibrillary acid protein
GFR	glomerular filtration rate
GGT	γ-glutamyl transpeptidase
GH	growth hormone
GHB	γ-hydroxybutyrate
GHRH	growth hormone–releasing hormone
G <sub>1</sub>	G protein, I polypeptide
GI	gastrointestinal

\*Image abbreviation only



ABBREVIATION	MEANING
GIP	gastric inhibitory peptide
GIST	gastrointestinal stromal tumor
GLUT	glucose transporter
GM	granulocyte macrophage
GM-CSF	granulocyte-macrophage colony stimulating factor
GMP	guanosine monophosphate
GnRH	gonadotropin-releasing hormone
GP	glycoprotein
G3P	glucose-3-phosphate
G6P	glucose-6-phosphate
G6PD	glucose-6-phosphate dehydrogenase
GPe	globus pallidus externa
GPi	globus pallidus interna
GPI	glycosyl phosphatidylinositol
GRP	gastrin-releasing peptide
G <sub>S</sub>	G protein, S polypeptide
GS	glycogen synthase
GSH	reduced glutathione
GSSG	oxidized glutathione
GTP	guanosine triphosphate
GTPase	guanosine triphosphatase
GU	genitourinary
H*	heterochromatin
H <sup>+</sup>	hydrogen ion
H <sub>1</sub> , H <sub>2</sub>	histamine receptors
H <sub>2</sub> S	hydrogen sulfide
HAART	highly active antiretroviral therapy
HAV	hepatitis A virus
HAVAb	hepatitis A antibody
Hb	hemoglobin
Hb <sup>+</sup>	oxidized hemoglobin
Hb <sup>-</sup>	ionized hemoglobin
HBeAb	hepatitis B core antibody
HBeAg	hepatitis B core antigen
HBeAb	hepatitis B early antibody
HBeAg	hepatitis B early antigen
HBsAb	hepatitis B surface antibody
HBsAg	hepatitis B surface antigen
HbCO <sub>2</sub>	carbaminohemoglobin
HBV	hepatitis B virus
HCC	hepatocellular carcinoma
hCG	human chorionic gonadotropin
HCO <sub>3</sub> <sup>-</sup>	bicarbonate
Hct	hematocrit
HCTZ	hydrochlorothiazide
HCV	hepatitis C virus
HDL	high-density lipoprotein
HDV	hepatitis D virus
H&E	hematoxylin and eosin
HEV	hepatitis E virus
HF	heart failure
Hfr	high-frequency recombination [cell]
HGPRT	hypoxanthine-guanine phosphoribosyltransferase
HHb	human hemoglobin

ABBREVIATION	MEANING
HHV	human herpesvirus
5-HIAA	5-hydroxyindoleacetic acid
HIE	hypoxic ischemic encephalopathy
His	histidine
HIT	heparin-induced thrombocytopenia
HIV	human immunodeficiency virus
HL	hepatic lipase
HLA	human leukocyte antigen
HMG-CoA	hydroxymethylglutaryl-coenzyme A
HMP	hexose monophosphate
HMSN	hereditary motor and sensory neuropathy
HMWK	high-molecular-weight kininogen
HNPPC	hereditary nonpolyposis colorectal cancer
hnRNA	heterogeneous nuclear ribonucleic acid
H <sub>2</sub> O	water
H <sub>2</sub> O <sub>2</sub>	hydrogen peroxide
HPA	hypothalamic-pituitary-adrenal [axis]
HPL	human placental lactogen
HPO	hypothalamic-pituitary-ovarian [axis]
HPV	human papillomavirus
HR	heart rate
HRE	hormone receptor element
HSV	herpes simplex virus
5-HT	5-hydroxytryptamine (serotonin)
HTLV	human T-cell leukemia virus
HTN	hypertension
HTR	hemolytic transfusion reaction
HUS	hemolytic-uremic syndrome
HVA	homovanillic acid
HZV	herpes zoster virus
IBD	inflammatory bowel disease
IBS	irritable bowel syndrome
IC	inspiratory capacity, immune complex
I <sub>Ca</sub>	calcium current [heart]
I <sub>f</sub>	funny current [heart]
ICA	internal carotid artery
ICAM	intracellular adhesion molecule
ICD	implantable cardioverter defibrillator
ICE	Integrated Clinical Encounter
ICF	intracellular fluid
ICP	intracranial pressure
ID	identification
ID <sub>50</sub>	median infective dose
IDL	intermediate-density lipoprotein
I/E	inspiratory/expiratory [ratio]
IF	immunofluorescence, initiation factor
IFN	interferon
Ig	immunoglobulin
IGF	insulin-like growth factor
I <sub>K</sub>	potassium current [heart]
IL	interleukin
IM	intramuscular
IMA	inferior mesenteric artery
IMED	International Medical Education Directory

\*Image abbreviation only

ABBREVIATION	MEANING
IMG	international medical graduate
IMP	inosine monophosphate
IMV	inferior mesenteric vein
I <sub>Na</sub>	sodium current [heart]
INO	internuclear ophthalmoplegia
INR	International Normalized Ratio
IO	inferior oblique [muscle]
IOP	intraocular pressure
IP <sub>3</sub>	inositol triphosphate
IPV	inactivated polio vaccine
IR	current × resistance [Ohm's law], inferior rectus [muscle]
IRV	inspiratory reserve volume
ITP	idiopathic thrombocytopenic purpura
IUD	intrauterine device
IUGR	intrauterine growth restriction
IV	intravenous
IVC	inferior vena cava
IVDU	intravenous drug use
IVIG	intravenous immunoglobulin
JAK/STAT	Janus kinase/signal transducer and activator of transcription [pathway]
JGA	juxtaglomerular apparatus
JVD	jugular venous distention
JVP	jugular venous pulse
K <sup>+</sup>	potassium ion
KatG	catalase-peroxidase produced by <i>M tuberculosis</i>
K <sub>e</sub>	elimination constant
K <sub>f</sub>	filtration constant
KG	ketoglutarate
K <sub>m</sub>	Michaelis-Menten constant
KOH	potassium hydroxide
L	left, liver
LA	left atrial, left atrium
LAD	left anterior descending coronary artery
LAF	left anterior fascicle
LAP	leukocyte alkaline phosphatase
Lat cond*	lateral condyle
Lb*	lamellar body
LCA	left coronary artery
LCAT	lecithin-cholesterol acyltransferase
LCC*	left common carotid artery
LCFA	long-chain fatty acid
LCL	lateral collateral ligament
LCME	Liaison Committee on Medical Education
LCMV	lymphocytic choriomeningitis virus
LCX	left circumflex coronary artery
LD	loading dose
LD <sub>50</sub>	median lethal dose
LDH	lactate dehydrogenase
LDL	low-density lipoprotein
LES	lower esophageal sphincter
LFA	leukocyte function-associated antigen
LFT	liver function test
LGN	lateral geniculate nucleus

ABBREVIATION	MEANING
LGV	left gastric vein
LH	luteinizing hormone
LLQ	left lower quadrant
LM	light microscopy, left main coronary artery
LMN	lower motor neuron
LOS	lipooligosaccharide
LP	lumbar puncture
LPA*	left pulmonary artery
LPL	lipoprotein lipase
LPS	lipopolysaccharide
LR	lateral rectus [muscle]
LT	labile toxin leukotriene
LV	left ventricle, left ventricular
Lys	lysine
M <sub>1</sub> -M <sub>5</sub>	muscarinic (parasympathetic) ACh receptors
MAC	membrane attack complex, minimal alveolar concentration
MALT	mucosa-associated lymphoid tissue
MAO	monoamine oxidase
MAOI	monoamine oxidase inhibitor
MAP	mean arterial pressure, mitogen-activated protein
MASP	mannose-binding lectin-associated serine protease
Max*	maxillary sinus
MBL	mannose-binding lectin
MC	midsystolic click
MCA	middle cerebral artery
MCAT	Medical College Admissions Test
MCHC	mean corpuscular hemoglobin concentration
MCL	medial collateral ligament
MCP	metacarpophalangeal [joint]
MCV	mean corpuscular volume
MD	maintenance dose
Med cond*	medial condyle
MELAS syndrome	mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes
MEN	multiple endocrine neoplasia
Mg <sup>2+</sup>	magnesium ion
MGN	medial geniculate nucleus
MgSO <sub>4</sub>	magnesium sulfate
MGUS	monoclonal gammopathy of undetermined significance
MHC	major histocompatibility complex
MI	myocardial infarction
MIF	müllerian inhibiting factor
MLCK	myosin light-chain kinase
MLF	medial longitudinal fasciculus
MMC	migrating motor complex
MMR	measles, mumps, rubella [vaccine]
6-MP	6-mercaptopurine
MPGN	membranoproliferative glomerulonephritis
MPO	myeloperoxidase
MPO-ANCA/p-ANCA	perinuclear antineutrophil cytoplasmic antibody
MR	medial rectus [muscle], mitral regurgitation
MRI	magnetic resonance imaging
miRNA	microribonucleic acid

\*Image abbreviation only

ABBREVIATION	MEANING
mRNA	messenger ribonucleic acid
MRSA	methicillin-resistant <i>S aureus</i>
MS	mitral stenosis, multiple sclerosis
MSH	melanocyte-stimulating hormone
MSM	men who have sex with men
mtDNA	mitochondrial DNA
mtRNA	mitochondrial RNA
mTOR	mammalian target of rapamycin
MTP	metatarsophalangeal [joint]
MTX	methotrexate
MUA/P	Medically Underserved Area and Population
MVO <sub>2</sub>	myocardial oxygen consumption
MVP	mitral valve prolapse
N*	nucleus
N/A	not applicable
Na <sup>+</sup>	sodium ion
NAD	nicotinamide adenine dinucleotide
NAD <sup>+</sup>	oxidized nicotinamide adenine dinucleotide
NADH	reduced nicotinamide adenine dinucleotide
NADP <sup>+</sup>	oxidized nicotinamide adenine dinucleotide phosphate
NADPH	reduced nicotinamide adenine dinucleotide phosphate
NBME	National Board of Medical Examiners
NBOME	National Board of Osteopathic Medical Examiners
NBPME	National Board of Podiatric Medical Examiners
NC	no change
NE	norepinephrine
NF	neurofibromatosis
NFAT	nuclear factor of activated T-cell
NH <sub>3</sub>	ammonia
NH <sub>4</sub> <sup>+</sup>	ammonium
NIDDM	non-insulin-dependent diabetes mellitus
NK	natural killer [cells]
N <sub>M</sub>	muscarinic ACh receptor in neuromuscular junction
NMDA	N-methyl-D-aspartate
NMJ	neuromuscular junction
NMS	neuroleptic malignant syndrome
N <sub>N</sub>	nicotinic ACh receptor in autonomic ganglia
NRMP	National Residency Matching Program
NNRTI	non-nucleoside reverse transcriptase inhibitor
NO	nitric oxide
N <sub>2</sub> O	nitrous oxide
NPH	neutral protamine Hagedorn, normal pressure hydrocephalus
NPV	negative predictive value
NRI	norepinephrine receptor inhibitor
NRTI	nucleoside reverse transcriptase inhibitor
NSAID	nonsteroidal anti-inflammatory drug
NSE	neuron-specific enolase
NSTEMI	non-ST-segment elevation myocardial infarction
Nu*	nucleolus
OAA	oxaloacetic acid
OCD	obsessive-compulsive disorder
OCP	oral contraceptive pill
OH	hydroxy

ABBREVIATION	MEANING
OH <sub>2</sub>	dihydroxy
1,25-OH D <sub>3</sub>	calcitriol (active form of vitamin D)
25-OH D <sub>3</sub>	storage form of vitamin D
3' OH	hydroxyl
OMT	osteopathic manipulative technique
OPV	oral polio vaccine
OR	odds ratio
OS	opening snap
OTC	ornithine transcarbamoylase
OVLT	organum vasculosum of the lamina terminalis
P-body	processing body (cytoplasmic)
P-450	cytochrome P-450 family of enzymes
PA	posteroanterior, pulmonary artery
PABA	<i>para</i> -aminobenzoic acid
Paco <sub>2</sub>	arterial Pco <sub>2</sub>
PACO <sub>2</sub>	alveolar Pco <sub>2</sub>
PAH	<i>para</i> -aminohippuric acid
PAN	polyarteritis nodosa
Pao <sub>2</sub>	partial pressure of oxygen in arterial blood
PAO <sub>2</sub>	partial pressure of oxygen in alveolar blood
PAP	Papanicolaou [smear], prostatic acid phosphatase
PAPPA	pregnancy-associated plasma protein A
PAS	periodic acid–Schiff
Pat*	patella
PBP	penicillin-binding protein
PC	plasma colloid osmotic pressure, platelet count, pyruvate carboxylase
PCA	posterior cerebral artery
PCL	posterior cruciate ligament
Pco <sub>2</sub>	partial pressure of carbon dioxide
PCom	posterior communicating [artery]
PCOS	polycystic ovarian syndrome
PCP	phencyclidine hydrochloride, <i>Pneumocystis jirovecii</i> pneumonia
PCR	polymerase chain reaction
PCT	proximal convoluted tubule
PCWP	pulmonary capillary wedge pressure
PD	posterior descending [artery]
PDA	patent ductus arteriosus, posterior descending artery
PDC	pyruvate dehydrogenase complex
PDE	phosphodiesterase
PDGF	platelet-derived growth factor
PDH	pyruvate dehydrogenase
PE	pulmonary embolism
PECAM	platelet–endothelial cell adhesion molecule
PECO <sub>2</sub>	expired air Pco <sub>2</sub>
PEP	phosphoenolpyruvate
PF	platelet factor
PFK	phosphofructokinase
PFT	pulmonary function test
PG	phosphoglycerate
P <sub>i</sub>	plasma interstitial osmotic pressure, inorganic phosphate
PICA	posterior inferior cerebellar artery
PID	pelvic inflammatory disease

\*Image abbreviation only

ABBREVIATION	MEANING
PO <sub>2</sub>	Po <sub>2</sub> in inspired air
PIP	proximal interphalangeal [joint]
PIP <sub>2</sub>	phosphatidylinositol 4,5-bisphosphate
PIP <sub>3</sub>	phosphatidylinositol 3,4,5-bisphosphate
PKD	polycystic kidney disease
PKR	interferon- $\alpha$ -induced protein kinase
PKU	phenylketonuria
PLP	pyridoxal phosphate
PLS	Personalized Learning System
PML	progressive multifocal leukoencephalopathy
PMN	polymorphonuclear [leukocyte]
P <sub>net</sub>	net filtration pressure
PNET	primitive neuroectodermal tumor
PNS	peripheral nervous system
Po <sub>2</sub>	partial pressure of oxygen
PO <sub>4</sub>	salt of phosphoric acid
PO <sub>4</sub> <sup>3-</sup>	phosphate
Pop*	popliteal artery
Pop a*	popliteal artery
Post*	posterior
PPAR	peroxisome proliferator-activated receptor
PPD	purified protein derivative
PPI	proton pump inhibitor
PPV	positive predictive value
PR3-ANCA/ c-ANCA	cytoplasmic antineutrophil cytoplasmic antibody
PrP	prion protein
PRPP	phosphoribosylpyrophosphate
PSA	prostate-specific antigen
PSS	progressive systemic sclerosis
PT	prothrombin time
PTH	parathyroid hormone
PTHrP	parathyroid hormone-related protein
PTSD	post-traumatic stress disorder
PTT	partial thromboplastin time
PV	plasma volume, venous pressure
Pv*	pulmonary vein
PVC	polyvinyl chloride
PVR	pulmonary vascular resistance
R	correlation coefficient, right, R variable [group]
R <sub>3</sub>	Registration, Ranking, & Results [system]
RA	right atrium
RAAS	renin-angiotensin-aldosterone system
RANK-L	receptor activator of nuclear factor- $\kappa$ B ligand
RAS	reticular activating system
RBC	red blood cell
RBF	renal blood flow
RCA	right coronary artery
REM	rapid eye movement
REr	rough endoplasmic reticulum
Rh	<i>rhesus</i> antigen
RLQ	right lower quadrant
RNA	ribonucleic acid
RNP	ribonucleoprotein

ABBREVIATION	MEANING
ROS	reactive oxygen species
RPF	renal plasma flow
RPGN	rapidly progressive glomerulonephritis
RPR	rapid plasma reagin
RR	relative risk, respiratory rate
rRNA	ribosomal ribonucleic acid
RS	Reed-Sternberg [cells]
RSC*	right subclavian artery
RSV	respiratory syncytial virus
RTA	renal tubular acidosis
RUQ	right upper quadrant
RV	residual volume, right ventricle, right ventricular
RVH	right ventricular hypertrophy
Rx	medical prescription
[S]	substrate concentration
SA	sinoatrial
SAA	serum amyloid-associated [protein]
SAM	S-adenosylmethionine
SARS	severe acute respiratory syndrome
SAT	Scholastic Aptitude Test
SC	subcutaneous
SCC	squamous cell carcinoma
SCD	sudden cardiac death
SCID	severe combined immunodeficiency disease
SCJ	squamocolumnar junction
SCM	sternocleidomastoid muscle
SCN	suprachiasmatic nucleus
SD	standard deviation
SE	standard error of the mean
SEP	Spoken English Proficiency
SER	smooth endoplasmic reticulum
SERM	selective estrogen receptor modulator
SGLT	sodium-glucose transporter
SHBG	sex hormone-binding globulin
SIADH	syndrome of inappropriate [secretion of] antidiuretic hormone
SIDS	sudden infant death syndrome
SLE	systemic lupus erythematosus
SLL	small lymphocytic lymphoma
SLT	Shiga-like toxin
SMA	superior mesenteric artery
SMX	sulfamethoxazole
SNARE	soluble NSF attachment protein receptor
SNe	substantia nigra pars compacta
SNP	single nucleotide polymorphism
SNr	substantia nigra pars reticulata
SNRI	serotonin and norepinephrine receptor inhibitor
snRNP	small nuclear ribonucleoprotein
SO	superior oblique [muscle]
SOAP	Supplemental Offer and Acceptance Program
Sp*	spleen
spp	species
SR	superior rectus [muscle]
SS	single stranded

\*Image abbreviation only

ABBREVIATION	MEANING
ssDNA	single-stranded deoxyribonucleic acid
SSPE	subacute sclerosing panencephalitis
SSRI	selective serotonin reuptake inhibitor
ssRNA	single-stranded ribonucleic acid
St*	stomach
ST	Shiga toxin
StAR	steroidogenic acute regulatory protein
STEMI	ST-segment elevation myocardial infarction
STI	sexually transmitted infection
STN	subthalamic nucleus
SV	splenic vein, stroke volume
SVC	superior vena cava
SVT	supraventricular tachycardia
$t_{1/2}$	half-life
$T_3$	triiodothyronine
$T_4$	thyroxine
TAPVR	total anomalous pulmonary venous return
TB	tuberculosis
TBG	thyroxine-binding globulin
3TC	dideoxythiacytidine [lamivudine]
TCA	tricarboxylic acid [cycle], tricyclic antidepressant
Tc cell	cytotoxic T cell
TCR	T-cell receptor
TDF	tenofovir disoproxil fumarate
TdT	terminal deoxynucleotidyl transferase
TE	tracheoesophageal
TFT	thyroid function test
TG	triglyceride
TGA	<i>trans</i> -Golgi apparatus
TGF	transforming growth factor
TGN	<i>trans</i> -Golgi network
Th cell	helper T cell
THF	tetrahydrofolic acid
TI	therapeutic index
TIA	transient ischemic attack
Tib*	tibia
TIBC	total iron-binding capacity
TIPS	transjugular intrahepatic portosystemic shunt
TLC	total lung capacity
$T_m$	maximum rate of transport
TMP	trimethoprim
TN	true negative
TNF	tumor necrosis factor
TNM	tumor, node, metastases [staging]
ToRCHeS	<i>Toxoplasma gondii</i> , rubella, CMV, HIV, HSV-2, syphilis
TP	true positive
tPA	tissue plasminogen activator
TPO	thyroid peroxidase, thrombopoietin
TPP	thiamine pyrophosphate
TPR	total peripheral resistance
TR	tricuspid regurgitation
TRAP	tartrate-resistant acid phosphatase
TRH	thyrotropin-releasing hormone

ABBREVIATION	MEANING
tRNA	transfer ribonucleic acid
TSH	thyroid-stimulating hormone
TSI	triple sugar iron
TSS	toxic shock syndrome
TSST	toxic shock syndrome toxin
TTP	thrombotic thrombocytopenic purpura
TTR	transthyretin
TV	tidal volume
Tx	translation [factor]
TXA <sub>2</sub>	thromboxane A <sub>2</sub>
UDP	uridine diphosphate
UMN	upper motor neuron
UMP	uridine monophosphate
UPD	uniparental disomy
URI	upper respiratory infection
USMLE	United States Medical Licensing Examination
UTI	urinary tract infection
UTP	uridine triphosphate
UV	ultraviolet
$\dot{V}_1, \dot{V}_2$	Vasopressin receptors
VC	vital capacity
$V_d$	volume of distribution
VD	physiologic dead space
V(D)J	heavy-chain hypervariable region [antibody]
VDRL	Venereal Disease Research Laboratory
VEGF	vascular endothelial growth factor
$V_H$	variable region, heavy chain [antibody]
VHL	von Hippel-Lindau [disease]
VIP	vasoactive intestinal peptide
VIPoma	vasoactive intestinal polypeptide-secreting tumor
VJ	light-chain hypervariable region [antibody]
VL	ventral lateral [nucleus]; variable region, light chain [antibody]
VLDL	very low density lipoprotein
VMA	vanillylmandelic acid
VMAT	vesicular monoamine transporter
$V_{max}$	maximum velocity
VPL	ventral posterior nucleus, lateral
VPM	ventral posterior nucleus, medial
VPN	vancomycin, polymyxin, nystatin [media]
$\dot{V}/\dot{Q}$	ventilation/perfusion [ratio]
VRE	vancomycin-resistant enterococcus
VSD	ventricular septal defect
$V_T$	tidal volume
vWF	von Willebrand factor
VZV	varicella-zoster virus
WBC	white blood cell
VMAT	vesicular monoamine transporter
XR	X-linked recessive
XX	normal complement of sex chromosomes for female
XY	normal complement of sex chromosomes for male
ZDV	zidovudine [formerly AZT]

\*Image abbreviation only

## SECTION IV


# Image Acknowledgments

In this edition, in collaboration with MediQ Learning, LLC, and a variety of other partners, we are pleased to include the following clinical images and diagrams for the benefit of integrative student learning.

☒ Portions of this book identified with the symbol ☒ are copyright © USMLE-Rx.com (MediQ Learning, LLC).

RU Portions of this book identified with the symbol RU are copyright © Dr. Richard Usatine and are provided under license through MediQ Learning, LLC.














✳ Portions of this book identified with the symbol ✳ are listed below by page number.












This symbol  refers to material that is available in the public domain.

This symbol  refers to the Creative Commons Attribution license, full text at <http://creativecommons.org/licenses/by/4.0/legalcode>.





This symbol  refers to the Creative Commons Attribution-Share Alike license, full text at: <http://creativecommons.org/licenses/by-sa/4.0/legalcode>.

### Biochemistry










- 32 **Heterochromatin: Image A.** This image is a derivative work, adapted from the following source, available under : Roller RA, et al. *Am Malacolog Bull* 1995;11:177-90.
- 45 **Cilia structure: Image A.**  Courtesy of Louisa Howard and Michael Binder. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MediQ Learning, LLC are reserved.
- 45 **Cilia structure: Image B.** Cilia structure of basal body. This image is a derivative work, adapted from the following source, available under : Riparbelli MG, Cabrera OA, Callaini G, et al. Unique properties of Drosophila spermatocyte primary cilia. *Biol Open* 2013 Nov 15;2(11):1137–1147. doi 10.1242/bio.20135355.
- 45 **Cilia structure: Image C.** Dextrocardia. This image is a derivative work, adapted from the following source, available under : Oluwadare O, Ayoka AO, Akomolafe RO, et al. The role of electrocardiogram in the diagnosis of dextrocardia with mirror image atrial arrangement and ventricular position in a young adult Nigerian in Ile-Ife: a case report. *J Med Case Rep* 2015;9:222. doi 10.1186/s13256-015-0695-4.
- 47 **Osteogenesis imperfecta: Image A.** Skeletal deformities in lower body of child. This image is a derivative work, adapted from the following source, available under : Vanakker OM, Hemelsoet D, De Paepe. Hereditary connective tissue diseases in young adult stroke: a comprehensive synthesis. *Stroke Res Treat* 2011;7:12903. doi 10.4061/2011/712903. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MediQ Learning, LLC are reserved.
- 47 **Osteogenesis imperfecta: Image B.** Skeletal deformities in upper extremity of child. This image is a derivative work, adapted from the following source, available under : Vanakker OM, Hemelsoet D, De Paepe. Hereditary connective tissue diseases in young adult stroke: a comprehensive synthesis. *Stroke Res Treat* 2011;7:12903. doi 10.4061/2011/712903. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MediQ Learning, LLC are reserved.
- 47 **Osteogenesis imperfecta: Image C.** Blue sclera. This image is a derivative work, adapted from the following source, available under : Courtesy of Fred H, van Dijk H. Images of memorable cases: cases 40, 41 & 42. Connexions Web site. December 3, 2008. Available at: <http://cnx.org/content/m15020/1.3/>. The image may have been modified by cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under .
- 48 **Ehlers-Danlos syndrome: Image A.** Finger hypermobility. This image is a derivative work, adapted from the following source, available under : Courtesy of Piotr Dolzonek. The image may have been modified by cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under .
- 51 **Karyotyping: Image A.** This image is a derivative work, adapted from the following source, available under : Paar C, Herber G, Voskova, et al. A case of acute myeloid leukemia (AML) with an unreported combination of chromosomal abnormalities: gain of isochromosome 5p, tetrasomy 8 and unbalanced translocation der(19)t(17;19)(q23;p13). *Mol Cytogenet* 2013;6:40. doi 10.1186/1755-8166-6-40.
- 51 **Fluorescence in situ hybridization: Image A.** This image is a derivative work, adapted from the following source, available under : Paar C, Herber G, Voskova, et al. A case of acute myeloid leukemia (AML) with an unreported combination of chromosomal abnormalities: gain of isochromosome 5p, tetrasomy 8 and unbalanced translocation der(19)t(17;19)(q23;p13). *Mol Cytogenet* 2013;6:40. doi 10.1186/1755-8166-6-40.
- 57 **Muscular dystrophies.** Fibrofatty replacement of muscle.  Courtesy of the US Department of Health and Human Services and Dr. Edwin P. Ewing, Jr. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MediQ Learning, LLC are reserved.

































- 63 **Vitamin B<sub>3</sub> (niacin).** Pellagra. This image is a derivative work, adapted from the following source, available under : van Dijk HA, Fred H. Images of memorable cases: case 2. Connexions Web site. Dec 4, 2008. Available at: <http://cnx.org/contents/3d3dcb2e-8e98-496f-91c2-fe94e93428a1@3@3/>.
- 66 **Vitamin D: Image A.** X-ray of lower extremity in child with rickets. This image is a derivative work, adapted from the following source, available under . Courtesy of Dr. Michael L. Richardson. The image may have been modified by cropping, labeling, and/or captions. MedIQ Learning, LLC makes this image available under .
- 67 **Malnutrition: Image A.** Child with kwashiorkor.  Courtesy of the US Department of Health and Human Services and Dr. Lyle Conrad.
- 67 **Marasmus: Image B.** Child with marasmus.  Courtesy of the US Department of Health and Human Services.
- 80 **Alkaptonuria.** Pigment granules on dorsum of hand. This image is a derivative work, adapted from the following source, available under : Vasudevan B, Sawhney MPS, Radhakrishnan S. Alkaptonuria associated with degenerative collagenous palmar plaques. *Indian J Dermatol* 2009;54:299-301. doi 10.4103/0019-5154.55650.
- 81 **Cystinuria.** Hexagonal stones in urine. This image is a derivative work, adapted from the following source, available under : Courtesy of Cayla Devine.
- 84 **Lysosomal storage diseases: Image D.** “Cherry-red” spot on macula in Tay-Sachs disease. This image is a derivative work, adapted from the following source, available under : Courtesy of Dr. Jonathan Trobe.
- 84 **Lysosomal storage diseases: Image A.** Angiokeratomas. This image is a derivative work, adapted from the following source, available under : Burlina AP, Sims KB, Politei JM, et al. Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel. *BMC Neurol* 2011;11:61. doi 10.1186/1471-2377-11-61. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MedIQ Learning, LLC are reserved.
- 84 **Lysosomal storage diseases: Image B.** Gaucher cells in Gaucher disease. This image is a derivative work, adapted from the following source, available under : Sokołowska B, Skomra D, Czartoryska B. et al. Gaucher disease diagnosed after bone marrow trephine biopsy—a report of two cases. *Folia Histochemica et Cytobiologica* 2011;49:352-356. doi 10.5603/FHC.2011.0048. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MedIQ Learning, LLC are reserved.
- 84 **Lysosomal storage diseases: Image C.** Foam cells in Niemann-Pick disease. This image is a derivative work, adapted from the following source, available under : Prieto-Potin I, Roman-Blas JA, Martinez-Calatrava MJ, et al. Hypercholesterolemia boosts joint destruction in chronic arthritis. An experimental model aggravated by foam macrophage infiltration. *Arthritis Res Ther* 2013;15:R81. doi 10.1186/ar4261.

## Immunology
































- 94 **Sinusoids of spleen.** Red and white pulp. This image is a derivative work, adapted from the following source, available under : Heinrichs S, Conover LF, Bueso-Ramos CE, et al. MYBL2 is a sub-haploinsufficient tumor suppressor gene in myeloid malignancy. *eLife* 2013;2:e00825. doi 10.7554/eLife.00825. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MedIQ Learning, LLC are reserved.
- 94 **Thymus: Image A.** Hassall corpuscles. This image is a derivative work, adapted from the following source, available under : Minato H, Kinoshita E, Nakada S, et al. Thymic lymphoid hyperplasia with multilocular thymic cysts diagnosed before the Sjögren syndrome diagnosis. *Diagn Pathol* 2015;10:103. doi 10.1186/s13000-015-0332-y.
- 113 **Ataxia-telangiectasia: Image A.** Spider angioma (telangiectasia). This image is a derivative work, adapted from the following source, available under : Liapakis IE, Englander M, Sinani R, et al. Management of facial telangiectasias with hand cautery. *World J Plast Surg* 2015 Jul; 4(2):127-133.
- 113 **Immunodeficiencies.** Giant granules in granulocytes in Chédiak-Higashi syndrome. This image is a derivative work, adapted from the following source, available under : Bharti S, Bhatia P, Bansal D, et al. The accelerated phase of Chédiak-Higashi syndrome: the importance of hematological evaluation. *Turk J Haematol* 2013;30:85-87. doi 10.4274/tjh.2012.0027. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MedIQ Learning, LLC are reserved.



































## Microbiology

- 122 **Stains: Image A.** *Trypanosoma lewisi* on Giemsa stain.  Courtesy of the US Department of Health and Human Services and Dr. Mae Melvin.
- 122 **Stains: Image B.** *Tropheryma whipplei* on periodic acid–Schiff stain. This image is a derivative work, adapted from the following source, available under : Dr. Ed Uthman.
- 122 **Stains: Image C.** *Mycobacterium tuberculosis* on Ziehl-Neelsen stain.  Courtesy of the US Department of Health and Human Services and Dr. George P. Kubica.
- 122 **Stains: Image D.** *Cryptococcus neoformans* on India ink stain.  Courtesy of the US Department of Health and Human Services.
- 122 **Stains: Image E.** *Coccidioides immitis* on silver stain.  Courtesy of the US Department of Health and Human Services and Dr. Edwin P. Ewing, Jr.
- 124 **Encapsulated bacteria.** Capsular swelling of *Streptococcus pneumoniae* using the Neufeld-Quellung test.  Courtesy of the US Department of Health and Human Services.
- 124 **Catalase-positive organisms: Image A.** Oxygen bubbles released during catalase reaction. This image is a derivative work, adapted from the following source, available under . Courtesy of Stefano Nase. The image may have been modified by cropping, labeling, and/or captions. MedIQ Learning, LLC makes this image available under .
- 127 **Bacterial spores.** This image is a derivative work, adapted from the following source, available under : Jones SW, Paredes

- CJ, Tracy B. The transcriptional program underlying the physiology of clostridial sporulation. *Genome Biol* 2008;9:R114. doi 10.1186/gb-2008-9-7-r114.
- 131  **$\alpha$ -hemolytic bacteria: Image A.**  $\alpha$ -hemolysis. This image is a derivative work, adapted from the following source, available under . Courtesy of Y. Tambe. The image may have been modified by cropping, labeling, and/or captions. MedIQ Learning, LLC makes this image available under .
- 131  **$\beta$ -hemolytic bacteria: Image A.**  $\beta$ -hemolysis. This image is a derivative work, adapted from the following source, available under . Courtesy of Y. Tambe. The image may have been modified by cropping, labeling, and/or captions. MedIQ Learning, LLC makes this image available under .
- 131 ***Staphylococcus aureus*.** Gram stain.  Courtesy of the US Department of Health and Human Services and Dr. Richard Facklam.
- 132 ***Streptococcus pneumoniae*.**  Courtesy of the US Department of Health and Human Services and Dr. Mike Miller.
- 132 ***Streptococcus pyogenes*: Image A. (group A streptococci).** Gram stain. This image is a derivative work, adapted from the following source, available under . Courtesy of Y. Tambe. The image may have been modified by cropping, labeling, and/or captions. MedIQ Learning, LLC makes this image available under .
- 133 ***Bacillus anthracis*.** Ulcer with black eschar.  Courtesy of the US Department of Health and Human Services and James H. Steele.
- 134 **Clostridia (with exotoxins): Image A.** Gas gangrene due to *Clostridium perfringens* infection. This image is a derivative work, adapted from the following source, available under : Courtesy of Engelbert Schröpfer, Stephan Rauthe, and Thomas Meyer.
- 134 **Clostridia (with exotoxins): Image B.** Pseudomembranous enterocolitis on colonoscopy. This image is a derivative work, adapted from the following source, available under . Courtesy of Klinikum Dritter Orden für die Überlassung des Bildes zur Veröffentlichung. The image may have been modified by cropping, labeling, and/or captions. MedIQ Learning, LLC makes this image available under .
- 135 ***Corynebacterium diphtheriae*: Image A.** Pseudomembranous pharyngitis. This image is a derivative work, adapted from the following source, available under . Courtesy of Wikimedia Commons. The image may have been modified by cropping, labeling, and/or captions. MedIQ Learning, LLC makes this image available under .
- 135 ***Listeria monocytogenes*.** Actin rockets. This image is a derivative work, adapted from the following source, available under : Schuppler M, Loessner MJ. The opportunistic pathogen *Listeria monocytogenes*: pathogenicity and interaction with the mucosal immune system. *Int J Inflamm* 2010;2010:704321. doi 10.4061/2010/704321. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MedIQ Learning, LLC are reserved.
- 135 ***Nocardia vs Actinomyces*: Image A.** *Nocardia* on acid-fast stain. This image is a derivative work, adapted from the following source, available under : Adhikari L, Dey S, Pal R. Mycetoma due to *Nocardia farcinica*. *J Glob Infect Dis* 2010;2:194-195. doi 0.4103/0974-777X.62868.
- 135 ***Nocardia vs Actinomyces*: Image B.** *Actinomyces israelii* on Gram stain.  Courtesy of the US Department of Health and Human Services.
- 136 **Mycobacteria.** Acid-fast stain.  Courtesy of the US Department of Health and Human Services and Dr. Edwin P. Ewing, Jr.
- 137 **Leprosy (Hansen disease): Image A.** “Glove and stocking” distribution. This image is a derivative work, adapted from the following source, available under : Bruno Jehle.
- 138 ***Neisseria*: Image A.** Photomicrograph.  Courtesy of the US Department of Health and Human Services and Dr. Mike Miller.
- 138 ***Haemophilus influenzae*: Image A.** Epiglottitis. This image is a derivative work, adapted from the following source, available under : Wikimedia Commons. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MedIQ Learning, LLC are reserved.
- 139 ***Legionella pneumophila*.**  Courtesy of the US Department of Health and Human Services and Grottola A, Forghieri F, Meacci M, et al. Severe pneumonia caused by *Legionella pneumophila* serogroup 11, Italy. *Emerg Infect Dis* 2012. doi 10.3201/eid1811.120216.
- 139 ***Pseudomonas aeruginosa*: Image A.** Blue-green pigment. This image is a derivative work, adapted from the following source, available under . Courtesy of Hansen. The image may have been modified by cropping, labeling, and/or captions. MedIQ Learning, LLC makes this image available under .
- 139 ***Pseudomonas aeruginosa*: Image B.** Ecthyma gangrenosum. This image is a derivative work, adapted from the following source, available under : Uludokumaci S, Balkan II, Mete B, et al. Ecthyma gangrenosum-like lesions in a febrile neutropenic patient with simultaneous *Pseudomonas* sepsis and disseminated fusariosis. *Turk J Haematol* 2013 Sep; 30(3):321-4. doi 10.4274/Tjh.2012.0030.
- 140 ***Klebsiella*.**  Courtesy of the US Department of Health and Human Services.
- 140 ***Campylobacter jejuni*.**  Courtesy of the US Department of Health and Human Services.
- 141 ***Vibrio cholerae*.** This image is a derivative work, adapted from the following source, available under : Phetsouvanh R, Nakatsu M, Arakawa E, et al. Fatal bacteremia due to immotile *Vibrio cholerae* serogroup O21 in Vientiane, Laos—a case report. *Ann Clin Microbiol Antimicrob* 2008;7:10. doi 10.1186/1476-0711-7-10.
- 142 ***Helicobacter pylori*.**  Courtesy of the US Department of Health and Human Services, Dr. Patricia Fields, and Dr. Collette Fitzgerald.
- 142 **Spirochetes.** Dark-field microscopic appearance.  Courtesy of the US Department of Health and Human Services.
- 142 **Lyme disease: Image A.** *Ixodes* tick.  Courtesy of the US Department of Health and Human Services and Dr. Michael L. Levin.
- 142 **Lyme disease: Image B.** Erythema migrans.  Courtesy of the US Department of Health and Human Services and James Gathany.



- 143 **Syphilis: Image A.** Painless chancre in 1° syphilis.  Courtesy of the US Department of Health and Human Services and M. Rein.
- 143 **Syphilis: Image B.** Treponeme on dark-field microscopy.  Courtesy of the US Department of Health and Human Services and Renelle Woodall.
- 143 **Syphilis: Image D.** Rash on palms. This image is a derivative work, adapted from the following source, available under : Drahansky M, Dolezel M, Urbanek J, et al. Influence of skin diseases on fingerprint recognition. *J Biomed Biotechnol* 2012;626148. doi 10.1155/2012/626148.
- 143 **Syphilis: Image E.** Condyloma lata.  Courtesy of the US Department of Health and Human Services and Susan Lindsley.
- 143 **Syphilis: Image F.** Gumma. This image is a derivative work, adapted from the following source, available under : Chakir K, Benchikhi H. Granulome centro-facial révélant une syphilis tertiaire. *Pan Afr Med J* 2013;15:82. doi 10.11604/pamj.2013.15.82.3011.
- 143 **Syphilis: Image G.** Congenital syphilis.  Courtesy of the US Department of Health and Human Services and Dr. Norman Cole.
- 143 **Syphilis: Image H.** Hutchinson teeth.  Courtesy of the US Department of Health and Human Services and Susan Lindsley.
- 144 ***Gardnerella vaginalis*.**  Courtesy of the US Department of Health and Human Services and M. Rein.
- 145 **Rickettsial diseases and vector-borne illnesses: Image A.** Rash of Rocky Mountain spotted fever.  Courtesy of the US Department of Health and Human Services.
- 145 **Rickettsial diseases and vector-borne illnesses: Image B.** *Ehrlichia morulae*. This image is a derivative work, adapted from the following source, available under : Dantas-Torres F. Canine vector-borne diseases in Brazil. *Parasit Vectors* 2008;1:25. doi 10.1186/1756-3305-1-25. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MedIQ Learning, LLC are reserved.
- 145 **Rickettsial diseases and vector-borne illnesses: Image C.** *Anaplasma phagocytophilum* in neutrophil.  Courtesy of the US Department of Health and Human Services and Dumler JS, Choi K, Garcia-Garcia JC, et al. Human granulocytic anaplasmosis. *Emerg Infect Dis* 2005. doi 10.3201/eid1112.050898.
- 146 ***Mycoplasma pneumoniae*.** This image is a derivative work, adapted from the following source, available under : Rottem S, Kosower NS, Kornspan JD. Contamination of tissue cultures by *Mycoplasma*. In: Ceccherini-Nelli L, ed: Biomedical tissue culture. doi 10.5772/51518.
- 147 **Systemic mycoses: Image A.** *Histoplasma*.  Courtesy of the US Department of Health and Human Services and Dr. D.T. McClenan.
- 147 **Systemic mycoses: Image B.** *Blastomyces dermatitidis* undergoing broad-base budding.  Courtesy of the US Department of Health and Human Services and Dr. Libero Ajello.
- 147 **Coccidioidomycosis: Image C.** Coccidioidomycosis with endospores.  Courtesy of the US Department of Health and Human Services.
- 147 **Systemic mycoses: Image D.** “Captain’s wheel” shape of *Paracoccidioides*.  Courtesy of the US Department of Health and Human Services and Dr. Lucille K. Georg.
- 148 **Cutaneous mycoses: Image G.** Tinea versicolor. This image is a derivative work, adapted from the following source, available under . Courtesy of Sarah (Rosenau) Korf. The image may have been modified by cropping, labeling, and/or captions. MedIQ Learning, LLC makes this image available under .
- 149 **Opportunistic fungal infections: Image A.** Budding yeast of *Candida albicans*. This image is a derivative work, adapted from the following source, available under . Courtesy of Y. Tambe. The image may have been modified by cropping, labeling, and/or captions. MedIQ Learning, LLC makes this image available under .
- 149 **Opportunistic fungal infections: Image B.** Germ tubes of *Candida albicans*. This image is a derivative work, adapted from the following source, available under . Courtesy of Y. Tambe. The image may have been modified by cropping, labeling, and/or captions. MedIQ Learning, LLC makes this image available under .
- 149 **Opportunistic fungal infections: Image C.** Oral thrush.  Courtesy of the US Department of Health and Human Services and Dr. Sol Silverman, Jr.
- 149 **Opportunistic fungal infections: Image E.** Conidiophores of *Aspergillus fumigatus*.  Courtesy of the US Department of Health and Human Services.
- 149 **Opportunistic fungal infections: Image F.** *Cryptococcus neoformans*.  Courtesy of the US Department of Health and Human Services and Dr. Leonor Haley.
- 149 **Opportunistic fungal infections: Image G.** *Cryptococcus neoformans* on mucicarmine stain.  Courtesy of the US Department of Health and Human Services and Dr. Leonor Haley.
- 149 **Opportunistic fungal infections: Image H.** *Mucor*.  Courtesy of the US Department of Health and Human Services and Dr. Lucille K. Georg.
- 150 ***Pneumocystis jirovecii*: Image A.** Interstitial opacities in lung. This image is a derivative work, adapted from the following source, available under : Chuang C, Zhanhong X, Yinyin G, et al. Unsuspected *Pneumocystis pneumonia* in an HIV-seronegative patient with untreated lung cancer: circa case report. *J Med Case Reports* 2007;1:15. doi 10.1186/1752-1947-1-115.
- 150 ***Pneumocystis jirovecii*: Image B.** Ground-glass opacities on CT. This image is a derivative work, adapted from the following source, available under : Oikonomou A and Prassopoulos P. Mimics in chest disease: interstitial opacities. *Insights Imaging* 2013;4:9-27. doi 10.1007/s13244-012-0207-7. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MedIQ Learning, LLC are reserved.
- 151 **Protozoa—GI infections: Image A.** *Giardia lamblia* trophozoite. This image is a derivative work, adapted from the following source, available under : Lipoldová M. *Giardia* and Vilém Dušan Lambli. *PLoS Negl Trop Dis* 2014;8:e2686. doi 10.1371/journal.pntd.0002686.
- 151 **Protozoa—GI infections: Image B.** *Giardia lamblia* cyst.  Courtesy of the US Department of Health and Human Services.

- 151 **Protozoa—GI infections: Image C.** *Entamoeba histolytica* trophozoites.  Courtesy of the US Department of Health and Human Services.
- 151 **Protozoa—GI infections: Image D.** *Entamoeba histolytica* cyst.  Courtesy of the US Department of Health and Human Services.
- 151 **Protozoa—GI infections: Image E.** *Cryptosporidium* oocysts.  Courtesy of the US Department of Health and Human Services.
- 152 **Toxoplasma gondii: Image A.** MRI toxoplasma. This image is a derivative work, adapted from the following source, available under : Agrawal A, Bhake A, Sangole VM, et al. Multiple-ring enhancing lesions in an immunocompetent adult. *J Glob Infect Dis* 2010 Sep-Dec; 2(3):313-4. doi 10.4103/0974-777X.68545.
- 152 **Protozoa—CNS infections: Image B.** *Toxoplasma gondii* tachyzoite.  Courtesy of the US Department of Health and Human Services and Dr. L.L. Moore, Jr.
- 152 **Protozoa—CNS infections: Image C.** *Naegleria fowleri* amoebas.  Courtesy of the US Department of Health and Human Services.
- 152 **Protozoa—CNS infections: Image D.** *Trypanosoma brucei gambiense*.  Courtesy of the US Department of Health and Human Services and Dr. Mae Melvin.
- 153 **Protozoa—hematologic infections: Image A.** *Plasmodium* trophozoite ring form.  Courtesy of the US Department of Health and Human Services.
- 153 **Protozoa—hematologic infections: Image B.** *Plasmodium* schizont containing merozoites.  Courtesy of the US Department of Health and Human Services and Steven Glenn.
- 153 **Protozoa—hematologic infections: Image C.** *Babesia*.  Courtesy of the US Department of Health and Human Services.
- 154 **Protozoa—others: Image A.** *Trypanosoma cruzi*.  Courtesy of the US Department of Health and Human Services and Dr. Mae Melvin.
- 154 **Protozoa—others: Image B.** *Leishmania donovani*.  Courtesy of the US Department of Health and Human Services and Dr. Francis W. Chandler. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MediQ Learning, LLC are reserved.
- 154 **Protozoa—others: Image C.** *Trichomonas vaginalis*.  Courtesy of the US Department of Health and Human Services.
- 155 **Nematodes (roundworms): Image A.** *Enterobius vermicularis* eggs.  Courtesy of the US Department of Health and Human Services, B.G. Partin, and Dr. Moore.
- 155 **Nematodes (roundworms): Image B.** *Ascaris lumbricoides* egg.  Courtesy of the US Department of Health and Human Services.
- 155 **Nematodes (roundworms): Image C.** Elephantiasis.  Courtesy of the US Department of Health and Human Services.
- 156 **Cestodes (tapeworms): Image A.** *Taenia solium* scolex. This image is a derivative work, adapted from the following source, available under . Courtesy of Robert J. Galindo. The image may have been modified by cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under .
- 156 **Trematodes (flukes): Image A.** *Schistosoma mansoni* egg with lateral spine.  Courtesy of the US Department of Health and Human Services.
- 156 **Cestodes (tapeworms): Image B.** Neurocysticercosis. This image is a derivative work, adapted from the following source, available under : Coyle CM, Tanowitz HB. Diagnosis and treatment of neurocysticercosis. *Interdiscip Perspect Infect Dis* 2009;2009:180742. doi 10.1155/2009/180742. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MediQ Learning, LLC are reserved.
- 156 **Trematodes (flukes): Image B.** *Schistosoma mansoni* egg with terminal spine.  Courtesy of the US Department of Health and Human Services.
- 156 **Echinococcus granulosus: Image C.**  Courtesy of the US Department of Health and Human Services.
- 156 **Cestodes (tapeworms): Image D.** Gross specimen of a hydatid cyst of *Echinococcus granulosus*.  Courtesy of the US Department of Health and Human Services and Dr. I. Kagan.
- 156 **Cestodes (tapeworms): Image E.** *Echinococcus granulosus* cyst in liver. This image is a derivative work, adapted from the following source, available under : Ma Z, Yang W, Yao Y, et al. The adventitia resection in treatment of liver hydatid cyst: a case report of a 15-year-old boy. *Case Rep Surg* 2014;2014:123149. doi 10.1155/2014/123149.
- 157 **Ectoparasites: Image A.** Scabies.  Courtesy of the US Department of Health and Human Services and J. Pledger.
- 157 **Ectoparasites: Image B.** Lice.  Courtesy of the US Department of Health and Human Services and Joe Miller
- 160 **Herpesviruses: Image A.** Keratoconjunctivitis in HSV-1 infection. This image is a derivative work, adapted from the following source, available under : Yang HK, Han YK, Wee WR, et al. Bilateral herpetic keratitis presenting with unilateral neurotrophic keratitis in pemphigus foliaceus: a case report. *J Med Case Rep* 2011;5:328. doi 10.1186/1752-1947-5-328.
- 160 **Herpesviruses: Image B.** Herpes labialis.  Courtesy of the US Department of Health and Human Services and Dr. Herrmann.
- 160 **Herpesviruses: Image E.** Shingles (varicella-zoster virus infection). This image is a derivative work, adapted from the following source, available under . Courtesy of Fisle. The image may have been modified by cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under .
- 160 **Herpesviruses: Image F.** Lymphadenopathy in VZV infection. This image is a derivative work, adapted from the following source, available under . Courtesy of Dr. James Heilman. The image may have been modified by cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under .
- 160 **Herpesviruses: Image G.** Atypical lymphocytes in Epstein-Barr virus infection. This image is a derivative work, adapted from the following source, available under : Dr. Ed Uthman. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MediQ Learning, LLC are reserved.
- 160 **Herpesviruses: Image I.** Roseola.  Courtesy of Emiliano Burzagli.

- 160 **Herpesvirus: Image J.** Kaposi sarcoma. Courtesy of the US Department of Health and Human Services.
- 162 **HSV identification: Image A.** Positive Tzanck smear in HSV-2 infection. This image is a derivative work, adapted from the following source, available under . Courtesy of Yale Rosen. The image may have been modified by cropping, labeling, and/or captions. MedIQ Learning, LLC makes this image available under .
- 164 **Rotavirus.** Courtesy of the US Department of Health and Human Services and Erskine Palmer.
- 165 **Rubella virus.** Rubella rash. Courtesy of the US Department of Health and Human Services.
- 165 **Measles (rubeola) virus: Image A.** Koplik spots. Courtesy of the US Department of Health and Human Services. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MedIQ Learning, LLC are reserved.
- 165 **Mumps virus.** Swollen neck and parotid glands. Courtesy of the US Department of Health and Human Services.
- 165 **Measles (rubeola) virus: Image B.** Rash of measles. Courtesy of the US Department of Health and Human Services.
- 166 **Croup (acute laryngotracheobronchitis).** Steeple sign. Reproduced, with permission, from Dr. Frank Gaillard and [www.radiopaedia.org](http://www.radiopaedia.org).
- 167 **Rabies virus: Image A.** Transmission electron micrograph. Courtesy of the US Department of Health and Human Services, Dr. Fred Murphy, and Sylvia Whitfield.
- 167 **Ebola virus.** Courtesy of the US Department of Health and Human Services and Cynthia Goldsmith.
- 167 **Rabies virus: Image B.** Negri bodies. Courtesy of the US Department of Health and Human Services and Dr. Daniel P. Perl.
- 176 **Osteomyelitis: Images A and B.** This image is a derivative work, adapted from the following source, available under : Pandey V, Rao SP, Rao S, et al. *Burkholderia pseudomallei* musculoskeletal infections (melioidosis) in India. *Indian J Orthop* 2010;44:216-220. doi 10.4103/0019-5413.61829.
- 177 **Common vaginal infections: Image C.** *Candida* vulvovaginitis. Courtesy of Mikael Häggström.
- 178 **ToRChES infections: Image A.** “Blueberry muffin” rash. This image is a derivative work, adapted from the following source, available under : Benmiloud S, Elhaddou G, Belghiti ZA, et al. Blueberry muffin syndrome. *Pan Afr Med J* 2012;13:23. PMID: PMC3527055.
- 178 **ToRChES infections: Image B.** Periventricular calcifications in congenital cytomegalovirus infection. This image is a derivative work, adapted from the following source, available under : Bonthius D, Perlman S. Congenital viral infections of the brain: lessons learned from lymphocytic choriomeningitis virus in the neonatal rat. *PLoS Pathog* 2007;3:e149. doi 10.1371/journal.ppat.0030149. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MedIQ Learning, LLC are reserved.
- 179 **Red rashes of childhood: Image C.** Child with scarlet fever. This image is a derivative work, adapted from the following source, available under : [www.badobadop.co.uk](http://www.badobadop.co.uk).
- 179 **Varicella-Zoster virus: Image D.** Chicken pox. Courtesy of the US Department of Health and Human Services.
- 180 **Donovanosis: Image A.** Courtesy of the US Department of Health and Human Services, CDC, and Dr. Pinozzi.
- 181 **Pelvic inflammatory disease: Image A.** Purulent cervical discharge. This image is a derivative work, adapted from the following source, available under . Courtesy of SOS-AIDS Amsterdam. The image may have been modified by cropping, labeling, and/or captions. MedIQ Learning, LLC makes this image available under .
- 181 **Pelvic inflammatory disease: Image B.** Adhesions in Fitz-Hugh–Curtis syndrome. Courtesy of Hic et nunc.
- 186 **Vancomycin.** Red man syndrome. This image is a derivative work, adapted from the following source, available under : O’Meara P, Borici-Mazi R, Morton R, et al. DRESS with delayed onset acute interstitial nephritis and profound refractory eosinophilia secondary to vancomycin. *Allergy Asthma Clin Immunol* 2011;7:16. doi 10.1186/1710-1492-7-16.

### Pathology

- 205 **Necrosis: Image A.** Coagulative necrosis. Courtesy of the US Department of Health and Human Services and Dr. Steven Rosenberg.
- 205 **Necrosis: Image B.** Liquefactive necrosis. Courtesy of Daftblogger.
- 205 **Necrosis: Image C.** Caseous necrosis. This image is a derivative work, adapted from the following source, available under . Courtesy of Dr. Yale Rosen. The image may have been modified by cropping, labeling, and/or captions. MedIQ Learning, LLC makes this image available under .
- 205 **Necrosis: Image D.** Fat necrosis. This image is a derivative work, adapted from the following source, available under . Courtesy of Patho. The image may have been modified by cropping, labeling, and/or captions. MedIQ Learning, LLC makes this image available under .
- 205 **Necrosis: Image E.** Fibrinoid necrosis. This image is a derivative work, adapted from the following source, available under . Courtesy of Dr. Yale Rosen. The image may have been modified by cropping, labeling, and/or captions. MedIQ Learning, LLC makes this image available under .
- 205 **Necrosis: Image F.** Acral gangrene. Courtesy of the US Department of Health and Human Services and William Archibald.
- 206 **Ischemia: Image A.** Cortical watershed area. This image is a derivative work, adapted from the following source, available under : Isabel C, Lecler A, Turc G, et al. Relationship between watershed infarcts and recent intra plaque haemorrhage in carotid atherosclerotic plaque. *PLoS One* 2014;9(10):e108712. doi 10.1371/journal.pone.0108712.
- 207 **Infarcts: red vs. pale: Image B.** Pale infarct. Courtesy of Armed Forces Institute of Pathology.
- 208 **Types of calcification: Image A.** Dystrophic calcification. This image is a derivative work, adapted from the following source, available under : Chun J-S, Hong R, Kim J-A. Osseous metaplasia with mature bone formation of the thyroid gland: three case reports. *Oncol Lett* 2013;6:977-979. doi 10.3892/

ol.2013.1475. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MediQ Learning, LLC are reserved.

- 208 **Types of calcification: Image B.** Metastatic calcification. This image is a derivative work, adapted from the following source, available under . Courtesy of Dr. Yale Rosen. The image may have been modified by cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under .
- 210 **Scar formation: Image A.** Hypertrophic scar. This image is a derivative work, adapted from the following source, available under : Baker R, Urso-Baiarda F, Linge C, et al. Cutaneous scarring: a clinical review. *Dermatol Res Pract* 2009;2009:625376. doi 10.1155/2009/625376.
- 210 **Scar formation: Image B.** Keloid scar. This image is a derivative work, adapted from the following source, available under . Courtesy of Dr. Andreas Settje. The image may have been modified by cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under .
- 211 **Granulomatous diseases.** Granuloma. Courtesy of Sanjay Mukhopadhyay.
- 213 **Amyloidosis: Image A.** Amyloid deposits on Congo red stain. This image is a derivative work, adapted from the following source, available under : Dr. Ed Uthman.
- 213 **Lipofuscin: Image A.** This image is a derivative work, adapted from the following source, available under . Courtesy of Nephron. The image may have been modified by cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under .
- 213 **Amyloidosis: Image B.** Amyloid deposits on Congo red stain under polarized light. This image is a derivative work, adapted from the following source, available under . Courtesy of Dr. Ed Uthman. The image may have been modified by cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under .
- 213 **Amyloidosis: Image C.** Amyloidosis on H&E stain. This image is a derivative work, adapted from the following source, available under : Mendoza JM, Peev V, Ponce MA, et al. Amyloid A amyloidosis with subcutaneous drug abuse. *J Renal Inj Prev* 2014;3:11-16. doi 10.12861/jrip.2014.06.
- 215 **Neoplastic progression: Image A.** Cervical tissue. This image is a derivative work, adapted from the following source, available under : Dr. Ed Uthman. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MediQ Learning, LLC are reserved.
- 220 **Psammoma bodies: Image A.** Courtesy of The Armed Forces Institute of Pathology.

























### Pharmacology

- 221 **Brain: Image A.** This image is a derivative work, adapted from the following source, available under . Courtesy of Jmarchn. The image may have been modified by cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under .
- 221 **Brain: Image B.** Brain metastasis. Courtesy of the US Department of Health and Human Services and The Armed Forces Institute of Pathology.

- 221 **Liver: Image C.** Liver metastasis. This image is a derivative work, adapted from the following source, available under . Courtesy of Dr. James Heilman The image may have been modified by cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under .
- 221 **Liver: Image D.** Liver metastasis. Courtesy of Haymanj.
- 221 **Bone: Image F.** Bone metastasis. This image is a derivative work, adapted from the following source, available under : Courtesy of Emmanuelm.

### Cardiology

- 271 **Coronary artery anatomy: Image A.** This image is a derivative work, adapted from the following source, available under : Zhang J, Chen L, Wang X, et al. Compounding local invariant features and global deformable geometry for medical image registration. *PLoS One* 2014;9(8):e105815. doi 10.1371/journal.pone.0105815.
- 288 **Congenital heart diseases: Image A.** Tetralogy of Fallot. This image is a derivative work, adapted from the following source, available under : Rashid AKM: Heart diseases in Down syndrome. In: Dey S, ed: Down syndrome. doi 10.5772/46009. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MediQ Learning, LLC are reserved.
- 288 **Congenital heart diseases: Image B.** Atrial septal defect. This image is a derivative work, adapted from the following source, available under : Teo KSL, Disney PJ, Dundon BK, et al. Assessment of atrial septal defects in adults comparing cardiovascular magnetic resonance with transesophageal echocardiography. *J Cardiovasc Magnet Resonance* 2010;12:44. doi 10.1186/1532-429X-12-44. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MediQ Learning, LLC are reserved.
- 288 **Congenital heart diseases: Image C.** Patent ductus arteriosus. This image is a derivative work, adapted from the following source, available under : Henjes CR, Nolte I, Wesfaedt P. Multidetector-row computed tomography of thoracic aortic anomalies in dogs and cats: patent ductus arteriosus and vascular rings. *BMC Vet Res* 2011;7:57. doi 10.1186/1746-6148-7-57.
- 288 **Congenital heart diseases: Image D.** Clubbing of fingers. Courtesy of Ann McGrath.
- 290 **Hypertension: Image A.** “String of beads” appearance in fibromuscular dysplasia. This image is a derivative work, adapted from the following source, available under : Plouin PF, Perdu J, LaBatide-Alanore A, et al. Fibromuscular dysplasia. *Orphanet J Rare Dis* 2007;7:28. doi 10.1186/1750-1172-2-28. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MediQ Learning, LLC are reserved.
- 291 **Arteriosclerosis: Image A.** Hyaline type. This image is a derivative work, adapted from the following source, available under . Courtesy of Nephron. The image may have been modified by cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under .
- 291 **Arteriosclerosis: Image B.** Hyperplastic type. This image is a derivative work, adapted from the following source, available under . Courtesy of Paco Larosa. The image may have

- been modified by cropping, labeling, and/or captions. MedIQ Learning, LLC makes this image available under .
- 291 Hyperlipidemia signs: Image C.** Tendinous xanthoma. This image is a derivative work, adapted from the following source, available under . Courtesy of Min.neel. The image may have been modified by cropping, labeling, and/or captions. MedIQ Learning, LLC makes this image available under .
- 291 Arteriosclerosis: Image C.** Monckeberg sclerosis (medial calcific sclerosis). This image is a derivative work, adapted from the following source, available under : Couri CE, da Silva GA, Martinez JA, Pereira FA, and de Paula F. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MedIQ Learning, LLC are reserved.
- 292 Atherosclerosis: Image A.** Carotid plaque. This image is a derivative work, adapted from the following source, available under : Dr. Ed Uthman. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MedIQ Learning, LLC are reserved.
- 293 Aortic dissection.** This image is a derivative work, adapted from the following source, available under : Apostolakis EE, Baikoussis NG, Katsanos K, et al. Postoperative peri-axillary seroma following axillary artery cannulation for surgical treatment of acute type A aortic dissection: case report. *J Cardiothor Surg* 2010;5:43. doi 0.1186/1749-8090-5-43. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MedIQ Learning, LLC are reserved.
- 296 Myocardial infarction complications: Image A.** Papillary muscle rupture. This image is a derivative work, adapted from the following source, available under : Routy B, Huynh T, Fraser R, et al. Vascular endothelial cell function in catastrophic antiphospholipid syndrome: a case report and review of the literature. *Case Rep Hematol* 2013;2013:710365. doi 10.1155/2013/710365.
- 296 Myocardial infarction complications: Image B.** Drawing of pseudoaneurysm. This image is a derivative work, adapted from the following source, available under : Patrick J. Lynch and Dr. C. Carl Jaffe.
- 296 Myocardial infarction complications: Image C.** Free wall rupture of left ventricle. This image is a derivative work, adapted from the following source, available under : Zacarias ML, da Trindade H, Tsutsu J, et al. Left ventricular free wall impeding rupture in post-myocardial infarction period diagnosed by myocardial contrast echocardiography: case report. *Cardiovasc Ultrasound* 2006;4:7. doi 10.1186/1476-7120-4-7.
- 297 Cardiomyopathies: Image A.** Dilated cardiomyopathy. This image is a derivative work, adapted from the following source, available under : Gho JM, van Es R, Stathonikos N, et al. High resolution systematic digital histological quantification of cardiac fibrosis and adipose tissue in phospholamban p.Arg14del mutation associated cardiomyopathy. *PLoS One* 2014;9:e94820. doi 10.1371/journal.pone.0094820.
- 298 Heart failure.** Pedal edema. This image is a derivative work, adapted from the following source, available under . Courtesy of Dr. James Heilman. The image may have been modified by cropping, labeling, and/or captions. MedIQ Learning, LLC makes this image available under .
- 299 Bacterial endocarditis: Image B.** This image is a derivative work, adapted from the following source, available under : Yang ML, Chen YH, Lin WR, et al. Case report: Infective endocarditis caused by *Brevundimonas vesicularis*. *BMC Infect Dis* 2006;6:179. doi 10.1186/1471-2334-6-179.
- 299 Bacterial endocarditis: Image A.** Janeway lesions on sole. This image is a derivative work, adapted from the following source, available under : DeNanneke.
- 300 Rheumatic fever.** Aschoff body and Anitschkow cells. This image is a derivative work, adapted from the following source, available under : Dr. Ed Uthman. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MedIQ Learning, LLC are reserved.
- 300 Acute pericarditis.** This image is a derivative work, adapted from the following source, available under : Bogaert J, Francone M. Cardiovascular magnetic resonance in pericardial diseases. *J Cardiovasc Magn Reson* 2009;11:14. doi 10.1186/1532-429X-11-14. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MedIQ Learning, LLC are reserved.
- 300 Cardiac tamponade.** This image is a derivative work, adapted from the following source, available under : Lin E, Boire A, Hemmige V, et al. Cardiac tamponade mimicking tuberculous pericarditis as the initial presentation of chronic lymphocytic leukemia in a 58-year-old woman: a case report. *J Med Case Rep* 2010;4:246. doi 10.1186/1752-1947-4-246. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MedIQ Learning, LLC are reserved.
- 302 Vasculitides: Image A.** Temporal arteritis histology. This image is a derivative work, adapted from the following source, available under . Courtesy of Marvin. The image may have been modified by cropping, labeling, and/or captions. MedIQ Learning, LLC makes this image available under .
- 302 Vasculitides: Image B.** Angiogram in patient with Takayasu arteritis.  Courtesy of the US Department of Health and Human Services and Justin Ly.
- 302 Vasculitides: Image C.** Microaneurysms in polyarteritis nodosa. Reproduced, with permission, from Dr. Frank Gaillard and www.radiopaedia.org.
- 302 Vasculitides: Image D.** Strawberry tongue in patient with Kawasaki disease. This image is a derivative work, adapted from the following source, available under : Natr.
- 302 Vasculitides: Image E.** Coronary artery aneurysm in Kawasaki disease. This image is a derivative work, adapted from the following source, available under : Wikimedia Commons. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MedIQ Learning, LLC are reserved.
- 302 Vasculitides: Image F.** Gangrene as a consequence of Buerger disease. This image is a derivative work, adapted from the following source, available under : Afsjarfard A, Mozaffar M, Malekpour F, et al. The wound healing effects of iloprost in patients with Buerger's disease: claudication and prevention of major amputations. *Iran Red Crescent Med J* 2011;13:420-423.
- 302 Vasculitides: Image G.** Granulomatosis with polyangiitis (formerly Wegener) and PR3-ANCA/c-ANCA.  Courtesy of M.A. Little.


























- 302 **Vasculitides: Image H.** Microscopic polyangiitis and MPO-ANCA/p-ANCA. Courtesy of the US Department of Health and Human Services and M.A. Little.
- 302 **Vasculitides: Image I.** Churg-Strauss syndrome histology. This image is a derivative work, adapted from the following source, available under . Courtesy of Dr. Michael Bonert. The image may have been modified by cropping, labeling, and/or captions. MedIQ Learning, LLC makes this image available under .
- 302 **Vasculitides: Image J.** Henoch-Schönlein purpura. Courtesy of Okwikikim.



























## Endocrine

- 312 **Thyroid development.** Thyroglossal duct cyst. This image is a derivative work, adapted from the following source, available under : Karlatti PD, Nagvekar S, Lekshmi TP, Kothari As. Migratory intralaryngeal thyroglossal duct cyst. *Indian J Radiol Imaging* 2010;20:115-117. doi 10.4103/0971-3026.63053. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MedIQ Learning, LLC are reserved.
- 324 **Adrenal insufficiency.** Mucosal hyperpigmentation in 1° adrenal insufficiency. Courtesy of FlatOut. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MedIQ Learning, LLC are reserved.
- 325 **Neuroblastoma: Image A.** CT scan of abdomen. This image is a derivative work, adapted from the following source, available under : Koumariou A, Oikonomopoulou P, Baka M, et al. Implications of the incidental finding of a MYCN amplified adrenal tumor: a case report and update of a pediatric disease diagnosed in adults. *Case Rep Oncol Med* 2013;2013:393128. doi 10.1155/2013/393128. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MedIQ Learning, LLC are reserved.
- 325 **Neuroblastoma: Image B.** Neuroblastoma, Homer-Write rosettes. Courtesy of Dr. Kristine Krafts.
- 326 **Pheochromocytoma.** This image is a derivative work, adapted from the following source, available under : Dr. Michael Feldman.
- 328 **Hashimoto thyroiditis: Image A.** Hashimoto thyroiditis, Hurthle cells. Courtesy of Dr. Kristine Krafts.
- 328 **Hypothyroidism: Image B.** Before and after treatment of congenital hypothyroidism. Courtesy of the US Department of Health and Human Services.
- 328 **Hypothyroidism: Image C.** Congenital hypothyroidism. This image is a derivative work, adapted from the following source, available under : Sadasiv Swain. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MedIQ Learning, LLC are reserved.
- 328 **Hypothyroidism: Image D.** Reidel thyroiditis histology. Courtesy of Dr. Kristine Krafts.
- 329 **Hyperthyroidism: Image B.** Scalloped colloid. Courtesy of Dr. Kristine Krafts.
- 330 **Thyroid adenoma: Image A.** Courtesy of Dr. Kristine Krafts.
- 332 **Hyperparathyroidism.** Multiple lytic lesions. This image is a derivative work, adapted from the following source, available under : Khaoula BA, Kaouther BA, Ines C, et al. An unusual presentation of primary hyperparathyroidism: pathological fracture. *Case Rep Orthop* 2011;2011:521578. doi 10.1155/2011/521578. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MedIQ Learning, LLC are reserved.
- 332 **Pituitary adenoma.** Reproduced, with permission, from Dr. Frank Gaillard and www.radiopaedia.org.
- 338 **Carcinoid syndrome.** Carcinoid tumor histology. Courtesy of Armed Forces Institute of Pathology.













## Gastrointestinal

- 344 **Intestinal atresia.** “Double bubble” sign of duodenal atresia. This image is a derivative work, adapted from the following source, available under : Alorainy IA, Barlas NB, Al-Boukai AA. Pictorial essay: infants of diabetic mothers. *Indian J Radiol Imaging* 2010;20:174-181. doi 0.4103/0971-3026.69349.
- 345 **Pancreas and spleen embryology.** Annular pancreas. This image is a derivative work, adapted from the following source, available under : Mahdi B, Selim S, Hassen T, et al. A rare cause of proximal intestinal obstruction in adults—annular pancreas: a case report. *Pan Afr Med J* 2011;10:56. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MedIQ Learning, LLC are reserved.
- 352 **Liver tissue architecture.** Kupffer cells. This image is a derivative work, adapted from the following source, available under . Courtesy of Dr. Michael Bonert. The image may have been modified by cropping, labeling, and/or captions. MedIQ Learning, LLC makes this image available under .
- 353 **Biliary structures.** Gallstones. This image is a derivative work, adapted from the following source, available under . Courtesy of J. Guntau. The image may have been modified by cropping, labeling, and/or captions. MedIQ Learning, LLC makes this image available under .
- 355 **Hernias: Image A.** Congenital diaphragmatic hernia. This image is a derivative work, adapted from the following source, available under : Tovar J. Congenital diaphragmatic hernia. *Orphanet J Rare Dis* 2012;7:1. doi 10.1186/1750-1172-7-1.
- 358 **Peyer patches.** This image is a derivative work, adapted from the following source, available under . Courtesy of Plainpaper. The image may have been modified by cropping, labeling, and/or captions. MedIQ Learning, LLC makes this image available under .
- 359 **Salivary gland tumors: Image A.** Pleomorphic adenoma histology. This image is a derivative work, adapted from the following source, available under . Courtesy of Wikimedia Commons. The image may have been modified by cropping, labeling, and/or captions. MedIQ Learning, LLC makes this image available under .
- 360 **Achalasia.** This image is a derivative work, adapted from the following source, available under : Farnoosh Farrokhi and Michael F. Vaezi. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MedIQ Learning, LLC are reserved.
- 360 **Esophageal pathologies: Image A.** Pneumomediastinum in Boerhaave syndrome. This image is a derivative work, adapted from the following source, available under . Courtesy of

- Wikimedia Commons. The image may have been modified by cropping, labeling, and/or captions. MedIQ Learning, LLC makes this image available under .
- 360 Esophageal pathologies: Image B.** Esophageal varices on endoscopy. This image is a derivative work, adapted from the following source, available under : Costaguta A, Alvarez F. Etiology and management of hemorrhagic complications of portal hypertension in children. *Int J Hepatol* 2012;2012:879163. doi 10.1155/2012/879163.
- 360 Esophageal pathologies: Image C.** Esophageal varices on CT. This image is a derivative work, adapted from the following source, available under : Courtesy of Hellerhoff. The image may have been modified by cropping, labeling, and/or captions. MedIQ Learning, LLC makes this image available under .
- 361 Barrett esophagus: Image A.** Endoscopy. This image is a derivative work, adapted from the following source, available under : Coda S, Thillainayagam AV. State of the art in advanced endoscopic imaging for the detection and evaluation of dysplasia and early cancer of the gastrointestinal tract. *Clin Exp Gastroenterol* 2014;7:133-150. doi 10.2147/CEG.S58157. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MedIQ Learning, LLC are reserved.
- 361 Barrett esophagus: Image B.** Goblet cells. This image is a derivative work, adapted from the following source, available under : Courtesy of Dr. Michael Bonert. The image may have been modified by cropping, labeling, and/or captions. MedIQ Learning, LLC makes this image available under .
- 362 Ménériere disease: Image A.** This image is a derivative work, adapted from the following source, available under : Courtesy of Hellerhoff. The image may have been modified by cropping, labeling, and/or captions. MedIQ Learning, LLC makes this image available under .
- 363 Ulcer complications: Image A.** Reproduced, with permission, from Dr. Frank Gaillard and www.radiopaedia.org.
- 364 Whipple disease: Image B.** Tropheryma Whippeli, PAS. This image is a derivative work, adapted from the following source, available under : Tran HA. Reversible hypothyroidism and Whipple's disease. *BMC Endocr Disord* 2006;6:3. doi 10.1186/1472-6823-6-3.
- 365 Inflammatory bowel diseases: Image A.** "String sign" on barium swallow in Crohn disease. This image is a derivative work, adapted from the following source, available under : Al-Mofarreh MA, Al Mofleh IA, Al-Teimi IN, et al. Crohn's disease in a Saudi outpatient population: is it still rare? *Saudi J Gastroenterol* 2009;15:111-116. doi 10.4103/1319-3767.45357. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MedIQ Learning, LLC are reserved.
- 365 Inflammatory bowel diseases: Images B (normal mucosa) and C (punched-out ulcers) in ulcerative colitis.** This image is a derivative work, adapted from the following source, available under : Ishikawa D, Ando T, Watanabe O, et al. Images of colonic real-time tissue sonoelastography correlate with those of colonoscopy and may predict response to therapy in patients with ulcerative colitis. *BMC Gastroenterol* 2011;11:29. doi 10.1186/1471-230X-11-29.
- 366 Appendicitis: Image A.** Fecalith. This image is a derivative work, adapted from the following source, available under : Courtesy of Dr. James Heilman. The image may have been modified by cropping, labeling, and/or captions. MedIQ Learning, LLC makes this image available under .
- 366 Diverticula of the gastrointestinal tract: Image B.** Diverticulitis. This image is a derivative work, adapted from the following source, available under : Courtesy of Dr. James Heilman. The image may have been modified by cropping, labeling, and/or captions. MedIQ Learning, LLC makes this image available under .
- 367 Zenker diverticulum.** This image is a derivative work, adapted from the following source, available under : Bernd Brägelmann.
- 368 Volvulus: Image A.** Coffee bean sign. This image is a derivative work, adapted from the following source, available under : Yigit M, Turkdogan KA. Coffee bean sign, whirl sign and bird's beak sign in the diagnosis of sigmoid volvulus. *Pan Afr Med J* 2014;19:56. doi 10.11604/pamj.2014.19.56.5142.
- 368 Intussusception: Image A.** Interoperative image of intussusception. This image is a derivative work, adapted from the following source, available under : Vasiliadis K, Kogopoulos E, Katsamakas M, et al. Ileocecal intussusception induced by a gastrointestinal stromal tumor. *World J Surg Oncol* 2008;6:133. doi 10.1186/1477-7819-6-133.
- 369 Acute mesenteric ischemia: Image A.** Necrosis due to occlusion of SMA. This image is a derivative work, adapted from the following source, available under : Van De Winkel N, Cheragwandi A, Nieboer K, et al. Superior mesenteric arterial branch occlusion causing partial jejunal ischemia: a case report. *J Med Case Reports* 2012;6:48. doi 10.1186/1752-1947-6-48.
- 369 Colonic ischemia: Image B.** Endoscopy showing dilated vessels. This image is a derivative work, adapted from the following source, available under : Gunjan D, Sharma V, Rana SS, et al. Small bowel bleeding: a comprehensive review. *Gastroenterol Rep* 2014 Nov; 2(4):262-75. doi 10.1093/gastro/gou025.
- 369 Adhesion: Image C.** Small bowel obstruction. This image is a derivative work, adapted from the following source, available under : Harrison S, Mahawar K, Brown D, et al. Acute appendicitis presenting as small bowel obstruction: two case reports. *Cases J* 2009 Nov; 28;2:9106. doi 10.1186/1757-1626-2-9106.
- 369 Necrotizing enterocolitis: Image D.** Pneumatosis intestinalis. This image is a derivative work, adapted from the following source, available under : Pelizzo G, Nakib G, Goruppi I, et al. Isolated colon ischemia with norovirus infection in preterm babies: a case series. *J Med Case Rep* 2013;7:108. doi 10.1186/1752-1947-7-108.
- 370 Colonic polyps: Image A.** Colonic polyps and cancer. This image is a derivative work, adapted from the following source, available under : M. Emmanuel.
- 371 Colorectal cancer: Image A.** Polyp on endoscopy. This image is a derivative work, adapted from the following source, available under : Chen C-W, Hsiao K-H, Yue C-T, et al. Invasive adenocarcinoma arising from a mixed hyperplastic/adenomatous polyp and synchronous transverse colon cancer. *World J Surg Oncol* 2013;11:214. doi 10.1186/1477-7819-11-214.














- 372 Cirrhosis and portal hypertension: Image A.** Splenomegaly and liver nodularity in cirrhosis. This image is a derivative work, adapted from the following source, available under . Courtesy of Inversitus. The image may have been modified by cropping, labeling, and/or captions. MedIQ Learning, LLC makes this image available under .
- 374 Non-alcoholic fatty liver disease: Image A.** This image is a derivative work, adapted from the following source, available under : El-Karakasy HM, El-Koofy NM, Anwar GM, et al. Predictors of non-alcoholic fatty liver disease in obese and overweight Egyptian children: single center study. *Saudi J Gastroenterol* 2011;17:40-46. doi 10.4103/1319-3767.74476.
- 374 Alcoholic liver disease: Image B.** Mallory bodies. This image is a derivative work, adapted from the following source, available under . Courtesy of Dr. Michael Bonert. The image may have been modified by cropping, labeling, and/or captions. MedIQ Learning, LLC makes this image available under .
- 374 Alcoholic liver disease: Image C.** Sclerosis in alcoholic cirrhosis. This image is a derivative work, adapted from the following source, available under . Courtesy of Dr. Michael Bonert. The image may have been modified by cropping, labeling, and/or captions. MedIQ Learning, LLC makes this image available under .
- 375 Hepatocellular carcinoma/hepatoma: Image A.** Gross specimen. Reproduced, with permission, from Jean-Christophe Fournet and Humpath.
- 375 Other liver tumors.** Cavernous liver hemangioma. This image is a derivative work, adapted from the following source, available under . Courtesy of Dr. Michael Bonert. The image may have been modified by cropping, labeling, and/or captions. MedIQ Learning, LLC makes this image available under .
- 375  $\alpha_1$ -antitrypsin deficiency.** Liver histology. This image is a derivative work, adapted from the following source, available under . Courtesy of Dr. Jerad M. Gardner. The image may have been modified by cropping, labeling, and/or captions. MedIQ Learning, LLC makes this image available under .
- 376 Jaundice.** Yellow sclera.  Courtesy of the US Department of Health and Human Services and Dr. Thomas F. Sellers.
- 378 Hemochromatosis.** Hemosiderin deposits. This image is a derivative work, adapted from the following source, available under : Mathew J, Leong MY, Morley N, et al. A liver fibrosis cocktail? Psoriasis, methotrexate and genetic hemochromatosis. *BMC Dermatol* 2005;5:12. doi 10.1186/1471-5945-5-12.
- 379 Gallstones (cholelithiasis): Image A.** Gross specimen. This image is a derivative work, adapted from the following source, available under : M. Emmanuel.
- 379 Gallstones (cholelithiasis): Image B.** Ultrasound. This image is a derivative work, adapted from the following source, available under . Courtesy of Dr. James Heilman. The image may have been modified by cropping, labeling, and/or captions. MedIQ Learning, LLC makes this image available under .
- 379 Porcelain gallbladder.** This image is a derivative work, adapted from the following source, available under : Fred H, van Dijk H. Images of memorable cases: case 19. Connexions Web site. December 4, 2008. Available at: <http://cnx.org/content/m14939/1.3/>. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MedIQ Learning, LLC are reserved.
- 380 Acute pancreatitis: Image A.** Acute exudative pancreatitis. This image is a derivative work, adapted from the following source, available under . Courtesy of Hellerhoff. The image may have been modified by cropping, labeling, and/or captions. MedIQ Learning, LLC makes this image available under .
- 380 Chronic pancreatitis: Image A.** This image is a derivative work, adapted from the following source, available under . Courtesy of Hellerhoff. The image may have been modified by cropping, labeling, and/or captions. MedIQ Learning, LLC makes this image available under .
- 380 Pancreatic adenocarcinoma: Image A.** Histology. This image is a derivative work, adapted from the following source, available under . Courtesy of KGH. The image may have been modified by cropping, labeling, and/or captions. MedIQ Learning, LLC makes this image available under .
- 380 Acute pancreatitis: Image B.** Pancreatic pseudocyst. This image is a derivative work, adapted from the following source, available under . Courtesy of Thomas Zimmerman. The image may have been modified by cropping, labeling, and/or captions. MedIQ Learning, LLC makes this image available under .
- 380 Pancreatic adenocarcinoma: Image B.** CT scan.  Courtesy of MBq. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MedIQ Learning, LLC are reserved.












### Hematology and Oncology

- 386 Erythrocyte.**  Courtesy of the US Department of Health and Human Services and Drs. Noguchi, Rodgers, and Schechter.
- 386 Thrombocyte (platelet).** This image is a derivative work, adapted from the following source, available under . Courtesy of Dr. Ed Uthman. The image may have been modified by cropping, labeling, and/or captions. MedIQ Learning, LLC makes this image available under .
- 386 Neutrophil.**  Courtesy of the US Department of Health and Human Services and B. Lennert.
- 387 Monocyte.** This image is a derivative work, adapted from the following source, available under . Courtesy of Dr. Graham Beards. The image may have been modified by cropping, labeling, and/or captions. MedIQ Learning, LLC makes this image available under .
- 387 Macrophage: Image A.** This image is a derivative work, adapted from the following source, available under : De Tommasi AS, Otranto D, Furlanello T, et al. Evaluation of blood and bone marrow in selected canine vector-borne diseases. *Parasit Vectors* 2014;7:534. doi 10.1186/s13071-014-0534-2.
- 387 Eosinophil.** This image is a derivative work, adapted from the following source, available under : Dr. Ed Uthman.
- 387 Basophil.** This image is a derivative work, adapted from the following source, available under . Courtesy of Dr. Erhabor Osaro. The image may have been modified by cropping, labeling, and/or captions. MedIQ Learning, LLC makes this image available under .
- 387 Mast cell: Image A.**  Courtesy of Wikimedia Commons.
- 388 Dendritic cell: Image A.** This image is a derivative work, adapted from the following source, available under : Cheng





- J-H, Lee S-Y, Lien Y-Y, et al. Immunomodulating activity of *Nymphaea rubra* roxb. extracts: activation of rat dendritic cells and improvement of the TH1 immune response. *Int J Mol Sci* 2012;13:10722-10735. doi 10.3390/ijms130910722.
- 388 Lymphocyte: Image A.** Lymphocyte with small amount of cytoplasm. This image is a derivative work, adapted from the following source, available under [CC BY](#): Fickleandfreckled.
- 389 Plasma cell: Image A.** [CC BY](#) Courtesy of the US Department of Health and Human Services and Dr. Francis W. Chandler. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MediQ Learning, LLC are reserved.
- 394 Pathologic RBC forms: Image A.** Acanthocyte (“spur cell”). Courtesy of Dr. Kristine Krafts.
- 394 Pathologic RBC forms: Image B.** Basophilic stippling. This image is a derivative work, adapted from the following source, available under [CC BY](#): van Dijk HA, Fred HL. Images of memorable cases: case 81. Connexions Web site. December 3, 2008. Available at <http://cnx.org/contents/3196bf3e-1e1e-4c4d-a1ac-d4fc9ab65443@4@4>.
- 394 Pathologic RBC forms: Image C.** Dacrocyte (“teardrop cell”). Courtesy of Dr. Kristine Krafts.
- 394 Pathologic RBC forms: Image D.** Degmacyte (“bite cell”). Courtesy of Dr. Kristine Krafts.
- 394 Pathologic RBC forms: Image E.** Echinocyte (“burr cell”). Courtesy of Dr. Kristine Krafts.
- 394 Pathologic RBC forms: Image F.** Elliptocyte. Courtesy of Dr. Kristine Krafts.
- 394 Pathologic RBC forms: Image G.** Macro-ovalocyte. Courtesy of Dr. Kristine Krafts.
- 394 Pathologic RBC forms: Image H.** Ringed sideroblast. This image is a derivative work, adapted from the following source, available under [CC BY](#). Courtesy of Paulo Henrique Orlandi Mourao. The image may have been modified by cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under [CC BY](#).
- 394 Pathologic RBC forms: Image I.** Schistocyte. Courtesy of Dr. Kristine Krafts.
- 394 Pathologic RBC forms: Image J.** Sickle cell. [CC BY](#) Courtesy of the US Department of Health and Human Services and the Sickle Cell Foundation of Georgia, Jackie George, and Beverly Sinclair.
- 394 Pathologic RBC forms: Image K.** Spherocyte. Courtesy of Dr. Kristine Krafts.
- 394 Pathologic RBC forms: Image L.** Target cell. Courtesy of Dr. Kristine Krafts.
- 395 Other RBC pathologies: Image A.** Heinz bodies. Courtesy of Dr. Kristine Krafts.
- 395 Howell-Jolly bodies: Image B.** This image is a derivative work, adapted from the following source, available under [CC BY](#): Serio B, Pezzullo L, Giudice V, et al. OPSI threat in hematological patients. *Transl Med UniSa* 2013 May-Aug; 6:2-10.
- 396 Microcytic (MCV < 80 fL), hypochromic anemia: Image C.**  $\beta$ -thalassemia. Courtesy of Dr. Kristine Krafts.
- 396 Microcytic (MCV < 80 fL), hypochromic anemia: Image D.** Lead lines in lead poisoning. Reproduced, with permission, from Dr. Frank Gaillard and [www.radiopaedia.org](http://www.radiopaedia.org).
- 396 Microcytic (MCV < 80 fL), hypochromic anemia: Image E.** Sideroblastic anemia. This image is a derivative work, adapted from the following source, available under [CC BY](#). Courtesy of Paulo Henrique Orlandi Moura. The image may have been modified by cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under [CC BY](#).
- 398 Macrocytic (MCV > 100 fL) anemia.** Megaloblastic anemia. This image is a derivative work, adapted from the following source, available under [CC BY](#): Dr. Ed Uthman.
- 400 Intrinsic hemolytic anemia: Image B.** Dactylitis. This image is a derivative work, adapted from the following source, available under [CC BY](#): Pedram M, Jaseb K, Haghi S, et al. First presentation of sickle cell anemia in a 3.5-year-old girl: a case report. *Iran Red Crescent Med J* 2012;14:184-185.
- 401 Extrinsic hemolytic anemia: Image A.** Autoimmune hemolytic anemia. Courtesy of Dr. Kristine Krafts.
- 403 Heme synthesis, porphyrias, and lead poisoning.** Basophilic stippling in lead poisoning. This image is a derivative work, adapted from the following source, available under [CC BY](#): van Dijk HA, Fred HL. Images of memorable cases: case 81. Connexions Web site. December 3, 2008. Available at <http://cnx.org/contents/3196bf3e-1e1e-4c4d-a1ac-d4fc9ab65443@4@4>.
- 403 Porphyria cutanea tarda: Image A.** Porphyria cutanea tarda. This image is a derivative work, adapted from the following source, available under [CC BY](#): Bovenschen HJ, Vissers WHPM. Primary hemochromatosis presented by porphyria cutanea tarda: a case report. *Cases J* 2009;2:7246. doi 10.4076/1757-1626-2-7246.
- 404 Coagulation disorders.** Hemarthrosis. This image is a derivative work, adapted from the following source, available under [CC BY](#): Rodriguez-Merchan EC. Prevention of the musculoskeletal complications of hemophilia. *Adv Prev Med* 2012;2012:201271. doi 10.1155/2012/201271.
- 408 Primary central nervous system lymphoma: Image C.** This image is a derivative work, adapted from the following source, available under [CC BY](#): Mansour A, Qandeel M, Abdel-Razeq H, et al. MR imaging features of intracranial primary CNS lymphoma in immune competent patients. *Cancer Imaging* 2014;14(1):22. doi 10.1186/1470-7330-14-22.
- 408 NonHodgkin lymphoma: Image C.** Mycosis fungoides. This image is a derivative work, adapted from the following source, available under [CC BY](#): Chaudhary S, Bansal C, Ranga U, et al. Erythrodermic mycosis fungoides with hypereosinophilic syndrome: a rare presentation. *Ecancermedicalsecience* 2013;7:337. doi 10.3332/ecancer.2013.337.
- 409 Multiple myeloma: Image B.** RBC rouleaux formation. Courtesy of Dr. Kristine Krafts.
- 409 Multiple myeloma: Image C.** Plasma cells. This image is a derivative work, adapted from the following source, available under [CC BY](#): Sharma A, Kaushal M, Chaturvedi NK, et al. Cytodiagnosis of multiple myeloma presenting as orbital involvement: a case report. *Cytojournal* 2006;3:19. doi 10.1186/1742-6413-3-19.
- 410 Leukemias: Image C.** Hairy cell leukemia. Courtesy of Dr. Kristine Krafts.

- 410 **Leukemias: Image E.** Chronic myelogenous leukemia. Courtesy of Dr. Kristine Krafts.
- 411 **Chronic myeloproliferative disorders: Image A.** Erythromelalgia in polycythemia vera. This image is a derivative work, adapted from the following source, available under : Fred H, van Dijk H. Images of memorable cases: case 151. Connexions Web site. December 4, 2008. Available at <http://cnx.org/content/m14932/1.3/>.
- 411 **Chronic myeloproliferative disorders: Image B.** Essential thrombocytosis with enlarged megakaryocytes. Courtesy of Dr. Kristine Krafts.
- 411 **Chronic myeloproliferative disorders: Image C.** Myelofibrosis. This image is a derivative work, adapted from the following source, available under : Dr. Ed Uthman.
- 411 **Chronic myeloproliferative disorders: Image D.** Dacrocyte (“teardrop cell”). Courtesy of Dr. Kristine Krafts.
- 414 **Warfarin.** Toxic effect. This image is a derivative work, adapted from the following source, available under : Fred H, van Dijk H. Images of memorable cases: cases 84 and 85. Connexions Web site. December 2, 2008. Available at <http://cnx.org/content/m14932/1.3/>.
- Musculoskeletal, Skin, and Connective Tissue**
- 424 **Common fractures: Image A.** Greenstick fracture. This image is a derivative work, adapted from the following source, available under : Randsborg PH, Sivertsen EA. Classification of distal radius fractures in children: good inter- and intraobserver reliability, which improves with clinical experience. *BMC Musculoskelet Disord* 2013;13:6. doi 10.1186/1471-2474-13-6.
- 424 **Myelin: Image A.** Myelinated neuron.  Courtesy of the Electron Microscopy Facility at Trinity College.
- 424 **Common fractures: Image B.** Buckle fracture. This image is a derivative work, adapted from the following source, available under : Randsborg PH, Sivertsen EA. Classification of distal radius fractures in children: good inter- and intraobserver reliability, which improves with clinical experience. *BMC Musculoskelet Disord* 2012;13:6. doi 10.1186/1471-2474-13-6.
- 425 **Common knee conditions: Image A.** ACL tear. This image is a derivative work, adapted from the following source, available under : Chang MJ, Chang CB, Choi J-Y, et al. Can magnetic resonance imaging findings predict the degree of knee joint laxity in patients undergoing anterior cruciate ligament reconstruction? *BMC Musculoskelet Disord* 2014;15:214. doi 10.1186/1471-2474-15-214. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MedIQ Learning, LLC are reserved.
- 425 **Rotator cuff muscles: Image A.** Glenohumeral instability. This image is a derivative work, adapted from the following source, available under : Koike Y, Sano H, Imamura I, et al. Changes with time in skin temperature of the shoulders in healthy controls and a patient with shoulder-hand syndrome. *Ups J Med Sci* 2010;115:260-265. doi 10.3109/03009734.2010.503354. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MedIQ Learning, LLC are reserved.
- 425 **Common knee conditions: Images B (prepatellar bursitis) and C (Baker cyst).** This image is a derivative work, adapted from the following source, available under : Hirji Z, Hunhun JS, Choudur HN. Imaging of the bursae. *J Clin Imaging Sci* 2011;1:22. doi 10.4103/2156-7514.80374. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MedIQ Learning, LLC are reserved.
- 426 **Wrist bones: Image B.** Anatomic snuff box. This image is a derivative work, adapted from the following source, available under : Rhemrev SJ, Ootes D, Beeres FJP, et al. Current methods of diagnosis and treatment of scaphoid fractures. *Int J Emerg Med* 2011;4:4. doi 10.1186/1865-1380-4-4.
- 428 **Thoracic outlet syndrome: Image A.** Cervical rib. This image is a derivative work, adapted from the following source, available under : Dahlin LB, Backman C, Duppe H, et al. Compression of the lower trunk of the brachial plexus by a cervical rib in two adolescent girls: case reports and surgical treatment. *J Brachial Plex Peripher Nerve Inj* 2009;4:14. doi 10.1186/1749-7221-4-14.
- 433 **Muscle conduction to contraction: Image A.** Human skeletal muscle.  Courtesy of Louisa Howard. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MedIQ Learning, LLC are reserved.
- 435 **Osteoporosis: Image A.** Vertebral compression fractures of spine. This image is a derivative work, adapted from the following source, available under : Sexton C, Crichlow C. Multiple myeloma: imaging evaluation of skeletal disease. *J Community Hosp Intern Med Perspect* 2013;3. doi 10.3402/jchimp.v3i2.21419.
- 435 **Osteopetrosis (marble bone disease): Image A.** This image is a derivative work, adapted from the following source, available under : Kant P, Sharda N, Bhowate RR. Clinical and radiological findings of autosomal dominant osteopetrosis type II: a case report. *Case Rep Dent* 2013;2013:707343. doi 10.1155/2013/707343.
- 436 **Osteomalacia/rickets: Image B.** This image is a derivative work, adapted from the following source, available under : Linglart A, Biosse-Duplan M, Briot K, et al. Therapeutic management of hypophosphatemic rickets from infancy to adulthood. *Endocr Connect* 2014;3:R13-R30. doi 10.1530/EC-13-0103.
- 436 **Paget disease of bone (osteitis deformans): Image A.** Thickened calvarium. This image is a derivative work, adapted from the following source, available under : Dawes L. Paget’s disease. [Radiology Picture of the Day Website]. Published June 21, 2007. Available at <http://www.radpod.org/2007/06/21/pagets-disease/>.
- 436 **Osteonecrosis (avascular necrosis): Image A.** Bilateral necrosis of femoral head. This image is a derivative work, adapted from the following source, available under : Ding H, Chen S-B, Lin S, et al. The effect of postoperative corticosteroid administration on free vascularized fibular grafting for treating osteonecrosis of the femoral head. *Sci World J* 2013;708014. doi 10.1155/2013/708014. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MedIQ Learning, LLC are reserved.
- 436 **Osteomalacia/rickets: Image B.** Rachitic rosary on chest X-ray. This image is a derivative work, adapted from the following source, available under : Essabar L, Meskini T, Ettair S, et al. Malignant infantile osteopetrosis: case report with

























- review of literature. *Pan Afr Med J* 2014;17:63. doi 10.11604/pamj.2014.17.63.3759.
- 438 Primary bone tumors: Image A.** Osteochondroma. This image is a derivative work, adapted from the following source, available under . Courtesy of Lucien Monfils. The image may have been modified by cropping, labeling, and/or captions. MedIQ Learning, LLC makes this image available under .
- 438 Primary bone tumors: Image B.** Giant cell tumor. Reproduced, with permission, from Dr. Frank Gaillard and www.radiopaedia.org.
- 438 Primary bone tumors: Image C.** Osteosarcoma. Reproduced, with permission, from Dr. Frank Gaillard and www.radiopaedia.org.
- 439 Rheumatoid arthritis: Image A.** Histology of rheumatoid nodule. This image is a derivative work, adapted from the following source, available under : Gomez-Rivera F, El-Naggar AK, Guha-Thakurta N, et al. Rheumatoid arthritis mimicking metastatic squamous cell carcinoma. *Head Neck Oncol* 2011;3:26. doi 10.1186/1758-3284-3-26.
- 440 Calcium pyrophosphate deposition disease: Image A.** This image is a derivative work, adapted from the following source, available under : Hahn M, Raithel M, Hagel A, et al. Chronic calcium pyrophosphate crystal inflammatory arthritis induced by extreme hypomagnesemia in short bowel syndrome. *BMC Gastroenterol* 2012;12:129. doi 10.1186/1471-230X-12-129.
- 440 Gout: Image B.** Uric acid crystals under polarized light. This image is a derivative work, adapted from the following source, available under . Courtesy of Robert J. Galindo. The image may have been modified by cropping, labeling, and/or captions. MedIQ Learning, LLC makes this image available under .
- 440 Calcium pyrophosphate deposition disease: Image A.** Calcium phosphate crystals. Courtesy of Medical Research Council and Drs. P. Diepke and K. Swan.
- 440 Gout: Image C.** Podagra. This image is a derivative work, adapted from the following source, available under : Roddy E. Revisiting the pathogenesis of podagra: why does gout target the foot? *J Foot Ankle Res* 2011;4:13. doi 10.1186/1757-1146-4-13.
- 441 Sjögren syndrome: Image A.** Lymphocytic infiltration.  Courtesy of the US Department of Health and Human Services.
- 441 Septic arthritis: Image A.** Joint effusion. This image is a derivative work, adapted from the following source, available under . Courtesy of Dr. James Heilman. The image may have been modified by cropping, labeling, and/or captions. MedIQ Learning, LLC makes this image available under .
- 441 Sjögren syndrome: Image B.** Dry tongue. This image is a derivative work, adapted from the following source, available under : Negrato CA, Tarzia O. Buccal alterations in diabetes mellitus. *Diabetol Metab Syndr* 2010;2:3. doi 10.1186/1758-5996-2-3.
- 442 Seronegative spondyloarthropathies: Image C, left.** Bamboo spine. This image is a derivative work, adapted from the following source, available under . Courtesy of Stevenfruitsmaak. The image may have been modified by cropping, labeling, and/or captions. MedIQ Learning, LLC makes this image available under .
- 442 Seronegative spondyloarthropathies: Image C, right.** Bamboo spine.  Courtesy of Heather Hawker.
- 443 Systemic lupus erythematosus: Image B.** Discoid rash. Courtesy of Dr. Kachiu Lee.
- 444 Sarcoidosis: Images B (X-ray of the chest) and C (CT of the chest).** This image is a derivative work, adapted from the following source, available under : Lönborg J, Ward M, Gill A, et al. Utility of cardiac magnetic resonance in assessing right-sided heart failure in sarcoidosis. *BMC Med Imaging* 2013;13:2. doi 10.1186/1471-2342-13-2.
- 445 Raynaud phenomenon: Image A.** This image is a derivative work, adapted from the following source, available under . Courtesy of Jamclaassen. The image may have been modified by cropping, labeling, and/or captions. MedIQ Learning, LLC makes this image available under .
- 446 Skin layers: Image A.** Epidermis layers. Courtesy of Dr. Kristine Krafts.
- 449 Common skin disorders: Image O.** Urticaria. This image is a derivative work, adapted from the following source, available under . Courtesy of Dr. James Heilman. The image may have been modified by cropping, labeling, and/or captions. MedIQ Learning, LLC makes this image available under .
- 450 Vascular tumors: Image C.** Cystic hygroma. This image is a derivative work, adapted from the following source, available under : Sannoh S, Quezada E, Merer DM, et al. Cystic hygroma and potential airway obstruction in a newborn: a case report and review of the literature. *Cases J* 2009;2:48. doi 10.1186/1757-1626-2-48. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MedIQ Learning, LLC are reserved.
- 450 Glomus tumor: Image D.** Glomus tumor under fingernail. This image is a derivative work, adapted from the following source, available under : Hazani R, Houle JM, Kasdan ML, et al. Glomus tumors of the hand. *Eplasty* 2008;8:e48. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MedIQ Learning, LLC are reserved.
- 451 Skin infections: Image C.** Erysipelas. This image is a derivative work, adapted from the following source, available under : Klaus D. Peter.
- 452 Blistering skin disorders: Image D.** Bullous pemphigoid on immunofluorescence. This image is a derivative work, adapted from the following source, available under : M. Emmanuel.
- 454 Skin cancer: Image D.** Basal cell carcinoma histopathology. This image is a derivative work, adapted from the following source, available under . Courtesy of Wikimedia Commons. The image may have been modified by cropping, labeling, and/or captions. MedIQ Learning, LLC makes this image available under .

### Neurology and Special Senses

































- 461 Forebrain anomalies: Image A.** Holoprosencephaly. This image is a derivative work, adapted from the following source, available under : Alorainy IA, Barlas NB, Al-Boukai AA. Pictorial essay: infants of diabetic mothers. *Indian J Radiol Imagin* 2010 Aug; 20(3):174-81. doi 10.4103/0971-3026.69349.
- 462 Posterior fossa malformations: Image A.** Chiari I malformation. This image is a derivative work, adapted from the following source, available under : Toldo I, De Carlo D, Mardari R, et al. Short lasting activity-related headaches with sudden onset in














children: a case-based reasoning on classification and diagnosis. *J Headache Pain* 2013;14(1):3. doi 10.1186/1129-2377-14-3.

- 462 **Syringomyelia: Image A.** Reproduced, with permission, from Dr. Frank Gaillard and [www.radiopaedia.org](http://www.radiopaedia.org).
- 462 **Posterior fossa malformations: Image B.** Dandy-Walker malformation. This image is a derivative work, adapted from the following source, available under [CC BY](https://creativecommons.org/licenses/by/4.0/): Krupa K, Bekiesinska-Figatowska M. Congenital and acquired abnormalities of the corpus callosum: a pictorial essay. *Biomed Res Int* 2013;2013:265619. doi 10.1155/2013/265619.
- 465 **Chromatolysis: Image A.** This image is a derivative work, adapted from the following source, available under [CC BY](https://creativecommons.org/licenses/by/4.0/). Courtesy of Nephron. The image may have been modified by cropping, labeling, and/or captions. MedIQ Learning, LLC makes this image available under [CC BY](https://creativecommons.org/licenses/by/4.0/).
- 468 **Limbic system: Image A.** This image is a derivative work, adapted from the following source, available under [CC BY](https://creativecommons.org/licenses/by/4.0/): Schopf V, Fischmeister FP, Windischberger C, et al. Effects of individual glucose levels on the neuronal correlates of emotions. *Front Hum Neurosci* 2013 May 21;7:212. doi 10.3389/fnhum.2013.00212.
- 473 **Dural venous sinuses: Image A.** This image is a derivative work, adapted from the following source, available under [CC BY](https://creativecommons.org/licenses/by/4.0/): Cikla U, Aagaard-Kienitz B, Turski PA, et al. Familial perimesencephalic subarachnoid hemorrhage: two case reports. *J Med Case Rep* 2014;8. doi 10.1186/1752-1947-8-380. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MedIQ Learning, LLC are reserved.
- 478 **Spinal cord and associated tracts: Image A.** Spinal cord cross-section. This image is a derivative work, adapted from the following source, available under [CC BY](https://creativecommons.org/licenses/by/4.0/): Regents of University of Michigan Medical School.
- 483 **Intracranial hemorrhage: Image A.** Axial CT of brain showing epidural blood. This image is a derivative work, adapted from the following source, available under [CC BY](https://creativecommons.org/licenses/by/4.0/). Courtesy of Hellerhoff. The image may have been modified by cropping, labeling, and/or captions. MedIQ Learning, LLC makes this image available under [CC BY](https://creativecommons.org/licenses/by/4.0/).
- 483 **Intracranial hemorrhage: Image B.** Axial CT of brain showing skull fracture and scalp hematoma. This image is a derivative work, adapted from the following source, available under [CC BY](https://creativecommons.org/licenses/by/4.0/). Courtesy of Hellerhoff. The image may have been modified by cropping, labeling, and/or captions. MedIQ Learning, LLC makes this image available under [CC BY](https://creativecommons.org/licenses/by/4.0/).
- 483 **Intracranial hemorrhage: Image C.** Subdural hematoma. This image is a derivative work, adapted from the following source, available under [CC BY](https://creativecommons.org/licenses/by/4.0/). Courtesy of Dr. James Heilman. The image may have been modified by cropping, labeling, and/or captions. MedIQ Learning, LLC makes this image available under [CC BY](https://creativecommons.org/licenses/by/4.0/).
- 483 **Intracranial hemorrhage: Image E.** Subarachnoid hemorrhage. This image is a derivative work, adapted from the following source, available under [CC BY](https://creativecommons.org/licenses/by/4.0/): Hakan T, Turk CC, Celik H. Intra-operative real time intracranial subarachnoid haemorrhage during glial tumour resection: a case report. *Cases J* 2008;1:306. doi 10.1186/1757-1626-1-306. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MedIQ Learning, LLC are reserved.
- 484 **Middle cerebral artery: Image A.** Large abnormality of the left MCA territory. This image is a derivative work, adapted from the following source, available under [CC BY](https://creativecommons.org/licenses/by/4.0/): Hakimelahi R, Yoo AJ, He J, et al. Rapid identification of a major diffusion/perfusion mismatch in distal internal carotid artery or middle cerebral artery ischemic stroke. *BMC Neurol* 2012 Nov 5;12:132. doi 10.1186/1471-2377-12-132. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MedIQ Learning, LLC are reserved.
- 484 **Lenticulostriate artery: Image B.** MRI diffusion weighted image shows a hypersensitive lesion on posterior limb of internal capsular. This image is a derivative work, adapted from the following source, available under [CC BY](https://creativecommons.org/licenses/by/4.0/): Zhou L, Ni J, Yao M, et al. High-resolution MRI findings in patients with capsular warning syndrome. *BMC Neurol* 2014;14:16. doi 10.1186/1471-2377-14-16.
- 484 **Posterior Inferior cerebellar artery: Image C.** This image is a derivative work, adapted from the following source, available under [CC BY](https://creativecommons.org/licenses/by/4.0/): Nohu A, Remke J, Ruland S. Ischemic posterior circulation stroke: a review of anatomy, clinical presentations, diagnosis, and current management. *Front Neurol* 2014 Apr 7;5:30. doi 10.3389/fneur.2014.00030.
- 484 **Posterior cerebral artery: Image D.** This image is a derivative work, adapted from the following source, available under [CC BY](https://creativecommons.org/licenses/by/4.0/): Nakao Y, Terai H. Embolic brain infarction related to posttraumatic occlusion of vertebral artery resulting from cervical spine injury: a case report. *J Med Case Rep* 2014; 8:344. doi 10.1186/1752-1947-8-344.
- 490 **Parkinson disease: Image A.** Lewy body in substantia nigra. This image is a derivative work, adapted from the following source, available under [CC BY](https://creativecommons.org/licenses/by/4.0/): Werner CJ, Heyny-von Hausseen R, Mall G, et al. Parkinson's disease. *Proteome Sci* 2008;6:8. doi 10.1186/1477-5956-6-8. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MedIQ Learning, LLC are reserved.
- 490 **Alzheimer disease: Image B.** Gross specimen of normal brain. This image is a derivative work, adapted from the following source, available under [CC BY](https://creativecommons.org/licenses/by/4.0/): Niedowicz DM, Nelson PT, Murphy MP. Alzheimer's disease: pathological mechanisms and recent insights. *Curr Neuropharmacol* 2011 Dec;9(4):674-84. doi 10.2174/157015911798376181.
- 490 **Alzheimer disease: Image C.** Gross specimen showing atrophy in Alzheimer. This image is a derivative work, adapted from the following source, available under [CC BY](https://creativecommons.org/licenses/by/4.0/): Niedowicz DM, Nelson PT, Murphy MP. Alzheimer's disease: pathological mechanisms and recent insights. *Curr Neuropharmacol* 2011 Dec; 9(4):674-84. doi 10.2174/157015911798376181.
- 490 **Dementia: Image B.** Neurofibrillary tangles in Alzheimer disease. Courtesy of Dr. Kristine Krafts.
- 490 **Frontotemporal dementia: Image F.** Gross specimen showing atrophy in FTD. This image is a derivative work, adapted from the following source, available under [CC BY](https://creativecommons.org/licenses/by/4.0/): Niedowicz DM, Nelson PT, Murphy MP. Alzheimer's disease: pathological mechanisms and recent insights. *Curr Neuropharmacol* 2011 Dec; 9(4):674-84. doi 10.2174/157015911798376181.










- 490 **Dementia: Image C.** Pick bodies in frontotemporal dementia. This image is a derivative work, adapted from the following source, available under : Niedowicz DM, Nelson PT, Murphy MP. Alzheimer's disease: pathological mechanisms and recent insights. *Curr Neuroparmacol* 2011;9:674-684. doi 10.2174/157015911798376181.
- 490 **Prions.** Spongiform changes in Creutzfeld-Jacob disease. This image is a derivative work, adapted from the following source, available under . Courtesy of DRdoubleB. The image may have been modified by cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under .
- 492 **Hydrocephalus: Image A.** Normal pressure hydrocephalus. Courtesy of Dr. Brian Walcott.
- 492 **Osmotic demyelination syndrome (central pontine myelinolysis): Image A.** This image is a derivative work, adapted from the following source, available under . Courtesy of Wikimedia Commons. The image may have been modified by cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under .
- 492 **Hydrocephalus: Image B.** Communicating hydrocephalus. This image is a derivative work, adapted from the following source, available under : Torres-Martin M, Pena-Granero C, Carceller F, et al. Homozygous deletion of *TNFRSF4*, *TP73*, *PPAP2B* and *DPYD* at 1p and *PDCD5* at 19q identified by multiplex ligation-dependent probe amplification (MLPA) analysis in pediatric anaplastic glioma with questionable oligodendroglial component. *Mol Cytogenet* 2014;7:1. doi 10.1186/1755-8166-7-1.
- 492 **Ex vacuo ventriculomegaly: Image C.** This image is a derivative work, adapted from the following source, available under : Ghetti B, Oblak AL, Boeve BF, et al. Invited review: Frontotemporal dementia caused by *microtubule-associated protein tau* gene (MAPT) mutations: a chameleon for neuropathology and neuroimaging. *Neurophathol Appl Neurobiol* 1015 Feb; 41(1):24-46. doi 10.1111/nan.12213.
- 493 **Multiple sclerosis: Image A.** Periventricular plaques. This image is a derivative work, adapted from the following source, available under : Buzzard KA, Broadley SA, Butzkueven H. What do effective treatments for multiple sclerosis tell us about the molecular mechanisms involved in pathogenesis? *Int J Mol Sci* 2012;13:12665-12709. doi 10.3390/ijms131012665.
- 494 **Progressive multifocal leukoencephalopathy: Image A.** This image is a derivative work, adapted from the following source, available under : Garrote H, de la Fuente A, Ona R, et al. Long-term survival in a patient with progressive multifocal leukoencephalopathy after therapy with rituximab, fludarabine and cyclophosphamide for chronic lymphocytic leukemia. *Exp Hematol Oncol* 2015;4:8. doi 10.1186/s40164-015-0003-4.
- 495 **Neurocutaneous disorders: Image A.** Sturge-Weber syndrome and port wine stain. This image is a derivative work, adapted from the following source, available under : Babaji P, Bansal A, Krishna G, et al. Sturge-Weber syndrome with osteohypertrophy of maxilla. *Case Rep Pediatr* 2013. doi 10.1155/2013/964596.
- 495 **Neurocutaneous disorders: Image B.** Leptomeningeal angioma in Sturge-Weber syndrome. Reproduced, with permission, from Dr. Frank Gaillard and www.radiopaedia.org.
- 495 **Neurocutaneous disorders: Image C.** Tuberous sclerosis. This image is a derivative work, adapted from the following source, available under : Fred H, van Dijk H. Images of memorable cases: case 143. Connexions Web site. December 4, 2008. Available at: <http://cnx.org/content/m14923/1.3/>.
- 495 **Neurocutaneous disorders: Image D.** Ash leaf spots in tuberous sclerosis. This image is a derivative work, adapted from the following source, available under : Tonekaboni SH, Tousi P, Ebrahimi A, et al. Clinical and para clinical manifestations of tuberous sclerosis: a cross sectional study on 81 pediatric patients. *Iran J Child Neurol* 2012;6:25-31. PMID PMC3943027.
- 495 **Neurocutaneous disorders: Image E.** Angiomyolipoma in tuberous sclerosis. This image is a derivative work, adapted from the following source, available under . Courtesy of KGH. The image may have been modified by cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under .
- 495 **Neurocutaneous disorders: Image F.** Café-au-lait spots in neurofibromatosis. This image is a derivative work, adapted from the following source, available under . Courtesy of Wikimedia Commons. The image may have been modified by cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under .
- 495 **Neurocutaneous disorders: Image G.** Lisch nodules in neurofibromatosis.  Courtesy of the US Department of Health and Human Services.
- 495 **Neurocutaneous disorders: Image H.** Cutaneous neurofibromas. This image is a derivative work, adapted from the following source, available under : Kim BK, Choi YS, Gwoo S, et al. Neurofibromatosis type 1 associated with papillary thyroid carcinoma incidentally detected by thyroid ultrasonography: a case report. *J Med Case Rep* 2012;6:179. doi 10.1186/1752-1947-6-179.
- 495 **Neurocutaneous disorders: Image I.** Cerebellar hemangioblastoma histology. This image is a derivative work, adapted from the following source, available under . Courtesy of Dr. Michael Bonert. The image may have been modified by cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under .
- 495 **Neurocutaneous disorders: Image J.** Cerebellar hemangioblastomas imaging. This image is a derivative work, adapted from the following source, available under : Park DM, Zhuang Z, Chen L, et al. von Hippel-Lindau disease-associated hemangioblastomas are derived from embryologic multipotent cells. *PLoS Medicine* Feb. 13, 2007. doi 10.1371/journal.pmed.0040060.
- 496 **Adult primary brain tumors: Image A.** Glioblastoma multiforme at autopsy. Courtesy of Armed Forces Institute of Pathology.
- 496 **Adult primary brain tumors: Image B.** Glioblastoma multiforme histology. This image is a derivative work, adapted from the following source, available under . Courtesy of Wikimedia Commons. The image may have been modified by cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under .
- 496 **Meningioma: Image C.** Meningioma with dural "tail." This image is a derivative work, adapted from the following source, available under : Smits A, Zetterling M, Lundin M, et al. Neurological impairment linked with cortico-subcortical infiltration of diffuse low-grade gliomas at initial diagnosis

supports early brain plasticity. *Front Neurol* 2015;6:137. doi 10.3389/fneur.2015.00137.

- 496 **Meningioma: Image D.** Meningioma, psammoma bodies. This image is a derivative work, adapted from the following source, available under . Courtesy of Nephron. The image may have been modified by cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under .
- 496 **Hemangioblastoma: Image E.** Cerebellar hemangioblastoma. This image is a derivative work, adapted from the following source, available under : Park DM, Zhengping Z, Chen L, et al. von Hippel-Lindau disease-associated hemangioblastomas are derived from embryologic multipotent cells. *PLoS Med* 2007 Feb; 4(2):e60. doi 10.1371/journal.pmed.0040060.
- 496 **Hemangioblastoma: Image F.** Minimal parenchyma in hemangioblastoma. This image is a derivative work, adapted from the following source, available under . Courtesy of Marvin 101. The image may have been modified by cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under .
- 496 **Schwannoma: Image G.** Schwannoma at cerebellopontine angle.  Courtesy of MRT-Bild.
- 496 **Schwannoma: Image H.** Schwann cell origin of schwannoma. This image is a derivative work, adapted from the following source, available under . Courtesy of Nephron. The image may have been modified by cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under .
- 496 **Oligodendroglioma: Image I.** Oligodendroglioma in frontal lobes. This image is a derivative work, adapted from the following source, available under : Celzo FG, Venstermans C, De Belder F, et al. Brain stones revisited—between a rock and a hard place. *Insights Imaging* 2013 Oct; 4(5):625-35. doi 10.1007/s13244-013-0279-z.
- 496 **Oligodendroglioma: Image J.** Oligodendroglioma, “fried egg” cells. This image is a derivative work, adapted from the following source, available under . Courtesy of Nephron. The image may have been modified by cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under .
- 496 **Pituitary adenoma: Image K.** Prolactinoma. This image is a derivative work, adapted from the following source, available under : Wang CS, Yeh TC, Wu TC, et al. Pituitary macroadenoma co-existent with supraclinoid internal carotid artery cerebral aneurysm: a case report and review of the literature. *Cases J* 2009;2:6459. doi 10.4076/1757-1626-2-6459.
- 496 **Adult primary brain tumors: Image L.** Field of vision in bitemporal hemianopia. This image is a derivative work, adapted from the following source, available under . Courtesy of Wikimedia Commons. The image may have been modified by cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under .
- 498 **Childhood primary brain tumors: Image A.** MRI of pilocytic astrocytoma. This image is a derivative work, adapted from the following source, available under : Hafez RFA. Stereotaxic gamma knife surgery in treatment of critically located pilocytic astrocytoma: preliminary result. *World J Surg Oncol* 2007;5:39. doi 10.1186/1477-7819-5-39.
- 498 **Childhood primary brain tumors: Image C.** CT of medulloblastoma. Courtesy of Armed Forces Institute of Pathology.
- 498 **Childhood primary brain tumors: Image D.** Medulloblastoma histology. This image is a derivative work, adapted from the following source, available under . Courtesy of KGH. The image may have been modified by cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under .
- 498 **Childhood primary brain tumors: Image E.** MRI of ependymoma. This image is a derivative work, adapted from the following source, available under . Courtesy of Hellerhoff. The image may have been modified by cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under .
- 498 **Childhood primary brain tumors: Image F.** Ependymoma histology. This image is a derivative work, adapted from the following source, available under . Courtesy of Nephron. The image may have been modified by cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under .
- 498 **Childhood primary brain tumors: Image G.** CT of craniopharyngioma. This image is a derivative work, adapted from the following source, available under : Garnet MR, Puget S, Grill J, et al. Craniopharyngioma. *Orphanet J Rare Dis* 2007;2:18. doi 10.1186/1750-1172-2-18.
- 498 **Childhood primary brain tumor: Image H.** Craniopharyngioma histology. This image is a derivative work, adapted from the following source, available under . Courtesy of Nephron. The image may have been modified by cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under .
- 501 **Friedreich ataxia: Image A.** Clinical kyphoscoliosis. This image is a derivative work, adapted from the following source, available under : Axelrod FB, Gold-von Simson. Hereditary sensory and autonomic neuropathies: types II, III, and IV. *Orphanet J Rare Dis* 2007;2:39. doi 10.1186/1750-1172-2-39.
- 502 **Facial nerve lesions: Image A.** This image is a derivative work, adapted from the following source, available under : Socolovsky M, Paez MD, Di Masi G, et al. Bell's palsy and partial hypoglossal to facial nerve transfer: Case presentation and literature review. *Surg Neurol Int* 2012;3:46. doi 10.4103/2152-7806.95391.
- 503 **Cholesteatoma: Image A.** This image is a derivative work, adapted from the following source, available under . Courtesy of Welleschik. The image may have been modified by cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under .
- 504 **Normal eye: Image A.** This image is a derivative work, adapted from the following source, available under . Courtesy of Jan Kaláb. The image may have been modified by cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under .
- 504 **Conjunctivitis: Image A.** This image is a derivative work, adapted from the following source, available under : Baiyeroru A, Bowman R, Gilbert C, et al. Managing eye health in young children. *Community Eye Health* 2010;23:4-11.
- 505 **Cataract: Image A.** Juvenile cataract. This image is a derivative work, adapted from the following source, available under : Roshan M, Vijaya PH, Lavanya GR, et al. A novel human CRYGD mutation in a juvenile autosomal dominant cataract. *Mol Vis* 2010;16:887-896. PMID 2875257.

- 506 Glaucoma: Images A (normal optic cup) and B (optic cup in glaucoma).** Courtesy of EyeRounds.
- 506 Uveitis: Image A.** This image is a derivative work, adapted from the following source, available under : Weber AC, Levison AL, Srivastava, et al. A case of *Listeria monocytogenes* endophthalmitis with recurrent inflammation and novel management. *J Ophthalmic Inflamm Infect* 2015;5(1):28. doi 10.1186/s12348-015-0058-8.
- 506 Age-related macular degeneration: Image A.**  Courtesy of the US Department of Health and Human Services.
- 506 Glaucoma: Image C.** Closed/narrow angle glaucoma. This image is a derivative work, adapted from the following source, available under : Low S, Davidson AE, Holder GE, et al. Autosomal dominant Best disease with an unusual electrooculographic light rise and risk of angle-closure glaucoma: a clinical and molecular genetic study. *Mol Vis* 2011;17:2272-2282. PMID PMC3171497. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MediQ Learning, LLC are reserved.
- 506 Glaucoma: Image D.** Acute angle closure glaucoma. This image is a derivative work, adapted from the following source, available under : Courtesy of Dr. Jonathan Trobe.
- 507 Diabetic retinopathy: Image A.** This image is a derivative work, adapted from the following source, available under : Stefanini FR, Badaró E, Falabella P, et al. Anti-VEGF for the management of diabetic macular edema. *J Immunol Res* 2014;2014:632307. doi 10.1155/2014/632307. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MediQ Learning, LLC are reserved.
- 507 Retinal vein occlusion: Image A.** This image is a derivative work, adapted from the following source, available under : Alasil T, Rauser ME. Intravitreal bevacizumab in the treatment of neovascular glaucoma secondary to central retinal vein occlusion: a case report. *Cases J* 2009;2:176. doi 10.1186/1757-1626-2-176. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MediQ Learning, LLC are reserved.
- 507 Retinal detachment: Image A.** Courtesy of EyeRounds.
- 508 Retinitis pigmentosa: Image A.** Courtesy of EyeRounds.
- 508 Retinitis: Image A.**  Courtesy of the US Department of Health and Human Services.
- 510 Ocular motility.** Testing ocular muscles. This image is a derivative work, adapted from the following source, available under . Courtesy of Au.yousef. The image may have been modified by cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under .
- 511 Cranial nerve III, IV, VI palsies: Image A.** Cranial nerve III damage. This image is a derivative work, adapted from the following source, available under : Hakim W, Sherman R, Rezk T, et al. An acute case of herpes zoster ophthalmicus with ophthalmoplegia. *Case Rep Ophthalmol Med* 1012; 2012:953910. doi 10.1155/2012/953910.
- 511 Cranial nerve III, IV, VI palsies: Image B.** Cranial nerve IV damage. This image is a derivative work, adapted from the following source, available under : Mendez JA, Arias CR, Sanchez D, et al. Painful ophthalmoplegia of the left eye in a 19-year-old female, with an emphasis in Tolosa-Hunt syndrome: a case report. *Cases J* 2009;2:8271. doi 10.4076/1757-1626-2-8271.
- 511 Cranial nerve III, IV, VI palsies: Image C.** Cranial nerve VI damage. This image is a derivative work, adapted from the following source, available under . Courtesy of Jordi March i Nogué. The image may have been modified by cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under .

## Renal

















- 548 Potter sequence (syndrome): Image A.** Courtesy of Armed Forces Institute of Pathology.
- 550 Ureters: course: Image A.** This image is a derivative work, adapted from the following source, available under . Courtesy of Wikimedia Commons. The image may have been modified by cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under .
- 551 Glomerular filtration barrier: Image A.** This image is a derivative work, adapted from the following source, available under : Feng J, Wei H, Sun Y, et al. Regulation of podocalyxin expression in the kidney of streptozotocin-induced diabetic rats with Chinese herbs (Yishen capsule). *BMC Complement Altern Med* 2013;13:76. doi 10.1186/1472-6882-13-76.
- 562 RBC casts: Image A.** Courtesy of Dr. Adam Weinstein.
- 562 WBC casts: Image B.** This image is a derivative work, adapted from the following source, available under : Perazella MA. Diagnosing drug-induced AIN in the hospitalized patient: A challenge for the clinician. *Clin Nephrol* 2014 Jun; 81(6):381-8. doi 10.5414/CN108301.
- 562 Waxy casts: Image D.** This image is a derivative work, adapted from the following source, available under : Courtesy of Iqbal Osman.
- 564 Nephritic syndrome: Image A.** Histology of acute poststreptococcal glomerulonephritis. This image is a derivative work, adapted from the following source, available under . Courtesy of Dr. Michael Bonert. The image may have been modified by cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under .
- 564 Nephritic syndrome: Image B.** This image is a derivative work, adapted from the following source, available under : Immunofluorescence of acute poststreptococcal glomerulonephritis. Oda T, Yoshizawa N, Yamakami K, et al. The role of nephritis-associated plasmin receptor (naplr) in glomerulonephritis associated with streptococcal infection. *Biomed Biotechnol* 2012;2012:417675. doi 10.1155/2012/417675.
- 564 Nephritic syndrome: Image C.** Histology of rapidly progressive glomerulonephritis.  Courtesy of the US Department of Health and Human Services and Uniformed Services University of the Health Sciences.
- 564 Membranoproliferative glomerulonephritis (MPGN): Image D.** Membranoproliferative glomerulonephritis with “tram tracks” appearance on PAS stain. Courtesy of Dr. Adam Weinstein.
- 564 Membranoproliferative glomerulonephritis (MPGN): Image E.** Membranoproliferative glomerulonephritis with “tram tracks” appearance on H&E stain. Courtesy of Dr. Adam Weinstein.

- 566 **Nephrotic syndrome: Image B.** Histology of focal segmental glomerulosclerosis. This image is a derivative work, adapted from the following source, available under . Courtesy of Dr. Michael Bonert. The image may have been modified by cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under .
- 566 **Nephrotic syndrome: Image D.** Diabetic glomerulosclerosis with Kimmelstiel-Wilson lesions. This image is a derivative work, adapted from the following source, available under . Courtesy of Doc Mari. The image may have been modified by cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under .
- 568 **Hydronephrosis: Image A.** Ultrasound. This image is a derivative work, adapted from the following source, available under . Courtesy of Wikimedia Commons. The image may have been modified by cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under .
- 568 **Renal cell carcinoma: Image A.** This image is a derivative work, adapted from the following source, available under . Courtesy of Image courtesy of Dr. Yale Rosen. The image may have been modified by cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under .
- 568 **Renal oncocytoma: Image A.** Gross specimen. This image is a derivative work, adapted from the following source, available under : M. Emmanuel.
- 568 **Renal cell carcinoma: Image B.** Gross specimen. Courtesy of Dr. Ed Uthman.
- 568 **Renal oncocytoma: Image B.** Histology. This image is a derivative work, adapted from the following source, available under . Courtesy of Dr. Michael Bonert. The image may have been modified by cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under .
- 568 **Renal cell carcinoma: Image C.** CT scan. This image is a derivative work, adapted from the following source, available under : Behnes CL, Schlegel C, Shoukier M, et al. Hereditary papillary renal cell carcinoma primarily diagnosed in a cervical lymph node: a case report of a 30-year-old woman with multiple metastases. *BMC Urol* 2013;13:3. doi 10.1186/1471-2490-13-3.
- 569 **Wilms tumor.** This image is a derivative work, adapted from the following source, available under : Refaie H, Sarhan M, Hafez A. Role of CT in assessment of unresectable Wilms tumor response after preoperative chemotherapy in pediatrics. *Sci World J* 2008;8:661-669. doi 10.1100/tsw.2008.96.
- 569 **Transitional cell carcinoma: Image A.** This image is a derivative work, adapted from the following source, available under : Geavlete B, Stanescu F, Moldoveanu C, et al. NBI cystoscopy and bipolar electrosurgery in NMIBC management—an overview of daily practice. *J Med Life* 2013;6:140-145.
- 570 **Pyelonephritis: Image B.** CT scan. Courtesy of Armed Forces Institute of Pathology.
- 572 **Acute tubular necrosis: Image A.** Muddy brown casts. This image is a derivative work, adapted from the following source, available under . Courtesy of Dr. Serban Nicolescu.
- 572 **Renal papillary necrosis.** Courtesy of the US Department of Health and Human Services, William D. Craig, Dr. Brent J. Wagner, and Mark D. Travis.
- 573 **Renal cyst disorders: Image C.** Ultrasound of simple cyst. This image is a derivative work, adapted from the following source, available under . Courtesy of Nevit Dilmen. The image may have been modified by cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under .




### Reproductive






































- 583 **Fetal alcohol syndrome: Image A.** This image is a derivative work, adapted from the following source, available under . Courtesy of Courtesy of Teresa Kellerman. The image may have been modified by cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under .
- 585 **Umbilical cord: Image A.** Cross-section of normal umbilical cord. This image is a derivative work, adapted from the following source, available under . Courtesy of Dr. Ed Uthman. The image may have been modified by cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under .
- 590 **Uterine (Müllerian) duct anomalies: Images A-D.** This image is a derivative work, adapted from the following source, available under : Ahmadi F, Zafarani F, Haghghi H, et al. Application of 3D ultrasonography in detection of uterine abnormalities. *Int J Fertil Sterili* 2011;4:144-147. PMID PMC4023499.
- 592 **Female reproductive epithelial histology: Image A.** Transformation zone. This image is a derivative work, adapted from the following source, available under : Dr. Ed Uthman. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MediQ Learning, LLC are reserved.
- 594 **Seminiferous tubules: Image A.** This image is a derivative work, adapted from the following source, available under . Courtesy of Dr. Anlt Rao. The image may have been modified by cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under .
- 606 **Pregnancy complications: Image A.** Ectopic pregnancy. This image is a derivative work, adapted from the following source, available under : Dr. Ed Uthman.
- 606 **Choriocarcinoma: Image B.** “Cannonball” metastases. This image is a derivative work, adapted from the following source, available under : Lekanidi K, Vlachou PA, Morgan B, et al. Spontaneous regression of metastatic renal cell carcinoma: case report. *J Med Case Reports* 2007;1:89. doi 10.1186/1752-1947-1-89.
- 609 **Polycystic ovarian syndrome (Stein-Leventhal syndrome): Image A.** This image is a derivative work, adapted from the following source, available under : Lujan ME, Chizen DR, Peppin AK, et al. Improving inter-observer variability in the evaluation of ultrasonographic features of polycystic ovaries. *Reprod Biol Endocrinol* 2008;6:30. doi 10.1186/1477-7827-6-30.
- 610 **Ovarian neoplasms: Image C.** Mature cystic teratoma. This image is a derivative work, adapted from the following source, available under . Courtesy of Dr. Michael Bonert. The image may have been modified by cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under .
- 610 **Ovarian neoplasms: Image D.** Call-Exner bodies. This image is a derivative work, adapted from the following source, available under : Katoh T, Yasuda M, Hasegawa K, et al. Estrogen-









- producing endometrioid adenocarcinoma resembling sex cord-stromal tumor of the ovary: a review of four postmenopausal cases. *Diagn Pathol* 2012;7:164. doi 10.1186/1746-1596-7-164.
- 610 Dysgerminoma: Image E.** This image is a derivative work, adapted from the following source, available under : Montesinos L, Acien P, Martinez-Beltran M, et al. Ovarian dysgerminoma and synchronic contralateral tubal pregnancy followed by normal intra-uterine gestation: a case report. *J Med Rep* 2012;6:399. doi 10.1186/1752-1947-6-399.
- 610 Ovarian neoplasms: Image F.** Yolk sac tumor. This image is a derivative work, adapted from the following source, available under . Courtesy of Jensflorian. The image may have been modified by cropping, labeling, and/or captions. MedIQ Learning, LLC makes this image available under .
- 612 Endometrial conditions: Image A.** Leiomyoma (fibroid), gross specimen. This image is a derivative work, adapted from the following source, available under . Hic et nunc.
- 612 Endometrial conditions: Image B.** Leiomyoma (fibroid) histology. This image is a derivative work, adapted from the following source, available under : Londero AP, Perego P, Mangioni C, et al. Locally relapsed and metastatic uterine leiomyoma: A case report. *J Med Case Rep* 2008;2:308. doi 10.1186/1752-1947-2-308. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MedIQ Learning, LLC are reserved.
- 612 Endometrial conditions: Images C (endometrial hyperplasia) and D (endometrial carcinoma).** This image is a derivative work, adapted from the following source, available under : Izadi-Mood N, Yarmohammadi M, Ahmadi SA, et al. Reproducibility determination of WHO classification of endometrial hyperplasia/well differentiated adenocarcinoma and comparison with computerized morphometric data in curettage specimens in Iran. *Diagn Pathol* 2009;4:10. doi 10.1186/1746-1596-4-10.
- 612 Endometritis: Image E.** Endometritis with inflammation of the endometrium. This image is a derivative work, adapted from the following source, available under : Montesinos L, Acien P, Martinez-Beltran M, et al. Ovarian dysgerminoma and synchronic contralateral tubal pregnancy followed by normal intra-uterine gestation: a case report. *J Med Rep* 2012;6:399. doi 10.1186/1752-1947-6-399.
- 612 Endometriosis: Image F.** Endometrial tissue found outside the uterus. This image is a derivative work, adapted from the following source, available under : Hastings JM, Fazleabas AT. A baboon model for endometriosis: implications for fertility. *Reprod Biol Endocrinol* 2006;4(Suppl 1):S7. doi 10.1186/1477-7827-4-S1-S7.
- 615 Fibroadenoma: Image A.** This image is a derivative work, adapted from the following source, available under : Gokhale S. Ultrasound characterization of breast masses. *Indian J Radiol Imaging* 2009 Aug; 19(3):242-7. doi 10.4103/0971-3026.54878.
- 615 Phyllodes tumor: Image B.** This image is a derivative work, adapted from the following source, available under : Muttarak MD, Lerttumnongtum P, Somwangjaroen A, et al. Phyllodes tumour of the breast. *Biomed Imaging Interv J* 2006 Apr-Jun; 2(2):e33. doi 10.2349/biij.2.2.e33.
- 615 Phyllodes tumor: Image C.** Muttarak M, Lerttumnongtum P, Somwangjaroen A, et al. Phyllodes tumour of the breast. *Biomed Imaging Interv J* 2006 Apr-Jun; 2(2):e33. doi 10.2349/biij.2.2.e33.
- 616 Malignant breast tumors: Image B.** Comedocarcinoma. This image is a derivative work, adapted from the following source, available under : Costarelli L, Campagna D, Mauri M, et al. Intraductal proliferative lesions of the breast—terminology and biology matter: premalignant lesions or preinvasive cancer? *Int J Surg Oncol* 2012;501904. doi 10.1155/2012/501904. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MedIQ Learning, LLC are reserved.
- 616 Malignant breast tumors: Image C.** Paget disease of breast. This image is a derivative work, adapted from the following source, available under : Muttarak M, Siriya B, Kongmebhoh P, et al. Paget's disease of the breast: clinical, imaging and pathologic findings: a review of 16 patients. *Biomed Imaging Interv J* 2011;7:e16. doi 10.2349/biij.7.2.e16.
- 616 Malignant breast tumors: Image D.** Invasive ductal carcinoma. This image is a derivative work, adapted from the following source, available under : Zhou X-C, Zhou, Ye Y-H, et al. Invasive ductal breast cancer metastatic to the sigmoid colon. *World J Surg Oncol* 2012;10:256. doi 10.1186/1477-7819-10-256.
- 616 Malignant breast tumors: Image E.** Invasive lobular carcinoma. This image is a derivative work, adapted from the following source, available under : Franceschini G, Manno A, Mule A, et al. Gastro-intestinal symptoms as clinical manifestation of peritoneal and retroperitoneal spread of an invasive lobular breast cancer: report of a case and review of the literature. *BMC Cancer* 2006;6:193. doi 10.1186/1471-2407-6-193.
- 616 Malignant breast tumors: Image F.** Peau d'orange of inflammatory breast cancer.  Courtesy of the US Department of Health and Human Services.
- 618 Varicocele: Image A.** Dilated pampiniform veins. Image courtesy of Dr. Bruce R. Gilbert.
- 618 Scrotal masses: Image A.** Congenital hydrocele. This image is a derivative work, adapted from the following source, available under : Leonardi S, Barone P, Gravina G, et al. Severe Kawasaki disease in a 3-month-old patient: a case report. *BMC Res Notes* 2013;6:500. doi 10.1186/1756-0500-6-500.

## Respiratory

- 627 Type II cells: Image A.** Alveolar epithelial type II cell. This image is a derivative work, adapted from the following source, available under : Fehrenbach H, Tews S, Fehrenbach A, et al. Improved lung preservation relates to an increase in tubular myelin-associated surfactant protein A. *Respir Res* 2005 Jun 21;6:60. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MedIQ Learning, LLC are reserved.
- 627 Neonatal respiratory distress syndrome: Image A.** This image is a derivative work, adapted from the following source, available under : Alorainy IA, Balas NB, Al-Boukai AA. Pictorial essay: infants of diabetic mothers. *Indian J Radiol Imaging* 2010;20:174-181. doi 10.4103/0971-3026.69349.
- 627 Pneumocytes: Image A.** Type II pneumocyte. This image is a derivative work, adapted from the following source, available under : Courtesy of Dr. Thomas Caceci.

- 629 Lung relations: Image A.** This image is a derivative work, adapted from the following source, available under : Wang JF, Wang B, Jansen JA, et al. Primary squamous cell carcinoma of lung in a 13-year-old boy: a case report. *Cases J* 2008 Aug 22;1(1):123. doi 10.1186/1757-1626-1-123. The image may have been modified by cropping, labeling, and/or captions. All rights to this adaptation by MediQ Learning, LLC are reserved.
- 636 Rhinosinusitis.** This image is a derivative work, adapted from the following source, available under : Streck P, Zagolski O, Sktadzien J. Fatty tissue within the maxillary sinus: a rare finding. *Head Face Med* 2006;2:28. doi 10.1186/1746-160X-2-28.
- 636 Deep venous thrombosis: Image A.** This image is a derivative work, adapted from the following source, available under . Courtesy of Dr. James Heilman. The image may have been modified by cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under .
- 637 Pulmonary emboli: Image C.** CT scan. This image is a derivative work, adapted from the following source, available under . Courtesy of Dr. Carl Chartrand-Lefebvre. The image may have been modified by cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under .
- 638 Obstructive lung diseases: Image A.** Centriacinar emphysema, gross specimen.  Courtesy of the US Department of Health and Human Services and Dr. Edwin P. Ewing, Jr.
- 638 Obstructive lung diseases: Image B.** CT of centriacinar emphysema. This image is a derivative work, adapted from the following source, available under : Oikonomou A, Prassopoulou P. Mimics in chest disease: interstitial opacities. *Insights Imaging* 2013;4:9-27. doi 10.1007/s13244-012-0207-7.
- 638 Obstructive lung diseases: Image C.** Emphysema histology. This image is a derivative work, adapted from the following source, available under . Courtesy of Dr. Michael Bonert. The image may have been modified by cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under .
- 638 Obstructive lung diseases: Image D.** Barrel-shaped chest in emphysema. This image is a derivative work, adapted from the following source, available under . Courtesy of Dr. James Heilman. The image may have been modified by cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under .
- 638 Obstructive lung diseases: Image E.** Mucus plugs in asthma. This image is a derivative work, adapted from the following source, available under . Courtesy of Dr. Yale Rosen. The image may have been modified by cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under .
- 638 Obstructive lung disease: Image F.** Curschmann spirals.  Courtesy of Dr. James Heilman.
- 638 Obstructive lung disease: Image H.** Bronchiectasis in cystic fibrosis. This image is a derivative work, adapted from the following source, available under . Courtesy of Dr. Yale Rosen. The image may have been modified by cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under .
- 639 Restrictive lung diseases: Image A.** This image is a derivative work, adapted from the following source, available under . Courtesy of IPFeditor. The image may have been modified by cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under .
- cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under .
- 640 Inhalational injury and sequelae. Images A (18 hours after inhalation injury) and B (11 days after injury).** This image is a derivative work, adapted from the following source, available under : Bai C, Huang H, Yao X, et al. Application of flexible bronchoscopy in inhalation lung injury. *Diagn Pathol* 2013;8:174. doi 10.1186/1746-1596-8-174.
- 641 Pneumoconioses: Image A.** Pleural plaques in asbestosis. This image is a derivative work, adapted from the following source, available under . Courtesy of Dr. Yale Rosen. The image may have been modified by cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under .
- 641 Pneumoconioses: Image B.** CT scan of asbestosis. This image is a derivative work, adapted from the following source, available under : Miles SE, Sandrini A, Johnson AR, et al. Clinical consequences of asbestos-related diffuse pleural thickening: a review. *J Occup Med Toxicol* 2008;3:20. doi 10.1186/1745-6673-3-20.
- 641 Pneumoconioses: Image C.** Ferruginous bodies in asbestosis. This image is a derivative work, adapted from the following source, available under . Courtesy of Dr. Michael Bonert. The image may have been modified by cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under .
- 642 Acute respiratory distress syndrome: Image A.** X-ray of the lungs. This image is a derivative work, adapted from the following source, available under . Courtesy of Samir. The image may have been modified by cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under .
- 644 Pleural effusions: Images A and B.** This image is a derivative work, adapted from the following source, available under : Toshikazu A, Takeoka H, Nishioka K, et al. Successful management of refractory pleural effusion due to systemic immunoglobulin light chain amyloidosis by vincristine adriamycin dexamethasone chemotherapy: a case report. *Med Case Rep* 2010;4:322. doi 10.1186/1752-1947-4-322.
- 645 Pneumonia: Image B.** Lobar pneumonia, gross specimen. This image is a derivative work, adapted from the following source, available under . Courtesy of Dr. Yale Rosen. The image may have been modified by cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under .
- 645 Pneumonia: Image C.** Acute inflammatory infiltrates in bronchopneumonia. This image is a derivative work, adapted from the following source, available under . Courtesy of Dr. Yale Rosen. The image may have been modified by cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under .
- 645 Pneumonia: Image D.** Bronchopneumonia, gross specimen. This image is a derivative work, adapted from the following source, available under . Courtesy of Dr. Yale Rosen. The image may have been modified by cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under .
- 646 Lung abscess: Image A.** Gross specimen. This image is a derivative work, adapted from the following source, available under . Courtesy of Dr. Yale Rosen. The image may have been modified by cropping, labeling, and/or captions. MediQ Learning, LLC makes this image available under .

- 646 **Pancoast tumor: Image A.** This image is a derivative work, adapted from the following source, available under : Manenti G, Raguso M, D'Onofrio S, et al. Pancoast tumor: the role of magnetic resonance imaging. *Case Rep Radiol* 2013;2013:479120. doi 10.1155/2013/479120.
- 646 **Superior vena cava syndrome: Images A (blanching of skin with pressure) and B (CT of chest).** This image is a derivative work, adapted from the following source, available under : Shaikh I, Berg K, Kman N. Thrombogenic catheter-associated superior vena cava syndrome. *Case Rep Emerg Med* 2013;2013:793054. doi 10.1155/2013/793054.
- 646 **Lung abscess: Image B.** X-ray. This image is a derivative work, adapted from the following source, available under : Dr. Yale Rosen.
- 647 **Lung cancer: Image B.** Adenocarcinoma histology. Courtesy of Armed Forces Institute of Pathology.
- 647 **Lung cancer: Image C.** Squamous cell carcinoma. This image is a derivative work, adapted from the following source, available under . Courtesy of Dr. James Heilman. The image may have been modified by cropping, labeling, and/or captions. MedIQ Learning, LLC makes this image available under .
- 647 **Lung cancer: Image E.** Large cell lung cancer. This image is a derivative work, adapted from the following source, available under : Jala VR, Radde BN, Haribabu B, et al. Enhanced expression of G-protein coupled estrogen receptor (GPER/GPR30) in lung cancer. *BMC Cancer* 2012;12:624. doi 10.1186/1471-2407-12-624.

# Index

## A

- Abacavir, 197, 199  
Abciximab, 118  
  Glycoprotein IIb/IIIa inhibitors, 415  
  thrombogenesis and, 393  
Abdominal aorta, **348**  
  atherosclerosis in, 292, 668  
  bifurcation of, 629  
Abdominal aortic aneurysm, 292  
Abdominal colic  
  lead poisoning, 397  
Abdominal distension  
  duodenal atresia and, 344  
Abdominal pain  
  Budd-Chiari syndrome, 375, 652  
  cilostazol/dipyridamole, 415  
  *Clostridium difficile*, 652  
  diabetic ketoacidosis and, 337  
  ectopic pregnancy, 607  
  Henoch-Schönlein purpura, 303, 655  
  hypercalcemia, 560  
  hyperparathyroidism, 332  
  intussusception, 368  
  irritable bowel syndrome, 366  
  McBurney sign, 656  
  Meckel diverticulum, 585  
  pancreas divisum, 345  
  pancreatic cancer, 380  
  panic disorder, 533  
  polyarteritis nodosa, 302  
  porphyria, 403  
  Rovsing sign, 656  
Abdominal wall defects, 344  
Abducens (CN VI), **476**  
  location in brain stem, 474  
  ocular motility and, 510  
  palsy of, 511  
Abducens nerve (CN VI), **476**  
  ocular motility, 510  
  palsy of, 511  
  pathway for, 476  
  ventral brain stem, 474  
Abductor digiti minimi muscle, 429  
Abductor pollicis brevis muscle, 429  
Abetalipoproteinemia, 89, 394  
Abnormal passive abduction, 424  
Abnormal passive adduction, 424  
ABO blood classification, 390  
ABO hemolytic disease  
  (newborn), **390**  
Abscess, 451  
Absence seizures, 487  
  drug therapy for, 514  
  treatment, 661  
Absolute risk reduction (ARR), 248, 669  
Absorption disorders and anemia, 396  
AB toxin, 128  
Abuse  
  confidentiality exceptions, 255  
  dependent personality disorder and, 535  
  intimate partner violence, 257  
Acalculia, 481  
Acamprosate  
  alcoholism, 541, 661  
  diarrhea, 240  
Acanthocytes, 394  
Acanthocytosis, 66  
Acantholysis, 448  
  pemphigus vulgaris and, 452  
Acanthosis, 448  
  psoriasis, 449  
Acanthosis nigricans, 217, 453  
  acanthosis and, 448  
  stomach cancer, 362  
Acarbose, 341  
  diarrhea, 240  
Accessory (CN XI), **476**  
  lesion in, 502  
  location in brain stem, 474  
Accessory nerve (CN XII), **476**  
  lesion in, 502  
  pathway for, 476  
  ventral brain stem, 474  
Accessory pancreatic duct, 345, 353  
Accuracy vs precision, **249**  
Acebutolol, 237  
  angina and, 305  
ACE inhibitors, **577**  
  acute coronary syndromes, 296  
  C1 esterase inhibitor deficiency, 103  
  dilated cardiomyopathy, 297  
  dry cough, 242  
  heart failure, 298  
  hypertension, 304  
  naming convention for, 244  
  preload/afterload effects, 273  
  teratogenicity, 582  
Acetaldehyde, 68  
Acetaldehyde dehydrogenase, 68  
Acetaminophen, **455**  
  vs aspirin for pediatric patients, 455  
  free radical injury and, 210  
  hepatic necrosis from, 240  
  for osteoarthritis, 439  
  tension headaches, 488  
  toxicity effects, 455  
  toxicity treatment for, 239  
Acetazolamide, 243, **575**  
  glaucoma, 521  
  metabolic acidosis, 561  
  in nephron physiology, **555**  
  pseudotumor cerebri, 491  
  site of action, 574  
Acetoacetate metabolism, 86  
Acetone breath, 337  
Acetylation, 41  
  chromatin, 32  
  posttranslation, 41  
Acetylcholine (ACh)  
  anticholinesterase effect on, 232  
  change with disease, 465  
  in nervous system, 229  
  opioid analgesics, **520**  
  pacemaker action potential and, 281  
Acetylcholine (ACh) receptor agonists, 520  
Acetylcholine (ACh) receptors, **229**  
  in cholinergic drugs, 231  
Acetylcholine (AChR) receptor, 217  
Acetylcholinesterase (AChE)  
  cholinesterase inhibitor poisoning, 232  
  malathion, 196  
  neural tube defects and, 461  
Acetylcholinesterase (AChE) inhibitors  
  Alzheimer disease, 518  
  in cholinergic drugs, 231  
  myasthenia gravis, 445  
  naming convention for, 244  
  toxicity treatment for, 239  
Acetyl-CoA carboxylase  
  fatty acid synthesis, 69  
  vitamin B<sub>7</sub> and, 64  
Achalasia, **360**  
  esophageal cancer and, 361  
Achilles reflex  
  lumbosacral radiculopathy, 432  
Achilles tendon xanthomas, 291, 652  
Achlorhydria  
  stomach cancer, 362  
  VIPomas, 356  
Achondroplasia, **435**  
  chromosome disorder, 60  
  endochondral ossification in, 434  
  inheritance, 56  
AChR (acetylcholine receptor), 217  
Acid-base physiology, **561**  
Acidemia, 561  
  diuretic effect on, 576  
Acidic amino acids, 77  
Acid maltase, 82  
Acidosis, **561**  
  contractility in, 273  
  hyperkalemia with, 560  
Acid phosphatase in neutrophils, 386  
Acid reflux  
  esophageal pathology and, 360  
  H<sub>2</sub> blockers for, 381  
  proton pump inhibitors for, 381  
Acid suppression therapy, **381**  
*Acinetobacter* spp  
  nosocomial infections, 181  
  taxonomy, 121  
*Acinetobacter baumannii*  
  highly resistant bacteria, 194  
Acne, 449  
  danazol, 622  
  PCOS, 609  
  skin papules, 447  
  tetracyclines for, 188  
Acoustic schwannomas, 652  
Acquired hydroceles, 618  
Acrodermatitis enteropathica, 67  
Acromegaly, **333**  
  GH, 317  
  octreotide for, 382  
  somatostatin analogs for, 315  
  somatostatin for, 342  
Acromion, 425  
ACTH. *See* Adrenocorticotropic hormone (ACTH)  
Actin  
  cytoskeleton, 44  
  muscular dystrophies, 57  
Actin filaments  
  epithelial cells, 447  
  muscle contraction, 433  
Acting out, 524  
Actinic keratosis, 453  
  associations of, 664  
  squamous cell carcinoma, 454

- Actinomyces* spp  
anaerobic organism, 123  
Gram-positive algorithm, 130  
*Nocardia* spp vs, 135  
penicillin G/V for, 183
- Actinomyces israelii*  
labs/findings, 657  
oral infections, 182  
pigment production, 125
- Action/willpower, 539
- Activated carriers, 71
- Activator proteins, 38
- Active errors, 262
- Active immunity, 107
- Acute chest syndrome, 400
- Acute cholestatic hepatitis  
as drug reaction, 240  
macrolides, 189
- Acute coronary syndrome  
ADP receptor inhibitors for, 415  
heparin for, 413  
nitrates for, 305  
treatments for, 296
- Acute cystitis, 562
- Acute disseminated  
encephalomyelitis, 494
- Acute dystonia, 233
- Acute gastritis, 362
- Acute glomerulonephritis, 571
- Acute hemolytic transfusion  
reactions, 110
- Acute hemorrhagic cystitis, 160
- Acute inflammation, 207
- Acute inflammatory demyelinating  
polyradiculopathy, 493
- Acute intermittent porphyria, 403
- Acute interstitial nephritis, 572
- Acute lymphoblastic leukemia  
(ALL), 410  
associations with, 664  
methotrexate for, 417  
oncogenes and, 218
- Acute mesenteric ischemia, 369  
presentation, 655
- Acute myelogenous leukemia  
(AML), 410  
chromosomal translocations, 412  
cytarabine for, 417  
myelodysplastic syndromes, 409
- Acute myeloid leukemia (AML)  
associations with, 664
- Acute pancreatitis, 380  
associations, 667  
DIC and, 665  
hyperparathyroidism, 332  
necrosis and, 205
- Acute pericarditis, 300
- Acute-phase proteins, 104
- Acute-phase reactants, 102  
IL-6, 104
- Acute poststreptococcal  
glomerulonephritis, 564
- Acute promyelocytic leukemia  
all-trans retinoic acid for, 62  
treatment, 661
- Acute pulmonary edema  
opioid analgesics, 520
- Acute pyelonephritis, 570  
labs/findings, 661  
renal papillary necrosis and, 572  
WBC casts in, 562
- Acute renal failure, 571
- Acute respiratory distress syndrome  
(ARDS), 642  
acute pancreatitis, 380  
eclampsia and, 608  
inhalational injury, 640
- Acute stress disorder, 534
- Acute transplant rejection, 115
- Acute tubular necrosis, 572  
granular casts in, 562  
intrinsic renal failure with, 571
- Acyclovir, 197
- Adalimumab, 118, 457  
for Crohn disease, 365
- Adaptive immunity, 95
- Addison disease, 324  
metabolic acidosis in, 561  
presentation, 656
- Additive drug interactions, 225
- Adductor longus muscle, 353
- Adenine  
methylation of, 32  
Shiga/Shiga-like toxins and, 128
- Adenocarcinomas  
carcinogens causing, 219  
esophagus, 361  
gallbladder, 379  
gastrointestinal, 217  
lungs, 647  
nomenclature for, 216  
nonbacterial thrombotic  
endocarditis and, 217  
pancreas, 353, 380  
pectinate line and, 351  
prostatic, 619  
stomach, 362, 665
- Adenohypophysis, 313  
embryologic derivatives, 581  
hypothalamus and, 466
- Adenomas  
bone, 437  
colorectal, 372  
nomenclature for, 216  
pituitary, 332  
primary hyperparathyroidism, 331  
salivary gland, 359  
thyroid, 330
- Adenomatous colonic polyps, 370
- Adenomyosis (endometrial), 612
- Adenopathy  
Kawasaki disease, 302  
Whipple disease, 656
- Adenosine  
as antiarrhythmic drug, 310  
cutaneous flushing, 239  
pacemaker action potential  
and, 281
- Adenosine deaminase deficiency,  
34, 113
- Adenosine triphosphate (ATP)  
in electron transport chain, 74  
in glycogen regulation, 81  
nephron physiology, 555  
production of, 71, 74  
in TCA cycle, 73  
in urea cycle, 78
- Adenosine triphosphate (ATP)  
synthase inhibitors, 74
- Adenoviruses  
characteristics of, 160  
conjunctivitis, 504  
pneumonia, 645  
viral envelope, 159  
watery diarrhea, 175
- Adherens junctions, 447
- Adhesions, 369
- Adipose lipolysis, 306
- Adipose stores  
fasting/starvation states, 87
- Adipose tissue  
estrogen production, 595
- Adjustment disorder, 533
- Adoption studies, 246
- ADP receptor inhibitors, 415
- ADP ribosyltransferases, 128
- Adrenal adenomas  
Cushing syndrome, 323  
hyperaldosteronism, 324
- Adrenal carcinomas  
Cushing syndrome, 323  
P-glycoprotein in, 220
- Adrenal cortex, 312  
embryologic derivatives, 581  
progesterone production, 595
- Adrenal hemorrhage, 652  
Waterhouse-Friderichsen  
syndrome, 324
- Adrenal hyperplasia  
Cushing syndrome, 323  
hyperaldosteronism and, 324
- Adrenal insufficiency, 324  
anovulation with, 609  
fludrocortisone for, 342  
vitamin B<sub>5</sub> deficiency, 63
- Adrenal medulla, 312  
innervation, 229  
neuroblastomas of, 325  
pheochromocytomas in, 326  
tumors, 668
- Adrenal steroids, 318
- Adrenocortical adenomas, 665
- Adrenocortical atrophy  
Addison disease, 324  
exogenous corticosteroids, 323
- Adrenocortical insufficiency  
as drug reaction, 240  
presentation, 656
- Adrenocorticotrophic hormone  
(ACTH)  
adrenal cortex regulation of, 312  
adrenal insufficiency and, 324  
in Cushing syndrome, 217, 323  
secretion of, 313  
signaling pathways of, 322
- Adrenoleukodystrophy, 494
- Adrenoreceptors, 231
- Adults  
common causes of death, 260
- Adult T-cell leukemia, 219
- Adult T-cell lymphoma, 408
- Advance directives, 255
- Aedes* mosquitoes  
yellow fever transmission, 164
- Aerobic metabolism  
ATP production, 71  
fed state, 87  
Vitamin B<sub>1</sub> (thiamine), 62
- Aerobic organisms  
culture requirements, 123
- Afferent arteriole, 550  
ANP/BNP effect on, 558  
constriction of, 553  
dopamine effects, 559  
filtration, 553
- Afferent nerves, 285
- Aflatoxin  
as carcinogen, 219  
hepatocellular carcinoma, 375
- Aflatoxins, 149
- African sleeping sickness, 152
- Afterload  
auscultation and, 278  
cardiac output, 273  
hydralazine, 304  
in shock, 299
- Agammaglobulinemia  
chromosome affected, 60
- Agars (bacterial culture), 123
- Age-related macular  
degeneration, 506
- Aggregatibacter*  
*actinomycetemcomitans*, 299
- Aging changes, 259
- Agnosia, 529
- Agonist potency and efficacy, 228
- Agoraphobia, 533
- Agranulocytosis  
clozapine, 543  
as drug reaction, 241  
epilepsy drugs, 514  
sulfa drug allergies, 243  
thionamides, 341
- Agraphia, 481
- AIDS (acquired immunodeficiency  
syndrome)  
bacillary angiomatosis, 450  
brain abscess, 176  
*Candida albicans*, 149  
cryptococcal meningitis, 195  
*Cryptosporidium*, 151  
Cytomegalovirus (CMV), 161  
diagnosis, 171  
human herpesvirus 8, 161  
labs/findings, 660  
marijuana for, 541  
mycobacteria, 136  
*Pneumocystis jirovecii*, 150  
primary central nervous system  
lymphoma (PCL), 408  
progressive multifocal  
leukoencephalopathy, 494  
retinitis, 161  
retroviruses, 163  
timecourse (untreated), 172  
*Toxoplasma gondii*, 152
- AIDS retinitis, 161
- Air emboli, 637

- Akathisia, 468, 489  
 Akinesia, 490  
 Akinesia in Parkinson disease, 655  
 ALA dehydratase in lead poisoning, 403  
 Alanine  
   ammonia transport, 78  
   pyruvate dehydrogenase complex deficiency, 73  
 Alanine aminotransferase (ALT), 73, 373  
 Alar plate, 460  
 Albendazole  
   cestodes, 156  
 Albinism, 448  
   catecholamine synthesis, 79  
   Chédiak-Higashi syndrome and, 113  
   locus heterogeneity, 53  
   ocular, 56  
 Albright hereditary osteodystrophy, 331  
 Albumin  
   acute-phase reactant, 102  
   calcium and, 319  
   as liver marker, 373  
   plasma volume and, 551  
 Albuminuria  
   glomerular filtration barrier, 551  
 Albuterol, 234  
   asthma, 649  
 Alcohol dehydrogenase  
   ethanol metabolism, 68  
 Alcohol exposure  
   in utero, 290  
 Alcoholic cirrhosis, 374  
   cholelithiasis and, 379  
   zinc deficiency, 67  
 Alcoholic hallucinosis, 542  
 Alcoholic hepatitis, 374  
 Alcoholic liver disease, 374  
 Alcoholism, 541  
   anemia, 398  
   in anemia taxonomy, 396  
   cardiomyopathy, 297  
   cataracts and, 505  
   cirrhosis caused by, 372  
   common organisms affecting, 175  
   cytochrome P-450 and, 243  
   delirium tremens, 542  
   esophageal cancer, 361  
   ethanol metabolism and, 68  
   folate deficiency, 398  
   gastritis in, 362  
   hepatitis, 352  
   hypertension and, 290  
   ketone bodies in, 86  
   *Klebsiella* in, 140  
   Korsakoff syndrome, 528  
   liver serum markers in, 373  
   lung abscesses and, 646  
   magnesium levels in, 320  
   Mallory-Weiss syndrome in, 360  
   osteonecrosis in, 436  
   osteoporosis and, 435  
   pancreatitis, 240, 380  
   porphyria, 403  
   sideroblastic anemia, 397  
   subdural hematomas, 483  
   treatment, 661  
   vitamin B<sub>1</sub> deficiency, 62  
   vitamin B<sub>9</sub> deficiency, 64  
   wet beriberi, 653  
 Alcohol-related disorders  
   readmissions with, 261  
 Alcohol use  
   essential tremor, 489  
   gout and, 440  
   head and neck cancer, 636  
   intoxication and withdrawal, 540  
   loss of orientation, 528  
   sexual dysfunction, 537  
   sleep, 467  
   suicide and, 532  
   teratogenic effects, 582  
 Alcohol withdrawal  
   benzodiazepines, 528  
   drug therapy, 542  
   hallucinations in, 529  
 Aldesleukin, 117  
 Aldolase B, 76  
 Aldose reductase, 77  
 Aldosterone, 558  
   adrenal cortex secretion of, 312  
   Gitelman syndrome as cause, 556  
   kidney effects, 559  
   nephron physiology, 555  
   primary adrenal insufficiency, 324  
   renal tubular acidosis, 562  
   SIADH, 334  
   signaling pathways for, 322  
   syndrome of apparent mineralocorticoid excess, 556  
 Aldosterone antagonists, 304  
 Aldosterone synthase, 318  
 Alemtuzumab, 118  
 Alendronate, 456  
 Alirocumab, 306  
 Aliskiren, 577  
 Alkalemia, 561  
   diuretic effects, 576  
 Alkaline phosphatase (ALP), 373, 436  
   bone disorder lab values, 437  
   hyperparathyroidism and, 332  
   Paget disease of bone, 436  
   in thyroid storm, 329  
   as tumor marker, 220  
 Alkalosis, 561  
   bulimia nervosa, 537  
   hypokalemia with, 560  
 Alkaptonuria, 80  
   tyrosine catabolism and, 79  
 ALK gene, 218  
   lung cancer, 647  
 Alkylating agents, 418  
   as carcinogens, 219  
   in cell cycle, 416  
   targets of, 416  
   teratogenicity of, 582  
 Allantois, 585  
 Allelic heterogeneity, 53  
 Allergic bronchopulmonary aspergillosis, 149  
 Allergic contact dermatitis, 449  
 Allergic reaction  
   blood transfusion, 110  
 Allergic rhinitis, 449  
 Allergies, 108  
 Allografts, 114  
 Allopurinol  
   for gout, 440, 457  
   gout, 661  
   kidney stones, 567  
   Lesch-Nyhan syndrome, 34  
   rash with, 241  
 All-trans retinoic acid  
   acute promyelocytic leukemia, 62, 661  
 Alopecia  
   doxorubicin, 418  
   etoposide/teniposide, 419  
   minoxidil for, 623  
   syphilis, 143  
   tinea capitis, 148  
   vitamin A toxicity, 62  
   vitamin B<sub>5</sub> deficiency, 63  
   vitamin B<sub>7</sub> deficiency, 64  
 $\alpha$ -1,4-glucosidase  
   glycogen metabolism, 82  
 $\alpha_1$ -antagonists  
   benign prostatic hyperplasia, 661  
   BPH treatment, 619  
   naming convention for, 244  
 $\alpha_1$ -antitrypsin  
   elastin and, 48  
 $\alpha_1$ -antitrypsin deficiency, 375  
   emphysema, 638  
 $\alpha_2$ -agonists, 235  
 $\alpha_2$ -antagonists, 546  
 $\alpha$ -adrenergic agonists, 648  
 $\alpha$ -agonists, 521  
 $\alpha$ -amanitin  
   RNA polymerase inhibition, 38  
 $\alpha$ -amylase, 358  
 $\alpha$ -antagonists  
   for pheochromocytomas, 326  
   pheochromocytomas, 663  
 $\alpha$ -blockers, 236  
   Beers criteria, 238  
   for cocaine overdose, 540  
 $\alpha$  cells, 313  
   glucagonomas in, 338  
   glucagon production by, 315  
 $\alpha$ -dystroglycan  
   muscular dystrophy, 57  
 $\alpha$ -fetoprotein  
   anencephaly, 657  
   ataxia-telangiectasia, 113  
   autosomal trisomies, 59  
   in hepatocellular carcinoma, 375  
   neural tube defects, 461  
   spina bifida, 657  
   as tumor marker, 220  
   yolk sac tumors, 618  
 $\alpha$ -galactosidase A  
   Fabry disease, 84  
 $\alpha$ -glucosidase inhibitors, 341  
 $\alpha$ -hemolytic bacteria, 131  
 $\alpha$ -ketoglutarate  
   hyperammonemia and, 78  
 $\alpha$ -ketoglutarate dehydrogenase  
   metabolic pathways, 70  
   TCA cycle, 73  
   vitamin B<sub>1</sub> and, 62  
 $\alpha$ -methyl dopa, 235  
 anemia and, 401  
   gestational hypertension, 608  
 $\alpha$ -synuclein, 490  
 $\alpha$ -thalassemia, 396  
   chromosome association, 60  
 $\alpha$  toxin, 129, 134  
 Alport syndrome, 565  
   cataracts and, 505  
   collagen deficiency in, 46  
   inheritance of, 55  
   presentation, 654  
 Alprazolam, 515  
 ALT (alanine transaminase)  
   hepatitis viruses, 168  
   toxic shock syndrome, 131  
 Alteplase, 391, 415  
 Alternative hypothesis, 251, 252  
 Altitude sickness, 635  
   acetazolamide for, 575  
 Altruism, 525  
 Aluminum hydroxide, 382  
 Alveolar gas equation, 634, 670  
 Alveolar period (development), 626  
 Alveolar PO<sub>2</sub>, 634  
 Alveolar sacs, 628  
 Alveolar ventilation, 630  
 Alveoli, 626  
   pneumocytes, 627  
 Alzheimer disease, 490  
   amyloidosis in, 213  
   dementia with, 529  
   Down syndrome and, 59  
   drug therapy for, 232, 518  
   labs/findings, 660, 665  
   neurotransmitters for, 465  
   ventriculomegaly with, 492  
*Amanita phalloides*  
   necrosis caused by, 240  
   RNA polymerase inhibition, 38  
 Amantadine, 197, 517  
 Ambiguous genitalia  
   46,XY DSD, 604  
   ovotesticular disorder of sex development, 603  
   placental aromatase deficiency, 604  
 Amebiasis, 151  
 Amenorrhea  
   anorexia nervosa, 537  
   antiandrogens, 623  
   cirrhosis, 372  
   Cushing syndrome, 323  
   cystic fibrosis, 56  
   ectopic pregnancy and, 607  
   menopause, 600  
   Müllerian agenesis, 589  
   PCOS, 609  
   pituitary prolactinomas, 315  
   Turner syndrome, 603  
 Amide local anesthetics, 519  
 Amikacin, 183, 187  
 Amiloride, 576  
   for diabetes insipidus, 334  
   nephron physiology, 555

- Amine precursor uptake  
decarboxylase (APUD), 325
- Amines  
MAO inhibitors, 546
- Amine whiff test, 144
- Amino acids  
blood-brain barrier and, 466  
branched, 80  
classification of, 77  
derivatives of, **79**  
genetic code for, 34  
in histones, 32  
ketogenic, 73  
metabolism, 86  
purine and pyrimidine synthesis, 33  
tRNA, 40  
urea cycle, 78
- Aminoaciduria  
normal pregnancy, 554
- Aminoacyl-tRNA, 41
- Aminoacyl-tRNA synthase, 40
- Aminocaproic acid  
for thrombolytic toxicity, 415
- Aminoglycosides, **187**  
acute tubular necrosis, 572  
magnesium levels and, 320  
mechanism (diagram), 183  
pregnancy use, 201  
*Pseudomonas aeruginosa*, 139, 663  
teratogenicity, 582  
toxicity of, 242
- Aminopenicillins  
mechanism and use, 184
- Amiodarone, 309  
cytochrome P-450 and, 243  
hypothyroidism, 240  
hypothyroidism with, 328  
photosensitivity, 241  
pulmonary fibrosis, 242  
restrictive lung disease, 639
- Amitriptyline, 545  
migraine headaches, 488  
tension headaches, 488
- Amlodipine, 304
- Ammonia  
Ornithine transcarbamylase  
deficiency, 79  
transport and intoxication, **78**
- Ammonium chloride  
for drug overdoses, 226
- Amnesia  
brain lesions, 481  
classification of, 528  
clinical drug-induced, 515, 519  
electroconvulsive therapy, **528**
- Amnionitis, 135
- Amniotic fluid abnormalities, **607**
- Amniotic fluid emboli, 637
- Amniotic fluid embolism, 637  
acute respiratory distress syndrome  
as cause, **642**
- Amoxapine, 545
- Amoxicillin  
clinical use, 184  
*Haemophilus influenzae*, 138  
*Helicobacter pylori*, 142  
Lyme disease, 142  
mechanism (diagram), 183  
prophylaxis, 194
- Amphetamines, 234  
intoxication and withdrawal, 540  
narcolepsy treatment, 538  
as noradrenergic drug, 231  
norepinephrine and, 231  
pulmonary arterial  
hypertension, 643  
as weak bases, 226
- Amphotericin B, 194  
*Candida albicans*, 149, 661  
clinical use, **195**  
*Naegleria fowleri*, 152  
opportunistic fungal infections, 149  
systemic mycoses, 147
- Ampicillin  
*Clostridium difficile*, 134  
endometritis, 612  
*Listeria monocytogenes*, 135  
mechanism and use, 184  
mechanism (diagram), 183  
meningitis, 176  
prophylaxis, 194
- Ampulla of Vater, 353
- Amygdaloid lesions, 481
- Amylase in pancreatitis, 380
- Amylin analogs, 341
- Amyloid angiopathy  
intraparenchymal hemorrhage, 483
- Amyloidosis, **213**, 566  
carpal tunnel syndrome, 426  
chronic inflammation, 207  
extraarticular manifestation, 439  
multiple myeloma, 409  
serum amyloid A in, 102  
amyloid precursor protein (APP), 490
- Amyotrophic lateral sclerosis (ALS)  
riluzole for, 518  
spinal cord lesions, 500
- Anabolic steroids  
hepatic adenomas and, 375
- Anaerobic metabolism  
glycolysis, 71  
pyruvate metabolism, 73
- Anaerobic organisms  
aspiration and, 175  
clindamycin, 188  
Clostridia (with exotoxins), 134  
culture requirements, **123**  
glycylines, 188  
*Nocardia* vs *Actinomyces*, 135  
metronidazole, 191  
overgrowth in vagina, 144  
pneumonia caused by, 175
- Anal cancer  
HIV and, 173  
oncogenic microbes and, 219
- Anal fissures, 351
- Anaphase, 42
- Anaphylaxis, 108  
blood transfusion, 110  
complement and, 103  
epinephrine for, 234  
IgA-containing products, 112  
shock with, 299
- Anaplasia, 214
- Anaplasma* spp  
anaplasmosis, 145  
transmission, 142, 144
- Anaplastic thyroid carcinomas, 330
- Anastrozole, 621  
reproductive hormones and, 620
- Anatomy  
endocrinal, 312–313  
gastrointestinal, 345–354  
hematologic/oncologic, 386–389  
musculoskeletal, 424–432  
neurological, 463–485  
renal, 550  
reproductive, 591–594  
respiratory, 628–629
- Anatomy of heart, 264, **271**
- Ancylostoma* spp  
diseases associated with, 157  
infection routes, 154  
microcytic anemia, 157  
transmission and treatment, 155
- Ancylostoma duodenale*, 155
- Androblastomas, 619
- Androgen-binding protein  
Sertoli cell secretion, 594
- Androgen insensitivity  
syndrome, **604**
- Androgen-receptor complex  
pharmacologic control, 620
- Androgen receptor defect, 604
- Androgens, **600**  
adrenal cortex secretion, 312  
adrenal steroids and, 318  
PCOS and, 609
- Androstenedione, 318, 600  
pharmacologic control, 620
- Anemia, **396**  
amphotericin B, 195  
*Ancylostoma*, 157  
anorexia nervosa, 537  
azathioprine, 116  
babesiosis, 153  
blood oxygen content, 633  
blood transfusion therapy, 407  
cephalosporins, 185  
chloramphenicol, 188  
cirrhosis, 372  
cold agglutinin disease, 655  
colorectal cancer, 371  
cytarabine and, 417  
dapsone, 190  
*Diphyllobothrium latum*, 156  
as drug reaction, 241  
epilepsy drugs, 514  
*Escherichia coli*, 140  
ESR in, 212  
extrinsic hemolytic, **401**  
fibroid tumors, 612  
G6PD deficiency, 75  
hepatitis, 200  
hookworms, 155  
intrinsic hemolytic, **400**  
isoniazid, 193  
kwashiorkor, 67  
lab values, **402**  
macrocytic, **398**  
macro-ovalocytes in, 394  
malaria, 153  
microcytic, hypochromic, 396  
multiple myeloma, 409  
nonhemolytic, normocytic, **399**  
nonhomologous end joining, 37  
normocytic, normochromic, **399**  
NRTIs, 199  
penicillin G, V, 185  
Plummer-Vinson syndrome, 360  
pregnancy and, 598  
pure red cell aplasia, 217  
recombinant cytokines for, 117  
renal failure, 571  
ringed sideroblasts in, 395  
sideroblastic, 63  
sirolimus, 116  
spherocytes in, 395  
sulfa drug allergies as cause, 243  
thionamides causing, 341  
trimethoprim, 190  
tropical sprue, 364  
vitamin B<sub>9</sub> deficiency, 64  
vitamin B<sub>12</sub> deficiency, 65  
vitamin E deficiency, 66  
Weil disease, 142  
Wilson disease, 378
- Anemia of chronic disease, 399  
hepcidin in, 102  
rheumatoid arthritis, 439
- Anemic infarcts, 207
- Anencephaly, 461  
labs/findings, 657  
polyhydramnios and, 607
- Anergy, **106**
- Anesthetics  
general principles, **518**  
inhaled, **519**  
intravenous, **519**  
local, **519**
- Aneuploidy, 603
- Aneurysms, **486**  
atherosclerosis, 292  
coarctation of aorta, 289  
Ehlers-Danlos syndrome and, 47  
MI, 294  
superior vena cava syndrome, 646  
vasculitides, 302
- Angelman syndrome  
chromosome association, 60  
imprinting, 54
- Angina, 293  
aortic stenosis, 279  
atherosclerosis, 292  
calcium channel blockers  
for, 304  
cilostazol/dipyridamole for, 415  
cocaine causing, 540  
drug therapy for, **305**  
glycoprotein IIb/IIa inhibitors  
for, 415  
hydralazine causing, 304  
nitrates for, 305  
presentation, 652  
ranolazine for, 305
- Angina pectoris  
β-blockers for, 237
- Angiodysplasia, 369

- Angioedema  
ACE inhibitors, 577  
C1 esterase inhibitor deficiency, 103  
scombroid poisoning, 238
- Angiofibromas, 495
- Angiogenesis  
bevacizumab and, 420  
in cancer, 215  
wound healing and, 211
- Angiokeratomas, 84
- Angiomatosis  
von Hippel-Lindau disease, 495, 655
- Angiomyolipomas, 495
- Angiosarcomas, 375, 450  
carcinogens causing, 219  
nomenclature for, 216
- Angiotensin II, 318, 558  
ACE inhibitor effects on, 577  
kidney effects, 559  
nephron physiology, 555  
signaling pathways for, 322
- Angiotensin II receptor blockers, 577  
heart failure, 298  
hypertension, 304  
naming convention for, 244  
preload/afterload effects, 273
- Angiotensinogen, 558
- Angry patients, 256
- Anhedonia, 531
- Anhidrosis  
Horner syndrome, 509, 655  
Pancoast tumor, 646
- Anidulafungin, 194, 196
- Aniline dyes  
transitional cell carcinoma and, 569
- Aniridia  
WAGR complex, 569
- Anisocytosis, 386
- Anitschkow cells, 300
- Ankylosing spondylitis, 442  
HLA-B27 and, 96  
labs/findings, 657  
therapeutic antibodies for, 118  
TNF- $\alpha$  inhibitors for, 457
- Annular pancreas, 345
- Anopheles* mosquito, 153
- Anopia  
visual field defects, 511
- Anorectal varices  
cirrhosis as cause, 372  
portal circulation, 350
- Anorexia nervosa, 537  
anovulation with, 609  
treatment, 661
- Anorexia (symptom)  
amphetamines, 540  
hypothalamus and, 466  
renal failure, 571
- Anosmia  
zinc deficiency, 67
- ANOVA tests, 253
- Anovulation  
common causes, 609  
endometrial hyperplasia, 612
- ANP. *See* Atrial natriuretic peptide (ANP)
- Antacids, 382  
metabolic alkalosis with, 561
- Anterior cerebral artery, 472  
cavernous sinus, 512  
cingulate herniation, 499  
circle of Willis, 473  
stroke, 484
- Anterior chamber (eye), 504
- Anterior communicating artery  
circle of Willis, 473  
saccular aneurysm, 486
- Anterior corticospinal tract, 478
- Anterior cruciate ligament (ACL)  
injury  
anterior drawer sign in, 424  
presentation, 652  
“unhappy triad,” 425
- Anterior drawer sign, 424, 652
- Anterior hypothalamus, 466
- Anterior inferior cerebellar artery, 473, 484
- Anterior perforated substance, 474
- Anterior pituitary gland, 313
- Anterior spinal artery  
complete occlusion, 500  
stroke, 484
- Anterior spinothalamic tract, 478
- Anterior superior  
pancreaticoduodenal artery, 349
- Anterior white commissure, 478
- Anterograde amnesia, 528  
benzodiazepines, 519  
brain lesions, 481
- Anthracois, 641  
restrictive disease, 639
- Anthracyclines, 239
- Anthrax, 127, 128, 133
- Anthrax toxin  
*Bacillus anthracis* and, 133
- Antiandrogens, 623
- Antianginal therapy, 305
- Antiapoptotic molecule  
oncogene product, 218
- Antiarrhythmic drugs, 308–310  
torsades de pointes, 239
- Anti- $\beta_2$  glycoprotein antibodies  
antiphospholipid syndrome, 443
- Antibiotics  
acne treatment, 449  
*Candida albicans* and, 149  
*Clostridium difficile* with, 652  
Jarlsch-Herxheimer reaction, 143  
long QT interval, 283  
selective growth media, 122  
torsades de pointes, 239
- Antibodies  
autoantibodies, 111  
exo- and endotoxins, 127, 129  
hepatitis viruses, 170  
structure and function, 100  
therapeutic, 118
- Anticardiolipin  
antiphospholipid syndrome, 443
- Anti-centromere antibodies, 657  
scleroderma, 446
- Anticholinergic drugs  
Beers criteria, 238  
toxicity treatment for, 239
- Anticholinesterase drugs, 232
- Anticipation (genetics), 52
- Anticoagulant drugs, 391  
acute coronary syndromes, 296  
antiphospholipid syndrome, 443  
atrial fibrillation, 284  
osteoporosis and, 435  
warfarin as, 414
- Anticoagulation  
coagulation cascade and, 392
- Anticodon loop, 40
- Anticonvulsant drugs  
for fibromyalgia, 444  
osteoporosis and, 435
- Antidepressant drugs, 544  
Beers criteria, 238  
for bulimia nervosa, 537  
for fibromyalgia, 444  
long QT interval with, 283  
torsades de pointes, 239
- Anti-desmoglein antibodies, 657
- Anti-digoxin Fab fragments, 239
- Antidiuretic hormone (ADH), 317, 558  
in diabetes insipidus, 334  
hypothalamus synthesis, 466  
kidney effects, 559  
nephron physiology, 555  
pituitary gland and, 313  
SIADH and, 334  
signaling pathways of, 322
- Antidiuretic hormone (ADH)  
antagonists, 342
- Anti-dsDNA antibodies  
lupus, 443
- Antiemetic drugs, 383  
long QT interval with, 283  
marijuana as, 541  
torsades de pointes, 239
- Anti-endomysial antibodies, 657
- Antiepileptic drugs  
cytochrome P-450 and, 243  
rash from, 241  
teratogenicity, 582
- Antifungal drugs  
mechanism and use, 194–196  
tinea versicolor, 148
- Antigenic shift/drift, 165
- Antigen-presenting cells (APCs)  
B cells as, 388  
CD28, 106  
dendritic cells as, 388  
MHC I and II and, 96  
naive T-cell activation, 99  
in spleen, 94
- Antigens  
active immunity, 107  
antibody structure and function, 100  
blood transfusion reactions, 110  
chronic mucocutaneous candidiasis, 112  
diversity of, 108  
for self, 97  
HLA I and II, 96  
lymphocyte recognition of, 94  
type and memory, 101  
vaccination, 107  
variations in, 106
- Anti-gliadin antibodies, 657
- Anti-glomerular basement membrane antibodies, 657
- Anti-HBc, 170
- Anti-HBe, 170
- Anti-HBs, 170
- Anthelmintic drugs, 196  
naming convention, 244
- Antihistamines  
Beers criteria, 238  
for scombroid poisoning, 238
- Antihistone antibodies, 657  
lupus, 443
- Antihypertensive drugs  
hypertension in pregnancy, 608  
sexual dysfunction, 537
- Anti-IgE monoclonal antibodies, 649
- Anti-IgG antibodies, 657
- Anti-inflammatory drugs, 455
- Antileukotrienes  
for asthma, 649
- Antimalarial drugs  
G6PD deficiency, 400
- Antimetabolites, 417  
in cell cycle, 416
- Antimicrobial drugs, 183–200  
naming conventions for, 244  
pregnancy contraindications, 201  
prophylaxis, 194
- Antimitochondrial antibodies, 657
- Antimuscarinic drugs  
Parkinson disease, 517  
toxicity treatment for, 239  
urgency incontinence, 569
- Antimuscarinic reaction, 242
- Antimycin A  
electron transport chain, 74
- Antimycobacterial drugs, 192
- Antineutrophil cytoplasmic antibodies, 657
- Anti-NMDA receptor encephalitis, 217
- Antinuclear antibodies (ANA), 657  
lupus, 443  
Sjögren syndrome, 441
- Antioxidants  
free radical elimination by, 210
- Antiparasitic drugs  
naming convention for, 244
- Antiphospholipid syndrome, 443
- Antiphospholipid syndrome  
autoantibodies, 111
- Antiplatelet antibodies, 657  
abciximab as, 118
- Antiplatelet drugs  
for acute coronary syndromes, 296
- Antiprogesterin drugs, 622
- Antiprotozoan drugs, 196
- Antipseudomonal drugs, 183  
cephalosporins, 185  
fluoroquinolones, 191  
penicillins, 184



- Antipsychotic drugs, **543**  
 antimuscarinic reaction, 242  
 dopaminergic pathways, 468  
 galactorrhea with, 315  
 long QT interval with, 283  
 naming convention for, 244  
 Parkinson-like syndrome, 242  
 PCP overdose, 541  
 prolactin and, 316  
 tardive dyskinesia, 242  
 torsades de pointes, 239  
 Tourette syndrome, 527, 542
- Anti-Smith antibodies  
 lupus, 443
- Antisocial personality disorder, 535  
 early-onset disorder, 527
- Antithrombin  
 coagulation cascade and, 392
- Antithrombin deficiency, 406
- Anti-topoisomerase antibodies, 657
- Antitoxins  
 as passive immunity, 107
- Anti-transglutaminase antibodies, 657
- Antitumor antibiotics, **418**
- Anti-U1 RNP antibodies, 443
- Antiviral therapy, **197**
- Anxiety  
 benzodiazepine withdrawal, 540  
 delirium tremens, 542  
 drugs for relief of, 515  
 hypercalcemia and, 560  
 hyperthyroidism and, 327  
 LSD, 541  
 MAO inhibitors for, 546  
 MDMA withdrawal, 541  
 neurotransmitters, 465  
 nicotine withdrawal, 540
- Anxiety disorder, **532**  
 atypical antipsychotics for, 543
- Aorta  
 aneurysm of, 292  
 coarctation of, **289**, 290  
 congenital heart disease, 288  
 diaphragm, 629  
 dissection in, 293  
 ECG and, 282  
 embryonic development, 268–269  
 fetal circulation, 270  
 gastrointestinal blood supply, **348**  
 horseshoe kidney and, 549  
 retroperitoneal, 345  
 in syphilitic heart disease, 300  
 traumatic rupture of, 292  
 “tree bark” appearance of, 300
- Aortic aneurysm, **292**  
 associations, 664  
 Ehlers-Danlos syndrome, 47  
 hypertension, 290  
 Marfan syndrome, 290  
 syphilitic heart disease, 300
- Aortic arch derivatives, **586**
- Aortic coarctation  
 labs/findings, 660
- Aortic dissection, **293**  
 associations with, 664  
 hypertension, 290  
 Marfan syndrome, 652  
 Marfan syndrome as cause, 290
- Aortic insufficiency  
 syphilitic heart disease, 300
- Aorticopulmonary septum, 269  
 embryologic derivatives, 581
- Aortic regurgitation  
 diastolic murmur in, 278  
 heart murmurs with, 279  
 Marfan syndrome, 290  
 presentation, 652  
 pulse pressure in, 272
- Aortic root dilation  
 heart murmur with, 279
- aortic stenosis  
 presentation, 656
- Aortic stenosis  
 ejection click and, 665  
 heart murmurs, 279  
 macroangiopathic anemia, 401  
 paradoxical splitting in, 277  
 presentation, 656  
 pulse pressure in, 272  
 S4 heart sound and, 668  
 systolic murmur in, 278  
 Williams syndrome, 290
- Aortic valve  
 cardiac cycle, 276  
 embryological development, 268  
 sclerosis, 278
- Aortitis  
 syphilis, 143, 180
- APC gene, 218  
 adenomatous colonic polyps  
 and, 370  
 colorectal cancer and, 372  
 familial adenomatous polyposis  
 and, 370
- “Ape hand” (median nerve  
 injury), 427, 429
- Apgar score, **599**
- Aphasia, **486**  
 dementia and, 529  
 MCA stroke, 484
- Apthous stomatitis  
 Crohn disease, 365
- Apixaban  
 as anticoagulant, 391  
 factor Xa inhibitors, **415**
- Aplasia cutis  
 methimazole, 341
- Aplasia cutis congenita  
 fetal methimazole exposure, 582
- Aplastic anemia, 399  
 in anemia taxonomy, 396  
 chloramphenicol, 188  
 as drug reaction, 241  
 Fanconi anemia, 656  
 neutropenia with, 402  
 thionamides, 341
- Aplastic crisis  
 hereditary spherocytosis, 400  
 sickle cell anemia, 400
- Apolipoproteins, **89**
- Aponeurosis of external oblique  
 muscle, 354
- Apoptosis, **204**  
 corticosteroids, 402  
 evasion in cancer, 215  
 malignant tumors, 216
- Appendages (appendages), 120
- Appendicitis, **366**  
 mittelschmerz vs, 596
- Appetite regulation, **317**
- “Apple core” lesion (X-ray), 371, 657
- Apraxia  
 dementia and, 529
- Aprepitant, 383
- Aquaporin  
 renin-angiotensin-aldosterone  
 system, 558
- Aqueous humor pathway, **505**
- Arabinoglycan synthesis, 192
- Arabinosyltransferase, 193
- Arachidonic acid pathway, **455**
- Arachnodactyly  
 Marfan syndrome, 652
- Arachnoid  
 CSF absorption, 473, 492  
 meninges, 465  
 meningioma, 496  
 ventricular system, 474
- Arcuate artery, 550
- Arcuate fasciculus  
 aphasia and, 486  
 diagram, 471
- Area postrema, 466
- Arenaviruses  
 characteristics of, 163, 164
- Arginine  
 classification, 77  
 cystinuria, 81  
 derivatives of, 79  
 histones, 32  
 kidney stones and, 567
- Arginosuccinate  
 urea cycle, 78
- Argyll Robertson pupils  
 presentation, 655  
 syphilis, 143, 180  
 tabes dorsalis, 500
- Arrhythmia  
 atrial fibrillation, 665
- Aripiprazole, 543
- Arm abduction, **425**
- Armadillos (disease vectors), 144
- Aromatase, 600
- Aromatase inhibitors, **621**  
 breast cancer, 661
- Aromatic amines  
 as carcinogens, 219
- Arrhythmia  
 amphotericin B, 195  
 amyloidosis and, 213  
 associations of, 665  
 diabetic ketoacidosis, 337  
 diphtheria, 135  
 hyperthyroidism, 327  
 hypokalemia and, 560  
 local anesthetics causing, 519  
 macrolides, 189  
 McArdle disease, 83  
 MI, 294  
 muscular dystrophy, 57  
 shock caused by, 299  
 sleep apnea and, 642  
 stimulants and, 540
- thyroid hormones and, 342  
 treatment, 661
- Arsenic  
 angiosarcomas, 375, 450  
 as carcinogen, 219  
 glycolysis and, 71  
 inhalational injury, 640  
 toxicity symptoms, 72  
 toxicity treatment for, 239
- Artemether, 196
- Arterial oxygen saturation, 633
- Arterial PCO<sub>2</sub>, 630, 634
- Arteries, anatomy of, 271
- Arteriosclerosis, 336
- Arteriosclerosis, **291**  
 pulmonary hypertension, 643
- Arteriovenous malformations  
 (AVMs), 303
- Arteritis  
 headaches, 488
- Artesunate  
 malaria, 153, 196
- Arthralgias  
 alkaptonuria, 80  
 coccidiomycosis, 147  
 Henoch-Schönlein  
 purpura, 303  
 hepatitis viruses, 168  
 rubella, 165  
 serum sickness, 109  
 vitamin A toxicity, 62
- Arthritis, **439**  
 AA amyloidosis and, 213  
 autoantibodies, 111  
 azathioprine for, 417  
*Campylobacter jejuni*, 140  
 carpal tunnel syndrome and, 426  
 celecoxib for, 456  
 chlamydiae, 146, 180  
 Crohn disease, 365  
 gonorrhea, 138, 176, 180  
 immunosuppressants, 116  
 inflammatory bowel disease, 96  
 LMN facial nerve palsy, 656  
 lupus, 443  
 Lyme disease, 142  
 Paget disease of bone, 652  
 parvovirus, 160  
 reactive arthritis, 442  
 septic, 441  
 Sjögren syndrome, 653  
*Staphylococcus aureus*, 131  
 Takayasu arteritis, 302  
 therapeutic antibodies, 118  
 ulcerative colitis, 365  
 Whipple disease, 656
- Arthropathy  
 hemochromatosis, 378
- Arthus reaction, 109
- Arylcyclohexylamines  
 intravenous anesthetics, 519
- Arylsulfatase A  
 metachromatic  
 leukodystrophy, 84
- Asbestos  
 carcinogenicity, 219  
 lung cancer and, 647

- Asbestosis  
characteristics, 641  
restrictive disease, 639
- Ascaris* spp, 154
- Ascaris lumbricoides*, 155
- Ascending aorta  
embryological development of, 268
- Ascending cholangitis, 379
- Ascending colon, 345
- Aschoff bodies, 300
- Ascites  
Budd-Chiari syndrome, 375, 652  
cirrhosis, 372  
hepatocellular carcinoma, 375  
Meigs syndrome, 610  
spontaneous bacterial peritonitis, 373
- Asenapine, 543
- Aseptic meningitis  
mumps, 166  
picornaviruses, 163
- Asherman syndrome, 622
- Ashkenazi Jews  
disease incidence, 84
- Ash-leaf spots, 495
- Aspartame, 80
- Aspartate  
urea cycle, 78
- Aspartate aminotransferase (AST), 373  
hepatitis, 168  
toxic shock syndrome, 131
- Aspartic acid, 77
- Aspart insulin, 340. *See also* Insulin
- Aspergillosis  
*Aspergillus fumigatus*, 149  
bronchiectasis, 639  
echinocandins, 196
- Aspergillus* spp  
as catalase-positive organism, 124  
chronic granulomatous disease, 105  
immunodeficiency infections, 114
- Aspergillus fumigatus*, 149  
HIV-positive adults, 173
- Aspiration  
ARDS and, 642  
in utero “breathing,” 626  
lung abscess, 646  
V/Q mismatch, 634
- Aspiration pneumonia  
alcoholics, 175  
clindamycin, 188  
*Klebsiella*, 140  
nosocomial infections, 181
- Aspirin, 456  
acute coronary syndromes, 296  
arachidonic acid pathway and, 455  
cyclooxygenase, 393  
hemolysis in G6PD deficiency, 241  
for ischemic stroke, 482  
Kawasaki disease, 302, 662  
polycythemia vera, 411  
Reye syndrome and, 373  
uncoupling agent, 74  
as weak acid, 226  
zero-order elimination of, 226
- Asplenia  
Howell-Jolly bodies, 395  
target cells, 395
- Asterixis, 489  
cirrhosis, 372  
hepatic encephalopathy, 374  
hyperammonemia, 78  
renal failure, 571
- Asthma, 638  
albuterol for, 234  
 $\beta$ -blockers and, 237  
breast milk and, 599  
cholinomimetic agents and, 232  
cromolyn sodium for, 387  
drug therapy, 649  
eczema and, 449  
eosinophilia and, 387  
epinephrine for, 234  
gastroesophageal reflux disease, 360  
immunosuppressants, 116  
muscarinic antagonists for, 233  
omalizumab for, 118  
pulsus paradoxus in, 300  
salmeterol for, 234  
type I hypersensitivity, 108
- Astigmatism, 504
- Astrocytes, 463  
foot processes, 466  
origin of, 460
- Astrocytomas, 664  
GFAP stain for, 44
- Ataxia  
abetalipoproteinemia, 89  
amantadine toxicity, 517  
Angelman syndrome, 54  
ataxia-telangiectasia, 37  
cerebellar hemisphere lesions, 481  
cerebellar vermis lesions, 481  
epilepsy drugs, 514  
Friedreich, 501  
hypnotics, 515  
metachromatic leukodystrophy, 84, 494  
normal pressure hydrocephalus, 492  
opsoclonus-myoclonus syndrome, 217  
peroxisome disease, 43  
prion disease, 174  
psychoactive drug intoxication, 540  
Rett syndrome, 527  
streptomycin, 193  
syphilis, 143  
tabes dorsalis, 500  
trinucleotide repeat expansion disease, 58, 60  
vitamin B<sub>12</sub> deficiency, 500  
Wernicke-Korsakoff syndrome, 62, 481, 541
- Ataxia-telangiectasia, 37, 113
- Atazanavin, 199
- Atazanavir, 197
- Atelectasis  
intrapleural pressures, 631  
physical findings with, 643
- Atenolol, 237, 309
- Ateriolosclerosis, 291
- Atherosclerosis, 292  
abdominal aortic aneurysms and, 292  
aortic aneurysms, 664  
diabetes mellitus and, 336  
familial dyslipidemias, 90  
homocystinuria as cause, 80  
sites of, 668  
stable angina with, 293  
transplant rejection, 115
- Athetosis, 481, 489
- ATM gene, 113
- Atomoxetine, 527, 661
- Atonic seizures, 487
- Atopic dermatitis, 449
- Atopic reactions, 108
- Atorvastatin, 306
- Atovaquone  
babesiosis, 153  
malaria, 153  
*P. falciparum*, 196  
for *Pneumocystis jirovecii*, 150
- ATPase, 378
- Atracurium, 520
- Atria  
cardiac tumors, 301  
embryological development of, 268–269
- Atrial amyloidosis, 213
- Atrial fibrillation  
 $\beta$ -blockers for, 309  
calcium channel blockers for, 310  
cardiac glycosides for, 307  
ECG tracing of, 284  
embolic risk with, 665  
embolic stroke, 482  
hypertension as cause, 290  
jugular venous pulse in, 276  
potassium channel blockers for, 309  
sleep apnea, 642
- Atrial flutter  
 $\beta$ -blockers for, 309  
ECG tracing of, 284  
potassium channel blockers for, 309
- Atrial natriuretic peptide (ANP), 285, 558  
amyloidosis and, 213  
kidney effects, 559  
in SIADH, 334  
signaling pathways for, 322
- Atrial septa  
embryological development of, 268
- Atrial septal defect (ASD), 289  
congenital rubella, 290  
diastolic murmur in, 278  
Down syndrome, 290  
fetal alcohol syndrome, 290
- Atrioventricular block  
 $\beta$ -blockers as cause, 237  
 $\beta$ -blockers in, 309  
calcium channel blockers, 304, 310  
ECG tracings, 284  
Lyme disease, 142
- Atrioventricular canals, 269
- Atrioventricular node  
conduction pathway, 282  
ECG and, 282
- Atrioventricular septal defect (AVSD), 59
- Atrioventricular valves  
embryological development of, 268
- Atrophic gastritis  
associations with, 665  
gastrin in, 356
- Atrophy, 214  
amyotrophic lateral sclerosis, 500  
cerebral, 483  
motor neuron signs, 499, 501  
neurodegenerative disorders, 490  
optic disc/nerve, 494, 506  
ventriculomegaly, 492
- Atropine, 233  
antimuscarinic reaction, 242  
for  $\beta$ -blocker overdose, 309  
cholinesterase inhibitor poisoning, 232  
toxicity treatment, 239
- Attention deficit disorder (ADD)  
amphetamines for, 234
- Attention-deficit hyperactivity disorder (ADHD), 527  
drug therapy for, 542  
smoking and, 582  
sympatholytic drugs for, 235  
Tourette syndrome, 527  
treatment, 661
- Attributable risk (AR), 248, 669
- Atypical antidepressants, 546
- Atypical antipsychotic drugs, 543  
bipolar disorder, 531, 661  
postpartum psychosis, 532  
schizophrenia, 530
- Atypical depression, 546
- Atypical lymphocytes, 657
- Atypical pneumonias  
chlamydiae, 146  
macrolides, 189  
typical organisms, 645
- Auditory cortex  
diagram, 471  
thalamic relay, 468
- Auditory hallucinations, 529, 530
- Auditory physiology, 503
- Auer rods, 657  
in AML, 410
- Auramine-rhodamine stain, 122
- Auscultation of heart, 278
- Auspitz sign, 449
- Autism spectrum disorder, 527  
double Y males and, 603  
fragile X syndrome, 58
- Autoantibodies, 111
- Autoclaves  
disinfection/sterilization, 200  
spore-forming bacteria, 127
- Autografts, 114
- Autoimmune anemia, 396
- Autoimmune diseases  
acute pericarditis, 300  
collagen and, 46  
preeclampsia and, 608  
self-antigen in, 97
- Autoimmune gastritis, 362
- Autoimmune hemolytic anemia, 108, 401  
cephalosporins, 185

- Autoimmune hepatitis, 111  
 Autoimmune hypothyroidism, 169  
 Autoimmune lymphoproliferative syndrome, 204  
 Autoimmune membranous nephropathy, 111  
 Autoimmune regulator (AIRE), 97  
 Autonomic drugs, 229–238  
   naming conventions for, 244  
 Autonomic insufficiency, 234  
 Autonomy (ethics), 253  
 Autoregulation of blood flow, **286**  
 Autosomal dominant disorders  
   Brugada syndrome, 285  
   hyper-IgE syndrome, 112  
 Autosomal dominant hyper-IgE syndrome  
   presentation, 655  
 Autosomal dominant inheritance diseases, 56  
   mode of, 55  
 Autosomal dominant polycystic kidney disease  
   (ADPKD), 573  
   chromosome association, 60  
   saccular aneurysms and, 486  
 Autosomal recessive disorders  
   adenosine deaminase deficiency, 113  
   Chédiak-Higashi syndrome, 113  
   IL-12 receptor deficiency, 112  
   leukocyte adhesion deficiency, 113  
   severe combined immunodeficiency, 113  
   Wilson disease, 378  
 Autosomal recessive inheritance diseases, 56  
   mode of, 55  
 Autosomal recessive polycystic kidney disease (ARPKD), 573  
   Potter sequence caused by, 548  
 Autosomal trisomies, **59**  
   karyotyping for, 51  
 Autosplenectomy  
   associations with, 664  
   sickle cell anemia, 400  
 Avascular necrosis, **436**  
   scaphoid bone, 426  
   sickle cell anemia, 400  
 Avoidant personality disorder, 535  
 Axillary lymph nodes, 93  
   breast cancer and, 616  
 Axillary nerve, 427  
 Axonal injury, 465  
 Axonemal dynein, 45  
 Azathioprine  
   allopurinol and, 457  
   antimetabolites, 417  
   in cell cycle, 416  
   for Crohn disease, 365  
   immunosuppressant, 116  
   pancreatitis caused by, 240  
   targets of, 117  
 Azithromycin, 138  
   babesiosis, 153  
   chlamydiae, 146  
   gonococci, 138  
   prophylaxis in HIV, 194  
   macrolides, 189  
   mechanism (diagram), 183  
   *Mycobacterium avium-intracellulare*, 136, 192  
 Azoles, **195**  
   mechanism (diagram), 194  
   opportunistic fungal infections, 149  
   vaginal infections, 177  
 Azotemia  
   acute interstitial nephritis, 572  
   nephritic syndrome and, 564  
 Aztreonam, 183, 186
- B**
- B7 protein  
   naive T-cell activation, 99  
 B19 virus, 160  
*Babesia* spp, 142, **153**  
   anemia, 401  
 Babesiosis, 153  
 Babinski reflex, 258  
   motor neuron signs, 499  
   primitive reflexes, 480  
 Bachmann bundle, 282  
 Bacillary angiomatosis, 450  
   animal transmission, 144  
   HIV-positive adults, 173  
 Bacilli, 121  
   Gram stain identification of, 130  
*Bacillus* spp  
   Gram-positive algorithm, 130  
   taxonomy, 121  
*Bacillus anthracis*, **133**  
   capsule composition, 120  
   exotoxin production, 128  
   spore formation, 127  
*Bacillus cereus*, **134**  
   food poisoning, 174, 665  
   spore formation, 127  
 Bacitracin  
   Gram-positive antibiotic test, 130  
   mechanism (diagram), 183  
   sensitivity to, 130, 132  
 Bacitracin response, 657  
 Back pain  
   G6PD deficiency and, 400  
 Baclofen  
   mechanism and use, **520**  
   multiple sclerosis, 493  
 Bacteremia  
   brain abscesses, 176  
   cutaneous anthrax, 133  
   daptomycin, 191  
   *Staphylococcus gallolyticus*, 133  
   *Streptococcus bovis*, 133  
   tuberculosis, 136  
 Bacteria  
   biofilm-producing, 125  
   encapsulated, 124  
   genetics, 126, 127  
   hemolytic, 131  
   highly resistant, **194**  
   normal flora, 174  
   pigment-producing, 125  
   special culture requirements, **123**  
   special populations, 182  
   spore-forming, **127**  
   stains for, 122  
   structures of, **120**  
   taxonomy, 121  
   virulence factors, 124, 125  
   zoonotic, 144  
 Bacterial capsules, 120  
 Bacterial endocarditis, **299**  
   daptomycin, 191  
   presentation, 656  
   *Staphylococcus aureus*, 131  
   *Streptococcus sanguinis*, 132  
 Bacterial meningitis, 664  
 Bacterial peritonitis  
   (spontaneous), 373  
 Bacterial toxins  
   effects of, **106**  
   neutralization of, 101  
 Bacterial vaginosis  
   characteristics of, 154, 177  
   *Gardnerella vaginalis*, 144  
*Bacteroides* spp  
   alcoholism, 175  
   anaerobic organism, 123  
   clindamycin, 188  
   lung abscesses, 646  
   metronidazole, 191  
   nosocomial infections, 181  
   taxonomy, 121  
*Bacteroides fragilis*, 174  
 “Bag of worms,” 618  
 Baker cyst, 425  
   tibial nerve injury, 430  
 BAK protein, 204  
 Balancing (quality measurement), 261  
 “Bamboo spine” (X-ray), 442, 657  
 Band cells, 386  
 Barbiturates  
   intoxication and withdrawal, 540  
   intravenous anesthetics, 519  
   mechanism and use, **515**  
   naming convention for, 244  
   sleep alterations, 467  
 Baroreceptors, **285**  
 Barr bodies, 32  
 Barrett esophagus, **361**  
   metaplasia and, 214  
*Bartonella* spp  
   animal transmission, 144  
   endocarditis, 299  
   taxonomy, 121  
*Bartonella henselae*  
   bacillary angiomatosis, 450  
   granulomatous diseases, 211  
   HIV-positive adults, 173  
*Bartonella quintana*, 157  
 Bartter syndrome, **556**  
   markers in, 560  
 Basal cell carcinomas, **454**  
   5-fluorouracil for, 417  
   sunburn and, 453  
 Basal ganglia, **470**  
   intraparenchymal hemorrhage, 483  
   lesions in, 481  
   microaneurysms, 486  
   movement disorders, **489**  
   thalamic connections, 468  
 Basal lamina, 46  
 Basal metabolic rate, 321  
 Basal plate, 460  
 Base excision repair, **37**  
 Basement membrane  
   Alport syndrome and, 565  
   autoantibodies to, 111  
   barrel hoop, 94  
   blood-brain barrier, 466  
   collagen in, 46  
   filtration, 553  
   glomerular filtration barrier, 551  
   in glomerulus, 550  
 Basic amino acids, 77  
 Basilar artery  
   circle of Willis, 473  
   herniation syndromes, 499  
   stroke effects, 485  
 Basilar membrane (cochlea), 503  
 Basiliximab  
   immunosuppressant, 116  
   targets of, 117  
 Basophilia, 387  
 Basophilic stippling, 394, 657  
   lead poisoning, 397  
   sideroblastic anemia, 397  
 Basophils, **387**  
   CML, 410  
   hypersensitivity reaction, 108  
   IgE antibody, 101  
 BAX protein, 204  
 B-cell lymphomas, 668  
   HIV-positive adults, 173  
   oncogenes and, 218  
 B cells, **388**  
   activation, **99**, 101  
   adaptive immunity, 95  
   anergy, 106  
   cell surface proteins, 106  
   class switching, 99  
   cytokines and, 104  
   disorders of, 112, 113  
   functions of, 97, 388  
   glucocorticoid effects, 116  
   immunodeficiency infections, **114**  
   in lymph node, 92  
   neoplasms, 408  
   non-Hodgkin lymphoma, 407  
   sirolimus effect, 116  
   spleen, 94  
 BCG vaccination, 136  
 BCG vaccine  
   IL-12 receptor deficiency and, 112  
   live attenuated, 107  
 BCL-2 gene, 218  
 Bcl-2 protein, 204  
 BCR-ABL gene, 218  
 Becker muscular dystrophy, **57**  
   presentation, 656  
 Beck triad of cardiac tamponade, 300, 654  
 Beckwith-Wiedemann, 569  
 Bedwetting. *See* Nocturnal enuresis  
 Beers criteria, **238**  
 Bell palsy, 502  
   Lyme disease, 142, 182  
   sarcoidosis and, 444

- Bell-shaped distribution, 251  
 Bence Jones protein, 409  
 Benzodiazoles, 155  
 “the bends,” 436  
 Beneficence (ethics), 253  
 Benign breast disease, **615**  
 Benign prostatic hyperplasia (BPH), **619**, 667  
    $\alpha$ -blockers for, 236  
   hydronephrosis and, 568  
   postrenal azotemia, 571  
   tamsulosin for, 623  
   treatment, 661  
 Benign tumors, 216  
 Benzathine penicillin G, 194  
 Benzene  
   aplastic anemia, 241, 399  
   myelodysplastic syndromes, 409  
 Benzidine as carcinogen, 219  
 Benzimidazole, 154  
 Benzoate, 78  
 Benzocaine, 519  
   methemoglobinemia, 632  
 Benzodiazepines, **515**  
   addictive risk, 515  
   alcohol withdrawal, 542, 661  
   anaesthetic adjuncts, 519  
   Beers criteria, 238  
   cocaine overdose, 540  
   epilepsy, 514  
   generalized anxiety disorder, 533  
   intoxication and  
     withdrawal, 540  
   naming convention for, 244  
   panic disorder, 533  
   PCP overdose, 541  
   phobias, 533  
   sleep, effect on, 467  
   toxicity treatment for, 239  
 Benzoyl peroxide for acne, 449  
 Benzotropine, 233, 517  
 Beriberi  
   cardiomyopathy, 297  
   vitamin B<sub>1</sub> deficiency, 62  
 Berkson bias, 250  
 Bernard-Soulier syndrome, 393, 405, 664  
 Berylliosis, **641**  
   granulomatous disease, 211  
 $\beta_1$ -blockade, 273  
 $\beta_2$ -agonists  
   asthma, 649  
   insulin and, 314  
   naming convention for, 244  
 $\beta_2$ -microglobulin  
   MHC I and II and, 96  
 $\beta$ -amyloid protein (Alzheimer disease), 213  
 $\beta$ -blockers, **237**  
   acute coronary syndromes, 296  
   angina, 305  
   antiarrhythmic drugs, **309**  
   aortic dissections, 293  
   for cocaine overdose, 234, 540  
   diabetes and, 237  
   dilated cardiomyopathy, 297  
   essential tremor, 489  
   glaucoma, 521  
   heart failure, 298  
   hydralazine and, 304  
   hyperkalemia, 560  
   hypertension, 304  
   hypertrophic cardiomyopathy, 297  
   juxtaglomerular apparatus  
   effects, 558  
   migraine headaches, 488  
   naming convention for, 244  
   overdose treatment, 309  
   for pheochromocytomas, 326  
   phobias, 533  
   for thyroid storm, 329  
   toxicity treatment for, 239  
 $\beta$  cells, 313  
   diabetes mellitus type 1 and 2, 337  
   insulinomas of, 338  
   insulin secretion by, 314  
 $\beta$ -dystroglycan, 57  
 $\beta$ -galactosidase, 138  
 $\beta$ -glucan, 196  
 $\beta$ -glucuronidase, 386  
 $\beta$ -hCG  
   autosomal trisomies, 59  
   as tumor marker, 220  
 $\beta$ -hemolysis, 129  
 $\beta$ -hemolytic bacteria, 131  
 $\beta$ -hydroxybutyrate, 86  
 $\beta$ -interferon  
   multiple sclerosis, 493  
 $\beta$ -lactam antibiotics, 183  
 $\beta$ -lactamase inhibitors, **184**  
 $\beta$ -lactams, 452  
 Betamethasone, 455  
 $\beta$ -thalassemia, 397  
   allelic heterogeneity, 53  
   chromosome association, 60  
   intron/exon splicing variants, 39  
 Betaxolol, 237  
 Bethanechol, 232  
 Bevacizumab, 118, **420**  
 Bezafibrate, 306  
 Bias and study errors, **250**  
 Bicarbonate  
   carbon dioxide transport, 635  
   drug overdoses, 226  
   GI secretion, 357  
   pancreatic insufficiency, 364  
   salicylate toxicity, 239  
   TCA toxicity, 239  
 Biceps brachii muscle  
   Erb palsy, 428  
 Biceps tendon, 425  
 Bicornuate uterus, 590  
 Bicuspid aortic valve  
   aortic dissection and, 293  
   coarctation of aorta and, 289  
   heart murmur with, 279  
   thoracic aortic aneurysms  
   and, 292  
   Turner syndrome, 290, 603  
 Bifurcation external landmarks, 629  
 Biguanide drugs, 340  
 Bilaminar disc, 580  
 Bilateral acoustic schwannomas, 652  
 Bilateral adenopathy, 444  
 Bilateral renal agenesis  
   oligohydramnios and, 607  
   Potter sequence, 548  
   pulmonary hypoplasia and, 626  
 Bile, **358**  
   hereditary hyperbilirubinemias, 377  
   secretin effect on, 356  
 Bile acid resins, 306  
 Bile acids  
   lipid transport, 88  
   reabsorption of, 306  
 Bile canaliculus, 352  
 Bile duct, 353  
 Bile ductule, 352  
 Bile salts, 358  
   in cholelithiasis, 379  
 Biliary cirrhosis, 372, 376  
   cystic fibrosis, 56  
   labs/findings, 657  
 Biliary colic, 379  
 Biliary structures, **353**  
 Biliary tract disease, **378**  
   *Clonorchis sinensis*, 157  
 Biliary tract infections  
   Enterococci, 133  
 Bilius vomiting, 367  
 Bilirubin, **359**  
   bile, 358  
   cholelithiasis, 379  
   hereditary hyperbilirubinemias, 377  
   liver marker, 373  
   toxic shock syndrome, 131  
 Bimatoprost, 521  
 Bimodal distribution, 251  
 Binge eating disorder, 537  
 Bioavailability, 225  
 Biochemistry, **32–89**  
   cellular, 42–48  
   genetics, 52–61  
   laboratory techniques, 48–52  
   metabolism, 68–90  
   molecular, 32–41  
   nutrition, 61–68  
 Biofilm-producing bacteria, 125  
 Biostatistics/epidemiology, **246–252**  
 Bipolar disorder, 530, **531**  
   drug therapy for, 542, 543  
   lithium for, 544  
   postpartum psychosis, 532  
   treatment, 661  
 Birbeck granules, 660  
   Langerhans cell histiocytosis, 412  
 “Bird’s beak” sign (X-ray), 360  
 Birds (disease vectors), 144, 146  
 Bismuth, **382**  
 Bisphosphonates, **456**  
   esophagitis with, 240  
   naming convention for, 244  
   for osteoporosis, 435  
 Bitemporal hemianopia, 511  
 Craniopharyngioma, 498  
 hypopituitarism as cause, 335  
 Nelson syndrome as cause, 332  
 optic chiasm compression, 486  
 pituitary adenoma, 496  
 visual field defects, 511  
 Bitot spots, 62  
 Bivalirudin, 413  
 BK virus, 160  
 Black eschar, 133  
 Blackflies (disease vectors), 155  
 Black liver, 665  
 Black lung disease, 641  
 Bladder, 592  
   bethanechol effect on, 232  
   BPH and, 619  
   Brenner tumor, 610  
   development of, 585  
   estrophy, 591  
   female anatomy, 606  
   lymphatic drainage, 591  
   placenta percreta, 606  
   spasm treatment, 233  
   transitional cell carcinoma, 569  
   urachus, 585  
 Bladder cancer  
   cisplatin/carboplatin for, 419  
   hematuria, with, 562  
   hypercalcemia and, 217  
   oncogenic microbes and, 219  
   *Schistosoma haematobium*,  
   156, 157  
 Blast crisis in CML, 665  
 Blastocyst implantation, 580  
*Blastomyces* spp  
   amphotericin B, 195  
   itraconazole, 195  
 Blastomycosis, **147**  
 Bleeding  
   adenomatous polyps, 370  
   control of, 346  
   direct factor Xa inhibitors, 415  
   direct thrombin inhibitors, 413  
   diverticulosis, 366  
   essential thrombocythemia, 411  
   glycoprotein IIb/IIIa inhibitors, 415  
   heparin, 413  
   inflammatory bowel disease, 365  
   peptic ulcer disease, 363  
   thrombolytics, 415  
   variceal, 356  
   warfarin, 414  
 Bleomycin, 418  
   in cell cycle, 416  
   pulmonary fibrosis, 242  
   targets of, 416  
 Bleomycin toxicity, 422, 639  
 Blepharospasm  
   dystonia, 489  
 Blindness  
   *Chlamydia trachomatis*, 146  
   conversion disorder, 536  
   giant cell arteritis, 302  
   neonatal, 138  
   *Onchocerca volvulus*, 155  
   temporal arteritis, 668  
   *Toxocara canis*, 155  
 Blistering skin disorders, **452**  
 Blood  
   chocolate-colored, 632  
   coagulation and kinin  
   pathways, 391  
   embryologic derivatives, 581

- Blood (*continued*)  
 hCG detection in, 598  
 metrorrhagia, 597  
 oxygen content, **633**  
 in placenta, 584  
 umbilical cord, 585  
 urethral injury, 593  
 viscosity of, 634
- Blood-brain barrier  
 anesthetics, 518  
 astrocytes, 463  
 function and mechanism, **466**  
 L-DOPA, 518
- Blood flow exercise response, 635
- Blood groups, **390**
- Blood pH  
 diuretic effects on, 576
- Blood pressure  
 $\alpha$ -blocker effect on, 236  
 angiotensin II effects, 558, 559  
 antianginal therapy, 305  
 antidiuretic hormone regulation of, 317  
 cortisol effect on, 319  
 fenoldopam and, 304  
 renal disorders and, 560  
 renin-angiotensin-aldosterone system, 558  
 sympathomimetic effect on, 235
- Blood-testis barrier, 466
- Blood transfusions, **407**  
 reactions, **110**
- Blood vessels  
 collagen in, 46  
 Ehlers-Danlos syndrome, 46  
 hereditary hemorrhagic telangiectasia, 303
- Bloody diarrhea, **175**  
 amebiasis, 151  
*Campylobacter jejuni*, 140, 144  
*Shigella*, 141  
 ulcerative colitis, 365
- Bloody stool, 351
- Blotting procedures, **49**
- Blown pupils, 511  
 CN III damage, 511  
 herniation syndromes, 499  
 saccular aneurysms, 486
- “Blue babies,” 288
- Blueberry muffin rash  
 cytomegalovirus, 178  
 rubella, 165, 178  
*Toxoplasma gondii*, 178
- “Blue kids,” 289
- Blue sclerae, 47  
 osteogenesis imperfecta, 652
- BNP. *See* Brain natriuretic peptide (BNP)
- Body dysmorphic disorder, 533
- Boerhaave syndrome, 360
- Bombesin, 325
- Bone cancer, 437  
 primary bone tumors, **438**
- Bone crises, 84
- Bone disorder lab values, **437**
- Bone disorders  
 “brown” tumor, 657  
 osteogenesis imperfecta, **47**  
 pain, 652  
 raised periosteum, 660  
 “soap bubble” (x-ray), 660
- Bone formation, **434**
- Bone fractures  
 child abuse sign, 526  
 fat embol from, 637
- Bone lesions  
 adult T-cell lymphoma, 408  
 Langerhans cell histiocytosis, 412  
 multiple myeloma, 409
- Bone marrow suppression, 195
- Bone marrow transplant  
 osteopetrosis, 435  
 severe combined immunodeficiency, 113
- Bones  
 collagen in, 46  
 cortisol effect on, 319  
 lytic/blastic metastases, 221  
 PTH effect on, 320  
 renal osteodystrophy, 571  
 T<sub>3</sub> hormone and, 321
- Bone tumors, **438**  
 “Boot-shaped” heart (X-ray), 657
- Borderline personality disorder, 535  
 dissociative identity disorder, 528
- Bordetella* spp, 121
- Bordetella pertussis*, **139**  
 culture requirements, 123  
 exotoxin production, 128  
 Gram-negative algorithm, 137  
 macrolides, 189  
 vaccines, 139
- Bordet-Gengou agar, 123
- Borrelia* spp, **142**  
 Giemsa stain, 122  
 taxonomy, 121
- Borrelia burgdorferi*  
 animal transmission, 144  
 coinfection with, 153  
 facial nerve palsy, 182  
 Lyme disease, **142**  
 tetracyclines, 188
- Borrelia recurrentis*  
 animal transmission, 144  
 antigenic variation, 106  
 vectors, 157
- Bortezomib, 420
- Bosentan, 648
- Botulinum, 231
- Botulinum toxin  
 lysogenic transduction, 126  
 passive antibodies for, 107  
 toxin effects, 128
- Botulism  
*Clostridium botulinum*, 134  
 exotoxin, 127
- Bovine spongiform encephalopathy (BSE), 174
- Bowel smooth muscle  
 activation, 232
- Bowel stenosis, 366
- Bowen disease, 617
- Bowenoid papulosis, 617
- Bowman capsule, 553
- Brachial artery, 432
- Brachial plexus lesions, **428**
- Brachiocephalic artery, 473
- Bradycardia  
 amiodarone and, 309  
 atropine for, 233  
 $\beta$ -blockers and, 237, 309  
 cholinesterase inhibitor poisoning, 232  
 dopamine for, 234  
 on ECG, 282  
 hypermagnesemia, 560  
 hypothyroidism, 327  
 RCA infarct, 271  
 reflex, 558  
 sympatholytic drugs and, 235
- Bradykinin  
 ACE inhibitors and, 577  
 breakdown of, 558  
 C1 esterase inhibitor deficiency, 103
- Bradykinin, 577
- BRAF gene, 218  
 melanomas and, 454  
 papillary thyroid carcinoma and, 330  
 vemurafenib and, 421
- Brain  
 blood flow autoregulation, 286  
 choriocarcinoma and, 618  
 embryologic derivatives, 581  
 embryology of, 460  
 glucose usage by, 314  
 ischemia in, 206  
 metastasis to, 221  
 ring-enhancing lesions, 660  
 T<sub>3</sub> hormone and, 321
- Brain abscesses  
 HIV-positive adults, 176  
*Toxoplasma gondii*, 152, 173
- Brain cysts, 157
- Brain infarcts, 205
- Brain injury  
 gastritis with, 362  
 hypopituitarism from, 335
- Brain lesions, **481**
- Brain natriuretic peptide (BNP), **285, 558**  
 in SIADH, 334  
 signaling pathways for, 322
- Brain stem  
 dorsal view, **475**  
 ventral view, **474**
- Brain tumors  
 adult primary, **496–497**  
 associations with, 664  
 biopsy findings, 660  
 childhood primary, 498  
 metastatic source, 221  
 nitrosureas for, 418
- Branched-chain ketoacid  
 dehydrogenase, 62
- Branchial apparatus, **586**
- Branchial arch derivatives, **587**
- Branchial cleft derivatives, **586**
- Branchial pouch derivatives, **588**
- Branching enzyme (glycogen metabolism), 82
- Branching filamentous bacteria  
 Gram stain identification, 130  
 taxonomy, 121
- Branching gram-positive rods/sulfur granules, 657
- BRCA1/BRCA2 genes, 218  
 breast cancer and, 616  
 ovarian neoplasms, 610
- Breast cancer, **616–617**  
 aromatase inhibitors for, 621  
 breastfeeding and, 599  
 hormonal contraception  
 contraindication, 622  
 hypercalcemia and, 217  
 incidence/mortality of, 216  
 key associations, 664  
 oncogenes and, 218  
 paclitaxel for, 419  
 paraneoplastic cerebellar degeneration and, 217  
 postmenopausal women, 661  
 tamoxifen for, 421  
 trastuzumab for, 421  
 tumor suppressor genes and, 218
- Breast disorders  
 benign, **615**  
 malignant, **616**
- Breastfeeding, 599  
 ovarian neoplasms and, 610
- Breast milk. *See also* Lactation  
 IgA antibodies in, 101  
 prolactin and, 316
- Breast/ovarian cancer  
 incomplete penetrance, 52
- Breast/ovarian cancers  
 BRCA1 mutation, 37
- Breast pathology, **614**
- Breast trauma, necrosis caused by, 205
- Brenner tumors, 610
- Bretylium, 231
- Brief psychotic disorder, 530
- Brimonidine, 521
- Brittle hair, 47
- Broad-base budding, 147
- Broad ligament, 592
- Broca area  
 aphasia, 486  
 diagram, 471  
 MCA stroke, 484
- Bromocriptine, 517. *See also* Dopamine agonists  
 prolactin and, 316
- Bronchi, 628
- Bronchial carcinoid tumors, 647
- Bronchiectasis  
*Aspergillus fumigatus*, 149  
 cystic fibrosis, 56  
 Kartagener syndrome, 45, 656
- Bronchioalveolar cell carcinomas, 647
- Bronchioles, 628  
 histamine receptors and, 230
- Bronchiolitis obliterans, 115
- Bronchiolitis obliterans organizing pneumonia (BOOP), 645
- Bronchitis  
 croup, 166  
 cystic fibrosis, 56  
*Haemophilus influenzae*, 138

- Bronchoconstriction, 649  
 Bronchodilation, 649  
   sympathetic receptors and, 230  
 Bronchogenic apical lung tumor, 657  
 Bronchogenic carcinomas  
   asbestosis and, 641  
   carcinogens causing, 219  
 Bronchogenic cysts, 626  
 Bronchopneumonia, 645  
 Bronchopulmonary dysplasia, 210  
   neonatal respiratory distress syndrome as cause, 627  
 “Brown” bone tumor, 657  
 Brown-Séquard syndrome, **501**  
   Horner syndrome, 509  
*Brucella* spp  
   Gram-negative algorithm, 137  
   intracellular organism, 124  
   taxonomy, 121  
   transmission, 144  
 Brucellosis, 144  
 Brugada syndrome, **283**, 293  
 Bruising  
   child abuse sign, 526  
   scurvy, 65  
 Brunner glands  
   duodenum, 347  
   ulcers and, 363  
 Brushfield spots, 59  
 Bruton agammaglobulinemia, 56, 112  
 Bruxism, 467  
 BTK gene, 112  
 Budd-Chiari syndrome, **375**  
   labs/findings, 659  
   portal hypertension, 372  
   presentation, 652  
 Budesonide, 649  
 Buerger disease, **302**  
   associations with, 667  
   treatment, 661  
 Buffalo hump, 323  
 Bulbus cordis, 268  
 Bulimia nervosa, 537  
   anovulation and, 609  
   drug therapy for, 542  
   Mallory-Weiss syndrome and, 360  
   SSRIs for, 545  
   treatment, 661  
 Bulk-forming laxatives, 383  
 Bullae, 447  
   necrotizing fasciitis, 451  
   Stevens-Johnson syndrome, 452  
 Bull neck, 128  
 Bullous impetigo, 451  
 Bullous pemphigoid, 447, 452  
   autoantibody, 111  
   type II hypersensitivity, 108  
 Bumetanide, **575**  
 BUN (blood urea nitrogen)  
   intrinsic renal failure, 571  
   nephritic syndrome, 563  
   ornithine transcarbamylase deficiency, 79  
   renal failure consequences, 571  
 BUN/creatinine ratio, 571  
 Bundle of His, 282  
 Bunyaviruses  
   characteristics of, 163, 164  
 Bupivacaine, 519  
 Buprenorphine  
   heroin addiction, 541  
   morphine and, 228  
   opioid withdrawal, 540  
 Bupropion, 546  
   major depressive disorder, 531  
   mechanism, 544  
   nicotine withdrawal, 540  
   seizures with, 242  
*Burkholderia cepacia*  
   characteristics of, 124  
   cystic fibrosis, 175  
   immunodeficiency infections, 114  
   taxonomy, 121  
 Burkitt lymphoma, 408  
   chromosomal translocations and, 412  
   EBV, 161  
   labs/findings, 660, 668  
   oncogenes and, 218  
   oncogenic microbes and, 219  
 Burns  
   acute gastric ulcer, 664  
   child abuse sign, 526  
   inhalational injuries and, 640  
   shock with, 299  
   sunburn, 453  
   testosterone/methyltestosterone for, 623  
 Bursitis  
   prepatellar, 425  
 Burton line  
   lead poisoning, 397  
   presentation, 652  
 Buspirone, **544**  
   generalized anxiety disorder, 533  
 Busulfan, 418  
   pulmonary fibrosis and, 242  
 Busulfan toxicity, 422  
   restrictive lung disease, 639  
 Butorphanol, **521**  
 Butterfly facial rash, 652  
**C**  
 C1 esterase inhibitor deficiency, 103  
 C3 deficiency, 103  
 C5a receptor, 386  
 C5-C9 deficiencies, 103  
 CA 15-3/CA27-29 (tumor markers), 220  
 CA 19-9 (tumor marker), 220  
 CA 125 levels, 610  
 CA 125 (tumor marker), 220  
 Cachexia, **221**  
   TNF- $\alpha$  and, 104  
 Café-au-lait spots  
   aplastic anemia and, 399  
   causes of, 652  
   McCune-Albright syndrome, 53  
   neurofibromatosis, 495  
 Caffeine intoxication and withdrawal, 540  
 Cahill cycle, 78  
 Caisson disease, 637  
 Calciferol (vitamin D), 559  
 Calcification, **208**  
 Calcineurin, 116  
 Calcinosis, 446  
 Calcitonin, **321**  
   medullary thyroid carcinoma production, 330  
   osteoporosis, 435  
   signaling pathways of, 322  
   tumor marker, 220  
 Calcium  
   in bone disorders, 437  
   calcitonin and, 321  
   in cardiac muscle, 280  
   in osteomalacia/rickets, 436  
   in Paget disease of bone, 436  
   PTH and, 320  
   rhomboïd crystals, 660  
   Vitamin D and, 319  
 Calcium carbonate, 382  
 Calcium channel blockers, **304**  
   angina, 304  
   antiarrhythmic drugs, **310**  
   contractility in, 273  
   cutaneous flushing, 239  
   gingival hyperplasia, 241  
   hypertension, 304  
   hypertrophic cardiomyopathy, 297  
   migraine headaches, 488  
   Raynaud phenomenon, 445  
 Calcium channels  
   ethosuximide effect on, 514  
   glucose and, 314  
   Lambert-Eaton myasthenic syndrome and, 217  
   myocardial action potential, 280  
   opioid effect on, 520  
   pacemaker action potential, 281  
   smooth muscle contraction, 434  
 Calcium homeostasis, **319**  
 Calcium oxalate nephrolithiasis, 65  
 Calcium pyrophosphate deposition disease, **440**  
 Calcium-sensing receptor (CaSR), 342  
 Calf pseudohypertrophy, 652  
 Caliciviruses  
   characteristics of, 159, 163  
 California encephalitis, 163  
 Call-Exner bodies, 611  
 Calluses (dermatology), 448  
 cAMP (cyclic adenosine monophosphate)  
   cilostazol/dipyridamole effect on, 415  
   endocrine hormone messenger, 322  
   exotoxin effects, 128  
   fructose biphosphatase-2 and, 72  
   glycogen regulation, 81  
   heat-labile/heat-stable toxin effects, 128  
   hyperparathyroidism, 332  
   PTH effect on, 320  
   *Vibrio cholerae*, 141  
 CAMP factor, 133  
*Campylobacter* spp  
   animal transmission, 144  
   bloody diarrhea, 175  
   reactive arthritis and, 442  
   taxonomy, 121  
*Campylobacter jejuni*, **140**  
   Gram-negative algorithm, 137  
   Guillain-Barré syndrome, 493  
 Canagliflozin, 341  
 Canalicular lung development, 626  
 Cancer  
   bacteremia with, 660  
   deaths from, **260**  
   common metastases, 221  
   epidemiology of, 216  
   ESR in, 212  
   intron/exon splicing variants and, 39  
   microRNAs and, 39  
   mortality of, 216  
   neoplastic progression, 215  
   pneumoconioses, 641  
   splice site mutations as cause, 36  
 Cancer drugs  
   cell cycle, **416**  
   targets, **416**  
 Cancer epidemiology, **216**  
 Candesartan, 577  
*Candida* spp  
   amphotericin B, 195  
   azoles, 195  
   catalase-positive organism, 124  
   echinocandins, 196  
   immunodeficiency infections, 114  
   osteomyelitis, 176  
   tricuspid valve endocarditis and, 299  
   vulvovaginitis, 177  
*Candida albicans*, **149**  
   HIV-positive adults, 173  
   T cell dysfunction, 112  
   treatment, 661  
 Candidate identification number (CIN), 5  
 Candidiasis  
   *Candida albicans*, 149  
   chronic mucocutaneous, 112  
   cortisol and, 319  
   nystatin, 195  
 Cannibalism, 174  
 Capillary fluid exchange, **287**, 670  
 Capillary supply (lymph node), 92  
 Capitate bone, 426  
 Capitation, 260  
 Caplan syndrome, 641  
 Capsid (viral), 158  
 Capsules (bacterial), 120  
 Captain’s wheel, 147  
 Captopril, 577  
 Caput medusae, 350  
 Carbachol, 232  
   glaucoma, 521  
 Carbamazepine  
   agranulocytosis, 241  
   aplastic anemia, 241  
   bipolar disorder, 531, 661

- Carbamazepine (*continued*)  
 cytochrome P-450 and, 243  
 epilepsy, 514  
 SIADH and, 240  
 teratogenicity, 582  
 tonic-clonic seizures, 663  
 trigeminal neuralgia, 664
- Carbamoyl phosphate, 78
- Carbamoyl phosphate synthetase, 69
- Carbapenems  
 mechanism and use, **186**  
 mechanism (diagram), **183**  
*Pseudomonas aeruginosa*, 139
- Carbidopa, **518**
- Carbohydrate absorption, **358**
- Carbon dioxide  
 transport of, **635**
- Carbonic anhydrase, 635
- Carbonic anhydrase inhibitors, 562
- Carbon monoxide (CO)  
 carboxyhemoglobin, 632  
 electron transport inhibition, 74  
 inhalational injuries, 640  
 poisoning, 633  
 toxicity treatment, 239
- Carbon tetrachloride  
 as carcinogen, 219  
 free radical injury and, 210
- Carboplatin, **419**  
 toxicities of, 422
- Carboxyhemoglobin, 632
- Carboxylases, 69
- Carboxypeptidase, 358
- Carcinoembryonic antigen (CEA)  
 (tumor marker), 220
- Carcinogens, **219**  
 griseofulvin, 196
- Carcinoid syndrome, **338**  
 bronchial carcinoid tumors, 647  
 somatostatin for, 342  
 treatment, 661
- Carcinoid tumors  
 octreotide for, 382  
 stomach, 362
- Carcinoma in situ, 215
- Carcinomas  
 bone, 437  
 colorectal, 372  
 invasive, 215  
 metastases of, 215, 221  
 nomenclature of, 216  
 primary hyperparathyroidism, 331  
 thyroid, 330
- Cardiac arrest  
 hypermagnesemia, 560
- Cardiac cycle, **276**
- Cardiac depression, 304
- Cardiac function curves, **275**
- Cardiac glycosides, **307**
- Cardiac looping, 268
- Cardiac muscle innervation, 229
- Cardiac output, **272**  
 equation for, 669  
 exercise and, 635  
 in pregnancy, 598  
 variables in, 273  
 $\dot{V}/\dot{Q}$  mismatch and, 634
- Cardiac tamponade, **300**  
 aortic dissection and, 293  
 jugular venous pulse in, 276  
 MI, **294, 296**  
 pulse pressure in, 272  
 shock, 299
- Cardiac troponin I, 295
- Cardiac tumors, **301**
- Cardinal ligament, 592
- Cardinal veins, 268
- Cardiobacterium* spp, 299
- Cardiogenic shock  
 MI, 294  
 presentation/treatment, 299  
 pulse pressure in, 272
- Cardiomegaly  
 Pompe disease, 83
- Cardiomegaly with apical trophy, 658
- Cardiomyopathy, **296**  
 auscultation changes with, 278  
 Chagas disease, 154  
 heart failure with, 298  
 Kussmaul sign in, 301  
 S4 heart sound and, 668  
 Starling curves, 274  
 sudden cardiac death, 293
- Cardiotoxicity  
 doxorubicin, 418  
 drugs causing, 422  
 methylxanthines, 649  
 trastuzumab, 421
- Cardiovascular drugs  
 naming conventions for, 244  
 reactions to, **239**
- Cardiovascular system, **268–310**  
 anatomy, 271  
 embryology, 268–270  
 pathology, 288–303  
 pharmacology, 304–310  
 physiology, 272–287  
 sclerolysis of, 446
- Carditis  
 Lyme disease, 142  
 rheumatic fever, 132, 300  
*Streptococcus pyogenes*, 132
- Carfilzomib, 420
- Carmustine, 418  
 in cell cycle, 416  
 pulmonary fibrosis, 242
- Carnitine, 85
- Carnitine acyltransferase I, 69
- Carotid artery  
 atherosclerosis in, 292, 668  
 bifurcation landmark, 629  
 embryonic development, 586  
 giant cell arteritis and, 302
- Carotid artery (internal)  
 cavernous sinus, 512  
 circle of Willis, 473  
 emboli from, 507
- Carotid sinus, 285
- Carpal bones, 426
- Carpal tunnel syndrome, **426**  
 lunate dislocation, 426  
 median nerve injury, 427  
 rheumatoid arthritis, 439
- Car seats for children, 258
- Carteolol, 521
- Cartilage  
 collagen in, 46  
 fluoroquinolone damage to, 241
- Carvedilol, 237, 309
- Casal necklace, 63
- Caseating granulomas, 139
- Caseating necrosis, 205  
 granulomatous diseases and, 211
- Case-control studies, 246
- Caspases, 204
- Casposfungin  
*Candida albicans*, 149, 661  
 echinocandins, 196  
 mechanism (diagram), 194
- Casts in urine, **562**
- Catabolism  
 amino acids, 78  
 fatty acids, 43  
 tyrosine, 79
- Catalase, 210
- Catalase-positive organisms, **124**
- Cataracts, **505**  
 corticosteroid toxicity, 116  
 diabetes mellitus and, 336  
 galactosemia, 76  
 muscular dystrophy, 57  
 rubella, 178  
 sorbitol, 77
- Catecholamines  
 adrenal medulla secretion, 312  
 amphetamines and, 234  
 contractility effects of, 273  
 ephedrine and, 234  
 pacemaker action potential  
 and, 281  
 pheochromocytoma effect  
 on, 326  
 synthesis of, **79**
- Cat scratch disease, 144
- as granulomatous disease, 211
- Cats, (disease vectors)  
*Campylobacter jejuni*, 140  
 osteomyelitis, 176  
*Pasteurella multocida*, 144, 182  
 Tinea corporis, 148  
*Toxoplasma gondii*, 152, 178
- Cauda equina syndrome, **500**
- Caudal fold closure defects, 344
- Caudal regression system, 582
- Caudate  
 basal ganglia (diagram), 470  
 Huntington disease, 490
- Cause-and-effect diagram, 262
- Cavernous hemangiomas, 375
- Cavernous sinus, **512**  
 dural venous sinuses, 473
- Cavernous sinus syndrome, 512
- CBSSA to USMLE score  
 prediction, 14
- CCR5 protein  
 HIV and, 171  
 maraviroc, 199  
 viral receptor, 162
- CD4 protein  
 viral receptor, 162
- CD4+ T cells (HIV), 172
- CD5 protein, 410
- CD20 protein, 106  
 in CLL, 410
- CD21 protein, 106  
 viral receptor, 162
- CD25 protein  
 cell surface protein, 106  
 regulatory T cells and, 98
- CD28 protein, 106
- CD34 protein, 106  
 leukocyte extravasation and, 209
- CD40L protein, 106
- CD40 protein, 106
- CDKN2A gene, 218
- CEA tumor marker, 371
- Cefaclor, 185
- Cefazolin  
 mechanism and use, 185  
 prophylaxis, 194
- Cefepime  
 mechanism and use, 185  
 mechanism (diagram), 183  
*Pseudomonas aeruginosa*, 139
- Cefotaxime, 185
- Cefoxitin  
 mechanism and use, 185  
 mechanism (diagram), 183
- Ceftaroline  
 mechanism and use, 185  
 mechanism (diagram), 183  
 MRSA, 194
- Ceftazidime  
 mechanism and use, 185  
*Pseudomonas aeruginosa*, 139
- Ceftriaxone  
*Chlamydia* spp, 146  
*Chlamydia trachomatis*, 661  
 for gonococci, 138  
 for *Haemophilus influenzae*, 138  
 mechanism and use, 185  
 mechanism (diagram), 183  
 meningitis, 176  
 meningococci, 138  
 prophylaxis, 194  
 typhoid fever, 141
- Cefuroxime  
 mechanism and use, 185
- Celecoxib, 243, **456**  
 arachidonic acid pathway, 455
- Celiac artery  
 mesenteric ischemia, 369  
 structures supplied, 348
- Celiac disease, **364**  
 antibodies in, 657  
 autoantibodies with, 111  
 biliary cirrhosis and, 378  
 dermatitis herpetiformis, 452  
 HLA genes and, 96  
 IgA deficiency, 112
- Celiac lymph nodes, 93
- Celiac trunk, **348, 349**
- Cell cycle phases, **42**
- Cell envelope (bacterial), 120
- Cell injury, **206**
- Cell lysis, 560
- Cell membrane  
 apoptosis and, 204

- Cell surface proteins  
 association and functions, **106**  
 leukocyte adhesion deficiency, 113  
 T cells and, **97, 98**
- Cell trafficking, **43**
- Cellular biochemistry, **42–48**
- Cellular inflammation, 207
- Cellulitis, 451  
*Pasteurella multocida*, 144  
*Streptococcus pyogenes*, 132
- Cell walls  
 bacterial, **120**
- Central canal of spinal cord, 478
- Central clearing, 148
- Central clearing (nuclei), 330
- Central diabetes insipidus, 334
- Central nervous system (CNS), **229**  
 anesthetic principles for, 518  
 antiarrhythmic adverse effects,  
 308, 309  
 depression, 515  
 nitrosoureas effect on, 418  
 origins of, **460**  
 shock from injury, 299
- Central pontine myelinolysis.  
 See Osmotic demyelination  
 syndrome
- Central post-stroke pain  
 syndrome, **485**
- Central retinal artery occlusion, **507**  
 “cherry-red” macular spot, 652
- Central sleep apnea, 642
- Central sulcus, 471
- Central tendency measures, 251
- Central tendon (diaphragm), 629
- Central vein, 206
- Central vertigo, 503
- Centriacinar emphysema, 638
- Centrilobular necrosis, 219
- Centromer autoantibodies, 111
- Cephalexin  
 mechanism and use, 185
- Cephalosporins  
 disulfam-like reaction, 242  
 mechanism and use, **185**  
 mechanism (diagram), 183  
 pseudomembranous colitis, 240  
*Pseudomonas aeruginosa*, 139
- Cephazolin, 183
- Ceramide, 84
- Ceramide trihexoside, 84
- Cerebellum, **469**  
 development of, 460  
 hemisphere lesions, 481  
 tonsils, 462  
 vermis lesions, 462, 481
- Cerebral aqueduct of Sylvius, 474
- Cerebral arteries  
 cavernous sinus, 512  
 cortical distribution, **472**
- Cerebral cortex  
 arterial distribution, 471  
 functional areas of, **471**
- Cerebral edema  
 diabetic ketoacidosis and, 337  
 hyperammonemia, 78  
 therapeutic hyperventilation, 472
- Cerebral hemispheres, 460
- Cerebral infarct, 529
- Cerebral peduncle, 474
- Cerebral perfusion, **472**
- Cerebral perfusion pressure, 472
- Cerebrospinal fluid (CSF)  
 blood-brain barrier and, 466  
 circulation of, 465, 473, 491  
 Guillain-Barré syndrome, 493  
 hydrocephalus, 492  
 multiple sclerosis, 493  
 neural tube defects, 461  
 neurodegenerative disorders, 491  
 origins, 460  
 poliomyelitis, 501  
 spinal cord, 478  
 ventricular system, 474  
 yellowish tint, 661
- Cerebrovascular disease  
 diabetes mellitus, 336
- Cereulide, 134
- Certolizumab, 118
- Ceruloplasmin  
 free radical elimination by, 210
- Cervical cancer, 609  
 carcinogens causing, 219  
 epidemiology of, 608  
 epithelial histology, 592  
 HIV-positive adults, 173  
 hydronephrosis from, 568  
 oncogenic microbes and, 219  
 papillomaviruses, 160
- Cervical dysplasia, 609
- Cervical lymphadenopathy, 652
- Cervical lymph nodes, 93
- Cervical rib, 428
- Cervicitis  
 sexually transmitted infections, **180**
- Cervix  
 anatomy of, 592  
 lymphatic drainage of, 591  
 pathology of, **609**
- Cestodes, **156**
- Cetirizine, 648
- Cetuximab, 118, **420**
- CFTR gene, 56  
 chronic pancreatitis and, 380
- cGMP (cyclic guanosine  
 monophosphate)  
 atrial natriuretic peptide  
 and, 285  
 endocrine hormone  
 messenger, 322  
 hydralazine and, 304  
 male sexual response, 593  
 PDE-5 inhibitors, effect on, 623  
 smooth muscle contraction, 434
- Chagas disease, 154  
 achalasia in, 360  
 cardiomyopathy in, 297  
 labs/findings, 658
- Chancroids, 180
- Chandelier sign, 181
- Chaperone protein, **41**
- Charcoal yeast extract culture  
*Legionella pneumophila*, 123,  
 139
- Charcot-Bouchard  
 microaneurysms, 483, 486
- Charcot joints  
 syphilis, 143  
 tabes dorsalis and, 500
- Charcot-Leyden crystals, 638
- Charcot-Marie-Tooth disease, 494
- Charcot triad, 379, 493
- Charging, tRNA, 40
- Chédiak-Higashi syndrome, 113
- Cheilosis, 63
- Chelation  
 hemochromatosis, 378  
 iron poisoning, 404  
 lead poisoning, 397
- Chemical tracheobronchitis, 640
- Chemokines, 104
- Chemoreceptors, **285**
- Chemotherapy  
 AML and, 410  
 malignant bone tumors, 438  
 myelodysplastic syndromes, 409  
 neutropenia with, 402  
 ondansetron, 383  
 pancreatic cancer, 380  
 readmissions with, 261
- Chemotoxicities, **422**
- Cherry hemangiomas, 450
- Cherry-red macular spot  
 diagnoses with, 652
- Cherry-red spot (macula), 507  
 lysosomal storage disease, 84
- Chest pain  
 Dressler syndrome, 652  
 on exertion, 652  
 panic disorder, 533  
 pneumothorax, 644  
 pulmonary embolism, 637
- Chest wall  
 elastic properties, **631**
- Chest X-rays  
 aortic dissections on, 293  
 balloon heart on, 297  
 eggshell calcification, 641  
 lung abscesses, 646  
 notched ribs on, 289  
 Wegener granulomatosis on, 302
- Chiari malformations, 462
- Chickenpox  
 rash, 179  
 VZV, 160
- Child abuse, **526**  
 osteogenesis imperfecta and, 47
- Childbirth  
 Budd-Chiari syndrome and, 375  
 contraction prevention, 595  
 endometritis after, 612  
 Graves disease and, 329  
 low birth weight, 599  
 misoprostol induction, 382  
 neonatal flora, 174  
 oxytocin, 599  
 oxytocin for induction of, 342  
 postpartum mood disturbances, **532**  
 preterm, as common cause of  
 death, 260  
 progesterone levels after, 595  
 Sheehan syndrome after, 335  
 stress incontinence and, 569
- Childhood disorders, **527**
- Child neglect, **526**
- Children  
 car seats for, 258  
 developmental milestones, **258**
- Chimeric monoclonal A<sub>b</sub>, 244
- Chipmunk facies, 397
- Chi-square tests, 253
- Chlamydia* spp, **146**  
 atypical infections, 175  
 Giemsa stain, 122  
 intracellular organism, 124  
 macrolides, 189  
 pneumonia, 645  
 reactive arthritis, 442  
 sulfonamides for, 190  
 taxonomy, 121  
 tetracyclines, 188
- Chlamydia, 180
- Chlamydia trachomatis*, 146  
 eosinophilia, 146  
 pelvic inflammatory disease, 181  
 pneumonia, 175  
 treatment, 661  
 UTIs, 570
- Chlamydia pneumoniae*, 146  
 pneumonia, 175
- Chlamydia psittaci*, 146  
 transmission, 144
- Chloasma, 448
- Chloramphenicol, **188**  
 aplastic anemia and, 241, 399  
 gray baby syndrome, 241  
 mechanism (diagram), 183  
 pregnancy, 201  
 protein synthesis inhibition, 187
- Chlordiazepoxide, 515  
 alcohol withdrawal, 542
- Chlorhexidine, 200
- Chloride channels  
 cystic fibrosis, 56
- Chloroquine, **196**  
 malaria, 153
- Chlorpheniramine, **648**
- Chlorpromazine, 543
- Chlorpropamide, 340
- Chlorthalidone, 576
- Chocolate agar  
*Haemophilus influenzae*,  
 123, 138
- Chocolate-colored blood, 632
- Chocolate cysts, 610, 613
- Cholangiocarcinomas  
*Clonorchis sinensis*, 156, 157  
 hyperbilirubinemia, 376  
 oncogenic microbes and, 219  
 sclerosing cholangitis, 378
- Cholangitis, 379
- Cholecalciferol, **319**. See  
 also Vitamin D
- Cholecystectomy  
 cholelithiasis, 379  
 porcelain gallbladder, 379
- Cholecystitis, 379
- Cholecystokinin (CCK)  
 functions, 356  
 secretory cell location, 357



- Cholelithiasis, **379**  
 acute pancreatitis, 380  
 bile ducts and, 353  
 biliary cirrhosis and, 378  
 Crohn disease, 365  
 hyperbilirubinemia and, 376  
 octreotide and, 382  
 somatostatinomas, 338
- Cholera toxin  
 lysogenic phage infection, 126  
 mechanism, 128
- Cholestasis serum markers, 373
- Cholesteatomas, **503**
- Cholesterol  
 atherosclerosis, 292  
 in bile, 358  
 cholelithiasis and, 379  
 functions, 46  
 hyperlipidemia signs, 291  
 lipid-lowering agents, 306  
 synthesis of, 69  
 vitamin B<sub>3</sub> effects, 63
- Cholesterol desmolase, 318
- Cholesterol ester transfer protein (CETP), 88
- Cholestyramine, 306
- Choline, 231
- Cholinergic agonists, 244
- Cholinergic drugs, 231
- Cholinergic effects, 307
- Cholinesterase inhibitors  
 diarrhea with, 240  
 poisoning from, **232**
- Cholinomimetic agents, **232, 521**
- Chondrocalcinosis, 440
- Chondrocytes  
 achondroplasia, 435  
 bone formation and, 434  
 osteoarthritis, 439
- Chondrosarcomas, 438
- Chordae rupture, 279
- Chorea  
 brain lesions, 481  
 Huntington disease, 490  
 movement disorders, 489
- Choriocarcinomas, **605**  
 hCG in, 598  
 hydatidiform mole, 605  
 methotrexate for, 417  
 testicular tumors, 618  
 theca-lutein cysts and, 610
- Choroid (ophthalmology)  
 closure of, 506
- Chorionic plate, 584
- Chorionic somatomammotropin, 598
- Chorionic villi  
 hydatidiform moles, 605  
 placenta, 584
- Chorioretinitis  
 congenital toxoplasmosis, 152, 178
- Choristomas, 216
- Choroid (ophthalmology)  
 inflammation, 506  
 neovascularization, 506  
 normal eye, 504
- Choroid plexus (CNS), 474
- Chromaffin cells  
 Diagram, 312  
 embryologic derivatives, 581  
 pheochromocytomas, 326
- Chromatin structure, **32**
- Chromatolysis, **465**
- Chromogranin A, 647
- Chromosomal disorders, **60**  
 karyotyping for, 51
- Chromosomal translocations, **412**
- Chronic adrenal insufficiency, 387
- Chronic gastritis, 362
- Chronic gout  
 treatment, 661
- Chronic granulomatous disease (CGD), **211**  
*Aspergillus fumigatus*, 149  
 catalase-positive microbes, 182  
 IFN- $\gamma$ , 200  
 immunodeficiencies and, 113  
 recombinant cytokines for, 117  
 respiratory burst in, 105
- Chronic inflammation, 207
- Chronic ischemic heart disease, 293
- Chronic kidney disease  
 in anemia taxonomy, 396  
 erythropoietin in, 559  
 focal segmental glomerulosclerosis, 566  
 hypertension and, 290
- Chronic lymphocytic leukemia (CLL), 410  
 age ranges, 664  
 immunosuppressants, 116  
 lab findings, 661  
 presentation, 655  
 rituximab for, 420  
 therapeutic antibodies, 118
- Chronic mesenteric ischemia, 369
- Chronic mucocutaneous candidiasis, 112
- Chronic myelogenous leukemia (CML), 410  
 age ranges, 664  
 basophilia caused by, 387  
 busulfan for, 418  
 chromosomal translocations and, 412  
 imatinib for, 420  
 oncogenes and, 218  
 Philadelphia chromosome, 668
- Chronic myeloproliferative disorders, **411**
- Chronic obstructive pulmonary disease (COPD)  
 albuterol for, 234  
 $\beta$ -blockers and, 237  
 cholinomimetic agents and, 232  
 muscarinic antagonists for, 233  
 salmeterol for, 234
- Chronic pancreatitis, **380**  
 pancreatic insufficiency from, 364
- Chronic placental insufficiency, 548
- Chronic pyelonephritis, 570  
 labs/findings, 660
- Chronic renal disease, 608
- Chronic renal failure, 331, 571  
 hyperphosphatemia with, 332
- Chronic respiratory disease, as  
 common cause of death, 260
- Chronic thromboembolic pulmonary hypertension, 643
- Chronic transplant rejection, 115
- Churg-Strauss syndrome, **303**  
 autoantibody with, 111  
 as granulomatous disease, 211  
 labs/findings, 657
- Chvostek sign, 560  
 hypoparathyroidism, 331
- Chylomicrons, 88, 89
- Chylothorax, 644
- Chymotrypsin, 358
- Cidofovir, **198**
- Cigarette smoke (carcinogen), 219
- Ciguatoxin, 238
- Cilastatin  
 imipenem and, 186  
 seizures with, 242
- Ciliary body, 504
- Ciliary ganglia, 509
- Cilia structure, **45**
- Ciliated cells, 628
- Cilostazol, **415**
- Cimetidine, 381  
 cytochrome P-450 and, 243  
 gynecomastia, 615
- Cinacalcet, **342**
- Cinchonism  
 antiarrhythmic causing, 308  
 neurologic drug reaction, 242
- Cingulate gyrus, 468
- Cingulate herniation, 499
- Ciprofloxacin  
 for Crohn disease, 365  
 cytochrome P-450 and, 243  
 fluoroquinolones, **191**  
 mechanism (diagram), 183  
 meningococci, 138  
*Mycobacterium avium-intracellulare*, 192  
 prophylaxis, 194  
*Pseudomonas aeruginosa*, 139
- Circadian rhythm  
 hypothalamic control, 466  
 sleep physiology, 467
- Circle of Willis, **473**  
 saccular aneurysms, 486
- Circulatory system  
 kidneys and, 550
- Circulatory system (fetal), **270**
- Cirrhosis, **372**  
 $\alpha_1$ -antitrypsin deficiency, 375  
 alcoholic, 67, 374  
 autoantibody with, 111  
 cholelithiasis and, 379  
 cystic fibrosis, 56  
 esophageal varices and, 360  
 fructose intolerance, 76  
 granulomatous disease, 211  
 gynecomastia, 615  
 hemochromatosis, 378  
 hepatocellular carcinomas, 375  
 loop diuretics for, 575  
 non-alcoholic fatty liver disease, 374  
 pleural effusion, 644  
 portal hypertension, 372  
 Wilson disease, 378
- Cisplatin, **419**  
 acute tubular necrosis, 572  
 in cell cycle, 416  
 Fanconi syndrome, 556  
 targets of, 416  
 toxicity of, 242, 422
- Citalopram, 545
- Citrate synthase, 70
- Citrobacter* spp  
 Gram-negative algorithm, 137  
 lactose fermentation, 138
- Citrulline, 78
- c-*KIT* gene, 218
- CKK hormone, 325
- CK-MB, 293, 295
- Cladribine, 417  
 in cell cycle, 416  
 for hairy cell leukemia, 410
- Clara cells, 627, 628
- Clarithromycin  
*Helicobacter pylori*, 142  
 HIV prophylaxis, 194  
 macrolides, **189**  
 mechanism (diagram), 183  
*Mycobacterium avium-intracellulare*, 192  
 pregnancy use, 201
- Clasp knife spasticity, 499
- Classical conditioning, **524**
- Class switching  
 CD40, 99  
 thymus-dependent antigens, 101
- Clathrin, 43
- Claudication  
 atherosclerosis, 292  
 Buerger disease, 302  
 cilostazol/dipyridamole for, 415  
 giant cell arteritis, 302
- Clavulanate  
*Haemophilus influenzae*, 138
- Clavulanic acid, 184
- Clawing of hand, **429**  
 Klumpke palsy, 428
- Clearance of drugs, 225
- Clear cell adenocarcinomas, 609  
 DES and, 621
- Cleft lip, 588
- Cleft palate, **588**  
 22q11 deletion syndromes, 61  
 Patau syndrome, 59  
 Pierre Robin sequence, 587  
 teratogens for, 582
- Clevipidine, 304  
 for hypertensive emergency, 304
- Clindamycin  
 bacterial vaginosis, 144  
*Clostridium difficile* and, 134  
 endometritis, 612  
 lung abscesses, 646  
 mechanism and use, **188**

- mechanism (diagram), 183  
metronidazole vs, 188  
protein synthesis inhibition, 187  
pseudomembranous colitis  
with, 240
- Clinical reflexes, **480**
- Clinical trials, 246
- Clinical vignette strategies, 21
- Clitoris  
genital homologs, 590
- “Clock-face” chromatin, 389, 409
- Clofazimine  
Hansen disease, 137  
*Mycobacterium leprae*, 192
- Clomiphene  
estrogen receptor modulators, 621  
hot flashes with, 240  
PCOS, 609  
reproductive hormones and, 620
- Clomipramine, 545  
obsessive-compulsive disorder, 533
- Clonidine, 235  
Tourette syndrome, 527
- Cloning methods (laboratory technique), **51**
- Clonorchis sinensis*  
diseases association, 157  
as oncogenic microbe, 219  
trematodes, **156**
- Clonus  
serotonin syndrome, 545
- Clopidogrel, 415  
acute coronary syndromes, 296  
for ischemic stroke, 482  
thrombogenesis and, 393
- Closed-angle glaucoma, 506  
pilocarpine for, 232
- Clostridium* spp, **134**  
anaerobic organism, 123  
Gram-positive algorithm, 130  
taxonomy, 121
- Clostridium botulinum*, **134**  
exotoxin production, 128  
food poisoning, 174  
spore formation, 127  
therapeutic uses, 134
- Clostridium difficile*, **134**  
antibiotic use and, 134, 181  
metronidazole, 191  
nosocomial infection, 181  
presentation of, 652  
proton pump inhibitors  
and, 381  
spore formation, 127  
vancomycin, 186  
watery diarrhea, 175
- Clostridium perfringens*, **134**  
clindamycin, 188  
exotoxin production, 129  
food poisoning, 174  
spore-formation, 127  
traumatic open wound, 182  
watery diarrhea, 175
- Clostridium tetani*, **134**  
exotoxin production, 128  
spore formation, 127
- Clotrimazole, 194, 195
- Clotting factors, 66
- Clozapine, 543  
agranulocytosis with, 241
- Clubbing  
adenocarcinoma, 647  
bronchiectasis, 639  
Eisenmenger syndrome, 289
- Clubbing (nails)  
cystic fibrosis, 56
- Club cells, 627
- Clue cells, 660  
bacterial vaginosis, 144, 177
- Cluster A personality disorders, 535
- Cluster B personality disorders, 535
- Cluster C personality disorders, 535
- Cluster headaches, 488, 516
- c-MYC gene, 218
- CNS lymphomas  
HIV-positive adults, 173  
oncogenic microbes and, 219
- CNS stimulants, **542**
- Coagulation, 66
- Coagulation cascade, **392**
- Coagulation disorders, **404**  
hereditary thrombosis  
syndromes, **406**  
platelet and coagulation, **406**
- Coagulation pathways, **391**
- Coagulative necrosis, 205  
MI, 294
- Coagulopathy  
postpartum hemorrhage, 607  
preeclampsia, 608
- Coal workers’ pneumoconiosis, **641**
- CoA production, 63, 68
- Coarctation of aorta, **289, 290**  
Turner syndrome, 603
- Cobblestone mucosa, 365
- Cocaine, 519  
 $\beta$ -blockers and, 237  
cardiomyopathy, 297  
coronary vasospasm, 239  
intoxication and withdrawal, 540  
liver processing of, 352  
as noradrenergic drug, 231  
placental abruption, 606  
pulmonary arterial  
hypertension, 643  
sympathomimetic action, 234  
teratogenicity, 582
- Coccidioides* spp  
silver stain, 122  
treatment, 195
- Coccidioidomycosis, **147**  
erythema nodosum and, 453  
HIV-positive adults, 173
- Cocciobacilli, 137
- Coccus bacteria  
antibiotic tests, 130  
Gram stain identification, 130  
taxonomy, 121
- Cochlea  
CN VIII, 476  
inner ear, 503  
presbycusis, 503
- Codeine, 520
- Codman triangle, 438, 660
- Codominance, **52**
- Codons  
genetic code features, 34  
start and stop, **37**
- Cofactors  
apolipoproteins, 89  
biotin, 64, 69  
cobalamin, 65  
copper, 47  
Menkes disease, 47  
pantothenic acid, 63  
phenylketonuria, 80  
precursors to organic, 61  
pyridoxine, 63  
pyruvate dehydrogenase  
complex, 72  
riboflavin, 63  
TCA cycle, 73  
thiamine, 70  
vitamin K, 66
- “Coffee bean” nuclei, 610
- Cognitive behavioral therapy (CBT), 527  
acute stress disorder, 534  
ADHD, 527, 661  
adjustment disorder, 533  
for anxiety disorders, 532  
for atypical depression, 531  
binge eating disorder, 537  
body dysmorphic disorder, 533  
conduct disorder, 527  
generalized anxiety disorder, 533  
major depressive disorder, 531  
obsessive-compulsive disorder, 533  
oppositional defiant disorder, 527  
panic disorder, 533  
phobias, 533  
postpartum depression, 532  
PTSD, 534
- Cohort studies, 246  
relative risk and, 248
- Coin lesion (X-ray), 647
- Colchicine  
acute gout attack, 661  
agranulocytosis, 241  
calcium pyrophosphate deposition  
disease, 440  
diarrhea with, 240  
gout, 440, 457  
microtubules and, 44  
myopathy with, 241
- Cold agglutinin disease, 655
- Cold agglutinins, 146
- Cold autoimmune hemolytic  
anemia, 401
- Colectomy  
adenomatous polyposis, 370  
inflammatory bowel disease, 365
- Colesevelam, 306
- Colectipol, 306
- Colistin B, 139
- Colitis  
*Clostridium difficile*, 134  
HIV-positive adults, 173  
oral vancomycin, 186  
pseudomembranous, 127, 175,  
184, 188
- Collagen  
aging, 48  
decreased/faulty production, 47  
osteoblasts and, 434  
in scar formation, 210  
synthesis/structure, **46**  
vitamin C, 65  
in wound healing, 211
- Collagenase in neutrophils, 386
- Collapsing pressure (alveoli), 627
- Collecting tubules  
defects in, 556  
diuretics and, 574  
nephron physiology, 555  
potassium-sparing diuretics  
and, 576
- Colles fracture, 435
- Colliculi, 475
- Colon  
histology of, 347  
ischemia in, 206
- Colon cancer  
5-fluorouracil for, 417  
irinotecan/topotecan for, 419  
labs/findings, 660  
metastases of, 221  
oncogenes and, 218  
*Staphylococcus gallolyticus*  
and, 133  
tumor suppressor genes and, 218
- Colonic ischemia, 369
- Colonic polyps, **370**
- Colorado tick fever, 163
- Color blindness, 193
- Colorectal cancer, **371**  
adenomatous polyposis and, 370  
bevacizumab for, 420  
cetuximab for, 420  
incidence/mortality in, 216  
labs/findings, 657  
Lynch syndrome, 37  
molecular pathogenesis of, **372**  
therapeutic antibodies, 118  
tumor suppressor genes and, 218
- Colovesical fistulas, 366
- Coltivirus, 163
- Coma  
adrenoleukodystrophy, 494  
benzodiazepine adverse effect, 515  
hepatic encephalopathy, 374  
herniation syndromes, 499  
hyperosmolar hyperglycemia  
nonketotic syndrome, 338  
hyponatremia, 560  
rabies, 167  
reticular activating system, 481  
Reye syndrome, 373  
thyroid storm, 329  
*Toxocara canis*, 155  
*Trypanosoma brucei*, 152
- Combined pathway for  
coagulation, 391
- Comedocarcinomas, 616
- Comma-shaped rods, 137
- Common bile duct, 346, 353
- Common cold, 164
- Common peroneal nerve, 430

- Common variable immunodeficiency (CVID), 112
- Communicating hydrocephalus, 492
- Competence (bacterial genetics), 126
- Competitive agonists, 228
- Competitive inhibitors, 224
- Complement, **103**
- activation inhibition, 131
  - binding of, 100
  - C-reactive protein, 102
  - disorders of, **103**
  - eculizumab, 118
  - endotoxin activation, 129
  - immunodeficiency infections, 114
  - immunoglobulin isotypes, **101**
  - innate immunity, 95
  - splenic dysfunction, 94
  - transplant rejection, 115
- Complement activation pathways, **103**
- Complementation (viral), 158
- Complex renal cysts, 573
- Compliance (lungs), 631
- Complications of pregnancy, **606–607**
- Comprehensive Basic Science Examination (CBSE), 10
- Comprehensive Basic Science Self-Assessment (CBSSA), 11
- Computer-Based Test (CBT)
- environment of, 3–4
  - exam schedule for, 7–8
  - structure of, 3
- COMT inhibitors, 517
- Conditioning (psychological), 524
- Conduct disorder, 527
- early onset disorder, 535
- Conducting zone (respiratory tree), 628
- Conduction aphasia, 486
- Conductive hearing loss, 503
- Condylomata acuminata, 449
- IFN- $\alpha$  for, 200
  - sexual transmission, 180
- Condylomata lata
- syphilis, 143, 180
- Confidence intervals, 252
- Confidentiality, **255**
- Confluence of the sinuses, 473
- Confounding bias, 250
- Congenital adrenal hyperplasias, **318**
- Congenital heart disease, **288–290**
- autosomal trisomies, 59
  - defect associations, **290**
  - maternal phenylketonuria, 80
  - pulmonary arterial hypertension, 643
  - rubella, 178
  - Turner syndrome, 656
- Congenital hydroceles, 618
- Congenital hypothyroidism, 328
- Congenital long QT syndrome, **283**
- Congenital lung malformations, **626**
- Congenital nevus, 447
- Congenital rubella
- cardiac defect associations, 290
  - heart murmur, 279
- Congenital solitary functioning kidney, **549**
- Congenital syphilis, 143
- Congenital toxoplasmosis, 152
- Congo red stain, 213, 566
- Conivaptan
- ADH antagonists, 334
  - SIADH, **342**
- Conjoined tendon, 354
- Conjugate vaccines, 124
- Conjugation (bacterial genetics), 126
- Conjunctival infections
- Kawasaki disease, 302
- Conjunctivitis, **504**
- adenoviridae, 160
  - chlamydia, 146, 180
  - gonococcal prophyllaxis, 194
  - gonococci, 138
  - Haemophilus influenzae*, 138
  - reactive arthritis, 442
  - rubeola, 166, 179, 182
  - urethritis and, 656
  - Zika virus, 167
- Connective tissue diseases
- aortic dissection and, 293
  - pulmonary arterial hypertension, 643
  - thoracic aortic aneurysms and, 292
- Connective tissue drug reactions, **241**
- Conn syndrome, 324
- Consent
- healthcare proxy, 257
  - minors, **254, 256**
- Consolidation (lung finding), 643
- Constipation, 520
- aluminum hydroxide as cause, 382
  - anal fissures, 351
  - calcium channel blockers, 304
  - Hirschsprung disease, 367
  - hypothyroidism, 327
  - irritable bowel syndrome, 366
  - loperamide, 382
  - ondansetron, 383
  - ranolazine, 305
  - vincristine, 419
- Constrictive pericarditis
- jugular venous pulse in, 276
  - Kussmaul sign, 301
- Contact activation pathway for coagulation, 391
- Contact dermatitis, 109
- Contemplation stage, 539
- Continuous heart murmurs, 279
- Contraception
- isotretinoin teratogenicity, 582
  - methods for, **622**
  - parental consent for minors and, 254
- Contractility in cardiac output, 273
- Contraction alkalosis, 56
- Conversion disorder, 536
- Coombs hemolysis, 235
- Coombs-positive hemolysis
- $\alpha$ -methyl dopa, 235
  - anemia with, 241
- Coombs-positive hemolytic anemia, 401
- Coombs test, 108, 401
- COPI/COPII, 43
- Copper deficiency, 397
- Copper intrauterine device, **622**
- Copper toxicity, 239
- Coprolalia, 527
- Copy number variations (CNV), 50
- Cord factor, 136
- Cori cycle, 78
- Cori disease, 83
- Corkscrew fibers, 498
- Cornea, 504
- collagen in, 46
- Corneal arcus
- familial hypercholesterolemia, 90
  - hyperlipidemia, 291
- Corneal reflex, 477
- Corneal vascularization, 63
- Corniculate cartilage, 587
- Coronary aneurysms, 652
- Coronary arteries
- anatomy of, **271**
  - atherosclerosis in, 292
  - occlusion of, 271
- Coronary artery atherosclerosis in, 668
- Coronary artery disease
- atrial fibrillation and, 284
  - diabetes mellitus and, 336
  - HMG-CoA reductase inhibitors for, 306
  - hormonal contraception contraindication, 622
  - hypertension and, 290
  - menopause and, 600
  - sudden cardiac death, 293
- Coronary sinus
- anomalous pulmonary return, 288
  - development, 268
- Coronary steal syndrome, 293
- Coronary vasospasm, 239
- Coronaviruses
- characteristics of, 163
  - genomes of, 159
- Cor pulmonale, 298, 633, 668
- obstructive lung disease, 638
  - pneumoconioses, 641
  - pulmonary hypertension, 643
  - right ventricular failure, 633
- Corpus albicans, 597
- Corpus cavernosum
- female homolog of, 590
  - lymphatic drainage of, 591
- Corpus luteum, 597
- hCG and, 598
  - progesterone production, 595
- Corpus spongiosum, 590
- Correct results, in statistical hypothesis testing, 252
- Correlation coefficient, 253
- Corticosteroids
- asthma, 649
  - cataracts, 505
  - CN VII paralysis, 502
  - Crohn disease, 365
  - Cushing syndrome, 323
- giant cell arteritis, 302
  - hyperglycemia with, 240
  - hypopituitarism, 335
  - immunosuppression, 116
  - lymphopenia with, 402
  - microscopic polyangiitis, 302
  - minimal change disease, 566
  - neutrophilia from, 402
  - osteonecrosis, 436
  - osteoporosis with, 241
  - pancreatitis with, 240
  - polyarteritis nodosa, 302
  - for polymyalgia rheumatica, 444
  - syndrome of apparent mineralocorticoid excess, 556
  - Takayasu arteritis, 302
  - targets of, 117
  - thyroid storm, 329
  - Wegener granulomatosis, 302
- Corticotropin-releasing hormone (CRH), **315**
- adrenal cortex regulation of, 312
  - cortisol regulation, 319
  - Cushing syndrome and, 323
  - signaling pathways of, 322
- Cortisol, **319**
- adrenal cortex secretion, 312
  - congenital adrenal hyperplasias and, 318
  - in Cushing syndrome, 323
  - primary adrenal insufficiency, 324
  - signaling pathways for, 322
- Cortisone, 455
- Corynebacterium* spp
- Gram-positive algorithm, 130
  - taxonomy, 121
- Corynebacterium diphtheriae*, **135**
- culture requirements for, 123
  - exotoxin production, 128
  - unvaccinated children, 182
- Cough, 520
- ACE inhibitors, 242, 577
  - asthma, 638
  - chronic bronchitis, 638
  - gastroesophageal reflux disease, 360
  - guaifenesin, 648
  - lung cancer, 647
  - Wegener granulomatosis, 302
- Councilman bodies
- yellow fever, 164
- Countertransference, **524**
- Courvoisier sign
- pancreatic cancer, 380
- Cowper gland, 593
- Cowpox, 160
- Coxiella* spp, 124
- Coxiella burnetii*
- animal transmission, 144
  - endocarditis caused by, 299
  - Q fever, 145
  - spore formation, 127
- Coxsackievirus
- acute pericarditis, 300
  - picornavirus, 164
  - presentation, 163
  - type A rash, 179

- Coxsackievirus type B  
cardiomyopathy, 297
- C-peptide  
insulin and, 314  
in insulinomas, 338
- Cranial nerves, 285, **476**  
branchial arch derivation, 587  
common lesions, **502**  
impingement of, 435  
nerve and vessel pathways, **476**  
nuclei of, **475**  
reflexes of, **477**
- Craniopharyngioma, 498
- Craniopharyngiomas, 581  
hypopituitarism with, 335
- Craniothabes, 436
- C-reactive protein (CRP)  
acute-phase reactants, 102  
innate immunity and, 95  
osteomyelitis, 176
- Creatine, 79
- Creatine kinase, 199
- Creatinine  
ACE inhibitor effects, 577  
acute renal failure, 571  
glomerular filtration rate  
and, 552  
nephritic syndrome, 563  
proximal convoluted  
tubules, 557
- Creatinine clearance, 552
- Cre-lox system, 52
- Cremasteric muscle and  
fascia, 354
- Crepitus in necrotizing  
fasciitis, 451
- CREST syndrome, 446  
biliary cirrhosis and, 378  
Raynaud phenomenon, 445
- CREST syndrome  
autoantibodies, 111
- Cretinism, 328, 582
- Creutzfeldt-Jakob disease, 174, 491  
dementia, 529
- “Crew cut” (skull X-ray), 397, 400
- CRH. *See* Corticotropin-releasing  
hormone (CRH)
- Cribriform plate, 476
- Cricoid cartilage, 587
- Cricothyroid muscle, 587
- Cri-du-chat syndrome, **60**
- Crigler-Najjar syndrome, 376, 377  
presentation, 656
- Crimean-Congo hemorrhagic  
fever, 163
- Crohn disease, 365  
azathioprine, 116  
B<sub>12</sub> deficiency, 398  
cholelithiasis and, 379  
as granulomatous disease, 211  
lesions in, 664  
natalizumab, 118  
spondyloarthritis and, 442  
sulfasalazine for, 382  
vitamin B<sub>12</sub> deficiency, 65
- Crossover studies, 250
- Cross-sectional studies, **246**
- Croup, **166**  
labs/findings, 660  
paramyxoviruses, 163, 165  
pulsus paradoxus in, 300
- CRP and ESR, 212
- Crust (skin), 447
- Cryoprecipitate, 407
- Crypt hyperplasia, 364
- Cryptococcal meningitis, 195
- Cryptococcosis, 149
- Cryptococcus* spp  
meningitis, 176  
treatment, 195  
urease-positive, 124
- Cryptococcus neoformans*, **149**  
HIV-positive adults, 173  
stains for, 122
- Cryptogenic organizing  
pneumonia, 645
- Cryptorchidism, **617**  
hypospadias, 591  
Sertoli cells and, 594  
testicular tumors, 618
- Cryptosporidium* spp, **151**  
HIV-positive adults, 173  
hyper-IgM syndrome and, 113  
watery diarrhea, 175
- Crypts of Lieberkühn, 347
- C-section deliveries  
neonatal flora, 174  
neonatal respiratory distress  
syndrome, 627
- Cuneiform cartilage, 587
- Curling ulcers  
gastritis, 362
- Currant jelly sputum, 140, 182  
*Klebsiella* pneumonia, 655  
“Currant jelly” stools, 368, 369
- Curschmann spirals, 638
- Cushing disease, 323
- Cushing-like symptoms  
protease inhibitors, 199
- Cushing reaction, 285
- Cushing syndrome, **323**  
acanthosis nigricans and, 453  
anovulation with, 609  
corticosteroids, 116  
paraneoplastic syndrome, 217  
small cell lung cancer, 647
- Cushing ulcers  
gastritis, 362
- Cutaneous anthrax, **133**  
edema toxin, 128
- Cutaneous flushing  
carcinoid syndrome, 338  
drugs causing, 239
- Cutaneous larva migrans, 155
- Cutaneous leishmaniasis, 154
- Cutaneous mycoses, **148**
- Cutaneous paraneoplastic  
syndromes, 217
- Cutis aplasia  
Patau syndrome, 59
- CXCR4  
viral receptor, 162
- CXCR4/CCR5 protein  
presence on cells, 106
- Cyanide  
electron transport chain, 74
- Cyanide poisoning  
induced methemoglobinemia, 632  
inhalation injury, 640  
nitroprusside, 304  
treatment for, 239
- Cyanopia, 623
- Cyanosis  
“blue babies,” 288  
“blue kids,” 289  
bronchitis, 638  
Eisenmenger syndrome, 289  
esophageal atresia, 344  
methemoglobinemia, 632  
patent ductus arteriosus, 289  
pulmonary hypertension, 643  
tetralogy of Fallot as cause, 288
- Cyclin-CDK complexes, 42
- Cyclin-dependent kinases (CDKs), 42
- Cyclins, 42
- Cyclobenzaprine, **520**
- Cyclooxygenase  
aspirin effect on, 393
- Cyclooxygenase inhibition  
irreversible, 456  
reversible, 455, 456  
selective, 456
- Cyclophilin targets, 117
- Cyclophosphamide, 418  
hemorrhagic cystitis with, 240  
microscopic polyangiitis, 302  
polyarteritis nodosa, 302  
SIADH caused by, 334  
SIADH with, 240  
toxicities of, 422  
transitional cell carcinoma  
and, 569  
Wegener granulomatosis, 302
- Cycloplegia  
atropine, 233  
muscarinic antagonists for, 233
- Cyclosporine  
gingival hyperplasia, 241  
gout, 241  
immunosuppressant, 116  
targets of, 117
- Cyctothymic disorder, 530, 531
- Cyproheptadine, 545
- Cyproterone, 620
- Cystathionine, 63
- Cystathionine synthase deficiency, 80
- Cysteine, 81
- Cystic duct, 353
- Cysticercosis, 156
- Cystic fibrosis, **56**  
*Aspergillus fumigatus*, 149  
bronchiectasis, 639  
chromosome association, 60  
common organisms, 175  
meconium ileus in, 369  
N-acetylcysteine, 648  
pancreatic insufficiency, 364  
*Pseudomonas aeruginosa*, 139  
vitamin deficiencies and, 61
- Cystic hygromas, 450  
Turner syndrome, 603
- Cystine, 567
- Cystinosis, 556
- Cystinuria, **81**
- Cystitis  
acute bacterial, 562, 570  
squamous cell carcinoma risk, 569
- Cytarabine, 417  
in cell cycle, 416
- Cytochrome C, 204
- Cytochrome P-450  
azoles, 195  
barbiturates and, 515  
cimetidine and, 381  
epilepsy drug effects on, 514  
griseofulvin, 196  
interactions with, 243  
macrolides, 189  
phenobarbital effect on, 514  
porphyria, 403  
rifamycins, 192  
ritonavir, 199
- Cytokeratin  
cytoskeletal element, 44  
in epithelial cells, 447
- Cytokine receptor, 218
- Cytokines, **104**  
bacterial toxins, 106  
corticosteroids and, 116  
Graves disease and, 329  
recombinant, **117**  
rejection reactions, 115  
type IV hypersensitivity, 109
- Cytokinesis, 42
- Cytomegalovirus (CMV)  
AIDS retinitis, 161  
cholecystitis and, 379  
clinical significance, **161**  
esophagitis and, 360  
HIV-positive adults, 173  
hyper-IgM syndrome and, 113  
immunodeficient patients, 114  
pneumonia, 645  
retinitis and, 508  
ToRCHeS infection, 178  
treatment, 198  
viral receptor, 162
- Cytoplasm  
cell cycle phase, 42  
cytoskeletal elements, 44  
glycolysis, 72  
HMP shunt, 75  
metabolism in, 68
- Cytoplasmic membrane  
(bacterial), 120
- Cytoplasmic processing bodies  
(P-bodies), 38
- Cytosine methylation, 32
- Cytoskeletal elements, **44**
- Cytosol, 433
- Cytotoxic T cells, **98**  
cell surface proteins, 106  
MHC I and II, 96
- Cytotrophoblasts, 584  
choriocarcinomas and, 605
- D**
- D<sub>2</sub> agonists, 543
- D<sub>2</sub> antagonists, 543

- Daclizumab  
   immunosuppression, 116  
   targets of, 117
- Dacrococytes, 394
- Dactinomycin, 418
- RNA polymerase inhibition, 38  
 targets of, 416
- Dactylitis  
   seronegative spondyloarthritis, 442  
   sickle cell anemia, 400
- Dalfopristin  
   mechanism (diagram), 183  
   VRE, 194
- Dalteparin, 413
- Danazol, **622**  
   endometriosis, 613  
   pseudotumor cerebri, 491  
   reproductive hormones and, 620
- Dandy-Walker syndrome, 462
- Dantrolene, 519, **520**, 543
- Dapagliflozin, 341
- Dapsone, **190**  
   dermatitis herpetiformis, 452  
   Hansen disease, 137  
   hemolysis in G6PD  
     deficiency, 241  
   *Mycobacterium leprae*, 192  
   *Pneumocystis jirovecii*, 150
- Daptomycin, **191**  
   MRSA, 194
- Dark-field microscopy, 142
- Darunavir  
   HIV therapy, 199  
   mechanism (diagram), 197
- Datura*, 233
- Daunorubicin, 418  
   dilated cardiomyopathy, 239
- DCC gene, 218
- D-dimer lab, 636
- Deafness  
   Alport syndrome, 565  
   congenital long QT syndrome, 283  
   congenital syphilis, 143  
   rubella, 178  
   syphilis, 178
- Deamination  
   base excision repair, 37  
   nucleotides, 33
- Death  
   aortic dissection in, 293  
   children, explaining to, 257  
   common causes, **260**  
   hyperosmolar hyperglycemia  
     nonketotic syndrome, 338  
   sudden cardiac death, 293  
   thyroid storm, 329
- Debranching enzyme  
   Cori disease, 83  
   glycogen metabolism, 82
- Decay-accelerating factor (DAF), 103
- Deceleration injury, 292
- Decidua basalis, 584
- Decision-making capacity, 254
- Decompression sickness, 637
- Deep brachial artery, 432
- Deep inguinal lymph nodes, 591
- Deep inguinal ring, 354
- Deep venous thrombosis  
   (DVT), **636**  
   direct factor Xa inhibitors for, 415  
   embolic stroke and, 482  
   glucagonomas and, 338  
   heparin for, 413  
   labs/findings, 659  
   tamoxifen/raloxifen and, 421
- Deer flies (disease vectors), 155
- Defensins, 95
- Deferasirox  
   hemochromatosis, 378  
   for iron poisoning, 239, 404
- Deferiprone  
   hemochromatosis, 378  
   for iron poisoning, 239
- Deferoxamine  
   hemochromatosis, 378  
   for iron poisoning, 239, 404
- Degenerate/redundant genetic  
   code, **34**
- Degmacytes, 394
- G6PD deficiency, 75  
 in G6PD deficiency, 400
- Dehydration  
   diabetic ketoacidosis, 337  
   DM type 2, 341  
   filtration changes and, 553  
   hyperosmolar hyperglycemic  
     state, 338  
   loop diuretics and, 575  
   mannitol and, 575  
   shock, 299
- Dehydrogenases, 69
- Deiodinase, 321
- Delavirdine  
   HIV therapy, 199  
   mechanism (diagram), 197
- Delirium, **528**  
   barbiturate withdrawal, 540  
   dementia, 529  
   diabetic ketoacidosis, 337  
   PCP, 541  
   thyroid storm, 329
- Delirium tremens (DTs), **542**  
   alcohol withdrawal, 540, 541
- $\Delta$  cells  
   endocrine pancreas, 313  
   somatostatinomas of, 338  
   somatostatin production, 356
- Delta virus, 163
- Delta wave sleep, 467
- Deltoid muscle  
   axillary nerve injury, 427  
   Erb palsy, 428
- Delusional disorder, **530**
- Delusions, 529  
   mesolimbic pathway, 468  
   schizophrenia, 530
- Demeclocycline, **342**. *See*  
   also Tetracyclines  
   diabetes insipidus and, 240, 334  
   for SIADH, 334
- Dementia, **529**  
   common brain lesions, 481  
   frontotemporal, 481  
   HIV-positive adults, 173
- metachromatic leukodystrophy,  
     84, 494
- neurodegenerative disorders,  
     490–491
- Pick disease, 660
- prion disease, 174
- splice site mutations, 36
- vitamin B<sub>3</sub> deficiency, 63
- Demyelination/dysmyelination  
   diseases of, **494**  
   vitamin B<sub>12</sub> deficiency, 500
- Dendritic cells, **388**  
   IL-10, 104  
   innate immunity, 95  
   Langerhans cell histiocytosis  
     and, 412  
   T- and B-cell activation, 97, 98, 99
- Dengue, 163
- Denial, 524
- Denosumab, 118  
   for osteoporosis, 435
- De novo pyrimidine and purine  
   synthesis, **33**  
   rate-determining enzyme, 69
- Dense deposit disease, 565
- Dental caries, 132
- Dental plaque  
   normal flora, 174  
   viridans streptococci, 125
- Dentate line, 351
- Dentate nucleus, 469
- Dentin  
   collagen in, 46  
   osteogenesis imperfecta, 47
- Dentinogenesis imperfecta, 47
- Denys-Drash syndrome, 569
- Dependent personality disorder, 535
- Depersonalization/derealization  
   disorder, 528  
   panic disorder, 533
- Depression  
   anorexia nervosa and, 537  
   atypical antipsychotics for, 543  
   atypical features in, **531**  
   benzodiazepine withdrawal, 540  
   dementia, 529  
   dissociative identity disorder, 528  
   drug therapy, 542  
   electroconvulsive therapy, 532  
   glucagonomas, 338  
   hyperparathyroidism, 332  
   marijuana withdrawal, 541  
   MDMA withdrawal, 541  
   metoclopramide, 383  
   mirtazapine for, 236  
   neurotransmitters for, 465  
   postpartum, 532  
   serotonin-norepinephrine reuptake  
     inhibitors (SNRIs) for, 545  
   sexual dysfunction caused by, 537  
   SSRIs for, 545  
   stimulant withdrawal, 540  
   suicide and, 532
- Deprivation effects (infants), **526**
- De Quervain thyroiditis, 328
- Demacantor* tick (disease  
   vector), 144
- Dermatitis  
   B-complex deficiency, 61  
   glucagonomas, 338  
   IPEX syndrome, 98  
   type IV hypersensitivity  
     reaction, 109  
   vitamin B<sub>5</sub> deficiency, 63  
   vitamin B<sub>7</sub> deficiency, 64
- Dermatitis herpetiformis, 452  
   celiac disease and, 364
- Dermatology, 430–439, 446–454  
   macroscopic terms, **447**  
   microscopic terms, **448**
- Dermatomes  
   landmarks, **480**
- Dermatomyositis, **445**  
   autoantibody with, 111
- Dermatophytes, 148
- Dermatophytoses, 195
- Dermis, 446
- Dermoid cysts, 610
- Descending colon, 345
- Desert bumps, 147
- Desflurane, 519
- Desipramine, 545
- Desloratadine, 648
- Desmin, 44
- Desmoplakin, 447
- Desmopressin  
   for hemophilia, 404
- Desmopressin acetate  
   central DI, 317, 342  
   DI treatment, 334
- Desmosome, 447  
   autoantibody to, 111
- Desvenlafaxine, 545
- Detached retina, **507**
- Detemir insulin, 340. *See also* Insulin
- Detrusor instability, 569
- Developmental delays  
   renal failure and, 571
- Developmental milestones, 258
- Dexamethasone. *See*  
   also Glucocorticoids  
   arachidonic acid pathway, 455  
   Cushing syndrome diagnosis, 323
- Dexlansoprazole, 381
- Dextrazoxane, 418  
   dilated cardiomyopathy  
     prevention, 239
- Dextroamphetamine, 542
- Dextrocardia, 268
- Dextromethorphan, 520, **648**
- DHT, 604
- Diabetes insipidus, **334**  
   antidiuretic hormone in, 317  
   demeclocycline and, 342  
   desmopressin acetate for, 342  
   drug reaction and, 240  
   lithium, 544  
   potassium-sparing diuretics for, 576  
   thiazides for, 576
- Diabetes mellitus, **336–337**. *See*  
   also Hyperglycemia  
   acanthosis nigricans, 453  
   atherosclerosis and, 292  
   atypical antipsychotics, 543  
   beta-blockers and, 237

- binge eating disorder, 537  
 carpal tunnel syndrome, 426  
 cataracts and, 505  
 chronic renal failure and, 571  
 CN III damage, 511  
 diabetic ketoacidosis, 337  
 diabetic retinopathy, 507  
 drug therapy for, **340–341**  
 endometrial cancer risk, 612  
 Friedreich ataxia, 501  
 fungal infections, 182  
 glaucoma and, 506  
 glucagonomas, 338  
 glucosuria in, 554  
 hemochromatosis, 378  
 hepatitis C, 169  
 hypertension and, 290, 304  
*Klebsiella*, 140  
 neonatal respiratory distress syndrome, 627  
 opportunistic infections, 149  
 pancreatic cancer, 380  
 polyhydramnios and, 607  
 preeclampsia and, 608  
 in pregnancy, 290  
*Pseudomonas aeruginosa*, 139  
 pycelonephritis and, 570  
 readmissions with, 261  
 renal papillary necrosis and, 572  
 sexual dysfunction, 537  
 tacrolimus and, 116  
 teratogenic potential, 582  
 type 1 vs type 2, 337  
 urinary tract infections, 177  
 UTIs and, 570
- Diabetes mellitus type 1, 337**  
 autoantibody with, 111  
 HLA subtypes with, 96  
 treatments for, 340
- Diabetes mellitus type 2, 337**  
 hyperosmolar hyperglycemia nonketotic syndrome, 338  
 treatments for, 340
- Diabetic glomerulonephropathy, 566**
- Diabetic ketoacidosis**  
 black eschar, 652  
 ketone bodies, 86  
 metabolic acidosis, 561
- Diabetic ketoacidosis (DKA), 337**  
 DM type 1 and, 336
- Diabetic nephropathy**  
 ACE inhibitors for, 577  
 angiotensin II receptor blockers for, 577
- Diabetic neuropathy, 545**
- Diabetic retinopathy, 507**
- Diagnosis errors, 262**
- Diagnostic maneuvers/signs**  
 Gower sign, 57
- Diagnostic test evaluation, 247**
- Dialectical behavior therapy, 535**
- Dialysis-related amyloidosis, 213**
- Diamond-Blackfan anemia, 398**
- Diapedesis, 209**
- Diaper rash**  
*Candida albicans*, 149  
 nystatin, 195
- Diaphoresis, 294**  
 acromegaly, 333  
 serotonin syndrome, 545
- Diaphragmatic hernias, 355**
- Diaphragm structures, 629**
- Diaphysis, 438**
- Diarrhea**  
 amebiasis, 151  
*Bacillus cereus*, 134  
 B-complex deficiency, 61  
 bismuth/sucralfate for, 382  
 bronchial carcinoid tumor, 647  
*Campylobacter jejuni*, 140  
 Celiac disease, 657  
 cholera toxin, 128  
 cholinesterase inhibitor poisoning, 232  
 clindamycin, 188  
*Clostridium difficile*, 134, 652  
*Cryptosporidium*, 151  
 as drug reaction, 240  
 ezetimibe, 306  
 giardiasis, 151  
 graft-versus-host disease, 115  
 HIV-positive adults, 173  
 hyperthyroidism and, 327  
 inflammatory bowel diseases, 365  
 irritable bowel syndrome, 366  
 lactase deficiency, 77  
 lactose intolerance, 364  
 leflunomide, 456  
 loperamide for, 382  
 magnesium deficiency from, 320  
 magnesium hydroxide, 382  
 malabsorption syndromes, 364  
 metabolic acidosis from, 561  
 metoclopramide, 383  
 misoprostol, 382  
 opioids for, 520  
 opioid withdrawal, 540  
 organisms causing, **175**  
 pellagra, 63  
 rotavirus, 164  
*Salmonella*, 141  
 SCID, 113  
 serotonin syndrome, 545  
*Shigella*, 141  
 threadworms, 155  
 thyroid storm and, 329  
*Vibrio cholerae*, 141  
 VIPomas, 356  
 vitamin C toxicity, 65  
 Whipple disease, 656  
*Yersinia enterocolitica*, 141
- Diastole**  
 cardiac cycle, 276  
 coronary blood flow, 271  
 heart failure and, 298  
 heart murmurs of, 278, 279  
 heart sounds of, 276, 278  
 increased heart rate and, 272
- Diastolic pressure, 272**
- Diazepam, 515**  
 alcohol withdrawal, 542  
 flumazenil and, 228  
 tetanus, 134
- Diclofenac, 456**  
 arachidonic acid pathway and, 455
- Dicloxacillin**  
 mechanism and use, 184  
 mechanism (diagram), 183
- Dicrotic notch, 276**
- Dicyclomine, 233**
- Didanosine**  
 HIV therapy, 199  
 mechanism (diagram), 197  
 pancreatitis, 240
- Diencephalon, 460**
- Diethylcarbazine**  
 antihelminthic, 196  
 nematode infections, 155
- Diethylstilbestrol (DES), 621**  
 teratogenicity, 582  
 vaginal tumors, 609
- Differential media, 122**
- Differentiation (tumor), 214**
- Diffuse cortical necrosis, 570**
- Diffuse glomerular disorders, 563**
- Diffuse large B-cell lymphoma (DLBCL), 408, 410**
- Diffuse proliferative glomerulonephritis (DPGN), 564, 661**
- Diffuse scleroderma, 446**
- Diffuse stomach cancer, 362**
- Diffuse systemic scleroderma, 657**
- Diffusion-limited gas exchange, 633**
- Digestion**  
 malabsorption syndromes, 364  
 secretory products for, **357–359**  
 ulcerative colitis and, 365
- Digestive tract**  
 anatomy and histology, **347**  
 ligaments of, **357**
- Digitalis**  
 contractility effects, 273  
 hyperkalemia and, 560  
 toxicity treatment for, 239
- Digitoxin, 45**
- Digoxin, 307**  
 antidote for, 118  
 for dilated cardiomyopathy, 297  
 sodium-potassium pump inhibition, 45  
 therapeutic index value of, 228
- Digoxin immune Fab, 118**
- Digoxin poisoning, 310**
- Dihydroergotamine, 488**
- Dihydrofolate reductase, 33**
- Dihydrofolic acid, 190**
- Dihydroorotate dehydrogenase**  
 leflunomide effect on, 33, 456
- Dihydropyridine calcium channel blockers, 244**
- Dihydropyridine receptor, 433**
- Dihydrorhodamine test, 113**
- Dihydrotestosterone (DHT)**  
 finasteride, 623  
 5 $\alpha$ -reductase deficiency, 604  
 function, 600  
 genital development, 590  
 pharmacologic control of, 620  
 sexual determination, 589
- Dihydroxyacetone-P, 76**
- Dilated cardiomyopathy, 297, 298**  
 doxorubicin, 418  
 as drug reaction, 239  
 hemochromatosis, 378  
 muscular dystrophy, 57  
 wet beriberi, 62
- Diltiazem, 304, 310**
- Dimenhydrinate, 648**
- Dimercaprol**  
 for arsenic toxicity, 239  
 for lead poisoning, 239, 397  
 for mercury poisoning, 239
- Dinitrophenol, 74**
- Dipalmitoylphosphatidylcholine, 627**
- Diphenhydramine, 648**
- Diphenoxylate, 520**
- Diphtheria**  
*Corynebacterium diphtheriae*, **135**  
 exotoxins, 126, 127, 128  
 unvaccinated children, 182  
 vaccine for, 135
- Diphyllobothrium latum***  
 B<sub>12</sub> deficiency, 398  
 disease association, 157  
 presentation, 156  
 vitamin B<sub>12</sub> deficiency, 65
- Diplococci, 137**
- Diplopia**  
 drug side effects, 514  
 myasthenia gravis, 445  
 osmotic demyelination syndrome, 492  
 pseudotumor cerebri, 491  
 vertigo with, 503
- Dipyridamole, 415**  
 for coronary steal syndrome, 293
- Direct Coombs test, 108**
- Direct factor Xa inhibitors, 415**
- Direct hernias, 354**
- Direct inguinal hernias, 355**
- Direct thrombin inhibitors, 413**
- Disc herniation, 432**
- Discounted fee-for-service, 260**
- Disease prevention, 259**
- Disease vectors**  
*Aedes* mosquitoes, 164  
*Anopheles* mosquito, 153  
 armadillos, 144  
 birds, 144, 146  
 black flies, 155  
 cats, 144  
 dogs, 140, 144  
 fleas, 144, 145  
 flies, 141, 144  
 horse flies, 155  
*Ixodes* ticks, 142  
 rodents, 163  
 ticks, 142, 145  
 zoonotic bacteria, **144**
- Disinfection/sterilization methods, 200**
- Disopyramide, 308**
- Disorganized speech, 530**
- Disorganized thought, 529**

- Dispersion measures, 251  
 Displacement, 524  
 Disseminated candidiasis, 149  
 Disseminated intravascular coagulation (DIC), **406**  
 acute myelogenous leukemia, 410  
 amniotic fluid emboli, 637  
 Ebola, 167  
 endotoxins, 127, 129  
 meningococci, 138  
 microangiopathic anemia, 401  
 placental abruption, 606  
 schistocytes in, 395  
 Waterhouse-Friderichsen syndrome, 324, 652  
 Dissociation, 524  
 Dissociative amnesia, 528  
 Dissociative disorders, **528**  
 Dissociative fugue, 528  
 Dissociative identity disorder, 528  
 Distal convoluted tubules, 550  
 defects in, 556  
 diuretics and, 574  
 filtration, 553  
 nephron physiology, 555  
 renal tubular acidosis of, 562  
 Distal humerus, 432  
 Distal interphalangeal (DIP) joints, 429  
 Distortions of hand, **429**  
 Distribution, statistical, 251  
 Distributive shock, 299  
 Disulfiram  
 alcoholism, 661  
 alcoholism treatment, 541  
 ethanol metabolism and, 68  
 Disulfiram-like reaction, 242  
 Diuresis  
 atrial natriuretic peptide, 285  
 for shock, 299  
 Diuretics  
 acute interstitial nephritis with, 572  
 dilated cardiomyopathy, 297  
 electrolyte changes, **576**  
 for glaucoma, 521  
 in gout, 457  
 heart failure, 298  
 hypertension treatment, 304  
 magnesium levels and, 320  
 pancreatitis, 240  
 for SIADH, 334  
 site of action, **574**  
 Diverticula, **366**, 668  
 Diverticulitis, 366  
 Diverticulosis, 366  
 Diverticulum, 366  
 Dizziness, 503  
 calcium channel blockers, 304  
 cholesteatoma, 503  
 drug side effects, 516, 518  
 nitrates, 305  
 ranolazine, 305  
 DMPK gene, 57  
 DNA  
 cloning methods, 51  
 free radical effect on, 210  
 introns vs exons, **39**  
 laddering in apoptosis, 204  
 methylation of, **32**  
 mutations in, **36**  
 repair of, **37**  
 replication of, **35**  
 DNA ligase, **35**  
 DNA polymerase inhibitors, 244  
 DNA polymerases, **35**  
 DNA topoisomerases, **35**  
 DNA viruses, **160**  
 characteristics, **159**  
 genomes, **158**  
 replication, 159  
 Dobutamine, 234  
 Docusate, 383  
 Dofetilide, 309  
 Dogs (disease vectors), 140, 144, 148, 156, 176, 182  
 Dominant inheritance, 55  
 Dominant negative mutations, 52  
 Dominant parietal cortex lesions, 481  
 Donepezil, 232  
 for Alzheimer disease, 518  
 Do not resuscitate order, 255  
 DOPA  
 tyrosine catabolism, 79  
 Dopamine, 234, 315  
 agonists, 517  
 atypical antipsychotic effects, 543  
 basal ganglia, 470  
 bupropion effect, 546  
 changes with disease, 465  
 derivation of, 79  
 Huntington disease, 490  
 kidney functions, 559  
 lactation and, 316  
 L-DOPA, 518  
 MAO inhibition, 518  
 MAO inhibitor effects, 546  
 in noradrenergic drugs, 231  
 Parkinson disease, **517**  
 pheochromocytoma secretion, 326  
 receptors, 470  
 vitamin B<sub>6</sub> and, 63  
 Dopamine agonists  
 prolactin and, 316  
 prolactinomas, 332  
 Dopamine antagonists, 316  
 Dopamine receptors, 230  
 Dopaminergic pathways, **468**  
 Doripenem  
 carbapenems, **186**  
 mechanism (diagram), 183  
 Dornase alfa (DNase), 56  
 Dorsal column of spinal cord, 478, 479  
 Dorsal interossei muscle, 429  
 Dorsal motor nucleus, 477  
 Dorsal optic radiation, 511  
 Dorsal pancreatic bud, 345  
 Dosage calculations, **225**  
 Double-blinded studies, 246  
 "Double bubble" sign (X-ray), 344  
 Double stranded viruses, 159  
 Double Y males, 603  
 Down syndrome, **59**  
 ALL and AML in, 410  
 cardiac defect association, 290  
 cataracts and, 505  
 chromosome associated with, 60  
 duodenal atresia and, 344  
 hCG in, 598  
 Hirschsprung disease and, 367  
 horseshoe kidney and, 549  
 presentation, 656  
 Doxazosin, 236  
 Doxepin, 545  
 Doxorubicin, 418  
 cardiomyopathy from, 297  
 dilated cardiomyopathy, 239  
 targets, 416  
 toxicities, 422  
 Doxycycline  
 chlamydiae, 146  
*Chlamydia trachomatis*, 661  
 gonococci, 138  
 lymphogranuloma venereum, 146  
 mechanism (diagram), 183  
 MRSA, 194  
*Mycoplasma pneumoniae*, 146  
 rickettsial/vector-borne disease, **145**  
 tetracyclines, **188**  
 DPC4/SMAD4 gene, 218  
 DPP-4 inhibitors, 341  
 Dressler syndrome, 294, 296, 300  
 presentation, 652  
 DRESS syndrome, 514  
 Drooling treatment, 233  
 Drug/chemical toxicity, 210  
 Drug clearance, 669  
 Drug-induced lupus, 111  
 Drugs  
 autonomic, **231**  
 cholinomimetic agents, 232  
 dosage calculations, 225  
 efficacy vs potency, **227**  
 elimination of, 226  
 errors in, 262  
 interactions, 225  
 metabolism of, **226**  
 patient difficulty with, 256  
 reactions to, **239–242**  
 therapeutic index, **228**  
 toxic dose, 228  
 toxicities, **239**  
 Drug trials, **246**  
 Dry beriberi, 62  
 Dry cough with ACE inhibitors, 242  
 Dry mouth  
 Lambert-Eaton myasthenic syndrome, 445  
 tricyclic antidepressants, 545  
 Dry skin, 62  
 Dubin-Johnson syndrome, 376, 377  
 Duchenne muscular dystrophy, **57**  
 frameshift mutation, 36  
 inheritance, 56  
 Ductal adenocarcinomas, 353  
 Ductal carcinoma in situ (DCIS), 616  
 Ductal carcinomas  
 malignant, 616  
 terminal lobular unit, 614  
 Ductus arteriosus, 270, 586  
 Ductus deferens  
 embryology, 589  
 ureter and, 550  
 Ductus venosus, 270  
 Duloxetine, 545  
 Duodenal atresia, **344**  
 Down syndrome, 59  
 Duodenal ulcers, 363  
 Duodenum  
 biliary structures and, 353  
 histology of, 347  
 location, 345  
 secretory cells, 357  
 Duplex collecting system, **549**  
 Dural venous sinuses, **473**  
 Duret hemorrhage, 499  
 Dwarfism, 333  
 achondroplasia, 435  
 D-xylose test, 364  
 Dynein, 44  
 Dynein motors, 167  
 Dysarthria, 486  
 cerebellar vermis lesions, 481  
 Friedreich ataxia as, 501  
 osmotic demyelination syndrome, 492  
 Dyschezia, 613  
 Dysentery  
*Entamoeba histolytica*, 151, 175  
*Escherichia coli*, 140  
*Shigella* spp, **128**, 141, 175  
 Dysgerminomas, 611  
 Dysgeusia, 67  
 Dyslipidemia, **90**  
 $\beta$ -blocker adverse effects, 309  
 $\beta$ -blockers, 237  
 renal failure and, 571  
 vitamin B<sub>3</sub> for, 63  
 Dysmenorrhea  
 adenomyosis, 612  
 copper IUD, 622  
 defined, 597  
 endometriomas, 610  
 endometriosis, 613  
 Dysmetria  
 stroke and, 484  
 vertigo and, 503  
 Dysmyelinating diseases, **494**  
 Dyspareunia, 537  
 endometriomas, 610  
 endometriosis, 613  
 Dyspepsia, 623  
 Dysphagia  
 esophageal pathologies and, **360–361**  
 heart enlargement and, 271  
 osmotic demyelination syndrome, 492  
 Plummer-Vinson syndrome, 396  
 stroke effects, 484  
 Zenker diverticulum, 367  
 Dysplasia, 214, 215  
 Dyspnea  
 aortic stenosis, 279  
 asthma, 638  
 emphysema, 655

- heart failure, 298  
 hypersensitivity pneumonitis, 639  
 hypertrophic cardiomyopathy, 297  
 hypothyroidism and, 327  
 late-onset, 638  
 sudden-onset, 637  
 Wegener granulomatosis, 302
- Dysthymia, 530, 531
- Dystonia  
 benzotropine for, 233  
 Lesch-Nyhan syndrome, 34  
 movement disorders, 489  
 nigrostriatal pathway and, 468
- Dystrophic calcification, 208
- Dystrophin gene, 57
- Dysuria, 619  
 cystitis, 177  
 urinary catheterization, 181  
 UTIs causing, 570
- E**
- Eardrum, 503
- Early-onset Alzheimer disease, 59
- Ear physiology, 503
- Eastern equine encephalitis, 163
- Eating disorders, 537
- Eaton agar  
*Mycoplasma pneumoniae*, 146  
 special culture requirements, 123
- Ebola virus, 163, 167
- Ebstein anomaly, 269, 288  
 fetal lithium exposure, 582  
 lithium, 544
- E-cadherin, 447  
 in neoplastic progression, 215
- Echinocandins, 194, 196
- Echinococcus granulosus*  
 cestodes, 156  
 disease association, 157
- Echinocytes, 394
- Echothiophate, 521
- Echovirus  
 picornavirus, 163, 164
- Eclampsia, 290, 608  
 benzodiazepines for, 515
- Ecthyma gangrenosum, 139
- Ectocervix, 592
- Ectoderm  
 branchial clefts, 586  
 derivatives of, 581
- Ectoparasites, 157
- Ectopic pregnancy, 607  
 appendicitis vs, 366  
*Chlamydia trachomatis*, 146  
 hCG in, 598  
 Kartagener syndrome, 45  
 methotrexate for, 417  
 salpingitis and, 181
- Ecuzumab, 118  
 for paroxysmal nocturnal  
 hemoglobinuria, 400
- Eczema  
 atopic dermatitis, 449  
 hyper-IgE syndrome, 112, 655  
 phenylketonuria, 80  
 skin scales in, 447  
 type I hypersensitivity, 108  
 Wiskott-Aldrich syndrome, 113, 660
- Eczematous dermatitis, 448
- Edema  
 acute poststreptococcal  
 glomerulonephritis, 564  
 Arthus reaction, 109  
 calcium channel blockers as  
 cause, 304  
 capillary fluid exchange and, 287  
 cirrhosis, 372  
 danazol, 622  
 diabetic ketoacidosis, 337  
 endotoxins, 129  
 fludrocortisone, 342  
 glitazone/thiazolidinediones, 340  
 glomerular filtration barrier  
 and, 551  
 heart failure as cause, 298  
 hyperammonia, 78  
 immunosuppressants, 116  
 inhalational injury, 640  
 Kawasaki disease as cause, 302  
 kwashiorkor, 67  
 loop diuretics for, 575  
 nephrotic syndrome, 566, 655  
 periorbital, 155, 157, 327  
 pitting, 298  
 pseudoephedrine/  
 phenylephrine, 648  
 pulmonary, 110, 575  
 pulmonary hypertension, 633  
*Trichinella spiralis*, 155, 157  
 trichinosis, 155  
 wet beriberi, 62
- Edema toxin, 128
- Edinger-Westphal nuclei, 509
- EDRF. *See* Endothelium-derived  
 relaxing factor (EDRF)
- Edrophonium, 232, 520
- Edwards syndrome, 59  
 cataracts and, 505  
 chromosome association, 60  
 hCG in, 598  
 horseshoe kidney and, 549
- Efavirenz  
 HIV-positive adults, 199  
 mechanism (diagram), 197
- Effective refractory period  
 Class IA antiarrhythmic  
 effect, 308  
 Class IC antiarrhythmic  
 effect, 308  
 myocardial action potential, 280
- Effective renal plasma flow, 552, 670
- Effects analysis for medical errors, 262
- Efferent/afferent nerves, 285
- Efferent arteriole, 550  
 angiotensin II, 559  
 ANP/BNP, 558  
 constriction of, 553  
 dopamine and, 559  
 filtration, 553
- Efficacy vs potency of drugs, 227
- EGF. *See* Epidermal growth factor  
 (EGF)
- EGFR gene, 647
- Ego defenses, 524, 525
- EHEC, 140
- Ehlers-Danlos syndrome, 47  
 collagen deficiency in, 46  
 heart murmur with, 279
- Ehrlichia chaffeensis*, 144
- Ehrlichiosis  
 animal transmission, 144  
 rickettsial/vector-borne, 145
- Eikenella* spp, 299
- Eisenmenger syndrome, 289
- Ejaculation  
 innervation of, 593  
 sperm pathway in, 593
- Ejaculatory ducts, 593  
 embryology of, 589
- Ejection fraction, 273, 669
- Ejection murmur, 656
- Elastase, 358  
 emphysema, 638
- Elastic recoil, 631
- Elastin, 48
- Elbow injuries, 426
- Electrocardiograms (ECGs), 282  
 acute pericarditis on, 300  
 cardiac tamponade on, 300  
 MI diagnosis with, 295  
 tracings of, 284
- Electroconvulsive therapy, 532  
 major depressive disorder, 531  
 postpartum psychosis, 532
- Electroencephalogram (EEG)  
 Creutzfeldt-Jakob disease, 491  
 sleep stages, 467
- Electrolyte disturbances, 560
- Electron transport chain, 74
- Electron transport inhibitors, 74
- Elek test, 135
- Elementary bodies (chlamydiae), 146
- Elephantiasis, 155
- 11 $\beta$ -hydroxylase, 318
- 11 $\beta$ -hydroxysteroid  
 dehydrogenase, 556
- 11-deoxycorticosterone, 318
- 11-deoxycortisol, 318  
 metyrapone and, 324
- Elfin facies, 60
- Elimination of drugs, 226  
 urine pH and, 226
- ELISA (enzyme-linked  
 immunosorbent assay), 51  
 HIV diagnosis, 171
- Elliocytes, 394
- Elliocytes, 394
- Elongation of protein synthesis, 41
- Eltrombopag, 117
- Emancipated minors, 254
- EMB agar  
*Escherichia coli*, 177  
 lactose-fermenting enterics, 138  
 special culture, 123
- Emboli  
 atherosclerosis, 292  
 atrial fibrillation, 284  
 atrial septal defect, 289  
 bacterial endocarditis, 299  
 patent foramen ovale, 268  
 pulmonary, 299
- Embolic stroke, 482
- Emboliform nucleus, 469
- Embolism  
 pulmonary, 561
- Embryogenesis  
 genes involved in, 580  
 intrinsic pathway and, 204
- Embryology  
 cardiovascular, 268–270  
 derivatives of, 581  
 erythropoiesis, 389  
 gastrointestinal, 344–345  
 genital, 589  
 neurological, 460–462  
 renal, 548–549  
 reproductive, 580–591  
 respiratory, 626–627  
 thyroid development, 312  
 USMLE Step 1 preparation, 264
- Embryonal carcinomas, 618
- Embryonic age calculation, 598
- Embryonic morphogenic, errors, 581
- Emollient laxatives, 383
- Emotionally distraught patients, 256
- Empagliflozin, 341
- Emphysema  
 $\alpha_1$ -antitrypsin deficiency, 375  
 compliance in, 631  
 diffusion in, 633  
 diffusion-limited gas exchange, 633  
 elastin in, 48  
 presentation, 655
- Empty sella syndrome, 335
- Emtricitabine  
 HIV-positive adults, 199  
 mechanism (diagram), 197
- Enalapril, 577
- Encapsulated bacteria, 124
- Encephalitis  
 anti-NMDA receptor, 217  
*Cryptococcus neoformans*, 149  
 cytomegalovirus, 173  
 guanosine analogs, 197  
 herpesviruses, 160, 176  
 HIV-positive adults, 173  
 HSV identification, 162  
 Lassa fever, 163  
 neonatal, 178  
 rubeola, 166  
 small cell lung cancer, 647  
 togaviruses, 163  
 West Nile virus, 176
- Encephalopathy  
 hepatic, 374  
 hypertensive emergency, 290  
 lead poisoning, 397  
 Lyme disease, 142  
 mitochondrial, 55  
 prion disease, 174  
 renal failure, 571  
 Reye syndrome, 373  
 Wernicke, 62
- End-diastolic volume, 272
- Endemic typhus, 144
- Endocannabinoids, 317
- Endocardial cushion, 268
- Endocardial fibroelastosis, 297



- Endocarditis  
 bacterial, **299**  
*Candida albicans*, 149  
 coarctation of aorta, 289  
*Coxiella burnetii*, 145  
 daptomycin, 191  
 enterococci, 133  
 heart murmurs, 279  
 heroin addiction and, 541  
 nonbacterial thrombotic, 217  
 prophylaxis, 194  
*Staphylococcus aureus*, 131  
*Streptococcus bovis*, 133  
 viridans streptococci, 125, 132
- Endocervix, 592
- Endochondrial ossification, 434
- Endocrinal drug reactions, **240**
- Endocrinal paraneoplastic syndromes, 217
- Endocrine hormone signaling pathways, **322**
- Endocrine pancreas cell types, **313**
- Endocrine system, **312–342**  
 anatomy, 312–313  
 embryology, 312  
 pathology, 323–339  
 pharmacology, 340–342  
 physiology, 314–322
- Endoderm  
 branchial pouch derivation, 586  
 derivatives of, 581
- Endodermal tubules, 626
- Endometrial artery, 584
- Endometrial cancer, 612  
 epidemiology of, 608  
 estrogens and, 621  
 Lynch syndrome and, 371  
 PCOS and, 609  
 progestins for, 622  
 tamoxifen and, 421  
 tumor suppressor genes and, 218
- Endometrial hyperplasia, 612  
 follicular cysts, 610  
 progesterone and, 595
- Endometrial vein, 584
- Endometriomas, 610
- Endometriosis, 613  
 danazol for, 622  
 endometriomas and, 610  
 ovarian neoplasms and, 610
- Endometritis, 612  
 pelvic inflammatory disease, 181
- Endometrium, 592  
 conditions of, **612**
- Endoneurium, 465
- Endoplasmic reticulum, 42, 43
- Endosomes, 43
- Endothelial cells  
 filtration and, 553  
 glomerulus, 550  
 leukocyte extravasation and, 209  
 in wound healing, 211
- Endothelium-derived relaxing factor (EDRF), 322
- Endotoxins, **127, 129**
- End-stage renal disease findings, 661
- End-systolic volume, 272
- Enflurane, 519  
 seizures with, 242
- Enfuvirtide  
 HIV-positive adults, 199  
 mechanism (diagram), 197
- Enhancers (gene expression), **38**
- Enoxacin, 191
- Enoxaparin, 413  
 deep venous thrombosis, 636
- Entacapone, 517
- Entamoeba histolytica*  
 amebiasis, **151**  
 bloody diarrhea, 175  
 metronidazole, 191
- Enteritis  
 vitamin B<sub>2</sub> deficiency, 63  
 vitamin B<sub>7</sub> deficiency, 64  
 vitamin B<sub>12</sub> deficiency, 65
- Enterobacter* spp  
 lactose fermentation, 138  
 nosocomial infection, 181  
 taxonomy, 121
- Enterobacter aerogenes*, 185
- Enterobius* spp  
 diseases association, 157  
 infection routes, 154
- Enterobius vermicularis*, 155
- Enterochromaffin-like cells, 325
- Enterococci, **133**  
 penicillins for, 184  
 vancomycin, 186  
 vancomycin-resistant (VRE), 133
- Enterococcus* spp  
 Gram-positive algorithm, 130  
 UTIs, 177
- Enterococcus faecalis*, 133
- Enterococcus faecium*, 133
- Enterohemorrhagic *Escherichia coli* (EHEC), 128, **140, 175**
- Enterohemorrhagic *Escherichia coli* (EHEC)  
 hemolytic-uremic syndrome, 405
- Enteroinvasive *Escherichia coli* (EIEC), 140, 175
- Enterokinase/enteropeptidase, 358
- Enterotoxigenic *Escherichia coli* (ETEC), 128, 140, 175
- Enterovirus meningitis, 176
- Enveloped viruses, 158
- Envelopes (viral), **159**
- env* gene, 171
- Enzyme kinetics, **224**  
 antagonists, 228  
 partial agonists, 228
- Enzymes  
 rate-determining, 69  
 terminology for, **69**
- Eosinopenias, 402
- Eosinophilia, 387  
*Aspergillus fumigatus*, 149  
*Chlamydia trachomatis*, 146  
 macrolides, 189
- Eosinophilic casts, 570
- Eosinophilic esophagitis, 360
- Eosinophils, **387**  
 corticosteroid effects, 402  
 in esophagus, 360  
 helminths, 154
- Ependymoma, 498
- Ephedrine, 234  
 as noradrenergic drug, 231
- Epicanthal folds  
 cri-du-chat syndrome, 60
- Down syndrome, 59
- Epidemics, 165
- Epidemic typhus, 144
- Epidemiology/biostatistics, **246–252**
- Epidermal growth factor (EGF)  
 signaling pathways for, 322  
 in wound healing, 211
- Epidermis, 446  
 embryologic derivatives, 581
- Epidermophyton*, 148
- Epididymis, 593  
 embryology of, 589
- Epididymitis, 180
- Epidural hematomas, 483
- Epigastric veins, 350
- Epiglottitis  
*Haemophilus influenzae*, 138  
 labs/findings, 660  
 unvaccinated children, 182
- Epilepsy  
 drug therapy, **514–515**  
 gustatory hallucinations in, 529  
 lung abscesses, 646  
 seizures, 487  
 splice site mutations, 36  
 Sturge-Weber syndrome, 495
- Epileptic patients  
 confidentiality exceptions, 255
- Epinephrine, 234. *See*  
 also Catecholamines  
 adrenal medulla secretion, 312  
 $\alpha$ -blockade of, 236  
 for anaphylactic reaction, 110  
 for glaucoma, 521  
 glycogen regulation and, **81**  
 in nervous system, 229  
 pheochromocytoma secretion, 326  
 tyrosine catabolism, 79  
 unopposed secretion of, 336  
 vitamin B<sub>6</sub> and, 63
- Epineurium, 465
- Epiphyseal tumors, 438
- Epiploic foramen of Winslow, 346
- Episcleritis  
 inflammatory bowel disease, 365
- Epispadias, 591
- Epistaxis, **636**  
 hereditary hemorrhagic telangiectasia, 303  
 Osler-Weber-Rendu syndrome, 656
- Epithelial cell junctions, **447**
- Epithelial cells  
 tumor nomenclature of, 216
- Epithelial hyperplasia, 615
- Epithelial tumors, 44
- Epithelium, 347
- Eplerenone, 576
- Epoetin alfa, 117
- Epoprostenol  
 pulmonary hypertension, 648
- Epstein-Barr virus (EBV), 161  
 aplastic anemia, 399  
 Burkitt lymphoma, 408
- false-positive VDRL, 143
- hairy leukoplakia and, 451
- head and neck cancer, 636
- HIV-positive adults, 173
- Hodgkin lymphoma, 407
- in immunodeficient patients, 114
- labs/findings, 657, 660
- oncogenesis of, 219
- receptors for, 162
- Eptifibatid, 415  
 thrombogenesis and, 393
- Erb palsy, 428
- Erectile dysfunction, 537  
 $\beta$ -blockers and, 237, 309  
 cimetidine, 381  
 Lambert-Eaton myasthenic syndrome, 445  
 PDE-5 inhibitors for, 623  
 Peyronie disease, 617  
 sildenafil, 648
- Erection  
 autonomic innervation, 593  
 ischemic priapism, 617
- Ergosterol synthesis, 194
- Ergosterol synthesis inhibitors, 244
- Ergot alkaloids, 239
- Eriotinib, **420**
- Errors (medical), 262
- Ertapenem, 183, 186
- Erysipelas, 451  
*Streptococcus pyogenes*, 132
- Erythema  
 complicated hernias, 355  
 Kawasaki disease, 302
- Erythema marginatum, 132, 300
- Erythema migrans, 142
- Erythema multiforme, 452
- Erythema nodosum, 147, 444, 453  
 inflammatory bowel disease, 365
- Erythroblastosis fetalis, 390  
 type II hypersensitivity, 108
- Erythrocytes, **386**  
 blood types, 390  
 casts in urine, 562  
 Coombs test, 401  
 DAF deficiency and, 103  
 erythropoietin and, 559  
 glucose usage by, 314  
 hereditary spherocytosis, 400  
 macrophages and, 387  
 multiple myeloma, 409  
 myeloproliferative disorders, 411  
 pathologic forms of, **394–395**
- Erythrocyte sedimentation rate (ESR), **212**  
 osteomyelitis, 176  
 subacute granulomatous thyroiditis, 328
- Erythrocytosis, 386  
 oxygen-hemoglobin dissociation curve, 632
- Erythromelalgia  
 essential thrombocythemia, 411  
 polycythemia vera, 411
- Erythromycin  
 diarrhea, 240  
 macrolides, 189

- mechanism (diagram), 183  
 prophylaxis, 194  
 protein synthesis inhibition, 187  
 reactions to, 240
- Erythroplasia of Queyrat, 617
- Erythropoiesis, 642
- Erythropoietin  
 anemia of chronic disease, 399  
 aplastic anemia, 399  
 high altitude, 635  
 polycythemia and, 217, 652  
 polycythemia vera, 411  
 release of, 559  
 signaling pathways for, 322
- Escherichia coli*, **140**  
 catalase-positive organism, 124  
 cephalosporins, 185  
 culture requirements, 123  
 EMB agar, 138  
 encapsulation, 124  
 galactosemia as cause, 76  
 Gram-negative algorithm, 137  
 immunodeficiency infections, 114  
 lactose fermentation, 138  
 meningitis, 176, 664  
 neonatal illness, 178  
 nosocomial infection, 181  
 penicillins for, 184  
 pneumonia, 175  
 prostatitis, 619  
 splenic dysfunction and, 94  
 taxonomy, 121  
 type III secretion system, 125  
 urinary tract infections, 570, 668  
 UTIs, 177
- Escherichia coli* O157:H7, 128, 140, 174, 175
- E-selectin, 209
- Esmolol, 237, 309
- Esomeprazole, 381
- Esophageal atresia, 344
- Esophageal cancer, **361**  
 achalasia and, 360
- Esophageal dysmotility  
 CREST syndrome, 446
- Esophageal squamous cell carcinomas, 360
- Esophageal strictures, 360
- Esophageal varices, 350, 360
- Esophageal veins, 350
- Esophageal webs, 360, 396
- Esophagitis, 360  
 bisphosphonates, 456  
 as drug reaction, 240  
 HIV-positive adults, 173
- Esophagus  
 blood supply and innervation, 348  
 diaphragm, 629  
 histology of, 347  
 pathologies of, **360**  
 portosystemic anastomosis, 350
- Essential amino acids, 77
- Essential fructosuria, 76
- Essential hypertension, 304
- Essential mixed  
 cryoglobulinemia, 169
- Essential thrombocythemia, 411
- Essential tremor, 489
- Esters as local anesthetics, 519
- Estradiol, 620
- Estriol  
 Down syndrome, 59  
 pharmacologic control, 620
- Estrogen, **595, 621**  
 androgen insensitivity syndrome, 604  
 benign breast tumors, 615  
 bone formation, 434  
 breast cancer, 616  
 contraception and, 622  
 endometrial carcinoma, 612  
 epiphyseal plate closure, 600  
 in genital development, 590  
 Granulosa cell tumors, 611  
 gynecomastia, 615  
 Klinefelter syndrome, 603  
 lactation and, 599  
 leiomyomata, 612  
 menopause, 600  
 menstrual cycle, 597  
 osteoporosis, 435  
 ovulation, 596  
 pregnancy, 598  
 premature ovarian failure, 609  
 progesterone and, 595  
 prolactin suppression of, 316  
 signaling pathways for, 322  
 thecoma, 610  
 Turner syndrome, 603
- Estrone, 620
- Eszopiclone, 515
- Etanercept, 457  
 lupus-like syndrome, 241
- Ethacrynic acid, **575**
- Ethambutol, 192, **193**
- Ethanol  
 as carcinogen, 219  
 metabolism, **68**  
 zero-order elimination of, 226
- Ethics, **253–256**  
 confidentiality, **255**  
 consent, 254  
 core principles of, **253–255**  
 directives, **255**  
 error disclosure, 262  
 religious beliefs and, 257  
 situations in, **256–257**
- Ethinyl estradiol, 621, 622
- Ethosuxamide, 514
- Ethosuximide  
 absence seizures, 661
- Ethylenediaminetetraacetate (EDTA), 397
- Ethylene glycol  
 metabolic acidosis, 561  
 toxicity treatment, 239
- Etonogestrel, 622
- Etoposide, **419**  
 in cell cycle, 416  
 targets of, 416
- Etoposide/teniposide, 35
- Euchromatin, **32**
- Eukaryotes  
 DNA replication, 35  
 functional gene organization, **38**  
 ribosomes in, 41  
 RNA processing, **38**
- Eustachian tubes  
 embryonic derivation, 588
- Evolocumab, 306
- Ewing sarcomas, 438  
 dactinomycin for, 418  
 labs/findings, 660
- Exanthem subitum, 161
- Excitatory pathway, 470
- Exclusive Provider Organization, 259
- Executioner caspases, 204
- Exemestane, 621
- Exenatide, 341
- Exercise  
 blood flow autoregulation, 286  
 cardiac output, 272  
 peripheral resistance, 275  
 respiratory response, 635  
 syncope with, 297  
 Tetralogy of Fallot, 288
- Exocrine glands, 229, 230
- Exons vs introns, **39**
- Exophytic mass (colorectal cancer), 371
- Exotoxin A  
*Pseudomonas aeruginosa*, 128, 139  
*Streptococcus pyogenes*, 129
- Exotoxins  
 features of, **127**  
 organisms with, 128–129
- Expectorants, 648
- Expiratory reserve volume (ERV), 630
- External hemorrhoids, 351
- External iliac arteries, 348
- External iliac lymph nodes, 591
- External inguinal ring, 355
- External spermatic fascia, 354
- Extinction (conditioning), 524
- Extracellular fluid (ECF), 551
- Extragenital germ cell tumors, **618**
- Extraperitoneal tissue, 354
- Extravascular hemolysis, 399
- Extrinsic hemolytic anemia, **401**
- Extrinsic pathway, **204**  
 coagulation, 391  
 warfarin and, 414
- Exudate pleural effusion, 644
- Exudate vs transudate, **212**
- Ex vacuo ventriculomegaly, 492
- Eye disorders  
 AIDS retinitis, 161  
 aniridia, 569  
 episcleritis, 365  
 red-green color blindness, 193  
 retinopathy, 196  
 retinopathy of prematurity, 627  
 scleritis, 439  
 uveitis, 365
- Eyes  
 anatomy of, **504**  
 aqueous humor pathway, 505  
 bilateral movement of, 513  
 cherry-red macular spot, 84  
 motility of, 510  
 scleral arcus, 90
- Ezetimibe, 306  
 diarrhea, 240
- F**
- Fab region of antibodies, 100
- Fabry disease, 84  
 inheritance, 56
- Facial dysmorphism, 582
- Facial nerve (CN VII), **476**  
 brain stem location, 474  
 branchial arch derivative, 587  
 lesions in, **502**  
 pathway for, 476  
 in tongue, 463
- Facial nerve palsy, 502  
 Lyme disease, 142
- Facies  
 abnormal, 61  
 “chipmunk,” 397  
 dysmorphism, 581  
 elfin, 60  
 epicanthal folds, 59, 60  
 flat, 59  
 moon, 323
- Factitious disorder, **536**
- Factor IX concentrate, 404
- Factor VIII concentrate, 404
- Factor V Leiden, 406
- Factor V Leiden mutation, 392
- Factor Xa  
 direct inhibitors of, 415  
 heparin effect on, 413
- Factor Xa inhibitors, 391
- Factor XI concentrate, 404
- Facultative intracellular organisms, 124
- FADH (flavin adenine dinucleotide), 73
- Failure mode analysis, 262
- Failure to thrive, 526  
 galactosemia, 76  
 orotic aciduria, 398  
 SCID, 113
- Falciform ligament, 346
- Fallopian tubes  
 anatomy, 592  
 epithelial histology, 592  
 fertilization, 598
- False-negative rate, 247
- False-positive rate, 247
- Falx cerebri, 499
- Famciclovir, **197**
- Familial adenomatous polyposis, 370  
 APC gene and, 372  
 chromosome association, 60  
 labs/findings, 660
- Familial dyslipidemias, **90**
- Familial hypercholesterolemia, **90**  
 presentation, 652
- Familial hypocalciuric hypercalcemia, 332
- Family discussions, 256
- Family therapy  
 separation anxiety, 527
- Famotidine, 381
- Fanconi anemia, 399  
 nonhomologous end joining and, 37  
 presentation, 656

- Fanconi syndrome, **556**  
 drug reaction and, 242  
 presentation, 655  
 renal tubular acidosis, 562  
 Wilson disease, 378
- Fascia  
 collagen in, 46
- Fasciculations, 499
- Fastigial nucleus, 469
- Fasting plasma glucose test, 336
- Fasting state, 72, 87
- Fast twitch muscle fibers, 433
- Fat emboli, 637
- Fatigue  
 adrenal insufficiency, 324  
 adrenocortical insufficiency, 656  
 heart failure and, 298  
 hypothyroidism, 327  
 MI signs, 294
- Fat necrosis, 205, 615
- Fat redistribution, 241
- Fat-soluble vitamins, **61**
- Fatty acids  
 gluconeogenesis, 74  
 metabolism of, **85**  
 oxidation of, 68, 69
- Fatty acid synthase, 63
- Fatty acid synthesis  
 metabolic site, 68  
 rate-determining enzyme, 69
- Fatty casts, 562  
 nephrotic syndrome, 566
- Fatty liver  
 nonalcoholic, 374  
 Reye syndrome, 373
- Fatty liver disease  
 hepatocellular carcinoma and, 375  
 labs/findings, 660
- Fava beans and G6PD deficiency, 400
- Fc region of antibodies, 100
- Febrile nonhemolytic transfusion  
 reaction, 110
- Febrile pharyngitis, 160
- Febuxostat  
 gout, 440, 457, 661  
 Lesch-Nyhan syndrome, 34
- Fecal elastase, 364
- Fecalith obstruction, 366
- Fecal microbiota transplant, 134
- Fecal retention, 528
- Feces  
 bilirubin excretion, 359  
 explosive expulsion of, 367
- Federation of State Medical Boards  
 (FSMB), 2
- Fed state, 72, 87
- Felty syndrome, 439
- Female genital embryology, 589
- Female reproductive anatomy, **592**
- Female reproductive epithelial  
 histology, **592**
- Femoral artery, 353
- Femoral hernias, 355
- Femoral nerve, 353, 430
- Femoral region, **353**
- Femoral ring, 353
- Femoral sheath, 353
- Femoral triangle, 353
- Femoral vein, 353
- Fenofibrate, 306
- Fenoldopam, 234, 304
- Fentanyl, 520
- Ferritin  
 acute-phase reactant, 102  
 anemia, 402  
 anemia of chronic disease, 399  
 iron deficiency anemia, 396  
 lab values in anemia, 402  
 sideroblastic anemia, 397
- Ferrochelatase, 403
- Fertility  
 double Y males, 603  
 GnRH and, 315  
 menstrual cycle, 597
- Fertilization, 596, 598
- Fetal alcohol syndrome,  
 290, 582, **583**  
 holoprosencephaly and, 461
- Fetal circulation, **270**
- Fetal death  
 parvovirus, 160
- Fetal development, **580**
- Fetal distress  
 placental abruption, 606  
 vasa previa, 607
- Fetal erythropoiesis, **389**
- Fetal hemorrhage, 582
- Fetal hypothyroidism, 328
- Fetal lung maturity, 627
- Fetal-postnatal derivatives, **270**
- Fetal respiration, 626
- Fetal tissue  
 collagen in, 46
- Fetor hepaticus, 372
- Fever  
 amphotericin B, 195  
 bacterial endocarditis, 299  
 childhood rashes, **179**  
 clindamycin, 188  
 complicated hernias, 355  
 endotoxins, 127  
 epiglottitis, 182  
 exotoxins, 129  
 following MI, 652  
 genital herpes, 180  
 high, 161, 164, 167, 179  
 Jarisch-Herxheimer reaction,  
 143  
 Legionnaires' disease, 139  
 low-grade, 139, 167, 407  
 malaria, 153  
 mononucleosis, 161  
*Pseudomonas aeruginosa*, 139  
 pulmonary anthrax, 133  
 recurring, 152  
*Rickettsia rickettsii*, 145  
*Salmonella* spp, 144  
*Salmonella typhi*, 141  
 seizures with, 161  
 Tetralogy of Fallot, 288  
 thyroid storm causing, 329  
 toxic shock syndrome, 131  
*Trichinella spiralis*, 155  
 tuberculosis, 136  
 vasculitides, 302  
 Waterhouse-Friderichsen  
 syndrome, 138  
 Weil disease, 142
- Fexofenadine, 648
- FGF. *See* Fibroblast growth factor
- FGF gene, 580
- Fibrates, 306  
 hepatitis and, 240  
 myopathy and, 241
- Fibrinogen  
 acute-phase reactant, 102  
 in cryoprecipitate, 407  
 ESR and, 212  
 platelet plug formation, 393  
 receptor for, 386  
 thrombocytes, 386  
 thrombogenesis, 393
- Fibrinoid necrosis, 205
- Fibrinolysis, 392
- Fibrinolytic system, 391
- Fibrinous pericarditis, 294
- Fibroadenomas, 614, 615
- Fibroblast growth factor (FGF)  
 signaling pathways for, 322  
 in wound healing, 211
- Fibroblast growth factor receptor  
 (FGFR3), 435
- Fibroblasts  
 cortisol and, 319  
 Graves disease, 329  
 in wound healing, 211
- Fibrocystic breast disease, 615
- Fibroid tumors, 612  
 leuprolide for, 621
- Fibromas, 610  
 nomenclature for, 216
- Fibromuscular dysplasia, 290
- Fibromyalgia, 444
- Fibronectin  
 cryoprecipitate, 407  
 thrombocytes, 386
- Fibrosarcomas, 216
- Fibrosis  
 diffusion-limited gas exchange, 633  
 silicosis, 641
- Fibrous plaque in atherosclerosis, 292
- Fick principle, 272
- Fidaxomicin, 134
- Fifth disease  
 B19 virus, 160  
 rash, 179  
 50S inhibitors, 187
- Filgrastim, 117
- Filoviruses  
 characteristics of, 163  
 Ebola, 167  
 negative-stranded, 164
- Filtration, **553**
- Filtration fraction, 670
- glomerular dynamics, 553
- Fimbria, 120, 592
- Financial considerations in  
 treatment, 257
- Finasteride, 623  
 reproductive hormones  
 and, 620
- Fingernails  
 glomus tumors under, 450
- First-order elimination, 226
- Fishbone diagram, 262
- Fishy smell, 144
- Fitz-Hugh-Curtis syndrome, 138, 181
- 5-aminosalicylic drugs, 365, 382
- 5 $\alpha$ -reductase  
 inhibitors for BPH, 619  
 deficiency, 589, 604  
 testosterone conversion, 600
- 5 $\alpha$ -reductase inhibitors  
 benign prostatic hyperplasia, 661
- 5-fluorouracil, 417  
 in cell cycle, 416  
 photosensitivity, 241  
 pyrimidine synthesis, 33  
 targets of, 416  
 toxicities of, 422
- 5-HT  
 MAO inhibitor effect on, 546  
 mechanism of, 544  
 opioid effects, 520  
 serotonin syndrome, 545  
 tramadol effect, 521  
 trazodone effects, 546
- 5-HT<sub>1B/1D</sub> agonists  
 naming convention for, 244
- 5-HT agonists, 516
- 5-hydroxyindoleacetic acid (5-HIAA)  
 in carcinoid syndrome, 338  
 neuroendocrine tumors, 325
- Fixation, 525
- Fixed splitting, 277
- Flaccid paralysis  
 botulinum toxin, 128, 134  
 LMN lesion, 501  
 motor neuron signs, 499
- Flagellin, 95
- Flagellum, 120
- Flash cards for USMLE Step 1  
 exam, 13
- Flat affect, 468
- Flat facies, 59
- Flavin nucleotides, 71
- Flaviviruses, 159, 163
- Fleas (disease vectors), 144, 145
- Flecainide, 308
- Flexor digiti minimi muscle, 429
- Flexor pollicis brevis muscle, 429
- Flies (disease vectors), 141, 155
- Floppy baby syndrome  
 botulinum toxin as cause, 128
- Clostridium botulinum* as  
 cause, 134  
 spinal cord lesions, 500
- Flow cytometry, **50**
- Flow volume loops, **637**
- Fluconazole  
*Candida albicans*, 661  
 mechanism and use, 195  
 mechanism (diagram), 194  
 opportunistic fungal infections, **149**  
 systemic mycoses, 147
- Flucytosine, **195**
- Hydrocortisone, **342**. *See*  
*also* Glucocorticoids

- Fluid compartments, **551**
- Flumazenil  
benzodiazepine overdose, 239, 515, 540  
diazepam and, 228  
nonbenzodiazepine hypnotics, 515
- Fluorescence in situ hybridization, **51**
- Fluorescent antibody stain, 122
- Fluoroquinolones, 35  
mechanism and use, **191**  
mechanism (diagram), 183  
*Mycoplasma pneumoniae*, 146  
pregnancy contraindication, 201  
*Pseudomonas aeruginosa*, 139  
tendon/cartilage damage with, 241  
typhoid fever, 141
- Fluoxetine, 545
- Fluphenazine, 543  
Tourette syndrome, 527, 542
- Flutamide, 623  
reproductive hormones and, 620
- Fluticasone, 649
- FMR1* gene, 58
- Foam cells  
in atherosclerosis, 292  
Niemann-Pick disease, 84
- Focal glomerular disorders, 563
- Focal hepatic necrosis, 240
- Focal necrotizing vasculitis, 302
- Focal neurological deficits  
hyperosmolar hyperglycemia nonketotic syndrome as cause, 338  
pituitary apoplexy, 335
- Focal neurological deficits  
pituitary adenoma, 332
- Focal segmental glomerulosclerosis, 566
- Focal seizures, 487
- Folate antagonists, 582
- Folate synthesis  
inhibition/block, 183, 190
- Folic acid  
antimicrobials and, 183  
neural tube defects and, 461  
in pregnancy, 64
- Follicles (lymph), 92
- Follicle-stimulating hormone (FSH)  
clomiphene effect, 621  
cryptorchidism, 617  
hCG and, 598, 618  
Kallmann syndrome, 604  
Klinefelter syndrome, 603  
leuprolide, 621  
menopause, 600  
ovulation/spermatogenesis and, 316  
PCOS, 609  
pharmacologic control of, 620  
premature ovarian failure, 609  
progesterone and, 595  
secretion of, 313  
signaling pathways of, 322  
spermatogenesis, 594  
Turner syndrome, 603
- Follicular conjunctivitis, 146
- Follicular cysts, 610
- Follicular lumen, 321
- Follicular lymphoma, 412
- Follicular lymphomas, 204, 408, 668  
chromosomal translocations and, 412
- Follicular phase, 597
- Follicular phase of menstrual cycle, 597
- Follicular thyroid carcinomas, 330
- Fomepizole  
ethanol metabolism and, 68  
toxicity treatment with, 239
- Fondaparinux, 391
- Food allergies and eczema, 449
- Food poisoning  
*Bacillus cereus*, 134  
causes of, 127, 174  
*Staphylococcus aureus*, 131  
toxic shock syndrome toxin, 129
- Food toxins, **238**
- Foot drop  
lead poisoning, 397
- Foramen cecum, 312
- Foramen magnum, 476
- Foramen of Magendie, 474
- Foramen of Monroe, 474
- Foramen ovale  
atrial septal defect, 289  
embryology, 268  
fetal circulation, 270  
retained patency of, 288
- Foramen ovale (skull), 476
- Foramen primum, 268
- Foramen rotundum, 476
- Foramen secundum, 268
- Foramen spinosum, 476
- Foramina of Luschka, 474
- Forebrain, 460
- Foregut  
blood supply/innervation of, 348  
development of, 344
- Formoterol, 649
- Fornix, 468
- Fornix (uterus), 592
- 46,XX/46,XY DSD, 604
- Fosamprenavir  
HIV-positive adults, 199  
mechanism (diagram), 197
- Foscarnet, **198**
- Fosphenytoin, 514
- Fossa ovalis, 270
- Fovea, 504  
cherry-red spot, 507
- FOXP3 protein, 98
- Fragile X syndrome, **58**  
chromosome association, 60  
dominant, inheritance of, 55
- Frameshift mutations, **36**  
muscular dystrophy and, 57
- Francisella* spp  
intracellular organism, 124  
taxonomy, 121
- Francisella tularensis*  
animal transmission, 144  
Gram-negative algorithm, 137
- Frataxin, 501
- Free fatty acids  
diabetic ketoacidosis and, 337  
fast/starvation states, 87  
lipid transport and, 88
- Free nerve endings, 464
- Free radical injury, 207, **210**
- Fresh frozen plasma, 407  
warfarin reversal, 664  
for warfarin toxicity, 239
- “Fried egg” cells, 611
- Friedreich ataxia, **501**  
chromosome association, 60  
hypertrophic cardiomyopathy, 297
- Frontal eye fields  
cortical functions, 471  
lesions in, 481
- Frontal lobe  
lesions in, 481  
stroke effects, 484
- Frontotemporal dementia, 490, 492
- Fructokinase, 76
- Fructose-1,6-bisphosphatase, 69  
gluconeogenesis, 74  
in metabolic pathways, 70
- Fructose-2,6-bisphosphate, **72**
- Fructose intolerance, 76
- Fructose metabolism  
disorders, 76  
pathways, 70
- Fructosuria, 76
- FSH. *See* Follicle-stimulating hormone
- FTA-ABS test, 143
- Fumarate, 78
- Functional residual capacity (FRC), 630  
chest wall and, 631  
in flow volume loops, 637
- Fundus, 592
- Fungal infections  
IL-12 receptor deficiency, 112  
thymic aplasia, 112
- Fungi  
culture requirements, 123  
immunocompromised patients, 175  
necrosis and, 205  
opportunistic infections, 149  
silver stain, 122  
topical infections, 195
- Funny current, 281, 310
- Furosemide, 243, **575**  
gout with, 241  
interstitial nephritis, 242  
pancreatitis, 240
- Fusion inhibitors, 199
- Fusobacterium* spp  
alcoholism, 175  
anaerobic metabolism, 123  
lung abscesses, 646
- G**
- G6PD  
deficiency, 56, **75**  
HMP shunt and, 69  
in respiratory burst, 105
- G6PD deficiency, 400  
in anemia taxonomy, 396  
degmocytes in, 394  
Heinz bodies in, 395
- GABA, 465  
barbiturate effects, 515  
basal ganglia and, 470  
benzodiazepine effect, 515  
changes with disease, 465  
derivation of, 79  
epilepsy drugs, 514  
Huntington disease, 490  
vitamin B<sub>6</sub> and, 63
- GABA channels, 196
- Gabapentin, 514
- GABA<sub>B</sub> receptor agonists, 493
- gag* gene, 171
- Gag reflex, 477
- Gait disturbance  
muscular dystrophy, 57
- Gait disturbances  
Parkinson disease, 655
- Galactocerebrosidase, 84  
Krabbe disease, 494
- Galactocerebroside, 84
- Galactokinase, 70
- Galactokinase deficiency, 76  
cataracts and, 505
- Galactorrhea  
antipsychotic drugs and, 315  
pituitary prolactinomas, 315  
tuberoinfundibular pathway, 468
- Galactose-1-phosphate, 70
- Galactose-1-phosphate uridylyltransferase, 76
- Galactose metabolism  
diagram, 70  
disorders of, **76**
- Galactosemia, 76  
cataracts and, 505
- Galantamine  
for Alzheimer disease, 518
- Galant reflex, 480
- Gallbladder  
biliary structures, 353  
blood supply and innervation of, 348  
regulatory substances, 356
- Gallbladder cancer  
porcelain gallbladder and, 379  
sclerosing cholangitis and, 378
- Gallstone ileus, 379
- Gallstones. *See* Cholelithiasis
- $\gamma$ -glutamyltransferase (GGT)  
alcohol use, 540
- $\gamma$ -glutamyl transpeptidase (GGT), 373
- $\gamma$ -interferon, 387
- Ganciclovir, **198**  
agranulocytosis, 241
- Ganglioneuromatosis, 656
- Gangrene  
Buerger disease, 302  
diabetes mellitus, 336
- Gangrenous necrosis, 205
- Gap junctions, 447
- Gardener’s pupil, 233
- Gardnerella* spp, 121

- Gardnerella vaginalis*, **144**  
labs/findings, 660
- Gardner syndrome, 370
- Gargoylism, 84
- Garlic breath, 72
- Gas gangrene  
alpha toxin, 129  
*Clostridium perfringens*,  
127, 134, 175
- Gastrectomy, 398
- Gastric acid, **357**  
histamine receptors and, 230  
regulatory substances and, 356
- Gastric adenocarcinomas  
acanthosis nigricans and, 453  
*Helicobacter pylori*, 142
- Gastric arteries  
celiac trunk, 349  
intrahepatic, 346
- Gastric bypass surgery  
ghrelin and, 356  
vitamin B<sub>12</sub> deficiency, 65
- Gastric cancer, **362**  
carcinogens causing, 219  
metastases of, 221  
oncogenes and, 218  
oncogenic microbes and, 219  
sign of Leser-Trélat and, 217  
trastuzumab for, 421
- Gastric obstruction, 363
- Gastric sclerosis, 446
- Gastric ulcers, 363  
NSAID toxicity, 456
- Gastric vessels, 346
- Gastrin, 356, 357  
signaling pathways for, 322  
somatostatinomas and, 338
- Gastrinomas, 342
- Gastritis, **362**  
associations, 664  
gastrin in, 356  
H<sub>2</sub> blockers for, 381  
*Helicobacter pylori*, 142  
proton pump inhibitors for, 381  
stomach cancer and, 362
- Gastrocolic ligament, 346
- Gastrooduodenal artery, 349
- Gastroenteritis  
caliciviruses, 163  
*Listeria monocytogenes*, 135  
rotavirus, 164  
*Salmonella* spp, 141
- Gastroepiploic arteries, 346, 349
- Gastroesophageal reflux disease  
esophageal cancer and, 361  
presentation, 360
- Gastrohepatic ligament, 346
- Gastrointestinal bleeding  
hereditary hemorrhagic  
telangiectasia, 303  
iron poisoning, 404  
Osler-Weber-Rendu syndrome,  
656
- Gastrointestinal drug reactions, **240**
- Gastrointestinal ligaments, **346**
- Gastrointestinal stromal tumors  
(GISTs), 218
- Gastrointestinal system, **344–383**  
anatomy, 345–354  
blood supply to, **348**  
embryology, 344–345  
innervation of, **348**  
pathology, 359–380  
pharmacology, 381–383  
physiology, 356–360  
regulatory substances, **356**  
secretory products, **357**
- Gastroschisis, 344
- Gastrosplenic ligament, 346
- Gaucher disease, 84  
osteonecrosis, 436
- Gaussian distribution, 251
- G-CSF. *See* Granulocyte-colony  
stimulating factor (G-CSF)
- Gel electrophoresis, 48
- Gemfibrozil, 306
- Gemifloxacin, 191
- Gender dysphoria, **537**
- Gender identity, 258
- Gene expression  
modifications, **52**  
regulation, **38**
- Gene inheritance modes, 55
- General anesthetic, 244
- Generalized anxiety disorder  
(GAD), 532, **533**  
buspirone, 544  
drug therapy for, 542  
Selective serotonin reuptake  
inhibitors (SSRIs) for, 545  
serotonin-norepinephrine  
reuptake inhibitors (SNRIs)  
for, 545
- Generalized seizures, 487
- Genetics, **52–61**  
22q11 deletion syndromes, 61  
autosomal dominant diseases, 56  
autosomal recessive diseases, 56  
autosomal trisomies, 59  
bacterial, **126, 127**  
chromosome disorders, 60  
code features, **34**  
genetic terms, 52–53  
inheritance modes, 55  
muscular dystrophies, 57  
trinucleotide repeat expansion  
diseases, 58  
viral, **158–159**  
X-linked recessive disorders, 56
- Genetic shift/drift, 165
- Genital herpes, 180
- Genitalia  
ambiguous, 589, 603, 604  
embryology of, **589**  
estrogen and, 595  
male/female homologs, **590**
- Genital tubercles, 590
- Genital ulcers, 180
- Genital warts, 180
- Genitofemoral nerve, 430
- Genitourinary drug reactions, **242**
- Genotyping microarrays, 50
- Gentamicin, 183, 187  
endometritis, 612
- Geriatric patients  
amyloidosis in, 213  
atropine in, 233  
Beers criteria in, 238  
changes in, **259**  
colonic ischemia and, 369  
common cause of death, 260  
drug metabolism in, 226  
lipofuscin in, 213  
Medicare for, 260  
nosocomial infections, 181  
osteoporosis, 435  
vascular skin tumors, 450  
volvulus in, 368  
Zenker diverticulum in, 367
- Germinal centers of lymph nodes, 92
- Germinal center (spleen), 94
- Gerstmann syndrome, 481
- Gestational age calculation, 598
- Gestational diabetes mellitus  
(GDM), 340
- Gestational hypertension, 608
- GFAP (glial fibrillary acid  
proteins), 44  
astrocyte marker, 463
- GH. *See* Growth hormone (GH)
- Ghon complex  
tuberculosis, 136
- Ghon focus, 136
- Ghrelin, 317, 356  
hunger and, 466
- GHRH. *See* Growth-hormone-  
releasing hormone
- Giant cell arteritis, **302**
- Giant cell pneumonia, 166
- Giant cells  
in chronic inflammation, 207
- Giant cell tumors, 438
- Giant cell tumors of bone, 660
- Giardia* spp  
watery diarrhea, 175
- Giardia lamblia*, **151**
- Giardiasis, 151
- Giemsa stain, 122  
*Borrelia*, 142  
chlamydiae, 146
- Gigantism, 317, 333
- Gilbert syndrome, 376, 377
- Gingival blue line, 652
- Gingival hyperplasia  
calcium channel blockers, 304  
cyclosporine, 116  
as drug reaction, 241  
epilepsy drugs and, 514
- Gingivostomatitis, 160
- Gitelman syndrome, **556**  
markers in, 560
- Glans penis, 593  
cancer of, 617  
lymphatic drainage of, 591
- Glanzmann thrombasthenia,  
393, 405
- Glargine insulin, 340. *See also*  
Insulin
- Glaucoma, **506**  
acetazolamide for, 575  
atropine, 233
- $\beta$ -blockers for, 237  
carbachol for, 232  
diabetes mellitus and, 336  
diagnosing, 232  
drug therapy for, **521**  
epinephrine for, 234  
pilocarpine for, 232  
Sturge-Weber syndrome, 495
- Glimepiride, 340
- Glioblastoma multiforme, 496  
associations, 664  
labs/findings, 660  
nitrosoureas for, 418
- Glioblastomas, 44
- Glipizide, 340
- Glitazones, 340
- Global aphasia, 486
- Global payment, 260
- Globoid cells  
Krabbe disease, 84, 494
- Globose nucleus, 469
- Globus pallidus externus, 470
- Glomerular diseases  
nomenclature, **563**
- Glomerular filtration barrier, **551**
- Glomerular filtration rate,  
**552, 670**  
ACE inhibitor effects, 577  
ANP effect on, 559  
glomerular dynamics in, 553  
juxtaglomerular apparatus, 558  
prerenal azotemia, 571
- Glomerulonephritis  
Alport syndrome, 565  
azathioprine for, 116  
bacterial endocarditis, 299  
intrinsic renal failure, 571  
labs/findings, 657, 660, 661  
pharyngitis, 132  
RBC casts in, 562  
*Streptococcus pyogenes*,  
129, 132  
Wegener granulomatosis, 302
- Glomerulus  
anatomy of, 550  
dynamics of, **553**
- Glomus tumors, 450
- Glossitis  
B-complex deficiency, 61  
megaloblastic anemia, 398  
Plummer-Vinson syndrome,  
360  
vitamin B<sub>3</sub> deficiency, 63  
vitamin B<sub>9</sub> deficiency, 64
- Glossopharyngeal nerve  
blood flow regulation, 285
- Glossopharyngeal nerve (CN IX),  
**476**  
brain stem location, 474  
branchial arch derivative, 587  
pathway for, 476  
tongue, 463
- Glossoptosis, 587
- GLP-1 analogs, 341
- Glucagon, **315**  
for  $\beta$ -blocker toxicity, 239, 309  
DPP-4 inhibitor effect on, 341

- fructose biphosphatase-2, 72  
 GLP-1 analog effect on, 341  
 glucagonomas and, 338  
 glycogen regulation, **81**  
 insulin and, 314, 315  
 production of, 313  
 signaling pathways of, 322  
 somatostatin and, 356  
 somatostatinomas and, 338
- Glucagon-like peptide 1 (GLP-1), 314
- Glucagonomas, **338**  
 MEN 1 syndrome, 339  
 somatostatin for, 342
- Glucocerebrosidase  
 Gaucher disease, 84
- Glucocerebroside, 84
- Glucocorticoids  
 acute gout attack, 661  
 adrenal insufficiency, 324  
 adrenal steroids and, 318  
 arachidonic acid pathway, 455  
 calcium pyrophosphate deposition disease, 440  
 Cushing syndrome diagnosis, 323  
 diabetes mellitus, 336  
 fat redistribution with, 241  
 gout, 440, 457  
 myopathy, 241  
 rheumatoid arthritis, 439  
 thyroid hormones and, 321
- Glucokinase  
 hexokinase vs, **71**  
 metabolic pathways, 70
- Gluconeogenesis, **74**  
 cortisol and, 319  
 diagram, 70  
 ethanol metabolism and, 68  
 in insulin deficiency, 336  
 metabolic site, 68  
 metformin effect on, 340  
 pyruvate metabolism and, 73  
 rate-determining enzyme for, 69  
 thyroid hormones and, 321
- Glucose  
 ATP production, 71  
 blood-brain barrier and, 466  
 clearance, **554**  
 diabetic ketoacidosis, 337  
 GH secretion and, 317  
 glycogen metabolism, 82  
 insulin and, 314  
 metabolism of, 36  
*Neisseria* fermentation, 138  
 for porphyria, 403  
 transporters, 314
- Glucose-6-phosphatase  
 gluconeogenesis, 74  
 HMP shunt, 75  
 Von Gierke disease, 83
- Glucose-dependent insulintropic peptide (GIP), **356**
- Glucosuria  
 glucose clearance, 554  
 in pregnancy, 554  
 SGLT-2 inhibitors, 341
- Glulisine insulin, 340. *See also* Insulin
- Glutamate  
 ammonia transport, 78  
 derivatives of, 79  
 opioid effects, 520
- Glutamic acid, 77
- Glutamic acid decarboxylase (GAD-65)  
 autoantibodies, 111
- Glutathione, 79  
 acetaminophen and, 455  
 in G6PD deficiency, 400
- Glutathione peroxidase, 105  
 free radical elimination by, 210
- Glutathione reductase, 105  
 NADPH and, 71
- Gluteus maximus muscle, 431
- Gluteus minimus muscle, 431
- GLUT transporters, 314
- Glyburide, 340
- Glyceraldehyde, 76
- Glycerol, 76
- Glycine  
 derivatives of, 79
- Glycocalyx, 120
- Glycogen, **82**  
 insulin and, 314  
 periodic acid-Schiff stain, 122  
 regulation of, **81**
- Glycogenesis  
 diagram, 70  
 rate-determining enzyme for, 69
- Glycogenolysis  
 diagram, 70  
 in insulin deficiency, 336  
 rate-determining enzyme for, 69  
 thyroid hormones and, 321
- Glycogen phosphorylase  
 glycogen metabolism, 82  
 glycogenolysis, 69
- Glycogen phosphorylase kinase, 81
- Glycogen storage diseases, **83**  
 Fanconi syndrome, 556
- Glycogen synthase, 69  
 glycogen metabolism, 82  
 glycogen regulation, 81
- Glycolysis  
 arsenic and, 71  
 diagram, 70  
 hexokinase/glucokinase in, 71  
 metabolic site, 68  
 metformin effect on, 340  
 pyruvate metabolism and, 73  
 rate-determining enzyme for, 69  
 regulation of, **72**  
 type 2 muscle fibers, 433
- Glycopeptides  
 mechanism (diagram), 183
- Glycoprotein IIb/IIa inhibitors, **415**
- Glycoproteins  
 bacterial pilus/fimbria, 120  
 HIV, 171  
 interferons, 200
- Glycopyrrolate, 233
- Glycosylation, 41
- Glycyrrhetic acid, 556
- GNAQ gene, 495
- GnRH. *See* Gonadotropin-releasing hormone (GnRH)
- Goblet cells, 347, 628
- Goiter, **327**  
 maternal hypothyroidism from, 328  
 maternal iodine deficiency, 582  
 in Riedel thyroiditis, 328
- Golfer's elbow, 426
- Golgi apparatus, 43  
 in plasma cells, 389
- Gonadal drainage, **591**
- Gonadal mosaicism, 53
- Gonadotropin, 610
- Gonadotropin-releasing hormone  
 agonists, 612, 613, 620  
 antagonists, 620  
 estrogen and, 595  
 hypothalamic-pituitary hormones, 315  
 Kallmann syndrome, 604  
 menopause, 600  
 menstrual cycle, 597  
 ovulation, 596  
 prolactin and, 316  
 signaling pathways for, 322  
 spermatogenesis, 594
- Gonoccal arthritis, 441
- Gonococci, vs meningococci, 138
- Gonorrhea  
 ceftriaxone, 185  
 gonococci, 138  
 prophylaxis, 194  
 STI, 180
- Goodpasture syndrome, 46, 564  
 autoantibody with, 111  
 HLA-DR2, 96  
 labs/findings, 657  
 restrictive lung disease, 639  
 type II hypersensitivity reactions, 108
- Good syndrome, 217
- Gottron papules, 445
- Gout, **440**  
 as drug reaction, 241  
 drug therapy for, **457**  
 kidney stones and, 567  
 lab findings, 659, 660  
 Lesch-Nyhan syndrome, 34  
 loop diuretics and, 575  
 presentation, 656  
 treatment, 661  
 Von Gierke disease, 83
- Gower maneuver/sign, 57
- Gp41, 199
- G-protein-linked 2nd messengers, **230**
- Grafts, **114**  
 Graft-versus-host disease, 115  
 type IV hypersensitivity, 109
- Gram-negative organisms  
 cell wall structure, 120  
 cephalosporins, 185  
 examples of, 121  
 lab algorithm, **137**
- Gram-positive cocci antibiotic tests, **130**
- Gram-positive organisms  
 cell wall structure, 120  
 cephalosporins, 185  
 examples, 121  
 lab algorithm, **130**  
 vancomycin, 186
- Gram stain identification, **122**
- Granular casts, 562  
 acute tubular necrosis, 572
- Granulocyte-colony stimulating factor (G-CSF), 322
- Granulocytes, 386  
 morulae, 145
- Granulocytopenia  
 trimethoprim, 190
- Granuloma inguinale, 180
- Granulomas, 207  
 macrophages and, 387  
 TNF- $\alpha$  and, 107
- Granulomatosis infantiseptica  
 as granulomatous disease, 211  
*Listeria monocytogenes*, 135
- Granulomatous disease, **211**  
 Hansen disease, 211  
 histoplasmosis, 211  
 hypervitaminosis D with, 437  
 vitamin D toxicity in, 66
- Granulosa cells, 595  
 tumors of, 611, 612
- Granzyme B  
 cytotoxic T cells, 97, 98  
 extrinsic pathway and, 204
- Grapefruit juice and cytochrome P-450, 243
- Graves disease  
 autoantibody with, 111  
 goiter caused by, 327  
 HLA-DR3 and, 96  
 hyperthyroidism, 329  
 type II hypersensitivity, 108
- Gray baby syndrome  
 chloramphenicol, 188, 201  
 chloramphenicol and, 241
- Great cerebral vein of Galen, 473
- Greater sac, 346
- Greenstick fracture, 424
- Grief, 532
- Criseofulvin, **196**  
 cytochrome P-450 interaction, 243  
 microtubules and, 44  
 pregnancy contraindication, 201
- Ground-glass appearance (X-ray), 173, 627
- Growth hormone (GH), **317, 342**  
 diabetes mellitus, 336  
 ghrelin and, 317  
 for hypopituitarism, 335  
 insulin resistance and, 314, 317  
 Laron syndrome, 333  
 secretion of, 313  
 signaling pathways for, 322  
 somatostatin, 333  
 thyroid hormones and, 321
- Growth hormone (GH) deficiency, 342

- Growth-hormone-releasing hormone  
GH and, 317  
hypothalamo-pituitary  
hormones, 315  
signaling pathways of, 322
- Growth media properties, **122**
- Growth signal in cancer, 215
- GTPase, 218
- GTP (guanosine triphosphate), 73  
smooth muscle contraction, 434
- Guaifenesin, 648
- Guanfacine, 235
- Guanine synthesis, 200
- Guanosine analogs  
mechanism and use, **197**
- Gubernaculum, 589, 591, 592
- Guessing during USMLE Step 1  
exam, 21
- Guillain-Barré syndrome, 493  
*Campylobacter jejuni*, 140  
endoneurium in, 465  
presentation, 655  
restrictive lung disease, 639  
Schwann cells in, 464
- Gummas  
syphilis, 143, 180
- Gustatory hallucinations, 529
- Guyon canal syndrome, **426**
- Gynecologic tumor  
epidemiology, **608**
- Gynecomastia, **615**  
antiandrogens for, 623  
azoles, 195  
choriocarcinomas, 618  
cimetidine, 381  
cirrhosis, 372  
Klinefelter syndrome, 603  
Leydig cells, 619  
potassium-sparing diuretics, 576  
SHBG and, 322  
spironolactone, 623  
tuberoinfundibular pathway, 468
- Gyrase, 183
- H**
- H<sub>1</sub> blockers, 242, **648**
- H<sub>2</sub> blockers, **381**
- Haemophilus* spp  
endocarditis, 299  
taxonomy, 121
- Haemophilus ducreyi*  
sexual transmission, 180
- Haemophilus influenzae*, **138**  
biofilm production, 125  
cephalosporins, 185  
chloramphenicol, 188  
culture requirements, 123  
Gram-negative algorithm, 137  
influenza, 165  
penicillins for, 184  
pneumonia, 175  
postviral infection, 175  
rhinosinusitis, 636  
vaccine, 176
- Haemophilus influenzae* type B  
chloramphenicol, 188  
encapsulation, 124  
IgA protease, 125
- immunodeficient patients, 114
- meningitis, 176
- rifamycins, 192
- splenic dysfunction, 94
- transformation, 126
- unvaccinated children, 182
- vaccine, 138
- Hair  
Menkes disease, 47  
vitamin C deficiency, 65
- Hairy cell leukemia, 410  
cladribine for, 417  
IFN- $\alpha$  for, 200
- Hairy leukoplakia, 451  
HIV-positive adults, 173
- Half-life equation, 225, 669
- Halitosis  
Zenker diverticulum, 367
- Hallucinations, **529**  
cocaine, 540  
delirium, 528  
memantine, 518  
mesolimbic pathway, 468  
pellagra, 63  
postpartum psychosis, 532  
schizophrenia, 530  
tricyclic antidepressants, 545
- Hallucinogen intoxication and  
withdrawal, 541
- Haloperidol, 543  
delirium, 528  
for Huntington disease, 518  
torsades de pointes, 239
- Halothane, 519  
hepatic necrosis, 240
- Hamartin protein, 218
- Hamartomas, 216  
tuberous sclerosis, 495
- Hamartomatous colonic polyps,  
370
- Hamate bone, 426
- Hammer toes, 501
- Hand  
distortions of, **429**  
gonococcal arthritis triad, 441  
"mechanic's hand," 445  
muscles of, **429**  
squamous cell carcinoma, 454
- Hand-foot-mouth disease, 179
- Hand grip in auscultation, 278
- Hand tremors, 327
- Hand-wringing, 527
- Hansen disease, **137**  
animal transmission, 144  
dapson, 190  
erythema nodosum, 453  
as granulomatous disease, 211
- Hantavirus, 163
- Happy puppet symptoms, 54
- Haptens  
acute interstitial nephritis, 572  
amiodarone as, 309
- Haptoglobin, 399
- Hardy-Weinberg equilibrium, 669
- Hardy-Weinberg population  
genetics, **53**
- Hartnup disease, **63**  
vitamin B<sub>3</sub> deficiency, 63
- Hashimoto thyroiditis, 328  
autoantibody with, 111  
cholangitis association with, 378  
goiter causes, 327  
HLA subtypes with, 96  
lymphoma association, 330
- Hassall corpuscles, 94
- Hay fever  
HLA-DR2 and, 96  
type I hypersensitivity, 108
- HbA<sub>1c</sub> test, 336
- HBcAg (hepatitis B core antigen), 170
- HbC disease, 400  
anemia taxonomy, 396  
target cells in, 395
- HBeAg (hepatitis B extracellular  
antigen), 170
- HbH disease, 396
- HBsAg (hepatitis B surface  
antigen), 170
- hCG. *See* Human chorionic  
gonadotropin (hCG)
- HCTZ. *See* Hydrochlorothiazide  
(HCTZ)
- HDL (high-density lipoprotein), 89
- Headaches, **488**  
 $\alpha$ -blockers, 236  
bupropion toxicity, 546  
caffeine withdrawal, 540  
Chiari I malformation, 462  
cimetidine, 381  
drug adverse effects,  
191, 195, 196, 200  
electroconvulsive therapy, 532  
ethosuxamide, 514  
genital herpes, 180  
hydralazine, 304  
hypersensitivity pneumonitis, 639  
malaria, 153  
*Mucor* spp and *Rhizopus* spp, 149  
*Mycoplasma pneumoniae*, 146  
nitrates, 305  
nonbenzodiazepine hypnotics, 515  
ondansetron, 383  
PDE-5 inhibitors, 623  
pituitary adenomas and, 332  
pituitary apoplexy, 335  
pseudotumor cerebri, 491  
ranolazine, 305  
Rocky Mountain spotted fever, 145  
sodium-channel blockers, 308  
subarachnoid hemorrhage, 656  
triptans for, 516  
vasculitides, 302
- Head and neck cancer, **636**  
cetuximab for, 118, 420
- Head trauma, 528
- Healing, wound, **211**
- Healthcare delivery, **259–262**
- Healthcare proxy, 257
- Health Maintenance  
Organization, 259
- Healthy worker effect, 250
- Hearing loss, **503**  
cytomegalovirus, 178  
osteogenesis imperfecta, 47  
Paget disease of bone, 436
- Heart  
autonomic nervous system, 229  
autoregulation of, 286  
electrocardiograms, **282**  
embryology, **268**  
fetal development, 580  
ischemia in, 206  
morphogenesis of, **268–269**  
normal pressures in, **286**  
sclerosis of, 446
- Heart auscultation, **278**
- Heart block, 271
- Heartburn, 360
- Heart disease  
common cause of death, 260  
congenital, 59, **288–289**  
Fabry disease, 84  
ischemic, 293  
QT prolongation, 72
- Heart failure, **298**  
ACE inhibitors for, 577  
acromegaly, 333  
acute tubular necrosis with, 572  
amiodarone, 309  
angiotensin II receptor  
blockers, 577  
aortic regurgitation as  
precursor, 279  
associations, 668  
atrial septal defect, 289  
 $\beta$ -blockers, 309  
 $\beta$ -blockers for, 237  
B-type natriuretic peptide in, 285  
calcium channel blockers, 310  
cardiac glycosides for, 307  
chronic ischemic heart disease, 293  
contractility in, 273  
diabetic ketoacidosis, 337  
disopyramide, 308  
dobutamine for, 234  
dopamine for, 234  
Ebstein anomaly, 288  
ejection fraction in, 273  
ESR in, 212  
fludrocortisone and, 342  
glitazone/thiazolidinediones, 340  
hydralazine for, 304  
hypertension, 290  
hypertension treatment in, 304  
hypertensive emergency and, 290  
jugular venous pulse in, 276  
loop diuretics for, 575  
MI, 294  
pleural effusion, 644  
potassium-sparing diuretics, 576  
pulse pressure in, 272  
readmissions with, 261  
renal failure causing, 571  
shock caused by, 299  
sleep apnea causing, 642  
systolic vs diastolic, 273  
thiazides for, 576  
ventricular septal defect, 289
- Heart murmurs, **279**  
aortic regurgitation, 652  
aortic stenosis, 656  
auscultation of, 278

- bacterial endocarditis, 299  
 cardiomyopathies, 297  
 patent ductus arteriosus, 289
- Heart rate, 235
- Heart sounds, **276**  
 associations, 668  
 auscultation of, 278  
 cardiac cycle, 276  
 cardiac tamponade, 300, 654  
 splitting in, **277**
- Heart transplant  
 dilated cardiomyopathy, 297
- Heart valve development, 269
- Heat-labile toxin, 128
- Heat shock proteins, 41
- Heat-stable toxin, 128
- Heinz bodies, 75, 395, 400
- Helicase, **35**
- Helicobacter* spp, 121
- Helicobacter pylori*, **142**  
 associations, 664  
 catalase-positive organism, 124  
 disease associated with, 362  
 Gram-negative algorithm, 137  
 metronidazole, 191  
 as oncogenic microbe, 219  
 penicillins for, 184  
 silver stain, 122  
 urease-positive, 124  
 urease-positive organism, 124
- Heliotrope rash, 445
- HELLP syndrome, 608  
 schistocytes in, 395
- Helminthic infections  
 eosinophils and, 387
- Helminths  
 immune response to, 154
- Helper T cells, **98**  
 cell surface proteins, 106  
 cytokine secretion, 104  
 in granulomatous diseases, 211
- Hemagglutinin  
 influenza viruses, 165  
 parainfluenza viruses, 166
- Hemangioblastomas, 496  
 polycythemia and, 217  
 von Hippel-Lindau disease, 495, 655
- Hemangiomas, 216
- Hemarthroses, 404
- Hemarthrosis, 65
- Hematemesis, 360  
 Mallory-Weiss syndrome, 656
- Hematin, 123, 138
- Hematochezia  
 colorectal cancer, 371  
 diverticulosis, 366  
 intestinal disorders, 369  
 Meckel diverticulum, 585
- Hematocrit  
 high altitude and, 635  
 polycythemia vera, 411
- Hematologic drug reactions, 241
- Hematology/oncology, **386–423**  
 anatomy, 386–389  
 pathology, 394–414  
 pharmacology, 413–421  
 physiology, 389–393
- Hematopoiesis, 409
- Hematopoietic stem cells, 106
- Hematuria  
 bladder cancer, 569  
 Henoch-Schönlein purpura, 655  
 hereditary hemorrhagic  
 telangiectasia, 303
- IgA nephropathy, 564
- kidney stones, 567
- nephritic syndrome, 564
- Osler-Weber-Rendu syndrome, 656
- protease inhibitors, 199
- renal cell carcinoma, 568
- renal cyst disorders, 573
- renal oncocytomas, 568
- RPGN, 564
- Schistosoma haematobium*, 157
- UTIs, 177
- Wegener granulomatosis, 302
- Wilms tumor, 569
- Heme  
 bilirubin and, 359  
 chloroquine, 196  
 for porphyria, 403  
 sideroblastic anemia and, 397  
 synthesis of, **68, 403**  
 vitamin B<sub>6</sub> and, 63
- Hemianopia, 511
- Hemiballismus, 489  
 brain lesions and, 481
- Hemicholinium, 231
- Hemidesmosome, 447  
 autoantibody to, 111
- Hemihyperplasia, 569
- Hemiparesis, 493  
 saccular aneurysms, 486
- Hemispatial neglect syndrome, 481
- Hemochromatosis, **378**  
 calcium pyrophosphate deposition  
 disease, 440  
 cardiomyopathy from, 297  
 chromosome association, 60  
 free radical injury and, 210  
 hepatocellular carcinoma and,  
 375  
 HLA-A3 and, 96
- Hemoglobin, **631**  
 carbon dioxide transport, 635  
 development of, 389  
 kinetics of, 224  
 modifications of, **632**
- Hemoglobin electrophoresis, **391**
- Hemoglobinuria  
 acute tubular necrosis and, 572  
 G6PD deficiency, 400  
 intravascular hemolysis, 399
- Hemolysis  
 alpha toxin as cause, 129  
*Clostridium perfringens* as  
 cause, 134  
 HELLP syndrome, 608  
 sulfonamides as cause, 190
- Hemolysis in G6PD deficiency, 241
- Hemolytic anemia, 399  
 autoimmune, 108, 185  
 babesiosis, 153  
 cephalosporins, 185
- cold agglutinin disease, 655  
 direct Coombs-positive, 241  
 folate deficiency caused by, 398  
 G6PD deficiency, 75  
 in taxonomy, 396  
 penicillin G, V, 183  
 pyruvate kinase deficiency as  
 cause, 400  
 ribavirin, 200  
 spherocytes in, 395  
 sulfa drug allergies, 243  
 vitamin E deficiency, 66  
 Wilson disease, 378
- Hemolytic disease of the  
 newborn, 108
- Hemolytic reactions and blood  
 types, 390
- Hemolytic-uremic syndrome  
*Escherichia coli*, 140, 175  
 exotoxins, 128  
 platelet disorders, 405  
 schistocytes in, 395
- Hemophilia, 404  
 deficiencies causing, 391  
 X-linked recessive disorder, 56
- Hemoptysis  
*Aspergillus fumigatus*, 173  
 bronchiectases, 639  
 choriocarcinomas, 605  
 lung cancer, 647  
 tuberculosis, 136  
 Wegener granulomatosis, 302
- Hemorrhage  
 acute pancreatitis, 380  
 acute tubular necrosis, 572  
 AIDS retinitis, 161  
 baroreceptors and, 285  
 bevacizumab, 420  
 delirium caused by, 528  
 Ebola virus, 167  
 intracranial, **483**  
 pulmonary, 133  
 shock from, 299  
 subarachnoid hemorrhage,  
 483, 486  
 ulcers, 363  
 Weil disease, 142
- Hemorrhagic cystitis  
 adenoviridae, 160  
 cyclophosphamide, 418  
 drug reaction, 242
- Hemorrhagic fever  
 bunyavirus, 163  
 filovirus, 163
- Hemorrhagic infarcts, 207
- Hemorrhagic stroke, 483
- Hemorrhoids, 351
- Hemosiderinuria, 399
- Hemostasis, 386
- Henderson-Hasselbalch  
 equation, 561, 670
- Henoch-Schönlein purpura, **303**  
 IgA nephropathy, 564  
 presentation, 655
- Hepadnaviruses  
 characteristics of, 159, 160  
 genome, 158
- Heparin, **413**  
 acute coronary syndromes, 296  
 for anticoagulation, 391  
 in basophils, 387  
 in coagulation cascade, 392  
 deep venous thrombosis, 636  
 mast cells and, 387  
 osteoporosis, 241  
 thrombocytopenia, 241  
 toxicity treatment, 239  
 warfarin vs, **414**
- Heparin-induced thrombocytopenia  
 (HIT), 413
- Hepatic adenomas, 375
- Hepatic arteries, 349, 352
- Hepatic ascites, 576
- Hepatic cirrhosis, 644
- Hepatic ducts, 353
- Hepatic encephalopathy, **374**  
 cirrhosis, 372
- Hepatic necrosis, 455
- Hepatic steatosis, 374
- Hepatic TG lipase, 88
- Hepatitis  
 alcoholic, 374  
 alcoholism, 541  
 aplastic anemia and, 399  
 autoimmune, 111  
 cirrhosis, 372  
 as drug reaction, 240  
 heroin addiction and, 541  
 hyperbilirubinemia, 376  
 Wilson disease, 378
- Hepatitis A (HAV)  
 characteristics of, **168**  
 picornavirus, 163, 164  
 serologic markers, 170  
 vaccine for, 107, 158
- Hepatitis antigens, **170**
- Hepatitis B (HBV)  
 characteristics of, **168**  
 extrahepatic manifestations, 169  
 hepatocellular carcinomas  
 and, 375  
 IFN- $\alpha$ , 200  
 medical importance, 160  
 membranous nephropathy, 566  
 MPGN and, 565  
 nosocomial infection, 181  
 as oncogenic microbe, 219  
 passive antibodies for, 107  
 polyarteritis nodosa and, 302  
 recombinant cytokines for, 117  
 serologic markers, 170  
 sexually transmitted infection, 180  
 treatment, 661
- Hepatitis C (HCV)  
 antigenic variation, 106  
 characteristics of, **168**  
 extrahepatic manifestations, 169  
 flaviviruses, 163  
 hepatocellular carcinoma and, 375  
 lichen planus, 453  
 membranous nephropathy, 566  
 MPGN and, 565  
 as oncogenic microbe, 219  
 recombinant cytokines for, 117  
 therapy for, **200**



- Hepatitis D (HDV), **168**  
Hepatitis E (HEV), **168**  
  hepevirus, 163  
Hepatitis viruses, **168**  
  aplastic anemia, 399  
  serologic markers for, 170  
Hepatocellular carcinomas, **375**  
  *Aspergillus fumigatus*, 149  
  Budd-Chiari syndrome and, 375  
  carcinogens causing, 219  
  cirrhosis and, 372  
  hemochromatosis, 378  
  non-alcoholic fatty liver disease, 374  
  oncogenic microbes, 219  
  polycythemia and, 217  
Hepatocytes, 82  
Hepatoduodenal ligament, 346  
Hepatomas, **375**  
Hepatomegaly  
  amyloidosis and, 213  
  Budd-Chiari syndrome, 375, 652  
  galactosemia, 76  
  hepatocellular carcinoma, 375  
  peroxisomal disease, 43  
  pulmonary hypertension, 633  
  Reye syndrome, 373  
  right heart failure, 298  
  Von Gierke disease, 83  
Hepatosplenomegaly  
   $\beta$ -thalassemia and, 397  
  biliary tract disease, 378  
  graft-versus-host disease, 115  
  hyperchylomicronemia, 90  
  leishmaniasis, 154  
  lysosomal storage diseases, 84  
  mononucleosis, 161  
  ToRCHeS infections, 178  
Hepatotoxicity  
  amiodarone, 309  
  bosentan, 648  
  carbamazepine, 514  
  danazol, 622  
  glitazone/thiazolidinediones, 340  
  HMG-CoA reductase inhibitors, 306  
  inhaled anesthetics, 519  
  isoniazid, 193  
  leflunomide, 456  
  methotrexate, 417  
  pyrazinamide, 193  
  rifamycins, 192  
  terbinafine, 195  
  thionamides, 341  
  valproic acid, 514  
  zileuton, 649  
Hepcidin  
  acute-phase reactant, 102  
  in anemia of chronic disease, 399  
Hepeviruses  
  characteristics, 163  
  genomes, 159  
  naked viruses, 159  
HER-2, 616  
“Herald patch” in pityriasis rosea, 453  
Herceptin (trastuzumab), 421  
Hereditary angioedema, 622  
Hereditary hemorrhagic telangiectasia, 303  
Hereditary hyperbilirubinemias, **377**  
Hereditary spherocytosis, 400  
  in anemia taxonomy, 396  
  spherocytes in, 395  
Hereditary thrombosis syndromes, **406**  
Heritable amyloidosis, 213  
Hermaphrodites, 604  
Hernias, **355**  
  site of, 354  
Herniation syndromes, **499**  
Heroin  
  addiction to, **541**  
  focal segmental glomerulosclerosis, 566  
  intoxication and withdrawal, 540  
  opioids for withdrawal, 520  
Herpes encephalitis, 48  
Herpes genitalis, 160  
Herpes labialis, 160  
Herpes simplex virus 1 (HSV-1), 160, 451  
  encephalitis, 668  
  STI, 180  
Herpes simplex virus 2 (HSV-2), 160, 451  
  STI, 180  
  ToRCHeS infection, 178  
Herpes simplex virus (HSV)  
  cidofovir, 198  
  erythema multiforme, 452  
  foscarnet for, 198  
  guanosine analogs, 197  
  identification, 162  
  meningitis caused by, 176  
  retinitis, 508  
Herpesviruses, **160–162**, 451  
  clinical significance, 160  
  envelope, 159  
Herpes zoster  
  dorsal root latency, 160  
  famciclovir, 197  
  retinitis, 508  
Herpetic whitlow, 160  
Hesselbach triangle, 355  
Heterochromatin, **32**  
Heterodimer, 44  
Heterodisomy, 53  
Heterogeneous nuclear RNA (hnRNA), 38  
Heteroplasmy, **53**  
Heterozygosity loss, 52  
Hexokinase  
  glucokinase vs, **71**  
  metabolic pathways, 70  
HFE gene  
  hemochromatosis and, 378  
HGPRT, 417  
HGPRT (hypoxanthine guanine phosphoribosyltransferase), 34  
HHNS, 338  
Hiatal hernias, 355  
Hiccups, 489  
High altitude respiratory response, 635  
High-frequency recombination (Hfr) cells, 126  
Highly active antiretroviral therapy (HAART), 199  
Hilar adenopathy, 652  
Hilar lymphadenopathy, 639  
Hilar lymph nodes, 93  
  silicosis, 641  
Hilar nodes, 136  
Hindbrain, 460  
Hindgut  
  blood supply/innervation of, 348  
  development of, 344  
Hip dislocation  
  nerve injury with, 431  
Hip muscles, 431  
Hippocampus  
  lesions in, 481  
  limbic system, 468  
  pyramidal cells, 206  
Hippurate test, for *Streptococcus agalactiae*, 133  
Hirschsprung disease, **367**  
  Down syndrome, 59  
Hirsutism  
  cyclosporine, 116  
  danazol, 622  
  epilepsy drugs and, 514  
  menopause, 600  
  PCOS, 609  
  SHBG and, 322  
Hirudin, 413  
Histaminase, 387  
Histamine receptors, 230  
Histamines  
  in basophils, 387  
  cortisol effect on, 319  
  derivatives of, 79  
  location of, 357  
  mast cells and, 387  
  seafood toxins, 238  
  signaling pathways for, 322  
  vitamin B<sub>6</sub> and, 63  
Histidine, 77  
  derivatives of, 79  
Histocompatibility complex I and II, **107**  
Histone acetylation, **32**  
Histone methylation, **32**  
Histones  
  autoantibody, 111  
*Histoplasma* spp  
  treatment, 195  
*Histoplasma capsulatum*  
  HIV-positive adults, 173  
  necrosis and, 205  
Histoplasmosis, **147**  
  as granulomatous disease, 211  
  erythema nodosum, 453  
  as granulomatous disease, 211  
Histrionic personality disorder, 535  
HIV (human immunodeficiency virus), **171**  
  antigenic variation, 106  
  aplastic anemia in, 399  
  cervical cancer and, 609  
  diagnosis, **171**  
  disease associations, 173  
  ex vacuo ventriculomegaly, 492  
  flow cytometry diagnosis, 50  
  focal segmental glomerulosclerosis, 566  
  hairy leukoplakia, 451  
  heroin addiction and, 541  
  Kaposi sarcoma, 161, 450  
  lymphopenia, 402  
  meningitis, 176  
  microglia in, 463  
  non-Hodgkin lymphoma and, 407  
  PCR diagnosis, 48  
  *Pneumocystis jirovecii*, 150  
  primary central nervous system lymphoma (PCL) and, 408  
  prophylaxis for HIV patients, **194**  
  pulmonary arterial hypertension, 643  
  retrovirus, 163  
  rifamycins in, 192  
  STI, 180  
  T cells and, 388  
  therapy for, 197, **199**  
  ToRCHeS infection, 178  
  untreated time course, 172  
  vaccination, 107  
  viral receptor, 162  
  Western blot diagnosis, 49  
HIZ shrinkage in muscle contraction, 433  
HLA genes, **96**  
  associations, 656, 657  
  celiac disease and, 364  
  disease associations, 328  
  DM type 1 association, 337  
  seronegative spondyloarthritis, 442  
  uveitis, 506  
HMG-CoA reductase  
  cholesterol synthesis, 69  
  metabolic pathways, 70  
HMG-CoA reductase inhibitors, 306  
  naming conventions, 244  
HMG-CoA synthase, 69  
HMP shunt, **75**  
  diagram, 70  
  metabolic site, 68  
  NADPH production, 71, 75  
  rate-determining enzyme, 69  
  Vitamin B<sub>1</sub> deficiency, 62  
Hoarseness  
  gastroesophageal reflux disease as cause, 360  
  heart enlargement, 271  
  lung cancer, 647  
  Pancoast tumor, 646  
“Hobnail” liver in alcoholic cirrhosis, 374  
Hodgkin lymphoma  
  bleomycin for, 418  
  non-Hodgkin vs, **407**  
  oncogenic microbes and, 219  
  paraneoplastic cerebellar degeneration and, 217

- types of, 668  
vinca alkaloids for, 419
- Holoprosencephaly, 461  
fetal alcohol syndrome, 583  
Patau syndrome, 59  
Sonic hedgehog gene and, 580
- Homan sign, 636
- Homatropine, 233
- Homeobox genes, 580
- Homer-Wright rosettes, 498
- Homicide, as common cause of death, 260
- Homocysteine  
B<sub>12</sub> deficiency, 398  
folate deficiency, 398  
vitamin B<sub>9</sub> deficiency, 64  
vitamin B<sub>12</sub> deficiency, 65
- Homocysteine methyltransferase deficiency in, 80  
vitamin B<sub>12</sub> and, 65
- Homocystinuria, 80
- Homovanillic acid (HVA)  
in neuroblastomas, 325  
tyrosine catabolism, 79
- Homunculus, 471
- Hookworms, 155
- Hormone replacement therapy, 621  
endometrial hyperplasia, 612  
estrogens for, 621  
for hypopituitarism, 335  
thrombotic complications, 241
- Hormone-sensitive lipase, 88
- Hormones (reproductive), 620
- Horn cysts, 449
- Horner syndrome, 488, 509  
labs/findings, 657  
lung cancer, 647  
Pancoast tumor, 646  
presentation, 655
- Horner-Wright rosettes, 325
- Horse flies (disease vector), 155
- Horseshoe kidney, 549  
Turner syndrome, 656
- Hospice care, 260
- Hospital readmissions, causes of, 261
- Hot flashes  
as drug reaction, 240  
menopause, 600
- "Hourglass stomach," 355
- Howell-Jolly bodies, 395, 657  
postsplenectomy, 94
- Hu antigens, 217
- Human chorionic gonadotropin (hCG), 598  
choriocarcinomas, 605, 618  
ectopic pregnancy, 607  
embryonal carcinomas, 618  
hydatidiform moles, 605  
pregnancy, 598  
secretion of, 580  
signaling pathways, 322
- Human factors design, 261
- Human growth hormone. *See* Growth hormone (GH)
- Human herpesvirus 6 (HHV-6), 161, 179
- Human herpesvirus 7 (HHV-7), 161
- Human herpesvirus 8 (HHV-8), 161, 173  
Kaposi sarcoma, 450  
as oncogenic microbe, 219
- Humanized monoclonal A<sub>b</sub>, 244
- Humanized monoclonal antibodies, 107
- Human papillomavirus 6 (HPV-6), 180
- Human papillomavirus 11 (HPV-11), 180
- Human papillomavirus 16 (HPV-16), 636
- Human papillomavirus (HPV)  
cervical pathology, 609  
HIV-positive adults, 173  
as oncogenic microbe, 219  
penile cancer, 617  
tumor epidemiology, 608  
verrucae, 449  
warts, 160
- Human placental lactogen, 598
- Humerus injury  
axillary nerve and, 427  
median nerve injury, 427  
radial nerve and, 427
- Humor, 525
- Hunger, 466
- Hunter syndrome, 56, 84
- Huntington disease, 529  
basal ganglia lesions, 481  
neurodegenerative disorder, 490  
neurotransmitters for, 465  
treatment, 518  
ventromegaly, 492
- Hurler syndrome, 84
- Hürthle cells, 328
- Hutchinson teeth, 143
- Hyaline arteriosclerosis, 291
- Hyaline casts, 562
- Hyaline membrane disease, 639
- Hydatid cysts, 157
- Hydatidiform moles, 605  
hCG in, 598  
theca-lutein cysts and, 610
- Hydralazine, 304  
gestational hypertension, 304, 608  
heart failure, 298  
lupus-like syndrome, 241
- Hydrocephalus, 492  
childhood tumors, 498  
dementia, 529  
headaches with, 488  
posterior fossa malformations, 462  
risk for developing, 483  
*Toxoplasma gondii*, 178  
toxoplasmosis, 152  
vertical gaze paralysis, 481
- Hydrochlorothiazide (HCTZ), 576  
for diabetes insipidus, 334  
hyperglycemia, 240  
pancreatitis, 240
- Hydrocortisone  
arachidonic acid pathway, 455
- Hydrogen peroxide, 200
- Hydronephrosis, 568  
BPH, 619  
horseshoe kidney, 549  
kidney stones, 567
- Hydrophobia, 167
- Hydrops fetalis  
α-thalassemia as cause, 396  
parvovirus, 160  
parvovirus B19, 178, 179  
syphilis, 178
- Hydrosalpinx, 181
- Hydrothorax, 610
- Hydroxychloroquine  
lupus, 443  
myopathy, 241  
rheumatoid arthritis, 439
- Hydroxylases, 69
- Hydroxylation, 41
- Hydroxyurea, 419  
in cell cycle, 416  
polycythemia vera, 411  
pruine synthesis, 33  
sickle cell anemia, 400  
targets of, 416
- Hyoid artery, 586
- Hyoscyamine, 233
- Hyperactivity, 327
- Hyperacute transplant rejection, 115
- Hyperaldosteronism, 324  
hypertension with, 290  
metabolic alkalosis, 561  
potassium-sparing diuretics for, 576
- Hyperammonemia, 78
- Hyperbilirubinemia  
cirrhosis as cause, 372  
hereditary, 377  
jaundice and, 376
- Hypercalcemia, 560  
acute pancreatitis caused by, 380  
adult T-cell lymphoma, 408  
bisphosphonates for, 456  
calcium carbonate as cause, 382  
diabetes insipidus, 334  
granulomatous diseases and, 211  
hyperparathyroidism, 332  
loop diuretics for, 575  
lung cancer, 647  
paraneoplastic syndrome, 217  
PTH-independent, 331  
sarcoidosis and, 444  
succinylcholine, 520  
teriparatide, 457  
thiazides as cause, 576  
vitamin D toxicity, 66  
Williams syndrome, 60
- Hypercalciuria  
hyperparathyroidism, 332  
thiazides for, 576  
vitamin D toxicity, 66
- Hypercapnia  
contractility in, 273
- Hypercholesterolemia, 90  
hypothyroidism, 327  
nephrotic syndrome, 655  
presentation, 652
- Hyperchylomicronemia, 90
- Hypercoagulability  
hereditary syndromes, 406  
pregnancy, 598  
warfarin adverse effect, 414
- Hyperemesis gravidarum, 605
- Hyperemia  
pseudoepherine/  
phenylephrine, 648
- Hyperestrogenism, 610
- Hyperglycemia. *See also* Diabetes mellitus  
Cushing syndrome, 323  
diabetic ketoacidosis, 337  
diabetic retinopathy, 507  
as drug reaction, 240  
glucagon and, 315  
hyperkalemia, 560  
immunosuppressants, 116  
niacin causing, 306  
pancreatic cell tumors, 338  
protease inhibitors, 199  
thiazides, 576  
vitamin B<sub>3</sub> toxicity, 63
- Hypergranulosis, 448
- Hyper-IgE syndrome  
presentation, 655
- Hyper-IgM syndrome, 113
- Hyperinsulinemia, 609
- Hyperkalemia, 560  
aliskiren, 577  
angiotensin II receptor blockers, 577  
cardiac glycosides, 307  
causes of, 560  
diabetic ketoacidosis, 337  
potassium-sparing diuretics, 576  
primary adrenal insufficiency, 324  
renal failure, 571  
SGLT2 inhibitors, 341
- Hyperkalemic renal tubular acidosis, 562
- Hyperkeratosis, 448, 449
- Hyperlipidemia, 291  
atherosclerosis and, 292  
atypical antipsychotics, 543  
glomerular filtration barrier and, 551  
immunosuppressants, 116  
nephrotic syndrome, 566  
thiazides, 576
- Hypermagnesemia, 560
- Hypermagnesemia, 560
- Hyperopia, 504
- Hyperorality  
Klüver-Bucy syndrome, 481
- Hyperosmolar coma  
DM type 2, 336
- Hyperosmolar hyperglycemic state, 338
- Hyperosmolarity, 560
- Hyperparathyroidism, 332  
associations, 668  
calcium pyrophosphate deposition disease, 440  
cinacalcet for, 342  
lab findings, 657  
lab values in, 437

- Hyperparathyroidism (*continued*)  
osteoporosis, 435  
renal osteodystrophy and, 571
- Hyperphagia  
depression with, 531  
hypothalamus and, 466  
Klüver-Bucy syndrome, 481  
Prader-Willi syndrome, 54
- Hyperphosphatemia, 560  
hyperparathyroidism  
(secondary), 332  
hypoparathyroidism, 331  
renal osteodystrophy and, 571
- Hyperpigmentation  
adrenocortical insufficiency, 656  
bleomycin, 418  
busulfan, 418  
fludrocortisone, 342  
hemochromatosis as cause, 378  
melasma, 448  
Peutz-Jeghers syndrome as  
cause, 370  
primary adrenal insufficiency, 324
- Hyperplasia, 214, 215  
adrenal, 323, 324  
parathyroid, 331, 332, 339
- Hyperplastic arteriolosclerosis, 291
- Hyperplastic polyps, 370
- Hyperprolactinemia, 315, 496  
anovulation, 609  
calcium channel blockers as  
cause, 304  
risperidone as cause, 543
- Hyperpyrexia  
tricyclic antidepressants, 545
- Hyperreflexia  
serotonin syndrome, 545
- Hyperresonance, 644
- Hypersensitivity pneumonitis,  
211, 639
- Hypersensitivity reactions, **108–109**  
blood transfusions, 110  
C3 deficiency, 103  
cephalosporins, 185  
Graves disease, 329  
helminths, 154  
IgE antibodies, 101  
to insulin, 340  
mast cells and, 387  
organ transplants, 115  
penicillins, 183, 184  
rheumatic fever, 300  
sulfonamides, 190
- Hypersexuality  
Klüver-Bucy syndrome, 481
- Hypersomnia, 531
- Hypertension, **290**  
ACE inhibitors for, 577  
acute poststreptococcal  
glomerulonephritis, 564  
alcohol withdrawal, 541  
aliskiren for, 577  
 $\alpha$ -blockers for, 236  
angiotensin II receptor blockers  
for, 577  
aortic dissection and, 293, 664  
atherosclerosis and, 292  
atrial fibrillation and, 284  
autosomal recessive polycystic  
kidney disease, 573  
 $\beta$ -blockers for, 237  
calcium channel blockers for, 304  
Charcot-Bouchard  
microaneurysms, 486  
Cushing syndrome, 323  
diabetes mellitus, 304  
endometrial cancer, 612  
Guillain-Barré syndrome, 493  
heart failure, 304  
hydralazine for, 304  
hyperaldosteronism, 324  
immunosuppressants, 116  
intraparenchymal  
hemorrhage, 483  
leflunomide, 456  
local anesthetics, 519  
loop diuretics for, 575  
MDMA, 541  
microangiopathic anemia, 401  
minoxidil, 623  
nephritic syndrome and, 564  
PCP, 541  
pheochromocytomas, 326  
placental abruption, 606  
polyarteritis nodosa, 302  
preeclampsia, 608  
in pregnancy, 235, 304  
pregnancy, **608**  
pseudoephedrine/  
phenylephrine, 648  
renal cyst disorders, 573  
renal failure, 571  
sleep apnea, 642  
syndrome of apparent  
mineralocorticoid  
excess, 556  
thiazides for, 576  
thoracic aortic aneurysms  
and, 292  
treatment for, **304**  
tyramine, 236  
tyramine ingestion, 546
- Hypertensive crisis  
MAO inhibitors as cause, 546  
phenoxybenzamine for, 236
- Hypertensive emergency, 290, **304**
- Hypertensive nephropathy, 290
- Hypertensive urgency, 290, 304
- Hyperthermia  
atropine as cause, 233  
MDMA, 541  
serotonin syndrome, 545
- Hyperthyroidism, **329**, 610  
amiodarone and, 309  
choriocarcinomas, 618  
hCG, 598  
hydatidiform moles, 605  
hypothyroidism vs, **327**  
mature cystic teratoma, 610  
osteoporosis, 435  
pulse pressure in, 272  
thionamides for, 341
- Hypertonia  
serotonin syndrome, 545
- Hypertriglyceridemia, 90  
acute pancreatitis caused by, 380
- Hypertrophic cardiomyopathy, 297  
Pompe disease, 83  
systolic murmur in, 278
- Hypertrophic osteoarthropathy, 647
- Hypertrophic pyloric stenosis, **345**
- Hypertrophic scars, 210
- Hypertrophy, 214
- Hypertropic cardiomyopathy, 501
- Hyperuricemia  
as drug reaction, 241  
gout, 440  
kidney stones and, 567  
Lesch-Nyhan syndrome, 34  
niacin and, 306  
pyrazinamide, 193  
thiazides, 576  
vitamin B<sub>3</sub> toxicity, 63
- Hyperventilation  
emphysema, 655  
metabolic acidosis, 561  
pregnancy, 598
- Hypervitaminosis D, 437
- Hypnagogic hallucinations, 529  
narcolepsy, 538
- Hypnopompic hallucinations, 529  
narcolepsy, 538
- Hypoalbuminemia  
alcoholic cirrhosis as cause, 374  
nephrotic syndrome, 563, 566, 655
- Hypocalcemia, 319, 560  
22q11 deletion syndromes, 61  
acute pancreatitis as cause, 380  
cinacalcet causing, 342  
DiGeorge syndrome, 588  
hypermagnesemia and, 560  
hyperparathyroidism, 332  
hypoparathyroidism, 331  
pseudohypoparathyroidism, 331  
renal osteodystrophy, 571  
thymic aplasia, 112  
thyroidectomy, 330
- Hypocalcemic tetany, 66
- Hypocholesterolemia  
hyperthyroidism, 327
- Hypocitraturia, 567
- Hypocretin, 538
- Hypodermis, 446
- Hypofibrinogenemia, 212
- Hypogammaglobulinemia, 217
- Hypoglossal canal, 476
- Hypoglossal nerve (CN XII), **476**  
brain stem location, 474  
lesion in, 502  
location in brain stem, 474  
pathway, 476  
tongue, 463
- Hypoglycemia  
amylin analogs, 341  
carnitine deficiency, 85  
fructose intolerance, 76  
GH secretion in, 317  
glucagon production with, 315  
gluconeogenesis and, 74  
insulin as cause, 340  
insulinomas, 338
- loss of orientation, 528  
low birth weight and, 599  
meglitinides, 341  
neonatal, 582  
Reye syndrome as cause, 373  
somatostatinomas, 338  
sulfonyleureas, 340  
Von Gierke disease, 83
- Hypoglycemic drugs, **340–341**
- Hypogonadism  
diagnosis of, 604  
estrogens for, 621  
gynecomastia, 615  
hemochromatosis as cause, 378  
Kallmann syndrome, 604  
Klinefelter syndrome, 603  
pituitary prolactinomas, 315  
Prader-Willi syndrome, 54  
testosterone/  
methyltestosterone, 623  
zinc deficiency, 67
- Hypogonadotropic  
hypogonadism, 604
- Hypokalemia, 560  
antacids as cause, 382  
Bartter syndrome, 556  
causes of, 560  
cystic fibrosis, 56  
on ECG, 282  
Gitelman syndrome, 556  
loop diuretics, 575  
nephrogenic DI, 334  
syndrome of apparent  
mineralocorticoid excess as  
cause, 556  
VIPomas as cause, 356
- Hypomagnesemia, 560
- Hypomania, 531
- Hypomaniac episodes, **531**
- Hyponatremia, 560  
cirrhosis as cause, 372  
MDMA as cause, 541  
osmotic demyelination  
syndrome, 492  
as paraneoplastic syndrome, 217  
thiazides, 576
- Hypoparathyroidism, **331**
- Hypophosphatemia, 560  
aluminum hydroxide as cause, 382  
hyperparathyroidism, 332
- Hypophosphatemic rickets, 55
- Hypopituitarism, **335**  
pituitary adenomas, 332
- Hypoproteinemia, 551
- Hyporeflexia  
LMN lesions, 501  
magnesium hydroxide as cause, 382
- Hypospadias, 591
- Hyposplenism, 395
- Hypotension  
acute tubular necrosis with, 572  
adrenal insufficiency, 324  
adrenocortical insufficiency, 656  
aliskiren, 577  
amphotericin B, 195  
angiotensin II receptor  
blockers, 577

- cardiac tamponade, 300  
 cilostazol/dipyridamol, 415  
 endotoxins, 127  
 ephedrine for, 234  
 Guillain-Barré syndrome, 493  
 hypermagnesemia, 560  
 local anesthetics, 519  
 magnesium hydroxide as  
   cause, 382  
 metronidazole, 191  
 midodrine for, 234  
 norepinephrine for, 234  
 orthostatic, 324  
 phenylephrine for, 234  
 scombroid poisoning, 238  
 SGLT2 and, 341  
 sympatholytic drugs and, 235  
 Waterhouse-Friderichsen  
   syndrome, 652
- Hypothalamic/pituitary  
 drugs, **342**
- Hypothalamic-pituitary  
 hormones, **315**
- Hypothalamus, **466**  
 ADH secretion, 317  
 sleep physiology, **467**  
 TRH and, 321
- Hypothenar muscles, 429  
 Klumpke palsy, 428
- Hypotheses (statistical), 251  
 testing, 252
- Hypothyroidism, **328**  
 amiodarone and, 309  
 anemia, 398  
 in anemia taxonomy, 396  
 carpal tunnel syndrome  
   and, 426  
 dementia, 529  
 as drug reaction, 240  
 hormone replacement, 342  
 hyperthyroidism vs, **327**  
 lithium, 544
- Hypotonia  
 carnitine deficiency, 85  
 Menkes disease, 47  
 Prader-Willi syndrome, 54
- Hypoventilation, 561
- Hypovolemia, 336
- Hypovolemic shock, 299
- Hypoxanthine, 457
- Hypoxanthine guanine  
 phosphoribosyltransferase  
 (HGPRT), 34
- Hypoxemia  
 alveolar gas equation, 634  
 obstructive lung disease, 638  
 oxygen deprivation, **634**  
 pulmonary emboli, 637  
 respiratory alkalosis and, 561
- Hypoxia  
 apoptosis caused by, 204  
 contractility in, 273  
 erythropoietin and, 559  
 hemoglobin modifications, 632  
 lung diseases, 643  
 nocturnal, 642  
 oxygen deprivation, 634  
 regions susceptible to, 206  
 renal, 632  
 vasoconstriction/vasodilation  
   and, 286
- Hypoxia inducible factor 1 $\alpha$ , 218
- Hypoxic stroke, 482
- Hysterectomy  
 adenomyosis, 612  
 cardinal ligament in, 592
- Hysteresis (lung and chest  
 wall), 631
- Hysteria  
 respiratory alkalosis from, 561
- I**
- Iatanoprost, 521
- Ibandronate, 456
- Ibuprofen, 456  
 arachidonic acid pathway  
   and, 455  
 hemolysis in G6PD deficiency, 241
- Ibutilide, 309
- ICAM-1 protein  
 in leukocyte extravasation, 209  
 viral receptor, 162
- I-cell disease, **43**
- I cells, 356
- Icosahedral viruses, 159
- Idealization, 525
- Identification, 525
- Idiopathic intracranial  
 hypertension, **491**
- Idiopathic thrombocytopenic  
 purpura (ITP)  
 labs/findings, 657  
 rituximab for, 118, 420  
 type II hypersensitivity  
   reactions, 108
- IDL (intermediate-density  
 lipoprotein), 89
- IFN- $\alpha$  (Interferon- $\alpha$ ), **105**  
 clinical uses, 117  
 natural killer cells, 97
- IFN- $\alpha$  (interferon- $\alpha$ )  
 clinical use, 200  
 hepatitis, 661
- IFN- $\beta$  (Interferon- $\beta$ ), **105**  
 clinical uses, 117, 200  
 natural killer cells, 97
- IFN- $\gamma$  (Interferon- $\gamma$ ), 104, 112  
 cachexia and, 221  
 clinical uses, 117, 200  
 granulomatous diseases and, 211  
 Graves disease and, 329  
 helper T cells, 98
- Ifosfamide, 418  
 Fanconi syndrome, 556  
 hemorrhagic cystitis, 242
- IgA antibodies, 101  
 ataxia-telangiectasia, 113  
 breast milk, 599  
 in celiac disease, 364  
 deficiency in, 112, 652  
 hyper-IgM syndrome, 113  
 multiple myeloma production  
   of, 409  
 passive immunity, 107  
 Peyer patches and, 358
- IgA nephropathy, 564  
 Henoch-Schönlein purpura  
   and, 303
- IgA protease, 125
- IgD antibodies, 101
- IgE antibodies, 101  
 ataxia-telangiectasia, 113  
 eczema, 449  
 hyper-IgM syndrome, 113  
 mast cells and, 387  
 type I hypersensitivity, 108
- IGF-1. *See* Insulin-like growth factor  
 1 (IGF-1)
- IgG antibodies, 101  
 anemia and, 401  
 ataxia-telangiectasia, 113  
 bullous pemphigoid, 452  
 complement activation and, 103  
 hepatitis A (HAV), 170  
 hyper-IgM syndrome, 113  
 multiple myeloma production  
   of, 409  
 multiple sclerosis, 493  
 as passive immunity, 107  
 pemphigus vulgaris, 452  
 in pregnancy, 390  
 in type III hypersensitivity  
   reactions, 109
- IgM antibodies, 101  
 anemia and, 401  
 in biliary cirrhosis, 378  
 complement activation and, 103  
 hepatitis A (HAV), 170  
 hyper-IgM syndrome, 113  
 in pregnancy, 390  
 in sclerosing cholangitis, 378  
 splenic dysfunction, 94
- IL-1 (Interleukin 1), 104  
 cachexia and, 221  
 endotoxins, 129
- IL-2 (Interleukin 2), 104  
 cyclosporine and, 116  
 natural killer cells, effect on, 97
- IL-3 (Interleukin 3), 104
- IL-4 (Interleukin 4), 104  
 helper T cells and, 98
- IL-5 (Interleukin 5), 104  
 helper T cells and, 98
- IL-6 (Interleukin 6), 104  
 acute-phase reactants and, 102  
 cachexia and, 221  
 endotoxins, 129
- IL-8 (Interleukin 8), 104  
 neutrophils and, 386
- IL-10 (Interleukin 10), 104  
 helper T cells and, 98
- IL-12 (Interleukin 12), 104  
 natural killer cells and, 97  
 receptor deficiency, 112
- IL-13 (Interleukin 13), 98
- Ileum, 347
- Ileus, 369  
 gallstone, 379
- Iliohypogastric nerve, 430
- Illness anxiety disorder, 536
- Iloperidone, 543
- Iloprost, 648
- Imatinib, 420
- IMG registration timeframe, 6
- Imipenem, 183, 186  
 seizures with, 242
- Imipramine, 545
- Immature ego defenses, 525
- Immature teratomas, 611
- Immune responses, **102–115**  
 acute-phase reactants, 97  
 autoantibodies, 111  
 cell surface proteins, 105  
 complement, 103  
 cytokines, 104  
 hypersensitivity types, 110–111  
 immunodeficiencies, 112–114  
 passive vs active, 107  
 respiratory burst, 105  
 transfusion reactions, 110
- Immune thrombocytopenia, 405
- Immune thrombocytopenic  
 purpura, 108  
 hepatitis C, 169
- Immunocompromised patients  
 acyclovir/famciclovir/  
   valacyclovir, 197  
*Candida albicans* in, 149  
 common organisms affecting, 175  
*Cryptococcus neoformans*, 149  
*Cryptosporidium*, 151  
 ecthyma gangrenosum, 139  
 esophagitis in, 360  
 fungal infections, 182  
*Listeria monocytogens*, 135  
*Pneumocystis jirovecii*, 150
- Immunodeficiency  
 infections in, 114  
 syndromes, **112–113**
- Immunodeficiency syndromes  
 flow cytometry diagnosis, 50
- Immunoglobins  
 for Kawasaki disease, 302
- Immunoglobulins  
 adaptive immunity and, 95  
 breast milk and, 599  
 Guillain-Barré syndrome, 493  
 isotypes of, **101**
- Immunology, **92–118**  
 immune responses, 102–115  
 immunosuppressants, 116–118  
 lymphocytes, 95–101  
 lymphoid structures, 92–94  
 immunomodulator signaling  
   pathways, 322
- Immunophenotype assessment, 50
- Immunosuppressants, **116**  
 for aplastic anemia, 399  
 for lupus, 443  
 for polymyositis/  
   dermatomyositis, 445  
 targets, **117**
- Immunosuppression  
 squamous cell carcinoma, 454  
 vitamin A deficiency, 62  
 vitamin C deficiency, 65

- Impaired glucose tolerance.  
See Insulin resistance
- Impetigo, 447  
crusts with, 451  
*Streptococcus pyogenes*, 132  
sunburn and, 453
- Implied consent, 254
- Imprinting (genetics), 54
- Inactivated vaccines, 107
- Incidence vs prevalence, 249
- Incomplete penetrance, 52
- Incorrect results, in statistical  
hypothesis testing, 252
- Incus bone, 503
- Incus (ossicles)  
branchial arch derivative, 587
- India ink stain, 122
- Indicator media, 122
- Indinavir  
HIV therapy, 199  
mechanism (diagram), 197
- Indirect Coombs test, 108
- Indirect inguinal hernias, 355
- Indomethacin, 456  
arachidonic acid pathway, 455  
for diabetes insipidus, 334  
gout, 440  
for PDA closure, 270
- Infarcts  
atherosclerosis, 292  
red vs pale, 207  
regions susceptible to, 206
- Inferior colliculi, 475
- Inferior gluteal nerve, 431
- Inferior mesenteric artery, 348  
horseshoe kidney, 549
- Inferior mesenteric lymph nodes, 93
- Inferior mesenteric vein, 350
- Inferior oblique muscle, 510
- Inferior phrenic arteries, 348
- Inferior rectal artery, 351
- Inferior rectal vein, 350
- Inferior rectus muscle, 510
- Inferior sagittal sinus, 473
- Inferior vena cava, 345  
diaphragm, 629  
gonadal drainage and, 591
- Infertility  
clomiphene, 621  
cystic fibrosis, 56  
ectopic pregnancy, 607  
endometriosis, 613  
impaired sperm mobility, 601  
Kallmann syndrome, 604  
Kartagener syndrome, 45, 656  
Klinefelter syndrome, 603  
leuprolide for, 621  
mumps, 166  
ovarian neoplasms, 610  
PCOS, 609  
salpingitis, 181  
septate uterus, 590  
varicoceles, 618
- Infiltrative cardiomyopathy, 297
- Infiltrative lymphohistiocytosis, 113
- Inflammation, 204–213  
acute-phase reactants, 102  
characteristics of, 207  
ESR in, 212  
IL-1 as cause, 104  
pathology of, 204–213
- Inflammatory bowel disease  
(IBD), 365  
AA amyloidosis and, 213  
azathioprine for, 417  
erythema nodosum, 453  
infliximab/adalimumab for, 457  
methotrexate for, 417  
sclerosing cholangitis and, 378  
spondyloarthritis, 442  
therapeutic antibodies, 118
- Inflammatory breast cancer, 616
- Inflammatory diseases  
*Staphylococcus aureus*, 131
- Inflammatory pseudopolyps, 370
- Infliximab, 118, 457  
for Crohn disease, 365  
for ulcerative colitis, 365  
ulcerative colitis, 664
- Influenza, 165  
antigenic variation, 106  
orthomyxovirus, 163  
pneumonia, 645  
Reye syndrome and, 373  
treatment/prevention, 197  
vaccine for, 107, 158
- Informed consent, 254
- Infraspinatus muscle  
Erb palsy, 428  
rotator cuff, 425
- Infundibulopelvic ligament, 592
- Infundibulum, 474
- Ingested seafood toxins, 238
- Inguinal canal, 354
- Inguinal hernia, 355, 591
- Inguinal ligament, 353, 354
- Inguinal triangle, 355
- Inhalational general anesthetic, 244
- Inhalational injury, 640
- Inhaled anesthetics, 519
- Inheritance modes, 55
- Inhibin  
cryptorchidism, 617  
Klinefelter syndrome, 603  
Sertoli cell secretion of, 594
- Inhibin A  
autosomal trisomies, 59
- Inhibitors of complement  
activation, 103
- Inhibitory pathway, 470
- Initiation of protein synthesis, 41
- Innate immunity, 95
- Inositol trisphosphate (IP<sub>3</sub>), 322
- Inotropes, 299
- Inotropy, 275
- Insomnia  
AChE inhibitors, 518  
barbiturates for, 515  
benzodiazepines, 515  
hyperthyroidism and, 327  
marijuana withdrawal, 541  
nonbenzodiazepine hypnotics, 515  
stimulants causing, 540
- Inspiration effect on auscultation, 278
- Inspiratory capacity (IC), 630
- Inspiratory reserve volume (IRV), 630
- Insulin, 314  
anabolic effects of, 314  
deficiency in, 336  
diabetes treatment, 340  
diabetic ketoacidosis, 337  
for HHNS, 338  
fructose biphosphatase-2 and, 72  
GIP effect on, 356  
glucagon and, 315  
glycogen regulation, 69, 81  
hypokalemia from, 560  
in pregnancy, 314  
production of, 313  
secretion of, 314  
signaling pathways for, 322  
somatostatin and, 356  
somatostatinomas and, 338  
sulfonylurea effect on, 340
- Insulin-like growth factor 1 (IGF-1)  
acromegaly, 333  
Laron syndrome, 333  
signaling pathways for, 322
- Insulinomas  
insulin and C-peptide in, 314  
MEN 1 syndrome, 339  
pancreatic cell tumor, 338
- Insulin resistance  
acanthosis nigricans and, 453  
acromegaly, 333  
cortisol, 319  
Cushing syndrome, 323  
DM type 2, 337  
GH, 314, 317  
glitazone/thiazolidinedione effect  
on, 340  
metformin effect on, 340  
PCOS, 609
- Insurance  
disregarding in treatment, 257  
Medicare/Medicaid as, 260  
types of plans, 259
- Integrase inhibitors, 199
- Integrins  
epithelial cells, 447  
viral, receptor, 162
- Intellectual disabilities  
WAGR complex, 569
- Intellectual disability  
autism and, 527  
fetal alcohol syndrome, 583  
Rett syndrome, 527
- Intellectualization, 525
- Intention tremor, 489  
cerebellar lesions, 481  
multiple sclerosis, 493
- Intention tremors  
multiple sclerosis, 655
- Interactions, drug, 225
- Intercostobrachial nerve, 427
- Interferon- $\alpha$   
myopathy, 241
- Interferon- $\gamma$  release assay (IGRA), 136
- Interferons, 105  
focal segmental  
glomerulosclerosis, 566  
mechanism and use, 200
- Interlobar artery, 550
- Interlobular artery, 550
- Intermediate filaments  
cytoskeletal element, 44
- Internal auditory meatus, 476
- Internal capsule  
intraparenchymal  
hemorrhage, 483  
stroke effects, 484
- Internal carotid artery  
cavernous sinus, 512  
circle of Willis, 473
- Internal hemorrhoids, 351
- Internal iliac arteries, 348
- Internal iliac artery, 270
- Internal iliac lymph nodes, 93, 591
- Internal inguinal ring, 355
- Internal jugular vein, 473
- Internal oblique muscle, 354
- Internal spermatic fascia, 354
- International Foundations of  
Medicine (IFOM), 12
- Internuclear ophthalmoplegia, 513  
multiple sclerosis, 655
- Interossei muscles, 429  
Klumpke palsy, 428  
ulnar nerve, 427
- Interpreting study results, 250
- Intersex, 604
- Interstitial fluid, 287
- Interstitial lung disease, 439
- Interstitial nephritis  
as drug reaction, 242  
NSAID toxicity, 456  
penicillins, 184
- Interstitial pneumonia, 645
- Interstitialium  
leukocyte extravasation and, 209
- Interventricular foramen, 269
- Interventricular septal rupture, 296
- Intestinal obstruction  
hernias as cause, 355  
superior mesenteric artery  
syndrome as cause, 348
- Intestinal stomach cancer, 362
- Intestinal villi, 347
- Intimate partner violence, 257
- Intracellular fluid (ICF), 551
- Intracellular organisms, 124
- Intracellular receptors  
endocrine hormone  
messengers, 322
- Intracranial hemorrhage, 483  
eclampsia, 608
- Intracranial pressure, 472  
hydrocephalus, 492  
papilledema, 508  
superior vena cava syndrome, 646
- Intraductal papillomas, 614, 615
- Intraocular pressure, 506
- Intraparenchymal hemorrhage, 483
- Intrauterine device (IUD)  
copper, 622  
endometritis, 612
- Intrauterine growth restriction  
(IUGR)  
low birth weight, 599  
substance abuse, 582

- Intravascular hemolysis, 399  
 Intravenous anesthetics, **519**  
 Intraventricular hemorrhage  
   low birth weight, 599  
   neonatal respiratory distress syndrome as cause, 627  
 Intrinsic factor, 357  
   location of, 357  
 Intrinsic hemolytic anemia, **400**  
 Intrinsic pathway, **204**  
   for coagulation, 391  
   coagulation defects of, 404  
   heparin and, 414  
 Intrinsic renal failure, 571  
 Introns vs exons, **39**  
 Intrusive thoughts, 533  
 Intussusception, **368**  
   Meckel diverticulum as cause, 367  
   presentation, 655  
 Inulin  
   extracellular volume and, 551  
   glomerular filtration rate and, 552  
   in proximal convoluted tubules, 557  
 Invariant chain, 96  
 Invasive breast carcinomas, 616  
 Invasive carcinomas, 215  
 In vivo biofilm-producing bacteria, **125**  
 Involuntary treatment, 255  
 Iodine  
   deficiency in, 327, 328  
   infection control, 200  
   teratogenicity, 582  
   thionamide effect on, 341  
 Iodophors, 200  
 IPEX syndrome, 98  
 Ipratropium, 233, 649  
 Irinotecan, **419**  
   in cell cycle, 416  
   targets of, 416  
 Irinotecan/topotecan, 35  
 Iris, 504  
 Iritis, 506  
 Iron  
   absorption of, 358  
   anemia, 402  
   anemia of chronic disease, 399  
   in hemochromatosis, 378  
   lab values in anemia, 402  
   metabolic acidosis, 561  
   sideroblastic anemia, 397  
   toxicity treatment, 239  
 Iron deficiency anemia, 396  
   in anemia taxonomy, 396  
   colorectal cancer as cause, 371  
   fibroid tumors, 612  
   Plummer-Vinson syndrome as cause, 360  
 Iron poisoning, **404**  
 Irritable bowel syndrome (IBS), **366**  
   antispasmodic drugs, 233  
 Ischemia, **206**, 634  
   atherosclerosis, 292  
   Fanconi syndrome, 556  
   necrosis and, 205  
 Ischemic brain disease, **482**  
 Ischemic heart disease, **293**  
 Ischemic priapism, 617  
 Ischemic stroke, **482**  
 Ishikawa diagram, 262  
 Islets of Langerhans, 313  
 Isocarboxazid, 546  
 Isocitrate dehydrogenase  
   metabolic pathways, 70  
   rate determining enzyme, 69  
 Isodisomy, 53  
 Isoflurane, 519  
 Isolation of affect, 525  
 Isoleucine  
   classification of, 77  
   maple syrup urine disease and, 80  
 Isoniazid, **193**  
   cytochrome P-450, 243  
   drug-induced SLE, 657  
   hemolysis in G6PD deficiency, 241  
   hepatitis, 240  
   lupus-like syndrome, 241  
   *Mycobacterium tuberculosis*, 192  
   seizures, 242  
   sideroblastic anemia, 397  
 Isoproterenol  
   norepinephrine vs, **235**  
   sympathomimetic action, 234  
 Isosorbide dinitrate, 305  
 Isosorbide mononitrate, 305  
 Isotretinoin  
   cystic acne, 62  
   teratogenicity, 582  
 Isovolumetric contraction, 276  
 Isovolumetric relaxation, 276  
 Isuccinate dehydrogenase, 74  
 Itraconazole  
   azoles, 195  
   mechanism (diagram), 194  
   *Sporothrix schenckii*, 150  
   systemic mycoses, 147  
 Ivabradine, 310  
 IV drug use  
   common organisms, 175  
   osteomyelitis, 176  
 Ivermectin, 196  
 IV phlebitis, 195  
 Ixodes ticks, 142, 144, 153  
**J**  
 JAK2 gene, 218  
   myeloproliferative disorders, 411  
 Janeway lesions, 655  
   bacterial endocarditis, 299  
 Jarisch-Herxheimer reaction, **143**  
 Jaundice, **376**  
   ABO hemolytic disease of the newborn, 390  
   alcoholic cirrhosis as cause, 374  
   biliary tract disease as cause, 378  
   cholangitis as cause, 379  
   cirrhosis as cause, 372  
   Crigler-Najjar syndrome, 656  
   as drug reaction, 240  
   fructose intolerance, 76  
   galactosemia, 76  
   graft-versus-host disease, 115  
   hepatitis B, 180  
   hepatocellular carcinoma as cause, 375  
   hereditary hyperbilirubinemias as cause, 377  
   leptospirosis, 142  
   painless, 656  
   pancreatic cancer as cause, 380  
   ToRCHeS infections, 178  
   yellow fever, 164  
 Jaw jerk reflex, 477  
 JC virus (John Cunningham virus)  
   HIV-positive adults, 173  
   polyomaviruses, 160  
   progressive multifocal leukoencephalopathy and, 494  
 JC virus (John Cunningham Virus)  
   immunocompromised patients, 114  
 Jejunum, 347  
 Jervell and Lange-Nielsen syndrome, 283  
 Jimson weed, 233  
 Jod-Basedow phenomenon, 329. *See also* Wolff-Chaikoff effect  
 JONES criteria (rheumatic fever), 132  
 J point in ECG, 282  
 Jugular foramen, 473, 476  
 Jugular venous distention (JVD), 298, 646  
 Jugular venous pulse, 276  
 Justice (ethics), 253  
 Juvenile idiopathic arthritis, 506  
 Juvenile polyposis, 370  
 Juxtaglomerular apparatus, **558**  
   filtration, 553  
   juxtaglomerular cells, 550  
   renin secretion, 558  
 Juxtaglomerular cells  
   tumors in, 324  
**K**  
 Kallikrein  
   C1 esterase inhibitor deficiency, 103  
   neutrophils and, 386  
 Kallmann syndrome, **604**  
 Kaposi sarcoma, 450  
   AIDS and, 180  
   bacillary angiomatosis vs, 450  
   HHV-8, 161  
   HIV-positive adults, 173  
   IFN- $\alpha$  for, 200  
   oncogenic microbes and, 219  
   recombinant cytokines for, 117  
 Kartagener syndrome, 45, 268  
   infertility with, 601  
   obstructive lung disease, 639  
   presentation, 656  
 Karyotyping, **51**  
 Kawasaki disease, **302**  
   presentation, 652, 656  
 Kayser-Fleischer rings  
   Wilson disease as cause, 378  
 K cells, 356  
 Kegel exercises, 569  
 Keloid scars, 210  
 Keratinocytes  
   sunburn, 453  
   in wound healing, 211  
 Keratin pearls, 647  
 Keratoacanthomas, 454  
 Keratoconjunctivitis, 160  
 Keratoconjunctivitis sicca, 441  
 Keratomalacia, 62  
 Kernicterus, 190, 201  
 Kernohan notch, 499  
 Ketamine, 519  
 Ketoconazole, 194, 195, 623  
   cytochrome P-450, 243  
   gynecomastia, 615  
   PCOS, 609  
   reproductive hormones and, 620  
 Ketogenesis  
   diabetic ketoacidosis, 337  
   diagram of, 70  
   insulin deficiency, 336  
   metabolic site, 68  
   rate-determining enzyme for, 69  
 Ketone bodies, **86**  
 Ketonemia, 336  
 Ketonuria, 336  
 Ketorolac, 456  
   arachidonic acid pathway, 455  
 Kidney  
   chronic graft nephropathy, 115  
   transplant prophylaxis, 116  
 Kidney disease  
   anemia of chronic disease and, 399  
   hypertension, 290  
 Kidney endocrine functions, **559**  
 Kidneys  
   autoregulation of, 286  
   embryologic derivation, 581  
   embryology of, **548**  
   in gastrointestinal anatomy, 345  
   hormones acting on, **559**  
   ischemia in, 206  
   sclerosis, 446  
   solitary functioning, 549  
 Kidney stones, **567**  
   Crohn disease as cause, 365  
   electrolyte disturbances, 560  
   hematuria with, 562  
   horseshoe kidney and, 549  
   hydronephrosis, 568  
   hyperparathyroidism, 332  
   postrenal azotemia, 571  
   UTIs, 177  
 Kiesselbach plexus, 636  
 Killed vaccines, 158  
 Killian triangle, 367  
 Kimmelstiel-Wilson nodules  
   diabetes mellitus, 336  
   diabetic glomerulonephropathy, 566  
 Kinases, 69  
 Kinesin, 44  
*Kingella* spp, 299  
 Kinin cascade, 391  
 Kinin pathways, **391**  
 kinky hair, 47  
 Kissing bug (disease vector), 154

- Klebsiella* spp, **140**  
 alcoholism, 175  
 currant jelly sputum, 182  
 Gram-negative algorithm, 137  
 kidney stones, 567  
 lactose fermentation, 138  
 nosocomial infections, 181  
 pneumonia, 645  
 taxonomy, 121  
 urease-positive, 124  
 urinary tract infections, 570
- Klebsiella pneumoniae*  
 cephalosporins, 185  
 encapsulation, 124  
 immunodeficient patients, 114  
 presentation, 655  
 splenic dysfunction, 94  
 UTIs caused by, 177
- Klinefelter syndrome, 603  
 chromosome association, 60  
 gynecomastia, 615  
 testicular tumors, 618
- Klumpke palsy, 428  
 Klüver-Bucy syndrome, 481  
 Knee pain from “unhappy triad,” 425
- Knees  
 common conditions of, **425**  
 examination of, **424**
- Knock-out/Knock-in genes, 52  
 Koilocytes, 609  
 condylomata acuminata, 180  
 Koilocytosis, 449  
 Koplik spots, 166, 179, 656  
 Korsakoff psychosis, 541  
 Korsakoff syndrome, 528  
 Krabbe disease, 84, 494  
 KRAS gene, 218  
 adenomatous colonic polyps and, 370  
 colorectal cancer and, 372  
 lung cancer and, 647
- Krukenberg tumor, 611  
 Krukenberg tumors, 362
- $K_m$ , 224  
 Kulchitsky cells, 325, 647  
 Kupffer cells, 352  
 Kuru, 174  
 Kussmaul respirations  
 in diabetic ketoacidosis, 337  
 Kussmaul sign, **301**  
 Kwashiorkor, **67**  
 Kyphoscoliosis, 501  
 Kyphosis, 80
- L**
- Labetalol, 237  
 gestational hypertension, 608  
 hypertension in pregnancy, 304  
 hypertensive emergency, 304
- Labia, 592  
 male homolog of, 590
- Labile cells, 42  
 Laboratory techniques, **48–52**  
 Lachman test, 424  
 Lac operons, **36**  
 Lacrimation reflex, 477
- Lactase deficiency, **77**  
 Lactation, **599**. *See also* Breast milk  
 dopamine and, 316  
 oxytocin for, 342  
 progesterone and, 595  
 prolactin and, 316  
 Sheehan syndrome and, 335
- Lactational mastitis, 615  
 Lactic acid dehydrogenase, 73  
 Lactic acidosis  
 ethanol metabolism and, 68  
 exercise and, 635  
 MELAS syndrome, 55  
 metabolic acidosis, 561  
 metformin, 340  
 pyruvate dehydrogenase complex deficiency, 73
- Lactiferous sinus, 614  
*Lactobacillus* spp  
 normal flora, 174  
 taxonomy, 121
- Lactoferrin  
 in neutrophils, 386  
 in respiratory burst, 105
- Lactose-fermenting enteric organisms, 123, **138**  
 Lactose intolerance, 364  
 Lactose metabolism, 36  
 Lactulose, 383  
 for hepatic encephalopathy, 374  
 hyperammonemia, 78
- Ladd bands, 367  
 Lambert-Eaton myasthenic syndrome, **445**  
 as paraneoplastic syndrome, 217  
 small cell lung cancer, 647
- Lamina propria, 347  
 Peyer patches in, 358  
 in Whipple disease, 364
- Lamins, 44  
 Lamivudine  
 HIV therapy, 199  
 mechanism (diagram), 197
- Lamotrigine  
 for epilepsy, 514  
 rash caused by, 241
- Lancet-shaped diplococci, 132  
 Landmark dermatomes, **480**  
 Langerhans cell histiocytosis, **412**  
 Langerhans cells, 388  
 Birbeck granules in, 660
- Language development, 258  
 Lanosterol synthesis, 194  
 Lansoprazole, 381  
 Lanugo, 537  
 Laplace law, 273, 627  
 Large cell carcinomas of lungs, 647
- Laron syndrome, **333**  
 Larva migrans, 155  
 Larynx, 628  
 Larynx muscles, 587  
 Lassa fever encephalitis, 163  
 Latent errors, 262  
 Lateral cerebellar lesions, 469  
 Lateral collateral ligament (LCL)  
 injury, 424
- Lateral corticospinal tract,  
 478, 479, 484  
 Lateral epicondylitis, 426  
 Lateral femoral circumflex artery, 436  
 Lateral femoral cutaneous nerve, 430  
 Lateral fold closure defects, 344  
 Lateral geniculate nucleus (LGN), 468  
 Lateral medullary syndrome, 484  
 Lateral pterygoid muscle, 587  
 Lateral rectus muscle, 510  
 Lateral spinothalamic tract, 478  
 Lateral thoracic artery, 432  
 Lateral ventricles  
 herniation syndromes, 499  
 optic radiation, 511  
 ventricular system, **474**
- Laxatives, 383  
 LDH in exudate vs transudate, 212  
 LDL (low-density lipoprotein), 89  
 Lead paralysis, 531  
 Lead poisoning, 397, **403**  
 acute tubular necrosis, 572  
 in anemia taxonomy, 396  
 basophilic stippling in, 394  
 Fanconi syndrome, 556  
 labs/findings, 657  
 presentation, 652  
 sideroblastic anemia, 397  
 treatment, 239
- Lead-time bias, 250  
 Lecithinase, 129, 134  
 Lecithin-cholesterol acetyltransferase)  
 activation of, 89  
 function, 88
- lecithins  
 lung maturity, 627  
 Lecithins, 627  
 Lectin pathway (complement activation), 103  
 Ledipasvir, 200  
 Leflunomide, 439, **456**  
 pyrimidine synthesis and, 33
- Left anterior descending artery  
 coronary circulation, 271  
 myocardial infarction and, 294
- Left anterior division, 282  
 Left bundle branch, 282  
 Left bundle branch block, 277  
 Left circumflex coronary artery, 271  
 Left common iliac artery, 348  
 Left gastroepiploic artery, 349  
 Left hemianopia with macular sparing, 511  
 Left heart disease, 643  
 Left horn of sinus venosus, 268  
 Left lower quadrant hemiopia, 511
- Left main coronary artery, 271  
 Left marginal artery, 271  
 Left posterior division, 282  
 Left recurrent laryngeal nerve, 586  
 Left shift, **402**  
 Left-to-right shunts, 289  
 Legg-Calvé-Perthes disease, 436  
*Legionella* spp  
 atypical organism, 175  
 culture requirements, 123
- intracellular organism, 124  
 macrolides, 189  
 nosocomial infection, 181  
 pneumonia, 645  
 silver stain, 122  
 taxonomy, 121
- Legionella pneumophila*, **139**  
 Legionnaires’ disease, 139  
 Leiomyomas, 612  
 nomenclature for, 216  
 polycythemia and, 217  
 Leiomyosarcomas, 216  
*Leishmania donovani*, **154**  
 Leishmaniasis, 154, 196
- Lens, 504  
 collagen in, 46  
 infantile cataracts, 76  
 subluxation of, 80
- Lenticulostriate artery, 484  
 Lenticorn nucleus, 470  
 Leonine facies, 137  
 Lepromatous Hansen disease, 137  
 Leptin, 317  
 hypothalamus, 466
- Leptospira* spp  
 animal transmission, 144  
 spirochete, 142
- Leptospira interrogans*, **142**  
 Leptospirosis, 142, 144  
 Lesch-Nyhan syndrome, **34**  
 gout, 440  
 inheritance, 56  
 labs/findings, 660
- Leser-Trélat sign, 217, 449  
 stomach cancer as cause, 362
- Lesser sac, 346  
 Lethal median dose, 228  
 Letrozole, 621  
 Leucine  
 classification of, 77  
 maple syrup urine disease and, 80
- Leucovorin, 417  
 Leukemias, **410**  
 allopurinol for, 457  
 aplastic anemia and, 399  
 carcinogens causing, 219  
 cyclophosphamide for, 418  
 cytarabine for, 417  
 doxorubicin for, 418  
 etoposide/teniposide for, 419  
 lymphomas vs, **407**  
 mucormycosis, 149  
 nomenclature for, 216  
 vinca alkaloids for, 419
- Leukocyte adhesion deficiency, 113, 209  
 Leukocyte alkaline phosphatase (LAP), 386  
 Leukocyte esterase, 177, 570  
 Leukocyte extravasation, **209**  
 Leukocytes, **386**  
 basophilia in CML, 387  
 extravasation of, 209  
 leukemias, 410  
 in urine, 177, 562, 570  
 Leukocytoclastic vasculitis, 169

- Leukocytosis  
*Clostridium difficile*, 652  
 diabetic ketoacidosis, 337  
 nosocomial infections, 181
- Leukodystrophies, 464, 494
- Leukopenia, **402**  
 cytarabine, 417  
 ganciclovir, 198  
 immunosuppressants and, 116  
 trimethoprim, 190
- Leukoplakia, 451
- Leukotriene receptor  
 antagonists, 455
- Leukotrienes, 455  
 basophils and, 387  
 cortisol effects, 319
- Leuprolide, **621**
- Levator veli palatin muscle, 587
- Levetiracetam, 514  
 tonic-clonic seizures, 663
- Levodopa, 517, **518**
- Levofloxacin  
 fluoroquinolones, 191  
 mechanism (diagram), 183  
*Pseudomonas aeruginosa*, 139
- Levomilnacipran, 545
- Levomorgestrel, 622
- Levothyroxine, **342**. *See also* Thyroid hormones
- Lewy bodies, 490
- Lewy body dementia, 490, 529
- Leydig cells  
 cryptorchidism, 617  
 endocrine function, 594  
 genital embryology, 589  
 tumors, 619
- LFA-1 antigens, 209
- LH. *See* Luteinizing hormone (LH)
- Libido  
 in geriatric patients, 259  
 testosterone and, 600
- Libman-Sacks endocarditis, 443
- Lice  
 disease vectors, 144, 145  
 head/scalp, 157  
 treatment, **196**
- Lichen planus, 169, 448, 453  
 presentation, 655
- Liddle syndrome, **556**  
 markers in, 560
- Lidocaine, 308, 519  
 arrhythmia, 661
- Life support  
 withdrawal, 257
- Li-Fraumeni syndrome  
 osteosarcomas, 438  
 tumor suppressor genes in, 218
- Ligaments, gastrointestinal, **346**
- Ligamentum arteriosum, 270
- Ligamentum teres hepatis, 270, 346
- Ligamentum venosum, 270
- Ligand receptors, 204
- Light criteria, 212
- Likelihood ratio (LR), 247
- Limbic system, **468**
- Limit dextrin, 82
- Limited scleroderma, 446
- Linagliptin, 341
- Lindane, 196
- Linea alba, 354
- Linear ulcers, in esophagitis, 360
- Linear viruses, 159
- Lines of Zahn, 637, 660
- Lineweaver-Burk plot, 224
- Linezolid, **189**  
 highly resistant organisms, 194  
 mechanism (diagram), 183  
 protein synthesis inhibition, 187
- Linkage disequilibrium, 52
- Lipase  
 as pancreatic secretions, 358  
 in pancreatitis, 380
- Lipid-lowering agents, **306**
- Lipids  
 metabolism of, 70  
 transport of, **88**  
 viral structure, 158
- Lipodystrophy  
 insulin and, 340  
 protease inhibitors, 199  
 tesamorelin for, 315
- Lipofuscin, **213**
- Lipoic acid, 72
- Lipoid nephrosis, 566
- Lipolysis  
 cortisol and, 319  
 insulin and, 314  
 in insulin deficiency, 336  
 niacin and, 306  
 sympathetic receptors and, 230  
 thyroid hormones and, 321
- Lipomas, 216
- Lipoprotein lipase, 88
- Lipoproteins, **89**
- Liposarcomas, 216
- Lipoteichoic acid, 120
- Liquefactive necrosis, 205
- Liraglutide, 341
- Lisch nodules  
 neurofibromatosis, 495, 652
- Lisinopril, 577
- Lispro insulin, 340. *See also* Insulin
- Listeria* spp  
 catalase-positive organism, 124  
 Gram-positive algorithm, 130  
 intracellular organism, 124  
 meningitis, 176  
 taxonomy, 121
- Listeria monocytogenes*, **135**  
 $\beta$ -hemolysis, 131  
 granulomatous diseases, 211  
 neonates, 178  
 penicillins for, 184
- Lithium, **544**  
 for bipolar disorder, 531, 661  
 diabetes insipidus and, 334, 240  
 hypothyroidism, 240, 328  
 prenatal exposure, 288, 290  
 teratogenicity, 582  
 therapeutic index value of, 228
- Live attenuated vaccines, 107, 158
- Livedo reticularis, 517
- Liver  
 blood supply and innervation  
 of, **348**  
 in gastrointestinal anatomy, 346  
 ischemia in, 206  
 lipid transport and, 88  
 as metastasis site, 221  
 tissue architecture, **352**
- Liver disease  
 acanthocytes in, 394  
 alcoholic, 374  
 anemia, 398  
 in anemia taxonomy, 396  
 cystic fibrosis, 56  
 echinocytes in, 394  
 labs/findings, 660  
 loading and maintenance dose  
 in, 225  
 target cells in, 395
- Liver failure  
 Budd-Chiari syndrome and, 375  
 movement disorder in, 489  
 Wilson disease as cause, 378
- Liver fluke  
 hyperbilirubinemia caused  
 by, 376  
 as oncogenic microbe, 219
- Liver pathology serum markers, **373**
- Liver tumors, **375**
- Living wills, 255
- Lleukoerythroblastic reaction, 402
- LMN facial nerve palsy  
 presentation, 656
- Loading dose, 225, 669
- Loa loa*, 154, 155
- Lobar pneumonia, 643, 645
- Lobular carcinomas, 614
- Local anesthetics, **519**  
 naming convention, 244
- Locked-in syndrome  
 basilar artery lesions, 485  
 osmotic demyelination  
 syndrome, 492
- Lockjaw  
*Clostridium tetani*, 134  
 tetanospasmin, 128
- Locus heterogeneity, **53**
- Löffler medium, 123
- Löffler syndrome, 297
- Lomustine, 418  
 in cell cycle, 416
- Lone Star tick (disease vector), 144
- Long QT syndrome  
 ranolazine, 305  
 sudden cardiac death, 293
- Loop diuretics, **575**  
 for heart failure, 298  
 metabolic alkalosis, 561  
 site of action, 574  
 toxicity of, 242
- Loop of Henle, 574
- Loperamide, **382**, 520
- Lopinavir  
 HIV therapy, 199  
 mechanism (diagram), 197
- Loratadine, 648
- Lorazepam, 515  
 alcohol withdrawal, 542
- Losartan, 577
- Lou Gehrig disease, 500
- Lovastatin, 306
- Low birth weight, **599**
- Löwenstein-Jensen agar, 123
- Lower esophageal sphincter  
 achalasia and, 360  
 in Barrett esophagus, 361
- Lower extremity nerves, **430**
- Lower left quadrant (LLQ)  
 pain, 366
- Lower motor neuron (LMN)  
 lesions, 501, 502
- LPS endotoxin, 120, 127, 129, 140
- LTB<sub>4</sub> (Leukotriene B<sub>4</sub>), 386, 455
- Lumbar puncture, 478, 491
- Lumbosacral radiculopathy, **432**
- Lumbrical muscles, 429  
 Klumpke palsy and, 428  
 median and ulnar nerves, 427
- Lumefantrine, 196
- Lunate bone, 426
- Lung abscesses, **646**
- Lung and chest wall expansion, **631**
- Lung cancer, **647**  
 apical tumor, 657  
 asbestosis and, 641  
 carcinogens causing, 219  
 cisplatin/carboplatin for, 419  
 eriotinib for, 420  
 hypercalcemia and, 217  
 incidence/mortality in, 216  
 metastases of, 221  
 neuromuscular paraneoplastic  
 syndromes and, 217  
 oncogenes and, 218  
 SIADH, 668  
 topotecan for, 419
- Lung diseases  
 obstructive, **638**  
 restrictive, **639**
- Lungs  
 anatomical relationships, **629**  
 autoregulation of, 286  
 development of, **626**  
 physical findings, **643**  
 sclerosis of, 446
- Lung volumes, **630**
- Lupus, **443**  
 acute interstitial nephritis, 572  
 anemia of chronic disease  
 and, 399  
 antiphospholipid syndrome, 443  
 autoimmune hemolytic anemia  
 and, 401  
 azathioprine for, 417  
 bacterial endocarditis, 299  
 DPGN, 564  
 HLA subtypes, 96  
 isoniazid, 193  
 lab/findings, 661  
 lymphopenia, 402  
 membranous nephropathy, 566  
 microangiopathic anemia, 401  
 neutropenia, 402  
 presentation, 652  
 Raynaud phenomenon, 445



- Lupus-like syndrome  
 $\alpha$ -methyl dopa, 235  
 as drug reaction, 241  
 hydralazine, 304  
 procainamide, 308  
 Lupus nephritis, 443  
 Lupus pernio, 444  
 Lurasidone, 543  
 Luteal phase, 597  
 Luteal phase of menstrual cycle, 597  
 Luteinizing hormone (LH)  
 clomiphene effect, 621  
 contraception, 622  
 cryptorchidism, 617  
 estrogen/progesterone, 595  
 hCG and, 584, 618  
 Klinefelter syndrome, 603  
 leuprolide, 621  
 menopause, 600  
 ovulation, 316, 596  
 PCOS, 609  
 pharmacologic control of, 620  
 premature ovarian failure, 609  
 secretion of, 313  
 sex development disorders, 604  
 signaling pathways of, 322  
 spermatogenesis, 316, 594  
 testosterone, 623  
 Turner syndrome, 603  
 Lyme disease, **142**  
 animal transmission, 144  
 AV block in, 284  
 ceftriaxone, 185  
 Lymphadenopathy  
 bilateral hilar, 639  
*Corynebacterium diphtheriae*,  
 128, 135  
 follicular lymphoma, 408  
 Kawasaki disease, 652  
 Lymphogranuloma venereum, 180  
 mononucleosis, 161  
 rubella, 165, 178, 179  
 serum sickness, 109  
 syphilis, 143, 180  
 tinea capitis, 148  
*Toxoplasma gondii*, 178  
*Trypanosoma brucei*, 152  
 Lymphatic gonadal drainage, 591  
 Lymphatic pleural effusion, 644  
 Lymphatic regional drainage, 93  
 deep inguinal nodes, 591  
 external iliac nodes, 591  
 gonadal drainage, 591  
 internal iliac nodes, 591  
 malignant breast tumors, 616  
 para-aortic lymph nodes., 591  
 superficial inguinal nodes., 591  
 Lymphedema, 603, 656  
 Lymph nodes, **92**  
 absent or scanty, 112  
 T cell differentiation, 97  
 TNM tumor staging, 216  
 tumor metastases, 221  
 Lymphocyte-depleted  
 lymphoma, 407  
 Lymphocyte-rich lymphoma, 407  
 Lymphocytes, **95–100, 388**  
 breast milk and, 599  
 CLL/small cell lymphocytic  
 lymphoma, 410  
 corticosteroid effect on, 402  
 lymph nodes, **92**  
 non-Hodgkin lymphoma, 408  
 spleen, 94  
 thymus, 94  
 Lymphocytic choriomeningitis virus  
 (LCMV), 163  
 Lymphocytosis, 94  
 Lymphogranuloma venereum,  
 146, 180  
 Lymphohistiocytosis, 113  
 Lymphoid hyperplasia, 366  
 Lymphoid structures, **92–93**  
 Lymphomas  
 allopurinol, 457  
 associations, 668  
 carcinogens causing, 219  
 celiac disease and, 364  
 cyclophosphamide for, 418  
 cytarabine for, 417  
 doxorubicin for, 418  
 EBV and, 161  
 etoposide/teniposide for, 419  
 hypercalcemia and, 217  
 leukemias vs, **407**  
 methotrexate for, 417  
 minimal change disease, 566  
 nomenclature for, 216  
 non-Hodgkin, 407, 408  
 oncogenic microbes, 219  
 of stomach, 362  
 thyroiditis association with, 330  
 Lymphopenias, 402  
 ataxia-telangiectasia, 113  
 corticosteroid effect on, 402  
 Lynch syndrome, 371  
 endometrial cancer, 612  
 mismatch repair and, 37  
 ovarian neoplasms, 610  
 Lysergic acid diethylamide  
 (LSD), 541  
 Lysine  
 classification of, 77  
 in cystinuria, 81  
 kidney stones, 567  
 for pyruvate dehydrogenase  
 complex deficiency, 73  
 Lysosomal  $\alpha$ -1,4-glucosidase, 83  
 Lysosomal storage diseases, 43, **84**  
 Lysozyme  
 innate immunity, 95  
 in neutrophils, 386  
*LYST* gene, 113  
 Lysyl oxidase, 47  
 Lytic bone lesions  
 adult T-cell lymphoma, 408  
 Langerhans cell histiocytosis, 412  
 multiple myeloma and, 409  
**M**  
 MacConkey agar, 122, 123, 138  
 Macroangiopathic anemia, 396, 401  
 Macrocytic anemia, 396, **398**  
 Macroglossia, 569  
 Macrolides, **189**  
 cytochrome P-450 and, 243  
 hypertrophic pyloric stenosis  
 and, 345  
*Legionella pneumophila*, 139  
 mechanism (diagram), 183  
*Mycoplasma pneumoniae*, 146  
 naming convention for, 244  
 protein synthesis inhibition, 187  
 torsades de pointes, 239  
 Macroorchidism, 58  
 Macro-ovalocytes, 394  
 Macrophages, **387**  
 alveolar, 628  
 apoptosis and, 204  
 bilirubin and, 359  
 binding of, 100  
 breast milk and, 599  
 cell surface proteins, 106  
 in chronic inflammation, 207  
 cytokine secretion, 104  
 endotoxin activation, 129  
 endotoxins/lipopolysaccharide, 106  
 innate immunity, 95  
 in lymph node, 92  
 lymphocyte interaction, 98  
 in MI, 294  
 necrosis and, 205  
 pneumoconioses, 641  
 in spleen, 94  
 in wound healing, 211  
 Macrosomia, 582  
 Macula densa, 550  
 filtration and, 553  
 juxtaglomerular apparatus, 558  
 Macular cherry-red spot, 84, 507, 652  
 Macular degeneration, **506**  
 Macules, 447  
 Maculopapular rash  
 graft-versus-host disease, 115  
 rubeola, 166  
 syphilis, 143  
 Magnesium  
 antiarrhythmic treatment, 310  
 cardiac glycoside toxicity, 307  
 proton pump inhibitor effect  
 on, 381  
 PTH regulation, 320  
 in renal disorders, 560  
 torsades de pointes and, 283  
 Magnesium citrate, 383  
 Magnesium hydroxide, 382, 383  
 Magnesium sulfate  
 preeclampsia/eclampsia, 608  
 Maintenance dose, 225, 669  
 Maintenance stage, 539  
 Major basic protein (MBP), 387  
 Major depressive disorder, 530, **531**  
 tricyclic antidepressants, 545  
 Major ducts (breast), 614  
 Malabsorption syndromes, **364, 365**  
 fat-soluble vitamin deficiencies, 61  
 osteoporosis, 435  
 Malaria  
 anemia in, 401  
 artesunate for, 196  
*Plasmodium*, 153  
 quinidine/quinine for, 196  
*Malassezia* spp, 148  
 Malathion, 196  
 Male genital embryology, 589  
 Male reproductive anatomy, **593**  
 Male sexual response, 593  
 Maleylacetoacetic acid, 79  
 Malignant hypertension  
 microangiopathic anemia, 401  
 RBC casts in, 562  
 Malignant hyperthermia, 519, 520  
 Malignant melanomas  
 IFN- $\alpha$  for, 200  
 recombinant cytokines, 117  
 Malignant mesotheliomas, 220  
 Malignant tumors, 216  
 Malingering, **536**  
 Malleus, 503  
 Malleus (ossicles), 587  
 Mallory bodies  
 in alcoholic hepatitis, 374  
 Mallory-Weiss syndrome,  
 360, 656  
 Malnutrition, **67**  
 superior mesenteric artery  
 syndrome and, 348  
 Malrotation, **367**  
 Maltese cross appearance, 153  
 “Maltese cross” sign, 562  
 MALT lymphomas  
*Helicobacter pylori*, 142  
 oncogenic microbes and, 219  
 Sjögren syndrome, 441  
 Mammary glands, 581  
 Mamillary bodies, 468, 474, 481  
 Korsakoff syndrome, 528  
 Wernicke-Korsakoff  
 syndrome, 541  
 Mandibular process, 587  
 Mango flies (disease vector), 155  
 Manic episodes, **530**  
 Mannitol, **575**  
 extracellular volume and, 551  
 site of action, 574  
 Mantle cell lymphoma, 408, 412  
 chromosomal translocations  
 and, 412  
 Mantle zone  
 lymph nodes, 92  
 spleen, 94  
 MAO inhibitors, **546**  
 atypical depression, 531  
 mechanism of, 544  
 Parkinson disease, 517  
 phobias, 533  
 selegiline/rasagiline, 518  
 serotonin syndrome, 545  
 tyramine and, 236  
 Maple syrup urine disease, **80**  
 Marantic endocarditis, 217  
 Marasmus, **67**  
 Maraviroc, 197, 199  
 Marburg hemorrhagic fever, 163  
 Marcus Gunn pupils, **509**  
 multiple sclerosis, 493  
 Marfanoid habitus  
 homocystinuria, 80  
 MEN 2B syndrome and, 339

- Marfan syndrome  
 aortic aneurysms, 664  
 aortic dissection and, 293  
 cardiac defect association, 290  
 cataracts, 505  
 chromosome association, 60  
 elastin and, 48  
 heart murmur with, 279  
 presentation, 652  
 thoracic aortic aneurysms and, 292
- Marginal zone lymphoma, 408
- Marijuana  
 intoxication and withdrawal, 541  
 schizophrenia and, 530
- Masseter muscle, 587
- Massive hepatic necrosis, 240
- Mast cells, **387**  
 IgE antibody and, 101
- Mastectomy and winged  
 scapula, 428
- Mastication muscles, **477**
- Mastitis, 614
- Mastoid air cells, 588
- Mastoiditis  
 brain abscesses, 176  
 Wegener granulomatosis, 302
- Maternal diabetes  
 cardiac defect association, 290
- Maternal-fetal placental barrier, 466
- Maternal PKU, 80
- Mature cystic teratomas, 610
- Mature ego defenses, 525
- Maxillary artery, 586
- Maxillary process, 587
- Mayer-Rokitansky-Küster-Hauser  
 syndrome, 589
- McArdle disease, 83
- McBurney point, 366
- McBurney sign, 656
- McCune-Albright syndrome, 53, 652
- McMurray test, 424
- MDMA (ecstasy), 541
- Mean, 251
- Mean arterial pressure, 272, 472, 669
- Measles, **166**, 179  
 paramyxovirus, 163, 165, 166  
 presentation, 656  
 unvaccinated children, 182  
 vaccine, 107, 158  
 vitamin A for, 62
- Measurement bias, 250
- Measures of central tendency, 251
- Measures of dispersion, 251
- Mebendazole, 196  
 microtubules and, 44
- “Mechanic’s hands” in  
 dermatomyositis, 445
- Meckel diverticulum, **367**, 585
- Meconium ileus, 369  
 cystic fibrosis, 56
- MECP2, 527
- Medial antebrachial cutaneous  
 nerve, 427
- Medial brachial cutaneous  
 nerve, 427
- Medial calcific sclerosis, 291
- Medial cerebellar lesions, 469
- Medial collateral ligament (MCL)  
 injury  
 abnormal passive abduction in, 424  
 in “unhappy triad,” 425
- Medial epicondylitis, 426
- Medial femoral circumflex artery, 436
- Medial geniculate nucleus  
 (MGN), 468
- Medial hypertrophy, 643
- Medial lemniscus, 484
- Medial longitudinal fasciculus, 513
- Medial medullary syndrome, 484
- Medial meniscal tear, 425
- Medial pterygoid muscle, 587
- Medial rectus muscle, 510
- Medial umbilical ligament, 270, 354
- Median, 251
- Median claw, 429
- Median nerve  
 carpal tunnel syndrome, 426  
 injury to, 427
- Median umbilical ligament,  
 354, 550
- Mediastinal lymph nodes, 93
- Mediastinitis, 133
- Medical abortion  
 ethical situations, 256  
 methotrexate for, 417
- Medical errors, **262**
- Medical power of attorney, 255
- Medicare/Medicaid, 260
- Medication errors, 262
- Medium-chain acyl-CoA  
 dehydrogenase  
 deficiency, 85
- Medroxyprogesterone, 622
- Medulla  
 lymph nodes, 92  
 thymus, 97
- Medulla (brain)  
 brain stem, 460  
 cranial nerves and nuclei, 474,  
 475  
 pyramids of, 474  
 spinal tracts and, 479  
 strokes in, 484–485
- Medullary carcinomas, 616
- Medullary cords (lymph nodes), 92
- Medullary cystic disease, 573
- Medullary pyramids (renal), 550
- Medullary thyroid carcinomas,  
 330, 339  
 oncogenes and, 218
- Medulloblastoma, 664, 498
- Mefloquine, 153
- Megacolon  
 Chagas disease, 154  
 in Hirschsprung disease, 367
- Megakaryocytes in essential  
 thrombocytopenia, 411
- Megaloblastic anemia, 396, 398  
 cytarabine, 417  
*Diphyllobothrium latum*, 156  
 as drug reaction, 241  
 epilepsy drugs, 514  
 macro-ovalocytes in, 394  
 orotic aciduria, 398
- trimethoprim, 190  
 tropical sprue as cause, 364
- Vitamin B<sub>9</sub> deficiency, 64  
 vitamin B<sub>12</sub> deficiency, 65
- Megestrol, 622
- Meglitinides, 341
- Meigs syndrome, 610
- Meissner corpuscles, 464
- Melanocytes  
 embryologic derivatives, 581  
 tumor nomenclature in, 216  
 in vitiligo, 448
- Melanocyte-stimulating hormone  
 secretion of, 313  
 signaling pathways of, 322
- Melanocytic nevus, 449
- Melanomas  
 nomenclature for, 216  
 oncogenes and, 218  
 of skin, 454  
 sunburn and, 453  
 tumor suppressor genes and, 218
- Melarsoprol, 152, 196
- Melasma, 448
- MELAS syndrome, 55
- Melatonin  
 circadian rhythms and, 467  
 derivation, 79
- Melena  
 Meckel diverticulum, 585  
 Meckel diverticulum as cause,  
 367  
 polyarteritis nodosa, 302
- Meloxicam, 456
- Memantine, 518
- Membrane attack complex  
 (MAC), 100  
 complement and, 103  
 in type II hypersensitivity, 108
- Membranoproliferative  
 glomerulonephritis  
 (MPGN), 565  
 DPGN and, 564  
 hepatitis B and C, 169
- Membranous glomerular  
 disorders, 563  
 hepatitis B and C, 169
- Membranous interventricular  
 septum, 269
- Membranous nephropathy, 566, 660
- Membranous ossification, 434
- Membranous ventricular  
 septum, 269
- Memory loss  
 anti-NMDA receptor  
 encephalitis, 217  
 Wernicke-Korsakoff syndrome, 62,  
 481, 541
- MEN1 gene, 218
- Ménétrier disease, **362**
- Ménière disease  
 vertigo with, 503
- Menin, 218
- Meninges, 465
- Meningiomas, 496  
 lab/findings, 660  
 Psammoma bodies in, 220
- Meningitis  
 ceftriaxone, 185  
 chloramphenicol, 188  
 coccidioidomycosis, 147  
 common causes, 176  
*Cryptococcus neoformans*, 149  
 CSF findings in, 176  
 fluconazole, 195  
 flucytosine, 195  
*Haemophilus influenzae*, 138  
 headaches with, 488  
 HIV-positive adults, 173  
*Listeria monocytogenes*, 135  
 meningococci, 138  
 mumps as cause, 166  
 in neonates, 178  
 rifamycin prophylaxis, 192  
*Streptococcus pneumoniae*, 132  
*Streptococcus agalactiae*, 133  
 tuberculosis, 136  
 unvaccinated children, 182
- Meningocele, 461
- Meningococcal prophylaxis, 194
- Meningococcal vaccine, 124
- Meningococemia  
 endotoxins, 127  
 meningococci, 138
- Meningococci, 138
- Meningoencephalitis  
 HSV-2, 178  
*Naegleria fowleri*, 152  
 West Nile virus, 163
- Meningomyelocele, 461
- Meniscal tear, 424, 425
- Menkes disease, 46, **47**
- Menometrorrhagia, 597
- Menopause, **600**  
 fibroid tumors in, 612  
 hormone replacement therapy, 621
- Menorrhagia, 597
- Membranoproliferative  
 adenomyosis, 612  
 anemia with, 396
- Menstrual cycle, **597**  
 estrogens for, 621
- Meperidine, 520
- Mepivacaine, 519
- Mercury poisoning, 239
- Merkel discs, 464
- Merlin protein, 218
- Meropenem, 183, 186
- MERS (Middle East respiratory  
 syndrome), 163
- Mesalamine, 365, 664
- Mesangial cells, 550  
 filtration, 553  
 juxtaglomerular apparatus, 558
- Mesencephalon, 460
- Mesenchymal tumors  
 nomenclature of, 216  
 vimentin stain for, 44
- Mesenteric arteries, 549
- Mesenteric ischemia, 369  
 presentation, 655
- Mesenteric veins, 350
- Mesocortical pathway, 468
- Mesoderm, 460  
 branchial arches derivation, 586  
 derivatives of, 581

- Mesolimbic pathway, 468  
 Mesonephric duct, 589  
 Mesonephros, 548  
 Mesosalpinx, 592  
 Mesotheliomas, **641**  
   carcinogens causing, 219  
   Psammoma bodies in, 220  
 Mesovarium, 592  
 Mestranol, 621  
 Metabolic acidosis, 561  
   adrenal insufficiency, 324  
   Fanconi syndrome, 556  
   neonatal respiratory distress syndrome, 627  
   renal failure, 571  
   symptoms of, 561  
 Metabolic alkalosis, 561  
   acetazolamide for, 575  
   causes of, 561  
   Gitelman syndrome, 556  
   hyperaldosteronism, 324  
   hypertrophic pyloric stenosis as cause, 345  
   loop diuretics, 575  
   syndrome of apparent  
     mineralocorticoid excess, 556  
     thiazides, 576  
 Metabolic fuel use, **87**  
 Metabolic syndrome  
   atypical antipsychotics, 543  
   non-alcoholic fatty liver disease and, 374  
 Metabolism, **68–90**  
   amino acid derivatives, 79  
   amino acids, 77  
   apolipoproteins, 89  
   catecholamine synthesis/tyrosine catabolism, 79  
   disorders of, 76, 77, 80–81, 83, 84–85, 90  
   of drugs, **226**  
   ethanol, **68**  
   fatty acid, 85  
   fuel use, 87  
   gluconeogenesis, 74  
   glycogen and, 82  
   lipoprotein functions, 89  
   pathway summary, 70  
   pyruvate, 73  
   rate-determining enzymes, 69  
   sites of, 68  
   TCA cycle, 73  
   urea cycle, 78  
 Metabolites, 544  
 Metacarpophalangeal (MCP) joints, 429  
 Metachromatic leukodystrophy, 84, 494  
 Metalloproteinases, 211  
 Metal storage diseases, 210  
 Metanephric mesenchyme, 548  
 Metanephries  
   pheochromocytoma, 326  
   tyrosine catabolism, 79  
 Metanephros, 548  
 Metaphase, 42  
 Metaphyseal tumors, 438  
 Metaplasia, 214  
   benign breast disease, 615  
   cervical, 592  
   esophagus, 361  
   gastric, 362  
 Metastases, **221**  
   of liver cancer, 375  
   of lung cancer, 647  
   neoplastic progression in, 215  
   ovarian, 664  
 Metastatic calcification, 208  
 Metastatic melanomas  
   recombinant cytokines for, 117  
   vemurafenib for, 421  
 Metencephalon, 460  
 Metformin, 340  
   diarrhea caused by, 240  
 Methacholine, 232  
 Methacholine challenge, 638, **649**  
 Methadone, 520  
   heroin addiction, 541  
   intoxication and withdrawal, 540  
   for opioid withdrawal, 540  
 Methamphetamine, 542  
 Methanol toxicity, 239  
 Methemoglobin, 632  
   toxicity treatment, 239  
 Methemoglobinemia, 632  
   local anesthetics and, 519  
 Methicillin, 240  
 Methimazole, 321, 341. *See also* Thionamides  
   agranulocytosis, 241  
   aplastic anemia, 241  
   teratogenicity, 582  
 Methionine, 190  
   classification of, 77  
   start codons, 37  
   tRNA charging, 40  
 Methotrexate, 417  
   in cell cycle, 416  
   folate deficiency, 398  
   hydatidiform moles, 605  
   megaloblastic anemia, 241  
   polymyositis/dematomyositis, 445  
   pulmonary fibrosis, 242  
   pyrimidine synthesis and, 33  
   rheumatoid arthritis, 439  
   targets of, 416  
   teratogenicity, 582  
   toxicities of, 422  
   toxicity, 639  
   vitamin B<sub>9</sub> deficiency, 64  
   as weak acid, 226  
 Methoxyflurane, 519  
 Methylation, 41  
 Methylcellulose, 383  
 Methyl dopa  
   Coombs-positive hemolytic anemia, 241  
   hypertension in pregnancy, 304  
 Methylene blue, 239, 632  
 Methylmalonic acid  
   vitamin B<sub>9</sub> deficiency, 64  
   vitamin B<sub>12</sub> deficiency, 65  
 Methylmalonyl-CoA mutase, 65  
 Methylmercury teratogenicity, 582  
 Methylphenidate  
   for ADHD, 527, 542, 661  
   CNS stimulant, 542  
 Methylprednisone, 455  
 Methyltestosterone, **623**  
 Methylxanthines, **649**  
 Metoclopramide, **383**  
   Parkinson-like syndrome, 242  
   tardive dyskinesia, 242  
 Metolazone, 576  
 Metoprolol, 237, 309  
 Metronidazole, **191**  
   bacterial vaginosis, 144  
   clindamycin vs, 188  
   *Clostridium difficile*, 134  
   for Crohn disease, 365  
   disulfiram-like reaction, 242  
   *Giardia lamblia*, 151  
   *Helicobacter pylori*, 142  
   mechanism (diagram), 183  
   *Trichomonas vaginalis*, 664  
   vaginal infections, 177  
   vaginitis, 154  
 Metrorrhagia, 597  
 Metyrapone, 324  
 Metyrosine, 231  
 Mevalonate synthesis, 306  
 Mexiletine, 308  
   arrhythmia, 661  
 Meyer loop, 511  
 MHC I and II, **96**  
   cell surface proteins, 106  
   dendritic cells and, 388  
 Micafungin, 194, 196  
 Michaelis-Menten kinetics, 224  
 Miconazole, 194, 195  
 Microalbuminuria, 336  
 Microangiopathic anemia, 401  
   in anemia taxonomy, 396  
 Microangiopathic hemolytic anemia  
   hypertensive emergency and, 290  
   intravascular hemolysis in, 399  
 Microarrays, **50**  
 Microbiology, **120–200**  
   antimicrobials, 183–200  
   bacteriology, 120–130  
   clinical bacteriology, 130–146  
   mycology, 147–150  
   parasitology, 151–157  
   systems, 174–182  
   virology, 158–173  
 Microcephaly  
   cri-du-chat syndrome, 60  
   fetal alcohol syndrome, 583  
   maternal phenylketonuria, 80  
   maternal X-ray exposure, 582  
   Patau syndrome, 59  
 Microcytic anemia, **396**  
   *Ancylostoma*, 157  
   key associations, 667  
 Microcytosis, 212  
 Microfilaments (cytoskeleton), 44  
 Microglia, 460, **463**  
 Micrognathia  
   Edwards syndrome, 59  
   Pierre Robin sequence, 587  
 Microhematuria, 400  
 Micromelia, 582  
 Microphthalmia, 59  
 MicroRNAs, **39**  
 Microscopic polyangiitis, **302**  
   labs/findings, 657  
   RPGN and, 564  
*Microsporium*, 148  
 Microtubule inhibitors, **419**  
   in cell cycle, 416  
 Microtubules, 44  
 Midazolam, 515, 519  
 Midbrain  
   development, 460  
   lesions in, 481  
 Middle cerebellar peduncle, 474  
 Middle cerebral artery (MCA)  
   in circle of Willis, 473  
   cortical distribution, 472  
   saccular aneurysms, 486  
   stroke effects, 484  
 Middle meningeal artery  
   epidural hematoma and, 483  
 Middle rectal vein, 350  
 Midgut  
   blood supply/innervation of, 348  
   development of, 344  
 Midodrine, 234  
 Midshaft of humerus, 432  
 Mifepristone, 622  
 Miglitol, 341  
 Migraine headaches, 488  
   butorphanol for, 521  
   hormonal contraception  
     contraindication, 622  
   TCAs as, prophylaxis, 545  
   triptans for, 516  
 Migrating motor complexes (MMC), 356  
 Migratory polyarthritis, 300  
 Milestones (developmental), 258  
 Miliary tuberculosis, 136  
 Milnacipran, 545  
 Milrinone, 305  
 Mineralocorticoids  
   adrenal insufficiency, 324  
   adrenal steroids and, 318  
 Mineral oil, 61  
 Minimal alveolar concentration, 518  
 Minimal change disease, 566  
 Minocycline, 183, 188  
 Minors, consent for, 254  
 Minoxidil, **623**  
 Minute ventilation, 630  
 Miosis  
   cholinesterase inhibitor  
     poisoning, 232  
   Horner syndrome, 509, 655  
   opioids, 520  
   Pancoast tumor, 646  
   pupillary control, 509  
   sympatholytic drugs, 235  
 Mirtazapine, 236, 546  
   anorexia nervosa, 661  
   major depressive disorder, 531  
   mechanism of, 544  
 Mismatch repair, **37**

- Misoprostol, **382**  
diarrhea, 240
- Missense mutations, **36**
- Mites/louse treatment, **196**
- Mitiglinide, 341
- Mitochondria  
high altitude and, 635  
metabolism in, 68  
muscle fibers, 433
- Mitochondrial encephalopathy, 55
- Mitochondrial inheritance, 55
- Mitochondrial myopathies, 55
- Mitosis, 42  
griseofulvin, 196
- Mitral regurgitation  
in MI, 294  
murmurs caused by, 278, 279  
S3 heart sound, 668  
tuberous sclerosis, 495
- Mitral stenosis  
left heart disease, 643  
murmurs caused by, 278, 279
- Mitral valve  
in cardiac cycle, 276  
regurgitation in, 300
- Mitral valve prolapse, 279  
fragile X syndrome, 58  
renal cyst disorders and, 573
- Mittelschmerz, 596
- Mivacurium, 520
- Mixed cellularity lymphoma, 407
- Mixed connective tissue disease, **443**  
anti-U1 RNP antibodies and, 39  
Raynaud phenomenon, 445
- Mixed transcortical aphasia, 486
- MMR vaccine, 158, 166
- Mobitz AV blocks, 284
- Modafinil, 538
- Mode, 251
- Molecular biochemistry, **32–41**
- Molecular motor proteins, 44
- Molluscum contagiosum, 160, 451
- Mönckeberg sclerosis, 291
- “Monday disease,” 305
- Monobactams, **186**  
mechanism (diagram), 183  
*Pseudomonas aeruginosa*, 139
- Monoclonal gammopathy of undetermined significance (MGUS), 409
- Monocytes, **386, 387**  
innate immunity and, 95  
morulae in, 145
- Mononucleosis  
anemia and, 401
- Monospot test, 161
- Montelukast, 649  
arachidonic acid pathway, 455
- Mood disorders, **530**  
readmissions with, 261
- Moon facies, 323
- Moraxella* spp  
Gram-negative algorithm, 137  
taxonomy, 121
- Moraxella catarrhalis*  
rhinosinusitis, 636
- Moro reflex, 258, 480
- Morphine, 520  
for acute coronary syndromes, 296  
buprenorphine and, 228  
intoxication and withdrawal, 540
- Morphogenesis of heart, 268–269
- Morulae, 145
- Mosaicism, **53**
- Mosquitoes (disease vectors)  
lymphatic filariasis, 155  
malaria, 153  
Zika virus, 167
- Motilin, 356
- Motion sickness, 233
- Motor cortex, 484
- Motor neuron signs, **499**
- Movement disorders, **489**
- Moxifloxacin, 191
- M phase, 42
- MPO-ANCA, 111
- M protein  
in multiple myeloma, 409  
rheumatic fever and, 132  
as virulence factor, 125
- mRNA  
aminoglycosides, 187  
hepatitis viruses, 168  
pre-mRNA splicing, **39**  
processing, 38  
protease inhibitors, 199  
stop codons, **37**  
viral genome, 159
- MRSA (methicillin-resistant *Staphylococcus aureus*)  
cephalosporins, 185  
highly resistant, 194  
nosocomial infections, 131  
oxazolidinones, 189  
vancomycin, 186
- MSH. *See* Melanocyte-stimulating hormone (MSH)
- mTOR, 116
- Mucicarmine stain, 122
- Mucinous cystadenocarcinomas, 611
- Mucinous cystadenomas, 610
- Mucociliary escalator, 628
- Mucoepidermoid carcinomas, 359
- Mucoid polysaccharide capsule, 139
- Mucopolysaccharides, 122
- Mucopolysaccharidoses, 84
- Mucor* spp  
amphotericin B for, 195  
opportunistic infection, 149  
presentation, 652
- Mucormycosis, 149  
diabetic ketoacidosis, 337
- Mucosa, 347
- Mucosal bleeding  
scurvy, 656
- Mucositis  
bleomycin, 418  
methotrexate, 417
- Mucus, 230
- Mulberry molars, 143
- Müllerian duct  
agenesis, 589  
anomalies of, **590**  
derivatives of, 589
- Müllerian inhibitory factor (MIF), 589  
Sertoli cell production, 594
- Multicystic dysplastic kidney, **549**
- Multifactorial pulmonary hypertension, 643
- Multiorgan drug reactions, **242**
- Multiple endocrine neoplasias (MEN syndromes), **339**  
Zollinger-Ellison syndrome, 338
- Multiple myeloma, **409**  
ESR in, 212  
Fanconi syndrome, 556  
lab/diagnostic findings, 660  
osteoporosis, 435  
as plasma cell cancer, 389
- Multiple sclerosis, **493**  
heart murmur with, 279  
HLA-DR2 and, 96  
IFN- $\beta$  for, 200  
internuclear ophthalmoplegia, 513  
natalizumab for, 118  
oligodendroglia in, 464  
presentation, 655  
recombinant cytokines for, 117  
as type IV hypersensitivity, 109
- Mumps, **166**  
acute pancreatitis caused by, 380  
paramyxovirus, 163, 165  
vaccine for, 107
- Munchausen syndrome, 536
- Munchausen syndrome by proxy, 536
- Muscarinic acetylcholine (ACh) receptors, 229
- Muscarinic antagonists, **233, 649**  
multiple sclerosis, 493  
neuromuscular blocking, 520  
Parkinson disease, 517
- Muscle fibers, **433**
- Muscle relaxants, 520
- Muscles  
conduction to contraction, **433**  
metabolism in, 82  
ragged red fibers in, 55
- Muscle spasms  
relaxants for, 520
- Muscle tumors  
stain for, 44
- Muscular dystrophies, **57**  
frameshift mutation, 36, 57  
presentation, 652, 656  
X-linked recessive disorder, 56
- Muscularis externa, 347
- Muscularis mucosa, 347
- Muscular ventricular septum, 269
- Musculocutaneous nerve, 427
- Musculoskeletal drug reactions, **241**
- Musculoskeletal system  
anatomy, 424–432  
pathology, 435–443  
pharmacology, 455–457
- Mutases, 69
- Mutations in DNA, **36**
- Mutism, 536
- Myalgias  
Ebola virus, 167  
fluoroquinolones, 191
- genital herpes, 180
- Jarisch-Herxheimer reaction, 143
- Lyme disease, 142
- meningitis, 182  
*Trichinella spiralis*, 157  
trichinosis, 155
- Myasthenia gravis, **445**  
diagnosis of, 232  
neostigmine for, 232  
as paraneoplastic syndrome, 217  
pyridostigmine for, 232  
restrictive lung disease, 639  
type II hypersensitivity, 108
- MYCL1 gene, 218
- MYCN gene, 218
- Mycobacterial cells, 192
- Mycobacterium* spp, **136**  
granulomatous diseases, 211  
intracellular organism, 124  
taxonomy, 121
- Mycobacterium avium-intracellulare*, **136**  
HIV-positive adults, 173  
prophylaxis with HIV, 194  
vertebral osteomyelitis, 176
- Mycobacterium leprae*  
animal transmission, 144  
diagnosis, 137  
rifamycins/dapsone, 192
- Mycobacterium marinum*, 136
- Mycobacterium pneumoniae*, 123
- Mycobacterium scrofulaceum*, 136
- Mycobacterium tuberculosis*, 136  
aerobic organism, 123  
culture requirements for, 123  
osteomyelitis, 176  
therapeutic agents, 192, 193
- Mycolic acid  
isoniazid, 193  
synthesis of, 192
- Mycology, **147–150**
- Mycophenolate, 33
- Mycophenolate mofetil, 116, 117
- Mycoplasma* spp  
atypical organisms, 175  
macrolides, 189  
pneumonia, 645  
pneumonia caused by, 175
- Mycoplasma pneumoniae*, **146**  
anemia and, 401  
erythema multiforme, 452  
tetracyclines, 188
- Mycoses  
cutaneous, **148**  
granulomatous diseases, 211  
systemic, **147**
- Mycosis fungoides, 408
- Mydriasis  
 $\alpha$ -agonists, 521  
G-protein-linked second receptor, 230  
muscarinic antagonists for, 233  
pupillary control, 509  
saccular aneurysm, 486
- Myelencephalon, 460
- Myelin, **464**
- Myelodysplastic syndromes, **409**  
sideroblastic anemia, 397

- Myelofibrosis, 411  
 dacrocytes in, 394
- Myeloperoxidase, 105  
 in neutrophils, 386
- Myeloproliferative disorders, **411**  
 AML, 410  
 basophilic, 387  
 chronic, **411**  
 hydroxyurea for, 419
- Myelosuppression  
 alkylating agents, **418**  
 antimetabolites, 417  
 drugs causing, **422**  
 hydroxyurea, 419  
 irinotecan/topotecan, **419**
- Myenteric nerve plexus, **347**
- Mylohyoid muscle, 587
- Myocardial action potential, **280**
- Myocardial depression, 519
- Myocardial infarction (MI), 293  
 β-blockers for, 237  
 Class IB antiarrhythmics after, **308**  
 complications of, **295**  
 diabetes mellitus, 336  
 diagnosis of, **295**  
 on ECG, 282  
 evolution of, 294  
 heart failure caused by, 298  
 heparin for, 413  
 homocystinuria, 80  
 hypertensive emergency and, 290  
 shock caused by, 299  
 thrombolytics for, 415
- Myocardial oxygen demand, 273
- Myocarditis  
*Corynebacterium diphtheriae*, 135  
 coxsackievirus, 163  
 diphtheria, 135  
 picornaviruses, 163  
*Toxocara canis*, 155
- Myoclonic seizures, 487
- Myoclonus, 489
- Myofibroblasts, 211
- Myoglobin  
 in muscle fibers, 433  
 oxygen-hemoglobin dissociation curve, 632
- Myoglobinuria  
 acute tubular necrosis, 572  
 McArdle disease, 83
- Myometrium, 592
- Myonecrosis, 134
- Myopathy  
 daptomycin, 191  
 as drug reaction, 241  
 interferons, 200  
 lipid-lowering agents and, 306
- Myophosphorylase, 83
- Myopia, 504  
 retinal detachment, 507
- Myosin  
 smooth muscle contraction, 434  
 striated muscle contraction, 433
- Myosin-light-chain kinase (MLCK), 434
- Myotonic dystrophy  
 cataracts and, 505
- Myotonic type I muscular dystrophy, **57**
- Myxedema  
 hypothyroidism, 327  
 thyroid hormones for, 342
- Myxomas, 301
- Myxomatous degeneration, 279
- N**
- N-acetylcysteine, 648  
 for acetaminophen toxicity, 239  
 for cystic fibrosis, 56
- N-acetylglucosaminyl-1-phosphotransferase, 43
- NADH (nicotinamide adenine dinucleotide)  
 electron transport chain, 74  
 fructose metabolism, 76  
 TCA cycle, 73
- Nadolol, 237
- NADPH (nicotinamide adenine dinucleotide phosphate)  
 ethanol metabolism, 68  
 HMP shunt and, 75  
 respiratory burst and, 105  
 universal electron acceptors, 71
- Naegleria fowleri*, **152**
- Nafcillin  
 characteristics of, 184  
 mechanism (diagram), 183
- Nails  
 clubbing, 56  
 glomus tumors under, 450  
 splinter hemorrhages, 299
- Naive T-cell activation, 99
- Naked viral genome infectivity, **159**
- Nalidixic acid, 183
- Naloxone  
 dextromethorphan overdose, 648  
 heroin addiction, 541  
 for opioid toxicity, 239  
 opioid toxicity, 520, 540
- Naltrexone  
 alcoholism, 541, 661  
 heroin addiction, 541  
 opioid toxicity, 520, 540
- Naproxen, 456  
 acute gout drugs, 457  
 arachidonic acid pathway, 455
- Narcissistic personality disorder, 535
- Narcolepsy, **538**  
 amphetamines for, 234  
 CNS stimulants for, 542  
 hypnagogic hallucinations, 529
- Nasal congestion, 648
- Nasal decongestion  
 ephedrine for, 234
- Nasal polyps  
 cystic fibrosis, 56
- Nasal septum perforation, 302
- Nasopharyngeal carcinomas  
 EBV and, 161  
 oncogenic microbes and, 219
- Natalizumab, 118  
 multiple sclerosis, 493  
 progressive multifocal leukoencephalopathy, 494
- Nateglinide, 341
- National Board of Medical Examiners (NBME), 2, 10
- Natriuresis, 558
- Natural killer (NK) cells, **97**  
 cell surface proteins, 106  
 function of, 388  
 innate immunity and, 95
- Nausea  
 adverse drug effects, 516  
 Alzheimer disease drugs, 518  
 anesthetics, 519  
 cardiac glycosides, 307  
 iron poisoning, 404  
 loperamide as cause, 382  
 MI as cause, 294  
 migraine headaches, 488  
 octreotide as cause, 382  
 Parkinson disease drugs, 517  
 polio presentation, 501  
 ranolazine, 305  
 renal failure, 571  
 vitamin A toxicity, 62  
 vitamin C toxicity, 65
- NE. See Norepinephrine (NE)
- Nebivolol, 237
- Necator* spp  
 disease associations, 157  
 infection routes, 154
- Necator americanus*, 155
- Neck and head cancer, **636**  
 cetuximab for, 420
- Necrosis, **205**  
 acute pancreatitis as cause, 380  
 Arthus reaction, 109  
 benign tumors, 216  
 calcification, 208  
 carbon tetrachloride, 219  
 caseating, 211  
 femoral head, 116, 436  
 fibrinoid, 439  
 glioblastoma multiforme, 496  
 hepatic, 455  
 ischemic brain disease, 482  
 jaw, 456  
 retinitis, 508  
 saponification, 205  
 scaphoid avascular, 426  
 skin, 452  
 transplant reaction, 115  
 warfarin, 414
- Necrotizing enterocolitis, 369  
 low birth weight, 599  
 neonatal respiratory distress syndrome and, 627
- Necrotizing fasciitis, 132, 451
- Necrotizing glomerulonephritis, 302
- Negative predictive value (NPV), 247, 669
- Negative reinforcement, 524
- Negative skew distribution, 251
- Negative-stranded viruses, 164
- Neglect (child), **526**
- Negri bodies, 167
- Neisseria* spp, **138**  
 C5-C9 deficiencies, 103  
 cephalosporins, 185
- fluoroquinolones, 191
- IgA protease, 125
- intracellular organism, 124
- taxonomy, 121
- transformation in, 126
- Neisseria gonorrhoeae*, 138  
 antigenic variation, 106  
 culture requirements, 123  
 Gram-negative algorithm, 137  
 osteomyelitis, 176  
 pelvic inflammatory disease, 181  
 septic arthritis, 441  
 STI, 180  
 UTIs with, 570
- Neisseria meningitidis*  
 chloramphenicol, 188  
 culture requirements, 123  
 encapsulation, 124  
 Gram-negative algorithm, 137  
 immunodeficient patients, 114  
 meningitis, 176  
 penicillin G/V for, 183  
 splenic dysfunction, 94  
 Waterhouse-Friderichsen syndrome, 324
- Nelson syndrome, **332**
- Nematodes, **155**  
 infection routes, 154
- Neomycin  
 aminoglycosides, 187  
 for hepatic encephalopathy, 374  
 mechanism (diagram), 183
- Neonatal respiratory distress syndrome (NRDS), **627**  
 restrictive lung disease, 639
- Neonates  
 ABO hemolytic disease of, **390**  
 Apgar score, 599  
*Candida albicans* in, 149  
*Chlamydia trachomatis* in, 146  
 coagulation cascade in, 392  
 conjunctivitis, 138, 146  
 deprivation effects, **526**  
 esophageal atresia in, 344  
 flora with C-section, 174  
 galactosemia in, 76  
 gastroenteritis, 164  
 gray baby syndrome in, 188  
 hemolytic anemia in, 400  
 herpes in, 160  
 HIV in, 171  
 hyperthermia in, 233  
 hypertrophic pyloric stenosis in, 345  
 indirect inguinal hernia in, 355  
 jaundice in, **376**  
 kernicterus, 190, 201  
*Listeria monocytogenes* in, 135  
 low birth weight, 599  
 meningitis in, 135, 178  
 necrotizing enterocolitis and, 369  
 Nikolsky sign, 451  
 obesity risk factors, 599  
 pneumonia in, 146  
 primitive reflexes in, 480

- Rh hemolytic disease of, **390**  
 sickle cell anemia in, 400  
*Streptococcus agalactiae* in, 133  
 vitamin deficiencies, 66
- Neoplasia, **204–211**  
 pathology of, 214–221  
 progression of, **215**
- Neostigmine, 232, 520
- Nephritic-nephrotic syndrome, 563
- Nephritic syndrome,  
 563, **564–565**, 566
- Nephritis, 575
- Nephrogenic diabetes insipidus, 334
- Nephrolithiasis, 569  
 calcium oxalate, 65
- Nephron physiology, **555**
- Nephropathy  
 diabetes mellitus, 336  
 hypertension and, 290  
 membranous, 111, 660  
 protease inhibitors, 199  
 transplant rejection, 115
- Nephrotic syndrome, 563, **566**  
 amyloidosis and, 213  
 charge barrier in, 551  
 ESR in, 212  
 fatty casts in, 562  
 labs/findings, 660  
 loop diuretics for, 575  
 pleural effusion, 644  
 presentation, 655
- Nephrotoxicity  
 aminoglycosides, 187  
 amphotericin B, 195  
 cidofovir, 198  
 cisplatin/carboplatin, 419  
 cladribine, 417  
 as drug reaction, 242  
 drugs causing, 422  
 immunosuppressants, 116  
 inhaled anesthetics, 519  
 streptomycin, 193  
 sulfonamides, 190  
 vancomycin, 186
- Nerve blockade in local  
 anesthetics, 519
- Nerve fibers, 465
- Nerves  
 lower extremity, **430**  
 upper extremity, **427**
- Nerve trunk, 465
- Net filtration pressure, 553
- Neural crest  
 derivatives of, 581
- Neural crest cells, 460, 464  
 neuroblastomas in, 325
- Neural development, **460**
- Neural fold, 460
- Neural plate, 460
- Neural tube, 460  
 fetal development, 580
- Neural tube defects, **461**  
 labs/findings, 657  
 maternal diabetes, 582  
 prevention, 64  
 valproic acid, 514  
 vitamin deficiency, 668
- Neuraminidase, 165, 166
- Neuroblastomas, **325**  
 Homer-Wright rosettes, 658  
 labs/findings, 668  
 neurofilament stain for, 44  
 oncogenes and, 218  
 opsoclonus-myoclonus ataxia  
 syndrome, 217
- Neurocutaneous disorders, **495**
- Neurocysticercosis, 156
- Neuroectoderm, 460  
 astrocytes derived from, 463  
 derivatives of, 580  
 pituitary gland, 313  
 teratomas, 611
- Neuroendocrine tumors, **325**
- Neurofibromatosis, 495, 505  
 chromosome association, 60  
 inheritance, 56  
 variable expressivity, 52
- Neurofibromatosis type 1  
 presentation, 652  
 tumor suppressor genes and, 218
- Neurofibromatosis type 2  
 presentation, 652  
 tumor suppressor genes and, 218
- Neurofilaments, 44
- Neurogenic ileus, 232
- Neurohumoral transmission, 229
- Neurohypophysis, 313  
 hypothalamus and, 466
- Neuroleptic drugs, 537
- Neuroleptic malignant  
 syndrome, 520
- Neuroleptic malignant syndrome  
 (NMS), 543
- Neurologic drug reactions, 242
- Neurology, 460–514  
 anatomy/physiology, 463–485  
 embryology, 460–462  
 ophthalmology, 504–511  
 pathology, 481–488  
 pharmacology, 514–521
- Neuromuscular blocking  
 drugs, **520**
- Neuromuscular junction  
 diseases, **445**
- Neuromuscular paraneoplastic  
 syndromes, 217
- Neuronal tumors, 44
- Neurons, **463**  
 local anesthetics, 519  
 origins of, 460  
 Parkinson disease, 517
- Neuropathic pain, 485
- Neuropathy  
 amyloidosis and, 213  
 diabetes mellitus, 336
- Neurosyphilis, 143  
 dementia, 529
- Neurotoxicity  
 cladribine, 417  
 immunosuppressants, 116  
 methylmercury exposure, 582  
 methylxanthines, 649  
 vincristine, 419
- Neurotransmitters, **465**
- Neurovascular pairing, **432**
- Neutralization (antibody), 100
- Neutropenia  
 ganciclovir, 198  
 interferons, 200  
 rheumatoid arthritis, 439
- Neutropenias, 402  
 ticlopidine, 415
- Neutrophil chemotaxis  
 endotoxins and, 129
- Neutrophils, **386**  
 chemotaxis, 103  
 CML, 410  
 corticosteroid effect on, 402  
 IL-8 and, 104  
 inflammation and, 207  
 innate immunity and, 95  
 in leukocyte adhesion  
 deficiency, 113  
 megaloblastic anemia, 398  
 in MI, 294  
 necrosis and, 205  
 nonmegaloblastic anemia, 398  
 pseudo-Pelger-Huet anomaly, 409  
 wound healing, 211
- Nevi, 216
- Nevirapine  
 cytochrome P-450 and, **243**  
 HIV therapy, 199  
 mechanism (diagram), 197
- Nevus flammeus  
 presentation, 656  
 Sturge-Weber syndrome, 495
- NF1* gene, 495  
 pheochromocytomas and, 326
- NF1/NF2* genes, 218
- NF- $\kappa$ B, 116
- N-formylmethionine (fMet), 37
- Niacin  
 cutaneous flushing, 239  
 gout, 241  
 hyperglycemia, 240  
 myopathy caused by, 241  
 tachyphylactic drug  
 interaction, 225
- Nicardipine, 304
- Nicotinamides, 71
- Nicotine intoxication and  
 withdrawal, 540
- Nicotinic acetylcholine  
 receptors, 162, 229
- Niemann-Pick disease, 84, 652
- Nifedipine, 304, 608
- Nifurtimox, 154, 196
- Night sweats  
 Pott disease, 652
- Night terrors, 467, 515
- Nigrostriatal pathway, 468
- Nikolsky sign, 451  
 pemphigus vulgaris, 452
- Nimodipine, 304, 483
- Nipple  
 eczematous patches, 616  
 intraductal papilloma, 615  
 lactational mastitis, 615  
 rash on, 655
- Nissl bodies, 42
- Nissl substance  
 chromatolysis, 465  
 neurons, 463
- Nitazoxanide, 151
- Nitrates, 305
- Nitric oxide, 356  
 derivation, 79  
 free radical injury and, 210
- Nitric oxide synthase, 434
- Nitrites  
 methemoglobin, 632  
 urinary tract infections, 177
- Nitroblue tetrazolium dye reduction  
 test, 113
- Nitrofurantoin  
 hemolysis in G6PD deficiency, 241  
 pulmonary fibrosis, 242
- Nitroglycerin, 305  
 acute coronary syndromes, 296  
 angina, 293
- Nitroprusside, 304
- Nitrosamines  
 as carcinogens, 219  
 stomach cancer and, 362
- Nitrosoureas, 418
- Nitrous oxide, 519
- Nizatidine, 381
- N-myc* oncogene, 325
- Nocardia* spp  
*Actinomyces* spp vs, 135  
 aerobic, 123  
 catalase-positive organism, 124  
 Gram-positive algorithm, 130  
 immunodeficient patients, 114  
 necrosis and, 205  
 sulfonamides for, 190  
 taxonomy, 121  
 urease-positive, 124
- Nocturia, 619
- Nocturnal enuresis, 317, 467
- Nodes of Ranvier, 464
- Nodular phlebitis, 302
- Nodular sclerosing Hodgkin  
 lymphoma, 668
- Nodular sclerosis lymphoma, 407
- Noise-induced hearing loss, 503
- Nonadherent patients, 256
- Non-alcoholic fatty liver disease, **374**
- Nonbacterial thrombotic  
 endocarditis, 217
- Nonbenzodiazepine hypnotics, **515**
- Noncaseating granulomas  
 restrictive lung disease, 639  
 sarcoidosis, 444
- Noncommunicating  
 hydrocephalus, 492
- Noncompetitive agonists, 228
- Noncompetitive inhibitors, 224
- Nondisjunction (meiosis), **59**
- Nondominant parietal cortex  
 lesions, 481
- Nonhemolytic anemia, **399**
- Non-Hodgkin lymphoma, **407, 408**  
 associations, 668  
 corticosteroids, 116  
 Hashimoto thyroiditis and, 328  
 hepatitis C, 169

- Non-Hodgkin lymphoma (*continued*)  
 HIV-positive adults, 173  
 Hodgkin lymphoma vs, **407**  
 oncogenes and, 218  
 rituximab for, 118, 420  
 vinca alkaloids for, 419
- Nonhomologous end joining, **37**
- Nonmaleficence (ethics), 253
- Nonmegaloblastic macrocytic anemia, 398
- Nonnormal distributions, 251
- Nonreceptor tyrosine kinase, 322
- Non-REM sleep stages, 467
- Non-response bias, 250
- Nonsense mutations, **36**
- Nonsteroidal anti-inflammatory drugs (NSAIDs), **456**  
 acute gout attack, 661  
 acute interstitial nephritis, 572  
 aplastic anemia, 241  
 Beers criteria, 238  
 calcium pyrophosphate deposition disease, 440  
 endometriosis, 613  
 gastric ulcers caused by, 363  
 gastritis caused by, 362  
 gout, 440, 457  
 headaches, 488  
 interstitial nephritis, 240, 242  
 loop diuretics and, 575  
 lupus, 443  
 membranous nephropathy, 566  
 osteoarthritis, 439  
 prostaglandin synthesis, 559  
 renal papillary necrosis, 572  
 rheumatoid arthritis, 439
- Non-ST-segment elevation MI  
 diagnosis of, 295  
 STEMI vs, 293  
 treatment, 296
- Noradrenergic drugs, 231
- Norepinephrine (NE). *See*  
*also* Catecholamines  
 adrenal medulla secretion, 312  
 amphetamines and, 231  
 bupropion effect on, 546  
 changes with disease, 465  
 circadian rhythm, 467  
 direct sympathomimetic, 234  
 isoproterenol vs, **235**  
 male sexual response, 593  
 MAO inhibitor effects, 546  
 in nervous system, 229  
 opioid effect on, 520  
 phenoxybenzamine and, 228  
 pheochromocytoma  
 secretion, 326  
 REM sleep and, 467  
 tramadol effects, 521  
 tyrosine catabolism, 79  
 vitamin B<sub>6</sub> and, 63
- Norethindrone, 622
- Norfloracin, 191
- Normal distribution, 251
- Normal pressure hydrocephalus, 492
- Normal splitting, 277
- Normetanephrine, 79
- Normocytic anemia, 396, **399**
- Norovirus  
 medical importance, 163  
 watery diarrhea, 175
- Northern blot, 49
- Nortriptyline, 545
- Nosocomial infections, **181**, 262  
 Ebola, 167  
*Klebsiella*, 140  
 pneumonias, 175  
*Pseudomonas aeruginosa*, 139  
 UTIs as, 177
- Notochord, 460  
 postnatal derivative of, 270
- Novobiocin  
 Gram-positive antibiotic  
 test, 130  
*Staphylococcus epidermidis*, 131
- NPH insulin, 340. *See also* Insulin
- NSE hormone, 325
- Nuclear envelope, 43
- Nucleic acids  
 pathogen-associated molecular  
 pattern (PAMP), 95  
 synthesis of, 194  
 in viruses, 158
- Nucleosides, 33
- Nucleotide excision repair, **37**
- Nucleotides, **33**  
 synthesis, 68
- Nucleotide triphosphate, 48
- Nucleus ambiguus, 477
- Nucleus cuneatus, 479
- Nucleus pulposus  
 collagen in, 46  
 fetal precursor, 270
- Nucleus pulposus herniation, 478
- Nucleus solitarius, 477
- Null hypothesis, 251, 252
- Number needed to harm  
 (NNH), 248, 669
- Number needed to treat (NNT),  
 248, 669
- Nutmeg liver, 298, 375
- Nutrition, **61–68**
- Nyctalopia, 62
- Nystagmus  
 cerebellum, 469  
 common lesions and, 481  
 Friedreich ataxia, 501  
 internuclear ophthalmoplegia, 513  
 multiple sclerosis, 493, 655  
 PCP as cause, 541  
 stroke and, 484  
 vertigo and, 503
- Nystatin, **195**  
*Candida albicans*, 149, 661  
 mechanism (diagram), 194
- O**
- Obesity  
 acanthosis nigricans, 453  
 amphetamines for, 234  
 anovulation with, 609  
 breast cancer risks, 616  
 cholelithiasis and, 379
- Cushing syndrome, 323  
 DM type 2 and, 337  
 empty sella syndrome and, 335  
 endometrial cancer, 612  
 esophageal cancer and, 361  
 focal segmental  
 glomerulosclerosis, 566  
 hypertension risk factors, 290  
 lateral femoral cutaneous  
 nerve, 430  
 leptin gene mutation, 317  
 olanzapine, 543  
 osteoarthritis/rheumatoid  
 arthritis, 439  
 PCOS and, 609  
 Prader-Willi syndrome, 54  
 renal cell carcinoma, 568  
 sleep apnea, 642  
 stress incontinence and, 569
- Obesity hypoventilation  
 syndrome, 642
- Obligate intracellular organisms, 124
- Oblique fissure, 629
- Observational studies, **246–253**  
 errors in, 250
- Observer-expectancy bias, 250
- Obsessive-compulsive disorder  
 (OCD), **533**  
 antipsychotic drugs for, 543  
 atypical antipsychotics for, 543  
 drug therapy for, 542  
 SSRIs for, 545  
 Tourette syndrome and, 527  
 tricyclic antidepressants for, 545  
 venlafaxine for, 545
- Obsessive-compulsive personality  
 disorder, 535
- Obstructive jaundice, 380
- Obstructive lung diseases, **638**  
 flow volume loops in, 637
- Obstructive shock, 299
- Obstructive sleep apnea, 642  
 pulse pressure in, 272  
 pulsus paradoxus in, 300
- Obturator nerve, 430
- Occipital cortex, 485
- Occipital lobe, 471
- Occipital sinus, 473
- Occult bleeding, 370
- Ocrotetide, 356, **382**  
 acromegaly, 333  
 carcinoid syndrome, 338  
 for carcinoid syndrome, 661  
 GH excess, 317  
 glucagonomas, 338  
 hypothalamic/pituitary drugs, 342
- Ocular albinism, 56
- Ocular hyperemia, 521
- Ocular motility, **510**
- Ocular muscles, 510
- Oculomotor nerve (CN III), **476**  
 cavernous sinus, 474  
 location in brain stem, 474  
 ocular motility, 510  
 palsy of, 483, 511  
 pathway for, 476  
 pupillary contraction, 509
- Odds ratio, 669
- Odds ratio (OR), 246, 248
- Odontoblasts, 581
- Ofloxacin, 191
- Okazaki fragments, 35
- Olanzapine, 543
- Olfactory bulb, 474
- Olfactory hallucinations, 529
- Olfactory nerve (CN I), **476**  
 brain stem location, 474  
 pathway for, 476
- Olfactory tract, 474
- Oligoclonal bands, 493
- Oligodendrocytes, 464, 494
- Oligodendroglia, 460
- Oligodendrogliomas, 496
- Oligohydramnios, 607  
 Potter sequence, 548
- Oligomenorrhea, 597, 609
- Oligomycin, 74
- Oligospermia, 382
- Oliguria, 564
- Omalizumab, 118, 649
- Omental foramen, 346
- Omeprazole, 381
- Omphalocele, 344
- Omphalomesenteric cysts, 367
- Onchocerca volvulus*, 154, 155
- Oncogenes, **218**
- Oncogenic microbes, **219**
- Ondansetron, **383**  
 torsades de pointes, 239
- 1,25-(OH)<sub>2</sub>D<sub>3</sub>  
 kidney endocrine function, 559  
 renal osteodystrophy, 571
- Onychomycosis  
 terbinafine, 195  
 tinea unguium, 148
- Oogenesis, **596**
- Oophorectomy, 592
- Open-angle glaucoma, 506  
 carbachol for, 232  
 epinephrine for, 234  
 pilocarpine for, 232
- Operant conditioning, **524**
- Ophthalmology, 504–511
- Ophthalmoplegia  
 cavernous sinus syndrome, 512  
 common lesions with, 481  
 internuclear, 513  
 multiple sclerosis, 493  
 Wernicke-Korsakoff syndrome,  
 62, 541
- Opioids, **520**  
 Beers criteria, 238  
 intoxication and withdrawal, 540  
 intravenous anesthetics, 519  
 pentazocine and, 521  
 sleep apnea, 642  
 toxicity treatment, 239
- Opponens digiti minimi muscle, 429
- Opponens pollicis muscle, 429
- Opportunistic fungal infections,  
**149–150**
- Oppositional defiant disorder, 527
- Oprelvekin, 117

- Opsoclonus-myoclonus syndrome, 217, 325
- Opsonins, 103
- Oposonization, 94, 100, 103
- Optic atrophy  
Krabbe disease, 494
- Optic canal, 476
- Optic chiasm, 474  
circle of Willis, 473  
pupillary reaction, 509
- Optic disc, 504  
papilledema in, 508
- Optic gliomas  
neurofibromatosis, 495, 652
- Optic nerve (CN II), **476**  
anatomy, 504  
embryologic derivation, 581  
Marcus Gunn pupils, 509  
optic tract, 474  
pathway, 476
- Optic neuritis, 493
- Optic neuropathy, 193
- Optochin  
Gram-positive antibiotic test, 130  
viridans streptococci, 132
- Oral advance directives, **255**
- Oral contraceptives (OCs)  
cytochrome P-450 and, 243  
endometriosis, 613  
hepatic adenomas and, 375  
melasma and, 448  
ovarian neoplasms, 610  
PCOS, 609  
prolactin effects on, 316  
reproductive hormones, 620  
SHBG effects on, 322
- Oral glucose tolerance test, 336
- Oral hairy leukoplakia, 173
- Oral rehydration therapy, 141
- Oral thrush, 173
- Orange body fluids, 192
- Orchiectomy, 617
- Orchiopexy, 617
- Orchitis, 166
- Orexigenic effect, 317
- Orexin, 538
- Organ failure, in acute  
pancreatitis, 380
- Organogenesis  
errors in, **581**  
fetal development, 580  
teratogens, **582**
- Organomegaly, 569
- Organophosphates  
poisoning by, 232  
toxicity treatment, 239
- Organ transplants  
azathioprine for, 417  
cytomegalovirus, 182  
hairy leukoplakia and, 451  
kidneys, 550  
WBC casts, 562
- Organum vasculosum of the lamina terminalis (OVL), 466
- Orientation, **528**
- Origin of replication, 35
- Orlistat, **383**  
diarrhea, 240
- Ornithine  
cystinuria, 81  
kidney stones and, 567  
urea cycle, 78
- Ornithine transcarbamylase, 70
- Ornithine transcarbamylase deficiency, **79**  
inheritance, 56
- Orotic acid, 79
- Orotic aciduria, 398  
in anemia taxonomy, 396
- “Orphan Annie eyes” nuclei, 330, 658
- Orthomyxoviruses  
characteristics of, 163, 164  
influenza viruses, 165  
segmented, 164
- Orthopnea, 298
- Orthostatic hypotension  
adrenal insufficiency, 324  
 $\alpha$ -blockers, 236  
phenoxybenzamine, 236  
SGLT2, 341
- Oseltamivir, 197
- Osler nodes, 655  
bacterial endocarditis, 299
- Osmotic demyelination syndrome, **492**  
SIADH and, 334
- Osmotic diarrhea, 364
- Osmotic diuresis  
hyperosmolar hyperglycemic state, 338  
insulin deficiency/  
insensitivity, 336
- Osmotic laxatives, 383
- Ossicles, 503
- Osteitis fibrosa cystica, 332, 434, 437, 657
- Osteoarthritis, **439**  
celecoxib for, 456  
presentation, 656
- Osteoblasts, 434  
bone formation, 434  
cortisol effect on, 319  
Paget disease of bone, 436  
teriparatide effect on, 457
- Osteochondromas, 438
- Osteoclasts, 434  
bisphosphonate effects, 456  
bone formation, 434  
Paget disease of bone, 436
- Osteodystrophy, 382
- Osteogenesis imperfecta, **47**  
bisphosphonates, 456  
collagen and, 46  
presentation, 652
- Osteogenic sarcomas, 436
- Osteomalacia  
hypophosphatemia, 560  
vitamin D deficiency, 66, 319
- Osteomalacia/rickets, **436**  
lab values in, 437
- Osteomas  
nomenclature for, 216
- Osteomyelitis, **176**  
diagnostic findings, 660  
*Pseudomonas aeruginosa*, 139  
sickle cell anemia, 400  
*Staphylococcus aureus*, 131
- Osteonecrosis, **436**  
bisphosphonates causing, 456
- Osteopenia, 436
- Osteopetrosis, **435**, 437
- Osteophytes, 439
- Osteoporosis, **435**  
bisphosphonates, 456  
corticosteroids, 116  
Cushing syndrome, 323  
denosumab, 118  
as drug reaction, 241  
estrogen, 434  
Gaucher disease, 84  
heparin, 413  
homocystinuria, 80  
hormone replacement therapy, 621  
lab values in, 437  
menopause, 600  
pituitary prolactinomas, 315  
raloxifene for, 621, 421  
teriparatide for, 457  
thiazides for, 576  
vertebral compression fractures, 668
- Osteosarcomas, 438  
nomenclature for, 216  
tumor suppressor genes and, 218
- Otitis externa, 139
- Otitis media  
brain abscesses caused by, 176  
*Haemophilus influenzae*, 125, 138  
Langerhans cell histiocytosis, 412  
*Streptococcus pneumoniae*, 132  
Wegener granulomatosis as cause, 302
- Otology, **503**
- Ototoxicity  
aminoglycosides, 187, 201  
aminoglycoside teratogenicity, 582  
cisplatin/carboplatin, 419  
as drug reaction, 242  
ethacrynic acid, 575  
loop diuretics, 575  
vancomycin, 186
- Ouabain, 45
- Outcome (quality measurement), 261
- Outer membrane, 120
- Outflow tract formation, 269
- Ovarian artery, 592
- Ovarian cancer  
breastfeeding and, 599  
cisplatin/carboplatin for, 419  
epidemiology of, 608  
hypercalcemia and, 217  
irinotecan/topotecan for, 419  
Lynch syndrome and, 371  
oncogenes and, 218  
paclitaxel for, 419  
Psammoma bodies in, 220  
tumor suppressor genes and, 218
- Ovarian cycle, 597
- Ovarian cysts, **610**
- Ovarian dysgenesis, 603
- Ovarian ligament, 592
- Ovarian teratomas, 217
- Ovarian tumors, **610–611**
- Ovaries  
anatomy of, 592  
descent of, **591**  
embryologic derivation, 581  
epithelial histology, 592  
estrogen production, 595  
lymphatic drainage, 591  
premature failure, 609
- Overactive bladder, 569
- Overflow incontinence, 569
- Oviducts, 589
- Ovotesticular disorder, 603
- Ovulation, **596**  
anovulation causes, 609  
progesterone and, 595  
prolactin effect on, 316
- Owl eye inclusions, 658
- Oxacillin  
characteristics of, 184  
mechanism (diagram), 183
- Oxazepam, 515
- Oxazolidinones, **189**
- Oxidative phosphorylation, **74**  
metabolic site, 68  
poisons, 74
- Oxybutynin, 233
- Oxygen  
in blood, 633  
for carbon monoxide poisoning, 239  
carboxyhemoglobin, 632  
cluster headaches, 488  
deprivation, **634**  
exercise and, 635  
hemoglobin, 631
- Oxygen-hemoglobin dissociation curve, **632**
- Oxygen toxicity, 210
- Oxytocin  
hypothalamic/pituitary drugs, 342  
hypothalamus production, 466  
lactation and, 599  
pituitary gland and, 313  
signaling pathways for, 322
- P**
- P-450, 193
- Pacemaker action potential, **281**
- Paceminer corpuscles, 464
- Paclitaxel, 419  
in cell cycle, 416  
microtubules and, 44  
targets of, 416
- Paget disease of bone, **436**  
bisphosphonates, 456  
lab values in, 437  
osteosarcomas and, 438  
presentation, 652  
woven bone in, 434
- Paget disease of breast, 614, 616  
presentation, 655
- Pain receptors, 464



- Palatine shelves, 588  
 Pale infarct vs red infarct, 207  
 Paliperidone, 543  
 Palivizumab, 118  
   pneumonia prophylaxis, 165  
   for RSV, 200  
 Pallor in aplastic anemia, 399  
 Palmar crease, 656  
 Palmar erythema, 372  
 Palmar interossei, muscle, 429  
 Palmar reflex, 480  
 Panacinar emphysema, 638  
 p-ANCA, 111  
   sclerosing cholangitis and, 378  
 Pancoast tumor, **646**  
   Horner syndrome and, 509  
   labs/findings, 657  
   lung cancer, 647  
   superior vena cava syndrome, **646**  
   thoracic outlet syndrome, 428  
 Pancreas  
   biliary structures and, 353  
   blood supply and innervation  
     of, 348  
   embryology, 345  
 Pancreas divisum, 345  
 Pancreatic buds, 345  
 Pancreatic cancer, **380**  
   5-fluorouracil for, 417  
   adenocarcinomas, **380**  
   biliary cirrhosis and, 378  
   carcinogens causing, 219  
   hyperbilirubinemia caused by, 376  
   metastases of, 221  
   nonbacterial thrombotic  
     endocarditis and, 217  
   oncogenes and, 218  
   presentation, 655  
   Trousseau's syndrome and, 217  
   tumor suppressor genes and, 218  
 Pancreatic cells, **313**. *See also*  $\alpha$  cells;  
    $\beta$  cells;  $\Delta$  cells  
 Pancreatic ducts, 345, 353  
 Pancreatic insufficiency, 364  
   chronic pancreatitis as cause, 380  
 Pancreatic lipase, 88  
 Pancreatic secretions, **358**  
 Pancreatitis, **380**  
   acute respiratory distress syndrome  
     as cause, 642  
   alcoholism, 541  
   corticosteroids and, 240  
   as drug reaction, 240  
   GLP-1 analogs and, 341  
   hyperchylomicronemia, 90  
   hyperparathyroidism as cause, 332  
   hypertriglyceridemia, 90  
   mumps, 166  
   necrosis and, 205  
   NRTIs, 199  
   pancreas divisum as cause, 345  
   pancreatic insufficiency caused  
     by, 364  
   valproic acid, 514  
 Pancuronium, 520  
 Pancytopenia, 399  
   Chédiak-Higashi syndrome, 113  
   cytarabine, 417  
   Gaucher disease, 84  
   leishmaniasis, 154  
   osteopetrosis and, 435  
   paroxysmal nocturnal  
     hemoglobinuria, 400  
 Pandemics, 165  
 Panic disorder, 532, **533**  
   drug therapy for, 542  
   SSRIs for, 545  
   venlafaxine for, 545  
 Pansystolic murmur, 278  
 P antigen, 165  
 Pantoprazole, 381  
 Papillary carcinomas, 216  
 Papillary muscle  
   blood supply to, 296  
   rupture, 294, 296  
 Papillary thyroid carcinomas, 330  
   carcinogens causing, 219  
   labs/findings, 660  
   Psammoma bodies in, 220  
 Papilledema, 491, **508**  
   hypertensive emergency and, 290  
 Papillomas, 216  
 Papillomaviruses  
   characteristics of, 160  
   DNA viruses, 159  
   genome, 158  
 PAPP-A  
   autosomal trisomies, 59  
 Pap smear, 609  
 Papules, 447  
 Para-aminohippuric acid (PAH), 552  
 Para-aortic lymph nodes, 93, 591  
 Paracoccidioidomycosis, **147**  
 Paracortex (lymph node), 92  
 Paracrine, 559  
 Paradoxical splitting, 277  
 Paraesophageal hernias, 355  
 Parainfluenza  
   croup, 166  
   paramyxovirus, 163, 165  
 Parakeratosis, 448  
 Paralysis  
   conversion disorder, 536  
   Guillain-Barré syndrome, 493  
   poliovirus, 182  
   rabies, 167  
   unvaccinated children, 182  
 Paralytic ileus, 419  
 Paramedian pontine reticular  
   formation lesions, 481  
 Paramesonephric duct, 589  
 Paramyxoviruses, **165**  
   characteristics of, 163, 164  
   croup, 166  
   measles, 166  
   mumps, 166  
 Paraneoplastic cerebellar  
   degeneration, 217  
 Paraneoplastic encephalomyelitis, 217  
 Paraneoplastic syndromes, **217**  
   lung cancer, 647  
   renal cell carcinoma and, 568  
   renal tumors, 668  
 Paranoia  
   amphetamines, 540  
   LSD as cause, 541  
 Paranoid personality disorder, 535  
 Parasites  
   eosinophilia with, 387  
 Parasitology, **151–157**  
 Parasympathetic nervous system, 229  
   male erection, 593  
 Parasympathetic receptors, 230  
 Parathyroid adenomas  
   hyperparathyroidism caused by, 332  
   MEN 1/MEN 2A syndromes, 339  
 Parathyroid disease diagnosis, **331**  
 Parathyroid hormone (PTH), **320**  
   bone disorders, 437  
   bone formation, 434  
   calcitonin and, 321  
   in hyperparathyroidism, 332  
   kidney effects, 559  
   nephron physiology, 555  
   osteomalacia/rickets, 436  
   Paget disease of bone, 436  
   pseudohypoparathyroidism  
     and, 331  
   signaling pathways of, 322  
   thymic aplasia, 112  
   vitamin D and, 319, 320  
 Parathyroid tumors  
   presentation, 655, 656  
 Paraumbilical vein, 350  
 Parental consent, 254  
 Paresthesias  
   panic disorder, 533  
   vitamin B<sub>12</sub> deficiency, 65  
 Parietal cell  
   autoantibody, 111  
 Parietal lobe, 471  
 Parietal peritoneum, 354  
 Parinaud syndrome, 475, 481, 498  
 Parkinson disease, 490  
   basal ganglia lesions, 481  
   benztropine for, 233  
   dopaminergic pathways, 468  
   drug therapy for, **517**  
   Lewy bodies, 490  
   neurotransmitters for, 465  
   nigrostriatal pathway and, 468  
   presentation, 655  
   proteasome and, 43  
   resting tremor in, 489  
 Parkinsonism  
   Wilson disease as cause, 378  
 Parkinson-like syndrome, 242  
 Parotid gland  
   embryologic derivation, 581  
   enlargement of, 441  
   tumors in, 359  
 Parotitis  
   bulimia nervosa, 537  
   mumps, 166  
 Paroxetine, 545  
 Paroxysmal nocturnal dyspnea, 298  
 Paroxysmal nocturnal  
   hemoglobinuria, 400  
   in anemia taxonomy, 396  
   CD55 deficiency, 103  
   eculizumab for, 118  
   flow cytometry diagnosis, 50  
   intravascular hemolysis in, 399  
   presentation, 655  
 Pars planitis, 506  
 Partial agonists, 228  
 Partial pressure, 633  
 Partial seizures, 487  
 Parvovirus  
   characteristics of, 160  
   DNA viruses, 159  
   genome of, 158  
   naked viruses, 159  
 Parvovirus B19  
   aplastic anemia, 399  
   hereditary spherocytosis, 400  
   hydrops fetalis, 178  
   rash, 179  
   receptors, 165  
 Passive aggression, 525  
 Passive immunity, **107**  
*Pasteurella* spp  
   Gram-negative algorithm, 137  
   taxonomy, 121  
*Pasteurella multocida*  
   osteomyelitis, 176  
   transmission, 144, 182  
 Patau syndrome, **59**  
   cataracts, 505  
   chromosome association, 60  
   hCG in, 598  
   holoprosencephaly, 461  
   horseshoe kidney and, 549  
 Patches, 447  
 Patellar reflex  
   lumbosacral radiculopathy, 432  
 Patent ductus arteriosus (PDA)  
   congenital rubella, 290  
   fetal alcohol syndrome, 290  
   heart murmur with, 279  
   indomethacin for, 456  
   mechanism and treatment, 289  
   misoprostol for, 382  
   neonatal respiratory distress  
     syndrome and, 627  
 Patent foramen ovale  
   atrial septal defect vs, 289  
   septal fusion failure, 268  
 Patent urachus, 585  
 Pathogen-associated molecular  
   patterns (PAMPs), 95  
 Pathogenic *Escherichia coli*  
   (EPEC), 140  
 Pathologic grief, **532**  
 Pathology, **203–221**  
   cardiovascular, 288–302  
   endocrine, 323–339  
   gastrointestinal, 359–380  
   hematologic/oncologic, 394–414  
   inflammation, 204–213  
   musculoskeletal/skin/connective  
     tissue, 435–443  
   neoplasia, 214–221  
   neurological, 481–488  
   psychiatric, 526–540  
   renal, 562–573  
   reproductive, 603–617  
   respiratory, 636–646  
   USMLE Step 1 preparation  
     for, 265  
 Patient payment models, **260**

- Pavlovian conditioning (classical conditioning), 524
- PCO<sub>2</sub>, 630
- PCP (phencyclidine)  
intoxication and withdrawal, 541
- PCSK9 inhibitors, 306
- PDE-3, 305
- PDE-5 inhibitors, 619, **623**  
benign prostatic hyperplasia, 661  
naming convention for, 244
- PDGF. *See* Platelet-derived growth factor (PDGF)
- PDSA cycle, **261**
- Pearson correlation coefficient (*r*), 253
- Peau d'orange, 616
- Pectinate line, **351**
- Pediatric patients  
aspirin use for, avoiding, 373  
common causes of death, 260  
common fractures, 424  
cystic fibrosis, 56  
dactinomycin for, 418  
disorders of, 527  
hemolytic-uremic syndrome, 405  
intussusception in, 368  
juvenile polyposis syndrome in, 370  
Munchausen syndrome by proxy, 536  
nephrotic syndrome in, 566  
neuroblastomas in, 325  
precocious puberty in, 53, 318  
primary brain tumors, **498**  
rashes, 179  
rhabdomyomas in, 301  
scalded skin syndrome, 451  
sleep terror disorder in, 538  
strawberry hemangiomas in, 450  
tetracycline side effects, 188  
unvaccinated, 182  
Wilms tumors in, 569
- Pegloticase, 457, 661
- Pegvisomant, 333
- Pellagra  
vitamin B<sub>3</sub> deficiency, 63
- Pelvic inflammatory disease (PID), **181**  
*Actinomyces*, 135  
chlamydia, 146, 180  
*Chlamydia trachomatis*, 146  
copper IUD, 622  
ectopic pregnancy, 607  
gonococci, 138  
gonorrhea, 180
- Pelvic pain  
endometriomas, 610  
endometriosis, 613
- Pelvis  
fracture and nerve injury, 430  
nerve injury with surgery, 430
- Pemphigus vulgaris, 452  
acantholysis and, 448  
autoantibody with, 111  
labs/findings, 657  
type II hypersensitivity, 108
- Penicillamine  
for copper toxicity, 239  
for lead poisoning, 239  
membranous nephropathy and, 566  
myopathy, 241  
for Wilson disease, 378
- Penicillin  
*Actinomyces* spp, 135  
antipseudomonal, 184  
Coombs-positive hemolytic anemia, 241  
mechanism (diagram), 183  
penicillinase-resistant, 184  
penicillinase-sensitive, 184  
prophylaxis, 194  
rash, 241  
for rheumatic fever, 300  
*Treponema pallidum*, 664
- Penicillinase-resistant penicillins, **184**
- Penicillinase-sensitive penicillins, **184**
- Penicillin G, V, **183**  
meningococci, 138  
prophylaxis, 194
- Penile cancer, 219
- Penis  
congenital abnormalities, **591**  
female homolog, 590  
lymphatic drainage, 591  
pathology of, **617**
- Pentamidine, 150
- Pentazocine, 520, **521**
- Pentobarbital, 515
- Pentostatin, 410
- PEP carboxykinase, 70
- Pepsin, 357
- Pepsinogen  
location of, 357  
somatostatin and, 356
- Peptic ulcer disease, **363**  
associations, 664  
cholinomimetic agents and, 232  
glycopyrrolate for, 233  
H<sub>2</sub> blockers for, 381  
*Helicobacter pylori*, 142  
misoprostol for, 382  
proton pump inhibitors for, 381  
Zollinger-Ellison syndrome, 338
- Peptidoglycan synthesis, 183
- Peptostreptococcus* spp  
alcoholism, 175  
lung abscesses, 646
- Perforation, caused by ulcers, 363
- Perforin  
cytotoxic T cells and, 98  
extrinsic pathway and, 204  
natural killer cells and, 97
- Performance anxiety, 537
- Perfusion, and ventilation, 634
- Perfusion-limited gas exchange, 633
- Periarteriolar lymphatic sheath (PALS), 94
- Pericardial cavity, 271
- Pericardial effusion, 647
- Pericardial tamponade  
labs/findings, 658
- Pericarditis  
acute, **300**  
fibrinous, 294  
jugular venous pulse in, 276  
Kussmaul sign in, 301  
picornaviruses, 163  
postinfarction, 294  
pulsus paradoxus in, 300  
renal failure, 571  
rheumatoid arthritis, 439
- Pericardium, 271
- Perinephric abscesses, 570
- Perineurium, 465
- Periodic acid-Schiff stain, 122  
glycogen storage diseases, 83
- Periorbital edema  
nephrotic syndrome, 655  
*Trichinella spiralis*, 157
- Peripartum cardiomyopathy, 297
- Periphral edema  
calcium channel blockers, 304  
cirrhosis as cause, 372  
left heart failure, 298  
nephrotic syndrome, 655
- Peripheral nerves, **465**
- Peripheral nervous system (PNS), **229**  
embryologic derivation, 581  
origins of, **460**
- Peripheral neuropathy  
alcoholism, 541  
Chédiak-Higashi syndrome, 113  
epilepsy drugs, 514  
Fabry disease, 84  
isoniazid, 193  
Krabbe disease, 84, 494  
NRTIs, 199  
oxazolidinones, 189  
sorbitol as cause, 77  
tricyclic antidepressants, 545  
vincristine as cause, 422  
vitamin B<sub>6</sub> deficiency, 63
- Peripheral resistance, 235
- Peripheral vascular disease, 292
- Peripheral vertigo, 503
- Periplasm, 120
- Perirenal space, 345
- Peristalsis  
motilin receptor agonists and, 356  
visible waves of, 345
- Peritoneum, 345  
hernias and, 355
- Peritonitis  
appendicitis, 366  
diverticulitis, 366  
spontaneous bacterial, 373
- Peritubular capillaries, 553
- Perivascular rosettes, 498
- Permanent cells, 42
- Permethrin, 157, 196
- Permissive drug interactions, 225
- Pernicious anemia  
autoantibody with, 111  
B<sub>12</sub> deficiency caused by, 398  
HLA-DR5 and, 96  
type IV hypersensitivity, 109  
vitamin B<sub>12</sub> deficiency, 65
- Peroxisome, **43**
- Persistent cervical sinus, 586
- Persistent depressive disorder, 531
- Persistent fetal circulation, 599
- Persistent thyroglossal duct, 312
- Persistent truncus arteriosus, 269, 288
- Personality, **534**
- Personality disorder, 534
- Personality disorders, **535–536**
- Personality traits, 534
- Pertussis toxin, 128, 139
- Pes cavus  
Charcot-Marie-Tooth disease, 494  
Friedreich ataxia, 501
- Petechiae  
aplastic anemia as cause, 399  
cirrhosis as cause, 372  
scurvy, 656
- Petechial rash  
fat emboli as cause, 637
- Peutz-Jeghers syndrome, 216, 370
- Peyer patches, 347, **358**  
IgA antibody production, 101  
intussusception and, 368  
*Salmonella/Shigella* invasion, 141
- Peyronie disease, 617
- PGI<sub>2</sub>, 455
- P-glycoprotein, **220**
- Phagocytes, 113
- Phagocytosis, 125
- Pharmacokinetics, **225**
- Pharmacology, **224–243**  
autonomic drugs, 229–238  
cardiovascular, 304–310  
endocrine, 340–342  
gastrointestinal, 381–383  
hematologic/oncologic, 413–421  
musculoskeletal/skin/connective tissue, 455–457  
neurology, 514–521  
pharmacodynamics, 226–228  
pharmacokinetics, 224–225  
psychiatric, 542–546  
renal, 574–577  
reproductive, 620–623  
respiratory, 648–649  
toxicities and side effects, 239–242  
USMLE Step 1 preparation for, 265
- Pharyngitis  
adenoviridae, 160  
*Corynebacterium diphtheriae*, 135  
diphtheria, 135  
mononucleosis, 161  
prophylaxis (rheumatic fever), 194  
*Streptococcus pyogenes*, 132  
unvaccinated children, 182
- Pharynx, 628  
blood supply and innervation of, 348
- Phenacetin, 569
- Phenelzine, 546
- Phenobarbital, 515  
cytochrome P-450 and, 243  
epilepsy, 514  
teratogenicity, 582  
as weak acid, 226
- Phenotypic mixing, 158

- Phenoxybenzamine, 236. *See*  
*also*  $\alpha$ -antagonists  
 norepinephrine and, 228  
 for pheochromocytomas, 326
- Phentolamine, 236
- Phenylalanine  
 classification of, 77  
 tyrosine catabolism, 79
- Phenylbutyrate, 78
- Phenylephrine, 234, **648**  
 $\alpha$ -blockade of, 236
- Phenylketones, 80
- Phenylketonuria, 79, **80**
- Phenytoin  
 cytochrome P-450 and, 243  
 drug-induced SLE, 657  
 epilepsy, 514  
 erythema multiforme, 452  
 folate deficiency caused by, 398  
 gingival hyperplasia, 241  
 lupus-like syndrome, 241  
 megaloblastic anemia, 241  
 teratogenicity, 582  
 tonic-clonic seizures, 663  
 vitamin B<sub>9</sub> deficiency, 64  
 zero-order elimination of, 226
- Pheochromocytomas, **326**  
 MEN 2A/MEN 2B and, 339  
 neurofibromatosis, 495  
 phenoxybenzamine for, 236  
 polycythemia and, 217  
 presentation, 652  
 von Hippel-Lindau disease, 495
- Philadelphia chromosome, 668  
 in myeloproliferative disorders, 411  
 translocations of, 412
- Phlebitis  
 IV amphotericin B, 195
- Phlebotomy, 378
- Phobias, 532, **533**
- Phocomelia, 582
- Phosphatases, 69
- Phosphate in bone disorders, 437
- Phosphoenolpyruvate  
 carboxykinase, 74
- Phosphofructokinase-1 (PFK-1)  
 glycolysis and, 69  
 metabolic pathways, 70
- Phospholipase A<sub>2</sub>  
 autoantibody to, 111
- Phospholipids, 358
- Phosphorus in Paget disease of  
 bone, 436
- Phosphorylases, 69
- Phosphorylation, 41
- Photophobia  
 headaches, 488  
 leptospirosis, 142  
 rabies, 167
- Photosensitivity  
 demeclocycline causing, 342  
 drugs causing, 241  
 lupus, 443  
 porphyria as cause, 403
- Photosensitivity (cutaneous)  
 simeprevir, 200  
 sulfonamides, 190  
 tetracyclines, 188
- Phototherapy for jaundice, 376
- Phrenic nerve, 629
- Phyllodes tumors, 614, 615
- Physical abuse (child), 526
- Physician-assisted suicide, 256
- Physiologic dead space, **630**, 670
- Physiologic neonatal  
 jaundice, **376**
- Physiology  
 cardiovascular, 272–286  
 endocrine, 314–322  
 gastrointestinal, 356–360  
 hematologic/oncologic, 389–393  
 neurological, 463–485  
 renal, 551–562  
 reproductive, 595–602  
 respiratory, 630–635  
 USMLE Step 1 preparation  
 for, 264
- Physostigmine  
 anticholinergic toxicity  
 treatment, 239  
 anticholinesterase, 232  
 glaucoma, 521
- Pick bodies, 490, 660
- Pick disease, 490
- Pickwickian syndrome, 642
- Picomaviruses, **164**  
 characteristics, 163  
 genomes, 159  
 naked viruses, 159
- Pierre Robin sequence, 587
- Pigmented skin disorders, **448**
- Pigment-producing bacteria, **125**
- Pigment stones, 379
- Pilocarpine, 232  
 glaucoma, 521
- Pilocytic astrocytoma, 498
- Pilus, 120
- Pimozide, 527, 542
- Pindolol, 237, 305
- Pineal gland, 475
- Pinealoma, 498
- Pinworms, 155
- Pioglitazone, 340
- Piperacillin  
 characteristics of, 184  
 mechanism (diagram), 183  
*Pseudomonas aeruginosa*, 139
- Piroxicam, 456
- Pisiform bone, 426
- Pitting edema, 298
- Pituitary adenomas, **332**, 496  
 acromegaly and, 333  
 GH and, 317  
 goiter and, 327  
 hypopituitarism, 335
- Pituitary apoplexy, 335
- Pituitary drugs, **342**
- Pituitary gland, **313**
- Pituitary hormones, 244
- Pituitary prolactinomas, 315
- Pituitary tumors  
 diabetes insipidus, 334  
 MEN 1 and, 339
- Pityriasis rosea, 453
- Pityrosporum* spp, 148
- PKD genes  
 renal cyst disorders and, 573
- Placebo, 246
- Placenta, **584**  
 estrogen production, 595  
 maternal-fetal barrier, 466  
 progesterone production, 595
- Placenta accreta/increta/  
 percreta, 606
- Placental abruption, 606  
 cocaine use, 582  
 diffuse cortical necrosis  
 (renal), 570  
 preeclampsia, 608
- Placental aromatase deficiency,  
**604**
- Placental insufficiency  
 oligohydramnios and, 607  
 Potter sequence, 548  
 preeclampsia, 608
- Placenta previa, 606
- Plague, 144
- Plantar reflex, 480
- Plaques (skin), 447
- Plasma cells, **389**
- Plasma membrane  
 cell trafficking, 43  
 sodium-potassium pump, 45
- Plasma osmolality  
 DI treatment, 334  
 insulin deficiency/  
 insensitivity, 336
- Plasmapheresis, 493, 564
- Plasma protein concentration,  
 553
- Plasminogen, 392
- Plasmodium* spp  
 chloroquine, 196  
 Giemsa stain for, 122  
*Plasmodium falciparum*,  
**153**, 196  
*Plasmodium malariae*, **153**  
*Plasmodium ovale*, **153**  
*Plasmodium vivax*, **153**
- Platelet-activating factor, 386
- Platelet-derived growth factor  
 in wound healing, 211  
 signaling pathways for, 322
- Platelet disorders, **405**
- Platelet plug formation, **393**
- Platysma muscle, 587
- Pleiotropy, **52**
- Pleomorphic adenomas, 359
- Pleomorphic bacteria, 121
- Pleural effusion, **644**  
 lung cancer, 647  
 mesothelioma, 641  
 physical findings, 643
- Pleuritis, 439
- Plicae circulares, 347
- Plummer-Vinson syndrome,  
 360, 396
- Pneumatosis intestinalis, 369
- Pneumococcal vaccine, 124
- Pneumoconioses, 639, **641**
- Pneumocystis* spp, 113
- Pneumocystis jirovecii*, **150**  
 dapson, 190  
 HIV-positive adults, 173  
 immunocompromised patients, 175  
 silver stain for, 122  
 TMP-SMX, 190
- Pneumocystis pneumonia*  
 HIV-positive adults, 173  
 prophylaxis, 194
- Pneumocytes, 626, 627, 628
- Pneumonia, **645**  
 acute respiratory distress  
 syndrome, 642  
 adenoviridae, 160  
 chlamydiae, 146  
 coccidioidomycosis, 147  
 common causes, 175  
 compliance in, 631  
*Haemophilus influenzae*, 138  
 inhalational injury, 640  
*Klebsiella pneumoniae*, 655  
*Mycoplasma pneumoniae*, 146  
*Pneumocystis jirovecii*, 150  
 proton pump inhibitors and, 381  
*Pseudomonas aeruginosa*, 139  
 Q fever, 145  
 readmissions with, 261  
*Staphylococcus aureus*, 131  
*Streptococcus pneumoniae*, 132  
*Streptococcus agalactiae*, 133  
 VZV, 160
- Pneumonitis  
 as granulomatous disease, 211  
 HIV-positive adults, 173
- Pneumothorax, 643, **644**
- Podagra  
 gout, 440  
 presentation, 656
- Podocytes, 550  
 in filtration, 553  
 glomerular filtration barrier  
 and, 551  
 nephrotic syndrome, 566
- Poikilocytosis, 386
- Point of Service, 259
- pol* gene, 171
- Poliomyelitis, 500, **501**  
 restrictive lung disease, 639  
 vaccine for, 107
- Poliovirus, 501  
 immunodeficient patients, 114  
 medical importance, 163  
 picornavirus, 164  
 unvaccinated children, 182
- Polyadenylation signal, 38
- Polyarteritis nodosa, 169, **302**  
 necrosis and, 205
- Polyarthralgias  
 gonococcal arthritis, 441  
 rubella, 178
- Polyarthritis  
 rheumatic fever, 132  
 rubella, 178
- Polycystic ovarian syndrome  
 (PCOS), **609**  
 anovulation, 609  
 antiandrogens, 623

- endometrial hyperplasia, 612  
 ovarian neoplasms, 610  
 Polycythemia, **411**  
   blood oxygen in, 633  
   bronchitis and, 638  
   Eisenmenger syndrome, 289  
   ESR in, 212  
   hepatocellular carcinoma as  
     cause, 375  
   low birth weight, 599  
   paraneoplastic syndrome, 216  
   presentation, 652  
   renal cell carcinoma, 568  
 Polycythemia vera, 411  
   Budd-Chiari syndrome and, 375  
 Polydactyly, 59  
 Polydipsia, 336  
 Polyenes, 194  
 Polyethylene glycol, 383  
 Polyhydramnios, 461, 607  
   esophageal atresia as cause, 344  
 Polymenorrhea, 597  
 Polymerase chain reaction (PCR), **48**  
 Polymyalgia rheumatica, **444**  
   associations, 668  
   ESR in, 212  
   giant cell arteritis and, 302  
 Polymyositis, **445**  
 Polymyxin B, 139  
 Polymyxins, 194  
 Polyneuritis, 62  
 Polyneuropathy, 403  
 Polyomaviruses  
   characteristics of, 160  
   DNA viruses, 159  
   genome, 158  
   naked viruses, 159  
 Polystotic fibrous dysplasia,  
   53, 652  
 Polyposis syndromes, **370**  
 Polyps (endometrial), 612  
 Polyuria  
   diabetes insipidus, 334  
   diabetes mellitus, 336, 337  
   Fanconi syndrome, 655  
   hyperosmolar hyperglycemia  
     state, 338  
   hyperparathyroidism, 332  
   lithium as cause, 544  
 Pompe disease, 83  
 Pons, 460, 474  
 Pontiac fever, 139  
 “Pope’s blessing” (median nerve  
   injury), 427, 429  
 Popliteal artery, 432  
   atherosclerosis in, 292, 668  
 Popliteal fossa, 432  
 Popliteal lymph nodes, 93  
 Porcelain gallbladder, 379  
 Porphobilinogen deaminase, 403  
 Porphyrin, **403**, 515  
 Porphyria cutanea tarda, 403  
 Porphyrin derivatives, 79  
 Portal hypertension, **372**  
   ARPKD, 573  
   pulmonary arterial  
     hypertension, 643  
   *Schistosoma* spp, 157  
     serum markers for, 373  
     varices and, 350  
   Portal triad, 346, 352  
   Portal vein, 346, 352  
     in fetal circulation, 270  
   Portal vein thrombosis, 372  
   Portosystemic anastomoses, **350**  
   Port-wine stain of face, 495, 656  
   Positive predictive value (PPV), 247,  
     249, 669  
   Positive reinforcement, 524  
   Positive skew distribution, 251  
   Postcapillary venule (lymph node), 92  
   Posterior cerebral artery,  
     472, 473, 485  
   Posterior chamber (eye), 504  
   Posterior circumflex artery, 432  
   Posterior communicating  
     artery, 473  
   Posterior cruciate ligament (PCL)  
     injury, 424  
   Posterior descending artery  
     (PDA), 271  
   Posterior drawer sign, 424  
   Posterior fossa  
     malformations, **462**  
   Posterior hypothalamus, 466  
   Posterior inferior cerebellar artery  
     circle of Willis, 473  
     stroke effects, 484  
   Posterior pituitary gland, 313  
   Posterior superior pancreaticoduodenal  
     arteries, 349  
   Posterior tibial artery, 432  
   Posterior urethral valves, 549  
   Posterior uveitis, 506  
   Postoperative ileus, 232  
   Postpartum blues, 532  
   Postpartum depression, 532  
   Postpartum hemorrhage, 607  
   Postpartum mood disturbances, **532**  
   Postpartum psychosis, 532  
   Postrenal azotemia, 571  
   Posttranslational modifications, **41**  
   Post-traumatic stress disorder  
     (PTSD), 532, **534**  
     dissociative identity disorder, 528  
     drug therapy for, 542  
     prazosin for, 236  
     SSRIs for, 545  
     venlafaxine, 545  
   Postural hypotension  
     midodrine for, 234  
     trazodone, 546  
   Postviral infections, 175  
   Potassium  
     amphotericin B, 195  
     in cardiac muscle, 280  
     diabetic ketoacidosis, 337  
     PTH and, 320  
     shifts in, **560**  
     torsades de pointes and, 283  
   Potassium channel blockers, **309**  
   Potassium channels  
     meglitinides and, 341  
     myocardial action potential, 280  
     opioid effect, 520  
     sulfonylurea effect on, 340  
   Potassium chloride, 240  
   Potassium iodide  
     *Sporothrix schenckii*, 150  
     for thyroid storm, 329  
   Potassium-sparing diuretics, 574, **576**  
   Potency of drugs, vs efficacy, 227  
   Pott disease, 176  
   Potter sequence, **548**, 581, 607  
     ARPKD, 573  
   Potter syndrome, 626  
   Poxviruses  
     characteristics of, 160  
     DNA viruses, 159  
     molluscum contagiosum, 451  
   PPAR- $\gamma$ , 341  
   PPAR- $\gamma$  activators, 244  
   PPD test, 136  
   Practice tests, 19  
   Prader-Willi syndrome  
     chromosome association, 60  
     ghrelin in, 317, 356  
     imprinting, 54  
   Pralidoxime, 232  
   Pramlintide, 240, 341  
   Prasugrel, 393, 415  
   Pravastatin, 306  
   Praziquantel  
     antihelminthic therapy, 196  
     tapeworms, 156  
     trematodes, 156  
   Prazosin, 236  
   Precision vs accuracy, 249  
   Precocious puberty  
     adrenal steroids and, 318  
     leuprolide, 621  
     McCune-Albright syndrome,  
       53, 652  
   Precontemplation stage, 539  
   Prednisolone  
     arachidonic acid pathway, 455  
     for thyroid storm, 329  
   Prednisone  
     arachidonic acid pathway, 455  
   Preeclampsia, 608  
   hydatidiform moles, 605  
   placental abruption, 606  
   Preferred Provider Organization, 259  
   Prefrontal cortex, 471  
   Pregnancy, **598**  
     advanced maternal age, 59  
     amniotic fluid abnormalities, **607**  
     anemia caused by, 396  
     carpal tunnel syndrome and, 426  
     choriocarcinomas and, 605  
     complications of, **606–607**  
     contraindicated antimicrobials, **201**  
     diabetes in. *See* Gestational  
       diabetes mellitus (GDM)  
     ESR in, 212  
     estrogen in, 595  
     ethical situations, 256–257  
     fetal circulation, 270  
     fetal hemoglobin, 631  
     fetal respiration, 626  
     fibroid tumors in, 612  
     folate deficiency caused by, 398  
     folic acid supplementation, 64  
     heparin in, 413  
     hypertension in, **608**  
     hypertension treatment in, 235, 304  
     hypothyroidism in, 328  
     insulin in, 314  
     *Listeria monocytogenes* in, 135  
     lithium in, 288, 290  
     maternal phenylketonuria, 80  
     melasma in, 448  
     normal urine changes in, 554  
     ovarian neoplasms and, 610  
     parental consent and, 254  
     prolactin and, 316  
     propylthiouracil in, 341  
     pyelonephritis and, 570  
     pyogenic granulomas and, 450  
     Rh factor in, 390  
     SHBG and, 322  
     stillbirth, 178  
     *Streptococcus agalactiae* in, 133  
     syphilis in, 143  
     termination of, 622  
     ToRCHeS infections, 178  
     Turner syndrome and, 603  
     twinning in, 583  
     urinary tract infections, 177  
     vitamin B<sub>9</sub> deficiency, 64  
   Pregnancy-induced hypertension, 608  
   Pregnenolone, 318  
   Preload in cardiac output, 273  
   Premature ejaculation, 545  
   Premature labor and delivery  
     cryptorchidism and, 617  
     low birth weight caused by, 599  
     murmur in prematurity, 279  
     neonatal respiratory distress  
       syndrome and, 627  
     smoking, 582  
   Premature ovarian failure, 609  
   Premenstrual dysphoric disorder  
     (PMDD), 545  
   Premotor cortex, 471  
   Prepatellar bursitis, 425  
   Preprocollagen, 46  
   Preproinsulin, 314  
   Prepuce, 593  
   Prerenal azotemia, 571  
   Presbycusis, 259  
   Presbyopia, 504  
   Presenilin, 490  
   Pressors, 299  
   Pressure-volume loops, **276**  
   Pretecal nuclei, 509  
   Preterm birth  
     common cause of death, 260  
   Pretest probability, 247  
   Prevalence  
     diagnostic test evaluation, 247  
     incidence vs, 249  
     observational studies, 246  
     relative risk, 248  
   *Prevotella* spp, 175  
   Priapism, **617**  
     sickle cell anemia, 400  
     trazodone and, 546

- Primaquine, 153  
hemolysis in G6PD deficiency, 241
- Primary adrenal insufficiency, **324**
- Primary amyloidosis, 659
- Primary biliary cirrhosis  
autoantibody with, 111  
as granulomatous disease, 211  
labs/findings, 657
- Primary central nervous system  
lymphoma (PCL), 408
- Primary glomerular disease, 563
- Primary hemostasis, **393**
- Primary hyperaldosteronism, 324  
hypertension with, 290  
markers in, 560
- Primary hyperparathyroidism, 331, 332
- Primary hypertension, 304
- Primary hypogonadism, 604
- Primary hyperparathyroidism, 331
- Primary sclerosing cholangitis, **378**  
ulcerative colitis, 365
- Primary spontaneous  
pneumothorax, 644
- Primase, **35**
- Primidone, 489
- Primitive atrium, 268
- Primitive pulmonary vein, 268
- Primitive reflexes, **480**
- Primitive ventricle, 268
- Pringle maneuver, 346
- PR interval, 284
- Prinzmetal angina  
calcium channel blockers for, 304  
ischemic manifestations, 293  
propranolol adverse effects, 309
- Prions, **174**
- Privacy and confidentiality, 255
- Probenecid, 243  
cidofovir with, 198  
for gout, 661  
gout, 457
- Procainamide, 308  
lupus-like syndrome, 241
- Procaine, 519
- Procarbazine, 242
- Procedure bias, 250
- Process (quality measurement), 261
- Processus vaginalis, 591
- Procoagulation, 392
- Progesterone, **595**  
granulosa cell tumors, 611  
lactation and, 599  
menstrual cycle, 597  
ovulation, 596  
pregnancy, 598  
signaling pathways for, 322
- Progesterin, **622**  
contraception, 622  
endometriosis, 613
- Progressive multifocal  
leukoencephalopathy  
(PML), 464, 494  
HIV-positive adults, 173  
polyomaviruses, 160  
rituximab, 420
- Proguanil, 196
- Projection, 525
- Prokaryotes  
DNA replication in, 35  
RNA polymerases in, 38
- Prolactin, **316**  
circadian rhythm, 467  
lactation and, 599  
pregnancy, 598  
secretion of, 313, 315  
signaling pathways for, 322  
tuberoinfundibular pathway, 468
- Prolactinomas  
dopamine agonists for, 316  
pituitary adenomas, 332
- Proliferative glomerular disorders, 563
- Prometaphase, 42
- Promoters (gene expression), **38**
- Promyelocytic leukemia, 62
- Pronephros, 548
- Proopiomelanocortin, 313
- Propafenone, 308
- Propranolol, 329
- Proper hepatic artery, 346
- Prophase, 42
- Propionibacterium* spp, 121
- Propionibacterium acnes*, 449
- Propionyl-CoA carboxylase  
metabolic pathways, 70  
vitamin B<sub>7</sub> and, 64
- Propofol, 519
- Propranolol, 237, 309  
essential tremor, 489
- Proprioception  
Friedreich ataxia, 501
- Propylthiouracil  
agranulocytosis, 241  
aplastic anemia, 241  
as inhibitor, 321  
thionamides, 341  
for thyroid storm, 329
- Prosencephalon, 460
- Prostacyclin, 455
- Prostaglandin analogs, 244
- Prostaglandins  
arachidonic acid pathway, 455  
aspirin effects, 456  
cortisol effect on, 319  
glaucoma, 521  
kidney functions, 559  
PDA and, 270
- Prostate cancer  
adenocarcinomas, **619**  
estrogens for, 621  
incidence/mortality of, 216  
leuprolide for, 621  
metastases of, 221  
tumor suppressor genes and, 218
- Prostate gland, 593  
female homolog of, 590  
lymphatic drainage of, 591
- Prostatic acid phosphatase  
(PAP), 619
- Prostatitis, **619**  
gonorrhea, 180
- Prosthetic devices  
osteomyelitis, 176  
*Staphylococcus epidermidis*, 131
- Prosthetic heart valves, 401
- Protamine sulfate, 239, 413
- Protease inhibitors  
acute pancreatitis, 380  
fat redistribution, 241  
HIV therapy, 199  
hyperglycemia, 240  
mechanism (diagram), 197  
naming convention for, 244
- Proteases, 358
- Proteasome, **43**
- Protein A, 125
- Proteinases, 386
- Protein C/S deficiency, 406
- Protein kinase A  
fructose biphosphatase-2 and, 72  
glycogen regulation, 81
- Protein metabolism, 70
- Protein phosphatase, 81
- Proteins  
free radical effect on, 210
- Protein synthesis, **41**, 183, 197  
insulin and, 314  
metabolic site, 68
- Protein synthesis inhibitors, **187**, 244
- Proteinuria  
ACE inhibitors for, 577  
angiotensin II receptor  
blockers, 577  
diabetes mellitus, 336  
nephritic syndrome, 564  
nephrotic syndrome, 563, 566, 655  
preeclampsia, 608  
serum sickness, 109
- Proteolysis  
cortisol and, 319  
in insulin deficiency, 336
- Proteus* spp  
Gram-negative algorithm, 137  
nosocomial infection, 181  
taxonomy, 121  
urease-positive, 124
- Proteus mirabilis*  
cephalosporins, 185  
kidney stones, 567  
penicillins for, 184  
urinary tract infections (UTIs),  
177, 570
- Prothrombin  
warfarin effect on, 414
- Prothrombin gene mutation, 406
- Protofilament, 44
- Proton pump inhibitors, **381**  
acute interstitial nephritis, 572  
Beers criteria, 238  
gastrin and, 356  
for *Helicobacter pylori*, 142  
naming convention for, 244
- Protozoa  
CNS infections, 152  
GI infections, 151  
hematologic infections, 153  
miscellaneous, 154  
watery diarrhea, 175
- Proximal convoluted tubules  
defects in, 556  
diuretics and, 574
- dopamine secretion by, 559  
glucose clearance and, 554  
ischemia susceptibility, 206  
physiology of, 555  
relative concentrations in, **557**  
renal cell carcinoma and, 568  
renal tubular acidosis of, 562
- Proximal interphalangeal (PIP)  
joints, 429
- PRPP (glutamine-phosphoribosyl-  
pyrophosphate) amidotrans-  
ferase, 69
- Pruritus  
anal, 155  
biliary tract disease, 378  
chloroquine, 196  
cutaneous mycoses, 148  
ectoparasites, 157  
histamine receptors and, 230
- Prussian blue stain, 641
- Psammoma bodies, **220**  
diseases with, 660  
mesotheliomas, 641  
papillary thyroid carcinoma, 330  
serous cystadenocarcinomas, 611
- PSA (prostate-specific antigen), 220
- Pseudoappendicitis, 141
- Pseudocyst, 380
- Pseudoephedrine, **648**
- Pseudoglandular lung  
development, 626
- Pseudogout, 440  
labs/findings, 660
- Pseudohermaphroditis, 604
- Pseudohyperaldosteronism  
Cushing syndrome and, 323
- Pseudohypoparathyroidism, 331
- Pseudomembranous colitis  
clindamycin, 188  
*Clostridium difficile*, 134  
as drug reaction, 240  
penicillins, 184  
spore-forming bacteria, 127  
vancomycin for, 186  
watery diarrhea, 175
- Pseudomembranous pharyngitis  
diphtheria, 135
- Pseudomonas* spp  
catalase-positive organism, 124  
ceftazidime, 185  
cystic fibrosis, 56, 175  
fluoroquinolones, 191  
Gram-negative algorithm, 137  
as nosocomial infection, 175  
osteomyelitis, 176  
penicillins for, 184  
taxonomy, 121  
tricuspid valve endocarditis, 299  
type III secretion system, 125
- Pseudomonas aeruginosa*, **139**  
aerobic organism, 123  
biofilm production, 125  
encapsulated, 124  
exotoxin production, 128  
immunodeficient patients, 114  
multidrug-resistant, 194  
nosocomial infection, 181

- pigment production, 125, 139  
 pyocyanin of, 105  
 splenic dysfunction and, 94  
 UTIs, 177
- Pseudo-Pelger-Huet anomaly, 409
- Pseudopseudohypoparathyroidism, 331
- Pseudotumor cerebri, **491**  
 acetazolamide for, 575  
 vitamin A toxicity, 62
- Pseudovirion, 158
- Psittacosis, 144
- Psoriasis, 449  
 arthritis and, 442  
 cyclosporine, 116  
 etanercept for, 457  
 hyperkeratosis/parakeratosis, 448  
 infliximab/adalimumab for, 457  
 methotrexate for, 417  
 skin lesions, 447  
 therapeutic antibodies, 118
- Psoriatic arthritis, 442  
 HLA-B27 and, 96  
 leflunomide for, 456  
 psoriasis and, 449
- Psychiatry, 524–546  
 pathology, 526–540  
 pharmacology, 542–546  
 psychology, 524–525
- Psychoactive drug intoxication and withdrawal, **540–541**
- Psychology, 524–525
- Psychosine, 494
- Psychosis, **529**  
 corticosteroids, 116  
 diabetic ketoacidosis, 337  
 drug therapy for, 543  
 LSD and, 541  
 lupus, 443  
 PCP and, 541  
 postpartum, 532
- Psychotherapy  
 anorexia/bulimia nervosa, 537  
 anorexia nervosa, 661  
 conduct disorder, 527  
 oppositional defiant disorder, 527
- Psychotic disorders  
 readmissions with, 261
- Psyllium, 383
- PTEN* gene, 218
- Pterygoid muscles, 587
- PTH. *See* Parathyroid hormone
- PTH-independent  
 hypercalcemia, 331
- PTH-related peptide (PTHrP), 320
- PTHrP (parathyroid hormone-related protein), 217
- Ptosis (eyelids)  
 CN III damage, 511  
 Horner syndrome, 509, 655  
 myasthenia gravis, 445  
 Pancoast tumor, 646
- Puberty  
 GH secretion in, 317  
 GnRH and, 315  
 Kallmann syndrome and, 604
- precocious, 53, 318  
 Tanner stages, 602
- Public health sciences, **246–263**
- Pudendal nerve, 431
- Pulmonary anthrax, **133**
- Pulmonary arterial hypertension (PAH), 643  
 high altitude and, 635
- Pulmonary artery, 586  
 fetal circulation, 270
- Pulmonary artery stenosis, 290
- Pulmonary capillary wedge pressure (PCWP), 286, 634
- Pulmonary circulation, **633**
- Pulmonary edema  
 acute respiratory distress syndrome as cause, 642  
 compliance in, 631  
 consolidation in, 643  
 left heart failure, 298  
 loop diuretics for, 575  
 LV failure, 296  
 mannitol, 575  
 nitrates for, 305  
 opioids for, 520  
 renal failure, 571
- Pulmonary embolism, **637**  
 deep venous thrombosis and, 636  
 direct factor Xa inhibitors for, 415  
 heparin for, 413  
 obstructive shock, 299  
 respiratory alkalosis, 561  
 tamoxifen/taloxifene and, 421  
 thrombolytics for, 415
- Pulmonary fibrosis  
 amiodarone and, 309  
 bleomycin, 418  
 busulfan, 418  
 compliance in, 631  
 diffusion in, 633  
 as drug reaction, 242  
 methotrexate, 417  
 restrictive lung disease, 639
- Pulmonary hemorrhage, 133
- Pulmonary hypertension, **643**  
 cor pulmonale, 633  
 drug therapy, **648**  
 PDE-5 inhibitors for, 623  
*Schistosoma*, 156  
 sleep apnea, 642
- Pulmonary hypoplasia, 626  
 Potter sequence, 548
- Pulmonary Langerhans cell histiocytosis, 639
- Pulmonary surfactant  
 club cells, 627  
 compliance and, 631  
 NRDS, 627
- Pulmonary trunk, 268
- Pulmonary vascular resistance (PVR), **634, 670**  
 chest wall and, 631
- Pulmonic regurgitation, 278
- Pulmonic stenosis  
 carcinoid syndrome, 338  
 systolic ejection murmur in, 278  
 wide splitting in, 277
- Pulmonic valves, 268
- “Pulseless disease,” 302
- Pulse pressure, 272
- Pulsus paradoxus, 300  
 asthma, 638  
 croup, 166
- Punched-out ulcers, 360
- Punishment, 524
- Pupil  
 anatomy, 504  
 CN III palsy, 511  
 control, 477, **509**
- Pure red cell aplasia, 217
- Purines, 190  
 de novo synthesis, 33  
 salvage deficiencies, **34**
- Purkinje cells  
 of cerebellum, 206, 469  
 in paraneoplastic cerebellar degeneration, 217
- Purkinje fibers, 282
- Purpura  
 aplastic anemia, 399  
 cirrhosis, 372
- Pustular psoriasis, 447
- Pustules, 447
- Putamen, 470  
 neurodegenerative disorders, 490
- Pyelonephritis, **570**  
 kidney stones, 567  
 labs/findings, 660, 661  
 urinary tract infections, 177  
 WBC casts in, 562
- Pygmalion effect, 250
- Pyloric sphincter, 357
- Pyloromyotomy, 345
- Pyoderma gangrenosum  
 inflammatory bowel disease, 365
- Pyogenic granulomas, 450
- Pyramidal cells, 206
- Pyramidal decussation, 474
- Pyramidalis muscle, 354
- Pyrantel pamoate, 196
- Pyrazinamide, **193**  
 gout, 241  
 hepatitis, 240  
*Mycobacterium tuberculosis*, 192
- Pyridostigmine, 232
- Pyridoxal phosphate, 63
- Pyrimethamine, 33, 196  
*Toxoplasma gondii*, 663
- Pyrimidine dimers, 37
- Pyrimidines, 33
- Pyrimidine synthesis, 456
- Pyruvate carboxylase, 73, 74  
 metabolic pathways, 70  
 vitamin B<sub>7</sub> and, 64
- Pyruvate dehydrogenase complex, **72**  
 deficiency, **73**  
 metabolic pathways, 70  
 vitamin B<sub>1</sub> and, 62
- Pyruvate kinase, 70
- Pyruvate kinase deficiency, 400  
 in anemia taxonomy, 396  
 echinocytes in, 394
- Pyruvate metabolism, **73**
- Pyuria, 572
- Q**
- Q fever  
 rickettsial disease, **145**  
 transmission, 144
- QRS complex, 282
- QT interval  
 atypical antipsychotic effect on, 543  
 Class IA antiarrhythmic effects, 308  
 congenital long QT syndrome, 283  
 drug-induced long, 283  
 ECG, 282  
 ondansetron effect on, 383  
 in torsades de pointes, 283
- Quality measurements, **261**
- Quantifying risk, 248
- Quetiapine, 543
- Quiescent cells, 42
- Quinidine, 153, 196, 308  
 cinchonism, 242  
 cytochrome P-450 and, 243  
 diarrhea, 240
- Quinine, 196
- Quinolone, 139, 183
- Quinupristin, 183, 194
- R**
- Rabies, **167**  
 active and passive immunity, 107  
 rhabdovirus, 163  
 vaccine, 158  
 viral receptors, 162
- Radial nerve, 427
- Radiation exposure  
 acute myelogenous leukemia and, 410  
 aplastic anemia, 399  
 apoptosis caused by, 204  
 as carcinogen, 219  
 free radical injury caused by, 210  
 hypopituitarism, 335  
 myelodysplastic syndromes, 409
- Radiation therapy  
 acute pericarditis and, 300  
 angiosarcomas, 450  
 lymphopenia, 402  
 for Nelson syndrome, 332  
 neutropenia, 402  
 osteosarcomas, 438  
 pancreatic cancer, 380  
 papillary thyroid carcinoma risk, 330  
 readmissions with, 261
- Radon  
 as carcinogen, 219  
 lung cancer, 647
- Ragged red muscle fibers, 55
- Rales, 298
- Raloxifene, **421, 621**
- Raltegravir, 197, 199
- Ramipril, 577
- Ranibizumab, 118  
 macular degeneration, 506
- Ranitidine, 381
- RANK-L, 320

- Ranolazine, **305**
- Rapid-eye movement (REM)  
sleep, **467**
- Rapidly progressive  
glomerulonephritis  
(RPGN), **564**
- Rapid squatting on auscultation, **278**
- Rasagiline, **518**
- Rasburicase, **421, 567**
- RAS gene, **330**
- Rashes  
butterfly, **652**  
carbapenems, **186**  
childhood, **179**  
cytomegalovirus, **178**  
desquamating, **652**  
fluoroquinolones, **191**  
Kawasaki disease, **302**  
lupus, **443**  
macrolides, **189**  
measles, **166**  
nipple/areola, **655**  
palms/soles, **655**  
penicillinase-sensitive penicillins as  
cause, **184**  
ricketsial diseases, **145**  
rubella, **165, 178**  
simeprevir, **200**  
syphilis as cause, **143, 180**  
unvaccinated children, **182**
- Rathke pouch, **313, 498**
- Rationalization, **525**
- Raynaud phenomenon, **445**  
Buerger disease, **302**  
calcium channel blockers for, **304**  
CREST syndrome, **446**  
presentation, **655**  
SLE, **652**
- Rb, **42**
- Rb gene, **218**
- Reabsorption rate, **554**
- Reaction formation, **525**
- Reactive arthritis, **442**  
*Campylobacter jejuni*, **140**  
chlamydia, **146, 180**  
HLA-B27 and, **96**  
presentation, **656**
- Reactive attachment disorder, **526**
- Reactive cellular changes, **214**
- Readmission recurrences, **261**
- Reassortment (viral), **158, 165**
- Recall bias in studies, **250**
- Receptor binding, **228**
- Receptors (viral), **162**
- Receptor tyrosine kinase  
hormone messenger, **322**  
as oncogene product, **218**
- Recessive inheritance, **55**
- Recombinant cytokines, **117**
- Recombination (viral), **158**
- Recruiting study participants, **250**
- Rectal veins, **350**
- Rectum  
anastomosis at, **350**  
blood supply and innervation, **348**  
familial adenomatous  
polyposis, **370**
- Hirschsprung disease, **367**  
ischemia susceptibility, **206**
- Rectus abdominis muscle, **354**
- Recurrent branch of median  
nerve, **427**
- Recurrent laryngeal nerve, **586**
- Recurrent laryngeal nerves, **586**
- Red cell casts, **302**
- Red-green color blindness, **193**
- Red infarct vs pale infarct, **207**
- Red man syndrome, **186**
- Redox reactions  
free radical injury and, **210**  
vitamin B<sub>2</sub> and, **63**
- Red pulp (spleen), **94**
- Red rashes of childhood, **179**
- Reduviid bug (disease vector), **154**
- Reed-Sternberg cells, **407**
- Refeeding syndrome, **537**
- Reflex bradycardia, **558**
- Reflexes  
clinical, **480**  
cranial nerve, **477**  
motor neuron sign, **499**  
primitive, **480**
- Reflex tachycardia, **236**
- Refractive errors (vision), **504**
- Refractory hypertension, **623**
- Refusing care, **257**  
minors, **257**
- Regadenoson, **293**
- Regan-Lowe medium, **123**
- Regional specification  
(brain), **460**
- Registering for exam, **5–6**
- Regression, **525**
- Regular insulin, **340**. *See also*  
Insulin
- Regulation of gene expression, **38**
- Regulatory T cells, **98**  
cell surface proteins, **106**
- Regurgitation in GERD, **360**
- Reheated rice syndrome, **134**
- Reichert cartilage, **587**
- Reid index, **638**
- Reinke crystals, **619, 660**
- Relapse stage, **539**
- Relapsing fever  
animal transmission, **144**  
lice, **157**
- Relative risk reduction (RRR), **248, 669**
- Relative risk (RR), **246, 248, 252, 669**
- Reliability, **249**
- Religious beliefs, **257**
- REM sleep, **467**
- Renal artery, **348, 550**  
horseshoe kidney, **549**
- Renal blood flow, **550, 670**  
endocrine function and, **559**
- Renal cell carcinomas, **568**  
associations, **668**  
bevacizumab for, **420**  
carcinogens causing, **219**  
chromosome association, **60**  
horseshoe kidney and, **549**
- hypercalcemia and, **217**
- IFN- $\alpha$  for, **200**
- metastases of, **221**
- recombinant cytokines, **117**
- therapeutic antibodies, **118**
- von Hippel-Lindau disease,  
**495, 655**
- Renal clearance, **552, 670**
- Renal cortex, **550**  
hydronephrosis, **568**
- Renal cyst disorders, **573**
- Renal disease  
ESR in, **212**  
lupus, **443**  
maintenance and loading dose  
in, **225**  
Wilson disease, **378**
- Renal drug reactions, **242**
- Renal failure  
diabetes mellitus, **336**  
Enterotoxigenic *Escherichia coli*  
(EHEC), **140**  
Fabry disease, **84**  
guanosine analogs, **197**  
labs/findings, **660**  
myoclonus in, **489**  
preeclampsia and, **608**  
prolactin elimination in, **316**  
tetracycline use in, **188**  
vitamin D deficiency, **319**
- Renal failure/disorders, **571**  
consequences of, **571**  
markers for, **560**  
NSAIDs, **559**  
renal cyst disorders, **573**  
waxy casts in, **562**
- Renal hypoxia, **632**
- Renal ischemia, **456**
- Renal medulla, **550**  
hydronephrosis, **568**
- Renal oncocytomas, **568**
- Renal osteodystrophy, **332, 571**
- Renal papillary necrosis, **572**  
pyelonephritis and, **570**  
sickle cell anemia, **400**
- Renal pelvis, **550**
- Renal plasma flow, **552**  
glomerular dynamics and, **553**
- Renal toxicity  
gancyclovir, **198**
- Renal tubular acidosis, **562**  
Fanconi syndrome, **655**  
metabolic acidosis, **561**
- Renal tubules  
anatomy of, **550**  
defects in, **556**  
in nephron physiology, **555**  
PTH and, **320**
- Renal vascular smooth muscle, **230**
- Renal vein, **550**
- Renin, **558**  
ACE inhibitor effect on, **577**  
aliskiren effect on, **577**  
in hyperaldosteronism, **324**  
renal disorders and, **560**  
sympathetic receptors and, **230**
- Renin-angiotensin, **312**
- Renin-angiotensin-aldosterone  
system, **558**
- Renin secreting tumors, **560**
- Renshaw cells, **128, 134**
- Reoviruses  
characteristics, **163**  
genome, **159**  
naked viruses, **159**  
segmented, **164**
- Repaglinide, **341**
- Reperfusion injury, **207, 294**
- Reperfusion therapy, **296**
- Replication fork, **35**
- Replication (viral), **159**
- Reportable diseases  
confidentiality exceptions, **255**
- Repression, **525**
- Repressor proteins, **36**
- Reproductive hormones, **620**
- Reproductive system, **580–621**  
anatomy, **591–594**  
drug reactions in, **240**  
embryology, **580–591**  
pathology, **603–617**  
pharmacology, **620–623**  
physiology, **595–602**
- Reptile (disease vectors), **144**
- Rescheduling exam, **6**
- Reserpine  
Huntington disease, **518**  
as noradrenergic drug, **231**  
Parkinson-like syndrome, **242**
- Residual volume (RV), **630, 637**
- Resistance equation, **670**
- Resistance in vessels, **274**
- Respiratory acidosis, **561**
- Respiratory alkalosis, **561**  
causes of, **561**  
high altitude, **635**  
pulmonary embolism, **637**
- Respiratory burst, **105**  
free radical injury and, **210**
- Respiratory depression  
barbiturates, **515, 540**  
benzodiazepines, **514, 540**  
epilepsy drugs, **514**  
inhaled anesthetics, **519**  
opioids, **520**  
tricyclic antidepressants, **545**
- Respiratory distress syndrome, **599**
- Respiratory drug reactions, **242**
- Respiratory rate (RR), **630**
- Respiratory syncytial virus (RSV)  
paramyxovirus, **163, 165**  
pneumonia, **175, 645**  
prophylaxis, **118**  
ribavirin, **200**
- Respiratory system, **626–649**  
anatomy, **628–629**  
embryology, **626–627**  
pathology, **636–646**  
pharmacology, **648–649**  
physiology, **630–635**
- Respiratory tract infections  
C3 deficiency, **103**
- Respiratory tree, **628**
- Respiratory zone, **628**

- Resting tremor, 489, 655
- Restrictive cardiomyopathy, 297  
amyloidosis and, 213  
S4 heart sound and, 668
- Restrictive lung diseases, **639**  
flow volume loops, 637  
sarcoidosis, 444
- Retepase, 391, 415
- Rete testis, 593
- RET gene, 218  
carcinoma risks with, 330  
Hirschsprung disease, 367  
pheochromocytomas, 326
- Reticular activating system, 481
- Reticular fibrous framework (spleen), 94
- Reticulate bodies, 146
- Reticulin, 46
- Reticulocytes, 386  
in aplastic anemia, 399  
intravascular hemolysis, 399
- Retina  
chronic hyperglycemia, 507  
degeneration of, 506  
embryologic derivation of, 581  
normal eye, 504  
vascular occlusions, 507  
visual field defects, 511  
von Hippel-Lindau disease, 495
- Retinal artery, 504
- Retinal detachment, **507**
- Retinal hemorrhage, 507  
child abuse sign, 526  
hypertensive emergency, 290  
Roth spots, 655
- Retinal vein, 504
- Retinal vein occlusion, **507**
- Retinitis, 506, **508**  
cidofovir, 198  
foscarnet, 198  
HIV-positive adults, 173
- Retinitis pigmentosa, **508**
- Retinoblastoma  
chromosome association, 60  
heterozygosity loss, 52
- Retinoblastomas  
osteosarcomas, 438  
tumor suppressor genes and, 218
- Retinoids, 449
- Retinopathy  
Alport syndrome, 565  
chloroquine, 196  
diabetes mellitus, 336  
hypertension, 290  
of prematurity, 210, 627  
sorbitol, 77
- Retrognathia, 548
- Retrograde amnesia, 528
- Retroperitoneal fibrosis, 568
- Retroperitoneal structures, **345**
- Retropective studies, 250
- Retroviruses  
characteristics, 163  
genomes, 159
- Rett syndrome, 527  
X-linked dominant  
inheritance, 55
- Reverse transcriptase, 171
- Reverse transcriptase  
inhibitors, 197
- Reye syndrome, **373**
- Reynolds pentad, 379
- Rhabdomyolysis  
daptomycin, 191  
hyperkalemia with, 560
- Rhabdomyomas, 301  
nomenclature for, 216  
tuberous sclerosis, 495
- Rhabdomyosarcomas  
dactinomycin for, 418  
desmin stain for, 44  
nomenclature for, 216
- Rhabdoviruses  
characteristics, 163  
negative-stranded, 164
- Rhagades, 143
- Rh blood classification, 390
- Rheumatic fever, **300**  
criteria for, 132  
heart murmur with, 279  
*Streptococcus pyogenes*, 132  
streptolysin O, 129  
type II hypersensitivity, 108
- Rheumatoid arthritis, **439**  
AA amyloidosis and, 213  
anemia of chronic disease, 399  
autoantibody with, 111  
azathioprine for, 417  
biliary cirrhosis, 378  
carpal tunnel syndrome and, 426  
celecoxib for, 456  
etanercept for, 457  
HLA-DR4 and, 96  
immunosuppressants, 116  
infliximab/adalimumab for, 457  
labs/findings, 657  
leflunomide for, 456  
methotrexate for, 417  
rituximab, 118  
rituximab for, 420  
uveitis, 506
- Rheumatoid factor, 111
- Rh hemolytic disease of the newborn, **390**
- Rhinitis  
phenylephrine for, 234  
type I hypersensitivity, 108
- Rhinosinusitis, **636**
- Rhinovirus  
picornavirus, 163, 164  
receptors for, 162
- Rhizopus* spp, **149**  
presentation, 652
- RhoGAM, 390
- Rhombencephalon, 460
- Rhomboid crystals, 660
- Ribavirin  
contraindicated in pregnancy, 201  
hepatitis, 661  
hepatitis C, 200  
purine synthesis, 33
- Rib notching, 660
- Ribose, 75
- Ribosomes, 42
- Rice-water diarrhea  
cholera toxin, 128  
organisms causing, 175  
*Vibrio cholerae*, 141
- Richter transformation, 410
- Ricketts, **436**  
Fanconi syndrome, 655  
hypophosphatemia, 560  
inheritance, 55  
lab values in, 437  
vitamin D deficiency, 66, 319
- Rickettsia* spp  
Giemsa stain for, 122  
intracellular organism, 124  
taxonomy, 121  
tetracyclines, 188
- Rickettsial diseases, **145**
- Rickettsia prowazekii*, 145  
transmission of, 144, 157
- Rickettsia rickettsii*, 145  
animal transmission, 144  
chloramphenicol, 188
- Rickettsia typhi*, 144, 145
- Riedel thyroiditis, 328
- Rifabutin, 192
- Rifamixin, 78
- Rifampin, 192  
acute interstitial nephritis, 572  
cytochrome P-450 and, 243  
Hansen disease, 137  
hepatitis, 240  
mechanism (diagram), 183  
*Mycobacterium leprae*, 192  
*Mycobacterium tuberculosis*, 192  
as prophylaxis, 194  
protease inhibitors and, 199  
RNA polymerase inhibition, 38
- Rifamycins, **192**
- Rifaximin, 374
- Rift Valley fever, 163
- Right anterior cardinal vein, 268
- Right bundle branch, 282
- Right bundle branch block, 277
- Right common cardinal vein, 268
- Right coronary artery (RCA)  
coronary circulation, 271  
infarct localization (ECG), 295  
occlusions of, 294
- Right external iliac artery, 348
- Right gastroepiploic artery, 349
- Right horn of sinus venosus, 268
- Right inferior phrenic artery, 348
- Right internal iliac artery, 348
- Right lower quadrant (RLQ) pain, 367
- Right lymphatic duct, 93
- Right marginal artery, 271
- Right renal artery, 348
- Right-to-left shunts, 288
- Right upper quadrant (RUQ)  
pain, 379
- Right ventricular hypertrophy (RVH)  
high altitude, 635  
pulmonary hypertension, 643
- Rigidity in Parkinson disease, 655
- Riluzole, **518**  
amyotrophic lateral sclerosis, 500
- Rimantadine, 197
- Ringed sideroblasts, 395
- Ringworm  
griseofulvin, 196  
tinea corporis, 148
- Risedronate, 456
- Risk quantification, **248**
- Risperidone, 530, 543
- Ristocetin, 393
- Risus sardonicus  
*Clostridium tetani*, 134  
tetanospasmin, 128
- Ritodrine, **622**
- Ritonavir  
cytochrome P-450 and, 243  
HIV therapy, 199  
mechanism (diagram), 197
- Rituximab, 118, **420**, 494
- Rivaroxaban, 415  
as anticoagulant, 391  
deep venous thrombosis, 636
- Rivastigmine, 232  
Alzheimer disease, 518
- River blindness, 155
- RNA  
interference, 52  
processing (eukaryotes), **38**
- RNA polymerases, **38**
- RNA viruses, **163**  
genome, **159**  
replication, 159
- Robertsonian translocation, **60**
- Rocker-bottom feet  
autosomal trisomies, 59
- Rocky Mountain spotted fever, **145**  
animal transmission, 144  
chloramphenicol, 188  
presentation, 655
- Rocuronium, 520
- Rod bacteria, 121
- Romaña sign, 154
- Romano-Ward syndrome, 283
- Romberg sign, 143, 500
- Romiplostim, 117
- Root cause analysis, 262
- Rooting reflex, 480
- Rosacea, 449
- Rose gardener's disease, 150
- Rosenthal fibers, 498
- Roseola  
HHV-6/HHV-7, 161  
rash, 179
- Rosiglitazone, 340
- Rostral fold closure defects, 344
- Rosuvastatin, 306
- Rotator cuff muscles, **425**
- Rotavirus, **164**  
diarrhea, 163, 175
- Rotenone, 74
- Roth spots, 299, 655
- Rotor syndrome, 376, 377
- Rough endoplasmic reticulum, **42**
- Rouleaux formation, 409, 660
- Round ligament of uterus, 592
- Rovsing sign, 366, 656
- Rubella, **165**  
cardiac defect association, 290  
cataracts, 505



- Rubella (*continued*)  
heart murmur with, 279  
rash, 179  
ToRCHeS infection, 178  
unvaccinated children, 182
- Ruffini corpuscles, 464
- Russell sign, 537
- Ryanodine receptor, 433
- S**
- Saber shins  
congenital syphilis, 143  
syphilis, 178
- Sabin poliovirus vaccine, 158, 163
- Sabouraud agar, 123, 149
- Saccular aneurysms, 486  
Ehlers-Danlos syndrome, 47  
renal cyst disorders and, 573
- Saccular lung development, 626
- Sacrococcygeal teratomas, 618
- Saddle nose  
congenital syphilis, 143  
Laron syndrome, 333  
syphilis, 178
- Safety culture, **261**
- Salicylates  
metabolic acidosis, 561  
respiratory alkalosis, 561  
toxicity treatment for, 239
- Salivary gland tumors, **359**
- Salivary stimulation, 232
- Salk polio vaccine, 158
- Salmeterol, 234, 649
- Salmonella* spp  
animal transmission, 144  
bloody diarrhea, 175  
encapsulated bacteria, 124  
food poisoning, 174  
Gram-negative algorithm, 137  
immunodeficient patients, 114  
intracellular organism, 124  
osteomyelitis, 176  
penicillins for, 184  
reactive arthritis, 442  
*Shigella* spp vs, **141**  
splenic dysfunction, 94  
taxonomy, 121  
TMP-SMX for, 190  
type III secretion system, 125
- Salmonella typhi*, 141
- Salpingitis  
ectopic pregnancy and, 607  
pelvic inflammatory disease, 181
- Sampling bias, 250
- Sandflies (disease vectors), 154
- Sandfly fever, 163
- Saponification, 205
- Saprophyticus*  
urease-positive, 124
- Saquinavir, 197, 199
- Sarcoidosis, **444**  
acute interstitial nephritis, 572  
cardiomyopathy with, 297  
erythema nodosum, 453  
as granulomatous disease, 211  
hypervitaminosis D, 437  
macrophages and, 387  
presentation, 652  
restrictive lung disease, 639  
uveitis, 506
- Sarcoma botryoides, 609
- Sarcomas  
metastases of, 221  
methotrexate for, 417  
nomenclature of, 216  
vimentin stain, 44
- Sarcoplasmic reticulum, 433
- Sargramostim, 117
- SARS (sudden acute respiratory syndrome), 163
- Sartorius muscle, 353
- Saturday night palsy, 427
- Saxagliptin, 341
- Scabies, 157, 196
- Scalded skin syndrome  
*Staphylococcus aureus*, 131  
toxic shock syndrome toxin, 129
- Scales (skin), 447
- Scaphoid bone, 426
- Scar formation, 207, **210**
- Scarlet fever  
presentation, 132, 656  
rash caused by, 179  
*Streptococcus pyogenes*, 132
- S cells, 356
- Schiller-Duval bodies, 611
- Schilling test, 398
- Schistocytes, 395  
HELLP syndrome, 608  
in intravascular hemolysis, 399  
in microangiopathic anemia, 401
- Schistosoma* spp, **156**, 157  
*Schistosoma haematobium*  
disease association, 156, 157  
as oncogenic microbe, 219  
squamous cell carcinoma of  
bladder, 569
- Schistosoma mansoni*, 156
- Schistosomiasis  
as granulomatous disease, 211  
portal hypertension, 372  
pulmonary arterial  
hypertension, 643
- Schizoaffective disorder, 530
- Schizoid personality disorder, 535
- Schizophrenia, **530**  
antipsychotics for, 543  
atypical antipsychotics for, 543  
drug therapy for, 542  
neurotransmitters for, 465  
readmissions with, 261
- Schizophreniform disorder, 530
- Schizotypal personality disorder, 535
- Schüffner stippling, 153
- Schwann cells, **464**  
Guillain-Barré syndrome, 493  
origin of, 460
- Schwannomas, 464, 496, 664
- Sciatic nerve, 430
- SCID (severe combined immunodeficiency disease), 113  
adenosine deaminase deficiency as  
cause, 34  
lymphopenia caused by, 402
- Sclerae, 504  
alkaptonuria, 80  
osteogenesis imperfecta, 47
- Scleritis, 439
- Sclerodactyly, 446
- Scleroderma, **446**  
autoantibody with, 111  
labs/findings, 657
- Sclerodermal esophageal dysmotility, 360
- Sclerosing adenosis, 615
- Sclerosing cholangitis, 376, 378  
ulcerative colitis as cause, 365
- Scombroid poisoning, 238
- Scopolamine, 233
- Scoring of USMLE Step 1 exam, 7, 8–9
- Scorpion sting, pancreatitis caused by, 380
- Scotoma, 511
- Scrotum, 593  
female homolog of, 590  
lymphatic drainage of, 591  
masses in, **618**
- Scurvy  
collagen synthesis and, 46  
presentation, 656  
vitamin C deficiency, 65
- Seafood toxins, **238**
- Seborrheic keratosis, 449
- Sebum, 449
- Secobarbital, 515
- Secondary adrenal insufficiency, 324
- Secondary biliary cholangitis, 378
- Secondary glomerular disease, 563
- Secondary hyperaldosteronism, 324
- Secondary hyperparathyroidism, 331, 332
- Secondary spontaneous pneumothorax, 644
- Secondary syphilis  
labs/findings, 655  
presentation, 656
- Second-wind phenomenon, 83
- Secretin  
regulatory substances, 356  
secretory cell location, 357  
somatostatinomas and, 338
- Secretion rate calculation, **554**
- Secretory vesicles, 43
- Segmental artery, 550
- Segmented viruses, **164**
- Seizures, **487**  
aluminum hydroxide, 382  
amphetamines, 540  
Angelman syndrome, 54  
barbiturates for, 515  
benzodiazepine withdrawal, 540  
 $\beta$ -blockers, 237  
bupropion, 546  
cytomegalovirus, 178  
delirium tremens, 542  
as drug reaction, 242  
electrolyte disturbances, 560  
enflurane, 242  
hyperosmolar hyperglycemia  
nonketotic syndrome as  
cause, 338
- hyperosmolar hyperglycemic state, 342
- imipenem/cilastatin, 242
- lupus, 443
- medium-chain acyl-CoA dehydrogenase deficiency, 85
- meropenem, 186
- PCP, 541
- phenylketonuria, 80
- serotonin syndrome, 545
- Taenia solium*, 157
- tramadol and, 521
- tuberous sclerosis, 495  
vitamin B<sub>6</sub> deficiency, 63
- Selection bias, 250
- Selective estrogen receptor modulators (SERMs), 421, 435, **621**
- Selective IgA deficiency, 112
- Selective media, 122
- Selective serotonin reuptake inhibitors (SSRIs)  
bulimia nervosa, 661  
diarrhea, 240  
naming convention for, 244  
SIADH caused by, 240
- Selegiline, 517, **518**, 546
- Selenium sulfide, 148
- Self-fulfilling prophecies, 250
- Seminal vesicles, 589, 593
- Seminiferous tubules, 593, **594**, 601
- Seminomas, 618, 668
- Semustine, 418
- Senna, 383
- Sensitivity (diagnostic tests), **247**
- Sensitivity equation, 669
- Sensorineural hearing loss, 503
- Sensory cortex, 484
- Sensory receptors, **464**
- Separation anxiety disorder, 527
- Separation anxiety in infants, 258
- Sepsis  
acute tubular necrosis, 572  
ARDS, 642  
immunodeficient patients, 114  
lymphopenia with, 402  
neutropenia with, 402  
*Pseudomonas aeruginosa*, 139  
shock with, 299  
*Streptococcus agalactiae* as  
cause, 133
- Septate uterus, 590
- Septation of heart chambers, 268
- Septic arthritis, **441**  
gonococci, 138  
*Staphylococcus aureus*, 131
- Septicemia  
*Listeria monocytogenes*, 135  
readmissions with, 261  
Waterhouse-Friderichsen syndrome, 324
- Septic shock  
diffuse cortical necrosis (renal), 570  
macrophages and, 387  
norepinephrine for, 234
- Septum primum, 268

- Septum secundum, 268  
 Serine, 218  
 Seronegative spondyloarthritis, **442**  
 Serosa, 347  
 Serositis, 443  
 Serotonin  
   in carcinoid syndrome, 338  
   changes with disease, 465  
   derivatives of, 79  
   vitamin B<sub>6</sub> and, 63  
 Serotonin-norepinephrine reuptake inhibitors (SNRIs)  
   fibromyalgia, 444  
 Serotonin syndrome, 516, 521, **545**  
   dextromethorphan, 648  
   MAO inhibitors, 546  
   MDMA, 541  
   oxazolidinones, 189  
 Serous cystadenocarcinomas, 610, 611  
 Serous cystadenomas, 610  
 Serous papillary cystadenocarcinomas of ovary, 220  
 Serrated colon polyps, **370**  
*Serratia* spp  
   catalase-positive organism, 124  
   Gram-negative algorithm, 137  
   immunodeficient patients, 114  
   lactose fermentation by, 138  
   taxonomy, 121  
*Serratia marcescens*  
   cephalosporins, 185  
   pigment production, 125  
   UTIs, 177  
 Serratus anterior muscle, 428  
 Sertoli cells  
   secretions of, 594  
   sexual determination, 589  
   tumors, 619  
 Sertraline, 545  
 Serum amyloid A, 102  
 Serum lactate, 336  
 Serum markers of liver pathology, **373**  
 Serum osmolality  
   antidiuretic hormone regulation of, 317  
   hyperosmolar hyperglycemia nonketotic syndrome, 338  
 Serum sickness, 109  
 Serum tumor markers, **220**  
 17 $\alpha$ -hydroxylase, 318  
 Sevoflurane, 519  
 Sex chromosome disorders, **603**  
 Sex hormone-binding globulin (SHBG), 322  
 Sex hormone disorders, **604**  
 Sex hormones  
   adrenal cortex secretion, 312  
 Sex pilus (bacterial genetics), 126  
 Sex steroid replacement, 335  
 Sexual abuse, 528  
 Sexual abuse (child), 526  
 Sexual development stages, 602  
 Sexual dysfunction, **537**  
    $\beta$ -blockers, 237  
    $\beta$ -blockers and, 309  
   cimetidine, 381  
   Lambert-Eaton myasthenic syndrome, 445  
   PDE-5 inhibitors for, 623  
   Peyronie disease and, 617  
   sildenafil, 648  
   tuberoinfundibular pathway, 468  
 Sexually transmitted infections (STIs), **180**  
   associations, 668  
   parental consent with, 254  
   sexual dysfunction, 537  
 Sézary syndrome, 408  
 SGLT-2 inhibitors, 341  
 Shagreen patches, 495  
 "Shawl and face" rash, 445  
 SHBG. *See* Sex hormone-binding globulin (SHBG)  
 Sheehan syndrome, 335, 606  
 Sheep (disease vectors), 156  
 Shield chest, 603  
 Shiga-like toxin, 128, 140  
 Shiga toxin, 126, 128, 141  
*Shigella* spp  
   bloody diarrhea, 175  
   exotoxin production, 128  
   penicillinase-sensitive penicillins for, 184  
   reactive arthritis, 442  
   vs *Salmonella* spp, **141**  
   taxonomy, 121  
   TMP-SMX, 190  
   type III secretion system, 125  
*Shigella boydii*, 141  
*Shigella dysenteriae*, 141  
*Shigella flexneri*, 141  
*Shigella sonnei*, 141  
 Shingles, 160  
 Shock, **299**  
   acute tubular necrosis, 572  
   ARDS, 642  
   dopamine for, 234  
   Ebola, 167  
   endotoxins, 127  
   norepinephrine for, 234  
   placental abruption, 606  
   pulmonary anthrax, 133  
   Waterhouse-Friderichsen syndrome and, 324  
 Short gastric arteries, 349  
 Shortness of breath, 533  
 SIADH, **334**  
   ADH antagonists for, 342  
   associations, 668  
   carbamazepine, 240, 514  
   cyclophosphamide, 240  
   demeclocycline for, 342  
   as drug reaction, 240  
   markers in, 560  
   small cell lung cancer, 647  
 Sialyl-Lewis<sup>x</sup>, 209  
 Sibling studies, 246  
 Sickle cell anemia, 400  
   in anemia taxonomy, 396  
   ESR in, 212  
   sickle cells in, 395  
 Sickle cell disease  
   autosplenectomy, 664  
   chromosome association, 60  
   focal segmental glomerulosclerosis, 566  
   missense mutation, 36  
   osteomyelitis, 176  
   osteonecrosis and, 436  
   priapism, 617  
   renal papillary necrosis, 572  
 Sickle cells, 395  
 Sideroblastic anemia, 395, 397  
   in anemia taxonomy, 396  
   labs/findings, 657  
   lead poisoning, 397  
   vitamin B<sub>6</sub> deficiency, 63  
 Sigmoid colon, 366, 668  
 Sigmoid sinus, 473  
 Signaling pathways  
   endocrine hormones, **322**  
   steroid hormones, **322**  
 Signal recognition particle (SRP), 43  
 Signet cell adenocarcinomas, 611  
 Signet ring cells, 362  
 Sign of Leser-Trélat, 217  
 Sildenafil, 617, 623  
   pulmonary hypertension, 648  
 Silencers (gene expression), **38**  
 Silent mutations, **36**  
 Silicosis, 639, **641**  
 Silver stain, 122, 139  
 Simeprevir, 200  
   hepatitis, 661  
 Simple pneumothorax, 643  
 Simple renal cysts, 573  
 Simvastatin, 306  
 Single nucleotide polymorphisms (SNPs), 50  
 Single-stranded binding proteins, 35  
 Sinusitis  
   brain abscesses, 176  
   C3 deficiency and, 103  
   Kartagener syndrome, 45, 656  
   Wegener granulomatosis, 302  
 Sinusoids (spleen), **94**  
 Sinus venosus, 268  
 Sirolimus  
   immunosuppressant, 116  
   targets of, 117  
 Sister Mary Joseph nodules, 362  
 Sitagliptin, 341  
 Situs inversus, 45, 656  
 6-mercaptopurine, 417  
   allopurinol and, 457  
   azathioprine, 116  
   in cell cycle, 416  
   purine synthesis, 33  
   targets of, 416  
   toxicities of, 422  
   for ulcerative colitis, 365  
   ulcerative colitis, 664  
 6-thioguanine, 416  
 Sjögren syndrome, **441**  
   acute interstitial nephritis with, 572  
   autoantibody with, 111  
   biliary cirrhosis and, 378  
   pilocarpine for, 232  
   rheumatoid arthritis, 439  
 Skeletal muscles  
   ACh receptors in, 229  
   autoregulation of, 286  
   glycogen metabolism in, 82  
   in nervous system, 229  
 Skin  
   autoregulation of, 286  
   collagen in, 46  
   pigmentation, 52, 80  
   vitamin D, 66  
   wrinkles of aging, 48  
 Skin cancer, **454**  
   albinism and, 448  
   Lynch syndrome and, 371  
   sunburn and, 453  
 Skin (dermatology), 446–456  
   blistering disorders, **452**  
   common disorders, **449**  
   infections, **451**  
   layers of, **446**  
   microscopic terms, **448**  
   morphology, **447**  
   vascular tumors, **450**  
 Skin drug reactions, **241**  
 Skin flora, 174  
 Skin infections, 139  
 Skin lesions  
   café-au-lait spots, 53, 399, 495  
   hyperextensibility, 47  
   inflammatory bowel disease, 365  
   kwashiorkor, 67  
   scaling, 148  
   scaly, 43, 62  
   telangiectasias, 303  
 Skinner's operant conditioning quadrant, 524  
 Skin ulcers, 154  
 Skip lesions, 365, 664  
 Slapped cheek rash, 179  
 Sleep  
   enuresis during, 342  
   ghrelin/leptin production, 317  
   GHRH production, 317  
 Sleep apnea, **642**  
   pulse pressure in, 272  
   pulsus paradoxus in, 300  
 Sleep disturbances  
   apnea, 642  
   menopause as cause, 600  
 Sleep physiology, **467**  
 Sleep problems  
   benzodiazepines, 467  
   benzodiazepines and, 540  
    $\beta$ -blockers, 237  
   delirium and, 528  
   generalized anxiety disorder, 533  
   in geriatric patients, 259  
   major depressive disorder, 531  
   paroxysmal nocturnal dyspnea, 298  
   stimulant withdrawal, 540  
   varenicline, 546  
 Sleep terror disorder, **538**  
 Sleepwalking, 467, 515  
 Sliding hiatal hernias, 355  
 Slipped capital femoral epiphysis, 436  
 Slow twitch muscle fibers, 433  
 Small bowel disease, 358

- Small cell lung cancer, **647**, 668  
 carcinogens causing, 219  
 Lambert-Eaton myasthenic syndrome, 445  
 neuromuscular paraneoplastic syndromes and, 217  
 topotecan for, 419
- Small intestine, 356
- Small lymphocytic lymphoma (SLL), 410
- Small nuclear ribonucleoproteins (snRNPs), 39
- Smallpox, 160
- Smoke inhalation, 640
- Smoking  
 abdominal aortic aneurysms and, 292  
 atherosclerosis and, 292  
 Buerger disease and, 302, 661  
 bupropion for cessation, 546  
 carcinogenicity of, 219  
 cataracts, 505  
 cervical cancer and, 609  
 colorectal cancer and, 371  
 emphysema, 638, 655  
 esophageal cancer and, 361  
 head and neck cancer, 636  
 hormonal contraception, 622  
 Legionnaires' disease, 139  
 lung cancer, 647  
 pancreatic cancer and, 380  
 placental abruption and, 606  
 renal cell carcinoma, 568  
 renal tumors, 668  
 saccular aneurysms, 486  
 squamous cell carcinoma of bladder, 569  
 stomach cancer and, 362  
 teratogenic effects, 582  
 transitional cell carcinoma, 569  
 varenicline for cessation, 546
- Smooth endoplasmic reticulum, **42**
- Smooth muscle  
 autoantibody to, 111  
 contraction of, **434**  
 glomus tumors, 450  
 nervous system and, 229  
 respiratory tree, 628  
 tumor nomenclature in, 216
- Smudge cells, 410
- SNRIs (serotonin-norepinephrine reuptake inhibitors), **545**  
 clinical use, 542  
 generalized anxiety disorder, 533  
 major depressive disorder, 531  
 mechanism of, 544  
 serotonin syndrome, 545
- Snuffles, 143
- Soap bubble on X-ray, 660
- Social anxiety disorder, 533  
 drug therapy for, 542  
 SSRIs for, 545  
 venlafaxine for, 545
- Sodium channel blockers, **308**
- Sodium channels  
 cystic fibrosis, 56  
 epilepsy drug effects, 514  
 glucose and, 314  
 local anesthetic effects, 519  
 pacemaker action potential and, 281  
 permethrin, 196
- Sodium oxybate, 538
- Sodium-potassium channels, 229
- Sodium-potassium pump, **45**
- Sodium stibogluconate, 154, 196
- Sofosbuvir, 200, 661
- Solifenacin, 233
- Solitary functioning kidney, **549**
- Solitary nucleus of medulla, 285
- Somatic hypermutation, 97
- Somatic mosaicism, 53
- Somatic symptom disorder, 536
- Somatosensory cortex, 471
- Somatostatin  
 glucagon and, 315  
 hypothalamic/pituitary drugs, 342  
 hypothalamic-pituitary hormones, 315  
 production of, 313  
 regulatory substances, 356  
 secretory cell locations, 357
- Somatostatinomas, **338**
- Somatotropin. *See* Growth hormone (GH)
- Sonic hedgehog gene, 580
- Sonic hedgehog signaling pathway, 461
- Sorbitol, **77**
- Sorbitol dehydrogenase, 77
- Sotalol, 309
- Southern blot, 49
- Southwestern blot, 49
- Space of Disse, 352
- Spaghetti and meatballs appearance, 148
- Spasticity, 515
- Spastic paralysis  
*Clostridium tetani*, 134  
 tetanospasmin, 128
- Specificity equation, 247, 669
- Spermatic cord, 354
- Spermatocetes, 618
- Spermatocytes, 594
- Spermatogenesis, 594, **601**  
 cryptorchidism and, 617  
 prolactin effect on, 316
- Spermatogonia, 594
- Sphenomandibular ligament, 587
- Sphenoparietal sinus, 473
- Spherical bacteria, 121
- Spherocytes, 395  
 extravascular hemolysis, 399
- Sphincter of Oddi, 353, 356
- Sphingolipidoses, 84
- Sphingomyelin, 84
- Sphingomyelinase, 84
- Spider angiomas  
 ataxia-telangiectasia, 113  
 cirrhosis, 372
- “Spike and dome” cells, 566
- Spikes on basement membrane, 660
- Spina bifida  
 Dandy-Walker syndrome, 462  
 labs/findings, 657  
 neural tube defect, 461
- Spina bifida cystica, 461
- Spina bifida occulta, 461
- Spinal cord  
 embryologic derivation, 581  
 lesions of, **500**  
 spinal nerves, **478**  
 tracts of, **478**, **479**
- Spinal tap, bloody/yellow, 657
- Spinohalamic tract, 479
- Spiral bacteria, 121
- Spirochetes, **142**
- Spirolactone, 576, 620, 623, 609  
 for heart failure, 298  
 metabolic acidosis, 561  
 for PCOS, 609
- Splay (glucose clearance), 554
- Spleen  
 blood supply and innervation of, 348  
 diagram of, 94  
 embryology, 345  
 in gastrointestinal anatomy, 346  
 ischemia susceptibility, 206  
 thrombocytes in, 386
- Splenectomy, 400
- Splenic artery, 349
- Splenomegaly  
 amyloidosis and, 213  
 anemia, 153  
 cirrhosis, 372  
 hairy cell leukemia, 410  
 hereditary spherocytosis, 400  
 histoplasmosis, 147  
 malaria, 153  
 rheumatoid arthritis, 439  
 visceral leishmaniasis, 154
- Spleno renal ligament, 346
- Spliceosome, 39
- Splice site mutations, **36**
- Splicing of pre-mRNA, **39**
- Splinter hemorrhages, 299, 656
- Splitting, 525  
 in borderline personality disorder, 535
- Splitting of heart sounds, **277**
- Spondyloarthropathy, 213
- Spongiosis, 448
- Spontaneous abortion  
 antiphospholipid syndrome, 443  
 fibroid tumors, 612  
*Listeria monocytogenes*, 135  
 syphilis, 178  
 Vitamin A excess, 582  
 warfarin, 582
- Spontaneous bacterial peritonitis, 373
- Sporadic porphyria cutanea tarda, 169
- Spore-forming bacteria, **127**
- Spores, 120
- Sporothrix schenckii*, **150**
- Sporotrichosis, 150
- Sprue  
 fat-soluble vitamin deficiencies and, 61  
 vitamin B<sub>12</sub> deficiency, 65
- Squalene epoxidase, 194, 195
- Squamous cell carcinomas  
 actinic keratoses and, 664  
 anus and cervix, 173  
 bladder, 156, **569**  
 carcinogens causing, 219  
 cervix, 609  
 cytokeratin stain, 44  
 esophagus, 360, 361, 665  
 head and neck, 636  
 hypercalcemia and, 217  
 lungs, 647  
 pectinate line and, 351  
 penis, 617  
 of skin, 454  
 sunburn and, 453
- Squamous epithelium, 628
- SRY gene, **589**
- SSRIs (selective serotonin reuptake inhibitors), **545**  
 adjustment disorder, 533  
 anxiety disorders, 532  
 atypical depression, 531  
 binge eating disorder, 537  
 clinical use, 542  
 generalized anxiety disorder, 533  
 major depressive disorder, 531  
 mechanism of, 544  
 obsessive-compulsive disorder, 533  
 panic disorder, 533  
 phobias, 533  
 postpartum depression, 532  
 PTSD, 534  
 sexual dysfunction from, 537
- Stable angina, 293
- Stable cells, 42
- Stab wounds and winged scapula, 428
- Staghorn calculi, 567
- Stains (bacterial), **122**
- Standard deviation, 251
- Standard error of the mean, 251
- Stapedial artery, 586
- Stapedius muscle, 587
- Stapes (middle ear), 503
- Stapes (ossicles), 587
- Staphylococcal scalded skin syndrome, 451
- Staphylococcus* spp  
 antibiotic tests for, 130  
 catalase-positive organism, 124  
 Chédiak-Higashi syndrome, 113  
 Gram-positive algorithm, 130  
 taxonomy, 121
- Staphylococcus aureus*, **131**  
 bacterial endocarditis, 299  
 β-hemolytic nature of, 131  
 brain abscesses, 176  
 cephalosporins, 185  
 cystic fibrosis, 56, 175  
 dapson, 191  
 exotoxin production, 129  
 food poisoning, 174  
 immunocompromised patients, 175  
 influenza, 165  
 IV drug use, 175  
 lung abscesses, 646

- nosocomial infection, 175, 181  
 osteomyelitis and, 176  
 penicillins for, 184  
 pigment production, 125  
 pneumonia, 645  
 postviral infection, 175  
 prophylaxis for, 194  
 septic arthritis, 441  
 skin infections, 451  
 T cell effects of, 106
- Staphylococcus epidermidis*, **131**  
 bacterial endocarditis, 299  
 Gram-positive testing, 130  
 in vivo biofilm production, 125  
 normal flora, 174  
 nosocomial infection, 181  
 osteomyelitis, 176  
 urease-positive, 124  
 vancomycin for, 186
- Staphylococcus gallolyticus*, 133  
*Staphylococcus pneumoniae*, 636  
*Staphylococcus saprophyticus*, **132**  
 Gram-positive testing, 130  
 kidney stones, 567  
 urinary tract infections, 570, 668  
 UTIs, 177
- Starling curve, **274**  
 Starling forces, 287  
 “Starry sky” appearance of B cells, 408
- Start and stop codons, **37**  
 Starvation, 87
- Statins  
 for acute coronary syndromes, 296  
 hepatitis, 240  
 myopathy, 241
- Statistical distribution, **251**  
 Statistical hypotheses, **251, 252, 253**  
 Statistical tests, **253**
- Status epilepticus, 487  
 treatment, 514, 515
- Stavudine, 197, 199  
 Steady state, 225  
 Steatohepatitis, 372
- Steatorrhea  
 cystic fibrosis, 56  
 malabsorption syndromes as cause, 364  
 octreotide as cause, 382  
 orlistat as cause, 383  
 somatostatinomas, 338
- Steeple sign (X-ray), 166, 660
- Stellate cells, 352
- Stellate infiltration of ductal carcinoma, 616
- Stem cells in aplastic anemia, 399
- Stercobilin, 359
- Steroid hormone signaling pathways, **322**
- Steroids  
 acute pancreatitis, 380  
 berylliosis, 641  
 lupus, 443  
 multiple sclerosis, 493  
 osteoporosis and, 435  
 polymyositis/dermatomyositis, 445  
 sarcoidosis, 444
- Steroids (exogenous)  
 adrenal insufficiency, 324  
 CRH levels in, 315
- Steroid synthesis, 68
- Stevens-Johnson syndrome, 190, 452, 514  
 as drug reaction, 241  
 sulfa drug allergies, 243
- Stimulant laxatives, 383
- Stimulants for ADHD, 527
- St. John’s wort, 243
- St. Louis encephalitis, 163
- Stomach  
 cholecystokinin effect on, 356  
 in gastrointestinal anatomy, 346  
 histology of, 347  
 sclerosis of, 446  
 secretin effect on, 356
- “Stone” bone appearance, 435
- Straight sinus, 473
- Stranger anxiety in infants, 258
- Strategies  
 clinical vignette, 21  
 test-taking, 20–21
- Strawberry cervix, 154, 177, 180
- Strawberry hemangiomas, 450, 668
- Strawberry tongue  
 causes of, 656  
 Kawasaki, 302  
 scarlet fever, 132
- Streak ovaries, 656
- Streptococcus* spp  
 antibiotic tests for, 130  
 Chédiak-Higashi syndrome, 113  
 Gram-positive algorithm, 130  
 septic arthritis, 441  
 taxonomy, 121
- Streptococcus agalactiae* (Group B strep), **133**  
 $\beta$ -hemolytic nature of, 131  
 encapsulated bacteria, 124  
 Gram-positive testing, 130  
 immunodeficient patients, 114  
 meningitis, 176  
 in neonates, 178  
 pneumonia, 175  
 prophylaxis for, 194  
 splenic dysfunction, 94
- Streptococcus bovis*, **133**  
 bacterial endocarditis, 299  
 colon cancer, 660  
 colorectal cancer and, 371
- Streptococcus mitis*, 132
- Streptococcus mutans*  
 biofilm production, 125  
 dental caries, 132  
 normal flora, 174
- Streptococcus pneumoniae*, **132**  
 $\alpha$ -hemolysis, 131  
 bacterial meningitis, 664  
 chloramphenicol, 188  
 cystic fibrosis, 175  
 encapsulated bacteria, 124  
 Gram-positive testing, 130  
 IgA protease and, 125  
 immunodeficient patients, 114  
 influenza, 165
- IV drug use and, 175  
 meningitis, 176  
 penicillin G/V for, 183  
 pneumonia, 175, 645  
 postviral infection, 175  
 splenic dysfunction, 94  
 transformation in, 126
- Streptococcus pyogenes* (Group A strep), **132**  
 acute poststreptococcal glomerulonephritis, 564  
 bacitracin response, 657  
 $\beta$ -hemolysis, 131  
 clindamycin, 188  
 exotoxin produced by, 129  
 Gram-positive testing, 130  
 M protein and, 125  
 penicillin G/V for, 183  
 rash, 179  
 skin infections, 451  
 T cell effects of, 106
- Streptococcus sanguinis*, 125
- Streptogramins, 194
- Streptokinase, 391, 415
- Streptolysin O, 129
- Streptomycin, 183, 187, **193**
- Streptozocin, 418
- Streptogramins, 183
- Stress incontinence, 569
- Striated muscle, 216
- Striatum, 470, 484
- “String sign” (X-ray), 365
- Stroke, **484**  
 ADP receptor inhibitors for, 415  
 atrial fibrillation and, 284  
 central post-stroke pain syndrome, 485  
 cilostazol/dipyridamole for, 415  
 direct factor Xa inhibitors for, 415  
 eclampsia, 608  
 homocystinuria, 80  
 hypertension, 290  
 hypertensive emergency and, 290  
 sickle cell anemia, 400  
 syphilis, 143  
 thrombolytics for, 415  
 vertigo, 503  
 warfarin for, 414
- Stroke volume, 273, 669
- Strongyloides* spp, 154
- Strongyloides stercoralis*, 155
- ST segment, 282
- ST-segment elevation MI (STEMI)  
 diagnosis of, 293, **295**  
 treatments for, 296
- Studies  
 error types, 246
- Studying for USMLE Step 1 exam  
 materials for, 18–19  
 in preclinical years, 13–14  
 timeline for, 14–17
- Study materials, 18–19
- Study schedule, 14–18
- Sturge-Weber syndrome, 495, 656
- Stylohyoid ligament, 587
- Stylohyoid muscle, 587
- Styloid process, 587
- Stylopharyngeus, 587
- Subacute cerebellar degeneration, 647
- Subacute combined degeneration, 65
- Subacute endocarditis  
 enterococci, 133  
*Staphylococcus gallolyticus*, 133
- Subacute granulomatous thyroiditis, 328
- Subacute sclerosing panencephalitis (SSPE), 166
- Subacute thyroiditis, 211
- Subarachnoid hemorrhage, 483, 488  
 labs/findings, 657, 661  
 nimodipine for, 304  
 presentation, 656
- Subarachnoid space, 478
- Subclavian arteries, 473, 586
- Subcutaneous fat  
 erythema nodosum in, 453  
 skin layers, 446
- Subcutaneous nodules, 132
- Subcutis, 446
- Subdural hematomas, 483  
 child abuse sign, 526
- Subendocardium, 206
- Sublimation, 525
- Submucosa, 347
- Submucosal gland, 347
- Submucosal polyps, 370
- Subscapularis muscle, 425
- Substance abuse  
 adult T-cell lymphoma and, 408  
*Candida albicans*, 149  
 delirium with, 528  
 dementia, 529  
 dissociative identity disorder and, 528  
 loss of orientation with, 528  
 parental consent, 254  
*Pseudomonas aeruginosa*, 139  
 stages of change in overcoming, **539**  
 suicide and, 532  
 torsades de pointes in, 283  
 tricuspid valve endocarditis and, 299
- Substance P, 520
- Substance P antagonist, 383
- Substance use disorder, **538**
- Substantia nigra  
 Parkinson disease, 655
- Substantia nigra pars compacta, 470
- Subthalamic nucleus, 470  
 lesions in, 481
- Subunit vaccines, 158
- Succimer  
 heavy metal toxicity, 239  
 lead poisoning, 397
- Succinate dehydrogenase, 63
- Succinylcholine, 520
- Succinyl-CoA  
 gluconeogenesis, 74  
 TCA cycle, 73
- Sucking reflex, 480
- Sucralfate, **382**
- Sudan stain, 364

- Sudden cardiac death, 293  
cocaine use, 540
- Sudden death  
cor pulmonale, 643  
pulmonary embolism, 637  
sleep apnea, 642
- Sudden infant death syndrome (SIDS), 599
- Suicidal patients, 256  
confidentiality exceptions and, 255  
elderly, 259
- Suicide  
bipolar disorder and, 531  
borderline personality disorder and, 535  
deaths from, **260**  
major depressive disorder and, 531  
physician-assisted, **256**  
risk factors for, **532**  
schizophrenia and, 530
- Sulfactam, 184
- Sulfadiazine, 190  
mechanism, 183  
*Toxoplasma gondii*, 152, 663
- Sulfa drugs, **243**  
acute pancreatitis, 380  
erythema multiforme, 452  
G6PD deficiency from, 400  
lupus-like syndrome, 241  
megaloblastic, **241**  
rash, 241
- Sulfamethoxazole, 183, 190
- Sulfapyridine, 382
- Sulfasalazine, 243, **382**, 439
- Sulfatides, 136, 494
- Sulfisoxazole, 183, 190
- Sulfonamides, **190**  
acute interstitial nephritis, 572  
cytochrome P-450 and, 243  
hemolysis in G6PD deficiency, 241  
hypothyroidism, 240  
mechanism, 183  
*Nocardia* spp, 135  
photosensitivity, 241  
pregnancy contraindication, 201  
trimethoprim, 190  
vitamin B<sub>9</sub> deficiency, 64
- Sulfonyleureas, 340  
disulfiram-like reaction, 242  
insulin and, 314
- Sulfur granules, 125, 135
- Sumatriptan, 516  
cluster headaches, 488  
coronary vasospasm, 239
- Sunburn, 453
- Superficial inguinal lymph nodes, 93
- Superficial inguinal nodes, 591
- Superficial inguinal ring, 354
- Superior cerebellar artery, 473
- Superior colliculi, 475
- Superior gluteal nerve, 431
- Superior mesenteric artery, 348
- Superior mesenteric artery (SMA) syndrome, 348
- Superior mesenteric lymph nodes, 93
- Superior mesenteric vein, 350
- Superior oblique muscle, 510
- Superior ophthalmic vein, 473
- Superior orbital fissure, 476
- Superior rectal artery, 351
- Superior rectal vein, 350
- Superior rectus muscle, 510
- Superior sagittal sinus, 473
- Superior sulcus tumors, 646
- Superior vena cava  
embryological development of, 268  
in fetal circulation, 270
- Superior vena cava syndrome, **646**  
lung cancer, 647  
Pancoast tumor, 646
- Superoxide dismutase, 105  
free radical elimination by, 210
- Suppression, 525
- Suprachiasmatic nucleus, 466  
sleep physiology and, 467
- Suprarenal arteries, 348
- Suprascapular nerve, 425
- Supraspinatus muscle, 425, 428
- Supratentorial mass, 499
- Supraventricular tachycardia  
adenosine for diagnosing, 310  
 $\beta$ -blockers for, 237, 309  
calcium channel blockers for, 310
- Suramin, 196
- Surface F protein, 165
- Surfactant, 631
- Surgical neck of humerus, 432
- Surgical procedures  
readmissions with, 261
- Surrogate decision-maker, 255
- Swan-Ganz catheter, 286
- Swarming, 177
- Sweat glands  
embryologic derivation, 581  
nervous system and, 229  
pilocarpine effects, 232
- Swiss cheese model, **262**
- Sydenham chorea, 132, 300
- Sylvian fissure, 471
- Sympathetic nervous system, 229  
male sexual response, 593
- Sympathetic receptors, 230
- Sympatholytic drugs, **235**
- Sympathomimetic drugs, **234**
- Symphysis pubis, 593
- Symptom duration, 534
- Syncope  
during exercise, 297  
pulsus parvus et tardus, 279
- Syncytiotrophoblasts  
 $\beta$ -hCG and, 220
- Syncytiotrophoblasts, 584, 598  
choriocarcinomas and, 605  
hCG secretion by, 598
- Syndrome of apparent  
mineralocorticoid excess (SAME), 556
- Syndrome of inappropriate antidiuretic hormone secretion. *See* SIADH
- Synergistic drug interactions, 225
- Syngeneic grafts, 114
- Syphilis, **143**  
as granulomatous disease, 211  
presentation, 655, 656  
prophylaxis for, 194  
STI, 180  
tabes dorsalis, 500  
testing for, 143  
thoracic aortic aneurysms and, 292  
ToRCHeS infection, 178
- Syphilitic heart disease, **300**
- Syringomyelia, **462**  
Horner syndrome, 509  
spinal cord lesions, 500
- Systemic mycoses, **147**
- Systemic primary carnitine deficiency, 85
- Systole  
cardiac cycle, 276  
heart murmurs of, 278, 279  
heart sounds of, 278
- Systolic ejection, 276
- Systolic murmur, 297
- Systolic pressure, 272
- T**
- Tabes dorsalis  
spinal cord lesions, 500  
syphilis, 143, 180
- Tachyarrhythmia  
isoproterenol for evaluating, 234  
thyroid storm, 329
- Tachycardia  
alcohol withdrawal, 541  
amphetamines, 540  
cause and prevention, 304, 305  
delirium tremens, 542  
MDMA as cause, 541  
metronidazole, 191  
PCP, 541  
phenoxybenzamine, 236  
pulmonary embolism, 637  
stimulants and, 540  
thyroid hormones, 342  
tricyclic antidepressants, 545  
Wolff-Parkinson-White syndrome, 283
- Tachyphylactic drug interactions, 225
- Tachypnea  
asthma, 638  
pulmonary embolism, 637
- Tacrine, 518
- Tacrolimus  
hyperglycemia, 240  
immunosuppression, 116  
targets of, 117
- Tactile hallucinations, 529  
cocaine, 540
- Tadalafil, 623
- Taenia solium*, 156, 157
- Takayasu arteritis, 211, **302**
- Talcosis, 211
- Tamoxifen, **421**, 621  
for breast cancer, 662  
hot flashes, 240
- Tamsulosin, 236, 619, **623**
- Tanner stages (sexual development), **602**
- Tarasoff decision, 255
- Tardive dyskinesia  
as drug reaction, 242  
metoclopramide adverse effect, 383  
nigrostriatal pathway, 468
- Target cells, 94, 395
- Tarsal tunnel syndrome, 430
- TATA box, 38
- Tau proteins, 660
- Taxonomy (bacterial), **121**
- Tay-Sachs disease  
frameshift mutation, 36  
lysosomal storage disease, 84  
presentation, 652
- Tazobactam, 184
- TBC. *See* Thyroid-binding globulin
- TCA cycle, **73**  
diagram, 70  
hyperammonemia, 78  
metabolic site, 68  
pyruvate metabolism, 73  
rate-determining enzyme for, 69
- T cells, **388**  
activation, **99**  
adaptive immunity, 95  
anergy, 106  
cell surface proteins, 106  
corticosteroid effects, 116  
cytokine secretion, 104  
cytotoxic, 98  
differentiation of, **97**  
disorders of, 112, 113  
functions, 97  
helper, 98  
leflunomide effects, 456  
lymph nodes, 92  
major functions of, 97  
neoplasms, 408  
regulatory, 98  
sirolimus effect, 116  
spleen, 94  
thymus, 94  
untreated HIV, 172
- Tearing stimulation, 232
- Teenagers  
common causes of death, 260
- Teeth  
congenital syphilis, 143  
demeclocycline and, 342  
dental caries, 132  
dentinogenesis imperfecta, 47  
discoloration, 188, 201, 241, 582  
enamel erosion (bulimia nervosa), 537  
Gardner syndrome, 370  
osteogenesis imperfecta, 47  
retained primary, 112  
Sjögren syndrome and, 441
- Telangiectasias  
ataxia-telangiectasia, 37  
autosomal dominant disease, 303  
basal cell carcinomas, 454  
CREST syndrome, 446  
Osler-Weber-Rendu syndrome, 656

- Telencephalon, 460  
 Tellurite agar, 123  
 Telomerase, **35**  
 Telophase, 42  
 Temazepam, 515  
 Temperature receptors, 464  
 Temperature regulation, 466  
 Temporal arteritis  
   associations, 668  
   ESR in, 212  
   as granulomatous disease, 211  
   polymyalgia rheumatica, 444  
 Temporalis muscle, 587  
 Temporal lobe, 471, 484  
 Temporal lobe encephalitis, 160  
 Tendinopathy (rotator cuff), 425  
 Tendinous xanthomas, 291  
   familial hypercholesterolemia, 90  
 Tendonitis  
   as drug reaction, 241  
   fluoroquinolones, 191  
 Tendons  
   collagen in, 46  
 Tenecteplase, 391, 415  
 Teniposide, **419**  
   in cell cycle, 416  
 Tennis elbow, 426  
 Tenofovir  
   Fanconi syndrome, 556  
   HIV therapy, 199  
   mechanism (diagram), 197  
 Tenosynovitis, 441  
 Tension headaches, 488  
 Tension pneumothorax, 643, 644  
 Tensor fascia latae muscle, 431  
 Tensor tympani muscle, 587  
 Tentorium cerebelli, 499  
 Teratogens, **582**  
   ACE inhibitors as, 577  
   aminoglycosides, 187  
   angiotensin II receptor blockers  
     as, 577  
   carbamazepine as, 514  
   griseofulvin, 196, 201  
   leflunomide, 456  
   lithium as, 544  
   methimazole as, 341  
   PTU in pregnancy, 341  
   ribavirin, 200, 201  
   vitamin A, 62  
   warfarin as, 414  
 Teratomas, 618  
 Terazosin, 236, 619  
 Terbinafine, 194, **195**  
 Terbutaline, **622**  
 Teres minor, 425  
 Teriparatide, 435, **457**  
 Terminal bronchioles, 626  
 Terminal deoxynucleotidyl transferase  
   (TdT), 100  
 Termination of protein synthesis, 41  
 Tertiary adrenal insufficiency, 324  
 Tertiary hyperparathyroidism, 332  
 Tertiary syphilis  
   aortic aneurysms, 664  
   as granulomatous disease, 211  
   presentation, 655, 656  
 Tesamorelin, 315  
 Testes, 593  
   descent of, **591**  
   embryologic derivation, 581  
   lymphatic drainage of, 591  
   progesterone production, 595  
 Testicular atrophy  
   alcoholism, 541  
   cirrhosis, 372  
   muscular dystrophy, 57  
 Testicular cancer  
   bleomycin for, 418  
   cisplatin/carboplatin for, 419  
 Testicular/ovarian arteries, 348  
 Testicular tumors, **618**  
   germ cell, 619  
   non-germ cell, 619  
 Testing agencies, 22  
 Testis-determining factor, 589  
 Testosterone, 600, **623**  
   androgen insensitivity  
     syndrome, 604  
   cryptorchidism, 617  
   Klinefelter syndrome, 603  
   Leydig cell secretion, 594  
   pharmacologic control, 620  
   Sertoli cells, 594  
   SHBG effect on, 322  
   signaling pathways for, 322  
   spermatogenesis, 594  
 Testosterone-secreting tumors, 604  
 Testosterone synthesis, 195  
 Test-taking strategy, 20–21  
 Tetanospasmin, 128, 134  
 Tetanus  
   exotoxins, 127  
   spore-forming bacteria, 127  
   vaccine, 134  
 Tetanus toxin, 107, 134  
 Tetany  
   hypocalcemia, 560  
   hypocalcemic, 66  
   hypoparathyroidism, 331  
   thymic aplasia, 112  
 Tetrabenazine  
   for Huntington disease, 518  
   Tourette syndrome, 527, 542  
 Tetracaine, 519  
 Tetracyclines, **188**  
   esophagitis, 240  
   Fanconi syndrome, 242, 556  
   mechanism (diagram), 183  
   photosensitivity, 241  
   protein synthesis  
     inhibition, 187  
   pseudotumor cerebri and, 491  
   teratogenicity, 201, 582  
   tooth discoloration, 241  
 Tetrahydrofolic acid, 64, 190  
 Tetralogy of Fallot, **288**  
   22q11 syndromes, 290  
   cyanosis caused by, 665  
   fetal alcohol syndrome, 290  
   lab findings in, 657  
   outflow tract formation, 269  
   thymic aplasia, 112  
 Tetrodotoxin, 238  
 TGF- $\beta$   
   regulatory T cells, 98  
   in wound healing, 211  
 Thalamus, 460, **468**  
   neuropathic pain, 485  
 Thalassemia, 396  
   in anemia taxonomy, 396  
   target cells in, 395  
 Thalidomide, 582  
 Thayer-Martin agar, 122, 123  
 Theca interna cells, 595  
 Theca-lutein cysts, 605, 610  
 Thecomas, 610  
 Thener muscles, 428, 429  
 Theophylline, 649  
   cytochrome P-450 and, 243  
   therapeutic index value of, 228  
 Therapeutic antibodies, **118**  
 Therapeutic index, **228**  
 Therapeutic privilege, 254  
 Thermogenin, 74  
 Thiazide diuretics  
   heart failure, 298  
   hypertension, 304  
 Thiazides, **576**  
   gout, 241  
   site of action, 574  
 Thiazolidinediones, 340  
 Thick ascending loop of Henle  
   Bartter syndrome and, 556  
   ethacrynic acid effect on, 575  
   loop diuretics effect on, 575  
   nephron physiology, 555  
 Thin descending loop of  
   Henle, 555  
 Thionamides, **341**  
 Thiopental, 515, 519  
 Thioridazine, 543  
 Thirst  
   hypothalamus and, 466  
   renin-angiotensin-aldosterone  
     system and, 558  
 30S inhibitors, 187  
 Thoracentesis, 644  
 Thoracic aortic aneurysm, 290, 292  
 Thoracic duct, 93  
 Thoracic outlet syndrome, 428  
 Threadworms, 155  
 Threonine, 77  
 Threonine kinase, 218  
 Thrombi  
   atherosclerosis, 292  
   mural, 296  
   post-MI, 294  
 Thrombin, 413  
 Thrombocytes  
   liver markers, 373  
   in wound healing, 211  
 Thrombocytes (platelets), **386**  
   aggregation inhibition, 415  
   chronic myeloproliferative  
     disorders, **411**  
   disorders, **405**  
   heparin adverse effects, 413  
   leukemias, 410  
   mixed coagulation disorders, **406**  
   platelet plug formation, 393  
   thrombolytics and, 415  
   transfusion of, 399, 407  
 Thrombocytopenia, 386  
   blood transfusion therapy for, 407  
   cirrhosis, 372  
   Class IA antiarrhythmics, 308  
   cytarabine, 417  
   as drug reaction, 241  
   *Escherichia coli*, 140  
   ganciclovir, 198  
   glycoprotein IIb/IIa inhibitors as  
     cause, 415  
   heparin adverse effects, 413  
   immunosuppressants, 116  
   oxazolidinones, 189  
   protease inhibitors, 199  
   recombinant cytokines, 117  
   sulfa drug allergies, 243  
   ToRCHeS infections, 178  
   Wiskott-Aldrich syndrome, 113  
 Thrombocytosis, 94  
 Thromboembolic event  
   atrial fibrillation, 284  
 Thrombogenesis, **393**  
 Thrombolytic drugs, 391, **415**  
 Thrombomodulin  
   in thrombogenesis, 393  
 Thrombophlebitis  
   pancreatic cancer, 380  
   vancomycin, 186  
 Thrombopoietin receptor  
   agonists, 117  
 Thrombopoietin signaling  
   pathways, 322  
 Thrombosis  
   celecoxib, 456  
   essential thrombocythemia, 411  
   homocystinuria, 80  
 Thrombotic complications, 241  
 Thrombotic endocarditis, 665  
 Thrombotic stroke, 482  
 Thrombotic thrombocytopenic  
   purpura (TTP), 395, **405**  
 Thromboxane, 455  
 Thrush  
   *Candida albicans*, 149  
   hairy leukoplakia vs, 451  
   HIV-positive adults, 173  
   nystatin, 195  
   SCID, 113  
 Thumbprint sign (X-ray), 138  
 Thumb sign (X-ray), 660  
 Thymic aplasia, 112, 588  
   chromosome association, 60  
   hypoparathyroidism, 331  
   lymphopenia with, 402  
   22q11 deletion syndromes, 61  
 Thymic cortex  
   T cell selection in, 97  
 Thymic hyperplasia, 445  
 Thymic shadow, 113  
 Thymidine, 190  
 Thymidine kinase, 197  
 Thymidylate, 33  
 Thymomas  
   Good syndrome and, 217  
   myasthenia gravis, 217, 445

- Thymus, **94**  
 benign neoplasm, **94**  
 fetal development, **312**  
 T cell differentiation, **97**  
 T cell origination in, **388**  
 Thymus-dependent antigens, **101**  
 Thymus-independent antigens, **101**
- Thyroglobulin  
 function of, **321**
- Thyroglobulin autoantibodies, **111**
- Thyroglossal duct cyst, **312**
- Thyroid adenomas, **327, 330**
- Thyroid cancer, **330**  
 associations, **668**  
 carcinogens causing, **219**  
 goiter, **327**  
 metastases of, **221**  
 Psammoma bodies in, **220**
- Thyroid cartilage, **587**
- Thyroid cysts, **327**
- Thyroid development, **312**
- Thyroidectomy, **330**
- Thyroid hormones, **321**  
 signaling pathways for, **322**  
 in toxic multinodular goiter, **329**
- Thyroiditis, **211**
- Thyroidization of kidney, **570**
- Thyroid lymphomas, **330**
- Thyroid peroxidase  
 thionamide effect on, **341**  
 thyroid hormones and, **321**
- Thyroid-regulating hormone (TRH)  
 signaling pathways for, **322**  
 thyroid hormones and, **321**
- Thyroid replacement therapy, **435**
- Thyroid-stimulating hormone  
 Graves disease and, **329**  
 hyperthyroidism, **327**  
 hypothyroidism, **327**  
 secretion of, **313**  
 signaling pathways of, **322**
- Thyroid storm, **329**
- Thyrotropin-releasing hormone (TRH), **315, 316**
- Thyroxine, **335**
- Thyroxine-binding globulin (TBCG), **321**
- Tiagabine, **514**
- TIBC  
 anemia of chronic disease, **399**  
 lab values in anemia, **402**
- Tibial nerve, **430**
- Ticagrelor, **415**
- Ticarcillin, **183**  
 characteristics of, **184**  
*Pseudomonas aeruginosa*, **139**
- Ticks (disease vectors), **144, 145, 153**
- Ticlopidine, **393, 415**
- Tics (Tourette syndrome), **527**
- Tidal volume (TV), **630**
- Tigecycline, **188, 194**
- Tight junctions, **447, 466**
- Timolol, **237, 309, 521**
- Tinea, **148, 196**
- Tinea capitis, **148**
- Tinea corporis, **148**
- Tinea cruris, **148**
- Tinea pedis, **148**
- Tinea unguium, **148**
- Tinea versicolor, **148**
- Tinel sign, **427**
- Tinnitus  
 streptomycin, **193**
- Tiotropium, **233**
- Tirofiban, **393, 415**
- Tissue factor activation, **129**
- Tissue factor pathway, **391**
- Tissue plasminogen activator (tPA)  
 for ischemic stroke, **482**
- TMP-SMX, **190**  
 hyperkalemic renal tubular acidosis, **562**  
 for *Pneumocystis jirovecii*, **150**  
 prophylaxis, **194**  
 UTI prophylaxis, **664**
- TNF- $\alpha$ , **104**  
 endotoxins and, **129**  
 extrinsic pathway and, **204**  
 in granulomatous diseases, **211**  
 Graves disease and, **329**
- TNF- $\alpha$  inhibitors, **439, 457**
- TNF (tumor necrosis factor), **221**
- TNM tumor staging, **216**
- Tobramycin, **183, 187**
- Togaviruses  
 characteristics of, **163**  
 genomes of, **159**  
 rubella as, **165**
- Tolbutamide, **340**
- Tolcapone, **517**
- Toll-like receptors (TLRs), **95**
- Tolterodine, **233**
- Tolvaptan, **334, 342**
- Tongue development, **463**
- Tonic-clonic seizures, **487**  
 drug therapy for, **514**  
 treatment, **663**
- Tonic seizures, **487**
- Tonsils  
 agammaglobulinemia, **112**  
 immune system organ, **92**
- Tophi in gout, **656**
- Topiramate  
 epilepsy, **514**  
 migraine headaches, **488**  
 pseudotumor cerebri, **491**
- Topoisomerase inhibitors, **416**
- Topoisomerases, **191**
- Topotecan, **416, 419**
- ToRCHES infections, **165, 178**  
 cataracts, **505**
- Torsades de pointes, **283**  
 Class IA antiarrhythmics, **308**  
 as drug reaction, **239**  
 hypomagnesemia, **560**  
 ibutilide, **309**  
 magnesium for, **310**  
 sotalol, **309**
- Torsemide, **575**
- Torus fracture, **424**
- Total anomalous pulmonary venous return (TAPVR), **288**
- Total lung capacity (TLC), **630**  
 flow volume loops, **637**
- Total parenteral nutrition (TPN), **379**
- Total peripheral resistance, **272, 275**
- Tourette syndrome, **527**  
 antipsychotics for, **543**  
 atypical antipsychotics for, **543**  
 drug therapy for, **542**  
 obsessive-compulsive disorder and, **533**  
 sympatholytic drugs for, **235**
- Toxic dose, **228**
- Toxic epidermal necrolysis, **452**
- Toxicities, **239**
- Toxic multinodular goiter, **329**
- Toxic shock-like syndrome, **132**
- Toxic shock syndrome, **129**  
 exotoxin A, **129**  
 presentation, **131**  
*Staphylococcus aureus*, **131**
- Toxic shock syndrome toxin, **129**
- Toxocara* spp, **154**
- Toxocara canis*, **155**
- Toxoplasma* spp, **176**  
*Toxoplasma gondii*, **152**  
 HIV-positive adults, **173**  
 labs/findings, **660**  
 ToRCHES infection, **178**  
 treatment, **663**
- Toxoplasmosis, **152**  
 PCL vs, **408**  
 prophylaxis, **190, 194**  
 pyrimethamine, **196**
- TP53* gene, **218**
- Trabecula  
 lymph node, **92**  
 spleen, **94**
- Trabecular outflow, **505**
- Trachea  
 bifurcation of, **629**  
 fetal development, **312**  
 respiratory tree, **628**
- Tracheoesophageal anomalies, **344**
- Tracheoesophageal fistula, **344**
- Tramadol, **521**  
 seizures, **242**
- Transcortical aphasia, **486**
- Transcription factor, **218**
- Transduction, **126**
- Transference, **524**
- Transferrin  
 acute-phase reactant, **102**  
 free radical elimination by, **210**  
 lab values in anemia, **402**
- Transformation, **126**
- Transfusion reaction, **108**
- Transient arthritis, **142**
- Transient ischemic attacks (TIAs), **415, 482**
- Transitional cell carcinomas, **219, 569**
- Transition metals and free radical injuries, **210**
- Transition (mutation), **36**
- Transjugular intrahepatic portosystemic shunt (TIPS), **350**
- Transketolase  
 metabolic pathways, **70**  
 vitamin B<sub>1</sub> and, **62**
- Transpeptidases, **183**
- Transplants  
 immunosuppressants in, **116**  
 rejection, **115**
- Transposition, **127**
- Transposition of great vessels, **288**  
 cyanosis with, **665**  
 embryologic development, **269**  
 maternal diabetes and, **290**
- Transsexualism, **537**
- Transtentorial herniation, **499**
- Transthyretin gene, **213**
- Transudate pleural effusion, **644**
- Transudate vs exudate, **212**
- Transversalis fascia, **345, 354**
- Transverse sinus, **473**
- Transversion (mutation), **36**
- Transversus abdominis muscle, **354**
- Transvestism, **537**
- Tr antigens, **217**
- Tranylcypromine, **546**
- Trapezium bone, **426**
- Trapezoid bone, **426**
- TRAP stain, **410**
- Trastuzumab, **118, 421**  
 toxicities of, **422**
- Trastuzumab (Herceptin), **421**
- Trauma  
 DIC and, **665**  
 pneumothorax, **644**
- Traumatic aortic rupture, **292**
- Traumatic pneumothorax, **644**
- Travelers' diarrhea, **140**
- Trazodone, **546**  
 mechanism of, **544**  
 priapism, **617**
- Trachea Collins syndrome, **587**
- Trematodes, **156**
- Tremor  
 immunosuppressants, **116**  
 resting, **489, 655**
- Trench fever, **157**
- Trendelenburg sign, **431**
- Treponema* spp, **142**
- Treponema pallidum*  
 granulomatous diseases caused by, **211**  
 penicillin G/V for, **183**  
 STI, **180**  
 syphilis, **143**  
 treatment, **664**
- TRH. *See* Thyrotropin-releasing hormone
- Triamcinolone, **455**
- Triamterene, **555, 576**
- Triazolam, **515**
- Trichinella* spp, **154**
- Trichinella spiralis*, **155, 157**
- Trichinosis, **155**
- Trichomonas* spp  
 vaginitis, **177**
- Trichomonas vaginalis*, **154, 180**
- Trichomoniasis, **180**
- Trichophyton* spp, **148**

- Tricuspid atresia, 269, 288  
 Tricuspid insufficiency, 276  
 Tricuspid regurgitation  
   carcinoid syndrome as cause, 338  
   Ebstein anomaly and, 288  
   heart murmurs with, 279  
   pansystolic murmur in, 278  
 Tricuspid stenosis, 278  
 Tricuspid valve endocarditis, 299  
 Tricyclic antidepressants (TCAs), **545**  
   antimuscarinic reaction, 242  
   fibromyalgia, **444**  
   generalized anxiety disorder, 533  
   mechanism of, 544  
   naming convention for, 244  
   as noradrenergic drug, 231  
   serotonin syndrome with, 545  
   torsades de pointes, 239  
   toxicity treatment for, 239  
   as weak bases, 226  
 Trientine, 378  
 Trifluoperazine, 543  
 Trigeminal nerve (CN V), **476**  
   brain stem location, 474  
   branchial arch derivative, 587  
   lesion in, 502  
   migraine headaches and, 488  
   neuralgia, 488  
   pathway for, 476  
   tongue, 463  
 Trigeminal neuralgia, 488  
   treatment, 664  
 Triglycerides  
   chylolothorax, 644  
   dietary, 88  
   hepatosteatorosis, 68  
   hypertriglyceridemia, 90  
   insulin and, 314  
   Von Gierke disease, 83  
 Trigone, 550  
 Triiodothyronine, **342**. *See*  
   also Thyroid hormones  
 Trimethoprim  
   folate deficiency with, 398  
   pyrimidine synthesis and, 33  
   teratogenicity, 582  
 Trimethoprim, **183**, **190**  
 Trimming (protein synthesis), 41  
 Trinucleotide repeat expansion  
   diseases, **58**  
 Triose kinase, 76  
 Triple-blinded studies, 246  
 Triptans, **516**  
   angina and, 293  
   for migraine headaches, 488  
 Triquetrum bone, 426  
 tRNA, **40**  
 Trochlea, 510  
 Trochlear nerve (CN IV), **476**  
   brain stem location, 474  
   cavernous sinus, 512  
   ocular motility, 510  
   palsy of, 511  
   pathway for, 476  
*Tropheryma whipplei*, 122, 364  
 Tropical sprue, 364  
 Tropicamide, 233  
 Troponin C, 433  
 Troponins, 293, 295  
 Trousseau sign, 331, 560  
 Trousseau syndrome  
   pancreatic cancer, 380  
   as paraneoplastic syndrome, 217  
 True-negative rate, 247  
 True-positive rate, 247  
 Truncal ataxia, 469  
 Truncus arteriosus  
   22q11 syndromes, 290  
   cyanosis with, 665  
   embryologic development, 268  
   thymic aplasia, 112  
*Trypanosoma brucei*, **152**, 196  
*Trypanosoma cruzi*, **154**  
   achalasia and, 360  
   nifurtimox for, 196  
 Trypanosome stain, 122  
 Trypsin, 358  
 Trypsinogen, 358  
 Tryptase, 387  
 Tryptophan, 77, 79  
 TSC1/TSC2 genes, 218  
 Tsetse flies (disease vectors), 152  
 TSH. *See* Thyroid-stimulating  
   hormone (TSH)  
 TSH receptor autoantibody, 111  
*t*-tests, 253  
 T-tubule membrane, 433  
 Tubal ligation, 610  
 Tuberculoid Hansen disease, 137  
 Tuberculosis, **136**  
   Addison disease, 324  
   corticosteroids and, 319  
   erythema nodosum, 453  
   as granulomatous disease, 211  
   isoniazid, 193  
   macrophages and, 387  
   necrosis and, 205  
   silicosis, 641  
    $\dot{V}/\dot{Q}$  mismatch, 634  
 Tuberin protein, 218  
 Tuberoinfundibular pathway, 468  
 Tuberosclerosis, 495  
   tumor suppressor genes and, 218  
 Tubocurarine, 520  
 Tubular necrosis, 571  
 Tubulointerstitial inflammation  
   WBC casts in, 562  
 Tularemia, 144  
 Tumor grade vs stage, 216  
 Tumor lysis syndrome, 421  
   gout, 440  
   hyperkalemia, 560  
   labs/findings, 660  
 Tumor markers  
   acute lymphoblastic leukemia, 410  
   pancreatic adenocarcinomas, 380  
   serum, **220**  
 Tumors  
   benign vs malignant, 216  
   grade vs stage, **216**  
   nomenclature of, **216**  
   TNM staging system, 216  
 Tumor suppressor genes, **218**  
 Tumor suppressors, 42  
 Tunica albuginea, 593, 617  
 Tunica muscularis externa, 347  
 Tunica serosa, 347  
 Tunica submucosa, 347  
 Tunica vaginalis, 591  
 Turcot syndrome, 370  
 Turner syndrome, **603**  
   cardiac defect association, 290  
   coarctation of aorta and, 289  
   cystic hygromas, 450  
   GH for, 342  
   horseshoe kidney, 549  
   presentation, 656  
 T wave, in ECG, 282  
 21-hydroxylase, 318  
 21-hydroxylase deficiency, 665  
 22q11 deletion syndromes,  
   **61**, 290  
 Twin concordance studies, 246  
 Twinning, **583**  
 2-naphthylamine, 219  
 TXA<sub>2</sub>  
   aspirin effects, 456  
   thrombogenesis, 393  
 Type I muscle fibers, 433  
 Type 2 muscle fibers, 433  
 Type I errors in hypothesis  
   testing, **252**  
 Type I hypersensitivity, 108  
   helminths, 154  
   IgE antibodies and, 101  
 Type I hypersensitivity reactions  
   mast cells and, 387  
 Type II errors in hypothesis  
   testing, 252  
 Type II hypersensitivity, 108  
   blood transfusions, 110  
   helminths, 154  
   organ transplants, 115  
 Type II hypersensitivity reactions  
   rheumatic fever, 300  
 Type III hypersensitivity, 109  
   C3 deficiency and, 103  
   organ transplants, 115  
 Type III hypersensitivity reactions  
   acute poststreptococcal  
   glomerulonephritis, 564  
 Type III secretion system, **125**  
 Type IV hypersensitivity, 109  
   graft-versus-host disease, 115  
 Type IV hypersensitivity reactions  
   contact dermatitis, 449  
 Typhoid fever, 141  
 Typhus, **145**  
   transmission of, 144, 157  
 Tyramine, 236  
 Tyrosinase, 448  
 Tyrosine  
   derivatives of, 79  
   as noradrenergic drug, 231  
 Tyrosine catabolism, **79**  
 Tyrosine kinase  
   endocrine hormone  
   messenger, 322  
   glycogen regulation, 81  
   insulin and, 314  
   as oncogene product, 218  
 Tyrosinemia, 556  
 Tyrosine phosphorylation, 314  
 Tzanck test, 162  
**U**  
 Ubiquitination, 41  
 UDP-glucose pyrophosphorylase, 82  
 UDP-glucuronosyl-transferase, 359  
 Ulcerative colitis, **365**  
   spondyloarthritis, 442  
   sulfasalazine for, 382  
   treatment, 664  
 Ulcers  
   bismuth/sucralfate for, 382  
   complications of, **363**  
   *Helicobacter pylori*, 142  
   Zollinger-Ellison syndrome, 338  
 Ulipristal, 622  
 Ulnar claw, 427, 429  
 Ulnar nerve, 426, 427  
 Ulnar nerve injury, 426  
 Umbilical artery, 270, 584, 585  
 Umbilical cord, **585**  
 Umbilical cord separation delay, 113  
 Umbilical vein, 584, 585  
   blood in, 270  
   postnatal derivative of, 270  
 Umbilicus, 350  
 UMP synthase, 398  
 Unambiguous genetic code, **34**  
 Uncal herniation, 499  
 Uncinate process, 345  
 Unconjugated  
   hyperbilirubinemia, 376  
 Uncoupling agents, 74  
 Uncus, 499  
 Undifferentiated thyroid  
   carcinomas, 330  
 Undulant fever, 144  
 "Unhappy triad"(knee injuries), 425  
 Unilateral renal agenesis, **549**  
 Uniparental disomy, **53**  
 Universal electron acceptors, **71**  
 Universal genetic code, **34**  
 Unnecessary procedure requests,  
   256–257  
 Unstable angina, 293, 296  
 Untreated HIV infection  
   timecourse, **172**  
 Unvaccinated children, 182  
 Upper extremity nerves, **427**  
 Upper motor neuron (UMN)  
   lesions, 502  
   Babinski response, 656  
 Upper respiratory infections (URIs)  
   asthma trigger, 638  
   rhinosinusitis, 636  
 Urachal cysts, 585  
 Urachus, 270, **585**  
 Uracil, 33  
 Urea, 79  
 Urea cycle, **78**  
   diagram, 70  
   metabolic site, 68  
   ornithine transcarbamylase  
   deficiency and, 79  
   rate-determining enzyme for, 69



- Ureaplasma* spp  
urease-positive, 124
- Urease, 177
- Urease-positive organisms, **124**
- Uremia  
acute pericarditis, 300  
ARDS, 642  
metabolic acidosis, 561  
renal failure, 571
- Ureter, 550, 589, 592, 593  
constriction of, 553  
course of, **550**  
embryology, 548  
horseshoe kidney, 549  
obstruction of, 568  
transitional cell carcinoma in, 569  
Y-shaped bifid, 549
- Ureteral orifice, 550
- Ureteric bud, 549
- Ureteropelvic junction  
obstruction, 549
- Urethra  
BPH, 619  
injury to, **593**
- Urethral orifice, 550
- Urethritis  
chlamydia, 146, 180  
*Chlamydia trachomatis*, 146  
gonorrhea, 180  
reactive arthritis, 442, 656
- Urge incontinence, 569  
drug therapy for, 233
- Uric acid  
gout, 457  
Lesch-Nyhan syndrome, 34  
Von Gierke disease, 83
- Urinary incontinence, **569**  
drug therapy for, 233  
ephedrine for, 234  
hydrocephalus, 492  
multiple sclerosis, 493
- Urinary retention  
atropine, 233  
bethanechol for, 232  
delirium, 528  
neostigmine for, 232  
tricyclic antidepressants, 545
- Urinary tract infections (UTIs),  
**177, 570**  
antimicrobial prophylaxis for, 194  
BPH, 619  
duplex collecting system and, 549  
enterococci as cause, 133  
*Klebsiella* as cause, 140  
organisms causing, **177**  
*Pseudomonas aeruginosa* and, 139  
pyelonephritis, 570  
*Staphylococcus saprophyticus* as  
cause, 132  
sulfa drug allergies, 243  
sulfonamides for, 190  
TMP-SMX for, 190
- Urine  
bilirubin and, 359  
casts in, **562**  
concentration of, 555  
diuretic effects on, 576
- Urine pH and drug elimination, **226**
- Urobilin, 359
- Urobilinogen  
extravascular hemolysis, 399  
intravascular hemolysis, 399
- Urogenital fold, 590
- Urogenital sinus, 548
- Uroporphyrinogen  
decarboxylase, 403
- Urosepsis, 570
- Urticaria, 447, 449  
ethosuxamide, 514  
scombroid poisoning, 238  
serum sickness, 109  
sulfa drug allergies, 243  
as type I hypersensitivity, 108
- USMLE Step 1 exam  
check-in process, 7  
clinical vignette strategies, 21  
content areas covered in, 3  
failing, 22–23  
goal-setting for, 12  
leaving exam early, 7  
overview of, 2  
passing rates for, 10  
practice exams for, 10, 19–20  
registering for, 5–6  
rescheduling, 6  
score notifications for, 7  
scoring of, 8–9  
studying for, 13–17  
testing agencies, 22  
testing locations, 6  
test-taking strategies, 20–21  
time budgeting during, 7–8  
types of questions on, 8
- Uterine artery, 550, 592
- Uteropelvic junction, 548
- Uterus  
anomalies of, **590**  
collagen in, 46  
epithelial histology, 592  
genital embryology, 589  
zygote implantation, 598
- Uterus didelphys, 590
- Uveitis, **506**  
inflammatory bowel disease, 365  
sarcoidosis, 444, 652  
seronegative spondyloarthritis, 442
- Uveoscleral outflow, 505
- U wave in ECG, 282
- V**
- Vaccination  
B- and T-cell disorders, 113  
B-cell disorders, 112  
splenectomy and, 94  
thymus-independent antigens, 101
- Vaccines, **107**  
*Bordetella pertussis*, 139  
diphtheria, 135  
encapsulated bacteria, 124  
*Haemophilus influenzae*, 138,  
176  
live attenuated, 158  
rabies, 167  
rotavirus, 164
- Salmonella typhi*, 141  
tetanus, 134  
viral, 158
- Vagal nuclei, **477**
- Vagina  
anatomy of, 592  
drainage of, 591  
epithelial histology of, 592  
genital embryology, 589
- Vaginal atrophy  
hormone replacement  
therapy, 621  
menopause, 600
- Vaginal bleeding  
cervical cancer, 609  
endometrial disease, 612  
endometriosis, 613  
granulosa cell tumors, 611  
hydatidiform moles, 605  
thecomas, 610
- Vaginal candidiasis  
nystatin, 195
- Vaginal clear cell  
adenocarcinomas, 582
- Vaginal infections, **177**
- Vaginal tumors, **609**
- Vaginismus, 537
- Vaginitis  
treatment, 661  
*Trichomonas* spp, 154, 177  
trichomoniasis, 180
- Vagus nerve (10th cranial nerve)  
baroreceptors/chemoreceptors  
and, 285  
cardiac glycoside effects, 307  
structures innervated, 357
- Vagus nerve (CN X), **476**  
brain stem location, 474  
as branchial arch derivative, 587  
lesions of, 502  
pathway for, 476  
tongue, 463
- Valacyclovir, **197**
- Validity, **249**
- Valine  
classification of, 77  
maple syrup urine disease, 80  
sickle cell disease, 36
- Valproate  
migraine headaches, 488  
teratogenicity, 582  
tonic-clonic seizures, 663
- Valproic acid  
bipolar disorder, 531, 661  
epilepsy, 514  
hepatic necrosis, 240  
pancreatitis, 240
- Valsalva maneuver, 278
- Valsartan, 577
- Valvular dysfunction, 299
- Vancomycin, **186**  
*Clostridium difficile*, 134  
cutaneous flushing, 239  
functioning of, 183  
meningitis, 176  
MRSA, 194  
toxicity of, 242
- Vanillylmandelic acid (VMA)  
in neuroblastomas, 325  
tyrosine catabolism, 79
- Vanishing bile duct syndrome, 115
- Vardenafil, 623
- Varenicline, 540, 546
- Variable expressivity, **52**
- Variance, 251
- Variant angina, 293
- Variceal bleeding, 237
- Varicella zoster virus (VZV),  
160, 447, 451  
guanosine analogs, 197  
immunodeficient patients, 114  
meningitis, 176  
rash, 179  
Reye syndrome, 373  
vaccine, 107
- Varices  
Budd-Chiari syndrome, 375  
portal-systemic anastomoses, 350
- Variocoelectomy, 618
- Varicoceles, 594, **618**
- Vasa previa, 607
- Vasa vasorum  
syphilis, 143
- Vascular dementia, 491
- Vascular function curves, **275**
- Vascular inflammation, 207
- Vascular tumors of skin, **450**
- Vasculitides, **302–303**
- Vasculitis  
intraparenchymal  
hemorrhage, 483  
methotrexate for, 417
- Vas deferens, 550, 589, 593
- Vasoactive intestinal polypeptide  
(VIP), 356
- Vasoconstriction, 558
- Vasoconstrictors, 519
- Vasodilation  
cilostazol/dipyridamole for, 415  
sympathetic receptors, 230
- Vasodilators  
afterload effects, 273  
aortic dissections, 293  
atrial natriuretic peptide as, 285  
coronary steal syndrome, 293  
nitrates as, 305
- Vasogenic edema, 466
- Vasopressin. *See* Antidiuretic  
hormone (ADH)
- Vasopressin receptors, 230
- V(D)J recombination, 95
- VDRL false positives, **143**
- Vecuronium, 520
- Veganism and B<sub>12</sub> deficiency, 398
- VEGF (vascular endothelial growth  
factor), 211
- Velocidfacial syndrome, 61
- Vemurafenib, **421, 454**
- Venlafaxine, 545  
clinical use, 542  
panic disorder, 533  
phobias, 533  
PTSD, 534
- Venodilators, 273

- Venous gonadal drainage, 591  
 Venous return, 275  
 Venous sinus thrombosis, 473  
 Venous thromboembolism, 414  
 Venous thrombosis, 400  
   heparin for, 413  
   paroxysmal nocturnal hemoglobinuria, 400  
 Ventilation, **630**  
   high altitude, 635  
   perfusion and, 634  
 Ventral lateral (VL) nucleus, 468  
 Ventral pancreatic bud, 345  
 Ventral posterolateral (VPL) nucleus, 468  
 Ventral posteromedial (VPM) nucleus, 468  
 Ventricles  
   embryology, 268  
   morphogenesis of, 269  
 Ventricular aneurysm  
   pseudoaneurysm, 296  
   true, 294  
 Ventricular arrhythmia, 294  
 Ventricular fibrillation  
   ECG tracing, 284  
   torsades de pointes, 283  
 Ventricular free wall rupture, 296  
 Ventricular septal defect (VSD), **289, 665**  
   congenital rubella, 290  
   cri-du-chat syndrome, 60  
   Down syndrome, 290  
   fetal alcohol syndrome, 290  
   heart murmurs, 279  
   outflow tract formation, 269  
   pansystolic murmur in, 278  
 Ventricular system, **474**  
 Ventriculomegaly, 530  
 Ventromedial, hypothalamus, 466  
 Verapamil, 304, 305, 310, 488  
 Vermal cortex lesions, 469  
 Verrucae, 449  
 Vertebrae  
   diaphragm, 629  
 Vertebral artery, 473  
 Vertebral compression fractures, 435, 668  
 Vertebral disc herniation, 478  
 Vertigo, **503**  
   Meniere disease as cause, 653  
   streptomycin, 193  
 Vesamicol, 231  
 Vesicles, 447  
 Vesicourachal diverticulum, 585  
 Vesicoureteral reflux, 549  
   hydronephrosis, 568  
   pyelonephritis, 570  
 Vesicular trafficking proteins, 43  
 Vestibular bulbs, 590  
 Vestibular schwannomas, 496  
 Vestibulocochlear nerve (CN VIII), **476**  
   acoustic neuromas, 464  
   brain stem location, 474  
   pathway for, 476  
 VHL gene, 218  
 pheochromocytomas and, 326  
*Vibrio* spp, 121  
*Vibrio cholerae*, **141**  
   exotoxin production, 128  
   Gram-negative algorithm, 137  
   watery diarrhea, 175  
*Vibrio parahaemolyticus*, 174  
*Vibrio vulnificus*, 174  
 Vigabatrin, 514  
 Vimentin, 44  
 Vinblastine, 419  
   in cell cycle, 416  
   microtubules and, 44  
 Vinca alkaloids, 416  
 Vincristine, 419  
   in cell cycle, 416  
   microtubules and, 44  
   toxicities of, 422  
 Vinyl chloride  
   angiosarcomas, 375, 450  
   as carcinogen, 219  
 VIPomas  
   MEN 1 syndrome, 339  
   octreotide for, 382  
   regulatory substances, 356  
 Viral encephalitis, 668  
 Viral envelopes, **159**  
 Virchow nodes, 362  
 Virchow triad, 636  
 Viridans streptococci, **132**  
    $\alpha$ -hemolysis, 131  
   bacterial endocarditis, 299  
   biofilm production, 125  
   brain abscesses, 176  
   Gram-positive algorithm, 130  
   normal flora, 174  
 Virilization, 318  
 Virology, **158–173**  
 Virulence factors  
   bacterial, 125  
   *Bordetella pertussis*, 139  
   *Escherichia coli*, 140  
   *Salmonella/Shigella*, 141  
   *Staphylococcus aureus*, 131  
 Viruses  
   diarrhea caused by, 175  
   enveloped, 158  
   genetics, 158  
   immunocompromised patients, 175  
   negative-stranded, 164  
   pneumonia, 175  
   receptors for, 162  
   replication of, 159  
   segmented, 164  
   structure of, 158  
   vaccines for, 158  
 Visceral larva migrans, 155  
 Visceral leishmaniasis, 154  
 Viscosity, 274  
 Vision loss  
   glaucoma, 506  
   hyperammonemia, 78  
   retinal disease, 507–508  
 Visual cortex, 471, 485  
 Visual field defects, **511**  
 Visual hallucinations, 529  
 Vital capacity (VC), 630  
 Vitamin A (retinol), 61, **62**  
   free radical elimination by, 210  
   pseudotumor cerebri, 491  
   teratogenicity, 582  
 Vitamin B<sub>1</sub> deficiency  
   brain lesions and, 481  
   Korsakoff syndrome, 528  
   Wernicke-Korsakoff syndrome, 541  
 Vitamin B<sub>1</sub> (thiamine)  
   functions of, **62, 70**  
   maple syrup urine disease, 80  
   pyruvate dehydrogenase complex, 72  
   solubility of, 61  
 Vitamin B<sub>2</sub> (riboflavin)  
   functions, **63**  
   pyruvate dehydrogenase complex and, 72  
   solubility of, 61  
 Vitamin B<sub>3</sub> (niacin)  
   derivatives of, 79  
   functions, **63**  
   lipid-lowering agent, 306  
   pyruvate dehydrogenase complex and, 72  
   solubility of, 61  
   vitamin B<sub>6</sub> and, 63  
 Vitamin B<sub>5</sub> (pantothenic acid)  
   functions, **63**  
   pyruvate dehydrogenase complex and, 72  
   solubility of, 61  
 Vitamin B<sub>6</sub> deficiency, 397  
   isoniazid, 193  
 Vitamin B<sub>6</sub> (pyridoxine)  
   functions, **63**  
   solubility of, 61  
 Vitamin B<sub>7</sub> (biotin)  
   activated carriers, 71  
   functions, **64**  
   functions of, 69  
   pyruvate metabolism, 73, 74  
   solubility of, 61  
 Vitamin B<sub>9</sub> deficiency, 398  
   in anemia taxonomy, 396  
   neutrophils in, 386  
 Vitamin B<sub>9</sub> (folate)  
   absorption of, 358  
   deficiency, 668  
   functions, **64**  
   solubility of, 61  
 Vitamin B<sub>12</sub> (cobalamin)  
   absorption of, 358  
   functions, **65**  
   solubility of, 61  
   veganism, 65  
 Vitamin B<sub>12</sub> deficiency, 398  
   in anemia taxonomy, 396  
   dementia caused by, 529  
   *Diphyllobothrium latum*, 156, 157  
   neutrophils in, 386  
   spinal cord lesions in, 500  
 Vitamin B<sub>6</sub>  
   isoniazid, 193  
   sideroblastic anemia, 397  
 Vitamin C (ascorbic acid)  
   free radical elimination by, 210  
   functions, **65**  
   methemoglobinemia, 632  
   methemoglobin toxicity, 239  
   solubility of, 61  
 Vitamin D, **319**. *See also* Cholecalciferol  
   functions, **66**  
   osteoporosis prophylaxis, 435  
   PTH and, 320  
   signaling pathways for, 322  
   solubility of, 61  
 Vitamin D deficiency, 319, 331  
   hyperparathyroidism, 437  
   osteomalacia/rickets, 436  
 Vitamin deficiencies, 668  
 Vitamin E  
   free radical elimination by, 210  
   functions, **66**  
   solubility of, 61  
 Vitamin K  
   coagulation cascade, 392  
   functions, **66**  
   solubility of, 61  
   warfarin reversal, 664  
   for warfarin toxicity, 239, 414  
 Vitamin K deficiency, 392, 404  
   cephalosporins, 185  
 Vitamin/mineral absorption, **358**  
 Vitamins, **61–67**  
   fat-soluble, **61**  
   water-soluble, **61**  
 Vitelline duct/fistula, **585**  
 Vitiligo, 448  
 Vitreous body  
   collagen in, 46  
 Vitreous chamber, 504  
 VLDL (very low-density lipoprotein), 89  
 Volume of distribution, 225, 669  
 Volvulus, **368**  
   malrotation, 367  
   Meckel diverticulum, 367  
 vomiting  
   GLP-1 analogs, 341  
 Vomiting  
   annular pancreas, 345  
   biliary colic, 379  
   bilious, 344, 367  
   chemotherapy-induced, 383  
   diabetic ketoacidosis, 337  
   Ebola virus, 167  
   food poisoning, 134  
   fructose intolerance, 76  
   glycylcyclines, 188  
   *Histoplasma capsulatum*, 173  
   hyperammonemia, 78  
   iron poisoning, 404  
   *Legionella* spp, 181  
   Mallory-Weiss syndrome, 360  
   maple syrup urine disease, 80  
   metabolic alkalosis from, 561  
   metoclopramide for, 383  
   MI and, 294  
   ondansetron for, 383  
   posttussive, 139  
   pyloric stenosis, 345  
   Reye syndrome, 373  
   *Salmonella* spp, 144

- Vomiting (*continued*)  
 threadworms, 155  
 toxic shock syndrome, 131  
 trichinosis, 155  
 vitamin C toxicity, 65
- Von Gierke disease, 83  
 gout, 440
- Von Hippel-Lindau disease, 495  
 chromosome association, 60  
 presentation, 655  
 renal cell carcinoma and, 568  
 tumor suppressor genes and, 218
- Von Willebrand disease, 393, 406
- Voriconazole, 194, 195
- V/Q mismatch, 634, 637
- V/Q ratio, 635
- VRE (vancomycin-resistant enterococci)  
 daptomycin, 191  
 enterococci, 133  
 highly resistant, 194  
 oxazolidinones, 189
- $V_{max}$ , 224
- Vulnerable child syndrome, 526
- Vulvar lymphatic drainage, 591
- Vulvovaginitis, 149, 177
- vWF  
 receptor for, 386  
 in thrombocytes, 386  
 in thrombogenesis, 393
- W**
- WAGR complex, 569
- “Waiter’s tip” (Erb palsy), 428
- Waiver to informed consent, 254
- Waiving right to confidentiality, 255
- Waldenström macroglobulinemia  
 multiple myeloma vs, 409
- Walking milestone, 258
- Walking pneumonia, 146
- Wallenberg syndrome, 484
- Wallerian, 465
- Wallerian degeneration (neurons), 463
- Wall tension, 273
- Warfarin, 414  
 adverse effects of, 406  
 coagulation cascade, 392  
 cytochrome P-450 and, 243  
 for DVT, 636  
 griseofulvin and, 196  
 heparin vs, 414  
 PT measurement, 404  
 reversal of, 664  
 teratogenicity, 582  
 therapeutic index value of, 228  
 toxicity treatment, 239, 407  
 vitamin K antagonist, 66
- Warm autoimmune hemolytic anemia, 401
- Warthin-Finkeldey giant cells, 166
- Warthin tumors, 359
- WAS gene, 113
- Waterhouse-Friderichsen syndrome, 324  
 meningococci, 138  
 presentation, 652
- Watershed zones, 206, 472
- Water-soluble vitamins, 61
- Waxy casts, 562, 661
- Weakness, 499
- Wegener granulomatosis, 302  
 autoantibody with, 111  
 as granulomatous disease, 211  
 labs/findings, 657, 659  
 restrictive lung disease, 639  
 RPGN and, 564
- Weight gain  
 atypical antipsychotics, 543  
 Cushing syndrome, 323  
 danazol, 622  
 duodenal ulcers, 363  
 glitazone/thiazolidinediones, 340  
 hypothyroidism, 327  
 major depressive disorder, 531  
 mirtazapine, 546  
 sulfonylureas, 340  
 valproic acid, 514
- Weight loss  
 adrenal insufficiency, 324  
 anorexia nervosa, 537  
 Celiac disease, 657  
 cholelithiasis and, 379  
 chronic mesenteric ischemia, 369  
 colorectal cancer, 371  
 diabetes mellitus, 336  
 esophageal cancer, 361  
 gastric ulcers, 363  
*Histoplasma capsulatum*, 173  
 hyperthyroidism, 327  
 major depressive disorder, 531  
 malabsorption syndromes, 364  
 metformin, 340  
*Mycobacterium avium-intracellulare*, 173  
 orlistat for, 383  
 pancreatic cancer, 380  
 for PCOS, 609  
 polyarteritis nodosa, 302  
 polymyalgia rheumatica, 444  
 pseudotumor cerebri treatment, 491  
 renal cell carcinoma, 568  
 sleep apnea, 642  
 stomach cancer, 362  
 for stress incontinence, 569  
 tuberculosis, 136  
 Whipple disease, 656
- Weil disease, 142
- Well-patient care, 258–259
- Wenckebach AV block, 284
- Werdnig-Hoffmann disease, 500
- Wernicke aphasia, 486
- Wernicke area, 471  
 stroke effects, 484
- Wernicke encephalopathy, 62, 541
- Wernicke-Korsakoff syndrome, 481, 541  
 vitamin B<sub>1</sub> deficiency, 62
- Western blot, 49  
 HIV diagnosis, 171
- Western equine encephalitis, 163
- West Nile virus, 163, 176
- Wet beriberi, 62
- Wharton jelly, 585
- Wheals, 447
- Wheezing  
 asthma, 638  
 bronchial carcinoid tumor, 647  
 lung cancer, 647
- Whipple disease, 364  
 periodic acid-Schiff stain for, 122  
 presentation, 656
- Whipple procedure  
 for pancreatic cancer, 380
- White pulp (spleen), 94
- Whooping cough  
*Bordetella pertussis*, 139  
 pertussis toxin, 128  
 Wickham striae, 453
- Wide splitting, 277
- Williams syndrome  
 cardiac defect association, 290  
 chromosome association, 60
- Wilms tumor, 569  
 chromosome association, 60  
 dactinomycin for, 418  
 neuroblastomas vs, 325  
 tumor suppressor genes and, 218
- Wilson disease, 378  
 chromosome association, 60  
 Fanconi syndrome, 556  
 free radical injury and, 210
- Winged scapula, 428
- Winters formula, 561, 670
- Wiskott-Aldrich syndrome, 113  
 labs/findings, 660  
 X-linked recessive disorder, 56
- Wnt-7* gene, 580
- Wobble, 34, 36
- Wolff-Chaikoff effect, 321, 328.  
*See also* Jod-Basedow phenomenon
- Wolffian duct, 589
- Wolff-Parkinson-White syndrome, 283
- Wound healing  
 phases of, 211  
 scar/keloid formation, 210
- Woven bone, 434
- Wright-Giemsa stain, 386
- Wright stain, 142
- Wrinkles of aging, 48
- Wrist bones, 426
- Wrist drop, 427  
 lead poisoning, 397
- Written advance directives, 255
- WT1/WT2* genes, 218
- Wuchereria bancrofti*, 154, 155
- X**
- Xanthine, 457
- Xanthine oxidase, 457
- Xanthine oxidase inhibitors, 440, 661
- Xanthochromia, 661
- Xanthochromic spinal tap, 483
- Xanthogranulomatous pyelonephritis, 570
- Xanthomas  
 familial dyslipidemias, 90  
 hyperlipidemia and, 291
- Xanthoma striatum palmare, 90
- Xenografts, 114
- Xeroderma pigmentosum, 37
- Xerosis cutis, 62
- Xerostomia, 232, 441
- X-linked agammaglobulinemia, 112
- X-linked dominant inheritance, 55
- X-linked recessive disorders  
 agammaglobulinemia, 112  
 hyper-IgM syndrome, 113  
 IL-2R gamma chain defect, 113  
 NADPH oxidase defect, 113  
 Wiskott-Aldrich syndrome, 113
- X-linked recessive inheritance, 55
- X-ray teratogenicity, 582
- Y**
- Yellow cerebrospinal fluid, 661
- Yellow fever, 163, 164  
 liver anatomy and, 352  
 vaccine, 107
- Yersinia* spp  
 Gram-negative algorithm, 137  
 reactive arthritis, 442  
 taxonomy, 121
- Yersinia enterocolitica*, 141, 175
- Yersinia pestis*  
 animal transmission, 144  
 intracellular organism, 124
- Yo antigens, 217
- Yolk sac tumors, 611, 618
- Z**
- Zafirlukast, 649  
 arachidonic acid pathway, 455
- Zaleplon, 515
- Zanamivir, 197
- Zenker diverticulum, 367, 665
- Zero-order elimination, 226
- Zidovudine  
 HIV therapy, 199  
 mechanism (diagram), 197
- Ziehl-Neelsen stain, 122
- Zika virus, 167
- Zileuton, 455, 649
- Zinc, 67  
 Wilson disease, 378
- Ziprasidone, 543
- Zoledronic acid, 456
- Zollinger-Ellison syndrome, 338  
 duodenal ulcers, 363  
 gastrin in, 356  
 MEN 1 syndrome, 339  
 proton pump inhibitors for, 381
- Zolpidem, 515
- Zona fasciculata, 312, 319
- Zona glomerulosa, 312
- Zona reticularis, 312
- Zonular fibers, 504
- Zoonotic bacteria, 144
- Zymogens, 358





# About the Editors



## Tao Le, MD, MHS

Tao developed a passion for medical education as a medical student. He currently edits more than 15 titles in the *First Aid* series. In addition, he is Founder and Chief Education Officer of USMLE-Rx for exam preparation and ScholarRx for undergraduate medical education. As a medical student, he was editor-in-chief of the University of California, San Francisco (UCSF) *Synapse*, a university newspaper with a weekly circulation of 9000. Tao earned his medical degree from UCSF in 1996 and completed his residency training in internal medicine at Yale University and fellowship training at Johns Hopkins University. Tao subsequently went on to cofound Medsn, a medical education technology venture, and served as its chief medical officer. He is currently chief of adult allergy and immunology at the University of Louisville.



## Vikas Bhushan, MD

Vikas is a writer, editor, entrepreneur, and teleradiologist on extended sabbatical. In 1990 he conceived and authored the original *First Aid for the USMLE Step 1*. His entrepreneurial endeavors include a student-focused medical publisher (S2S), an e-learning company, and an ER teleradiology practice (24/7 Radiology). Firmly anchored to the Left Coast, Vikas completed a bachelor's degree at the University of California Berkeley; an MD with thesis at UCSF; and a diagnostic radiology residency at UCLA. His eclectic interests include technology, information design, photography, South Asian diasporic culture, and avoiding a day job. Always finding the long shortcut, Vikas is an adventurer, knowledge seeker, and occasional innovator. He enjoys novice status as a kiteboarder and single father, and strives to raise his children as global citizens.



## Matthew Sochat, MD

Matthew is a third-year internal medicine resident at Temple University Hospital in Philadelphia, pursuing a career in hematology-oncology. He completed medical school in 2013 at Brown University and is a 2008 graduate of the University of Massachusetts, Amherst, where he studied biochemistry and the classics. Pastimes include skiing, cooking/baking, traveling, the company of friends/loved ones (especially his wonderful wife), the Spanish language, and computer/video gaming. Be warned: Matt also loves to come up with corny jokes at (in) opportune moments.



## Yash Chavda, DO

Yash is an emergency medicine resident at St. Barnabas Hospital in the Bronx. He earned his medical degree from NYIT College of Osteopathic Medicine, and completed his undergraduate degrees in biology and psychology at CUNY Baruch College in 2010. Yash has many interests outside of medicine and enjoys spending time with his loved ones. He is a developing photographer, former web/graphic designer (who still dabbles), video gamer, foodie, and avid explorer who wants to travel the world (whenever he actually gets a chance). He hopes to always keep improving at everything he does.



## Kimberly Kallianos, MD

Originally from Atlanta, Kimberly graduated from the University of North Carolina at Chapel Hill in 2006 and from Harvard Medical School in 2011. She completed her radiology residency at the University of California, San Francisco (UCSF) in 2016 and is currently a cardiac and pulmonary imaging fellow at UCSF.



## Mehboob Kalani, MD

Mehboob is a second-year internal medicine resident at Allegheny Health Network Medical Education Consortium in Pittsburgh. He was born in Karachi, Pakistan, grew up in Toronto, Canada, and pursued medicine upon completing high school. He earned his bachelor's and medical degrees at American University of Integrative Sciences in 2015. After residency, his interests lie in pulmonary critical care medicine, and he is researching COPD exacerbation treatment and readmission rates. In his limited leisure time, Mehboob enjoys playing or watching soccer, long drives, and family gatherings.



## Andrew Zureick

Andrew is a medical student at the University of Michigan and is currently conducting research in radiation oncology. He earned his bachelor's degree at Dartmouth College in 2013, graduating Phi Beta Kappa and *Summa Cum Laude* with High Honors in Chemistry. He is a coauthor of *What Every Science Student Should Know*, a guidebook for undergraduate STEM majors published in 2016 by the University of Chicago Press. His interests include medical education and health policy. In his spare time, he enjoys playing the piano, golf, tennis, and creative writing.